<SEC-DOCUMENT>0000886163-25-000012.txt : 20250228
<SEC-HEADER>0000886163-25-000012.hdr.sgml : 20250228
<ACCEPTANCE-DATETIME>20250228160216
ACCESSION NUMBER:		0000886163-25-000012
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		112
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250228
DATE AS OF CHANGE:		20250228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIGAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000886163
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				770160744
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33093
		FILM NUMBER:		25689885

	BUSINESS ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-550-7500

	MAIL ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>lgnd-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:8c134d1d-ab0c-4379-9892-d916b4e62e37,g:28b275e3-fcb1-4a6c-a0ef-95ede04b9eea,d:fca968692f35492e968bd282f4512e0b-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:lgnd="http://www.ligand.com/20241231" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2024" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lgnd-20241231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-32">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-33">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-35">0000886163</ix:nonNumeric><ix:nonNumeric contextRef="c-29" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="f-270">http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202006Member</ix:nonNumeric><ix:nonNumeric contextRef="c-82" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-611">P1Y0M0D</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-128" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-709">12.50</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-129" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-710">2.08</ix:nonFraction><ix:nonNumeric contextRef="c-82" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-1090">P1Y0M0D</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" id="f-1303">http://fasb.org/us-gaap/2024#GainLossOnInvestments</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="f-1309">http://www.ligand.com/20241231#NonCashChangeInEstimatedFairValueOfContingentValueRights</ix:nonNumeric><ix:nonNumeric contextRef="c-22" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" id="f-1313">http://fasb.org/us-gaap/2024#GainLossOnInvestments</ix:nonNumeric><ix:nonNumeric contextRef="c-22" name="us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" id="f-1320">http://www.ligand.com/20241231#NonCashChangeInEstimatedFairValueOfContingentValueRights</ix:nonNumeric><ix:nonNumeric contextRef="c-6" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-1373">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="f-1374">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-424" name="lgnd:ShareBasedCompensationInitialOfferingPeriod" id="f-1686">P6M</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lgnd-20241231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>lgnd:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="contract"><xbrli:measure>lgnd:contract</xbrli:measure></xbrli:unit><xbrli:unit id="right"><xbrli:measure>lgnd:right</xbrli:measure></xbrli:unit><xbrli:unit id="pure"><xbrli:measure>lgnd:pure</xbrli:measure></xbrli:unit><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="position"><xbrli:measure>lgnd:position</xbrli:measure></xbrli:unit><xbrli:unit id="cvr"><xbrli:measure>lgnd:cvr</xbrli:measure></xbrli:unit><xbrli:unit id="complaint"><xbrli:measure>lgnd:complaint</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusPartneredProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:FinancialRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:FinancialRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:FinancialRoyaltyAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueAndOtherIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueAndOtherIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueAndOtherIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:NucorionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:NucorionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:NucorionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:APEIRONMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:APEIRONMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lgnd:DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lgnd:DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lgnd:DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:RecordatiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusPartneredProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusPartneredProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">lgnd:PrimordialGeneticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2010-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyRylazeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyRylazeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyRylazeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:FilspariMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:FilspariMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:FilspariMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyTeriparatideInjectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyTeriparatideInjectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyTeriparatideInjectionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:VaxneuvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:VaxneuvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:VaxneuvanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCoreMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCOVIDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCOVIDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCOVIDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2007-01-01</xbrli:startDate><xbrli:endDate>2007-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lgnd:RestrictedStockUnitsAndPerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-29</xbrli:startDate><xbrli:endDate>2024-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MK4830Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-29</xbrli:startDate><xbrli:endDate>2024-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:INCAGN2390Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-29</xbrli:startDate><xbrli:endDate>2024-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:INCAGN2385Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-29</xbrli:startDate><xbrli:endDate>2024-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:BMS986442Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-29</xbrli:startDate><xbrli:endDate>2024-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:UGN301Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-29</xbrli:startDate><xbrli:endDate>2024-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:AGEN2373Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-29</xbrli:startDate><xbrli:endDate>2024-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:BOTBALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-29</xbrli:startDate><xbrli:endDate>2024-05-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:APEIRONMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-15</xbrli:startDate><xbrli:endDate>2024-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:APEIRONMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:InvIOsHoldingAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-15</xbrli:startDate><xbrli:endDate>2024-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:InvIOsHoldingAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:InvIOsHoldingAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-15</xbrli:startDate><xbrli:endDate>2024-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-27</xbrli:startDate><xbrli:endDate>2023-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-27</xbrli:startDate><xbrli:endDate>2023-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-18</xbrli:startDate><xbrli:endDate>2023-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-18</xbrli:startDate><xbrli:endDate>2023-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-18</xbrli:startDate><xbrli:endDate>2023-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lgnd:MilestoneAxis">lgnd:BelowMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PeliCRM197Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PeliCRM197Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="lgnd:MilestoneAxis">lgnd:AboveMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PeliCRM197Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lgnd:ConsiderationClassficationAxis">lgnd:EquityMethodInvestmentsAllocationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lgnd:ConsiderationClassficationAxis">lgnd:EquitySecuritiesAllocationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="lgnd:ConsiderationClassficationAxis">lgnd:DerivativeAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-18</xbrli:startDate><xbrli:endDate>2023-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusPartneredProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">lgnd:PrimordialGeneticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusPartneredProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">lgnd:PrimordialGeneticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:QARZIBAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:QARZIBAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ToleranceTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ToleranceTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:EnsifentrineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:EnsifentrineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:InvIOsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:InvIOsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:OvidTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:OvidTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:OvidTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:APEIRONMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:QARZIBAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:APEIRONMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:InvIOsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:ToleranceTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:ToleranceTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:EnsifentrineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:EnsifentrineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-31</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:OvidTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:SoticlestatMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:VikingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:VikingTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:VikingTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:VikingTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lgnd:PartnerProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lgnd:PartnerProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lgnd:PartnerProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:VikingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lgnd:CollarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lgnd:OtherDerivativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:InvIOsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:InvIOsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">lgnd:ZelsuvmiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">lgnd:ZelsuvmiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusPartneredProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusPartneredProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusPartneredProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2010-01-01</xbrli:startDate><xbrli:endDate>2010-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2010-01-01</xbrli:startDate><xbrli:endDate>2010-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:Phase3ClinicalTrialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">lgnd:OfficeInBostonMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">lgnd:OfficeInJupiterFloridaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-15</xbrli:startDate><xbrli:endDate>2023-05-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">lgnd:NotesRepurchasedDuringCurrentPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-12</xbrli:startDate><xbrli:endDate>2023-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-12</xbrli:startDate><xbrli:endDate>2023-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-12</xbrli:startDate><xbrli:endDate>2023-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-12</xbrli:startDate><xbrli:endDate>2023-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-12</xbrli:startDate><xbrli:endDate>2023-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-12</xbrli:startDate><xbrli:endDate>2023-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-02</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:OmniabSeparationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:OmniabSeparationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgnd:AtTheMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgnd:AtTheMarketEquityOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lgnd:USDistrictCourtForTheNorthernDistrictOfOhioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-31</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lgnd:CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lgnd:CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:FCX007Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lgnd:PurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-24</xbrli:startDate><xbrli:endDate>2025-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:FCX007Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-24</xbrli:startDate><xbrli:endDate>2025-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:FCX007Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">lgnd:OtherPurchasersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-24</xbrli:startDate><xbrli:endDate>2025-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-24</xbrli:startDate><xbrli:endDate>2025-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ifca968692f35492e968bd282f4512e0b_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">_____________________________________________________________________________________________</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.276%"><tr><td style="width:1.0%"/><td style="width:2.717%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:95.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the Fiscal Year Ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2024</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.024%"><tr><td style="width:1.0%"/><td style="width:2.857%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.943%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;.</span></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commission File No.&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-33093</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><img src="lgnd-20241231_g1.jpg" alt="Logo_2023.jpg" style="height:99px;margin-bottom:5pt;vertical-align:text-bottom;width:284px"/></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">LIGAND PHARMACEUTICALS INC</ix:nonNumeric>ORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.661%"><tr><td style="width:1.0%"/><td style="width:65.869%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.707%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.024%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">77-0160744</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(IRS Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">555 Heritage Drive, Suite 200</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Jupiter</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">Florida</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">33458</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">858</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">550-7500</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.482%"><tr><td style="width:1.0%"/><td style="width:36.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.302%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Name of Each Exchange on Which Registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $.001 per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">LGND</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Global Market</ix:nonNumeric></span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">None</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Securities Exchange Act of 1934.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric>&#160;&#160;&#9746;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ndicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;  &#8220;smaller reporting company&#8221; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">emerging growth company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> in Rule 12b-2 of the Exchange Act. </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.547%"><tr><td style="width:1.0%"/><td style="width:15.151%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.980%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.413%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.055%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.857%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" id="f-23">Large Accelerated Filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;Filer </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated&#160;Filer&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-24">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">&#9746;</ix:nonNumeric></span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#9744;</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate market value of the Registrant&#8217;s voting and non-voting stock held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-8" name="dei:EntityPublicFloat" scale="9" id="f-29">1.1</ix:nonFraction> billion based on the last sales price of the Registrant&#8217;s Common Stock on the Nasdaq Global Market of the Nasdaq Stock Market LLC on June&#160;28, 2024. For purposes of this calculation, shares of Common Stock held by directors, officers and 10% stockholders known to the Registrant have been deemed to be owned by affiliates which should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the Registrant or that such person is controlled by or under common control with the Registrant.</span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of February&#160;25, 2025, the Registrant had <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">19,255,353</ix:nonFraction> shares of Common Stock outstanding.</span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:5pt;text-align:center"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Portions of the Proxy Statement for the Registrant&#8217;s 2025 Annual Meeting of Stockholders to be filed with the Commission within 120 days of December&#160;31, 2024 are incorporated by reference in Part&#160;III of this Annual Report on Form&#160;10-K.&#160;With the exception of those portions that are specifically incorporated by reference in this Annual Report on Form&#160;10-K, such Proxy Statement shall not be deemed filed as part of this Report or incorporated by reference herein.</span></div></ix:nonNumeric><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ifca968692f35492e968bd282f4512e0b_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:7.111%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:84.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.766%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_13">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_16">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_16">19</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_19">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_19">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_22">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_22">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_25">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_28">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_31">46</a></span></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_37">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_37">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_40">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_40">47</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_43">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_55">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_55">54</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_58">Consolidated Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_58">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_127">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_127">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_130">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_130">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_133">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_130">100</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_136">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_130">100</a></span></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part III</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_142">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_142">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_145">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_145">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_148">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_148">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_151">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_151">103</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_154">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_154">103</a></span></div></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part IV</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_160">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_160">104</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_163">Form 10-K - Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_160">104</a></span></div></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_166">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_166">109</a></span></div></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-top:9pt;text-indent:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.170%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GLOSSARY OF TERMS AND ABBREVIATIONS</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Abbreviation</span></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definition</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023 Notes</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$750.0 million aggregate principal amount of convertible senior unsecured notes due 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agenus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agenus Inc., Agenus Royalty Fund, LLC, and/or Agenus Holdings 2024, LLC </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldeyra</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aldeyra Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASC </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounting Standards Codification</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ASU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounting Standards Update </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aziyo</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aziyo Med, LLC</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Baxter</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Baxter International, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BeiGene</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BeiGene, Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BendaRx</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BendaRx Corp.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">BLA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Biologics license application</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASI</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CASI Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">cGMP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Good Manufacturing Practice</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Company</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ligand Pharmaceuticals Incorporated, including subsidiaries</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Convertible Note</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Convertible Promissory Note</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">COPD</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chronic obstructive pulmonary disease </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cormatrix</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cormatrix Cardiovascular, Inc. </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corvus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corvus Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit Agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit Agreement, dated as of October 12, 2023, as amended, among Ligand Pharmaceuticals Incorporated, certain of its subsidiaries, as Guarantors (as defined therein), the Lenders (as defined therein), and Citibank, N.A., as Administrative Agent, Swingline Lender and L/C Issuer</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CVR</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent value right</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CyDex</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CyDex Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Daiichi Sankyo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Daiichi Sankyo Company, Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DMF</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Drug Master File</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ESG</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Environmental, Social and Governance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ECM</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Extracellular matrix</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eisai</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eisai Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Elutia</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Elutia Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EPA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Environmental Protection Agency</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee Stock Purchase Plan, as amended and restated</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">European Union</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exelixis </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exelixis, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FASB</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial Accounting Standards Board</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FDA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Food and Drug Administration</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FY 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Company's fiscal year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FY 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Company's fiscal year ended December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FY 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Company's fiscal year ended December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Generally accepted accounting principles in the United States</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GCSF</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granulocyte-colony stimulating factor</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Gilead Sciences, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Hikma</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Hikma Pharmaceuticals PLC</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hovione</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Hovione FarmCiencia, S.A.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IND</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investigational New Drug</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IRS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Internal Revenue Service</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intravenous</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jazz Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ligand</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ligand Pharmaceuticals Incorporated, including subsidiaries</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-top:9pt;text-indent:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.630%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.170%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LTP</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liver targeting prodrug</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marinus </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marinus Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Melinta</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Melinta Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck &amp; Co., Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metabasis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metabasis Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NDA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Drug Application</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NOLs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Operating Losses</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Novan</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Novan, Inc. (n/k/a NVN Liquidation, Inc.)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novartis AG</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nucorion </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Nucorion Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OmniAb</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OmniAb Operations, Inc. (f/k/a OmniAb, Inc.)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ono</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ono Pharmaceutical Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Opthea</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Opthea Limited</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orange Book</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Publication identifying drug products approved by the FDA based on safety and effectiveness</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palvella Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PDUFA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prescription Drug User Fee Act</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfenex</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfenex Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pfizer, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phoenix Tissue</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phoenix Tissue Repair</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSU</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance stock unit</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Research and Development</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolving Credit Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The revolving credit facility under the Credit Agreement</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSU </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock unit</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sage</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sage Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sanofi SA</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SARM</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selective Androgen Receptor Modulator</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SEC</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Securities and Exchange Commission</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sedor</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sedor Pharmaceuticals, Inc., or RODES, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Seelos</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Seelos Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selexis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selexis, SA</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sermonix</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sermonix Pharmaceuticals, LLC</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SII</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Serum Institute of India</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">SQ Innovation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">SQ Innovation, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sunshine Lake Pharma</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sunshine Lake Pharma Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Takeda Pharmaceuticals Company Limited</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Act</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Tax Cuts and Jobs Act</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Teva</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Teva Pharmaceuticals USA, Inc., Teva Pharmaceutical Industries Ltd. and Actavis, LLC </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Travere</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Travere Inc.</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TR-Beta</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thyroid hormone receptor beta</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vernalis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ligand UK Limited (f/k/a Vernalis plc)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Verona</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Verona Pharma plc</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viking Therapeutics</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xi'an Xintong Pharmaceuticals Research Co. Ltd.</span></td></tr></table></div><div style="margin-top:9pt;text-indent:24pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:24pt"><span><br/></span></div><div style="margin-top:9pt"><span><br/></span></div><div id="ifca968692f35492e968bd282f4512e0b_10"></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="ifca968692f35492e968bd282f4512e0b_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cautionary Note Regarding Forward-Looking Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following report together with the more detailed information regarding our company, our common stock and our financial statements and notes to those statements appearing elsewhere in this document. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This report contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties and reflect Ligand&#8217;s judgment as of the date of this report. Although our forward-looking statements reflect the good faith judgment of our management, these statements can only be based on facts and factors currently known by us. Consequently, these forward-looking statements are inherently subject to risks and uncertainties, and actual results and outcomes may differ materially from results and outcomes discussed in the forward-looking statements.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">All statements contained herein, other than statements of historical fact, could be deemed to be forward-looking statements. In some instances, forward-looking statements can be identified by the use of forward-looking words such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;plan,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;would,&#8221; &#8220;continue,&#8221; &#8220;seeks,&#8221; &#8220;pro forma,&#8221; or &#8220;anticipates,&#8221; or other similar words (including their use in the negative), or by discussions of future matters such as those related to our future results of operations and financial position, royalties and milestones under license agreements, Captisol material sales, product development, and product regulatory filings and approvals, and the timing thereof, Ligand's status as a high-growth company, as well as other statements that are not historical in nature. You should be aware that the occurrence of any of the events discussed in Part I under Item 1A under the caption &#8220;Risk Factors&#8221; of this report could negatively affect our results of operations, financial condition and the trading price of our stock.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The cautionary statements made in this report are intended to be applicable to all related forward-looking statements wherever they may appear in this report. We urge you not to place undue reliance on these forward-looking statements, which  reflect our good-faith beliefs (or those of indicated third parties) and speak only as of the date of this report. Except as required by law, we disclaim any intent or obligation to update these forward-looking statements beyond the date of this report, even if new information becomes available in the future. This caution is made under the safe harbor provisions of Section&#160;21E of the Securities Exchange Act of 1934, as amended.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References to &#8220;Ligand Pharmaceuticals Incorporated,&#8221; &#8220;Ligand,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; include Ligand Pharmaceuticals Incorporated and our wholly-owned subsidiaries.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partner Information</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding partnered products and programs comes from information publicly released by our partners and licensees.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K includes trademarks, trade names and service marks owned by us. Ligand</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BEPro&#8482;, Captisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CyDex</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, LTP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, LTP Technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NITRICIL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and ZELSUVMI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are protected under applicable intellectual property laws and are our property. All other trademarks, trade names and service marks including, but not limited to Pelican Expression Technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, PeliCRM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Pfenex Expression Technology</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, OmniAb</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Kyprolis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Evomela</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Veklury</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Livogiva</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Bonteo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Zulresso</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Rylaze</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vaxneuvance&#8482;, Pneumosil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Minnebro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Baxdela</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Nexterone</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Noxafil</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Duavee</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Filspari</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Ohtuvayre&#8482;, Qarziba</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks referred to in this report may appear without the &#174;, &#8482; or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to such trademarks, trade names and service marks. Use or display by us of other parties&#8217; trademarks, trade dress or products is not intended to and does not imply a relationship with, or endorsement or sponsorship of, us by the trademark or trade dress owners.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.988%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Business</span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Our business model seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Our business model focuses on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing our technology to help partners discover and develop medicines. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate our revenue. We operate two infrastructure-light royalty-generating IP platform technologies. Our Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Our NITRICIL platform technology facilitates &#8220;tunable&#8221; dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. We have established multiple alliances, licenses and other business relationships with the world&#8217;s leading biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Gilead Sciences and Baxter.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue consists of three primary elements: royalties from commercialized products, sales of our Captisol material to partners, and contract revenue from license fees and milestones payments. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Strategy and Execution</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical royalty aggregator, focused on investing in differentiated late-stage assets and operating royalty-generating, infrastructure-light platform technologies. Since our transition to this business model in 2007, we have deployed over $1 billion of capital to build our diverse portfolio. In 2022, Ligand made a deliberate decision to focus on an efficient, high margin, low infrastructure version of our historical model. Following the spin-offs of our OmniAb antibody discovery business in November 2022 and the Pelican Expression Technology subsidiary in September 2023, our focus is to continue to expand our pipeline by aggregating royalty rights in mid- to late-stage development and commercial biopharma products, while maintaining a lean infrastructure and high-margin business. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model is highly differentiated from a traditional biotechnology company in several important ways. First, we have limited infrastructure requirements, enabling us to maintain relatively high operating margins. Second, we can enable development over a broad range of therapeutic areas and can be strategic and balanced about the size of our investments to achieve a highly diversified portfolio. Third, our business model mitigates the high volatility and risk associated with building a business around a single or small number of assets. With this approach, we have the ability to mitigate the impact of binary clinical outcomes inherent in the biopharmaceutical industry, thereby facilitating cash flows that are more predictable. Finally, we can target the size of our investments to achieve appropriate risk management across the portfolio.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an organization, we bring a highly experienced team and financial strength to execute on our strategy. There is high demand for capital and low availability of structured capital in the segment of the biopharmaceutical market in which we operate, creating significant investment opportunities for Ligand. Unlike open-market equity investing, many of our investments take place under Confidential Disclosure Agreements (CDAs), allowing us access to in-depth, advantageous diligence materials. Our flexible investment structures are designed to mitigate risks and help accommodate different transaction structures in line with our partners' goals. We believe our business model is highly scalable and has significant growth potential. We have assembled a talented, long-tenured team with deep industry relationships, investment experience and industry knowledge. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From a more tactical perspective, we execute our strategy using four key approaches: royalty monetization, special situations, project finance, and IP technology platform investments. With royalty monetization, we purchase rights on existing royalty contracts that are owned by inventors, academic institutions or companies. There are advantages of royalty investing as a model since royalties 1) require minimal infrastructure, 2) are non-dilutable and 3) their cash flows are often protected in bankruptcy. In special situations investing, we can acquire or restructure companies with valuable assets or partnerships and realize the value of those assets by incubating and partnering the product assets, or holding preestablished royalty contracts/assets. Ligand has a track record of doing this successfully with investments such as:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Pharmacopeia acquisition in 2008, which yielded Travere&#8217;s Filspari</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Metabasis acquisition in 2010, which contributed to the creation of Viking Therapeutics</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Vernalis acquisition in 2018, which yielded Verona&#8217;s Ohtuvayre</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Pfenex acquisition in 2020, which yielded five of our major commercial programs &#8211; Capvaxive, Vaxnuevance, Rylaze, Pneumosil, and Teriparatide, as well as our equity interest in Primrose Bio</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Novan acquisition in 2023, which yielded ZELSUVMI</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Apeiron acquisition in 2024, which yielded Qarziba</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Project finance involves the provision of development capital to fund late-stage clinical programs in return for royalty contracts that we negotiate, creating synthetic royalties on the future sales of those products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, with IP technology platform acquisitions, we look for platforms that are infrastructure-light with existing royalties in place while providing the potential for new royalties through operating those platforms. Ideal technology IP platforms will be scalable and have broad applicability. Our Captisol and NITRICIL businesses are excellent examples of successful platform technology investments. </span></div><div style="margin-bottom:6pt;text-align:center;text-indent:27pt"><img src="lgnd-20241231_g2.jpg" alt="image.jpg" style="height:360px;margin-bottom:5pt;vertical-align:text-bottom;width:696px"/></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a specific set of criteria we use to assess potential investments. The first is time to cash flow, as we seek products that are within a few years of regulatory approval and commercialization. Typically, this means we invest in Phase 3 assets, although we also evaluate opportunities to invest from Phase 2 assets to approved assets. In terms of an asset's clinical profile, we are looking for strong data supporting both efficacy and safety, and products which will ultimately deliver significant value to patients and to the healthcare system. We also look for strong market exclusivity, which can be achieved through intellectual property and/or regulatory protections. Structural alignment with our counterparty and the commercial counterparty is also a key criteria of the investments we make. Ultimately, we look for assets with favorable risk-reward profiles, which have above average probability of technical and regulatory success and can be commercialized effectively.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div><img src="lgnd-20241231_g3.jpg" alt="Investment criteria.jpg" style="height:357px;margin-bottom:5pt;vertical-align:text-bottom;width:696px"/></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Technologies</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through a combination of research and acquisitions, we have created a partnered portfolio with a wide variety of underlying technologies. This diversification provides the added benefits of exposure to a wider breadth of scientific innovation, more licensing opportunities and lower impact of individual patent expiry.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Captisol Technology</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Captisol is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This unique technology has enabled FDA-approved products, including Gilead&#8217;s Veklury, Amgen&#8217;s Kyprolis, Baxter&#8217;s Nexterone, and Acrotech Biopharma&#8217;s Evomela. There are many Captisol-enabled products currently in various stages of development. We maintain a broad global patent portfolio for Captisol with the latest expiration date in 2033. Other patent applications covering methods of making Captisol, if issued, extend the expiration date to 2041.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to solid Captisol powder, we offer our partners access to cGMP manufactured aqueous Captisol concentrate. This product offering was established in 2017 to reduce cycle time and increase Captisol production capacity for large-volume drug products. We maintain both Type IV and Type V DMFs with the FDA. These DMFs contain manufacturing and safety information relating to Captisol that our licensees can reference when developing Captisol-enabled drugs. We also have active DMFs in Japan, China and Canada. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NITRICIL Technology Platform</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NITRICIL technology platform was acquired through our Novan acquisition in 2023. This product leverages nitric oxide's naturally occurring antimicrobial and immunomodulatory effects to develop new therapies for unmet medical needs across multiple therapeutic areas. Our nitric oxide platform allows for &#8220;tunable&#8221; dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a broad range of indications. NITRICIL is currently leveraged in one FDA approved product, ZELSUVMI. Clinical development success positions the NITRICIL platform well for future expansions into other indications.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">HepDirect, LTP and BEPro Technology Platform</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HepDirect and LTP technology platforms are our proprietary liver-targeting prodrug technologies that can deliver many different chemical classes of drugs to the liver by using a chemical modification that renders an active pharmaceutical ingredient (&#8220;API&#8221;) biologically inactive until cleaved by a liver-specific enzyme. These technologies may improve the efficacy and/or safety of certain drugs and can be applied to marketed or new drug products to treat liver diseases or diseases caused by hemostasis imbalance of circulating molecules controlled by the liver. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BEPro technology platform is a next generation prodrug technology distinct from HepDirect and LTP prodrug technologies, expanding use to non-liver related diseases. BEPro is specifically applicable to nucleotides and nucleotide analogs </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the development of compounds with improved product profiles. Ligand has demonstrated benefits in cell penetration and oral, intravenous and inhaled pharmacokinetics with BEPro-enabled nucleotide analogs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pelican Expression Technology (owned by Primrose Bio, of which Ligand owns 31.4% as of December 31, 2024)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pelican Expression Technology platform is a robust, validated, cost-effective and scalable platform for recombinant protein production and is especially well suited for complex, large-scale proteins. Global manufacturers have demonstrated consistent success with the platform, and the technology is currently outlicensed for multiple commercial and development-stage programs. The versatility of the platform has been demonstrated in the production of enzymes, peptides, antibody derivatives and engineered non-natural proteins. The platform contributes significant value to biopharmaceutical development programs by shortening timelines and reducing costs associated with research and development through commercial manufacturing of therapeutics and vaccines. Given pharmaceutical industry trends toward large molecules with increased structural complexities, the Pelican Expression Technology platform is well positioned to meet these growing needs as one of the most comprehensive and broadly available, commercially validated protein production platforms in the industry. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024 and Recent Investment Highlights</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2025, we announced that we entered into a royalty financing agreement with Castle Creek Biosciences, Inc., a late-stage cell and gene therapy company, to support Castle Creek&#8217;s D-Fi (FCX-007) Phase 3 clinical study. D-Fi is an injectable autologous gene-modified cell therapy in development for the treatment of dystrophic epidermolysis bullosa (&#8220;DEB&#8221;), candidate for the treatment of DEB, a devastating, painful, and debilitating rare genetic skin disorder. Under the terms of the agreement, we have invested $50 million in exchange for a mid-single digit royalty on worldwide sales of D-Fi and a portion of a future milestone payment upon D-Fi achieving FDA approval. An additional $25 million was secured from a syndicate of co-investors in return for a high-single digit royalty on worldwide sales of D-Fi. </span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout 2024 and into January of 2025, we acquired additional royalties from several Ohtuvayre inventors, bringing our total Ohtuvayre royalty to 3%.</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024, we acquired Apeiron Biologics AG (&#8220;Apeiron&#8221;), which holds royalty rights to Qarziba (dinutuximab beta) for the treatment of high-risk neuroblastoma in patients aged 12 months and above, for $100 million. In addition, we agreed to pay Apeiron shareholders additional consideration based on future commercial and regulatory events, including up to $28 million if Qarziba royalties exceed certain predetermined thresholds by either 2030 or 2034, and pay additional earn-outs on specific future commercial and regulatory events. Qarziba was approved by the European Medicines Agency in 2017 and is commercially available in more than 35 countries. We receive a tiered mid-teen royalty on sales of Qarziba from Recordati. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (3), Acquisitions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, following on our first two investments in 2018 and 2023, we invested an additional $2.5M in Palvella in the form of a convertible notes, which upon Pavella's merger with Pieris, converted to common shares of Pavella.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, we committed $75 million to a royalty financing agreement (the &#8220;Agenus Agreement&#8221;) with Agenus intended to support Agenus&#8217; key development initiatives in the ongoing botensilimab and balstilimab (&#8220;BOT/BAL&#8221;) clinical development program, including a Phase 3 trial in its lead indication of patients with metastatic, relapsed/refractory, microsatellite stable (MSS) colorectal cancer, not microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR), who are without active liver metastases (r/r MSS CRC NLM), along with other launch readiness activities. Under the terms of the Agenus Agreement, we paid $75 million to Agenus at closing. In addition, we have the option to invest an additional $25 million on the same terms on a pro rata basis. In return for our initial $75 million payment, we are entitled to receive 18.75% of future royalties and 31.875% of future milestone payments related to six of Agenus&#8217; clinical-stage oncology programs. For five of these programs the partner has either returned, not exercised a license option or indicated they would no longer pursue development including BMS-986442, AGEN2373, INCAGN2385 and INCAGN2390 and MK-4830. UGN-301 is currently being evaluated in Phase 1 trials in bladder cancer by UroGen Pharma. Additionally, we will receive a 2.625% synthetic royalty on future global net sales generated by BOT/BAL. The royalties and milestone payments owed could be adjusted up or down based upon pre-determined future events and achievement of certain milestones. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (2), Agenus Transaction.&#8221;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Novan Acquisition</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, the Bankruptcy Court approved a $12.2 million bid from Ligand to purchase certain assets of Novan, Inc. (&#8220;Novan&#8221;), including its lead product candidate berdazimer topical gel, 10.3% (&#8220;berdazimer gel&#8221;), all assets related to the NITRICIL technology platform and the rights to one development stage asset. Prior to Novan's bankruptcy, we had a royalty interest in berdazimer gel. Berdazimer gel was subsequently approved by the FDA in January 2024, with a brand name of ZELSUVMI. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2024, Ligand announced the creation of Pelthos Therapeutics (&#8220;Pelthos&#8221;) under the leadership of Scott Plesha as Chief Executive Officer. Pelthos is focused on the commercialization of innovative, safe, and efficacious therapeutic products </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for patients suffering from conditions with limited treatment options. ZELSUVMI, its first product, is the first and only FDA-approved prescription medicine for the treatment of the highly transmissible molluscum contagiosum (molluscum) viral skin infection in adults and pediatric patients one year of age and older. It is the first and only FDA approved topical prescription medication for this infection that can be applied by patients, parents and caregivers at home, outside of a physician's office, or other medical setting. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZELSUVMI received a Novel Drug designation from the U.S. FDA in January 2024 to treat molluscum viral skin infection. ZELSUVMI was developed using Pelthos' proprietary nitric oxide-based NITRICIL technology platform. As we incubate this newly acquired business, the Pelthos team is actively preparing for a potential strategic transaction and subsequent commercial launch by mid-2025 of the assets acquired in the Novan acquisition (including ZELSUVMI and other assets that may be developed using the NITRICIL technology platform).  Consistent with our business model, we are engaging with potential commercial partners and outside investors to maximize the value of these assets for Ligand stockholders through a licensing or other strategic transaction involving Pelthos. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (3), Acquisitions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial and Clinical Stage Partnered Portfolio</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a large royalty portfolio including 12 major commercial-stage revenue-generating royalty assets and over 75 additional active programs with future revenue-generating potential, including over 85 that are programs that are fully-funded by our partners. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides an overview of royalty receipts on our commercial-stage revenue-generating royalty assets:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.540%"><tr><td style="width:1.0%"/><td style="width:12.121%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.289%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.641%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.508%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Partner</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty Rate</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Royalty Receipts (in millions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated 2024 Product Revenue<br/>&#160;(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen/Ono/Beigene</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5% - 3.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$38.4</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,627.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Qarziba</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recordati</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tiered mid-teen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$14.6</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rylaze</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Low single digit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$13.7</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$409.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filspari</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Travere</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nephropathy</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$12.2</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$135.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acrotech/CASI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$8.7</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$44.8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Teriparatide</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alvogen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25%-40% </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">2</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$8.2</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$30.2</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infectious Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Low single digit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$5.2</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$791.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pneumosil</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Serum Institute</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infectious Disease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Low single digit</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$3.8</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$161.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nexterone</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Baxter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Low single digit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2.8</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$70.1</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ohtuvayre </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">3</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Verona</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Respiratory Disease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2.7</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$41.6</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capvaxive</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infectious Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Low single digit</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.6</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$95.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tzield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metabolic Disease</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less than 1%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.2</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$58.0</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 Other Products</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$8.5</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="6" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Royalty Receipts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$119.6</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Amortization of Financial Royalty Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">4</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$10.8</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="9" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP Income from Royalty Assets</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$108.8</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">NOTES:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Based on our agreement with Recordati, sales of Qarziba are undisclosed.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) We receive tiered profit sharing of 25% on quarterly profits less than $3.75 million, 35% on quarterly profits greater than $3.75 million but less than $7.5 million and 40% on quarterly profits greater than $7.5 million. If therapeutic equivalence is achieved, quarterly profit changes to 50% of quarterly profits.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Ohtuvayre royalty receipts include an allocation of contractually earned milestones and royalties pertaining to financial royalty assets.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Amounts represent the adjustments to the effective interest income recognized to total contractual payments recognized in the period. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Commercial-Stage Royalty Receipt Generating Assets</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following programs represent important revenue-generating components of our current portfolio. For information about the royalties owed to us for certain of these programs, see &#8220;Royalties&#8221; later in this business section.</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kyprolis (Amgen, Ono, BeiGene)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We supply Captisol to Amgen for use with Kyprolis (carfilzomib) and granted Amgen an exclusive product-specific license under our patent rights with respect to Captisol. Kyprolis is formulated with Ligand&#8217;s Captisol technology and is approved for the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In combination with dexamethasone, lenalidomide plus dexamethasone, daratumumab plus dexamethasone, or daratumumab and hyaluronidase-fihj and dexamethasone, or isatuximab and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our agreement with Amgen may be terminated by either party in the event of material breach or bankruptcy, or unilaterally by Amgen with prior written notice, subject to certain surviving obligations. Absent early termination, the agreement will terminate upon expiration of the obligation to pay royalties. Under this agreement, we are entitled to receive revenue from clinical and commercial Captisol material sales and a 1.5% to 3.0% royalty on annual net sales of Kyprolis. Amgen&#8217;s obligation to pay royalties does not expire until four years after the expiration of the last-to-expire patent covering Captisol. Our patents and applications relating to the Captisol component of Kyprolis are not expected to expire until 2033.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qarziba (Recordati)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalties on Qarziba (dinutuximab beta) sales through our acquisition of Apeiron, announced in July 2024. Qarziba is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells. Dinutuximab beta was approved by the European Medicines Agency in 2017 for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qarziba is commercially available in more than 35 countries. We receive a tiered mid-teen royalty on worldwide sales of Qarziba from Recordati and are entitled to receive over $25 million in potential milestone payments. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (3), Acquisitions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Filspari (Travere, CSL Vifor, Renalys) </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2012, we licensed the world-wide rights to Filspari (sparsentan) to Travere Therapeutics. In September 2024, Travere received full </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval from the FDA for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filspari</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was previously under accelerated approval, for the treatment of immunoglobulin A nephropathy (IgAN). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filspari</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the first and only dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and is the first non-immunosuppressive treatment indicated for IgAN. In February 2024, Travere and its partner CSL Vifor received approval for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filspari</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of IgAN in Europe. Additionally, Travere has partnered with Renalys Pharma to develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filspari</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Japan and other Asian countries. Renalys completed enrollment in its registrational Phase III clinical trial of sparsentan for IgAN in January 2025.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2025, Travere announced completion of its Type C meeting with the FDA and plans to submit a supplemental New Drug Application (sNDA) seeking traditional approval of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filspari</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for focal segmental glomerulosclerosis (FSGS). The sNDA will be based on existing data from the Phase 3 DUPLEX and Phase 2 DUET studies of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filspari</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and is expected to be submitted around the end of the first quarter of 2025.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our lic</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ense agreement with Travere, we are entitled to receive potential milestone payments, as well as a 9% royalty on worldwide sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ohtuvayre (Verona, Nuance)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired a royalty on Verona's Ohtuvayre (ensifentrine) through our acquisition of Vernalis in 2018 and acquired additional rights from Ohtuvayre inventors during the course of 2024 continuing through January 2025, bringing our royalty rate to 3% of global net sales. Ohtuvayre is a first-in-class selective dual inhibitor of the enzymes phosphodiesterase 3 and phosphodiesterase 4 (&#8220;PDE3 and PDE4&#8221;) that combines bronchodilator and non-steroidal anti-inflammatory effects in one molecule. Ohtuvayre is delivered directly to the lungs through a standard jet nebulizer without the need for high inspiratory flow rates or complex hand-breath coordination. Ohtuvayre was approved by the FDA in June 2024 for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") in adult patients. Ohtuvayre is the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in adult patients in more than 20 years. Verona sublicensed the right to develop and commercialize Ohtuvayre in Hong Kong, Macau, Taiwan, and mainland China to Nuance Pharma.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Verona is currently conducting Phase 2 trials for indication expansion in non-cystic fibrosis bronchiectasis, as well as a fixed-dose combination of ensifentrine + Long-Acting Muscarinic Antagonist (LAMA) for maintenance treatment of COPD. In </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 2024, Nuance Pharma (private), completed enrollment in its pivotal Phase 3 clinical trial evaluating Ohtuvayre for the maintenance treatment of COPD in China. Results from the trial are expected in 2025.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rylaze (Jazz Pharmaceuticals)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, Jazz announced the U.S. launch of Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), previously referred to as JZP458. Rylaze, which was approved by the FDA in June 2021, is a recombinant erwinia asparaginase used as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients one month or older who have developed hypersensitivity to E. coli-derived asparaginase. In September 2023, Jazz announced that the European Commission (EC) had granted marketing authorization for Rylaze, to be marketed as Enrylaze. Jazz began a rolling launch in the second half of 2023.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are eligible to receive tiered low-single digit royalties based on worldwide net sales of Rylaze, Enrylaze and any products resulting from this collaboration.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vaxneuvance (Merck)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vaxneuvance, a 15-valent pneumococcal conjugate vaccine, also known as V114, was approved in the U.S. in July of 2021 for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in adults 18 years of age and older, and subsequently in children 6 weeks through 17 years of age in June of 2022. Vaxneuvance was also approved in Europe in October 2022 for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years and older and in infants, children and adolescents from 6 weeks to less than 18 years of age. Vaxneuvance utilizes CRM197 vaccine carrier protein, which is produced using the patent-protected Pelican Expression Technology platform, which we acquired in October 2020 through our acquisition of Pfenex. We are entitled to low single digit royalties derived from net sales of Vaxneuvance. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capvaxive (Merck)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capvaxive, a 21 valent pneumococcal vaccine, also known as V116, was approved by the FDA in June 2024 for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in adults 18 years of age and older. Capvaxive is the first pneumococcal conjugate vaccine specifically designed for adults, and its 21 covered serotypes account for approximately 85% of cases of invasive pneumococcal disease among individuals 50 and over, including 8 serotypes not covered by any currently approved vaccines. Following the FDA approval, the US Centers for Disease Control and Prevention&#8217;s Advisory Committee on Immunization Practices (&#8220;ACIP&#8221;) voted to update the adult age-based pneumococcal vaccination guidelines to recommend Capvaxive for pneumococcal vaccination in adults 50 years of age and older. Additionally, ACIP issued a shared clinical decision-making recommendation for a supplemental dose of Capvaxive for adults 65 years of age and older who have completed their vaccine series with both PCV13 (pneumococcal 13-valent conjugate vaccine) and PPSV23 (pneumococcal 23-valent polysaccharide vaccine).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capvaxive utilizes CRM197 vaccine carrier protein, which is produced using the patent-protected Pelican Expression Technology platform, which we acquired in October 2020 through our acquisition of Pfenex. The FDA approval of Capvaxive triggered a $2 million milestone payment to Ligand, and we are entitled to a low single digit royalty on worldwide net sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pneumosil (Serum Institute of India, SII)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SII began commercialization of its 10-valent pneumococcal conjugate vaccine, Pneumosil, which is produced using CRM197 made in the Pelican Expression Technology platform, in the second quarter of 2020. Pneumosil is designed primarily to help fight against pneumococcal pneumonia among children, with an advantage of targeting the most prevalent serotypes of the bacterium causing serious illness in developing countries. Pneumosil achieved WHO Prequalification in December 2019, allowing the product to be procured by United Nations agencies and Gavi, the Vaccine Alliance, and subsequently achieved Indian Marketing Authorization in July 2020, and SII announced commercial launch of the product in India in December 2020. We are entitled to a low-single digit royalty on net product sales of Pneumosil.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Teriparatide Injection Product (PF708) (Alvogen/Adalvo)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired the teriparatide injection product with the acquisition of Pfenex in October 2020. Teriparatide injection is a drug indicated for various uses including the treatment of osteoporosis in certain patients at high risk for fracture. Teriparatide injection was developed using our Pelican Expression Technology and was approved by the FDA in 2019 in accordance with the 505(b)(2) regulatory pathway, with FORTEO as the reference product. Our commercialization partner, Alvogen, launched the product in June 2020 in the United States. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alvogen has exclusively licensed the rights to commercialize and manufacture the teriparatide injection product in the U.S., while Adalvo has the rights to commercialize in the E.U. and other territories outside the U.S.. In accordance with our agreements with Alvogen, we are eligible to receive tiered gross profit sharing of between 25% and 40% of quarterly profits prior </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to an &#8220;A&#8221; therapeutic equivalence designation, which increases to a flat 50% if an &#8220;A&#8221; rating is achieved. In accordance with our agreements with Adalvo, we may be eligible to receive milestones and may also be eligible to receive up to 60% of gross profit derived from product sales and regional license fees, if approved, depending on geography, cost of goods sold and sublicense fees.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evomela (Acrotech and CASI)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We supply Captisol to, and receive royalties from, Acrotech Biopharma for sales of Evomela in the United States, and CASI Pharmaceuticals for sales in China. Evomela is a Captisol-enabled melphalan IV formulation which is approved by the FDA for use in two indications:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a high-dose conditioning treatment prior to autologous stem cell transplantation (&#8220;ASCT&#8221;) in patients with multiple myeloma; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the license agreement, Acrotech Biopharma has marketing rights worldwide excluding China, and CASI Pharmaceuticals has rights to market in China. We are eligible to a 20% royalty on global net sales of the Captisol-enabled melphalan product and revenue from Captisol material sales. Acrotech and CASI&#8217;s obligation to pay royalties will expire at the end of the life of the relevant patents or when a competing product is launched, whichever is earlier, but in no event less than ten years from commercial launch. Our patents and applications relating to the Captisol component of melphalan are not expected to expire until 2033. As described herein, we have entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a generic version of Evomela in the United States in 2026, or earlier under certain circumstances. Absent early termination, the agreement will terminate upon expiration of the obligation to pay royalties. In December 2024, Acrotech issued a termination process letter to CASI alleging the Company materially breached the license agreement and failed to cure such breach, thus terminating the license agreement. CASI can continue to distribute Evomela in China for a reasonable wind down period not to exceed 24 months.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nexterone (Baxter)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a license agreement with Baxter, related to Nexterone, a Captisol-enabled formulation of amiodarone, which is marketed in the United States and Canada. We supply Captisol to Baxter for use in accordance with the terms of a license agreement and a separate supply agreement between us and Baxter. Under the terms of the license agreement, we will continue to earn milestone payments, a low single digit royalty, and revenue from Captisol material sales. We will earn royalties on net sales of Nexterone through early 2033.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tzield (Sanofi)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired a royalty of less than 1% on net sales of Tzield through our acquisition of Tolerance Therapeutics (&#8220;Tolerance&#8221;) in the fourth quarter of 2023. Tzield is the first disease-modifying therapy to be approved in type 1 diabetes (&#8220;T1D&#8221;). It is a CD3-directed antibody indicated to delay the onset of Stage 3 T1D in adults and children aged 8 years and older with Stage 2 T1D. Tzield was granted Breakthrough Therapy Designation in 2019 and was approved by the FDA in November 2022. Tzield is marketed by Sanofi, following its acquisition of Provention Bio, Inc., the developer of Tzield, in 2023 for $2.9 billion. Sanofi also announced data from Tzield&#8217;s PROTECT Phase 3 trial, which showed Tzield&#8217;s potential to slow the progression of Stage 3 T1D in newly diagnosed children and adolescents. Tzield met the study&#8217;s primary endpoint, significantly slowing the decline of C-peptide levels, compared to placebo. Sanofi recently announced they have filed for Tzield's approval in Europe and China, expecting responses in the second half of 2025. Under our agreement with Tolerance, we are entitled to receive royalties through December 1, 2032.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Key Partnered Programs</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a highly diversified partnered pipeline of assets that either have or are nearing regulatory approval that we consider particularly noteworthy given the area of research or value of the license terms. We are eligible to receive milestone payments and royalties on these programs. This list does not include all of our partnered programs. In the case of Captisol-related programs, we are also eligible to receive revenue for the sale of Captisol material supply. The following table represents development-stage assets with disclosed royalty rates:</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.672%"><tr><td style="width:1.0%"/><td style="width:28.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.977%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.901%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#333399;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Development stage assets with disclosed royalties</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Program</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Licensee</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0a2299;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty Rate</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bot/Bal</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agenus</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.625%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UGN-301</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UroGen</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.625 - 3.75%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ciforadenant</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corvus</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mid-single digit to low-teen royalty</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DGAT-1</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0% - 7.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FBPase Inhibitor (VK0612)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.5% - 9.5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lasofoxifene</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sermonix</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0% - 10.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MB07133</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Oral EPO</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5% - 8.5%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pradefovir</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Qtorin rapamycin</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0% - 9.8%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SARM (VK5211)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.25% - 9.25%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TR Beta (VK2809 and VK0214)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5% - 7.5%</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Veklury (Gilead)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We supply Captisol to Gilead for sales of Veklury (remdesivir). Gilead received marketing approval from the FDA in October 2020. Veklury is an antiviral treatment for COVID-19. The product has regulatory approvals for the treatment of moderate or severe COVID-19 in over 70 countries. We are supplying Captisol to Gilead under a 10-year supply agreement. We are also supplying Captisol to Gilead&#8217;s voluntary licensing generic partners who are manufacturing remdesivir for 127 low- and middle-income countries. We receive our commercial compensation for this program through the sale of Captisol.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Botensilimab and Balstilimab (BOT/BAL) (Agenus)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, we entered into the Agenus Agreement to support BOT/BAL clinical development, confirmatory Phase 3 trial, and launch readiness activities. Botensilimab is an investigational multifunctional anti-CTLA-4 immune activator (antibody) designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to &#8220;cold&#8221; tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses. Over 900 patients have been treated with botensilimab in Phase 1 and Phase 2 clinical trials. Botensilimab alone, or in combination with Agenus&#8217; investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. Ligand is entitled to a 2.625% synthetic royalty on future global net sales generated by BOT/BAL pursuant to the Agenus Agreement. This rate may be adjusted depending on future events. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UGN-301</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, under the terms of the Agenus Agreement, we are eligible for a tiered royalty of 2.625% to 3.75% on future net sales and 31.875% of the future milestone payments made by UroGen to Agenus related to UGN-301. The royalties and milestone payments owed to us could be adjusted up or down based upon predetermined future events and achievements of certain milestones. UGN-301 is an anti-CTLA-4 monoclonal antibody (zalifrelimab), prepared with reverse-thermal hydrogel for intravesical administration into the bladder. Intravesical administration of UGN-301 is designed to increase drug concentrations in the bladder without significant systemic exposure, potentially diminishing the systemic toxicity associated with CTLA-4 blockade. UroGen is evaluating UGN-301 as a monotherapy and as combination therapy for the intravesical treatment of high-grade non-muscle invasive bladder cancer.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TR-Beta - VK2809 and VK0214 (Viking) </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Viking, is developing VK2809, a novel selective thyroid hormone receptor beta (TR-beta) agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia and non-alcoholic steatohepatitis (NASH; also referred to as metabolic dysfunction associated steatohepatitis, MASH). Viking completed a Phase 2b clinical trial (the VOYAGE study) in patients with biopsy-confirmed NASH. At the 52-week mark, the drug reduced liver fat content by an average of 37% to 55% compared to baseline, with all treatment arms showing statistically significant improvements compared to placebo.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">VK0214, another novel, orally available, TR-beta agonist, is in development for the potential treatment of X-linked adrenoleukodystrophy (&#8220;X-ALD&#8221;). VK0214 has been evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (&#8220;AMN&#8221;) form of X-ALD. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement with Viking, we may be entitled to up to $375 million of development, regulatory and commercial milestones and a tiered royalty of 3.5% to 7.5% on potential future net sales of VK-2809 and VK-0214. Our TR-beta programs partnered with Viking are subject to CVR sharing, and a portion of the cash received will be paid out to CVR holders.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ciforadenant &#8211; CPI-444 (Corvus)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partner, Corvus, is conducting a Phase 1b/2 clinical trial evaluating ciforadenant as a potential first line therapy for metastatic renal cell cancer (RCC) in combination with ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1). The Phase 1b/2 study is being conducted by the Kidney Cancer Research Consortium (KCRC) and is led by The University of Texas MD Anderson Cancer Center. Under the terms of our agreement with Corvus, we are entitled to development and regulatory milestones and tiered royalties on potential future sales. Under the terms of our agreement with Corvus, we are entitled to milestones and tiered royalties ranging from mid-single digit to low-teens on potential future net sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qtorin rapamycin (Palvella)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired economic rights to Qtorin&#8482; 3.9% rapamycin anhydrous gel (Qtorin rapamycin, formerly PTX-022) from Palvella in December 2018. Qtorin rapamycin is a novel, topical formulation of high-strength rapamycin currently in development for the treatment of Microcystic Lymphatic Malformations (&#8220;Microcystic LM&#8221;) and cutaneous venous malformations (&#8220;VMs&#8221;). The FDA has granted Breakthrough Therapy Designation, Fast Track Designation, and Orphan Designation to Qtorin rapamycin for the treatment of Microcystic LM. Microcystic LM is a chronically debilitating and lifelong genetic disease affecting an estimated more than 30,000 patients in the U.S. There are currently no FDA-approved treatments for Microcystic LM. Palvella is currently conducting a Phase 3 trial evaluating Qtorin rapamycin for the treatment of Microcystic LM and a Phase 2 trial evaluating Qtorin rapamycin for the treatment of cutaneous VMs. Under the terms of our agreement with Palvella, we are entitled to milestones and a tiered royalty of 8.0% to 9.8%. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lasofoxifene (Sermonix) </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our partner, Sermonix has a license for the development of oral lasofoxifene, its lead investigational drug, for the United States and additional territories. Lasofoxifene is a selective estrogen receptor modulator in development for the treatment of breast cancer, discovered through the research collaboration between Pfizer and Ligand. Sermonix is currently conducting the Phase 3 ELAINE-3 clinical trial to assess the efficacy of lasofoxifene in combination with Eli Lilly and Company&#8217;s CDK4/6 inhibitor abemaciclib (Verzenio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) compared to fulvestrant and abemaciclib in pre- and post-menopausal subjects with locally advanced or metastatic ER+/HER2- breast cancer with an ESR1 mutation. In January 2024, Sermonix entered into a strategic collaboration and exclusive license agreement with Henlius for the rights to develop, manufacture and commercialize lasofoxifene in China. Henlius is currently conducting a Phase 3 ELAINE-3 multi-regional clinical trial in China.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our agreement with Sermonix, we are entitled to receive potential regulatory and commercial milestone payments, as well as a tiered royalty of 6% to 10% on potential future net sales. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Xinshumu (pradefovir) (Xi'an Xintong)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xi'an Xintong received marketing approval from the Chinese National Medical Products Administration (NMPA) for Xinshumu (pradefovir mesylate tablets) in October 2024. Xinshumu is the first liver-targeted, novel Hepatitis B drug developed based on the HepDirect&#8482; liver-targeting prodrug technology that utilizes a chemically modified prodrug of the active compound which is stable in blood and intestines and is activated by a liver specific CYP subtype enzyme to achieve high liver concentration of the active drug and low systemic exposure, reducing side effects in other organs for improved safety. Under the terms of our agreement with Xi'an Xintong, we are entitled to an annual licensing maintenance fee, milestones and a 9% royalty on potential future sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MB07133 (Xi'an Xintong)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Xi'an Xintong is also developing MB07133, a liver specific, HepDirect prodrug of cytarabine monophosphate, for the potential treatment of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. MB07133 is currently in Phase 2 in China. We are entitled to an annual licensing maintenance fee and a 6% royalty on potential future sales.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Full Portfolio Details</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assembled one of the largest portfolios of biopharmaceutical assets in the industry which provides investors the opportunity to participate in the biotech industry while mitigating the industry&#8217;s usual inherent clinical binary risks. Our portfolio consists of assets which currently generate revenue through royalties on commercial products, as well as Captisol sales on commercial products. In addition to these assets, we have a substantial pipeline of development stage assets that currently generate contractual payments through milestone and license fees with future potential for royalties and Captisol material sales for those programs under our Captisol technology.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.816%"><tr><td style="width:1.0%"/><td style="width:36.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.325%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approved</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Partner Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Therapeutic Area</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acrotech/CASI</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alvogen/Adalvo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Teriparatide</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Women's Health</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alvogen/Hikma/Nanjing King-Friend</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Voriconazole</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amgen/Beigene/Ono</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Baxter</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nexterone</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardiovascular</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eisai</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fycompa</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Elutia</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ECM portfolio</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Medical device/Cardiology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exelixis/Daiichi-Sankyo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Minnebro</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardiovascular</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gilead</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Veklury</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ingenus</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxotere</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rylaze</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Melinta</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Baxdela</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Menarini</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Frovatriptan</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fareva</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noxafil-IV</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capvaxive</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pelthos</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZELSUVMI</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Novartis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mekinist</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outlook Therapeutics</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lytenava</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ophthalmology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Posaconazole</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Duavee</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pfizer</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vfend-IV</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Recordati</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Qarziba</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sage</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Zulresso</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sanofi</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tzield</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Metabolic </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sedor/Lupin</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sesquient</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Serum Institute of India</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pneumosil</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Serum Institute of India</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Men5</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Travere</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filspari</span></div></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Verona</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ohtuvayre</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Respiratory Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pradefovir</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase 3/Pivotal or Regulatory Submission Stage</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Partner Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Therapeutic Area</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aldeyra</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reproxalap</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BendaRx</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bendamustine</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marinus</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ganaxalone IV</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ohara Pharmaceuticals</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">JPH203</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Opthea</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OPT-302</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ophthalmology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outlook Therapeutics</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ONS-5010</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Palvella</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Qtorin rapamycin</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other/Undisclosed</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sermonix</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lasofoxifene</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SQ Innovation</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CE-Furosemide</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cardiovascular Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sunshine Lake</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vilazodone</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.816%"><tr><td style="width:1.0%"/><td style="width:36.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.324%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.325%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase 2</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Partner Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Therapeutic Area</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Agenus</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Bot/Bal</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Anebulo</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ANEB-001</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corvus</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ciforadenant</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CurX</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CE-Topiramate</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Phoenix Tissue</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PTR-01</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genetic Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sato</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SB206 (Japan)</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Verona</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ensifentrine (nebulizer)</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-Cystic Fibrosis Bronchiectasis</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Verona</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ensifentrine + LAMA (Nebulizer)</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">COPD</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VK5211</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VK2809</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inflammatory/Metabolic</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Xi'an Xintong</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MB07133</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Phase 1</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Partner Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Therapeutic Area</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Arcellx</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ACLX-001</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Arcellx</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ACLX-002</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Beloteca</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CE-Ziprasidone</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">China Resources Double Crane</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CX2101A</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">COVID 19</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">InvIOs</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">APN401</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jazz</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">JZP-341</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long Acting Erwinia Asparaginase</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Jupiter Biomedical Research</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Viright</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Merck</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">V117</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pneumococcal</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nucorion</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NUC-1010</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UroGen</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">UGN-301</span></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vaxxas</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nanopatch</span></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Infectious Disease</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Viking</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VK-0214</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genetic Disease</span></td></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of selected programs available for license</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to ZELSUVMI, discussed above, we have a number of unpartnered programs focused on a wide-range of potential indications or diseases with the potential for further development or licensing:</span></div><div style="margin-bottom:6pt;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.390%"><tr><td style="width:1.0%"/><td style="width:41.515%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.361%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Program</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Development Stage</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Targeted Indication or Disease</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CE-Iohexol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diagnostics</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Luminespib/Hsp90 Inhibitor</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CE-Sertraline, Oral Concentrate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depression</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CCR1 Antagonist</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CE-Busulfan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CE-Cetirizine Injection</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allergy</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CE-Silymarin for Topical formulation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sun damage</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FLT3 Kinase Inhibitors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Oncology</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GCSF Receptor Agonist</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preclinical</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Blood disorders</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contract with a third-party manufacturer, Hovione, for Captisol production. Hovione operates FDA-inspected sites in the United States, Macau, Ireland and Portugal. Manufacturing operations for Captisol are performed primarily at Hovione's Portugal and Ireland facilities. We believe we maintain adequate inventory of Captisol to meet our current partner needs and that our Captisol capacity will be sufficient to meet future partner needs.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of a Captisol supply interruption, we are permitted to designate and, with Hovione&#8217;s assistance, qualify one or more alternate suppliers. If the supply interruption continues beyond a designated period, we may terminate our agreement with Hovione. In addition, if Hovione cannot supply our requirements of Captisol due to an uncured force majeure event, we may also obtain Captisol from a third party and have previously identified such parties.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The original term of the agreement was through December 2024 and has been automatically renewed through December 2026. The agreement automatically renews for successive two-year renewal terms. Either party can give written notice of its intention to terminate the agreement no less than two years prior to the expiration of renewal term. In addition, either party may terminate the agreement for the uncured material breach or bankruptcy of the other party or an extended force majeure event. We may terminate the agreement for extended supply interruption, regulatory action related to Captisol or other specified events. We have ongoing minimum purchase commitments under our agreement with Hovione.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the drugs we and our licensees and partners are developing may compete with existing therapies or other drugs in development by other companies. Furthermore, academic institutions, government agencies and other public and private organizations conducting research may seek patent protection with respect to potentially competing products or technologies and may establish collaborative arrangements with our competitors.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Captisol business may face competition from other suppliers of similar cyclodextrin excipients or other technologies that are aimed to increase solubility or stability of APIs. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitive position also depends upon our ability to obtain patent protection or otherwise develop proprietary products or processes. For a discussion of the risks associated with competition, see below under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Item 1A. Risk Factors.&#8221;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate and Governance Highlights</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to policies and practices focused on environmental sustainability, positively impacting our social community and maintaining and cultivating good corporate governance. By focusing on such ESG policies and practices, we believe we can affect a meaningful and positive change in our community and maintain our open, collaborative corporate culture. We will continue our proactive shareholder and employee engagement in 2025. See www.ligand.com for information about our ESG policies and practices. However, note that the information contained on our website is not intended to be part of this filing.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental, Health and Safety (&#8220;EHS&#8221;)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to providing a safe and healthy workplace, promoting environmental excellence in our communities, and complying with all relevant regulations and industry standards. We establish and monitor programs to reduce pollution, prevent injuries, and maintain compliance with applicable regulations. By focusing on such practices, we believe we can affect a meaningful, positive change in our community and maintain a healthy and safe environment. In early 2025, we completed our $2.6 million solar investment at Kansas University Innovation Park; made Environmental, Social and Governance (&#8220;ESG&#8221;) related charitable donations; and evolved numerous programs from our ESG-focused outreach committees. We expect to continue our effort and to refine our EHS policies and practices in 2025. More information on our EHS policies and initiatives is available on our website at www.ligand.com. However, note that the information contained on our website is not intended to be part of this filing.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research and development, manufacturing and marketing of pharmaceutical products are subject to regulation by numerous governmental authorities in the United States and other countries. We and our partners, depending on specific activities performed, are subject to these regulations. In the United States, pharmaceuticals are subject to regulation by both federal and various state authorities, including the FDA. In the U.S., the Federal Food, Drug and Cosmetic Act and the Public Health Service Act govern the research and development, testing, manufacture, quality, safety, efficacy, labeling, storage, record keeping, approval, advertising and promotion of pharmaceutical products. These activities are subject to additional regulations that apply at the state level. There are similar regulations in other countries as well. For both currently marketed products and products in development, failure to comply with applicable regulatory requirements at any time during the product development process, approval process or after approval, can, among other things, result in delays, the suspension of regulatory approvals, regulatory enforcement actions, as well as possible civil and criminal sanctions. In addition, changes in existing regulations could have a material adverse effect on us or our partners. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, FDA approval is required before a drug or biological product may be marketed in the United States, and these products are also subject to other federal, state, and local statutes and regulations. The process required by the FDA before pharmaceutical products may be marketed in the United States generally involves the following:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of extensive preclinical laboratory tests and preclinical animal studies, certain of which must be performed in accordance with Good Laboratory Practice regulations and other applicable requirements;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an IND application, which must become effective before human clinical studies may begin;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an independent institutional review board or ethics committee at each clinical site before each clinical study may be initiated;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical studies in accordance with Good Clinical Practice (&#8220;GCP&#8221;) requirements to establish the safety and efficacy, or with respect to biologics, the safety, purity and potency of the product candidate for each proposed indication;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparation of and submission to the FDA of an NDA or BLA after completion of all pivotal clinical studies that include substantial evidence of safety, purity, and potency of the drug from analytical studies and from results of nonclinical testing and clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA advisory committee review, where appropriate and if applicable;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination by the FDA within 60 days of its receipt of an NDA or BLA to file the application for review;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the proposed product is produced to assess compliance with cGMP, and potential FDA inspection of nonclinical study and clinical trial sites that generated the data in support of the NDA or BLA to ensure compliance with GCP; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of an NDA or BLA prior to any commercial marketing or sale of the drug in the United States.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. There also are continuing user fee requirements, under which the FDA assesses an annual program fee for each product identified in an approved NDA or BLA. Drug and biologic manufacturers and their subcontractors are required to register their establishments with the FDA and some state agencies, and are subject to periodic unannounced inspections by the FDA and some state agencies for compliance with cGMPs, which among other things, impose certain procedural and documentation requirements upon BLA or NDA holders and any third-party manufacturers. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting requirements upon manufacturers and their subcontractors. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMPs and other aspects of regulatory compliance.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA closely regulates the marketing, labeling, advertising and promotion of drug products and biologics. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences for non-compliance include, among other things:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on post-approval clinical studies;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal of the FDA to permit the import or export of products;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandated modification of promotional materials and labeling and the issuance of corrective information;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of the risks associated with government regulations, see below under &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors.&#8221;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents and Proprietary Rights</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that patents and other proprietary rights are important to our business. Our policy is to file patent applications to protect technology, inventions and improvements to our inventions that are considered important to the development of our business. We also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to develop and maintain our competitive position.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents are issued or pending for the following key products or product families. The scope and type of patent protection provided by each patent family is defined by the claims in the various patents. Patent terms may vary by jurisdiction and depend on a number of factors including potential patent term adjustments, patent term extensions, and terminal disclaimers. For each product or product family, the patents and/or applications referred to are in force in at least the United States, and for most products and product families, the patents and/or applications are also in force in European jurisdictions, Japan and other jurisdictions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Captisol </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents and pending patent applications covering Captisol and methods of making Captisol are owned by us. The patents covering the Captisol product with the latest expiration date is expected to be in 2033 (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">see, e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., U.S. Patent No. 9,493,582 (expires Feb. 27, 2033)). Other patent applications covering methods of making Captisol, if issued, potentially have terms to 2041. We also own several patents and pending patent applications covering drug products containing Captisol as a component. Globally, we own over 400 issued patents covering all of the foregoing Captisol compositions, methods and related technology. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ten Captisol patents in several families are listed in the Orange Book in connection with one or more prescription drugs currently on the market. These Captisol-enabled drugs include Nexterone (Baxter), Kyprolis (Amgen), Noxafil (Merck), Evomela (Acrotech/CASI), Baxdela (Melinta) and Zulresso (Sage). These patents are listed in the table below, and each patent family containing these patents has pending and/or granted counterparts in Europe, China and Japan.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.275%"><tr><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:61.180%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Orange Book-listed Captisol Patents</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Country</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Patent No.</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Title</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:112%">Expiration (nominal)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:112%;position:relative;top:-3.15pt;vertical-align:baseline"> &#8225;</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">7635773</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Sulfoalkyl Ether Cyclodextrin Compositions</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">03/13/2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">8410077</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Sulfoalkyl Ether Cyclodextrin Compositions</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">03/13/2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">9200088</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Sulfoalkyl Ether Cyclodextrin Compositions</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">03/13/2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10117951</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Sulfoalkyl Ether Cyclodextrin Compositions</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">03/13/2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">9750822</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Sulfoalkyl Ether Cyclodextrin Compositions</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">03/13/2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">9493582</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Alkylated Cyclodextrin Compositions And Processes For Preparing And Using The Same</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">2/27/2033</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10040872</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Alkylated Cyclodextrin Compositions And Processes For Preparing And Using The Same</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10/21/2033</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10864183</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Injectable Nitrogen Mustard Compositions Comprising A Cyclodextrin Derivative And Methods Of Making And Using The Same</span></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">5/28/2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">10940128</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Injectable Melphalan Compositions Comprising A Cyclodextrin Derivative And Methods Of Making And Using The Same</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">5/28/2030</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">United States</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">11020363</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Injectable Nitrogen Mustard Compositions Comprising A Cyclodextrin Derivative And Methods Of Making And Using The Same</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">5/28/2030</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#8225;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Expiration dates are calculated as 20 years from the earliest nonprovisional filing date to which priority is claimed, and do not take into account disclaimers or extensions that are or may be available in these jurisdictions.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to compliance with the terms of the respective agreements, our rights to receive royalty payments under our licenses with our exclusive licensors typically extend for the life of the patents covering such developments. For a discussion of the risks associated with patent and proprietary rights, see below under </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Item 1A. Risk Factors.&#8221;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kyprolis </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents protecting Kyprolis include those owned by Amgen and those owned by us. The United States patent listed in the Orange Book relating to Kyprolis owned by Amgen with the latest expiration date is not expected to expire until 2029. Patents and applications owned by Ligand relating to the Captisol component of Kyprolis are not expected to expire until 2033. Amgen </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filed suit against several generic drug companies over their applications to make generic versions of Kyprolis. Several generics have settled with Amgen on confidential terms. However, it has been publicly reported that the U.S. launch date for at least Breckenridge Pharmaceuticals&#8217; generic product will be on a date that is held as confidential in 2027 or sooner, depending on certain occurrences. One generic company, Cipla Limited/Cipla USA, Inc. chose not to settle the litigation with Amgen, and proceeded to trial. The District Court upheld the validity of patent claims from three of the patents and the judgment was upheld on appeal.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ligand UK Development Limited</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of our sale of Vernalis (R&amp;D) Limited to HitGen in December 2020, Ligand retained a portfolio of fully-funded shots on goal, which now include S65487, a Bcl-2 inhibitor, and S64315, an Mcl-1 inhibitor for treatment of cancers, both of which are partnered with Servier in collaboration with Novartis. These programs and their IP are now owned by Ligand UK Development Limited, which has a worldwide patent portfolio of approximately 100 granted patents in over 40 countries. This patent portfolio is mature, with expected expiry dates up to 2033.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pelican Expression Technology Platform</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the merger of Pelican and Primrose, Pfenex assigned a global patent portfolio consisting of over 200 patents and over 25 pending patent applications to Pelican, while retaining four patents and five pending patent applications directed to methods of producing Erwinia asparaginase. Additionally, as part of the merger of Pelican and Primrose, Pfenex acquired a non-exclusive, worldwide, royalty-free, irrevocable, and fully sublicensable license to a portfolio of approximately 90 patents and approximately 15 pending patent applications which cover various aspects of the Pelican Expression Technology platform that are critical in helping support and retain contractual relationships including Jazz&#8217;s Rylaze, Merck&#8217;s Vaxneuvance and Capvaxive vaccines, Alvogen&#8217;s Teriparatide, and Serum Institute of India&#8217;s vaccine programs, including Pneumosil and MenFive vaccines, among others. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novan</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the Novan acquisition described above, we acquired a robust IP portfolio that consists of over 45 U.S. patents, 120 non-U.S. patents, and 25 pending patent applications worldwide along with substantial know-how and trade secrets. This IP portfolio provides material coverage for our platform technologies, licensed products and product candidates, in addition to ZELSUVMI, which was approved by the FDA on January 5, 2024. There are 14 issued U.S. patents covering ZELSUVMI which are listed in the Orange Book and which are expected to expire during the time period beginning in 2026 and ending in 2035. Upon the initial approval of ZELSUVMI, we applied for 1,280 days of patent term extension, or PTE, for the U.S. patent covering ZELSUVMI compositions. Assuming grant of the PTE application, the term of this patent may be extended from February 27, 2034, to August 30, 2037. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Apeiron</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Apeiron in July 2024, we acquired a mature IP portfolio comprising of more than 300 patents worldwide. This IP portfolio supports a number of licensed products and product candidates, and comprises over 60 patents related to Qarziba with expected expiry dates between 2032 and 2034. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize and take care of our employees by offering a wide range of competitive pay, recognition, and benefit programs. We are proud to provide our employees the opportunity to grow and advance as we invest in their education and career development. As of December&#160;31, 2024, we have 68 full-time employees, of whom 24 are involved directly in scientific research and development activities. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on skilled, experienced, and innovative employees to conduct the operations of the Company. Our key human capital objectives include identifying, recruiting, retaining, incentivizing and integrating our existing and new employees. We frequently benchmark our compensation practices and benefits programs against those of comparable industries and in the geographic areas where our facilities are located. We believe that our compensation and employee benefits are competitive and allow us to attract and retain skilled labor throughout our organization. Our notable health, welfare and retirement benefits include:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">equity awards through our 2002 Stock Incentive Plan;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">subsidized health insurance;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">401(k) Plan with matching contributions;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tuition assistance program; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">paid time off.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value diversity at all levels and continue to focus on extending our diversity and inclusion initiatives across our workforce. As of December 31, 2024, approximately 18% and 9% of our workforce are Asian and Hispanic, respectively. Additionally, 48% of our workforce is female and 52% is male. We believe that our business benefits from the different perspectives a diverse workforce brings.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to maintain an inclusive environment free from discrimination of any kind, including sexual or other discriminatory harassment. Our employees have multiple avenues available through which inappropriate behavior can be reported, including a confidential hotline. All reports of inappropriate behavior are promptly investigated with appropriate action taken to stop such behavior.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Information</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial and other information about us is available on our website at www.ligand.com. We make available on our website, without charge, copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. You may obtain copies of these documents by visiting the SEC&#8217;s website at www.sec.gov. In addition, we use X (@Ligand_LGND) and our investor relations website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Investors should monitor our X account and our website, in addition to following our press releases, SEC filings, public conference calls and webcasts. These website addresses and the information accessible through our X account are not intended to function as hyperlinks, and the information contained in our website and in the SEC&#8217;s website is not intended to be a part of this filing. </span></div><div style="text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="ifca968692f35492e968bd282f4512e0b_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.024%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ITEM&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RISK FACTORS</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following is a summary description of some of the many risks we face in our business. You should carefully review these risks in evaluating our business and making an investment decision with respect to our securities, including the businesses of our subsidiaries. You should also consider the other information described in this report, including the information contained in our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; Additional risks not presently known to us or that we currently deem immaterial also may impair our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Summary of Risks Related to our Business:</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks and uncertainties, including those described below. The principal risks and uncertainties affecting our business include, but are not limited to, the following:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our business operations and reliance on third parties, including</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to collect future revenue, including from sales of products from our collaboration partners, Captisol material sales and licensing relationships, and other collaboration relationships, is not guaranteed;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to source Captisol from our sole supplier may be impacted by a supply interruption; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The success of our partnered programs could be adversely affected by a change in our collaboration partners&#8217; strategy or focus and/or development or regulatory hurdles, and market acceptance of such programs is not guaranteed; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks related to the biopharmaceutical product market in general, including changes in growth rate, competition resulting from new technologies and developments, and other sales risks; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks related to our ability to receive adequate information about the biopharmaceutical products we acquire and invest in and our underlying assumptions regarding future cash flow and revenue generation from such products; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our collaboration partners may become insolvent.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our intellectual property, including</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third party intellectual property rights may prevent us or our partners from developing our potential products; our and our partners&#8217; intellectual property may not prevent competition; and any intellectual property issues may be expensive and time consuming to resolve;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks related to our ability to obtain and maintain sufficient intellectual property protection for our products, platforms and technology; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks related to the validity, scope and enforceability of our and our collaboration partners&#8217; patents and other intellectual property; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other intellectual property-related risks, including the scope and validity of in-licenses from third parties, claims and disputes regarding patent infringement and other intellectual property rights that may be brought by third parties, changes in relevant patent and other intellectual property law, and the confidentiality of our trade secrets and other proprietary information.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to government regulation and legal proceedings, including</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market acceptance and sales of any approved product will depend significantly on the availability and adequacy of coverage and reimbursement from third-party payors and may be affected by existing and future healthcare reform measures;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory approval of our product candidates can be time-consuming and unpredictable and is not guaranteed; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks related to our and our collaboration partners&#8217; compliance with healthcare, environmental and other applicable laws and regulations. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks related to our strategic transactions, including</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Difficulties from strategic acquisitions and other M&amp;A transactions could adversely affect our stock price, operating results and results of operations; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks we may face if we do not consummate a strategic transaction involving our Pelthos business and continue to operate Pelthos on a go-forward basis.</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other risks and uncertainties affecting our business, including</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes or modifications in financial accounting standards or tax laws may harm our results of operations; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Risks related to our accounting methodologies and tax status; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Other general risks and uncertainties affecting our business. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business Operations and Reliance on Third Parties:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future revenue based on Kyprolis, Qarziba, Filspari, Evomela, Teriparatide and Rylaze, as well as royalties from our other partnered products, may be lower than expected.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our royalty revenue is based on sales of Kyprolis by Amgen, sales of Qarziba by Recordati, sales of Filspari by Travere, sales of Evomela by Acrotech Biopharma, sales of Teriparatide by Alvogen/Adalvo and sales of Rylaze by Jazz. Royalties, including payments from the foregoing partners, are expected to be a substantial portion of our ongoing revenues for the foreseeable future. Any setback that may occur with respect to any of our partners' products, and in particular Kyprolis, could significantly impair our operating results and/or reduce our revenue and the market price of our stock. Setbacks for the products could include problems with shipping, distribution, manufacturing, product safety, marketing, government regulation or reimbursement, licenses and approvals, intellectual property rights, including failure by any of the foregoing partners to enforce their respective intellectual property rights, competition with existing or new products and physician or patient acceptance of the products, as well as higher than expected total rebates, returns, discounts, or unfavorable exchange rates. These products also are or may become subject to generic competition. For example, we entered into a settlement agreement with Teva and Acrotech Biopharma (the holder of the NDA for Evomela) which will allow Teva to market a generic version of Evomela in the United States on June 1, 2026, or earlier under certain circumstances. The entry of generic competition for Evomela may materially and adversely affect the revenue we derive from Evomela sales. Also, Amgen previously settled patent litigation related to Kyprolis on confidential terms with several parties, but it was publicly reported that the U.S. launch date for at least Breckenridge Pharmaceuticals&#8217; applicable generic product will be &#8220;on a date that is held as confidential in 2027 or sooner, depending on certain occurrences.&#8221; </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future revenue from sales of Captisol material to our license partners may be lower than expected.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from sales of Captisol material to our collaboration partners, including Amgen, represent approximately half of our royalty revenues. Any setback that may occur with respect to Captisol could significantly impair our operating results and/or reduce the market price of our stock. Setbacks for Captisol could include problems with shipping, distribution, manufacturing, product safety, marketing, government regulation or reimbursement, licenses and approvals, intellectual property rights, competition with existing or new products and physician or patient acceptance of the products using Captisol. In addition, we may continue to generate no revenue from Captisol sales related to remdesivir due to a number of factors, including alternative treatments for COVID-19 that have been or will be developed by other companies and the decrease in COVID-19 infections, in which case the commercial opportunity could be limited. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If products or product candidates incorporating Captisol material were to cause any unexpected adverse events, the perception of Captisol safety could be seriously harmed. If this were to occur, we may not be able to sell Captisol unless and until we are able to demonstrate that the adverse event was unrelated to Captisol, which we may not be able to do. Further, the FDA could require us to submit additional information for regulatory review or approval, including data from extensive safety testing or clinical testing of products using Captisol. This would be expensive and it may delay the marketing of Captisol-enabled products and receipt of revenue related to those products, which could significantly impair our operating results and/or reduce the market price of our stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A supply chain interruption may impact our ability to obtain Captisol material. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain Captisol from Hovione, our third party manufacturer, primarily at their facilities in Ireland and Portugal. If Hovione were to cease to be able, for any reason, to supply Captisol to us in the amounts we require, or decline to supply Captisol to us, we would be required to seek an alternative source, which could potentially take a considerable length of time and impact our revenue and customer relationships. In the event of a Captisol supply interruption, we are permitted to designate and, with Hovione&#8217;s assistance, qualify one or more alternate suppliers, although there is no assurance that we could do so timely or at acceptable costs, if at all. In addition to manufacturing at Hovione&#8217;s facilities in Ireland and Portugal, we have processing capacity for Captisol in both the United States and England.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain inventory of Captisol, which has a five-year shelf life, at three geographically dispersed storage locations in the United States and Europe. If we were to encounter problems maintaining our inventory, such as natural disasters, at one or more of these locations, it could lead to supply interruptions. In addition, we rely on Hovione to expand manufacturing capacity </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Captisol and any failure by Hovione to timely implement such increased capacity could adversely affect our ability to supply Captisol to our partners. While we believe we maintain adequate inventory of Captisol to meet our current partner needs, and our Captisol capacity will be sufficient to meet future partner needs, our estimates and projections for Captisol demand may not be correct and any supply interruptions could materially adversely impact our operating results.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future revenue from royalties on Captisol partnered products may be lower than expected.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently depend on our contractual arrangements with our partners and licensees to sell products using our Captisol technology. These agreements generally provide that our partners may terminate the agreements at will. If our partners discontinue sales of products using Captisol, fail to obtain regulatory approval for products using Captisol, fail to satisfy their obligations under their agreements with us, choose to utilize a competing product, or if we are unable to establish new licensing and marketing relationships then revenue from royalties on Captisol partnered products could be decreased and our financial results and growth prospects could be materially affected. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, under most of our Captisol out licenses, the amount of royalties we receive will be reduced or will cease when the relevant patent expires. Our low-chloride patents and foreign equivalents are not expected to expire until 2033, our high purity patents and foreign equivalents are not expected to expire until 2029 and our morphology patents and foreign equivalents are not expected to expire until 2026 in the United States; however, the initially filed patents relating to Captisol expired starting in 2010 in the United States and in 2016 in most countries outside the United States. If our other intellectual property rights are not sufficient to prevent a generic form of Captisol from coming to market, and if in such case our partners choose to terminate their agreements with us, our Captisol revenue may decrease significantly.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely heavily on collaboration relationships to generate milestone and royalty payments and our collaboration partners have significant discretion when deciding whether to pursue any development program, and any failure by our partners to successfully develop a product candidate or a termination or breach of any of the related agreements could reduce our milestone and license fee revenue, and potentially reduce future royalties.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy for developing and commercializing many of our product candidates includes entering into collaboration agreements, outlicenses, and development funding and royalty purchase agreements with corporate and other collaboration partners. These agreements give our collaboration partners significant discretion when deciding whether or not to pursue any development program. Our existing collaborations may not continue or be successful, and we may be unable to enter into future collaboration arrangements to develop and commercialize our unpartnered assets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our collaboration partners may develop products, either alone or with others, that compete with the types of products they are developing with us (or that we are developing on our own). This would result in increased competition for our or our partners' programs. If product candidates are approved for marketing under our collaboration programs, revenues we receive will depend on the manufacturing, marketing and sales efforts of our collaboration partners, who generally retain commercialization rights under the collaboration agreements. Generally, our current collaboration partners also have the right to terminate their collaborations at will or under specified circumstances. If any of our collaboration partners breach (for example, by not making required payments when due, or at all) or terminate their agreements with us or otherwise fail to conduct their collaboration activities successfully, including due to insolvency events, ongoing product development under these agreements will be delayed or terminated. Disputes or litigation may also arise with our collaborators (with us and/or with one or more third parties), including those over ownership rights to intellectual property, know-how or technologies developed with our collaboration partners. Such disputes or litigation could adversely affect our rights to one or more of our product candidates. Any such dispute or litigation could delay, interrupt or terminate the collaboration research, development and commercialization of certain potential products, create uncertainty as to ownership rights of intellectual property, or could result in litigation or arbitration. The occurrence of any of these problems could be time-consuming and expensive and could adversely affect our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our collaboration partners may change their strategy or the focus of their development and commercialization efforts with respect to our partnered programs, and the success of our partnered programs could be adversely affected.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our collaboration partners terminate their collaborations with us or do not commit sufficient resources to the development, manufacture, marketing or distribution of our partnered programs, we could be required to devote additional resources to our partnered programs, seek new collaboration partners or abandon such partnered programs, all of which could reduce our revenues and otherwise have an adverse effect on our business. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, biopharmaceutical development is inherently uncertain and very few therapeutic candidates ultimately progress through clinical development and receive approval for commercialization. If our partners do not receive regulatory approval for a sufficient number of therapeutic candidates originating from our partnerships, we may not be able to sustain our business model. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates, and the product candidates of our partners, face significant development and regulatory hurdles prior to partnering and/or marketing which could delay or prevent licensing, sales-based royalties and/or milestone revenue.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before we or our partners obtain the approvals necessary to sell any of our unpartnered assets or partnered programs, we must show through preclinical studies and human testing that each potential product is safe and effective. We and/or our partners have a number of partnered programs and unpartnered assets moving toward or currently awaiting regulatory action. Failure to show any product's safety and effectiveness could delay or prevent regulatory approval of a product and could, and has in the past, adversely affected our business. The product development and clinical trials process is complex and uncertain. For example, the results of preclinical studies and initial clinical trials may not necessarily predict the results from later large-scale clinical trials. In addition, clinical trials may not demonstrate a product's safety and effectiveness to the satisfaction of the regulatory authorities. A number of companies have suffered significant setbacks in advanced clinical trials or in seeking regulatory approvals, despite promising results in earlier trials. The FDA may also require additional clinical trials after regulatory approvals are received. Such additional trials may be expensive and time-consuming, and failure to successfully conduct those trials could jeopardize continued commercialization of a product.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The speed at which we and our partners complete our scientific studies and clinical trials depends on many factors, including, but not limited to, the ability to obtain adequate supplies of the products to be tested and patient enrollment. Patient enrollment is a function of many factors, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial and other potential drug candidates being studied. Delays in patient enrollment for our or our partners&#8217; trials may result in increased costs and longer development times. In addition, our partners have rights to control product development and clinical programs for products developed under our collaborations. As a result, these partners may conduct these programs more slowly or in a different manner than expected. Moreover, even if clinical trials are completed, we or our partners still may not apply for FDA or foreign regulatory approval in a timely manner, or the FDA or foreign regulatory authority still may not grant approval.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate discovery, early-stage development, and product reformulation programs may require substantial additional capital to complete successfully. Our partners&#8217; development programs may require substantial additional capital to complete successfully, arising from costs to: conduct research, preclinical testing and human studies; establish pilot scale and commercial scale manufacturing processes and facilities; and establish and develop quality control, regulatory, marketing, sales and administrative capabilities to support these programs. While we expect to fund our research and development activities from cash generated from operations to the extent possible, if we are unable to do so, we may need to complete additional equity or debt financings or seek other external means of financing. These financings could depress our stock price. If additional funds are required to support our operations and we are unable to obtain them on terms favorable to us, we may be required to cease or reduce further development or commercialization of our products, to sell some or all of our technology or assets or to merge with another entity.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biopharmaceutical products are subject to sales risks.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biopharmaceutical product sales may be lower than expected due to a number of reasons, including pricing pressures, insufficient demand, product competition, failure of clinical trials, lack of market acceptance, changes in the marketer&#8217;s strategic priorities, obsolescence, lack of acceptance by government healthcare programs or private insurance plans, loss of patent protection, government regulations or other factors, and development-stage product candidates may fail to reach the market. Unexpected side effects, safety or efficacy concerns can arise with respect to a product, leading to product recalls, withdrawals, declining sales or litigation. As a result, payments of our royalties may be reduced or ceased. In addition, these payments may be delayed, causing our near-term financial performance to be weaker than expected which could have an adverse effect on our business.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New products and technologies of other companies may render some or all of our or our potential milestone and royalty providers&#8217; product candidates noncompetitive or obsolete.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry is a highly competitive and rapidly evolving industry. New developments by others may render our potential milestone and royalty providers&#8217; product candidates or technologies obsolete or uncompetitive. Current marketers of products may undertake these development efforts in order to improve their products or to avoid paying our royalty. In addition, as biopharmaceutical companies increasingly devote significant resources to innovate next-generation products and therapies using gene editing and new curative modalities, such as cell and gene therapy, products on which we have a milestone or royalty rights may become obsolete. Positive developments in connection with a potentially competing product may have an adverse impact on our future potential for receiving revenue derived from development milestones and royalties. For example, if another product is perceived to have a competitive advantage, or another product&#8217;s failure is perceived to increase the likelihood that our licensed product will fail, our potential milestone and royalty providers may halt development of product candidates in which we have an interest. Adverse competition, obsolescence or governmental and regulatory action or healthcare policy changes could significantly affect the revenues, including royalty-related revenues, of the products which generate our potential milestones and royalties. Finally, because many of the companies with which we do business also are in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the biotechnology industry, the volatility of that industry can affect us indirectly as well as directly. The same factors that affect us directly also can adversely affect us indirectly by affecting the ability of our partners and others with whom we do business to meet their obligations to us and reduce our ability to realize the value of the consideration provided to us by these other companies in connection with their licensing of our products.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition in acquiring existing &#8220;passive&#8221; royalties and locating suitable passive royalties to acquire.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a limited number of suitable and attractive opportunities to acquire high-quality royalties available in the market. Many potential royalty acquisition targets do not meet our criteria, and for those that do, we may face significant competition for these acquisitions from companies that market the products on which royalties are paid, financial institutions and others. This competition to acquire such royalties may increase. These competitors may be able to access lower cost capital, may be larger than us, may cause the price we pay for such royalty assets to increase, may have relationships that provide them access to opportunities before us, or may be willing to acquire royalties for lower projected returns than we are. Unsuccessful attempts to acquire new royalties because of transactions that do not meet our criteria or because of such competition could result in significant costs to us, could hurt our reputation and divert management and financial resources. Ligand may have to pursue different avenues such as project finance and special situations in order to create and capture royalty value.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Information available to us about the biopharmaceutical products underlying the royalties we purchase and invest in may be limited and, therefore, our ability to analyze each product and its potential future cash flow may be similarly limited.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may have limited information concerning the products generating the royalties we are evaluating for acquisition. At times, the information we have regarding products following our acquisition of a royalty may be limited to the information that is available in the public domain. Therefore, there may be material information that relates to such products that we would like to know but do not have and may not be able to obtain. For example, we do not always know the results of studies conducted by marketers of the products or others or the nature or amount of any complaints from doctors or users of such products. In addition, the market data that we obtain independently may also prove to be incomplete or incorrect. Due to these and other factors, the actual cash flow from a royalty may be significantly lower than our estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A significant portion of our future income is dependent upon numerous royalty-specific assumptions and, if these assumptions prove not to be accurate, we may not achieve our expected rates of returns.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model is based on multiple-year internal and external forecasts regarding product sales and numerous product-specific assumptions in connection with each royalty acquisition, including where we have limited information regarding the product, sales of our products and licenses to our technology. There can be no assurance that the assumptions underlying our financial models, including those regarding product sales or competition, patent expirations, exclusivity terms, license terms or license terminations for the products underlying our portfolio, products and technology, are accurate. These assumptions involve a significant element of subjective judgment and may be adversely affected by post-acquisition changes in market conditions and other factors affecting the underlying product or technology. The risks relating to these assumptions may be exacerbated for development-stage product candidates due to the uncertainties around their development, labeling, regulatory approval, commercialization timing, manufacturing and supply, competing products or related factors. With respect to our partnered programs, our assumptions regarding the financial stability or operational or marketing capabilities of the partner obligated to pay us royalties or license, milestone or other service payments, may also prove, and in the past have proven, to be incorrect. Due to these and other factors, the assets in our current portfolio or future assets, or our current or future products or technology, may not generate expected returns or returns in line with our historical financial performance or in the time periods we expect or at all, which could adversely affect our financial condition and results of operation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The insolvency of any of our partners or third-parties who are developing or commercializing products to which we have economic rights could adversely affect our receipt of cash flows on the related milestones or royalties that we own.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our partners or third-parties who are developing or commercializing products to which we have economic rights were to become insolvent and seek to reorganize under Chapter 11 of Title 11 of the U.S. Code, as amended, or the Bankruptcy Code, or liquidate under Chapter 7 of the Bankruptcy Code (or foreign equivalent), such event could delay or impede the payment of the amounts due to us under any license agreement, royalty purchase agreement or other contract under which we have acquired economic rights, pending a resolution of the insolvency proceeding. Unless we obtained a secured interest, any unpaid royalty payments under our license agreements with our partners and third-parties due for the period prior to the filing of the bankruptcy proceeding could become unsecured claims against such partner or third-party, which might not be paid in full or at all. The actual payment of such post-filing royalty payments could be delayed for a substantial period of time and might not be in the full amount due under such agreements. Given the nature of our royalty purchase agreements, royalty payments due to our partners or third-parties prior to or after a bankruptcy proceeding may not be subject to the insolvency proceeding and may be considered our property, meaning there is a reduced risk of payment delay and/or non-payment. Nevertheless, a partner or third-party or another party with an interest in an insolvency proceeding may attempt to recharacterize the royalty purchase agreement and claim that the royalty payments are property of the bankruptcy estate, in which case we would rely upon contractual protections related to such recharacterizations, which may not be respected in bankruptcy. In addition, certain </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of agreements with our partners or third-parties permit us to take a secured interest in the intellectual property underlying the licenses and royal purchase agreements and/or other collateral, which may improve our risk profile in an insolvency proceeding. However, even if such transactions are collateralized, we may be, or may become, under-secured in that collateral, or such collateral may lose value or may be liquidated at prices not sufficient to recover the full amount we are due pursuant to the terms of the agreements covering the particular assets, and we therefore may not be able to recuperate our capital expenditures associated with such transaction. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases and depending on the terms of the agreement, we are not the licensor and instead are dependent on the licensor to enforce its right to royalties under an agreement with a licensee. In any bankruptcy proceeding, the licensor would be prevented by the automatic stay from taking any action to enforce its rights without the permission of the bankruptcy court. In addition, such partner or third-party could elect to reject the license agreement. Though this would prohibit such partner or third-party from continuing to market the applicable product, it would require the licensor to undertake a new effort to market the applicable product with another distributor. Such proceedings could adversely affect the ability of a partner or other payor to make payments with respect to a royalty, and could consequently adversely affect our business, financial condition or results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial success of our product candidates will depend upon the degree of market acceptance by physicians, patients, third-party payers and others in the medical community.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercial success of our products, if approved for marketing, will depend in part on the medical community, patients and third-party payers accepting our product candidates as effective and safe. If these products do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of our products, if approved for marketing, will depend on a number of factors, including:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety and efficacy of the products, and advantages over alternative treatments;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the labeling of any approved product;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects, including any limitations or warnings contained in a product&#8217;s approved labeling;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence of the disease or condition for which the product is approved;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence, and timing of market introduction, of competitive products;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our and our collaboration partners&#8217; marketing strategy; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining adequate pricing and reimbursement; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sufficient third-party insurance coverage or governmental reimbursement, which may depend on our ability to provide compelling evidence that a product meaningfully improves health outcomes to support such insurance coverage or reimbursement.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a potential product displays a favorable efficacy and safety profile in preclinical studies and clinical trials, market acceptance of the product will not be known until after it is launched. Any failure to achieve market acceptance for our product candidates will harm our business, results and financial condition.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, government agencies, as well as private organizations involved in healthcare, from time to time publish guidelines or recommendations to healthcare providers and patients. Such guidelines or recommendations can be very influential and may adversely affect product usage directly (for example, by recommending a decreased dosage of a product in conjunction with a concomitant therapy) or indirectly (for example, by recommending a competitive product over a product in which we have an ownership or royalty interest). Consequently, we do not know if physicians or patients will adopt or use products in which we have an ownership or royalty interest for their approved indications.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third party intellectual property may prevent us or our partners from developing our potential products; our and our partners&#8217; intellectual property may not prevent competition; and any intellectual property issues may be expensive and time consuming to resolve.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture, use or sale of our potential products or our licensees' products or potential products may infringe the patent rights of others. If others obtain patents with conflicting claims, we may be required to obtain licenses to those patents or to develop or obtain alternative technology. We may not be able to obtain any such licenses on acceptable terms, or at all. Any failure to obtain such licenses could delay or prevent us from pursuing the development or commercialization of our potential products, platform and technology.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, our success will depend on our ability and the ability of our partners to obtain and maintain patents and other intellectual property rights for our and their potential products and technologies. Our patent position is uncertain and involves complex legal and technical questions for which legal principles are unresolved.&#160;Even if we or our partners do obtain patents, such patents may not adequately protect the technology we own or have licensed.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We permit our partners to list our patents that cover their branded products in the Orange Book. If a third party submits a new drug application (&#8220;NDA&#8221;) or abbreviated new drug application (&#8220;ANDA&#8221;) for a generic drug product that relies in whole or in part on studies contained in our partner&#8217;s NDA for their branded product, the third party will have the option to certify to the FDA that, in the opinion of that third party, the patents listed in the Orange Book for our partner&#8217;s branded product are invalid, unenforceable, or will not be infringed by the manufacture, use or sale of the third party&#8217;s generic drug product. A third party certification that a new product will not infringe Orange Book-listed patents, or that such patents are invalid, is called a paragraph IV patent certification. If the third party submits a paragraph IV patent certification to the FDA, a notice of the paragraph IV patent certification must be sent to the NDA owner and the owner of the patents that are subject to the paragraph IV patent certification notice once the third-party&#8217;s NDA or ANDA is accepted for filing by the FDA. A lawsuit may then be initiated to defend the patents identified in the notice. The filing of a patent infringement lawsuit within 45 days of the receipt of notice of a paragraph IV patent certification automatically prevents the FDA from approving the generic NDA or ANDA until the earlier of the expiration of a 30-month period, the expiration of the patents, the entry of a settlement order stating that the patents are invalid or not infringed, a decision in the infringement case that is favorable to the NDA or ANDA applicant, or such shorter or longer period as the court may order. If a patent infringement lawsuit is not initiated within the required 45-day period, the third-party&#8217;s NDA or ANDA will not be subject to the 30-month stay.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several third parties have challenged, and additional third parties may challenge, the patents covering our partner&#8217;s branded products, including Kyprolis and Evomela, which could result in the invalidation or unenforceability of some or all of the relevant patent claims. We may from time to time become party to litigation or other proceedings as a result of Paragraph IV certifications. For example, as a result of the settlement of one such matter, Teva will be permitted to market a generic version of Evomela in the United States on June 1, 2026 or earlier under certain circumstances. The terms of the settlement agreement are otherwise confidential. Also, as noted above, Amgen previously settled patent litigation related to Kyprolis on confidential terms with several parties, but it has been publicly reported that the U.S. launch date for at least Breckenridge Pharmaceuticals&#8217; applicable generic product will be &#8220;on a date that is held as confidential in 2027 or sooner, depending on certain occurrences.&#8221; </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we cannot assure you that all of the potentially relevant prior art information that was or is deemed available to a person of skill in the relevant art prior to the priority date of the claimed invention-relating to our and our partners&#8217; patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent from issuing from a pending patent application, and we or our partners may be subject to a third party pre-issuance submission of prior art to the USPTO. Even if our patent applications do successfully issue and even if such patents cover our or our partner&#8217;s products or potential products, third parties may initiate litigation or opposition, interference, re-examination, post-grant review, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review, nullification or derivation action in court or before patent offices, or similar proceedings challenging the validity, enforceability or scope of such patents, which may result in the patent claims being narrowed or invalidated, may allow third parties to commercialize our or our partners&#8217; products and compete directly with us and our partners, without payment to us or our partners, or limit the duration of the patent protection of our and our partners&#8217; technology and products. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, similar to what other companies in our industry have experienced, we expect our competitors and others may have patents or may in the future obtain patents and claim that making, having made, using, selling, offering to sell or importing our technologies infringes these patents. Defense of infringement and other claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. Parties making claims against us may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources, or may be able to obtain injunctive or other relief, which could block our ability to develop, commercialize and sell products or services and could result in the award of substantial damages against us, including treble damages, attorney&#8217;s fees, costs and expenses if we are found to have willfully infringed. In the event of a successful claim of infringement against us, we may be required to pay damages and ongoing royalties and obtain one or more licenses from third parties, or be prohibited from selling certain products or services. As discussed above, we may not be able to obtain these licenses on acceptable or commercially reasonable terms, if at all, or these licenses may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we could encounter delays in product or service introductions while we attempt to develop alternative products or services to avoid infringing third-party patents or proprietary rights. Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing products or services, and the prohibition of sale of any of our technologies could materially affect our business and our ability to gain market acceptance for our technology.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business, and may result in unfavorable results that could adversely impact our ability to prevent third parties from competing with our partner&#8217;s products </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or technologies. Any adverse outcome of such litigation or other proceedings could result in one or more or our patents being held invalid or unenforceable, which could adversely affect our ability to successfully execute our business strategy and negatively impact our financial condition and results of operations. However, given the unpredictability inherent in litigation, we cannot predict or guarantee the outcome of these matters or any other litigation. Regardless of how these matters are ultimately resolved, these matters may be costly, time-consuming and distracting to our management, which could have a material adverse effect on our business. It may be necessary for us to pursue litigation or adversarial proceedings before the patent office in order to enforce our patent and proprietary rights or to determine the scope, coverage and validity of the proprietary rights of others. The outcome of any such litigation might not be favorable to us, and even if we were to prevail, such litigation could result in substantial costs and diversion of resources and could have a material adverse effect on our business, operating results or financial condition.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and or applications will be due to the U.S. and various foreign patent offices at various points over the lifetime of our and our licensees&#8217; patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside patent annuity service to pay these fees when due. Additionally, the U.S. and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We engage reputable law firms and other third party professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, during the course of this kind of litigation, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any conflicts with the patent rights of others could significantly reduce the coverage of our patents or limit our ability to obtain meaningful patent protection. For example, our European patent related to Agglomerated forms of Captisol was limited during an opposition proceeding, and the rejection of our European patent application related to High Purity Captisol was upheld on appeal. In addition, any determination that our patent rights are invalid may result in early termination of our agreements with our license partners and could adversely affect our ability to enter into new license agreements. We also rely on unpatented trade secrets and know-how to protect and maintain our competitive position. We require our employees, consultants, licensees and others to sign confidentiality agreements when they begin their relationship with us. These agreements may be breached, and we may not have adequate remedies for any breach. In addition, our competitors may independently discover our trade secrets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also need to initiate litigation, which could be time-consuming and expensive, to enforce our proprietary rights or to determine the scope and validity of others' rights. If this occurs, a court may find our patents or those of our licensors invalid or may find that we have infringed on a competitor's rights. In addition, if any of our competitors have filed patent applications in the United States prior to March 2013 which claim technology we also have invented, the United States Patent and Trademark Office may require us to participate in expensive interference proceedings to determine who has the right to a patent for the technology. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our agreements with some of our partners, suppliers or other entities with whom we do business require us to defend or indemnify these parties to the extent they become involved in infringement claims, including the types of claims described above. We could also voluntarily agree to defend or indemnify third parties in instances where we are not obligated to do so if we determine it would be important to our business relationships. If we are required or agree to defend or indemnify third parties in connection with any infringement claims, we could incur significant costs and expenses that could adversely affect our business, financial condition, results of operations and prospects. The occurrence of any of the foregoing problems could be time-consuming and expensive and could adversely affect our financial position, liquidity and results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain sufficient intellectual property protection for our products, platform and technology, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize technologies or a platform similar or identical to ours, and our ability to successfully sell our platform and services may be impaired.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our ability to obtain and maintain adequate protection of the intellectual property we may own solely and jointly with others or otherwise have rights to, particularly patents, in the United States and in other countries with respect to our platform, our software and our technologies, without infringing the intellectual property rights of others.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to protect and enhance the proprietary technologies that we believe are important to our business, including seeking patents intended to cover our platform and related technologies and uses thereof, as we deem appropriate. However, obtaining and enforcing patents in our industry is costly, time-consuming and complex, and we may fail to apply for patents on important products and technologies in a timely fashion or at all, or we may fail to apply for patents in potentially relevant jurisdictions. There can be no assurance that the claims of our patents (or any patent application that issues as a patent), will exclude others from making, using, importing, offering for sale, or selling products or services that are substantially similar to ours. We also rely on trade secrets to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. In countries where we have not sought and do not seek patent protection, third parties may be able to manufacture and sell our technology without our permission, and we may not be able to stop them from doing so. We may not be able to file and prosecute all necessary or desirable patent applications, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. We may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents licensed to third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that none of our pending patent applications will result in issued patents in a timely fashion or at all, and even if patents are granted, they may not provide a basis for intellectual property protection of commercially viable products or services, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties or deemed unenforceable by a court. It is possible that others will design around our current or future patented technologies. As a result, our owned and licensed patents and patent applications comprising our patent portfolio may not provide us with sufficient rights to exclude others from commercializing technology and products similar to any of our products, platform and technology.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may identify third party intellectual property and technology we may need to acquire or license in order to engage in our business, including to develop or commercialize new technologies. However, such licenses may not be available to us on acceptable terms or at all. Furthermore, geopolitical actions in the United States and in foreign countries could increase the uncertainties and costs surrounding the prosecution or maintenance of our patent applications or those of any current or future license partners and the maintenance, enforcement or defense of our issued patents or those of any current or future license partners. For example, the United States and foreign government actions related to Russia&#8217;s conflict in Ukraine may limit or prevent filing, prosecution, and maintenance of patent applications in Russia. Government actions may also prevent maintenance of issued patents in Russia. These actions could result in abandonment or lapse of our or our license partners&#8217; patents or patent applications, resulting in partial or complete loss of patent rights in Russia. If such an event were to occur, it could have a material adverse effect on our business. In addition, a decree was adopted by the Russian government in March 2022, allowing Russian companies and individuals to exploit inventions owned by patentees from the United States without consent or compensation. Consequently, we or our license partners would not be able to prevent third parties from practicing our or our inventions in Russia or from selling or importing products made using our inventions in and into Russia. Accordingly, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issued patents directed to our platform and technology could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability. Some of our patents or patent applications (including licensed patents) may be challenged at a future point in time in opposition, derivation, reexamination, inter partes review, post-grant review or interference. Any successful third party challenge to our patents in this or any other proceeding could result in the unenforceability or invalidity of such patents or amendment to our patents in such a way that any resulting protection may lead to increased competition to our business, which could harm our business. In addition, in patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. The outcome following legal assertions of invalidity and unenforceability during patent litigation is unpredictable. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on certain aspects of our platform technologies. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future products, platform and technology.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be aware of all third party intellectual property rights potentially relating to our products, platform and technology. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until approximately 18 months after filing or, in some cases, not until such patent applications issue as patents. We or our licensors might not have been the first to make the inventions included in each of our pending patent applications and we or our licensors might not have been the first to file patent applications for these inventions. There is also no assurance that all of the potentially relevant prior art relating to our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patents and patent applications or licensed patents and patent applications has been found, which could be used by a third party to challenge their validity, or prevent a patent from issuing from a pending patent application. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine the priority of these inventions, we may have to participate in interference proceedings (with respect to patent applications filed prior to March 2013), derivation proceedings or other post-grant proceedings declared by the USPTO that could result in substantial cost to us. The outcome of such proceedings is uncertain. No assurance can be given that other patent applications will not have priority over our patent applications. In addition, changes to the patent laws of the United States allow for various post-grant opposition proceedings that have not been extensively tested, and their outcome is therefore uncertain. Furthermore, if third parties bring these proceedings against our patents, we could experience significant costs and management distraction.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The validity, scope and enforceability of any patents that cover our partners&#8217; biologic product candidate can be challenged by third parties.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For biologics, the Biologics Price Competition and Innovation Act of 2009, BPCIA, provides a mechanism for one or more third parties to seek FDA approval to manufacture or sell biosimilar or interchangeable versions of brand name biological products. Due to the large size and complexity of biological products, as compared to small molecules, a biosimilar must be &#8220;highly similar&#8221; to the reference product with &#8220;no clinically meaningful differences between the two.&#8221; The BPCIA does not require reference product sponsors to list patents in an Orange Book and does not include an automatic 30-month stay of FDA approval upon the timely filing of a lawsuit. The BPCIA, however, does require a formal pre-litigation process which includes the exchange of information between a biosimilar applicant and a reference biologic sponsor that includes the identification of relevant patents and each parties&#8217; basis for infringement and invalidity. After the exchange of this information, sponsors may then initiate a lawsuit within 30 days to defend the patents identified in the exchange. If the biosimilar applicant successfully challenges the asserted patent claims it could result in the invalidation of, or render unenforceable, some or all of the relevant patent claims or result in a finding of non-infringement. Such litigation or other proceedings to enforce or defend intellectual property rights are often very complex in nature, may be very expensive and time-consuming, may divert our management&#8217;s attention from our core business, and may result in unfavorable results that could limit our partners&#8217; ability to prevent third parties from competing with their products or product candidates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products, platform and technology. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents, and may diminish our ability to protect our inventions, obtain, maintain, enforce and protect our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our future owned and licensed patents. Depending on future actions by the United States Congress, the United States courts, the USPTO and the relevant law-making bodies in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our or our license partners&#8217; ability to obtain new patents and patents that we or our license partners&#8217; might obtain in the future. For example, on June 1, 2023, the European Union Patent Package (&#8220;EU Patent Package&#8221;) regulations were implemented with the goal of providing a single pan-European Unitary Patent and a new European Unified Patent Court (&#8220;UPC&#8221;) for litigation involving European patents. As a result, all European patents, including those issued prior to ratification of the EU Patent Package, now by default automatically fall under the jurisdiction of the UPC. It is uncertain how the UPC will impact granted European patents in the biotechnology and pharmaceutical industries. Our or our license partners&#8217; European patent applications, if issued, could be challenged in the UPC. During the first seven years of the UPC&#8217;s existence, the UPC legislation allows a patent owner to opt its European patents out of the jurisdiction of the UPC. We or our license partners may decide to opt out future European patents from the UPC, but doing so may preclude us or our license partners from realizing the benefits of the UPC. Moreover, if we or our license partners do not meet all of the formalities and requirements for opt-out under the UPC, our or our license partners&#8217; future European patents could remain under the jurisdiction of the UPC. The UPC will provide our and our license partners&#8217; competitors with a new forum to centrally revoke our European patents, and allow for the possibility of a competitor to obtain pan-European injunction. Such a loss of patent protection could have a material adverse impact on our or our license partners business and ability to commercialize our technology and product candidates and, resultantly, on our business, financial condition, prospects and results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on in-licenses from third parties. If we lose these rights, our business may be materially and adversely affected, our ability to develop improvements to our technology platform may be negatively and substantially impacted, and if disputes arise, we may be subjected to future litigation, as well as the potential loss of or limitations on our ability to incorporate the technology covered by these license agreements.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to royalty-bearing license agreements that grant us rights to practice certain patent rights that are related to our products, platform and technology. In spite of our efforts to comply with our obligations under our in-license agreements, our licensors might conclude that we have materially breached our obligations under our license agreements and might </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">therefore, including in connection with any aforementioned disputes, terminate the relevant license agreement, thereby removing or limiting our ability to develop and commercialize technology covered by these license agreements. If any such in-license is terminated, or if the licensed patents fail to provide the intended exclusivity, competitors or other third parties might have the freedom to market or develop technologies similar to ours. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, absent the rights granted to us under our license agreements, we may infringe the intellectual property rights that are the subject of those agreements, we may be subject to litigation by the licensor, and if such litigation by the licensor is successful we may be required to pay damages to our licensor, or we may be required to cease our development and commercialization activities that are deemed infringing, and in such event we may ultimately need to modify our activities or technologies to design around such infringement, which may be time- and resource-consuming, and which ultimately may not be successful. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our rights to certain components of our technology platform, may be licensed to us on a non-exclusive basis. The owners of these non-exclusively licensed technologies are therefore free to license them to third parties, including our competitors, on terms that may be superior to those offered to us, which could place us at a competitive disadvantage.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, our licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing or otherwise violating the licensor&#8217;s rights. In addition, certain of our agreements with third parties may provide that intellectual property arising under these agreements, such as data that could be valuable to our business, will be owned by the third party, in which case, we may not have adequate rights to use such data or have exclusivity with respect to the use of such data, which could result in third parties, including our competitors, being able to use such data to compete with us.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our licensors may be subject to claims that former employees, partners or other third parties have an interest in our or our in-licensed patents, trade secrets or other intellectual property as an inventor or co-inventor. Litigation may be necessary to defend against these and other claims challenging inventorship of our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our systems, including our software, workflows, consumables and reagents. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees, and certain partners or partners may defer engaging with us until the particular dispute is resolved. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our information and our trade secrets, the value of our technology could be materially and adversely affected and our business could be harmed.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology and other proprietary information, including parts of our technology platform, and to maintain our competitive position. However, trade secrets and know-how can be difficult to protect. In addition to pursuing patents on our technology, we take steps to protect our intellectual property and proprietary technology by entering into agreements, including confidentiality agreements, non-disclosure agreements and intellectual property assignment agreements, with our employees, consultants, academic institutions, corporate partners and, when needed, our advisers. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. For example, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Such agreements may not be enforceable or may not provide meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches of the agreements, and we may not be able to prevent such unauthorized disclosure, which could adversely impact our ability to establish or maintain a competitive advantage in the market. If we are required to assert our rights against such party, it could result in significant cost and distraction.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monitoring unauthorized disclosure and detection of unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable. In addition, some courts both within and outside the United States may be less willing, or unwilling, to protect trade secrets. Further, we may need to share our trade secrets and confidential know-how with current or future partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also seek to preserve the integrity and confidentiality of our confidential proprietary information by maintaining physical security of our premises and physical and electronic security of our information technology systems, but it is possible that these security measures could be breached. If any of our confidential proprietary information were to be lawfully obtained or independently developed by a competitor or other third party, absent patent protection, we would have no right to prevent such competitor from using that technology or information to compete with us, which could harm our competitive position. If any of our trade secrets were to be disclosed to or independently discovered by a competitor or other third party, it could harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risks Related to Government Regulation and Legal Proceedings:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market acceptance and sales of any approved product will depend significantly on the availability and adequacy of coverage and reimbursement from third-party payors and may be affected by existing and future healthcare reform measures.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the products we may market or license to our collaboration partners and the royalties we receive will depend in large part on the extent to which coverage and reimbursement is available from government and health administration authorities, private health maintenance organizations and health insurers, and other healthcare payors. Significant uncertainty exists as to the reimbursement status of healthcare products. Healthcare payors, including Medicare, are challenging the prices charged for medical products and services. Government and other healthcare payors are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement for medical products. Even if a product is approved by the FDA, insurance coverage may not be available, and reimbursement levels may be inadequate, to cover the costs associated with the research, development, marketing and sale of the product. If government and other healthcare payors do not provide adequate coverage and reimbursement levels for any product, market acceptance and any sales could be reduced.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislation is implemented to reign in rising healthcare expenditures. By way of example, the Affordable Care Act (&#8220;ACA&#8221;) was enacted in 2010 and included a number of provisions affecting the pharmaceutical industry, including, among other things, annual, non-deductible fees on any entity that manufactures or imports some types of branded prescription drugs and increases in Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program. Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Thus, the ACA will remain in effect in its current form.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, beginning April 1, 2013, Medicare payments to providers were reduced under the sequestration required by the Budget Control Act of 2011, which will remain in effect through 2032, unless additional Congressional action is taken. Additionally, on January 2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. On March 11, 2021, the American Rescue Plan Act of 2021 was signed into law, which eliminated the statutory Medicaid drug rebate cap, beginning January 1, 2024. Previously, the Medicaid rebate was capped at 100% of a drug&#8217;s average manufacturer price, or AMP.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional changes that may affect our business include the expansion of new programs such as Medicare payment for performance initiatives for physicians under the Medicare Access and CHIP Reauthorization Act of 2015, or MACRA, which was fully implemented in 2019. At this time, it is unclear how the introduction of this Medicare quality payment program will impact overall physician reimbursement. The cost of prescription pharmaceuticals in the United States has also been the subject of considerable discussion in the United States. There have been several Congressional inquiries, as well as legislative and regulatory initiatives and executive orders designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the federal government and the individual states in the United States have become increasingly active in developing proposals, passing legislation and implementing regulations designed to control drug pricing, including price or patient reimbursement constraints, discounts, formulary flexibility, marketing cost disclosure, drug price increase reporting, and other transparency measures. These types of initiatives may result in additional reductions in Medicare, Medicaid, and other healthcare funding.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most significantly, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;) into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health and Human Services (&#8220;HHS&#8221;) to implement many of these provisions through guidance, as opposed to regulation, for the initial years. HHS has and will continue to issue and update guidance as these programs are implemented. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. The impact of the IRA on the pharmaceutical industry cannot yet be fully determined, but is likely to be significant. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage and payment criteria and in additional downward pressure on the prices that can be realized for any approved drug. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us or our partners from being able to generate revenue, attain profitability, or commercialize drugs. Individual states in the United States have also become increasingly active in implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for drug candidates or additional pricing pressures. Further, the new presidential administration could result in policy shifts that may affect us in ways we cannot foresee. We cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our commercialization partners market products in a manner that violates healthcare laws, we may be subject to civil or criminal penalties.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaboration partners are subject to federal and state healthcare laws, including fraud and abuse, government price reporting, anti-kickback, false claims, physician payment transparency and civil monetary penalties. These laws may impact, among other things, financial arrangements with physicians, sales, marketing and education programs and the manner in which any of those activities are implemented. If our operations or those of our collaboration partners are found to be in violation of any of those laws or any other applicable governmental regulations, we or our collaboration partners may be subject to penalties, including civil and criminal penalties, damages, fines, imprisonment, exclusion from government healthcare programs or the curtailment or restructuring of operations, any of which could adversely affect our ability to operate our business and our financial condition.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate calculations vary among products and programs. The calculations are complex and are often subject to interpretation by our collaboration partners, governmental or regulatory agencies, and the courts. CMS, the Department of Health &amp; Human Services Office of Inspector General, and other governmental agencies have pursued manufacturers that were alleged to have failed to report these data to the government in a timely or accurate manner. Governmental agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. We cannot assure you that any submissions by our collaboration partners to federal healthcare programs, and other governmental drug pricing programs, will not be found to be incomplete or incorrect.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in and actual or perceived failures to comply with applicable data privacy, security and protection laws, regulations, standards and contractual obligations may adversely affect our business, operations and financial performance.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our partners may be subject to federal, state, and foreign laws and regulations that govern data privacy and security. The legislative and regulatory landscape for privacy and data protection continues to evolve, and there has been an increasing focus on privacy and data protection issues, which may affect our business and may increase our compliance costs and exposure to liability. In the United States, numerous federal and state laws and regulations govern the collection, use, disclosure, and protection of personal information, including state data breach notification laws, federal and state health information privacy laws, and federal and state consumer protection laws. Each of these laws is subject to varying interpretations by courts and government agencies, creating complex compliance issues. If we fail to comply with applicable laws and regulations we could be subject to penalties or sanctions, including criminal penalties if we knowingly obtain or disclose individually identifiable health information from a covered entity in a manner that is not authorized or permitted by the Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and regulations implemented thereunder (collectively, &#8220;HIPAA&#8221;) or applicable state laws.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain states have also adopted comparable privacy and security laws and regulations, which govern the privacy, processing and protection of health-related and other personal information. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;) went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as well as a private right of action for data breaches that has increased the likelihood of, and risks associated with data breach litigation. Further, the California Privacy Rights Act (&#8220;CPRA&#8221;) generally went into effect on January 1, 2023, and significantly amends the CCPA. It imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Additional compliance investment and potential business process changes may be required. Similar laws have passed in other states and are continuing to be proposed at the state and federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also or may become subject to rapidly evolving data protection laws, rules and regulations in foreign jurisdictions. For example, the European Union General Data Protection Regulation (&#8220;GDPR&#8221;) governs certain collection and other processing activities involving personal data about individuals in the European Economic Area (&#8220;EEA&#8221;). Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the United States, and the efficacy and longevity of current transfer mechanisms between the EEA and the United States remains uncertain. Case law from the Court of Justice of the European Union (&#8220;CJEU&#8221;) states that reliance on the standard contractual clauses - a standard form of contract approved by the European Commission as an adequate personal data transfer mechanism - alone may not necessarily be sufficient in all circumstances and that transfers must be assessed on a case-by-case basis. On October 7, 2022, President Biden signed an Executive Order on &#8216;Enhancing Safeguards for United States Intelligence Activities&#8217; which introduced new redress mechanisms and binding safeguards to address the concerns raised by the CJEU in relation to data transfers from the EEA to the United States and which formed the basis of the new EU-US Data Privacy Framework (&#8220;DPF&#8221;), as released on December 13, 2022. The European Commission adopted its Adequacy Decision in relation to the DPF on July 10, 2023, rendering the DPF effective as a GDPR transfer mechanism to U.S. entities self-certified under the DPF. The DPF also introduced a new redress mechanism for E.U. citizens which addresses a key concern in the previous CJEU judgments and may mean transfers under standard contractual clauses are less likely to be challenged in future. With the advice of outside counsel and privacy experts, we take appropriate steps to ensure transfers of personal data outside the EEA and the UK, including to the United States, are conducted in a manner consistent with applicable law and legal requirements. We expect the existing legal complexity and uncertainty regarding international personal data transfers to continue. In particular, we expect the DPF Adequacy Decision to be challenged and international transfers to the United States and to other jurisdictions more generally to continue to be subject to enhanced scrutiny by regulators. As a result, we may have to make certain operational changes and we will have to implement revised standard contractual clauses and other relevant documentation for existing data transfers within required time frames. Since the beginning of 2021, after the end of the transition period following the United Kingdom&#8217;s departure from the European Union, we are also subject to the United Kingdom data protection regime, which imposes separate but similar obligations to those under the GDPR and comparable penalties, including fines of up to &#163;17.5 million or 4% of a noncompliant company&#8217;s global annual revenue for the preceding financial year, whichever is greater. On October 12, 2023, the UK Extension to the DPF came into effect (as approved by the UK Government), as a UK GDPR data transfer mechanism to U.S. entities self-certified under the UK Extension to the DPF. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the FTC also has authority to initiate enforcement actions against entities that make deceptive statements about privacy and data sharing in privacy policies, fail to limit third-party use of personal health information, fail to implement policies to protect personal health information or engage in other unfair practices that harm customers or that may violate Section 5 of the FTC Act. Failing to take appropriate steps to keep consumers&#8217; personal information secure can constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Additionally, federal and state consumer protection laws are increasingly being applied by FTC and states&#8217; attorneys general to regulate the collection, use, storage, and disclosure of personal or personally identifiable information, through websites or otherwise, and to regulate the presentation of website content.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with applicable data privacy and security laws, rules and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners&#8217; ability to operate in certain jurisdictions. Each of these constantly evolving laws can be subject to varying interpretations. If we fail to comply with any such laws, rules or regulations, we may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">face government investigations and/or enforcement actions, fines, civil or criminal penalties, private litigation or adverse publicity that could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we or our partners are ultimately unable to obtain regulatory approval for product candidates, our business will be substantially harmed. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of drugs and biologics are subject to extensive regulation by the FDA in the U.S. and by comparable foreign regulatory authorities in foreign markets. In the U.S., neither we nor our partners are permitted to market our product candidates in the U.S. until we receive approval of a biologics license application (&#8220;BLA&#8221;) or an NDA from the FDA. The process of obtaining such regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population. Approval policies or regulations may change, and the FDA and comparable regulatory authorities have substantial discretion in the approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development of product candidates, regulatory approval of a product candidate is never guaranteed. Of the large number of drugs in development, only a small percentage successfully complete the FDA or foreign regulatory approval processes and are commercialized. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to obtaining approval to commercialize a drug or biological product candidate in the U.S. or abroad, we or our partners must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe and effective for their intended uses, and in the case of biological products in the U.S., that such product candidates are safe, pure and potent. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we or our partners believe available nonclinical or clinical data support the safety purity, potency or efficacy of our product candidates, such data may not be sufficient to obtain approval from the FDA and comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us or our partners to conduct additional preclinical studies or clinical trials for our product candidates either prior to or post-approval, or may object to elements of clinical development programs. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may disagree with the design or execution of clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative or ambiguous results from clinical trials or results may not meet the level of statistical significance or persuasiveness required by the FDA or comparable foreign regulatory agencies for approval;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">serious and unexpected drug-related side effects may be experienced by participants in clinical trials or by individuals using drugs similar to the applicable product candidates;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we or our partners seek approval;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may not accept clinical data from trials that are conducted at clinical facilities or in countries where the standard of care is potentially different from that of their own country;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our partners may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may disagree with our or our partners&#8217; interpretation of data from preclinical studies or clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may not agree that the data collected from clinical trials are acceptable or sufficient to support the submission of a BLA, NDA or other submission or to obtain regulatory approval in the U.S. or elsewhere, and such authorities may impose requirements for additional preclinical studies or clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may disagree with us or our partners regarding the formulation, labeling and/or product specifications;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval may be granted only for indications that are significantly more limited than those sought by us or our partners, and/or may include significant restrictions on distribution and use;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may find deficiencies in the manufacturing processes or facilities of the third-party manufacturers utilized for clinical and commercial supplies; or</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product testing, administrative review periods and agreements with pricing authorities. Even if we or our partners eventually complete clinical trials and receive approval of a BLA, NDA or comparable foreign marketing application for our product candidates, the FDA or comparable foreign regulatory authority may grant approval contingent on the performance of costly additional clinical trials and/or the implementation of burdensome monitoring requirements to address safety concerns. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate, which could materially and adversely impact our revenues, business and prospects. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical products are subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For any regulatory approvals that we or our partners may receive for our respective product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will remain subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as ongoing compliance with current Good Manufacturing Practices (&#8220;cGMPs&#8221;) and Good Clinical Practice requirements for any clinical trials that we or they may conduct. In addition, manufacturers of drug and biological products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. In addition, regulatory approvals require the submission of periodic reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product, and such approvals may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a Risk Evaluation and Mitigation Strategy as a condition of approval, which could include requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we, our partners or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. In addition, failure to comply with FDA and other comparable foreign regulatory requirements may lead to administrative or judicially imposed sanctions, including:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of approvals; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizures or detentions, or refusal to permit the import or export of products; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any event or penalty described above may inhibit our or our partners&#8217; ability to commercialize and generate revenue from products and could require us or our partners to expend significant time and resources in response and could generate negative publicity. In addition, the FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be promulgated that could prevent, limit or delay marketing authorization of any product candidates we or our partners develop. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We or our collaboration partners may rely on orphan drug status to develop and commercialize certain of our product candidates, but orphan drug designations may not confer marketing exclusivity or other expected commercial benefits and we or our collaboration partners may not be able to obtain orphan drug designations for our other product candidates.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may rely on orphan drug exclusivity for product candidates that we may develop. Orphan drug status confers seven years of marketing exclusivity in the United States under the Federal Food Drug, and Cosmetic Act, and up to ten years of marketing exclusivity in Europe for a particular product in a specified indication, subject to certain conditions. However, we may be unable to obtain orphan drug designations for any of our product candidates that we are currently developing or may pursue. Even if we do obtain orphan drug designations and are the first to obtain marketing approval of our product candidates </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the applicable indications, we will not be able to rely on these designations to exclude other companies from manufacturing or selling biological products using the same principal molecular structural features for the same indication beyond these timeframes. Furthermore, any marketing exclusivity in Europe can be reduced from ten years to six years if the initial designation criteria have significantly changed since the market authorization of the orphan product.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For any product candidate for which we may be granted orphan drug designation in a particular indication, it is possible that another company also holding orphan drug designation for the same product candidate will receive marketing approval for the same indication before we do. If that were to happen, our applications for that indication may not be approved until the competing company&#8217;s period of exclusivity expires. Even if we are the first to obtain marketing authorization for an orphan drug indication in the United States, there are circumstances under which a competing product may be approved for the same indication during the seven-year period of marketing exclusivity, such as if the later product is shown to be clinically superior to our orphan product, or if the later product is deemed a different product than ours. Further, the seven-year marketing exclusivity would not prevent competitors from obtaining approval of the same product candidate as ours for indications other than those in which we have been granted orphan drug designation, or for the use of other types of products in the same indications as our orphan product. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business or the business of our partners.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. The new presidential administration is expected to result in decreases to government agency funding and personnel across departments, which may have an adverse effect on review times or other processing functions.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business or the business of our partners. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. If the timing of FDA&#8217;s review and approval of new products is delayed, the timing of our or our partners&#8217; development process may be delayed which would result in delayed milestone revenues and materially harm our operations of business.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the COVID-19 pandemic, the FDA postponed most inspections of domestic and foreign manufacturing facilities at various points. Even though the FDA has resumed standard inspection operations of domestic facilities where feasible, any resurgence of the COVID-19 virus or future pandemics may lead to further inspectional or administrative delays. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to future pandemics. If a prolonged government shutdown occurs, or if global health concerns continue to hinder or prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our or our partners&#8217; regulatory submissions, which could have a material adverse effect on our business. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If plaintiffs bring product liability lawsuits against us or our partners, we or our partners may incur substantial liabilities and may be required to limit commercialization of our approved products and product candidates.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As is common in our industry, we and our partners face an inherent risk of product liability as a result of the clinical testing of our product candidates in clinical trials and face an even greater risk for commercialized products. Although we are not currently a party to product liability litigation, if we are sued, we may be held liable if any product or product candidate we develop causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, liability claims may result in decreased demand for any product candidates, partnered products or products that we may develop, injury to our reputation, discontinuation of clinical trials, costs to defend litigation, substantial monetary awards to clinical trial participants or patients, loss of revenue and product recall or withdrawal from the market and the inability to commercialize any products that we develop. We have product liability insurance that covers our clinical trials up to a $15.0&#160;million annual limit. Our insurance coverage may not be sufficient to cover all of our product liability related expenses or losses and may not cover us for any expenses or losses we may suffer. If we are sued for any injury caused by our product candidates, partnered products or any future products, our liability could exceed our total assets.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face risks related to handling of hazardous materials and other regulations governing environmental safety.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to complex and stringent environmental, health, safety and other governmental laws and regulations that both public officials and private individuals may seek to enforce. Our activities that are subject to these regulations include, among other things, our use of hazardous materials and the generation, transportation and storage of waste. Although we have secured clearance from the EPA historically, and currently are operating in material compliance with applicable EPA rules and regulations, our business could be adversely affected if we discover that we or an acquired business is not in material compliance with these rules and regulations. In the future, we may pursue the use of other surfactant substances that will require clearance from the EPA, and we may fail to obtain such clearance. Existing laws and regulations may also be revised or reinterpreted, or new laws and regulations may become applicable to us, whether retroactively or prospectively, that may have a negative effect on our business and results of operations. It is also impossible to eliminate completely the risk of accidental environmental contamination or injury to individuals. In such an event, we could be liable for any damages that result, which could adversely affect our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may also be subject to other laws and regulations not specifically targeting the healthcare industry.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain regulations not specifically targeting the healthcare industry also could have material effects on our operations. For example, the California Financing Law (the &#8220;CFL&#8221;), Division 9, Sections 22000-22780.1 of the California Financial Code, could be applied to us as a result of loans or similar arrangements we enter into with partners. If a regulator were to take the position that such loans were covered by the California Financing Law, we could be subject to regulatory action that could impair our ability to continue to operate and may have a material adverse effect on our profitability and business as we currently do not hold a CFL finance lenders license. Pursuant to an exemption under the CFL, a person may make five or fewer commercial loans with a California nexus in a 12-month period without a CFL finance lenders license if such loans are &#8220;incidental&#8221; to the business of the person making the loan. This exemption, however, creates some uncertainty as to which loans could be deemed as incidental to our business. In addition, there is another exemption that would allow a person without a CFL finance lenders license to make a single commercial loan with a California nexus in a 12-month period.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Risk Related to Our Strategic Transactions:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any difficulties from strategic acquisitions and other M&amp;A transactions could adversely affect our stock price, operating results and results of operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may acquire companies, businesses and products with significant royalty assets or where we believe we could create significant synthetic royalties or that otherwise complement or augment our existing business. We may not be able to integrate any acquired business successfully or operate any acquired business profitably or these acquired businesses may not perform as we project. Integrating any newly acquired business could be expensive and time-consuming. Integration efforts often take a significant amount of time, place a significant strain on managerial, operational and financial resources and could prove to be more difficult or expensive than we predict. The diversion of our management's attention and any delay or difficulties encountered in connection with any future acquisitions we may consummate could result in the disruption of our ongoing business or inconsistencies in standards and controls that could negatively affect our ability to maintain third-party relationships. Moreover, we may need to raise additional funds through public or private debt or equity financing, or issue additional shares, to acquire any businesses or products, which may result in dilution for stockholders or the incurrence of indebtedness. In addition, the acquisition of operating biopharmaceutical companies could result in the assumption of, or exposure to, liabilities of the acquired business that are not inherent in our other royalty acquisitions, such as direct exposure to product liability claims, high fixed costs or an expansion of our operations and expense structure, thereby potentially decreasing our profitability.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our efforts to acquire companies, business or product candidates or to enter into other significant transactions, we conduct business, legal and financial due diligence with the goal of identifying and evaluating material risks involved in the transaction. Despite our efforts, we ultimately may be unsuccessful in ascertaining or evaluating all such risks and, as a result, might not realize the intended advantages of the transaction. If we fail to realize the expected benefits from acquisitions we may consummate in the future or have consummated in the past, whether as a result of unidentified risks, integration difficulties, regulatory setbacks, litigation with current or former employees and other events, our business, results of operations and financial condition could be adversely affected. If we acquire product candidates, we will also need to make certain assumptions about, among other things, development costs, the likelihood of receiving regulatory approval and the market for such product candidates. Our assumptions may prove to be incorrect, which could cause us to fail to realize the anticipated benefits of these transactions.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we will likely experience significant charges to earnings in connection with our efforts, if any, to consummate acquisitions. For transactions that are ultimately not consummated, these charges may include fees and expenses for investment bankers, attorneys, accountants and other advisors in connection with our efforts. Even if our efforts are successful, we may incur, as part of a transaction, substantial charges for closure costs associated with elimination of duplicate operations and facilities and acquired in-process research and development charges. In either case, the incurrence of these charges could adversely affect our results of operations for particular quarterly or annual periods.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also seek to expand our market opportunity by acquiring securities issued by biopharmaceutical companies. Where we acquire equity securities as all or part of the consideration for M&amp;A acquisitions or other business development activities, the value of those securities will fluctuate, and may depreciate. We may not control the companies in which we acquire securities, and as a result, we may have limited ability to determine management, operational decisions or policies of such companies. Further, such transactions may face risks and liabilities that due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess. In addition, as a result of our business model, we may receive material non-public information about other companies. Where such information relates to a company whose equity securities we hold, we may be delayed or prevented from selling such securities when we would otherwise choose to do so, and such delay or prohibition may result in a loss or reduced gain on such securities. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Pelthos business may suffer from uncertain business operations if we do not consummate a transaction or enter into commercial partnerships involving Pelthos. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with our business model, we are engaging with potential commercial partners to maximize the value for our stockholders of the assets we acquired through the Novan acquisition that are held by our Pelthos business (including ZELSUVMI and other assets that may be developed using the NITRICIL technology platform) through a licensing or other strategic transaction involving Pelthos. If we do not consummate a transaction or enter into commercial partnerships, we will continue to be exposed to uncertainties with respect to the continued operations of the Pelthos business. Such uncertainties may affect our results of operations similarly to those faced by our Captisol business as described above under &#8220;Risks Related to Our Business Operations and Reliance on Third Parties.&#8221; </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Risks:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the royalties from the sales of Kyprolis, Evomela and other products sold by our partners; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our collaboration partners&#8217; preclinical and clinical programs;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of Captisol purchases for use in clinical trials and commercial products; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to our internal development programs, which may change from time to time;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditures that we may incur to acquire or develop additional product candidates and platform technologies; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future accounting pronouncements or changes in our accounting policies. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results and revenues. This variability and unpredictability could result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes or modifications in financial accounting standards, including those related to revenue recognition, may harm our results of operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the FASB either alone or jointly with other organizations, promulgates new accounting principles that could have an adverse impact on our results of operations. For example, in May 2014, FASB issued an accounting standard for revenue recognition-Accounting Standards Codification Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or ASC 606-that supersedes most current revenue recognition guidance. The guidance requires a company to recognize revenue upon transfer of goods or services to a customer at an amount that reflects the expected consideration to be received in exchange for those goods or services. The guidance became effective in fiscal 2018. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 606, Ligand estimates and books royalties in the same quarter that our partners report the sale of the underlying product. We rely on our partners&#8217; earning releases and other information from our partners to determine the sales of our partners&#8217; products and to estimate the related royalty revenues. If our partners report incorrect sales, or if our partners delay reporting of their earnings release, our royalty estimates may need to be revised and/or our financial reporting may be delayed. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or regulations that are applied adversely to us may have a material adverse effect on our business, cash flow, financial condition, or results of operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New tax laws, statutes, rules, regulations, or ordinances could be enacted at any time. For instance, the recently enacted Inflation Reduction Act imposes, among other rules, a 15% minimum tax on the book income of certain large corporations and a 1% excise tax on certain corporate stock repurchases. Further, existing tax laws, statutes, rules, regulations, or ordinances could be interpreted differently, changed, repealed, or modified at any time. Any such enactment, interpretation, change, repeal, or modification could adversely affect us, possibly with retroactive effect. In particular, changes in corporate tax rates, the realization of our net deferred tax assets, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act, as amended by the CARES Act or any future tax reform legislation, could have a material impact on the value of our deferred tax assets, result in significant one-time charges, and increase our future tax expenses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be subject to certain limitations. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had U.S. federal and state net operating loss carryforwards (&#8220;NOLs&#8221;) of approximately $21.4 million and $162.8 million, respectively. Our federal NOLs expire through 2037 and our state NOLs begin to expire in 2028, if not utilized. Under the Tax Act, any federal NOLs arising in taxable years ending after December 31, 2017 will carry forward indefinitely. As of December&#160;31, 2024, we had federal and California research and development tax credit carryforwards of approximately $6.2 million and $29.5 million, respectively. The federal research and development tax credit carryforwards expire in various years through 2040, if not utilized. The California research and development credit will carry forward indefinitely. Under Sections 382 and 383 of Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) if a corporation undergoes an &#8220;ownership change,&#8221; the corporation&#8217;s ability to use its pre-change NOLs and other pre-change tax attributes, such as research tax credits, to offset its future post-change income and taxes may be limited. In general, an &#8220;ownership change&#8221; occurs if there is a cumulative change in our ownership by &#8220;5% shareholders&#8221; that exceeds 50 percentage points over a rolling three-year period. Similar rules may apply under state tax laws. We believe we have experienced certain ownership changes in the past and have reduced our deferred tax assets related to NOLs and research and development tax credit carryforwards accordingly. In the event that it is determined that we have in the past experienced additional ownership changes, or if we experience one or more ownership changes as a result future transactions in our stock, then we may be further limited in our ability to use our NOLs and other tax assets to reduce taxes owed on the net taxable income that we earn in the event that we attain profitability. Furthermore, under the Tax Act, although the treatment of tax losses generated in tax years beginning before December 31, 2017 has generally not changed, tax losses generated in tax years beginning after December 31, 2017 may only offset 80% of our taxable income. This change may require us to pay federal income taxes in future years despite having potentially generated a loss for federal income tax purposes in prior years. Any such limitations on the ability to use our NOLs and other tax assets could adversely impact our business, financial condition and operating results. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the OmniAb Distribution, together with certain related transactions (including the OmniAb Separation), failed to qualify as a reorganization under Sections 355 and 368(a)(1)(D) of the Code, or the OmniAb Merger failed to qualify as a reorganization under Section 368(a) of the Code, we could incur significant tax liabilities.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2022, we entered into (i) an Agreement and Plan of Merger (the &#8220;OmniAb Merger Agreement&#8221;), among Ligand, OmniAb, Avista Public Acquisition Corp. II, a Cayman Islands exempted company (&#8220;APAC&#8221;), and Orwell Merger Sub, Inc., a wholly owned subsidiary of APAC (&#8220;Merger Sub&#8221;), and (ii) a Separation and Distribution Agreement (the &#8220;OmniAb Separation and Distribution Agreement&#8221;), among Ligand, OmniAb and APAC. Prior to the effective time of the OmniAb Merger (defined below), APAC migrated to and domesticated as a Delaware corporation (&#8220;New OmniAb&#8221;) in accordance with the terms and conditions of the OmniAb Merger Agreement. Pursuant to the OmniAb Separation and Distribution Agreement, we, prior to the effective time of the OmniAb Merger (i) transferred our then-antibody discovery business (the &#8220;OmniAb Business&#8221;), including certain of our related subsidiaries, to OmniAb (the &#8220;OmniAb Separation&#8221;) and (ii) in connection therewith, distributed 100% of OmniAb&#8217;s common stock held by Ligand to Ligand stockholders (the &#8220;OmniAb Distribution&#8221;). We also contributed to OmniAb cash and certain specific assets and liabilities constituting the OmniAb Business. Following the OmniAb Separation and the OmniAb Distribution, on November 1, 2022, in accordance with and subject to the terms and conditions of the OmniAb Merger Agreement, Merger Sub merged with and into OmniAb, with OmniAb continuing as the surviving company and wholly-owned subsidiary of New OmniAb on and after the effective time of the merger (the &#8220;OmniAb Merger&#8221;). In addition, New OmniAb changed its corporate name to &#8220;OmniAb, Inc.&#8221; concurrently upon the effectiveness of the OmniAb Merger. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OmniAb Separation, OmniAb Distribution and OmniAb Merger (collectively, together with certain related transactions, the &#8220;OmniAb Transactions&#8221;) were conditioned upon receipt of a tax opinion from outside counsel to the effect that the OmniAb Separation and OmniAb Distribution qualified as a reorganization under Sections 355 and 368(a)(1)(D) of the Code, that the OmniAb Merger would not cause Section 355(e) of the Code to apply to the OmniAb Separation or OmniAb Distribution and that the OmniAb Merger would be treated as a reorganization under Section 368(a) of the Code. The opinion was delivered in connection with the closing of the OmniAb Merger and was based on, among other things, certain facts, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assumptions, representations and undertakings from us, OmniAb, APAC and New OmniAb, including those regarding the past and future conduct of the companies&#8217; respective businesses and other matters. If any of these facts, assumptions, representations, or undertakings were incorrect or not satisfied, we may not be able to rely on the opinion, and we and our stockholders could be subject to significant U.S. federal income tax liabilities. In addition, the opinion is not binding on the IRS or the courts, and notwithstanding the opinion, the IRS could determine on audit that the OmniAb Transactions do not qualify as a tax-free reorganization if it determines that any of the facts, assumptions, representations or undertakings on which the opinion is based are not correct or have been violated or that the OmniAb Transactions should be taxable for other reasons, including as a result of a significant change in stock or asset ownership after the OmniAb Transactions. If the OmniAb Transactions are ultimately determined not to qualify as a reorganization, we and our stockholders that are subject to U.S. federal income tax could incur significant U.S. federal income tax liabilities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The OmniAb Separation and OmniAb Distribution may expose Ligand to potential liabilities arising out of state and federal fraudulent conveyance laws and legal dividend requirements.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OmniAb Separation and OmniAb Distribution are subject to review under various state and federal fraudulent conveyance laws. Fraudulent conveyance laws generally provide that an entity engages in a constructive fraudulent conveyance when (i) the entity transfers assets and does not receive fair consideration or reasonably equivalent value in return; and (ii) the entity: (a) is insolvent at the time of the transfer or is rendered insolvent by the transfer; (b) has unreasonably small capital with which to carry on its business; or (c) intends to incur or believes it will incur debts beyond its ability to repay its debts as they mature. An unpaid creditor or an entity acting on behalf of a creditor (including without limitation a trustee or debtor-in-possession in a bankruptcy by New OmniAb or Ligand or any of their respective subsidiaries) may bring an action alleging that the OmniAb Separation or OmniAb Distribution or any of the related transactions constituted a constructive fraudulent conveyance. If a court accepts these allegations, it could impose a number of remedies, including without limitation, voiding New OmniAb&#8217;s claims against Ligand, requiring New OmniAb stockholders to return to Ligand some or all of the shares of New OmniAb common stock issued via the OmniAb Transactions, or providing Ligand with a claim for money damages against New OmniAb in an amount equal to the difference between the consideration received by Ligand and OmniAb&#8217;s fair market value at the time of the OmniAb Distribution.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The measure of insolvency for purposes of the fraudulent conveyance laws will vary depending on which jurisdiction&#8217;s law is applied. Generally, an entity would be considered insolvent if (i) the present fair saleable value of its assets is less than the amount of its liabilities (including contingent liabilities); (ii) the present fair saleable value of its assets is less than its probable liabilities on its debts as such debts become absolute and matured; (iii) it cannot pay its debts and other liabilities (including contingent liabilities and other commitments) as they mature; or (iv) it has unreasonably small capital for the business in which it is engaged. We cannot assure you what standard a court would apply to determine insolvency or that a court would determine that New OmniAb or Ligand or any of their subsidiaries were solvent at the time of or after giving effect to the OmniAb Distribution.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OmniAb Distribution is also subject to review under state corporate distribution statutes. Under the Delaware General Corporation Law, a corporation may only pay dividends to its stockholders either (i) out of its surplus (net assets minus capital) or (ii) if there is no such surplus, out of its net profits for the fiscal year in which the dividend is declared or the preceding fiscal year. Although Ligand intended to make the OmniAb Distribution entirely from surplus, we cannot assure you that a court will not later determine that some or all of the OmniAb Distribution was unlawful.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The occurrence of a catastrophic disaster could disrupt our business, damage our facilities beyond insurance limits, increase our costs and expenses, or we could lose key data which could cause us to curtail or cease operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are vulnerable to damage, business disruptions and/or loss of vital data from natural or man-made disasters, such as earthquakes, tornadoes, severe weather conditions, power loss, fire, floods and similar events, as well as from accidental loss or destruction. If any disaster were to occur, our ability to operate our business could be seriously impaired. We have property, liability, and business interruption insurance which may not be adequate to cover our losses resulting from disasters or other similar significant business interruptions, and we do not plan to purchase additional insurance to cover such losses due to the cost of obtaining such coverage. Any significant losses that are not recoverable under our insurance policies could seriously impair our business, financial condition and prospects. Our ability to obtain Captisol supply from our third-party manufactures could be disrupted if the operations of these manufacturers were affected by a natural or man-made disaster or other business interruption. In addition, we rely on our partners to generate most of our revenues through royalties, Captisol sales and development activities and any disruptions to their business as a result of such disasters could negatively impact our revenues.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on information technology system and any failure, inadequacy, interruption or security lapse of our information technology systems, including any cyber security incidents, could harm our ability to operate our business effectively.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is increasingly dependent on critical, complex and interdependent information technology systems, including internet-based systems, to support business processes as well as internal and external communications. We operate some of these systems and networks, but we also rely on third-party providers for various products and services across our operations. Despite the implementation of security measures, our information technology systems and those of our partners and third party service providers are vulnerable to attack, damage, and interruption from cyber-attacks, computer viruses and malware (e.g. ransomware), security breaches, unauthorized access, natural disasters, terrorism, war, telecommunication and electrical failures, hacking, phishing attacks and other social engineering schemes, employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported actors or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Attacks upon information technology systems are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives and expertise. Furthermore, because the technologies used to obtain unauthorized access to, or to sabotage or disrupt, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. We may also face increased cybersecurity risks due to our reliance on internet technology and the number of our and our service providers&#8217; employees who are (and may continue to be) working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. The White House, SEC and other regulators have also increased their focus on companies&#8217; cybersecurity vulnerabilities and risks.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain of our service providers are from time to time, subject to cyberattacks and security incidents. While we do not believe that we have experienced any significant system failures, accidents or security breaches, if such an event were to occur and cause interruptions in our or our critical third parties&#8217; operations, it could lead to the loss of trade secrets or other intellectual property, as well as the public exposure of personal information of our employees and others, and could result in a material disruption of our clinical and commercialization activities and business operations, in addition to possibly requiring substantial expenditures to remedy. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and our business, reputation, and financial condition could be harmed. Any losses, costs or liabilities may not be covered by, or may exceed the coverage limits of, any or all applicable insurance policies.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The terms of our Credit Agreement may limit our flexibility in operating our business and adversely affect our financial health and competitive position, and all of our obligations under our Credit Agreement are secured by certain of our collateral and the collateral of certain of our subsidiaries, as Guarantors. If we default on these obligations, our lenders could foreclose on such assets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, we entered into a $75.0 million Revolving Credit Facility with Citibank, N.A. as the Administrative Agent. We, our material domestic subsidiaries, as Guarantors, and the Lenders entered into the Credit Agreement with the Administrative Agent, under which the Lenders, the Swingline Lender and the L/C Issuer agreed to make loans and other financial accommodations to us in an aggregate amount of up to $75.0 million. Borrowings under the Credit Agreement are secured by certain of our collateral and that of the Guarantors. In specified circumstances, additional guarantors are required to be added. As a result, if we default on any of our obligations under the Credit Agreement, the Lenders could foreclose on their security interest and liquidate some or all of the collateral, which would harm our business, financial condition and results of operations and could require us to reduce or cease operations. On July 8, 2024, we entered into the first amendment (the &#8220;Amendment&#8221;) to the Credit Agreement, which amends the Credit Agreement to increase the aggregate revolving credit facility amount from $75 million to $125 million.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this report, we have been borrowed approximately $0.6 million under the Revolving Credit Facility. In order to service any indebtedness we may incur in the future, we would need to generate cash from our operating activities or other financings. Our ability to generate cash is subject, in part, to our ability to successfully execute our business strategy, as well as general economic, financial, competitive, regulatory and other factors beyond our control. Our business may not be able to generate sufficient cash flow from operations, and future borrowings or other financings may not be available to us in an amount sufficient to enable us to service our indebtedness and fund our other liquidity needs. To the extent we are required to use cash from operations or the proceeds of any future financing to service our indebtedness instead of funding working capital or other general corporate purposes, we will be less able to plan for, or react to, changes in our business, industry and in the economy generally. This could place us at a competitive disadvantage compared to our competitors that have less indebtedness.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary affirmative and negative covenants that limit our ability to engage in certain transactions that may be in our long-term best interest. The affirmative covenants include, among others, covenants requiring us to maintain a leverage ratio of no greater than 2.50 to 1.00 (increasing to 3.00 to 1.00 with respect to the fiscal quarter in which a material permitted acquisition is consummated and the immediately subsequent three fiscal quarters thereafter) and maintain minimum consolidated EBITDA (as defined in the Credit Agreement) for any trailing four-quarter period of not less than $45 million. The negative covenants include, among others, limitations on our ability to incur indebtedness and certain liens, make certain investments, become liable under contingent obligations in certain circumstances, make certain restricted payments, make certain dispositions within guidelines and limits, engage in certain affiliate transactions, alter our fundamental business and make certain fundamental changes.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we are currently in compliance with the covenants contained in the Credit Agreement, we may breach these covenants in the future. Our ability to comply with these covenants may be affected by events and factors beyond our control. In the event that we breach one or more covenants, the Lenders may choose to declare an event of default and require that we immediately repay all amounts outstanding under the agreement, terminate any commitment to extend further credit and foreclose on the collateral. The occurrence of any of these events could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use or draw down on our Credit Agreement or use other debt in connection with our capital deployment, which magnifies the potential for loss if the royalties acquired do not generate sufficient income to us.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We draw down on or use debt to finance a portion of our deployed capital. The use of debt creates an opportunity for an increased return but also increases the risk of loss if our assets do not generate sufficient income to us. The interest expense and other costs incurred in connection with such borrowings may not be covered by our cash flow and the level of our indebtedness could limit our ability to respond to changing business conditions. Our Credit Agreement imposes, and other debt we may incur in the future may impose, affirmative and negative covenants that could impact our operations and affect the number and size of the royalties that we may pursue. Therefore, no assurance can be given that we will be able to take advantage of favorable conditions or opportunities as a result of any restrictive covenants under our Credit Agreement or other future indebtedness. There can also be no assurance that additional debt financing, either to replace or increase existing debt financing, will be available when needed or, if available, will be obtainable on terms that are commercially reasonable. In addition, to the extent that interest rates at which we borrow increase, our borrowing costs will increase and our leveraging strategy will become more costly, which could lead to diminished net profits.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment charges pertaining to goodwill, identifiable intangible assets or other long-lived assets from our mergers and acquisitions could have an adverse impact on our results of operations and the market value of our common stock.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total purchase price pertaining to our acquisitions in recent years have been allocated to net tangible assets, identifiable intangible assets, in-process research and development and goodwill. To the extent the value of goodwill or identifiable intangible assets or other long-lived assets become impaired, we will be required to incur material charges relating to the impairment. Any impairment charges could have a material adverse impact on our results of operations and the market value of our common stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investments are subject to market and credit risks that could diminish their value and these risks could be greater during periods of extreme volatility or disruption in the financial and credit markets, which could adversely impact our business, financial condition, results of operations, liquidity and cash flows.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments are subject to risks of credit defaults and changes in market values. Periods of macroeconomic weakness or recession, heightened volatility or disruption in the financial and credit markets, including as a result of the change in presidential administration, and any resulting economic uncertainty, could increase these risks, potentially resulting in other than temporary impairment of assets in our investment portfolio. Any event reducing the estimated fair value of these securities, other than on a temporary basis, could have a material and adverse effect on our business, results of operations, financial condition, liquidity and cash flows. If our investment manager fails to react appropriately to difficult market, economic and geopolitical conditions, our investment portfolio could incur material losses.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a risk management framework in place to identify, assess and prioritize risks, including the market and credit risks to which our investments are subject. As part of that framework, we test our investment portfolio based on various market scenarios. Under certain stressed market scenarios, unrealized losses on our investment portfolio could lead to material reductions in its carrying value.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A decline in fair value below the amortized cost of a security requires management to assess whether an impairment has occurred. The decision on whether to record an impairment is determined in part by our assessment of the financial condition and prospects of a particular issuer, projections of future cash flows and recoverability of the particular security as well as management&#8217;s assertion of whether it is more likely than not that we will sell the particular security before recovery.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our charter documents and concentration of ownership may hinder or prevent change of control transactions.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions contained in our certificate of incorporation and bylaws may discourage transactions involving an actual or potential change in our ownership. In addition, our Board of Directors may issue shares of common or preferred stock without any further action by the stockholders. Our directors, officers and certain of our institutional investors collectively beneficially own a significant portion of our outstanding common stock. Such provisions and issuances may have the effect of delaying or preventing a change in our ownership. If changes in our ownership are discouraged, delayed or prevented, it would be more difficult for our current Board of Directors to be removed and replaced, even if you or our other stockholders believe that such actions are in the best interests of us and our stockholders.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by our directors, officers or other employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the General Corporation Law of Delaware or our amended and restated certificate of incorporation or amended and restated bylaws, or (iv) any action asserting a claim governed by the internal affairs doctrine. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act provides for concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder, and as such, the exclusive jurisdiction clauses set forth above would not apply to such suits. The choice of forum provisions in our amended and restated bylaws may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to these provisions, however, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation and bylaws has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been volatile and could experience a sudden decline in value.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market prices for securities of biotechnology and pharmaceutical companies have historically been highly volatile, and the market has experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. Continued volatility in the overall capital markets could reduce the market price of our common stock in spite of our operating performance. Further, high stock price volatility could result in higher share-based compensation expense.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has experienced significant price and volume fluctuations and may continue to experience volatility in the future. Many factors may have a significant impact on the market price of our common stock, including, but not limited to, the following factors: results of or delays in our preclinical studies and clinical trials; the success of our collaboration agreements; publicity regarding actual or potential medical results relating to products under development by us or others; announcements of technological innovations or new commercial products by us or others; developments in patent or other proprietary rights by us or others; comments or opinions by securities analysts or major stockholders or changed securities analysts&#8217; reports or recommendations; future sales or shorting of our common stock by existing stockholders; regulatory developments or changes in regulatory guidance; litigation or threats of litigation; economic and other external factors or other disaster or crises; the departure of any of our officers, directors or key employees; period-to-period fluctuations in financial results; and price and volume fluctuations in the overall stock market.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to remediate any material weakness in our internal control over financial reporting or otherwise fail to maintain an effective system of internal controls, we may not be able to accurately and timely report our financial results, in which case our business may be harmed, investors may lose confidence in the accuracy and completeness of our financial reports, and the price of our common stock may decline.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting and for evaluating and reporting on the effectiveness of our system of internal control, including monitoring corrective actions. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with GAAP. We are required to furnish annually a report by management of its assessment of the effectiveness of our internal control over </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">financial reporting as of the end of our most recent fiscal year. In addition, our independent registered public accounting firm is required to provide a related attestation report on our internal control over financial reporting.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our 2024 year-end assessment of internal control over financial reporting, we determined that the previously identified material weakness related to the ineffective process-level control activities in the business combination processes were remediated as of December 31, 2024. For further discussion of the material weakness identified and our remedial efforts, see Item 9A. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Controls and Procedures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to monitor and remediate successfully any future material weakness or other deficiencies in our internal control over financial reporting: the accuracy and timing of our financial reporting may be adversely affected; our liquidity, our access to capital markets, the perceptions of our creditworthiness, and our ability to complete acquisitions may be adversely affected; we may be unable to maintain compliance with applicable securities laws, Nasdaq listing requirements, and the covenants under our debt instruments regarding the timely filing of periodic reports; we may be subject to regulatory investigations and penalties; and investors may lose confidence in our financial reporting. If any such event or circumstance were to occur, our stock price could decline and our business, financial condition and results of operations could be materially adversely affected.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Unfavorable global economic and political conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our results of operations and ability to invest in and expand our business, meet our financial obligations, attract and retain collaboration partners and to raise additional capital and meet our liquidity needs could be materially negatively affected by prevailing economic and political conditions generally, both in the United States and elsewhere around the world. Concerns over inflation, energy costs, geopolitical issues, the new presidential administration in the U.S., military conflicts, including the wars between Russia and Ukraine and Israel and Hamas, terrorism, public health emergencies or pandemics, the availability and cost of credit, and the U.S. financial markets have in the past contributed to, and may continue in the future to contribute to, increased volatility and diminished expectations for the economy and the markets. Sanctions imposed by the United States and other countries in response to military conflicts, including the wars between Russia and Ukraine and Israel and Hamas, significant natural disasters (including as a result of climate change), new or increased tariffs or other barriers to trade, changes to fiscal or monetary policy or government budget dynamics (particularly in the biotechnology and pharmaceutical industries), higher interest rates and economic inflation, declines in economic growth or recession, geopolitical instability and other unstable market and macroeconomic conditions may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. Domestic and international equity markets periodically experience heightened volatility and turmoil.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems. All of these events may have an adverse effect on us. In the event of a market downturn, our results of operations could be adversely affected by those factors in many ways, including making it more difficult for us to raise funds if necessary, and our stock price may further decline. We cannot provide assurance that our investments are not subject to adverse changes in market value. If our investments experience adverse changes in market value, we may have less capital to fund our operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to risks arising from pandemic and epidemic diseases.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future pandemics, including the residual effects of the COVID-19 pandemic, or other public health epidemics, pose the risk that we or our employees, contractors, including our CROs, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to spread of the disease within these groups or due to shutdowns that may be requested or mandated by governmental authorities. Although we have lifted the restrictions we previously imposed on in-person access to our facilities and currently do not believe the COVID-19 pandemic is having a material impact on our business, we cannot guarantee that pandemics, such as COVID-19 or the emergence of variants thereof, or a similar event, will not impact our operations in the future.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of our partners reported that their operations were impacted by the COVID-19 pandemic, with such impacts including delays in research and development programs and deprioritizing clinical trials in favor of treating patients who had contracted the virus or to prevent the spread of the virus. In addition, certain of our partners reported negative impacts on product sales which impacted our royalty revenues. Although we believe that we and our partners have adjusted our business practices to the impacts of the COVID-19 pandemic, in the future, we may experience similar pandemics or epidemic diseases that could severely impact our business, drug manufacturing and supply chain, nonclinical activities and clinical trials and our partners&#8217; business may be impacted in similar ways, including due to delays or difficulties in enrolling patients in clinical trials, diversion of healthcare resources away from the conduct of clinical trials, interruption of, or delays in receiving, supplies of Captisol or other product or product candidates from contract manufacturing organizations due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems, which may result in cancellations of Captisol orders or refunds if </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we fail to deliver Captisol timely, interruption or delays to discovery and development pipelines and difficulties launching or commercializing products, including due to reduced access to doctors as a result of social distancing protocols. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the COVID-19 pandemic impacted the trading price of shares of our common stock. The extent to which the emergence of new variants of COVID-19, or any other outbreak of a pandemic or epidemic disease, impacts our results will depend on future developments that are highly uncertain and cannot be predicted, including new information that may emerge concerning the severity of the virus and the actions to contain its impact. Further, to the extent any pandemic or epidemic disease adversely affects our business and financial results, it may also have the effect of heightening many of the other risks described in this section. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research reports about our business or if they make adverse recommendations regarding an investment in our stock, our stock price and trading volume may decline.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock can be influenced by the research and reports that industry or securities analysts publish about our business. Currently, coverage of our Company by industry and securities analysts is limited. Investors have many investment opportunities and may limit their investments to companies that receive greater coverage from analysts. If additional industry or securities analysts do not commence coverage of the Company, the trading price of our stock could be negatively impacted. If one or more of the analysts downgrade our stock or comment negatively on our prospects, our stock price may decline. If one or more of these analysts cease to cover our industry or fail to publish reports about the Company regularly, our common stock could lose visibility in the financial markets, which could also cause our stock price or trading volume to decline. Further, incorrect judgments, estimates or assumptions made by research analysts may adversely affect our stock price, particularly if subsequent performance falls below the levels that were projected by the research analyst(s), even if we did not set or endorse such expectations. Any of these events could cause further volatility in our stock price and could result in substantial declines in the value of our stock.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cyber-attacks or other failures in telecommunications or information technology systems could result in information theft, data corruption and significant disruption of our business operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize information technology systems and networks to process, transmit and store electronic information in connection with our business activities. As use of digital technologies has increased, cyber incidents, including deliberate attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication. These threats pose a risk to the security of our systems and networks and the confidentiality, availability and integrity of our data. We have been subject to these attacks in the past and expect to be subject to them in the future. There can be no assurance that we will be successful in preventing cyber-attacks or mitigating their effects. Any cyber-attack or destruction or loss of data could adversely affect our business. In addition, we may suffer reputational harm or face litigation as a result of cyber-attacks or other data security breaches and may incur significant additional expense to implement further data protection measures or as a result of being found liable for data losses or theft from such a breach.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The biopharmaceutical industry may be negatively affected by federal government deficit reduction policies, which could reduce the value of the royalties that we hold.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to contain the U.S. federal deficit, the biopharmaceutical industry could be considered a potential source of savings and could be the target of legislative proposals aimed at reducing federal expenditures. Government action to reduce U.S. federal spending on entitlement programs, including Medicare, Medicaid or other publicly funded or subsidized health programs, or to lower drug spending, may affect payment for the products that generate our royalties. These and any other cost controls or any significant additional taxes or fees that may be imposed on the biopharmaceutical industry as part of deficit reduction efforts could reduce cash flows from our royalties and therefore adversely affect our business, financial condition or results of operations.</span></div><div id="ifca968692f35492e968bd282f4512e0b_19"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unresolved Staff Comments</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="ifca968692f35492e968bd282f4512e0b_22"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;1C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cybersecurity</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cybersecurity Risk Management and Strategy </span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-36" continuedAt="f-36-1" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. Our cybersecurity risk management program includes a cybersecurity incident response plan. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We design and assess our program based on the National Institute of Standards and Technology (&#8220;NIST&#8221;), the International Organization for Standardization (&#8220;ISO&#8221;) and other applicable industry standards. This does not imply that we </span></div></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-36-1"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">meet any particular technical standards, specifications, or requirements, only that we use the NIST, ISO and other standards as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-37" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-38">Our cybersecurity risk management program is integrated into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.</ix:nonNumeric></span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk management program includes:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise information technology environment;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a security team principally responsible for managing (i) our cybersecurity risk assessment processes, (ii) our security controls, and (iii) our response to cybersecurity incidents;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-39">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cybersecurity awareness training of our employees, incident response personnel, and senior management; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-40">a third-party risk management process for service providers, suppliers, and vendors.</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-41">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition.</ix:nonNumeric></span></div></ix:continuation><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cybersecurity Governance</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-43" continuedAt="f-43-1" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-42" continuedAt="f-42-1" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-45" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-44" escape="true">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#8220;Committee&#8221;) oversight of cybersecurity and other information technology risks. The Committee oversees management&#8217;s implementation of our cybersecurity risk management program.</ix:nonNumeric></ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-46" escape="true">The Committee receives regular reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential.</ix:nonNumeric> </span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-47" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-48">The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also receives briefings from senior management on our cyber risk management program. Board members receive presentations on cybersecurity topics from senior management, or external experts as part of the Board&#8217;s continuing education on topics that impact public companies.</ix:nonNumeric></span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-49" continuedAt="f-49-1">Our senior management team, including the Senior Director, IT and Facilities, is responsible for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-50" escape="true">The Senior Director, IT and Facilities has over 20 years of industry experiences leading and overseeing cybersecurity programs at public and private companies.</ix:nonNumeric></ix:nonNumeric></span></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-43-1"><ix:continuation id="f-42-1"><ix:continuation id="f-49-1">Our senior management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat</ix:continuation> intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information technology environment.</ix:continuation></ix:continuation>  </span></div><div id="ifca968692f35492e968bd282f4512e0b_25"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Properties</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our principal facilities leased as of December&#160;31, 2024, including the location and size of each facility, and their designated use. We believe our facilities are adequate for our current and near-term needs, and we will be able to locate additional facilities, as needed. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-top:5pt;text-indent:24pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"/><td style="width:13.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Approximate <br/>Square Feet</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operation</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jupiter, FL</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,650</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate headquarters</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 2026</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">San Diego, CA</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,850</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Boston, MA</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,840</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2029</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Las Vegas, NV</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,100</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lawrence, KS</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,700</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office and laboratory</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 2032</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Durham, NC</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,300</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Office and laboratory</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2032</span></td></tr></table></div><div style="margin-top:5pt;text-indent:24pt"><span><br/></span></div><div style="margin-top:5pt;text-indent:24pt"><span><br/></span></div><div id="ifca968692f35492e968bd282f4512e0b_28"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Proceedings</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2019, we received three civil complaints filed in the U.S. District Court for the Northern District of Ohio on behalf of several Indian tribes. The Northern District of Ohio is the Court that the Judicial Panel on Multi-District Litigation (&#8220;JPML&#8221;) has assigned more than one thousand civil cases which have been designated as a Multi-District Litigation (&#8220;MDL&#8221;) and captioned In Re: National Prescription Opiate Litigation. The allegations in these complaints focus on the activities of defendants other than the Company and no individualized factual allegations have been advanced against us in any of the three complaints. We reject all claims raised in the complaints and intend to vigorously defend these matters.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 22, 2024, CyDex Pharmaceuticals, Inc. filed a Verified Complaint in the Delaware Court of Chancery against Bexson Biomedical, Inc. (&#8220;Bexson&#8221;), asserting claims for declaratory relief and breach of contract arising out of a Captisol In Vivo Agreement (the &#8220;In Vivo Agreement&#8221;) between the parties, pursuant to which CyDex provided Bexson with research-grade Captisol and related confidential and proprietary information for a potential new formulation of ketamine being developed by Bexson. CyDex alleges that Bexson breached its obligations under the In Vivo Agreement, including by misusing confidential information and materials provided by CyDex and by using CyDex&#8217;s confidential information and materials to file patent applications that purport to cover formulations that are &#8220;not ketamine.&#8221; CyDex also asserts that Bexson failed to return and destroy Cydex&#8217;s confidential information and materials as required by the Agreement. CyDex seeks relief including specific performance of certain co-ownership provisions of the Agreement and disgorgement from Bexson for any benefits obtained in violation of the In Vivo Agreement. On September 27, 2024, Bexson filed a Motion to Dismiss the Verified Complaint. A Verified Amended Complaint was filed by CyDex on November 6, 2024, and a Motion to Dismiss the Verified Amended Complaint was filed by Bexson on January 17, 2025. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.</span></div><div id="ifca968692f35492e968bd282f4512e0b_31"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mine Safety Disclosures</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ifca968692f35492e968bd282f4512e0b_34"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ifca968692f35492e968bd282f4512e0b_37"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the Nasdaq Global Market under the symbol &#8220;LGND.&#8221; As of February&#160;25, 2025, there were approximately 320 holders of record of the common stock.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. We expect to retain our future earnings, if any, for use in the operation and expansion of our business, to pay down debt and potentially for share repurchases. Any future determination to pay dividends on common stock will be at the discretion of our Board of Directors and will depend upon our financial condition, results of operations, capital requirements and such other factors as the board deems relevant. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fiscal year ended December&#160;31, 2024, we did not repurchase any shares of our common stock under the stock repurchase program approved by our Board of Directors in April 2023, which allowed us to acquire up to $50 million of our common stock from time to time through April 2026.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-bottom:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below shows the five-year cumulative total stockholder return assuming the investment of $100 and is based on the returns of the component companies weighted monthly according to their market capitalization. The graph compares total stockholder returns of our common stock, of all companies traded on the Nasdaq Stock market, as represented by the Nasdaq Composite</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Index, and of the Nasdaq Biotechnology Stock Index, as prepared by The Nasdaq Stock Market Inc.</span></div><div style="margin-bottom:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stockholder return shown on the graph below is not necessarily indicative of future performance and we will not make or endorse any predictions as to future stockholder returns.</span></div><div style="margin-bottom:6pt;text-indent:24pt"><img src="lgnd-20241231_g4.jpg" alt="2024 Stock Performance.jpg" style="height:352px;margin-bottom:5pt;vertical-align:text-bottom;width:652px"/></div><div style="margin-top:9pt;text-align:center;text-indent:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Value of $100 Invested Over Time</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"/><td style="width:34.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.855%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.542%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.864%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12/31/2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12/31/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12/31/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12/31/2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12/31/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12/31/2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ligand</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94.04&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150.81&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NASDAQ Composite-Total Return</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144.92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177.06&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172.77&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NASDAQ Biotechnology Index</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126.45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118.87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div id="ifca968692f35492e968bd282f4512e0b_40"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">[RESERVED]</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:24pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:24pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:24pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:24pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:24pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:24pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:24pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:24pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:24pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:24pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:24pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:24pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:24pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="ifca968692f35492e968bd282f4512e0b_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></td></tr></table></div><div><span><br/></span></div><div id="ifca968692f35492e968bd282f4512e0b_46"></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Management's Discussion and Analysis of Financial Condition and Results of Operations (MD&amp;A) will help readers understand our results of operations, financial condition, and cash flows. It is provided in addition to the accompanying consolidated financial statements and notes.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">OmniAb Transactions</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2022, we entered into (i) an Agreement and Plan of Merger (the &#8220;OmniAb Merger Agreement&#8221;), among Ligand, OmniAb, Avista Public Acquisition Corp. II, a Cayman Islands exempted company (&#8220;APAC&#8221;), and Orwell Merger Sub, Inc., a wholly owned subsidiary of APAC (&#8220;Merger Sub&#8221;), and (ii) a Separation and Distribution Agreement (the &#8220;OmniAb Separation and Distribution Agreement&#8221;), among Ligand, OmniAb and APAC. Prior to the effective time of the OmniAb Merger (defined below), APAC migrated to and domesticated as a Delaware corporation (&#8220;New OmniAb&#8221;) in accordance with the terms and conditions of the OmniAb Merger Agreement. Pursuant to the OmniAb Separation and Distribution Agreement, we, prior to the effective time of the OmniAb Merger (i) transferred our then-antibody discovery business (the &#8220;OmniAb Business&#8221;), including certain of our related subsidiaries, to OmniAb (the &#8220;OmniAb Separation&#8221;) and (ii) in connection therewith, distributed 100% of OmniAb&#8217;s common stock held by Ligand to Ligand stockholders (the &#8220;OmniAb Distribution&#8221;). We also contributed to OmniAb cash and certain specific assets and liabilities constituting the OmniAb Business. Following the OmniAb Separation and the OmniAb Distribution, on November 1, 2022, in accordance with and subject to the terms and conditions of the OmniAb Merger Agreement, Merger Sub merged with and into OmniAb, with OmniAb continuing as the surviving company and wholly-owned subsidiary of New OmniAb on and after the effective time of the merger (the &#8220;OmniAb Merger&#8221;). In addition, New OmniAb changed its corporate name to &#8220;OmniAb, Inc.&#8221; concurrently upon the effectiveness of the OmniAb Merger.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the OmniAb Distribution, we do not beneficially own any shares of common stock in OmniAb and no longer consolidate OmniAb into our financial results for periods ending after October 31, 2022. As a result, OmniAb's historical financial results through the OmniAb Separation are reflected in our consolidated financial statements as discontinued operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our MD&amp;A is organized as follows:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Results of Operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Detailed discussion of our revenue and expenses for twelve months ended December&#160;31, 2024 and 2023. A comparison of our results of operations for twelve months ended December&#160;31, 2024 and 2023 can be found under &#8220;Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this Annual Report.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Liquidity and Capital Resources.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Discussion of key aspects of our consolidated statements of cash flows, changes in our financial position, and our financial commitments.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Critical Accounting Policies and Estimates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discussion of significant changes we believe are important to understand the assumptions and judgments underlying our consolidated financial statements.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Recent Accounting Pronouncements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For summary of recent accounting pronouncements applicable to our consolidated financial statements, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (1), Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue and Other Income</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FY 2024 vs. FY 2023</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from intangible royalty assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,814&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Captisol</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract revenue and other income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue and other income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,133&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,314&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,819&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue and other income increased by $35.8&#160;million, or 27%, to $167.1&#160;million in 2024 compared to $131.3&#160;million in 2023 primarily due to the $23.8&#160;million increase in royalties. The increase in royalties in 2024 was primarily due to income from Qarziba financial royalty asset acquired in the third quarter of 2024 and an increase in sales of Travere Therapeutics&#8217; Filspari. Captisol sales increased by $2.5&#160;million to $30.9&#160;million in 2024 compared to $28.4&#160;million in 2023. The higher Captisol sales were due to the timing of customer orders. Contract revenue and other revenue increased by $9.5&#160;million primarily due to milestone payments earned from Verona Pharma upon the approval and commercial launch of Ohtuvayre.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from intangible royalty assets is a function of our partners' product sales and the applicable royalty rate. Kyprolis royalty rate is under a tiered royalty rate structure with the highest being 3%. Evomela has a contractually fixed royalty rate of 20%. Teriparatide injection has a tiered gross profit share between 25% and 40% on sales that have been adjusted for certain deductible items as defined in the respective license agreement. The Rylaze and Vaxnuevance royalty rates are in the low single digits. Filspari has a fixed royalty rate of 9%. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents revenue from intangible royalty assets by program (in millions):</span></div><div style="text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.769%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024 Estimated Partner Product Sales</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Royalty Rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024 Royalty Revenue </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 Estimated Partner Product Sales</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Royalty Rate</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023 Royalty Revenue</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Kyprolis</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,627.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,503.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rylaze</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.4%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Filspari</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.0%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.0%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.0%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Teriparatide injection</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.2%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.8%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">791.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">653.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">451.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">272.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,489.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,945.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) We receive tiered profit sharing of 25% on quarterly profits less than $3.75 million, 35% on quarterly profits greater than $3.75 million but less than $7.5 million and 40% on quarterly profits greater than $7.5 million.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Costs and Expense</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FY 2024 vs. FY 2023</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of Captisol</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(695)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,112)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,790&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financial royalty assets impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value adjustment to partner program derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189,739&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121,493&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,246&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total operating costs and expenses for 2024 increased by $68.2 million or 56% compared with 2023. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of Captisol increased year over year in 2024 primarily due to higher sales of Captisol during 2024 compared to 2023. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any one time, we are working on multiple programs. As such, we generally do not track our R&amp;D expenses on a specific program basis. Our R&amp;D expenses decreased by $3.1 million in 2024 compared to 2023, with the decrease primarily attributable to lower employee related expenses and lab supplies resulting from the Pelican spin-off in September 2023. The decrease was partially offset by additional costs associated with incubating the Pelthos business.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses increased by $25.9 million in 2024 compared to 2023, with the increase primarily driven by higher stock-based compensation expenses for investments made in building out our business development and investment team. Additionally, a one-time, non-cash stock award modification expense related to the departure of Ligand's former Chief Operating Officer and costs associated with incubating the Pelthos Therapeutics business contributed to the increase.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial royalty asset impairment was $30.6 million for 2024 primarily due to Takeda's decision to discontinue the soticlestat program.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value adjustment to partner program derivatives was $15.1 million for 2024 primarily due to certain Agenus partners discontinuing development of their partnered programs. These programs may be relicensed at a later date, and Ligand would retain its economic interest upon any relicense activity.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not provide forward-looking estimates of costs and time to complete our ongoing research and development projects as such estimates would involve a high degree of uncertainty. Uncertainties include our inability to predict the outcome of research and clinical studies, regulatory requirements placed upon us by regulatory authorities such as the FDA and EMA, our inability to predict the decisions of our partners, our ability to fund research and development programs, competition from other entities of which we may become aware in future periods, predictions of market potential for products that may be derived from our work, and our ability to recruit and retain personnel or third-party contractors with the necessary knowledge and skills to perform certain research. Refer to &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; for additional discussion of the uncertainties surrounding our research and development initiatives.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on Sale of Pelican</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain on sale of Pelican in the amount of $2.1 million for 2023 represents the excess of the fair value of 1) our investment in Primrose Bio and other economic rights; 2) the carrying amount of Pelican business assets and liabilities together with allocated goodwill as of September 18, 2023, the date of sale; and 3) $15 million consideration paid.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense)</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FY 2024 vs. FY 2023</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain (loss) from short-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,024&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,365&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,381)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-operating expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54,918)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,702)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,216)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,124&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,718&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,594)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in the gain (loss) from short-term investments of $28.7 million is primarily driven by the realized gain of $60.0 million from the sale of 0.7 million shares of Viking common stock in 2024, compared to the $44.4 million realized gain from the sales of 5.0 million shares of Viking common shares in 2023. In addition, the increase was driven by changes in the fair value of our ownership in Viking common stock (an unrealized gain of $9.0 million in 2024 compared to an unrealized gain of $2.6 million in 2023) and a $7.1 million net gain on the arrangements we executed and exercised in 2024 to hedge against the fluctuation in Viking's share price. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists primarily of interest earned on our short-term investments and remained relatively steady in 2024 compared to 2023. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense in 2024 consists primarily of a royalty and milestone payments purchase agreement, entered by Novan in 2019, and assumed as part of the Novan acquisition in September 2023. Interest expense in 2023 consists primarily of the 0.75% coupon cash interest expense in addition to the non-cash accretion of discount (including the amortization of debt issuance costs) on our 2023 Notes. In May 2023, the 2023 Notes matured, and we paid the remaining $76.9 million principal amount and $0.3 million accrued interest in cash. See additional information in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (10), Debt.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other non-operating expense, net, primarily consists of mark-to-market adjustments on derivatives (other than Viking Share Collar and Put and the partner program derivatives) and CVRs and losses on equity method investments. Other non-operating expense, net, increased by $53.2 million in 2024 compared to 2023, primarily due to the $25.8 million loss from revaluation of Primrose investments, the $12.8 million equity method loss from Primrose Bio, the $12.1 million loss from change in fair value of derivative assets, and the $3.0 million impairment loss related to Neuritek warrants in 2024.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income tax benefit (expense)</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FY 2024 vs. FY 2023</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:58.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.035%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense (benefit) from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,660&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(61,142)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,550)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,841)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,032)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,819&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57,851)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective Tax Rate</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">260&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for 2024 and 2023 was 260% and 15%, respectively. Our tax rate is affected by recurring items, such as the U.S. federal and state statutory tax rates and the relative amounts of income we earn in those jurisdictions, which we expect to be fairly consistent in the near term. It is also affected by discrete items that may occur in any given year, but are not consistent from year to year. In 2024, the variance from the U.S. federal statutory rate of 21% was primarily attributable to increase in foreign includable income and non-deductible stock based compensation. In 2023, the variance from the U.S. federal statutory rate of 21% was primarily due the decrease in unrecognized tax benefits. The items below also had an impact on the difference between our statutory U.S. rate.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024 </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$5.6 million (224.2%) increase from foreign includable income</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$3.9 million (155.6%) increase from Section 162(m) limitation</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$3.2 million (128.3%) decrease from foreign tax credit</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$1.6 million (65.0%) decrease from valuation allowance</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$1.1 million (44.3%) increase from foreign rate differential</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.8 million (33.0%) decrease from the foreign-derived intangible income deduction</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.6 million (23.9%) increase from the return to provision</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.2 million (9.1%) decrease from research &amp; development tax credit</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$7.2 million (11.3%) decrease from unrecognized tax benefits</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$2.2 million (3.4%) increase from the return to provision</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$1.2 million (1.9%) decrease from stock based compensation</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$1.0 million (1.6%) decrease from the foreign-derived intangible income deduction</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">$0.8 million (1.3%) decrease from Section 162(m) limitation</span></div><div id="ifca968692f35492e968bd282f4512e0b_49"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, we had approximately $256.2 million in cash, cash equivalents, and short-term investments. Cash and cash equivalents and short-term investments decreased by $85.9 million from last year, due to factors described in the &#8220;Cash Flow Summary&#8221; below. Our primary source of liquidity, other than our holdings of cash, cash equivalents, and investments, has been cash flows from operations. Our ability to generate cash from operations provides us with the financial flexibility we need to meet operating, investing, and financing needs.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have liquidated our short-term investments and/or issued debt and equity securities to finance our business needs as a supplement to cash provided by operating activities. Our short-term investments include U.S. government debt securities, investment-grade corporate debt securities, bond funds and certificates of deposit. We have established guidelines relative to diversification and maturities of our investments in order to provide both safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates. Additionally, we own </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certain securities which are classified as short-term investments that we received as a result of a milestone and an upfront license payment as well as 1.0 million shares of common stock in Viking.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, we entered into an At-The-Market Equity Offering Sales Agreement (the &#8220;Sales Agreement&#8221;) with Stifel, Nicolaus &amp; Company, Incorporated (the &#8220;Agent&#8221;), under which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $100 million in &#8220;at the market&#8221; offerings through the Agent (the &#8220;ATM Offering&#8221;). The shelf registration statement relating to such shares included a prospectus covering the offering, issuance and sale of up to $100 million of our common stock from time to time through the ATM Offering. The shares to be sold under the Sales Agreement may be issued and sold pursuant to the shelf registration statement. During 2024, we issued 360,325 shares of common stock in the ATM Offering, generating net proceeds of $37.4&#160;million, net of commissions and other transaction costs.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make payments under operating leases, including rental commitments on leases that have not yet commenced. For information on these obligations, see detail in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (9), Leases.&#8221;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have commitments under our supply agreement with Hovione for Captisol purchases. The total purchase obligation as of December&#160;31, 2024 was $21.6 million, of which $9.0&#160;million is expected to be paid within a year and the remaining amount is expected to be paid between 1 to 3 years.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, our Board approved a stock repurchase program authorizing, but not requiring, the repurchase of up to $50 million of our common stock from time to time through April 2026. We expect to acquire shares, if at all, primarily through open-market transactions in accordance with all applicable requirements of Rule 10b-18 of the Exchange Act. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. Authorization to repurchase $50 million of our common stock remained available as of December&#160;31, 2024. See &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 5. Market for Registrant's Common Equity, Related Stockholder Matters, and Issuer Purchase of Equity Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2023, we entered into a $75 million Revolving Credit Facility with Citibank, N.A. as the Administrative Agent. We, our material domestic subsidiaries, as Guarantors (as defined in the Credit Agreement), and the Lenders (each as defined in the Credit Agreement) entered into the Credit Agreement with the Administrative Agent, under which the Lenders, the Swingline Lender and the L/C Issuer (each as defined in the Credit Agreement) agreed to make loans and other financial accommodations to us in an aggregate amount of up to $75 million. Borrowings under the Revolving Credit Facility accrue interest at a rate equal to either Term SOFR or a specified base rate plus an applicable margin linked to our leverage ratio, ranging from 1.75% to 2.50% per annum for Term SOFR loans and 0.75% to 1.50% per annum for base rate loans. The Revolving Credit Facility is subject to a commitment fee payable on the unused Revolving Credit Facility commitments ranging from 0.30% to 0.45%, depending on our leverage ratio. During the term of the Revolving Credit Facility, we may borrow, repay and re-borrow amounts available under the Revolving Credit Facility, subject to voluntary reductions of the swing line, letter of credit and revolving credit commitments. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 8, 2024, we entered into the first Amendment to the Revolving Credit Facility which amends the Credit Agreement to, among other things, increase the aggregate revolving credit facility amount from $75 million to $125 million.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Credit Agreement are secured by certain of our collateral and that of the Guarantors. In specified circumstances, additional guarantors are required to be added. The Credit Agreement contains customary affirmative and negative covenants, including certain financial maintenance covenants, and events of default applicable to us. In the event of violation of the representations, warranties and covenants made in the Credit Agreement, we may not be able to utilize the Revolving Credit Facility or repayment of amounts owed thereunder could be accelerated. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had $124.4&#160;million in available borrowing under the Revolving Credit Facility, after utilizing $0.6&#160;million for letter of credit. The maturity date of the Revolving Credit Facility, as amended, is October 12, 2026. As of December&#160;31, 2024, there were no events of default or violation of any covenants under our financing obligations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that existing funds, cash generated from operations and existing sources of and access to financing are adequate to satisfy our needs for working capital; capital expenditure and debt service requirements; continued advancement of research and development efforts; potential stock repurchases; and other business initiatives we plan to strategically pursue, including acquisitions and strategic investments. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had $3.7&#160;million in fair value of contingent consideration liabilities associated with the acquisitions to be settled in future periods.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Summary</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:58.395%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.541%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.664%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143,664)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,682)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">163,624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59,947)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(275,990)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, we generated cash from operations primarily from revenue and other operating income. We used cash for investing activities primarily for the Apeiron Acquisition and Agenus Transaction. During the year, we generated cash from financing activities, primarily including net proceeds from the sales of shares of common stock in the ATM Offering, and net proceeds from stock options exercises and ESPP.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, we generated cash from operations primarily from revenue and other operating income. We used cash for investing activities primarily for the purchases of financial royalty assets, the Novan acquisition and our investment in Primrose Bio, partially offset by cash from the sale and maturity of short-term investments including Viking shares. During the year, we used cash for financing activities, including the repayment of the remaining $76.9 million principal amount upon maturity of the 2023 Notes and $0.3 million accrued interest in cash.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we generated cash from operations primarily from revenue and other operating income. We generated cash from investing activities primarily from the sale and maturity of short-term investments. During the year, we used cash for financing activities, including the payments related to the extinguishment of certain 2023 Notes.</span></div><div id="ifca968692f35492e968bd282f4512e0b_52"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent liabilities in the consolidated financial statements and accompanying notes. The SEC has defined a company&#8217;s critical accounting policies as the ones that are most important to the portrayal of the company&#8217;s financial condition and results of operations, and which require the company to make its most difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Based on this definition, we have identified the critical accounting policies and judgments addressed below. We also have other key accounting policies, which involve the use of estimates, judgments, and assumptions that are significant to understanding our results. For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (1), Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; Although we believe that our estimates, assumptions, and judgments are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments, or conditions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment Assessment of Finite-lived Intangibles</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly perform reviews to determine if an event occurred that may indicate the carrying values of our intangible assets are impaired. If indicators of impairment exist, we assess the recoverability of the affected long-lived assets by comparing its carrying amounts to its undiscounted cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value exceeds the fair value. Factors that may indicate potential impairment include a significant decline in our stock price and market capitalization compared to net book value, significant changes in the ability of an asset to generate positive cash flows and the pattern of utilization of a particular asset.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to estimate the fair value of identifiable intangible assets, we estimate the present value of future cash flows from those assets. The key assumptions that we use in our discounted cash flow model are the amount and timing of estimated future cash flows to be generated by the asset over an extended period of time and a rate of return that considers the relative risk of achieving the cash flows, the time value of money, and other factors that a willing market participant would consider. Significant judgment is required to estimate the amount and timing of future cash flows and the relative risk of achieving those cash flows. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assumptions and estimates about future values and remaining useful lives are complex and often subjective. They can be affected by a variety of factors, including external factors such as industry and economic trends, and internal factors such as changes in our business strategy and our internal forecasts. For example, if our future operating results do not meet current forecasts or if we experience a sustained decline in our market capitalization that is determined to be indicative of a reduction in fair value of our reporting unit, we may be required to record future impairment charges for purchased intangible assets. Impairment charges could materially decrease our future net income and result in lower asset values on our balance sheet.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Royalty Assets - Recognition of Income</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial royalty assets represent a portfolio of future milestone and royalty payment rights acquired that are passive in nature (i.e., we do not own the intellectual property or have the right to commercialize the underlying products).</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is recalculated in each reporting period as the difference between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by accrued interest income (except for assets under the non-accrual method) and decreased by cash receipts in the period to arrive at the ending balance.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. Income is calculated by multiplying the carrying value of the financial royalty asset by the periodic effective interest rate. We account for financial royalty assets related to developmental pipeline or recently commercialized products on a non-accrual basis. Developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. Newly commercialized products typically do not have an established reliable sales pattern, and thus have uncertain cash flows.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Partnered Programs Derivative Assets Acquired in Agenus Transaction</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Partnered Programs acquired in the transaction with Agenus are accounted for as derivative assets under ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and were recorded at fair value at acquisition. These derivative assets are marked to fair value at each subsequent reporting period. To determine the fair value of the derivative assets, the Company applied a discounted cash flow model using observable and unobservable market data for inputs, including the estimated amount and timing of the expected cash flows and the probability of success of underlying clinical programs which considers the level of risk appropriate for a respective program stage.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the summary of recent accounting pronouncements applicable to our consolidated financial statements, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 8. Financial Statements and Supplementary Data&#8212;Notes to Consolidated Financial Statements&#8212;Note (1), Basis of Presentation and Summary of Significant Accounting Policies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div id="ifca968692f35492e968bd282f4512e0b_55"></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quantitative and Qualitative Disclosures About Market Risk</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risk from interest rates and equity prices which could affect our results of operations, financial condition and cash flows. We manage our exposure to these market risks through our regular operating and financing activities.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment Portfolio Risk</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, our investment portfolio included investments in available-for-sale securities of $183.9 million, including the investment in Viking common stock of $40.2 million. These securities are subject to market risk and may decline in value based on market conditions.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit risk through our counterparties, including risks associated with royalty assets, receivables, and financial instruments such as derivatives and available-for-sale debt securities. Most of our royalty assets and receivables come from contractual agreements that generate royalties based on sales of pharmaceutical products across the United States, Europe, and other regions. This risk is primarily mitigated by the broad range of marketers responsible for paying royalties and the geographic diversity of product sales. Our royalty portfolio includes products marketed by leading biopharmaceutical companies such as Amgen, Merck, Jazz, Recordati, and Sanofi. As of December&#160;31, 2024, Recordati was the largest individual marketer and payor of our financial royalty assets, representing 54% of these assets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively monitor the financial performance and creditworthiness of counterparties to our royalty agreements, derivative financial instruments, and available-for-sale debt securities to assess and respond to changes in their credit profiles. So far, we have not incurred any significant losses related to the collection of income or revenue from royalty assets, available-for-sale debt securities, or the settlement of derivative financial instruments. However, if a counterparty faces bankruptcy or financial difficulties and fails to meet its obligations under a derivative financial instrument, we could face substantial difficulties or delays in recovering amounts owed during bankruptcy or reorganization.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our licensing and business operations, we are exposed to foreign currency risk. Foreign currency exposures arise from transactions denominated in a currency other than the functional currency and from foreign denominated revenues and profit translated into U.S. dollars. As a result, our revenues from royalty payments are exposed to risks associated with fluctuations in foreign exchange rates. These currency fluctuations could cause our operating results to differ materially from expectations, potentially leading to substantial gains or losses from the remeasurement of company balances. While historically&#160;&#160;&#160;&#160; we have primarily transacted with customers and vendors in U.S. dollars, as our international operations expand, our exposure to the effects of fluctuations in currency exchange rates increase. We expect to continue to expand the number of transactions with our customers that are denominated in foreign currencies in the future. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase Captisol from Hovione, located in Lisbon, Portugal and Cork, Ireland. Payments to Hovione are denominated and paid in U.S. dollars; however, the unit price of Captisol contains an adjustment factor which is based on the sharing of foreign currency risk between the two parties. Currently, we do not hedge our exposure to foreign currency fluctuations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, we generate Qarziba royalty revenue and incur operating expenses at our non-U.S. locations in the local currency for such locations. Fluctuations in the exchange rates between the U.S. dollar and other currencies could result in an increase to the U.S. dollar equivalent of related income and expenses. These fluctuations in currency exchange rates may affect the reported value of foreign-denominated revenues, expenses, assets, and liabilities when translated into U.S. dollars.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to changes in interest rates related primarily to our investment portfolio. Our investment policy and strategy are focused on the preservation of capital and supporting our liquidity requirements. We use a combination of internal and external management to execute our investment strategy. We typically invest in highly rated securities, with the primary objective of minimizing the risk of principal loss. Our investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. We have historically maintained a relatively short average maturity for our investment portfolio, and we believe a hypothetical 100 basis point adverse move in interest rates across all maturities would not materially impact the fair market value of the portfolio in either period. </span></div><div id="ifca968692f35492e968bd282f4512e0b_58"></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Financial Statements and Supplementary Data</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div id="ifca968692f35492e968bd282f4512e0b_61"></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:94.061%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_64">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-51">42</ix:nonNumeric>)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_64">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_67">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_67">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_70">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_70">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_73">Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_73">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_76">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_76">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_79">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_79">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_82">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_82">65</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="ifca968692f35492e968bd282f4512e0b_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Ligand Pharmaceuticals Incorporated</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Ligand Pharmaceuticals Incorporated (the Company) as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 28, 2025 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.188%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Impairment assessment of finite-lived intangibles </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024, the Company&#8217;s finite-lived intangible assets totaled $266.6 million. As discussed in Note 1 to the consolidated financial statements, the Company reviews finite-lived intangible assets for impairment whenever events or changes in circumstances indicate the carrying amount may not be recoverable.  The Company did not identify indicators of impairment for its finite-lived intangibles at December 31, 2024. <br/>Auditing management&#8217;s assessment of impairment is challenging due to the degree of subjective auditor judgment necessary in evaluating management&#8217;s process to identify potential indicators of impairment and the related assessment of the severity of such indicators in determining whether a triggering event has occurred. A high degree of auditor judgment was required to evaluate potential triggering events which included market conditions, industry and economic trends, changes in regulations, clinical success and historical and forecasted financial results. The evaluation of triggering events could have a significant effect on the Company&#8217;s impairment assessment and the determination of whether further quantitative analysis of finite-lived intangible assets was required.<br/></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.188%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding of management&#8217;s process to identify indicators of impairment, including the qualitative analysis and related inputs and assumptions used in performing the analyses. We evaluated the design and tested the operating effectiveness of the controls that address the identification of indicators of impairment. For example, we tested controls over management&#8217;s assessment of indicators of impairment. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the Company&#8217;s evaluation of indicators of impairment for finite-lived intangibles, our audit procedures included, among others, assessing the methodologies and testing the completeness and accuracy of the Company&#8217;s analysis of events or changes in circumstances. As part of our evaluation, we considered market conditions, industry and economic trends, changes in regulations, clinical success and historical and forecasted financial results, in assessing whether an indicator of impairments exists.<br/></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial royalty assets - recognition of income<br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><br/></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed in Note 6 to the consolidated financial statements, the Company&#8217;s total financial royalty assets, net, were $195.0 million as of December 31, 2024. For the year ended December 31, 2024, the Company recognized income from financial royalty assets of $13.4 million. As explained in Note 1 and 6 to the consolidated financial statements, the Company&#8217;s financial royalty assets are measured at amortized cost and income is recognized using the prospective effective interest method. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing management&#8217;s recognition of income under the effective interest method involved complex auditor judgment, as the assumptions used to forecast the prospective interest rate include estimates of expected future cash flows from the underlying royalties and are therefore affected by uncertainties such as future demand for the underlying product.</span></div><div><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls related to the recognition of income on financial royalty assets. This included testing controls over management&#8217;s review of the significant assumptions and other inputs used in estimating the forecasted cash flows. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the income recognized, our audit procedures included, among others, evaluating the completeness and accuracy of the data used to develop the key assumption identified above. For example, we tested the inputs to the model, principally comprising of historic product sales and estimates of nearer-term sales.  We also evaluated management&#8217;s expected future cash flows for the products underlying the royalties and performed a sensitivity analysis over the resulting forecasted product sales. <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/><br/><br/><br/><br/><br/><br/></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:123pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:123pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:45pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.966%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:82.188%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Agenus partnered programs in Agenus acquisition</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed in Note 2 and 7 to the consolidated financial statements, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeNet" format="ixt:num-dot-decimal" scale="6" id="f-52">21.3</ix:nonFraction>&#160;million of non-current derivative assets in acquired rights from future milestone and royalty payments (&#8220;Agenus partnered programs&#8221;) in the Agenus acquisition.  As of December 31, 2024, total non-current derivative assets in the Agenus partnered programs were $6.3&#160;million and unrealized losses from derivative instruments were $15.0&#160;million. To determine the fair value of the derivative assets, the Company applied a discounted cash flow model using observable and unobservable market data for inputs, including the probability of technical and regulatory success of underlying clinical programs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing management&#8217;s estimate of the fair value of the derivative assets involved complex auditor judgment because the fair value calculations were sensitive to changes in assumptions described above, and certain inputs used in the determination of the fair value were based on unobservable data, including the probability of technical and regulatory success of underlying clinical programs.</span></div><div><span><br/></span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls related to the valuation of derivative assets. This included testing controls over management&#8217;s review of the significant assumptions and other inputs used in the valuation models.  <br/></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures included, among others, evaluating the methodology used in the valuation models and the significant assumptions described above. We compared the significant assumptions to published data for clinical trials. We involved our valuation specialists to assist in the evaluation including assessing whether the methodology used in developing the estimate was consistent with valuation practice given the characteristics of the derivative and to develop an independent value of the assets. <br/></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-53">Ernst&#160;&amp; Young&#160;LLP</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2016.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-54">San Diego, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;28, 2025</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="ifca968692f35492e968bd282f4512e0b_67"></div><hr style="page-break-after:always"/><div style="min-height:38.25pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except par value)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:72.908%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.530%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents </span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-55">72,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-56">22,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-57">183,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-58">147,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">38,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-60">32,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-61">14,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-62">23,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-63">4,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-64">6,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">1,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">1,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">16,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">2,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">331,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">237,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 13pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-71">266,648</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-72">299,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-73">105,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-74">103,370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term portion of financial royalty assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNonCurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">185,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNonCurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">62,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncurrent derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">10,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-78">3,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-79">15,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-80">15,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-81">6,907</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-82">6,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-83">2,766</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-84">3,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Equity method investment in Primrose Bio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-86">12,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-87">10,908</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-88">36,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="f-89">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="f-90">214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-91">6,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-92">6,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-93">941,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-94">787,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY </span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-95">5,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-96">2,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-97">27,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-98">12,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:TaxesPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-99">1,199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue   </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-100">1,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-101">1,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current contingent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:CurrentPortionOfLiabilityForContingentValueRights" scale="3" id="f-102">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lgnd:CurrentPortionOfLiabilityForContingentValueRights" scale="3" id="f-103">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-104">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-105">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-106">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-107">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-108">37,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-109">16,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-110">2,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-111">1,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:LiabilityForContingentValueRights" format="ixt:num-dot-decimal" scale="3" id="f-112">3,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lgnd:LiabilityForContingentValueRights" format="ixt:num-dot-decimal" scale="3" id="f-113">2,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-114">5,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-115">5,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-116">32,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-117">31,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-118">30,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-119">27,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-120">111,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-121">86,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-122"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-6" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-123"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-124"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-125">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-126"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-127">5,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-128"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-129"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-130"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-131">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> issued and outstanding at December 31, 2024 and 2023</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-132">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-133">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-134"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-135">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-136"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-137">60,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-138"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-139">19,106</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-140"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-141">17,556</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2024 and 2023, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-142">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-143">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-144">337,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-145">198,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-146">5,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-147">817</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-148">498,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-149">503,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-150">830,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-151">700,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities and stockholders&#8217; equity </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-152">941,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-153">787,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="ifca968692f35492e968bd282f4512e0b_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:62.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.664%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.373%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenues and other income:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from intangible royalty assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-154">95,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-155">83,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-156">72,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-157">13,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-158">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-159">385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-160">108,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-161">84,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-162">72,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Captisol</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-163">30,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-164">28,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-165">104,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract revenue and other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-166">27,477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-167">17,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-168">18,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenues and other income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-169">167,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-170">131,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-171">196,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of Captisol</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostDirectMaterial" format="ixt:num-dot-decimal" scale="3" id="f-172">11,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:CostDirectMaterial" format="ixt:num-dot-decimal" scale="3" id="f-173">10,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:CostDirectMaterial" format="ixt:num-dot-decimal" scale="3" id="f-174">52,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="f-175">32,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="f-176">33,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="f-177">34,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-178">21,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-179">24,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-180">36,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-181">78,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-182">52,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-183">70,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial royalty assets impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-184">30,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="f-185">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="f-186">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value adjustments to partner program derivatives</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:num-dot-decimal" scale="3" id="f-187">15,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:fixed-zero" scale="3" id="f-188">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:DerivativeGainLossOnDerivativeNet" format="ixt:fixed-zero" scale="3" id="f-189">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-190">189,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-191">121,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:OperatingCostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-192">193,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Gain on sale of Pelican</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="f-193">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="3" id="f-194">2,121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="f-195">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating income (loss) from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-196">22,606</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-197">11,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-198">3,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-operating income and expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain from short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-199">75,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-200">46,365</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-201">28,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-202">8,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-203">7,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-204">2,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-205">3,037</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-206">656</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-207">1,799</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-operating (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-208">54,918</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-209">1,702</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-210">4,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total non-operating income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-211">25,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-212">51,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-213">32,974</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income tax from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-214">2,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-215">63,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-216">36,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-217">6,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-218">9,841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-219">41,230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss) from continuing operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-220">4,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-221">53,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperations" format="ixt:num-dot-decimal" scale="3" id="f-222">5,219</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss from discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-223">1,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-224">28,142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net income (loss):</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-225">4,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-226">52,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-227">33,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic net income (loss) from continuing operations per share</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-228">0.22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-229">3.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-23" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-230">0.31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic net loss from discontinued operations per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="f-231">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="f-232">0.10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-23" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="f-233">1.67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Basic net income (loss) per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-234">0.22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-235">3.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-23" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-236">1.98</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in basic per share calculation</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-237">18,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-238">17,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-239">16,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted net income (loss) from continuing operations per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-240">0.22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-241">3.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-23" decimals="2" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-242">0.31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted net loss from discontinued operations per share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="f-243">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="f-244">0.09</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-23" decimals="2" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="f-245">1.67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Diluted net income (loss) per share</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-246">0.22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-247">2.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-23" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-248">1.98</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in diluted per share calculation</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-249">18,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-250">17,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-251">16,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div id="ifca968692f35492e968bd282f4512e0b_73"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:67.181%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.713%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-252">4,032</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-253">52,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-254">33,361</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized net gain (loss) on available-for-sale securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-255">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-256">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-257">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-258">5,170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="3" id="f-260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-261">9,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-262">52,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-263">33,428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">62</span></div></div></div><div id="ifca968692f35492e968bd282f4512e0b_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENT OF STOCKHOLDERS&#8217; EQUITY </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.458%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.374%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">paid-in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">capital</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">comprehensive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">income (loss)</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retain earnings</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">stockholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">equity</span></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-24" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-264">16,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-265">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-266">372,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-267">917</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-268">449,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-269">821,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-270">ASU 2020-06 adoption, net of tax</span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-271">51,130</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-272">35,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-273">15,997</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-274">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-275">5,004</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-276">5,004</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-277">60,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-278">60,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized net loss on available-for-sale securities, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-279">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-280">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bond hedge transaction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="lgnd:AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" scale="3" id="f-281">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" scale="3" id="f-282">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OmniAb Distribution</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="lgnd:AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" format="ixt:num-dot-decimal" scale="3" id="f-283">229,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" format="ixt:num-dot-decimal" scale="3" id="f-284">229,732</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-285">33,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-286">33,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-287">16,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-288">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-289">147,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-290">984</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-291">450,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-292">597,485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="f-293">605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-294">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-295">17,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-296">17,902</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-297">25,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-298">25,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized net gain on available-for-sale securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-299">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-300">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Final OmniAb Distribution</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="lgnd:AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" format="ixt:num-dot-decimal" scale="3" id="f-301">1,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="lgnd:AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" format="ixt:num-dot-decimal" scale="3" id="f-302">1,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Final tax impact of OmniAb Distribution</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="lgnd:AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" format="ixt:num-dot-decimal" scale="3" id="f-303">5,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" format="ixt:num-dot-decimal" scale="3" id="f-304">5,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-305">52,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-306">17,556</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-307">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-308">198,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-309">817</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-310">503,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-311">700,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-312">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="f-313">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-314">60,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-315">60,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock, net of commissions and fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="f-316">360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-317">37,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-318">37,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-319">41,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-320">41,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized net gain on available-for-sale securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-321">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-322">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-323">5,170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-324">5,170</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-325">4,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-326">4,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-53" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-327">19,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-328">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-329">337,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-330">5,942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-331">498,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-332">830,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="ifca968692f35492e968bd282f4512e0b_79"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:59.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-333">4,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-334">52,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-335">33,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of Pelican</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="f-336">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="3" id="f-337">2,121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:fixed-zero" scale="3" id="f-338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in estimated fair value of contingent liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights" scale="3" id="f-339">683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights" scale="3" id="f-340">265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights" scale="3" id="f-341">748</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Depreciation of fixed assets and amortization of intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-342">35,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-343">36,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-344">51,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain from short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:GainLossOnShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-345">67,901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:GainLossOnShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-346">46,365</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:GainLossOnShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-347">28,540</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization/accretion of premium (discount) on investments, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-348">1,331</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="f-349">1,318</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="f-350">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of debt discount and issuance fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-351">486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-352">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-353">734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loss (gain) on derivative instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="3" id="f-354">20,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="f-355">250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:fixed-zero" scale="3" id="f-356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on debt extinguishment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-359">4,192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash income from financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:NonCashIncomeFromFinancialRoyaltyAssets" format="ixt:num-dot-decimal" scale="3" id="f-360">5,467</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:NonCashIncomeFromFinancialRoyaltyAssets" scale="3" id="f-361">878</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:NonCashIncomeFromFinancialRoyaltyAssets" scale="3" id="f-362">164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CECL adjustment to financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="lgnd:CurrentAndExpectedCreditLossAdjustment" format="ixt:num-dot-decimal" scale="3" id="f-363">4,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:CurrentAndExpectedCreditLossAdjustment" format="ixt:num-dot-decimal" scale="3" id="f-364">3,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:CurrentAndExpectedCreditLossAdjustment" format="ixt:fixed-zero" scale="3" id="f-365">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Impairment loss of financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:ImpairmentLossOnFinancialRoyaltyAssets" format="ixt:num-dot-decimal" scale="3" id="f-366">30,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:ImpairmentLossOnFinancialRoyaltyAssets" scale="3" id="f-367">924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:ImpairmentLossOnFinancialRoyaltyAssets" format="ixt:fixed-zero" scale="3" id="f-368">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Lease amortization expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-369">2,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-370">1,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" format="ixt:num-dot-decimal" scale="3" id="f-371">5,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-372">41,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-373">25,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-374">60,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses from equity method investment in Primrose Bio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-375">12,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-376">1,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value adjustment to Primrose Bio securities investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="3" id="f-378">25,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:fixed-zero" scale="3" id="f-379">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:fixed-zero" scale="3" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-381">15,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-382">11,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-383">20,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="f-384">7,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="f-385">739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="f-386">365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of acquisitions and dispositions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-387">6,459</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-388">2,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-389">55,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-390">9,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-391">10,870</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-392">12,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other economic rights</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent" format="ixt:fixed-zero" scale="3" id="f-393">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-394">5,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent" format="ixt:fixed-zero" scale="3" id="f-395">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-396">13,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-397">4,704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-398">3,340</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income taxes receivable and payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-399">2,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-400">1,781</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-401">1,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-402">1,308</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-403">419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-404">6,281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets and liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="3" id="f-405">1,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="3" id="f-406">9,865</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" format="ixt:num-dot-decimal" scale="3" id="f-407">6,342</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-408">97,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-409">49,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-410">137,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of financial royalty assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:PaymentsToAcquireFinancialRoyaltyAssets" format="ixt:num-dot-decimal" scale="3" id="f-411">17,819</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:PaymentsToAcquireFinancialRoyaltyAssets" format="ixt:num-dot-decimal" scale="3" id="f-412">50,328</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:PaymentsToAcquireFinancialRoyaltyAssets" format="ixt:fixed-zero" scale="3" id="f-413">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:ProceedsFromFinancialRoyaltyAssets" format="ixt:num-dot-decimal" scale="3" id="f-414">7,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:ProceedsFromFinancialRoyaltyAssets" scale="3" id="f-415">418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:ProceedsFromFinancialRoyaltyAssets" scale="3" id="f-416">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-417">1,821</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-418">3,521</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-419">17,923</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-420">226,384</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-421">126,764</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-422">51,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from sale of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-423">229,367</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-424">148,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-425">209,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturity of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-426">33,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-427">45,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-428">24,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for equity method investment - Nucorion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-429">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-430">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="f-431">750</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for investment in Primrose Bio</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="f-432">998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="3" id="f-433">15,249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:fixed-zero" scale="3" id="f-434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for Palvella notes receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireNotesReceivable" format="ixt:num-dot-decimal" scale="3" id="f-435">2,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:PaymentsToAcquireNotesReceivable" format="ixt:fixed-zero" scale="3" id="f-436">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:PaymentsToAcquireNotesReceivable" format="ixt:fixed-zero" scale="3" id="f-437">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for Novan acquisition, net of restricted cash received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-438">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-439">10,405</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for the Agenus transaction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForDerivativeInstrumentInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-441">75,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:PaymentsForDerivativeInstrumentInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-442">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:PaymentsForDerivativeInstrumentInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for Apeiron acquisition, net of cash received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-444">91,996</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-445">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for InvIOs investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="3" id="f-447">4,196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="f-448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:fixed-zero" scale="3" id="f-449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from Viking Share Collar and Viking Share Put</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromDerivativeInstrumentInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-450">7,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ProceedsFromDerivativeInstrumentInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:ProceedsFromDerivativeInstrumentInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-453">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:fixed-zero" scale="3" id="f-454">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="f-455">960</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash used in (provided by) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-456">143,664</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-457">11,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-458">163,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:59.488%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.547%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from common stock issuance, net of commissions and fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-459">37,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-460">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash transferred to OmniAb at OmniAb Separation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:PaymentsForSeparation" format="ixt:fixed-zero" scale="3" id="f-462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:PaymentsForSeparation" format="ixt:fixed-zero" scale="3" id="f-463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:PaymentsForSeparation" format="ixt:num-dot-decimal" scale="3" id="f-464">1,840</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repayment at maturity/repurchase of 2023 Notes </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-466">76,854</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-467">260,949</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments under finance lease obligations </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-468">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-469">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="f-470">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for transaction costs related to OmniAb Transactions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-471">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-472">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-473">6,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for debt issuance costs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="f-474">426</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" scale="3" id="f-475">949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-476">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from bond hedge settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromHedgeFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-477">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ProceedsFromHedgeFinancingActivities" format="ixt:fixed-zero" scale="3" id="f-478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:ProceedsFromHedgeFinancingActivities" scale="3" id="f-479">202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net proceeds from stock option exercises and ESPP</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-480">65,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-481">22,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-482">3,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-483">5,136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-484">4,547</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-485">8,236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:PaymentsToContingentValueRightHoldersFinancingActivity" format="ixt:fixed-zero" scale="3" id="f-486">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:PaymentsToContingentValueRightHoldersFinancingActivity" format="ixt:fixed-zero" scale="3" id="f-487">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:PaymentsToContingentValueRightHoldersFinancingActivity" format="ixt:num-dot-decimal" scale="3" id="f-488">1,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash provided by (used) in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-489">97,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-490">59,947</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-491">275,990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-492">1,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-493">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="f-494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-495">49,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-496">22,052</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-497">25,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-498">22,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-499">45,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-500">19,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of year</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-501">72,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-502">22,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-503">45,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental disclosure of cash flow information</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-504">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="f-505">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-506">1,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes paid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-507">19,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-508">8,770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-509">11,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisitions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Fair value of tangible assets acquired, net of cash and restricted cash received</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" format="ixt:num-dot-decimal" scale="3" id="f-510">8,965</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" format="ixt:num-dot-decimal" scale="3" id="f-511">17,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" format="ixt:fixed-zero" scale="3" id="f-512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="f-513">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-514">3,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="f-515">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-516">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-517">10,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:fixed-zero" scale="3" id="f-518">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Financial royalty assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets" format="ixt:num-dot-decimal" scale="3" id="f-519">106,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets" format="ixt:fixed-zero" scale="3" id="f-520">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets" format="ixt:fixed-zero" scale="3" id="f-521">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Liabilities assumed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-522">23,125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-523">21,891</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:fixed-zero" scale="3" id="f-524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash paid for acquisitions</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-525">91,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-526">10,405</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-527">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Supplemental schedule of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued Primrose transaction costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:BusinessCombinationAcquisitionCostIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-528">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:BusinessCombinationAcquisitionCostIncurredButNotYetPaid" scale="3" id="f-529">998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:BusinessCombinationAcquisitionCostIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-530">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Addition of right-of-use assets and lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-531">1,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-532">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-533">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued royalty from financial royalty assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" scale="3" id="f-535">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-536">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued purchases of financial royalty assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" scale="3" id="f-538">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-539">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued debt issuance costs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:AccruedDebtIssuanceCostsIncurredButNotYetPaid" scale="3" id="f-540">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:AccruedDebtIssuanceCostsIncurredButNotYetPaid" scale="3" id="f-541">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:AccruedDebtIssuanceCostsIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-542">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued fixed asset purchases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="f-543">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="f-544">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-545">2,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gain (loss) on available-for-sale investments, net of tax</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-546">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-547">167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="f-548">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to these consolidated financial statements.</span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div id="ifca968692f35492e968bd282f4512e0b_82"></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="ifca968692f35492e968bd282f4512e0b_85"></div><div style="margin-top:14pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless the context requires otherwise, references in this report to &#8220;Ligand,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; the &#8220;Company,&#8221; and &#8220;our&#8221; refer to Ligand Pharmaceuticals Incorporated and its consolidated subsidiaries.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-549" continuedAt="f-549-1" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="f-549-1" continuedAt="f-549-2"><ix:nonNumeric contextRef="c-1" name="lgnd:BusinessSpinOffAndMigrationPolicyTextBlock" id="f-550" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. We do this by providing financing, licensing our technologies or both.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-551" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="f-552" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-553">one</ix:nonFraction> operating and <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-554">one</ix:nonFraction> reportable segment: development and licensing of biopharmaceutical assets. The Company's Chief Operating Decision Maker (&#8220;CODM&#8221;) is Todd Davis, our Chief Executive Officer. The CODM uses net income (loss) from continuing operations as a single segment profit or loss measure to evaluate our single segment performance, and in deciding whether to reinvest into the existing assets, or to new potential opportunities. Our CODM relies on internal management reporting processes that provide information on segment operating income (loss) for making financial decisions and allocating resources. CODM does not evaluate, manage or measure performance of segments using asset information.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="f-555" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information on significant segment expenses that are regularly provided to the CODM, and other segment items included within the reported segment profit or loss measure, is presented in a table below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total revenues and other income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-556">167,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-557">131,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-558">196,245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-559">41,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-560">25,743</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-561">60,285</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other segment items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="f-562">32,959</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="f-563">33,654</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" format="ixt:num-dot-decimal" scale="3" id="f-564">34,237</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-565">2,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-566">2,905</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="3" id="f-567">3,841</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="3" id="f-568">8,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="3" id="f-569">7,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:InterestIncomeOperating" format="ixt:num-dot-decimal" scale="3" id="f-570">2,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-571">3,037</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:InterestExpenseNonoperating" scale="3" id="f-572">656</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:InterestExpenseNonoperating" format="ixt:num-dot-decimal" scale="3" id="f-573">1,799</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other *</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-574">99,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-575">22,248</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-576">103,348</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income (loss) from continuing operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-577">4,032</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-578">53,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-579">5,219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">* Other items for the years ended December 31, 2024, 2023, and 2022, include the amount of other general, administrative, research and development expenses of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:OtherExpenseItemsNet" scale="6" id="f-580">56.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:OtherExpenseItemsNet" scale="6" id="f-581">48.7</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:OtherExpenseItemsNet" scale="6" id="f-582">42.0</ix:nonFraction> million (net of share-based compensation and depreciation expenses), respectively, and additional income and expense items that are presented in consolidated statements of operations such as financial royalty assets impairment, Fair value adjustments to partner program derivatives, cost of Captisol and other non-operating income and expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="f-583" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to the previously issued audited consolidated financial statements to conform with the current period presentation. Specifically, within the consolidated balance sheet as of December 31, 2023, our commercial license and other economic rights line has been reclassified to long-term portion of financial royalty assets, net, and to other assets, and a portion of other investments has been reclassified from other assets. Moreover, noncurrent derivative assets as of December 31, 2023, have been reclassified from other assets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, within the consolidated statements of operations for the years ended December 31, 2023 and 2022, royalties have been reclassified to revenue from intangible royalty assets, and a portion of the contract revenue has been reclassified to income from financial royalty assets.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-549-2" continuedAt="f-549-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:DiscontinuedOperationsPolicyTextBlock" id="f-584" continuedAt="f-584-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued operations</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><ix:continuation id="f-584-1" continuedAt="f-584-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the spin-off of the OmniAb Business in November 2022 in connection with the OmniAb Transactions met the criteria for classification as a discontinued operation in accordance with ASC Subtopic 205-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued Operations</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-584-2"> (&#8220;ASC 205-20&#8221;).</ix:continuation> For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (5), Spin-off of OmniAb&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All disclosures have been adjusted to reflect continuing operations.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-585" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationsPolicy" id="f-586" continuedAt="f-586-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they incurred. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-586-1">Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-587" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Business Risk</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="f-588" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue and other income from significant partners, which is defined as 10% or more of our total revenue, was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-70" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-589">23</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-71" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-590">33</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-72" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-591">45</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-73" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-592">12</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-74" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-593">20</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-75" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-594">16</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;<ix:nonFraction unitRef="number" contextRef="c-76" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-595">10</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-77" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-596">10</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;<ix:nonFraction unitRef="number" contextRef="c-78" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-597">10</ix:nonFraction>%</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit risk through our counterparties, including risks associated with royalty assets, receivables, and financial instruments such as derivatives and available-for-sale debt securities. Most of our royalty assets and receivables come from contractual agreements that generate royalties based on sales of pharmaceutical products across the United States, Europe, and other regions. This risk is primarily mitigated by the broad range of marketers responsible for paying royalties and the geographic diversity of product sales. Our royalty portfolio includes products marketed by leading biopharmaceutical </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-549-3" continuedAt="f-549-4"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies such as Amgen, Merck, Jazz, Recordati, and Sanofi. As of December&#160;31, 2024, Recordati was the largest individual marketer and payor of our financial royalty assets, representing <ix:nonFraction unitRef="number" contextRef="c-79" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-598">54</ix:nonFraction>% of the financial royalty asset balance.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively monitor the financial performance and creditworthiness of counterparties to our royalty agreements, derivative financial instruments, and available-for-sale debt securities to assess and respond to changes in their credit profiles. So far, we have not incurred any significant losses related to the collection of income or revenue from royalty assets, available-for-sale debt securities, or the settlement of derivative financial instruments. However, if a counterparty faces bankruptcy or financial difficulties and fails to meet its obligations under a derivative financial instrument, we could face substantial delays in recovering amounts owed during bankruptcy or reorganization.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain Captisol primarily from two sites related to a single supplier, Hovione.&#160;If this supplier were not able to supply the requested amounts of Captisol from each site, and if our safety stocks of material were depleted, we would be unable to continue to derive revenues from the sale of Captisol until we obtained material from an alternative source, which could take a considerable length of time.</span></div><ix:nonNumeric contextRef="c-1" name="lgnd:CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" id="f-599" continuedAt="f-599-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments with maturities of three months or less from the date of acquisition. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Investments</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments primarily consist of investments in debt and equity securities. We classify our short-term investments as &#8220;available-for-sale&#8221;. Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statements of comprehensive income (loss), net of tax, and unrealized gains and losses on equity securities included the consolidated statements of operations. We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and include net realized gains and losses as a component of non-operating income and expenses within the consolidated statements of operations. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of certificates of deposit, corporate debt securities, and securities of government-sponsored entities. Debt securities have effective maturities greater than&#160;three months and less than thirty-six months from the date of acquisition. Debt securities available-for-sale in an unrealized loss position are assessed for current expected credit losses. We start by assessing whether we intend to sell the security, or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-599-1">Equity securities consist of bond funds, investments in privately held companies (non-marketable equity securities), and companies that have completed initial public offerings (marketable equity securities). Bond funds are valued at their publicly quoted net asset value (&#8220;NAV&#8221;) price on the last day of the period. Our non-marketable equity securities without readily determinable market values are initially measured at cost and adjusted to fair value for observable transactions for identical or similar investments of the same issuer or impairment. Our marketable equity securities are measured at fair value. Equity investments are classified as short-term investments, equity method investment in Primrose Bio, or other investments, based on the nature of the securities and their availability for use in current operations.</ix:continuation> </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Balance Sheet Account Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CreditLossFinancialInstrumentPolicyTextBlock" id="f-600" continuedAt="f-600-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses </span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-600-1">Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers.</ix:continuation> During the years ended December&#160;31, 2024, 2023 and 2022, we considered the current and expected future economic and market conditions and concluded a decrease of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="f-601">0.1</ix:nonFraction>&#160;million, an increase of $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="f-602">0.2</ix:nonFraction>&#160;million, and a decrease of $<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" sign="-" name="us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="f-603">0.3</ix:nonFraction>&#160;million of allowance for credit losses, respectively. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-549-4" continuedAt="f-549-5"><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-604" continuedAt="f-604-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-604-1">Inventory, which consists of finished goods (Captisol), is stated at the lower of cost or net realizable value. We determine cost using the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements.</ix:continuation> During the years ended December&#160;31, 2024, 2023 and 2022, we recorded an obsolete inventory charge of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-605">0.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-606">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-607">1.1</ix:nonFraction>&#160;million, respectively. In addition to finished goods, as of December&#160;31, 2024 and 2023, inventory included prepayments of $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-608">3.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-609">4.6</ix:nonFraction>&#160;million, respectively, to our supplier for Captisol.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-610" continuedAt="f-610-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from <span style="-sec-ix-hidden:f-611">one</span> to <ix:nonNumeric contextRef="c-83" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-612">nine years</ix:nonNumeric>, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><ix:continuation id="f-610-1" continuedAt="f-610-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Balance Sheet Account Details</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-610-2">.&#8221;</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-613" continuedAt="f-613-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at the reporting unit level at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment at the reporting unit level during the fourth quarter of 2024, noting no impairment. </span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-613-1">Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset.</ix:continuation> We did not identify indicators of impairment for the finite-lived intangibles at December&#160;31, 2024.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Balance Sheet Account Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; </span></div><ix:nonNumeric contextRef="c-1" name="lgnd:FinancialRoyaltyAssetsPolicyTextBlock" id="f-614" continuedAt="f-614-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Royalty Assets, net (formerly known as Commercial License Rights)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial royalty assets represent a portfolio of future milestone and royalty payment rights acquired that are passive in nature (i.e., we do not own the intellectual property or have the right to commercialize the underlying products).</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we account for financial royalty assets under ASC 310, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is recalculated in each reporting period as the difference between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-549-5" continuedAt="f-549-6"><ix:continuation id="f-614-1"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by accrued interest income (except for assets under the non-accrual method) and decreased by cash receipts in the period to arrive at the ending balance.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate financial royalty assets for recoverability on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the total amount of expected undiscounted cash flows is below the amortized cost basis, we measure and record an allowance for the change in expected cash flows. This allowance is measured as the difference between the financial royalty asset&#8217;s amortized cost basis and the net present value of the expected future cash flows, calculated using the original effective interest rate. In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance in part or in full.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above allowance, we recognize an allowance for current expected credit losses under ASC 326, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our financial royalty assets. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the credit loss provision.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of financial royalty assets is presented net of the cumulative allowances for changes in expected future cash flows and expected credit losses. The initial amount and subsequent revisions in allowances for changes in expected future cash flows and expected credit losses are recorded as part of general and administrative expenses on the consolidated statements of operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we are reasonably certain that a part of a financial royalty asset&#8217;s net carrying value (or all of it) is not recoverable, we recognize an impairment which is recorded in financial royalty assets impairment on the consolidated statements of operations. To the extent there was an allowance previously recorded for this asset, the amount of such impairment is written off against the allowance at the time that such a determination is made. Any future recoveries from such impairment are recognized when cash is collected in a respective period earnings.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of financial royalty assets represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter. This portion is presented in other current assets on our consolidated balance sheets, net of the allowance for expected credit losses.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (6), Financial Royalty Assets, net (formerly known as Commercial License Rights)&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativesPolicyTextBlock" id="f-615" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Assets</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative assets include instruments used for risk-management purposes, and other instruments. Derivative assets which are not used for risk management purposes, include: (a) acquired rights in future milestone and royalty payments from Agenus Partnered Programs (as defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (2), Agenus Transaction&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), (b) Agenus Warrant (as defined </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (2), Agenus Transaction&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), (c) option to invest up to $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="lgnd:DerivativeInstrumentAdditionalMaximumInvestment" scale="6" id="f-616">25</ix:nonFraction> million to milestone and royalty rights which expires on June 30, 2025 (&#8220;Upsize Option&#8221;), and (d) rights to receive from Primrose Bio <ix:nonFraction unitRef="number" contextRef="c-84" decimals="2" name="lgnd:MilestoneCompensationRate" scale="-2" id="f-617">50</ix:nonFraction>% of milestones on <ix:nonFraction unitRef="contract" contextRef="c-85" decimals="INF" name="lgnd:NumberOfContracts" format="ixt-sec:numwordsen" scale="0" id="f-618">two</ix:nonFraction> contracts previously entered into by Primordial Genetics.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2024, we entered into a collar arrangement to hedge against the fluctuation risk in Viking's share price (the &#8220;Viking Share Collar&#8221;). However, because the Viking stock investment is remeasured at fair value through earnings under ASC 321, the Viking Share Collar is not eligible for hedge accounting, but is considered as an economic hedge. The Viking Share Collar was fully exercised during three month period ending December 31, 2024. During the three months ended December 31, 2024, we entered into a put arrangement to hedge against the fluctuation risk in Viking's share price (the &#8220;Viking Share Put&#8221;) which expired within the same quarter.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivatives are measured at fair value on the consolidated balance sheets. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (8), Fair Value Measurement&#8221; and &#8220;Note (7), Balance Sheet Account Details&#8221;.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsPolicy" id="f-619" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investment</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments that we do not consolidate but in which we have significant influence over the operating and financial policies of the investee are classified as equity method investments and are accounted for using the equity method of accounting.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In applying the equity method of accounting, investments are initially recorded at cost and are subsequently adjusted based on our proportionate share of net income or loss of the investee, net of any distributions received from the investee and any impairment.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (4), Sale of Pelican Business and Investment in Primrose Bio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-549-6" continuedAt="f-549-7"><ix:nonNumeric contextRef="c-1" name="lgnd:OtherInvestmentsPolicyPolicyTextBlock" id="f-620" continuedAt="f-620-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Investments</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><ix:continuation id="f-620-1" continuedAt="f-620-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other investments represent our investments in equity securities of third parties in which we do not have control or significant influence. Our equity securities investments do not have a readily determinable or estimable fair value and are measured using the measurement alternative, which is cost less impairment, if any, and adjustments resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. The amount of such impairment or adjustment recognized during the period is presented in other non-operating (expense) income, net in our consolidated statements of operations. For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Balance Sheet Account Details</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-620-2">.&#8221;</ix:continuation> </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Liabilities</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of CyDex in January 2011, we recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Metabasis in January 2010, we issued Metabasis stockholders <ix:nonFraction unitRef="right" contextRef="c-86" decimals="INF" name="lgnd:NumberOfContingentValueRightsIssued" format="ixt-sec:numwordsen" scale="0" id="f-621">four</ix:nonFraction> tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any change in fair value is recorded in other non-operating (expense) income, net in our consolidated statements of operations. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (8), Fair Value Measurement&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Balance Sheet Account Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-622" continuedAt="f-622-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue and Other Income</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, income from financial royalty assets, and contract revenue for license fees, technical, regulatory and sales-based milestone payments. Other operating income is primarily related to milestone income received for financial royalty assets that have been fully amortized or where there is no underlying asset recognized on the consolidated balance sheets. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the following five-step model in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Intangible Royalty Assets</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalty revenue from intangible royalty assets on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than when the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted in the period in which they become known, typically the following quarter.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Financial Royalty Assets</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2024, we introduced a new line item &#8220;income from financial royalty assets&#8221;, which was included in &#8220;contract revenue&#8221; in prior periods. Accordingly, the prior year period amounts have been reclassified to align with the current period presentation.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. Income is calculated by multiplying the carrying value of the financial royalty asset by the periodic effective interest rate.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for financial royalty assets related to developmental pipeline or recently commercialized products on a non-accrual basis. Developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. Newly commercialized products typically do not have an established reliable sales pattern, and thus have uncertain cash flows.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Captisol Sales</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Captisol sales is recognized when control of Captisol material is transferred or intellectual property license rights are granted to our customers in an amount that reflects the consideration we expect to receive from our customers </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-549-7" continuedAt="f-549-8"><ix:continuation id="f-622-1" continuedAt="f-622-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in exchange for those products or rights. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. For Captisol material or intellectual property license rights, we consider our performance obligation satisfied once we have transferred control of the product or granted the intellectual property rights, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost of freight and shipping when control over Captisol material has transferred to the customer as an expense in cost of Captisol in our consolidated statements of operations. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Revenue and Other Income</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers often include variable consideration in the form of contingent milestone payments. We include contingent milestone payments in the estimated transaction price when it is probable a significant reversal in the amount of cumulative revenue recognized will not occur. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone payment is based on sales, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some customer contracts are sublicenses which require that we make payments to an upstream licensor related to license fees, milestones and royalties which we receive from customers. In such cases, we evaluate the determination of gross revenue as a principal versus net revenue as an agent reporting based on each individual agreement.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income is primarily related to milestone income received for financial royalty assets that have been fully amortized or where there is no underlying asset recognized on the consolidated balance sheets.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div></ix:continuation><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-622-2">Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue and certain service revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue.</ix:continuation> During the year ended December&#160;31, 2024, the amount recognized as revenue that was previously deferred at December&#160;31, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-623">1.3</ix:nonFraction> million. During the year ended December&#160;31, 2023, the amount recognized as revenue that was previously deferred at December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-624">0.1</ix:nonFraction> million. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-625" continuedAt="f-625-1" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties for 2024, 2023 and 2022 for continuing operations are reported as below (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-626">38,377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-627">35,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-628">30,116</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rylaze </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-629">13,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-630">13,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-631">8,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filspari</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-632">12,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-633">2,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-634">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-635">8,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-636">10,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-637">10,197</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Teriparatide injection </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-638">8,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-639">11,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-640">15,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-641">5,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-642">4,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-643">1,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-644">8,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-645">6,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-646">6,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from intangible royalty assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-647">95,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-648">83,910</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-649">72,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-650">13,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-651">1,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-652">385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-653">108,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-654">84,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-655">72,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-549-8" continuedAt="f-549-9"><ix:continuation id="f-625-1"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregation of Captisol and contract revenue and other income for continuing operations (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.601%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Captisol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Captisol - Core</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-656">30,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-657">28,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-658">16,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Captisol - COVID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-659">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-661">88,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Captisol</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-662">30,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-663">28,372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-664">104,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract revenue and other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-665">25,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-666">17,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-667">18,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-668">1,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-669">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-670">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total contract revenue and other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-671">27,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-672">17,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-673">18,838</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(a) Captisol - COVID represents revenue on Captisol supplied for use in formulation with remdesivir, an antiviral treatment for COVID-19.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-674" continuedAt="f-674-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-674-1">Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, contract research organization (&#8220;CRO&#8221;) costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-675" continuedAt="f-675-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur share-based compensation expense related to restricted stock, ESPP, and stock options.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit (&#8220;RSU&#8221;) and performance stock unit (&#8220;PSU&#8221;) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment. A limited amount of PSUs contain a market condition dependent upon the Company&#8217;s relative and absolute total stockholder return over a <ix:nonNumeric contextRef="c-123" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-676">three-year</ix:nonNumeric> period, with a range of <ix:nonFraction unitRef="number" contextRef="c-124" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-677">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-125" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-678">200</ix:nonFraction>% of the target amount granted to be issued under the award. Share-based compensation expense for these PSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the market conditions.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock purchases under our ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatility of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be <ix:nonFraction unitRef="number" contextRef="c-126" decimals="2" name="us-gaap:EquitySecuritiesFvNiMeasurementInput" scale="-2" id="f-679">0</ix:nonFraction>% given that except for 2007, during which we declared a cash dividend on our common stock of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-680">2.50</ix:nonFraction> per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the <ix:nonNumeric contextRef="c-128" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-681">six month</ix:nonNumeric> anniversary of the date of grant, and 1/48 each month thereafter for <ix:nonNumeric contextRef="c-129" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-682">forty-two months</ix:nonNumeric>. RSUs and PSUs granted to employees vest over <ix:nonNumeric contextRef="c-130" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-683">three years</ix:nonNumeric>. All option awards generally expire <ix:nonNumeric contextRef="c-131" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-684">ten years</ix:nonNumeric> from the date of grant.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-675-1">Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-549-9" continuedAt="f-549-10"><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-685" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-686" continuedAt="f-686-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income (Loss) Per Share</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares consist of shares issuable under the 2023 Notes, stock options and restricted stock. Although we paid off the 2023 Notes in May 2023, it would have a dilutive impact when the average market price of our common stock exceeded the maximum conversion price during the year ended December 31, 2023. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (11), Stockholders&#8217; Equity&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><ix:continuation id="f-686-1" continuedAt="f-686-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Share</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-686-2">, if a company had a discontinuing operation, the company uses income from continuing operations, adjusted for preferred dividends and similar adjustments, as its control number to determine whether potential common shares a dilutive.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-687" continuedAt="f-687-1" escape="true">The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):</ix:nonNumeric></span><ix:continuation id="f-687-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:62.189%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.649%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-688">18,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-689">17,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-690">16,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dilutive potential common shares:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-132" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-691">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-133" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-692">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-134" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-693">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-135" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-694">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-136" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-695">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-137" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-696">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;2023 Convertible Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-138" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-697">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-139" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="3" id="f-698">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-140" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="3" id="f-699">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares used to compute diluted income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-700">18,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-701">17,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-702">16,868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Potentially dilutive shares excluded from calculation due to anti-dilutive effect</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-703">1,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-704">4,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-23" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-705">6,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-706" continuedAt="f-706-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Euro is the functional currency of Apeiron and the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Translation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-549-10"><ix:continuation id="f-706-1"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-707" continuedAt="f-707-1" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-707-1">Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented for unrealized gains and losses on available-for-sale debt securities and foreign currency translation adjustments.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-708" escape="true"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Updates, Recently Adopted</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have adopted the updated accounting guidance in our Annual Report on the Form 10-K for the year ended December&#160;31, 2024. We have updated our segment disclosure (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (1), Basis of Presentation and Summary of Significant Accounting Policies&#8221;) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including, among other required items, the information on significant segment expenses that are regularly provided to the CODM and included within the reported segment profit or loss measure.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December 15, 2024, with early adoption permitted. We have not yet completed the assessment of the impact of ASU 2023-09 on our consolidated financial statements.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income (Subtopic 220-40): Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update requires entities to disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. We are currently evaluating the new guidance to determine the impact it may have on our consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.</span></div></ix:nonNumeric></ix:continuation><div id="ifca968692f35492e968bd282f4512e0b_768"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:AssetAcquisitionTextBlock" id="f-711" continuedAt="f-711-1" escape="true">Agenus Transaction</ix:nonNumeric></span></div><ix:continuation id="f-711-1" continuedAt="f-711-2"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 29, 2024, we closed the transactions pursuant to the $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="lgnd:FinancialRoyaltyAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-712">75</ix:nonFraction>&#160;million purchase and sale agreement (the &#8220;Agenus Agreement&#8221;), dated May 6, 2024, among us and Agenus Inc., </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agenus Royalty Fund, LLC, and Agenus Holdings 2024, LLC </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(collectively, &#8220;Agenus&#8221;). Under the terms of the Agenus Agreement, we received (i) <ix:nonFraction unitRef="number" contextRef="c-142" decimals="INF" name="lgnd:FinanceRoyaltyAgreementRoyaltyRate" scale="-2" id="f-713">18.75</ix:nonFraction>% of the licensed royalties and <ix:nonFraction unitRef="number" contextRef="c-143" decimals="INF" name="lgnd:FinanceRoyaltyAgreementMilestoneProceedsRate" scale="-2" id="f-714"><ix:nonFraction unitRef="number" contextRef="c-144" decimals="INF" name="lgnd:FinanceRoyaltyAgreementMilestoneProceedsRate" scale="-2" id="f-715"><ix:nonFraction unitRef="number" contextRef="c-145" decimals="INF" name="lgnd:FinanceRoyaltyAgreementMilestoneProceedsRate" scale="-2" id="f-716"><ix:nonFraction unitRef="number" contextRef="c-146" decimals="INF" name="lgnd:FinanceRoyaltyAgreementMilestoneProceedsRate" scale="-2" id="f-717"><ix:nonFraction unitRef="number" contextRef="c-147" decimals="INF" name="lgnd:FinanceRoyaltyAgreementMilestoneProceedsRate" scale="-2" id="f-718"><ix:nonFraction unitRef="number" contextRef="c-148" decimals="INF" name="lgnd:FinanceRoyaltyAgreementMilestoneProceedsRate" scale="-2" id="f-719">31.875</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the future licensed milestones paid to Agenus on six-partnered oncology programs, including BMS-986442 (Bristol Myers Squibb), AGEN2373 (Gilead Sciences), INCAGN2385 and INCAGN2390 (Incyte), MK-4830 (Merck), and UGN-301 (UroGen Pharma) (collectively referred as &#8220;Agenus Partnered Programs&#8221;), and (ii) a synthetic <ix:nonFraction unitRef="number" contextRef="c-149" decimals="INF" name="lgnd:RoyaltyFinancingAgreementPercentageOfGlobalNetSales" scale="-2" id="f-720">2.625</ix:nonFraction>% royalty on future global net sales of Agenus&#8217; novel immuno-oncology botensilimab in combination with balstilimab (&#8220;BOT/BAL&#8221;) program, collectively subject to certain events which may adjust the royalty and milestone percentages paid to us. In addition, we received the option to commit an additional $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-6" name="lgnd:DerivativeInstrumentAdditionalMaximumInvestment" format="ixt:num-dot-decimal" scale="6" id="f-721">25</ix:nonFraction>&#160;million in the same assets on a pro rata basis which expires on June 30, 2025 (&#8220;Upsize Option&#8221;). We have also agreed to allow Agenus to raise up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="lgnd:FinancialRoyaltyMaximumCapitalSourcing" format="ixt:num-dot-decimal" scale="6" id="f-722">100</ix:nonFraction>&#160;million bringing the total syndicated purchase price up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="lgnd:MaximumFinancingRoyaltyAsset" format="ixt:num-dot-decimal" scale="6" id="f-723">200</ix:nonFraction>&#160;million. As part of the Agenus Agreement, Agenus granted us security over certain assets related to the programs included in the Agenus Agreement, subject to certain customary exceptions. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with entry into the Agenus Agreement, Agenus issued us a <ix:nonNumeric contextRef="c-141" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:durwordsen" id="f-724">5-year</ix:nonNumeric> warrant (&#8220;Agenus Warrant&#8221;) to purchase <ix:nonFraction unitRef="shares" contextRef="c-141" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-725">867,052</ix:nonFraction> shares of its common stock, at an exercise price equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-141" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-726">17.30</ix:nonFraction>.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for all Agenus Partnered Programs, Agenus Warrant and Upsize Option as derivative assets. All derivatives, except for Upsize Option, were presented in noncurrent derivative assets line in our consolidated balance sheets. Agenus Partnered Programs were recognized as derivative assets under ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as they have different underlyings (milestone payments and royalties). The commercial milestones and royalties are dependent on the development milestones and the commercial milestone and royalties underlyings are not determined to be predominate. The derivative assets were recorded at fair value as of May 29, 2024, and are marked to fair value at each subsequent reporting period. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-711-2"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Agenus Partnered Programs derivative assets is determined as a present value of expected future cash flows adjusted for the level of risk appropriate for a respective program stage. As of Agenus Transaction date, it was $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeNet" format="ixt:num-dot-decimal" scale="6" id="f-727">21.3</ix:nonFraction>&#160;million. During the three months ended September 30, 2024, certain Agenus partners discontinued development of their partnered programs. These programs may be relicensed at a later date, and Ligand would retain its economic interest upon any relicense activity. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Agenus Warrant is determined using a Black-Scholes model. The following assumptions were used as of May 29, 2024, and December&#160;31, 2024, respectively: expected term of <ix:nonFraction unitRef="pure" contextRef="c-150" decimals="1" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="f-728">4.0</ix:nonFraction> years and <ix:nonFraction unitRef="pure" contextRef="c-151" decimals="1" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="f-729">3.4</ix:nonFraction> years, volatility of <ix:nonFraction unitRef="number" contextRef="c-152" decimals="2" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="f-730">84</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-153" decimals="2" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="f-731">102</ix:nonFraction>%, risk-free rate of <ix:nonFraction unitRef="number" contextRef="c-154" decimals="3" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="f-732">4.7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-155" decimals="4" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="f-733">4.3</ix:nonFraction>%, Agenus stock price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-156" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="f-734">15.03</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-157" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" id="f-735">2.74</ix:nonFraction>. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Upsize Option was determined using the binomial option pricing model under which we assessed and considered the possible upwards and downwards scenarios through the expiration date of the Upsize Option. The fair value of the Upsize Option was written down to zero as of December&#160;31, 2024.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the Agenus Partnered Program derivative assets, Agenus Warrant, and Upsize Option, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (8), Fair Value Measurements&#8221;.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the acquired BOT/BAL rights as a financial royalty asset which is currently put under the non-accrual method as management cannot reliably estimate future cash flows from this program. The amount of BOT/BAL financial royalty asset was determined as a residual value from the $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="lgnd:FinancialRoyaltyAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-736">75</ix:nonFraction>&#160;million aggregate investment amount, less fair value of all acquired derivative assets as of May 29, 2024. For additional information on the Agenus BOT/BAL rights, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (6), Financial Royalty Assets, net (formerly known as Commercial License Rights)&#8221;.</span></div></ix:continuation><div id="ifca968692f35492e968bd282f4512e0b_94"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-737" continuedAt="f-737-1" escape="true">Acquisitions</ix:nonNumeric></span></div><ix:continuation id="f-737-1" continuedAt="f-737-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Apeiron </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2024, we acquired all the outstanding shares of Biologics AG (&#8220;Apeiron&#8221;), including the royalty rights to Qarziba (dinutuximab beta) for the treatment of high-risk neuroblastoma (the &#8220;Apeiron Acquisition&#8221;) for $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="f-738">100.5</ix:nonFraction>&#160;million base consideration. We funded the Apeiron Acquisition from our available cash on hand. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to base consideration, we would also pay Apeiron shareholders an additional consideration based on future commercial and regulatory events, including up to $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-739">28</ix:nonFraction>&#160;million if Qarziba royalties exceed certain predetermined thresholds by either 2030 or 2034, and pay additional earn-outs on specific future events, primarily related to Qarziba regulatory approval and commercialization in the USA.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated this acquisition in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to discern whether the assets and operations of Apeiron met the definition of a business. We accounted for this transaction as assets acquisition.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="f-740">4.9</ix:nonFraction>&#160;million of transaction costs related to the Apeiron Acquisition, which were included in the amount of total purchase consideration. All assets acquired (except for contract assets) and liabilities assumed in the Apeiron Acquisition were recognized at their fair values. Contract assets acquired were recognized on a relative fair value basis. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-741" continuedAt="f-741-1" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-742">13,437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract assets (financial royalty assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets" format="ixt:num-dot-decimal" scale="3" id="f-743">106,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-744">8,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-745">3,740</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable" format="ixt:num-dot-decimal" scale="3" id="f-746">1,276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-747">18,109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total fair value of net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-748">105,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets acquired are accounted for as financial royalty assets, similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30. The acquired contracts assets include Qarziba and other development phase contract assets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As Qarziba is a commercial phase program, we are able to reasonably estimate future cash flows and, as such, we recognize income from Qarziba financial royalty assets starting from the Apeiron Acquisition effective date, which is calculated by multiplying the carrying value of the financial royalty asset by the periodic effective interest rate. As described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (1), Basis of Presentation and Significant Accounting Policies&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is recalculated in each reporting period as the differences between expected cash flows and actual cash flows are realized and as </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-737-2" continuedAt="f-737-3"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">there are changes to expected future cash flows. We account for other Apeiron development phase financial royalty assets on a non-accrual basis as there is a higher level of uncertainty over the related expected cash flows.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For tax purposes this transaction is treated as a stock purchase. As a result, we will not obtain a tax stepped-up basis in Apeiron&#8217;s underlying assets and will assume the carryover tax basis. As part of the tax purchase price accounting, deferred tax liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-749">18.1</ix:nonFraction>&#160;million have been recorded to reflect the difference between the book and tax basis of the acquired assets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the earnout liabilities in the Apeiron Acquisition in accordance with ASC450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and will recognize respective liability when the contingency is resolved, and the liability becomes payable. No earnout liability is recognized as of the acquisition date or as of December&#160;31, 2024.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Apeiron Acquisition, we have also invested $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="f-750">4.2</ix:nonFraction>&#160;million (including $<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="lgnd:EquityIssuanceCost" format="ixt:num-dot-decimal" scale="6" id="f-751">0.2</ix:nonFraction>&#160;million transaction costs) in InvIOs Holding AG (&#8220;InvIOs&#8221;) common shares, a privately held spin-off of Apeiron. This investment was part of an &#8364;<ix:nonFraction unitRef="eur" contextRef="c-162" decimals="-6" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" scale="6" id="f-752">8</ix:nonFraction> million (approximately $<ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:PaymentsToAcquireEquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="f-753">8.8</ix:nonFraction>&#160;million) round with other investors which would help finance the research and development of three innovative early-stage immuno-oncology assets. Apeiron has previously outlicensed these assets to InvIOs and is entitled to future royalties and milestone payments.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the result of this investment, we did not obtain control or significant influence in InvIOs. We determined that common stock of InvIOs did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. When fair value becomes determinable, from observable price changes in orderly transactions, our investment will be marked to fair value.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novan</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 27, 2023, we closed the transaction to acquire certain assets of Novan, Inc. (&#8220;Novan&#8221;) pursuant to the agreement we entered into with Novan on July 17, 2023 for $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="f-754">15</ix:nonFraction> million in cash (which agreement contemplated Novan filing for bankruptcy relief) and provided up to $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="f-755">15</ix:nonFraction> million in debtor-in-possession (&#8220;DIP&#8221;) financing inclusive of a $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="f-756">3</ix:nonFraction> million bridge loan funded on the same day. Novan filed for Chapter 11 reorganization on July 17, 2023. On September 27, 2023, the bankruptcy court approved our $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="f-757">12.2</ix:nonFraction> million bid to purchase from Novan its lead product candidate berdazimer topical gel, <ix:nonFraction unitRef="number" contextRef="c-166" decimals="3" name="lgnd:BusinessCombinationAcquiredPercentage" scale="-2" id="f-758">10.3</ix:nonFraction>%, all other assets related to the NITRICIL technology platform and the rights to one commercial stage asset. The remaining commercial assets of Novan will be sold to other parties. The approved $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="f-759">12.2</ix:nonFraction> million bid was credited to the $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="f-760">15</ix:nonFraction> million DIP financing, with the balance of $<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:CashAcquiredFromAcquisition" scale="6" id="f-761">2.8</ix:nonFraction> million and accrued interest repaid to us. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was accounted for as business combination. We recorded $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" scale="6" id="f-762">3.1</ix:nonFraction> million of acquisition-related costs for legal, due diligence and other costs in connection with the acquisition within operating expenses in our consolidated statement of operations for the year ended December 31, 2023. </span></div><ix:continuation id="f-741-1"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have finalized purchase accounting for the Novan acquisition. The following table sets forth an allocation of the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.327%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="f-763">583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-764">13,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" format="ixt:num-dot-decimal" scale="3" id="f-765">3,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" scale="3" id="f-766">137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" format="ixt:num-dot-decimal" scale="3" id="f-767">1,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets acquired </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-768">10,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-769">3,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="f-770">4,508</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-771">3,683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-3" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-772">13,700</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for Novan, including restricted cash received</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-773">10,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DIP loan fees and interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="lgnd:BusinessCombinationLoanFeesAndInterest" format="ixt:num-dot-decimal" scale="3" id="f-774">1,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-3" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="3" id="f-775">12,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-737-3"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="INF" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:fixed-zero" scale="0" id="f-776">None</ix:nonFraction> of the goodwill is deductible for tax purposes. Acquired intangible assets of $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-777">10.7</ix:nonFraction>&#160;million related to core technology. The fair value of the core technology was based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the licensing of the related technologies. These projected cash flows were discounted to present value using a discount rate of <ix:nonFraction unitRef="number" contextRef="c-163" decimals="2" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" scale="-2" id="f-778">29</ix:nonFraction>%. The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of <ix:nonNumeric contextRef="c-163" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-779">15</ix:nonNumeric> years. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired other liabilities of $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" format="ixt:num-dot-decimal" scale="6" id="f-780">13.7</ix:nonFraction>&#160;million related to a royalty and milestone payments purchase agreement, entered by Novan in 2019 and assumed as part of the acquisition, which previously provided Novan $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="lgnd:ContingentMilestonePurchaseAgreement" format="ixt:num-dot-decimal" scale="6" id="f-781">25</ix:nonFraction>&#160;million of funding used primarily in the clinical development of berdazimer topical gel, <ix:nonFraction unitRef="number" contextRef="c-166" decimals="3" name="lgnd:BusinessCombinationAcquiredPercentage" scale="-2" id="f-782">10.3</ix:nonFraction>%. Pursuant to the purchase agreement, Novan will pay ongoing quarterly payments, calculated based on an applicable percentage per product of any upfront fees, milestone payments, royalty payments or equivalent payments received by Novan pursuant to any out-license agreement, net of any upfront fees, milestone payments, royalty payments or equivalent payments paid by Novan to third parties pursuant to any agreements under which Novan has in-licensed intellectual property with respect to such products. If Novan decides to commercialize any product on its own following regulatory approval, as opposed to commercializing through an out-license agreement or other third-party arrangement, Novan will be obligated to pay a low single digits royalty on net sales of such products. This contract liability was fair valued based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the related programs mentioned above, by applying a discount rate of <ix:nonFraction unitRef="pure" contextRef="c-167" decimals="INF" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-783">14</ix:nonFraction>% (revenue risk-adjusted discount rate).</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2024, we announced the creation of Pelthos Therapeutics to focus on the commercialization of innovative, safe, and efficacious therapeutic products for patients suffering from conditions with limited treatment options. ZELSUVMI (berdazimer topical gel, <ix:nonFraction unitRef="number" contextRef="c-166" decimals="3" name="lgnd:BusinessCombinationAcquiredPercentage" scale="-2" id="f-784">10.3</ix:nonFraction>%), its first product, is the FDA-approved prescription medicine for the treatment of the highly transmissible molluscum contagiosum (molluscum) viral skin infection in adults and pediatric patients one year of age and older. ZELSUVMI received a Novel Drug designation from the FDA in January 2024 to treat molluscum viral skin infection. ZELSUVMI was developed using Pelthos' proprietary nitric oxide-based NITRICIL technology platform. The rights to ZELSUVMI and all assets related to the NITRICIL technology platform were acquired from Novan in September 2023 in the Novan acquisition described above.</span></div></ix:continuation><div id="ifca968692f35492e968bd282f4512e0b_91"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-785" continuedAt="f-785-1" escape="true">Sale of Pelican Business and Investment in Primrose Bio</ix:nonNumeric></span></div><ix:continuation id="f-785-1" continuedAt="f-785-2"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 18, 2023, we entered into a merger agreement, pursuant to which our subsidiary, Pelican Technology Holdings, Inc. (&#8220;Pelican&#8221;) became a wholly owned subsidiary of Primrose Bio. Primrose Bio is a private company focused on synthetic biology. Pelican has developed technology related to PET (protein expression technology) and PelicCRM197 (vaccine material), and has property and equipment, as well as leased property in San Diego, CA. As part of the transaction, we received <ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="lgnd:DisposalGroupIncludingDiscontinuedOperationShareConsideration" format="ixt:num-dot-decimal" scale="0" id="f-786">2,146,957</ix:nonFraction> common shares, <ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="lgnd:DisposalGroupIncludingDiscontinuedOperationShareConsideration" format="ixt:num-dot-decimal" scale="0" id="f-787">4,278,293</ix:nonFraction> preferred shares and <ix:nonFraction unitRef="shares" contextRef="c-170" decimals="INF" name="lgnd:DisposalGroupIncludingDiscontinuedOperationShareConsideration" format="ixt:num-dot-decimal" scale="0" id="f-788">474,746</ix:nonFraction> restricted shares of Primrose Bio. Simultaneous with the merger, we entered into a Purchase and Sale Agreement with Primrose Bio and contributed $<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="lgnd:ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" scale="6" id="f-789">15</ix:nonFraction> million in exchange for <ix:nonFraction unitRef="number" contextRef="c-84" decimals="2" name="lgnd:MilestoneCompensationRate" scale="-2" id="f-790">50</ix:nonFraction>% of potential development milestones and certain commercial milestones from <ix:nonFraction unitRef="contract" contextRef="c-85" decimals="INF" name="lgnd:NumberOfContracts" format="ixt-sec:numwordsen" scale="0" id="f-791">two</ix:nonFraction> contracts previously entered into by Primordial Genetics. In addition, starting January 1, 2025, we will receive <ix:nonFraction unitRef="number" contextRef="c-172" decimals="3" name="lgnd:SalesContractInterestInSalesRevenue" scale="-2" id="f-792">25</ix:nonFraction>% of sales revenue of PeliCRM197 above $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="lgnd:SalesRevenueMilestone" scale="6" id="f-793">3</ix:nonFraction> million and <ix:nonFraction unitRef="number" contextRef="c-174" decimals="3" name="lgnd:SalesContractInterestInSalesRevenue" scale="-2" id="f-794">35</ix:nonFraction>% of all PeliCRM197 licensing revenue in perpetuity.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We retained contractual relationships utilizing the Pelican Expression Technology, including the commercial royalty rights to Jazz&#8217;s Rylaze, Merck&#8217;s Vaxneuvance and V116 vaccines, Alvogen&#8217;s Teriparatide, Serum Institute of India&#8217;s vaccine programs, including Pneumosil and MenFive vaccines, among others.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="f-795" continuedAt="f-795-1" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the sale of Pelican meets the definition of a deconsolidation of a business. Net assets sold together with allocated goodwill and cash consideration paid were as follows (in thousands):</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-785-2" continuedAt="f-785-3"><ix:continuation id="f-795-1" continuedAt="f-795-2"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-796">8,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-797">19,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets" scale="3" id="f-798">717</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-799">8,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset" scale="3" id="f-800">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" scale="3" id="f-801">630</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" scale="3" id="f-802">495</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-803">8,445</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" scale="3" id="f-804">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net assets sold</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationNetAsset" format="ixt:num-dot-decimal" scale="3" id="f-805">27,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocated goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" format="ixt:num-dot-decimal" scale="3" id="f-806">4,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash consideration paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="lgnd:ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" format="ixt:num-dot-decimal" scale="3" id="f-807">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationNetContributions" format="ixt:num-dot-decimal" scale="3" id="f-808">47,063</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="lgnd:ScheduleOfFairValueOfTheConsiderationTableTextBlock" id="f-809" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the consideration received includes the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="3" id="f-810">13,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="3" id="f-811">32,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="3" id="f-812">3,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" format="ixt:num-dot-decimal" scale="3" id="f-813">49,184</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill allocated to the selling business based on the relative fair value of the Pelican business and Ligand that was written off was $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:num-dot-decimal" scale="6" id="f-814">4.1</ix:nonFraction>&#160;million, resulting in a $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="6" id="f-815">2.1</ix:nonFraction>&#160;million gain on sale of Pelican recorded to income (loss) from operations for the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs of $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:BusinessExitCosts1" format="ixt:num-dot-decimal" scale="6" id="f-816">1.2</ix:nonFraction>&#160;million were allocated to the equity method investment and equity securities based on the relative fair value.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, we will receive <ix:nonFraction unitRef="number" contextRef="c-172" decimals="3" name="lgnd:SalesContractInterestInSalesRevenue" scale="-2" id="f-817">25</ix:nonFraction>% of sales revenue of PeliCRM197 above $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="lgnd:SalesRevenueMilestone" format="ixt:num-dot-decimal" scale="6" id="f-818">3.0</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="number" contextRef="c-174" decimals="3" name="lgnd:SalesContractInterestInSalesRevenue" scale="-2" id="f-819">35</ix:nonFraction>% of all PeliCRM197 licensing revenue in perpetuity. The considerations were recognized as contingent consideration under the loss recovery model and they will be measured based on the gain contingency model under ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and thus, will be recognized as the underlying contingencies are resolved.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we will receive <ix:nonFraction unitRef="number" contextRef="c-84" decimals="2" name="lgnd:MilestoneCompensationRate" scale="-2" id="f-820">50</ix:nonFraction>% of potential development milestones and certain commercial milestones from <ix:nonFraction unitRef="contract" contextRef="c-85" decimals="INF" name="lgnd:NumberOfContracts" format="ixt-sec:numwordsen" scale="0" id="f-821">two</ix:nonFraction> contracts previously entered into by Primordial Genetics. The considerations were recognized as derivative assets with a fair value of $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-822">3.2</ix:nonFraction>&#160;million, at the disposition date, which was included in noncurrent derivative assets in our <ix:nonNumeric contextRef="c-1" name="lgnd:DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" id="f-823">consolidated balance sheets</ix:nonNumeric>. They are recognized as derivative assets under ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as they have two underlyings (development and commercial milestones) and (i) the commercial milestones are dependent on the development milestones and (ii) the commercial milestone underlying is not determined to be predominate. The derivative assets are recorded at fair value as of September 18, 2023, and will be marketed to fair value at each reporting period going forward. During the year ended December&#160;31, 2024, an adjustment of $(<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="6" id="f-824">0.1</ix:nonFraction>)&#160;million was recorded to market the derivative assets to fair value and was included in fair value adjustments to partner program derivatives in our consolidated statement of operations. During the year ended December&#160;31, 2023, an adjustment of $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="6" id="f-825">0.3</ix:nonFraction>&#160;million was recorded to market the derivative assets to fair value and was included in other non-operating (expense) income, net in our consolidated statement of operations. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (8), Fair Value Measurement&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Balance Sheet Account Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Primrose Bio</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. Since the preferred stock and restricted share investment in Primrose Bio has a substantive liquidation preference, it is not substantially similar to the common stock investment and is therefore recorded as an equity security under ASC 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our common stock investment in Primrose Bio under the equity method as we have the ability to exercise significant influence over Primrose Bio's operating and financial results. In applying the equity method, we record the investment at fair value. Our proportionate share of net loss of Primrose Bio is recorded in our consolidated statements of operations. Our equity method investment is reviewed for indicators of impairment at each reporting period and is written down to fair value if there is evidence of a loss in value that is other-than-temporary. In June 2024, Primrose Bio received an equity </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-785-3" continuedAt="f-785-4"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment from an equity firm. In July 2024, Primrose Bio raised additional funds from another equity firm. As a result, we recognized an impairment loss on our equity method investment in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:num-dot-decimal" scale="6" id="f-826">5.8</ix:nonFraction>&#160;million during the year ended December&#160;31, 2024. There was <ix:nonFraction unitRef="usd" contextRef="c-185" decimals="INF" name="us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment" format="ixt:fixed-zero" scale="0" id="f-827">no</ix:nonFraction> impairment to our equity method investment during the year ended December&#160;31, 2023. Our share of the net loss of Primrose Bio for the years ended December&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-828">7.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="f-829">1.8</ix:nonFraction>&#160;million, respectively, which reduced Ligand's equity method investment accordingly. Any income or loss from our equity method investment (including the impairment) is presented in other non-operating (expense) income, net in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the Series A preferred stock and reserve stock investments in Primrose Bio did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investments at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. When fair value becomes determinable, from observable price changes in orderly transactions, our investments will be marked to fair value. Our investments in Series A preferred stock and reserve stock have been reduced by $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-4" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" format="ixt:num-dot-decimal" scale="6" id="f-830">25.8</ix:nonFraction>&#160;million during the year ended December&#160;31, 2024 in connection with the above mentioned equity funding received by Primrose Bio in June and July 2024. There were no no observable price changes or impairment to our investments in Series A preferred stock and reserve stock during the year ended December&#160;31, 2023. Any income or loss from our investments in Series A preferred stock and reserve stock (including the impairment) is presented in other non-operating (expense) income, net in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Former President and Chief Operating Officer Matt Korenberg served as a board member of Primrose Bio beginning in the fourth quarter of 2023. His employment with Ligand concluded in October 2024, after which Lauren Hay, Vice President of Strategic Planning &amp; Investment Analytics, succeeded him as a board member of Primrose Bio. </span></div></ix:continuation><div id="ifca968692f35492e968bd282f4512e0b_97"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:continuation id="f-785-4" continuedAt="f-785-5">Spin-off of OmniAb</ix:continuation></span></div><ix:continuation id="f-785-5" continuedAt="f-785-6"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2022, we entered into the OmniAb Separation and Distribution Agreement to separate our OmniAb Business and the OmniAb Merger Agreement, pursuant to which Merger Sub would merge with and into OmniAb, with OmniAb continuing as the surviving corporation and wholly owned subsidiary of New OmniAb following the effectiveness of such merger, resulting in New OmniAb&#8217;s acquisition of our OmniAb Business, in a Reverse Morris Trust transaction (collectively, the &#8220;OmniAb Transactions&#8221;). </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the final closing date of the OmniAb Transactions on November 1, 2022, the historical financial results of OmniAb have been reflected in our consolidated financial statements as discontinued operations under GAAP for all periods presented through the date of the OmniAb Distribution. Pursuant to the OmniAb Separation and Distribution Agreement, Ligand contributed to OmniAb cash and certain specific assets and liabilities constituting the OmniAb Business. Pursuant to the OmniAb Distribution, Ligand distributed on a pro rata basis to its stockholders as of October 26, 2022 shares of the common stock of OmniAb representing <ix:nonFraction unitRef="number" contextRef="c-186" decimals="INF" name="lgnd:DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed" scale="-2" id="f-831">100</ix:nonFraction>% of Ligand&#8217;s interest in OmniAb. Immediately following the OmniAb Distribution, Merger Sub merged with and into OmniAb, with OmniAb continuing as the surviving company in the OmniAb Merger and as a wholly owned subsidiary of New OmniAb. The entire transaction was completed on November 1, 2022, and following the OmniAb Merger, New OmniAb is an independent, publicly traded company whose common stock trades on NASDAQ under the symbol &#8220;OABI.&#8221; After the OmniAb Distribution, we do not beneficially own any shares of common stock in OmniAb and no longer consolidate OmniAb into our financial results for periods ending after November 1, 2022. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued operations</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the OmniAb Merger, the Company determined its OmniAb Business qualified for discontinued operations accounting treatment in accordance with ASC 205-20. We recognized a $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" sign="-" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="f-832">1.7</ix:nonFraction> million tax provision adjustment related to deferred taxes during the year ended December 31, 2023 that was attributable to the discontinued operations. <ix:continuation id="f-795-2" continuedAt="f-795-3">The following table summarizes revenue and expenses of the discontinued operations for the year ended December 31, 2022 (in thousands):</ix:continuation></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-795-3"><ix:continuation id="f-785-6"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-833">1,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-834">25,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" format="ixt:num-dot-decimal" scale="3" id="f-835">26,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-836">10,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-837">38,466</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-838">13,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" format="ixt:num-dot-decimal" scale="3" id="f-839">62,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" sign="-" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-840">36,132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain from short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments" format="ixt:fixed-zero" scale="3" id="f-841">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" format="ixt:fixed-zero" scale="3" id="f-842">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" scale="3" id="f-843">554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense" scale="3" id="f-844">554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" format="ixt:num-dot-decimal" scale="3" id="f-845">35,578</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" sign="-" name="us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation" format="ixt:num-dot-decimal" scale="3" id="f-846">7,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" sign="-" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" format="ixt:num-dot-decimal" scale="3" id="f-847">28,142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the significant non-cash items, capital expenditures of the discontinued operations, and financing activities that are included in the consolidated statements of cash flows for the year ended December 31, 2022 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" sign="-" name="lgnd:DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration" scale="3" id="f-848">554</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-849">13,218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense" format="ixt:num-dot-decimal" scale="3" id="f-850">9,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for acquisition, net of cash acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:CapitalExpenditureDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-852">5,572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="lgnd:PaymentsToContingentValueRightHoldersInvestingActivity" scale="3" id="f-853">960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="lgnd:PaymentsToContingentValueRightHoldersFinancingActivity" format="ixt:num-dot-decimal" scale="3" id="f-854">1,545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="lgnd:DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-855">2,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="ifca968692f35492e968bd282f4512e0b_100"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="lgnd:FinancialRoyaltyAssetsTextBlock" id="f-856" continuedAt="f-856-1" escape="true">Financial Royalty Assets, net (formerly known as Commercial License Rights)</ix:nonNumeric></span></div><ix:continuation id="f-856-1" continuedAt="f-856-2"><ix:nonNumeric contextRef="c-1" name="lgnd:ScheduleOfFinancialRoyaltyAssetsTableTextBlock" id="f-857" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, financial royalty assets consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.677%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.605%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross carrying value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Allowance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross carrying value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Allowance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Qarziba</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="lgnd:FinancialRoyaltyAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-858">105,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="lgnd:FinancialRoyaltyAssetsAllowance" scale="3" id="f-859">484</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-860">104,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="lgnd:FinancialRoyaltyAssetsGross" format="ixt:fixed-zero" scale="3" id="f-861">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="lgnd:FinancialRoyaltyAssetsAllowance" format="ixt:fixed-zero" scale="3" id="f-862">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNet" format="ixt:fixed-zero" scale="3" id="f-863">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agenus (Bot/Bal)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="lgnd:FinancialRoyaltyAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-864">40,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="lgnd:FinancialRoyaltyAssetsAllowance" scale="3" id="f-865">408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-866">40,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="lgnd:FinancialRoyaltyAssetsGross" format="ixt:fixed-zero" scale="3" id="f-867">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="lgnd:FinancialRoyaltyAssetsAllowance" format="ixt:fixed-zero" scale="3" id="f-868">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNet" format="ixt:fixed-zero" scale="3" id="f-869">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tolerance Therapeutics (Tzield)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="lgnd:FinancialRoyaltyAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-870">25,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="lgnd:FinancialRoyaltyAssetsAllowance" scale="3" id="f-871">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-872">25,512</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="lgnd:FinancialRoyaltyAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-873">25,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="lgnd:FinancialRoyaltyAssetsAllowance" scale="3" id="f-874">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-875">25,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ensifentrine inventors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="lgnd:FinancialRoyaltyAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-876">15,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="lgnd:FinancialRoyaltyAssetsAllowance" scale="3" id="f-877">157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-878">15,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="lgnd:FinancialRoyaltyAssetsGross" format="ixt:fixed-zero" scale="3" id="f-879">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="lgnd:FinancialRoyaltyAssetsAllowance" format="ixt:fixed-zero" scale="3" id="f-880">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNet" format="ixt:fixed-zero" scale="3" id="f-881">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Elutia (CorMatrix)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="lgnd:FinancialRoyaltyAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-882">9,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="lgnd:FinancialRoyaltyAssetsAllowance" format="ixt:num-dot-decimal" scale="3" id="f-883">2,268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-884">7,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="lgnd:FinancialRoyaltyAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-885">13,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="lgnd:FinancialRoyaltyAssetsAllowance" format="ixt:num-dot-decimal" scale="3" id="f-886">7,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-887">5,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">InvIOs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="lgnd:FinancialRoyaltyAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-888">1,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="lgnd:FinancialRoyaltyAssetsAllowance" scale="3" id="f-889">62</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-890">1,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="lgnd:FinancialRoyaltyAssetsGross" format="ixt:fixed-zero" scale="3" id="f-891">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="lgnd:FinancialRoyaltyAssetsAllowance" format="ixt:fixed-zero" scale="3" id="f-892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNet" format="ixt:fixed-zero" scale="3" id="f-893">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selexis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="lgnd:FinancialRoyaltyAssetsGross" scale="3" id="f-894">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="lgnd:FinancialRoyaltyAssetsAllowance" scale="3" id="f-895">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNet" scale="3" id="f-896">147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="lgnd:FinancialRoyaltyAssetsGross" scale="3" id="f-897">940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="lgnd:FinancialRoyaltyAssetsAllowance" scale="3" id="f-898">179</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNet" scale="3" id="f-899">761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ovid (Soticlestat)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="lgnd:FinancialRoyaltyAssetsGross" format="ixt:fixed-zero" scale="3" id="f-900">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="lgnd:FinancialRoyaltyAssetsAllowance" format="ixt:fixed-zero" scale="3" id="f-901">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNet" format="ixt:fixed-zero" scale="3" id="f-902">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="lgnd:FinancialRoyaltyAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-903">30,310</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="lgnd:FinancialRoyaltyAssetsAllowance" scale="3" id="f-904">303</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-905">30,007</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:FinancialRoyaltyAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-906">198,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:FinancialRoyaltyAssetsAllowance" format="ixt:num-dot-decimal" scale="3" id="f-907">3,538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-908">195,049</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lgnd:FinancialRoyaltyAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-909">70,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lgnd:FinancialRoyaltyAssetsAllowance" format="ixt:num-dot-decimal" scale="3" id="f-910">8,073</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lgnd:FinancialRoyaltyAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-911">62,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) The amounts of allowance include accumulated allowance for changes in expected cash flows and current expected credit losses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(2) The amounts include $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="lgnd:FinancialRoyaltyAssetsNetCurrent" scale="6" id="f-912">10.0</ix:nonFraction> million current portion of financial royalty assets which represents an estimation for current quarter royalty receipts that are collected during the subsequent quarter. This portion is presented in other current assets on our consolidated balance sheet as of December&#160;31, 2024.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial royalty assets represent a portfolio of future milestone and royalty payment rights acquired in the Apeiron Acquisition in July 2024, from Agenus in May 2024, Selexis, S.A. (&#8220;Selexis&#8221;) in April 2013 and May 2015, CorMatrix Cardiovascular, Inc. (&#8220;CorMatrix&#8221;) in May 2016, which was later acquired by Aziyo (Aziyo changed its corporate name to Elutia Inc. (&#8220;Elutia&#8221;) in September 2023) in 2017, Ovid Therapeutics Inc. (&#8220;Ovid&#8221;) in October 2023, Tolerance Therapeutics, Inc. (&#8220;Tolerance Therapeutics&#8221;) in November 2023, and from certain ensifentrine inventors in March and August 2024.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, we recorded a $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="lgnd:ImpairmentLossOnFinancialRoyaltyAssets" scale="6" id="f-913">30.3</ix:nonFraction> million impairment loss for Ovid (Soticlestat) financial royalty asset and a $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="lgnd:ImpairmentLossOnFinancialRoyaltyAssets" scale="6" id="f-914">0.3</ix:nonFraction> million impairment loss for Selexis financial royalty asset. During the year ended December&#160;31, 2023, we recorded a $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="lgnd:ImpairmentLossOnFinancialRoyaltyAssets" scale="6" id="f-915">0.9</ix:nonFraction> million impairment loss for Selexis financial royalty asset as a result of reduced programs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Apeiron Financial Royalty Assets</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (3), Acquisitions&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we acquired certain financial royalty assets within the Apeiron Acquisition, including Qarziba and certain InvIOs programs, recorded at $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets" scale="6" id="f-916">104.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets" scale="6" id="f-917">1.3</ix:nonFraction> million, respectively as of Apeiron Acquisition date. As Qarziba is a commercial phase program, we are able to reasonably estimate future cash flows and, as such, we recognized income from Qarziba financial royalty assets starting from the Apeiron Acquisition effective date. We accounted for InvIOs financial royalty assets using the non-accrual method until we are able to reliably estimate future cash flows.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tzield Agreement</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we acquired Tolerance Therapeutics for $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="f-918">20</ix:nonFraction> million in cash. Tolerance Therapeutics is a holding company, owned by the inventors of Tzield (teplizumab), and is owed a royalty of less than <ix:nonFraction unitRef="number" contextRef="c-213" decimals="2" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="f-919">1</ix:nonFraction>% on worldwide net sales of Tzield. Tzield is marketed by Sanofi, starting in 2023. For tax purposes this transaction was treated as a stock deal, so there is no step-up in basis and tax attributes. Therefore, during the year ended December&#160;31, 2024, a deferred tax liability (DTL) of $<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="f-920">5.5</ix:nonFraction> million was recognized on the book basis and tax basis difference and recorded to the book value of the Tolerance Therapeutics&#8217; financial royalty asset. Due to the early stages of Tzield's commercialization, management has placed the investment on the non-accrual method until we are able to reliably estimate future cash flows.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ensifentrine Inventors Agreements</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and August 2024, we acquired future milestone and royalty rights related to ensifentrine from certain ensifentrine inventors for a total of $<ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="lgnd:FinancialRoyaltyAssetsGross" scale="6" id="f-921">3.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="lgnd:FinancialRoyaltyAssetsGross" scale="6" id="f-922">13.6</ix:nonFraction> million, respectively. On June 26, 2024, Verona Pharma plc received FDA approval for ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease (&#8220;COPD&#8221;). During the third quarter of 2024, Verona started commercial sales of ensifentrine (marketed as Ohtuvayre) in the U.S. Due to the early stages of Ohtuvayre's commercialization, management has placed the investment on the non-accrual method until we are able to reliably estimate future cash flows.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Elutia Agreement</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, Ligand entered into a purchase agreement to acquire certain financial royalty assets from CorMatrix. In 2017, CorMatrix sold its marketed products to Elutia where Elutia assumed the Ligand royalty obligation. In 2017, we amended the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-856-2" continuedAt="f-856-3"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terms of the royalty agreement with Elutia where we received $<ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-6" name="us-gaap:ProceedsFromRoyaltiesReceived" scale="6" id="f-923">10</ix:nonFraction> million to buydown the royalty rates on the products CorMatrix sold to Elutia (the &#8220;CorMatrix Asset Sale&#8221;). Per the amended agreement with Elutia, we will receive a <ix:nonFraction unitRef="number" contextRef="c-217" decimals="INF" name="lgnd:ProductRoyaltyPercentage" scale="-2" id="f-924">5</ix:nonFraction>% royalty, with certain annual minimum payments, on the products Elutia acquired in the CorMatrix Asset Sale and up to $<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="INF" name="lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" scale="6" id="f-925">10</ix:nonFraction> million of milestones tied to cumulative net sales of these products. The royalty agreement will terminate on May 31, 2027. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, due to Elutia's nonpayment of the minimum payments under the amended royalty agreement over several quarters, we placed the Elutia asset on the non-accrual method. In January 2024, we executed an amendment to our agreement with Elutia which will allow us to reliably estimate future cash flows. As such, the Elutia asset was switched from the non-accrual method to the effective interest method during the first quarter of 2024. We further considered the current and expected future economic and market conditions, current company performance and recent payments received from Elutia. During the years ended December&#160;31, 2024 and 2023, we recorded a reduction of $<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" sign="-" name="lgnd:CommercialLicenseRightsCreditLossAdjustment" scale="6" id="f-926">5.2</ix:nonFraction> million and an increase of $<ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="lgnd:CommercialLicenseRightsCreditLossAdjustment" scale="6" id="f-927">3.2</ix:nonFraction> million, respectively, to Elutia allowance of expected credit loss. The credit loss adjustments were included in general and administrative expense in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Soticlestat Agreement</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, we made an investment of $<ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-6" name="lgnd:ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" scale="6" id="f-928">30</ix:nonFraction> million to acquire a <ix:nonFraction unitRef="number" contextRef="c-221" decimals="2" name="lgnd:SalesContractInterestInSalesRevenue" scale="-2" id="f-929">13</ix:nonFraction>% portion of the royalties and milestones owed to Ovid Therapeutics related to the potential approval and commercialization of soticlestat. </span></div></ix:continuation><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-856-3">In June 2024, Takeda announced topline results of the phase 3 clinical trial of soticlestat, narrowly missing its primary endpoint to reduce convulsive seizure frequency compared to placebo in patients with Dravet syndrome, and missing its primary endpoint to reduce major motor drop seizure frequency compared to a placebo in patients with Lennox-Gastaut syndrome. In January 2025, Takeda announced its decision to discontinue its soticlestat program. As a result, in the year ended December&#160;31, 2024, we recognized a full impairment of the soticlestat financial royalty asset.</ix:continuation> </span></div><div id="ifca968692f35492e968bd282f4512e0b_115"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-930" continuedAt="f-930-1" escape="true">Balance Sheet Account Details</ix:nonNumeric></span></div><ix:continuation id="f-930-1" continuedAt="f-930-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Investments</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesTextBlock" id="f-931" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2024 and 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">gains</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">losses</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-932">78,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-933">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-934">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-935">78,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-936">23,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-937">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-938">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-939">23,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-940">22,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-941">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-942">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-943">22,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-944">15,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-945">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-946">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-947">15,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-948">9,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-949">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-950">6,595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-951">3,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-952">150,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-953">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-954">6,626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-955">143,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bond fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-956">63,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-957">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-958">537</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-959">63,226</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-960">17,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-961">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-962">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-963">17,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-964">14,850</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-965">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-966">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-967">14,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-968">11,578</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-969">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-970">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-971">11,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-972">6,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-973">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-974">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-975">6,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-976">1,007</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-977">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="f-978">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-979">1,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-980">5,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="f-981">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-982">5,235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="f-983">540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-984">120,874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-985">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:num-dot-decimal" scale="3" id="f-986">5,783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-987">115,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) from short-term investments on our consolidated statements of operations includes both realized and unrealized gain (loss) from our short-term investments in public equity and warrant securities, and realized gain (loss) from available-for-sale debt securities. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-930-2" continuedAt="f-930-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-988" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-989">127,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-990">127,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="f-991">12,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="3" id="f-992">12,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-993">140,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="3" id="f-994">140,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="f-995" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12 months or greater</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of Deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-996">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-997">6,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-998">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-999">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1000">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1001">6,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-1002">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="f-1003">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-1004">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="f-1005">3,026</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1006">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1007">3,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-1008">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-1009">9,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-1010">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-1011">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1012">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1013">9,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-1014">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-1015">29,965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-1016">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="f-1017">4,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1018">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1019">34,729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-1020">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-1021">46,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-1022">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="f-1023">7,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1024">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1025">54,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of Deposit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-1026">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-1027">4,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-1028">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-1029">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1030">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1031">4,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-1032">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-1033">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-1034">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="f-1035">1,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1036">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1037">2,857</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-1038">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-1039">10,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-1040">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-1041">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1042">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1043">10,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-1044">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-1045">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-1046">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="3" id="f-1047">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1048">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1049">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" format="ixt:fixed-zero" scale="3" id="f-1050">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="3" id="f-1051">998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-1052">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="f-1053">1,502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1054">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1055">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="3" id="f-1056">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="3" id="f-1057">17,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="f-1058">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="f-1059">2,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="f-1060">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" format="ixt:num-dot-decimal" scale="3" id="f-1061">20,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy is capital preservation and we only invested in U.S.-dollar denominated investments. We held a total of <ix:nonFraction unitRef="position" contextRef="c-5" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="f-1062">45</ix:nonFraction> securities which were in an unrealized loss position with a total of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-4" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="6" id="f-1063">0.03</ix:nonFraction> million unrealized losses as of December&#160;31, 2024. We believe that we will collect the principal and interest due on our debt securities that have an amortized cost in excess of fair value. The unrealized losses are largely due to changes in interest rates and not to unfavorable changes in the credit quality associated with these securities that impacted our assessment on collectability of principal and interest. In July 2024, we sold certain securities before the recovery of the amortized cost basis to fund the Apeiron Acquisition. Accordingly, we wrote down the amortized cost of $<ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-4" name="lgnd:DebtSecuritiesAvailableForSaleAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1064">0.05</ix:nonFraction>&#160;million during the second quarter of 2024. We do not intend to sell these securities and it is unlikely that we will be required to sell these securities before the recovery of the amortized cost basis as of December&#160;31, 2024. Accordingly, there was <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" format="ixt:fixed-zero" scale="0" id="f-1065">no</ix:nonFraction> credit loss recognized for the year ended December&#160;31, 2024. There was <ix:nonFraction unitRef="usd" contextRef="c-22" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" format="ixt:fixed-zero" scale="0" id="f-1066">no</ix:nonFraction> credit losses recognized for the year ended December&#160;31, 2023. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Investments: Investment in Viking</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held <ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="us-gaap:CommonStockValueOutstanding" scale="6" id="f-1067">1.0</ix:nonFraction> million shares of Viking common stock as of December&#160;31, 2024, and we account for it as an investment in available-for-sale equity securities, which is measured at fair value, with changes in fair value recognized in net income. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and December&#160;31, 2023, our investment in Viking was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1068">40.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1069">32.2</ix:nonFraction> million, respectively, and was included in short-term investments on the consolidated balance sheets. During the year ended December&#160;31, 2024, we sold <ix:nonFraction unitRef="shares" contextRef="c-236" decimals="-5" name="lgnd:NumberOfSharesSoldOfEquityMethodInvestee" scale="6" id="f-1070">0.7</ix:nonFraction> million shares of Viking common stock and recognized a total realized gain of $<ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-5" name="us-gaap:GainLossOnInvestments" scale="6" id="f-1071">60.0</ix:nonFraction> million. During the year ended December&#160;31, 2023, we sold <ix:nonFraction unitRef="shares" contextRef="c-237" decimals="-5" name="lgnd:NumberOfSharesSoldOfEquityMethodInvestee" scale="6" id="f-1072">5.0</ix:nonFraction> million shares of Viking common stock and recognized a total realized gain of $<ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="us-gaap:GainLossOnInvestments" scale="6" id="f-1073">44.4</ix:nonFraction> million. There were <ix:nonFraction unitRef="shares" contextRef="c-238" decimals="-5" name="lgnd:NumberOfSharesSoldOfEquityMethodInvestee" format="ixt:fixed-zero" scale="0" id="f-1074">no</ix:nonFraction> sales of Viking common stock during the year ended December 31, 2022. </span></div></ix:continuation><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-930-3" continuedAt="f-930-4"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment, net</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-1075" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lab and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1076">6,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1077">7,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1078">10,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1079">10,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1080">1,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-1081">716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1082">4,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1083">4,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1084">23,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-1085">22,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1086">8,268</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1087">6,655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-1088">15,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-1089">15,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which ranges from <span style="-sec-ix-hidden:f-1090">one</span> to <ix:nonNumeric contextRef="c-83" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-1091">nine years</ix:nonNumeric>. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1092">2.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1093">2.9</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1094">3.8</ix:nonFraction> million was recognized for the years ended December&#160;31, 2024, 2023, and 2022, respectively, and was included in general and administrative and research and development expenses in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and intangible assets, net</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="f-1095" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and identifiable intangible assets consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1096">105,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1097">103,370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Completed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1098">39,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1099">42,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1100">19,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1101">20,894</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1102">2,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1103">2,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1104">1,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1105">1,710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1106">29,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1107">29,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1108">20,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1109">19,161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contractual relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1110">360,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1111">360,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1112">122,638</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-1113">93,782</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total goodwill and other identifiable intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1114">371,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1115">402,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in a goodwill carrying value for the year ended December 31, 2024, relates to finalization of Novan Acquisition purchase accounting in the first quarter of 2024. Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of up to <ix:nonNumeric contextRef="c-83" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1116">20</ix:nonNumeric> years. Amortization expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="6" id="f-1117">33.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="6" id="f-1118">33.7</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="6" id="f-1119">34.2</ix:nonFraction> million were recognized for the years ended December&#160;31, 2024, 2023, and 2022, respectively. Estimated amortization expense for the years ending December&#160;31, 2025 through 2029 is $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="f-1120"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="f-1121"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="f-1122"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="f-1123"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="f-1124">32.7</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> million per year. For each of the years ended December&#160;31, 2024, 2023, and 2022, there was <ix:nonFraction unitRef="usd" contextRef="c-22" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-1125"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-1126"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-1127">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of intangible assets with finite lives.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" id="f-1128" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative assets consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Primrose mRNA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1129">3,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1130">3,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agenus Partner Programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1131">6,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1132">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agenus Warrant (<ix:nonNumeric contextRef="c-259" name="us-gaap:DerivativeTermOfContract" format="ixt-sec:duryear" id="f-1133">5</ix:nonNumeric> years contractual term)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" scale="3" id="f-1134">806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1135">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total noncurrent derivative assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1136">10,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DerivativeAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1137">3,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-930-4" continuedAt="f-930-5"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the fair value of Agenus Partner Programs and Primrose mRNA derivative that amounted to $(<ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-5" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="f-1138">15.0</ix:nonFraction>) million and $(<ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-5" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="f-1139">0.1</ix:nonFraction>) million, respectively, for the year ended December&#160;31, 2024, was included in fair value adjustments to partner program derivatives in the consolidated statement of operations. A net increase in fair value of Viking Share Collar and Viking Share Put that amounted to $<ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-5" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="f-1140">7.1</ix:nonFraction> million for the year ended December 31, 2024, was recognized in gain from short-term investments in the consolidated statements of operations. A change in the fair value of other derivatives that amounted to $(<ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="f-1141">12.1</ix:nonFraction>) million for the year ended December&#160;31, 2024, was recognized in other non-operating (expense) income, net in the consolidated statements of operations. We acquired the Primrose mRNA derivative on September 18, 2023 with the sale of Pelican business and investment in Primrose Bio transaction. A change in the fair value of the Primrose mRNA derivative that amounted to $<ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-5" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="f-1142">0.3</ix:nonFraction> million during the year ended December&#160;31, 2023 was included in the consolidated statements of operations. We did not have any other derivative instruments during the years ended December&#160;31, 2023 and 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Investments</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SummaryInvestmentHoldingsTextBlock" id="f-1143" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other investments consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities in Primrose Bio</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1144">6,712</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1145">32,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">InvIOs investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1146">4,196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:fixed-zero" scale="3" id="f-1147">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuritek warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:fixed-zero" scale="3" id="f-1148">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1149">3,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palvella Series C preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:fixed-zero" scale="3" id="f-1150">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1151">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total other investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1152">10,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1153">36,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2024, we recognized a full impairment for our investment in Neuritek warrants. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 13, 2024, Palvella Therapeutics, Inc. (&#8220;Palvella&#8221;) announced the completion of its previously announced merger with Pieris Pharmaceuticals, Inc. (&#8220;Pieris&#8221;). The combined company will operate under the name Palvella Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market on December 16, 2024, under the ticker symbol &#8220;PVLA&#8221;. In conjunction with the transaction, the Series C Preferred Shares we held were converted to common shares using an exchange ratio of approximately <ix:nonFraction unitRef="number" contextRef="c-276" decimals="4" name="us-gaap:PreferredStockConvertibleConversionRatio" scale="0" id="f-1154">0.3095</ix:nonFraction>, converting the <ix:nonFraction unitRef="shares" contextRef="c-276" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-1155">189,112</ix:nonFraction> Series C preferred shares into <ix:nonFraction unitRef="shares" contextRef="c-277" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="f-1156">58,524</ix:nonFraction> common shares. We account for the Palvella common shares as a short-term investment included in our consolidated balance sheet. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Assets and Other Current Assets</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets include economic rights related to the 2023 expansion of our strategic partnership with Palvella to accelerate Phase 3 development of Qtorin rapamycin for the treatment of Microcystic Lymphatic Malformations (&#8220;Microcystic LM&#8221;). According to the terms of the second amendment to our development funding and royalties agreement with Palvella (the &#8220;Palvella Second Amendment&#8221;), Palvella received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-6" name="lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" scale="6" id="f-1157">5</ix:nonFraction> million from Ligand. In return for the upfront payment, among other contractual changes, the tiered royalty payable by Palvella to Ligand was increased to between <ix:nonFraction unitRef="number" contextRef="c-279" decimals="3" name="lgnd:SalesContractInterestInSalesRevenue" scale="-2" id="f-1158">8.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-280" decimals="3" name="lgnd:SalesContractInterestInSalesRevenue" scale="-2" id="f-1159">9.8</ix:nonFraction>% based on annual aggregate worldwide net sales of Qtorin rapamycin. We are not obligated to provide additional funding to Palvella for development or commercialization of Qtorin.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the economic rights related to Palvella should be characterized as a funded research and development arrangement, because the contract designated the funds usage for research and development activities, and thus we account for them in accordance with ASC 730-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We reduce our asset as the funds are expended by Palvella. As of December&#160;31, 2024, of the $<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-6" name="lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" scale="6" id="f-1160">5</ix:nonFraction> million upfront funding related to the Palvella Second Amendment, $<ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-1161">1.2</ix:nonFraction> million of the funding to Palvella was expended. Our CEO and director, Todd Davis, is a director of Palvella. Mr. Davis recused himself from both board's consideration of the agreement between us and Palvella, including any financial analysis, the terms of the Palvella Second Amendment and the vote to approve the Palvella Second Amendment and the related transactions.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, we funded Palvella $<ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-5" name="us-gaap:AccountsReceivableNetNoncurrent" scale="6" id="f-1162">2.5</ix:nonFraction> million in exchange for a convertible note with a maturity of <ix:nonNumeric contextRef="c-282" name="lgnd:AccountsReceivableTerm" format="ixt-sec:durwordsen" id="f-1163">three years</ix:nonNumeric>, which is included in other assets in the consolidated balance sheets. In conjunction with Pavella's merger with Pieris as discussed above, the convertible note automatically converted into Pavella common shares. The $<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-5" name="lgnd:AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount" scale="6" id="f-1164">2.6</ix:nonFraction> million principal and interest converted into <ix:nonFraction unitRef="shares" contextRef="c-283" decimals="INF" name="lgnd:AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-1165">184,595</ix:nonFraction> shares, using a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-284" decimals="4" name="lgnd:AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice" scale="0" id="f-1166">13.9965</ix:nonFraction> per share. We account for the Palvella common shares as a short-term investment in our consolidated balance sheet. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets primarily include $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="lgnd:FinancialRoyaltyAssetsNetCurrent" scale="6" id="f-1167">10.0</ix:nonFraction> million current portion of financial royalty assets (disclosed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (6), Financial Royalty Assets, net (formerly known as Commercial License Rights)&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and $<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="f-1168">4.5</ix:nonFraction> million inventory (raw materials and work in process related to the manufacturing of finished goods) for the preparation of commercial supplies of ZELSUVMI by Pelthos Therapeutics, a wholly owned subsidiary of Ligand. For additional information on ZELSUVMI, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (3), Acquisitions&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-1169" continuedAt="f-1169-1" escape="true">Below is a summary of the ZELSUVMI related inventory included in other current assets (in thousands):</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-930-5"><ix:continuation id="f-1169-1"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-1170">3,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="f-1171">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="f-1172">603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="f-1173">420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Pelthos inventory in other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-1174">4,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:InventoryNet" scale="3" id="f-1175">615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-1176" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalties owed to third parties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1177">6,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="3" id="f-1178">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1179">5,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1180">4,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UK value-added tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="lgnd:ValueAddedTaxReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1181">5,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lgnd:ValueAddedTaxReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-1182">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1183">4,858</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1184">2,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subcontractor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:AccruedSubcontractorExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1185">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lgnd:AccruedSubcontractorExpensesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1186">1,756</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer deposit </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:AccruedCustomerDepositsCurrent" scale="3" id="f-1187">621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lgnd:AccruedCustomerDepositsCurrent" scale="3" id="f-1188">621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplier</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:AccruedSupplierExpensesCurrent" format="ixt:fixed-zero" scale="3" id="f-1189">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lgnd:AccruedSupplierExpensesCurrent" scale="3" id="f-1190">303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts owed to former licensees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:LicenseeAccrualCurrent" format="ixt:fixed-zero" scale="3" id="f-1191">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lgnd:LicenseeAccrualCurrent" scale="3" id="f-1192">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1193">3,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1194">1,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1195">27,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1196">12,467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent liabilities</span></div><ix:nonNumeric contextRef="c-1" name="lgnd:ScheduleofContingentLiabilitiesTableTextBlock" id="f-1197" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes roll-forward of contingent liabilities as of December&#160;31, 2024 and 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"/><td style="width:20.201%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.698%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.698%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.734%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.698%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.698%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.739%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cydex</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="f-1198">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="f-1199">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="f-1200">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="f-1201">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="f-1202">200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="f-1203">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" scale="3" id="f-1204">383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metabasis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1205">3,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" format="ixt:fixed-zero" scale="3" id="f-1206">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="f-1207">551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1208">2,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" format="ixt:fixed-zero" scale="3" id="f-1209">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="f-1210">420</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1211">3,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1212">3,513</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="f-1213">50</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="f-1214">265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1215">3,198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="f-1216">200</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" scale="3" id="f-1217">683</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1218">3,681</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other long-term liabilities</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="f-1219" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novan (Pelthos) contract liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1220">15,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1221">13,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:UnrecognizedTaxBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1222">14,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lgnd:UnrecognizedTaxBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1223">14,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="3" id="f-1224">65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherSundryLiabilitiesNoncurrent" scale="3" id="f-1225">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1226">30,163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1227">27,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="ifca968692f35492e968bd282f4512e0b_103"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="f-1228" continuedAt="f-1228-1" escape="true">Fair Value Measurement</ix:nonNumeric></span></div><ix:continuation id="f-1228-1" continuedAt="f-1228-2"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure certain financial assets and liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described in the below with level 1 having the highest priority and level 3 having the lowest:</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs such as quoted prices in active markets </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="f-1229" continuedAt="f-1229-1" escape="true"><ix:continuation id="f-1228-2" continuedAt="f-1228-3"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments, excluding Viking</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1230">143,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1231">81,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1232">61,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1233">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1234">40,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1235">40,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1236">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1237">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><ix:nonNumeric contextRef="c-1" name="lgnd:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" id="f-1238"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></ix:nonNumeric></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-1239">10,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-1240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-1241">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-1242">10,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1243">194,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1244">122,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1245">61,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1246">10,583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent liabilities - CyDex</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" scale="3" id="f-1247">383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1248">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1249">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" scale="3" id="f-1250">383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1251">3,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1253">3,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1254">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1255">3,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1256">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1257">3,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-1258">383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments, excluding Viking</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1259">115,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1260">7,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1261">107,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1262">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1263">32,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1264">32,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1265">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-3" name="us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent" format="ixt:fixed-zero" scale="3" id="f-1266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><ix:nonNumeric contextRef="c-22" name="lgnd:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" id="f-1267"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></ix:nonNumeric></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-1268">3,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-1269">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="3" id="f-1270">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-3" name="us-gaap:DerivativeAssets" format="ixt:num-dot-decimal" scale="3" id="f-1271">3,531</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1272">150,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1273">39,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1274">107,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1275">3,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent liabilities - CyDex</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" scale="3" id="f-1276">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1277">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" scale="3" id="f-1279">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1280">2,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1282">2,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" name="lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1283">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1284">3,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-1285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-1286">2,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" id="f-1287">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) Excluding our investment in Viking, corporate equity securities, and US government securities, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in bond funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we had investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and were at level 3 of the fair value hierarchy, based on Black-Scholes value estimated by management on the last day of the period. This investment in warrants expired in January 2024.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(2) Derivative assets include instruments used for risk-management purposes, and other instruments. Derivative assets which are not used for risk management purposes include: (a) acquired rights in future milestone and royalty payments from Agenus Partnered Programs, (b) Agenus Warrant, (c) Upsize Option, (d) Viking Share Collar (e) and rights to receive from Primrose Bio <ix:nonFraction unitRef="number" contextRef="c-84" decimals="2" name="lgnd:MilestoneCompensationRate" scale="-2" id="f-1288">50</ix:nonFraction>% of milestones on <ix:nonFraction unitRef="contract" contextRef="c-85" decimals="INF" name="lgnd:NumberOfContracts" format="ixt-sec:numwordsen" scale="0" id="f-1289">two</ix:nonFraction> contracts previously entered into by Primordial Genetics. The considerations were recognized as derivative assets included under current derivative assets and noncurrent derivative assets in our consolidated balance sheet. They are recognized as derivative assets under ASC 815, Derivatives and Hedging. The fair value of the Agenus Partnered Programs and the Primrose Bio derivative assets was determined using a discounted cash flow approach, utilizing the mostly-likely cash flows which considered the probability of success for the underlying clinical programs. The discount rate used contemplates the underlying credit and business risk of the partnered programs. At December&#160;31, 2024, the discount rates used range between <ix:nonFraction unitRef="number" contextRef="c-330" decimals="2" name="us-gaap:DerivativeAssetMeasurementInput" scale="-2" id="f-1290">15</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-331" decimals="2" name="us-gaap:DerivativeAssetMeasurementInput" scale="-2" id="f-1291">28</ix:nonFraction>%. At December&#160;31, 2023, the discount rate used was <ix:nonFraction unitRef="number" contextRef="c-332" decimals="2" name="us-gaap:DerivativeAssetMeasurementInput" scale="-2" id="f-1292">25</ix:nonFraction>%. The fair value of the Agenus Warrant was determined using a Black-Scholes-Merton model. The fair value of the Upsize Option was determined using a binomial option pricing model.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(3) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders <ix:nonFraction unitRef="cvr" contextRef="c-333" decimals="INF" name="lgnd:BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare" format="ixt-sec:numwordsen" scale="0" id="f-1293">four</ix:nonFraction> tradable CVRs, <ix:nonFraction unitRef="cvr" contextRef="c-333" decimals="INF" name="lgnd:BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries" format="ixt-sec:numwordsen" scale="0" id="f-1294">one</ix:nonFraction> CVR from each of <ix:nonFraction unitRef="cvr" contextRef="c-334" decimals="INF" name="lgnd:NumberOfContingentValueRightsSeries" format="ixt-sec:numwordsen" scale="0" id="f-1295">four</ix:nonFraction> respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every <ix:nonNumeric contextRef="c-333" name="lgnd:BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders" format="ixt-sec:durwordsen" id="f-1296">six months</ix:nonNumeric> as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate </span></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-1228-3" continuedAt="f-1228-4"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="f-1229-1">significantly based upon quoted market prices and actual amounts paid under the agreements may be materially different than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#946; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $<ix:nonFraction unitRef="usd" contextRef="c-335" decimals="INF" name="us-gaap:Investments" scale="6" id="f-1297">375</ix:nonFraction> million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $<ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-5" name="us-gaap:ContractWithCustomerAssetGross" scale="6" id="f-1298">10</ix:nonFraction> million payment upon initiation of a Phase 3 clinical trial.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-1300" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-1299" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2024 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="f-1301">3,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions to derivative assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="f-1302">35,888</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1303">Fair value adjustments to derivative assets</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" format="ixt:num-dot-decimal" scale="3" id="f-1304">20,010</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of derivative assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:num-dot-decimal" scale="3" id="f-1305">8,826</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2024</span></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="f-1306">10,583</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-1307">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments to CVR holders and other contingent payments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="f-1308">200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1309">Fair value adjustments to contingent liabilities</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-1310">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2024</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-1311">383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2023 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" scale="3" id="f-1312">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1313">Fair value adjustments to equity security warrants</span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="f-1314">135</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions to derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" format="ixt:num-dot-decimal" scale="3" id="f-1315">3,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value adjustments to derivative assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" scale="3" id="f-1316">250</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" format="ixt:num-dot-decimal" scale="3" id="f-1317">3,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-1318">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments to CVR holders and other contingency payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:PaymentsToContingentValueRightHolders" scale="3" id="f-1319">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1320">Fair value adjustments to contingent liabilities</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="f-1321">286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="f-1322">320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Measured on a Non-Recurring Basis</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to our goodwill, intangible assets with estimated useful lives and long-lived assets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate goodwill annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate intangible assets with estimated useful lives whenever circumstances occur indicating that intangible assets may not be recoverable. An impairment evaluation is based on an undiscounted cash flow analysis at the lowest level at which cash flows of the long-lived assets are largely independent of other groups of assets and liabilities.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="c-22" decimals="INF" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="0" id="f-1323"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="0" id="f-1324"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="f-1325"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="f-1326">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of our goodwill, intangible assets, or long-lived assets recorded during the years ended December&#160;31, 2024 and 2023. Other than the finance lease equipment discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (9), Leases&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there was <ix:nonFraction unitRef="usd" contextRef="c-23" decimals="INF" name="us-gaap:GoodwillAndIntangibleAssetImpairment" format="ixt:fixed-zero" scale="0" id="f-1327"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="f-1328">no</ix:nonFraction></ix:nonFraction> impairment of our goodwill, intangible assets, or long-lived assets recorded during the year ended and December&#160;31, 2022. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and cash equivalents, accounts receivable, other current assets, financial royalty assets, accounts payable, accrued liabilities, deferred revenue, current operating lease liabilities, current finance lease liabilities and Novan (Pelthos) other long-term liabilities are financial instruments and are recorded at cost in the consolidated balance sheets. The estimated </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-1228-4" continuedAt="f-1228-5"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair value of the Novan (Pelthos) other long-term liabilities is $<ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-5" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1329">19.1</ix:nonFraction>&#160;million compared to a carrying value of $<ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-5" name="us-gaap:OtherLiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1330">15.9</ix:nonFraction>&#160;million. The estimated fair value of the remaining financial instruments approximates their carrying value.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets Not Measured at Fair Value</span></div></ix:continuation><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1228-5">Financial royalty assets are measured and carried on the balance sheet at amortized cost using the effective interest method or on a non-accrual basis. Management calculates the fair value of financial royalty assets using a forecasted royalty receipts. The projected future cash flows derive from royalty payments and milestones, then discounted using appropriate individual discount rates. The fair value of financial royalty assets and other economic rights assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. The estimated fair value and related carrying values of financial royalty assets as of December&#160;31, 2024 were $<ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-5" name="lgnd:FinancialRoyaltyAssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1331">196.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-5" name="lgnd:FinancialRoyaltyAssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1332">195.0</ix:nonFraction>&#160;million, respectively. The estimated fair value and related carrying value of the financial royalty assets as of December&#160;31, 2023 were $<ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-5" name="lgnd:FinancialRoyaltyAssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1333">75.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-5" name="lgnd:FinancialRoyaltyAssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1334">62.3</ix:nonFraction>&#160;million, respectively. To determine the fair value of long-term financial royalty assets, we estimated future underlying product sales, applied a probability of technical and regulatory success for development stage programs, estimated a timeline for any development and regulatory milestones, and applied a discount rate based on the level of partner execution and commercialization risk, in the range of <ix:nonFraction unitRef="number" contextRef="c-341" decimals="2" name="lgnd:FinancialRoyaltyAssetMeasurementInput" scale="-2" id="f-1335">15</ix:nonFraction>-30% and <ix:nonFraction unitRef="number" contextRef="c-342" decimals="2" name="lgnd:FinancialRoyaltyAssetMeasurementInput" scale="-2" id="f-1336">10</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="c-343" decimals="2" name="lgnd:FinancialRoyaltyAssetMeasurementInput" scale="-2" id="f-1337">45</ix:nonFraction>% as of December 31, 2024, and 2023, respectively.</ix:continuation> Weighted average discount rate (weighted by relative fair value) was 19% and 18% as of December 31, 2024, and 2023, respectively.</span></div><div id="ifca968692f35492e968bd282f4512e0b_106"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-1339" continuedAt="f-1339-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeFinanceLeasesTextBlock" id="f-1338" continuedAt="f-1338-1" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-1339-1" continuedAt="f-1339-2"><ix:continuation id="f-1338-1" continuedAt="f-1338-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance lease</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020 and January 2021, we entered into an agreement and the first amendment with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol, respectively. The agreements are considered to include an embedded finance lease under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as it provides the Company the right to use the underlying equipment to exclusively manufacture Captisol. As of December 31, 2021, we had fully paid consideration of $<ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-5" name="lgnd:PurchaseCommitmentConsiderationPaidToDate" scale="6" id="f-1340">69.1</ix:nonFraction> million for prepaid inventory and capacity ramp-up fee. We allocated consideration in the agreements between lease and non-lease components using relative standalone prices. Since the inception of the agreements, we have allocated $<ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-5" name="lgnd:PurchaseCommitmentConsiderationPaidAllocatedToInventory" scale="6" id="f-1341">50.2</ix:nonFraction> million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and being amortized to cost of Captisol based on the usage. The remaining balance of $<ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="f-1342">18.9</ix:nonFraction> million was recognized as a right of use asset. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, given the COVID status, our forecast for COVID-related Captisol had been significantly reduced, which triggered an indicator of impairment of the right of use asset. We performed a recoverability test at the asset group level by comparing the sum of the estimated undiscounted future cash flows attributable to the asset group to its carrying value and identified the asset was impaired. We recorded a $<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:FinanceLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-1343">9.8</ix:nonFraction>&#160;million of impairment charge based on the fair value of the right of use asset which has been recognized in cost of Captisol in our consolidated statement of operations for the year ended December 31, 2022. As of December 31, 2022, the remaining right of use asset balance was $<ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-1344">4.0</ix:nonFraction>&#160;million which will be amortized straight-line over the remaining <ix:nonNumeric contextRef="c-346" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="f-1345">6</ix:nonNumeric> years lease term. During the years ended December&#160;31, 2024 and 2023, <ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="f-1346"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="f-1347">no</ix:nonFraction></ix:nonFraction> impairment to this asset group was recorded as there were no indicators of impairment. As of December&#160;31, 2024 and 2023, the remaining right of use asset balance is $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-1348">2.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-1349">3.4</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating lease </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease certain office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to <ix:nonNumeric contextRef="c-83" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:durwordsen" id="f-1350">eight years</ix:nonNumeric>, some of which include options to extend the leases for up to <ix:nonNumeric contextRef="c-83" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-1351">five years</ix:nonNumeric>. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-1339-2"><ix:continuation id="f-1338-2"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, we entered into lease agreements for our offices located in Boston, Massachusetts, and Jupiter, Florida, which resulted in a $<ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-5" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-1352"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-5" name="lgnd:LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" format="ixt:num-dot-decimal" scale="6" id="f-1353">1.6</ix:nonFraction></ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-5" name="lgnd:LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" format="ixt:num-dot-decimal" scale="6" id="f-1354"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-5" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-1355">0.1</ix:nonFraction></ix:nonFraction>&#160;million, respectively, increase in both operating lease assets and operating lease liabilities at lease commencement. During the year ended December 31, 2023, we entered into an amendment to the lease agreement for our office located in San Diego, California, which resulted in a $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="lgnd:LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" format="ixt:num-dot-decimal" scale="6" id="f-1356"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="f-1357">1.1</ix:nonFraction></ix:nonFraction>&#160;million increase in both operating lease assets and operating lease liabilities at lease commencement.</span></div><ix:nonNumeric contextRef="c-1" name="lgnd:AssetsAndLiabilitiesLesseeTableTextBlock" id="f-1358" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease assets and liabilities (in thousands) are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1359">6,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1360">6,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1361">2,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1362">3,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1363">9,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lgnd:LeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1364">9,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1365">1,266</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-1366">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-1367">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="f-1368">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:LeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1369">1,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lgnd:LeaseLiabilityCurrent" scale="3" id="f-1370">410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1371">5,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1372">5,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1373"><span style="-sec-ix-hidden:f-1374">Long-term finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-1375">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="f-1376">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities   </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:LeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1377">7,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lgnd:LeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1378">6,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="f-1380" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-1379" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of operating and finance lease liabilities as of December&#160;31, 2024 are as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.391%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.499%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1381">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-1382">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1383">1,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-1384">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1385">1,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-1386">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1387">1,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-1388">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1389">1,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="3" id="f-1390">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1391">2,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="f-1392">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-1393">9,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="f-1394">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:OperatingLeaseLiabilityTenantImprovementAllowance" scale="3" id="f-1395">418</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:FinanceLeaseLiabilityTenantImprovementAllowance" format="ixt:fixed-zero" scale="3" id="f-1396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-1397">1,983</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-1398">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1399">7,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="f-1400">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, our operating leases had a weighted-average remaining lease term of <ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1401">5.8</ix:nonNumeric> years and a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1402">7.5</ix:nonFraction>%. As of December&#160;31, 2023, our operating leases had a weighted-average remaining lease term of <ix:nonNumeric contextRef="c-6" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1403">7.4</ix:nonNumeric> years and a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1404">7.7</ix:nonFraction>%. Cash paid for amounts included in the measurement of operating lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="f-1405">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="f-1406">1.4</ix:nonFraction> million, respectively, for the years ended December&#160;31, 2024 and 2023. Operating lease expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="f-1407">1.3</ix:nonFraction> million (net of sublease income of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SubleaseIncome" scale="6" id="f-1408">0.1</ix:nonFraction> million) and $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="f-1409">1.4</ix:nonFraction> million (net of sublease income of $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:SubleaseIncome" scale="6" id="f-1410">0.3</ix:nonFraction> million) for the years ended December&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, our finance leases had a weighted-average remaining lease term of <ix:nonNumeric contextRef="c-5" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1411">3.3</ix:nonNumeric> years and a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1412">6.6</ix:nonFraction>%. As of December&#160;31, 2023, our finance leases had a weighted-average remaining lease term of <ix:nonNumeric contextRef="c-6" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1413">3.4</ix:nonNumeric> years and a weighted-average discount rate of <ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1414">6.8</ix:nonFraction>%. We excluded the Hovione equipment lease in the calculation of weighted average remaining lease term and weighted average discount rate because the Hovione lease was fully paid off as of December 31, 2021. Cash paid for amounts included in the measurement of these finance lease liabilities was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-4" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="6" id="f-1415">0.02</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-4" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" format="ixt:num-dot-decimal" scale="6" id="f-1416">0.05</ix:nonFraction>&#160;million, respectively, for the years ended December&#160;31, 2024 and 2023. Finance lease expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="f-1417">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="f-1418">0.7</ix:nonFraction> million, respectively, for the years ended December&#160;31, 2024 and 2023.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="ifca968692f35492e968bd282f4512e0b_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-1419" continuedAt="f-1419-1" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="f-1419-1" continuedAt="f-1419-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-349" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1420">0.75</ix:nonFraction>% Convertible Senior Notes due 2023</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we issued $<ix:nonFraction unitRef="usd" contextRef="c-349" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-1421">750</ix:nonFraction> million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-349" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1422">0.75</ix:nonFraction>% per year, payable semi-annually. The net proceeds from the offering, after deducting the initial purchasers' discount and offering expenses, were approximately $<ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-5" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" id="f-1423">733.1</ix:nonFraction> million. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2023 Notes, we incurred $<ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-5" name="us-gaap:DeferredFinanceCostsGross" scale="6" id="f-1424">16.9</ix:nonFraction> million of issuance costs, which primarily consisted of underwriting, legal and other professional fees and was being amortized to interest expense using the effective interest method over the <ix:nonNumeric contextRef="c-350" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-1425">five years</ix:nonNumeric> expected life of the 2023 Notes. On May 15, 2023, the 2023 Notes maturity date, we paid the remaining $<ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-1426">76.9</ix:nonFraction> million principal amount and $<ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-5" name="us-gaap:InterestPaid" scale="6" id="f-1427">0.3</ix:nonFraction> million accrued interest in cash. The effective interest rate for the year ended December 31, 2023 was <ix:nonFraction unitRef="number" contextRef="c-352" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1428">0.5</ix:nonFraction>%. During the year ended December 31, 2023, we recognized a total of $<ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-5" name="us-gaap:InterestExpenseDebt" scale="6" id="f-1429">0.6</ix:nonFraction> million in interest expense, including $<ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-5" name="us-gaap:InterestExpenseDebtExcludingAmortization" scale="6" id="f-1430">0.4</ix:nonFraction> million in contractual interest expense and $<ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="f-1431">0.2</ix:nonFraction> million in amortized issuance costs. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, we repurchased $<ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-5" name="us-gaap:DebtInstrumentRepurchaseAmount" scale="6" id="f-1432">266.4</ix:nonFraction> million in principal amount of the 2023 Notes for $<ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" scale="6" id="f-1433">261.4</ix:nonFraction> million in cash, including accrued interest of $<ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-5" name="us-gaap:InterestPaid" scale="6" id="f-1434">0.5</ix:nonFraction> million We accounted for the repurchase as a debt extinguishment, which resulted in a gain of $<ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="6" id="f-1435">4.2</ix:nonFraction> million reflected in other non-operating (expense) income, net, in our consolidated statement of operations for the year ended December 31, 2022, and a $<ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-5" sign="-" name="lgnd:IncreaseDecreaseInDebtDiscount" scale="6" id="f-1436">1.3</ix:nonFraction> million reduction in debt discount. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Bond Hedge and Warrant Transactions</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the 2023 Notes, in May 2018, we entered into convertible bond hedges and sold warrants covering <ix:nonFraction unitRef="shares" contextRef="c-349" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-1437">3,018,327</ix:nonFraction> shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the 2023 Notes. The convertible bond hedges have an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-349" decimals="2" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" id="f-1438">206.65</ix:nonFraction> per share and are exercisable when and if the 2023 Notes are converted. We paid $<ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-5" name="lgnd:PaymentsforConvertibleBondHedges" scale="6" id="f-1439">140.3</ix:nonFraction> million for these convertible bond hedges. If upon conversion of the 2023 Notes, the price of our common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below are separate transactions entered into by us and are not part of the terms of the 2023 Notes. Holders of the 2023 Notes and warrants did not have any rights with respect to the convertible bond hedges.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants covering <ix:nonFraction unitRef="shares" contextRef="c-349" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-1440">3,018,327</ix:nonFraction> shares of common stock with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-349" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-1441">315.38</ix:nonFraction> per share, subject to certain adjustments. We received $<ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="6" id="f-1442">90.0</ix:nonFraction> million for these warrants. The warrants have various expiration dates ranging from August 15, 2023 to February 6, 2024. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. The common stock issuable upon exercise of the warrants will be in unregistered shares, and we do not have the obligation and do not intend to file any registration statement with the SEC registering the issuance of the shares under the warrants.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, in connection with the repurchases of $<ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-5" name="lgnd:DebtInstrumentRepurchasedAmountDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-1443">227.8</ix:nonFraction>&#160;million in principal of the 2023 Notes for $<ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-5" name="us-gaap:RepaymentsOfNotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1444">223.7</ix:nonFraction>&#160;million in cash, including accrued interest of $<ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-5" name="us-gaap:InterestPaid" format="ixt:num-dot-decimal" scale="6" id="f-1445">0.4</ix:nonFraction>&#160;million made during the six months ended June 30, 2022, we entered into Bond Hedge Unwind Agreements with Barclays Bank PLC, Deutsche Bank AG, and Goldman Sachs &amp; Co. LLC to unwind a portion of the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there are no warrants that remain outstanding. The warrants expired on February 6, 2024.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Facility</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2023, we entered into a $<ix:nonFraction unitRef="usd" contextRef="c-358" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1446">75</ix:nonFraction> million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) with Citibank, N.A. as the Administrative Agent (as defined in the Credit Agreement). We, our material domestic subsidiaries, as Guarantors (as defined in the Credit Agreement), and the Lenders (as defined in the Credit Agreement) entered into a credit agreement (the &#8220;Credit Agreement&#8221;) with the Administrative Agent, under which the Lenders, the Swingline Lender and the L/C Issuer (each as defined in the Credit Agreement) agreed to make revolving loans, swingline loans and other financial accommodations to us (including the issuance of letters of credit) in an aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="c-358" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1447">75</ix:nonFraction> million. Borrowings under the Revolving Credit Facility accrue interest at a rate equal to either Term Secured Overnight Financing Rate (&#8220;Term SOFR&#8221;) or a specified base rate plus an applicable margin linked to our leverage ratio, ranging from <ix:nonFraction unitRef="number" contextRef="c-359" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1448">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-360" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1449">2.50</ix:nonFraction>% per annum for Term SOFR loans and <ix:nonFraction unitRef="number" contextRef="c-361" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1450">0.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-362" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1451">1.50</ix:nonFraction>% per annum for base rate loans. The Revolving Credit Facility is subject to a commitment fee payable on the unused Revolving Credit Facility commitments ranging from <ix:nonFraction unitRef="number" contextRef="c-363" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="f-1452">0.30</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-364" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="f-1453">0.45</ix:nonFraction>%, depending on our leverage ratio. During the term of the Revolving Credit Facility, we may borrow, repay and re-borrow amounts available under the Revolving Credit Facility, subject to voluntary reductions of the swing line, letter of credit and revolving credit commitments.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-1419-2"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Revolving Credit Facility are secured by certain of our collateral and that of the Guarantors. In specified circumstances, additional guarantors are required to be added to the Credit Agreement. The Credit Agreement contains customary affirmative and negative covenants, including certain financial maintenance covenants, and events of default applicable to us. In the event of violation of the representations, warranties and covenants made in the Credit Agreement, we may not be able to utilize the Revolving Credit Facility or repayment of amounts owed thereunder could be accelerated. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to Revolving Credit Facility</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 8, 2024, we entered into the first amendment (the &#8220;Amendment&#8221;) to the Credit Agreement, which amends the Credit Agreement to, among other things, increase the aggregate revolving credit facility amount from $<ix:nonFraction unitRef="usd" contextRef="c-358" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1454">75</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="c-365" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="f-1455">125</ix:nonFraction> million.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had $<ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1456">124.4</ix:nonFraction>&#160;million in available borrowing under the Revolving Credit Facility, after utilizing $<ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="f-1457">0.6</ix:nonFraction>&#160;million for letter of credit. As of December&#160;31, 2023, we had $<ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-5" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1458">74.5</ix:nonFraction>&#160;million in available borrowing under the Revolving Credit Facility, after utilizing $<ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-5" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="6" id="f-1459">0.5</ix:nonFraction>&#160;million for letter of credit. The maturity date of the Revolving Credit Facility, as amended, is October 12, 2026. As of December&#160;31, 2024 and 2023, there were no events of default or violation of any covenants under our financing obligations.</span></div></ix:continuation><div id="ifca968692f35492e968bd282f4512e0b_118"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-1460" continuedAt="f-1460-1" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="f-1460-1" continuedAt="f-1460-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-1461" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense from continuing operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense as a component of:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1462">3,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1463">6,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1464">10,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1465">37,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1466">19,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1467">39,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1468">41,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1469">25,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-1470">50,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion and Modification of Equity Awards Outstanding at Separation Date</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the OmniAb Separation on November 1, 2022, under the provisions of the existing plans, we adjusted our outstanding equity awards in accordance with the OmniAb Merger Agreement to preserve the intrinsic value of the awards immediately before and after the OmniAb Distribution. Upon the OmniAb Distribution, employees holding stock options, restricted stock units and performance restricted stock units denominated in pre-OmniAb Distribution Ligand stock received a number of otherwise-similar awards either in post-OmniAb Distribution Ligand stock or in a combination of post-OmniAb Distribution Ligand stock and OmniAb stock based on conversion ratios outlined for each group of employees in the OmniAb Merger Agreement. The equity awards that were granted prior to March 2, 2022 were converted under the shareholder method, wherein employees holding outstanding equity awards received equity awards in both Ligand and OmniAb. For equity awards granted after March 2, 2022, for Ligand employees, the number of awards that were outstanding at the OmniAb Separation were proportionately adjusted into post-OmniAb Distribution Ligand stock to maintain the aggregate intrinsic value of the awards at the date of the OmniAb Separation; for OmniAb employees, the number of awards that were outstanding at the OmniAb Separation were proportionately adjusted into post-OmniAb Distribution OmniAb stock to maintain the aggregate intrinsic value of the awards at the date of the OmniAb Separation. The conversion ratio was determined based on the relative values of Ligand common stock in the &#8220;regular way&#8221; and &#8220;ex-distribution&#8221; markets during the five-trading day period prior to the closing of the business combination.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These modified awards otherwise retained substantially the same terms and conditions, including term and vesting provisions. Additionally, we will not incur any future compensation cost related to equity awards held by OmniAb employees and directors. We will incur future compensation cost related to OmniAb equity awards held by our employees.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Plans</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, our stockholders approved the amendment and restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan (the &#8220;2002 Plan&#8221;). The amended and restated 2002 Plan, which is referred to herein as the &#8220;Restated Plan&#8221; was amended to increase the shares available for issuance by <ix:nonFraction unitRef="shares" contextRef="c-374" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="6" id="f-1471">1.0</ix:nonFraction> million. In June 2024, our stockholders approved the amendment and restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan, which increased the shares available for issuance by <ix:nonFraction unitRef="shares" contextRef="c-375" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="6" id="f-1472">1.3</ix:nonFraction> million.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, our board of directors (the &#8220;Board&#8221;) approved the Ligand Pharmaceuticals Incorporated 2022 Employment Inducement Plan (the &#8220;2022 Inducement Plan&#8221;). The terms of the 2022 Inducement Plan are substantially similar </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-1460-2" continuedAt="f-1460-3"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the terms of the Restated Plan with the exception that incentive stock options may not be issued under the 2022 Inducement Plan and awards under the 2022 Inducement Plan may only be issued to eligible recipients under the applicable Nasdaq Listing Rules. The 2022 Inducement Plan was adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Board has initially reserved <ix:nonFraction unitRef="shares" contextRef="c-376" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-1473">300,000</ix:nonFraction> shares of the Company&#8217;s common stock for issuance pursuant to awards granted under the 2022 Inducement Plan. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, there were <ix:nonFraction unitRef="shares" contextRef="c-377" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="f-1474">1.6</ix:nonFraction> million shares available for future option grants or direct issuance under the Restated Plan and the 2022 Inducement Plan.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-1475" continuedAt="f-1475-1" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of our stock option plan activity and related information:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:49.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.244%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1476">2,199,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-28" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1477">106.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-29" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1478">6.34</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1479">113,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-378" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-1480">863,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-378" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1481">91.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-378" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-1482">34,941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-378" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1483">38.56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-378" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1484">40,069</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-378" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1485">78.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at October 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-379" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1486">2,987,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-379" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1487">102.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-378" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1488">0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1489">14,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at October 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-379" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-1490">1,769,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-379" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1491">102.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-378" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1492">0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-1493">13,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options vested and expected to vest as of October 31, 2022, before the OmniAb Separation and Regrant</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-379" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1494">2,987,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-379" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-1495">102.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-378" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1496">0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1497">14,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancellation due to OmniAb Separation, Before Regrant</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-380" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1498">2,987,833</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at November 1, 2022, Before Regrant</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-381" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:fixed-zero" scale="0" id="f-1499">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-382" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-1500">3,584,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-382" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1501">60.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-382" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-1502">50,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-382" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1503">30.24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-382" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1504">542,838</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-382" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1505">56.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1506">2,991,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-41" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1507">61.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-382" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1508">6.07</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1509">30,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-1510">1,559,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-41" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1511">60.83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-382" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1512">4.51</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-1513">17,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1514">2,991,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-41" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-1515">61.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-382" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1516">6.07</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1517">30,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-1518">537,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1519">72.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-1520">489,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1521">45.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-22" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1522">399,371</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1523">66.61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1524">2,640,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1525">65.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-22" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1526">5.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1527">8,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-1528">1,784,209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1529">64.90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-22" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1530">4.26</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-1531">7,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1532">2,640,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-1533">65.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-22" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1534">5.63</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1535">8,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-1536">783,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1537">86.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-1538">1,080,135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1539">60.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1540">117,114</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-1541">74.58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1542">2,226,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1543">75.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1544">6.58</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1545">71,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-1546">1,229,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1547">72.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1548">5.02</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-1549">43,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-1550">2,226,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-1551">75.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-1552">6.58</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1553">71,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="f-1475-1">(1) Options granted primarily relate to the modifications in connection with the OmniAb Separation which resulted in new stock option grants at the modification date fair value.</ix:continuation> </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of all stock options granted during 2024, 2023 and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1554">37.81</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1555">36.65</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-23" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1556">28.90</ix:nonFraction> per share, respectively. The total intrinsic value of all options exercised during 2024, 2023 and 2022 was approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-1557">38.6</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-1558">12.0</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-1559">4.6</ix:nonFraction> million, respectively. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received from options exercised, net of fees paid, in 2024, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="f-1560">65.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="f-1561">22.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="f-1562">2.6</ix:nonFraction> million, respectively. </span></div></ix:continuation><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-1460-3" continuedAt="f-1460-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="f-1563" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a further breakdown of the options outstanding as of December&#160;31, 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.040%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.212%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of exercise prices</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">remaining life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">in&#160;years</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">exercise price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">exercisable</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">exercise&#160;price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-386" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1564">32.78</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-386" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1565">52.84</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-387" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1566">281,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-386" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1567">5.78</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-387" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1568">49.42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-387" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1569">195,152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-387" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1570">48.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-388" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1571">54.81</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-388" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1572">63.62</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-389" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1573">228,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-388" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1574">4.10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-389" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1575">58.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-389" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1576">191,316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-389" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1577">58.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-390" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1578">64.65</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-390" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1579">68.74</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-391" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1580">312,067</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-390" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1581">5.12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-391" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1582">67.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-391" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1583">245,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-391" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1584">67.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-392" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1585">69.39</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-392" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1586">73.76</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-393" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1587">233,288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-392" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1588">7.66</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-393" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1589">70.78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-393" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1590">125,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-393" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1591">71.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-394" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1592">73.92</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-394" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1593">75.09</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-395" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1594">288,134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-394" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1595">7.73</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-395" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1596">74.76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-395" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1597">105,797</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-395" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1598">74.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-396" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1599">78.56</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-396" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1600">88.27</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-397" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1601">155,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-396" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1602">8.57</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-397" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1603">82.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-397" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1604">32,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-397" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1605">81.71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-398" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1606">89.20</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-398" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1607">89.20</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-399" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1608">444,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-398" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1609">8.35</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-399" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1610">89.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-399" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1611">103,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-399" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1612">89.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-400" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1613">89.86</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-400" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1614">103.42</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-401" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1615">244,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-400" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1616">4.64</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-401" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1617">98.53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-401" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1618">218,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-401" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1619">98.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-402" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1620">104.30</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-402" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1621">114.15</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-403" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1622">28,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-402" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1623">6.73</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-403" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1624">110.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-403" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1625">12,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-403" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1626">114.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-404" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1627">122.70</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="c-404" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1628">122.70</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-405" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1629">10,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-404" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1630">9.92</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-405" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1631">122.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-405" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:fixed-zero" scale="0" id="f-1632">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-405" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" format="ixt:fixed-zero" scale="0" id="f-1633">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="0" id="f-1634">2,226,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1635">6.58</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="f-1636">75.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="0" id="f-1637">1,229,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="f-1638">72.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-1639" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.701%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-406" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1640">3.5</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-407" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1641">4.5</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-408" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1642">3.7</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-409" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1643">4.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-410" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1644">1.4</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-411" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1645">4.3</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-406" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1646">44</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-407" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1647">46</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-408" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1648">45</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-409" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1649">54</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-410" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1650">49</ix:nonFraction>%-<ix:nonFraction unitRef="number" contextRef="c-411" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-1651">55</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-406" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1652">4.1</ix:nonNumeric> to <ix:nonNumeric contextRef="c-407" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1653">4.8</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-408" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1654">4.7</ix:nonNumeric> to <ix:nonNumeric contextRef="c-409" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1655">5.3</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-410" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1656">2.0</ix:nonNumeric> to <ix:nonNumeric contextRef="c-411" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1657">6.5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, there was $<ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-1658">34.0</ix:nonFraction> million of total unrecognized compensation cost related to non-vested stock options under the 2002 Plan. That cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-413" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1659">2.5</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, there was $<ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="6" id="f-1660">0.1</ix:nonFraction> million of total unrecognized compensation cost related to non-vested OmniAb stock options received in connection with the OmniAb Transactions described above. That cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-415" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1661">0.5</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Activity</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="f-1662" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our restricted stock activity and related information:&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:69.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-416" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1663">348,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-416" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1664">75.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-417" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1665">203,752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-417" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1666">83.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-417" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1667">181,246</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-417" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1668">74.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-417" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1669">20,054</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-417" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1670">65.35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-418" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1671">350,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-418" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1672">81.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-419" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1673">318,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-419" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1674">85.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-419" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1675">167,308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-419" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1676">84.28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-419" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1677">64,313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-419" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1678">77.28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-420" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-1679">437,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-420" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1680">83.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, unrecognized compensation cost related to non-vested stock awards under the 2002 Plan amounted to $<ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="f-1681">19.6</ix:nonFraction> million. That cost is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-422" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1682">1.4</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-1460-4"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-423" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-1683">24,493</ix:nonFraction> shares of our common stock are available for future issuance under the Amended Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-424" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" format="ixt:num-dot-decimal" scale="0" id="f-1684">1,250</ix:nonFraction> shares of Ligand common stock per calendar year at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to <ix:nonFraction unitRef="number" contextRef="c-424" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-1685">85</ix:nonFraction>% of the fair market value of the common stock on the first of a <span style="-sec-ix-hidden:f-1686">six</span> month offering period or purchase date, whichever is lower. There were <ix:nonFraction unitRef="shares" contextRef="c-424" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1687">6,308</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-425" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1688">5,080</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-426" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-1689">8,479</ix:nonFraction> shares issued under the ESPP in 2024, 2023 and 2022, respectively. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, our Board of Directors has approved a stock repurchase program authorizing, but not requiring, the repurchase of up to $<ix:nonFraction unitRef="usd" contextRef="c-427" decimals="INF" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="f-1690">50</ix:nonFraction> million of our common stock from time to time through April 2026. We expect to acquire shares, if at all, primarily through open-market transactions in accordance with all applicable requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. During the years ended December&#160;31, 2024, 2023 and 2022, we did <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:fixed-zero" scale="0" id="f-1691"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:fixed-zero" scale="0" id="f-1692"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:fixed-zero" scale="0" id="f-1693">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t repurchase any common stock, respectively. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the Market Equity Offering Program</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, we filed a registration statement on Form S-3 (the &#8220;Shelf Registration Statement&#8221;), which became automatically effective upon filing, covering the offering of common stock, preferred stock, debt securities, warrants and units. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, we also entered into an At-The-Market Equity Offering Sales Agreement (the &#8220;Sales Agreement&#8221;) with Stifel, Nicolaus &amp; Company, Incorporated (the &#8220;Agent&#8221;), under which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-428" decimals="-5" name="lgnd:SaleOfStockAuthorizedOfferingAmount" format="ixt:num-dot-decimal" scale="6" id="f-1694">100</ix:nonFraction>&#160;million in &#8220;at the market&#8221; offerings through the Agent (the &#8220;ATM Offering&#8221;). The Shelf Registration Statement included a prospectus covering the offering, issuance and sale of up to $<ix:nonFraction unitRef="usd" contextRef="c-428" decimals="-5" name="lgnd:SaleOfStockAuthorizedOfferingAmount" format="ixt:num-dot-decimal" scale="6" id="f-1695">100</ix:nonFraction>&#160;million of our common stock from time to time through the ATM Offering. The shares to be sold under the Sales Agreement may be issued and sold pursuant to the Shelf Registration Statement. During the year ended December&#160;31, 2024, we issued <ix:nonFraction unitRef="shares" contextRef="c-429" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-1696">360,325</ix:nonFraction> shares of common stock in the ATM Offering, generating proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-1697">37.4</ix:nonFraction>&#160;million, net of commissions and other transaction costs. During the year ended December&#160;31, 2023 and 2022, we did not issue any shares of common stock in the ATM Offering.</span></div></ix:continuation><div id="ifca968692f35492e968bd282f4512e0b_121"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-1698" continuedAt="f-1698-1" escape="true">Commitment and Contingencies: Legal Proceedings</ix:nonNumeric></span></div><ix:continuation id="f-1698-1" continuedAt="f-1698-2"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record an estimate of a loss when the loss is considered probable and estimable. Where a liability is probable and there is a range of estimated loss and no amount in the range is more likely than any other number in the range, we record the minimum estimated liability related to the claim in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As additional information becomes available, we assess the potential liability related to our pending litigation and revises our estimates. Revisions in our estimates of potential liability could materially impact our results of operations. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2019, we received <ix:nonFraction unitRef="complaint" contextRef="c-430" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-1699">three</ix:nonFraction> civil complaints filed in the U.S. District Court for the Northern District of Ohio on behalf of several Indian tribes. The Northern District of Ohio is the Court that the Judicial Panel on Multi-District Litigation (&#8220;JPML&#8221;) has assigned more than one thousand civil cases which have been designated as a Multi-District Litigation (&#8220;MDL&#8221;) and captioned In Re: National Prescription Opiate Litigation. The allegations in these complaints focus on the activities of defendants other than the Company and no individualized factual allegations have been advanced against us in any of the <ix:nonFraction unitRef="complaint" contextRef="c-430" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="f-1700">three</ix:nonFraction> complaints. We reject all claims raised in the complaints and intend to vigorously defend these matters. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 22, 2024, CyDex Pharmaceuticals, Inc. filed a Verified Complaint in the Delaware Court of Chancery against Bexson Biomedical, Inc. (&#8220;Bexson&#8221;), asserting claims for declaratory relief and breach of contract arising out of a Captisol In Vivo Agreement (the &#8220;In Vivo Agreement&#8221;) between the parties, pursuant to which CyDex provided Bexson with research-grade Captisol and related confidential and proprietary information for a potential new formulation of ketamine being developed by Bexson. CyDex alleges that Bexson breached its obligations under the In Vivo Agreement, including by misusing confidential information and materials provided by CyDex and by using CyDex&#8217;s confidential information and materials to file patent applications that purport to cover formulations that are &#8220;not ketamine.&#8221; CyDex also asserts that Bexson failed to return and destroy Cydex&#8217;s confidential information and materials as required by the Agreement. CyDex seeks relief including specific performance of certain co-ownership provisions of the Agreement and disgorgement from Bexson for any benefits obtained in violation of the In Vivo Agreement. On September 27, 2024, Bexson filed a Motion to Dismiss the Verified Complaint. A Verified Amended Complaint was filed by CyDex on November 6, 2024, and a Motion to Dismiss the Verified Amended Complaint was filed by Bexson on January 17, 2025. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-1698-2"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.</span></div></ix:continuation><div id="ifca968692f35492e968bd282f4512e0b_124"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1701" continuedAt="f-1701-1" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-1702" escape="true"><ix:continuation id="f-1701-1" continuedAt="f-1701-2"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2024, 2023, and 2022, the Company has the following income before income tax from continuing operations (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.590%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.282%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1703">25,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1704">62,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-433" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1705">33,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-434" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1706">28,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-435" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1707">1,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-436" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1708">2,672</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1709">2,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1710">63,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1711">36,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:66.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.048%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1712">18,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1713">1,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1714">10,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1715">718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1716">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-1717">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1718">3,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-1719">780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="f-1720">452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1721">22,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-1722">188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1723">10,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred expense (benefit):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1724">17,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1725">9,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1726">3,656</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-1727">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-1728">655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1729">34,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1730">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-1732">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1733">15,800</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1734">10,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1735">30,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total income tax expense (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1736">6,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1737">9,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1738">41,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-1701-2" continuedAt="f-1701-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1739" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:66.941%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.062%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.063%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax at federal statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="f-1740">529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-1741">13,448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-1742">7,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subpart F income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationOtherIncome" format="ixt:num-dot-decimal" scale="3" id="f-1743">5,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationOtherIncome" scale="3" id="f-1744">479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationOtherIncome" scale="3" id="f-1745">853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Officer compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" format="ixt:num-dot-decimal" scale="3" id="f-1746">3,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" scale="3" id="f-1747">844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" format="ixt:num-dot-decimal" scale="3" id="f-1748">5,869</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign tax differential on income/loss of foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="f-1749">1,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-1750">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="f-1751">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="f-1752">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1753">1,241</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1754">1,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision to return adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" scale="3" id="f-1755">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" format="ixt:num-dot-decimal" scale="3" id="f-1756">2,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" format="ixt:num-dot-decimal" scale="3" id="f-1757">2,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate change for changes in federal, foreign or state law</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="f-1758">111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="f-1759">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate" scale="3" id="f-1760">535</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:IncomeTaxReconciliationContingentValueRights" scale="3" id="f-1761">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="lgnd:IncomeTaxReconciliationContingentValueRights" scale="3" id="f-1762">116</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:IncomeTaxReconciliationContingentValueRights" scale="3" id="f-1763">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" scale="3" id="f-1764">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1765">7,206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" scale="3" id="f-1766">158</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt repurchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" format="ixt:fixed-zero" scale="3" id="f-1767">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" format="ixt:fixed-zero" scale="3" id="f-1768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" scale="3" id="f-1769">626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-1770">85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-1771">397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-1772">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" scale="3" id="f-1773">324</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" scale="3" id="f-1774">405</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" scale="3" id="f-1775">256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FDII</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount" scale="3" id="f-1776">832</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount" format="ixt:num-dot-decimal" scale="3" id="f-1777">1,037</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount" format="ixt:num-dot-decimal" scale="3" id="f-1778">2,395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1779">1,638</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1780">1,184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1781">24,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" format="ixt:num-dot-decimal" scale="3" id="f-1782">3,232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" format="ixt:fixed-zero" scale="3" id="f-1783">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsForeign" format="ixt:fixed-zero" scale="3" id="f-1784">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-1785">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-1786">876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="f-1787">460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1788">6,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1789">9,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1790">41,230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities as of December&#160;31, 2024 and 2023 are shown below. We assess the positive and negative evidence to determine if sufficient future taxable income will be generated to realize the existing deferred tax assets. Our evaluation of evidence resulted in management concluding that the majority of our deferred tax assets will be realized. However, we maintain a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of December&#160;31, 2024, 2023 and 2022. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a non-current deferred income tax asset or liability (as applicable). <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1791" continuedAt="f-1791-1" escape="true">Deferred tax assets (liabilities) are comprised of the following (in thousands):</ix:nonNumeric></span><ix:continuation id="f-1791-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1792">40,385</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1793">45,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1794">24,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1795">26,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:DeferredTaxAssetsCapitalizedResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1796">7,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lgnd:DeferredTaxAssetsCapitalizedResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-1797">4,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1798">10,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-1799">11,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-1800">13,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-1801">15,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1802">96,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1803">103,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1804">55,649</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-1805">57,699</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1806">40,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1807">46,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identified intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1808">69,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-1809">66,966</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="f-1810">3,991</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:num-dot-decimal" scale="3" id="f-1811">10,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1812">73,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1813">77,470</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1814">32,452</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1815">31,408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-1701-3"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had federal net operating loss carryforwards set to expire through 2037 of $<ix:nonFraction unitRef="usd" contextRef="c-437" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1816">21.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-438" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1817">162.8</ix:nonFraction> million of state net operating loss carryforwards that begin to expire in 2028. We also have $<ix:nonFraction unitRef="usd" contextRef="c-439" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1818">6.2</ix:nonFraction> million of federal research and development credit carryforwards, which expire through 2040. We have $<ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1819">29.5</ix:nonFraction> million of California research and development credit carryforwards that have no expiration date. In addition, we have approximately $<ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1820">98.4</ix:nonFraction> million of non-U.S. net operating loss carryovers and approximately $<ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1821">14.4</ix:nonFraction> million of non-U.S. capital loss carryovers that have no expiration date.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had federal net operating loss carryforwards set to expire through 2037 of $<ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1822">48.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1823">165.1</ix:nonFraction> million of state net operating loss carryforwards that begin to expire in 2028. We also had $<ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1824">8.5</ix:nonFraction> million of federal research and development credit carryforwards, which expire through 2040. We had $<ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1825">29.4</ix:nonFraction> million of California research and development credit carryforwards that have no expiration date. In addition, we had approximately $<ix:nonFraction unitRef="usd" contextRef="c-447" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-1826">95.5</ix:nonFraction> million of non-U.S. net operating loss carryovers and approximately $<ix:nonFraction unitRef="usd" contextRef="c-448" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-1827">16.5</ix:nonFraction> million of non-U.S. capital loss carryovers that have no expiration date. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, utilization of our net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December&#160;31, 2024 are net of any previous limitations due to Section 382 and 383.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Our remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying consolidated balance sheet.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-1828" escape="true"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2024, 2023 and 2022 is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:66.988%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.048%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1829">22,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1830">29,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1831">29,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-1832">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-1833">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="f-1834">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-1835">477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-1836">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-1837">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-1838">396</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-1839">6,783</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="f-1840">512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1841">22,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1842">22,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1843">29,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits at December&#160;31, 2024 is $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="6" id="f-1844">20.7</ix:nonFraction> million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2024 and December&#160;31, 2023, we recognized an immaterial amount of interest and penalties. We file income tax returns in the United States, various state jurisdictions, Austria, and United Kingdom with varying statutes of limitations. The federal statute of limitation remains open for the 2021 tax year to the present.&#160;he United Kingdom statute of limitation remains open for the 2020 tax year to the present. The Austrian statute of limitation remains open for the 2020 tax year to the present.&#160;Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized. The Company's 2019 and 2020 California tax returns are under examination by the California Franchise Tax Board. The Company does not anticipate that the examination will result in a material adjustment to its financial statements. No other income tax returns are currently under examination. We believe our reserve for unrecognized tax benefits and contingent tax issues is adequate with respect to all open years.</span></div></ix:continuation><div id="ifca968692f35492e968bd282f4512e0b_911"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-1845" continuedAt="f-1845-1" escape="true">Subsequent Event</ix:nonNumeric></span></div><ix:continuation id="f-1845-1" continuedAt="f-1845-2"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2025, we entered into a Purchase and Sale Agreement (the &#8220;Agreement&#8221;) with Castle Creek Biosciences, Inc., Castle Creek Biosciences, LLC (collectively, &#8220;Castle Creek&#8221;) and a syndicate of co-investors for which Ligand acted as representative (collectively, including Ligand, the &#8220;Purchasers&#8221;), to support Castle Creek&#8217;s autologous human fibroblast cell-based gene therapy genetically modified to express COL7, also known as FCX-007 (dabocemagene autoficel) (&#8220;D-Fi&#8221;) Phase 3 clinical study, its lead candidate for patients with dystrophic epidermolysis bullosa (&#8220;DEB&#8221;). </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Agreement, we and the other Purchasers obtained, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-449" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="f-1846">75</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-450" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="f-1847">50</ix:nonFraction> million of which was paid by Ligand and $<ix:nonFraction unitRef="usd" contextRef="c-451" decimals="-6" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="f-1848">25</ix:nonFraction>&#160;million of which was paid by the other Purchasers collectively, (i) a high single digit royalty on worldwide sales of D-Fi and (ii) warrants to purchase shares of Castle Creek Biosciences, Inc. Series D-1 Preferred Stock. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><ix:continuation id="f-1845-2"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the transaction we also acquired an unsecured subordinated promissory note issued by Castle Creek Biosciences, LLC with an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-452" decimals="-5" name="us-gaap:ReceivableWithImputedInterestFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1849">8.3</ix:nonFraction>&#160;million, which is due and payable upon Castle Creek&#8217;s receipt of U.S. Food and Drug Administration approval of D-Fi for treatment of DEB and certain other conditions to payment. We paid $<ix:nonFraction unitRef="usd" contextRef="c-453" decimals="-5" name="us-gaap:PaymentsToAcquireNotesReceivable" format="ixt:num-dot-decimal" scale="6" id="f-1850">1.8</ix:nonFraction>&#160;million for the unsecured subordinated promissory note.</span></div></ix:continuation><div id="ifca968692f35492e968bd282f4512e0b_127"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ifca968692f35492e968bd282f4512e0b_130"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Controls and Procedures</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are responsible for maintaining disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports we file under the Exchange Act is recorded, processed, summarized and reported within the specified time periods and accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. As of the end of the period covered by this Annual Report on Form 10-K, we have carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, and have concluded we have remediated our previously reported material weakness described below and our disclosure controls and procedures were effective at a reasonable assurance level as of December&#160;31, 2024.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company. Internal control over financial reporting is a process to provide reasonable assurance regarding the reliability of our financial reporting for external purposes in accordance with accounting principles generally accepted in the United States of America. Internal control over financial reporting includes maintaining records that in reasonable detail accurately and fairly reflect our transactions; providing reasonable assurance that transactions are recorded as necessary for preparation of our financial statements in accordance with generally accepted accounting principles; providing reasonable assurance that receipts and expenditures are made in accordance with our management and directors; and providing reasonable assurance that unauthorized acquisition, use or disposition of company assets that could have a material effect on our financial statements would be prevented or detected on a timely basis. Because of its inherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatement of our financial statements would be prevented or detected.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework established by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;) as set forth in the 2013 Internal Control-Integrated Framework. Based on our evaluation under the 2013 framework in Internal Control - Integrated Framework, management concluded that we have remediated our previously reported material weakness in our disclosure controls and procedures and our internal controls over financial reporting were effective as of December&#160;31, 2024.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following material weakness was identified by the Company in its fiscal year ended December&#160;31, 2023: management concluded that the Company did not implement and maintain effective controls related to the valuation of the acquired intangible and contract liability, specifically controls over the review of cash flow forecasts used in the valuation of the acquired intangible asset and the discount rate used in the valuation of the contract liability. The deficiencies in our internal control over financial reporting due to the material weakness described above did not result in any misstatement in our consolidated financial statements or other disclosures. These deficiencies created, however, a reasonable possibility that a material misstatement in our consolidated financial statements would not be prevented or detected on a timely basis.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remediation of Certain Previously Identified Material Weaknesses in Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to address the identified material weakness and enhance our internal controls related to our business combination purchase price allocation process, we continue to maintain our financial reporting process we followed to prepare consolidated financial statements in accordance with GAAP for audit committee meetings on a quarterly and annual basis. We have hired additional accounting personnel and third party consultants with appropriate knowledge, experience, and/or training commensurate with our technical accounting and financial reporting requirements to enhance the process going forward. Our ongoing remediation efforts are focused on continued employee training related to internal control over financial reporting. As a result of these remediation activities, management has determined that management's controls were designed appropriately and at a sufficient level of precision, and have been operating effectively for a sufficient period of time, such that the material weakness previously identified as of December&#160;31, 2023 has been remediated as of December&#160;31, 2024.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as discussed above, there were no changes in our internal control over financial reporting that occurred during our latest fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Our implementation of our remediating plans for the material weakness, described above, resulted in changes in our internal control over financial reporting.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst&#160;&amp; Young LLP, an independent registered public accounting firm, has audited the Company&#8217;s consolidated financial statements included in this Annual Report on Form 10-K and has issued an attestation report, included herein, on the effectiveness of our internal control over financial reporting as of December&#160;31, 2024.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Stockholders and Board of Directors of Ligand Pharmaceuticals Incorporated</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Ligand Pharmaceuticals Incorporated&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control&#8212;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Ligand Pharmaceuticals Incorporated (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on the COSO criteria.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2024 and 2023, the related consolidated statements of operations, comprehensive income (loss), stockholders&#8217; equity and cash flows for each of the three years in the period ended December 31, 2024, and the related notes and our report dated February 28, 2025 expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Ernst &amp; Young LLP</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;28, 2025</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="ifca968692f35492e968bd282f4512e0b_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.198%"><tr><td style="width:1.0%"/><td style="width:28.330%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:69.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Information</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">     Rule 10b5-1 Trading Arrangements</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended December&#160;31, 2024, none of our officers or directors <ix:nonNumeric contextRef="c-454" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1851"><ix:nonNumeric contextRef="c-454" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1852">adopted</ix:nonNumeric></ix:nonNumeric>, modified or <ix:nonNumeric contextRef="c-454" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1853"><ix:nonNumeric contextRef="c-454" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1854">terminated</ix:nonNumeric></ix:nonNumeric> any such trading arrangements.</span></div><div><span><br/></span></div><div id="ifca968692f35492e968bd282f4512e0b_136"></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">     </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.847%"><tr><td style="width:1.0%"/><td style="width:9.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> None</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ifca968692f35492e968bd282f4512e0b_139"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part III</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ifca968692f35492e968bd282f4512e0b_142"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Directors, Executive Officers and Corporate Governance</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Conduct</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors has adopted a Code of Conduct and Ethics Policy (&#8220;Code of Conduct&#8221;) that applies to all officers, directors and employees. The Company will promptly disclose (1) the nature of any amendment to the Code of Conduct that applies to our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions and (2) the nature of any waiver, including an implicit waiver, from a provision of our Code of Conduct that is granted to one of these specified officers, the name of such person who is granted the waiver and the date of the waiver on our website in the future. The Code of Conduct can be accessed via our website (http://www.ligand.com), Corporate Overview page. You may also request a free copy by writing to: Investor Relations, Ligand Pharmaceuticals Incorporated, 3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other information under Item&#160;10 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2024.&#160;</span></div><div><span><br/></span></div><div id="ifca968692f35492e968bd282f4512e0b_145"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Executive Compensation</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;11 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2024.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ifca968692f35492e968bd282f4512e0b_148"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;12, including the information required by Item 201(d) of Regulation S-K, is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2024.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span><br/></span></div><div id="ifca968692f35492e968bd282f4512e0b_151"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Certain Relationships and Related Transactions, and Director Independence</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;13 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2024.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ifca968692f35492e968bd282f4512e0b_154"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Principal Accountant Fees and Services</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Item&#160;14 is hereby incorporated by reference to Ligand&#8217;s Definitive Proxy Statement to be filed with the SEC within 120 days of December&#160;31, 2024.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="ifca968692f35492e968bd282f4512e0b_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div id="ifca968692f35492e968bd282f4512e0b_160"></div><div style="-sec-extract:summary"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:9.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:88.050%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item&#160;15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibits and Financial Statement Schedule</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a) The following documents are included as part of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Financial statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:91.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.672%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_61">Index to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_61">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_64">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_64">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_67">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_67">60</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_70">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_70">61</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_73">Consolidated Statements of Comprehensive Income (Loss)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_73">62</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_76">Consolidated Statements of Stockholders&#8217; Equity </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_76">63</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_79">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_79">64</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_82">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ifca968692f35492e968bd282f4512e0b_82">65</a></span></div></td></tr></table></div><div style="margin-top:9pt;padding-left:58.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Schedules not included herein have been omitted because they are not applicable or the required information is in the consolidated financial statements or notes thereto.</span></div><div style="margin-top:9pt;padding-left:58.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) The following exhibits are filed as part of this Form 10-K and this list includes the Exhibit Index.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description of Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date of Filing</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312522083443/d337089dex21.htm">2.1*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement and Plan of Merger, dated as of March, 23, 2022, by and among Avista Public Acquisition Corp. II, Ligand Pharmaceuticals Incorporated, OmniAb, Inc. and Orwell Merger Sub Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 24, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312522083443/d337089dex22.htm">2.2*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation and Distribution Agreement, dated as of March 23, 2022, by and among Avista Public Acquisition Corp. II, Ligand Pharmaceuticals Incorporated and OmniAb, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 24, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616324000071/exhibit21apeironbiologicsa.htm">2.3*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agreement on the Acquisition of Stocks in Apeiron Biologics AG entered on July 8, 2024, between Ligand Pharmaceuticals Incorporated and the sellers. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 7, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000119312510264942/dex31.htm">3.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amended and Restated Certificate of Incorporation of the Company. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-58823</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">July 9, 1998</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616301000008/0000886163-01-000008-0002.txt">3.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated June 14, 2000 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0-20720</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 29, 2001</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616304000015/ex3-6.txt">3.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated June 30, 2004 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0-20720</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 5, 2004</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510264942/dex31.htm">3.4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of Amendment of the Amended and Restated Certificate of Incorporation of the Company, dated November 17, 2010</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November&#160;19, 2010</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000157/exhibit36.htm">3.5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of Amendment of the Amended and Restated Certification of Incorporation of the Company, dated June 19, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-233130</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 8, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616324000013/exhibit31fifthamendedandre.htm">3.6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fifth Amended and Restated Bylaws of the Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 19, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616318000030/lgndexhibi41.htm">4.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Specimen stock certificate for shares of the common stock of the Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616321000050/exhibit43_ligand-descripti.htm">4.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description of Registered Securities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 24, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000038/ligand-2022annualmeetingpr.htm#i858b093ea9a44e01b80bfe450a9cebf2_350">10.1#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2002 Stock Incentive Plan (as amended and restated effective June 10, 2022)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DEF 14A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 22, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appendix A</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000063/lgnd-2019annualmeetingproxy.htm#sb6e62536bc644ccb9ea4178e9b4c6808">10.2#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2002 Employee Stock Purchase Plan (as amended and restated effective June 6, 2019)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 24, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Appendix B</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000031/lgnd-ex105_optionagreement.htm">10.3#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Stock Option Grant Notice and Stock Option Agreement under the Company&#8217;s 2002 Stock Incentive Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 24, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000095013706000420/a16037orexv10w289.txt">10.4#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Stock Issuance Agreement for non-employee directors under the Company&#8217;s 2002 Stock Incentive Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-131029</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January&#160;13, 2006</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.289</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/formofrsugrantnoticeexhibi.htm">10.5#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Company&#8217;s 2002 Stock Incentive Plan </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/lgnd-rsugrantnoticeperform.htm">10.6#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Company&#8217;s 2002 Stock Incentive Plan - Performance-Based RSU Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616307000132/ex10-1.txt">10.7#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Executive Officer Change in Control Severance Agreement </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August&#160;22, 2007</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616323000027/a103-changeinctrlseverance.htm">10.8#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Change in Control Severance Agreement</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 8, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616323000007/exhibit_108xligand-amended.htm">10.9#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amended and Restated Severance Plan, effective November 1, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 28, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616323000050/a101_ligand-directorcompen.htm">10.10#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director Compensation and Stock Ownership Policy, as amended and restated, effective August 4, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 9, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000117/exhibit_102xligand-2022ind.htm">10.11#*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022 Employment Inducement Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 9, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616324000009/exhibit1012_amendmenttolig.htm">10.12#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment to 2022 Employee Inducement Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 29, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000117/exhibit_103xligand-formofs.htm">10.13#*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Stock Option Agreement under the Company&#8217;s 2022 Employment Inducement Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 9, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000117/exhibit104_ligand-formofrs.htm">10.14#*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Restricted Stock Unit Award Agreement under the Company&#8217;s 2022 Employment Inducement Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 9, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000117/exhibit_105xligand-formofp.htm">10.15#*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Performance-Based Restricted Stock Unit Award Agreement under the Company&#8217;s 2022 Employment Inducement Plan</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 9, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616323000007/exhibit1014_ligand-separat.htm">10.16#*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Separation Agreement, effective December 12, 2022, by and between Ligand Pharmaceuticals Incorporated and John Higgins</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 28, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.14</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616323000007/exhibit1015_ligand-severan.htm">10.17#**</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Severance Agreement, effective December 5, 2022, by and between Ligand Pharmaceuticals Incorporated and Todd C. Davis</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 28, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616324000078/exhibit102-severanceagreem.htm">10.18#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Severance Agreement and General Release dated as of August 2, 2024, between Ligand Pharmaceuticals Incorporated and Mr. Korenberg.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 8, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000129/exhibit101-taxmattersagree.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000129/exhibit101-taxmattersagree.htm">9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Matters Agreement, dated as of November 1, 2022, by and among OmniAb, Inc.(f/k/a Avista Public Acquisition Corp. II) Ligand Pharmaceuticals Incorporated and OmniAb Operations, Inc. (f/k/a OmniAb, Inc.)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 4, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000135/exhibit101-aremployeematte.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000135/exhibit101-aremployeematte.htm">20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000135/exhibit101-aremployeematte.htm">*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amended and Restated Employee Matters Agreement, dated as of August 18, 2022, by and among Ligand Pharmaceuticals Incorporated, OmniAb Operations, Inc. (f/k/a OmniAb, Inc.), OmniAb, Inc. (f/k/a Avista Public Acquisition Corp. II) and Orwell Merger Sub Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 8, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex102.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex102.htm">1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TR Beta Contingent Value Rights Agreement, dated January 27, 2010, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January&#160;28, 2010</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex104.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312510015242/dex104.htm">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General Contingent Value Rights Agreement, dated January 27, 2010, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January&#160;28, 2010</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511018895/dex101.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511018895/dex101.htm">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment of General Contingent Value Rights Agreement, dated January 26, 2011, among the Company, Metabasis Therapeutics, Inc., David F. Hale and Mellon Investor Services LLC </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January&#160;31, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000057/amendment_ofxgeneralxcvrxa.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000057/amendment_ofxgeneralxcvrxa.htm">4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment of General Contingent Value Rights Agreement dated May 20, 2014 among the Company, Metabasis Therapeutics, Inc., David F. Hale and Computershare Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000057/amendment_ofxtrxbetaxcvrxa.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000057/amendment_ofxtrxbetaxcvrxa.htm">5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment of TR Beta Contingent Value Rights Agreement dated May 20, 2014 among the Company, Metabasis Therapeutics, Inc., David F. Hale and Computershare, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 22, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10100.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10100.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10100.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Captisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Supply Agreement, dated December&#160;20, 2002, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited and Hovione International Limited </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10101.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10101.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10101.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1st Amendment to Captisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Supply Agreement, dated July&#160;29, 2005, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited and Hovione International Limited </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.101</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10102.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10102.htm">8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2nd&#160;Amendment to Captisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Supply Agreement, dated March&#160;1, 2007, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited, and Hovione International Limited </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.102</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10103.htm">10.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10103.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10103.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3rd&#160;Amendment to Captisol&#174; Supply Agreement, dated January&#160;25, 2008, among CyDex, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited, and Hovione International Limited </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.103</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10104.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10104.htm">30</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10104.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4th&#160;Amendment to Captisol</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Supply Agreement, dated September 28, 2009, among CyDex Pharmaceuticals, Inc., Hovione&#160;LLC, Hovione FarmaCiencia&#160;S.A., Hovione Pharmascience Limited and Hovione International Limited </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.104</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10105.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10105.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10105.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License Agreement, dated September&#160;3, 1993, between CyDex L.C. and The University of Kansas </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.105</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10106.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10106.htm">2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Amendment to License Agreement, dated February 24, 1998, between CyDex, Inc. and The University of Kansas</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.106</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10107.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10107.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10107.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Amendment to License Agreement, dated August&#160;4, 2004, between CyDex, Inc. and The University of Kansas </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.107</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10111.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10111.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10111.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acknowledgement Agreement, dated February 22, 2008, between CyDex, Inc. and The University of Kansas </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.111</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10108.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10108.htm">5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10108.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exclusive License Agreement, dated June&#160;4, 1996, between Pfizer,&#160;Inc. and The University of Kansas </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.108</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10110.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10110.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000119312511055119/dex10110.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Addendum to Nonexclusive License Agreement, dated December&#160;11, 2001, between CyDex, Inc. and Pfizer,&#160;Inc. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 3, 2011</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumlicenseagreement-e.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumlicenseagreement-e.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumlicenseagreement-e.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License Agreement, by and between CyDex Pharmaceuticals, Inc. and Spectrum Pharmaceuticals, Inc., dated as of March 8, 2013 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 8, 2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumsupplyagreement-ex.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumsupplyagreement-ex.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000040/spectrumsupplyagreement-ex.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supply Agreement, by and between CyDex Pharmaceuticals, Inc. and Spectrum Pharmaceuticals, Inc., dated as of March 8, 2013 </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 8, 2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">10.3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Addendum, dated May 22, 2019, by and among Ligand Pharmaceuticals Incorporated, CyDex Pharmaceuticals, Inc., and Acrotech Biopharma LLC (as successor-in-interest to Spectrum Pharmaceuticals, Inc.), to that certain License Agreement between Ligand Pharmaceuticals Incorporated and Spectrum Pharmaceuticals, Inc., dated March 8, 2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 8, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000078/ligand-selexisroyaltystrea.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000078/ligand-selexisroyaltystrea.htm">40</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616313000078/ligand-selexisroyaltystrea.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty Stream and Milestone Payments Purchase Agreement, dated April 29, 2013, between the Company and Selexis S.A. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 1, 2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000090/ligand-vikingxmasterlicens.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000090/ligand-vikingxmasterlicens.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000090/ligand-vikingxmasterlicens.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Master License Agreement dated May 21, 2014 among the Company, Metabasis Therapeutics, Inc. and Viking Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 5, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000110/lgnd-vikingxamendmentno1to.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000110/lgnd-vikingxamendmentno1to.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616314000110/lgnd-vikingxamendmentno1to.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Amendment to Master License Agreement dated September 6, 2014 among the Company, Metabasis Therapeutics, Inc. and Viking Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 31, 2014</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616315000085/lgndvikingmasterlicenseagr.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616315000085/lgndvikingmasterlicenseagr.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616315000085/lgndvikingmasterlicenseagr.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Second Amendment to Master License Agreement, dated April 8, 2015, among the Company, Metabasis Therapeutics, Inc. and Viking Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 5, 2015</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616319000041/lgnd123118exhibit1048-.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616319000041/lgnd123118exhibit1048-.htm">4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616319000041/lgnd123118exhibit1048-.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Development Funding and Royalties Agreement, dated December 13, 2018, by and between Ligand Pharmaceuticals Incorporated and Palvella Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 28, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.48</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616324000009/exhibit1044_palvella-first.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616324000009/exhibit1044_palvella-first.htm">5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment  No. 1 to Development Funding and Royalties Agreement, dated as of May 22, 2020, by and between the Company and Palvella Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 29, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.44</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616324000009/ligand-ex1045xpalvellaxame.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616324000009/ligand-ex1045xpalvellaxame.htm">6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amendment No. 2 to Development Funding and Royalties Agreement, dated as of November 29, 2023, by and between the Company and Palvella Therapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 29, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.45</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000030/lgnd_123121xexhibit1037.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000030/lgnd_123121xexhibit1037.htm">7</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616322000030/lgnd_123121xexhibit1037.htm">**</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sublicense Agreement between the Company, Pharmacopeia, Inc. and Retrophin LLC dated as of February 16, 2012, as amended through Amendment No. 5 to Sublicense Agreement, dated March 20, 2018.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 28, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">8</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000119312516582835/d178557dex101.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest Purchase Agreement, dated May 3, 2016, between the Company and CorMatrix Cardiovascular, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K/A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 9, 2016</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616317000091/ex102lgndcormatrixarinte.htm">10.4</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616317000091/ex102lgndcormatrixarinte.htm">9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amended and Restated Interest Purchase Agreement, dated May 31, 2017, between the Company and CorMatrix Cardiovascular, Inc. </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-033093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 9, 2017</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">50</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-d.htm">#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Indemnification Agreement between the Company and each of its directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.60</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-o.htm">10.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-o.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616318000030/indemnificationagreement-o.htm">#</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form of Indemnification Agreement between the Company and each of its officers</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1, 2018</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.61</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">10.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/886163/000088616319000156/exhibit101ligand-amend.htm">&#8224;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Addendum, dated May 22, 2019, by and among Ligand Pharmaceuticals Incorporated, CyDex Pharmaceuticals, Inc., and Acrotech Biopharma LLC (as successor-in-interest to Spectrum Pharmaceuticals, Inc.), to that certain License Agreement between Ligand Pharmaceuticals Incorporated and Spectrum Pharmaceuticals, Inc., dated March 8, 2013</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 8, 2019</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000119312522255529/d379227dex12.htm">10.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000119312522255529/d379227dex12.htm">3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">At-the-Market Equity Offering Sales Agreement, dated September 30, 2022, by and between the Registrant and Stifel, Nicolaus &amp; Company, Incorporated</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">S-3ASR</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">333-267678</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.449%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.794%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616323000075/edgarizedcitiligandcredita.htm">10.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616323000075/edgarizedcitiligandcredita.htm">4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit Agreement, dated as of October 12, 2023, by and among the Registrant, certain of its subsidiaries, as Guarantors (as defined therein), the Lenders (as defined therein), and Citibank, N.A., as Administrative Agent, Swingline Lender and L/C Issuer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October 18, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616324000071/exhibit101_ligand-firstame.htm">10.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616324000071/exhibit101_ligand-firstame.htm">5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Amendment to Credit Agreement, dated as of July 8, 2024, among Ligand Pharmaceuticals Incorporated, certain of its subsidiaries, as Guarantors, the Lenders, and Citibank, N.A., as Administrative Agent, Swingline Lender and L/C Issuer.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 7, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616324000071/exhibit102_ligand-agenusxp.htm">10.5</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616324000071/exhibit102_ligand-agenusxp.htm">6</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616324000071/exhibit102_ligand-agenusxp.htm">*</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase and Sale Agreement, dated May 6, 2024, by and among Ligand Pharmaceuticals Incorporated, Agenus Inc., Agenus Royalty Fund, LLC, and Agenus Holdings 2024, LLC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">August 7, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit191_insidertradingc.htm">19.1</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-1855">Insider Trading Policy</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123124xexhibit211.htm">21.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subsidiaries of the Company </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123124xexhibit231.htm">23.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consent of Independent Registered Public Accounting Firm</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123124xexhibit311.htm">31.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by Principal Executive Officer, Pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123124xexhibit312.htm">31.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certification by Principal Financial Officer, Pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="lgnd_123124xexhibit321.htm">32.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certifications by Principal Executive Officer and Principal Financial Officer, Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/886163/000088616324000009/exhibit97_ligand-clawbackp.htm">97</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Policy for Recovery of Erroneously Awarded Compensation</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">001-33093</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 29, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The following financial information from our Annual Report on Form 10-K for the fiscal year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, formatted in iXBRL (inline eXtensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statement of Comprehensive Income, (iv) Consolidated Statements of Stockholders' Equity, (v) Consolidated Statements of Cash Flows, and (vi) the Notes to Consolidated Financial Statements. </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The cover page from the Company's Annual Report on Form 10-K for the fiscal year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">, formatted in Inline XBRL and contained in Exhibit 101.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div><span><br/></span></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Confidential treatment has been requested for portions of this exhibit. These portions have been omitted and submitted separately to the Securities and Exchange Commission.</span></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicates management contract or compensatory plan.</span></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">*&#160;&#160;&#160;&#160;Certain schedules and annexes have been omitted in accordance with Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or annex will be furnished as a supplement to the U.S. Securities and Exchange Commission upon request.</span></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">**&#160;&#160;&#160;&#160;Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:6pt"><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div id="ifca968692f35492e968bd282f4512e0b_163"></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:46.198%"><tr><td style="width:1.0%"/><td style="width:28.330%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:69.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Item 16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Form 10-K Summary</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None</span></div><div id="ifca968692f35492e968bd282f4512e0b_166"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:61.695%"><tr><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.104%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIGAND&#160;PHARMACEUTICALS&#160;INCORPORATED</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;&#160;&#160;&#160;T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ODD</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> C. D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVIS&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Todd C. Davis,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: February&#160;28, 2025 </span></div><div style="margin-top:9pt;text-indent:24pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:38.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.229%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;TODD C. DAVIS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Todd C. Davis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160; OCTAVIO ESPINOZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Octavio Espinoza</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JOHN W. KOZARICH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director and Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">John W. Kozarich</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:4pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JASON M. ARYEH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jason M. Aryeh</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;NANCY R. GRAY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nancy R. Gray</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160; JASON HAAS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Jason Haas</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;JOHN L. LAMATTINA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">John L. LaMattina</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;STEPHEN L. SABBA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Stephen L. Sabba</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;MARTINE ZIMMERMANN</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2025</span></td></tr><tr style="height:18pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Martine Zimmermann</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">109</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>2
<FILENAME>exhibit191_insidertradingc.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i74debb75d9804cd9a53858dff35d24f1_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 19.1</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED<br>INSIDER TRADING COMPLIANCE PROGRAM</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CP-LAW-001</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Insider Trading Compliance Program (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Program</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) consists of five sections&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section I provides an overview&#59; Section II sets forth the policies of Ligand Pharmaceuticals Incorporated (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) prohibiting insider trading&#59; Section III explains insider trading&#59; Section IV consists of various procedures which have been put in place by the Company to prevent insider trading&#59; and Section V explains 10b5-1 trading plans.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.34pt;text-decoration:underline">SUMMARY</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Preventing insider trading is necessary to comply with securities laws and to preserve the reputation and integrity of the Company as well as that of all persons affiliated with it. &#8220;Insider trading&#8221; occurs when any person purchases or sells a security while in possession of inside information relating to the security.  As explained in Section III below, &#8220;inside information&#8221; is information which is considered to be both &#8220;material&#8221; and &#8220;non-public.&#8221; Insider trading is a crime and the penalties for violating the law include imprisonment, disgorgement of profits, civil fines of up to three (3) times the profit gained or loss avoided, and criminal fines of up to $5,000,000 for individuals and $25,000,000 for entities.  Insider trading is also prohibited by this Program and could result in serious sanctions, including dismissal.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Program applies to all officers, directors and employees of the Company and extends to all activities within and outside an individual&#8217;s duties at the Company.  Every officer, director and employee must review this Program.  Questions regarding the Program should be directed to Andrew Reardon, the Company&#8217;s Chief Legal Officer (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Compliance Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), at (857) 758-9567.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.68pt;text-decoration:underline">STATEMENT OF POLICIES PROHIBITING INSIDER TRADING</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No officer, director or employee shall purchase or sell any type of security while in possession of material, non-public information relating to the security, whether the issuer of such security is the Company or any other company.  Except for the exercise of options that does not involve the sale of Company securities (e.g., the cashless exercise of a Company stock option does involve the sale of Company securities and therefore would not qualify under this exception) or a trade executed under an approved 10b5-1 trading plan, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">no officer, director or employee shall purchase or sell any security of the Company during the period beginning one (1) week before the end of any fiscal quarter of the Company and ending one (1) full trading day after the public release of earnings data for such fiscal quarter whether or not the Company or any of its officers, directors or employees is in possession of material, non-public information (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Black-Out Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the purposes of this Program, a &#8220;trading day&#8221; shall mean a day on which national stock exchanges are open for trading and a &#8220;security&#8221; shall include contingent value rights (CVRs).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 19.1</font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No officer, director or employee shall directly or indirectly tip material, non-public information to anyone while in possession of such information.  In addition, material, non-public information should not be communicated to anyone outside the Company under any circumstances (absent prior approval by the Compliance Officer and execution of an appropriate confidentiality agreement), or to anyone within the Company other than on a need-to-know basis.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.02pt;text-decoration:underline">EXPLANATION OF INSIDER TRADING</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As noted above, &#8220;insider trading&#8221; refers to the purchase or sale of a security while in possession of &#8220;material,&#8221; &#8220;non-public&#8221; information relating to the security. &#8220;Securities&#8221; include not only stocks, bonds, notes and debentures, but also options, warrants and similar instruments. &#8220;Purchase&#8221; and &#8220;sale&#8221; are defined broadly under the federal securities laws. &#8220;Purchase&#8221; includes not only the actual purchase of a security, but any contract to purchase or otherwise acquire a security. &#8220;Sale&#8221; includes not only the actual sale of a security, but any contract to sell or otherwise dispose of a security.  These definitions extend to a broad range of transactions including conventional cash-for-stock transactions, conversions, the grant and exercise of stock options and acquisitions and exercises of warrants or puts, calls or other options related to a security.  It is generally understood that insider trading includes the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Trading by insiders while in possession of material, non-public information&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Trading by persons other than insiders while in possession of material, non-public information where the information either was given in breach of an insider&#8217;s fiduciary duty to keep it confidential or was misappropriated&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Communicating or tipping material, non-public information to others, including recommending the purchase or sale of a security while in possession of such information.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">WHAT FACTS ARE MATERIAL&#63;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The materiality of a fact depends upon the circumstances.  A fact is considered &#8220;material&#8221; if there is a substantial likelihood that a reasonable investor would consider it important in making a decision to buy, sell or hold a security or where the fact is likely to have a significant effect on the market price of the security.  Material information can be positive or negative and can relate to virtually any aspect of a company&#8217;s business or to any type of security, debt or equity.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Examples of material information include (but are not limited to) certain facts concerning&#58;  dividends&#59; corporate earnings or earnings forecasts&#59; possible mergers or acquisitions&#59; major litigation&#59; significant developments in borrowings or financings&#59; information concerning product developments&#59; important business developments&#59; and major litigation developments.  Moreover, material information does not have to be related to a company&#8217;s business.  For example, the contents of a forthcoming newspaper column that is expected to affect the market price of a security can be material.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The mere fact that something about the subject matter was previously material does not mean that new information about the subject matter is necessarily material.  For example, the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 19.1</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">entry into an agreement may be material, but the termination of the same agreement may not be material (or vice versa).  A general quantitative financial test is whether the information impacts more or less than 5% of net income for the income statement items and 5% of the balance sheet for balance sheet only items, but it is important to remember that such tests are only an initial guideline and that the evaluation of any particular item must consider all of the relevant facts and circumstances.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A good general rule of thumb&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">when in doubt, do not trade.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Another useful rule of thumb is </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">if in doubt, don&#8217;t guess, but instead ask.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Officers and Directors (current and former with respect to each) should be particularly careful, since avoiding the appearance of engaging in a securities transaction on the basis of non-public material information can be as important as avoiding a transaction actually based upon such information.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt;text-decoration:underline">WHAT IS NON-PUBLIC&#63;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Information is &#8220;non-public&#8221; if it is not available to the general public.  In order for information to be considered public, it must be widely disseminated in a manner making it generally available to investors through such media as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Dow Jones</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Reuters</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">The Wall Street</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Business Wire</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Associated Press</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">United Press International</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The circulation of rumors, even if accurate and reported in the media, does not constitute effective public dissemination.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, even after a public announcement, a reasonable period of time must lapse in order for the market to react to the information.  This period of time may vary depending on the particular circumstances for a given company&#59; in the case of the Company, you should wait until the close of business one (1) full trading day after the information has been made available to the public before engaging in any transaction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">WHO IS AN INSIDER&#63;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;Insiders&#8221; include officers, directors and employees of a company and anyone else who has material inside information about a company.  Insiders have independent fiduciary duties to their company and its stockholders not to trade on material, non-public information relating to the company&#8217;s securities.  All officers, directors and employees of the Company should consider themselves insiders with respect to material, non-public information about the Company&#8217;s business, activities and securities.  Officers, directors and employees may not trade the Company&#8217;s securities while in possession of material, non-public information relating to the Company nor tip (or communicate except on a need-to-know basis) such information to others.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The policies and prohibitions contained in this Program will continue to apply to the officer, director or employee after the termination of his or her employment or service with the Company for so long as he or she is in possession of material non-public information about the Company.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Any transaction by a former insider within 90 days of termination (180 days in the case of an officer and director) must be pre-cleared under this Program.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any transaction by an investment fund or partnership over which a director has investment, voting or dispositive power must also be pre-cleared in accordance with this Program.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 19.1</font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">It should be noted that trading by members of an officer&#8217;s, director&#8217;s or employee&#8217;s household can be the responsibility of such officer, director or employee under certain circumstances and could give rise to legal and Company-imposed sanctions.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">TRADING BY PERSONS OTHER THAN INSIDERS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insiders may be liable for communicating or tipping material, non-public information to a third party (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">tippee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and insider trading violations are not limited to trading or tipping by insiders.  Persons other than insiders also can be liable for insider trading, including tippees who trade on material, non-public information tipped to them or individuals who trade on material, non-public information which has been misappropriated.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tippees inherit an insider&#8217;s duties and are liable for trading on material, non-public information illegally tipped to them by an insider.  Similarly, just as insiders are liable for the insider trading of their tippees, so are tippees who pass the information along to others who trade.  In other words, a tippee&#8217;s liability for insider trading is no different from that of an insider.  Tippees can obtain material, non-public information by receiving overt tips from others or through, among other things, conversations at social, business or other gatherings.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt;text-decoration:underline">PENALTIES FOR ENGAGING IN INSIDER TRADING</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Penalties for trading on or tipping material, non-public information can extend significantly beyond any profits made or losses avoided, both for individuals engaging in such unlawful conduct and their employers.  The Securities and Exchange Commission (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and the Department of Justice have made the civil and criminal prosecution of insider trading violations a top priority.  Enforcement remedies available to the government or private plaintiffs under the federal securities laws include&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">SEC administrative sanctions&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Securities industry self-regulatory organization sanctions&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Civil injunctions&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Damage awards to private plaintiffs&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Disgorgement of all profits&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Civil fines for the violator of up to three (3) times the amount of profit gained or loss avoided&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Civil fines for the employer or other controlling person of a violator (i.e., where the violator is an employee or other controlled person) of up to the greater of $1,000,000 or three (3) times the amount of profit gained or loss avoided by the violator&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Criminal fines for individual violators of up to $5,000,000 ($25,000,000 for an entity)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Jail sentences of up to twenty (20) years.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 19.1</font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, insider trading could result in serious sanctions by the Company, including dismissal.  Insider trading violations are not limited to violations of the federal securities laws&#59; other federal and state civil or criminal laws, such as the laws prohibiting mail and wire fraud and the Racketeer Influenced and Corrupt Organizations Act, also may be violated upon the occurrence of insider trading.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Violations of this Program may result in disciplinary action up to and including immediate termination.  In addition, the Company in its discretion may advise appropriate government officials of any apparent violations of law.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Program is in no way intended to modify the at-will nature of your employment with the Company.  Except for the aspects of this Program delegated herein to the Compliance Officer, the CFO and the Secretary (for purposes of this Program, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Administrative Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) shall jointly and in their sole discretion, interpret and administer this Program.  This Program may not be amended or supplemented except in writing and with the express approval of the Board of Directors or the Administrative Committee.  In particular, employees may not rely on any oral statements that are inconsistent with this Program, nor which purport to change or add to it.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.67pt;text-decoration:underline">EXAMPLES OF INSIDER TRADING</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Examples of insider trading cases include actions brought against&#58;  corporate officers, directors and employees who traded a company&#8217;s securities after learning of significant confidential corporate developments&#59; friends, business associates, family members and other tippees of such officers, directors and employees who traded the securities after receiving such information&#59; government employees who learned of such information in the course of their employment&#59; and other persons who misappropriated, and took advantage of, confidential information from their employers.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following are illustrations of insider trading violations.  These illustrations are hypothetical and, consequently, not intended to reflect on the actual activities or business of the Company or any other entity.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trading by Insider</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">An officer of X Corporation learns that earnings to be reported by X Corporation will increase dramatically.  Prior to the public announcement of such earnings, the officer purchases X Corporation&#8217;s stock.  The officer, an insider, is liable for all profits as well as penalties of up to three (3) times the amount of all profits.  The officer also is subject to, among other things, criminal prosecution, including up to $5,000,000 in additional fines and twenty (20) years in jail.  Depending upon the circumstances, X Corporation and the individual to whom the officer reports also could be liable as controlling persons.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Trading by Tippee</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">An officer of X Corporation tells a friend that X Corporation is about to publicly announce that it has concluded an agreement for a major acquisition.  This tip causes the friend to purchase X Corporation&#8217;s stock in advance of the announcement.  The officer is </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 19.1</font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">jointly liable with his friend for all of the friend&#8217;s profits and each is liable for all penalties of up to three (3) times the amount of the friend&#8217;s profits.  In addition, the officer and his friend are subject to, among other things, criminal prosecution, as described above.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.67pt;text-decoration:underline">INSIDER REPORTING REQUIREMENTS, SHORT-SWING PROFITS AND SHORT SALES</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">REPORTING OBLIGATIONS UNDER SECTION 16(A)--SEC FORMS 3, 4 AND 5</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 16(a) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">1934 Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), generally requires all officers, directors and 10% stockholders, within ten (10) days after the insider becomes an officer, director or 10% stockholder, to file with the SEC an &#8220;Initial Statement of Beneficial Ownership of Securities&#8221; on SEC Form 3 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Form 3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) listing the amount of the Company&#8217;s Common Stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), options and warrants which the insider beneficially owns.  Following the initial filing on Form 3, every change in the beneficial ownership of the Company&#8217;s Stock, options and warrants must be reported on SEC Form 4 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Form 4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) within two (2) days after the date on which such change occurs or in certain cases on SEC Form 5 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Form 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) within forty-five (45) days after fiscal year end.  Form 4 must be filed even if, as a result of balancing transactions, there has been no net change in holdings.  In deciding the month during which a purchase or sale on the open market occurs for purposes of filing Form 4, the trade date rather than the settlement date is ordinarily determinative.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Special rules apply in certain situations.  If any officer or director purchases or sells any Stock within six (6) months after the event which required him or her to file Form 3, the Form 4 filed with respect to that purchase or sale must also report any other purchases or sales he or she made within the preceding six (6) months which were not previously reported.  Similarly, if an officer or director purchases or sells any Stock within six (6) months after his or her termination from such position, the transaction must be reported on Form 4 if he or she made any purchase or sale within the preceding six (6) months and prior to termination.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">RECOVERY OF PROFITS UNDER SECTION 16(B)</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the purpose of preventing the unfair use of information which may have been obtained by an insider, any profits realized by any officer, director or 10% stockholder from any &#8220;purchase&#8221; and &#8220;sale&#8221; of Stock during a six (6) month period, so called &#8220;short-swing profits,&#8221; may be recovered by the Company.  When such a purchase and sale occurs, good faith is no defense.  The insider is liable even if compelled to sell for personal reasons, and even if the sale takes place after full disclosure and without the use of any inside information.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The liability of an insider under Section 16(b) of the 1934 Act is only to the Company itself.  The Company, however, cannot waive its right to short-swing profits, and any Company stockholder can bring suit in the name of the Company.  In this connection it must be remembered that reports of ownership filed with the SEC on Form 3, Form 4 or Form 5 pursuant to Section 16(a) (discussed above) are readily available to the public, and certain attorneys carefully monitor these reports for potential Section 16(b) violations.  In addition, liabilities </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 19.1</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">under Section 16(b) may require separate disclosure in the Company&#8217;s annual report to the SEC on Form 10-K or its proxy statement for its annual meeting of stockholders.  No suit may be brought more than two (2) years after the date the profit was realized.  However, if the insider fails to file a report of the transaction under Section 16(a), as required, the two (2) year limitation period does not begin to run until after the transactions giving rise to the profit have been disclosed.  Failure to report transactions and late filing of reports require separate disclosure in the Company&#8217;s proxy statements.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Officers and directors should consult the attached &#8220;Short-Swing Profit Rule Section 16(b) Checklist&#8221; attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Attachment A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> in addition to consulting with the Compliance Officer prior to engaging in any transactions involving the Company&#8217;s securities, including without limitation, the Company&#8217;s Stock, options or warrants.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">SHORT SALES PROHIBITED UNDER SECTION 16(C)</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 16(c) of the 1934 Act prohibits insiders absolutely from making short sales of the Company&#8217;s Stock, i.e., sales of shares which the insider does not own at the time of sale or sales of Stock against which the insider does not deliver the shares within twenty (20) days after the sale.  Under certain circumstances, the purchase or sale of put or call options, or the writing of such options, can result in a violation of Section 16(c).  Insiders violating Section 16(c) face criminal liability.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Compliance Officer should be consulted if you have any questions regarding reporting obligations, short-swing profits or short sales under Section 16.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.67pt;text-decoration:underline">PROHIBITION OF RECORDS FALSIFICATIONS AND FALSE STATEMENTS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 13(b)(2) of the 1934 Act requires companies subject to the 1934 Act to maintain proper internal books and records and to devise and maintain an adequate system of internal accounting controls.  The SEC has supplemented the statutory requirements by adopting rules that prohibit (1) any person from falsifying records or accounts subject to the above requirements and (2) officers or directors from making any materially false, misleading or incomplete statement to any accountant in connection with any audit or filing with the SEC.  These provisions reflect the SEC&#8217;s intent to discourage officers, directors and other persons with access to the Company&#8217;s books and records from taking action that might result in the communication of materially misleading financial information to the investing public.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.68pt;text-decoration:underline">STATEMENT OF PROCEDURES PREVENTING INSIDER TRADING</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following procedures have been established, and will be maintained and enforced, by the Company to prevent insider trading.  Every officer, director and employee is required to follow these procedures.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 19.1</font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">IDENTIFYING MATERIAL, NON-PUBLIC INFORMATION</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Prior to directly or indirectly trading any security of the Company, every officer, director and employee is required to contact the Compliance Officer (as part of the pre-clearance procedure discussed below in Section D) and make an initial determination whether the Company and&#47;or such officer, director or employee is in possession of material, non-public information relating to such security.  In making such assessment, the explanations of &#8220;material&#8221; and &#8220;non-public&#8221; information set forth above should be of assistance.  If after consulting with the Compliance Officer it is determined that the Company and&#47;or such officer, director or employee is in possession of material, non-public information, there may be no trading of such security.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt;text-decoration:underline">INFORMATION RELATING TO THE COMPANY</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">ACCESS TO INFORMATION</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Access to material, non-public information about the Company, including the Company&#8217;s business, earnings or prospects, should be limited to officers, directors and employees of the Company on a need-to-know basis.  In addition, such information should not be communicated to anyone outside the Company under any circumstances or to anyone within the Company on an other than need-to-know basis.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In communicating material, non-public information to employees of the Company, all officers, directors and employees must take care to emphasize the need for confidential treatment of such information and adherence to the Company&#8217;s policies with regard to confidential information.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">INQUIRIES FROM THIRD PARTIES</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INQUIRIES FROM THIRD PARTIES, SUCH AS INDUSTRY ANALYSTS OR MEMBERS OF THE MEDIA, ABOUT THE COMPANY SHOULD BE DIRECTED TO INVESTOR RELATIONS AT (858) 550-7500.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">LIMITATIONS ON ACCESS TO THE COMPANY INFORMATION</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following procedures are designed to maintain confidentiality with respect to the Company&#8217;s business operations and activities.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">ALL OFFICERS, DIRECTORS AND EMPLOYEES SHOULD TAKE ALL STEPS AND PRECAUTIONS NECESSARY TO RESTRICT ACCESS TO, AND SECURE, MATERIAL, NON-PUBLIC INFORMATION BY, AMONG OTHER THINGS&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Maintaining the confidentiality of Company related transactions&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Conducting their business and social activities so as not to risk inadvertent disclosure of confidential information.  Review of confidential documents in public places should be conducted so as to prevent access by unauthorized persons&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 19.1</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Restricting access to documents and files (including computer files) containing material, non-public information to individuals on a need-to-know basis (including maintaining control over the distribution of documents and drafts of documents)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Promptly removing and cleaning up all confidential documents and other materials from conference rooms following the conclusion of any meetings&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Disposing of all confidential documents and other papers, after there is no longer any business or other legally required need, through shredders when appropriate&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Restricting access to areas likely to contain confidential documents or material, non-public information&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Avoiding the discussion of material, non-public information in places where the information could be overheard by others such as in elevators, restrooms, hallways, restaurants, airplanes or taxicabs.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">PERSONNEL INVOLVED WITH MATERIAL, NON-PUBLIC INFORMATION, TO THE EXTENT FEASIBLE, SHOULD CONDUCT THEIR BUSINESS AND ACTIVITIES IN AREAS SEPARATE FROM OTHER COMPANY ACTIVITIES.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">PRE-CLEARANCE OF TRADES BY OFFICERS, DIRECTORS AND EMPLOYEES</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To provide assistance in preventing inadvertent violations of applicable securities laws and to avoid the appearance of impropriety in connection with the purchase and sale of the Company securities and the securities of other companies with which the Company has an existing or potential business relationship, the Company has instituted the following procedures.  All transactions in Company securities (including without limitation, acquisitions and dispositions of the Company&#8217;s Stock, the exercise of stock options and the sale of the Company&#8217;s Stock issued upon exercise of stock options) by officers, directors and employees must be pre- cleared by the Compliance Officer.  Additionally, except for the exercise of options for cash (but not the sale of such shares), the granting of stock awards, and the receipt or purchase of shares in settlement of any restricted stock unit agreement or stock appreciation rights agreement (but not the sale of any such shares), including the payment of any associated taxes through the surrender or sale of shares received from such stock award (or the right to receive such shares), neither the Company nor any of its officers, directors or employees may trade in any securities of the Company during the Black-Out Period.  Also, please consult the &#8220;Insider Trading Reminders&#8221; attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Attachment B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subject to the general rule described above, officers, directors and employees who, due to unavoidable and extraordinary circumstances, need to engage in a transaction in Company securities outside of the trading window periods must contact the Compliance Officer.  The Compliance Officer, with advice from counsel, will attempt to determine whether the relevant officer, director or employee is in possession of non-public material information which would restrict such person&#8217;s ability to trade in Company securities.  If it is determined, in the Compliance Officer&#8217;s sole discretion, that there is no non-public material information within the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 19.1</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">possession of such person, then provided the circumstances reflect an appropriate level of need, the officer, director or employee may be allowed to trade in Company securities.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Additionally, the Compliance Officer maintains a list (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Restricted List</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) listing those companies with respect to which the officers, directors and employees must obtain pre-clearance from the Compliance Officer before trading in their securities.  The Restricted List will contain the names of&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">all public companies with respect to which any officer, director or employee of the Company has acquired non-public information as a result of their role with the Company that may be material to the trading markets, including companies in which the Company does not have any ownership&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">all public companies for which any officer, director or employee of the Company serves as a director or officer and with which the Company has an existing or potential business relationship.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Compliance Officer will promptly inform the officers, directors and employees of changes to the Restricted List.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">If a company is listed on the Restricted List, you are strictly prohibited from engaging in any transaction in that company&#8217;s securities without obtaining &#8220;pre-clearance&#8221; from the Compliance Officer.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Further, to avoid the appearance of impropriety, the officers, directors and employees should take reasonable measures to ensure that their affiliates do not trade in the securities of the Company or of the companies on the Restricted List&#59; provided that the affiliates of the officers, directors and employees may be permitted to trade in such securities if the officer, director or employee takes reasonable measures to ensure that he or she is &#8220;walled off&#8221; from the investment decisions with respect to such securities and does not provide any inside information with respect to such securities to the affiliates making such investment decisions.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt;text-decoration:underline">AVOIDANCE OF CERTAIN AGGRESSIVE OR SPECULATIVE TRADING</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Officers, directors and employees and their respective family members (including spouses, minor children or any other family members living in the same household), should ordinarily not directly or indirectly participate in transactions involving trading activities which by their aggressive or speculative nature may give rise to an appearance of impropriety.  Such activities would include the purchase of put or call options, or the writing of such options.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">RULE 10B5-1 TRADING PLANS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">OVERVIEW</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SEC Rule 10b5-1 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Rule 10b5-1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), will protect directors, officers and employees from insider trading liability under Rule 10b5-1 for transactions under a previously established contract, plan or instruction to trade the Company&#8217;s Stock (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Trading Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) entered into in good faith and in accordance with the terms of Rule 10b5-1 of the 1934 Act and all applicable </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 19.1</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">state laws and shall be exempt from the trading restrictions set forth in the Program.  The initiation of, and any modification to, any such Trading Plan will be deemed to be a transaction in the Company&#8217;s securities and such initiation or modification is subject to all limitations and prohibitions of transactions involving the Company&#8217;s securities.  Each such Trading Plan, and any modification thereof, shall be submitted to and pre-approved by the Compliance Officer, or such other person as the Company&#8217;s board of directors may designate from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">Authorizing Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), who may impose such conditions on the implementation and operation of the Trading Plan as the Authorizing Officer deems necessary or advisable.  However, compliance of the Trading Plan to the terms of Rule 10b5-1 and the execution of transactions pursuant to the Trading Plan are the sole responsibility of the person initiating the Trading Plan, not the Company or the Authorizing Officer.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Rule 10b5-1 presents an opportunity for insiders to establish arrangements to sell (or purchase) Company Stock without the restrictions of windows and blackout periods even when there is undisclosed material information.  A Trading Plan might also help reduce negative publicity that may result when key executives sell the Company&#8217;s Stock.  Rule 10b5-1 only provides an &#8220;affirmative defense&#8221; in the event there is an insider-trading lawsuit.  It does not prevent someone from bringing a lawsuit.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A director, officer and employee may enter into a Trading Plan only when he or she is not in possession of material, nonpublic information, and only during a trading window period outside of the Black-Out Period.  Although transactions effected under a Trading Plan will not require further pre-clearance at the time of the trade, any transaction (including the quantity and price) made pursuant to a Trading Plan of a Section 16 reporting person must be reported to the Company promptly on the day of each trade to permit the Company&#8217;s filing coordinator to assist in the preparation and filing of a required Form 4.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">From time to time, for legal or other reasons, the Authorizing Officer may direct that purchases and sales pursuant to any Trading Plan be suspended or discontinued.  Failure to discontinue purchases and sales as directed shall constitute a violation of the terms of this Section V and result in a loss of the exemption set forth herein.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Officers, directors and employees may adopt Trading Plans with brokers that outline a pre-set plan for trading of the Company&#8217;s Stock, including the exercise of options.  Trading Plans are to be implemented only during open window periods and when the individual is not aware of any material non-public information.  Trades pursuant to a Trading Plan may occur at any time.  An individual may adopt more than one Trading Plan.  Please review the following description of how a Trading Plan works.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to Rule 10b5-1, an individual&#8217;s purchase or sale of securities will not be &#8220;on the basis of&#8221; material non-public information if&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">First, before becoming aware of the information, the individual enters into a binding contract to purchase or sell the securities, provides instructions to another person to sell the securities or adopts a written plan for trading the securities (i.e., the Trading Plan).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 19.1</font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Second, the Trading Plan must either&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">specify the amount of securities to be purchased or sold, the price at which the securities are to be purchased or sold and the date on which the securities are to be purchased or sold&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">include a written formula or computer program for determining the amount, price and date of the transactions&#59; or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">prohibit the individual from exercising any subsequent influence over the purchase or sale of the Company&#8217;s Stock under the Trading Plan in question.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:31.8pt">Third, the purchase or sale must occur pursuant to the Trading Plan and the individual must not enter into a corresponding hedging transaction or alter or deviate from the Trading Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt;text-decoration:underline">REVOCATION&#47;AMENDMENTS TO TRADING PLANS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">REVOCATION OF TRADING PLANS SHOULD OCCUR ONLY IN UNUSUAL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">CIRCUMSTANCES, AND EFFECTIVENESS OF ANY REVOCATION OF A TRADING</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">PLAN WILL BE SUBJECT TO THE PRIOR REVIEW AND APPROVAL OF THE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">AUTHORIZING OFFICER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  REVOCATION IS EFFECTED UPON WRITTEN NOTICE TO THE BROKER.  HOWEVER, IF THE INDIVIDUAL TERMINATES THE TRADING PLAN AFTER THE FIRST OPTION EXERCISE OR STOCK SALE, THEN THE INDIVIDUAL MUST CANCEL ALL OUTSTANDING TRADING PLANS AND AGREE NOT TO ENTER INTO ANOTHER TRADING PLAN UNTIL SIX (6) MONTHS AFTER TERMINATION OF THE TRADING PLAN.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Under certain circumstances, a Trading Plan must be revoked.  This includes circumstances such as the announcement of a merger or the occurrence of an event that would cause the transaction either to violate the law or to have an adverse effect on the Company.  The Authorizing Officer or administrator of the Company&#8217;s stock plans is authorized to notify the broker in such circumstances, thereby insulating the insider in the event of revocation.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Amendments to Trading Plans will not be allowed.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">DISCRETIONARY PLANS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DISCRETIONARY TRADING PLANS, WHERE THE DISCRETION OR CONTROL OVER TRADING IS TRANSFERRED TO A BROKER, ARE PERMITTED IF PRE- APPROVED BY THE AUTHORIZING OFFICER.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Authorizing Officer of the Company must pre-approve any Trading Plan, arrangement or trading instructions, etc., involving potential sales or purchases of the Company&#8217;s Stock or option exercises, including but not limited to, blind trusts, limit orders or hedging strategies.  The actual transactions effected pursuant to a pre-approved Trading Plan will not be subject to further pre-clearance for transactions in the Company&#8217;s Stock once the Trading Plan or other arrangement has been pre-approved.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 19.1</font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.34pt;text-decoration:underline">REPORTING (IF REQUIRED)</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SEC FORM 144 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">FORM 144</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) WILL BE FILLED OUT AND FILED BY THE INDIVIDUAL&#47;BROKERAGE FIRM IN ACCORDANCE WITH THE EXISTING RULES REGARDING FORM 144 FILINGS.  A FOOTNOTE AT THE BOTTOM OF THE FORM 144 SHOULD INDICATE THAT THE TRADES &#8220;ARE IN ACCORDANCE WITH A TRADING PLAN THAT COMPLIES WITH RULE 10B5-1 AND EXPIRES</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"> &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221; FOR SECTION 16 REPORTING PERSONS, FORM 4S SHOULD BE FILED BEFORE THE END OF THE SECOND (2ND) BUSINESS DAY FOLLOWING THE DATE THAT THE BROKER, DEALER OR PLAN ADMINISTRATOR INFORMS THE INDIVIDUAL THAT A TRANSACTION WAS EXECUTED, PROVIDED THAT THE DATE OF SUCH NOTIFICATION IS NOT LATER THAN THE THIRD (3RD) BUSINESS DAY FOLLOWING THE TRADE DATE.  A SIMILAR FOOTNOTE SHOULD BE PLACED AT THE BOTTOM OF THE FORM 4 AS OUTLINED ABOVE.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">E.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25pt;text-decoration:underline">OPTIONS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CASH EXERCISE OF OPTIONS CURRENTLY CAN BE EXECUTED AT ANY TIME.  SAME DAY SALES EXERCISES OF OPTIONS ARE SUBJECT TO TRADING WINDOWS.  HOWEVER, THE COMPANY WILL PERMIT SAME DAY SALES UNDER TRADING PLANS.  IF A BROKER IS REQUIRED TO EXECUTE A SAME DAY SALE IN ACCORDANCE WITH A TRADING PLAN, THEN THE COMPANY MUST HAVE EXERCISE FORMS ATTACHED TO THE TRADING PLAN THAT ARE SIGNED, UNDATED AND WITH THE NUMBER OF SHARES TO BE EXERCISED LEFT BLANK.  ONCE A BROKER DETERMINES THAT THE TIME IS RIGHT TO EXERCISE THE OPTION AND DISPOSE OF THE SHARES IN ACCORDANCE WITH THE TRADING PLAN, THE BROKER WILL NOTIFY THE COMPANY IN WRITING AND THE ADMINISTRATOR OF THE COMPANY&#8217;S STOCK PLANS WILL FILL IN THE NUMBER OF SHARES AND THE DATE OF EXERCISE ON THE PREVIOUSLY SIGNED EXERCISE FORM.  THE INSIDER SHOULD NOT BE INVOLVED WITH THIS PART OF THE EXERCISE.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">F.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:25.67pt;text-decoration:underline">TRADES OUTSIDE OF A TRADING PLAN</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DURING AN OPEN WINDOW, TRADES WHICH DIFFER FROM TRADING PLAN INSTRUCTIONS THAT ARE ALREADY IN PLACE ARE ALLOWED AS LONG AS THE TRADING PLAN CONTINUES TO BE FOLLOWED.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">The Trading Plans do not exempt the individuals from complying with the Section 16 six (6) month short-swing profit rules or liability.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">G.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.67pt;text-decoration:underline">PUBLIC ANNOUNCEMENTS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THE COMPANY MAY MAKE A PUBLIC ANNOUNCEMENT THAT TRADING PLANS ARE BEING IMPLEMENTED IN ACCORDANCE WITH RULE 10B5-1.  IT WILL CONSIDER IN EACH CASE WHETHER A PUBLIC ANNOUNCEMENT OF A PARTICULAR TRADING PLAN SHOULD BE MADE.  IT MAY ALSO MAKE PUBLIC </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 19.1</font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ANNOUNCEMENTS OR RESPOND TO INQUIRIES FROM THE MEDIA AS TRANSACTIONS ARE MADE UNDER A TRADING PLAN.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">H.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.67pt;text-decoration:underline">PLEDGING THE COMPANY&#8217;S STOCK TO SECURE MARGIN OF OTHER LOANS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THE COMPANY DOES NOT PERMIT OFFICERS AND DIRECTORS TO PLEDGE THE COMPANY&#8217;S STOCK AS COLLATERAL TO SECURE LOANS.  SUCH PLEDGES ALSO CANNOT BE CARRIED OUT THROUGH A TRADING PLAN.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:28.34pt;text-decoration:underline">PUT AND CALL OPTIONS AND OTHER HEDGING TRANSACTIONS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PUT AND CALL OPTIONS AND OTHER HEDGING TRANSACTIONS WILL NOT BE PERMITTED UNDER A TRADING PLAN.  IN FACT, SUCH TRANSACTIONS OUTSIDE OF A TRADING PLAN MAY DESTROY THE PROTECTION AFFORDED BY A TRADING PLAN.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:19.68pt;text-decoration:underline">EXECUTION AND RETURN OF CERTIFICATION OF COMPLIANCE</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">After reading this Program all officers, directors and employees should execute and return to the Compliance Officer the applicable Certification of Compliance form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Attachment C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14</font></div></div></div><div id="i74debb75d9804cd9a53858dff35d24f1_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Attachment A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SHORT-SWING PROFIT RULE SECTION 16(b) CHECKLIST</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Note&#58;  ANY combination of PURCHASE AND SALE or SALE AND PURCHASE within six (6) months of each other results in a violation of Section 16(b), and the &#8220;profit&#8221; must be recovered by the Company.  It makes no difference how long the shares being sold have been held--or that you are an insider for only one of the two matching transactions.  The highest priced sale will be matched with the lowest priced purchase within the six (6) month period.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SALES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If a sale is to be made by an officer, director or 10% stockholder (or any family member living in the same household)&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">HAVE THERE BEEN ANY PURCHASES BY THE INSIDER (OR FAMILY MEMBERS LIVING IN THE SAME HOUSEHOLD) WITHIN THE PAST SIX (6) MONTHS&#63;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">HAVE THERE BEEN ANY OPTION EXERCISES WITHIN THE PAST SIX (6) MONTHS&#63;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">ARE ANY PURCHASES (OR OPTION EXERCISES) ANTICIPATED OR REQUIRED WITHIN THE NEXT SIX (6) MONTHS&#63;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">HAS A FORM 4 BEEN PREPARED&#63;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Note&#58;  If a sale is to be made by an affiliate of the Company and unregistered stock is to be sold, has a Form 144 been prepared and has the broker been reminded to sell pursuant to Rule 144&#63;</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURCHASES AND OPTIONS EXERCISES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If a purchase or option exercise for stock is to be made&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">HAVE THERE BEEN ANY SALES BY THE INSIDER (OR FAMILY MEMBERS LIVING IN THE SAME HOUSEHOLD) WITHIN THE PAST SIX (6) MONTHS&#63;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">ARE ANY SALES ANTICIPATED OR REQUIRED WITHIN THE NEXT SIX (6) MONTHS (SUCH AS TAX-RELATED OR YEAR-END TRANSACTIONS)&#63;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt">HAS A FORM 4 BEEN PREPARED&#63;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BEFORE PROCEEDING WITH A PURCHASE OR SALE, CONSIDER WHETHER YOU ARE AWARE OF MATERIAL, NON-PUBLIC INFORMATION WHICH COULD AFFECT THE PRICE OF THE STOCK.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A</font></div></div></div><div id="i74debb75d9804cd9a53858dff35d24f1_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Attachment B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSIDER TRADING REMINDERS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Before engaging in any transaction in the Company&#8217;s securities, please read the following&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Both the federal securities laws and the Company&#8217;s policy prohibit transactions in the Company&#8217;s securities at a time when you may be in possession of material information about the Company which has not been publicly disclosed.  This also applies to members of your household as well as all others whose transactions may be attributable to you.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Material information, in short, is any information which could affect the price of the securities.  Either positive or negative information may be material.  Once a public announcement has been made, you should wait until the close of business one (1) full trading day after the information has been made available to the public before engaging in any transaction.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Except for the exercise of options that does not involve the sale of Company securities (e.g., the cashless exercise of a Company stock option does involve the sale of Company securities and therefore would not qualify under this exception), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">neither the Company nor any of its officers, directors or designated employees may trade in any securities of the Company during the period beginning one (1) week before the end of any fiscal quarter of the Company and ending on the close of business one (1) full trading day after the public release of earnings data for such quarter whether or not the Company or any of its officers, directors or employees is in possession of material, non-public information.  Important&#58;  All transactions by officers, directors and designated employees must be pre-cleared with the Compliance Officer.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For further information and guidance, please refer to our Insider Trading Compliance Program and do not hesitate to contact the Compliance Officer.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ALL TRANSACTIONS IN LIGAND PHARMACEUTICALS INCORPORATED SECURITIES BY OFFICERS, DIRECTORS AND DESIGNATED EMPLOYEES MUST BE PRE-CLEARED BY CONTACTING the Compliance Officer, Andrew Reardon, the Company&#8217;s Chief Legal Officer, at (857) 758-9567.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>lgnd_123124xexhibit211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i76c33381fdf84c29bb4a5ced8dc14064_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIST OF SUBSIDIARIES</font></div><div><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.250%"><tr><td style="width:1.0%"></td><td style="width:49.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.477%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction of Incorporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apeiron Biologics GmbH</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CyDex Pharmaceuticals, Inc. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LHNC, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand Holdings UK Ltd.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand UK Development Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ligand UK Limited</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">England and Wales</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Metabasis Therapeutics, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Neurogen Corporation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pelthos Therapeutics Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfenex Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmacopeia, LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Seragen, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vernalis Therapeutics, Inc.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>lgnd_123124xexhibit231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie0478d28e14e4240b86e791b29247442_1"></div><div style="min-height:40.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consent of Independent Registered Public Accounting Firm</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1) Registration Statement (Form S-8 No. 333-280733) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated,<br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2) Registration Statement (Form S-8 No. 333-277587) pertaining to the 2022 Employment Inducement Plan of Ligand Pharmaceuticals Incorporated,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(3) Registration Statement (Form S-3 ASR No. 333-267678) of Ligand Pharmaceuticals Incorporated,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(4) Registration Statement (Form S-8 No. 333-266737) pertaining to the 2022 Employment Inducement Plan of Ligand Pharmaceuticals Incorporated,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(5) Registration Statement (Form S-8 No. 333-265545) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) Registration Statement (Form S-8 No. 333-252480) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7) Registration Statement (Form S-8 No. 333-233130) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated,</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8) Registration Statement (Form S-8 No. 333-212775) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9) Registration Statement (Form S-8 No. 333-182547) pertaining to the 2002 Stock Incentive Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10) Registration Statement (Form S-8 No. 333-160132) pertaining to the 2002 Stock Incentive Plan, as amended and restated, and Employee Stock Purchase Plan, as amended and restated of Ligand Pharmaceuticals Incorporated, and</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11) Registration Statement (Form S-8 No. 333-131029) pertaining to the 2002 Stock Incentive Plan and 2002 Employee Stock Purchase Plan of Ligand Pharmaceuticals Incorporated&#59; </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February&#160;28, 2025, with respect to the consolidated financial statements of Ligand Pharmaceuticals Incorporated and the effectiveness of internal control over financial reporting of Ligand Pharmaceuticals Incorporated included in this Annual Report (Form 10-K) of Ligand Pharmaceuticals Incorporated for the year ended December&#160;31, 2024.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Ernst &#38; Young LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;28, 2025</font></div><div><font><br></font></div><div style="height:130.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>lgnd_123124xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i17513f9d1752456d8b0197554b3f8c09_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">I, Todd C. Davis, certify that&#58;</font></div><div style="margin-bottom:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.064%"><tr><td style="width:1.0%"></td><td style="width:11.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.089%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Annual Report on Form 10-K of Ligand Pharmaceuticals Incorporated&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">            </font></div><div style="padding-left:108pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.557%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:14pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Todd C. Davis</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:14pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd C. Davis</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:12pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:12pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;  February&#160;28, 2025</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>lgnd_123124xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="id14f68a21cdd47d89f088be25556849a_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">I, Octavio Espinoza, certify that&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I have reviewed this Annual Report on Form 10-K of Ligand Pharmaceuticals Incorporated&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">c)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">d)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.130%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:72pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">b)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="margin-bottom:7pt"><font><br></font></div><div style="margin-bottom:7pt;padding-left:72pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.839%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Octavio Espinoza</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Octavio Espinoza</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="margin-bottom:7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;     February&#160;28, 2025</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>lgnd_123124xexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="if138990d92824edaaabe16829a493a6d_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%">Exhibit 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">In connection with the Annual Report of Ligand Pharmaceuticals Incorporated (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Todd C. Davis, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:7pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:8.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.223%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:10.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.944%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt;text-indent:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Todd C. Davis</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Todd C. Davis</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">In connection with the Annual Report of Ligand Pharmaceuticals Incorporated (the &#8220;Company&#8221;) on Form 10-K for the year ended December&#160;31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Octavio Espinoza, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div style="margin-bottom:7pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.198%"><tr><td style="width:1.0%"></td><td style="width:10.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:3pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended&#59; and</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:10.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.068%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.230%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.206%"></td><td style="width:0.1%"></td></tr><tr style="height:13pt"><td colspan="15" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 28, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:2pt;padding-right:2pt;text-indent:2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Octavio Espinoza</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Octavio Espinoza</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer</font></div><div style="margin-bottom:2pt;margin-top:2pt;padding-left:2pt;padding-right:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>lgnd-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:8c134d1d-ab0c-4379-9892-d916b4e62e37,g:28b275e3-fcb1-4a6c-a0ef-95ede04b9eea-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lgnd="http://www.ligand.com/20241231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ligand.com/20241231">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.ligand.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.ligand.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>9952151 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS">
        <link:definition>9952154 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY">
        <link:definition>9952155 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>9952156 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>9952157 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>9952158 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AgenusTransaction" roleURI="http://www.ligand.com/role/AgenusTransaction">
        <link:definition>9952159 - Disclosure - Agenus Transaction</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.ligand.com/role/Acquisitions">
        <link:definition>9952160 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofPelicanBusinessandInvestmentinPrimroseBio" roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBio">
        <link:definition>9952161 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinoffofOmniAb" roleURI="http://www.ligand.com/role/SpinoffofOmniAb">
        <link:definition>9952162 - Disclosure - Spin-off of OmniAb</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRights" roleURI="http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRights">
        <link:definition>9952163 - Disclosure - Financial Royalty Assets, net (formerly known as Commercial License Rights)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetails">
        <link:definition>9952164 - Disclosure - Balance Sheet Account Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.ligand.com/role/FairValueMeasurement">
        <link:definition>9952165 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.ligand.com/role/Leases">
        <link:definition>9952166 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.ligand.com/role/Debt">
        <link:definition>9952167 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.ligand.com/role/StockholdersEquity">
        <link:definition>9952168 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesLegalProceedings" roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings">
        <link:definition>9952169 - Disclosure - Commitment and Contingencies: Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.ligand.com/role/IncomeTaxes">
        <link:definition>9952170 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://www.ligand.com/role/SubsequentEvent">
        <link:definition>9952171 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.ligand.com/role/AcquisitionsTables">
        <link:definition>9955513 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofPelicanBusinessandInvestmentinPrimroseBioTables" roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioTables">
        <link:definition>9955514 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinoffofOmniAbTables" roleURI="http://www.ligand.com/role/SpinoffofOmniAbTables">
        <link:definition>9955515 - Disclosure - Spin-off of OmniAb (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsTables" roleURI="http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsTables">
        <link:definition>9955516 - Disclosure - Financial Royalty Assets, net (formerly known as Commercial License Rights) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsTables" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsTables">
        <link:definition>9955517 - Disclosure - Balance Sheet Account Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.ligand.com/role/FairValueMeasurementTables">
        <link:definition>9955518 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.ligand.com/role/LeasesTables">
        <link:definition>9955519 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.ligand.com/role/StockholdersEquityTables">
        <link:definition>9955520 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.ligand.com/role/IncomeTaxesTables">
        <link:definition>9955521 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails">
        <link:definition>9955522 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Segment Profit or Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9955523 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails">
        <link:definition>9955524 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails">
        <link:definition>9955525 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails">
        <link:definition>9955526 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AgenusTransactionDetails" roleURI="http://www.ligand.com/role/AgenusTransactionDetails">
        <link:definition>9955527 - Disclosure - Agenus Transaction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.ligand.com/role/AcquisitionsNarrativeDetails">
        <link:definition>9955528 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>9955529 - Disclosure - Acquisitions - Fair Values of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>9955530 - Disclosure - Acquisitions - Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails" roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails">
        <link:definition>9955531 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails" roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails">
        <link:definition>9955532 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio - Net Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails" roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails">
        <link:definition>9955533 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio - Fair Value of the Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinoffofOmniAbNarrativeDetails" roleURI="http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails">
        <link:definition>9955534 - Disclosure - Spin-off of OmniAb - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails" roleURI="http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails">
        <link:definition>9955535 - Disclosure - Spin-off of OmniAb - Schedule of Revenue and Expenses of the Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails" roleURI="http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails">
        <link:definition>9955536 - Disclosure - Spin-off of OmniAb - Schedule of Non-cash Items and Capital Expenditures of the Discontinued Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails" roleURI="http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails">
        <link:definition>9955537 - Disclosure - Financial Royalty Assets, net (formerly known as Commercial License Rights) - Schedule of Financial Royalty Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails" roleURI="http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails">
        <link:definition>9955538 - Disclosure - Financial Royalty Assets, net (formerly known as Commercial License Rights) - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsInvestmentCategoriesDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails">
        <link:definition>9955539 - Disclosure - Balance Sheet Account Details - Investment Categories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails">
        <link:definition>9955540 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails">
        <link:definition>9955541 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsNarrativeDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails">
        <link:definition>9955542 - Disclosure - Balance Sheet Account Details - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsPropertyandEquipmentDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails">
        <link:definition>9955543 - Disclosure - Balance Sheet Account Details - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails">
        <link:definition>9955544 - Disclosure - Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails">
        <link:definition>9955545 - Disclosure - Balance Sheet Account Details - Schedule of Derivative Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsOtherInvestmentDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsOtherInvestmentDetails">
        <link:definition>9955546 - Disclosure - Balance Sheet Account Details - Other Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsInventoryinOtherAssetsDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails">
        <link:definition>9955547 - Disclosure - Balance Sheet Account Details - Inventory in Other Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsAccruedLiabilitiesDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails">
        <link:definition>9955548 - Disclosure - Balance Sheet Account Details - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsContingentLiabilitiesDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails">
        <link:definition>9955549 - Disclosure - Balance Sheet Account Details - Contingent Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails" roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails">
        <link:definition>9955550 - Disclosure - Balance Sheet Account Details - Other Long-term Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>9955551 - Disclosure - Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" roleURI="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails">
        <link:definition>9955552 - Disclosure - Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementNarrativeDetails" roleURI="http://www.ligand.com/role/FairValueMeasurementNarrativeDetails">
        <link:definition>9955553 - Disclosure - Fair Value Measurement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.ligand.com/role/LeasesNarrativeDetails">
        <link:definition>9955554 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" roleURI="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails">
        <link:definition>9955555 - Disclosure - Leases - Operating and Finance Lease Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails">
        <link:definition>9955556 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1">
        <link:definition>9955556 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://www.ligand.com/role/DebtNarrativeDetails">
        <link:definition>9955557 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityShareBasedCompensationDetails" roleURI="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails">
        <link:definition>9955558 - Disclosure - Stockholders' Equity - Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.ligand.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>9955559 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionPlanActivityDetails" roleURI="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails">
        <link:definition>9955560 - Disclosure - Stockholders' Equity - Stock Option Plan Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityBreakdownofOptionsOutstandingDetails" roleURI="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails">
        <link:definition>9955561 - Disclosure - Stockholders' Equity - Breakdown of Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAssumptionsDetails" roleURI="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails">
        <link:definition>9955562 - Disclosure - Stockholders' Equity - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedStockActivityDetails" roleURI="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails">
        <link:definition>9955563 - Disclosure - Stockholders' Equity - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesLegalProceedingsNarrativeDetails" roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails">
        <link:definition>9955564 - Disclosure - Commitment and Contingencies: Legal Proceedings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeBeforeIncomeTaxFromContinuingOperationsDetails" roleURI="http://www.ligand.com/role/IncomeTaxesIncomeBeforeIncomeTaxFromContinuingOperationsDetails">
        <link:definition>9955565 - Disclosure - Income Taxes - Income Before Income Tax From Continuing Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" roleURI="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails">
        <link:definition>9955566 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails">
        <link:definition>9955567 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.ligand.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9955568 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxesDetails" roleURI="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails">
        <link:definition>9955569 - Disclosure - Income Taxes - Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails">
        <link:definition>9955570 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventDetails" roleURI="http://www.ligand.com/role/SubsequentEventDetails">
        <link:definition>9955571 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lgnd_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_FinancialRoyaltyAssetsNonCurrent" abstract="false" name="FinancialRoyaltyAssetsNonCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CurrentPortionOfLiabilityForContingentValueRights" abstract="false" name="CurrentPortionOfLiabilityForContingentValueRights" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LiabilityForContingentValueRights" abstract="false" name="LiabilityForContingentValueRights" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_IntangibleRoyaltyAssetsMember" abstract="true" name="IntangibleRoyaltyAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_FinancialRoyaltyAssetsMember" abstract="true" name="FinancialRoyaltyAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_MaterialSalesCaptisolMember" abstract="true" name="MaterialSalesCaptisolMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ContractRevenueAndOtherIncomeMember" abstract="true" name="ContractRevenueAndOtherIncomeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_NucorionMember" abstract="true" name="NucorionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_PrimroseBioMember" abstract="true" name="PrimroseBioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_APEIRONMember" abstract="true" name="APEIRONMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_NovanIncMember" abstract="true" name="NovanIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" abstract="false" name="NonCashChangeInEstimatedFairValueOfContingentValueRights" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_GainLossOnShortTermInvestments" abstract="false" name="GainLossOnShortTermInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_NonCashIncomeFromFinancialRoyaltyAssets" abstract="false" name="NonCashIncomeFromFinancialRoyaltyAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CurrentAndExpectedCreditLossAdjustment" abstract="false" name="CurrentAndExpectedCreditLossAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ImpairmentLossOnFinancialRoyaltyAssets" abstract="false" name="ImpairmentLossOnFinancialRoyaltyAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" abstract="false" name="FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PaymentsToAcquireFinancialRoyaltyAssets" abstract="false" name="PaymentsToAcquireFinancialRoyaltyAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ProceedsFromFinancialRoyaltyAssets" abstract="false" name="ProceedsFromFinancialRoyaltyAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PaymentsForSeparation" abstract="false" name="PaymentsForSeparation" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" abstract="false" name="PaymentsToContingentValueRightHoldersFinancingActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid" abstract="false" name="BusinessCombinationAcquisitionCostIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" abstract="false" name="AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" abstract="false" name="AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid" abstract="false" name="AccruedDebtIssuanceCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_FinancialRoyaltyAssetsTextBlock" abstract="false" name="FinancialRoyaltyAssetsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lgnd_OtherBalanceSheetDetailsAbstract" abstract="true" name="OtherBalanceSheetDetailsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_BusinessSpinOffAndMigrationPolicyTextBlock" abstract="false" name="BusinessSpinOffAndMigrationPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" abstract="false" name="CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lgnd_FinancialRoyaltyAssetsPolicyTextBlock" abstract="false" name="FinancialRoyaltyAssetsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lgnd_OtherInvestmentsPolicyPolicyTextBlock" abstract="false" name="OtherInvestmentsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock" abstract="false" name="ScheduleOfFairValueOfTheConsiderationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lgnd_ScheduleOfFinancialRoyaltyAssetsTableTextBlock" abstract="false" name="ScheduleOfFinancialRoyaltyAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lgnd_ScheduleofContingentLiabilitiesTableTextBlock" abstract="false" name="ScheduleofContingentLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember" abstract="true" name="DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_OtherExpenseItemsNet" abstract="false" name="OtherExpenseItemsNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BasisOfPresentationTable" abstract="true" name="BasisOfPresentationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_MetabasisTherapeuticsMember" abstract="true" name="MetabasisTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_RestrictedStockUnitsAndPerformanceSharesMember" abstract="true" name="RestrictedStockUnitsAndPerformanceSharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_TwoThousandTwoStockIncentivePlanMember" abstract="true" name="TwoThousandTwoStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_VestingPeriodOneMember" abstract="true" name="VestingPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_VestingPeriodTwoMember" abstract="true" name="VestingPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_AgenusPartneredProgramMember" abstract="true" name="AgenusPartneredProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_PrimordialGeneticsMember" abstract="true" name="PrimordialGeneticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_BasisOfPresentationLineItems" abstract="true" name="BasisOfPresentationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_DerivativeInstrumentAdditionalMaximumInvestment" abstract="false" name="DerivativeInstrumentAdditionalMaximumInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_MilestoneCompensationRate" abstract="false" name="MilestoneCompensationRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lgnd_NumberOfContracts" abstract="false" name="NumberOfContracts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_NumberOfContingentValueRightsIssued" abstract="false" name="NumberOfContingentValueRightsIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_PartnerAMember" abstract="true" name="PartnerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_PartnerBMember" abstract="true" name="PartnerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_PartnerCMember" abstract="true" name="PartnerCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_RecordatiMember" abstract="true" name="RecordatiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_RoyaltyKyprolisMember" abstract="true" name="RoyaltyKyprolisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_RoyaltyRylazeMember" abstract="true" name="RoyaltyRylazeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_FilspariMember" abstract="true" name="FilspariMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_RoyaltyEvomelaMember" abstract="true" name="RoyaltyEvomelaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_RoyaltyTeriparatideInjectionMember" abstract="true" name="RoyaltyTeriparatideInjectionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_VaxneuvanceMember" abstract="true" name="VaxneuvanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_RoyaltyOtherMember" abstract="true" name="RoyaltyOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_MaterialSalesCaptisolCoreMember" abstract="true" name="MaterialSalesCaptisolCoreMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_MaterialSalesCaptisolCOVIDMember" abstract="true" name="MaterialSalesCaptisolCOVIDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ContractRevenueMember" abstract="true" name="ContractRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_LicenseFeesMember" abstract="true" name="LicenseFeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_AgenusInc.Member" abstract="true" name="AgenusInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_BMS986442Member" abstract="true" name="BMS986442Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_AGEN2373Member" abstract="true" name="AGEN2373Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_INCAGN2385Member" abstract="true" name="INCAGN2385Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_INCAGN2390Member" abstract="true" name="INCAGN2390Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_MK4830Member" abstract="true" name="MK4830Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_UGN301Member" abstract="true" name="UGN301Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_BOTBALMember" abstract="true" name="BOTBALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_FinancialRoyaltyAssetsNet" abstract="false" name="FinancialRoyaltyAssetsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_FinanceRoyaltyAgreementRoyaltyRate" abstract="false" name="FinanceRoyaltyAgreementRoyaltyRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate" abstract="false" name="FinanceRoyaltyAgreementMilestoneProceedsRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales" abstract="false" name="RoyaltyFinancingAgreementPercentageOfGlobalNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lgnd_FinancialRoyaltyMaximumCapitalSourcing" abstract="false" name="FinancialRoyaltyMaximumCapitalSourcing" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_MaximumFinancingRoyaltyAsset" abstract="false" name="MaximumFinancingRoyaltyAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_InvIOsHoldingAGMember" abstract="true" name="InvIOsHoldingAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_EquityIssuanceCost" abstract="false" name="EquityIssuanceCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationAcquiredPercentage" abstract="false" name="BusinessCombinationAcquiredPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ContingentMilestonePurchaseAgreement" abstract="false" name="ContingentMilestonePurchaseAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationLoanFeesAndInterest" abstract="false" name="BusinessCombinationLoanFeesAndInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PeliCRM197Member" abstract="true" name="PeliCRM197Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_MilestoneAxis" abstract="true" name="MilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_MilestoneDomain" abstract="true" name="MilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_BelowMilestoneMember" abstract="true" name="BelowMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_AboveMilestoneMember" abstract="true" name="AboveMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_PelicanTechnologyHoldingsIncMember" abstract="true" name="PelicanTechnologyHoldingsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationShareConsideration" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" abstract="false" name="ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_SalesRevenueMilestone" abstract="false" name="SalesRevenueMilestone" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_SalesContractInterestInSalesRevenue" abstract="false" name="SalesContractInterestInSalesRevenue" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" abstract="false" name="DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationNetAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationNetContributions" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ConsiderationClassficationAxis" abstract="true" name="ConsiderationClassficationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_ConsiderationClassficationDomain" abstract="true" name="ConsiderationClassficationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_EquityMethodInvestmentsAllocationMember" abstract="true" name="EquityMethodInvestmentsAllocationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_EquitySecuritiesAllocationMember" abstract="true" name="EquitySecuritiesAllocationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_DerivativeAssetsMember" abstract="true" name="DerivativeAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract" abstract="true" name="DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" abstract="true" name="BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract" abstract="true" name="NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract" abstract="true" name="NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PaymentsToContingentValueRightHoldersInvestingActivity" abstract="false" name="PaymentsToContingentValueRightHoldersInvestingActivity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract" abstract="true" name="DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_QARZIBAMember" abstract="true" name="QARZIBAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ToleranceTherapeuticsMember" abstract="true" name="ToleranceTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_EnsifentrineMember" abstract="true" name="EnsifentrineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ElutiaAndCorMatrixMember" abstract="true" name="ElutiaAndCorMatrixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_InvIOsMember" abstract="true" name="InvIOsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_SelexisMember" abstract="true" name="SelexisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_OvidTherapeuticsMember" abstract="true" name="OvidTherapeuticsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_FinancialRoyaltyAssetsGross" abstract="false" name="FinancialRoyaltyAssetsGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_FinancialRoyaltyAssetsAllowance" abstract="false" name="FinancialRoyaltyAssetsAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_FinancialRoyaltyAssetsNetCurrent" abstract="false" name="FinancialRoyaltyAssetsNetCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_SoticlestatMember" abstract="true" name="SoticlestatMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ProductRoyaltyPercentage" abstract="false" name="ProductRoyaltyPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" abstract="false" name="AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CommercialLicenseRightsCreditLossAdjustment" abstract="false" name="CommercialLicenseRightsCreditLossAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_VikingTherapeuticsInc.Member" abstract="true" name="VikingTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_PalvellaTherapeuticsIncMember" abstract="true" name="PalvellaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_OtherDerivativesMember" abstract="true" name="OtherDerivativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_PartnerProgramsMember" abstract="true" name="PartnerProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_CollarsMember" abstract="true" name="CollarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_VikingsMember" abstract="true" name="VikingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_DebtSecuritiesAvailableForSaleAmortization" abstract="false" name="DebtSecuritiesAvailableForSaleAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_NumberOfSharesSoldOfEquityMethodInvestee" abstract="false" name="NumberOfSharesSoldOfEquityMethodInvestee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lgnd_AccountsReceivableTerm" abstract="false" name="AccountsReceivableTerm" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount" abstract="false" name="AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued" abstract="false" name="AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice" abstract="false" name="AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lgnd_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ZelsuvmiMember" abstract="true" name="ZelsuvmiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_ValueAddedTaxReceivableNetCurrent" abstract="false" name="ValueAddedTaxReceivableNetCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AccruedSubcontractorExpensesCurrent" abstract="false" name="AccruedSubcontractorExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AccruedCustomerDepositsCurrent" abstract="false" name="AccruedCustomerDepositsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_AccruedSupplierExpensesCurrent" abstract="false" name="AccruedSupplierExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LicenseeAccrualCurrent" abstract="false" name="LicenseeAccrualCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CydexPharmaceuticalsIncMember" abstract="true" name="CydexPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ContingentLiabilityRollForward" abstract="true" name="ContingentLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" abstract="false" name="BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PaymentsToContingentValueRightHolders" abstract="false" name="PaymentsToContingentValueRightHolders" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" abstract="false" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_UnrecognizedTaxBenefitsNoncurrent" abstract="false" name="UnrecognizedTaxBenefitsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ContingentLiabilitiesMember" abstract="true" name="ContingentLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_CyDexMember" abstract="true" name="CyDexMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_MetabasisMember" abstract="true" name="MetabasisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" abstract="true" name="DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_Phase3ClinicalTrialMember" abstract="true" name="Phase3ClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" abstract="false" name="DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" abstract="false" name="BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare" abstract="false" name="BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries" abstract="false" name="BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_NumberOfContingentValueRightsSeries" abstract="false" name="NumberOfContingentValueRightsSeries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders" abstract="false" name="BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lgnd_FinancialRoyaltyAssetsFairValueDisclosure" abstract="false" name="FinancialRoyaltyAssetsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_FinancialRoyaltyAssetMeasurementInput" abstract="false" name="FinancialRoyaltyAssetMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lgnd_OfficeInBostonMassachusettsMember" abstract="true" name="OfficeInBostonMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_OfficeInJupiterFloridaMember" abstract="true" name="OfficeInJupiterFloridaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_PurchaseCommitmentConsiderationPaidToDate" abstract="false" name="PurchaseCommitmentConsiderationPaidToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" abstract="false" name="PurchaseCommitmentConsiderationPaidAllocatedToInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" abstract="false" name="LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LeaseRightOfUseAsset" abstract="false" name="LeaseRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LeaseLiabilityCurrent" abstract="false" name="LeaseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_LeaseLiability" abstract="false" name="LeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_OperatingLeaseLiabilityTenantImprovementAllowance" abstract="false" name="OperatingLeaseLiabilityTenantImprovementAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" abstract="false" name="FinanceLeaseLiabilityTenantImprovementAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ConvertibleSeniorNotesDue2023Member" abstract="true" name="ConvertibleSeniorNotesDue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember" abstract="true" name="NotesRepurchasedDuringCurrentPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_IncreaseDecreaseInDebtDiscount" abstract="false" name="IncreaseDecreaseInDebtDiscount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PaymentsforConvertibleBondHedges" abstract="false" name="PaymentsforConvertibleBondHedges" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DebtInstrumentRepurchasedAmountDuringPeriod" abstract="false" name="DebtInstrumentRepurchasedAmountDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_OmniabSeparationMember" abstract="true" name="OmniabSeparationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_AmendedESPPMember" abstract="true" name="AmendedESPPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_AtTheMarketEquityOfferingMember" abstract="true" name="AtTheMarketEquityOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_EmployeeStockPurchasePlanAbstract" abstract="true" name="EmployeeStockPurchasePlanAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_ShareBasedCompensationInitialOfferingPeriod" abstract="false" name="ShareBasedCompensationInitialOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lgnd_CorporateShareRepurchaseAbstract" abstract="true" name="CorporateShareRepurchaseAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lgnd_SaleOfStockAuthorizedOfferingAmount" abstract="false" name="SaleOfStockAuthorizedOfferingAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeOneMember" abstract="true" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeFiveMember" abstract="true" name="ExercisePriceRangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeSixMember" abstract="true" name="ExercisePriceRangeSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeSevenMember" abstract="true" name="ExercisePriceRangeSevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeEightMember" abstract="true" name="ExercisePriceRangeEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeNineMember" abstract="true" name="ExercisePriceRangeNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_ExercisePriceRangeTenMember" abstract="true" name="ExercisePriceRangeTenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" abstract="true" name="USDistrictCourtForTheNorthernDistrictOfOhioMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome" abstract="false" name="EffectiveIncomeTaxRateReconciliationOtherIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_IncomeTaxReconciliationContingentValueRights" abstract="false" name="IncomeTaxReconciliationContingentValueRights" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" abstract="false" name="EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" abstract="false" name="EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" abstract="true" name="CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment" abstract="false" name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" abstract="false" name="DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lgnd_PurchasersMember" abstract="true" name="PurchasersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_OtherPurchasersMember" abstract="true" name="OtherPurchasersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lgnd_FCX007Member" abstract="true" name="FCX007Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>lgnd-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:8c134d1d-ab0c-4379-9892-d916b4e62e37,g:28b275e3-fcb1-4a6c-a0ef-95ede04b9eea-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lgnd-20241231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a2703df6-5685-4bad-bc9c-8791384995f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3622d554-a9b9-49d7-92e2-1dc35aa8135c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a2703df6-5685-4bad-bc9c-8791384995f4" xlink:to="loc_us-gaap_AssetsCurrent_3622d554-a9b9-49d7-92e2-1dc35aa8135c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_708a168a-ce2a-46a5-aa5a-c535f9d852f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a2703df6-5685-4bad-bc9c-8791384995f4" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_708a168a-ce2a-46a5-aa5a-c535f9d852f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_cd79543b-96bf-4a5a-bd92-5db00fbdf411" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a2703df6-5685-4bad-bc9c-8791384995f4" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_cd79543b-96bf-4a5a-bd92-5db00fbdf411" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bcde6ae8-10af-40ae-b562-f2dcdf58425e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a2703df6-5685-4bad-bc9c-8791384995f4" xlink:to="loc_us-gaap_Goodwill_bcde6ae8-10af-40ae-b562-f2dcdf58425e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dad02574-f197-419b-866c-6b712b89c4be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a2703df6-5685-4bad-bc9c-8791384995f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_dad02574-f197-419b-866c-6b712b89c4be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8da1d54e-350d-4132-98fb-cdb114c8f1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a2703df6-5685-4bad-bc9c-8791384995f4" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8da1d54e-350d-4132-98fb-cdb114c8f1e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_86b89dbc-a3da-4904-a553-fa25f88ec8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a2703df6-5685-4bad-bc9c-8791384995f4" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_86b89dbc-a3da-4904-a553-fa25f88ec8ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_ec16f7a0-e96b-4e34-8e7b-a6b4b5f13f98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a2703df6-5685-4bad-bc9c-8791384995f4" xlink:to="loc_us-gaap_EquityMethodInvestments_ec16f7a0-e96b-4e34-8e7b-a6b4b5f13f98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_36f7649d-52df-430b-b252-395d8b650385" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a2703df6-5685-4bad-bc9c-8791384995f4" xlink:to="loc_us-gaap_OtherInvestments_36f7649d-52df-430b-b252-395d8b650385" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7c3346d6-dbee-4942-b15a-e503f56b4a25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a2703df6-5685-4bad-bc9c-8791384995f4" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7c3346d6-dbee-4942-b15a-e503f56b4a25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsNonCurrent_4ce7d995-bf95-47df-8f72-ad1a70f33ffc" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsNonCurrent"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a2703df6-5685-4bad-bc9c-8791384995f4" xlink:to="loc_lgnd_FinancialRoyaltyAssetsNonCurrent_4ce7d995-bf95-47df-8f72-ad1a70f33ffc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_1621e1d6-81df-4a7a-9fde-1f23b3139125" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_a2703df6-5685-4bad-bc9c-8791384995f4" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_1621e1d6-81df-4a7a-9fde-1f23b3139125" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1ba621e1-4399-4473-a070-9304855c17f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a491f411-d624-4800-8684-74db1482908f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1ba621e1-4399-4473-a070-9304855c17f6" xlink:to="loc_us-gaap_Liabilities_a491f411-d624-4800-8684-74db1482908f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_3b8c3233-c7bb-4924-be0d-9606081a283d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1ba621e1-4399-4473-a070-9304855c17f6" xlink:to="loc_us-gaap_CommitmentsAndContingencies_3b8c3233-c7bb-4924-be0d-9606081a283d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c167fcde-3376-4560-87f0-898e0ba52f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1ba621e1-4399-4473-a070-9304855c17f6" xlink:to="loc_us-gaap_StockholdersEquity_c167fcde-3376-4560-87f0-898e0ba52f2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_aaedc5ea-34c0-4db6-ad5c-fa1f2409b333" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7d70d8b0-7fbb-4fc7-a971-043223105335" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aaedc5ea-34c0-4db6-ad5c-fa1f2409b333" xlink:to="loc_us-gaap_AccountsPayableCurrent_7d70d8b0-7fbb-4fc7-a971-043223105335" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c6699c8e-e625-4437-ba62-03b27837169f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aaedc5ea-34c0-4db6-ad5c-fa1f2409b333" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c6699c8e-e625-4437-ba62-03b27837169f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_d205ae2c-d03a-4b54-9bb6-fd3fc10d7a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aaedc5ea-34c0-4db6-ad5c-fa1f2409b333" xlink:to="loc_us-gaap_TaxesPayableCurrent_d205ae2c-d03a-4b54-9bb6-fd3fc10d7a3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_81d0a910-b493-40e8-9bd0-f66babd2b134" xlink:href="lgnd-20241231.xsd#lgnd_CurrentPortionOfLiabilityForContingentValueRights"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aaedc5ea-34c0-4db6-ad5c-fa1f2409b333" xlink:to="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_81d0a910-b493-40e8-9bd0-f66babd2b134" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7d0e87f1-11e7-441e-8d94-9c4779ebf2f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aaedc5ea-34c0-4db6-ad5c-fa1f2409b333" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7d0e87f1-11e7-441e-8d94-9c4779ebf2f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ead279ea-6ac2-4061-b335-014de8d13dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aaedc5ea-34c0-4db6-ad5c-fa1f2409b333" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ead279ea-6ac2-4061-b335-014de8d13dd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_fb731a24-082c-45ad-b331-c160214f5b60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_aaedc5ea-34c0-4db6-ad5c-fa1f2409b333" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_fb731a24-082c-45ad-b331-c160214f5b60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_593c7c9a-ca67-4d14-97f0-68454c213e26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_23a1b3c9-4c61-472b-9923-dc4dc6ffb0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_593c7c9a-ca67-4d14-97f0-68454c213e26" xlink:to="loc_us-gaap_LiabilitiesCurrent_23a1b3c9-4c61-472b-9923-dc4dc6ffb0eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRights_812ca765-c3d0-4957-90fc-32cdfce90ccc" xlink:href="lgnd-20241231.xsd#lgnd_LiabilityForContingentValueRights"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_593c7c9a-ca67-4d14-97f0-68454c213e26" xlink:to="loc_lgnd_LiabilityForContingentValueRights_812ca765-c3d0-4957-90fc-32cdfce90ccc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_fd84c438-75a7-489f-83a1-18af94229f27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_593c7c9a-ca67-4d14-97f0-68454c213e26" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_fd84c438-75a7-489f-83a1-18af94229f27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b1f148c4-79e5-4492-a4d4-70f8812a9e99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_593c7c9a-ca67-4d14-97f0-68454c213e26" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b1f148c4-79e5-4492-a4d4-70f8812a9e99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f3cec0cb-3f01-4dbe-b1fc-a1804106b8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_593c7c9a-ca67-4d14-97f0-68454c213e26" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f3cec0cb-3f01-4dbe-b1fc-a1804106b8d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeNoncurrent_57b3c088-61ed-479f-90d1-ccae5c22444f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_593c7c9a-ca67-4d14-97f0-68454c213e26" xlink:to="loc_us-gaap_DeferredIncomeNoncurrent_57b3c088-61ed-479f-90d1-ccae5c22444f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f053d4b6-2a4d-4d31-9ac0-31530020067c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_88effe79-3949-4f67-bde0-1579a4fc4db4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f053d4b6-2a4d-4d31-9ac0-31530020067c" xlink:to="loc_us-gaap_PreferredStockValue_88effe79-3949-4f67-bde0-1579a4fc4db4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_59c2e26d-876b-4c82-81ab-bac104aaf309" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f053d4b6-2a4d-4d31-9ac0-31530020067c" xlink:to="loc_us-gaap_CommonStockValue_59c2e26d-876b-4c82-81ab-bac104aaf309" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1ade93ab-a34e-4b6f-a53d-a3f0d6e1fd53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f053d4b6-2a4d-4d31-9ac0-31530020067c" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1ade93ab-a34e-4b6f-a53d-a3f0d6e1fd53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6c4b3335-df39-4f98-bf38-27027e88851f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f053d4b6-2a4d-4d31-9ac0-31530020067c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6c4b3335-df39-4f98-bf38-27027e88851f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_230256f4-d380-4d1f-bd52-e198e15c238c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f053d4b6-2a4d-4d31-9ac0-31530020067c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_230256f4-d380-4d1f-bd52-e198e15c238c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bbf32c60-f388-4ae2-85ad-dc50c93537f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_072ad962-778d-45b8-833e-bb5dee5b4117" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bbf32c60-f388-4ae2-85ad-dc50c93537f2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_072ad962-778d-45b8-833e-bb5dee5b4117" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_4f9437bc-07a8-4309-b45e-5b6699e6d859" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bbf32c60-f388-4ae2-85ad-dc50c93537f2" xlink:to="loc_us-gaap_ShortTermInvestments_4f9437bc-07a8-4309-b45e-5b6699e6d859" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_aad9ada7-371f-4191-b54f-48ca468673b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bbf32c60-f388-4ae2-85ad-dc50c93537f2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_aad9ada7-371f-4191-b54f-48ca468673b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e0cd1340-69f3-424f-bde2-d5f63e907b35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bbf32c60-f388-4ae2-85ad-dc50c93537f2" xlink:to="loc_us-gaap_InventoryNet_e0cd1340-69f3-424f-bde2-d5f63e907b35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_05dd3686-0f38-47ab-b5b3-f2f19f443f31" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bbf32c60-f388-4ae2-85ad-dc50c93537f2" xlink:to="loc_us-gaap_IncomeTaxesReceivable_05dd3686-0f38-47ab-b5b3-f2f19f443f31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_fa52c845-6cad-4157-b50b-ef98c1e5400c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bbf32c60-f388-4ae2-85ad-dc50c93537f2" xlink:to="loc_us-gaap_OtherAssetsCurrent_fa52c845-6cad-4157-b50b-ef98c1e5400c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_0f9d5727-7926-419d-ad64-b81be4255ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bbf32c60-f388-4ae2-85ad-dc50c93537f2" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_0f9d5727-7926-419d-ad64-b81be4255ed3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lgnd-20241231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc267c8a-ce02-4737-beb5-604f4f6d358b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3e0db0b8-4011-4a6d-a4b3-33099e44a4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc267c8a-ce02-4737-beb5-604f4f6d358b" xlink:to="loc_us-gaap_OperatingIncomeLoss_3e0db0b8-4011-4a6d-a4b3-33099e44a4bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_65be76b3-0ec8-4ec5-82e9-9fdcebc337ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fc267c8a-ce02-4737-beb5-604f4f6d358b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_65be76b3-0ec8-4ec5-82e9-9fdcebc337ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f559c358-befa-4362-8100-380f76ea3416" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_b59c01f5-cc59-42e4-b75a-99f97244ed93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_f559c358-befa-4362-8100-380f76ea3416" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_b59c01f5-cc59-42e4-b75a-99f97244ed93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_db3d52a7-a1ae-44ad-8c31-a39e32d7360d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_f559c358-befa-4362-8100-380f76ea3416" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_db3d52a7-a1ae-44ad-8c31-a39e32d7360d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_b5db98d1-4567-40b5-b3a9-d33bec3b83e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial_0c0ebf58-fb19-4977-bbee-4258fb46bb72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostDirectMaterial"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_b5db98d1-4567-40b5-b3a9-d33bec3b83e3" xlink:to="loc_us-gaap_CostDirectMaterial_0c0ebf58-fb19-4977-bbee-4258fb46bb72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_f741cc25-519a-4b91-a75d-05902943e5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_b5db98d1-4567-40b5-b3a9-d33bec3b83e3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_f741cc25-519a-4b91-a75d-05902943e5e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7993800d-03b4-475c-a987-68bc7bdbbbe1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_b5db98d1-4567-40b5-b3a9-d33bec3b83e3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7993800d-03b4-475c-a987-68bc7bdbbbe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_c8a23a6b-9ffb-4092-bc5f-9c1e99f5100e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_b5db98d1-4567-40b5-b3a9-d33bec3b83e3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_c8a23a6b-9ffb-4092-bc5f-9c1e99f5100e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_618546e4-6895-44a0-bee6-057c9707f6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_b5db98d1-4567-40b5-b3a9-d33bec3b83e3" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_618546e4-6895-44a0-bee6-057c9707f6e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_12163ee3-761d-4b18-b624-8b226ab13a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_b5db98d1-4567-40b5-b3a9-d33bec3b83e3" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_12163ee3-761d-4b18-b624-8b226ab13a6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3eb02336-e273-4ee8-8ad1-5ed6dbb93b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_a4aa76fa-63b8-4792-903b-973b8f5000ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_3eb02336-e273-4ee8-8ad1-5ed6dbb93b4e" xlink:to="loc_us-gaap_GainLossOnInvestments_a4aa76fa-63b8-4792-903b-973b8f5000ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_30bb64c5-50d5-425d-b905-3a59800b385a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_3eb02336-e273-4ee8-8ad1-5ed6dbb93b4e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_30bb64c5-50d5-425d-b905-3a59800b385a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_af764911-f610-4125-ac1f-b62898a69f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_3eb02336-e273-4ee8-8ad1-5ed6dbb93b4e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_af764911-f610-4125-ac1f-b62898a69f8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_cf75de13-7e14-4992-9996-9cc1208903ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_3eb02336-e273-4ee8-8ad1-5ed6dbb93b4e" xlink:to="loc_us-gaap_InterestExpenseNonoperating_cf75de13-7e14-4992-9996-9cc1208903ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_82f83daf-d11c-452a-bb0e-816d634b6f72" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8dab017a-cc45-49ea-8399-90c6a232aefc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_82f83daf-d11c-452a-bb0e-816d634b6f72" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8dab017a-cc45-49ea-8399-90c6a232aefc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_1177020b-aaf7-4e2b-a86f-9449faf0e05f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_82f83daf-d11c-452a-bb0e-816d634b6f72" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_1177020b-aaf7-4e2b-a86f-9449faf0e05f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_e029b7cb-8d0c-4b9b-8104-a9728ec9f363" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_82f83daf-d11c-452a-bb0e-816d634b6f72" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_e029b7cb-8d0c-4b9b-8104-a9728ec9f363" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_0154c130-af54-436f-b4f4-cebad73d4700" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_66eb558d-6a87-45bd-9d66-4ff600d7f161" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_0154c130-af54-436f-b4f4-cebad73d4700" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_66eb558d-6a87-45bd-9d66-4ff600d7f161" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_157db23a-821f-42c6-9059-2512e722c47b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_0154c130-af54-436f-b4f4-cebad73d4700" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_157db23a-821f-42c6-9059-2512e722c47b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_c2859723-87d3-4ac5-bb32-526290a93469" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b4cf293f-c397-44c5-abce-ca07a31e8839" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_c2859723-87d3-4ac5-bb32-526290a93469" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b4cf293f-c397-44c5-abce-ca07a31e8839" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ff6c6033-9384-4b7d-989c-d2a462ddb135" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_c2859723-87d3-4ac5-bb32-526290a93469" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ff6c6033-9384-4b7d-989c-d2a462ddb135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9dedec3c-d0ba-4d64-8847-f236ea407025" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_c74749d5-8e52-4d47-81de-56fd8f231e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9dedec3c-d0ba-4d64-8847-f236ea407025" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_c74749d5-8e52-4d47-81de-56fd8f231e7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_ab54fb4c-b77c-428a-9f22-56b01a1d16fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9dedec3c-d0ba-4d64-8847-f236ea407025" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_ab54fb4c-b77c-428a-9f22-56b01a1d16fb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="lgnd-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_82fe1cc2-a659-4f01-8f86-530d66747d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_445d78ee-9c8b-4fda-9f54-1a9dcde8be83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_82fe1cc2-a659-4f01-8f86-530d66747d3e" xlink:to="loc_us-gaap_NetIncomeLoss_445d78ee-9c8b-4fda-9f54-1a9dcde8be83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_641e6c18-3260-42d4-9c3f-bd5b34561794" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_82fe1cc2-a659-4f01-8f86-530d66747d3e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_641e6c18-3260-42d4-9c3f-bd5b34561794" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_8ed9a466-3390-4910-81d8-8fa8f23ce765" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_82fe1cc2-a659-4f01-8f86-530d66747d3e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_8ed9a466-3390-4910-81d8-8fa8f23ce765" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lgnd-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d8076e54-873e-438a-b5be-78394c30ef37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_us-gaap_NetIncomeLoss_d8076e54-873e-438a-b5be-78394c30ef37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_51dad263-839a-46e6-aec7-e10ee40f1d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_51dad263-839a-46e6-aec7-e10ee40f1d0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_995fe3f3-f49a-454e-bc01-ce27276ea69b" xlink:href="lgnd-20241231.xsd#lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_995fe3f3-f49a-454e-bc01-ce27276ea69b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_bd32f00b-29e1-44a5-a9af-9b3b506f4571" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_bd32f00b-29e1-44a5-a9af-9b3b506f4571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_GainLossOnShortTermInvestments_1ff3c184-656a-4086-aded-6596d381b040" xlink:href="lgnd-20241231.xsd#lgnd_GainLossOnShortTermInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_lgnd_GainLossOnShortTermInvestments_1ff3c184-656a-4086-aded-6596d381b040" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a179913e-a081-4241-aceb-99b488039c75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_a179913e-a081-4241-aceb-99b488039c75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f18caa77-a477-4ae7-ae8d-f8a43dca7dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_f18caa77-a477-4ae7-ae8d-f8a43dca7dc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_60c7c251-900f-45d4-93ca-70d3659b9507" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_60c7c251-900f-45d4-93ca-70d3659b9507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashIncomeFromFinancialRoyaltyAssets_63ca47ce-5273-42d8-a266-1d852d7ed217" xlink:href="lgnd-20241231.xsd#lgnd_NonCashIncomeFromFinancialRoyaltyAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_lgnd_NonCashIncomeFromFinancialRoyaltyAssets_63ca47ce-5273-42d8-a266-1d852d7ed217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CurrentAndExpectedCreditLossAdjustment_4c84d0e3-47a6-4101-9b4c-d5b8918713ae" xlink:href="lgnd-20241231.xsd#lgnd_CurrentAndExpectedCreditLossAdjustment"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_lgnd_CurrentAndExpectedCreditLossAdjustment_4c84d0e3-47a6-4101-9b4c-d5b8918713ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ImpairmentLossOnFinancialRoyaltyAssets_dafc6659-79e5-45b0-a432-18f6b12a4536" xlink:href="lgnd-20241231.xsd#lgnd_ImpairmentLossOnFinancialRoyaltyAssets"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_lgnd_ImpairmentLossOnFinancialRoyaltyAssets_dafc6659-79e5-45b0-a432-18f6b12a4536" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization_7ff091bf-a417-439e-934c-07b5db246f14" xlink:href="lgnd-20241231.xsd#lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization_7ff091bf-a417-439e-934c-07b5db246f14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3b9e56f3-e6cc-4c24-9a82-c6b0e42a629b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_us-gaap_ShareBasedCompensation_3b9e56f3-e6cc-4c24-9a82-c6b0e42a629b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_71621b84-3890-4c37-88aa-6497ca9f8792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_71621b84-3890-4c37-88aa-6497ca9f8792" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_b8c86418-0797-4dcb-8064-5545ded5809e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_b8c86418-0797-4dcb-8064-5545ded5809e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_312031ed-6bc3-413f-a93a-17f61ad0b757" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_312031ed-6bc3-413f-a93a-17f61ad0b757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_e8bb1100-64ae-4f2f-8e71-9e33f365b0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_e8bb1100-64ae-4f2f-8e71-9e33f365b0c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d1ae5b6e-36bf-42fb-9fa1-6c36017c4ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_d1ae5b6e-36bf-42fb-9fa1-6c36017c4ea6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_f16b71f8-f536-417f-85f6-e7f9b0e5193b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_f16b71f8-f536-417f-85f6-e7f9b0e5193b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_421f14ac-5103-4f83-80e1-71e289793e20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_421f14ac-5103-4f83-80e1-71e289793e20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_05cfb07c-7060-45e9-84d4-a0229de10b71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="21" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_05cfb07c-7060-45e9-84d4-a0229de10b71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_5c07d1c3-f4e0-40f5-8b11-e67f3343a97e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent"/>
    <link:calculationArc order="22" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_5c07d1c3-f4e0-40f5-8b11-e67f3343a97e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_79585228-4adf-4e06-9057-66ef89d4212a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="23" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_79585228-4adf-4e06-9057-66ef89d4212a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_f6f358f7-1990-4b7e-a748-ea04b071a019" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="24" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_f6f358f7-1990-4b7e-a748-ea04b071a019" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c7e2b81c-84dc-4703-ba68-7a8eff2acd7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="25" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3cea2a7c-e5a8-4c92-8f15-684db86445ff" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c7e2b81c-84dc-4703-ba68-7a8eff2acd7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8c64d53f-4cd8-4734-aeb1-0ca1ba90d57b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7fa78d2f-37d8-413c-bbd6-d6316816e6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8c64d53f-4cd8-4734-aeb1-0ca1ba90d57b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7fa78d2f-37d8-413c-bbd6-d6316816e6e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_73d20ffa-ebcc-48b2-af65-7f0db668eddb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8c64d53f-4cd8-4734-aeb1-0ca1ba90d57b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_73d20ffa-ebcc-48b2-af65-7f0db668eddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_51241234-425f-4ac1-acef-a117b5cc3109" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8c64d53f-4cd8-4734-aeb1-0ca1ba90d57b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_51241234-425f-4ac1-acef-a117b5cc3109" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28fc580a-4676-40e7-a98c-1fae25971a1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8c64d53f-4cd8-4734-aeb1-0ca1ba90d57b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_28fc580a-4676-40e7-a98c-1fae25971a1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd8e63c-69bc-4e16-aa38-8d8552ac677a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsForSeparation_807f9b7b-fec0-4e46-aa10-44cef58666bc" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsForSeparation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd8e63c-69bc-4e16-aa38-8d8552ac677a" xlink:to="loc_lgnd_PaymentsForSeparation_807f9b7b-fec0-4e46-aa10-44cef58666bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_9c84d86e-af8e-4d3b-92ed-7ae084b39a63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd8e63c-69bc-4e16-aa38-8d8552ac677a" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_9c84d86e-af8e-4d3b-92ed-7ae084b39a63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_eadbd8b8-2329-4505-9926-4324d9cc41b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd8e63c-69bc-4e16-aa38-8d8552ac677a" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_eadbd8b8-2329-4505-9926-4324d9cc41b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_f32b6805-a4d1-4c39-b98c-f4fa6edc9c07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd8e63c-69bc-4e16-aa38-8d8552ac677a" xlink:to="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_f32b6805-a4d1-4c39-b98c-f4fa6edc9c07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities_232f0a65-356b-4b6d-8a31-4cfb9c56b2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd8e63c-69bc-4e16-aa38-8d8552ac677a" xlink:to="loc_us-gaap_ProceedsFromHedgeFinancingActivities_232f0a65-356b-4b6d-8a31-4cfb9c56b2e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_32cd24c1-6a22-492b-a8b5-8f0fbfe7ec6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd8e63c-69bc-4e16-aa38-8d8552ac677a" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_32cd24c1-6a22-492b-a8b5-8f0fbfe7ec6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_08187ce7-a5f9-41cb-a9bc-44a782813c3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd8e63c-69bc-4e16-aa38-8d8552ac677a" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_08187ce7-a5f9-41cb-a9bc-44a782813c3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_f20a2c45-5d19-435e-82b1-5535a7df1c02" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd8e63c-69bc-4e16-aa38-8d8552ac677a" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_f20a2c45-5d19-435e-82b1-5535a7df1c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2c0c2ab2-a028-4a81-b5e5-14cd3f390109" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd8e63c-69bc-4e16-aa38-8d8552ac677a" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_2c0c2ab2-a028-4a81-b5e5-14cd3f390109" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5ba153c2-d3a5-4c5c-bc1b-c150543333d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6fd8e63c-69bc-4e16-aa38-8d8552ac677a" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5ba153c2-d3a5-4c5c-bc1b-c150543333d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52b11dfc-a90b-4e86-890e-aebb2f3d1a60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_465031db-fad5-48d4-848a-b6bc94f7b215" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52b11dfc-a90b-4e86-890e-aebb2f3d1a60" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_465031db-fad5-48d4-848a-b6bc94f7b215" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_56634f6e-58ab-4a76-9697-c9a340d2e06b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52b11dfc-a90b-4e86-890e-aebb2f3d1a60" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_56634f6e-58ab-4a76-9697-c9a340d2e06b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromFinancialRoyaltyAssets_3211390d-1c1b-42d3-a2a9-dee46576caee" xlink:href="lgnd-20241231.xsd#lgnd_ProceedsFromFinancialRoyaltyAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52b11dfc-a90b-4e86-890e-aebb2f3d1a60" xlink:to="loc_lgnd_ProceedsFromFinancialRoyaltyAssets_3211390d-1c1b-42d3-a2a9-dee46576caee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_1e7ce765-c99e-4eb1-8679-6199494df4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52b11dfc-a90b-4e86-890e-aebb2f3d1a60" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_1e7ce765-c99e-4eb1-8679-6199494df4d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_8ef113dd-7865-422c-acea-19e86c67a53f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52b11dfc-a90b-4e86-890e-aebb2f3d1a60" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_8ef113dd-7865-422c-acea-19e86c67a53f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_5475d7da-544b-412e-90ea-0e4627299ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52b11dfc-a90b-4e86-890e-aebb2f3d1a60" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_5475d7da-544b-412e-90ea-0e4627299ccf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d7fb6c69-014d-4423-ba98-37927175e0a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52b11dfc-a90b-4e86-890e-aebb2f3d1a60" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d7fb6c69-014d-4423-ba98-37927175e0a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_05c2d3bd-5793-4c87-98b3-e3e0fda9a009" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52b11dfc-a90b-4e86-890e-aebb2f3d1a60" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_05c2d3bd-5793-4c87-98b3-e3e0fda9a009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToAcquireFinancialRoyaltyAssets_54568dad-1bcd-4d03-b2bf-69a139cd066d" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsToAcquireFinancialRoyaltyAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52b11dfc-a90b-4e86-890e-aebb2f3d1a60" xlink:to="loc_lgnd_PaymentsToAcquireFinancialRoyaltyAssets_54568dad-1bcd-4d03-b2bf-69a139cd066d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_e3e7451f-3887-41d0-a478-b0f5b8d65d34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52b11dfc-a90b-4e86-890e-aebb2f3d1a60" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_e3e7451f-3887-41d0-a478-b0f5b8d65d34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentInvestingActivities_a9b61133-e2b2-4fb5-be30-b2548e7e41e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForDerivativeInstrumentInvestingActivities"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52b11dfc-a90b-4e86-890e-aebb2f3d1a60" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentInvestingActivities_a9b61133-e2b2-4fb5-be30-b2548e7e41e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_73407606-897e-403b-bf26-95f53f0fc2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52b11dfc-a90b-4e86-890e-aebb2f3d1a60" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_73407606-897e-403b-bf26-95f53f0fc2dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_da4ebc3d-7eb5-4c88-a1f4-f2a60fb6cfb5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52b11dfc-a90b-4e86-890e-aebb2f3d1a60" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_da4ebc3d-7eb5-4c88-a1f4-f2a60fb6cfb5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_56e9289b-f289-44d3-9234-2a18ffd32d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_52b11dfc-a90b-4e86-890e-aebb2f3d1a60" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_56e9289b-f289-44d3-9234-2a18ffd32d2a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3847e982-bda4-417a-b31e-ad7e5378abe0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_98a855d4-157f-40f9-a56a-56174ee8b4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3847e982-bda4-417a-b31e-ad7e5378abe0" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_98a855d4-157f-40f9-a56a-56174ee8b4cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_369c7518-11da-4435-9746-8031e874773f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3847e982-bda4-417a-b31e-ad7e5378abe0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_369c7518-11da-4435-9746-8031e874773f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c111bbb4-0efe-4556-b72b-e57bd6a3d523" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_17d3ffb6-b75f-41ac-847f-2c40f1d94c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c111bbb4-0efe-4556-b72b-e57bd6a3d523" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_17d3ffb6-b75f-41ac-847f-2c40f1d94c7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_928737a6-0c1a-4d57-b4ca-513031aa2299" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c111bbb4-0efe-4556-b72b-e57bd6a3d523" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_928737a6-0c1a-4d57-b4ca-513031aa2299" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets_11b087a8-81e0-4800-954f-5061a54be231" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c111bbb4-0efe-4556-b72b-e57bd6a3d523" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets_11b087a8-81e0-4800-954f-5061a54be231" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_14382001-c409-4899-82c8-f39dafc277f8" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c111bbb4-0efe-4556-b72b-e57bd6a3d523" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_14382001-c409-4899-82c8-f39dafc277f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable_be2cc8ae-75c6-474d-899c-8e1e12203f58" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c111bbb4-0efe-4556-b72b-e57bd6a3d523" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable_be2cc8ae-75c6-474d-899c-8e1e12203f58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e8ca6e20-e93f-4c51-8285-10c59c23cf76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c111bbb4-0efe-4556-b72b-e57bd6a3d523" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_e8ca6e20-e93f-4c51-8285-10c59c23cf76" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3b1580fa-2776-4723-82d0-3e8664910904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1658cd07-733a-48f9-836f-14744147840a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3b1580fa-2776-4723-82d0-3e8664910904" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1658cd07-733a-48f9-836f-14744147840a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationLoanFeesAndInterest_55663ff9-cad9-4fd1-bc8b-5dd150fd502d" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationLoanFeesAndInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3b1580fa-2776-4723-82d0-3e8664910904" xlink:to="loc_lgnd_BusinessCombinationLoanFeesAndInterest_55663ff9-cad9-4fd1-bc8b-5dd150fd502d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_2daa40f0-c090-404c-8780-82eb48ef4709" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_57c79eb3-c200-404c-8bbb-2e0bfbea898d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_2daa40f0-c090-404c-8780-82eb48ef4709" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_57c79eb3-c200-404c-8bbb-2e0bfbea898d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_f4e6c01d-f1d6-426d-b312-cdeae87385ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_2daa40f0-c090-404c-8780-82eb48ef4709" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_f4e6c01d-f1d6-426d-b312-cdeae87385ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_a191f9c4-25d8-45ed-bfb1-926eaeb68385" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_2daa40f0-c090-404c-8780-82eb48ef4709" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_a191f9c4-25d8-45ed-bfb1-926eaeb68385" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_740f7611-7fb7-4237-9cb6-09f71f242e3c" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_2daa40f0-c090-404c-8780-82eb48ef4709" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_740f7611-7fb7-4237-9cb6-09f71f242e3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset_423f0fab-b504-4d54-b4f6-785acabb8a2f" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_2daa40f0-c090-404c-8780-82eb48ef4709" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset_423f0fab-b504-4d54-b4f6-785acabb8a2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_ec1c949b-0771-4404-87cc-595285f91803" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_2daa40f0-c090-404c-8780-82eb48ef4709" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_ec1c949b-0771-4404-87cc-595285f91803" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_245c114f-eae0-4038-8336-7cefd0fca389" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_2daa40f0-c090-404c-8780-82eb48ef4709" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_245c114f-eae0-4038-8336-7cefd0fca389" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities_29aa172f-6bca-407f-bf50-7c76a48b82d2" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_2daa40f0-c090-404c-8780-82eb48ef4709" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities_29aa172f-6bca-407f-bf50-7c76a48b82d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_e54585cc-d0b6-4600-a9e1-7be57b0eab38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_2daa40f0-c090-404c-8780-82eb48ef4709" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_e54585cc-d0b6-4600-a9e1-7be57b0eab38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_9e2ba8a2-201f-44d4-9243-aa6493594429" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_927ecff5-aedc-41fc-a332-0a472111face" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_9e2ba8a2-201f-44d4-9243-aa6493594429" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_927ecff5-aedc-41fc-a332-0a472111face" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_23742133-6f38-41a9-93d3-0c7e7a15bd26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_9e2ba8a2-201f-44d4-9243-aa6493594429" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_23742133-6f38-41a9-93d3-0c7e7a15bd26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_94f890a4-1983-470c-bbeb-7eed4e6b8189" xlink:href="lgnd-20241231.xsd#lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_9e2ba8a2-201f-44d4-9243-aa6493594429" xlink:to="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_94f890a4-1983-470c-bbeb-7eed4e6b8189" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_bbc0bf43-4e91-4a28-92a8-fc7dd6e5de23" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments_576112d0-c7bc-46c8-8c2c-b7897cd58879" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_bbc0bf43-4e91-4a28-92a8-fc7dd6e5de23" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments_576112d0-c7bc-46c8-8c2c-b7897cd58879" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_5b7ae023-2559-44b8-bd2d-b12a47ae9903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_bbc0bf43-4e91-4a28-92a8-fc7dd6e5de23" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_5b7ae023-2559-44b8-bd2d-b12a47ae9903" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_f26bb769-f47e-44a2-bcdf-6d00e3d01ac8" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_bbc0bf43-4e91-4a28-92a8-fc7dd6e5de23" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_f26bb769-f47e-44a2-bcdf-6d00e3d01ac8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_a2fb1f68-fb34-4ba0-9042-d0c2dcb9cd29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_e1c57d3e-9c95-4e7f-adcf-de8c77f36c65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_a2fb1f68-fb34-4ba0-9042-d0c2dcb9cd29" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_e1c57d3e-9c95-4e7f-adcf-de8c77f36c65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_e1be6b3b-da22-434f-9bc5-2be2787537f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_a2fb1f68-fb34-4ba0-9042-d0c2dcb9cd29" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_e1be6b3b-da22-434f-9bc5-2be2787537f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5c41c5bd-6c12-4387-b607-0e0d306bcd09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_acba691c-dd64-45ba-b564-fb1d7d6a34c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5c41c5bd-6c12-4387-b607-0e0d306bcd09" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_acba691c-dd64-45ba-b564-fb1d7d6a34c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_ebce1cb9-a48a-48da-b028-8803987ed8aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5c41c5bd-6c12-4387-b607-0e0d306bcd09" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_ebce1cb9-a48a-48da-b028-8803987ed8aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_4937047b-5d3e-4f70-a51b-9652fb0b2505" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_0de30a90-77c5-434e-9022-c93324431df2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_4937047b-5d3e-4f70-a51b-9652fb0b2505" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_0de30a90-77c5-434e-9022-c93324431df2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_0b8a3fe4-f63d-479c-80ce-b0ba668c5c08" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_4937047b-5d3e-4f70-a51b-9652fb0b2505" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_0b8a3fe4-f63d-479c-80ce-b0ba668c5c08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_a7ff47ab-2ec9-4ad0-9f0e-4f7643277b81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_1194f211-12cb-4d2c-8c6b-ddbd17156766" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_a7ff47ab-2ec9-4ad0-9f0e-4f7643277b81" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_1194f211-12cb-4d2c-8c6b-ddbd17156766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_d3b646e3-b752-41b5-ab7f-bb8b41c5abbe" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_a7ff47ab-2ec9-4ad0-9f0e-4f7643277b81" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_d3b646e3-b752-41b5-ab7f-bb8b41c5abbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_deb6b959-3032-45be-afcc-c1bfd1e30db5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_a7ff47ab-2ec9-4ad0-9f0e-4f7643277b81" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_deb6b959-3032-45be-afcc-c1bfd1e30db5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsNet_c01f2020-388a-435c-9745-34f49a153de8" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsGross_01a322f0-1e5f-4238-a24c-e6535ba98f93" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_FinancialRoyaltyAssetsNet_c01f2020-388a-435c-9745-34f49a153de8" xlink:to="loc_lgnd_FinancialRoyaltyAssetsGross_01a322f0-1e5f-4238-a24c-e6535ba98f93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsAllowance_e5f0d0e2-79b3-40b3-b1c2-af08a08f14da" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_FinancialRoyaltyAssetsNet_c01f2020-388a-435c-9745-34f49a153de8" xlink:to="loc_lgnd_FinancialRoyaltyAssetsAllowance_e5f0d0e2-79b3-40b3-b1c2-af08a08f14da" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsInvestmentCategoriesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6c8e74bf-9f0d-4115-aa4e-aaec4e1bbeba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_66aa6beb-0b59-4532-9fdf-63fd5585bf23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6c8e74bf-9f0d-4115-aa4e-aaec4e1bbeba" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_66aa6beb-0b59-4532-9fdf-63fd5585bf23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c2b01894-3613-45e7-a157-45294e886840" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6c8e74bf-9f0d-4115-aa4e-aaec4e1bbeba" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c2b01894-3613-45e7-a157-45294e886840" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c92da913-2064-4f2e-bf6d-ee562b0b821c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_6c8e74bf-9f0d-4115-aa4e-aaec4e1bbeba" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c92da913-2064-4f2e-bf6d-ee562b0b821c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_3479c327-d546-4ba7-8da1-585013eebf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_83b47444-8ba9-4c12-9426-248958198f52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_3479c327-d546-4ba7-8da1-585013eebf5c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_83b47444-8ba9-4c12-9426-248958198f52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_407bed04-b262-4f08-a3fd-3ca86c038b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_3479c327-d546-4ba7-8da1-585013eebf5c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_407bed04-b262-4f08-a3fd-3ca86c038b7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_e6cdba72-1134-4432-a75c-5e85b3b4dae1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_85e3040a-0773-4cf9-bc9d-29eaefd0fc96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_e6cdba72-1134-4432-a75c-5e85b3b4dae1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_85e3040a-0773-4cf9-bc9d-29eaefd0fc96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_340ac23b-dbdf-42ef-b686-3f3f6d79cff7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_e6cdba72-1134-4432-a75c-5e85b3b4dae1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_340ac23b-dbdf-42ef-b686-3f3f6d79cff7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_e610da6a-660c-41a0-bc1f-74d271b4b6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_5f6a77ce-b36b-4076-8bbb-7a4bdbd0b284" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_e610da6a-660c-41a0-bc1f-74d271b4b6a3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_5f6a77ce-b36b-4076-8bbb-7a4bdbd0b284" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f2c2f099-1a17-4068-999d-aa6f81696956" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_e610da6a-660c-41a0-bc1f-74d271b4b6a3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f2c2f099-1a17-4068-999d-aa6f81696956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_b683d600-ad49-40db-aa64-67d9da2a7c77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_1e778a06-0c41-41a7-8015-702216b77208" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_b683d600-ad49-40db-aa64-67d9da2a7c77" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_1e778a06-0c41-41a7-8015-702216b77208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_9f396fb6-6611-4c7c-a5bc-a67102904543" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_b683d600-ad49-40db-aa64-67d9da2a7c77" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_9f396fb6-6611-4c7c-a5bc-a67102904543" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_dde101f8-3065-491e-8ab8-a9907f93b8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_85313854-db1e-4498-a6f6-9635976b1b60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_dde101f8-3065-491e-8ab8-a9907f93b8b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_85313854-db1e-4498-a6f6-9635976b1b60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6ccda350-b954-430a-bffb-e128668dd21f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_dde101f8-3065-491e-8ab8-a9907f93b8b4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6ccda350-b954-430a-bffb-e128668dd21f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_70edb515-de87-4d6b-9179-1e2127c8a752" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_223df24e-9036-4883-836a-e0ffd669d039" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_70edb515-de87-4d6b-9179-1e2127c8a752" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_223df24e-9036-4883-836a-e0ffd669d039" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_871545e8-bd98-48ae-8e1b-4b38de0a7aea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_70edb515-de87-4d6b-9179-1e2127c8a752" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_871545e8-bd98-48ae-8e1b-4b38de0a7aea" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsInventoryinOtherAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5ea286e8-96f6-4726-ba88-daa4fefe32e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e925b18b-da56-46b3-83f9-f4a60c905b34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_5ea286e8-96f6-4726-ba88-daa4fefe32e2" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_e925b18b-da56-46b3-83f9-f4a60c905b34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_db48231d-8cae-4ca7-bf21-358103b9fe3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_5ea286e8-96f6-4726-ba88-daa4fefe32e2" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_db48231d-8cae-4ca7-bf21-358103b9fe3d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_dd2f9d4e-399d-40e2-9fe3-71d74fb9ea1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_2e1a3787-bd1a-498d-aa3a-a7d32f86e0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_dd2f9d4e-399d-40e2-9fe3-71d74fb9ea1b" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_2e1a3787-bd1a-498d-aa3a-a7d32f86e0f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_ee13325f-adc6-45f9-97ef-e85e9c18be89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_dd2f9d4e-399d-40e2-9fe3-71d74fb9ea1b" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_ee13325f-adc6-45f9-97ef-e85e9c18be89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSupplierExpensesCurrent_ca970669-ccf3-44be-829b-87f49409ff55" xlink:href="lgnd-20241231.xsd#lgnd_AccruedSupplierExpensesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_dd2f9d4e-399d-40e2-9fe3-71d74fb9ea1b" xlink:to="loc_lgnd_AccruedSupplierExpensesCurrent_ca970669-ccf3-44be-829b-87f49409ff55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSubcontractorExpensesCurrent_41e106e6-c674-406d-8671-f6b429719dc7" xlink:href="lgnd-20241231.xsd#lgnd_AccruedSubcontractorExpensesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_dd2f9d4e-399d-40e2-9fe3-71d74fb9ea1b" xlink:to="loc_lgnd_AccruedSubcontractorExpensesCurrent_41e106e6-c674-406d-8671-f6b429719dc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ed0a2f43-177f-4131-b091-fd13aac0096f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_dd2f9d4e-399d-40e2-9fe3-71d74fb9ea1b" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ed0a2f43-177f-4131-b091-fd13aac0096f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fdc425b1-eee2-4d73-be0c-48f94b0efcd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_dd2f9d4e-399d-40e2-9fe3-71d74fb9ea1b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_fdc425b1-eee2-4d73-be0c-48f94b0efcd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseeAccrualCurrent_769c0826-d9a7-4253-9c06-d73c1d6654d5" xlink:href="lgnd-20241231.xsd#lgnd_LicenseeAccrualCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_dd2f9d4e-399d-40e2-9fe3-71d74fb9ea1b" xlink:to="loc_lgnd_LicenseeAccrualCurrent_769c0826-d9a7-4253-9c06-d73c1d6654d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedCustomerDepositsCurrent_0abcb583-6766-42ed-a555-def8f91f7306" xlink:href="lgnd-20241231.xsd#lgnd_AccruedCustomerDepositsCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_dd2f9d4e-399d-40e2-9fe3-71d74fb9ea1b" xlink:to="loc_lgnd_AccruedCustomerDepositsCurrent_0abcb583-6766-42ed-a555-def8f91f7306" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ValueAddedTaxReceivableNetCurrent_48963f86-cf75-4e36-8d18-56409cb729c4" xlink:href="lgnd-20241231.xsd#lgnd_ValueAddedTaxReceivableNetCurrent"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_dd2f9d4e-399d-40e2-9fe3-71d74fb9ea1b" xlink:to="loc_lgnd_ValueAddedTaxReceivableNetCurrent_48963f86-cf75-4e36-8d18-56409cb729c4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_9d0a7d68-bfea-4fb2-837a-14b2688c6ced" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_60e985cb-2845-41c7-bfe4-2111fe52d45b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_9d0a7d68-bfea-4fb2-837a-14b2688c6ced" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_60e985cb-2845-41c7-bfe4-2111fe52d45b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_UnrecognizedTaxBenefitsNoncurrent_1f2c6846-16a2-4c7e-9678-f7026d0ea4b2" xlink:href="lgnd-20241231.xsd#lgnd_UnrecognizedTaxBenefitsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_9d0a7d68-bfea-4fb2-837a-14b2688c6ced" xlink:to="loc_lgnd_UnrecognizedTaxBenefitsNoncurrent_1f2c6846-16a2-4c7e-9678-f7026d0ea4b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_265283fe-4288-4f86-a41b-34f72c2aac9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_9d0a7d68-bfea-4fb2-837a-14b2688c6ced" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_265283fe-4288-4f86-a41b-34f72c2aac9b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_9b4efc9d-45da-49b4-b3fd-6d822efb9e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_c6814718-f5bd-40fd-8a67-1a27d07cb053" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_9b4efc9d-45da-49b4-b3fd-6d822efb9e7a" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_c6814718-f5bd-40fd-8a67-1a27d07cb053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_2573d502-a4ce-47af-9b66-29c9379c5682" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_fa2d0abe-8973-4a10-aa62-0a24af37643f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_2573d502-a4ce-47af-9b66-29c9379c5682" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_fa2d0abe-8973-4a10-aa62-0a24af37643f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_8ccb249f-bc77-4d5d-9539-85eadc745496" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_2573d502-a4ce-47af-9b66-29c9379c5682" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_8ccb249f-bc77-4d5d-9539-85eadc745496" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_2391211c-1bc0-41c3-970e-75cd7e4b7c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_2573d502-a4ce-47af-9b66-29c9379c5682" xlink:to="loc_us-gaap_DerivativeAssets_2391211c-1bc0-41c3-970e-75cd7e4b7c8c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiabilityCurrent_bfbd7d6c-0aa3-4884-8ba6-5c53a0ecf874" xlink:href="lgnd-20241231.xsd#lgnd_LeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c51bfac2-bf2c-403b-976d-e560123a30fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiabilityCurrent_bfbd7d6c-0aa3-4884-8ba6-5c53a0ecf874" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c51bfac2-bf2c-403b-976d-e560123a30fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_fa61b65c-a149-44e6-9476-c09c2bc64d11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiabilityCurrent_bfbd7d6c-0aa3-4884-8ba6-5c53a0ecf874" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_fa61b65c-a149-44e6-9476-c09c2bc64d11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseRightOfUseAsset_e6fb8aad-b3b9-4e16-a708-055fb5f4e419" xlink:href="lgnd-20241231.xsd#lgnd_LeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b092099a-1e80-4836-920c-53926221edd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseRightOfUseAsset_e6fb8aad-b3b9-4e16-a708-055fb5f4e419" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b092099a-1e80-4836-920c-53926221edd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_a22411f5-d039-4128-ac5e-93c104285c32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseRightOfUseAsset_e6fb8aad-b3b9-4e16-a708-055fb5f4e419" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_a22411f5-d039-4128-ac5e-93c104285c32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiability_87daec02-af6c-4f3a-872d-d24aabfe3ada" xlink:href="lgnd-20241231.xsd#lgnd_LeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiabilityCurrent_8da0fca1-c96b-4683-a27a-08f126a1e06f" xlink:href="lgnd-20241231.xsd#lgnd_LeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiability_87daec02-af6c-4f3a-872d-d24aabfe3ada" xlink:to="loc_lgnd_LeaseLiabilityCurrent_8da0fca1-c96b-4683-a27a-08f126a1e06f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8785a128-e291-4976-ad08-6a04279238ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiability_87daec02-af6c-4f3a-872d-d24aabfe3ada" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8785a128-e291-4976-ad08-6a04279238ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_94b66a4c-08a0-4b0e-9e9c-5edc0e57f726" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_lgnd_LeaseLiability_87daec02-af6c-4f3a-872d-d24aabfe3ada" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_94b66a4c-08a0-4b0e-9e9c-5edc0e57f726" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_41274e1a-7146-4492-a125-aca02057905a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_7097fef4-fc1d-41b1-8d4b-0953a2e70aaa" xlink:href="lgnd-20241231.xsd#lgnd_FinanceLeaseLiabilityTenantImprovementAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_41274e1a-7146-4492-a125-aca02057905a" xlink:to="loc_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_7097fef4-fc1d-41b1-8d4b-0953a2e70aaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_2a7c57cd-c43a-430a-bdf4-585e50e27436" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_41274e1a-7146-4492-a125-aca02057905a" xlink:to="loc_us-gaap_FinanceLeaseLiability_2a7c57cd-c43a-430a-bdf4-585e50e27436" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_f211d7c4-2ca6-4059-a782-ba89f149152d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_41274e1a-7146-4492-a125-aca02057905a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_f211d7c4-2ca6-4059-a782-ba89f149152d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44750f62-d1dc-482a-a5bd-e20cb9b9b195" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e0338f58-286b-4b69-99c4-71a86e96d334" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44750f62-d1dc-482a-a5bd-e20cb9b9b195" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e0338f58-286b-4b69-99c4-71a86e96d334" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_98a10d57-9629-4408-a62b-383d8d42e552" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44750f62-d1dc-482a-a5bd-e20cb9b9b195" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_98a10d57-9629-4408-a62b-383d8d42e552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_eedfc9c7-3317-4c77-ab48-62826ea79efd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44750f62-d1dc-482a-a5bd-e20cb9b9b195" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_eedfc9c7-3317-4c77-ab48-62826ea79efd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9254ba71-4937-4510-a823-ced5b12a14bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44750f62-d1dc-482a-a5bd-e20cb9b9b195" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9254ba71-4937-4510-a823-ced5b12a14bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_b6026fba-da13-4f3e-8587-2b8ceb37155e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44750f62-d1dc-482a-a5bd-e20cb9b9b195" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_b6026fba-da13-4f3e-8587-2b8ceb37155e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b33ff48a-7fe0-4869-92fc-7692e5b0ad9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44750f62-d1dc-482a-a5bd-e20cb9b9b195" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b33ff48a-7fe0-4869-92fc-7692e5b0ad9f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="lgnd-20241231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_646357d7-38a6-4c6c-af95-8f377a4d1638" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_bff1d3b4-454d-4079-bf41-d1c8706dada6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_646357d7-38a6-4c6c-af95-8f377a4d1638" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_bff1d3b4-454d-4079-bf41-d1c8706dada6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_c3fa23f8-472a-41b1-a0f9-8c02a4ea5d67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_646357d7-38a6-4c6c-af95-8f377a4d1638" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_c3fa23f8-472a-41b1-a0f9-8c02a4ea5d67" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_11afdf20-912e-4d20-948e-9309052a5423" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_646357d7-38a6-4c6c-af95-8f377a4d1638" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_11afdf20-912e-4d20-948e-9309052a5423" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_4fb1f38c-c615-4a44-9529-82da4a0bc9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_646357d7-38a6-4c6c-af95-8f377a4d1638" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_4fb1f38c-c615-4a44-9529-82da4a0bc9c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_780bd84c-e9df-44a0-bb0a-03722a1b2021" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_646357d7-38a6-4c6c-af95-8f377a4d1638" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_780bd84c-e9df-44a0-bb0a-03722a1b2021" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_bfbc3063-6b5c-4c6b-8eca-42258ef63cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_646357d7-38a6-4c6c-af95-8f377a4d1638" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_bfbc3063-6b5c-4c6b-8eca-42258ef63cd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4df17b29-9036-446b-8b4e-de52436a1b78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance_02af1124-0db3-498d-9d1e-bccd3199672c" xlink:href="lgnd-20241231.xsd#lgnd_OperatingLeaseLiabilityTenantImprovementAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4df17b29-9036-446b-8b4e-de52436a1b78" xlink:to="loc_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance_02af1124-0db3-498d-9d1e-bccd3199672c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d53b1236-ce2b-4ad7-b540-7e7653fae584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4df17b29-9036-446b-8b4e-de52436a1b78" xlink:to="loc_us-gaap_OperatingLeaseLiability_d53b1236-ce2b-4ad7-b540-7e7653fae584" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6efe44ac-0736-462c-bb8d-79d0db831fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_4df17b29-9036-446b-8b4e-de52436a1b78" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6efe44ac-0736-462c-bb8d-79d0db831fdd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_437abcfd-d714-417b-867e-58fe1ebaa452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8eeeb023-015d-465d-b3d2-462e535fc949" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_437abcfd-d714-417b-867e-58fe1ebaa452" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_8eeeb023-015d-465d-b3d2-462e535fc949" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f923ea7d-f2c0-4635-8795-4e18d3631e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_437abcfd-d714-417b-867e-58fe1ebaa452" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f923ea7d-f2c0-4635-8795-4e18d3631e0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d1320c18-caf3-4fe6-a75e-74918c8be67f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_db092c87-071d-49b7-a052-fbda05e6282c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d1320c18-caf3-4fe6-a75e-74918c8be67f" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_db092c87-071d-49b7-a052-fbda05e6282c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_84c30053-77ee-43bc-ab09-8891700dd418" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d1320c18-caf3-4fe6-a75e-74918c8be67f" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_84c30053-77ee-43bc-ab09-8891700dd418" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2019bc5f-e192-446b-999d-359b838d8f92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d1320c18-caf3-4fe6-a75e-74918c8be67f" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2019bc5f-e192-446b-999d-359b838d8f92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9100e534-c2d6-4f8c-854b-c9aba90ee162" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_bbed3bd9-fc7a-4875-bc7a-f5bf6eb922fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9100e534-c2d6-4f8c-854b-c9aba90ee162" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_bbed3bd9-fc7a-4875-bc7a-f5bf6eb922fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8ea3a7d9-ddeb-4771-bf5e-21b433fd205c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9100e534-c2d6-4f8c-854b-c9aba90ee162" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8ea3a7d9-ddeb-4771-bf5e-21b433fd205c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_74c58f41-48e7-4de9-a396-a19cbee87a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_9100e534-c2d6-4f8c-854b-c9aba90ee162" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_74c58f41-48e7-4de9-a396-a19cbee87a3c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1ba339b4-0183-4876-af7b-8c0614a0129e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome_0f8347c5-d360-4770-be54-151fd8ffd04e" xlink:href="lgnd-20241231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ba339b4-0183-4876-af7b-8c0614a0129e" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome_0f8347c5-d360-4770-be54-151fd8ffd04e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_655626f8-c798-425e-b0f7-4d771e556f99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ba339b4-0183-4876-af7b-8c0614a0129e" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_655626f8-c798-425e-b0f7-4d771e556f99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_a54b0d73-5fe0-488f-80eb-37b7ee1a4e13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ba339b4-0183-4876-af7b-8c0614a0129e" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_a54b0d73-5fe0-488f-80eb-37b7ee1a4e13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_31bf0a10-318b-4ed2-bf89-f176780a5ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ba339b4-0183-4876-af7b-8c0614a0129e" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_31bf0a10-318b-4ed2-bf89-f176780a5ac5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_19ea0704-1f50-4a64-bb10-ae61247b6a23" xlink:href="lgnd-20241231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ba339b4-0183-4876-af7b-8c0614a0129e" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_19ea0704-1f50-4a64-bb10-ae61247b6a23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount_a86a5517-9ee2-48a3-b80e-00df1b1e3a87" xlink:href="lgnd-20241231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ba339b4-0183-4876-af7b-8c0614a0129e" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount_a86a5517-9ee2-48a3-b80e-00df1b1e3a87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_b0245aaf-6d86-463b-82a6-f95353fd0689" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ba339b4-0183-4876-af7b-8c0614a0129e" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_b0245aaf-6d86-463b-82a6-f95353fd0689" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_75d4b577-174a-4fea-8b3a-10ecd5ec2e79" xlink:href="lgnd-20241231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ba339b4-0183-4876-af7b-8c0614a0129e" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_75d4b577-174a-4fea-8b3a-10ecd5ec2e79" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount_7d680354-c247-4934-b444-f91f2098b7db" xlink:href="lgnd-20241231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ba339b4-0183-4876-af7b-8c0614a0129e" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount_7d680354-c247-4934-b444-f91f2098b7db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_7549dc64-f456-400c-9c01-d93e2d60b217" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ba339b4-0183-4876-af7b-8c0614a0129e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_7549dc64-f456-400c-9c01-d93e2d60b217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5c31028a-b552-4b6a-840e-b4b67cf2d06e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ba339b4-0183-4876-af7b-8c0614a0129e" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5c31028a-b552-4b6a-840e-b4b67cf2d06e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationContingentValueRights_5b61ab2a-d447-4f40-833c-c0455823b987" xlink:href="lgnd-20241231.xsd#lgnd_IncomeTaxReconciliationContingentValueRights"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ba339b4-0183-4876-af7b-8c0614a0129e" xlink:to="loc_lgnd_IncomeTaxReconciliationContingentValueRights_5b61ab2a-d447-4f40-833c-c0455823b987" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c0536960-d8cb-4b2b-bcfa-6dc4ff4c2ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ba339b4-0183-4876-af7b-8c0614a0129e" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_c0536960-d8cb-4b2b-bcfa-6dc4ff4c2ee1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_50e5235c-1230-402b-9dee-2def3d289d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ba339b4-0183-4876-af7b-8c0614a0129e" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_50e5235c-1230-402b-9dee-2def3d289d3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_8923991f-7b77-40f3-9707-26cf894ac7f3" xlink:href="lgnd-20241231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ba339b4-0183-4876-af7b-8c0614a0129e" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_8923991f-7b77-40f3-9707-26cf894ac7f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_a193a06b-d49a-47f4-8edc-515fa85880eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ba339b4-0183-4876-af7b-8c0614a0129e" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_a193a06b-d49a-47f4-8edc-515fa85880eb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#IncomeTaxesDeferredTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_a4c66898-f79e-4a3e-ba7a-eb04e40a99f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_fd592fe3-4b9f-4627-898e-1309bfe8fd85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_a4c66898-f79e-4a3e-ba7a-eb04e40a99f2" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_fd592fe3-4b9f-4627-898e-1309bfe8fd85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_e42e1e95-0a4d-47a1-bd2a-ea402c595f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_a4c66898-f79e-4a3e-ba7a-eb04e40a99f2" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_e42e1e95-0a4d-47a1-bd2a-ea402c595f3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_39a663dc-c87b-4880-8655-3312504ed196" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_4552d0e3-f9d6-4582-9fe8-5815b9229667" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_39a663dc-c87b-4880-8655-3312504ed196" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_4552d0e3-f9d6-4582-9fe8-5815b9229667" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_34eefeba-9cad-47c0-82d2-6f43b50a2893" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_39a663dc-c87b-4880-8655-3312504ed196" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_34eefeba-9cad-47c0-82d2-6f43b50a2893" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_57e27234-64ab-4f34-8b18-5fed572b59c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_e0771fb4-bcc4-4708-8939-c4a703cd7c04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_57e27234-64ab-4f34-8b18-5fed572b59c3" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_e0771fb4-bcc4-4708-8939-c4a703cd7c04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9f49638a-7c80-42d8-a150-0af03a9f5785" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_57e27234-64ab-4f34-8b18-5fed572b59c3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_9f49638a-7c80-42d8-a150-0af03a9f5785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_184e750f-55c1-4cc2-936f-4b2e9820fd04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_57e27234-64ab-4f34-8b18-5fed572b59c3" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_184e750f-55c1-4cc2-936f-4b2e9820fd04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_49aae10e-0ecd-4663-83dc-451f25e2ddb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_57e27234-64ab-4f34-8b18-5fed572b59c3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_49aae10e-0ecd-4663-83dc-451f25e2ddb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment_efefdce3-2193-4051-9374-b31cd82f3513" xlink:href="lgnd-20241231.xsd#lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_57e27234-64ab-4f34-8b18-5fed572b59c3" xlink:to="loc_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment_efefdce3-2193-4051-9374-b31cd82f3513" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ddea0a49-28ae-46fe-8b70-448781b5bbdd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_39529192-8f72-4571-b600-eadabf2d1cb9" xlink:href="lgnd-20241231.xsd#lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_ddea0a49-28ae-46fe-8b70-448781b5bbdd" xlink:to="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_39529192-8f72-4571-b600-eadabf2d1cb9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_f48b1784-f133-44ab-b33d-7594c0dea1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_ddea0a49-28ae-46fe-8b70-448781b5bbdd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_f48b1784-f133-44ab-b33d-7594c0dea1b0" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>lgnd-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:8c134d1d-ab0c-4379-9892-d916b4e62e37,g:28b275e3-fcb1-4a6c-a0ef-95ede04b9eea-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lgnd-20241231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ec366523-c2fd-455a-b09a-9e269b6d0ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_StatementTable_ec366523-c2fd-455a-b09a-9e269b6d0ee4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0fad5cdd-f19c-4613-b4ec-3c4cee759a0a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_ec366523-c2fd-455a-b09a-9e269b6d0ee4" xlink:to="loc_srt_ProductOrServiceAxis_0fad5cdd-f19c-4613-b4ec-3c4cee759a0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0fad5cdd-f19c-4613-b4ec-3c4cee759a0a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0fad5cdd-f19c-4613-b4ec-3c4cee759a0a" xlink:to="loc_srt_ProductsAndServicesDomain_0fad5cdd-f19c-4613-b4ec-3c4cee759a0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eb2bcab4-04a1-45ad-88ca-62afd73f62cb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0fad5cdd-f19c-4613-b4ec-3c4cee759a0a" xlink:to="loc_srt_ProductsAndServicesDomain_eb2bcab4-04a1-45ad-88ca-62afd73f62cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_e941b5ef-388f-4e5f-bd81-47f8fedaa68d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eb2bcab4-04a1-45ad-88ca-62afd73f62cb" xlink:to="loc_us-gaap_RoyaltyMember_e941b5ef-388f-4e5f-bd81-47f8fedaa68d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IntangibleRoyaltyAssetsMember_40c5f2cd-16e9-4068-8fef-5f837c821165" xlink:href="lgnd-20241231.xsd#lgnd_IntangibleRoyaltyAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_e941b5ef-388f-4e5f-bd81-47f8fedaa68d" xlink:to="loc_lgnd_IntangibleRoyaltyAssetsMember_40c5f2cd-16e9-4068-8fef-5f837c821165" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsMember_72d4d273-0994-471b-9ee2-9b69de8c8821" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_e941b5ef-388f-4e5f-bd81-47f8fedaa68d" xlink:to="loc_lgnd_FinancialRoyaltyAssetsMember_72d4d273-0994-471b-9ee2-9b69de8c8821" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_dbe3d144-927d-4df4-8d08-8f91340ee5f1" xlink:href="lgnd-20241231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eb2bcab4-04a1-45ad-88ca-62afd73f62cb" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_dbe3d144-927d-4df4-8d08-8f91340ee5f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueAndOtherIncomeMember_3e8a4a6f-5e4b-442b-b767-1e1062ac38be" xlink:href="lgnd-20241231.xsd#lgnd_ContractRevenueAndOtherIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_eb2bcab4-04a1-45ad-88ca-62afd73f62cb" xlink:to="loc_lgnd_ContractRevenueAndOtherIncomeMember_3e8a4a6f-5e4b-442b-b767-1e1062ac38be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_685b96e0-8eec-48de-a36f-407a4e55a701" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_RevenuesAbstract_685b96e0-8eec-48de-a36f-407a4e55a701" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_35934040-568f-468c-89e0-ed3a4ff2d9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_685b96e0-8eec-48de-a36f-407a4e55a701" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_35934040-568f-468c-89e0-ed3a4ff2d9a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_342aac4c-ca2f-4f6d-848e-3b2557432bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_342aac4c-ca2f-4f6d-848e-3b2557432bfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial_29d8897d-8f84-4540-b7ad-ed78ce8d37e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostDirectMaterial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_342aac4c-ca2f-4f6d-848e-3b2557432bfb" xlink:to="loc_us-gaap_CostDirectMaterial_29d8897d-8f84-4540-b7ad-ed78ce8d37e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_18505dcd-ebe3-4103-84ae-ce02e4c580ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_342aac4c-ca2f-4f6d-848e-3b2557432bfb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_18505dcd-ebe3-4103-84ae-ce02e4c580ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_558a2660-a0ce-4110-95f5-24d849edad0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_342aac4c-ca2f-4f6d-848e-3b2557432bfb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_558a2660-a0ce-4110-95f5-24d849edad0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_cc8cd605-24a8-4ae1-b758-d412e379e52c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_342aac4c-ca2f-4f6d-848e-3b2557432bfb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_cc8cd605-24a8-4ae1-b758-d412e379e52c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c877132f-1fcd-4b77-a80f-a917b6c8aaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_342aac4c-ca2f-4f6d-848e-3b2557432bfb" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c877132f-1fcd-4b77-a80f-a917b6c8aaf4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_3384e06c-21bf-41f6-bd84-980b66d9f5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_342aac4c-ca2f-4f6d-848e-3b2557432bfb" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_3384e06c-21bf-41f6-bd84-980b66d9f5e4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_0950f046-f818-44b1-af80-d700bad7f315" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_342aac4c-ca2f-4f6d-848e-3b2557432bfb" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_0950f046-f818-44b1-af80-d700bad7f315" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_3005550d-a81d-4be3-871b-db649b6aab0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_3005550d-a81d-4be3-871b-db649b6aab0a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_74941871-ffe0-4f97-b9bb-2ba1bb8d48d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_OperatingIncomeLoss_74941871-ffe0-4f97-b9bb-2ba1bb8d48d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_97cc24fb-25bb-485c-9045-c02d3ea1e544" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_97cc24fb-25bb-485c-9045-c02d3ea1e544" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_096e9d5e-1de3-4c52-8621-a04b1bb79ada" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_97cc24fb-25bb-485c-9045-c02d3ea1e544" xlink:to="loc_us-gaap_GainLossOnInvestments_096e9d5e-1de3-4c52-8621-a04b1bb79ada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_89495922-f4af-4919-bfa4-68c52f247997" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_97cc24fb-25bb-485c-9045-c02d3ea1e544" xlink:to="loc_us-gaap_InvestmentIncomeInterest_89495922-f4af-4919-bfa4-68c52f247997" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_e811ae35-195a-4ad3-92cc-8d1446db02ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_97cc24fb-25bb-485c-9045-c02d3ea1e544" xlink:to="loc_us-gaap_InterestExpenseNonoperating_e811ae35-195a-4ad3-92cc-8d1446db02ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6a19f033-f94b-4012-a5f8-e15e9630fbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_97cc24fb-25bb-485c-9045-c02d3ea1e544" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6a19f033-f94b-4012-a5f8-e15e9630fbeb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8de67a66-99f1-4f90-8a30-3fe6077a9387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_97cc24fb-25bb-485c-9045-c02d3ea1e544" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8de67a66-99f1-4f90-8a30-3fe6077a9387" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_730ad9af-a391-4418-b3d6-44dd8a3a0855" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_730ad9af-a391-4418-b3d6-44dd8a3a0855" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a8669c98-b4a3-47b0-8b05-bc83fe849f29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a8669c98-b4a3-47b0-8b05-bc83fe849f29" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_0f854bc0-3c01-4c46-b8cf-880143c2f3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_0f854bc0-3c01-4c46-b8cf-880143c2f3f1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b7d6c9db-edc2-46fc-9bb8-bd7028742f35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b7d6c9db-edc2-46fc-9bb8-bd7028742f35" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_319b5f7b-1ae4-42d8-a038-a5adc080e30f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_NetIncomeLoss_319b5f7b-1ae4-42d8-a038-a5adc080e30f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b0658d0b-79d5-49d6-bbad-3822e2fdcddb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b0658d0b-79d5-49d6-bbad-3822e2fdcddb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_cd0d5516-862d-4c03-93d2-422760d17de9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_cd0d5516-862d-4c03-93d2-422760d17de9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7b8a96aa-556f-4124-9964-1d711a99b996" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_EarningsPerShareBasic_7b8a96aa-556f-4124-9964-1d711a99b996" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_581e1a8a-2c8f-4281-af30-827b5db38ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_581e1a8a-2c8f-4281-af30-827b5db38ea9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_7e020a7d-b135-488f-98c7-ead42f15dd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_7e020a7d-b135-488f-98c7-ead42f15dd3f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_1a81cb7b-e0ac-48f1-a226-db044ad5bd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_1a81cb7b-e0ac-48f1-a226-db044ad5bd3b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6829d89a-de6f-450a-a435-4b03fc7d51c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6829d89a-de6f-450a-a435-4b03fc7d51c1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_03e2b33b-ffe2-4e3f-a991-054dcd6e48b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_03e2b33b-ffe2-4e3f-a991-054dcd6e48b6" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="lgnd-20241231.xsd#CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4f289711-1f24-42d6-bfc1-dc4d47d93cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4fb5a648-e8f3-4025-94a1-91fd991505b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_4f289711-1f24-42d6-bfc1-dc4d47d93cbe" xlink:to="loc_us-gaap_StatementTable_4fb5a648-e8f3-4025-94a1-91fd991505b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6d1fd264-c0aa-4753-bdcd-5b51cc4a8f20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4fb5a648-e8f3-4025-94a1-91fd991505b1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6d1fd264-c0aa-4753-bdcd-5b51cc4a8f20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6d1fd264-c0aa-4753-bdcd-5b51cc4a8f20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6d1fd264-c0aa-4753-bdcd-5b51cc4a8f20" xlink:to="loc_us-gaap_EquityComponentDomain_6d1fd264-c0aa-4753-bdcd-5b51cc4a8f20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_76e4c569-4d7c-446e-b243-9d7775e6954c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6d1fd264-c0aa-4753-bdcd-5b51cc4a8f20" xlink:to="loc_us-gaap_EquityComponentDomain_76e4c569-4d7c-446e-b243-9d7775e6954c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e968c2ce-1f59-462c-b02d-90288aceb7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_76e4c569-4d7c-446e-b243-9d7775e6954c" xlink:to="loc_us-gaap_CommonStockMember_e968c2ce-1f59-462c-b02d-90288aceb7a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d4abef03-2180-4868-93cb-19bb1a04563e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_76e4c569-4d7c-446e-b243-9d7775e6954c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d4abef03-2180-4868-93cb-19bb1a04563e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_172781f6-b056-4b46-8f8e-f144af5b4506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_76e4c569-4d7c-446e-b243-9d7775e6954c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_172781f6-b056-4b46-8f8e-f144af5b4506" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_100679af-0242-48fd-9b1b-4e0c3919678b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_76e4c569-4d7c-446e-b243-9d7775e6954c" xlink:to="loc_us-gaap_RetainedEarningsMember_100679af-0242-48fd-9b1b-4e0c3919678b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cefb75b0-536d-47ad-a46c-3976f39def60" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4fb5a648-e8f3-4025-94a1-91fd991505b1" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cefb75b0-536d-47ad-a46c-3976f39def60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_cefb75b0-536d-47ad-a46c-3976f39def60_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cefb75b0-536d-47ad-a46c-3976f39def60" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_cefb75b0-536d-47ad-a46c-3976f39def60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c27bc332-df51-414d-b61c-b890ff65ca50" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cefb75b0-536d-47ad-a46c-3976f39def60" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c27bc332-df51-414d-b61c-b890ff65ca50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4025b45a-7b38-4eca-afc5-38a223cde0d5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c27bc332-df51-414d-b61c-b890ff65ca50" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4025b45a-7b38-4eca-afc5-38a223cde0d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_4f289711-1f24-42d6-bfc1-dc4d47d93cbe" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8c26cdc7-a7c4-4be5-ad46-d62a78ceeffd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8c26cdc7-a7c4-4be5-ad46-d62a78ceeffd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3582ff2a-bb0c-4ab6-bd9f-20bc156d5a58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_StockholdersEquity_3582ff2a-bb0c-4ab6-bd9f-20bc156d5a58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_33f6a3da-84c2-495f-8cfc-060774d95982" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_33f6a3da-84c2-495f-8cfc-060774d95982" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c0bcaf32-c518-4ee6-a3f2-28ca5a9b038f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c0bcaf32-c518-4ee6-a3f2-28ca5a9b038f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2433e666-254f-4679-8137-35f5fcc19687" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2433e666-254f-4679-8137-35f5fcc19687" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6fa062db-06ef-40db-9d61-5d450d339401" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6fa062db-06ef-40db-9d61-5d450d339401" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0db395f7-aa0f-452e-94f4-af4a41beb42a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0db395f7-aa0f-452e-94f4-af4a41beb42a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_967d6a2c-85e2-4d9c-98ae-d8831c61becb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_967d6a2c-85e2-4d9c-98ae-d8831c61becb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d9d467d8-333b-4f8e-a4d9-d52de9819751" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d9d467d8-333b-4f8e-a4d9-d52de9819751" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction_4a06e686-2c71-4997-b7de-c0f38a6fe673" xlink:href="lgnd-20241231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction_4a06e686-2c71-4997-b7de-c0f38a6fe673" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation_33fd9c2d-263e-4178-a54c-f06b651069e0" xlink:href="lgnd-20241231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation_33fd9c2d-263e-4178-a54c-f06b651069e0" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation_35e82f8a-75cc-40ee-854c-e74ca5f1c68a" xlink:href="lgnd-20241231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation_35e82f8a-75cc-40ee-854c-e74ca5f1c68a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision_f3ddce9a-b53e-413b-8635-303117b9ae1a" xlink:href="lgnd-20241231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision_f3ddce9a-b53e-413b-8635-303117b9ae1a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3855f016-2d2a-4695-b3c3-28a692d8764f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_NetIncomeLoss_3855f016-2d2a-4695-b3c3-28a692d8764f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9b1c3f5c-65d8-4c07-b785-8557d5dc39b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8e4ef09f-eac3-42c1-83d6-75c59e01d308" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lgnd-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bd8ed404-59d7-4453-a0c8-2ec5f690ef79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_StatementTable_bd8ed404-59d7-4453-a0c8-2ec5f690ef79" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_af317fc1-7316-4725-a8f5-40ffbf3bd3ee" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_bd8ed404-59d7-4453-a0c8-2ec5f690ef79" xlink:to="loc_srt_OwnershipAxis_af317fc1-7316-4725-a8f5-40ffbf3bd3ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_af317fc1-7316-4725-a8f5-40ffbf3bd3ee_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_af317fc1-7316-4725-a8f5-40ffbf3bd3ee" xlink:to="loc_srt_OwnershipDomain_af317fc1-7316-4725-a8f5-40ffbf3bd3ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_7668555f-f2a8-4959-ac8b-db32df494097" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_af317fc1-7316-4725-a8f5-40ffbf3bd3ee" xlink:to="loc_srt_OwnershipDomain_7668555f-f2a8-4959-ac8b-db32df494097" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NucorionMember_4f706fa7-1061-451f-a376-907638bd78e0" xlink:href="lgnd-20241231.xsd#lgnd_NucorionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_7668555f-f2a8-4959-ac8b-db32df494097" xlink:to="loc_lgnd_NucorionMember_4f706fa7-1061-451f-a376-907638bd78e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember_ebe068f4-1fac-40ad-90a3-e2912065e368" xlink:href="lgnd-20241231.xsd#lgnd_PrimroseBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_7668555f-f2a8-4959-ac8b-db32df494097" xlink:to="loc_lgnd_PrimroseBioMember_ebe068f4-1fac-40ad-90a3-e2912065e368" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1853032e-425b-410a-918e-9b950e7979f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_bd8ed404-59d7-4453-a0c8-2ec5f690ef79" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1853032e-425b-410a-918e-9b950e7979f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1853032e-425b-410a-918e-9b950e7979f8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1853032e-425b-410a-918e-9b950e7979f8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1853032e-425b-410a-918e-9b950e7979f8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36c3465f-adb2-40d8-b1a2-dab8ad46f1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1853032e-425b-410a-918e-9b950e7979f8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36c3465f-adb2-40d8-b1a2-dab8ad46f1c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_APEIRONMember_78ce6ef9-36f6-4963-9690-e4018a03bd04" xlink:href="lgnd-20241231.xsd#lgnd_APEIRONMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36c3465f-adb2-40d8-b1a2-dab8ad46f1c8" xlink:to="loc_lgnd_APEIRONMember_78ce6ef9-36f6-4963-9690-e4018a03bd04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanIncMember_091e3885-40cd-4020-81e1-e0520da596f2" xlink:href="lgnd-20241231.xsd#lgnd_NovanIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36c3465f-adb2-40d8-b1a2-dab8ad46f1c8" xlink:to="loc_lgnd_NovanIncMember_091e3885-40cd-4020-81e1-e0520da596f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9a57d541-4ad1-443a-933d-15a7363b1169" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9a57d541-4ad1-443a-933d-15a7363b1169" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fed767c0-c2ad-4c3a-bc18-4fb473741316" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9a57d541-4ad1-443a-933d-15a7363b1169" xlink:to="loc_us-gaap_NetIncomeLoss_fed767c0-c2ad-4c3a-bc18-4fb473741316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9a57d541-4ad1-443a-933d-15a7363b1169" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_043acf63-b498-40aa-b575-14b8a850ac41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_043acf63-b498-40aa-b575-14b8a850ac41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_0b6fbd5f-290f-4009-9341-80c55a846fd2" xlink:href="lgnd-20241231.xsd#lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_0b6fbd5f-290f-4009-9341-80c55a846fd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f84e687c-2d82-4543-b542-f67df8cdba82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f84e687c-2d82-4543-b542-f67df8cdba82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_GainLossOnShortTermInvestments_9c60540b-6959-49e5-9917-c266d214bc14" xlink:href="lgnd-20241231.xsd#lgnd_GainLossOnShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_lgnd_GainLossOnShortTermInvestments_9c60540b-6959-49e5-9917-c266d214bc14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ca1c0886-6c63-41ed-a846-6a244902fd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ca1c0886-6c63-41ed-a846-6a244902fd2b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4ea2efea-5bf5-48d4-aa7e-1649a4253f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4ea2efea-5bf5-48d4-aa7e-1649a4253f8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_064be873-89f6-4324-aeb4-a2e696892cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_064be873-89f6-4324-aeb4-a2e696892cd0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_db70070d-f9a6-455e-9ab7-9f1c96f70f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_db70070d-f9a6-455e-9ab7-9f1c96f70f5c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashIncomeFromFinancialRoyaltyAssets_740de040-7f14-47a4-b1bd-dd7427a7b04b" xlink:href="lgnd-20241231.xsd#lgnd_NonCashIncomeFromFinancialRoyaltyAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_lgnd_NonCashIncomeFromFinancialRoyaltyAssets_740de040-7f14-47a4-b1bd-dd7427a7b04b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CurrentAndExpectedCreditLossAdjustment_dbf6f8f8-fc57-4c97-9384-9e95e6ff4466" xlink:href="lgnd-20241231.xsd#lgnd_CurrentAndExpectedCreditLossAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_lgnd_CurrentAndExpectedCreditLossAdjustment_dbf6f8f8-fc57-4c97-9384-9e95e6ff4466" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ImpairmentLossOnFinancialRoyaltyAssets_4a5c84b3-56df-43bd-afae-51f9ce067148" xlink:href="lgnd-20241231.xsd#lgnd_ImpairmentLossOnFinancialRoyaltyAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_lgnd_ImpairmentLossOnFinancialRoyaltyAssets_4a5c84b3-56df-43bd-afae-51f9ce067148" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization_b961f09c-0095-449d-a3cd-fb0b25072a12" xlink:href="lgnd-20241231.xsd#lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization_b961f09c-0095-449d-a3cd-fb0b25072a12" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_59cabd7c-2458-4992-bfe9-9b429a97ebd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_ShareBasedCompensation_59cabd7c-2458-4992-bfe9-9b429a97ebd7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_38c7c1aa-aa42-4454-8618-2949862d881f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_38c7c1aa-aa42-4454-8618-2949862d881f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_bc536292-d94a-4300-9449-83cca512640e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_bc536292-d94a-4300-9449-83cca512640e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_0c9c8231-a40a-43bf-8284-98b77e42bb24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_0c9c8231-a40a-43bf-8284-98b77e42bb24" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_45ecb04a-2847-4e5f-b859-7ac6174e2803" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_45ecb04a-2847-4e5f-b859-7ac6174e2803" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e11cfe06-c6cd-4283-beba-da0f1ffef8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e11cfe06-c6cd-4283-beba-da0f1ffef8ab" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cc8f714a-9670-4e3f-971e-277556f7cce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e11cfe06-c6cd-4283-beba-da0f1ffef8ab" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cc8f714a-9670-4e3f-971e-277556f7cce4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_38bff757-2f53-4c05-b064-2954e4924cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e11cfe06-c6cd-4283-beba-da0f1ffef8ab" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_38bff757-2f53-4c05-b064-2954e4924cc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_2514b1d0-42e1-45e3-9618-6b0490db6559" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e11cfe06-c6cd-4283-beba-da0f1ffef8ab" xlink:to="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_2514b1d0-42e1-45e3-9618-6b0490db6559" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ec7cde7f-a566-4944-a279-a4e606c2f736" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e11cfe06-c6cd-4283-beba-da0f1ffef8ab" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ec7cde7f-a566-4944-a279-a4e606c2f736" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_6cec93d1-c497-4c08-bc66-536ee030c612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e11cfe06-c6cd-4283-beba-da0f1ffef8ab" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_6cec93d1-c497-4c08-bc66-536ee030c612" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e7b0da38-f430-4963-9985-8b30f4c8fc38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e11cfe06-c6cd-4283-beba-da0f1ffef8ab" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e7b0da38-f430-4963-9985-8b30f4c8fc38" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_fdc0b892-cd60-47b8-947f-7f0b8b7f6d60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e11cfe06-c6cd-4283-beba-da0f1ffef8ab" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_fdc0b892-cd60-47b8-947f-7f0b8b7f6d60" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8ae574-00f2-4283-98e2-7518854e8139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9a57d541-4ad1-443a-933d-15a7363b1169" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8ae574-00f2-4283-98e2-7518854e8139" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToAcquireFinancialRoyaltyAssets_c98a8bd6-93c1-4fd0-acbd-aeb39479b9d5" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsToAcquireFinancialRoyaltyAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_lgnd_PaymentsToAcquireFinancialRoyaltyAssets_c98a8bd6-93c1-4fd0-acbd-aeb39479b9d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromFinancialRoyaltyAssets_b875bb58-777c-4a83-a6e9-512650068a02" xlink:href="lgnd-20241231.xsd#lgnd_ProceedsFromFinancialRoyaltyAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_lgnd_ProceedsFromFinancialRoyaltyAssets_b875bb58-777c-4a83-a6e9-512650068a02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9373d096-bcaa-4d04-ac13-b7101994f131" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9373d096-bcaa-4d04-ac13-b7101994f131" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_e0f77ed0-4f37-4542-946f-c32f4d524e74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_e0f77ed0-4f37-4542-946f-c32f4d524e74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_a092d61d-dec5-4b48-b1fe-8f91d52e5759" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_a092d61d-dec5-4b48-b1fe-8f91d52e5759" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_c8b8750d-c3a8-4cd2-90b1-f55ecefa81c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_c8b8750d-c3a8-4cd2-90b1-f55ecefa81c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_da16297d-d423-432c-b145-c1209dee8907" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_da16297d-d423-432c-b145-c1209dee8907" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_4e6ae19b-0a58-4d5f-88c3-768f45edaf78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_4e6ae19b-0a58-4d5f-88c3-768f45edaf78" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_fb3f20a8-132c-4655-8b76-95eaf922b11f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_fb3f20a8-132c-4655-8b76-95eaf922b11f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentInvestingActivities_e398a77e-fecd-4370-ba4e-35940c79ab91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForDerivativeInstrumentInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentInvestingActivities_e398a77e-fecd-4370-ba4e-35940c79ab91" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_8cbe4544-d053-40a0-a133-d1d41a2e5bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_8cbe4544-d053-40a0-a133-d1d41a2e5bd4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_ab97978d-54c6-44b6-8be2-a70095a3f4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_ab97978d-54c6-44b6-8be2-a70095a3f4a0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_c080c07e-2f15-4d0e-8d95-6e9118df7318" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_c080c07e-2f15-4d0e-8d95-6e9118df7318" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6fa5de85-f501-4e74-b5df-c1be10c6981f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6fa5de85-f501-4e74-b5df-c1be10c6981f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0bb9819-216e-4b7f-ae8b-aad4a05936ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0bb9819-216e-4b7f-ae8b-aad4a05936ab" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_aa854855-f30d-4d37-ac3c-26d75c55434e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_aa854855-f30d-4d37-ac3c-26d75c55434e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsForSeparation_06cc7831-9334-4412-b685-f224227c27b3" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsForSeparation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_lgnd_PaymentsForSeparation_06cc7831-9334-4412-b685-f224227c27b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_3cfd7234-3b46-4622-94bf-7074806f1ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_3cfd7234-3b46-4622-94bf-7074806f1ecc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_beb8abed-72ad-495d-b3ed-16ec3e799db1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_beb8abed-72ad-495d-b3ed-16ec3e799db1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_3e5ca1f3-84a3-47b4-8d5e-7b8972edac53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_3e5ca1f3-84a3-47b4-8d5e-7b8972edac53" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_4f3c26a2-c444-4e45-b90c-cb9ab99741e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_4f3c26a2-c444-4e45-b90c-cb9ab99741e2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities_0fcf35d9-bb87-45f3-9fd3-e61f8ffb519b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_us-gaap_ProceedsFromHedgeFinancingActivities_0fcf35d9-bb87-45f3-9fd3-e61f8ffb519b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ac8915bb-36b5-4595-be3b-3465dc2ec493" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ac8915bb-36b5-4595-be3b-3465dc2ec493" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5fe9a709-5d14-4275-ac64-293eef771fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5fe9a709-5d14-4275-ac64-293eef771fc3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_63e57fea-9889-402f-b35a-5897f2313fa0" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_63e57fea-9889-402f-b35a-5897f2313fa0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92d51198-f981-406f-8d22-0a68311a216b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92d51198-f981-406f-8d22-0a68311a216b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2e26903b-77ac-4fce-bbd3-5567b9d75763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2e26903b-77ac-4fce-bbd3-5567b9d75763" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3573b3dc-13ec-4dd4-93ba-afc1763f5e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3573b3dc-13ec-4dd4-93ba-afc1763f5e7a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f83bc288-526f-43d5-b247-abdffe8772ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f83bc288-526f-43d5-b247-abdffe8772ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f67f8e4b-90f2-49f0-a06c-df124943e9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6fcc5328-5d0c-4055-a0fc-e2b07c59ef7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6fcc5328-5d0c-4055-a0fc-e2b07c59ef7b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_48ad26b2-e7bb-48aa-81dd-86960e949792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6fcc5328-5d0c-4055-a0fc-e2b07c59ef7b" xlink:to="loc_us-gaap_InterestPaidNet_48ad26b2-e7bb-48aa-81dd-86960e949792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_f560c9c9-ecc8-41be-aa18-8307dd84a3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6fcc5328-5d0c-4055-a0fc-e2b07c59ef7b" xlink:to="loc_us-gaap_IncomeTaxesPaid_f560c9c9-ecc8-41be-aa18-8307dd84a3a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_713413b9-9e48-42cf-8786-351f594b2068" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_713413b9-9e48-42cf-8786-351f594b2068" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived_8d8b819a-3316-437d-b719-1d0f4b5f8f32" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_713413b9-9e48-42cf-8786-351f594b2068" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived_8d8b819a-3316-437d-b719-1d0f4b5f8f32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_245f2fe3-c97a-4a74-a355-671b6de75ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_713413b9-9e48-42cf-8786-351f594b2068" xlink:to="loc_us-gaap_Goodwill_245f2fe3-c97a-4a74-a355-671b6de75ca7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9b021f66-2afc-47bf-9a4e-32e251f82903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_713413b9-9e48-42cf-8786-351f594b2068" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9b021f66-2afc-47bf-9a4e-32e251f82903" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets_ff45db59-2000-49b2-8a09-224aa57b3228" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_713413b9-9e48-42cf-8786-351f594b2068" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets_ff45db59-2000-49b2-8a09-224aa57b3228" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3116f9cb-d158-4e55-aa6b-f32eaa746e86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_713413b9-9e48-42cf-8786-351f594b2068" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3116f9cb-d158-4e55-aa6b-f32eaa746e86" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d47a8be6-a4ed-4e16-aba8-f53eb578dca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7f10b06b-4ebe-4e6c-89ce-42dd4dfca0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7f10b06b-4ebe-4e6c-89ce-42dd4dfca0e2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid_89fca591-4a27-4931-8aba-10a6f4d5994a" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7f10b06b-4ebe-4e6c-89ce-42dd4dfca0e2" xlink:to="loc_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid_89fca591-4a27-4931-8aba-10a6f4d5994a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2d64cf1a-b447-4e7d-9526-bbfb78857109" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7f10b06b-4ebe-4e6c-89ce-42dd4dfca0e2" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2d64cf1a-b447-4e7d-9526-bbfb78857109" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid_ffa65098-11f9-4fed-a53c-21c661cc617c" xlink:href="lgnd-20241231.xsd#lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7f10b06b-4ebe-4e6c-89ce-42dd4dfca0e2" xlink:to="loc_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid_ffa65098-11f9-4fed-a53c-21c661cc617c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid_c1cd5e66-5aeb-4fdd-9236-4ca017804455" xlink:href="lgnd-20241231.xsd#lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7f10b06b-4ebe-4e6c-89ce-42dd4dfca0e2" xlink:to="loc_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid_c1cd5e66-5aeb-4fdd-9236-4ca017804455" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid_3e870d76-0064-4387-afbb-4e0eaee1c023" xlink:href="lgnd-20241231.xsd#lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7f10b06b-4ebe-4e6c-89ce-42dd4dfca0e2" xlink:to="loc_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid_3e870d76-0064-4387-afbb-4e0eaee1c023" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1cf69463-8519-4316-98cc-ae37362161ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7f10b06b-4ebe-4e6c-89ce-42dd4dfca0e2" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1cf69463-8519-4316-98cc-ae37362161ed" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_8fa32fe2-e2eb-46b9-83da-061fecf475a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7f10b06b-4ebe-4e6c-89ce-42dd4dfca0e2" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_8fa32fe2-e2eb-46b9-83da-061fecf475a9" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e63fc92d-daa2-4e34-9945-a0b36513f4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_0d8f319d-a69a-48aa-afd6-58371402dd03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e63fc92d-daa2-4e34-9945-a0b36513f4fb" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_0d8f319d-a69a-48aa-afd6-58371402dd03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d59da3a9-39b9-412c-8919-f5b98724ac44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_0d8f319d-a69a-48aa-afd6-58371402dd03" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d59da3a9-39b9-412c-8919-f5b98724ac44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d59da3a9-39b9-412c-8919-f5b98724ac44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d59da3a9-39b9-412c-8919-f5b98724ac44" xlink:to="loc_us-gaap_SegmentDomain_d59da3a9-39b9-412c-8919-f5b98724ac44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_23e30a27-dfba-4a92-a9de-26e091700be7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d59da3a9-39b9-412c-8919-f5b98724ac44" xlink:to="loc_us-gaap_SegmentDomain_23e30a27-dfba-4a92-a9de-26e091700be7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember_f4e86cf1-f152-449c-83b1-40eb4bce35f7" xlink:href="lgnd-20241231.xsd#lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_23e30a27-dfba-4a92-a9de-26e091700be7" xlink:to="loc_lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember_f4e86cf1-f152-449c-83b1-40eb4bce35f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5f04af90-421d-49b4-a694-7c9ed885cf01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e63fc92d-daa2-4e34-9945-a0b36513f4fb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5f04af90-421d-49b4-a694-7c9ed885cf01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_20578c2d-c4a4-4c8a-aaf2-2aa891577cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e63fc92d-daa2-4e34-9945-a0b36513f4fb" xlink:to="loc_us-gaap_ShareBasedCompensation_20578c2d-c4a4-4c8a-aaf2-2aa891577cc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_b972aed1-f0ac-405d-b98e-0a80487751dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e63fc92d-daa2-4e34-9945-a0b36513f4fb" xlink:to="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_b972aed1-f0ac-405d-b98e-0a80487751dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_042d065d-d8f7-41be-ac15-783254437e94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_b972aed1-f0ac-405d-b98e-0a80487751dd" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_042d065d-d8f7-41be-ac15-783254437e94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_753d159c-54ce-4c8c-bf4f-5f69673c482e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_b972aed1-f0ac-405d-b98e-0a80487751dd" xlink:to="loc_us-gaap_Depreciation_753d159c-54ce-4c8c-bf4f-5f69673c482e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_db6b95ab-bbc0-40ca-a04e-89e6986c448e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_b972aed1-f0ac-405d-b98e-0a80487751dd" xlink:to="loc_us-gaap_InterestIncomeOperating_db6b95ab-bbc0-40ca-a04e-89e6986c448e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_c6ed7b42-1a66-49d7-8486-a5044a13c603" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_b972aed1-f0ac-405d-b98e-0a80487751dd" xlink:to="loc_us-gaap_InterestExpenseNonoperating_c6ed7b42-1a66-49d7-8486-a5044a13c603" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_bbbbe2bf-8420-4c59-9cad-22db6ebbea1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_b972aed1-f0ac-405d-b98e-0a80487751dd" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_bbbbe2bf-8420-4c59-9cad-22db6ebbea1a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_83ba56e6-ca42-4e13-b707-a94a1cca00a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e63fc92d-daa2-4e34-9945-a0b36513f4fb" xlink:to="loc_us-gaap_OperatingIncomeLoss_83ba56e6-ca42-4e13-b707-a94a1cca00a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherExpenseItemsNet_b8b8cbb3-cb40-42db-ada6-99f26fd0ba23" xlink:href="lgnd-20241231.xsd#lgnd_OtherExpenseItemsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e63fc92d-daa2-4e34-9945-a0b36513f4fb" xlink:to="loc_lgnd_OtherExpenseItemsNet_b8b8cbb3-cb40-42db-ada6-99f26fd0ba23" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:href="lgnd-20241231.xsd#lgnd_BasisOfPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:href="lgnd-20241231.xsd#lgnd_BasisOfPresentationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_50d897f4-7f55-4fcc-ab36-ebe1977c83b3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:to="loc_srt_ProductOrServiceAxis_50d897f4-7f55-4fcc-ab36-ebe1977c83b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_50d897f4-7f55-4fcc-ab36-ebe1977c83b3_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_50d897f4-7f55-4fcc-ab36-ebe1977c83b3" xlink:to="loc_srt_ProductsAndServicesDomain_50d897f4-7f55-4fcc-ab36-ebe1977c83b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4c00eb70-992d-4cd1-80d1-f8f9995aadde" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_50d897f4-7f55-4fcc-ab36-ebe1977c83b3" xlink:to="loc_srt_ProductsAndServicesDomain_4c00eb70-992d-4cd1-80d1-f8f9995aadde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_4b6c10dc-2417-4967-9967-5dd8d4ef5470" xlink:href="lgnd-20241231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4c00eb70-992d-4cd1-80d1-f8f9995aadde" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_4b6c10dc-2417-4967-9967-5dd8d4ef5470" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d4cc9eba-db1a-4114-b4e0-d52c46281dcc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:to="loc_srt_RangeAxis_d4cc9eba-db1a-4114-b4e0-d52c46281dcc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d4cc9eba-db1a-4114-b4e0-d52c46281dcc_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d4cc9eba-db1a-4114-b4e0-d52c46281dcc" xlink:to="loc_srt_RangeMember_d4cc9eba-db1a-4114-b4e0-d52c46281dcc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_728f9e9d-70ff-4787-9b86-8680531a67fd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d4cc9eba-db1a-4114-b4e0-d52c46281dcc" xlink:to="loc_srt_RangeMember_728f9e9d-70ff-4787-9b86-8680531a67fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_99d781ab-9828-4812-b69c-8fa50756b16f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_728f9e9d-70ff-4787-9b86-8680531a67fd" xlink:to="loc_srt_MinimumMember_99d781ab-9828-4812-b69c-8fa50756b16f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_facc2ead-c3eb-45b4-ac07-bc643a7906c2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_728f9e9d-70ff-4787-9b86-8680531a67fd" xlink:to="loc_srt_MaximumMember_facc2ead-c3eb-45b4-ac07-bc643a7906c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f62955a4-5e93-42d4-9c12-cc2d6b8fe2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f62955a4-5e93-42d4-9c12-cc2d6b8fe2f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f62955a4-5e93-42d4-9c12-cc2d6b8fe2f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f62955a4-5e93-42d4-9c12-cc2d6b8fe2f6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f62955a4-5e93-42d4-9c12-cc2d6b8fe2f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f6e7057-369b-4fd0-a81d-1606d5345745" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f62955a4-5e93-42d4-9c12-cc2d6b8fe2f6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f6e7057-369b-4fd0-a81d-1606d5345745" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_1dc82361-d398-4148-90f1-004850fb2ddb" xlink:href="lgnd-20241231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f6e7057-369b-4fd0-a81d-1606d5345745" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_1dc82361-d398-4148-90f1-004850fb2ddb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2b94a76e-fbd4-4b0c-889e-5bb859dd5e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:to="loc_us-gaap_AwardTypeAxis_2b94a76e-fbd4-4b0c-889e-5bb859dd5e8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b94a76e-fbd4-4b0c-889e-5bb859dd5e8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2b94a76e-fbd4-4b0c-889e-5bb859dd5e8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2b94a76e-fbd4-4b0c-889e-5bb859dd5e8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95fa2ed5-6420-4191-b75a-dbcd1fa05c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2b94a76e-fbd4-4b0c-889e-5bb859dd5e8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95fa2ed5-6420-4191-b75a-dbcd1fa05c8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ad242745-fd79-47ff-8532-245b8c84ab9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95fa2ed5-6420-4191-b75a-dbcd1fa05c8f" xlink:to="loc_us-gaap_PerformanceSharesMember_ad242745-fd79-47ff-8532-245b8c84ab9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d9bf4b58-e4b4-4e74-b705-01c0025f7ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95fa2ed5-6420-4191-b75a-dbcd1fa05c8f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d9bf4b58-e4b4-4e74-b705-01c0025f7ba3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_50f53d0c-7666-45bc-8542-6f4f50a76392" xlink:href="lgnd-20241231.xsd#lgnd_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95fa2ed5-6420-4191-b75a-dbcd1fa05c8f" xlink:to="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_50f53d0c-7666-45bc-8542-6f4f50a76392" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_18798fe9-c0bd-4e90-8ebd-6b32d756bc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_18798fe9-c0bd-4e90-8ebd-6b32d756bc8a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_18798fe9-c0bd-4e90-8ebd-6b32d756bc8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_18798fe9-c0bd-4e90-8ebd-6b32d756bc8a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_18798fe9-c0bd-4e90-8ebd-6b32d756bc8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0d523f04-5f7e-4dfd-a43b-13f39656400e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_18798fe9-c0bd-4e90-8ebd-6b32d756bc8a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0d523f04-5f7e-4dfd-a43b-13f39656400e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_feaec0e6-2074-4180-8117-cd01060b3370" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0d523f04-5f7e-4dfd-a43b-13f39656400e" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_feaec0e6-2074-4180-8117-cd01060b3370" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_653187a2-6e2d-4c38-8b32-e9bda2b507c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:to="loc_us-gaap_PlanNameAxis_653187a2-6e2d-4c38-8b32-e9bda2b507c9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_653187a2-6e2d-4c38-8b32-e9bda2b507c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_653187a2-6e2d-4c38-8b32-e9bda2b507c9" xlink:to="loc_us-gaap_PlanNameDomain_653187a2-6e2d-4c38-8b32-e9bda2b507c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_89980042-a423-4e9a-89f0-9aa28812166d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_653187a2-6e2d-4c38-8b32-e9bda2b507c9" xlink:to="loc_us-gaap_PlanNameDomain_89980042-a423-4e9a-89f0-9aa28812166d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_5429c535-ea54-46f8-8f0b-e8f3e6fd80a4" xlink:href="lgnd-20241231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_89980042-a423-4e9a-89f0-9aa28812166d" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_5429c535-ea54-46f8-8f0b-e8f3e6fd80a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7aeeea15-534f-4569-8377-0068d17f8010" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:to="loc_us-gaap_VestingAxis_7aeeea15-534f-4569-8377-0068d17f8010" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7aeeea15-534f-4569-8377-0068d17f8010_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_7aeeea15-534f-4569-8377-0068d17f8010" xlink:to="loc_us-gaap_VestingDomain_7aeeea15-534f-4569-8377-0068d17f8010_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_3e956301-cc9d-4aa5-aac2-5dae2cf55270" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_7aeeea15-534f-4569-8377-0068d17f8010" xlink:to="loc_us-gaap_VestingDomain_3e956301-cc9d-4aa5-aac2-5dae2cf55270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodOneMember_a0bdfa21-7f46-4a63-8113-a96013d2ee8f" xlink:href="lgnd-20241231.xsd#lgnd_VestingPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_3e956301-cc9d-4aa5-aac2-5dae2cf55270" xlink:to="loc_lgnd_VestingPeriodOneMember_a0bdfa21-7f46-4a63-8113-a96013d2ee8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodTwoMember_5edbed73-1af6-4af9-a074-2d0b693f8ad2" xlink:href="lgnd-20241231.xsd#lgnd_VestingPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_3e956301-cc9d-4aa5-aac2-5dae2cf55270" xlink:to="loc_lgnd_VestingPeriodTwoMember_5edbed73-1af6-4af9-a074-2d0b693f8ad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6248ca3b-8360-4cdc-80b6-3e2d688eaf63" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:to="loc_srt_CounterpartyNameAxis_6248ca3b-8360-4cdc-80b6-3e2d688eaf63" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6248ca3b-8360-4cdc-80b6-3e2d688eaf63_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6248ca3b-8360-4cdc-80b6-3e2d688eaf63" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6248ca3b-8360-4cdc-80b6-3e2d688eaf63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_caefe348-4708-4e94-8d80-1d30a8704d10" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6248ca3b-8360-4cdc-80b6-3e2d688eaf63" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_caefe348-4708-4e94-8d80-1d30a8704d10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AgenusPartneredProgramMember_76addeb8-3d6c-427e-9d9c-b68251a7ae4c" xlink:href="lgnd-20241231.xsd#lgnd_AgenusPartneredProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_caefe348-4708-4e94-8d80-1d30a8704d10" xlink:to="loc_lgnd_AgenusPartneredProgramMember_76addeb8-3d6c-427e-9d9c-b68251a7ae4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_db1d494a-e4f5-4488-a009-5ce40a501f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_db1d494a-e4f5-4488-a009-5ce40a501f2a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_db1d494a-e4f5-4488-a009-5ce40a501f2a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_db1d494a-e4f5-4488-a009-5ce40a501f2a" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_db1d494a-e4f5-4488-a009-5ce40a501f2a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_2ffce470-a328-4836-92c4-741a1a9f0df9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_db1d494a-e4f5-4488-a009-5ce40a501f2a" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_2ffce470-a328-4836-92c4-741a1a9f0df9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimordialGeneticsMember_9ed685eb-cae8-4fa8-b1a1-59c7d10c3bea" xlink:href="lgnd-20241231.xsd#lgnd_PrimordialGeneticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_2ffce470-a328-4836-92c4-741a1a9f0df9" xlink:to="loc_lgnd_PrimordialGeneticsMember_9ed685eb-cae8-4fa8-b1a1-59c7d10c3bea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_0a279ed5-4a73-4a75-b69c-e6f92f8bc979" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_NumberOfOperatingSegments_0a279ed5-4a73-4a75-b69c-e6f92f8bc979" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_b725e81f-ccab-48f7-b3ba-e3e276153e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_NumberOfReportableSegments_b725e81f-ccab-48f7-b3ba-e3e276153e2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_539776b1-c70d-480d-83e1-16cf1495536e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_539776b1-c70d-480d-83e1-16cf1495536e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_d907db82-15d2-4177-9afa-9ce772f45a67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_InventoryWriteDown_d907db82-15d2-4177-9afa-9ce772f45a67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6dcf92f6-cfda-40a0-b609-0a210eb03ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_InventoryNet_6dcf92f6-cfda-40a0-b609-0a210eb03ac1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5a12aa6f-12c3-4a6c-bea5-44b21eb018a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5a12aa6f-12c3-4a6c-bea5-44b21eb018a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeInstrumentAdditionalMaximumInvestment_9e40a8e3-8458-4d40-87b1-594dfe370016" xlink:href="lgnd-20241231.xsd#lgnd_DerivativeInstrumentAdditionalMaximumInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_lgnd_DerivativeInstrumentAdditionalMaximumInvestment_9e40a8e3-8458-4d40-87b1-594dfe370016" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneCompensationRate_13a5ae32-07d3-464a-91ed-547e2c774990" xlink:href="lgnd-20241231.xsd#lgnd_MilestoneCompensationRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_lgnd_MilestoneCompensationRate_13a5ae32-07d3-464a-91ed-547e2c774990" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContracts_f2e6d9cc-1cda-47e9-b7ae-e4a0416e1d0e" xlink:href="lgnd-20241231.xsd#lgnd_NumberOfContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_lgnd_NumberOfContracts_f2e6d9cc-1cda-47e9-b7ae-e4a0416e1d0e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsIssued_57f812e2-ed1a-4efc-a153-26ea7aca5f4e" xlink:href="lgnd-20241231.xsd#lgnd_NumberOfContingentValueRightsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_lgnd_NumberOfContingentValueRightsIssued_57f812e2-ed1a-4efc-a153-26ea7aca5f4e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5998eb79-b753-40fa-b37e-acbb86c44941" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5998eb79-b753-40fa-b37e-acbb86c44941" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e91ce11f-05ed-4986-b9b3-7de611826119" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e91ce11f-05ed-4986-b9b3-7de611826119" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ffe9b4ac-0ae7-4e0c-b2f2-6f80ac949c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ffe9b4ac-0ae7-4e0c-b2f2-6f80ac949c2a" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_6e0e184a-484d-4f36-93b8-e8065d0b2b06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_6e0e184a-484d-4f36-93b8-e8065d0b2b06" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_e0129b6c-f2be-4fa1-8104-6bc786ff1201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_e0129b6c-f2be-4fa1-8104-6bc786ff1201" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_296f31c1-05be-46a2-9d34-7c4c50a200b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_296f31c1-05be-46a2-9d34-7c4c50a200b1" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6f68a72f-c9b8-4d75-9388-9134bbf2bb04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fa192bc2-bc54-4ac0-9ba3-88d6b54320f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6f68a72f-c9b8-4d75-9388-9134bbf2bb04" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fa192bc2-bc54-4ac0-9ba3-88d6b54320f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_9ac41b23-c579-44bc-82c4-48116a2e14f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fa192bc2-bc54-4ac0-9ba3-88d6b54320f9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_9ac41b23-c579-44bc-82c4-48116a2e14f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9ac41b23-c579-44bc-82c4-48116a2e14f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9ac41b23-c579-44bc-82c4-48116a2e14f1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9ac41b23-c579-44bc-82c4-48116a2e14f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f71864fe-d95b-47d7-a027-aa6771551b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9ac41b23-c579-44bc-82c4-48116a2e14f1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f71864fe-d95b-47d7-a027-aa6771551b7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c4d29a7a-edc4-41a7-86f6-9ccbd69bbe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f71864fe-d95b-47d7-a027-aa6771551b7d" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c4d29a7a-edc4-41a7-86f6-9ccbd69bbe6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1f1794c5-106a-4a6c-977e-259c47f2a62d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fa192bc2-bc54-4ac0-9ba3-88d6b54320f9" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1f1794c5-106a-4a6c-977e-259c47f2a62d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1f1794c5-106a-4a6c-977e-259c47f2a62d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1f1794c5-106a-4a6c-977e-259c47f2a62d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1f1794c5-106a-4a6c-977e-259c47f2a62d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f82137d2-3883-44a9-b72f-bfdbc4b21121" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1f1794c5-106a-4a6c-977e-259c47f2a62d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f82137d2-3883-44a9-b72f-bfdbc4b21121" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_cef178cc-8c5a-4abe-9b14-1f7b5c780366" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f82137d2-3883-44a9-b72f-bfdbc4b21121" xlink:to="loc_us-gaap_SalesRevenueNetMember_cef178cc-8c5a-4abe-9b14-1f7b5c780366" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_11b30854-654b-4012-8fbf-93901dd559f1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fa192bc2-bc54-4ac0-9ba3-88d6b54320f9" xlink:to="loc_srt_MajorCustomersAxis_11b30854-654b-4012-8fbf-93901dd559f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_11b30854-654b-4012-8fbf-93901dd559f1_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_11b30854-654b-4012-8fbf-93901dd559f1" xlink:to="loc_srt_NameOfMajorCustomerDomain_11b30854-654b-4012-8fbf-93901dd559f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b5320e7d-ec79-4d5b-89be-53baffa7fc32" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_11b30854-654b-4012-8fbf-93901dd559f1" xlink:to="loc_srt_NameOfMajorCustomerDomain_b5320e7d-ec79-4d5b-89be-53baffa7fc32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerAMember_18458d6d-591b-422a-8949-c34d1368ea82" xlink:href="lgnd-20241231.xsd#lgnd_PartnerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b5320e7d-ec79-4d5b-89be-53baffa7fc32" xlink:to="loc_lgnd_PartnerAMember_18458d6d-591b-422a-8949-c34d1368ea82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerBMember_0f869856-743e-4ce8-9bb9-7b40c2927e7d" xlink:href="lgnd-20241231.xsd#lgnd_PartnerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b5320e7d-ec79-4d5b-89be-53baffa7fc32" xlink:to="loc_lgnd_PartnerBMember_0f869856-743e-4ce8-9bb9-7b40c2927e7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerCMember_54bad47a-b98a-4b7c-ae42-8a71a0b93c8c" xlink:href="lgnd-20241231.xsd#lgnd_PartnerCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b5320e7d-ec79-4d5b-89be-53baffa7fc32" xlink:to="loc_lgnd_PartnerCMember_54bad47a-b98a-4b7c-ae42-8a71a0b93c8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RecordatiMember_f8f2552e-9b82-4dca-bf8a-8f60e02cfe75" xlink:href="lgnd-20241231.xsd#lgnd_RecordatiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b5320e7d-ec79-4d5b-89be-53baffa7fc32" xlink:to="loc_lgnd_RecordatiMember_f8f2552e-9b82-4dca-bf8a-8f60e02cfe75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_0db3d63a-1c30-479d-831a-0ad9b15aa4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6f68a72f-c9b8-4d75-9388-9134bbf2bb04" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_0db3d63a-1c30-479d-831a-0ad9b15aa4ca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f8998d28-3517-4d0a-9340-4615bbf7f05f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_dd5d33db-3112-4e6a-8cbb-276974a31c74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f8998d28-3517-4d0a-9340-4615bbf7f05f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_dd5d33db-3112-4e6a-8cbb-276974a31c74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b395cef8-6aed-496c-84fd-553fdf38d1ff" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_dd5d33db-3112-4e6a-8cbb-276974a31c74" xlink:to="loc_srt_ProductOrServiceAxis_b395cef8-6aed-496c-84fd-553fdf38d1ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b395cef8-6aed-496c-84fd-553fdf38d1ff_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b395cef8-6aed-496c-84fd-553fdf38d1ff" xlink:to="loc_srt_ProductsAndServicesDomain_b395cef8-6aed-496c-84fd-553fdf38d1ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0ec5e294-8485-4f88-be6e-77ff5177d1eb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b395cef8-6aed-496c-84fd-553fdf38d1ff" xlink:to="loc_srt_ProductsAndServicesDomain_0ec5e294-8485-4f88-be6e-77ff5177d1eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0ec5e294-8485-4f88-be6e-77ff5177d1eb" xlink:to="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyKyprolisMember_bc19278d-1c7f-4a0d-8720-27254b6085bd" xlink:href="lgnd-20241231.xsd#lgnd_RoyaltyKyprolisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:to="loc_lgnd_RoyaltyKyprolisMember_bc19278d-1c7f-4a0d-8720-27254b6085bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyRylazeMember_b794d98e-131b-444d-a19d-56a00b7c7300" xlink:href="lgnd-20241231.xsd#lgnd_RoyaltyRylazeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:to="loc_lgnd_RoyaltyRylazeMember_b794d98e-131b-444d-a19d-56a00b7c7300" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FilspariMember_0bcc6079-d313-4091-9daa-60591376e4c6" xlink:href="lgnd-20241231.xsd#lgnd_FilspariMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:to="loc_lgnd_FilspariMember_0bcc6079-d313-4091-9daa-60591376e4c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyEvomelaMember_c5cef263-4223-4262-8d02-64080c838e4b" xlink:href="lgnd-20241231.xsd#lgnd_RoyaltyEvomelaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:to="loc_lgnd_RoyaltyEvomelaMember_c5cef263-4223-4262-8d02-64080c838e4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyTeriparatideInjectionMember_165ca026-2444-4060-8546-dadaca8ea3b8" xlink:href="lgnd-20241231.xsd#lgnd_RoyaltyTeriparatideInjectionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:to="loc_lgnd_RoyaltyTeriparatideInjectionMember_165ca026-2444-4060-8546-dadaca8ea3b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VaxneuvanceMember_56cf6884-815e-42ab-be79-11fc9471fe21" xlink:href="lgnd-20241231.xsd#lgnd_VaxneuvanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:to="loc_lgnd_VaxneuvanceMember_56cf6884-815e-42ab-be79-11fc9471fe21" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyOtherMember_397db251-4dfd-4ea3-965b-a7df242af34d" xlink:href="lgnd-20241231.xsd#lgnd_RoyaltyOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:to="loc_lgnd_RoyaltyOtherMember_397db251-4dfd-4ea3-965b-a7df242af34d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IntangibleRoyaltyAssetsMember_17f6804a-b351-4595-8505-8ec52a903ca1" xlink:href="lgnd-20241231.xsd#lgnd_IntangibleRoyaltyAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:to="loc_lgnd_IntangibleRoyaltyAssetsMember_17f6804a-b351-4595-8505-8ec52a903ca1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsMember_c229d865-ef82-4ec6-8cba-88d825f0d198" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:to="loc_lgnd_FinancialRoyaltyAssetsMember_c229d865-ef82-4ec6-8cba-88d825f0d198" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_7e6e72d2-5cc2-47b1-bdd7-cbc946ba460e" xlink:href="lgnd-20241231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0ec5e294-8485-4f88-be6e-77ff5177d1eb" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_7e6e72d2-5cc2-47b1-bdd7-cbc946ba460e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolCoreMember_2f951190-78fd-4512-be5c-1102600df182" xlink:href="lgnd-20241231.xsd#lgnd_MaterialSalesCaptisolCoreMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_MaterialSalesCaptisolMember_7e6e72d2-5cc2-47b1-bdd7-cbc946ba460e" xlink:to="loc_lgnd_MaterialSalesCaptisolCoreMember_2f951190-78fd-4512-be5c-1102600df182" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolCOVIDMember_a28e7cdc-f763-4fb1-9851-f498c92fefac" xlink:href="lgnd-20241231.xsd#lgnd_MaterialSalesCaptisolCOVIDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_MaterialSalesCaptisolMember_7e6e72d2-5cc2-47b1-bdd7-cbc946ba460e" xlink:to="loc_lgnd_MaterialSalesCaptisolCOVIDMember_a28e7cdc-f763-4fb1-9851-f498c92fefac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_c4ac1cef-262c-4440-885a-da09220771a3" xlink:href="lgnd-20241231.xsd#lgnd_ContractRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0ec5e294-8485-4f88-be6e-77ff5177d1eb" xlink:to="loc_lgnd_ContractRevenueMember_c4ac1cef-262c-4440-885a-da09220771a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_0a796fd7-5dc7-4178-a40d-f6dbebaafc23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContractRevenueMember_c4ac1cef-262c-4440-885a-da09220771a3" xlink:to="loc_us-gaap_ServiceMember_0a796fd7-5dc7-4178-a40d-f6dbebaafc23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMember_67f926aa-1197-4a1f-9c8f-7fbdf558c066" xlink:href="lgnd-20241231.xsd#lgnd_LicenseFeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContractRevenueMember_c4ac1cef-262c-4440-885a-da09220771a3" xlink:to="loc_lgnd_LicenseFeesMember_67f926aa-1197-4a1f-9c8f-7fbdf558c066" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e1a298dd-cede-4af6-886e-2308c1917f79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f8998d28-3517-4d0a-9340-4615bbf7f05f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e1a298dd-cede-4af6-886e-2308c1917f79" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_4f066fac-b19b-4dc3-90e7-bf771575f540" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_7c456c21-2112-4f4e-a33c-ca2a0aa2b50a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_4f066fac-b19b-4dc3-90e7-bf771575f540" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_7c456c21-2112-4f4e-a33c-ca2a0aa2b50a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dd834177-e36a-411c-bba5-46aa3bcc0610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_7c456c21-2112-4f4e-a33c-ca2a0aa2b50a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dd834177-e36a-411c-bba5-46aa3bcc0610" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd834177-e36a-411c-bba5-46aa3bcc0610_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dd834177-e36a-411c-bba5-46aa3bcc0610" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dd834177-e36a-411c-bba5-46aa3bcc0610_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f2bff3a7-ab1e-4598-9bc7-ea799c1489f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dd834177-e36a-411c-bba5-46aa3bcc0610" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f2bff3a7-ab1e-4598-9bc7-ea799c1489f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d9a28991-b6e9-4b43-ab6c-02be8f7dd2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f2bff3a7-ab1e-4598-9bc7-ea799c1489f3" xlink:to="loc_us-gaap_RestrictedStockMember_d9a28991-b6e9-4b43-ab6c-02be8f7dd2bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cfe2c28e-df5e-440a-ade1-ee7cf0efb4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f2bff3a7-ab1e-4598-9bc7-ea799c1489f3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cfe2c28e-df5e-440a-ade1-ee7cf0efb4ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_dd59891a-c2cf-40b3-9138-b03374ae0d71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f2bff3a7-ab1e-4598-9bc7-ea799c1489f3" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_dd59891a-c2cf-40b3-9138-b03374ae0d71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_85597d54-81ab-463a-8d44-70b682c8d382" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_4f066fac-b19b-4dc3-90e7-bf771575f540" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_85597d54-81ab-463a-8d44-70b682c8d382" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1e5e4b4e-1dda-45b7-b032-a69f818959b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_4f066fac-b19b-4dc3-90e7-bf771575f540" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1e5e4b4e-1dda-45b7-b032-a69f818959b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3019cf1f-8b02-4c76-a7c4-55122be3e1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_4f066fac-b19b-4dc3-90e7-bf771575f540" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3019cf1f-8b02-4c76-a7c4-55122be3e1d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_51b68657-e30c-4d71-9578-9b48b815d8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_4f066fac-b19b-4dc3-90e7-bf771575f540" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_51b68657-e30c-4d71-9578-9b48b815d8e1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AgenusTransactionDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#AgenusTransactionDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/AgenusTransactionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_fafa6d1f-a6f8-4c6f-9f1e-da59e1b2159e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_us-gaap_AssetAcquisitionTable_fafa6d1f-a6f8-4c6f-9f1e-da59e1b2159e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_26ec8753-4dc7-43ca-8345-095a09489b4f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_fafa6d1f-a6f8-4c6f-9f1e-da59e1b2159e" xlink:to="loc_srt_CounterpartyNameAxis_26ec8753-4dc7-43ca-8345-095a09489b4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26ec8753-4dc7-43ca-8345-095a09489b4f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_26ec8753-4dc7-43ca-8345-095a09489b4f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26ec8753-4dc7-43ca-8345-095a09489b4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92330c18-512f-464c-a83e-6eddfb5834f0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_26ec8753-4dc7-43ca-8345-095a09489b4f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92330c18-512f-464c-a83e-6eddfb5834f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AgenusInc.Member_a6e934b3-f143-4f5d-8a11-f05eacbec924" xlink:href="lgnd-20241231.xsd#lgnd_AgenusInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92330c18-512f-464c-a83e-6eddfb5834f0" xlink:to="loc_lgnd_AgenusInc.Member_a6e934b3-f143-4f5d-8a11-f05eacbec924" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AgenusPartneredProgramMember_025f0987-1acc-42fd-ba72-8aaeb65367cb" xlink:href="lgnd-20241231.xsd#lgnd_AgenusPartneredProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92330c18-512f-464c-a83e-6eddfb5834f0" xlink:to="loc_lgnd_AgenusPartneredProgramMember_025f0987-1acc-42fd-ba72-8aaeb65367cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_39fb2c5b-8ee0-4083-8e39-f4f0172bd6b3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_fafa6d1f-a6f8-4c6f-9f1e-da59e1b2159e" xlink:to="loc_srt_ProductOrServiceAxis_39fb2c5b-8ee0-4083-8e39-f4f0172bd6b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_39fb2c5b-8ee0-4083-8e39-f4f0172bd6b3_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_39fb2c5b-8ee0-4083-8e39-f4f0172bd6b3" xlink:to="loc_srt_ProductsAndServicesDomain_39fb2c5b-8ee0-4083-8e39-f4f0172bd6b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8c445437-13b2-43b2-86d9-bc7c83abbde5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_39fb2c5b-8ee0-4083-8e39-f4f0172bd6b3" xlink:to="loc_srt_ProductsAndServicesDomain_8c445437-13b2-43b2-86d9-bc7c83abbde5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BMS986442Member_cb56b2c7-4c6a-4409-8aa6-b8f49da7cf3e" xlink:href="lgnd-20241231.xsd#lgnd_BMS986442Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8c445437-13b2-43b2-86d9-bc7c83abbde5" xlink:to="loc_lgnd_BMS986442Member_cb56b2c7-4c6a-4409-8aa6-b8f49da7cf3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AGEN2373Member_75cb8b14-fca7-443b-80ae-02f8676781a1" xlink:href="lgnd-20241231.xsd#lgnd_AGEN2373Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8c445437-13b2-43b2-86d9-bc7c83abbde5" xlink:to="loc_lgnd_AGEN2373Member_75cb8b14-fca7-443b-80ae-02f8676781a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_INCAGN2385Member_b107e762-8679-47ac-a438-dab0e4229c46" xlink:href="lgnd-20241231.xsd#lgnd_INCAGN2385Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8c445437-13b2-43b2-86d9-bc7c83abbde5" xlink:to="loc_lgnd_INCAGN2385Member_b107e762-8679-47ac-a438-dab0e4229c46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_INCAGN2390Member_ad980790-1b98-4e83-b804-8b33ffffc79b" xlink:href="lgnd-20241231.xsd#lgnd_INCAGN2390Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8c445437-13b2-43b2-86d9-bc7c83abbde5" xlink:to="loc_lgnd_INCAGN2390Member_ad980790-1b98-4e83-b804-8b33ffffc79b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MK4830Member_d08a5dfd-327d-4ba8-a57a-fa51ec1d341e" xlink:href="lgnd-20241231.xsd#lgnd_MK4830Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8c445437-13b2-43b2-86d9-bc7c83abbde5" xlink:to="loc_lgnd_MK4830Member_d08a5dfd-327d-4ba8-a57a-fa51ec1d341e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_UGN301Member_1b70c612-c8eb-419e-94b7-b19bd573ceea" xlink:href="lgnd-20241231.xsd#lgnd_UGN301Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8c445437-13b2-43b2-86d9-bc7c83abbde5" xlink:to="loc_lgnd_UGN301Member_1b70c612-c8eb-419e-94b7-b19bd573ceea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BOTBALMember_4110a2ec-37e1-48dc-8b0f-ae3054ec0151" xlink:href="lgnd-20241231.xsd#lgnd_BOTBALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8c445437-13b2-43b2-86d9-bc7c83abbde5" xlink:to="loc_lgnd_BOTBALMember_4110a2ec-37e1-48dc-8b0f-ae3054ec0151" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_19dcec56-9e80-461b-ab5d-f9917e3dd674" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_fafa6d1f-a6f8-4c6f-9f1e-da59e1b2159e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_19dcec56-9e80-461b-ab5d-f9917e3dd674" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_19dcec56-9e80-461b-ab5d-f9917e3dd674_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_19dcec56-9e80-461b-ab5d-f9917e3dd674" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_19dcec56-9e80-461b-ab5d-f9917e3dd674_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7ba8b8b6-47e2-489f-9d8c-e467a2a832e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_19dcec56-9e80-461b-ab5d-f9917e3dd674" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7ba8b8b6-47e2-489f-9d8c-e467a2a832e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_2b325ff0-c00a-4af7-8b2b-e5e6de6a862e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7ba8b8b6-47e2-489f-9d8c-e467a2a832e7" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_2b325ff0-c00a-4af7-8b2b-e5e6de6a862e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_43e4b8b9-ab84-41bb-b24e-e064d2d2ff9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7ba8b8b6-47e2-489f-9d8c-e467a2a832e7" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_43e4b8b9-ab84-41bb-b24e-e064d2d2ff9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_d254ad0f-320f-419d-a987-ede817bba468" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7ba8b8b6-47e2-489f-9d8c-e467a2a832e7" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_d254ad0f-320f-419d-a987-ede817bba468" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_b43449f4-e925-40ca-9411-0dd90065122d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7ba8b8b6-47e2-489f-9d8c-e467a2a832e7" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_b43449f4-e925-40ca-9411-0dd90065122d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsNet_f1649d78-adf8-4223-bd29-6f0f50b86f7e" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_lgnd_FinancialRoyaltyAssetsNet_f1649d78-adf8-4223-bd29-6f0f50b86f7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceRoyaltyAgreementRoyaltyRate_8af6138c-4a33-48c0-a877-c6cbedb81d55" xlink:href="lgnd-20241231.xsd#lgnd_FinanceRoyaltyAgreementRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_lgnd_FinanceRoyaltyAgreementRoyaltyRate_8af6138c-4a33-48c0-a877-c6cbedb81d55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate_1fd716dc-16e7-4ea1-be5c-f0045b449a8b" xlink:href="lgnd-20241231.xsd#lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate_1fd716dc-16e7-4ea1-be5c-f0045b449a8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales_c030c36d-37fc-4056-9b42-63438b9ea3a1" xlink:href="lgnd-20241231.xsd#lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales_c030c36d-37fc-4056-9b42-63438b9ea3a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeInstrumentAdditionalMaximumInvestment_8c30ccbd-f89d-44b6-ac39-724f5e94e7a4" xlink:href="lgnd-20241231.xsd#lgnd_DerivativeInstrumentAdditionalMaximumInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_lgnd_DerivativeInstrumentAdditionalMaximumInvestment_8c30ccbd-f89d-44b6-ac39-724f5e94e7a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyMaximumCapitalSourcing_4d05a07f-873d-4a71-8e3d-79fe506a9eee" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyMaximumCapitalSourcing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_lgnd_FinancialRoyaltyMaximumCapitalSourcing_4d05a07f-873d-4a71-8e3d-79fe506a9eee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaximumFinancingRoyaltyAsset_46f2c2e1-4789-42db-9ed2-12c9448ed8e6" xlink:href="lgnd-20241231.xsd#lgnd_MaximumFinancingRoyaltyAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_lgnd_MaximumFinancingRoyaltyAsset_46f2c2e1-4789-42db-9ed2-12c9448ed8e6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_bf5be6eb-8bb8-4143-ba95-f372fcd81650" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_bf5be6eb-8bb8-4143-ba95-f372fcd81650" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1f2f98fb-2b1e-4281-9a0c-6f1a1e11ab93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1f2f98fb-2b1e-4281-9a0c-6f1a1e11ab93" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3ff0f89c-ce9a-4655-bc03-d1358e1e633d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3ff0f89c-ce9a-4655-bc03-d1358e1e633d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_dfcc54ce-3e94-412e-bbf3-bb0ccd966293" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_dfcc54ce-3e94-412e-bbf3-bb0ccd966293" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_a41492eb-638c-4f94-916c-722f8cc258f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_a41492eb-638c-4f94-916c-722f8cc258f6" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_509c2a1a-6022-4c63-ab93-e5ba0effce2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_509c2a1a-6022-4c63-ab93-e5ba0effce2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_173fdc17-0ce1-415e-a19d-a6b6e927c64f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_509c2a1a-6022-4c63-ab93-e5ba0effce2d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_173fdc17-0ce1-415e-a19d-a6b6e927c64f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_173fdc17-0ce1-415e-a19d-a6b6e927c64f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_173fdc17-0ce1-415e-a19d-a6b6e927c64f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_173fdc17-0ce1-415e-a19d-a6b6e927c64f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d7b06bd-6483-463f-8331-19fd9f18469d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_173fdc17-0ce1-415e-a19d-a6b6e927c64f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d7b06bd-6483-463f-8331-19fd9f18469d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_APEIRONMember_1cb8c37c-044b-4f6c-80f6-4f2090dade6f" xlink:href="lgnd-20241231.xsd#lgnd_APEIRONMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d7b06bd-6483-463f-8331-19fd9f18469d" xlink:to="loc_lgnd_APEIRONMember_1cb8c37c-044b-4f6c-80f6-4f2090dade6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanIncMember_7fd1c172-0edf-4dce-9ea5-ed8c1a9d830e" xlink:href="lgnd-20241231.xsd#lgnd_NovanIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d7b06bd-6483-463f-8331-19fd9f18469d" xlink:to="loc_lgnd_NovanIncMember_7fd1c172-0edf-4dce-9ea5-ed8c1a9d830e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_06dec5cf-55df-4f6d-81d8-0082a325919f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_509c2a1a-6022-4c63-ab93-e5ba0effce2d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_06dec5cf-55df-4f6d-81d8-0082a325919f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_06dec5cf-55df-4f6d-81d8-0082a325919f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_06dec5cf-55df-4f6d-81d8-0082a325919f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_06dec5cf-55df-4f6d-81d8-0082a325919f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_fde8c3d8-1993-40f0-8074-45547c545962" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_06dec5cf-55df-4f6d-81d8-0082a325919f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_fde8c3d8-1993-40f0-8074-45547c545962" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvIOsHoldingAGMember_35dfea52-b4cb-4c7c-90c0-c514a2b5e39b" xlink:href="lgnd-20241231.xsd#lgnd_InvIOsHoldingAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_fde8c3d8-1993-40f0-8074-45547c545962" xlink:to="loc_lgnd_InvIOsHoldingAGMember_35dfea52-b4cb-4c7c-90c0-c514a2b5e39b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b7a185d-9280-4774-9ced-1276fc1bc52e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_509c2a1a-6022-4c63-ab93-e5ba0effce2d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b7a185d-9280-4774-9ced-1276fc1bc52e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1b7a185d-9280-4774-9ced-1276fc1bc52e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b7a185d-9280-4774-9ced-1276fc1bc52e" xlink:to="loc_us-gaap_RelatedPartyDomain_1b7a185d-9280-4774-9ced-1276fc1bc52e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1a2b0aa7-8610-4ded-babf-ba6cda06869a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b7a185d-9280-4774-9ced-1276fc1bc52e" xlink:to="loc_us-gaap_RelatedPartyDomain_1a2b0aa7-8610-4ded-babf-ba6cda06869a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_f65c102c-e187-4568-bf20-28f5105e3022" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_1a2b0aa7-8610-4ded-babf-ba6cda06869a" xlink:to="loc_us-gaap_InvestorMember_f65c102c-e187-4568-bf20-28f5105e3022" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2c16a918-c0c5-48e0-87c0-a314b7d1ddf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_509c2a1a-6022-4c63-ab93-e5ba0effce2d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2c16a918-c0c5-48e0-87c0-a314b7d1ddf7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2c16a918-c0c5-48e0-87c0-a314b7d1ddf7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2c16a918-c0c5-48e0-87c0-a314b7d1ddf7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2c16a918-c0c5-48e0-87c0-a314b7d1ddf7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4a1d1dc1-c823-4ce7-a5ec-8f57b09ca809" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2c16a918-c0c5-48e0-87c0-a314b7d1ddf7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4a1d1dc1-c823-4ce7-a5ec-8f57b09ca809" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_cee44ae9-078e-4e9f-b9f1-c4ffa3ed92b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BridgeLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4a1d1dc1-c823-4ce7-a5ec-8f57b09ca809" xlink:to="loc_us-gaap_BridgeLoanMember_cee44ae9-078e-4e9f-b9f1-c4ffa3ed92b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_92e8e5d6-ac27-4efb-aba8-2fba53d58e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_509c2a1a-6022-4c63-ab93-e5ba0effce2d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_92e8e5d6-ac27-4efb-aba8-2fba53d58e8c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_92e8e5d6-ac27-4efb-aba8-2fba53d58e8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_92e8e5d6-ac27-4efb-aba8-2fba53d58e8c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_92e8e5d6-ac27-4efb-aba8-2fba53d58e8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fbd8a2c4-ffc3-45ba-a5d3-9483a94ce195" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_92e8e5d6-ac27-4efb-aba8-2fba53d58e8c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fbd8a2c4-ffc3-45ba-a5d3-9483a94ce195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_0615d781-15dd-4ad5-8f96-050202aeb584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fbd8a2c4-ffc3-45ba-a5d3-9483a94ce195" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_0615d781-15dd-4ad5-8f96-050202aeb584" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_36cfe184-ca3c-4826-8a31-6323060c50df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_509c2a1a-6022-4c63-ab93-e5ba0effce2d" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_36cfe184-ca3c-4826-8a31-6323060c50df" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_36cfe184-ca3c-4826-8a31-6323060c50df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_36cfe184-ca3c-4826-8a31-6323060c50df" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_36cfe184-ca3c-4826-8a31-6323060c50df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_07bac1bb-bf08-47b9-baba-66ff7675bed3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_36cfe184-ca3c-4826-8a31-6323060c50df" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_07bac1bb-bf08-47b9-baba-66ff7675bed3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_9ea1e819-b606-4bee-9e25-a88bf957cccd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_07bac1bb-bf08-47b9-baba-66ff7675bed3" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_9ea1e819-b606-4bee-9e25-a88bf957cccd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_8b8e6af1-b295-4732-bf2d-1eff02f5ee3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_509c2a1a-6022-4c63-ab93-e5ba0effce2d" xlink:to="loc_us-gaap_ValuationTechniqueAxis_8b8e6af1-b295-4732-bf2d-1eff02f5ee3f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_8b8e6af1-b295-4732-bf2d-1eff02f5ee3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_8b8e6af1-b295-4732-bf2d-1eff02f5ee3f" xlink:to="loc_us-gaap_ValuationTechniqueDomain_8b8e6af1-b295-4732-bf2d-1eff02f5ee3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_3131c4cb-2a36-4c8e-ad54-2a3300bbd4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_8b8e6af1-b295-4732-bf2d-1eff02f5ee3f" xlink:to="loc_us-gaap_ValuationTechniqueDomain_3131c4cb-2a36-4c8e-ad54-2a3300bbd4e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_a91376c1-2b50-42ca-b1f5-1eb20a4b4599" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_3131c4cb-2a36-4c8e-ad54-2a3300bbd4e1" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_a91376c1-2b50-42ca-b1f5-1eb20a4b4599" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f5358406-0c10-4323-aead-78a7ed76e352" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f5358406-0c10-4323-aead-78a7ed76e352" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5eae43a4-ad99-461a-95f3-b0f883e99a34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5eae43a4-ad99-461a-95f3-b0f883e99a34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_86f41374-6f40-49ca-a48b-f2d81bc17d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_86f41374-6f40-49ca-a48b-f2d81bc17d1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_f0b51771-3af7-43ca-a4d1-3509a6f3625a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_f0b51771-3af7-43ca-a4d1-3509a6f3625a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_61c12336-40af-467a-9ef6-874fe001d3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_61c12336-40af-467a-9ef6-874fe001d3b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EquityIssuanceCost_f167f3ce-0345-4ba1-ade5-00130b647650" xlink:href="lgnd-20241231.xsd#lgnd_EquityIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_lgnd_EquityIssuanceCost_f167f3ce-0345-4ba1-ade5-00130b647650" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_ef616604-d767-44c9-8182-ba013d6d5d98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_ef616604-d767-44c9-8182-ba013d6d5d98" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6e8ce1fc-96b3-47e2-af6c-90b1301c7ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6e8ce1fc-96b3-47e2-af6c-90b1301c7ec9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_cd0e2106-0e7e-434d-9b7c-ca0424a7a145" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_cd0e2106-0e7e-434d-9b7c-ca0424a7a145" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAcquiredPercentage_cdeff4a4-ff5e-4dda-99e9-4e3f6d992e10" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationAcquiredPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_lgnd_BusinessCombinationAcquiredPercentage_cdeff4a4-ff5e-4dda-99e9-4e3f6d992e10" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_08d830b5-87c4-4660-a732-0e64761c9531" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_08d830b5-87c4-4660-a732-0e64761c9531" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_93e787c5-56d3-4a0e-ba80-df09b73a88a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_93e787c5-56d3-4a0e-ba80-df09b73a88a5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_beed2651-1164-4240-b551-98c27bcfed17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_beed2651-1164-4240-b551-98c27bcfed17" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_d247ab07-dbd1-4c10-aa81-205cb3c05867" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_d247ab07-dbd1-4c10-aa81-205cb3c05867" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_f7f68861-917f-46c7-8d76-a6812427836f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_f7f68861-917f-46c7-8d76-a6812427836f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_5834fafb-5eb2-4dc7-8179-e052779c927f" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_5834fafb-5eb2-4dc7-8179-e052779c927f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentMilestonePurchaseAgreement_739f616c-01cf-463d-8c4d-1aa1541f66a7" xlink:href="lgnd-20241231.xsd#lgnd_ContingentMilestonePurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_lgnd_ContingentMilestonePurchaseAgreement_739f616c-01cf-463d-8c4d-1aa1541f66a7" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_3c383fc3-44a4-4fbf-a1bd-4e89eb2cf8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_3c383fc3-44a4-4fbf-a1bd-4e89eb2cf8ac" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b18d9e11-5bd4-45e1-aa0a-338b25edd3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0b51deff-b04e-419c-b6f8-8a6f4b788dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b18d9e11-5bd4-45e1-aa0a-338b25edd3ab" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0b51deff-b04e-419c-b6f8-8a6f4b788dbf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_01afd8bf-86a9-418c-9284-6d69d792497d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0b51deff-b04e-419c-b6f8-8a6f4b788dbf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_01afd8bf-86a9-418c-9284-6d69d792497d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01afd8bf-86a9-418c-9284-6d69d792497d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_01afd8bf-86a9-418c-9284-6d69d792497d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01afd8bf-86a9-418c-9284-6d69d792497d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3d17ed30-24e3-4b99-ba0a-c2212d93832b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_01afd8bf-86a9-418c-9284-6d69d792497d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3d17ed30-24e3-4b99-ba0a-c2212d93832b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_APEIRONMember_3f61a630-5f90-418a-9083-ece430aa2f0c" xlink:href="lgnd-20241231.xsd#lgnd_APEIRONMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3d17ed30-24e3-4b99-ba0a-c2212d93832b" xlink:to="loc_lgnd_APEIRONMember_3f61a630-5f90-418a-9083-ece430aa2f0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_edcb9b67-73c0-4cd7-baad-0568d9e45069" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b18d9e11-5bd4-45e1-aa0a-338b25edd3ab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_edcb9b67-73c0-4cd7-baad-0568d9e45069" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets_8e93b9dc-6348-455c-827e-5fc41269ebf1" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b18d9e11-5bd4-45e1-aa0a-338b25edd3ab" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets_8e93b9dc-6348-455c-827e-5fc41269ebf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_de617cc0-525a-4c08-80ff-ba6497453442" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b18d9e11-5bd4-45e1-aa0a-338b25edd3ab" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_de617cc0-525a-4c08-80ff-ba6497453442" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_a29ca3a1-ec58-415b-997c-bf3fbbefea0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b18d9e11-5bd4-45e1-aa0a-338b25edd3ab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_a29ca3a1-ec58-415b-997c-bf3fbbefea0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable_0dc6f12e-9c46-4fed-9b6e-3cdb4629a3ff" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b18d9e11-5bd4-45e1-aa0a-338b25edd3ab" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable_0dc6f12e-9c46-4fed-9b6e-3cdb4629a3ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ee810d47-c1ca-4cd1-909f-099378141424" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b18d9e11-5bd4-45e1-aa0a-338b25edd3ab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ee810d47-c1ca-4cd1-909f-099378141424" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2b058a0d-31df-45c7-b19e-15040ab69dab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b18d9e11-5bd4-45e1-aa0a-338b25edd3ab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2b058a0d-31df-45c7-b19e-15040ab69dab" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_55d863eb-a5d4-4436-8564-72fcd648f075" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_55d863eb-a5d4-4436-8564-72fcd648f075" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ef505f1b-e899-480b-aa8c-38510a209307" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_55d863eb-a5d4-4436-8564-72fcd648f075" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ef505f1b-e899-480b-aa8c-38510a209307" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ef505f1b-e899-480b-aa8c-38510a209307_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ef505f1b-e899-480b-aa8c-38510a209307" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ef505f1b-e899-480b-aa8c-38510a209307_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04f01989-d8cd-4dab-916f-4e0fa5578266" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ef505f1b-e899-480b-aa8c-38510a209307" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04f01989-d8cd-4dab-916f-4e0fa5578266" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanIncMember_02b8389e-4091-4011-a6ba-af465476fb52" xlink:href="lgnd-20241231.xsd#lgnd_NovanIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04f01989-d8cd-4dab-916f-4e0fa5578266" xlink:to="loc_lgnd_NovanIncMember_02b8389e-4091-4011-a6ba-af465476fb52" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6ef24731-6bf0-4a46-bfd0-17e3c2653488" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6ef24731-6bf0-4a46-bfd0-17e3c2653488" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_b0f111a6-c7f7-476b-9e18-e30de9ce84f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_b0f111a6-c7f7-476b-9e18-e30de9ce84f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_2f3a6fcb-5157-4f98-9cc0-b6d061366709" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_2f3a6fcb-5157-4f98-9cc0-b6d061366709" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_65416db6-e9d1-4897-8b2e-9cb64bb33487" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_65416db6-e9d1-4897-8b2e-9cb64bb33487" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_2cdb29fd-e68c-450d-b2c5-794d89a362e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_2cdb29fd-e68c-450d-b2c5-794d89a362e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_691dd7c5-da63-4021-aff8-190b845cef4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_691dd7c5-da63-4021-aff8-190b845cef4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_83149b9a-0f05-4695-9c38-320873f40448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_us-gaap_Goodwill_83149b9a-0f05-4695-9c38-320873f40448" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_662e2ed4-0cbd-4890-847c-db6d74f3ef99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_662e2ed4-0cbd-4890-847c-db6d74f3ef99" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_6cca5e4a-a431-4604-9242-fa96e7ad696a" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_6cca5e4a-a431-4604-9242-fa96e7ad696a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_7a98c77f-9a91-4a48-8dc5-1cda666b3c0d" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_7a98c77f-9a91-4a48-8dc5-1cda666b3c0d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_cb29aca2-9f52-4f77-98da-320646d00c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_cb29aca2-9f52-4f77-98da-320646d00c1b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationLoanFeesAndInterest_7fa799bc-c022-4948-a08f-c7d1661233b9" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationLoanFeesAndInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_lgnd_BusinessCombinationLoanFeesAndInterest_7fa799bc-c022-4948-a08f-c7d1661233b9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_27e16252-3df5-4c95-80ff-d21a7eeeb73b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_27e16252-3df5-4c95-80ff-d21a7eeeb73b" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_ecff4c64-82aa-4255-aee1-f91a44a73df3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_ecff4c64-82aa-4255-aee1-f91a44a73df3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_ecff4c64-82aa-4255-aee1-f91a44a73df3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_ecff4c64-82aa-4255-aee1-f91a44a73df3" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_ecff4c64-82aa-4255-aee1-f91a44a73df3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_315f5527-f04c-4ae5-9ee6-4b38cc50f77e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_ecff4c64-82aa-4255-aee1-f91a44a73df3" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_315f5527-f04c-4ae5-9ee6-4b38cc50f77e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimordialGeneticsMember_3904cbcf-0676-4add-ab80-4d91ffba4565" xlink:href="lgnd-20241231.xsd#lgnd_PrimordialGeneticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_315f5527-f04c-4ae5-9ee6-4b38cc50f77e" xlink:to="loc_lgnd_PrimordialGeneticsMember_3904cbcf-0676-4add-ab80-4d91ffba4565" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_9b0d01a5-3f82-494d-a55f-c249297868ad" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_srt_StatementScenarioAxis_9b0d01a5-3f82-494d-a55f-c249297868ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9b0d01a5-3f82-494d-a55f-c249297868ad_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_9b0d01a5-3f82-494d-a55f-c249297868ad" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9b0d01a5-3f82-494d-a55f-c249297868ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f00eae3c-1c8b-492e-a428-391e0ccbe7fb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_9b0d01a5-3f82-494d-a55f-c249297868ad" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f00eae3c-1c8b-492e-a428-391e0ccbe7fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_1a5ae47f-fc43-4704-a87c-c53913608f5b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f00eae3c-1c8b-492e-a428-391e0ccbe7fb" xlink:to="loc_srt_ScenarioForecastMember_1a5ae47f-fc43-4704-a87c-c53913608f5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_36fc4a41-3a57-435d-a89b-52ea3b03a90c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_srt_CounterpartyNameAxis_36fc4a41-3a57-435d-a89b-52ea3b03a90c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36fc4a41-3a57-435d-a89b-52ea3b03a90c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_36fc4a41-3a57-435d-a89b-52ea3b03a90c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_36fc4a41-3a57-435d-a89b-52ea3b03a90c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_594cd391-43f2-4835-98d8-798bb0f537bd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_36fc4a41-3a57-435d-a89b-52ea3b03a90c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_594cd391-43f2-4835-98d8-798bb0f537bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember_cb7ab2bc-56fb-4658-8a6a-cc4f396da537" xlink:href="lgnd-20241231.xsd#lgnd_PrimroseBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_594cd391-43f2-4835-98d8-798bb0f537bd" xlink:to="loc_lgnd_PrimroseBioMember_cb7ab2bc-56fb-4658-8a6a-cc4f396da537" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AgenusPartneredProgramMember_50bb83cf-963c-4acb-bc43-7c3e5c736100" xlink:href="lgnd-20241231.xsd#lgnd_AgenusPartneredProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_594cd391-43f2-4835-98d8-798bb0f537bd" xlink:to="loc_lgnd_AgenusPartneredProgramMember_50bb83cf-963c-4acb-bc43-7c3e5c736100" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_318bdb39-d995-49b9-b301-1ec39edba7c2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_srt_ProductOrServiceAxis_318bdb39-d995-49b9-b301-1ec39edba7c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_318bdb39-d995-49b9-b301-1ec39edba7c2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_318bdb39-d995-49b9-b301-1ec39edba7c2" xlink:to="loc_srt_ProductsAndServicesDomain_318bdb39-d995-49b9-b301-1ec39edba7c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e16b8691-ccdf-4d48-a5e5-5998869e6a11" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_318bdb39-d995-49b9-b301-1ec39edba7c2" xlink:to="loc_srt_ProductsAndServicesDomain_e16b8691-ccdf-4d48-a5e5-5998869e6a11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PeliCRM197Member_a5b8eb9c-6755-4d85-8175-9c7be9989ee5" xlink:href="lgnd-20241231.xsd#lgnd_PeliCRM197Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e16b8691-ccdf-4d48-a5e5-5998869e6a11" xlink:to="loc_lgnd_PeliCRM197Member_a5b8eb9c-6755-4d85-8175-9c7be9989ee5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneAxis_d0337a49-db9d-4917-813e-eb70f11938d2" xlink:href="lgnd-20241231.xsd#lgnd_MilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_lgnd_MilestoneAxis_d0337a49-db9d-4917-813e-eb70f11938d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneDomain_d0337a49-db9d-4917-813e-eb70f11938d2_default" xlink:href="lgnd-20241231.xsd#lgnd_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lgnd_MilestoneAxis_d0337a49-db9d-4917-813e-eb70f11938d2" xlink:to="loc_lgnd_MilestoneDomain_d0337a49-db9d-4917-813e-eb70f11938d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneDomain_57b979ec-d759-459a-801a-eb77589344ca" xlink:href="lgnd-20241231.xsd#lgnd_MilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lgnd_MilestoneAxis_d0337a49-db9d-4917-813e-eb70f11938d2" xlink:to="loc_lgnd_MilestoneDomain_57b979ec-d759-459a-801a-eb77589344ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BelowMilestoneMember_fb7999ea-01bc-49d9-b3f8-13a311f5ce6f" xlink:href="lgnd-20241231.xsd#lgnd_BelowMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_MilestoneDomain_57b979ec-d759-459a-801a-eb77589344ca" xlink:to="loc_lgnd_BelowMilestoneMember_fb7999ea-01bc-49d9-b3f8-13a311f5ce6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AboveMilestoneMember_551212d4-030e-4690-98a5-0c3cf4f05da5" xlink:href="lgnd-20241231.xsd#lgnd_AboveMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_MilestoneDomain_57b979ec-d759-459a-801a-eb77589344ca" xlink:to="loc_lgnd_AboveMilestoneMember_551212d4-030e-4690-98a5-0c3cf4f05da5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_03476b5d-834a-4666-9133-ac1fdfb4feef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_03476b5d-834a-4666-9133-ac1fdfb4feef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_03476b5d-834a-4666-9133-ac1fdfb4feef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_03476b5d-834a-4666-9133-ac1fdfb4feef" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_03476b5d-834a-4666-9133-ac1fdfb4feef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_521dddda-8ff7-4773-9bb1-c7bcd7d7ec19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_03476b5d-834a-4666-9133-ac1fdfb4feef" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_521dddda-8ff7-4773-9bb1-c7bcd7d7ec19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_4e0dc57e-5133-4229-a379-75cc9b4b1ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_521dddda-8ff7-4773-9bb1-c7bcd7d7ec19" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_4e0dc57e-5133-4229-a379-75cc9b4b1ff3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3806be3b-3b49-4816-8b14-9455b1561705" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3806be3b-3b49-4816-8b14-9455b1561705" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3806be3b-3b49-4816-8b14-9455b1561705_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3806be3b-3b49-4816-8b14-9455b1561705" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_3806be3b-3b49-4816-8b14-9455b1561705_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4a246384-5d37-4015-a1a1-d45c092dce37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3806be3b-3b49-4816-8b14-9455b1561705" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4a246384-5d37-4015-a1a1-d45c092dce37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PelicanTechnologyHoldingsIncMember_d2f48674-eb65-4357-b9e3-bf45d332e14e" xlink:href="lgnd-20241231.xsd#lgnd_PelicanTechnologyHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4a246384-5d37-4015-a1a1-d45c092dce37" xlink:to="loc_lgnd_PelicanTechnologyHoldingsIncMember_d2f48674-eb65-4357-b9e3-bf45d332e14e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e24a1398-5cb2-4667-8fee-daacbf20f08b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e24a1398-5cb2-4667-8fee-daacbf20f08b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e24a1398-5cb2-4667-8fee-daacbf20f08b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e24a1398-5cb2-4667-8fee-daacbf20f08b" xlink:to="loc_us-gaap_ClassOfStockDomain_e24a1398-5cb2-4667-8fee-daacbf20f08b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3cb0fdbc-43cb-460f-a889-c466e7ac4be0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e24a1398-5cb2-4667-8fee-daacbf20f08b" xlink:to="loc_us-gaap_ClassOfStockDomain_3cb0fdbc-43cb-460f-a889-c466e7ac4be0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c6b40ba8-0f9b-4c2d-91e1-0448a97728cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3cb0fdbc-43cb-460f-a889-c466e7ac4be0" xlink:to="loc_us-gaap_CommonStockMember_c6b40ba8-0f9b-4c2d-91e1-0448a97728cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_7e92b4f4-a4b0-4b71-80c0-923505df8d27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3cb0fdbc-43cb-460f-a889-c466e7ac4be0" xlink:to="loc_us-gaap_PreferredStockMember_7e92b4f4-a4b0-4b71-80c0-923505df8d27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_050e9b69-b552-4fd1-9fbb-1e9a9ea0e0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_us-gaap_AwardTypeAxis_050e9b69-b552-4fd1-9fbb-1e9a9ea0e0e8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_050e9b69-b552-4fd1-9fbb-1e9a9ea0e0e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_050e9b69-b552-4fd1-9fbb-1e9a9ea0e0e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_050e9b69-b552-4fd1-9fbb-1e9a9ea0e0e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d493c89-2ddb-4104-b6b7-33513a7de101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_050e9b69-b552-4fd1-9fbb-1e9a9ea0e0e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d493c89-2ddb-4104-b6b7-33513a7de101" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e7f67d82-af33-4147-8837-06ee2418a9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d493c89-2ddb-4104-b6b7-33513a7de101" xlink:to="loc_us-gaap_RestrictedStockMember_e7f67d82-af33-4147-8837-06ee2418a9fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5015dcaa-51e1-499f-aab3-01746fba35ab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5015dcaa-51e1-499f-aab3-01746fba35ab" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5015dcaa-51e1-499f-aab3-01746fba35ab_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5015dcaa-51e1-499f-aab3-01746fba35ab" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5015dcaa-51e1-499f-aab3-01746fba35ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3ce50969-e66e-4ba9-9f21-7b2e453d3524" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5015dcaa-51e1-499f-aab3-01746fba35ab" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3ce50969-e66e-4ba9-9f21-7b2e453d3524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember_fa5ece35-7bc5-4747-8496-5e15dd2e24d4" xlink:href="lgnd-20241231.xsd#lgnd_PrimroseBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3ce50969-e66e-4ba9-9f21-7b2e453d3524" xlink:to="loc_lgnd_PrimroseBioMember_fa5ece35-7bc5-4747-8496-5e15dd2e24d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration_235958bb-49e8-4110-b786-c286ca6d562f" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration_235958bb-49e8-4110-b786-c286ca6d562f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_cac12d7d-bd9b-4566-be30-ddb503958b2a" xlink:href="lgnd-20241231.xsd#lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_cac12d7d-bd9b-4566-be30-ddb503958b2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneCompensationRate_4f6897fa-0bef-43de-a380-58f286aead84" xlink:href="lgnd-20241231.xsd#lgnd_MilestoneCompensationRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_lgnd_MilestoneCompensationRate_4f6897fa-0bef-43de-a380-58f286aead84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContracts_f892ab2a-d54f-423a-acc6-830d7bdac7c9" xlink:href="lgnd-20241231.xsd#lgnd_NumberOfContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_lgnd_NumberOfContracts_f892ab2a-d54f-423a-acc6-830d7bdac7c9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SalesRevenueMilestone_d81bf852-7e1d-4a57-9140-7ba9d87ee407" xlink:href="lgnd-20241231.xsd#lgnd_SalesRevenueMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_lgnd_SalesRevenueMilestone_d81bf852-7e1d-4a57-9140-7ba9d87ee407" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SalesContractInterestInSalesRevenue_646367f5-bbfa-4988-ab49-1fc69e5c594c" xlink:href="lgnd-20241231.xsd#lgnd_SalesContractInterestInSalesRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_lgnd_SalesContractInterestInSalesRevenue_646367f5-bbfa-4988-ab49-1fc69e5c594c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_f0022e18-e66e-47c3-98ad-3aa1f61d2b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_f0022e18-e66e-47c3-98ad-3aa1f61d2b8b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_dc6e8030-22a9-4b5f-af01-9861af253acd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_dc6e8030-22a9-4b5f-af01-9861af253acd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_12bd0306-e2b8-4c80-a087-5cb12053f71e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessExitCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_us-gaap_BusinessExitCosts1_12bd0306-e2b8-4c80-a087-5cb12053f71e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_08750b65-5b51-44e9-bee9-2464d766f00b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_08750b65-5b51-44e9-bee9-2464d766f00b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_adc8107d-a0d4-4446-9570-d17621a89479" xlink:href="lgnd-20241231.xsd#lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_adc8107d-a0d4-4446-9570-d17621a89479" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_a3a02416-3b09-4099-8c2d-56a855ae8f90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_a3a02416-3b09-4099-8c2d-56a855ae8f90" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_3e5509ed-9e78-49d3-899e-55183d28ef45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_3e5509ed-9e78-49d3-899e-55183d28ef45" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0dcc3191-06d6-4e28-ac6a-517f45dd99d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0dcc3191-06d6-4e28-ac6a-517f45dd99d1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_0926fcf6-a296-4929-8a01-2a6056b96d69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_0926fcf6-a296-4929-8a01-2a6056b96d69" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f964d8d6-3959-45cb-8050-3950d6622083" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f964d8d6-3959-45cb-8050-3950d6622083" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_998b6a26-1da5-4071-8f88-c768344c150e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f964d8d6-3959-45cb-8050-3950d6622083" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_998b6a26-1da5-4071-8f88-c768344c150e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_998b6a26-1da5-4071-8f88-c768344c150e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_998b6a26-1da5-4071-8f88-c768344c150e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_998b6a26-1da5-4071-8f88-c768344c150e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_27d2d933-33a1-4fe8-9656-95ce8618cddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_998b6a26-1da5-4071-8f88-c768344c150e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_27d2d933-33a1-4fe8-9656-95ce8618cddc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_266fd6b1-ae4b-4b06-8944-f7c5efac2f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_27d2d933-33a1-4fe8-9656-95ce8618cddc" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_266fd6b1-ae4b-4b06-8944-f7c5efac2f8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_725175b5-633d-47a9-a9f9-4c11a0d8cb99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f964d8d6-3959-45cb-8050-3950d6622083" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_725175b5-633d-47a9-a9f9-4c11a0d8cb99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_725175b5-633d-47a9-a9f9-4c11a0d8cb99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_725175b5-633d-47a9-a9f9-4c11a0d8cb99" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_725175b5-633d-47a9-a9f9-4c11a0d8cb99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4fb3c57e-61fd-4b54-a7bf-5924ef26b5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_725175b5-633d-47a9-a9f9-4c11a0d8cb99" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4fb3c57e-61fd-4b54-a7bf-5924ef26b5a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PelicanTechnologyHoldingsIncMember_3c40f5e0-eef7-48c8-8ac6-d6590db0fb3c" xlink:href="lgnd-20241231.xsd#lgnd_PelicanTechnologyHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4fb3c57e-61fd-4b54-a7bf-5924ef26b5a1" xlink:to="loc_lgnd_PelicanTechnologyHoldingsIncMember_3c40f5e0-eef7-48c8-8ac6-d6590db0fb3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_92ffc6f7-e4b1-482d-9203-666b5a4f507b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_92ffc6f7-e4b1-482d-9203-666b5a4f507b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_2e12e289-6b20-4df0-92e6-8c01618f7405" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_2e12e289-6b20-4df0-92e6-8c01618f7405" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_8fa7cc54-fbc5-4fb4-b7a7-6b4bd28bc937" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_8fa7cc54-fbc5-4fb4-b7a7-6b4bd28bc937" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_67a366a1-5192-4748-9827-a083f1c1faae" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_67a366a1-5192-4748-9827-a083f1c1faae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset_b088a7b0-7e18-4445-af15-de3074840fd4" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset_b088a7b0-7e18-4445-af15-de3074840fd4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_c64b3db9-cc5f-4ccf-a076-75bdfeed534f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_c64b3db9-cc5f-4ccf-a076-75bdfeed534f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_7007cca8-8f79-418b-a4d7-1909fde57365" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_7007cca8-8f79-418b-a4d7-1909fde57365" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities_6eecc6d1-f711-4958-9fbd-70c0a3d7ece2" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities_6eecc6d1-f711-4958-9fbd-70c0a3d7ece2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_4a987cad-52a3-4c0f-abbf-c5d6bd407e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_4a987cad-52a3-4c0f-abbf-c5d6bd407e8e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_f0499e04-18ad-4ed3-aad8-4eb146e8ccfa" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_f0499e04-18ad-4ed3-aad8-4eb146e8ccfa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_c58902ac-1948-4fa6-9e0a-a7f3d2eeeee6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_c58902ac-1948-4fa6-9e0a-a7f3d2eeeee6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_043c0868-741d-4a96-970f-d4fda5eff8e9" xlink:href="lgnd-20241231.xsd#lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_043c0868-741d-4a96-970f-d4fda5eff8e9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_71504b95-63e5-4cbf-860b-b98112a76881" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_71504b95-63e5-4cbf-860b-b98112a76881" xlink:type="arc" order="12"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e9b9d945-ad88-4315-9a61-a74aab7624c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ade1da6c-2748-47c8-9e8a-a40f18e418ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e9b9d945-ad88-4315-9a61-a74aab7624c7" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ade1da6c-2748-47c8-9e8a-a40f18e418ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_8ea74014-8c6f-4078-a1d4-8c5919d2376c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ade1da6c-2748-47c8-9e8a-a40f18e418ad" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_8ea74014-8c6f-4078-a1d4-8c5919d2376c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_8ea74014-8c6f-4078-a1d4-8c5919d2376c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8ea74014-8c6f-4078-a1d4-8c5919d2376c" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_8ea74014-8c6f-4078-a1d4-8c5919d2376c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e997a2ee-bd5c-4526-9466-061c69c253f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8ea74014-8c6f-4078-a1d4-8c5919d2376c" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e997a2ee-bd5c-4526-9466-061c69c253f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e33db3b1-bcc2-4c8f-9d90-edcea782a9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e997a2ee-bd5c-4526-9466-061c69c253f2" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e33db3b1-bcc2-4c8f-9d90-edcea782a9a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102c2a5-ac5c-4bde-9f04-76c8a88d639d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ade1da6c-2748-47c8-9e8a-a40f18e418ad" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102c2a5-ac5c-4bde-9f04-76c8a88d639d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1102c2a5-ac5c-4bde-9f04-76c8a88d639d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102c2a5-ac5c-4bde-9f04-76c8a88d639d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1102c2a5-ac5c-4bde-9f04-76c8a88d639d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cd129850-fe48-4624-854e-899417433d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102c2a5-ac5c-4bde-9f04-76c8a88d639d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cd129850-fe48-4624-854e-899417433d3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PelicanTechnologyHoldingsIncMember_f29c261e-9050-4cc0-8f96-9c404f694ccd" xlink:href="lgnd-20241231.xsd#lgnd_PelicanTechnologyHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cd129850-fe48-4624-854e-899417433d3e" xlink:to="loc_lgnd_PelicanTechnologyHoldingsIncMember_f29c261e-9050-4cc0-8f96-9c404f694ccd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationClassficationAxis_9fc1318b-89ab-439e-8781-3dbc76dcdd79" xlink:href="lgnd-20241231.xsd#lgnd_ConsiderationClassficationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ade1da6c-2748-47c8-9e8a-a40f18e418ad" xlink:to="loc_lgnd_ConsiderationClassficationAxis_9fc1318b-89ab-439e-8781-3dbc76dcdd79" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationClassficationDomain_9fc1318b-89ab-439e-8781-3dbc76dcdd79_default" xlink:href="lgnd-20241231.xsd#lgnd_ConsiderationClassficationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lgnd_ConsiderationClassficationAxis_9fc1318b-89ab-439e-8781-3dbc76dcdd79" xlink:to="loc_lgnd_ConsiderationClassficationDomain_9fc1318b-89ab-439e-8781-3dbc76dcdd79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationClassficationDomain_a3bb084b-cd9c-4dfb-9a26-bd0c840389bb" xlink:href="lgnd-20241231.xsd#lgnd_ConsiderationClassficationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lgnd_ConsiderationClassficationAxis_9fc1318b-89ab-439e-8781-3dbc76dcdd79" xlink:to="loc_lgnd_ConsiderationClassficationDomain_a3bb084b-cd9c-4dfb-9a26-bd0c840389bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EquityMethodInvestmentsAllocationMember_796bfb25-8c50-4897-8031-a4121dbf5ac1" xlink:href="lgnd-20241231.xsd#lgnd_EquityMethodInvestmentsAllocationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ConsiderationClassficationDomain_a3bb084b-cd9c-4dfb-9a26-bd0c840389bb" xlink:to="loc_lgnd_EquityMethodInvestmentsAllocationMember_796bfb25-8c50-4897-8031-a4121dbf5ac1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EquitySecuritiesAllocationMember_a6a7d904-bbaa-475b-9388-97cf087d925f" xlink:href="lgnd-20241231.xsd#lgnd_EquitySecuritiesAllocationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ConsiderationClassficationDomain_a3bb084b-cd9c-4dfb-9a26-bd0c840389bb" xlink:to="loc_lgnd_EquitySecuritiesAllocationMember_a6a7d904-bbaa-475b-9388-97cf087d925f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeAssetsMember_c1c978f1-face-4fd6-8d40-099a723b04b9" xlink:href="lgnd-20241231.xsd#lgnd_DerivativeAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ConsiderationClassficationDomain_a3bb084b-cd9c-4dfb-9a26-bd0c840389bb" xlink:to="loc_lgnd_DerivativeAssetsMember_c1c978f1-face-4fd6-8d40-099a723b04b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_bac6d76a-6b5d-425c-8cea-c9daf3833f74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e9b9d945-ad88-4315-9a61-a74aab7624c7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_bac6d76a-6b5d-425c-8cea-c9daf3833f74" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SpinoffofOmniAbNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_719c49d6-3c3b-4895-aad0-dbc510381a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cc59c8f7-91e3-425f-b408-d835e84f9e17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_719c49d6-3c3b-4895-aad0-dbc510381a9e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cc59c8f7-91e3-425f-b408-d835e84f9e17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_7f54708a-853d-4da7-b4d6-c92cd22bbeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cc59c8f7-91e3-425f-b408-d835e84f9e17" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_7f54708a-853d-4da7-b4d6-c92cd22bbeb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_7f54708a-853d-4da7-b4d6-c92cd22bbeb7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7f54708a-853d-4da7-b4d6-c92cd22bbeb7" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_7f54708a-853d-4da7-b4d6-c92cd22bbeb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b3260f29-debf-4c38-9bf8-f6106408a769" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7f54708a-853d-4da7-b4d6-c92cd22bbeb7" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b3260f29-debf-4c38-9bf8-f6106408a769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_dc319cf6-1abd-4715-948d-8727956bb0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_b3260f29-debf-4c38-9bf8-f6106408a769" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_dc319cf6-1abd-4715-948d-8727956bb0ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_96245b7f-3721-4e68-90a0-c672ff1c1ec6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cc59c8f7-91e3-425f-b408-d835e84f9e17" xlink:to="loc_srt_StatementScenarioAxis_96245b7f-3721-4e68-90a0-c672ff1c1ec6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_96245b7f-3721-4e68-90a0-c672ff1c1ec6_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_96245b7f-3721-4e68-90a0-c672ff1c1ec6" xlink:to="loc_srt_ScenarioUnspecifiedDomain_96245b7f-3721-4e68-90a0-c672ff1c1ec6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7d758e1b-b446-4168-a216-fb83887e47ef" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_96245b7f-3721-4e68-90a0-c672ff1c1ec6" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7d758e1b-b446-4168-a216-fb83887e47ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioAdjustmentMember_d2d84b71-727e-46c6-aca2-3437eb91ab58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScenarioAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_7d758e1b-b446-4168-a216-fb83887e47ef" xlink:to="loc_us-gaap_ScenarioAdjustmentMember_d2d84b71-727e-46c6-aca2-3437eb91ab58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3465aee0-9c5f-4f1b-b767-eedf6c8f8697" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3465aee0-9c5f-4f1b-b767-eedf6c8f8697_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_dece00f0-c8e2-4039-baee-5d526f7f9d23" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed_68ed47dc-e0e1-4598-b0f0-f9fb12efe971" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_719c49d6-3c3b-4895-aad0-dbc510381a9e" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed_68ed47dc-e0e1-4598-b0f0-f9fb12efe971" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7205a04c-332f-444c-ac2e-a2fbefc21e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_719c49d6-3c3b-4895-aad0-dbc510381a9e" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7205a04c-332f-444c-ac2e-a2fbefc21e9b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2d25b822-8394-42b0-a758-162278ff69cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2d25b822-8394-42b0-a758-162278ff69cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_26cd54fa-11b1-4837-a608-972bb7decdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2d25b822-8394-42b0-a758-162278ff69cf" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_26cd54fa-11b1-4837-a608-972bb7decdc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_26cd54fa-11b1-4837-a608-972bb7decdc3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_26cd54fa-11b1-4837-a608-972bb7decdc3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_26cd54fa-11b1-4837-a608-972bb7decdc3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4e452300-7b82-4c08-8d8d-2c77065d859c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_26cd54fa-11b1-4837-a608-972bb7decdc3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4e452300-7b82-4c08-8d8d-2c77065d859c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_87791f03-ebc5-45d0-9a65-b830801fb37c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4e452300-7b82-4c08-8d8d-2c77065d859c" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_87791f03-ebc5-45d0-9a65-b830801fb37c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_99859ea6-a282-4262-9491-d9e2e0d0f05b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2d25b822-8394-42b0-a758-162278ff69cf" xlink:to="loc_srt_ProductOrServiceAxis_99859ea6-a282-4262-9491-d9e2e0d0f05b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_99859ea6-a282-4262-9491-d9e2e0d0f05b_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_99859ea6-a282-4262-9491-d9e2e0d0f05b" xlink:to="loc_srt_ProductsAndServicesDomain_99859ea6-a282-4262-9491-d9e2e0d0f05b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0d867e6d-9043-4e8b-bbbb-5b013cdc918e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_99859ea6-a282-4262-9491-d9e2e0d0f05b" xlink:to="loc_srt_ProductsAndServicesDomain_0d867e6d-9043-4e8b-bbbb-5b013cdc918e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_c8960038-6fa3-4743-a346-0beb5b02254a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0d867e6d-9043-4e8b-bbbb-5b013cdc918e" xlink:to="loc_us-gaap_RoyaltyMember_c8960038-6fa3-4743-a346-0beb5b02254a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_9b607db4-b5ea-420a-9ca3-7fed9ec1c699" xlink:href="lgnd-20241231.xsd#lgnd_ContractRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0d867e6d-9043-4e8b-bbbb-5b013cdc918e" xlink:to="loc_lgnd_ContractRevenueMember_9b607db4-b5ea-420a-9ca3-7fed9ec1c699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_088847ff-23f0-4696-ba84-54f1297c640b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_088847ff-23f0-4696-ba84-54f1297c640b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_5262f459-4a2f-4322-a342-b2957e6cb11a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_088847ff-23f0-4696-ba84-54f1297c640b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_5262f459-4a2f-4322-a342-b2957e6cb11a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_9ed86156-1066-470b-8425-00e4f68e048a" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_9ed86156-1066-470b-8425-00e4f68e048a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_dfff7126-4024-48af-ab2f-edcc9960fc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_9ed86156-1066-470b-8425-00e4f68e048a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_dfff7126-4024-48af-ab2f-edcc9960fc3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_440bb73d-e947-425b-9e1a-f394bf949307" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_9ed86156-1066-470b-8425-00e4f68e048a" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_440bb73d-e947-425b-9e1a-f394bf949307" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_96d12c58-ab4c-4719-9d03-bbc1f91630a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_9ed86156-1066-470b-8425-00e4f68e048a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_96d12c58-ab4c-4719-9d03-bbc1f91630a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_62fefbdf-0283-4419-bcc8-d68102435421" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_9ed86156-1066-470b-8425-00e4f68e048a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_62fefbdf-0283-4419-bcc8-d68102435421" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_dec421be-dd44-41bc-9de6-fb81ebc58a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_dec421be-dd44-41bc-9de6-fb81ebc58a7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_62339bc6-9c23-42b5-bdfc-ad521e9c7b05" xlink:href="lgnd-20241231.xsd#lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:to="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_62339bc6-9c23-42b5-bdfc-ad521e9c7b05" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments_52966caf-6731-465c-9900-0202aa432767" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_62339bc6-9c23-42b5-bdfc-ad521e9c7b05" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments_52966caf-6731-465c-9900-0202aa432767" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_68932c48-7f50-4e28-a721-530efd74899d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_62339bc6-9c23-42b5-bdfc-ad521e9c7b05" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_68932c48-7f50-4e28-a721-530efd74899d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_360962d0-70f8-452b-8fc5-a2def0eace19" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_62339bc6-9c23-42b5-bdfc-ad521e9c7b05" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_360962d0-70f8-452b-8fc5-a2def0eace19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_3d591630-6f1c-4406-b008-4cc6a4a7e70c" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_3d591630-6f1c-4406-b008-4cc6a4a7e70c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_f76efe2e-87ff-44cc-b241-7cbe9e3335d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_f76efe2e-87ff-44cc-b241-7cbe9e3335d4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_a54bdae7-7773-4f6a-9061-910a0de6f739" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_a54bdae7-7773-4f6a-9061-910a0de6f739" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6fceecc4-d2bf-4a3a-a266-0d7ef71a0fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6fceecc4-d2bf-4a3a-a266-0d7ef71a0fb6" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_10b39894-9650-4b5f-8e88-85e41f0d978c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_dc2c6870-060e-43c7-baa3-f0f5ea5059db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_10b39894-9650-4b5f-8e88-85e41f0d978c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_dc2c6870-060e-43c7-baa3-f0f5ea5059db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_76a46369-f4a4-4307-9f5d-6ae15ae7741d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_dc2c6870-060e-43c7-baa3-f0f5ea5059db" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_76a46369-f4a4-4307-9f5d-6ae15ae7741d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_76a46369-f4a4-4307-9f5d-6ae15ae7741d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_76a46369-f4a4-4307-9f5d-6ae15ae7741d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_76a46369-f4a4-4307-9f5d-6ae15ae7741d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_520f583c-c79f-464f-ae09-3c7233dd380e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_76a46369-f4a4-4307-9f5d-6ae15ae7741d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_520f583c-c79f-464f-ae09-3c7233dd380e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_352b0e9a-b410-42c0-b7b7-c2b3f6a09341" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_520f583c-c79f-464f-ae09-3c7233dd380e" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_352b0e9a-b410-42c0-b7b7-c2b3f6a09341" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_c746cfa5-6557-4e54-bbad-19da0fdc3bd9" xlink:href="lgnd-20241231.xsd#lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_10b39894-9650-4b5f-8e88-85e41f0d978c" xlink:to="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_c746cfa5-6557-4e54-bbad-19da0fdc3bd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration_24641f7a-69f0-4dbd-9eed-b8b83e6fdf25" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_c746cfa5-6557-4e54-bbad-19da0fdc3bd9" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration_24641f7a-69f0-4dbd-9eed-b8b83e6fdf25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_d8644bc4-ac6d-4485-9b0e-82f9706353b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_c746cfa5-6557-4e54-bbad-19da0fdc3bd9" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_d8644bc4-ac6d-4485-9b0e-82f9706353b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense_d36eaf12-df1b-4ca8-8664-22a96e7e0477" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_c746cfa5-6557-4e54-bbad-19da0fdc3bd9" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense_d36eaf12-df1b-4ca8-8664-22a96e7e0477" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_ec46a937-ed13-4834-91a5-6a17e1a222f5" xlink:href="lgnd-20241231.xsd#lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_10b39894-9650-4b5f-8e88-85e41f0d978c" xlink:to="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_ec46a937-ed13-4834-91a5-6a17e1a222f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired_d7ce6f73-074f-443b-9116-e7360d1c7979" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_ec46a937-ed13-4834-91a5-6a17e1a222f5" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired_d7ce6f73-074f-443b-9116-e7360d1c7979" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpenditureDiscontinuedOperations_c79b68b3-a886-47b6-b480-872fb1901fec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_ec46a937-ed13-4834-91a5-6a17e1a222f5" xlink:to="loc_us-gaap_CapitalExpenditureDiscontinuedOperations_c79b68b3-a886-47b6-b480-872fb1901fec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity_269a83d4-8bdb-42bf-bb16-e42a0e5a87d0" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsToContingentValueRightHoldersInvestingActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_ec46a937-ed13-4834-91a5-6a17e1a222f5" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity_269a83d4-8bdb-42bf-bb16-e42a0e5a87d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract_69a344f9-4155-4e17-97c0-8fd3eb9343b9" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_10b39894-9650-4b5f-8e88-85e41f0d978c" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract_69a344f9-4155-4e17-97c0-8fd3eb9343b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_37f97fc2-ab16-4aa8-905f-da34eefc9573" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract_69a344f9-4155-4e17-97c0-8fd3eb9343b9" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_37f97fc2-ab16-4aa8-905f-da34eefc9573" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2a220a10-59ed-44c3-b4b1-b51b55485d92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_10b39894-9650-4b5f-8e88-85e41f0d978c" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2a220a10-59ed-44c3-b4b1-b51b55485d92" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid_a6eea7a4-2cab-4963-86c8-53de362785cd" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2a220a10-59ed-44c3-b4b1-b51b55485d92" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid_a6eea7a4-2cab-4963-86c8-53de362785cd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_35ad0854-d938-4345-b206-5be53202071d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e8f68082-d37d-4765-a6a8-b8b5dca60390" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_35ad0854-d938-4345-b206-5be53202071d" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e8f68082-d37d-4765-a6a8-b8b5dca60390" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1004c702-709f-4a03-95a8-1fffd663c8b2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e8f68082-d37d-4765-a6a8-b8b5dca60390" xlink:to="loc_srt_CounterpartyNameAxis_1004c702-709f-4a03-95a8-1fffd663c8b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1004c702-709f-4a03-95a8-1fffd663c8b2_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1004c702-709f-4a03-95a8-1fffd663c8b2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1004c702-709f-4a03-95a8-1fffd663c8b2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1004c702-709f-4a03-95a8-1fffd663c8b2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_QARZIBAMember_e5f712b8-b38b-4951-bd6c-1e3340c0c9c9" xlink:href="lgnd-20241231.xsd#lgnd_QARZIBAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:to="loc_lgnd_QARZIBAMember_e5f712b8-b38b-4951-bd6c-1e3340c0c9c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AgenusInc.Member_2e35b4bc-a813-4fce-bcc1-7f5dc385aede" xlink:href="lgnd-20241231.xsd#lgnd_AgenusInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:to="loc_lgnd_AgenusInc.Member_2e35b4bc-a813-4fce-bcc1-7f5dc385aede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ToleranceTherapeuticsMember_62458815-9355-4a8c-966c-0017bcbaea98" xlink:href="lgnd-20241231.xsd#lgnd_ToleranceTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:to="loc_lgnd_ToleranceTherapeuticsMember_62458815-9355-4a8c-966c-0017bcbaea98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EnsifentrineMember_180465a5-71a1-4c8f-9c2c-b15d2692b53b" xlink:href="lgnd-20241231.xsd#lgnd_EnsifentrineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:to="loc_lgnd_EnsifentrineMember_180465a5-71a1-4c8f-9c2c-b15d2692b53b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ElutiaAndCorMatrixMember_38ef31df-38c0-49fd-96ad-b6cf61f05845" xlink:href="lgnd-20241231.xsd#lgnd_ElutiaAndCorMatrixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:to="loc_lgnd_ElutiaAndCorMatrixMember_38ef31df-38c0-49fd-96ad-b6cf61f05845" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvIOsMember_aee05cf6-af41-4b47-b87c-099281f53b89" xlink:href="lgnd-20241231.xsd#lgnd_InvIOsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:to="loc_lgnd_InvIOsMember_aee05cf6-af41-4b47-b87c-099281f53b89" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisMember_ca73e043-e5fb-47d8-91f6-70719315bad0" xlink:href="lgnd-20241231.xsd#lgnd_SelexisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:to="loc_lgnd_SelexisMember_ca73e043-e5fb-47d8-91f6-70719315bad0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OvidTherapeuticsMember_22e10280-160b-4c3e-a802-8131afa91fcd" xlink:href="lgnd-20241231.xsd#lgnd_OvidTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:to="loc_lgnd_OvidTherapeuticsMember_22e10280-160b-4c3e-a802-8131afa91fcd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsGross_95f6234c-0cf8-4cf1-9bc0-b3719e6181e9" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_35ad0854-d938-4345-b206-5be53202071d" xlink:to="loc_lgnd_FinancialRoyaltyAssetsGross_95f6234c-0cf8-4cf1-9bc0-b3719e6181e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsAllowance_e59a0c34-2518-4bb4-aab6-3e60b78023aa" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_35ad0854-d938-4345-b206-5be53202071d" xlink:to="loc_lgnd_FinancialRoyaltyAssetsAllowance_e59a0c34-2518-4bb4-aab6-3e60b78023aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsNet_1d711f13-40c4-4458-8356-c15249621706" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_35ad0854-d938-4345-b206-5be53202071d" xlink:to="loc_lgnd_FinancialRoyaltyAssetsNet_1d711f13-40c4-4458-8356-c15249621706" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsNetCurrent_fbcd1ac5-8244-4bcd-ad7d-07dec1596200" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_35ad0854-d938-4345-b206-5be53202071d" xlink:to="loc_lgnd_FinancialRoyaltyAssetsNetCurrent_fbcd1ac5-8244-4bcd-ad7d-07dec1596200" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f209a7b3-7a95-49ca-8f57-ff5f6c90b4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f209a7b3-7a95-49ca-8f57-ff5f6c90b4c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_71626936-8dc6-4b7a-9494-0f7d7bdd8460" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f209a7b3-7a95-49ca-8f57-ff5f6c90b4c0" xlink:to="loc_srt_CounterpartyNameAxis_71626936-8dc6-4b7a-9494-0f7d7bdd8460" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71626936-8dc6-4b7a-9494-0f7d7bdd8460_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_71626936-8dc6-4b7a-9494-0f7d7bdd8460" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_71626936-8dc6-4b7a-9494-0f7d7bdd8460_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41fd63bc-39bf-4586-9153-36c96341fe79" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_71626936-8dc6-4b7a-9494-0f7d7bdd8460" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41fd63bc-39bf-4586-9153-36c96341fe79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OvidTherapeuticsMember_765c9ca9-dda1-466c-9505-0954f890da38" xlink:href="lgnd-20241231.xsd#lgnd_OvidTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41fd63bc-39bf-4586-9153-36c96341fe79" xlink:to="loc_lgnd_OvidTherapeuticsMember_765c9ca9-dda1-466c-9505-0954f890da38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisMember_aa366eb3-d37a-4770-b58d-cc410f4abaf2" xlink:href="lgnd-20241231.xsd#lgnd_SelexisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41fd63bc-39bf-4586-9153-36c96341fe79" xlink:to="loc_lgnd_SelexisMember_aa366eb3-d37a-4770-b58d-cc410f4abaf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ElutiaAndCorMatrixMember_f257581f-b06a-4fd4-8e92-57e91acd6196" xlink:href="lgnd-20241231.xsd#lgnd_ElutiaAndCorMatrixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41fd63bc-39bf-4586-9153-36c96341fe79" xlink:to="loc_lgnd_ElutiaAndCorMatrixMember_f257581f-b06a-4fd4-8e92-57e91acd6196" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EnsifentrineMember_c18961fe-2e44-4f63-9f52-1cdcca9297e7" xlink:href="lgnd-20241231.xsd#lgnd_EnsifentrineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41fd63bc-39bf-4586-9153-36c96341fe79" xlink:to="loc_lgnd_EnsifentrineMember_c18961fe-2e44-4f63-9f52-1cdcca9297e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_21ca4897-b923-4116-9ecf-675ec19a3ca6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f209a7b3-7a95-49ca-8f57-ff5f6c90b4c0" xlink:to="loc_srt_ProductOrServiceAxis_21ca4897-b923-4116-9ecf-675ec19a3ca6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_21ca4897-b923-4116-9ecf-675ec19a3ca6_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_21ca4897-b923-4116-9ecf-675ec19a3ca6" xlink:to="loc_srt_ProductsAndServicesDomain_21ca4897-b923-4116-9ecf-675ec19a3ca6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d0c197b9-45d8-4578-beea-cd84d39e89b9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_21ca4897-b923-4116-9ecf-675ec19a3ca6" xlink:to="loc_srt_ProductsAndServicesDomain_d0c197b9-45d8-4578-beea-cd84d39e89b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SoticlestatMember_d6b1ad6c-4301-4f06-a2c6-59b9b6a192a4" xlink:href="lgnd-20241231.xsd#lgnd_SoticlestatMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d0c197b9-45d8-4578-beea-cd84d39e89b9" xlink:to="loc_lgnd_SoticlestatMember_d6b1ad6c-4301-4f06-a2c6-59b9b6a192a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvIOsMember_ca814099-5e74-43c5-9bba-6faf9414af48" xlink:href="lgnd-20241231.xsd#lgnd_InvIOsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d0c197b9-45d8-4578-beea-cd84d39e89b9" xlink:to="loc_lgnd_InvIOsMember_ca814099-5e74-43c5-9bba-6faf9414af48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_QARZIBAMember_51c92dc1-4277-4ec2-9efb-4e009c575488" xlink:href="lgnd-20241231.xsd#lgnd_QARZIBAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d0c197b9-45d8-4578-beea-cd84d39e89b9" xlink:to="loc_lgnd_QARZIBAMember_51c92dc1-4277-4ec2-9efb-4e009c575488" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d680904d-6a64-4173-89ae-63d2ebe99fb1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f209a7b3-7a95-49ca-8f57-ff5f6c90b4c0" xlink:to="loc_srt_RangeAxis_d680904d-6a64-4173-89ae-63d2ebe99fb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d680904d-6a64-4173-89ae-63d2ebe99fb1_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d680904d-6a64-4173-89ae-63d2ebe99fb1" xlink:to="loc_srt_RangeMember_d680904d-6a64-4173-89ae-63d2ebe99fb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_23eee21f-9510-4ffe-aaf0-151a26c5e779" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d680904d-6a64-4173-89ae-63d2ebe99fb1" xlink:to="loc_srt_RangeMember_23eee21f-9510-4ffe-aaf0-151a26c5e779" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4894b216-3d20-4d7d-bb2a-c764696412fc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_23eee21f-9510-4ffe-aaf0-151a26c5e779" xlink:to="loc_srt_MaximumMember_4894b216-3d20-4d7d-bb2a-c764696412fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d5308f75-c4b2-462d-98af-04a7c6f69849" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f209a7b3-7a95-49ca-8f57-ff5f6c90b4c0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d5308f75-c4b2-462d-98af-04a7c6f69849" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5308f75-c4b2-462d-98af-04a7c6f69849_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d5308f75-c4b2-462d-98af-04a7c6f69849" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d5308f75-c4b2-462d-98af-04a7c6f69849_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_85c0aa40-9cd9-490c-8514-5d8018be4dae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d5308f75-c4b2-462d-98af-04a7c6f69849" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_85c0aa40-9cd9-490c-8514-5d8018be4dae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ToleranceTherapeuticsMember_f2cb78ff-2d79-404f-a432-b8856902d00b" xlink:href="lgnd-20241231.xsd#lgnd_ToleranceTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_85c0aa40-9cd9-490c-8514-5d8018be4dae" xlink:to="loc_lgnd_ToleranceTherapeuticsMember_f2cb78ff-2d79-404f-a432-b8856902d00b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_APEIRONMember_accf0e56-5883-438f-8258-a477a43f211f" xlink:href="lgnd-20241231.xsd#lgnd_APEIRONMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_85c0aa40-9cd9-490c-8514-5d8018be4dae" xlink:to="loc_lgnd_APEIRONMember_accf0e56-5883-438f-8258-a477a43f211f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ImpairmentLossOnFinancialRoyaltyAssets_a05398a5-176b-47c7-8393-59bd174daf50" xlink:href="lgnd-20241231.xsd#lgnd_ImpairmentLossOnFinancialRoyaltyAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_lgnd_ImpairmentLossOnFinancialRoyaltyAssets_a05398a5-176b-47c7-8393-59bd174daf50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets_5d32ae45-29c1-4cf8-8dab-d5a0ae4b0840" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets_5d32ae45-29c1-4cf8-8dab-d5a0ae4b0840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_c9112d76-dd3c-4d01-bc8d-be0300c69aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_c9112d76-dd3c-4d01-bc8d-be0300c69aeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProductRoyaltyPercentage_c0cb5ccc-405f-443d-ad93-2bfb4eacf132" xlink:href="lgnd-20241231.xsd#lgnd_ProductRoyaltyPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_lgnd_ProductRoyaltyPercentage_c0cb5ccc-405f-443d-ad93-2bfb4eacf132" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_40678b35-b716-4b96-ba8a-66c65d329dca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_40678b35-b716-4b96-ba8a-66c65d329dca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsGross_e112a74b-9f0c-48c5-aca4-eb43206e109b" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_lgnd_FinancialRoyaltyAssetsGross_e112a74b-9f0c-48c5-aca4-eb43206e109b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_c2048395-78ae-4604-8a56-96071f2c7879" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_c2048395-78ae-4604-8a56-96071f2c7879" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_5239267a-89fd-49f8-bda6-d2c3b22e4232" xlink:href="lgnd-20241231.xsd#lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_5239267a-89fd-49f8-bda6-d2c3b22e4232" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsCreditLossAdjustment_220ea29d-41ae-4518-a434-a8952e463144" xlink:href="lgnd-20241231.xsd#lgnd_CommercialLicenseRightsCreditLossAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_lgnd_CommercialLicenseRightsCreditLossAdjustment_220ea29d-41ae-4518-a434-a8952e463144" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_8b5ea1db-4aca-4892-812f-a16885e4769d" xlink:href="lgnd-20241231.xsd#lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_8b5ea1db-4aca-4892-812f-a16885e4769d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SalesContractInterestInSalesRevenue_e3bf8f10-8204-4b62-bd8e-80b2be9a8caa" xlink:href="lgnd-20241231.xsd#lgnd_SalesContractInterestInSalesRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_lgnd_SalesContractInterestInSalesRevenue_e3bf8f10-8204-4b62-bd8e-80b2be9a8caa" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsInvestmentCategoriesDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e61fa37e-1628-4776-afc9-1ea706638760" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7d32c418-0930-4813-8ca2-7d5c3b89e1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e61fa37e-1628-4776-afc9-1ea706638760" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7d32c418-0930-4813-8ca2-7d5c3b89e1bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a5024319-aa57-4035-a370-ba3d4278fb19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7d32c418-0930-4813-8ca2-7d5c3b89e1bf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a5024319-aa57-4035-a370-ba3d4278fb19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a5024319-aa57-4035-a370-ba3d4278fb19_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a5024319-aa57-4035-a370-ba3d4278fb19" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a5024319-aa57-4035-a370-ba3d4278fb19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e853239-99b4-483e-a1bb-2efb866727c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a5024319-aa57-4035-a370-ba3d4278fb19" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e853239-99b4-483e-a1bb-2efb866727c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_663a39b2-8eaa-48b2-ae16-04ceb336c70e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e853239-99b4-483e-a1bb-2efb866727c5" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_663a39b2-8eaa-48b2-ae16-04ceb336c70e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_9306fc34-9499-4cb0-b13f-9632dea7dbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MutualFundMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e853239-99b4-483e-a1bb-2efb866727c5" xlink:to="loc_us-gaap_MutualFundMember_9306fc34-9499-4cb0-b13f-9632dea7dbbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a514d6cc-2f92-46f8-83ce-f8fbec8e7fce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e853239-99b4-483e-a1bb-2efb866727c5" xlink:to="loc_us-gaap_CommercialPaperMember_a514d6cc-2f92-46f8-83ce-f8fbec8e7fce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_36e2fc2c-04ef-4816-ad13-2a1a9ca07cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DemandDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e853239-99b4-483e-a1bb-2efb866727c5" xlink:to="loc_us-gaap_DemandDepositsMember_36e2fc2c-04ef-4816-ad13-2a1a9ca07cd0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_cb927720-a9b0-40c5-9f01-66522b08c668" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e853239-99b4-483e-a1bb-2efb866727c5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_cb927720-a9b0-40c5-9f01-66522b08c668" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_b8d9484b-ad77-4bb1-bdc3-330996df0efa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e853239-99b4-483e-a1bb-2efb866727c5" xlink:to="loc_us-gaap_EquitySecuritiesMember_b8d9484b-ad77-4bb1-bdc3-330996df0efa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_f07eb9ea-cf79-4e3f-bda4-cadece2b0d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e853239-99b4-483e-a1bb-2efb866727c5" xlink:to="loc_us-gaap_MunicipalBondsMember_f07eb9ea-cf79-4e3f-bda4-cadece2b0d9b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2a32ab0d-b1f8-43c0-9e2a-a675a7020734" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e61fa37e-1628-4776-afc9-1ea706638760" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2a32ab0d-b1f8-43c0-9e2a-a675a7020734" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8064a3e3-4340-4960-94ba-2297caa07628" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e61fa37e-1628-4776-afc9-1ea706638760" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8064a3e3-4340-4960-94ba-2297caa07628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f5a881af-7454-4fd3-8022-10637aab089b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e61fa37e-1628-4776-afc9-1ea706638760" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f5a881af-7454-4fd3-8022-10637aab089b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_825d074b-c9d3-4d16-992a-052b021a9ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e61fa37e-1628-4776-afc9-1ea706638760" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_825d074b-c9d3-4d16-992a-052b021a9ec1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_c335594e-72ad-4b98-bc47-688dd66c8070" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_e6b039a5-de8b-4dba-bc92-b69fa1db10bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_c335594e-72ad-4b98-bc47-688dd66c8070" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_e6b039a5-de8b-4dba-bc92-b69fa1db10bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a3a5bbe0-f29c-4e22-853d-4b7cc34717c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_e6b039a5-de8b-4dba-bc92-b69fa1db10bf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a3a5bbe0-f29c-4e22-853d-4b7cc34717c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a3a5bbe0-f29c-4e22-853d-4b7cc34717c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a3a5bbe0-f29c-4e22-853d-4b7cc34717c1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a3a5bbe0-f29c-4e22-853d-4b7cc34717c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75e127fa-0374-40f3-b6bc-3c90140bbe7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a3a5bbe0-f29c-4e22-853d-4b7cc34717c1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75e127fa-0374-40f3-b6bc-3c90140bbe7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_0714bb33-ebba-4987-9fbb-5a7800034f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DemandDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75e127fa-0374-40f3-b6bc-3c90140bbe7d" xlink:to="loc_us-gaap_DemandDepositsMember_0714bb33-ebba-4987-9fbb-5a7800034f4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_97863994-007e-4eec-9189-642deed5a0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75e127fa-0374-40f3-b6bc-3c90140bbe7d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_97863994-007e-4eec-9189-642deed5a0f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_bf76f93b-bc71-4866-b087-a9d854a177ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75e127fa-0374-40f3-b6bc-3c90140bbe7d" xlink:to="loc_us-gaap_CommercialPaperMember_bf76f93b-bc71-4866-b087-a9d854a177ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_3a044963-1349-4e6e-98fd-214df50cedfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75e127fa-0374-40f3-b6bc-3c90140bbe7d" xlink:to="loc_us-gaap_MunicipalBondsMember_3a044963-1349-4e6e-98fd-214df50cedfb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_5b0bb8da-769d-41c2-b112-4e6057d4471d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75e127fa-0374-40f3-b6bc-3c90140bbe7d" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_5b0bb8da-769d-41c2-b112-4e6057d4471d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_3a89d610-3c09-496e-9b9e-8629d246a441" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_c335594e-72ad-4b98-bc47-688dd66c8070" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_3a89d610-3c09-496e-9b9e-8629d246a441" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b9f970fc-bc01-4137-aa6a-58ff57e2edb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_3a89d610-3c09-496e-9b9e-8629d246a441" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b9f970fc-bc01-4137-aa6a-58ff57e2edb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b7135532-8f9e-45f9-ab72-6e1e7e4f4c19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_3a89d610-3c09-496e-9b9e-8629d246a441" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b7135532-8f9e-45f9-ab72-6e1e7e4f4c19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_26e30e73-f4c5-4c29-a17e-eb58dadc8743" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_3a89d610-3c09-496e-9b9e-8629d246a441" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_26e30e73-f4c5-4c29-a17e-eb58dadc8743" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_75947f6f-44df-43e4-b845-d89d8c6eee44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_c335594e-72ad-4b98-bc47-688dd66c8070" xlink:to="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_75947f6f-44df-43e4-b845-d89d8c6eee44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f168b3e2-2600-41b8-bc93-a6dcc0c53d74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_75947f6f-44df-43e4-b845-d89d8c6eee44" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f168b3e2-2600-41b8-bc93-a6dcc0c53d74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_b34540b4-46b4-487b-b739-fba8fa98f917" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_75947f6f-44df-43e4-b845-d89d8c6eee44" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_b34540b4-46b4-487b-b739-fba8fa98f917" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f5cf5e5a-5aa0-4e4e-aef7-529ea48425b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_75947f6f-44df-43e4-b845-d89d8c6eee44" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f5cf5e5a-5aa0-4e4e-aef7-529ea48425b8" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7ba36316-804e-4fd3-b5ee-bd1f6fe36b2d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:to="loc_srt_RangeAxis_7ba36316-804e-4fd3-b5ee-bd1f6fe36b2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7ba36316-804e-4fd3-b5ee-bd1f6fe36b2d_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7ba36316-804e-4fd3-b5ee-bd1f6fe36b2d" xlink:to="loc_srt_RangeMember_7ba36316-804e-4fd3-b5ee-bd1f6fe36b2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_faa7fb93-ec89-44dd-9a3a-1f761acdf72e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7ba36316-804e-4fd3-b5ee-bd1f6fe36b2d" xlink:to="loc_srt_RangeMember_faa7fb93-ec89-44dd-9a3a-1f761acdf72e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dd05dfcd-d508-48c3-9131-d0de75697451" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_faa7fb93-ec89-44dd-9a3a-1f761acdf72e" xlink:to="loc_srt_MinimumMember_dd05dfcd-d508-48c3-9131-d0de75697451" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c7df9769-e391-40ab-92fb-110a2753e581" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_faa7fb93-ec89-44dd-9a3a-1f761acdf72e" xlink:to="loc_srt_MaximumMember_c7df9769-e391-40ab-92fb-110a2753e581" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_93530d59-96f5-4ee1-889a-4ccf1c1fe859" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:to="loc_srt_OwnershipAxis_93530d59-96f5-4ee1-889a-4ccf1c1fe859" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_93530d59-96f5-4ee1-889a-4ccf1c1fe859_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_93530d59-96f5-4ee1-889a-4ccf1c1fe859" xlink:to="loc_srt_OwnershipDomain_93530d59-96f5-4ee1-889a-4ccf1c1fe859_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f590c60e-e014-4406-a624-3b8665f4cc0d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_93530d59-96f5-4ee1-889a-4ccf1c1fe859" xlink:to="loc_srt_OwnershipDomain_f590c60e-e014-4406-a624-3b8665f4cc0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VikingTherapeuticsInc.Member_ef8c5dba-049f-4806-8165-9226f3d46708" xlink:href="lgnd-20241231.xsd#lgnd_VikingTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_f590c60e-e014-4406-a624-3b8665f4cc0d" xlink:to="loc_lgnd_VikingTherapeuticsInc.Member_ef8c5dba-049f-4806-8165-9226f3d46708" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5c16ec17-0630-4ba8-8228-75c6df9acfe7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:to="loc_srt_CounterpartyNameAxis_5c16ec17-0630-4ba8-8228-75c6df9acfe7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c16ec17-0630-4ba8-8228-75c6df9acfe7_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5c16ec17-0630-4ba8-8228-75c6df9acfe7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5c16ec17-0630-4ba8-8228-75c6df9acfe7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83ddffc1-2070-4892-975d-f6287d900081" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5c16ec17-0630-4ba8-8228-75c6df9acfe7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83ddffc1-2070-4892-975d-f6287d900081" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember_1da0a7bd-77e3-4534-8099-24b44c0860b3" xlink:href="lgnd-20241231.xsd#lgnd_PrimroseBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83ddffc1-2070-4892-975d-f6287d900081" xlink:to="loc_lgnd_PrimroseBioMember_1da0a7bd-77e3-4534-8099-24b44c0860b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaTherapeuticsIncMember_0c171526-80e4-4b71-9822-ac9ac6cc21a0" xlink:href="lgnd-20241231.xsd#lgnd_PalvellaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83ddffc1-2070-4892-975d-f6287d900081" xlink:to="loc_lgnd_PalvellaTherapeuticsIncMember_0c171526-80e4-4b71-9822-ac9ac6cc21a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AgenusInc.Member_8c767161-1e1d-4cfa-96c3-efb93a20a2b1" xlink:href="lgnd-20241231.xsd#lgnd_AgenusInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83ddffc1-2070-4892-975d-f6287d900081" xlink:to="loc_lgnd_AgenusInc.Member_8c767161-1e1d-4cfa-96c3-efb93a20a2b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_cb72b054-456e-4058-ac5d-ceeec8001556" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_cb72b054-456e-4058-ac5d-ceeec8001556" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cb72b054-456e-4058-ac5d-ceeec8001556_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cb72b054-456e-4058-ac5d-ceeec8001556" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cb72b054-456e-4058-ac5d-ceeec8001556_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b649751f-9d9c-4718-84fe-3d93c0d74a10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cb72b054-456e-4058-ac5d-ceeec8001556" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b649751f-9d9c-4718-84fe-3d93c0d74a10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherDerivativesMember_401aaab1-6ccf-46d5-a308-e1993f739411" xlink:href="lgnd-20241231.xsd#lgnd_OtherDerivativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b649751f-9d9c-4718-84fe-3d93c0d74a10" xlink:to="loc_lgnd_OtherDerivativesMember_401aaab1-6ccf-46d5-a308-e1993f739411" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerProgramsMember_077e48c3-30a4-42b6-9d6d-915d82cf34ab" xlink:href="lgnd-20241231.xsd#lgnd_PartnerProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b649751f-9d9c-4718-84fe-3d93c0d74a10" xlink:to="loc_lgnd_PartnerProgramsMember_077e48c3-30a4-42b6-9d6d-915d82cf34ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CollarsMember_f557d911-9e26-4073-98da-a06706101147" xlink:href="lgnd-20241231.xsd#lgnd_CollarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b649751f-9d9c-4718-84fe-3d93c0d74a10" xlink:to="loc_lgnd_CollarsMember_f557d911-9e26-4073-98da-a06706101147" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e1c13cb1-c322-4326-a875-b595a49c81b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e1c13cb1-c322-4326-a875-b595a49c81b4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e1c13cb1-c322-4326-a875-b595a49c81b4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e1c13cb1-c322-4326-a875-b595a49c81b4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e1c13cb1-c322-4326-a875-b595a49c81b4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60b51c27-82c7-4f43-8581-19c5e2b19d48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e1c13cb1-c322-4326-a875-b595a49c81b4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60b51c27-82c7-4f43-8581-19c5e2b19d48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember_66d76e78-52cb-41f1-afec-3f79cf5314a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60b51c27-82c7-4f43-8581-19c5e2b19d48" xlink:to="loc_us-gaap_RoyaltyAgreementsMember_66d76e78-52cb-41f1-afec-3f79cf5314a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_128e7406-08f7-4f0e-a4da-d3e09468794a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_128e7406-08f7-4f0e-a4da-d3e09468794a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_128e7406-08f7-4f0e-a4da-d3e09468794a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_128e7406-08f7-4f0e-a4da-d3e09468794a" xlink:to="loc_us-gaap_EquityComponentDomain_128e7406-08f7-4f0e-a4da-d3e09468794a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_09281e94-0bbe-4f28-b7fd-18aecf9dcb82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_128e7406-08f7-4f0e-a4da-d3e09468794a" xlink:to="loc_us-gaap_EquityComponentDomain_09281e94-0bbe-4f28-b7fd-18aecf9dcb82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2998a279-b3f0-4230-b572-4ed9e843ebed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_09281e94-0bbe-4f28-b7fd-18aecf9dcb82" xlink:to="loc_us-gaap_CommonStockMember_2998a279-b3f0-4230-b572-4ed9e843ebed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1bacccb4-4fb6-4ecb-9565-08a6e656c4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1bacccb4-4fb6-4ecb-9565-08a6e656c4e6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1bacccb4-4fb6-4ecb-9565-08a6e656c4e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1bacccb4-4fb6-4ecb-9565-08a6e656c4e6" xlink:to="loc_us-gaap_ClassOfStockDomain_1bacccb4-4fb6-4ecb-9565-08a6e656c4e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cb475dba-90d9-419b-8b99-a78273b616e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1bacccb4-4fb6-4ecb-9565-08a6e656c4e6" xlink:to="loc_us-gaap_ClassOfStockDomain_cb475dba-90d9-419b-8b99-a78273b616e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_ddc1ccf4-1926-4598-b6fd-ce3fccbe0127" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_cb475dba-90d9-419b-8b99-a78273b616e1" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_ddc1ccf4-1926-4598-b6fd-ce3fccbe0127" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7faab6f1-72c9-4d78-946a-9756f6b57e01" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7faab6f1-72c9-4d78-946a-9756f6b57e01" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7faab6f1-72c9-4d78-946a-9756f6b57e01_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7faab6f1-72c9-4d78-946a-9756f6b57e01" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7faab6f1-72c9-4d78-946a-9756f6b57e01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9b078588-95f5-4061-9f33-d35bd99cc900" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7faab6f1-72c9-4d78-946a-9756f6b57e01" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9b078588-95f5-4061-9f33-d35bd99cc900" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VikingsMember_7f612c5d-c465-47b0-80ad-77097f54d931" xlink:href="lgnd-20241231.xsd#lgnd_VikingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9b078588-95f5-4061-9f33-d35bd99cc900" xlink:to="loc_lgnd_VikingsMember_7f612c5d-c465-47b0-80ad-77097f54d931" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_d8b703fd-449b-42d7-8710-2780ccf69e78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_d8b703fd-449b-42d7-8710-2780ccf69e78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_7467e7b7-2216-496f-a4a5-b7bc1c114894" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_7467e7b7-2216-496f-a4a5-b7bc1c114894" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtSecuritiesAvailableForSaleAmortization_5b22481b-56a8-47c1-8147-2e7a31c4e3cb" xlink:href="lgnd-20241231.xsd#lgnd_DebtSecuritiesAvailableForSaleAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_lgnd_DebtSecuritiesAvailableForSaleAmortization_5b22481b-56a8-47c1-8147-2e7a31c4e3cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_8b499e36-4342-4609-a712-24075a69d383" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_8b499e36-4342-4609-a712-24075a69d383" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_b2627603-d3c8-4acf-9f1c-cf3c2a056d39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_CommonStockValueOutstanding_b2627603-d3c8-4acf-9f1c-cf3c2a056d39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a1fa8a34-8f29-482f-b7c6-dac2eb1cb5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a1fa8a34-8f29-482f-b7c6-dac2eb1cb5bf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_7bfc4849-29e2-439d-a236-c8bc67244e55" xlink:href="lgnd-20241231.xsd#lgnd_NumberOfSharesSoldOfEquityMethodInvestee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_7bfc4849-29e2-439d-a236-c8bc67244e55" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_7459d788-9bd2-4ca8-9bb6-014962ff7403" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_GainLossOnInvestments_7459d788-9bd2-4ca8-9bb6-014962ff7403" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b7f57c94-105e-4e71-9815-6395e1e2d307" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b7f57c94-105e-4e71-9815-6395e1e2d307" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b923a64e-7432-4f9a-8833-d7764c1e0b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_Depreciation_b923a64e-7432-4f9a-8833-d7764c1e0b2c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7dfbe655-c27d-4b5f-8c1c-06bfb9f5c051" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7dfbe655-c27d-4b5f-8c1c-06bfb9f5c051" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_50df5e9f-478e-4d76-9083-346c9da457bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_50df5e9f-478e-4d76-9083-346c9da457bd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_bac86fa4-5fd4-462f-b324-ea8991c9a105" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_bac86fa4-5fd4-462f-b324-ea8991c9a105" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_fff5b6bb-0ff8-48a5-8ca9-4da0a204494d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_fff5b6bb-0ff8-48a5-8ca9-4da0a204494d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2e188ec8-9f96-44b9-b01a-e3738d3eeaff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2e188ec8-9f96-44b9-b01a-e3738d3eeaff" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_37baa425-eb88-4712-b234-2287ce891191" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_37baa425-eb88-4712-b234-2287ce891191" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_57c4e4ff-7285-40fb-9e41-26d39c4338d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_57c4e4ff-7285-40fb-9e41-26d39c4338d1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_4f769986-abaa-4af4-bedc-b7cdb426e172" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_4f769986-abaa-4af4-bedc-b7cdb426e172" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5b05957b-6430-40b1-a214-8554827f818d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5b05957b-6430-40b1-a214-8554827f818d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_640a075a-a0c7-4473-acd8-d98c954bc375" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_640a075a-a0c7-4473-acd8-d98c954bc375" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ac1dad27-9f4d-40a0-84cf-a6d37d546021" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ac1dad27-9f4d-40a0-84cf-a6d37d546021" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4f15f220-bad9-426a-86c3-5e8741e38774" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4f15f220-bad9-426a-86c3-5e8741e38774" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_5847c4b4-6136-4181-9035-7ef6f0e4e581" xlink:href="lgnd-20241231.xsd#lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_5847c4b4-6136-4181-9035-7ef6f0e4e581" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SalesContractInterestInSalesRevenue_aecf9b04-ed37-4943-ad90-e07a3cdee80b" xlink:href="lgnd-20241231.xsd#lgnd_SalesContractInterestInSalesRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_lgnd_SalesContractInterestInSalesRevenue_aecf9b04-ed37-4943-ad90-e07a3cdee80b" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b73be4fc-9dbc-47c6-bd7d-180b7cc360cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b73be4fc-9dbc-47c6-bd7d-180b7cc360cb" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_e5d916b8-f80e-43ed-b12e-5ef4c5c15e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_AccountsReceivableNetNoncurrent_e5d916b8-f80e-43ed-b12e-5ef4c5c15e9b" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableTerm_6da463ae-0766-40e6-8da0-d980b56888c5" xlink:href="lgnd-20241231.xsd#lgnd_AccountsReceivableTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_lgnd_AccountsReceivableTerm_6da463ae-0766-40e6-8da0-d980b56888c5" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount_274b5e0f-0636-46d4-8fc0-3f3edf500b8d" xlink:href="lgnd-20241231.xsd#lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount_274b5e0f-0636-46d4-8fc0-3f3edf500b8d" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued_b60d2ecb-cd61-4103-8861-0f2bc013db6a" xlink:href="lgnd-20241231.xsd#lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued_b60d2ecb-cd61-4103-8861-0f2bc013db6a" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice_ef0264dc-c112-451a-94de-3b98a94d1c28" xlink:href="lgnd-20241231.xsd#lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice_ef0264dc-c112-451a-94de-3b98a94d1c28" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsNetCurrent_423109f3-b082-4b74-aa59-13a9412b8f96" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_lgnd_FinancialRoyaltyAssetsNetCurrent_423109f3-b082-4b74-aa59-13a9412b8f96" xlink:type="arc" order="30"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_44877795-c7ab-4fb2-909c-b467b9df2025" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5371cb65-6b3c-4c00-a410-a5da0f83865c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_44877795-c7ab-4fb2-909c-b467b9df2025" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5371cb65-6b3c-4c00-a410-a5da0f83865c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_58930ade-cf92-4ebf-8484-47a749d9c3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5371cb65-6b3c-4c00-a410-a5da0f83865c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_58930ade-cf92-4ebf-8484-47a749d9c3c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_58930ade-cf92-4ebf-8484-47a749d9c3c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_58930ade-cf92-4ebf-8484-47a749d9c3c5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_58930ade-cf92-4ebf-8484-47a749d9c3c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b499efde-c6b3-4e5d-b749-7e2b4bcb553d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_58930ade-cf92-4ebf-8484-47a749d9c3c5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b499efde-c6b3-4e5d-b749-7e2b4bcb553d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_a6d703bb-cc63-4c07-a900-1ccd3f9f2aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b499efde-c6b3-4e5d-b749-7e2b4bcb553d" xlink:to="loc_us-gaap_OfficeEquipmentMember_a6d703bb-cc63-4c07-a900-1ccd3f9f2aa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_97068b44-ba24-4e57-834f-138e18025829" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b499efde-c6b3-4e5d-b749-7e2b4bcb553d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_97068b44-ba24-4e57-834f-138e18025829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ComputerEquipmentAndSoftwareMember_bdb55889-ba3d-4f7b-a93e-006dd0fe1215" xlink:href="lgnd-20241231.xsd#lgnd_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b499efde-c6b3-4e5d-b749-7e2b4bcb553d" xlink:to="loc_lgnd_ComputerEquipmentAndSoftwareMember_bdb55889-ba3d-4f7b-a93e-006dd0fe1215" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_2de0f136-3015-4678-9d06-53dbd321e51a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b499efde-c6b3-4e5d-b749-7e2b4bcb553d" xlink:to="loc_us-gaap_ConstructionInProgressMember_2de0f136-3015-4678-9d06-53dbd321e51a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b3a4e2d1-662f-434a-8474-bc06414e8112" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_44877795-c7ab-4fb2-909c-b467b9df2025" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b3a4e2d1-662f-434a-8474-bc06414e8112" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_32c43f9d-a784-42be-b0a0-fce06112c6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_44877795-c7ab-4fb2-909c-b467b9df2025" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_32c43f9d-a784-42be-b0a0-fce06112c6e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a1731633-8366-4d3e-8e43-d937333b53de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_44877795-c7ab-4fb2-909c-b467b9df2025" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a1731633-8366-4d3e-8e43-d937333b53de" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_29758cd8-72c3-4885-af1a-3c493e0cb700" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_58b5e3f0-4bda-4b6d-9520-650157567f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_29758cd8-72c3-4885-af1a-3c493e0cb700" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_58b5e3f0-4bda-4b6d-9520-650157567f9a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8e73e4be-46a5-423f-9796-b2f6ac34b3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_58b5e3f0-4bda-4b6d-9520-650157567f9a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8e73e4be-46a5-423f-9796-b2f6ac34b3d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8e73e4be-46a5-423f-9796-b2f6ac34b3d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8e73e4be-46a5-423f-9796-b2f6ac34b3d7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_8e73e4be-46a5-423f-9796-b2f6ac34b3d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89fae857-1452-47db-ae6a-2af229050e36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8e73e4be-46a5-423f-9796-b2f6ac34b3d7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89fae857-1452-47db-ae6a-2af229050e36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentedTechnologyMember_3446c553-976c-4001-afef-fd0722cb3c07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentedTechnologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89fae857-1452-47db-ae6a-2af229050e36" xlink:to="loc_us-gaap_PatentedTechnologyMember_3446c553-976c-4001-afef-fd0722cb3c07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_6bd44dba-1277-4f32-8bbd-2e03b1ff3eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89fae857-1452-47db-ae6a-2af229050e36" xlink:to="loc_us-gaap_TradeNamesMember_6bd44dba-1277-4f32-8bbd-2e03b1ff3eb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_053c5144-15d3-4e5d-9f26-7dc3f7a3ca49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89fae857-1452-47db-ae6a-2af229050e36" xlink:to="loc_us-gaap_CustomerRelationshipsMember_053c5144-15d3-4e5d-9f26-7dc3f7a3ca49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_67fcc97c-dcee-4537-910a-f77f5a520c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89fae857-1452-47db-ae6a-2af229050e36" xlink:to="loc_us-gaap_ContractualRightsMember_67fcc97c-dcee-4537-910a-f77f5a520c2c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5c573623-f692-4d98-b435-b33a11331b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_29758cd8-72c3-4885-af1a-3c493e0cb700" xlink:to="loc_us-gaap_Goodwill_5c573623-f692-4d98-b435-b33a11331b9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d00e9556-73d7-4d3c-8ad8-80fe59e35220" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_29758cd8-72c3-4885-af1a-3c493e0cb700" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d00e9556-73d7-4d3c-8ad8-80fe59e35220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_28906b56-4067-437e-a4f0-203baa874018" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_29758cd8-72c3-4885-af1a-3c493e0cb700" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_28906b56-4067-437e-a4f0-203baa874018" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_5beda22a-ddba-47d8-bb7e-9f354ce338e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_29758cd8-72c3-4885-af1a-3c493e0cb700" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_5beda22a-ddba-47d8-bb7e-9f354ce338e9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_3235b9e6-c632-4261-81bf-ae6cc8a5d6df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_f7756c4c-cc08-41ed-b1de-048508af3c20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_3235b9e6-c632-4261-81bf-ae6cc8a5d6df" xlink:to="loc_us-gaap_DerivativeTable_f7756c4c-cc08-41ed-b1de-048508af3c20" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d4ba61b4-127e-4a4e-931c-521d20c8b5da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f7756c4c-cc08-41ed-b1de-048508af3c20" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d4ba61b4-127e-4a4e-931c-521d20c8b5da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d4ba61b4-127e-4a4e-931c-521d20c8b5da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d4ba61b4-127e-4a4e-931c-521d20c8b5da" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d4ba61b4-127e-4a4e-931c-521d20c8b5da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_dc130610-93ac-4b8f-be30-f9a7e9eaacbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d4ba61b4-127e-4a4e-931c-521d20c8b5da" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_dc130610-93ac-4b8f-be30-f9a7e9eaacbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerProgramsMember_8289264b-eca0-4a8b-9696-abccf6cef03f" xlink:href="lgnd-20241231.xsd#lgnd_PartnerProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc130610-93ac-4b8f-be30-f9a7e9eaacbe" xlink:to="loc_lgnd_PartnerProgramsMember_8289264b-eca0-4a8b-9696-abccf6cef03f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_e67ec2e2-bda4-4c31-8947-b7ca06f19da8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc130610-93ac-4b8f-be30-f9a7e9eaacbe" xlink:to="loc_us-gaap_StockOptionMember_e67ec2e2-bda4-4c31-8947-b7ca06f19da8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fe2f35a5-f413-4efd-83f7-33a312c4dbad" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_f7756c4c-cc08-41ed-b1de-048508af3c20" xlink:to="loc_srt_CounterpartyNameAxis_fe2f35a5-f413-4efd-83f7-33a312c4dbad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe2f35a5-f413-4efd-83f7-33a312c4dbad_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_fe2f35a5-f413-4efd-83f7-33a312c4dbad" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_fe2f35a5-f413-4efd-83f7-33a312c4dbad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdc35a56-e724-4fc3-a334-45bf7f31e261" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_fe2f35a5-f413-4efd-83f7-33a312c4dbad" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdc35a56-e724-4fc3-a334-45bf7f31e261" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember_e9fd924e-b830-4ec4-bc6b-eac551581f8d" xlink:href="lgnd-20241231.xsd#lgnd_PrimroseBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdc35a56-e724-4fc3-a334-45bf7f31e261" xlink:to="loc_lgnd_PrimroseBioMember_e9fd924e-b830-4ec4-bc6b-eac551581f8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AgenusInc.Member_1ef782ec-2630-4ec3-bc63-68ae22e5aead" xlink:href="lgnd-20241231.xsd#lgnd_AgenusInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdc35a56-e724-4fc3-a334-45bf7f31e261" xlink:to="loc_lgnd_AgenusInc.Member_1ef782ec-2630-4ec3-bc63-68ae22e5aead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_d6999858-99c6-4ee1-a3e1-c7c5f1c6deff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_3235b9e6-c632-4261-81bf-ae6cc8a5d6df" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_d6999858-99c6-4ee1-a3e1-c7c5f1c6deff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_318f3023-f0f8-4be8-b304-59985dc042b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_3235b9e6-c632-4261-81bf-ae6cc8a5d6df" xlink:to="loc_us-gaap_DerivativeTermOfContract_318f3023-f0f8-4be8-b304-59985dc042b6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsOtherInvestmentDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsOtherInvestmentDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsOtherInvestmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cddd925b-5ad7-444f-81b5-0adef82033f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable_f7596038-6ae3-44c9-a1da-3f907ce756ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cddd925b-5ad7-444f-81b5-0adef82033f1" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsTable_f7596038-6ae3-44c9-a1da-3f907ce756ff" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f323904c-3a44-4d99-9503-8d9e56a27f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_f7596038-6ae3-44c9-a1da-3f907ce756ff" xlink:to="loc_us-gaap_InvestmentTypeAxis_f323904c-3a44-4d99-9503-8d9e56a27f6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_f323904c-3a44-4d99-9503-8d9e56a27f6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_f323904c-3a44-4d99-9503-8d9e56a27f6b" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_f323904c-3a44-4d99-9503-8d9e56a27f6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5ba2365c-9ec7-4965-a27e-c9a769e8c3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_f323904c-3a44-4d99-9503-8d9e56a27f6b" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5ba2365c-9ec7-4965-a27e-c9a769e8c3aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_f35644ca-ef80-4f29-a7a7-141770871867" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5ba2365c-9ec7-4965-a27e-c9a769e8c3aa" xlink:to="loc_us-gaap_EquitySecuritiesMember_f35644ca-ef80-4f29-a7a7-141770871867" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2a16a18c-73b4-4a6c-8352-d7e6dbf2230f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5ba2365c-9ec7-4965-a27e-c9a769e8c3aa" xlink:to="loc_us-gaap_WarrantMember_2a16a18c-73b4-4a6c-8352-d7e6dbf2230f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d4790d48-a5a7-45a6-a535-91697e58832f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5ba2365c-9ec7-4965-a27e-c9a769e8c3aa" xlink:to="loc_us-gaap_PreferredStockMember_d4790d48-a5a7-45a6-a535-91697e58832f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_efd2d502-b922-47af-968e-cda394b13f79" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_f7596038-6ae3-44c9-a1da-3f907ce756ff" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_efd2d502-b922-47af-968e-cda394b13f79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_efd2d502-b922-47af-968e-cda394b13f79_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_efd2d502-b922-47af-968e-cda394b13f79" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_efd2d502-b922-47af-968e-cda394b13f79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f747c3a2-c977-463f-b67b-056b3ec6fa88" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_efd2d502-b922-47af-968e-cda394b13f79" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f747c3a2-c977-463f-b67b-056b3ec6fa88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember_8319055c-7613-4647-9b99-466b85001914" xlink:href="lgnd-20241231.xsd#lgnd_PrimroseBioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f747c3a2-c977-463f-b67b-056b3ec6fa88" xlink:to="loc_lgnd_PrimroseBioMember_8319055c-7613-4647-9b99-466b85001914" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvIOsMember_bd790d13-30ad-4aac-b60b-811d189e8c1d" xlink:href="lgnd-20241231.xsd#lgnd_InvIOsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f747c3a2-c977-463f-b67b-056b3ec6fa88" xlink:to="loc_lgnd_InvIOsMember_bd790d13-30ad-4aac-b60b-811d189e8c1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_66a06ec4-2bd8-46d6-95bd-18203f9fb492" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cddd925b-5ad7-444f-81b5-0adef82033f1" xlink:to="loc_us-gaap_OtherInvestments_66a06ec4-2bd8-46d6-95bd-18203f9fb492" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsInventoryinOtherAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_0dd05d4c-f3f6-4c07-8a45-eb12471ab97c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_a5a842f6-1aea-4d24-b5b6-718d7cefe1df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_0dd05d4c-f3f6-4c07-8a45-eb12471ab97c" xlink:to="loc_us-gaap_InventoryCurrentTable_a5a842f6-1aea-4d24-b5b6-718d7cefe1df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_50bd9e45-cb28-47e0-8fef-c6734d5bc867" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_a5a842f6-1aea-4d24-b5b6-718d7cefe1df" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_50bd9e45-cb28-47e0-8fef-c6734d5bc867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_50bd9e45-cb28-47e0-8fef-c6734d5bc867_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_50bd9e45-cb28-47e0-8fef-c6734d5bc867" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_50bd9e45-cb28-47e0-8fef-c6734d5bc867_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_06d55be6-9084-44c3-a97c-13e0d3efd87e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_50bd9e45-cb28-47e0-8fef-c6734d5bc867" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_06d55be6-9084-44c3-a97c-13e0d3efd87e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ZelsuvmiMember_861126ae-1f44-4e92-8c6c-a71149f3e7e0" xlink:href="lgnd-20241231.xsd#lgnd_ZelsuvmiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_06d55be6-9084-44c3-a97c-13e0d3efd87e" xlink:to="loc_lgnd_ZelsuvmiMember_861126ae-1f44-4e92-8c6c-a71149f3e7e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c00bba22-a05d-412c-be14-b2b8187b5ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_0dd05d4c-f3f6-4c07-8a45-eb12471ab97c" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c00bba22-a05d-412c-be14-b2b8187b5ba5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_6a79b36e-de5f-4086-9699-7770ba75a88d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_0dd05d4c-f3f6-4c07-8a45-eb12471ab97c" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_6a79b36e-de5f-4086-9699-7770ba75a88d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f24148c9-c078-4250-8375-945756ec1451" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_0dd05d4c-f3f6-4c07-8a45-eb12471ab97c" xlink:to="loc_us-gaap_InventoryNet_f24148c9-c078-4250-8375-945756ec1451" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsContingentLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_95aec6db-e179-4ab5-9628-d87d19d214ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98339afc-3484-4ddd-8a7a-c303b4268314" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_95aec6db-e179-4ab5-9628-d87d19d214ae" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98339afc-3484-4ddd-8a7a-c303b4268314" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_87d858c6-e59f-4bda-bf8a-613caee99eef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98339afc-3484-4ddd-8a7a-c303b4268314" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_87d858c6-e59f-4bda-bf8a-613caee99eef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_87d858c6-e59f-4bda-bf8a-613caee99eef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_87d858c6-e59f-4bda-bf8a-613caee99eef" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_87d858c6-e59f-4bda-bf8a-613caee99eef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac6e91c5-7ac3-4aeb-9209-d326112c5f11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_87d858c6-e59f-4bda-bf8a-613caee99eef" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac6e91c5-7ac3-4aeb-9209-d326112c5f11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CydexPharmaceuticalsIncMember_d66e16b0-8431-48ce-bbc0-1941ecaf1782" xlink:href="lgnd-20241231.xsd#lgnd_CydexPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac6e91c5-7ac3-4aeb-9209-d326112c5f11" xlink:to="loc_lgnd_CydexPharmaceuticalsIncMember_d66e16b0-8431-48ce-bbc0-1941ecaf1782" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_e7490c23-2b9d-4cdf-b069-ad5bfcad78f0" xlink:href="lgnd-20241231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac6e91c5-7ac3-4aeb-9209-d326112c5f11" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_e7490c23-2b9d-4cdf-b069-ad5bfcad78f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilityRollForward_7c22b456-47a6-4513-996a-6c84189dd132" xlink:href="lgnd-20241231.xsd#lgnd_ContingentLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_95aec6db-e179-4ab5-9628-d87d19d214ae" xlink:to="loc_lgnd_ContingentLiabilityRollForward_7c22b456-47a6-4513-996a-6c84189dd132" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_7ab616d0-25a1-4c76-88f5-71d65671ca1c" xlink:href="lgnd-20241231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_7c22b456-47a6-4513-996a-6c84189dd132" xlink:to="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_7ab616d0-25a1-4c76-88f5-71d65671ca1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders_072233d1-c979-492e-bf69-d528383071c1" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_7c22b456-47a6-4513-996a-6c84189dd132" xlink:to="loc_lgnd_PaymentsToContingentValueRightHolders_072233d1-c979-492e-bf69-d528383071c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_92cef78e-71e5-4a1a-ba1b-bc5c80e7ec4d" xlink:href="lgnd-20241231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_ContingentLiabilityRollForward_7c22b456-47a6-4513-996a-6c84189dd132" xlink:to="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_92cef78e-71e5-4a1a-ba1b-bc5c80e7ec4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_e5dceed6-167f-4be6-ade2-301f5ea1dee5" xlink:href="lgnd-20241231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8830ed81-a86f-4fff-9424-2bd1eb53f462" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8830ed81-a86f-4fff-9424-2bd1eb53f462" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8830ed81-a86f-4fff-9424-2bd1eb53f462_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8830ed81-a86f-4fff-9424-2bd1eb53f462" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8830ed81-a86f-4fff-9424-2bd1eb53f462_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_264e2c3c-b916-4cf6-a3f3-b6cddc8d4b12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8830ed81-a86f-4fff-9424-2bd1eb53f462" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_264e2c3c-b916-4cf6-a3f3-b6cddc8d4b12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0f5975cc-1969-4232-9f19-80c29b9f29bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_264e2c3c-b916-4cf6-a3f3-b6cddc8d4b12" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0f5975cc-1969-4232-9f19-80c29b9f29bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a797a2a0-0c3e-46a8-a53d-f4f011d967b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a797a2a0-0c3e-46a8-a53d-f4f011d967b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a797a2a0-0c3e-46a8-a53d-f4f011d967b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a797a2a0-0c3e-46a8-a53d-f4f011d967b1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a797a2a0-0c3e-46a8-a53d-f4f011d967b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7a75974-9466-4d38-bad0-7fc8f60f64de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a797a2a0-0c3e-46a8-a53d-f4f011d967b1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7a75974-9466-4d38-bad0-7fc8f60f64de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5f05a6d5-6211-4c67-8b57-fe56ab785634" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7a75974-9466-4d38-bad0-7fc8f60f64de" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5f05a6d5-6211-4c67-8b57-fe56ab785634" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7949cade-02b3-4c21-a7eb-26dc958cf092" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7a75974-9466-4d38-bad0-7fc8f60f64de" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7949cade-02b3-4c21-a7eb-26dc958cf092" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8b67fc34-7741-4364-9285-a3a2b6fca557" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7a75974-9466-4d38-bad0-7fc8f60f64de" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8b67fc34-7741-4364-9285-a3a2b6fca557" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_37047524-c1ba-4ac3-925f-fb6eccb701a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_37047524-c1ba-4ac3-925f-fb6eccb701a0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37047524-c1ba-4ac3-925f-fb6eccb701a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_37047524-c1ba-4ac3-925f-fb6eccb701a0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_37047524-c1ba-4ac3-925f-fb6eccb701a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf4153a6-be75-413d-8d94-2a1bf7e29dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_37047524-c1ba-4ac3-925f-fb6eccb701a0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf4153a6-be75-413d-8d94-2a1bf7e29dc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_dc4bbcb0-1e2e-49b9-9f46-bb653171b967" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf4153a6-be75-413d-8d94-2a1bf7e29dc0" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_dc4bbcb0-1e2e-49b9-9f46-bb653171b967" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilitiesMember_04fe4217-c2de-40be-905d-52efc15bc987" xlink:href="lgnd-20241231.xsd#lgnd_ContingentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf4153a6-be75-413d-8d94-2a1bf7e29dc0" xlink:to="loc_lgnd_ContingentLiabilitiesMember_04fe4217-c2de-40be-905d-52efc15bc987" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ed746267-2c5e-4ba3-b1c8-c9b46bd8e201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ed746267-2c5e-4ba3-b1c8-c9b46bd8e201" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed746267-2c5e-4ba3-b1c8-c9b46bd8e201_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ed746267-2c5e-4ba3-b1c8-c9b46bd8e201" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ed746267-2c5e-4ba3-b1c8-c9b46bd8e201_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47ec1724-f6f0-43e2-ac95-87b175dd7ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ed746267-2c5e-4ba3-b1c8-c9b46bd8e201" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47ec1724-f6f0-43e2-ac95-87b175dd7ee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CyDexMember_1b207c1d-94fe-45c3-8fb2-4e6f2c62a08f" xlink:href="lgnd-20241231.xsd#lgnd_CyDexMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47ec1724-f6f0-43e2-ac95-87b175dd7ee8" xlink:to="loc_lgnd_CyDexMember_1b207c1d-94fe-45c3-8fb2-4e6f2c62a08f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisMember_5c8f7afa-5c50-4b30-a358-f3e3d19a1bf6" xlink:href="lgnd-20241231.xsd#lgnd_MetabasisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47ec1724-f6f0-43e2-ac95-87b175dd7ee8" xlink:to="loc_lgnd_MetabasisMember_5c8f7afa-5c50-4b30-a358-f3e3d19a1bf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9dd042ba-1245-43bb-8f7f-98373e4b6d81" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_srt_RangeAxis_9dd042ba-1245-43bb-8f7f-98373e4b6d81" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9dd042ba-1245-43bb-8f7f-98373e4b6d81_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9dd042ba-1245-43bb-8f7f-98373e4b6d81" xlink:to="loc_srt_RangeMember_9dd042ba-1245-43bb-8f7f-98373e4b6d81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4d4bb288-3f1f-4d33-af7c-c58108ff0732" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9dd042ba-1245-43bb-8f7f-98373e4b6d81" xlink:to="loc_srt_RangeMember_4d4bb288-3f1f-4d33-af7c-c58108ff0732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_558e52c5-3662-4990-a7d3-e7b580c718e3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4d4bb288-3f1f-4d33-af7c-c58108ff0732" xlink:to="loc_srt_MaximumMember_558e52c5-3662-4990-a7d3-e7b580c718e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_da044070-074f-405d-80d7-34e389844b1c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4d4bb288-3f1f-4d33-af7c-c58108ff0732" xlink:to="loc_srt_MinimumMember_da044070-074f-405d-80d7-34e389844b1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_caf30ac1-f736-4331-99e0-27e3faa5c663" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_caf30ac1-f736-4331-99e0-27e3faa5c663" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_caf30ac1-f736-4331-99e0-27e3faa5c663_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_caf30ac1-f736-4331-99e0-27e3faa5c663" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_caf30ac1-f736-4331-99e0-27e3faa5c663_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_80126a06-8634-434c-ab85-88127ea7ae4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_caf30ac1-f736-4331-99e0-27e3faa5c663" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_80126a06-8634-434c-ab85-88127ea7ae4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_0b3f4fe1-f46a-492a-8e53-58d1b2506b23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_80126a06-8634-434c-ab85-88127ea7ae4c" xlink:to="loc_us-gaap_TransferredOverTimeMember_0b3f4fe1-f46a-492a-8e53-58d1b2506b23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_721ba9fe-a1e5-435b-add2-cc6ffc415d55" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_srt_ProductOrServiceAxis_721ba9fe-a1e5-435b-add2-cc6ffc415d55" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_721ba9fe-a1e5-435b-add2-cc6ffc415d55_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_721ba9fe-a1e5-435b-add2-cc6ffc415d55" xlink:to="loc_srt_ProductsAndServicesDomain_721ba9fe-a1e5-435b-add2-cc6ffc415d55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_de10a7dc-c891-4b30-953c-21e8e30145bf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_721ba9fe-a1e5-435b-add2-cc6ffc415d55" xlink:to="loc_srt_ProductsAndServicesDomain_de10a7dc-c891-4b30-953c-21e8e30145bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_b27c10f7-0195-4df0-9611-fdde041f4e80" xlink:href="lgnd-20241231.xsd#lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_de10a7dc-c891-4b30-953c-21e8e30145bf" xlink:to="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_b27c10f7-0195-4df0-9611-fdde041f4e80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_Phase3ClinicalTrialMember_2fc5a933-65f7-4690-812a-30739e14855b" xlink:href="lgnd-20241231.xsd#lgnd_Phase3ClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_de10a7dc-c891-4b30-953c-21e8e30145bf" xlink:to="loc_lgnd_Phase3ClinicalTrialMember_2fc5a933-65f7-4690-812a-30739e14855b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_d25f8b3d-3078-47be-8aed-1bb6152c819b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_d25f8b3d-3078-47be-8aed-1bb6152c819b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_d25f8b3d-3078-47be-8aed-1bb6152c819b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_d25f8b3d-3078-47be-8aed-1bb6152c819b" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_d25f8b3d-3078-47be-8aed-1bb6152c819b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_9fdc92bf-5c7c-4c56-9567-927c291ef3da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_d25f8b3d-3078-47be-8aed-1bb6152c819b" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_9fdc92bf-5c7c-4c56-9567-927c291ef3da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimordialGeneticsMember_51a6bf9d-59c7-445e-85cd-621d9a8b7789" xlink:href="lgnd-20241231.xsd#lgnd_PrimordialGeneticsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_9fdc92bf-5c7c-4c56-9567-927c291ef3da" xlink:to="loc_lgnd_PrimordialGeneticsMember_51a6bf9d-59c7-445e-85cd-621d9a8b7789" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_10dd9916-cf42-4d2b-9570-93a0160a728a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_srt_CounterpartyNameAxis_10dd9916-cf42-4d2b-9570-93a0160a728a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_10dd9916-cf42-4d2b-9570-93a0160a728a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_10dd9916-cf42-4d2b-9570-93a0160a728a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_10dd9916-cf42-4d2b-9570-93a0160a728a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76b7eede-d8bb-4d95-a716-cbe8bfd43c5e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_10dd9916-cf42-4d2b-9570-93a0160a728a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76b7eede-d8bb-4d95-a716-cbe8bfd43c5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AgenusPartneredProgramMember_4613bc45-69ef-4978-811b-4b35daa4cf82" xlink:href="lgnd-20241231.xsd#lgnd_AgenusPartneredProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76b7eede-d8bb-4d95-a716-cbe8bfd43c5e" xlink:to="loc_lgnd_AgenusPartneredProgramMember_4613bc45-69ef-4978-811b-4b35daa4cf82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f6a41a3a-a495-4fed-83ee-bd953fe22868" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f6a41a3a-a495-4fed-83ee-bd953fe22868" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f6a41a3a-a495-4fed-83ee-bd953fe22868_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f6a41a3a-a495-4fed-83ee-bd953fe22868" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f6a41a3a-a495-4fed-83ee-bd953fe22868_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e9762ebb-f29f-4f36-b884-45b384ae8214" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f6a41a3a-a495-4fed-83ee-bd953fe22868" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e9762ebb-f29f-4f36-b884-45b384ae8214" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_27fff6f0-5b1b-44e3-bdbb-9f1475b4f440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e9762ebb-f29f-4f36-b884-45b384ae8214" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_27fff6f0-5b1b-44e3-bdbb-9f1475b4f440" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_29ada7f5-4991-4df4-8378-218037b9a892" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_29ada7f5-4991-4df4-8378-218037b9a892" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_9efda20b-7882-4446-a1e9-7a6b7682e091" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_9efda20b-7882-4446-a1e9-7a6b7682e091" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_97d29cc4-5223-44dc-a345-cbeeeee89d77" xlink:href="lgnd-20241231.xsd#lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_97d29cc4-5223-44dc-a345-cbeeeee89d77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_2cd9f74a-56c7-4094-b1b8-f8b2187dc6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_us-gaap_DerivativeAssets_2cd9f74a-56c7-4094-b1b8-f8b2187dc6c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d0f2f74b-76e6-4a75-aec7-a8e1c1dbb152" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d0f2f74b-76e6-4a75-aec7-a8e1c1dbb152" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_a552d1d9-a7bd-4dfc-bd86-c318dbe0deef" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_a552d1d9-a7bd-4dfc-bd86-c318dbe0deef" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_0b9fb021-2001-4bd0-9370-51c62abdc623" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_0b9fb021-2001-4bd0-9370-51c62abdc623" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneCompensationRate_45dc849b-dab7-4b81-8591-9c4c649c97d9" xlink:href="lgnd-20241231.xsd#lgnd_MilestoneCompensationRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_lgnd_MilestoneCompensationRate_45dc849b-dab7-4b81-8591-9c4c649c97d9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContracts_b317c155-c395-403f-b2cb-e8307b5b0c28" xlink:href="lgnd-20241231.xsd#lgnd_NumberOfContracts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_lgnd_NumberOfContracts_b317c155-c395-403f-b2cb-e8307b5b0c28" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetMeasurementInput_aadde2cf-ca41-4319-98cd-2210ed45bbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_us-gaap_DerivativeAssetMeasurementInput_aadde2cf-ca41-4319-98cd-2210ed45bbcf" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare_5526425f-bbb1-447c-bfa7-229b1589bdec" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare_5526425f-bbb1-447c-bfa7-229b1589bdec" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries_12b64e1e-523a-4665-8b44-594727d9658c" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries_12b64e1e-523a-4665-8b44-594727d9658c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsSeries_702e02c4-f510-46cf-9f2b-cf11fe1464ab" xlink:href="lgnd-20241231.xsd#lgnd_NumberOfContingentValueRightsSeries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_lgnd_NumberOfContingentValueRightsSeries_702e02c4-f510-46cf-9f2b-cf11fe1464ab" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders_5eca65c8-9e06-460b-8506-cc4a757f1e98" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders_5eca65c8-9e06-460b-8506-cc4a757f1e98" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_ca15d998-24c4-4447-8471-2d9112299e50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_us-gaap_Investments_ca15d998-24c4-4447-8471-2d9112299e50" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_43059917-e110-4781-9540-35b410ca65e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_43059917-e110-4781-9540-35b410ca65e6" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#FairValueMeasurementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/FairValueMeasurementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aac8ead-b25c-45f2-a725-c2b6312228bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e9c483c-a572-4b41-8a3a-5b50309d5cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aac8ead-b25c-45f2-a725-c2b6312228bb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e9c483c-a572-4b41-8a3a-5b50309d5cbd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_63877f66-c56c-42be-8250-cefab65056a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e9c483c-a572-4b41-8a3a-5b50309d5cbd" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_63877f66-c56c-42be-8250-cefab65056a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_63877f66-c56c-42be-8250-cefab65056a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_63877f66-c56c-42be-8250-cefab65056a6" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_63877f66-c56c-42be-8250-cefab65056a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b0daa886-42a4-4549-a748-810e71bd5213" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_63877f66-c56c-42be-8250-cefab65056a6" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b0daa886-42a4-4549-a748-810e71bd5213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53b6194a-06ff-45a6-9693-fb0ef998077a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b0daa886-42a4-4549-a748-810e71bd5213" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53b6194a-06ff-45a6-9693-fb0ef998077a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_4ef9ab0b-d1a8-40fd-a773-7a5707bbe560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53b6194a-06ff-45a6-9693-fb0ef998077a" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_4ef9ab0b-d1a8-40fd-a773-7a5707bbe560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_bd7abc7f-0538-4918-9250-51a01a555bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53b6194a-06ff-45a6-9693-fb0ef998077a" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_bd7abc7f-0538-4918-9250-51a01a555bb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1240e084-83b4-4656-9231-1d4a2c7a1331" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e9c483c-a572-4b41-8a3a-5b50309d5cbd" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1240e084-83b4-4656-9231-1d4a2c7a1331" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1240e084-83b4-4656-9231-1d4a2c7a1331_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1240e084-83b4-4656-9231-1d4a2c7a1331" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1240e084-83b4-4656-9231-1d4a2c7a1331_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1d800e0b-05b2-47d8-b3db-0fd184ec9687" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1240e084-83b4-4656-9231-1d4a2c7a1331" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1d800e0b-05b2-47d8-b3db-0fd184ec9687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_4dd7e6ed-6b82-43fc-a0c3-4a8b29c31582" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1d800e0b-05b2-47d8-b3db-0fd184ec9687" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_4dd7e6ed-6b82-43fc-a0c3-4a8b29c31582" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_df65c29f-940f-45ab-8941-936d489cd3e0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e9c483c-a572-4b41-8a3a-5b50309d5cbd" xlink:to="loc_srt_RangeAxis_df65c29f-940f-45ab-8941-936d489cd3e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_df65c29f-940f-45ab-8941-936d489cd3e0_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_df65c29f-940f-45ab-8941-936d489cd3e0" xlink:to="loc_srt_RangeMember_df65c29f-940f-45ab-8941-936d489cd3e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_11673f93-741c-4a72-b9e9-d77cb76178c8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_df65c29f-940f-45ab-8941-936d489cd3e0" xlink:to="loc_srt_RangeMember_11673f93-741c-4a72-b9e9-d77cb76178c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_703288a6-1ba4-4ba2-8a8d-9ae663cd2d34" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_11673f93-741c-4a72-b9e9-d77cb76178c8" xlink:to="loc_srt_MinimumMember_703288a6-1ba4-4ba2-8a8d-9ae663cd2d34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_14f2d1c4-9e78-453a-9555-a585076b84bc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_11673f93-741c-4a72-b9e9-d77cb76178c8" xlink:to="loc_srt_MaximumMember_14f2d1c4-9e78-453a-9555-a585076b84bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_6b6e77f3-9a22-4105-9581-fb6f58954a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aac8ead-b25c-45f2-a725-c2b6312228bb" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_6b6e77f3-9a22-4105-9581-fb6f58954a4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_a8689a4e-d3d3-4bc5-98e2-a31cd81f2650" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aac8ead-b25c-45f2-a725-c2b6312228bb" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_a8689a4e-d3d3-4bc5-98e2-a31cd81f2650" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_934c152b-dec0-497a-993b-10a56d9f5397" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aac8ead-b25c-45f2-a725-c2b6312228bb" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_934c152b-dec0-497a-993b-10a56d9f5397" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsFairValueDisclosure_291fffb2-038a-4fa8-bc77-ca0f74ab0ec1" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aac8ead-b25c-45f2-a725-c2b6312228bb" xlink:to="loc_lgnd_FinancialRoyaltyAssetsFairValueDisclosure_291fffb2-038a-4fa8-bc77-ca0f74ab0ec1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetMeasurementInput_f6369fbc-6050-4578-976b-278fb89efa75" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aac8ead-b25c-45f2-a725-c2b6312228bb" xlink:to="loc_lgnd_FinancialRoyaltyAssetMeasurementInput_f6369fbc-6050-4578-976b-278fb89efa75" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_aeafd35e-9a45-4ade-a967-f899d21405bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_aeafd35e-9a45-4ade-a967-f899d21405bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f19d1723-c9e2-4c51-b111-c07672641902" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aeafd35e-9a45-4ade-a967-f899d21405bc" xlink:to="loc_srt_ProductOrServiceAxis_f19d1723-c9e2-4c51-b111-c07672641902" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f19d1723-c9e2-4c51-b111-c07672641902_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f19d1723-c9e2-4c51-b111-c07672641902" xlink:to="loc_srt_ProductsAndServicesDomain_f19d1723-c9e2-4c51-b111-c07672641902_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2eb9c994-ea17-40cc-b61a-26b2d8575be6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f19d1723-c9e2-4c51-b111-c07672641902" xlink:to="loc_srt_ProductsAndServicesDomain_2eb9c994-ea17-40cc-b61a-26b2d8575be6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_3de9dc50-35b0-45b5-87e8-bd860d37d233" xlink:href="lgnd-20241231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2eb9c994-ea17-40cc-b61a-26b2d8575be6" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_3de9dc50-35b0-45b5-87e8-bd860d37d233" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6272099e-afa8-4b98-a1fc-297aeae2cfbe" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aeafd35e-9a45-4ade-a967-f899d21405bc" xlink:to="loc_srt_RangeAxis_6272099e-afa8-4b98-a1fc-297aeae2cfbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6272099e-afa8-4b98-a1fc-297aeae2cfbe_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6272099e-afa8-4b98-a1fc-297aeae2cfbe" xlink:to="loc_srt_RangeMember_6272099e-afa8-4b98-a1fc-297aeae2cfbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_39124bd0-206e-4188-aabc-f8da378b2ec4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6272099e-afa8-4b98-a1fc-297aeae2cfbe" xlink:to="loc_srt_RangeMember_39124bd0-206e-4188-aabc-f8da378b2ec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_97fd45ed-ea5e-4e18-bb04-6c1c75675071" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_39124bd0-206e-4188-aabc-f8da378b2ec4" xlink:to="loc_srt_MaximumMember_97fd45ed-ea5e-4e18-bb04-6c1c75675071" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_6871b503-f9fb-4119-a5f8-82b9f46a42ed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aeafd35e-9a45-4ade-a967-f899d21405bc" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_6871b503-f9fb-4119-a5f8-82b9f46a42ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_6871b503-f9fb-4119-a5f8-82b9f46a42ed_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_6871b503-f9fb-4119-a5f8-82b9f46a42ed" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_6871b503-f9fb-4119-a5f8-82b9f46a42ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_bf11dfb4-53f5-42c3-b80a-e0cb9370f7ed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_6871b503-f9fb-4119-a5f8-82b9f46a42ed" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_bf11dfb4-53f5-42c3-b80a-e0cb9370f7ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OfficeInBostonMassachusettsMember_fa56947d-3a0b-4b76-a86c-503cb085a1ab" xlink:href="lgnd-20241231.xsd#lgnd_OfficeInBostonMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_bf11dfb4-53f5-42c3-b80a-e0cb9370f7ed" xlink:to="loc_lgnd_OfficeInBostonMassachusettsMember_fa56947d-3a0b-4b76-a86c-503cb085a1ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OfficeInJupiterFloridaMember_39d4e839-1f72-468b-add9-b722fadea03b" xlink:href="lgnd-20241231.xsd#lgnd_OfficeInJupiterFloridaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_bf11dfb4-53f5-42c3-b80a-e0cb9370f7ed" xlink:to="loc_lgnd_OfficeInJupiterFloridaMember_39d4e839-1f72-468b-add9-b722fadea03b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate_62f9a87d-a288-482f-8b2f-94d362e6cc21" xlink:href="lgnd-20241231.xsd#lgnd_PurchaseCommitmentConsiderationPaidToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate_62f9a87d-a288-482f-8b2f-94d362e6cc21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_ad8c6a76-af53-401e-9ef0-6c71ce27ed24" xlink:href="lgnd-20241231.xsd#lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_ad8c6a76-af53-401e-9ef0-6c71ce27ed24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_e81836c6-7b9e-4bb2-9f06-0462437824ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_e81836c6-7b9e-4bb2-9f06-0462437824ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseImpairmentLoss_a462a0c4-0d96-4be1-8097-3ef2d3df6c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_FinanceLeaseImpairmentLoss_a462a0c4-0d96-4be1-8097-3ef2d3df6c5a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_2adc313c-160b-4fbe-b36e-1593b4056a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_2adc313c-160b-4fbe-b36e-1593b4056a9d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_cb3d53a0-c637-4936-8347-3c5327cac4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_cb3d53a0-c637-4936-8347-3c5327cac4d9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_6eea99ec-d84a-48b8-80a7-1ac705b01729" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_AssetImpairmentCharges_6eea99ec-d84a-48b8-80a7-1ac705b01729" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_fd7abb75-1a56-4f18-9dad-3a4955e7d1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_fd7abb75-1a56-4f18-9dad-3a4955e7d1c8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c3552b56-9272-4503-aae5-2180a39a4368" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c3552b56-9272-4503-aae5-2180a39a4368" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification_e9b79aa2-4e48-4d7f-9436-ccb87afdaff6" xlink:href="lgnd-20241231.xsd#lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification_e9b79aa2-4e48-4d7f-9436-ccb87afdaff6" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_df4c223f-db84-4d8f-bfc6-58dc9b0c635a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_df4c223f-db84-4d8f-bfc6-58dc9b0c635a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3f12688c-a105-4bf0-a430-c4885fe91ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3f12688c-a105-4bf0-a430-c4885fe91ad7" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_58aecaca-ae0d-4bd8-96bd-12e022390a97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_58aecaca-ae0d-4bd8-96bd-12e022390a97" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_eba1b99f-c4c7-484e-8f0a-f9aac534442c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_OperatingLeasePayments_eba1b99f-c4c7-484e-8f0a-f9aac534442c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_2e73d68b-79e4-48ca-8280-24779c756ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_OperatingLeaseExpense_2e73d68b-79e4-48ca-8280-24779c756ad8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_622275f3-46f0-460e-9edd-0ff6ca16dcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_SubleaseIncome_622275f3-46f0-460e-9edd-0ff6ca16dcc1" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_839d4404-2d27-4786-b3fc-0c751cf7751c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_839d4404-2d27-4786-b3fc-0c751cf7751c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_0d8d3425-8b51-4be1-ab8a-bf7b7ce48df9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_0d8d3425-8b51-4be1-ab8a-bf7b7ce48df9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_6159b62c-0fdc-459d-ab2a-c1d5ff6c4598" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_6159b62c-0fdc-459d-ab2a-c1d5ff6c4598" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_ea8d77c0-413f-4519-b7bf-e2d4a798d8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_ea8d77c0-413f-4519-b7bf-e2d4a798d8cc" xlink:type="arc" order="19"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7c2e3bea-d23f-4541-b49e-ee82843c93e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_DebtInstrumentTable_7c2e3bea-d23f-4541-b49e-ee82843c93e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_61e2e278-8d31-4414-a7b5-7154fcbbaacb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7c2e3bea-d23f-4541-b49e-ee82843c93e5" xlink:to="loc_us-gaap_DebtInstrumentAxis_61e2e278-8d31-4414-a7b5-7154fcbbaacb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_61e2e278-8d31-4414-a7b5-7154fcbbaacb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_61e2e278-8d31-4414-a7b5-7154fcbbaacb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_61e2e278-8d31-4414-a7b5-7154fcbbaacb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0ecce62a-f3d9-48c5-a04f-b4a1c3578b15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_61e2e278-8d31-4414-a7b5-7154fcbbaacb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0ecce62a-f3d9-48c5-a04f-b4a1c3578b15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2023Member_5256dd61-6a16-47ab-bbbd-c521da261140" xlink:href="lgnd-20241231.xsd#lgnd_ConvertibleSeniorNotesDue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0ecce62a-f3d9-48c5-a04f-b4a1c3578b15" xlink:to="loc_lgnd_ConvertibleSeniorNotesDue2023Member_5256dd61-6a16-47ab-bbbd-c521da261140" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5e516867-70eb-4c6a-9ea0-2bd7ae711dda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7c2e3bea-d23f-4541-b49e-ee82843c93e5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5e516867-70eb-4c6a-9ea0-2bd7ae711dda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5e516867-70eb-4c6a-9ea0-2bd7ae711dda_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5e516867-70eb-4c6a-9ea0-2bd7ae711dda" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5e516867-70eb-4c6a-9ea0-2bd7ae711dda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_696b3308-de7f-49bc-a2ed-00d56f758f44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5e516867-70eb-4c6a-9ea0-2bd7ae711dda" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_696b3308-de7f-49bc-a2ed-00d56f758f44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_b496246a-98d1-49e3-a017-a85b06d26e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_696b3308-de7f-49bc-a2ed-00d56f758f44" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_b496246a-98d1-49e3-a017-a85b06d26e8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_e707a22c-23ef-4933-a949-bf09fe760ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_696b3308-de7f-49bc-a2ed-00d56f758f44" xlink:to="loc_us-gaap_LineOfCreditMember_e707a22c-23ef-4933-a949-bf09fe760ab6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis_31d27bc8-891c-460e-8430-ecf7ab6ea077" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7c2e3bea-d23f-4541-b49e-ee82843c93e5" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAxis_31d27bc8-891c-460e-8430-ecf7ab6ea077" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_31d27bc8-891c-460e-8430-ecf7ab6ea077_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_31d27bc8-891c-460e-8430-ecf7ab6ea077" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_31d27bc8-891c-460e-8430-ecf7ab6ea077_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_78d3d0cc-01b4-4bc8-bcd4-fcb14d8121f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_31d27bc8-891c-460e-8430-ecf7ab6ea077" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_78d3d0cc-01b4-4bc8-bcd4-fcb14d8121f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember_5d1d7628-1297-4b49-8813-647a2ac97f7a" xlink:href="lgnd-20241231.xsd#lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_78d3d0cc-01b4-4bc8-bcd4-fcb14d8121f6" xlink:to="loc_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember_5d1d7628-1297-4b49-8813-647a2ac97f7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_266d9c19-f2e7-472f-95dd-7f72a34b36ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7c2e3bea-d23f-4541-b49e-ee82843c93e5" xlink:to="loc_us-gaap_CreditFacilityAxis_266d9c19-f2e7-472f-95dd-7f72a34b36ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_266d9c19-f2e7-472f-95dd-7f72a34b36ba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_266d9c19-f2e7-472f-95dd-7f72a34b36ba" xlink:to="loc_us-gaap_CreditFacilityDomain_266d9c19-f2e7-472f-95dd-7f72a34b36ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9a7e5920-6f2e-43b5-a013-4fb04fab81a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_266d9c19-f2e7-472f-95dd-7f72a34b36ba" xlink:to="loc_us-gaap_CreditFacilityDomain_9a7e5920-6f2e-43b5-a013-4fb04fab81a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_8f94fbe3-a5d8-42af-a312-c0e5e8bd8e06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_9a7e5920-6f2e-43b5-a013-4fb04fab81a1" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_8f94fbe3-a5d8-42af-a312-c0e5e8bd8e06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_90dd15cb-27df-4ead-a70a-9dff62779bd4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7c2e3bea-d23f-4541-b49e-ee82843c93e5" xlink:to="loc_srt_RangeAxis_90dd15cb-27df-4ead-a70a-9dff62779bd4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_90dd15cb-27df-4ead-a70a-9dff62779bd4_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_90dd15cb-27df-4ead-a70a-9dff62779bd4" xlink:to="loc_srt_RangeMember_90dd15cb-27df-4ead-a70a-9dff62779bd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_41a74ee3-9b35-4d69-9658-225eec77dbed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_90dd15cb-27df-4ead-a70a-9dff62779bd4" xlink:to="loc_srt_RangeMember_41a74ee3-9b35-4d69-9658-225eec77dbed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_000150fc-ebad-4430-aba9-d5a10646e6e4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_41a74ee3-9b35-4d69-9658-225eec77dbed" xlink:to="loc_srt_MinimumMember_000150fc-ebad-4430-aba9-d5a10646e6e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e3df17d4-e8e9-4160-a500-66bbfd516140" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_41a74ee3-9b35-4d69-9658-225eec77dbed" xlink:to="loc_srt_MaximumMember_e3df17d4-e8e9-4160-a500-66bbfd516140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_94b68f74-ca49-4772-b8b7-0cfa06f9f399" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_7c2e3bea-d23f-4541-b49e-ee82843c93e5" xlink:to="loc_us-gaap_VariableRateAxis_94b68f74-ca49-4772-b8b7-0cfa06f9f399" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_94b68f74-ca49-4772-b8b7-0cfa06f9f399_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_94b68f74-ca49-4772-b8b7-0cfa06f9f399" xlink:to="loc_us-gaap_VariableRateDomain_94b68f74-ca49-4772-b8b7-0cfa06f9f399_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e819bd9b-089e-4309-b67f-db5fc8ebc68b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_94b68f74-ca49-4772-b8b7-0cfa06f9f399" xlink:to="loc_us-gaap_VariableRateDomain_e819bd9b-089e-4309-b67f-db5fc8ebc68b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_17c4c560-7fdf-4e99-bfce-cf144da7a542" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_e819bd9b-089e-4309-b67f-db5fc8ebc68b" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_17c4c560-7fdf-4e99-bfce-cf144da7a542" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_d9c73f1e-bda3-41d8-836b-095631d13711" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_e819bd9b-089e-4309-b67f-db5fc8ebc68b" xlink:to="loc_us-gaap_BaseRateMember_d9c73f1e-bda3-41d8-836b-095631d13711" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_52e78a12-5e53-4ceb-92ec-22aac8d156a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_52e78a12-5e53-4ceb-92ec-22aac8d156a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_35d54e4b-5543-4cf6-b33d-e74aa2dc5b18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_35d54e4b-5543-4cf6-b33d-e74aa2dc5b18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_6de9e039-b8ae-4112-9021-a57f728c56a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_6de9e039-b8ae-4112-9021-a57f728c56a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_f6580e3f-9103-4ebc-a539-47d7f7e6b6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_f6580e3f-9103-4ebc-a539-47d7f7e6b6d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_2bec4dab-35d8-4ce2-a7ea-dab386431e99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_DebtInstrumentTerm_2bec4dab-35d8-4ce2-a7ea-dab386431e99" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8431c95f-556f-4131-975b-f0b5e4e674fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_8431c95f-556f-4131-975b-f0b5e4e674fa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_7ef0a56b-635a-4111-a007-96cfc3ab183d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_InterestPaid_7ef0a56b-635a-4111-a007-96cfc3ab183d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_df280f59-5884-45b7-9bbc-7736ae7bce05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_df280f59-5884-45b7-9bbc-7736ae7bce05" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_2972013d-cf2e-418d-ab67-411f77b39620" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_InterestExpenseDebt_2972013d-cf2e-418d-ab67-411f77b39620" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_c805bc3b-8042-4c6c-a56a-886863f5fffe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_c805bc3b-8042-4c6c-a56a-886863f5fffe" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_60e1fd01-471e-46fd-8b55-e115a435973b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_60e1fd01-471e-46fd-8b55-e115a435973b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_09183971-c360-42e4-abd7-9a68106da451" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_09183971-c360-42e4-abd7-9a68106da451" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_26bbe26a-70db-4d9e-94c3-1f612c9bc03e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_26bbe26a-70db-4d9e-94c3-1f612c9bc03e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c8113cde-1bfb-454f-8201-4f77e39e1a40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c8113cde-1bfb-454f-8201-4f77e39e1a40" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInDebtDiscount_90eda8cb-c45a-4481-8a45-02159f7557c6" xlink:href="lgnd-20241231.xsd#lgnd_IncreaseDecreaseInDebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_lgnd_IncreaseDecreaseInDebtDiscount_90eda8cb-c45a-4481-8a45-02159f7557c6" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_efb016a8-8914-402c-800a-2b830ba3c1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_efb016a8-8914-402c-800a-2b830ba3c1b9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c460417d-e534-4ddd-baaf-1333b0012e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c460417d-e534-4ddd-baaf-1333b0012e0e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsforConvertibleBondHedges_d5dd6528-3972-46fe-8781-0296a877e83a" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsforConvertibleBondHedges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_lgnd_PaymentsforConvertibleBondHedges_d5dd6528-3972-46fe-8781-0296a877e83a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d35202cf-2f97-4263-abe3-195398bf4972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d35202cf-2f97-4263-abe3-195398bf4972" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_63a9d460-140a-40fd-b488-fa8226059953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_63a9d460-140a-40fd-b488-fa8226059953" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod_db480ef7-6cfa-4ea8-93a4-e54f05311e53" xlink:href="lgnd-20241231.xsd#lgnd_DebtInstrumentRepurchasedAmountDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod_db480ef7-6cfa-4ea8-93a4-e54f05311e53" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_213d5838-dbfd-48d8-b775-98f69bf24e99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_213d5838-dbfd-48d8-b775-98f69bf24e99" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_003f8dc0-881a-4248-bfe7-9f3fbdc7ae70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_003f8dc0-881a-4248-bfe7-9f3fbdc7ae70" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_f46d277c-0785-4e60-8d56-d14f9efb4e63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_f46d277c-0785-4e60-8d56-d14f9efb4e63" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_e8593c6b-a2b7-415a-a477-860a9d24f328" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_e8593c6b-a2b7-415a-a477-860a9d24f328" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_9fb1689a-d339-4bbe-b6b2-1a6bb6805b84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_9fb1689a-d339-4bbe-b6b2-1a6bb6805b84" xlink:type="arc" order="25"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#StockholdersEquityShareBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0ba5cdd-a114-43aa-90a3-bd2801f7eca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f04f8c2f-94ef-4b67-82f5-41d98406699e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0ba5cdd-a114-43aa-90a3-bd2801f7eca6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f04f8c2f-94ef-4b67-82f5-41d98406699e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6652e6a1-75ae-498d-ad14-51f078baa14f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f04f8c2f-94ef-4b67-82f5-41d98406699e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6652e6a1-75ae-498d-ad14-51f078baa14f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6652e6a1-75ae-498d-ad14-51f078baa14f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6652e6a1-75ae-498d-ad14-51f078baa14f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6652e6a1-75ae-498d-ad14-51f078baa14f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_eb98ff9f-3627-4bab-b7be-c4b89a29af35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6652e6a1-75ae-498d-ad14-51f078baa14f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_eb98ff9f-3627-4bab-b7be-c4b89a29af35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_868bda6e-0c45-4d01-8448-0f1f1954070b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_eb98ff9f-3627-4bab-b7be-c4b89a29af35" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_868bda6e-0c45-4d01-8448-0f1f1954070b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_30208e09-3483-4a58-a30c-ab16eab389dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_eb98ff9f-3627-4bab-b7be-c4b89a29af35" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_30208e09-3483-4a58-a30c-ab16eab389dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_03857e91-c78d-49b0-8649-d7378c22a160" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0ba5cdd-a114-43aa-90a3-bd2801f7eca6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_03857e91-c78d-49b0-8649-d7378c22a160" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_481e8d34-22ee-42d6-bb2c-1d36ffea3ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_481e8d34-22ee-42d6-bb2c-1d36ffea3ba5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9ce0c698-4b26-4665-b500-5a42e1766bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_481e8d34-22ee-42d6-bb2c-1d36ffea3ba5" xlink:to="loc_us-gaap_PlanNameAxis_9ce0c698-4b26-4665-b500-5a42e1766bbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_9ce0c698-4b26-4665-b500-5a42e1766bbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_9ce0c698-4b26-4665-b500-5a42e1766bbc" xlink:to="loc_us-gaap_PlanNameDomain_9ce0c698-4b26-4665-b500-5a42e1766bbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7181244e-1874-4194-8d28-c441f36d8f62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_9ce0c698-4b26-4665-b500-5a42e1766bbc" xlink:to="loc_us-gaap_PlanNameDomain_7181244e-1874-4194-8d28-c441f36d8f62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_f216b3de-eef7-476a-ad57-3b6fd39f4a40" xlink:href="lgnd-20241231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7181244e-1874-4194-8d28-c441f36d8f62" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_f216b3de-eef7-476a-ad57-3b6fd39f4a40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OmniabSeparationMember_467d05e0-f47d-4004-8ab7-2301427e224e" xlink:href="lgnd-20241231.xsd#lgnd_OmniabSeparationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7181244e-1874-4194-8d28-c441f36d8f62" xlink:to="loc_lgnd_OmniabSeparationMember_467d05e0-f47d-4004-8ab7-2301427e224e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmendedESPPMember_e0dec66a-e6e4-4376-88e9-d1101c4bd751" xlink:href="lgnd-20241231.xsd#lgnd_AmendedESPPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7181244e-1874-4194-8d28-c441f36d8f62" xlink:to="loc_lgnd_AmendedESPPMember_e0dec66a-e6e4-4376-88e9-d1101c4bd751" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_73d00295-e159-4bee-bc79-f2351c0bdf33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_481e8d34-22ee-42d6-bb2c-1d36ffea3ba5" xlink:to="loc_us-gaap_AwardTypeAxis_73d00295-e159-4bee-bc79-f2351c0bdf33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73d00295-e159-4bee-bc79-f2351c0bdf33_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_73d00295-e159-4bee-bc79-f2351c0bdf33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_73d00295-e159-4bee-bc79-f2351c0bdf33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad197081-e277-433e-9f65-fe4b8d24386b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_73d00295-e159-4bee-bc79-f2351c0bdf33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad197081-e277-433e-9f65-fe4b8d24386b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_38169ec9-d4d0-44b7-9a2e-940d8a7ef011" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad197081-e277-433e-9f65-fe4b8d24386b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_38169ec9-d4d0-44b7-9a2e-940d8a7ef011" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d1592916-bdd3-4ad5-8215-184c31a062e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad197081-e277-433e-9f65-fe4b8d24386b" xlink:to="loc_us-gaap_RestrictedStockMember_d1592916-bdd3-4ad5-8215-184c31a062e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_646b1f1e-ee0d-4c80-afe3-93a412a33c81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_481e8d34-22ee-42d6-bb2c-1d36ffea3ba5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_646b1f1e-ee0d-4c80-afe3-93a412a33c81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_646b1f1e-ee0d-4c80-afe3-93a412a33c81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_646b1f1e-ee0d-4c80-afe3-93a412a33c81" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_646b1f1e-ee0d-4c80-afe3-93a412a33c81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c1ecc432-361f-4531-b66e-8228af170c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_646b1f1e-ee0d-4c80-afe3-93a412a33c81" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c1ecc432-361f-4531-b66e-8228af170c3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AtTheMarketEquityOfferingMember_d47dabe7-ace1-4fdb-a4c0-8a6046d5247c" xlink:href="lgnd-20241231.xsd#lgnd_AtTheMarketEquityOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c1ecc432-361f-4531-b66e-8228af170c3f" xlink:to="loc_lgnd_AtTheMarketEquityOfferingMember_d47dabe7-ace1-4fdb-a4c0-8a6046d5247c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_4ff402d2-5160-4fad-89b7-61a359cb8952" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_4ff402d2-5160-4fad-89b7-61a359cb8952" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4a6bb64b-7640-4ebc-aef6-baf9eb7c606f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4a6bb64b-7640-4ebc-aef6-baf9eb7c606f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2155a81b-8295-43dc-b21d-98e9572c060e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2155a81b-8295-43dc-b21d-98e9572c060e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1ecc2c54-6aff-4ffd-83dc-83df1f714c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1ecc2c54-6aff-4ffd-83dc-83df1f714c0d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8867b531-6bd9-4ec6-8cd5-7d8a2dc15a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8867b531-6bd9-4ec6-8cd5-7d8a2dc15a6f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_48de8285-ee1c-4327-ab39-69714e667164" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_48de8285-ee1c-4327-ab39-69714e667164" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_57e7c035-f520-45f6-b6a6-a8d6cdaa9110" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_57e7c035-f520-45f6-b6a6-a8d6cdaa9110" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f11f9345-ae6d-499f-95f6-067f84207528" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f11f9345-ae6d-499f-95f6-067f84207528" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1f247d53-e20f-4af1-9e7c-e8b457b3e610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1f247d53-e20f-4af1-9e7c-e8b457b3e610" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EmployeeStockPurchasePlanAbstract_4e1ce780-21cc-4595-835b-28b7c73543d8" xlink:href="lgnd-20241231.xsd#lgnd_EmployeeStockPurchasePlanAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_lgnd_EmployeeStockPurchasePlanAbstract_4e1ce780-21cc-4595-835b-28b7c73543d8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_d3330967-29af-4755-8019-fff5f9ff34cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_4e1ce780-21cc-4595-835b-28b7c73543d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_d3330967-29af-4755-8019-fff5f9ff34cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7d90fdb7-44e3-405e-b026-a9a92d98d1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_4e1ce780-21cc-4595-835b-28b7c73543d8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7d90fdb7-44e3-405e-b026-a9a92d98d1e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ShareBasedCompensationInitialOfferingPeriod_15ed1ff7-53b6-442e-a2c7-af7506ff35fb" xlink:href="lgnd-20241231.xsd#lgnd_ShareBasedCompensationInitialOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_4e1ce780-21cc-4595-835b-28b7c73543d8" xlink:to="loc_lgnd_ShareBasedCompensationInitialOfferingPeriod_15ed1ff7-53b6-442e-a2c7-af7506ff35fb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_8aad1935-3b12-40a1-b626-2f4f0670315d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_4e1ce780-21cc-4595-835b-28b7c73543d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_8aad1935-3b12-40a1-b626-2f4f0670315d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorporateShareRepurchaseAbstract_b7588697-93d4-4016-b93e-909d89f4f709" xlink:href="lgnd-20241231.xsd#lgnd_CorporateShareRepurchaseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_lgnd_CorporateShareRepurchaseAbstract_b7588697-93d4-4016-b93e-909d89f4f709" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_a4334695-28dd-4088-9b87-d91bc453f113" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_b7588697-93d4-4016-b93e-909d89f4f709" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_a4334695-28dd-4088-9b87-d91bc453f113" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_e64367bb-193e-41f5-9d9c-527f62ecd115" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_b7588697-93d4-4016-b93e-909d89f4f709" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_e64367bb-193e-41f5-9d9c-527f62ecd115" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SaleOfStockAuthorizedOfferingAmount_60a2bb31-6d9f-4bed-b020-90e27f7e508b" xlink:href="lgnd-20241231.xsd#lgnd_SaleOfStockAuthorizedOfferingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_b7588697-93d4-4016-b93e-909d89f4f709" xlink:to="loc_lgnd_SaleOfStockAuthorizedOfferingAmount_60a2bb31-6d9f-4bed-b020-90e27f7e508b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1a9b1acb-03f9-483c-8b5b-9b7f25ed50f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_b7588697-93d4-4016-b93e-909d89f4f709" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1a9b1acb-03f9-483c-8b5b-9b7f25ed50f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_723397b1-a2ed-44cc-8bc4-11b2962c2832" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_b7588697-93d4-4016-b93e-909d89f4f709" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_723397b1-a2ed-44cc-8bc4-11b2962c2832" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#StockholdersEquityBreakdownofOptionsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5eac6c4-ba6d-4a82-8fe3-06a6f02eeba3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9579d046-3482-4c91-bace-5e20765359de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5eac6c4-ba6d-4a82-8fe3-06a6f02eeba3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9579d046-3482-4c91-bace-5e20765359de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0ed196d9-e9b4-45af-ab2a-3c3be60d180f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9579d046-3482-4c91-bace-5e20765359de" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0ed196d9-e9b4-45af-ab2a-3c3be60d180f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0ed196d9-e9b4-45af-ab2a-3c3be60d180f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0ed196d9-e9b4-45af-ab2a-3c3be60d180f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0ed196d9-e9b4-45af-ab2a-3c3be60d180f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0ed196d9-e9b4-45af-ab2a-3c3be60d180f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeOneMember_7af95dda-130f-42b5-a011-dd976a72a916" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeOneMember_7af95dda-130f-42b5-a011-dd976a72a916" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTwoMember_39c68177-6a46-4615-bffa-af7cfe2f110b" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeTwoMember_39c68177-6a46-4615-bffa-af7cfe2f110b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeThreeMember_61038d75-4b85-4481-944c-7af4b0f8bf42" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeThreeMember_61038d75-4b85-4481-944c-7af4b0f8bf42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFourMember_f66989e7-303f-4f97-b169-ff8c69a466bb" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeFourMember_f66989e7-303f-4f97-b169-ff8c69a466bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFiveMember_728e9bc5-c66e-4ca9-87c0-7f2bad2fce8c" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeFiveMember_728e9bc5-c66e-4ca9-87c0-7f2bad2fce8c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSixMember_9a5fbbc2-d922-48f5-8364-a7a3b99fb3ab" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeSixMember_9a5fbbc2-d922-48f5-8364-a7a3b99fb3ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSevenMember_d1b4951c-98e3-488b-a058-676053f1f837" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeSevenMember_d1b4951c-98e3-488b-a058-676053f1f837" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeEightMember_057dedd1-dd85-4be0-bc6d-9808edc89269" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeEightMember_057dedd1-dd85-4be0-bc6d-9808edc89269" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeNineMember_0fab30f9-8f99-4765-bd0d-127304811f94" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeNineMember_0fab30f9-8f99-4765-bd0d-127304811f94" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTenMember_f353c223-5992-4cb9-b812-962ca5f15010" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeTenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeTenMember_f353c223-5992-4cb9-b812-962ca5f15010" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_7f7785ef-7913-447d-ba91-fcfdaa5a4592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5eac6c4-ba6d-4a82-8fe3-06a6f02eeba3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_7f7785ef-7913-447d-ba91-fcfdaa5a4592" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_763df597-da87-4501-a6fc-41e300f01e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5eac6c4-ba6d-4a82-8fe3-06a6f02eeba3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_763df597-da87-4501-a6fc-41e300f01e9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_f51ef6b7-a43e-4de7-bc10-5bb2d4f559c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5eac6c4-ba6d-4a82-8fe3-06a6f02eeba3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_f51ef6b7-a43e-4de7-bc10-5bb2d4f559c2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_c78cd117-f0ec-49ff-b2ed-bca511414c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5eac6c4-ba6d-4a82-8fe3-06a6f02eeba3" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_c78cd117-f0ec-49ff-b2ed-bca511414c6f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_52b50f05-8e7f-4ede-91e7-b6de9a62f767" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5eac6c4-ba6d-4a82-8fe3-06a6f02eeba3" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_52b50f05-8e7f-4ede-91e7-b6de9a62f767" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_3d0f6837-7038-4f88-8865-69c42e20be7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5eac6c4-ba6d-4a82-8fe3-06a6f02eeba3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_3d0f6837-7038-4f88-8865-69c42e20be7d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_d7a98251-829a-40f6-b509-2b815debb94f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5eac6c4-ba6d-4a82-8fe3-06a6f02eeba3" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_d7a98251-829a-40f6-b509-2b815debb94f" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#StockholdersEquityAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d348455e-2a0a-4a4f-b2e1-db5626e37a68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a881c79-4f48-42fc-abc9-4bbc3b682ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d348455e-2a0a-4a4f-b2e1-db5626e37a68" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a881c79-4f48-42fc-abc9-4bbc3b682ab7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd63df32-a6e2-4948-89cc-d2e78179daeb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a881c79-4f48-42fc-abc9-4bbc3b682ab7" xlink:to="loc_srt_RangeAxis_fd63df32-a6e2-4948-89cc-d2e78179daeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fd63df32-a6e2-4948-89cc-d2e78179daeb_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fd63df32-a6e2-4948-89cc-d2e78179daeb" xlink:to="loc_srt_RangeMember_fd63df32-a6e2-4948-89cc-d2e78179daeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0008e6c-2c89-44d3-a830-1ccec42e905b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fd63df32-a6e2-4948-89cc-d2e78179daeb" xlink:to="loc_srt_RangeMember_d0008e6c-2c89-44d3-a830-1ccec42e905b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6cc571b9-433e-4987-b2aa-320e8123a467" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d0008e6c-2c89-44d3-a830-1ccec42e905b" xlink:to="loc_srt_MinimumMember_6cc571b9-433e-4987-b2aa-320e8123a467" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f316f2ad-246d-4d57-9cbc-66213902bcec" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d0008e6c-2c89-44d3-a830-1ccec42e905b" xlink:to="loc_srt_MaximumMember_f316f2ad-246d-4d57-9cbc-66213902bcec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4a5c5837-2f28-42d0-95f2-b83e8b70a53f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d348455e-2a0a-4a4f-b2e1-db5626e37a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4a5c5837-2f28-42d0-95f2-b83e8b70a53f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40c328d6-d05f-4f0f-bd99-e031739f7413" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d348455e-2a0a-4a4f-b2e1-db5626e37a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40c328d6-d05f-4f0f-bd99-e031739f7413" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8842a378-272c-468b-8453-72781ae66d75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d348455e-2a0a-4a4f-b2e1-db5626e37a68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8842a378-272c-468b-8453-72781ae66d75" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#StockholdersEquityRestrictedStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dca12d26-0812-427b-a728-7fdea7de3ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_225674b6-1e8f-4093-a6d0-60c48a8671f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dca12d26-0812-427b-a728-7fdea7de3ebb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_225674b6-1e8f-4093-a6d0-60c48a8671f6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8977cf70-965e-4396-b13d-882a370735e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_225674b6-1e8f-4093-a6d0-60c48a8671f6" xlink:to="loc_us-gaap_AwardTypeAxis_8977cf70-965e-4396-b13d-882a370735e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8977cf70-965e-4396-b13d-882a370735e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8977cf70-965e-4396-b13d-882a370735e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8977cf70-965e-4396-b13d-882a370735e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e2460dd-3078-4b31-bd1f-7ba1f985776b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8977cf70-965e-4396-b13d-882a370735e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e2460dd-3078-4b31-bd1f-7ba1f985776b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_11aa212f-ad28-45a1-8c39-92a4492f144b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e2460dd-3078-4b31-bd1f-7ba1f985776b" xlink:to="loc_us-gaap_RestrictedStockMember_11aa212f-ad28-45a1-8c39-92a4492f144b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4f7ade80-0aec-4b4e-9ee2-522a3d22e96a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dca12d26-0812-427b-a728-7fdea7de3ebb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4f7ade80-0aec-4b4e-9ee2-522a3d22e96a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_566613fa-a357-4769-8698-611c539db4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4f7ade80-0aec-4b4e-9ee2-522a3d22e96a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_566613fa-a357-4769-8698-611c539db4bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_deb6e4c6-d1cb-4949-9ee8-9635aa753752" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4f7ade80-0aec-4b4e-9ee2-522a3d22e96a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_deb6e4c6-d1cb-4949-9ee8-9635aa753752" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_492b0a7c-e3d7-4559-baca-971cac26d840" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4f7ade80-0aec-4b4e-9ee2-522a3d22e96a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_492b0a7c-e3d7-4559-baca-971cac26d840" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c3258b68-d4f7-4d76-98b7-67d2fbe4d3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4f7ade80-0aec-4b4e-9ee2-522a3d22e96a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c3258b68-d4f7-4d76-98b7-67d2fbe4d3bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1d77dc8b-c543-426b-b37c-ec5fcc36a672" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a569f00f-731a-42dd-9232-42533e6679a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dca12d26-0812-427b-a728-7fdea7de3ebb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a569f00f-731a-42dd-9232-42533e6679a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2124647f-0254-4ab9-9e54-cd4f72634c89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a569f00f-731a-42dd-9232-42533e6679a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2124647f-0254-4ab9-9e54-cd4f72634c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5cc14d68-6697-4935-9133-375b05b6db3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a569f00f-731a-42dd-9232-42533e6679a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5cc14d68-6697-4935-9133-375b05b6db3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cafb332d-418d-4cbb-a36f-63ffeec1bad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a569f00f-731a-42dd-9232-42533e6679a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cafb332d-418d-4cbb-a36f-63ffeec1bad9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c1429205-30ca-40cf-997a-475efae5e9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a569f00f-731a-42dd-9232-42533e6679a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c1429205-30ca-40cf-997a-475efae5e9bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a00da48c-d4a8-4ac1-b4ea-2864d0127d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#CommitmentandContingenciesLegalProceedingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_acd675ef-bb6a-4e44-957d-aac934490e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_088f9163-0ceb-4a87-99d1-4ab5e2d50072" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_acd675ef-bb6a-4e44-957d-aac934490e2a" xlink:to="loc_us-gaap_LossContingenciesTable_088f9163-0ceb-4a87-99d1-4ab5e2d50072" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_235ed266-8a5a-41b6-8457-eac5fcf6ac7c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_088f9163-0ceb-4a87-99d1-4ab5e2d50072" xlink:to="loc_srt_LitigationCaseAxis_235ed266-8a5a-41b6-8457-eac5fcf6ac7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_235ed266-8a5a-41b6-8457-eac5fcf6ac7c_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_235ed266-8a5a-41b6-8457-eac5fcf6ac7c" xlink:to="loc_srt_LitigationCaseTypeDomain_235ed266-8a5a-41b6-8457-eac5fcf6ac7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4056aea2-4b2e-469a-a397-61c0d53e600b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_235ed266-8a5a-41b6-8457-eac5fcf6ac7c" xlink:to="loc_srt_LitigationCaseTypeDomain_4056aea2-4b2e-469a-a397-61c0d53e600b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_55dde826-aca8-4d07-ae0c-d2247922cbf0" xlink:href="lgnd-20241231.xsd#lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4056aea2-4b2e-469a-a397-61c0d53e600b" xlink:to="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_55dde826-aca8-4d07-ae0c-d2247922cbf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b708a673-cefa-44ee-82e3-8a59017fe535" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_acd675ef-bb6a-4e44-957d-aac934490e2a" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b708a673-cefa-44ee-82e3-8a59017fe535" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesIncomeBeforeIncomeTaxFromContinuingOperationsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#IncomeTaxesIncomeBeforeIncomeTaxFromContinuingOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/IncomeTaxesIncomeBeforeIncomeTaxFromContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_0dd8be9e-ea93-48cc-b5c2-dd44adfbf192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_6a66ba43-d03e-40ce-800b-a9db3e1f89cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0dd8be9e-ea93-48cc-b5c2-dd44adfbf192" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_6a66ba43-d03e-40ce-800b-a9db3e1f89cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_36562b1c-72da-42e3-9b25-8eeb014243bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_6a66ba43-d03e-40ce-800b-a9db3e1f89cf" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_36562b1c-72da-42e3-9b25-8eeb014243bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_36562b1c-72da-42e3-9b25-8eeb014243bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_36562b1c-72da-42e3-9b25-8eeb014243bd" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_36562b1c-72da-42e3-9b25-8eeb014243bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_42b0e471-3708-4db1-bda3-4a01f37e4b47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_36562b1c-72da-42e3-9b25-8eeb014243bd" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_42b0e471-3708-4db1-bda3-4a01f37e4b47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_e1904c49-debb-49e5-b667-825bd4f64bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_42b0e471-3708-4db1-bda3-4a01f37e4b47" xlink:to="loc_us-gaap_DomesticCountryMember_e1904c49-debb-49e5-b667-825bd4f64bb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_b6965b0f-a531-423c-a96e-f7a4b49784b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_42b0e471-3708-4db1-bda3-4a01f37e4b47" xlink:to="loc_us-gaap_ForeignCountryMember_b6965b0f-a531-423c-a96e-f7a4b49784b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_031aff1a-8597-43a8-919e-0972ae1f6b44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0dd8be9e-ea93-48cc-b5c2-dd44adfbf192" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_031aff1a-8597-43a8-919e-0972ae1f6b44" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6827b21-d6ab-4fff-b174-a6bc865f500f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_d5d43038-29ef-4315-8866-cb19078e8fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6827b21-d6ab-4fff-b174-a6bc865f500f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_d5d43038-29ef-4315-8866-cb19078e8fa0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0f02055f-4067-4fb9-9b88-326f1e628925" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d5d43038-29ef-4315-8866-cb19078e8fa0" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0f02055f-4067-4fb9-9b88-326f1e628925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0f02055f-4067-4fb9-9b88-326f1e628925_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0f02055f-4067-4fb9-9b88-326f1e628925" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0f02055f-4067-4fb9-9b88-326f1e628925_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1af08f46-c773-4531-8659-a77cfebe71cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0f02055f-4067-4fb9-9b88-326f1e628925" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1af08f46-c773-4531-8659-a77cfebe71cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_6ab45732-371e-454b-97a0-f11117a81a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1af08f46-c773-4531-8659-a77cfebe71cc" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_6ab45732-371e-454b-97a0-f11117a81a1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5477fa2b-3542-4b2d-bfa7-2af4a7b0a6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1af08f46-c773-4531-8659-a77cfebe71cc" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_5477fa2b-3542-4b2d-bfa7-2af4a7b0a6f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_2b7a9aa1-747d-4b00-bae6-3a47021543bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1af08f46-c773-4531-8659-a77cfebe71cc" xlink:to="loc_us-gaap_ForeignCountryMember_2b7a9aa1-747d-4b00-bae6-3a47021543bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_388f718a-5358-481a-840e-c3bd822531da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d5d43038-29ef-4315-8866-cb19078e8fa0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_388f718a-5358-481a-840e-c3bd822531da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_388f718a-5358-481a-840e-c3bd822531da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_388f718a-5358-481a-840e-c3bd822531da" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_388f718a-5358-481a-840e-c3bd822531da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_36ee8aab-2a32-4477-acb0-472f82bf8fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_388f718a-5358-481a-840e-c3bd822531da" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_36ee8aab-2a32-4477-acb0-472f82bf8fe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_f47df681-2449-4e77-a783-343e46de022f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_36ee8aab-2a32-4477-acb0-472f82bf8fe3" xlink:to="loc_us-gaap_ResearchMember_f47df681-2449-4e77-a783-343e46de022f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_f497fd44-03e9-40f9-bb51-2b39cbfce757" xlink:href="lgnd-20241231.xsd#lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_36ee8aab-2a32-4477-acb0-472f82bf8fe3" xlink:to="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_f497fd44-03e9-40f9-bb51-2b39cbfce757" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_afbb7066-f0e3-43f6-b017-1f8dd7d61246" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_36ee8aab-2a32-4477-acb0-472f82bf8fe3" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_afbb7066-f0e3-43f6-b017-1f8dd7d61246" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_ef6f3750-5285-46a6-8933-cc53086e98fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6827b21-d6ab-4fff-b174-a6bc865f500f" xlink:to="loc_us-gaap_OperatingLossCarryforwards_ef6f3750-5285-46a6-8933-cc53086e98fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_80d224ed-598c-4c4d-a4cf-0c06f97bd144" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6827b21-d6ab-4fff-b174-a6bc865f500f" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_80d224ed-598c-4c4d-a4cf-0c06f97bd144" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1eb154bc-60ba-48d2-9fa6-1f9b084aec54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6827b21-d6ab-4fff-b174-a6bc865f500f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1eb154bc-60ba-48d2-9fa6-1f9b084aec54" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SubsequentEventDetails"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_1a753b4d-c8e5-4f43-b255-16cfa99ce352" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_0c2a28f2-68ca-4ca5-9bbc-8a498661a55b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1a753b4d-c8e5-4f43-b255-16cfa99ce352" xlink:to="loc_us-gaap_SubsequentEventTable_0c2a28f2-68ca-4ca5-9bbc-8a498661a55b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9958bfa3-6c7b-4590-ba18-2884b68a5d04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_0c2a28f2-68ca-4ca5-9bbc-8a498661a55b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9958bfa3-6c7b-4590-ba18-2884b68a5d04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9958bfa3-6c7b-4590-ba18-2884b68a5d04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9958bfa3-6c7b-4590-ba18-2884b68a5d04" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9958bfa3-6c7b-4590-ba18-2884b68a5d04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_adb1a9db-93ba-4476-8ab5-30017830af0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9958bfa3-6c7b-4590-ba18-2884b68a5d04" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_adb1a9db-93ba-4476-8ab5-30017830af0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ebe65841-5ea5-44f4-b81d-0cbaa1512c14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_adb1a9db-93ba-4476-8ab5-30017830af0f" xlink:to="loc_us-gaap_SubsequentEventMember_ebe65841-5ea5-44f4-b81d-0cbaa1512c14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_beebe1c8-ceaa-4a9e-b822-7389310ac6d4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_0c2a28f2-68ca-4ca5-9bbc-8a498661a55b" xlink:to="loc_dei_LegalEntityAxis_beebe1c8-ceaa-4a9e-b822-7389310ac6d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_beebe1c8-ceaa-4a9e-b822-7389310ac6d4_default" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_beebe1c8-ceaa-4a9e-b822-7389310ac6d4" xlink:to="loc_dei_EntityDomain_beebe1c8-ceaa-4a9e-b822-7389310ac6d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0119f749-86e1-460a-8a30-741ca13ff0f5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_beebe1c8-ceaa-4a9e-b822-7389310ac6d4" xlink:to="loc_dei_EntityDomain_0119f749-86e1-460a-8a30-741ca13ff0f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchasersMember_483a4642-955f-4ea1-b073-de2c47026ca9" xlink:href="lgnd-20241231.xsd#lgnd_PurchasersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0119f749-86e1-460a-8a30-741ca13ff0f5" xlink:to="loc_lgnd_PurchasersMember_483a4642-955f-4ea1-b073-de2c47026ca9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherPurchasersMember_fde5dab0-1e74-45c1-ae30-e0ec41ac6c2d" xlink:href="lgnd-20241231.xsd#lgnd_OtherPurchasersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0119f749-86e1-460a-8a30-741ca13ff0f5" xlink:to="loc_lgnd_OtherPurchasersMember_fde5dab0-1e74-45c1-ae30-e0ec41ac6c2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f23271dd-3293-4ae0-af63-ea239a89e219" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_0c2a28f2-68ca-4ca5-9bbc-8a498661a55b" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f23271dd-3293-4ae0-af63-ea239a89e219" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f23271dd-3293-4ae0-af63-ea239a89e219_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f23271dd-3293-4ae0-af63-ea239a89e219" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f23271dd-3293-4ae0-af63-ea239a89e219_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_69d45c00-e9ee-48fd-9a6b-a1c1b314ff78" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f23271dd-3293-4ae0-af63-ea239a89e219" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_69d45c00-e9ee-48fd-9a6b-a1c1b314ff78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FCX007Member_66f1d839-d491-4d6c-bea8-01ce65840537" xlink:href="lgnd-20241231.xsd#lgnd_FCX007Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_69d45c00-e9ee-48fd-9a6b-a1c1b314ff78" xlink:to="loc_lgnd_FCX007Member_66f1d839-d491-4d6c-bea8-01ce65840537" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_a4d57451-d031-4f60-b758-edea51022e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1a753b4d-c8e5-4f43-b255-16cfa99ce352" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_a4d57451-d031-4f60-b758-edea51022e5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestFaceAmount_b46c5d2b-dae1-4811-b398-cf269bab549e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableWithImputedInterestFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1a753b4d-c8e5-4f43-b255-16cfa99ce352" xlink:to="loc_us-gaap_ReceivableWithImputedInterestFaceAmount_b46c5d2b-dae1-4811-b398-cf269bab549e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_c4031943-c58f-426c-9658-25caaf8b6856" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1a753b4d-c8e5-4f43-b255-16cfa99ce352" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_c4031943-c58f-426c-9658-25caaf8b6856" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_8ff58f25-64b0-4f97-96f8-304f502f862d" xlink:href="lgnd-20241231.xsd#lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_8ff58f25-64b0-4f97-96f8-304f502f862d" xlink:type="arc" order="691"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>lgnd-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:8c134d1d-ab0c-4379-9892-d916b4e62e37,g:28b275e3-fcb1-4a6c-a0ef-95ede04b9eea-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_lgnd_ContingentLiabilitiesMember_d256fb40-3c0f-4e3d-89fb-f7969e4dcf4d_terseLabel_en-US" xlink:label="lab_lgnd_ContingentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_lgnd_ContingentLiabilitiesMember_label_en-US" xlink:label="lab_lgnd_ContingentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Liabilities [Member]</link:label>
    <link:label id="lab_lgnd_ContingentLiabilitiesMember_documentation_en-US" xlink:label="lab_lgnd_ContingentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilitiesMember" xlink:href="lgnd-20241231.xsd#lgnd_ContingentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContingentLiabilitiesMember" xlink:to="lab_lgnd_ContingentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_39f25cf2-f578-49ae-8c38-6e3a4a1ae737_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_InvIOsMember_5e49f7a1-28da-4075-a307-12f065a7ecc6_terseLabel_en-US" xlink:label="lab_lgnd_InvIOsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">InvIOs</link:label>
    <link:label id="lab_lgnd_InvIOsMember_label_en-US" xlink:label="lab_lgnd_InvIOsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">InvIOs [Member]</link:label>
    <link:label id="lab_lgnd_InvIOsMember_documentation_en-US" xlink:label="lab_lgnd_InvIOsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">InvIOs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvIOsMember" xlink:href="lgnd-20241231.xsd#lgnd_InvIOsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_InvIOsMember" xlink:to="lab_lgnd_InvIOsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_89e2e615-bb0d-4192-8a4f-2e06091a5907_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term, vested and expected to vest (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e2e2eaa3-f5cc-467e-9228-af596566f897_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MilestoneCompensationRate_fd8fa978-506d-40ad-af1c-f2772bd276eb_terseLabel_en-US" xlink:label="lab_lgnd_MilestoneCompensationRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of milestones (as a percent)</link:label>
    <link:label id="lab_lgnd_MilestoneCompensationRate_label_en-US" xlink:label="lab_lgnd_MilestoneCompensationRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Compensation Rate</link:label>
    <link:label id="lab_lgnd_MilestoneCompensationRate_documentation_en-US" xlink:label="lab_lgnd_MilestoneCompensationRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Compensation Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneCompensationRate" xlink:href="lgnd-20241231.xsd#lgnd_MilestoneCompensationRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MilestoneCompensationRate" xlink:to="lab_lgnd_MilestoneCompensationRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_454b37d3-06bc-4c80-b7e6-c6a39fd0e920_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment at maturity/repurchase of 2023 Notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_eceeb4d0-3fa7-4e73-b9de-8e9106e6209a_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeTenMember_1c83347a-d804-4aa3-a8ad-dc5b959143de_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$122.70-$122.70</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTenMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Ten [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTenMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Ten [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTenMember" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeTenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeTenMember" xlink:to="lab_lgnd_ExercisePriceRangeTenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_30ef9a62-8d0e-462c-9fe2-0bebc74c9d8e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax at federal statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_43cae12a-0318-44d0-af0d-1a29c7fd83ff_terseLabel_en-US" xlink:label="lab_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Asset Noncurrent, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:label id="lab_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_label_en-US" xlink:label="lab_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset Noncurrent, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:label id="lab_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_documentation_en-US" xlink:label="lab_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Asset Noncurrent, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:href="lgnd-20241231.xsd#lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:to="lab_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_aca9f6b3-2916-468f-923f-f2ba1efc386f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5d01c00d-188b-4672-aa88-f0ebf1dbb60b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_46ee5af3-2800-45e3-803d-b9d061567f8d_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_8d1b4a5c-ff5d-41f3-b972-db1a5af153bb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturity of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_6e3eb623-c5cc-44ed-af97-2074379b89de_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScenarioAdjustmentMember_159b5296-34c0-464b-a0ba-db2d7241f30b_terseLabel_en-US" xlink:label="lab_us-gaap_ScenarioAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario, Adjustment</link:label>
    <link:label id="lab_us-gaap_ScenarioAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_ScenarioAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScenarioAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScenarioAdjustmentMember" xlink:to="lab_us-gaap_ScenarioAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_f81f66f5-c170-41bd-baaf-e72a375f6d89_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_dcbeafb6-26e9-44a9-89f6-06b4970e90aa_periodStartLabel_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Commercial rights, beginning of period</link:label>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_bcf83af7-f395-4cfd-bfcc-ad912e0fbf41_periodEndLabel_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Commercial rights, end of period</link:label>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_label_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition Contingent Consideration Potential Cash Payment at End of Period</link:label>
    <link:label id="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_documentation_en-US" xlink:label="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition Contingent Consideration Potential Cash Payment at End of Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:href="lgnd-20241231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:to="lab_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_e463c715-2e01-4549-9179-2c6a3f092a5c_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember_0fd15f1f-51ac-4a3a-b73f-f88338da912b_terseLabel_en-US" xlink:label="lab_lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and Licensing of Biopharmaceutical Assets</link:label>
    <link:label id="lab_lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember_label_en-US" xlink:label="lab_lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Licensing of Biopharmaceutical Assets [Member]</link:label>
    <link:label id="lab_lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember_documentation_en-US" xlink:label="lab_lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development And Licensing of Biopharmaceutical Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember" xlink:href="lgnd-20241231.xsd#lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember" xlink:to="lab_lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_c8040efa-4052-434d-bbad-4f955434f49d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend declared (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_5bf25d06-747d-451c-9bdf-41a59e1e63b7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, Intangible Assets and Other Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsSeries_24da1127-49d6-4f5d-bf82-aa03c2533d62_terseLabel_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsSeries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of CVR Series</link:label>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsSeries_label_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsSeries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Contingent Value Rights Series</link:label>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsSeries_documentation_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsSeries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Contingent Value Rights Series</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsSeries" xlink:href="lgnd-20241231.xsd#lgnd_NumberOfContingentValueRightsSeries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberOfContingentValueRightsSeries" xlink:to="lab_lgnd_NumberOfContingentValueRightsSeries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a8971be9-f4ce-4e34-b4f1-87e67d6c7d18_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_470a087d-770a-4ac2-80da-a51ba014f1f2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_1f38513a-1472-4781-a044-5a68090ea960_terseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:href="lgnd-20241231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid_f7b85e6f-3b00-4fd3-b7ad-e3ab5ddc2e89_verboseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operations, Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_401f161f-20f8-4b1e-b820-597a41dfa33f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for InvIOs investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_8a96aa4b-f264-4324-ba25-fadddcb29c0b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for InvIOs investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:to="lab_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_b278a7ed-9e69-47c4-91e7-881e175e9d18_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_5781d645-718b-4442-bfb8-12be1127cfb1_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="lab_us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_1bb25871-9fc3-4a00-a8c5-7ff0a01e8d5f_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_898f9002-e704-4c87-af44-10855a24744b_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_13edeb1f-1690-4dba-9b58-3346ee98a831_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from stock option exercises and ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_621bb263-604c-4e9c-988c-fc256faf237e_terseLabel_en-US" xlink:label="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional royalties receivable under sales-based milestones</link:label>
    <link:label id="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_label_en-US" xlink:label="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Royalties Receivable Under Sales-based Milestones</link:label>
    <link:label id="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_documentation_en-US" xlink:label="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Royalties Receivable Under Sales-based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:href="lgnd-20241231.xsd#lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:to="lab_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_473cbfb2-c220-48f6-8331-62f85fee1895_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_7977901a-fdfa-43d3-917c-bc140622d41d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments to partner program derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_12026fc4-2fed-48dc-8465-5d5933dff429_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments to partner program derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_6e42b6a4-2260-477a-96ee-19b63a408b75_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_OtherInvestmentsPolicyPolicyTextBlock_c32d2205-763f-4c93-948d-d26b3a8e9848_terseLabel_en-US" xlink:label="lab_lgnd_OtherInvestmentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Investments</link:label>
    <link:label id="lab_lgnd_OtherInvestmentsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_lgnd_OtherInvestmentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investments Policy [Policy Text Block]</link:label>
    <link:label id="lab_lgnd_OtherInvestmentsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_lgnd_OtherInvestmentsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Investments Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherInvestmentsPolicyPolicyTextBlock" xlink:href="lgnd-20241231.xsd#lgnd_OtherInvestmentsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_OtherInvestmentsPolicyPolicyTextBlock" xlink:to="lab_lgnd_OtherInvestmentsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BelowMilestoneMember_fbe0bb48-d794-406c-9476-12e1ea288035_terseLabel_en-US" xlink:label="lab_lgnd_BelowMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Below 3 million</link:label>
    <link:label id="lab_lgnd_BelowMilestoneMember_label_en-US" xlink:label="lab_lgnd_BelowMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Below Milestone [Member]</link:label>
    <link:label id="lab_lgnd_BelowMilestoneMember_documentation_en-US" xlink:label="lab_lgnd_BelowMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Below Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BelowMilestoneMember" xlink:href="lgnd-20241231.xsd#lgnd_BelowMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BelowMilestoneMember" xlink:to="lab_lgnd_BelowMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_41f2cc61-6bf9-4bf6-a76d-8d55cc1674bf_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_104795b3-b1c7-4b3d-9f9b-268bb2214dbb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_812d14cd-d0a7-4709-b14d-c2f92de7b20b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_99d8d961-590d-48d8-b0a0-815fa1081254_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_dda6e745-f655-4f4b-9a1f-82586aa9e4ef_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Definite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_11b88b1b-d4b2-4a6b-b38e-9a8f9cf2210a_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PurchasersMember_17774d27-45ac-4f59-8264-397fd42a9986_terseLabel_en-US" xlink:label="lab_lgnd_PurchasersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchasers</link:label>
    <link:label id="lab_lgnd_PurchasersMember_label_en-US" xlink:label="lab_lgnd_PurchasersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchasers [Member]</link:label>
    <link:label id="lab_lgnd_PurchasersMember_documentation_en-US" xlink:label="lab_lgnd_PurchasersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchasers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchasersMember" xlink:href="lgnd-20241231.xsd#lgnd_PurchasersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PurchasersMember" xlink:to="lab_lgnd_PurchasersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_df53d166-4238-4798-bace-8a5ac0799105_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">FDII</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, FDII, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0c764e19-fa09-4a38-b054-de7fe9654436_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeNoncurrent_2ad594cd-9cea-4a53-86c9-a1d66c4c5ae2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeNoncurrent" xlink:to="lab_us-gaap_DeferredIncomeNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bf3fbb1f-da14-4339-9b66-0a1121e8811b_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_fe3afb34-b9a5-4b07-84d2-7f86a5a940a1_terseLabel_en-US" xlink:label="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Contingent Liabilities</link:label>
    <link:label id="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Contingent Liabilities [Table Text Block]</link:label>
    <link:label id="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Contingent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:href="lgnd-20241231.xsd#lgnd_ScheduleofContingentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:to="lab_lgnd_ScheduleofContingentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsNonCurrent_ce982f65-677d-436a-ad79-487858d12fe1_terseLabel_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of financial royalty assets, net</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsNonCurrent_label_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsNonCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets, Non Current</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsNonCurrent_documentation_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsNonCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets, Non Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsNonCurrent" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsNonCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FinancialRoyaltyAssetsNonCurrent" xlink:to="lab_lgnd_FinancialRoyaltyAssetsNonCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_df140e39-e479-4773-a5d9-2fe5482f89de_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_6c11ba00-d39c-4f69-8dc0-e9bd0c2aba3f_verboseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Lab and office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeEightMember_c7c27986-bf11-4b99-985a-96afbd9448e3_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$89.86-$103.42</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeEightMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Eight [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeEightMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeEightMember" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeEightMember" xlink:to="lab_lgnd_ExercisePriceRangeEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_b67753a0-2732-494d-acbf-311424f4e184_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1fc8a5eb-ab37-47a0-b057-2e6d40d6fea0_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_920bf152-63d4-4d0a-90f8-854d3aec2a07_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term of finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_bb33ee7a-c128-487e-ad0d-ccdcc1418e6d_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeTwoMember_7a6c8610-4ce1-46be-bd61-c37b06603990_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$54.81-$63.62</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTwoMember" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeTwoMember" xlink:to="lab_lgnd_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_0411246c-f372-40f2-99b3-3f121334f078_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_3dde4583-e7d2-42c9-96d9-e51d096faecb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized net gain (loss) on available-for-sale securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_582dd80d-ba76-421d-9900-53a10c82916a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrealized net gain (loss) on available-for-sale securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_8bddf935-cfe2-4adc-a344-6f599d287941_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_19e0cbce-4960-4964-b508-df66f9379e4d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash paid for debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PartnerBMember_bd6a61e6-33cb-4efd-ae8f-b786732166c9_terseLabel_en-US" xlink:label="lab_lgnd_PartnerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Partner B</link:label>
    <link:label id="lab_lgnd_PartnerBMember_label_en-US" xlink:label="lab_lgnd_PartnerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partner B [Member]</link:label>
    <link:label id="lab_lgnd_PartnerBMember_documentation_en-US" xlink:label="lab_lgnd_PartnerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Partner B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerBMember" xlink:href="lgnd-20241231.xsd#lgnd_PartnerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PartnerBMember" xlink:to="lab_lgnd_PartnerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_452f10e4-2faa-41dc-9878-07d9fbe9606e_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_880fab92-df64-4648-9928-056483bf3af2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_e748c05e-0bd3-43da-9fbb-809f86232384_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss (gain) on derivative instruments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_9f0b3cca-707b-4620-8fe5-1d1cca9f0127_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on derivative instruments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_1fff14a3-87d4-40af-b1e9-8096b2243182_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3fa412e3-1397-439f-9986-95c1a1541a75_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0e623d74-e8a0-4c41-977b-21b97dec006b_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_656851ba-198d-427a-8316-9ebb47a211f0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_fcb5c731-8bbd-4638-b7fd-4a48ec6a7000_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_e1f0ece3-00f1-4f16-a33d-ca3e5931b634_negatedTerseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Change in uncertain tax positions</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:href="lgnd-20241231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived_460038a5-5c07-4452-989b-bcba964f0146_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of tangible assets acquired, net of cash and restricted cash received</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired Net of Cash And Restricted Cash Received</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired Net of Cash And Restricted Cash Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_2e799f31-1ea9-4d7c-b025-5f5e01d97545_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ProceedsFromFinancialRoyaltyAssets_587b0398-138a-4eaa-8aaa-89e8d56611a7_terseLabel_en-US" xlink:label="lab_lgnd_ProceedsFromFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from financial royalty assets</link:label>
    <link:label id="lab_lgnd_ProceedsFromFinancialRoyaltyAssets_label_en-US" xlink:label="lab_lgnd_ProceedsFromFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Financial Royalty Assets</link:label>
    <link:label id="lab_lgnd_ProceedsFromFinancialRoyaltyAssets_documentation_en-US" xlink:label="lab_lgnd_ProceedsFromFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Financial Royalty Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromFinancialRoyaltyAssets" xlink:href="lgnd-20241231.xsd#lgnd_ProceedsFromFinancialRoyaltyAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ProceedsFromFinancialRoyaltyAssets" xlink:to="lab_lgnd_ProceedsFromFinancialRoyaltyAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a353a297-6384-4df7-b998-44b2f34546b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_90681d4e-3342-4845-ab2f-cc41ee883aa9_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_5a891152-9e6a-4c6f-bdb3-0b91d8937119_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_bcb8e36e-68a2-4c91-9cbd-4ee90eb6cade_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_e7363b97-3649-4e13-b065-3b8ec0a39212_terseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_a68a342b-d639-4e1c-959e-d11eb559f00f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_87d7fe68-34d1-48f6-bdda-171aebbebb1a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_5ea6ea06-2c31-49ca-892d-c581c1dbca6b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Depreciation of property and equipment</link:label>
    <link:label id="lab_us-gaap_Depreciation_4a658886-c37d-4ab0-ab14-09f001741792_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeNet_fa9cca43-44c2-4a91-b05a-a385d7b7e768_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Fair Value, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0b0220e4-a201-4023-803d-09c9ec55019b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_695a83a5-0dc6-4ecc-85c0-e4ac2f62623a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_SalesRevenueMilestone_2f9e47b5-4bd6-4e65-af23-fd2da5e18a87_terseLabel_en-US" xlink:label="lab_lgnd_SalesRevenueMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales revenue milestone</link:label>
    <link:label id="lab_lgnd_SalesRevenueMilestone_label_en-US" xlink:label="lab_lgnd_SalesRevenueMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue Milestone</link:label>
    <link:label id="lab_lgnd_SalesRevenueMilestone_documentation_en-US" xlink:label="lab_lgnd_SalesRevenueMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Revenue Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SalesRevenueMilestone" xlink:href="lgnd-20241231.xsd#lgnd_SalesRevenueMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_SalesRevenueMilestone" xlink:to="lab_lgnd_SalesRevenueMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_88bcf52c-050c-4f8d-a614-e85948eddf0f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate of finance leases (as a percent)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VestingPeriodOneMember_c726e44b-c986-4851-bbc5-ef633cbb9d3e_terseLabel_en-US" xlink:label="lab_lgnd_VestingPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vest 1/8 on the six month anniversary of the date of grant</link:label>
    <link:label id="lab_lgnd_VestingPeriodOneMember_label_en-US" xlink:label="lab_lgnd_VestingPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Period One [Member]</link:label>
    <link:label id="lab_lgnd_VestingPeriodOneMember_documentation_en-US" xlink:label="lab_lgnd_VestingPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodOneMember" xlink:href="lgnd-20241231.xsd#lgnd_VestingPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VestingPeriodOneMember" xlink:to="lab_lgnd_VestingPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_3b24a4ec-488d-4942-a550-56c5f1ef7358_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_9e116805-cdec-49eb-a7ba-108394210749_verboseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsFairValueDisclosure_291819ef-ffbb-4689-9a53-113465d5fdb9_terseLabel_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial royalty assets, fair value disclosure</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsFairValueDisclosure_label_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets, Fair Value Disclosure</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsFairValueDisclosure_documentation_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsFairValueDisclosure" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FinancialRoyaltyAssetsFairValueDisclosure" xlink:to="lab_lgnd_FinancialRoyaltyAssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_1f689f8e-7be7-4e07-95ff-6bc0d072b527_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_2e2d3589-d223-4627-bc5f-ccd84b5c1c14_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_330fb764-8858-4cc5-b514-a26044760d61_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_7591b910-6a1a-4b5d-80cf-d40d31104942_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate notes/bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_6b77e8ce-544b-4336-be51-08a642e266e8_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate notes/bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_57e46d76-7f52-4dd1-b28f-ec2dc4de270c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Plan Activity by Exercise Price Range</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_a7317555-c4ca-4da5-ab36-6e077e10f2a1_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_QARZIBAMember_c4544213-453b-40a6-846e-c7d19073bb69_verboseLabel_en-US" xlink:label="lab_lgnd_QARZIBAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Qarziba</link:label>
    <link:label id="lab_lgnd_QARZIBAMember_label_en-US" xlink:label="lab_lgnd_QARZIBAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">QARZIBA [Member]</link:label>
    <link:label id="lab_lgnd_QARZIBAMember_documentation_en-US" xlink:label="lab_lgnd_QARZIBAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">QARZIBA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_QARZIBAMember" xlink:href="lgnd-20241231.xsd#lgnd_QARZIBAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_QARZIBAMember" xlink:to="lab_lgnd_QARZIBAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_17b85444-90b6-4f7a-968a-e1f52a7ab342_negatedTerseLabel_en-US" xlink:label="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less tenant improvement allowance</link:label>
    <link:label id="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_label_en-US" xlink:label="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Tenant Improvement Allowance</link:label>
    <link:label id="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_documentation_en-US" xlink:label="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Tenant Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" xlink:href="lgnd-20241231.xsd#lgnd_FinanceLeaseLiabilityTenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" xlink:to="lab_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeSixMember_53f296ab-f60c-4ecc-ab28-36fadc7f23c2_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$78.56-$88.27</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSixMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Six [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSixMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSixMember" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeSixMember" xlink:to="lab_lgnd_ExercisePriceRangeSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_bdcdc5ab-6f2d-4529-afd8-54847e8afe8d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e0f0c3bb-7e64-43d6-b73e-c78eedd7005a_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_1e8cd714-455c-4fc7-9597-eca99ce5809c_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_57db85d0-2fe0-439f-a0f8-23a167a91889_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7193131d-1b34-44a6-8763-42ff40135939_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d459cff7-8bd5-4c06-891e-890dda7f4892_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_bb943609-e94d-4b4f-91f8-c110faeae892_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ee54cc5d-74e0-41e0-a324-25dacaa3a09a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_81bf5963-9dd8-4d11-87a2-5c1e5a607ac9_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average estimated useful life of finite-lived intangible assets acquired (in years)</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_cb7cc991-3f9f-4d03-a313-8241a8bf2ab0_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_59889bc2-2c65-4fe4-9cf8-efeb937f83c1_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_329ecf6f-08c6-4fe4-be06-7dc2928aab44_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_451e29fd-45a8-429b-b018-e5b4d50ba5bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Assets at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Assets at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_43f4cee0-690b-4fcc-b7ee-b561175c5d54_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_aa19aee0-2992-4640-a0df-30a937ba2031_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_0446b839-45e6-4238-8f85-3486f7995501_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_be660e07-7c33-484a-b81e-e78cf8a8879f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit losses related to available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_1da8171f-3a78-47ad-811e-78f5721e2e2d_negatedTerseLabel_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Identified intangibles</link:label>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_label_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_documentation_en-US" xlink:label="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Finite-Lived Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:href="lgnd-20241231.xsd#lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:to="lab_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ComputerEquipmentAndSoftwareMember_540dc3ee-af6f-4917-829f-e566984947d3_verboseLabel_en-US" xlink:label="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_lgnd_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_lgnd_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer equipment and software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ComputerEquipmentAndSoftwareMember" xlink:href="lgnd-20241231.xsd#lgnd_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ComputerEquipmentAndSoftwareMember" xlink:to="lab_lgnd_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_5defb372-1840-485a-b100-a18e443db47a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_c029f36d-660a-44d6-a058-d4f3a767c682_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_ec5ebbb4-8b13-4318-a03d-670239f3633c_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment , gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_da9349fb-c191-4f02-864f-15b6cc55bbfe_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_c10e47ea-3924-49a5-b233-db02b33075d2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_23d4a05b-2164-4882-bc48-d650783e1609_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_02edf08a-d921-4962-a712-504ef51c0b0f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_OtherExpenseItemsNet_3c72dc58-ffd6-4280-9417-9708e1efe677_terseLabel_en-US" xlink:label="lab_lgnd_OtherExpenseItemsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense items, net</link:label>
    <link:label id="lab_lgnd_OtherExpenseItemsNet_label_en-US" xlink:label="lab_lgnd_OtherExpenseItemsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Expense Items, Net</link:label>
    <link:label id="lab_lgnd_OtherExpenseItemsNet_documentation_en-US" xlink:label="lab_lgnd_OtherExpenseItemsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Expense Items, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherExpenseItemsNet" xlink:href="lgnd-20241231.xsd#lgnd_OtherExpenseItemsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_OtherExpenseItemsNet" xlink:to="lab_lgnd_OtherExpenseItemsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract_2b7c4910-9abb-4de5-9f0c-5d630572190c_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Financing Activities [Abstract]</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_fa317d93-bf13-4687-9ca9-b12d149e7edb_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ab659c0d-15e3-4ac0-9676-8e69287652f5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in diluted per share calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dc2dcdc0-5935-4355-87e4-c523789c5839_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used to compute diluted income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EnsifentrineMember_e1040619-b752-4502-8a3b-027f7cf0ea00_terseLabel_en-US" xlink:label="lab_lgnd_EnsifentrineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ensifentrine inventors</link:label>
    <link:label id="lab_lgnd_EnsifentrineMember_label_en-US" xlink:label="lab_lgnd_EnsifentrineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ensifentrine [Member]</link:label>
    <link:label id="lab_lgnd_EnsifentrineMember_documentation_en-US" xlink:label="lab_lgnd_EnsifentrineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ensifentrine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EnsifentrineMember" xlink:href="lgnd-20241231.xsd#lgnd_EnsifentrineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EnsifentrineMember" xlink:to="lab_lgnd_EnsifentrineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_0c7ff581-76be-455e-9fe6-93bbca6699aa_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a748c6f7-083f-4adc-bce0-30fe935c9679_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_381f6cc2-c1f6-414b-8c5f-8df175b957a7_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_4a52dc36-34b8-4eee-ac20-09b2199d8a07_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_6334149e-18ce-4ba9-9481-6efc1b0a041e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability, measurement input</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8ed4a786-5e36-4cc5-95f2-b80d8cba08ae_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_a4daa1a9-6eac-47f8-abb7-0e9eabc1f685_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BMS986442Member_7c894217-95c6-4a5a-9d21-8ae3e84609a8_terseLabel_en-US" xlink:label="lab_lgnd_BMS986442Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BMS-986442</link:label>
    <link:label id="lab_lgnd_BMS986442Member_label_en-US" xlink:label="lab_lgnd_BMS986442Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BMS-986442 [Member]</link:label>
    <link:label id="lab_lgnd_BMS986442Member_documentation_en-US" xlink:label="lab_lgnd_BMS986442Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BMS-986442</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BMS986442Member" xlink:href="lgnd-20241231.xsd#lgnd_BMS986442Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BMS986442Member" xlink:to="lab_lgnd_BMS986442Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_6b1fa245-57bd-4ccc-809a-bc528659430c_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_31a4852f-95c7-4128-992d-c6ff459daa48_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_91905c49-037c-48f1-a985-a0575dbba1b5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_248cfa5b-43f4-49bf-b75a-c09a6f30dbfd_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letters of credit outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b05bf909-8f07-4bb3-9ff7-8444bcc89ea5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_068da443-ccae-43c6-9d4b-caeaad8d330f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_5908e613-f23a-4b88-bcf5-644ee59069c1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assets and Liabilities Measured at Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_93ae560d-5288-4bbc-8adf-447728674701_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_26a9a142-e66a-4bc5-9037-2592dec21ce7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable_2b37119f-fd0c-4db7-adf2-1677c0d45a0b_negatedTerseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax payable</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Income Tax Payable</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Income Tax Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d964ef6c-e9e4-4a4c-b0a7-16a839c4d81f_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_a8edba91-58c9-4a79-8ce4-d057d4803991_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_15447698-4086-42ff-9277-71d3e84d7e0b_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_596c4f55-706c-41d5-aeba-2248fac9e9c1_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_e8207f5c-c088-489e-9b7f-088370987c84_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated amortization expense for 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_6e8fdecf-2b35-4ac1-94ac-c738ed0080b6_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term in Years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_0d83588e-7714-4430-9006-ac09a57afc8b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill acquired that is expected to be deductible for tax purposes</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_5cae60ad-7571-45a1-92d7-7528a7c02771_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_3b33f116-0add-4304-999e-271e838ff501_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f999201f-6bfb-4ccb-b279-2848c93a5f7b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_12355ab0-7713-4268-9562-e92118b51678_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_f8f51b6c-c835-4f29-a672-e6bc70f63960_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_fad69f53-0cf1-45a5-9546-02a929515cbf_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebtExcludingAmortization_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="lab_us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_923f240d-4f48-4d85-ba8b-699eafef6474_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining contractual term, exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f51bff6f-054c-4073-b8db-27efeb0dd02f_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_SalesContractInterestInSalesRevenue_15001f62-ef01-4d6b-89e3-4c7e3e8b6bd1_terseLabel_en-US" xlink:label="lab_lgnd_SalesContractInterestInSalesRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest in sales revenue (as a percent)</link:label>
    <link:label id="lab_lgnd_SalesContractInterestInSalesRevenue_label_en-US" xlink:label="lab_lgnd_SalesContractInterestInSalesRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Contract, Interest In Sales Revenue</link:label>
    <link:label id="lab_lgnd_SalesContractInterestInSalesRevenue_documentation_en-US" xlink:label="lab_lgnd_SalesContractInterestInSalesRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Contract, Interest In Sales Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SalesContractInterestInSalesRevenue" xlink:href="lgnd-20241231.xsd#lgnd_SalesContractInterestInSalesRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_SalesContractInterestInSalesRevenue" xlink:to="lab_lgnd_SalesContractInterestInSalesRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_e93c6786-41dd-46e6-acd1-9e34e1fd6c6c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_148298a0-97bc-44b2-ae5c-e7d6b3a7319f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_52aec6df-0bd1-4ad6-83a4-70ef3e2f50d6_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_f567554e-e4ec-42df-8654-a578ec4c98ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ebb17873-9d50-40fe-bf24-85420bfe0b50_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2b545854-23d0-4b94-9a9d-6499eb568fd7_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_84312b52-d725-4a4a-b786-0185fa48dea4_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_be9f276d-fd0e-4eb3-b9c1-f0eebddfffab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Weighted-Average Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_977b5bc3-a325-45fd-9ba7-9b9d45aebe72_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1e81c690-fae9-49a6-94d6-ee5998aa4b8e_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income tax from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bddb02fa-118d-4940-aeac-33d61f009ce6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income before income tax from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_95b53580-2677-4c22-97af-a9608c6fc44e_totalLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Net Contributions</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Net Contributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_e0fba61a-932d-4907-bb91-778c77653eaa_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MilestoneAxis_bbe06dc0-36b6-4f82-9f03-813c5901e3d4_terseLabel_en-US" xlink:label="lab_lgnd_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_lgnd_MilestoneAxis_label_en-US" xlink:label="lab_lgnd_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone [Axis]</link:label>
    <link:label id="lab_lgnd_MilestoneAxis_documentation_en-US" xlink:label="lab_lgnd_MilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneAxis" xlink:href="lgnd-20241231.xsd#lgnd_MilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MilestoneAxis" xlink:to="lab_lgnd_MilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_0e6315fa-bcfa-46c4-90f9-62e8b392a0ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Amounts of Major Classes of Assets and Liabilities Related to Assets Held for Sale</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ConsiderationClassficationDomain_25dc22ab-0048-4920-a8df-b5c81b327c49_terseLabel_en-US" xlink:label="lab_lgnd_ConsiderationClassficationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration Classfication [Domain]</link:label>
    <link:label id="lab_lgnd_ConsiderationClassficationDomain_label_en-US" xlink:label="lab_lgnd_ConsiderationClassficationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration Classfication [Domain]</link:label>
    <link:label id="lab_lgnd_ConsiderationClassficationDomain_documentation_en-US" xlink:label="lab_lgnd_ConsiderationClassficationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consideration Classfication [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationClassficationDomain" xlink:href="lgnd-20241231.xsd#lgnd_ConsiderationClassficationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ConsiderationClassficationDomain" xlink:to="lab_lgnd_ConsiderationClassficationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_4b163c27-46f0-4f41-a8fa-a2f654366cb3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_69498c3b-2c8f-4645-aa55-c26186058f18_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocated goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_612d9110-3935-4077-9387-0e7ccc53dfb6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5989a24e-32b5-4b18-a939-2e60549fee16_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_6d94be9f-b53f-4384-883f-14e4c31ccd24_verboseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_eef1a917-76da-4057-b789-0e1c38a9ded2_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_a7a8b4a4-83a7-4fb1-a38b-10ea7141cafe_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Diluted net income (loss) per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_a8086dbc-939a-4b9a-9259-f7c1bfc6629f_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_d71ba718-49ef-4d3f-a37b-92d04b2c2034_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_015113b6-866e-4926-9e42-9ebebcb95e0e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_e2e8c835-bff3-4465-80f7-a71a34881fcf_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_8c7ceafb-260c-4f9a-be65-ebd315a46b7e_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0648bfac-bbea-4f2b-be33-4c5f76e5334a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting right (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_8525443d-dab1-4b9b-b7a1-3d881b639c01_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments to equity security warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_d4208853-5e17-4019-8eb5-a8ec286901db_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_39d94175-7f97-4ea9-8029-7fd5b73773af_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_94cd8ac6-cb06-4d3f-bf83-d33be479e16f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_6f7fe465-ef6c-4a39-b618-a6946106437a_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid_c1acc8e7-aa1c-4d03-bb40-0492e5be39e7_terseLabel_en-US" xlink:label="lab_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued purchases of financial royalty assets</link:label>
    <link:label id="lab_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid_label_en-US" xlink:label="lab_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Commercial License Rights Purchases Incurred But Not Yet Paid</link:label>
    <link:label id="lab_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Commercial License Rights Purchases Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" xlink:href="lgnd-20241231.xsd#lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" xlink:to="lab_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_b02a1d8c-ef7e-460e-8bce-2415677df3b5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Condensed Balance Sheet:</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_e7775b8e-77d2-498b-b781-69d31776132a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments to derivative assets</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_10ef312e-b148-42d6-aea4-eca8f080def7_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_abd7bc2e-5f2c-4948-91ac-93df182f0292_terseLabel_en-US" xlink:label="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs and PSUs</link:label>
    <link:label id="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_label_en-US" xlink:label="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units and Performance Shares [Member]</link:label>
    <link:label id="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_documentation_en-US" xlink:label="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units and Performance Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:href="lgnd-20241231.xsd#lgnd_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:to="lab_lgnd_RestrictedStockUnitsAndPerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AuditInformationAbstract_label_en-US" xlink:label="lab_lgnd_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_lgnd_AuditInformationAbstract_documentation_en-US" xlink:label="lab_lgnd_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AuditInformationAbstract" xlink:href="lgnd-20241231.xsd#lgnd_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AuditInformationAbstract" xlink:to="lab_lgnd_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_TwoThousandTwoStockIncentivePlanMember_c243f853-0236-46ec-97ae-b72cc9b09e43_terseLabel_en-US" xlink:label="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2002 Stock Incentive Plan</link:label>
    <link:label id="lab_lgnd_TwoThousandTwoStockIncentivePlanMember_label_en-US" xlink:label="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two thousand Two Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_lgnd_TwoThousandTwoStockIncentivePlanMember_documentation_en-US" xlink:label="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand two Stock Incentive Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:href="lgnd-20241231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:to="lab_lgnd_TwoThousandTwoStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_99eb7c36-c87d-4799-a2df-091344162d7a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_33d168e3-1c88-4efe-b568-cd1c61cd78c2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate_71c20683-70f0-44b0-b5db-64eac4feb2b8_terseLabel_en-US" xlink:label="lab_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future milestones right to receive (as a percent)</link:label>
    <link:label id="lab_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate_label_en-US" xlink:label="lab_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Royalty Agreement, Milestone Proceeds Rate</link:label>
    <link:label id="lab_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate_documentation_en-US" xlink:label="lab_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Royalty Agreement, Milestone Proceeds Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate" xlink:href="lgnd-20241231.xsd#lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate" xlink:to="lab_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_79e19eeb-68f9-4333-acd1-a1c94af2e76b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EquitySecuritiesAllocationMember_b816fea9-c692-43af-886e-b154efe6434e_terseLabel_en-US" xlink:label="lab_lgnd_EquitySecuritiesAllocationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_lgnd_EquitySecuritiesAllocationMember_label_en-US" xlink:label="lab_lgnd_EquitySecuritiesAllocationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities Allocation [Member]</link:label>
    <link:label id="lab_lgnd_EquitySecuritiesAllocationMember_documentation_en-US" xlink:label="lab_lgnd_EquitySecuritiesAllocationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities Allocation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EquitySecuritiesAllocationMember" xlink:href="lgnd-20241231.xsd#lgnd_EquitySecuritiesAllocationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EquitySecuritiesAllocationMember" xlink:to="lab_lgnd_EquitySecuritiesAllocationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IncreaseDecreaseInDebtDiscount_d69bfdbe-db05-4767-baee-be9d1dd9479e_negatedTerseLabel_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInDebtDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reduction in debt discount</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseInDebtDiscount_label_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Debt Discount</link:label>
    <link:label id="lab_lgnd_IncreaseDecreaseInDebtDiscount_documentation_en-US" xlink:label="lab_lgnd_IncreaseDecreaseInDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInDebtDiscount" xlink:href="lgnd-20241231.xsd#lgnd_IncreaseDecreaseInDebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IncreaseDecreaseInDebtDiscount" xlink:to="lab_lgnd_IncreaseDecreaseInDebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_308b34d2-94dc-498c-979f-a86b320e83c4_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period in which cost is expected to be recognized (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_da0b8eeb-3dad-4d6d-8c9e-9edca189ac5c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues and other income</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification_00dfef76-4236-42b5-9fc3-caeb836a8a0e_terseLabel_en-US" xlink:label="lab_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in operating lease assets</link:label>
    <link:label id="lab_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification_label_en-US" xlink:label="lab_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Increase (Decrease) In Operating Lease Assets Due To Modification</link:label>
    <link:label id="lab_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification_documentation_en-US" xlink:label="lab_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Increase (Decrease) In Operating Lease Assets Due To Modification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" xlink:href="lgnd-20241231.xsd#lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" xlink:to="lab_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_60cf3bde-5c6b-4484-a48d-4b882e60a071_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Write-downs related to obsolete inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_bd0c3d88-9e96-4bd8-af2b-386e630931c1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_bc71732a-a02e-495f-a171-eb2e8ba3887c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in (provided by) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_06585282-ddc4-4b5c-a4a8-1481aa3bec91_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2842c720-beab-4356-8b8a-273f83e8657f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase the number of shares under the 2002 Stock Incentive Plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_2a055875-e3c9-4a69-ac2c-0a484c4082d7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_4e3d14c5-9d24-407e-98b8-d07d59343d3d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_d17e34af-f83c-4926-94c7-b5249de697c4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_5242adbf-3d5b-4fec-9671-14e691cad30b_verboseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Fair Value Disclosure</link:label>
    <link:label id="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:to="lab_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_17b1a4a9-c8fc-429f-b5ae-c4f3ea273fc3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_4c228809-e3ce-40c9-9d95-0c0102ceaa4f_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance_80b856e3-5675-408e-a718-19a1a7559e08_negatedTerseLabel_en-US" xlink:label="lab_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less tenant improvement allowance</link:label>
    <link:label id="lab_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance_label_en-US" xlink:label="lab_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Tenant Improvement Allowance</link:label>
    <link:label id="lab_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance_documentation_en-US" xlink:label="lab_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Tenant Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance" xlink:href="lgnd-20241231.xsd#lgnd_OperatingLeaseLiabilityTenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance" xlink:to="lab_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights_34f8dd48-4f7b-4743-90ca-c1a1e920edb3_terseLabel_en-US" xlink:label="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current contingent liabilities</link:label>
    <link:label id="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights_label_en-US" xlink:label="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Portion of Liability for Contingent Value Rights</link:label>
    <link:label id="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current portion of liability for contingent value rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:href="lgnd-20241231.xsd#lgnd_CurrentPortionOfLiabilityForContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:to="lab_lgnd_CurrentPortionOfLiabilityForContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_13785812-0a51-4507-8e8b-3d4a224c43c1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_005f6e16-81c3-45c7-900e-b5788b76ee9d_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberOfContracts_917c69ef-4683-407f-9d68-115fffb35408_terseLabel_en-US" xlink:label="lab_lgnd_NumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of contracts</link:label>
    <link:label id="lab_lgnd_NumberOfContracts_label_en-US" xlink:label="lab_lgnd_NumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Contracts</link:label>
    <link:label id="lab_lgnd_NumberOfContracts_documentation_en-US" xlink:label="lab_lgnd_NumberOfContracts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContracts" xlink:href="lgnd-20241231.xsd#lgnd_NumberOfContracts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberOfContracts" xlink:to="lab_lgnd_NumberOfContracts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_d6137031-84a4-4b86-a73e-8db54721ecda_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NovanIncMember_d53a443e-c33b-42a6-bc72-6e2cc73a1a4e_verboseLabel_en-US" xlink:label="lab_lgnd_NovanIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Novan, Inc.</link:label>
    <link:label id="lab_lgnd_NovanIncMember_label_en-US" xlink:label="lab_lgnd_NovanIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novan, Inc. [Member]</link:label>
    <link:label id="lab_lgnd_NovanIncMember_documentation_en-US" xlink:label="lab_lgnd_NovanIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Novan, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanIncMember" xlink:href="lgnd-20241231.xsd#lgnd_NovanIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NovanIncMember" xlink:to="lab_lgnd_NovanIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_2396b30f-25a0-414f-8610-aa1897dc9b25_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_267fe188-5ffc-4025-9b9a-a6a96b9f0573_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vikings common stock outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_6e1664e8-741b-4526-bc53-ad274ffaf75d_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_e1394950-c133-47f2-8629-fd8d8e60b591_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_45a756a3-43bf-485a-b98e-97f9c5ce5550_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_ecd5f721-2982-45c8-a2cf-f0247c801e8a_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_55f20c79-b950-499b-9144-c1d731061220_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_a715d55c-8787-4c6c-9f2c-28680d4b4684_negatedTerseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provision to return adjustments</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:href="lgnd-20241231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_8da1899d-3c9a-4c07-9f39-4c190b3d0ccf_terseLabel_en-US" xlink:label="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating and Finance Lease Assets and Liabilities</link:label>
    <link:label id="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets and Liabilities, Lessee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="lgnd-20241231.xsd#lgnd_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_49cea243-1245-44db-aea8-85f131136961_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryTypeDomain_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:to="lab_us-gaap_PublicUtilitiesInventoryTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_e5952982-c02b-4eb0-a7ac-236871a67636_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash consideration paid</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9619add2-f93f-426d-be58-4cdacf4cb6ac_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_2d4d51ec-1450-48fc-83bc-2da8ee3cc27c_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b249a0bc-499a-4ee9-8226-ea886bdbb8c2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6ab2a9f5-dd4f-4e7a-951c-c956a6f06c73_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13bbd3b0-165b-40e0-96e0-d26eae2671ae_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeFourMember_02b2f409-aa7c-4533-896d-5b9df870045b_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$69.39-$73.76</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFourMember" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeFourMember" xlink:to="lab_lgnd_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_66793ad8-376d-44ad-8bb3-87c4fb7b97bb_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of civil complaints filed against entity</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForDerivativeInstrumentInvestingActivities_367e8119-00b8-495f-9911-59090736cbe2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForDerivativeInstrumentInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for the Agenus transaction</link:label>
    <link:label id="lab_us-gaap_PaymentsForDerivativeInstrumentInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForDerivativeInstrumentInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Derivative Instrument, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForDerivativeInstrumentInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForDerivativeInstrumentInvestingActivities" xlink:to="lab_us-gaap_PaymentsForDerivativeInstrumentInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ConvertibleSeniorNotesDue2023Member_e4f09d5f-76e4-4a49-9e84-ccde169804d4_terseLabel_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Convertible Senior Notes</link:label>
    <link:label id="lab_lgnd_ConvertibleSeniorNotesDue2023Member_label_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes due 2023 [Member]</link:label>
    <link:label id="lab_lgnd_ConvertibleSeniorNotesDue2023Member_documentation_en-US" xlink:label="lab_lgnd_ConvertibleSeniorNotesDue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Senior Notes due 2023</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2023Member" xlink:href="lgnd-20241231.xsd#lgnd_ConvertibleSeniorNotesDue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ConvertibleSeniorNotesDue2023Member" xlink:to="lab_lgnd_ConvertibleSeniorNotesDue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_934a5024-a59e-4a79-bc3b-cdeb0059590b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_OtherLiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_c49e6c6b-9361-4ee9-8dc7-4aa6233f7a40_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_c6430f92-92aa-4f31-9bb7-c13eda1fe198_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_598b8056-de51-46c7-acf0-b017998c1c62_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a5391e7c-47cf-454c-b0e9-ccfbccbb0b57_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_66b446b3-2371-4571-875b-61412d200add_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VikingsMember_af6ac2c3-45b0-4025-9610-ba3b29a536b1_terseLabel_en-US" xlink:label="lab_lgnd_VikingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vikings</link:label>
    <link:label id="lab_lgnd_VikingsMember_label_en-US" xlink:label="lab_lgnd_VikingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vikings [Member]</link:label>
    <link:label id="lab_lgnd_VikingsMember_documentation_en-US" xlink:label="lab_lgnd_VikingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vikings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VikingsMember" xlink:href="lgnd-20241231.xsd#lgnd_VikingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VikingsMember" xlink:to="lab_lgnd_VikingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_9a1cab17-f767-49af-960a-3b76305777a1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_d54ef308-274b-457b-9ff5-26c0e93d5798_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3dbe2af0-48b5-47b6-9330-e4b4ffc8a04f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_09a4d90a-68b8-44f5-af6a-afd2bee8c675_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_cdc26110-05c9-4795-8ba9-98e36c4cc5c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_d28a4b31-3f8e-4de6-83f1-74849249bd67_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash paid for equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsPolicyTextBlock_468529ca-dd8b-4094-9177-90a15f11788d_terseLabel_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets, net (formerly known as Commercial License Rights)</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsPolicyTextBlock_label_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets [Policy Text Block]</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsPolicyTextBlock_documentation_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsPolicyTextBlock" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FinancialRoyaltyAssetsPolicyTextBlock" xlink:to="lab_lgnd_FinancialRoyaltyAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_0429e0c9-0056-436f-9299-857aac26b7dd_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_SegmentDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="lab_us-gaap_SegmentDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_35b9196c-a8ab-4882-a4ff-c0125ff3e011_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetGross_6d4742c7-3eea-481e-a613-193690c4f770_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross contract asset</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetGross_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetGross" xlink:to="lab_us-gaap_ContractWithCustomerAssetGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_97315934-dc2a-47d3-b65b-297810a6cd96_terseLabel_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:label id="lab_us-gaap_PublicUtilitiesInventoryAxis_label_en-US" xlink:label="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis" xlink:to="lab_us-gaap_PublicUtilitiesInventoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision_66266d5b-ebdd-40ac-9934-bbde76bd770d_terseLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final tax impact of OmniAb Distribution</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Tax Return To Provision</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid In Capital, Tax Return To Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" xlink:href="lgnd-20241231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7860c470-0bd4-4207-ac94-9d4cca214cd0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_d173861d-092a-45df-843e-e7485620e1d9_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain from short-term investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration_3e7bb53e-ae76-4504-bc0c-a90f9c499211_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares received as consideration</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Share Consideration</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Share Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_329e283b-464b-48c8-88cb-3e5cfc19bad7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_06142b64-79cd-49e4-9efc-fac4537d3ac5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_f0ef0711-62fd-4cf1-bb4d-b63b84f4238f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturity of Finance Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_fb5d8ac1-3643-402b-99c6-d60f813179db_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_559413dd-5c29-4e53-ac74-c99708466b18_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired_cdd5cfc9-958b-42e2-a976-d777bf1e49f1_negatedTerseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for acquisition, net of cash acquired</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsAllowance_0e8c260a-69cf-4e88-a0ab-58e2d8e5038e_negatedTerseLabel_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Allowance</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsAllowance_label_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets, Allowance</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsAllowance_documentation_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets, Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsAllowance" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FinancialRoyaltyAssetsAllowance" xlink:to="lab_lgnd_FinancialRoyaltyAssetsAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_34b20bf1-09a8-4e46-b4e6-043dffcac56d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted net loss from discontinued operations (in USD per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_UnrecognizedTaxBenefitsNoncurrent_2de6c14d-c7fd-4bc0-910d-ab3ec7097ae7_terseLabel_en-US" xlink:label="lab_lgnd_UnrecognizedTaxBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_lgnd_UnrecognizedTaxBenefitsNoncurrent_label_en-US" xlink:label="lab_lgnd_UnrecognizedTaxBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits - Noncurrent</link:label>
    <link:label id="lab_lgnd_UnrecognizedTaxBenefitsNoncurrent_documentation_en-US" xlink:label="lab_lgnd_UnrecognizedTaxBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits - Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_UnrecognizedTaxBenefitsNoncurrent" xlink:href="lgnd-20241231.xsd#lgnd_UnrecognizedTaxBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_UnrecognizedTaxBenefitsNoncurrent" xlink:to="lab_lgnd_UnrecognizedTaxBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_9649cf76-c151-451a-8e25-9722c0c31965_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock_42bc12e0-84c0-4bfc-96a7-6515c192bd29_terseLabel_en-US" xlink:label="lab_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business</link:label>
    <link:label id="lab_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock_label_en-US" xlink:label="lab_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Spin-Off And Migration [Policy Text Block]</link:label>
    <link:label id="lab_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock_documentation_en-US" xlink:label="lab_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Spin-Off And Migration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock" xlink:href="lgnd-20241231.xsd#lgnd_BusinessSpinOffAndMigrationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock" xlink:to="lab_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_d4913f2b-f0f7-4e89-ad62-f14109c2e8e5_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_0fa745ca-809e-494e-826f-16dcc984c6a7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PartnerCMember_97153647-071c-4e0f-9443-a5b4ca1970e2_terseLabel_en-US" xlink:label="lab_lgnd_PartnerCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Partner C</link:label>
    <link:label id="lab_lgnd_PartnerCMember_label_en-US" xlink:label="lab_lgnd_PartnerCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partner C [Member]</link:label>
    <link:label id="lab_lgnd_PartnerCMember_documentation_en-US" xlink:label="lab_lgnd_PartnerCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Partner C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerCMember" xlink:href="lgnd-20241231.xsd#lgnd_PartnerCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PartnerCMember" xlink:to="lab_lgnd_PartnerCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_e67a5115-7f24-4197-9668-fc63addad423_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining lease term of operating leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_8da70a0f-85f3-48f0-b7b6-5c166a9fa5db_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from Viking Share Collar and Viking Share Put</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Derivative Instrument, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities" xlink:to="lab_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_66bbc87c-88b7-40ba-804a-a7bca1403425_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Losses from equity method investment in Primrose Bio</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_5ec1941a-80ad-45e3-9b65-ea06c8fa687a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Losses from equity method investment in Primrose Bio</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_38add7f2-3455-4631-9d39-0138c84189b3_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility, interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_c1e7a8eb-0845-4477-b3a6-691b164e31a9_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue from Significant Partners</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeNineMember_f52eeb02-e29e-4aa8-8145-edff23ea6f3a_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$104.30-$114.15</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeNineMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Nine [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeNineMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Nine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeNineMember" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeNineMember" xlink:to="lab_lgnd_ExercisePriceRangeNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_f79ae49c-ceb5-419a-9221-37188589e4c5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-operating income and expenses:</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VestingPeriodTwoMember_59506017-660c-4171-b2bf-bd5bad2933bd_terseLabel_en-US" xlink:label="lab_lgnd_VestingPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vest 1/48 each month for forty-two months</link:label>
    <link:label id="lab_lgnd_VestingPeriodTwoMember_label_en-US" xlink:label="lab_lgnd_VestingPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Period Two [Member]</link:label>
    <link:label id="lab_lgnd_VestingPeriodTwoMember_documentation_en-US" xlink:label="lab_lgnd_VestingPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vesting Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodTwoMember" xlink:href="lgnd-20241231.xsd#lgnd_VestingPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VestingPeriodTwoMember" xlink:to="lab_lgnd_VestingPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpenditureDiscontinuedOperations_3c7745b5-f77f-464d-83ca-c3f9466a634f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchase of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpenditureDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditure, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:to="lab_us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_047acb6c-f631-4861-8459-5cd398f24a9a_negatedLabel_en-US" xlink:label="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in estimated fair value of contingent liabilities</link:label>
    <link:label id="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_label_en-US" xlink:label="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Change In Estimated Fair Value Of Contingent Value Rights</link:label>
    <link:label id="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Change In Estimated Fair Value Of Contingent Value Rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:href="lgnd-20241231.xsd#lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:to="lab_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IncomeTaxReconciliationContingentValueRights_18825201-731a-4f56-9419-bd7edf27ae1b_terseLabel_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_lgnd_IncomeTaxReconciliationContingentValueRights_label_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Reconciliation, Contingent Value Rights</link:label>
    <link:label id="lab_lgnd_IncomeTaxReconciliationContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Tax Reconciliation, Contingent Value Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:href="lgnd-20241231.xsd#lgnd_IncomeTaxReconciliationContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:to="lab_lgnd_IncomeTaxReconciliationContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid_5fd65632-7fec-44b5-ac04-334774197abc_terseLabel_en-US" xlink:label="lab_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued debt issuance costs</link:label>
    <link:label id="lab_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Debt Issuance Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Debt Issuance Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid" xlink:href="lgnd-20241231.xsd#lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid" xlink:to="lab_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_25569ec9-831f-4e2e-a52c-7896c69d6e6b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_b34e05f8-ad3d-4517-9497-125cbad71713_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_3994efad-da01-4145-b4cc-df1991ba8a51_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionLineItems" xlink:to="lab_us-gaap_AssetAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_ac383561-2194-4a42-bc76-959abe86c2b2_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes</link:label>
    <link:label id="lab_us-gaap_ConvertibleNotesPayableMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleNotesPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleNotesPayableMember" xlink:to="lab_us-gaap_ConvertibleNotesPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_425f2b8f-b837-4f37-bd12-fb73b36d0df2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net of acquisitions and dispositions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_80e82e1d-f372-4b24-8399-d88ffce76ec3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount_787d5d5f-107a-4660-bfbd-72a5f125488f_verboseLabel_en-US" xlink:label="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock shares, amount</link:label>
    <link:label id="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount_label_en-US" xlink:label="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Converted Instrument Amount</link:label>
    <link:label id="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount_documentation_en-US" xlink:label="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Converted Instrument Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount" xlink:href="lgnd-20241231.xsd#lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount" xlink:to="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FCX007Member_2c1f90b6-7c93-4e84-ac46-6a0a4a21fd7b_terseLabel_en-US" xlink:label="lab_lgnd_FCX007Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FCX-007</link:label>
    <link:label id="lab_lgnd_FCX007Member_label_en-US" xlink:label="lab_lgnd_FCX007Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FCX-007 [Member]</link:label>
    <link:label id="lab_lgnd_FCX007Member_documentation_en-US" xlink:label="lab_lgnd_FCX007Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FCX-007</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FCX007Member" xlink:href="lgnd-20241231.xsd#lgnd_FCX007Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FCX007Member" xlink:to="lab_lgnd_FCX007Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrMember_662eefe2-2ec8-4980-b0b7-1955c1a79e00_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_f68bb5d1-02cf-418b-90c8-1c2a8d548481_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proportion of fair market value of common stock at which stock is purchased under ESPP (as a percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_c7edaa76-188c-482c-b08e-0581464fbbf8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_5e7557fe-7427-436c-ac19-4aa64d17e25e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_6cd57a52-7ba6-4267-ae16-abc87a86677b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1a05fa98-0908-4ad4-8462-81660586a6ff_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options vested and expected to vest at end of period (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_208ebc50-cc6d-4b3f-afdf-fcb7f084d178_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ShareBasedCompensationInitialOfferingPeriod_ec7ff76a-b255-4b20-a899-3c7771cb3feb_terseLabel_en-US" xlink:label="lab_lgnd_ShareBasedCompensationInitialOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial offering period</link:label>
    <link:label id="lab_lgnd_ShareBasedCompensationInitialOfferingPeriod_label_en-US" xlink:label="lab_lgnd_ShareBasedCompensationInitialOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation, Initial Offering Period</link:label>
    <link:label id="lab_lgnd_ShareBasedCompensationInitialOfferingPeriod_documentation_en-US" xlink:label="lab_lgnd_ShareBasedCompensationInitialOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation, Initial Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ShareBasedCompensationInitialOfferingPeriod" xlink:href="lgnd-20241231.xsd#lgnd_ShareBasedCompensationInitialOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ShareBasedCompensationInitialOfferingPeriod" xlink:to="lab_lgnd_ShareBasedCompensationInitialOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_9a259fcf-5fb1-4678-a9dd-f926758ec737_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_30a04e04-5824-4e0d-9a40-a8cfd1334cb6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Level 3 Financial Instruments, Liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_ac123057-309b-4737-9492-3242021537ef_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock_1f5f1c5e-5cdb-4048-8946-442311c21966_terseLabel_en-US" xlink:label="lab_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value of the Consideration</link:label>
    <link:label id="lab_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock_label_en-US" xlink:label="lab_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Fair Value Of The Consideration [Table Text Block]</link:label>
    <link:label id="lab_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Fair Value Of The Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock" xlink:href="lgnd-20241231.xsd#lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock" xlink:to="lab_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2747d9fa-4eea-490c-8f70-22b72ea67b27_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_45bc7e2e-e49e-4ebf-836a-b08d4fe93dbc_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_96902779-a408-4df9-9b76-430872ff45fa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_23ef6d67-96c3-4d1f-8c26-d784e9a6ed01_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_07984d1d-fcc6-459a-8f14-4677068e3756_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_OvidTherapeuticsMember_b8f0c27a-0fe4-4122-86e1-65db92b8defd_terseLabel_en-US" xlink:label="lab_lgnd_OvidTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ovid (Soticlestat)</link:label>
    <link:label id="lab_lgnd_OvidTherapeuticsMember_label_en-US" xlink:label="lab_lgnd_OvidTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ovid Therapeutics [Member]</link:label>
    <link:label id="lab_lgnd_OvidTherapeuticsMember_documentation_en-US" xlink:label="lab_lgnd_OvidTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ovid Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OvidTherapeuticsMember" xlink:href="lgnd-20241231.xsd#lgnd_OvidTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_OvidTherapeuticsMember" xlink:to="lab_lgnd_OvidTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AtTheMarketEquityOfferingMember_12612472-e7eb-4dab-ab67-ec6e9ed6512d_terseLabel_en-US" xlink:label="lab_lgnd_AtTheMarketEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-The-Market Equity Offering</link:label>
    <link:label id="lab_lgnd_AtTheMarketEquityOfferingMember_label_en-US" xlink:label="lab_lgnd_AtTheMarketEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-The Market Equity Offering [Member]</link:label>
    <link:label id="lab_lgnd_AtTheMarketEquityOfferingMember_documentation_en-US" xlink:label="lab_lgnd_AtTheMarketEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-The Market Equity Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AtTheMarketEquityOfferingMember" xlink:href="lgnd-20241231.xsd#lgnd_AtTheMarketEquityOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AtTheMarketEquityOfferingMember" xlink:to="lab_lgnd_AtTheMarketEquityOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_9b2eaadb-bb5c-40f4-b14f-cdec67cc7903_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2f3392a4-cf1c-473c-8eb8-f79c718e7eb7_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_0acd2743-8bf5-4831-81f2-0e07de76a8bf_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContractRevenueAndOtherIncomeMember_b5d1e5c5-94d8-4db8-8a8b-79483a99955b_terseLabel_en-US" xlink:label="lab_lgnd_ContractRevenueAndOtherIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract revenue and other income</link:label>
    <link:label id="lab_lgnd_ContractRevenueAndOtherIncomeMember_label_en-US" xlink:label="lab_lgnd_ContractRevenueAndOtherIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Revenue And Other Income [Member]</link:label>
    <link:label id="lab_lgnd_ContractRevenueAndOtherIncomeMember_documentation_en-US" xlink:label="lab_lgnd_ContractRevenueAndOtherIncomeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Revenue And Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueAndOtherIncomeMember" xlink:href="lgnd-20241231.xsd#lgnd_ContractRevenueAndOtherIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContractRevenueAndOtherIncomeMember" xlink:to="lab_lgnd_ContractRevenueAndOtherIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_c3c3591f-950a-4092-b79b-068663e2e956_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustments to contingent liabilities</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ValueAddedTaxReceivableNetCurrent_4b31dc16-38d2-4920-89a5-f97526556f4b_negatedTerseLabel_en-US" xlink:label="lab_lgnd_ValueAddedTaxReceivableNetCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">UK value-added tax</link:label>
    <link:label id="lab_lgnd_ValueAddedTaxReceivableNetCurrent_label_en-US" xlink:label="lab_lgnd_ValueAddedTaxReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Value Added Tax Receivable Net, Current</link:label>
    <link:label id="lab_lgnd_ValueAddedTaxReceivableNetCurrent_documentation_en-US" xlink:label="lab_lgnd_ValueAddedTaxReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value Added Tax Receivable Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ValueAddedTaxReceivableNetCurrent" xlink:href="lgnd-20241231.xsd#lgnd_ValueAddedTaxReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ValueAddedTaxReceivableNetCurrent" xlink:to="lab_lgnd_ValueAddedTaxReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_96c5fda8-90c2-4e37-9aa9-1423cb91560b_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_eec4d3e3-2d3c-454d-89b3-56e9818a97a4_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk Free Interest Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_fd9a49ec-7ca1-428f-8b19-6e7e98cbcfe5_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_c6a6409f-3139-48ec-8d02-c4416ee55c25_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PartnerProgramsMember_7cb80040-6ac8-4817-a6c4-3bb63e398b49_terseLabel_en-US" xlink:label="lab_lgnd_PartnerProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Partner Programs</link:label>
    <link:label id="lab_lgnd_PartnerProgramsMember_label_en-US" xlink:label="lab_lgnd_PartnerProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partner Programs [Member]</link:label>
    <link:label id="lab_lgnd_PartnerProgramsMember_documentation_en-US" xlink:label="lab_lgnd_PartnerProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Partner Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerProgramsMember" xlink:href="lgnd-20241231.xsd#lgnd_PartnerProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PartnerProgramsMember" xlink:to="lab_lgnd_PartnerProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries_e7c620b3-9605-4b69-8e9a-360b0424ab06_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of CVRs issued from each CVR series</link:label>
    <link:label id="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries_label_en-US" xlink:label="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Number of Contingent Value Rights Issued from Each Contingent Value Right Series</link:label>
    <link:label id="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Number of Contingent Value Rights Issued from Each Contingent Value Right Series</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries" xlink:to="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_2243e811-f306-4e7e-ba8c-1e2bbd6bb525_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_8d375326-48f9-47ad-8445-5ef3b0779a26_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_51286f26-2cbf-4ff7-b3a1-3035ea331649_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS)</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_91fea8c0-5568-4dad-8426-b13dd53e1190_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_67c05baf-08cc-4d2b-93d2-c70062a51fdd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Tax Effect of Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:to="lab_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7d064763-9867-4743-b174-99da2188f02f_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_e7e1a584-3080-4ffb-bfb8-78e8e128fe3b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_923f5605-3685-4c37-818d-510cf293b11c_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_66e27821-73c1-4886-b601-8df0c15f7a36_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent earn-out payment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_036c37b0-21e1-4faf-bd1c-98ca5b369c48_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_70fcda67-a29a-4395-8faa-130e1e0942d4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue and Other Income</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_f1172618-f86f-4a95-9070-34eb32d14439_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_4e3cb4ca-1750-4ba8-815b-06b54bc2832e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_c70dc032-043b-4497-8ce2-51486fbc0694_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Palvella Series C preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyKyprolisMember_ad3009c7-47f0-45e6-99c9-646da6230e59_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyKyprolisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Kyprolis</link:label>
    <link:label id="lab_lgnd_RoyaltyKyprolisMember_label_en-US" xlink:label="lab_lgnd_RoyaltyKyprolisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty, Kyprolis [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyKyprolisMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyKyprolisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty, Kyprolis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyKyprolisMember" xlink:href="lgnd-20241231.xsd#lgnd_RoyaltyKyprolisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyKyprolisMember" xlink:to="lab_lgnd_RoyaltyKyprolisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_394cb8d6-cb50-4ce5-a2a3-1b0a8a1b4bc9_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available borrowing</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetMeasurementInput_1db1ec5e-1a5c-4535-9c03-37fcbb294efd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetMeasurementInput" xlink:to="lab_us-gaap_DerivativeAssetMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_c8200ea8-367b-4294-92e7-9021c9d5fa4f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate change for changes in federal, foreign or state law</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_3ba009f1-a913-4841-9862-dcd733bb80d5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Grant&#160;Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_bf732d25-d858-4f60-8165-0b4d4226dcdc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_c4c0b188-5f8b-4d9c-8d16-0481c37e931b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected Term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_ef6bcc87-67a8-418a-94aa-d03d8d1a1dfa_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PartnerAMember_4ff33f91-a39e-4b78-be35-8022684ab6c2_terseLabel_en-US" xlink:label="lab_lgnd_PartnerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Partner A</link:label>
    <link:label id="lab_lgnd_PartnerAMember_label_en-US" xlink:label="lab_lgnd_PartnerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partner A [Member]</link:label>
    <link:label id="lab_lgnd_PartnerAMember_documentation_en-US" xlink:label="lab_lgnd_PartnerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Partner A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerAMember" xlink:href="lgnd-20241231.xsd#lgnd_PartnerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PartnerAMember" xlink:to="lab_lgnd_PartnerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_ad1124c1-8f73-4ec5-8ab1-80e4f2b745f5_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_05ef76fc-f718-406b-81c6-d66c780b5ee6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AboveMilestoneMember_f1f7438b-deaf-47eb-89df-e8c8efc1ac8c_terseLabel_en-US" xlink:label="lab_lgnd_AboveMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Above 3 million</link:label>
    <link:label id="lab_lgnd_AboveMilestoneMember_label_en-US" xlink:label="lab_lgnd_AboveMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Above Milestone [Member]</link:label>
    <link:label id="lab_lgnd_AboveMilestoneMember_documentation_en-US" xlink:label="lab_lgnd_AboveMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Above Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AboveMilestoneMember" xlink:href="lgnd-20241231.xsd#lgnd_AboveMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AboveMilestoneMember" xlink:to="lab_lgnd_AboveMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_63afa246-ec22-487c-9905-5f12c1568737_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_25895f15-4ec6-4495-9609-37f790e4f9b2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_425d38a5-5f31-4d36-a1c2-5ddf4e8681a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_16f81103-dd7b-4bcb-b6f6-9f16907a8bb5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross" xlink:to="lab_us-gaap_DeferredFinanceCostsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_9b8d5dcc-cbc2-4157-ac7e-608e3b013144_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_c56c8d0c-b155-4f90-824d-859f98ec3ad9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fair value adjustment to Primrose Bio securities investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_1c89499e-7e13-43f3-ba85-1913943dd5f8_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_be7c17e5-06fd-498c-b451-087d548e7db8_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount_6cb01b73-ccbe-43c1-8fb0-4e9e35ffd9fd_terseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt repurchases</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Debt Repurchases, Amount</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Debt Repurchases, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" xlink:href="lgnd-20241231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_OtherPurchasersMember_a2fd6f7b-8450-490e-92fa-77189e7ad472_terseLabel_en-US" xlink:label="lab_lgnd_OtherPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Purchasers</link:label>
    <link:label id="lab_lgnd_OtherPurchasersMember_label_en-US" xlink:label="lab_lgnd_OtherPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Purchasers [Member]</link:label>
    <link:label id="lab_lgnd_OtherPurchasersMember_documentation_en-US" xlink:label="lab_lgnd_OtherPurchasersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Purchasers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherPurchasersMember" xlink:href="lgnd-20241231.xsd#lgnd_OtherPurchasersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_OtherPurchasersMember" xlink:to="lab_lgnd_OtherPurchasersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_376427d0-207d-44e1-969d-b8b89e31c27b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ce3278ab-684e-4ffb-a435-47f654627c73_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_ae006430-670d-403e-a036-380a2d11651b_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reported Value</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_OtherBalanceSheetDetailsAbstract_label_en-US" xlink:label="lab_lgnd_OtherBalanceSheetDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Balance Sheet Details [Abstract]</link:label>
    <link:label id="lab_lgnd_OtherBalanceSheetDetailsAbstract_documentation_en-US" xlink:label="lab_lgnd_OtherBalanceSheetDetailsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Balance Sheet Details [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract" xlink:href="lgnd-20241231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract" xlink:to="lab_lgnd_OtherBalanceSheetDetailsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice_6eac98a0-eb9f-445e-9f92-0301b5c64bd3_terseLabel_en-US" xlink:label="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt conversion price per share (in USD per share)</link:label>
    <link:label id="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice_label_en-US" xlink:label="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Converted Instrument , Conversion Price</link:label>
    <link:label id="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice_documentation_en-US" xlink:label="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Converted Instrument , Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice" xlink:href="lgnd-20241231.xsd#lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice" xlink:to="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsMember_3076e1ab-4742-4649-ab4b-676b1a175107_terseLabel_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from financial royalty assets</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsMember_547ae1c2-14f6-4582-a7cf-670bb58c963b_verboseLabel_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income from financial royalty assets</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsMember_label_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets [Member]</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsMember_documentation_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsMember" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FinancialRoyaltyAssetsMember" xlink:to="lab_lgnd_FinancialRoyaltyAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_ade638bf-e6ee-45a1-9423-8342aec89d58_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_37b0d183-b112-4f51-93c8-6df1d8990da6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_508aae2b-8705-4b50-868f-50fa00529d9f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_bcf9930e-61f4-4b91-89e7-b46b4ecaaf19_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for Apeiron acquisition, net of cash received</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Business Two, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1486c705-e4f2-4585-bd93-b3e11c32323c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_8d16fea3-f9fa-42d7-92f9-d52a13a3294b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount of 2023 notes outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_31e3b144-7563-41ce-b680-56fec6053373_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Core Technology</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_02ef33d7-557a-4120-b358-59ac03ae6de1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_9beed888-e0c3-40ac-8736-a884a740b432_terseLabel_en-US" xlink:label="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US District Court for the Northern District of Ohio</link:label>
    <link:label id="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_label_en-US" xlink:label="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US District Court for the Northern District of Ohio [Member]</link:label>
    <link:label id="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_documentation_en-US" xlink:label="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">US District Court for the Northern District of Ohio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:href="lgnd-20241231.xsd#lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:to="lab_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_0f6a6357-6252-48ea-ad52-679708463b2c_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic net loss from discontinued operations (in USD per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_5b1a1724-1e67-4be6-92ba-a230aadf9833_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasuries</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_583659ea-6159-4c74-8909-61492e7fd1de_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasuries</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b9cf7591-1ac9-45b5-af5e-0e7b1e87fe79_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_677ff37b-bcf2-4ead-8f3c-7f416477d3a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed_5653df93-2888-4d39-8bba-9e62e40cdb26_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of voting interests disposed (as a percent)</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Percentage Of Voting Interests Disposed</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Percentage Of Voting Interests Disposed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2bc4df60-67d9-4fe8-a7f7-54d1fb1e5ea4_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationLoanFeesAndInterest_c33f9856-5908-4688-b5ac-390ac153200b_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationLoanFeesAndInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">DIP loan fees and interest</link:label>
    <link:label id="lab_lgnd_BusinessCombinationLoanFeesAndInterest_label_en-US" xlink:label="lab_lgnd_BusinessCombinationLoanFeesAndInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Loan Fees And Interest</link:label>
    <link:label id="lab_lgnd_BusinessCombinationLoanFeesAndInterest_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationLoanFeesAndInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Loan Fees And Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationLoanFeesAndInterest" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationLoanFeesAndInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationLoanFeesAndInterest" xlink:to="lab_lgnd_BusinessCombinationLoanFeesAndInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_8ec18555-3947-46fd-8d5c-a49f0218f562_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_62aea3bd-0f6b-4932-b025-f5406ecf5cf9_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_86b50278-758e-4f84-a9d4-32dea3d4af24_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current expense (benefit):</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_560a5f03-571c-4789-af10-5cc5e1fb9170_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_5ee1f400-c5b9-44f9-93f4-4080a394eb55_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss (gain) on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireNotesReceivable_942aa309-5d55-4f21-8d1d-441a64c7e4ff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for Palvella notes receivable</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireNotesReceivable_67fcd8f9-e5e9-4d7d-a3b2-b36e27ddb685_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire notes</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireNotesReceivable_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireNotesReceivable" xlink:to="lab_us-gaap_PaymentsToAcquireNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_08a7072b-dbf2-451a-907e-0e99f6b48a37_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_43fbb937-df15-495d-8215-56f29d25d5ae_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_83fcea9e-2512-4468-82cf-bdc6674cd811_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_4101f909-97f7-4958-b1d2-1e0a6564aa17_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash acquired from acquisition</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_8ceeb1d0-1583-4f7f-b85a-0295f36b2ab4_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Option</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_SelexisMember_5bff89e1-eb72-4418-99e2-a834d4fd088a_terseLabel_en-US" xlink:label="lab_lgnd_SelexisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selexis</link:label>
    <link:label id="lab_lgnd_SelexisMember_label_en-US" xlink:label="lab_lgnd_SelexisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selexis [Member]</link:label>
    <link:label id="lab_lgnd_SelexisMember_documentation_en-US" xlink:label="lab_lgnd_SelexisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Selexis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisMember" xlink:href="lgnd-20241231.xsd#lgnd_SelexisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_SelexisMember" xlink:to="lab_lgnd_SelexisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_227009c2-2c8d-4829-8a1d-97e0b33fb956_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments under finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_2e81cfe1-9d3b-4c6c-a011-be60a83b8110_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Debt Securities in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyTeriparatideInjectionMember_ea3ef38f-266b-4781-bfb1-372d5cf5ae28_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyTeriparatideInjectionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Teriparatide injection</link:label>
    <link:label id="lab_lgnd_RoyaltyTeriparatideInjectionMember_label_en-US" xlink:label="lab_lgnd_RoyaltyTeriparatideInjectionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty, Teriparatide Injection [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyTeriparatideInjectionMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyTeriparatideInjectionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty, Teriparatide Injection</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyTeriparatideInjectionMember" xlink:href="lgnd-20241231.xsd#lgnd_RoyaltyTeriparatideInjectionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyTeriparatideInjectionMember" xlink:to="lab_lgnd_RoyaltyTeriparatideInjectionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CorporateShareRepurchaseAbstract_39f610bd-3e4c-4a35-86d0-a4751b48d901_terseLabel_en-US" xlink:label="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Share Repurchase</link:label>
    <link:label id="lab_lgnd_CorporateShareRepurchaseAbstract_label_en-US" xlink:label="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Share Repurchase [Abstract]</link:label>
    <link:label id="lab_lgnd_CorporateShareRepurchaseAbstract_documentation_en-US" xlink:label="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Share Repurchase [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorporateShareRepurchaseAbstract" xlink:href="lgnd-20241231.xsd#lgnd_CorporateShareRepurchaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract" xlink:to="lab_lgnd_CorporateShareRepurchaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_381b2044-adb3-42ad-b570-9b1a57df73a2_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_37267824-8696-47fa-8288-d6b16a13a7eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes receivable</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BasisOfPresentationTable_e08ccbb4-5e69-4a67-961a-16b82ede53e0_terseLabel_en-US" xlink:label="lab_lgnd_BasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation [Table]</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationTable_label_en-US" xlink:label="lab_lgnd_BasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation [Table]</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationTable_documentation_en-US" xlink:label="lab_lgnd_BasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basis of Presentation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationTable" xlink:href="lgnd-20241231.xsd#lgnd_BasisOfPresentationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BasisOfPresentationTable" xlink:to="lab_lgnd_BasisOfPresentationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4890efd4-42a1-4f20-a9ed-d8f1695ebc34_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_71fe58ee-e7cb-4264-b63b-66f0117f37c7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_d84719b5-1da6-4244-bb09-7b521c83e940_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_2b4bdc77-b9af-415a-b531-588277f44cbf_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_35267dfb-b905-466c-9385-48b234163ad0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CyDexMember_dae0f1b7-fafa-432d-9f39-ad047861b299_terseLabel_en-US" xlink:label="lab_lgnd_CyDexMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CyDex</link:label>
    <link:label id="lab_lgnd_CyDexMember_label_en-US" xlink:label="lab_lgnd_CyDexMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CyDex [Member]</link:label>
    <link:label id="lab_lgnd_CyDexMember_documentation_en-US" xlink:label="lab_lgnd_CyDexMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">CyDex</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CyDexMember" xlink:href="lgnd-20241231.xsd#lgnd_CyDexMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CyDexMember" xlink:to="lab_lgnd_CyDexMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3c2d0068-e84f-4359-902f-ed0b288b21e1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_54861224-7e2c-4cdc-8b79-da4171e4082c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_5a0e8a3b-9d2d-47e0-ae88-b2964ac5a70d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agenus Transaction</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTextBlock" xlink:to="lab_us-gaap_AssetAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome_d1b414a7-7827-4947-9a1c-b8db2d2761e3_terseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subpart F income</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Income</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome" xlink:href="lgnd-20241231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_af298433-abce-4198-8fbd-4deaa876cd4c_terseLabel_en-US" xlink:label="lab_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</link:label>
    <link:label id="lab_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_label_en-US" xlink:label="lab_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</link:label>
    <link:label id="lab_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_documentation_en-US" xlink:label="lab_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:href="lgnd-20241231.xsd#lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:to="lab_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b4667eec-bbc7-4556-8729-44fd9b5836a9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3470b77a-29b1-4edf-8226-6d5efdef9d8d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_69f554ba-da78-44d6-b6e2-890824df247c_negatedTerseLabel_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_c17b1982-b08a-46fc-897a-2512e9aac56e_negatedLabel_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments to CVR holders and other contingent payments</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_label_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Contingent Value Right Holders</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHolders_documentation_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments to contingent value right holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsToContingentValueRightHolders" xlink:to="lab_lgnd_PaymentsToContingentValueRightHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_8be779b3-b381-492e-b0d4-72862265f82f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_ca4f1119-261a-401d-ac22-b8b05fb2b4c9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_b9a74edd-f35a-4cb7-9634-f68dde5e67c6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_efee8285-4221-43c9-b814-401a53762cce_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_0dc94219-7f9f-4e9e-9045-5c3e4b5e2cb0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturity of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContingentLiabilityRollForward_bf6417c5-c3a6-4b6e-ba7e-35d6465abaf6_terseLabel_en-US" xlink:label="lab_lgnd_ContingentLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Liability</link:label>
    <link:label id="lab_lgnd_ContingentLiabilityRollForward_label_en-US" xlink:label="lab_lgnd_ContingentLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Liability [Roll Forward]</link:label>
    <link:label id="lab_lgnd_ContingentLiabilityRollForward_documentation_en-US" xlink:label="lab_lgnd_ContingentLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilityRollForward" xlink:href="lgnd-20241231.xsd#lgnd_ContingentLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContingentLiabilityRollForward" xlink:to="lab_lgnd_ContingentLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsForSeparation_fcc4fecf-17d7-40dc-bbf8-46f6171f27d6_negatedTerseLabel_en-US" xlink:label="lab_lgnd_PaymentsForSeparation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net cash transferred to OmniAb at OmniAb Separation</link:label>
    <link:label id="lab_lgnd_PaymentsForSeparation_label_en-US" xlink:label="lab_lgnd_PaymentsForSeparation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Separation</link:label>
    <link:label id="lab_lgnd_PaymentsForSeparation_documentation_en-US" xlink:label="lab_lgnd_PaymentsForSeparation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Separation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsForSeparation" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsForSeparation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsForSeparation" xlink:to="lab_lgnd_PaymentsForSeparation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_784aab94-21ca-4ccb-8f61-365376fdc4b7_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss):</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_7dabc390-7f6f-4b2b-a1be-4de1d8d192ea_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a2870c40-25f0-4368-9240-e27f83339abd_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccountsReceivableTerm_cda05fce-f01c-4588-a75f-aefed3a4f058_terseLabel_en-US" xlink:label="lab_lgnd_AccountsReceivableTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible note maturity period (in years)</link:label>
    <link:label id="lab_lgnd_AccountsReceivableTerm_label_en-US" xlink:label="lab_lgnd_AccountsReceivableTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Term</link:label>
    <link:label id="lab_lgnd_AccountsReceivableTerm_documentation_en-US" xlink:label="lab_lgnd_AccountsReceivableTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableTerm" xlink:href="lgnd-20241231.xsd#lgnd_AccountsReceivableTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccountsReceivableTerm" xlink:to="lab_lgnd_AccountsReceivableTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_75ed351c-f67d-4af4-9c1a-58b6d4074cdc_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_GainLossOnShortTermInvestments_3ee06852-def1-45a6-bed6-dabfa7416b31_negatedTerseLabel_en-US" xlink:label="lab_lgnd_GainLossOnShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain from short-term investments</link:label>
    <link:label id="lab_lgnd_GainLossOnShortTermInvestments_label_en-US" xlink:label="lab_lgnd_GainLossOnShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Short-Term Investments</link:label>
    <link:label id="lab_lgnd_GainLossOnShortTermInvestments_documentation_en-US" xlink:label="lab_lgnd_GainLossOnShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_GainLossOnShortTermInvestments" xlink:href="lgnd-20241231.xsd#lgnd_GainLossOnShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_GainLossOnShortTermInvestments" xlink:to="lab_lgnd_GainLossOnShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_9c8ced47-7b40-497a-8c8e-25e2531ae1b5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Condensed Statement of Operations:</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_20b04d87-fbcc-4850-9c2b-289fbbeb0d75_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_89b10e46-200d-4c2a-8b97-517c7b459fcd_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Loss Carryforward</link:label>
    <link:label id="lab_us-gaap_CapitalLossCarryforwardMember_label_en-US" xlink:label="lab_us-gaap_CapitalLossCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Loss Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalLossCarryforwardMember" xlink:to="lab_us-gaap_CapitalLossCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_50f35e79-99a2-4531-ae8a-b7843059f517_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d02bcbb7-e775-422d-a7f5-d477edb50983_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7c1dcc2a-5d69-4eb7-99b4-4848abe3f7bf_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_9cbfa9a6-1783-4ada-9c60-3690962aba52_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term of operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_c1cd9985-21c3-4afa-9b8a-e088522026de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_79d97cad-ce5e-42c8-9556-7d314d3996b9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_4ed32fe3-c546-4cd0-8335-37c5144dbf53_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_f968cba5-d991-4af7-9421-eb235149d9ed_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_f03758a9-b4c5-4ff3-8a10-0b4036279deb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MetabasisMember_bd15d203-eab4-42e2-8926-5f94a9325097_terseLabel_en-US" xlink:label="lab_lgnd_MetabasisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Metabasis</link:label>
    <link:label id="lab_lgnd_MetabasisMember_label_en-US" xlink:label="lab_lgnd_MetabasisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Metabasis [Member]</link:label>
    <link:label id="lab_lgnd_MetabasisMember_documentation_en-US" xlink:label="lab_lgnd_MetabasisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Metabasis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisMember" xlink:href="lgnd-20241231.xsd#lgnd_MetabasisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MetabasisMember" xlink:to="lab_lgnd_MetabasisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_INCAGN2385Member_b3266f7c-1c83-46b3-a975-7478c3fca513_terseLabel_en-US" xlink:label="lab_lgnd_INCAGN2385Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCAGN2385</link:label>
    <link:label id="lab_lgnd_INCAGN2385Member_label_en-US" xlink:label="lab_lgnd_INCAGN2385Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">INCAGN2385 [Member]</link:label>
    <link:label id="lab_lgnd_INCAGN2385Member_documentation_en-US" xlink:label="lab_lgnd_INCAGN2385Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">INCAGN2385</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_INCAGN2385Member" xlink:href="lgnd-20241231.xsd#lgnd_INCAGN2385Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_INCAGN2385Member" xlink:to="lab_lgnd_INCAGN2385Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_6f02213c-1257-4053-95e7-982955ed954a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted net income (loss) from continuing operations (in USD per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_2cc15f70-272a-4a00-9cf1-e9833fe6de1c_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investment Categories</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_e6a78264-7bb7-45ba-bf29-a9b7d7fb27b0_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income (Expense)</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_403acaf1-459b-4953-bdac-b67b18b29421_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_9fc00f69-cb1e-4579-8977-1bedfbe58605_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill written off</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_b246e6b1-3379-44eb-be31-4b0e63576ed8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BOTBALMember_90970eb5-a0c4-4ebe-a134-472104ebe37b_terseLabel_en-US" xlink:label="lab_lgnd_BOTBALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BOT/BAL</link:label>
    <link:label id="lab_lgnd_BOTBALMember_label_en-US" xlink:label="lab_lgnd_BOTBALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BOT/BAL [Member]</link:label>
    <link:label id="lab_lgnd_BOTBALMember_documentation_en-US" xlink:label="lab_lgnd_BOTBALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BOT/BAL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BOTBALMember" xlink:href="lgnd-20241231.xsd#lgnd_BOTBALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BOTBALMember" xlink:to="lab_lgnd_BOTBALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_8506eb6c-8dc6-4c9d-9f8b-8f5e42a12556_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_db4d2c63-d384-4c15-a2fe-90455b249821_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_1412de1e-7ba0-4c49-bd3c-d7c959481c18_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions to derivative assets</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestorMember_99838b28-8e64-4dc0-af07-6f81748dedc3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investor</link:label>
    <link:label id="lab_us-gaap_InvestorMember_label_en-US" xlink:label="lab_us-gaap_InvestorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investor [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember" xlink:to="lab_us-gaap_InvestorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_ff5b257b-acd9-4b90-9010-113f250c6198_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8f3e6a13-4fb8-4c5f-9cb4-927ae1854459_netLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Shares used in basic per share calculation (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_60f337d0-18c4-4fcf-8973-35c61eca9722_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_9a49e2a6-7807-4afc-8590-9078f5f0231f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">12 months or greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LeaseLiability_61750697-752c-41d9-ae15-805442433f97_totalLabel_en-US" xlink:label="lab_lgnd_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_lgnd_LeaseLiability_label_en-US" xlink:label="lab_lgnd_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Liability</link:label>
    <link:label id="lab_lgnd_LeaseLiability_documentation_en-US" xlink:label="lab_lgnd_LeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiability" xlink:href="lgnd-20241231.xsd#lgnd_LeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LeaseLiability" xlink:to="lab_lgnd_LeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_0cccf9c2-a33c-4de1-a516-f1fc7cf6d597_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount and issuance fees</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation_d61f8958-5c48-49e6-8bdf-2504fc5817c0_negatedTerseLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Final OmniAb Distribution</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid in Capital, Increase Due To Separation</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments To Additional Paid in Capital, Increase Due To Separation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" xlink:href="lgnd-20241231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_b1bbfe35-6f18-455f-9513-009bce7642c0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_f3a0d00d-d8c9-4a60-a9df-ce736ae6a2b3_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_e4a8c53c-059d-4077-919d-b49137eee540_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_1d0af27c-b071-4950-b375-2596c6281560_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_67cca128-231c-4dfb-a4be-2a059832d7b3_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_e754cd69-bc13-4f1d-9d13-ecc27dfb2c40_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_280bb5b0-a73d-4ee3-b7b2-2464fb1b6079_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_82ca28ed-c05d-401c-b072-f248b4ceb6c1_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AgenusInc.Member_c7fb3ed5-1ede-49fa-a982-a6a9ddcfe95e_terseLabel_en-US" xlink:label="lab_lgnd_AgenusInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agenus, Inc.</link:label>
    <link:label id="lab_lgnd_AgenusInc.Member_833da5fc-05e6-40b5-b9ce-c93b42d1f2a3_verboseLabel_en-US" xlink:label="lab_lgnd_AgenusInc.Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Agenus (Bot/Bal)</link:label>
    <link:label id="lab_lgnd_AgenusInc.Member_label_en-US" xlink:label="lab_lgnd_AgenusInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agenus, Inc. [Member]</link:label>
    <link:label id="lab_lgnd_AgenusInc.Member_documentation_en-US" xlink:label="lab_lgnd_AgenusInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agenus, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AgenusInc.Member" xlink:href="lgnd-20241231.xsd#lgnd_AgenusInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AgenusInc.Member" xlink:to="lab_lgnd_AgenusInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_0a2ed834-472f-4ba7-9926-90141b44bee5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentedTechnologyMember_d1ef1fb7-7f7d-46a5-8b78-613fe8c6ffe9_verboseLabel_en-US" xlink:label="lab_us-gaap_PatentedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Completed technology</link:label>
    <link:label id="lab_us-gaap_PatentedTechnologyMember_label_en-US" xlink:label="lab_us-gaap_PatentedTechnologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patented Technology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentedTechnologyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentedTechnologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentedTechnologyMember" xlink:to="lab_us-gaap_PatentedTechnologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ToleranceTherapeuticsMember_709c873a-9a6a-48ab-aba4-cff33bada8b7_terseLabel_en-US" xlink:label="lab_lgnd_ToleranceTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tolerance Therapeutics (Tzield)</link:label>
    <link:label id="lab_lgnd_ToleranceTherapeuticsMember_label_en-US" xlink:label="lab_lgnd_ToleranceTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tolerance Therapeutics [Member]</link:label>
    <link:label id="lab_lgnd_ToleranceTherapeuticsMember_documentation_en-US" xlink:label="lab_lgnd_ToleranceTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tolerance Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ToleranceTherapeuticsMember" xlink:href="lgnd-20241231.xsd#lgnd_ToleranceTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ToleranceTherapeuticsMember" xlink:to="lab_lgnd_ToleranceTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_d70984c3-7d62-47cf-94f5-82acc62dc7bd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_566303a7-c41e-48e4-8eee-2b209c1a8ce8_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total noncurrent derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_e3366702-a91d-41ff-9733-28e15aac428c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_e81c6fc4-a3b5-44a4-9659-466616d0a896_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9d639f44-35f1-41e5-83ae-0abf5df7b44d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DerivativeInstrumentAdditionalMaximumInvestment_29306f0d-a463-4d3c-a79c-9ce6761b7e03_terseLabel_en-US" xlink:label="lab_lgnd_DerivativeInstrumentAdditionalMaximumInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional maximum investment</link:label>
    <link:label id="lab_lgnd_DerivativeInstrumentAdditionalMaximumInvestment_label_en-US" xlink:label="lab_lgnd_DerivativeInstrumentAdditionalMaximumInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument, Additional Maximum Investment</link:label>
    <link:label id="lab_lgnd_DerivativeInstrumentAdditionalMaximumInvestment_documentation_en-US" xlink:label="lab_lgnd_DerivativeInstrumentAdditionalMaximumInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Instrument, Additional Maximum Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeInstrumentAdditionalMaximumInvestment" xlink:href="lgnd-20241231.xsd#lgnd_DerivativeInstrumentAdditionalMaximumInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DerivativeInstrumentAdditionalMaximumInvestment" xlink:to="lab_lgnd_DerivativeInstrumentAdditionalMaximumInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MutualFundMember_a7e2c497-4b47-42f3-b4e9-635b8e54dcd1_terseLabel_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bond fund</link:label>
    <link:label id="lab_us-gaap_MutualFundMember_label_en-US" xlink:label="lab_us-gaap_MutualFundMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mutual Fund [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MutualFundMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MutualFundMember" xlink:to="lab_us-gaap_MutualFundMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_7c1df028-9047-48c7-84fc-a34270ef692b_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtTypeDomain_b278868a-f8b4-4906-adb9-0d5ce5188213_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="lab_us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_17db3087-bad3-4a68-8081-2b927091938b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Income (Loss) per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid_47483f17-1698-4e5b-955e-035939823a57_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Primrose transaction costs</link:label>
    <link:label id="lab_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid_label_en-US" xlink:label="lab_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Cost Incurred But Not Yet Paid</link:label>
    <link:label id="lab_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Cost Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid" xlink:to="lab_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_175b259f-962b-4b33-8036-0fea94252893_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_a6818a0e-13ad-48ed-bb3d-165d02d5ea1c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_8070933a-ca84-4bc9-ad5f-a87c6653fff5_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_67ce4377-3e98-4f71-8103-6fe8e78277aa_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CollarsMember_bca7db27-1808-4037-aaec-275784cbf277_terseLabel_en-US" xlink:label="lab_lgnd_CollarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collars</link:label>
    <link:label id="lab_lgnd_CollarsMember_label_en-US" xlink:label="lab_lgnd_CollarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collars [Member]</link:label>
    <link:label id="lab_lgnd_CollarsMember_documentation_en-US" xlink:label="lab_lgnd_CollarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CollarsMember" xlink:href="lgnd-20241231.xsd#lgnd_CollarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CollarsMember" xlink:to="lab_lgnd_CollarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_0abb9681-175a-475c-951b-9dc28c76cbcd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment in Primrose Bio</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_9529145b-90a7-4be3-ba85-22b78b201816_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_3afdfaa9-f551-4f31-9677-2c1449e69ab1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_83c3a1d1-ee4a-4fc8-afdd-921dc5ce4ce1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in operating lease liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_c1ae16e6-3971-48b8-8801-a542f7158f31_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total goodwill and other identifiable intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_5f3eb1bb-81a1-4f1b-8eed-003a5fb86f27_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred expense (benefit):</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseImpairmentLoss_4ae16238-9cde-49dc-980d-953ccda38184_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease, impairment charges</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseImpairmentLoss" xlink:to="lab_us-gaap_FinanceLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_6a0a0ee4-fdec-412d-a75e-b50a4b60d38f_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_2872da79-c6d2-4959-94ba-a163e2b7037b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_456e96ac-493d-4495-8ec2-5d28006ad27f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_af933bae-4eb7-40bf-93f3-fa87862ae390_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated amortization expense for 2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_65f5947b-2e3e-4cb7-90ea-89ae25877fd2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_f49f8256-a12a-4647-8c61-456a6d45ef2c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0baecef7-d4d7-404f-ab34-8e5091200e7a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b2440c84-c467-4fb3-93c2-e9306c1a16b0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_10837f75-c3be-4265-ac39-6ce118d72196_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_88c34d0f-528c-45ae-b180-980dc945b9a2_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostDirectMaterial_415068d3-b9de-4f81-9e67-b0b7146c36a0_terseLabel_en-US" xlink:label="lab_us-gaap_CostDirectMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Captisol</link:label>
    <link:label id="lab_us-gaap_CostDirectMaterial_label_en-US" xlink:label="lab_us-gaap_CostDirectMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost, Direct Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostDirectMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostDirectMaterial" xlink:to="lab_us-gaap_CostDirectMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_d719455f-c8c0-47e6-bc41-043b66e9c857_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares available for future option grants (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_e46d74ea-1f52-43fe-9981-3a7f4d96e83d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4ed237e3-3cb6-4213-bbab-8f98ee6294f4_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_63f9d91c-c1b2-48a3-bc31-cedb1a09e792_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyRylazeMember_b500bab8-13e2-478b-8273-861abea9f82d_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyRylazeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rylaze</link:label>
    <link:label id="lab_lgnd_RoyaltyRylazeMember_label_en-US" xlink:label="lab_lgnd_RoyaltyRylazeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty, Rylaze [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyRylazeMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyRylazeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty, Rylaze</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyRylazeMember" xlink:href="lgnd-20241231.xsd#lgnd_RoyaltyRylazeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyRylazeMember" xlink:to="lab_lgnd_RoyaltyRylazeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesIndustryMember_880bed45-0dec-467e-a883-b420cb77726f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesIndustryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Industry Sector [Domain]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesIndustryMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesIndustryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Industry Sector [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember" xlink:to="lab_us-gaap_EquitySecuritiesIndustryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_d67dafce-7033-4785-8434-a58bdf114cfd_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_e09ff74e-71fc-49ab-b619-fd9590ed133a_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants term (in years)</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_61cf40b8-23e2-46bf-8483-2d0d666f617a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_64308fd4-920d-4591-8114-1429be1930ba_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_ed02de62-2b38-4d91-98c0-a03da263e704_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_2c16e582-a37f-45d3-b904-2d376bee06b8_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment of equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Other-than-Temporary Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:to="lab_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_765de46f-ce3d-4974-8074-2bf5b30b292a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_f1264ab0-b53d-4979-b33c-2a5b546191cd_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AgenusPartneredProgramMember_abafc997-8320-494c-9bfa-97e8166c7bbf_terseLabel_en-US" xlink:label="lab_lgnd_AgenusPartneredProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Agenus Partnered Program</link:label>
    <link:label id="lab_lgnd_AgenusPartneredProgramMember_label_en-US" xlink:label="lab_lgnd_AgenusPartneredProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Agenus Partnered Program [Member]</link:label>
    <link:label id="lab_lgnd_AgenusPartneredProgramMember_documentation_en-US" xlink:label="lab_lgnd_AgenusPartneredProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Agenus Partnered Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AgenusPartneredProgramMember" xlink:href="lgnd-20241231.xsd#lgnd_AgenusPartneredProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AgenusPartneredProgramMember" xlink:to="lab_lgnd_AgenusPartneredProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_d7340353-8c18-4435-bb0d-ccb9bec17ebc_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_dd208626-b01c-4d3d-b007-f9f95953d307_totalLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net assets sold</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Net Asset</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Net Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_IntangibleRoyaltyAssetsMember_cc3b1a0b-b99e-482a-8de0-45cb10a61b74_terseLabel_en-US" xlink:label="lab_lgnd_IntangibleRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from intangible royalty assets</link:label>
    <link:label id="lab_lgnd_IntangibleRoyaltyAssetsMember_36376fbb-3165-461c-a270-8a0dbdf00b0d_verboseLabel_en-US" xlink:label="lab_lgnd_IntangibleRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue from intangible royalty assets</link:label>
    <link:label id="lab_lgnd_IntangibleRoyaltyAssetsMember_label_en-US" xlink:label="lab_lgnd_IntangibleRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Royalty Assets [Member]</link:label>
    <link:label id="lab_lgnd_IntangibleRoyaltyAssetsMember_documentation_en-US" xlink:label="lab_lgnd_IntangibleRoyaltyAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Royalty Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IntangibleRoyaltyAssetsMember" xlink:href="lgnd-20241231.xsd#lgnd_IntangibleRoyaltyAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_IntangibleRoyaltyAssetsMember" xlink:to="lab_lgnd_IntangibleRoyaltyAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_90fb4e69-7e55-4313-bf6d-e3dfc32e1029_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock aggregate offering price</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_8a005202-8f41-4441-a47b-f52693c35a92_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_ee571283-ff80-4e15-b556-bbfb74662c79_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_4dce0045-633c-44cd-baed-f15617aa0430_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsIssued_f2741132-5979-4da4-abb1-0946bfdcb4ed_terseLabel_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of contingent value rights</link:label>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsIssued_label_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Contingent Value Rights Issued</link:label>
    <link:label id="lab_lgnd_NumberOfContingentValueRightsIssued_documentation_en-US" xlink:label="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Contingent Value Rights Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsIssued" xlink:href="lgnd-20241231.xsd#lgnd_NumberOfContingentValueRightsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberOfContingentValueRightsIssued" xlink:to="lab_lgnd_NumberOfContingentValueRightsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_67eb7e9b-78e5-4c52-ab93-41608e3fc5c4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_3cd0263f-a3a4-49f3-9741-0f48daa38ec5_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LeaseRightOfUseAsset_71e839f0-9e99-479f-b015-3020222058d8_totalLabel_en-US" xlink:label="lab_lgnd_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease assets</link:label>
    <link:label id="lab_lgnd_LeaseRightOfUseAsset_label_en-US" xlink:label="lab_lgnd_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_lgnd_LeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_lgnd_LeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseRightOfUseAsset" xlink:href="lgnd-20241231.xsd#lgnd_LeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LeaseRightOfUseAsset" xlink:to="lab_lgnd_LeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_94b639fd-1243-4d96-b93f-8879a84f9d78_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_cff6b7f8-cdeb-4943-a9b5-dbbc3a769b82_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_827d0032-85c5-440a-b050-d7a23d65f183_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_37a6d039-5b54-46fb-bfa7-69f3d455b86f_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_7b132e57-8159-4187-8054-a589fd80b0b2_verboseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trade name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_UGN301Member_c0f849c3-ef21-44bc-a26b-b9a604376544_terseLabel_en-US" xlink:label="lab_lgnd_UGN301Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UGN-301</link:label>
    <link:label id="lab_lgnd_UGN301Member_label_en-US" xlink:label="lab_lgnd_UGN301Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UGN-301 [Member]</link:label>
    <link:label id="lab_lgnd_UGN301Member_documentation_en-US" xlink:label="lab_lgnd_UGN301Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UGN-301</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_UGN301Member" xlink:href="lgnd-20241231.xsd#lgnd_UGN301Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_UGN301Member" xlink:to="lab_lgnd_UGN301Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_acba4b50-9a99-4684-91fe-7e1d298e4352_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_83e38f5f-27de-4ba0-9cac-0677236a5e09_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued_7aa97d1c-283c-4551-aa7a-dbd86cc1a1ea_terseLabel_en-US" xlink:label="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued upon conversion of preferred stock (in shares)</link:label>
    <link:label id="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued_label_en-US" xlink:label="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Converted Instrument Shares Issued</link:label>
    <link:label id="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued_documentation_en-US" xlink:label="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Converted Instrument Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued" xlink:href="lgnd-20241231.xsd#lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued" xlink:to="lab_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NucorionMember_a44b372f-4beb-49f0-b681-690b5fc82a07_terseLabel_en-US" xlink:label="lab_lgnd_NucorionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nucorion</link:label>
    <link:label id="lab_lgnd_NucorionMember_label_en-US" xlink:label="lab_lgnd_NucorionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nucorion [Member]</link:label>
    <link:label id="lab_lgnd_NucorionMember_documentation_en-US" xlink:label="lab_lgnd_NucorionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nucorion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NucorionMember" xlink:href="lgnd-20241231.xsd#lgnd_NucorionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NucorionMember" xlink:to="lab_lgnd_NucorionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_b27022a5-b0e4-4cd4-940c-ccaf01737ee1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ConsiderationClassficationAxis_b0edca56-b4f7-46b4-b2f4-e2a1d39f6f3b_terseLabel_en-US" xlink:label="lab_lgnd_ConsiderationClassficationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration Classfication [Axis]</link:label>
    <link:label id="lab_lgnd_ConsiderationClassficationAxis_label_en-US" xlink:label="lab_lgnd_ConsiderationClassficationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration Classfication [Axis]</link:label>
    <link:label id="lab_lgnd_ConsiderationClassficationAxis_documentation_en-US" xlink:label="lab_lgnd_ConsiderationClassficationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consideration Classfication</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationClassficationAxis" xlink:href="lgnd-20241231.xsd#lgnd_ConsiderationClassficationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ConsiderationClassficationAxis" xlink:to="lab_lgnd_ConsiderationClassficationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_291d7a2c-0a33-41dd-9132-8f179ef8daae_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value (In thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_64c8a144-7a97-4e2b-a92e-e13c4e60b633_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_087b5faf-4f64-47ee-9dd5-a1f50e3037a2_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental schedule of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AGEN2373Member_9288cf72-3cd1-43fd-b1d9-25c5010a4a50_terseLabel_en-US" xlink:label="lab_lgnd_AGEN2373Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AGEN2373</link:label>
    <link:label id="lab_lgnd_AGEN2373Member_label_en-US" xlink:label="lab_lgnd_AGEN2373Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AGEN2373 [Member]</link:label>
    <link:label id="lab_lgnd_AGEN2373Member_documentation_en-US" xlink:label="lab_lgnd_AGEN2373Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AGEN2373</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AGEN2373Member" xlink:href="lgnd-20241231.xsd#lgnd_AGEN2373Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AGEN2373Member" xlink:to="lab_lgnd_AGEN2373Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_c1943317-1c75-4c46-aa74-371f5cffe4e1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ElutiaAndCorMatrixMember_ef5f3df6-f85d-46d7-9986-d411167310d8_terseLabel_en-US" xlink:label="lab_lgnd_ElutiaAndCorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Elutia (CorMatrix)</link:label>
    <link:label id="lab_lgnd_ElutiaAndCorMatrixMember_label_en-US" xlink:label="lab_lgnd_ElutiaAndCorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Elutia and CorMatrix [Member]</link:label>
    <link:label id="lab_lgnd_ElutiaAndCorMatrixMember_documentation_en-US" xlink:label="lab_lgnd_ElutiaAndCorMatrixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Elutia and CorMatrix</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ElutiaAndCorMatrixMember" xlink:href="lgnd-20241231.xsd#lgnd_ElutiaAndCorMatrixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ElutiaAndCorMatrixMember" xlink:to="lab_lgnd_ElutiaAndCorMatrixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MilestoneDomain_39028d60-1c3f-49c7-a472-53df5ac9b265_terseLabel_en-US" xlink:label="lab_lgnd_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_lgnd_MilestoneDomain_label_en-US" xlink:label="lab_lgnd_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:label id="lab_lgnd_MilestoneDomain_documentation_en-US" xlink:label="lab_lgnd_MilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneDomain" xlink:href="lgnd-20241231.xsd#lgnd_MilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MilestoneDomain" xlink:to="lab_lgnd_MilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_20fb5c09-a250-464d-ab67-5a76da49d7a4_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of Pelican</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_3bd63888-67dc-4727-9934-d2644978ef79_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of Pelican</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_82cf0575-91df-46eb-87be-258800e59558_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of business</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_977c1e0f-7dfe-4dbc-9479-fd95ad621aa6_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate used to value intangible assets acquired (as a percent)</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_600df1e2-273e-42e1-95ad-d36c3d4475ee_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares repurchased in period</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedSupplierExpensesCurrent_57169419-98f3-4b54-8c37-2e39436367b1_terseLabel_en-US" xlink:label="lab_lgnd_AccruedSupplierExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier</link:label>
    <link:label id="lab_lgnd_AccruedSupplierExpensesCurrent_label_en-US" xlink:label="lab_lgnd_AccruedSupplierExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Supplier Expenses, Current</link:label>
    <link:label id="lab_lgnd_AccruedSupplierExpensesCurrent_documentation_en-US" xlink:label="lab_lgnd_AccruedSupplierExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Supplier Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSupplierExpensesCurrent" xlink:href="lgnd-20241231.xsd#lgnd_AccruedSupplierExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedSupplierExpensesCurrent" xlink:to="lab_lgnd_AccruedSupplierExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_69ee6698-1127-4004-ac29-a02d2f681a66_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants issued in public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_200ef658-6bca-463e-9dc5-3a50d3586e02_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_95d14ad7-7f7d-47c4-a8ee-e28b8454800d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BasisOfPresentationLineItems_702929df-ce94-48a7-936e-acb2ea55c3e4_terseLabel_en-US" xlink:label="lab_lgnd_BasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationLineItems_label_en-US" xlink:label="lab_lgnd_BasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation [Line Items]</link:label>
    <link:label id="lab_lgnd_BasisOfPresentationLineItems_documentation_en-US" xlink:label="lab_lgnd_BasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basis of presentation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationLineItems" xlink:href="lgnd-20241231.xsd#lgnd_BasisOfPresentationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BasisOfPresentationLineItems" xlink:to="lab_lgnd_BasisOfPresentationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_2c79968a-0eb4-4020-a065-62ead59cc193_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_e5489580-a06b-4762-a776-aa6e60c8b6bc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from royalties received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Royalties Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_8ddd55f0-fde2-4ec9-9a8b-27a58c317cfc_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_f5c8f94a-7465-41a9-aa76-efc64dcd2b73_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_0d4e9cc8-3217-47f8-afaa-991183f3a703_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6395a4bf-fbf5-42bc-86df-6bfbaab66672_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1a11e55b-b87d-42f3-8a2b-aa4ed67fe1e8_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_c7195326-4268-4151-92d4-b1ae38938656_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Viking common stock</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_f192a47f-e03f-4ff6-a2e7-2a4dd5b68853_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization/accretion of premium (discount) on investments, net</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_6c86f999-b457-48a5-9a3a-3e49584758bc_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_9480f958-9190-4a6f-8d4c-40ae97e8b819_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_44cd2f63-e188-4eef-9641-70a0d1c81e94_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_aa4527f3-8bb6-4c7a-81f1-6c62f5683159_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest portion of repurchased amount of debt instrument</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b274a49e-ceb7-4fb3-af23-42a94fa0cdf0_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a93f0e51-d480-40ef-ad52-3376c21105ed_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vested (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VikingTherapeuticsInc.Member_557d6013-85bc-4464-be56-eab79d47e6b5_terseLabel_en-US" xlink:label="lab_lgnd_VikingTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Viking Therapeutics, Inc.</link:label>
    <link:label id="lab_lgnd_VikingTherapeuticsInc.Member_label_en-US" xlink:label="lab_lgnd_VikingTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Viking Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_lgnd_VikingTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_lgnd_VikingTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Viking Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VikingTherapeuticsInc.Member" xlink:href="lgnd-20241231.xsd#lgnd_VikingTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VikingTherapeuticsInc.Member" xlink:to="lab_lgnd_VikingTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets_4167233b-0e36-4751-94b2-2867634a68f4_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial royalty assets</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets_beca7707-d40b-43f0-8167-58780c77b047_verboseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract assets (financial royalty assets)</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract Assets</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_c3934f62-022f-4c70-98ea-16cfc7f4e595_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PrimroseBioMember_9db77dd6-446a-402c-9a2d-0e3f53a3d0f2_terseLabel_en-US" xlink:label="lab_lgnd_PrimroseBioMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Primrose Bio</link:label>
    <link:label id="lab_lgnd_PrimroseBioMember_label_en-US" xlink:label="lab_lgnd_PrimroseBioMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Primrose Bio [Member]</link:label>
    <link:label id="lab_lgnd_PrimroseBioMember_documentation_en-US" xlink:label="lab_lgnd_PrimroseBioMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Primrose Bio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember" xlink:href="lgnd-20241231.xsd#lgnd_PrimroseBioMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PrimroseBioMember" xlink:to="lab_lgnd_PrimroseBioMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_8016bdf4-bb37-41fb-8daf-e33564eabebc_verboseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Neuritek warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ca741c47-26c1-407b-a0f3-7f8829651052_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_47ad12a6-09c0-43a3-8b83-fb509a393710_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_5d984e6a-657d-4ee2-8928-1af3b25b0fa1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RecordatiMember_f87f7677-23c6-4014-9355-f6ed84a74d08_terseLabel_en-US" xlink:label="lab_lgnd_RecordatiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recordati</link:label>
    <link:label id="lab_lgnd_RecordatiMember_label_en-US" xlink:label="lab_lgnd_RecordatiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recordati [Member]</link:label>
    <link:label id="lab_lgnd_RecordatiMember_documentation_en-US" xlink:label="lab_lgnd_RecordatiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Recordati</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RecordatiMember" xlink:href="lgnd-20241231.xsd#lgnd_RecordatiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RecordatiMember" xlink:to="lab_lgnd_RecordatiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_28a370b8-a54a-42da-9371-e671d71a6e3a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_1b902111-e947-436d-a2c3-4b22797707ad_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_b22fb433-6c9f-48d0-aa33-c34d9add39bc_negatedTerseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_3d2f8f7a-e204-48e2-bad4-41547f9bd166_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Debt Securities by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1570495c-9ebe-48c7-b264-770fd41a13eb_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_d1ca61ee-f9b4-4ad6-9151-8a4cbc264095_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Received amount expended</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_72f85f48-bfc5-43e2-b646-ef7650c8d785_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use asset recognized</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_2bbd1311-cb46-4005-a1fa-483361a62303_terseLabel_en-US" xlink:label="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_label_en-US" xlink:label="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations, Investing Actives [Abstract]</link:label>
    <link:label id="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_documentation_en-US" xlink:label="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations, Investing Actives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract" xlink:href="lgnd-20241231.xsd#lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract" xlink:to="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_22f869ca-5511-4289-97db-646680e58ba0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_06f5f53e-02b3-4487-8f70-cb4c1ba279e3_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_86821f54-1ad1-422b-989f-b077c0a40daa_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_2c764503-1e75-407b-81de-0f4949c1b87d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_406fe723-7dd4-43d6-be9d-4cab7e648b7b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_fe5e7287-7d09-4dbb-9b8c-b20c6af48286_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_1b404364-44f5-4ba4-af0d-24ccc6572216_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and Amortization, Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:to="lab_us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_fc0640e9-553e-45f0-aaf2-180dc7f417f8_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PalvellaTherapeuticsIncMember_15c3e66e-f5d0-4086-b194-00b0fecb755c_terseLabel_en-US" xlink:label="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Palvella</link:label>
    <link:label id="lab_lgnd_PalvellaTherapeuticsIncMember_label_en-US" xlink:label="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Palvella Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_lgnd_PalvellaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Palvella Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaTherapeuticsIncMember" xlink:href="lgnd-20241231.xsd#lgnd_PalvellaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PalvellaTherapeuticsIncMember" xlink:to="lab_lgnd_PalvellaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_02b51186-3c70-4b47-bc41-7246488dc3fa_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and intangible asset impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_41e3f1ec-693f-4811-a480-4dda8cd96706_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_40c2b3fe-e730-4280-852c-d623cc3c0280_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash paid for Novan acquisition, net of restricted cash received</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_feeceea3-d87e-4c55-b478-19c4eae13a5f_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net cash paid for acquisitions</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_b4f59096-6d27-4409-a848-46aec117e41b_totalLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash paid for Novan, including restricted cash received</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_432a9be5-0760-4159-b319-ed0db047743c_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DemandDepositsMember_9f42b27e-a43f-417f-a056-66b8c894c184_terseLabel_en-US" xlink:label="lab_us-gaap_DemandDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of Deposit</link:label>
    <link:label id="lab_us-gaap_DemandDepositsMember_18d3b733-e5e3-4180-8472-604f32fad9fd_verboseLabel_en-US" xlink:label="lab_us-gaap_DemandDepositsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Certificates of Deposit</link:label>
    <link:label id="lab_us-gaap_DemandDepositsMember_label_en-US" xlink:label="lab_us-gaap_DemandDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Demand Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DemandDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DemandDepositsMember" xlink:to="lab_us-gaap_DemandDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ImpairmentLossOnFinancialRoyaltyAssets_528d121f-f4c3-4b11-9abd-b59bf3e4495d_terseLabel_en-US" xlink:label="lab_lgnd_ImpairmentLossOnFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss of financial royalty assets</link:label>
    <link:label id="lab_lgnd_ImpairmentLossOnFinancialRoyaltyAssets_label_en-US" xlink:label="lab_lgnd_ImpairmentLossOnFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment Loss On Financial Royalty Assets</link:label>
    <link:label id="lab_lgnd_ImpairmentLossOnFinancialRoyaltyAssets_documentation_en-US" xlink:label="lab_lgnd_ImpairmentLossOnFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Impairment Loss On Financial Royalty Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ImpairmentLossOnFinancialRoyaltyAssets" xlink:href="lgnd-20241231.xsd#lgnd_ImpairmentLossOnFinancialRoyaltyAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ImpairmentLossOnFinancialRoyaltyAssets" xlink:to="lab_lgnd_ImpairmentLossOnFinancialRoyaltyAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_SoticlestatMember_0a1e519d-a546-4779-956b-5b203ffa80a4_terseLabel_en-US" xlink:label="lab_lgnd_SoticlestatMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soticlestat</link:label>
    <link:label id="lab_lgnd_SoticlestatMember_label_en-US" xlink:label="lab_lgnd_SoticlestatMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soticlestat [Member]</link:label>
    <link:label id="lab_lgnd_SoticlestatMember_documentation_en-US" xlink:label="lab_lgnd_SoticlestatMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Soticlestat</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SoticlestatMember" xlink:href="lgnd-20241231.xsd#lgnd_SoticlestatMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_SoticlestatMember" xlink:to="lab_lgnd_SoticlestatMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_41bb8ecc-cc7a-40a3-94ec-5f771ac84680_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsTextBlock_7e9997c4-5811-4cc2-9bc9-963fb2ad91d3_terseLabel_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets, net (formerly known as Commercial License Rights)</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsTextBlock_label_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets [Text Block]</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsTextBlock_documentation_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsTextBlock" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FinancialRoyaltyAssetsTextBlock" xlink:to="lab_lgnd_FinancialRoyaltyAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_a4f9257a-f1be-4931-a2b1-fe5fe53ee330_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeFiveMember_951f53f1-c61b-4546-942a-3060e2a08cf4_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$73.92-$75.09</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFiveMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeFiveMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFiveMember" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeFiveMember" xlink:to="lab_lgnd_ExercisePriceRangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_05d8f80a-8092-404a-be3f-93f220bff3ea_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseNonoperating_label_en-US" xlink:label="lab_us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseNonoperating" xlink:to="lab_us-gaap_InterestExpenseNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_641dc76a-8bb9-4af9-8fb1-d4ff32aaaad2_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_0a73d452-607c-4207-b7fb-3f618f40cd16_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_282e2c47-f501-4871-b152-23eb6bc1bbd1_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operations, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:to="lab_us-gaap_DiscontinuedOperationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_0610beaf-7c83-4c3b-b072-d1f8365c7ed7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_9e206b0c-06d4-4dfd-8f9b-7d60946946fe_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContractRevenueMember_941d737a-a520-4ba8-b437-068121c465eb_verboseLabel_en-US" xlink:label="lab_lgnd_ContractRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract revenue and other income</link:label>
    <link:label id="lab_lgnd_ContractRevenueMember_11377fcb-139c-40ec-8822-dbfc046a2823_netLabel_en-US" xlink:label="lab_lgnd_ContractRevenueMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Contract revenue</link:label>
    <link:label id="lab_lgnd_ContractRevenueMember_label_en-US" xlink:label="lab_lgnd_ContractRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Revenue [Member]</link:label>
    <link:label id="lab_lgnd_ContractRevenueMember_documentation_en-US" xlink:label="lab_lgnd_ContractRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember" xlink:href="lgnd-20241231.xsd#lgnd_ContractRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContractRevenueMember" xlink:to="lab_lgnd_ContractRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5e48b831-9e56-47af-a971-36e980f03f05_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_70b70919-5c39-4642-8e43-7297c13d8c67_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares allowed to purchase in employee stock purchase plan per employee (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_OmniabSeparationMember_2bc5c526-d3d5-47e0-99fd-d6aeb4617616_terseLabel_en-US" xlink:label="lab_lgnd_OmniabSeparationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Omniab Separation</link:label>
    <link:label id="lab_lgnd_OmniabSeparationMember_label_en-US" xlink:label="lab_lgnd_OmniabSeparationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Omniab Separation [Member]</link:label>
    <link:label id="lab_lgnd_OmniabSeparationMember_documentation_en-US" xlink:label="lab_lgnd_OmniabSeparationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Omniab Separation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OmniabSeparationMember" xlink:href="lgnd-20241231.xsd#lgnd_OmniabSeparationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_OmniabSeparationMember" xlink:to="lab_lgnd_OmniabSeparationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_631ecda5-491e-4499-95aa-cd5245f60239_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt conversion price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ca7ef457-1045-4724-aea5-24ddd3bce42f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_94273e12-1f9f-4656-a33f-8bddd79ca991_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">12 months or greater</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_98085ae4-ec33-40eb-a1bd-d970a248fe9f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsTable_d6f3c06d-7ea6-4f90-a032-23a103b7dbd1_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Holdings [Table]</link:label>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsTable_label_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Holdings [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:to="lab_us-gaap_SummaryOfInvestmentHoldingsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_9170a1c9-ea9a-4921-a8e8-80a926cbf15c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining lease term of finance leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_6a536da7-5772-40b0-ba4f-e5219a3ecaca_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_27dc40e8-f4bf-417a-b7be-4f5d132c366d_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AmendedESPPMember_c7d2c4fc-df40-488c-86d4-2774cd0a124d_terseLabel_en-US" xlink:label="lab_lgnd_AmendedESPPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amended ESPP</link:label>
    <link:label id="lab_lgnd_AmendedESPPMember_label_en-US" xlink:label="lab_lgnd_AmendedESPPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended ESPP [Member]</link:label>
    <link:label id="lab_lgnd_AmendedESPPMember_documentation_en-US" xlink:label="lab_lgnd_AmendedESPPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended ESPP [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmendedESPPMember" xlink:href="lgnd-20241231.xsd#lgnd_AmendedESPPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AmendedESPPMember" xlink:to="lab_lgnd_AmendedESPPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_4c448048-86fc-4f9e-b7f5-1e43a3647cb7_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_04d05786-2910-40ac-95a5-4b88a5d2c5cb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_05022455-3aa9-48d6-80f4-a0c75d0f843c_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Right-of-Use Assets</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_a261b72e-f639-4a79-8828-c06622f3a919_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lower range of exercise prices (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset_e20072d3-646b-47fd-88ea-1973284fd5d6_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Financing Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Financing Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetNoncurrent_381fe67e-071d-4f72-a592-abe5886f3193_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible note</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetNoncurrent" xlink:to="lab_us-gaap_AccountsReceivableNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_88e43ab4-67ee-4489-9fb6-5554c648f1d6_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-Maturity, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2d2e2d12-7c5a-433b-a5b2-a39a92898d6a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c74de567-776b-4a7a-906c-326e8cb1062a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationAcquiredPercentage_6f4759e0-23e3-4858-bb12-870977313d65_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationAcquiredPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired (as a percent)</link:label>
    <link:label id="lab_lgnd_BusinessCombinationAcquiredPercentage_label_en-US" xlink:label="lab_lgnd_BusinessCombinationAcquiredPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquired Percentage</link:label>
    <link:label id="lab_lgnd_BusinessCombinationAcquiredPercentage_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationAcquiredPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Acquired Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAcquiredPercentage" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationAcquiredPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationAcquiredPercentage" xlink:to="lab_lgnd_BusinessCombinationAcquiredPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity_23bcd7c3-9ef4-4357-b6e2-4e5a5efadb7f_negatedTerseLabel_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments to CVR Holders</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity_label_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Contingent Value Right Holders, Investing Activity</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity_documentation_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments to Contingent Value Right Holders, Investing Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsToContingentValueRightHoldersInvestingActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity" xlink:to="lab_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_c3d2480e-722d-4a0b-8948-47c30607939d_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_ec3a9d82-590b-41fe-80a7-01db32757b1a_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues and other income:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_39da73d1-8d2c-42da-8ff8-81bbe38878dd_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FinanceRoyaltyAgreementRoyaltyRate_3fa34665-da46-4ad3-930b-79b232569b4d_terseLabel_en-US" xlink:label="lab_lgnd_FinanceRoyaltyAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties right to receive (as a percent)</link:label>
    <link:label id="lab_lgnd_FinanceRoyaltyAgreementRoyaltyRate_label_en-US" xlink:label="lab_lgnd_FinanceRoyaltyAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Royalty Agreement, Royalty Rate</link:label>
    <link:label id="lab_lgnd_FinanceRoyaltyAgreementRoyaltyRate_documentation_en-US" xlink:label="lab_lgnd_FinanceRoyaltyAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Royalty Agreement, Royalty Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceRoyaltyAgreementRoyaltyRate" xlink:href="lgnd-20241231.xsd#lgnd_FinanceRoyaltyAgreementRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FinanceRoyaltyAgreementRoyaltyRate" xlink:to="lab_lgnd_FinanceRoyaltyAgreementRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsNet_9c439b1f-680f-428b-9523-c4d6dbdfe45b_terseLabel_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty assets</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsNet_cd4fddc7-dbf9-40f6-9fa6-ceda67e2dd7c_totalLabel_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net carrying value</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsNet_label_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets, Net</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsNet_documentation_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsNet" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FinancialRoyaltyAssetsNet" xlink:to="lab_lgnd_FinancialRoyaltyAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_08893c6e-c99f-4bcc-b4d8-044798423bd6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_46714b69-85e3-4897-b8c4-1a5bf09a2857_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ef3abf0b-e458-40ab-a496-59f661d2f8bf_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_a7d1e864-d2cf-4a89-aa88-333bbc638893_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CurrentAndExpectedCreditLossAdjustment_de7974b1-5be7-4c5e-a859-f7b13d6a053c_terseLabel_en-US" xlink:label="lab_lgnd_CurrentAndExpectedCreditLossAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CECL adjustment to financial royalty assets</link:label>
    <link:label id="lab_lgnd_CurrentAndExpectedCreditLossAdjustment_label_en-US" xlink:label="lab_lgnd_CurrentAndExpectedCreditLossAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current And Expected Credit Loss Adjustment</link:label>
    <link:label id="lab_lgnd_CurrentAndExpectedCreditLossAdjustment_documentation_en-US" xlink:label="lab_lgnd_CurrentAndExpectedCreditLossAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current And Expected Credit Loss Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CurrentAndExpectedCreditLossAdjustment" xlink:href="lgnd-20241231.xsd#lgnd_CurrentAndExpectedCreditLossAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CurrentAndExpectedCreditLossAdjustment" xlink:to="lab_lgnd_CurrentAndExpectedCreditLossAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_fb38611b-a11e-4d06-b8a9-0814aee756e4_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued under amended ESSP (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PelicanTechnologyHoldingsIncMember_bb00a76c-ca60-4a35-b512-62df4ba99626_terseLabel_en-US" xlink:label="lab_lgnd_PelicanTechnologyHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pelican Technology Holdings, Inc.</link:label>
    <link:label id="lab_lgnd_PelicanTechnologyHoldingsIncMember_label_en-US" xlink:label="lab_lgnd_PelicanTechnologyHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pelican Technology Holdings, Inc. [Member]</link:label>
    <link:label id="lab_lgnd_PelicanTechnologyHoldingsIncMember_documentation_en-US" xlink:label="lab_lgnd_PelicanTechnologyHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pelican Technology Holdings, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PelicanTechnologyHoldingsIncMember" xlink:href="lgnd-20241231.xsd#lgnd_PelicanTechnologyHoldingsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PelicanTechnologyHoldingsIncMember" xlink:to="lab_lgnd_PelicanTechnologyHoldingsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments_0e12c763-3027-4bea-8bca-aecfe0654791_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain from short-term investments</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gain (Loss) On Short-Term Investments</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gain (Loss) On Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_4d95cb9d-88da-4a80-b0ec-024bd2fd2daa_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8fd8551b-1a91-49b2-ace4-a35a97fc934e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_86b088d5-3774-482e-9ded-7aa1e88ffc6b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_149116de-1caa-44dc-8d7f-e02c74891205_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_fb20fdd3-8250-43df-b91f-1b2cc0d0fa22_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under employee stock compensation plans, net (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_0886ca2e-71ea-41b6-8981-e0f74a2a0a6e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders_58f3ea96-f155-4499-9a3e-a43d14c9dea7_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Frequency of cash payments to CVR holders</link:label>
    <link:label id="lab_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders_label_en-US" xlink:label="lab_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Frequency of Cash Payments to Contingent Value Rights Holders</link:label>
    <link:label id="lab_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Frequency of Cash Payments to Contingent Value Rights Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders" xlink:to="lab_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_eaf66ba8-7d3c-4be8-8683-4fa4c3c09f6f_terseLabel_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transferred over Time</link:label>
    <link:label id="lab_us-gaap_TransferredOverTimeMember_label_en-US" xlink:label="lab_us-gaap_TransferredOverTimeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transferred over Time [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransferredOverTimeMember" xlink:to="lab_us-gaap_TransferredOverTimeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_6f6e9e14-646a-439b-adaa-dcb20f51c849_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill and Other Identifiable Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_67c107d2-120b-441d-a9d2-edcd2732a190_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_fc93cabb-97a8-420f-8b58-a341bc8d2c3c_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible asset, useful life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_08f3d6ce-df50-40b7-8aba-a5c6da2f14b0_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, fair value</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_cafe4591-a1c9-4662-a25f-b6eab3f50729_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_a73865ee-6c62-4e00-a996-8898fd960e57_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_5a84489b-8414-4a3e-a6d0-3942c484db97_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_615a4149-9448-4b1b-888f-675b57340317_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_2ae76856-d97f-4344-b1bb-9559196bada8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_952eb4c7-ea70-4e90-a87a-31cc54736057_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_651458fc-334f-4b31-8631-fc805b5db524_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Updates, Recently Adopted and Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_27957134-db3e-4663-bda7-4d94ec110dc1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_739b433c-5d92-4772-9e10-da4ca5761ba2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_9d877880-d206-4f9c-8cc9-97824f0a24b6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_41bd1386-4498-478e-8a35-c3558828a167_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a8bac4a7-9a01-4628-830b-8b55854b6ecd_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_c01c354b-90fc-446e-919c-6a16cd339e4a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss from discontinued operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6f12ffea-be1a-43a5-9896-000b5f6066a1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_fc52f004-2f37-47d4-aeba-6b9b10a21410_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tangible asset impairment charges</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_ed548a16-0fdf-49bc-bee2-5dd551be049e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_9ea9a6aa-e07c-483e-bc8b-da159f3ec264_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_26aade5b-6312-4be7-817b-601c3d2927bd_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_34e51d81-3244-44d9-8b53-12324781c8c4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for transaction costs related to OmniAb Transactions</link:label>
    <link:label id="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Merger Related Costs, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:to="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_1e65401b-5998-4d8b-abe8-8f6e7a5c337f_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAxis_6d4c5a34-2580-4b65-bc6b-058d88e7caef_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt [Axis]</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAxis_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid_490524d1-c0b7-4568-b1d0-3078a18837f5_terseLabel_en-US" xlink:label="lab_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued royalty from financial royalty assets</link:label>
    <link:label id="lab_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid_label_en-US" xlink:label="lab_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalty From Commercial License Rights Incurred But Not Yet Paid</link:label>
    <link:label id="lab_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Royalty From Commercial License Rights Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" xlink:href="lgnd-20241231.xsd#lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" xlink:to="lab_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_d1407672-cfe0-4f95-9bd5-6f6194ed77a4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent liability measurement input (as a percent)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_8f21d979-5563-4cee-b4b6-18ba7b011e22_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_39087371-6881-4a12-84ba-38b2869e95ca_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_2bff2ed7-637a-4c7c-a4c7-a485d90357eb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset adjustment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_c81c8b99-2cf5-448b-91e7-af53ae28fd36_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MaximumFinancingRoyaltyAsset_0c70453e-3477-46cf-8ec6-732556003020_terseLabel_en-US" xlink:label="lab_lgnd_MaximumFinancingRoyaltyAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum financing royalty asset</link:label>
    <link:label id="lab_lgnd_MaximumFinancingRoyaltyAsset_label_en-US" xlink:label="lab_lgnd_MaximumFinancingRoyaltyAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Financing Royalty Asset</link:label>
    <link:label id="lab_lgnd_MaximumFinancingRoyaltyAsset_documentation_en-US" xlink:label="lab_lgnd_MaximumFinancingRoyaltyAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Financing Royalty Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaximumFinancingRoyaltyAsset" xlink:href="lgnd-20241231.xsd#lgnd_MaximumFinancingRoyaltyAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MaximumFinancingRoyaltyAsset" xlink:to="lab_lgnd_MaximumFinancingRoyaltyAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_f902a1fc-1b62-456c-a9bd-049debde3d59_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest on debt instrument (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_cd7d7ba5-0d75-4aab-bff3-e646d70bed0c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant derivative</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_fdb780ae-6f67-4f6a-b8b7-0c87e23a8842_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedSubcontractorExpensesCurrent_475458f5-e8c9-4284-a654-1969bb16c0c7_terseLabel_en-US" xlink:label="lab_lgnd_AccruedSubcontractorExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subcontractor</link:label>
    <link:label id="lab_lgnd_AccruedSubcontractorExpensesCurrent_label_en-US" xlink:label="lab_lgnd_AccruedSubcontractorExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Subcontractor Expenses, Current</link:label>
    <link:label id="lab_lgnd_AccruedSubcontractorExpensesCurrent_documentation_en-US" xlink:label="lab_lgnd_AccruedSubcontractorExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Subcontractor Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSubcontractorExpensesCurrent" xlink:href="lgnd-20241231.xsd#lgnd_AccruedSubcontractorExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedSubcontractorExpensesCurrent" xlink:to="lab_lgnd_AccruedSubcontractorExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_d48d04e4-ee17-46d1-b902-b3a930ef88fc_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_2581550a-b07e-4565-8222-899dca0e5558_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in Viking common stock</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_cc82b964-1bb7-4736-b024-517cf61d8387_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesCPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_ddb93ddb-7b53-4fb9-9a92-15d547e8eb87_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone and other</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_f77ffa0a-bcce-460b-9eb5-31df29e1b0c9_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total non-operating income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ZelsuvmiMember_e3ee6a5d-0a19-4631-931d-1ceb83d08ae9_terseLabel_en-US" xlink:label="lab_lgnd_ZelsuvmiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zelsuvmi</link:label>
    <link:label id="lab_lgnd_ZelsuvmiMember_label_en-US" xlink:label="lab_lgnd_ZelsuvmiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zelsuvmi [Member]</link:label>
    <link:label id="lab_lgnd_ZelsuvmiMember_documentation_en-US" xlink:label="lab_lgnd_ZelsuvmiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zelsuvmi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ZelsuvmiMember" xlink:href="lgnd-20241231.xsd#lgnd_ZelsuvmiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ZelsuvmiMember" xlink:to="lab_lgnd_ZelsuvmiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EquityMethodInvestmentsAllocationMember_3e6193ff-d6a8-41ec-a8ea-81c85b778f47_terseLabel_en-US" xlink:label="lab_lgnd_EquityMethodInvestmentsAllocationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment</link:label>
    <link:label id="lab_lgnd_EquityMethodInvestmentsAllocationMember_label_en-US" xlink:label="lab_lgnd_EquityMethodInvestmentsAllocationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments Allocation [Member]</link:label>
    <link:label id="lab_lgnd_EquityMethodInvestmentsAllocationMember_documentation_en-US" xlink:label="lab_lgnd_EquityMethodInvestmentsAllocationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments Allocation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EquityMethodInvestmentsAllocationMember" xlink:href="lgnd-20241231.xsd#lgnd_EquityMethodInvestmentsAllocationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EquityMethodInvestmentsAllocationMember" xlink:to="lab_lgnd_EquityMethodInvestmentsAllocationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_4bd53ff2-1745-4b04-a5b2-b5a24b1c25e2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ContingentMilestonePurchaseAgreement_51ea7fba-acd2-41b7-99a0-00355a3bb994_terseLabel_en-US" xlink:label="lab_lgnd_ContingentMilestonePurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_lgnd_ContingentMilestonePurchaseAgreement_label_en-US" xlink:label="lab_lgnd_ContingentMilestonePurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Milestone Purchase Agreement</link:label>
    <link:label id="lab_lgnd_ContingentMilestonePurchaseAgreement_documentation_en-US" xlink:label="lab_lgnd_ContingentMilestonePurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Milestone Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentMilestonePurchaseAgreement" xlink:href="lgnd-20241231.xsd#lgnd_ContingentMilestonePurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ContingentMilestonePurchaseAgreement" xlink:to="lab_lgnd_ContingentMilestonePurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyOtherMember_2c85dc68-a0b9-4f99-ae3f-351b5ab55122_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_lgnd_RoyaltyOtherMember_label_en-US" xlink:label="lab_lgnd_RoyaltyOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty, Other [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyOtherMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyOtherMember" xlink:href="lgnd-20241231.xsd#lgnd_RoyaltyOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyOtherMember" xlink:to="lab_lgnd_RoyaltyOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_2f93ebf4-eca3-4ab1-bca5-2390e9044d87_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_9acbb8bb-a793-4319-8992-9fd3e8f1a4d0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_f4248d37-ed8d-4138-a1c6-7ffa1bae970c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_1a364dc3-8947-442e-952e-42457d879565_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) from continuing operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_4d11abb6-bd3c-420b-81e0-048579389810_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_c7e8c845-b1b5-4689-9690-f6bb80754f0b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_8ed3d736-61f4-448c-bbc5-020f3931c2ce_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segment</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_7181515a-c9d0-4c2d-8052-0df26bae4089_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_380f9f2d-6f0a-4a2a-9945-9723c064a018_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_4c21dda1-479e-4391-a65e-c1345e935bc7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeThreeMember_040aeaa3-5db5-44e8-96d4-035d4bfbbbf3_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$64.65-$68.74</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeThreeMember" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeThreeMember" xlink:to="lab_lgnd_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_7c88d63c-0a3a-415a-a087-b8d45c0d7ba1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_6d5ba4dd-4178-4425-b2a2-434ebc3fdfca_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f5879cba-72cf-44f6-a356-b92ff16ef689_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_aea08357-54a8-4ce6-ab4a-62562826eafd_terseLabel_en-US" xlink:label="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development, regulatory, &amp; commercial milestones and tiered royalties</link:label>
    <link:label id="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_label_en-US" xlink:label="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties [Member]</link:label>
    <link:label id="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_documentation_en-US" xlink:label="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:href="lgnd-20241231.xsd#lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:to="lab_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_17d8bf2b-9fc9-4056-80ad-502b3a092e3d_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Addition of right-of-use assets and lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesByIndustryAxis_e1d29940-53ec-4d8f-9d26-2cd2ab46c326_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesByIndustryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Industry Sector [Axis]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesByIndustryAxis_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesByIndustryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Industry Sector [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis" xlink:to="lab_us-gaap_EquitySecuritiesByIndustryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales_b4528698-86d0-4664-b951-99b074188260_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future royalties (as a percent)</link:label>
    <link:label id="lab_lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales_label_en-US" xlink:label="lab_lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Financing Agreement, Percentage Of Global Net Sales</link:label>
    <link:label id="lab_lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales_documentation_en-US" xlink:label="lab_lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Financing Agreement, Percentage Of Global Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales" xlink:href="lgnd-20241231.xsd#lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales" xlink:to="lab_lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_1e4905af-0d15-4b4d-be03-4c3b419b76ea_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_7bec558a-e2fa-4b73-ad87-e9c846df7ea6_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4c5fc8cb-61d8-47a5-bb99-cfd610092bfe_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_692a457c-2c6f-4709-886d-7fb0a8a55e02_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_dfb4ef70-038c-4ec5-a5f1-d4ac8b65f1ee_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities incurred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_082e10c7-d640-4813-ad6e-116e65e45614_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_4b6bdbb0-5204-4919-b1cd-a46dada5b2f1_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_846954db-f5b9-43e5-bb57-5a9c62b465d7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_5dfa12f5-5341-471a-af86-92a5df0ae6f9_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Pelthos inventory in other current assets</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_179f8ff5-a403-4bce-a615-0422a5429141_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_2ec1ca1f-4640-4148-a54a-393597ad3ae6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_4755ebcd-1ea8-4e29-9020-12b885c0233f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_dd95662e-6134-4ef3-9835-1d67184a6077_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_416d5057-6975-47c4-898b-27bb58541197_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_6cd14f97-9cb0-4dce-88e1-8551109bb718_terseLabel_en-US" xlink:label="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock sold of equity method investee (in shares)</link:label>
    <link:label id="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_label_en-US" xlink:label="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Shares Sold Of Equity Method Investee</link:label>
    <link:label id="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_documentation_en-US" xlink:label="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Shares Sold Of Equity Method Investee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfSharesSoldOfEquityMethodInvestee" xlink:href="lgnd-20241231.xsd#lgnd_NumberOfSharesSoldOfEquityMethodInvestee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NumberOfSharesSoldOfEquityMethodInvestee" xlink:to="lab_lgnd_NumberOfSharesSoldOfEquityMethodInvestee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_4f02fb50-2b7d-4a4b-bd2f-e43c2eb7ef4f_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_930bbdd0-017e-4c91-b8cc-7a45b441d818_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total fair value of net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_b166a0ca-35c7-458d-a805-86b3138f22cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_88a9423a-86a1-433b-b6ee-91c7b39ac067_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_04d806b4-54da-4a73-8665-fdbb011b35a5_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_0cbf0f15-49a6-4917-aa3b-6e03d986f569_terseLabel_en-US" xlink:label="lab_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration paid for an interest in potential development milestone</link:label>
    <link:label id="lab_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_456f5c8f-4307-4918-8af7-1708789e485b_verboseLabel_en-US" xlink:label="lab_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash consideration paid</link:label>
    <link:label id="lab_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_label_en-US" xlink:label="lab_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration Paid For An Interest In Potential Development Milestone</link:label>
    <link:label id="lab_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_documentation_en-US" xlink:label="lab_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consideration Paid For An Interest In Potential Development Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" xlink:href="lgnd-20241231.xsd#lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" xlink:to="lab_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_8b554935-6151-4b6e-a404-f6f1e030bd4d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_47133da9-2eb2-4be1-80f2-22cb5bf4dbd3_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_9cf79991-65fe-4ee2-a0ce-248e1cd74c1f_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, term of contract (in years)</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_c8c78db8-de81-424e-8d4b-7fd6e5c9a585_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_41d72c0f-1bb3-4eb4-b2b1-435540934df3_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7409d685-0ed9-44af-ba07-54a625ff93f9_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_258cc909-46dc-414e-9c8f-d211d3ca89b3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Assets</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_a2e7781b-b375-4a22-8826-11a4042a4e2b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable and Allowance for Credit Losses</link:label>
    <link:label id="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Loss, Financial Instrument [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:to="lab_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_487a56ad-a444-4003-b404-3d42d4e5e865_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Level 3 Financial Instruments, Assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod_ce9992be-9842-4873-9608-e9e9ec065eb4_terseLabel_en-US" xlink:label="lab_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchased amount</link:label>
    <link:label id="lab_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod_label_en-US" xlink:label="lab_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchased Amount During Period</link:label>
    <link:label id="lab_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod_documentation_en-US" xlink:label="lab_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchased Amount During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod" xlink:href="lgnd-20241231.xsd#lgnd_DebtInstrumentRepurchasedAmountDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod" xlink:to="lab_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_6f54e6c8-8656-4e52-8300-46822fad29d0_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_89e71626-2ea3-4165-a0a9-33d1b9d5bd00_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment items:</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment, Reconciliation of Other Items from Segments to Consolidated [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:to="lab_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_b91ac6bc-4b0e-45c1-9b0c-91872c862226_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_2d130576-55ce-4663-8b2c-14e127b4ea39_verboseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalties</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_5cab176a-7c28-4efc-905c-05e562c1a300_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novan (Pelthos) contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_1e5b3574-c629-4d3d-87c0-63692982804c_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions:</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_7f052ad8-2dd2-4b00-a399-bbcd3d181be7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income taxes receivable and payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ProductRoyaltyPercentage_628d6d8c-5452-4aaa-a6f2-94391e0cd576_terseLabel_en-US" xlink:label="lab_lgnd_ProductRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product royalty (as a percent)</link:label>
    <link:label id="lab_lgnd_ProductRoyaltyPercentage_label_en-US" xlink:label="lab_lgnd_ProductRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Royalty Percentage</link:label>
    <link:label id="lab_lgnd_ProductRoyaltyPercentage_documentation_en-US" xlink:label="lab_lgnd_ProductRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product Royalty Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProductRoyaltyPercentage" xlink:href="lgnd-20241231.xsd#lgnd_ProductRoyaltyPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ProductRoyaltyPercentage" xlink:to="lab_lgnd_ProductRoyaltyPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_OtherDerivativesMember_ae4ef455-c230-4539-b13b-efcee891efdf_terseLabel_en-US" xlink:label="lab_lgnd_OtherDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Derivatives</link:label>
    <link:label id="lab_lgnd_OtherDerivativesMember_label_en-US" xlink:label="lab_lgnd_OtherDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Derivatives [Member]</link:label>
    <link:label id="lab_lgnd_OtherDerivativesMember_documentation_en-US" xlink:label="lab_lgnd_OtherDerivativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherDerivativesMember" xlink:href="lgnd-20241231.xsd#lgnd_OtherDerivativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_OtherDerivativesMember" xlink:to="lab_lgnd_OtherDerivativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_24bf14e6-1481-475a-bd05-8361aa0ec0e0_terseLabel_en-US" xlink:label="lab_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_label_en-US" xlink:label="lab_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Browse Taxonomy Disposal Group, Including Discontinued Operation, Other Income (Expense) [Abstract]</link:label>
    <link:label id="lab_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_documentation_en-US" xlink:label="lab_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Browse Taxonomy Disposal Group, Including Discontinued Operation, Other Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" xlink:href="lgnd-20241231.xsd#lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" xlink:to="lab_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_f3bb2b64-a3dd-4e5e-8126-784e8475488a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_995f2a5a-2e15-4cb9-a826-3df64dee15fd_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeOneMember_807ae471-4b77-4994-9a49-198f4429b90f_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">$32.78-$52.84</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeOneMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeOneMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeOneMember" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeOneMember" xlink:to="lab_lgnd_ExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_e5dfa633-77f2-4d30-841e-3e817ee18105_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_e05c84ce-0103-4d87-b1ea-124f834d607c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_99e94c27-4705-4eb9-b50c-320df7cfc9d3_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b3102987-e33b-4250-9d28-13714da46aeb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_a0070b07-191d-417e-af5d-25f9e8f0df36_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction_4db5b750-0c90-4c69-8c1f-b313ae90b94b_terseLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bond hedge transaction</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid In Capital, Bond Hedge Transaction</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid In Capital, Bond Hedge Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" xlink:href="lgnd-20241231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_ed6b6afb-60d6-4062-9025-84a994feb4b7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_8ce6d7be-ed5b-4e2d-8f57-814de553a921_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b64b0817-f068-4877-8292-a4e389fa0653_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic net income (loss) from continuing operations (in USD per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_9fa3189f-2399-4c61-a78e-4e97556f9b4f_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_367452eb-abed-4e05-a772-387a94f2583c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_eef3f4ee-e5fc-41b7-9ad1-540e73c77db0_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_766e1b72-e4ba-481a-9bc1-dbc671e4aaca_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Investments_879d2030-9792-4d1b-b9c9-433837ac43ad_terseLabel_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_Investments_label_en-US" xlink:label="lab_us-gaap_Investments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Investments" xlink:to="lab_us-gaap_Investments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_fe572bba-3c58-410c-a008-ac64706e728e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_1639441c-75ab-4a23-b0c8-1b0d3a83260f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other economic rights</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Intangible Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:to="lab_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_265fa674-cab0-4c66-ab6b-39aeab4ecab7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of debt instrument (in years)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_f0dec42e-159b-4395-ae15-3a84ebe5fe47_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchased amount of debt instrument</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_1e785a01-f5a0-48c6-b544-f19430d35fed_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_c0bf5ac3-aa9a-4824-8bb6-877a149650b3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated amortization expense for 2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PrimordialGeneticsMember_0cc08361-0e84-46fd-8a9f-abd81c8972a9_terseLabel_en-US" xlink:label="lab_lgnd_PrimordialGeneticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Primordial Genetics</link:label>
    <link:label id="lab_lgnd_PrimordialGeneticsMember_label_en-US" xlink:label="lab_lgnd_PrimordialGeneticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Primordial Genetics [Member]</link:label>
    <link:label id="lab_lgnd_PrimordialGeneticsMember_documentation_en-US" xlink:label="lab_lgnd_PrimordialGeneticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Primordial Genetics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimordialGeneticsMember" xlink:href="lgnd-20241231.xsd#lgnd_PrimordialGeneticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PrimordialGeneticsMember" xlink:to="lab_lgnd_PrimordialGeneticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_d8cf9bc1-fd51-4bb2-bc92-81ec94af1ec9_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_OfficeInBostonMassachusettsMember_cee28506-acb1-45f6-b272-be5a9dfafe78_terseLabel_en-US" xlink:label="lab_lgnd_OfficeInBostonMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office in Boston, Massachusetts</link:label>
    <link:label id="lab_lgnd_OfficeInBostonMassachusettsMember_label_en-US" xlink:label="lab_lgnd_OfficeInBostonMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office in Boston Massachusetts [Member]</link:label>
    <link:label id="lab_lgnd_OfficeInBostonMassachusettsMember_documentation_en-US" xlink:label="lab_lgnd_OfficeInBostonMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Office in Boston Massachusetts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OfficeInBostonMassachusettsMember" xlink:href="lgnd-20241231.xsd#lgnd_OfficeInBostonMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_OfficeInBostonMassachusettsMember" xlink:to="lab_lgnd_OfficeInBostonMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_7a294cbc-191f-46ac-98ce-b027a90d28d9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other non-operating (expense) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestments_2de1d859-eae0-47c0-abf5-a90fbeb328f0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other investments</link:label>
    <link:label id="lab_us-gaap_OtherInvestments_034340c2-63a5-41a5-bd47-10f2ba97d037_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total other investments</link:label>
    <link:label id="lab_us-gaap_OtherInvestments_label_en-US" xlink:label="lab_us-gaap_OtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestments" xlink:to="lab_us-gaap_OtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization_d77f2fe2-3433-4178-83c0-586bdbb6d532_terseLabel_en-US" xlink:label="lab_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease amortization expense</link:label>
    <link:label id="lab_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease And Operating Lease, Right-of-Use Asset, Amortization</link:label>
    <link:label id="lab_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization_documentation_en-US" xlink:label="lab_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finance Lease And Operating Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" xlink:href="lgnd-20241231.xsd#lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" xlink:to="lab_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_a1d8b891-20d6-4e05-9b32-e263416a0295_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_9d7f6b77-2238-4420-b9ec-77424835f9e7_verboseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_760fd4fd-1dc6-43d2-a9ba-38a74f4c20f1_negatedLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Liabilities</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4d206211-15d3-4e50-bfa1-63fc6fb7763d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_d1276e93-5165-4941-a2aa-6de5502e12cf_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash received from options exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_58f9818e-7610-4b7f-a81d-fc79beb34387_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost, restricted stock</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ScheduleOfFinancialRoyaltyAssetsTableTextBlock_fe0a4c1c-3d30-4e19-8ed6-4a067b8a40b1_terseLabel_en-US" xlink:label="lab_lgnd_ScheduleOfFinancialRoyaltyAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Financial Royalty Assets</link:label>
    <link:label id="lab_lgnd_ScheduleOfFinancialRoyaltyAssetsTableTextBlock_label_en-US" xlink:label="lab_lgnd_ScheduleOfFinancialRoyaltyAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Financial Royalty Assets [Table Text Block]</link:label>
    <link:label id="lab_lgnd_ScheduleOfFinancialRoyaltyAssetsTableTextBlock_documentation_en-US" xlink:label="lab_lgnd_ScheduleOfFinancialRoyaltyAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Financial Royalty Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleOfFinancialRoyaltyAssetsTableTextBlock" xlink:href="lgnd-20241231.xsd#lgnd_ScheduleOfFinancialRoyaltyAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ScheduleOfFinancialRoyaltyAssetsTableTextBlock" xlink:to="lab_lgnd_ScheduleOfFinancialRoyaltyAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_79f670d4-8f88-4e61-acd3-7a11ed8e103a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_5a07b9dd-58bb-491b-aca8-e55a92a4d054_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_2495e0c6-eda6-4413-a6a2-ccd89d61707e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred transaction costs</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="lab_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_d299b969-01a7-460f-a8e0-6971bf023234_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_9f9aee73-ed21-4b55-96bb-a4aa1dc018e5_negatedLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangibles</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_df9f2abe-14bd-4b0b-bd48-3f5156420f76_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_a9e92166-59ca-4e98-b3ec-94781e59305a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities_7cb389d5-db64-4de2-92b2-c7ad3b101e8a_negatedTerseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Long-term Operating Lease Liabilities</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Long-term Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_4d234409-9f67-4db2-8ef9-8edaf0939ac4_terseLabel_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion of consideration allocated to inventory</link:label>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_label_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Consideration Paid, Allocated to Inventory</link:label>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_documentation_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Consideration Paid, Allocated to Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:href="lgnd-20241231.xsd#lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:to="lab_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MaterialSalesCaptisolCOVIDMember_28453320-0c2e-4b90-a52c-33b5638eeb69_terseLabel_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolCOVIDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Captisol - COVID</link:label>
    <link:label id="lab_lgnd_MaterialSalesCaptisolCOVIDMember_label_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolCOVIDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Sales, Captisol, COVID [Member]</link:label>
    <link:label id="lab_lgnd_MaterialSalesCaptisolCOVIDMember_documentation_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolCOVIDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Material Sales, Captisol, COVID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolCOVIDMember" xlink:href="lgnd-20241231.xsd#lgnd_MaterialSalesCaptisolCOVIDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MaterialSalesCaptisolCOVIDMember" xlink:to="lab_lgnd_MaterialSalesCaptisolCOVIDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_4cb1487d-bb5c-4320-b3a4-dce49fccf9ce_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_a18558bd-1530-4eff-a6c8-fcadcd5b8284_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_be8c7799-0d04-4121-8d34-988274850d37_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on available-for-sale investments, net of tax</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5186c252-61a2-465a-8b61-1adc6298ffba_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LiabilityForContingentValueRights_3df00a8b-33f7-4d12-b6e7-89e4b8e9224a_verboseLabel_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term contingent liabilities</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRights_label_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability For Contingent Value Rights</link:label>
    <link:label id="lab_lgnd_LiabilityForContingentValueRights_documentation_en-US" xlink:label="lab_lgnd_LiabilityForContingentValueRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability for contingent value rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRights" xlink:href="lgnd-20241231.xsd#lgnd_LiabilityForContingentValueRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LiabilityForContingentValueRights" xlink:to="lab_lgnd_LiabilityForContingentValueRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_de92c0be-a340-405e-a167-e6b62d491236_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of positions in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_15c33d9d-8c10-43b6-879e-a2b22a3c64aa_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromHedgeFinancingActivities_0cb87216-aa17-4bcf-944a-d3ec794da807_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from bond hedge settlement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromHedgeFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Hedge, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromHedgeFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_23dcbf69-4c62-4263-89b5-adaf019ce38a_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_50a6b828-63e3-4a2c-9301-3d10fd03fb10_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business exit costs</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsGross_27ea6b1b-1bea-4add-9899-40e2e8c3bd12_terseLabel_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross carrying value</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsGross_label_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets, Gross</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsGross_documentation_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsGross" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FinancialRoyaltyAssetsGross" xlink:to="lab_lgnd_FinancialRoyaltyAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockConvertibleConversionRatio_371004f3-26d0-4fb4-817c-3aee4b4a684b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange ratio</link:label>
    <link:label id="lab_us-gaap_PreferredStockConvertibleConversionRatio_label_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="lab_us-gaap_PreferredStockConvertibleConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0b97314a-5995-44ad-a00a-01440a7d5196_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9f7770a0-3970-4fc2-831f-0365de7f161b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LeaseLiabilityCurrent_b4c3f26d-d5e3-41fa-96a1-959943753f3f_totalLabel_en-US" xlink:label="lab_lgnd_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current lease liabilities</link:label>
    <link:label id="lab_lgnd_LeaseLiabilityCurrent_label_en-US" xlink:label="lab_lgnd_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Liability, Current</link:label>
    <link:label id="lab_lgnd_LeaseLiabilityCurrent_documentation_en-US" xlink:label="lab_lgnd_LeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiabilityCurrent" xlink:href="lgnd-20241231.xsd#lgnd_LeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LeaseLiabilityCurrent" xlink:to="lab_lgnd_LeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_1dd5480e-fef1-429d-bea2-510ff7c9ba99_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss of financial royalty assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0ad6f995-7666-4a55-8476-82ff5e61fbb4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitment and Contingencies: Legal Proceedings</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_9aa283c8-d78c-4dbe-abe0-2ce018a0ceb4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_efeae50e-4e1d-448f-82a2-592ccce942b5_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_474b85ac-eef6-4f24-a7df-ded5a227dffa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_f300e20d-0371-41e4-b6b8-1f8f717c7661_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9349155a-4fc5-43a2-80b3-b09e36289cb3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of commissions and fees (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_b9029736-12a6-42e9-914e-744296e0aac5_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer</link:label>
    <link:label id="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems_label_en-US" xlink:label="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Major Customer [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_8c4cce6a-2df1-448d-a438-28d5e8e3c05f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_c1be1a5c-b144-47e9-9a2e-1f22d32c86ec_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_6926dc76-cb2e-48e3-9c64-97e5ad943185_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:to="lab_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_Phase3ClinicalTrialMember_86627d5e-a308-4a2c-8753-06296ac69bf2_terseLabel_en-US" xlink:label="lab_lgnd_Phase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phase 3 clinical trial</link:label>
    <link:label id="lab_lgnd_Phase3ClinicalTrialMember_label_en-US" xlink:label="lab_lgnd_Phase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial [Member]</link:label>
    <link:label id="lab_lgnd_Phase3ClinicalTrialMember_documentation_en-US" xlink:label="lab_lgnd_Phase3ClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_Phase3ClinicalTrialMember" xlink:href="lgnd-20241231.xsd#lgnd_Phase3ClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_Phase3ClinicalTrialMember" xlink:to="lab_lgnd_Phase3ClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_1c2fe634-674d-40f7-8068-d86b658029fe_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MaterialSalesCaptisolCoreMember_70c14229-66ca-48c1-8391-cc8ca5290d67_terseLabel_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolCoreMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Captisol - Core</link:label>
    <link:label id="lab_lgnd_MaterialSalesCaptisolCoreMember_label_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolCoreMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Sales, Captisol, Core [Member]</link:label>
    <link:label id="lab_lgnd_MaterialSalesCaptisolCoreMember_documentation_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolCoreMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Material Sales, Captisol, Core</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolCoreMember" xlink:href="lgnd-20241231.xsd#lgnd_MaterialSalesCaptisolCoreMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MaterialSalesCaptisolCoreMember" xlink:to="lab_lgnd_MaterialSalesCaptisolCoreMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_942d314d-150a-4b5a-9cb5-112c0d0d4877_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_cd0ff60f-9197-4d02-827c-e32a37b71e25_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finance lease assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetMeasurementInput_3d0bdab2-54a2-492a-a655-d7bcbbdf336b_terseLabel_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial royalty assets, measurement input (percent)</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetMeasurementInput_label_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Royalty Asset, Measurement Input</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetMeasurementInput_documentation_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Royalty Asset, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetMeasurementInput" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FinancialRoyaltyAssetMeasurementInput" xlink:to="lab_lgnd_FinancialRoyaltyAssetMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_9ef83b6c-11d7-4f54-ab2c-4e45886ab9ce_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_68874558-b5c5-41eb-8c62-e533479e2d27_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_f49e0851-9e85-484d-bffe-ea84ffcc2dcd_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties owed to third parties</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BridgeLoanMember_f7f47495-e8f8-4d56-b81a-b7eb47bbb01e_terseLabel_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bridge Loan</link:label>
    <link:label id="lab_us-gaap_BridgeLoanMember_label_en-US" xlink:label="lab_us-gaap_BridgeLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bridge Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BridgeLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember" xlink:to="lab_us-gaap_BridgeLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_24cc4fbb-51a2-41e6-bb97-5815b599159e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_2f37b0a0-9a95-4c75-af42-341fb46530a1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining life in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember_ac8e8072-cb6d-45a3-a57a-d9842a8cc28c_terseLabel_en-US" xlink:label="lab_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Repurchased During Current Period, Two</link:label>
    <link:label id="lab_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember_label_en-US" xlink:label="lab_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Repurchased During Current Period, Two [Member]</link:label>
    <link:label id="lab_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember_documentation_en-US" xlink:label="lab_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes Repurchased During Current Period, Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember" xlink:href="lgnd-20241231.xsd#lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember" xlink:to="lab_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsNetCurrent_61b9afcd-2fa2-430d-92d9-b45b9dff5e26_terseLabel_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial royalty liability current</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsNetCurrent_label_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets, Net Current</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyAssetsNetCurrent_documentation_en-US" xlink:label="lab_lgnd_FinancialRoyaltyAssetsNetCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Royalty Assets, Net Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsNetCurrent" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FinancialRoyaltyAssetsNetCurrent" xlink:to="lab_lgnd_FinancialRoyaltyAssetsNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_353409e8-9587-4780-9d63-3cf6df12fe12_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ed56a562-4568-469c-b287-f88644df4398_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_502e5c7e-3a3d-474e-a86f-793f8ebfeb22_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems_3e732b6f-11b7-4b75-90e8-24f4a7c7743c_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Investment Holdings</link:label>
    <link:label id="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems_label_en-US" xlink:label="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Investment Holdings [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:to="lab_us-gaap_SummaryOfInvestmentHoldingsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_76ff55d2-edfb-42b2-982c-5936fdf5b0e0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_f26e2e10-a5ed-41b8-b473-6a0f88c7e1a2_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_56d4eb74-d579-4abe-92ed-abc2fe351493_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_5a9fe534-b533-4a25-9ae7-c5e254aea27f_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_accc6581-1a5b-46c4-bf48-c9107c23ec6b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Number of Positions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:to="lab_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_5e16e345-08cd-4e76-b47c-9eba49e201b6_totalLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_a61a0e07-c4c0-4e00-b5fa-eaa330ed56db_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercise of derivative assets</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MaterialSalesCaptisolMember_900f0b53-e232-4c76-acce-d447ea1ad6fc_terseLabel_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Captisol</link:label>
    <link:label id="lab_lgnd_MaterialSalesCaptisolMember_4f903fc0-b6f5-4343-8037-7e789f7634a7_verboseLabel_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Captisol</link:label>
    <link:label id="lab_lgnd_MaterialSalesCaptisolMember_label_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Sales, Captisol [Member]</link:label>
    <link:label id="lab_lgnd_MaterialSalesCaptisolMember_documentation_en-US" xlink:label="lab_lgnd_MaterialSalesCaptisolMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Material Sales, Captisol [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember" xlink:href="lgnd-20241231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MaterialSalesCaptisolMember" xlink:to="lab_lgnd_MaterialSalesCaptisolMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_InvIOsHoldingAGMember_8573c322-8cf6-4e76-838a-b0faa8e9f175_terseLabel_en-US" xlink:label="lab_lgnd_InvIOsHoldingAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">InvIOs Holding AG</link:label>
    <link:label id="lab_lgnd_InvIOsHoldingAGMember_label_en-US" xlink:label="lab_lgnd_InvIOsHoldingAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">InvIOs Holding AG [Member]</link:label>
    <link:label id="lab_lgnd_InvIOsHoldingAGMember_documentation_en-US" xlink:label="lab_lgnd_InvIOsHoldingAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">InvIOs Holding AG</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvIOsHoldingAGMember" xlink:href="lgnd-20241231.xsd#lgnd_InvIOsHoldingAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_InvIOsHoldingAGMember" xlink:to="lab_lgnd_InvIOsHoldingAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_df073c75-309b-4aaf-b709-04d7faa38773_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_4ca752b5-215e-4f6d-b989-b7a6b7bf7377_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire productive asset</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CydexPharmaceuticalsIncMember_8a16a13d-30bc-4f01-82b4-19a513bc2003_verboseLabel_en-US" xlink:label="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cydex</link:label>
    <link:label id="lab_lgnd_CydexPharmaceuticalsIncMember_label_en-US" xlink:label="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cydex Pharmaceuticals, Inc [Member]</link:label>
    <link:label id="lab_lgnd_CydexPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cydex Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CydexPharmaceuticalsIncMember" xlink:href="lgnd-20241231.xsd#lgnd_CydexPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CydexPharmaceuticalsIncMember" xlink:to="lab_lgnd_CydexPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_435989af-70dc-4e91-9a6e-ceaecbe67dcb_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_a91809f0-29f9-42c0-a512-7e92a2f9801f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_aeef4718-9647-4000-88b5-d8034fb986e6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_39a4e58c-9365-4f69-8983-3957954267ca_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AccruedCustomerDepositsCurrent_82111979-f647-4722-a617-8b8ffc6efd06_terseLabel_en-US" xlink:label="lab_lgnd_AccruedCustomerDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer deposit</link:label>
    <link:label id="lab_lgnd_AccruedCustomerDepositsCurrent_label_en-US" xlink:label="lab_lgnd_AccruedCustomerDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Customer Deposits, Current</link:label>
    <link:label id="lab_lgnd_AccruedCustomerDepositsCurrent_documentation_en-US" xlink:label="lab_lgnd_AccruedCustomerDepositsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Customer Deposits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedCustomerDepositsCurrent" xlink:href="lgnd-20241231.xsd#lgnd_AccruedCustomerDepositsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AccruedCustomerDepositsCurrent" xlink:to="lab_lgnd_AccruedCustomerDepositsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_7df9b381-a53e-41dc-b85a-70a3263a3b5a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_5c2650cf-a961-4d46-9840-3e6b0bb3f585_terseLabel_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Metabasis Therapeutics</link:label>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_6aa087d0-b39e-4488-ac0b-333bb88df40e_verboseLabel_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Metabasis</link:label>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_label_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Metabasis Therapeutics [Member]</link:label>
    <link:label id="lab_lgnd_MetabasisTherapeuticsMember_documentation_en-US" xlink:label="lab_lgnd_MetabasisTherapeuticsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Metabasis Therapeutics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember" xlink:href="lgnd-20241231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MetabasisTherapeuticsMember" xlink:to="lab_lgnd_MetabasisTherapeuticsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_d19fd15e-b6fa-412a-92c4-1d410909e353_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PeliCRM197Member_5ac8ca8f-d981-41ab-9654-c1e9320fcbf3_terseLabel_en-US" xlink:label="lab_lgnd_PeliCRM197Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PeliCRM197</link:label>
    <link:label id="lab_lgnd_PeliCRM197Member_label_en-US" xlink:label="lab_lgnd_PeliCRM197Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PeliCRM197 [Member]</link:label>
    <link:label id="lab_lgnd_PeliCRM197Member_documentation_en-US" xlink:label="lab_lgnd_PeliCRM197Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PeliCRM197</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PeliCRM197Member" xlink:href="lgnd-20241231.xsd#lgnd_PeliCRM197Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PeliCRM197Member" xlink:to="lab_lgnd_PeliCRM197Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_5edc0533-6a89-4128-803d-e87ef26ca64f_netLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_b7a1dbdc-88b3-476f-baea-0694186786c9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_3b1eb6c2-193b-4a87-a8fe-3bf27f079f5c_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_53f5ef40-4519-47a0-bcab-002f67328e78_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant date fair value per share of stock options (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_708ba68d-fe26-44be-b0e0-f51a91912ec1_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-Known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CommercialLicenseRightsCreditLossAdjustment_db9bfa58-de34-4c1b-949d-ce184b16539a_terseLabel_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsCreditLossAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Reduction) credit loss adjustment</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsCreditLossAdjustment_label_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsCreditLossAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial License Rights, Credit Loss Adjustment</link:label>
    <link:label id="lab_lgnd_CommercialLicenseRightsCreditLossAdjustment_documentation_en-US" xlink:label="lab_lgnd_CommercialLicenseRightsCreditLossAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial License Rights, Credit Loss Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsCreditLossAdjustment" xlink:href="lgnd-20241231.xsd#lgnd_CommercialLicenseRightsCreditLossAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CommercialLicenseRightsCreditLossAdjustment" xlink:to="lab_lgnd_CommercialLicenseRightsCreditLossAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_6844d8e9-678c-48bf-a0c5-fbd96b08efc6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_73785039-a0d5-406f-ae6a-1fcf1aab7c26_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualRightsMember_9af97630-e9dd-4e9e-93c3-01cc771e3223_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual relationships</link:label>
    <link:label id="lab_us-gaap_ContractualRightsMember_label_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualRightsMember" xlink:to="lab_us-gaap_ContractualRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_ad1fce2a-48a1-48dd-90e9-c898a8b101dc_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Technique, Discounted Cash Flow</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_de40822b-26c1-494e-81f8-3bdc8ec7cd96_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EmployeeStockPurchasePlanAbstract_9adcc1a3-2c25-4441-8101-d6a33f42050a_terseLabel_en-US" xlink:label="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_lgnd_EmployeeStockPurchasePlanAbstract_label_en-US" xlink:label="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Abstract]</link:label>
    <link:label id="lab_lgnd_EmployeeStockPurchasePlanAbstract_documentation_en-US" xlink:label="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EmployeeStockPurchasePlanAbstract" xlink:href="lgnd-20241231.xsd#lgnd_EmployeeStockPurchasePlanAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract" xlink:to="lab_lgnd_EmployeeStockPurchasePlanAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_adf5d0c7-ba3c-464f-8493-fa8162bd28b8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_f539ae14-2e09-4760-b44d-93c4ce69a454_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate of operating leases (as a percent)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_f67758e0-3baf-4e86-b843-1fac7f88ba3e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used) in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_9eab516d-1c6b-410c-911e-b4ee6cb75b08_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_8fd88aae-1118-4304-86e8-122257832c1a_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_2aa4ceec-1a15-4a03-ab0b-74400d4de76d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_734c5a90-2649-4f13-ab65-938c19fc5be0_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) of allowance for credit loss</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_a0cfa66a-d00b-406d-b90d-8fcd4d24a408_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_3a211ce8-141c-403e-81bf-467fcc213c85_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payments for acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DebtSecuritiesAvailableForSaleAmortization_27c74c64-a909-4f73-babe-9cccf2b2f2e3_terseLabel_en-US" xlink:label="lab_lgnd_DebtSecuritiesAvailableForSaleAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized cost</link:label>
    <link:label id="lab_lgnd_DebtSecuritiesAvailableForSaleAmortization_label_en-US" xlink:label="lab_lgnd_DebtSecuritiesAvailableForSaleAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortization</link:label>
    <link:label id="lab_lgnd_DebtSecuritiesAvailableForSaleAmortization_documentation_en-US" xlink:label="lab_lgnd_DebtSecuritiesAvailableForSaleAmortization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtSecuritiesAvailableForSaleAmortization" xlink:href="lgnd-20241231.xsd#lgnd_DebtSecuritiesAvailableForSaleAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DebtSecuritiesAvailableForSaleAmortization" xlink:to="lab_lgnd_DebtSecuritiesAvailableForSaleAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_e571a70b-1aef-4fcd-bfdf-3caadd0c9a7f_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation of fixed assets and amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_3969598e-cace-4de1-843c-521392cdfb5b_terseLabel_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:label id="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis_label_en-US" xlink:label="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Timing of Transfer of Good or Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:to="lab_us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_5eb70a11-883e-4464-bc46-bb0d97278c8b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c46726f1-b43d-4250-ab3e-c51dbef7e201_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e7ef6131-db4d-4d72-bd39-84b472c4065c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_bcbbde8f-ade5-4fd8-aafd-fd5c13e1a31d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign tax differential on income/loss of foreign subsidiaries</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_c0778088-52b4-4f2a-ba4f-eb614cc7bec6_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableWithImputedInterestFaceAmount_cdbb7417-e627-462f-bc5e-dc87cb769928_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivable with imputed interest</link:label>
    <link:label id="lab_us-gaap_ReceivableWithImputedInterestFaceAmount_label_en-US" xlink:label="lab_us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable with Imputed Interest, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableWithImputedInterestFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:to="lab_us-gaap_ReceivableWithImputedInterestFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare_38a909ef-cff1-42ab-8a2d-41d6da9650d2_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of CVRs issued per acquiree share</link:label>
    <link:label id="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare_label_en-US" xlink:label="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Number of Contingent Value Rights Issued per Acquiree Share</link:label>
    <link:label id="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Number of Contingent Value Rights Issued per Acquiree Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare" xlink:to="lab_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_606f1c8d-dbab-470a-89d1-7d3e3d9fc12c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_b59dbf2c-09b7-4413-bfc3-fc171e23d385_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_b41e32be-7c45-434c-817b-8fddc9b20f5c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_3ad4fe5f-e365-42c7-b88a-bfe91281229f_negatedLabel_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments to CVR Holders</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_b99631cc-39b3-4fff-91cb-da6c07844681_negatedTerseLabel_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments to CVR Holders</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_label_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Contingent Value Right Holders, Financing Activity</link:label>
    <link:label id="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_documentation_en-US" xlink:label="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments to Contingent Value Right Holders, Financing Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:to="lab_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_359f97dc-14bf-41f8-b4e6-21105b7a6c5e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_34da1481-23a2-425e-9942-723614e409ff_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of commissions and fees</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_87952444-d1fb-4abb-af6c-05de723e41bb_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_VaxneuvanceMember_df911318-5494-484d-b14f-68df9450d3a0_terseLabel_en-US" xlink:label="lab_lgnd_VaxneuvanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vaxneuvance</link:label>
    <link:label id="lab_lgnd_VaxneuvanceMember_label_en-US" xlink:label="lab_lgnd_VaxneuvanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vaxneuvance [Member]</link:label>
    <link:label id="lab_lgnd_VaxneuvanceMember_documentation_en-US" xlink:label="lab_lgnd_VaxneuvanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vaxneuvance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VaxneuvanceMember" xlink:href="lgnd-20241231.xsd#lgnd_VaxneuvanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_VaxneuvanceMember" xlink:to="lab_lgnd_VaxneuvanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_dda5116a-0bfd-4126-8745-07da874a08d2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_fe48f8cf-7e37-498e-bb14-ce6327b80d5c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 60,000 shares authorized; 19,106 and 17,556 shares issued and outstanding at December&#160;31, 2024 and 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FinancialRoyaltyMaximumCapitalSourcing_eddd8e86-b917-4772-b428-1520f0c36b3d_terseLabel_en-US" xlink:label="lab_lgnd_FinancialRoyaltyMaximumCapitalSourcing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum capital sourcing</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyMaximumCapitalSourcing_label_en-US" xlink:label="lab_lgnd_FinancialRoyaltyMaximumCapitalSourcing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Royalty, Maximum Capital Sourcing</link:label>
    <link:label id="lab_lgnd_FinancialRoyaltyMaximumCapitalSourcing_documentation_en-US" xlink:label="lab_lgnd_FinancialRoyaltyMaximumCapitalSourcing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Royalty, Maximum Capital Sourcing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyMaximumCapitalSourcing" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyMaximumCapitalSourcing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FinancialRoyaltyMaximumCapitalSourcing" xlink:to="lab_lgnd_FinancialRoyaltyMaximumCapitalSourcing" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_4151b151-18f9-459d-b27b-88a918e6e00a_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_283907f9-82ad-4f44-958e-fd9dfb871bc8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_ExercisePriceRangeSevenMember_fc045a16-67af-4351-ad46-4b9d952bbc57_terseLabel_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">89.2</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSevenMember_label_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range Seven [Member]</link:label>
    <link:label id="lab_lgnd_ExercisePriceRangeSevenMember_documentation_en-US" xlink:label="lab_lgnd_ExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Exercise Price Range Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSevenMember" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeSevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_ExercisePriceRangeSevenMember" xlink:to="lab_lgnd_ExercisePriceRangeSevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_56f1d361-3f75-4625-83ab-616c8376c1ab_totalLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other expense, net</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Nonoperating Income (Expense)</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_35f3dc51-baef-4341-8686-4e450156e293_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DerivativeAssetsMember_83b8a7d5-3650-46a0-a8ad-9387a14ffa3a_terseLabel_en-US" xlink:label="lab_lgnd_DerivativeAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative assets</link:label>
    <link:label id="lab_lgnd_DerivativeAssetsMember_label_en-US" xlink:label="lab_lgnd_DerivativeAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Assets [Member]</link:label>
    <link:label id="lab_lgnd_DerivativeAssetsMember_documentation_en-US" xlink:label="lab_lgnd_DerivativeAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeAssetsMember" xlink:href="lgnd-20241231.xsd#lgnd_DerivativeAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DerivativeAssetsMember" xlink:to="lab_lgnd_DerivativeAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_APEIRONMember_e1e5a696-e369-4fde-a14f-01bf8973b2c7_terseLabel_en-US" xlink:label="lab_lgnd_APEIRONMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">APEIRON</link:label>
    <link:label id="lab_lgnd_APEIRONMember_label_en-US" xlink:label="lab_lgnd_APEIRONMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APEIRON [Member]</link:label>
    <link:label id="lab_lgnd_APEIRONMember_documentation_en-US" xlink:label="lab_lgnd_APEIRONMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">APEIRON</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_APEIRONMember" xlink:href="lgnd-20241231.xsd#lgnd_APEIRONMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_APEIRONMember" xlink:to="lab_lgnd_APEIRONMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_f448818d-6c17-4f69-82e3-2b35923a49cb_terseLabel_en-US" xlink:label="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_label_en-US" xlink:label="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations, Operating Activities [Abstract]</link:label>
    <link:label id="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_documentation_en-US" xlink:label="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract" xlink:href="lgnd-20241231.xsd#lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract" xlink:to="lab_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_d3e34d19-dee5-462c-af72-7ab8326d1143_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_37ade580-72c3-48f9-8abf-3161e47c01b5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LicenseFeesMember_5597f907-5731-4290-b5f6-6513ea98ef3b_terseLabel_en-US" xlink:label="lab_lgnd_LicenseFeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_lgnd_LicenseFeesMember_label_en-US" xlink:label="lab_lgnd_LicenseFeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Fees [Member]</link:label>
    <link:label id="lab_lgnd_LicenseFeesMember_documentation_en-US" xlink:label="lab_lgnd_LicenseFeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMember" xlink:href="lgnd-20241231.xsd#lgnd_LicenseFeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LicenseFeesMember" xlink:to="lab_lgnd_LicenseFeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3a8c9d19-2d56-4e6f-ae41-8691a0bb8752_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial royalty assets impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b2be4b49-9c5d-4aee-b880-f5076d28196e_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_79f2f3fd-15d8-49dd-80ce-63fcae79cf8f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2024 and 2023</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_8d657ab0-0d70-46ca-b1bd-01cc7f50f907_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State, net of federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_829c00d0-c765-4caa-8451-009f4b6ff2aa_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_54c610ce-d965-4972-804f-c009380e4208_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_10229d22-51a3-4d0f-8e84-70bf14b9d652_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Basic net income (loss) per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense_5bd137f8-6a85-416c-8821-61edb92b242f_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Share-Based Payment Arrangement, Expense</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_c6465ab6-c367-4f25-a079-e466d91fe52f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from common stock issuance, net of commissions and fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_a6fad422-0287-45f2-8f71-e442e9027ab7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_63b690c9-66c6-4913-b8e7-2469c75c9fb3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_54a34dc3-3b5b-41d8-bce4-428938a7c597_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_8295c2b4-c1c0-4cbf-b96c-df06c8130a7b_terseLabel_en-US" xlink:label="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California and New Jersey Research Tax Credit Carryforward</link:label>
    <link:label id="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_label_en-US" xlink:label="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">California and New Jersey Research Tax Credit Carryforward [Member]</link:label>
    <link:label id="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_documentation_en-US" xlink:label="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">California and New Jersey Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:href="lgnd-20241231.xsd#lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:to="lab_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8229266d-7d37-4bf7-a925-0abbf5352092_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued fixed asset purchases</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_ba1bf5f9-171c-4051-8fa7-3656b6a6f940_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from debt issuance</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_SaleOfStockAuthorizedOfferingAmount_b90b99d8-797c-4dac-a49d-b1ebe4d153cc_terseLabel_en-US" xlink:label="lab_lgnd_SaleOfStockAuthorizedOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, authorized offering amount</link:label>
    <link:label id="lab_lgnd_SaleOfStockAuthorizedOfferingAmount_label_en-US" xlink:label="lab_lgnd_SaleOfStockAuthorizedOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Authorized Offering Amount</link:label>
    <link:label id="lab_lgnd_SaleOfStockAuthorizedOfferingAmount_documentation_en-US" xlink:label="lab_lgnd_SaleOfStockAuthorizedOfferingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Authorized Offering Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SaleOfStockAuthorizedOfferingAmount" xlink:href="lgnd-20241231.xsd#lgnd_SaleOfStockAuthorizedOfferingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_SaleOfStockAuthorizedOfferingAmount" xlink:to="lab_lgnd_SaleOfStockAuthorizedOfferingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_cf39fa25-04d0-4bd3-bcc5-f94b6ff7d6dd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_890d8a3d-e45b-4007-9686-f87474f76fca_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e93a1cb2-faa3-4ae7-b385-70a202c0af3b_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_3feff236-b4d1-483b-a3cf-a271c59b03f9_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Business Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EquityIssuanceCost_a4b3869e-adf2-468e-a0bf-8ed2608ea506_terseLabel_en-US" xlink:label="lab_lgnd_EquityIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity issuance cost</link:label>
    <link:label id="lab_lgnd_EquityIssuanceCost_label_en-US" xlink:label="lab_lgnd_EquityIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Issuance Cost</link:label>
    <link:label id="lab_lgnd_EquityIssuanceCost_documentation_en-US" xlink:label="lab_lgnd_EquityIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Issuance Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EquityIssuanceCost" xlink:href="lgnd-20241231.xsd#lgnd_EquityIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EquityIssuanceCost" xlink:to="lab_lgnd_EquityIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1869e24a-9fdb-49c6-8bca-7894d9360f76_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Estimated amortization expense for 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_72437749-0cf8-4b48-8b0f-3af386698e65_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_90f4b91a-6ac8-49d3-965e-4a05d7a5dabd_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_07cb11f9-b8b5-4628-ac24-eb8f028304f4_totalLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_7f92449c-eec9-4a5d-be06-8ffb74d86b54_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment_32bc403a-f8f0-4581-a510-a233e1d65f3c_terseLabel_en-US" xlink:label="lab_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized R&amp;D</link:label>
    <link:label id="lab_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment_label_en-US" xlink:label="lab_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capitalized Research And Development</link:label>
    <link:label id="lab_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment_documentation_en-US" xlink:label="lab_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Capitalized Research And Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:href="lgnd-20241231.xsd#lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="lab_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_320f16cf-428a-46b1-9159-04624b1422cd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Sundry Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_03a3fc0c-f385-4e95-9810-c38709a7b742_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d0faf39f-7d15-47c4-b90b-602f69c60d43_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price of warrants (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_83c8028e-4399-4437-ae90-a5afbee550aa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_INCAGN2390Member_3d118bd4-8c39-4076-a90b-f8530f9509a6_terseLabel_en-US" xlink:label="lab_lgnd_INCAGN2390Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCAGN2390</link:label>
    <link:label id="lab_lgnd_INCAGN2390Member_label_en-US" xlink:label="lab_lgnd_INCAGN2390Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">INCAGN2390 [Member]</link:label>
    <link:label id="lab_lgnd_INCAGN2390Member_documentation_en-US" xlink:label="lab_lgnd_INCAGN2390Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">INCAGN2390</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_INCAGN2390Member" xlink:href="lgnd-20241231.xsd#lgnd_INCAGN2390Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_INCAGN2390Member" xlink:to="lab_lgnd_INCAGN2390Member" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_MK4830Member_70f1b3b6-a13a-4f9b-a095-8a93a378d00e_terseLabel_en-US" xlink:label="lab_lgnd_MK4830Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MK-4830</link:label>
    <link:label id="lab_lgnd_MK4830Member_label_en-US" xlink:label="lab_lgnd_MK4830Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MK-4830 [Member]</link:label>
    <link:label id="lab_lgnd_MK4830Member_documentation_en-US" xlink:label="lab_lgnd_MK4830Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MK-4830</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MK4830Member" xlink:href="lgnd-20241231.xsd#lgnd_MK4830Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_MK4830Member" xlink:to="lab_lgnd_MK4830Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d9c18e1c-ae41-44ff-931e-8192bd5a7bc1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Plan Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f6d047af-6cc6-429f-b0e2-de54a40cdd69_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_227c9f3c-56b6-4945-a3e9-b5cde06fe95b_verboseLabel_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_label_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities</link:label>
    <link:label id="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_documentation_en-US" xlink:label="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:href="lgnd-20241231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:to="lab_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation_ecd280c0-f94c-40ca-9381-44182c087713_negatedTerseLabel_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">OmniAb Distribution</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation_label_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Decrease Due To Separation</link:label>
    <link:label id="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation_documentation_en-US" xlink:label="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Decrease Due To Separation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" xlink:href="lgnd-20241231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" xlink:to="lab_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_159d6213-4e87-4f46-8dfb-12b5920950a1_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of Pelican Business and Investment in Primrose Bio</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_7f8df617-b704-4c49-ad3c-8140ec8b78b1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Spin-off of OmniAb</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_FilspariMember_50b39a8b-1677-4092-85f5-00717ac6b9a8_terseLabel_en-US" xlink:label="lab_lgnd_FilspariMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Filspari</link:label>
    <link:label id="lab_lgnd_FilspariMember_label_en-US" xlink:label="lab_lgnd_FilspariMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Filspari [Member]</link:label>
    <link:label id="lab_lgnd_FilspariMember_documentation_en-US" xlink:label="lab_lgnd_FilspariMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Filspari</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FilspariMember" xlink:href="lgnd-20241231.xsd#lgnd_FilspariMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_FilspariMember" xlink:to="lab_lgnd_FilspariMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5fab3d6a-efcf-4f4d-8457-20240a2df580_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration_0b8c04b8-74eb-4a3e-bfa8-43d23d706632_terseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Change in Amount of Contingent Consideration</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Change in Amount of Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_6ebba7af-ce25-4dc2-a2e6-158ef95560f7_terseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_aeb3d44c-25c4-46a7-9769-a2e0203e3ffe_verboseLabel_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_label_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets</link:label>
    <link:label id="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_documentation_en-US" xlink:label="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" xlink:to="lab_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_d9b1f800-dea4-4712-888b-7aa112bbe673_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b0eda428-5016-4980-b036-5d4562c167be_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_5e340aa3-a84d-42fe-b5e5-25d9d5939eb6_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_8d285bfa-e67c-4ed2-ab9f-466dccaa0755_verboseLabel_en-US" xlink:label="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents &amp; Short-term Investments</link:label>
    <link:label id="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_label_en-US" xlink:label="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]</link:label>
    <link:label id="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_documentation_en-US" xlink:label="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:href="lgnd-20241231.xsd#lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:to="lab_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput_2bc79ba8-b26a-41e3-8662-e0a7dc0d56cb_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement input (as a percent)</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:to="lab_us-gaap_EquitySecuritiesFvNiMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsToAcquireFinancialRoyaltyAssets_e6d073d4-e886-46b4-8b80-24e278fa97ea_negatedTerseLabel_en-US" xlink:label="lab_lgnd_PaymentsToAcquireFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of financial royalty assets</link:label>
    <link:label id="lab_lgnd_PaymentsToAcquireFinancialRoyaltyAssets_label_en-US" xlink:label="lab_lgnd_PaymentsToAcquireFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments To Acquire Financial Royalty Assets</link:label>
    <link:label id="lab_lgnd_PaymentsToAcquireFinancialRoyaltyAssets_documentation_en-US" xlink:label="lab_lgnd_PaymentsToAcquireFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments To Acquire Financial Royalty Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToAcquireFinancialRoyaltyAssets" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsToAcquireFinancialRoyaltyAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsToAcquireFinancialRoyaltyAssets" xlink:to="lab_lgnd_PaymentsToAcquireFinancialRoyaltyAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_08f5d2b4-9c8d-420a-be5a-1def6cc1ffca_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_eed4624b-96c7-4ac8-9508-9b41dd5fd4cb_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_LicenseeAccrualCurrent_7888a564-01d6-4cc6-9508-c5c5239e84cf_terseLabel_en-US" xlink:label="lab_lgnd_LicenseeAccrualCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts owed to former licensees</link:label>
    <link:label id="lab_lgnd_LicenseeAccrualCurrent_label_en-US" xlink:label="lab_lgnd_LicenseeAccrualCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensee Accrual, Current</link:label>
    <link:label id="lab_lgnd_LicenseeAccrualCurrent_documentation_en-US" xlink:label="lab_lgnd_LicenseeAccrualCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensee Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseeAccrualCurrent" xlink:href="lgnd-20241231.xsd#lgnd_LicenseeAccrualCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_LicenseeAccrualCurrent" xlink:to="lab_lgnd_LicenseeAccrualCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_RoyaltyEvomelaMember_1baae004-059b-4270-adbd-ef5662bfed45_terseLabel_en-US" xlink:label="lab_lgnd_RoyaltyEvomelaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Evomela</link:label>
    <link:label id="lab_lgnd_RoyaltyEvomelaMember_label_en-US" xlink:label="lab_lgnd_RoyaltyEvomelaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty, Evomela [Member]</link:label>
    <link:label id="lab_lgnd_RoyaltyEvomelaMember_documentation_en-US" xlink:label="lab_lgnd_RoyaltyEvomelaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty, Evomela</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyEvomelaMember" xlink:href="lgnd-20241231.xsd#lgnd_RoyaltyEvomelaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_RoyaltyEvomelaMember" xlink:to="lab_lgnd_RoyaltyEvomelaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_NonCashIncomeFromFinancialRoyaltyAssets_2dfdf2d7-8ac7-47ad-bb85-6637e374ec3e_negatedTerseLabel_en-US" xlink:label="lab_lgnd_NonCashIncomeFromFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash income from financial royalty assets</link:label>
    <link:label id="lab_lgnd_NonCashIncomeFromFinancialRoyaltyAssets_label_en-US" xlink:label="lab_lgnd_NonCashIncomeFromFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash Income From Financial Royalty Assets</link:label>
    <link:label id="lab_lgnd_NonCashIncomeFromFinancialRoyaltyAssets_documentation_en-US" xlink:label="lab_lgnd_NonCashIncomeFromFinancialRoyaltyAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-cash Income From Financial Royalty Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashIncomeFromFinancialRoyaltyAssets" xlink:href="lgnd-20241231.xsd#lgnd_NonCashIncomeFromFinancialRoyaltyAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_NonCashIncomeFromFinancialRoyaltyAssets" xlink:to="lab_lgnd_NonCashIncomeFromFinancialRoyaltyAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_056f1358-21e3-434a-bbc0-e5aaa42e7bb6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_9a211d67-dfcc-4bae-8346-3f6e35f4aee8_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_61b08ce8-220c-4167-ba65-07672d775a82_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_c942b7da-a539-45b0-8f4d-675736a345e4_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_990f08f2-c8ce-4dce-baee-db758aa0a119_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_685e3f2d-2bd0-4500-be7e-24b4519346df_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated amortization expense for 2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b1a586cb-a8d7-4d8a-8935-cad8e3a41f2b_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_aed7f3fa-b552-4bae-9a5a-823a23725c8a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_74806fa8-3bcf-47a8-b410-0d95ec55b950_verboseLabel_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_label_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Costs and Expenses [Abstract]</link:label>
    <link:label id="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_documentation_en-US" xlink:label="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract" xlink:to="lab_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyAgreementsMember_b36fcc83-b9cb-4dad-950e-1426feda4d33_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Agreements</link:label>
    <link:label id="lab_us-gaap_RoyaltyAgreementsMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyAgreementsMember" xlink:to="lab_us-gaap_RoyaltyAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_0874a28b-0c3d-4b75-b3dd-406c2af4dbe6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_03b99766-f420-430d-916a-066b68dc44a2_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_089b7714-1229-4796-94cc-133bbca0c509_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_c891471e-3603-4ded-b4a3-87c6874b2dfa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decrease in value of investment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_28584028-62ec-478f-b623-485df999b98d_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a92d4781-e9e1-4410-8d45-6eb1195577f5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_059a673e-8605-4cae-b9b4-d1a5e4f36610_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_13ea6aac-8968-4f6d-a428-d57ddac8e8b6_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Account Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PaymentsforConvertibleBondHedges_99ba71df-53ea-4884-960b-8b58267c8fff_terseLabel_en-US" xlink:label="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for convertible bond hedges</link:label>
    <link:label id="lab_lgnd_PaymentsforConvertibleBondHedges_label_en-US" xlink:label="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Convertible Bond Hedges</link:label>
    <link:label id="lab_lgnd_PaymentsforConvertibleBondHedges_documentation_en-US" xlink:label="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments for Convertible Bond Hedges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsforConvertibleBondHedges" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsforConvertibleBondHedges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PaymentsforConvertibleBondHedges" xlink:to="lab_lgnd_PaymentsforConvertibleBondHedges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_82bc5a7b-445a-4bcc-a9f6-170b400adf13_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_2fa301fa-6f0e-41a3-8ef6-2db00847d0a4_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputSharePriceMember" xlink:to="lab_us-gaap_MeasurementInputSharePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_2f54ae69-c048-48a5-b2de-d3022f53fd37_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_87795ecd-cccd-4eef-8548-e999b548149a_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_d57a028f-cf13-4f44-9d17-7dd9c2bb55f1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_954b5f14-92e1-4cf1-afe2-9064030f8a86_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_ab28ed30-708e-4604-b1b4-8de65123300d_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_fe5ebf47-be38-407b-aa0c-405162312444_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_69a1ed4d-ecd9-42b9-ab80-8be308da3061_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_03f3d2d4-7c0c-4aa0-9e24-2ece00c3769a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_OfficeInJupiterFloridaMember_815bf553-69d0-4494-866e-3a337c228ddd_terseLabel_en-US" xlink:label="lab_lgnd_OfficeInJupiterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office in Jupiter, Florida</link:label>
    <link:label id="lab_lgnd_OfficeInJupiterFloridaMember_label_en-US" xlink:label="lab_lgnd_OfficeInJupiterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office in Jupiter Florida [Member]</link:label>
    <link:label id="lab_lgnd_OfficeInJupiterFloridaMember_documentation_en-US" xlink:label="lab_lgnd_OfficeInJupiterFloridaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Office in Jupiter Florida</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OfficeInJupiterFloridaMember" xlink:href="lgnd-20241231.xsd#lgnd_OfficeInJupiterFloridaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_OfficeInJupiterFloridaMember" xlink:to="lab_lgnd_OfficeInJupiterFloridaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_20123312-204f-4f95-bbff-6bceef5b952d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_5b888e37-ed65-4071-87b2-55c16cf68102_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_c73b4269-dc7b-4724-aea0-46392851a5f7_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_092a3e11-7be6-40e2-8f6d-6d82805886b4_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retain earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_0e650179-c83f-4d83-b421-3a5a1fc43641_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Long Term Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_54efc781-3f29-44d5-9588-c5f11df68079_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount_bff0e72f-3957-4ff7-8ea9-ca25200a24b4_terseLabel_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Officer compensation</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount_label_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Officer Compensation, Amount</link:label>
    <link:label id="lab_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount_documentation_en-US" xlink:label="lab_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Officer Compensation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" xlink:href="lgnd-20241231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" xlink:to="lab_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_7fcf3876-23ee-400b-b56b-947771e1913c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_f6769f11-c9f2-4576-a165-ead00dc30122_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upper range of exercise prices (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryInvestmentHoldingsTextBlock_94ab6be8-57c3-4132-9222-fc0f8b92f918_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryInvestmentHoldingsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Investment Holdings</link:label>
    <link:label id="lab_us-gaap_SummaryInvestmentHoldingsTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryInvestmentHoldingsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Investment Holdings [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryInvestmentHoldingsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryInvestmentHoldingsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryInvestmentHoldingsTextBlock" xlink:to="lab_us-gaap_SummaryInvestmentHoldingsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e10c9f01-32ea-4235-9be8-6c188ec65e18_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate_566075e2-e58b-4e8d-98e1-868e6032e515_terseLabel_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration paid to date</link:label>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate_label_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Consideration Paid to Date</link:label>
    <link:label id="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate_documentation_en-US" xlink:label="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Commitment, Consideration Paid to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:href="lgnd-20241231.xsd#lgnd_PurchaseCommitmentConsiderationPaidToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:to="lab_lgnd_PurchaseCommitmentConsiderationPaidToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0e7f2fde-8ab4-425a-a71b-f61004b69759_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_d17be3c9-6444-4735-b5bb-2c56528bea8f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate202006Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdate202006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate202006Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate202006Member" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>lgnd-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:8c134d1d-ab0c-4379-9892-d916b4e62e37,g:28b275e3-fcb1-4a6c-a0ef-95ede04b9eea-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ligand.com/role/Cover" xlink:type="simple" xlink:href="lgnd-20241231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_89878e2f-8b7a-4d32-9fd3-28742fb69db8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_DocumentType_89878e2f-8b7a-4d32-9fd3-28742fb69db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_61c24a99-03fc-4da4-a3b7-75238bc19c4e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_DocumentAnnualReport_61c24a99-03fc-4da4-a3b7-75238bc19c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f45f63c1-d9c0-4dea-9330-52a3cd25d7d3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_DocumentPeriodEndDate_f45f63c1-d9c0-4dea-9330-52a3cd25d7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_cea72e96-449b-402b-a0eb-c754c524c766" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_CurrentFiscalYearEndDate_cea72e96-449b-402b-a0eb-c754c524c766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_9795af09-a08d-4240-a68d-d25c97357ba0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_DocumentTransitionReport_9795af09-a08d-4240-a68d-d25c97357ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_62342548-78fc-4ecc-a0b3-41d62ea7312c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_EntityFileNumber_62342548-78fc-4ecc-a0b3-41d62ea7312c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_6bd4b3ba-a86b-46ef-b9e6-a1f3633711d7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_EntityRegistrantName_6bd4b3ba-a86b-46ef-b9e6-a1f3633711d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_328c8b84-afb2-421b-a905-f40fdd023a9f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_EntityIncorporationStateCountryCode_328c8b84-afb2-421b-a905-f40fdd023a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c1eaac82-f2ee-4106-b472-7083054aa9d5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_EntityTaxIdentificationNumber_c1eaac82-f2ee-4106-b472-7083054aa9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_82ecb213-90cc-4865-8d06-2d91e18e1811" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_EntityAddressAddressLine1_82ecb213-90cc-4865-8d06-2d91e18e1811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_1fd77ba3-70e0-419e-a141-702c29330393" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_EntityAddressCityOrTown_1fd77ba3-70e0-419e-a141-702c29330393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_fee8a66d-d868-4a8d-864c-29b3d8933bce" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_EntityAddressStateOrProvince_fee8a66d-d868-4a8d-864c-29b3d8933bce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8a081217-b933-47bf-a1f9-6948ee476bc6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_EntityAddressPostalZipCode_8a081217-b933-47bf-a1f9-6948ee476bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3cfa0e3b-9a06-4130-9263-94a131565c44" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_CityAreaCode_3cfa0e3b-9a06-4130-9263-94a131565c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_3d7e1418-729d-4811-a4ca-8233c4f6eeae" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_LocalPhoneNumber_3d7e1418-729d-4811-a4ca-8233c4f6eeae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_16d863c6-fc95-46a5-8230-c3636d62e544" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_Security12bTitle_16d863c6-fc95-46a5-8230-c3636d62e544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_6c5a2e2b-053b-45f5-a770-3d1ea2f679b0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_TradingSymbol_6c5a2e2b-053b-45f5-a770-3d1ea2f679b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2f20cf14-455c-4c4b-8242-1bf4c7a3d879" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_SecurityExchangeName_2f20cf14-455c-4c4b-8242-1bf4c7a3d879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_f1dc5bd9-e893-455f-9a62-e1d44ec6ec4e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_f1dc5bd9-e893-455f-9a62-e1d44ec6ec4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_7af5b07c-7b8b-487c-a3ff-13f7dfb8f648" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_EntityVoluntaryFilers_7af5b07c-7b8b-487c-a3ff-13f7dfb8f648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d4302682-22f2-426e-a59f-53d1f9c9a641" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_EntityCurrentReportingStatus_d4302682-22f2-426e-a59f-53d1f9c9a641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_31cce93f-b796-407b-99ff-db20e5a56145" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_EntityInteractiveDataCurrent_31cce93f-b796-407b-99ff-db20e5a56145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b7e3752d-c8a6-4b8d-ac3e-499df7ec1f2d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_EntityFilerCategory_b7e3752d-c8a6-4b8d-ac3e-499df7ec1f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_aca9522e-de1a-4f0a-959a-527f536ec018" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_EntitySmallBusiness_aca9522e-de1a-4f0a-959a-527f536ec018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c2cf6a1b-16d2-48be-bffa-950266498990" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_EntityEmergingGrowthCompany_c2cf6a1b-16d2-48be-bffa-950266498990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_4d529eae-662d-4410-94cd-5bfadbd7eb1a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_IcfrAuditorAttestationFlag_4d529eae-662d-4410-94cd-5bfadbd7eb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_9c27430d-22e9-4ecd-9915-f2a48f9912f3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_9c27430d-22e9-4ecd-9915-f2a48f9912f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5f1ec3c7-a1b1-4291-9190-7ef0188fb819" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_EntityShellCompany_5f1ec3c7-a1b1-4291-9190-7ef0188fb819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_3503c8c2-f6e2-4e25-805e-43e4a2d5c42b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_EntityPublicFloat_3503c8c2-f6e2-4e25-805e-43e4a2d5c42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3a9aee52-8765-4b5e-8a39-69e2796ec7e7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3a9aee52-8765-4b5e-8a39-69e2796ec7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_cecd2249-a81c-48e5-81e0-8aed88a3a912" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_cecd2249-a81c-48e5-81e0-8aed88a3a912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_6a864096-f496-4111-9e51-a9c6bbc093d1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_AmendmentFlag_6a864096-f496-4111-9e51-a9c6bbc093d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_de6ccaea-a09a-47cf-b57e-de57ec671c53" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_DocumentFiscalYearFocus_de6ccaea-a09a-47cf-b57e-de57ec671c53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_886539df-a2b7-41e5-8c14-9c1c914296da" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_DocumentFiscalPeriodFocus_886539df-a2b7-41e5-8c14-9c1c914296da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_df739613-35b1-4f3b-82a3-0b5ff4481059" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_b695e9e1-6f1f-417a-9bcf-1e175b69579d" xlink:to="loc_dei_EntityCentralIndexKey_df739613-35b1-4f3b-82a3-0b5ff4481059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AuditInformation" xlink:type="simple" xlink:href="lgnd-20241231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AuditInformationAbstract_51d9d5f8-e2e5-46e5-a756-624ad81bbbe1" xlink:href="lgnd-20241231.xsd#lgnd_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_8af2dd44-e5fd-4deb-8aef-c002e5f01c5f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_AuditInformationAbstract_51d9d5f8-e2e5-46e5-a756-624ad81bbbe1" xlink:to="loc_dei_AuditorName_8af2dd44-e5fd-4deb-8aef-c002e5f01c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_4dc345bf-1398-425c-bff0-d9df567a07f4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_AuditInformationAbstract_51d9d5f8-e2e5-46e5-a756-624ad81bbbe1" xlink:to="loc_dei_AuditorLocation_4dc345bf-1398-425c-bff0-d9df567a07f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_49ac810f-c0cb-4105-8374-778f88f14d9e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_AuditInformationAbstract_51d9d5f8-e2e5-46e5-a756-624ad81bbbe1" xlink:to="loc_dei_AuditorFirmId_49ac810f-c0cb-4105-8374-778f88f14d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="lgnd-20241231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d330fd17-9a3f-4ec8-b772-e57fcd266121" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_17a3b52c-1d1f-44e4-832a-a9cef231cadb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d330fd17-9a3f-4ec8-b772-e57fcd266121" xlink:to="loc_us-gaap_AssetsAbstract_17a3b52c-1d1f-44e4-832a-a9cef231cadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_9dbd31af-4c55-4866-b4c1-0f8b1ec3d4cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17a3b52c-1d1f-44e4-832a-a9cef231cadb" xlink:to="loc_us-gaap_AssetsCurrentAbstract_9dbd31af-4c55-4866-b4c1-0f8b1ec3d4cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3d831286-cb5d-40a5-8b41-00ec28a9b463" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dbd31af-4c55-4866-b4c1-0f8b1ec3d4cc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3d831286-cb5d-40a5-8b41-00ec28a9b463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_5ceb1863-c496-4819-a064-6e79e916d1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dbd31af-4c55-4866-b4c1-0f8b1ec3d4cc" xlink:to="loc_us-gaap_ShortTermInvestments_5ceb1863-c496-4819-a064-6e79e916d1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_51c3121c-3635-4ea5-8179-fcd21ce9b002" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dbd31af-4c55-4866-b4c1-0f8b1ec3d4cc" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_51c3121c-3635-4ea5-8179-fcd21ce9b002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d0fdf3b7-c7a7-468f-9f6a-0eaa9490dd39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dbd31af-4c55-4866-b4c1-0f8b1ec3d4cc" xlink:to="loc_us-gaap_InventoryNet_d0fdf3b7-c7a7-468f-9f6a-0eaa9490dd39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_e3fc31c0-acfc-437d-b915-13ea8eaf0d23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dbd31af-4c55-4866-b4c1-0f8b1ec3d4cc" xlink:to="loc_us-gaap_IncomeTaxesReceivable_e3fc31c0-acfc-437d-b915-13ea8eaf0d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_70925c9f-88e7-4f56-88fb-db49b5d97517" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dbd31af-4c55-4866-b4c1-0f8b1ec3d4cc" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_70925c9f-88e7-4f56-88fb-db49b5d97517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_faca165c-84f6-4149-ad2f-74bf454b97e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dbd31af-4c55-4866-b4c1-0f8b1ec3d4cc" xlink:to="loc_us-gaap_OtherAssetsCurrent_faca165c-84f6-4149-ad2f-74bf454b97e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f16c7ddb-80e0-460d-b5ee-60d809237a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_9dbd31af-4c55-4866-b4c1-0f8b1ec3d4cc" xlink:to="loc_us-gaap_AssetsCurrent_f16c7ddb-80e0-460d-b5ee-60d809237a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a28adb63-28d5-4db1-b992-b8880117f9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17a3b52c-1d1f-44e4-832a-a9cef231cadb" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a28adb63-28d5-4db1-b992-b8880117f9a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f804f35b-83d6-4db8-9b44-81d1f30c85f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17a3b52c-1d1f-44e4-832a-a9cef231cadb" xlink:to="loc_us-gaap_Goodwill_f804f35b-83d6-4db8-9b44-81d1f30c85f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsNonCurrent_54f1e380-e870-4f58-881c-985f5a71046c" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsNonCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17a3b52c-1d1f-44e4-832a-a9cef231cadb" xlink:to="loc_lgnd_FinancialRoyaltyAssetsNonCurrent_54f1e380-e870-4f58-881c-985f5a71046c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_b18a66d4-618e-4ceb-8598-215ad7063839" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17a3b52c-1d1f-44e4-832a-a9cef231cadb" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_b18a66d4-618e-4ceb-8598-215ad7063839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_72540487-3e6a-42de-ac1a-1f60c9226550" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17a3b52c-1d1f-44e4-832a-a9cef231cadb" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_72540487-3e6a-42de-ac1a-1f60c9226550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_d56cbd26-bf41-451a-bd2d-d2b6c24e341b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17a3b52c-1d1f-44e4-832a-a9cef231cadb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_d56cbd26-bf41-451a-bd2d-d2b6c24e341b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_1ef54804-8a63-44d4-a76c-b32e3676839b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17a3b52c-1d1f-44e4-832a-a9cef231cadb" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_1ef54804-8a63-44d4-a76c-b32e3676839b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_3452c890-cb01-4459-a304-17cfbcaf4207" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17a3b52c-1d1f-44e4-832a-a9cef231cadb" xlink:to="loc_us-gaap_EquityMethodInvestments_3452c890-cb01-4459-a304-17cfbcaf4207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_47431205-f0dc-4d29-a0c9-a23e39743ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17a3b52c-1d1f-44e4-832a-a9cef231cadb" xlink:to="loc_us-gaap_OtherInvestments_47431205-f0dc-4d29-a0c9-a23e39743ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_1ab82017-7a23-41f9-8727-36c408013873" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17a3b52c-1d1f-44e4-832a-a9cef231cadb" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_1ab82017-7a23-41f9-8727-36c408013873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_68bd763e-ef7d-4489-9cb3-8cfc96dbb88c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17a3b52c-1d1f-44e4-832a-a9cef231cadb" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_68bd763e-ef7d-4489-9cb3-8cfc96dbb88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0a548701-56b5-431f-92ba-3c55d7736e56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_17a3b52c-1d1f-44e4-832a-a9cef231cadb" xlink:to="loc_us-gaap_Assets_0a548701-56b5-431f-92ba-3c55d7736e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c87b7231-379b-4ffd-87ef-c5493d5fee89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d330fd17-9a3f-4ec8-b772-e57fcd266121" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c87b7231-379b-4ffd-87ef-c5493d5fee89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_cebb52e2-22fd-4c0a-8434-494fa94adac7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c87b7231-379b-4ffd-87ef-c5493d5fee89" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_cebb52e2-22fd-4c0a-8434-494fa94adac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_d0027e5d-623a-4d9c-8f54-13b765ed4401" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cebb52e2-22fd-4c0a-8434-494fa94adac7" xlink:to="loc_us-gaap_AccountsPayableCurrent_d0027e5d-623a-4d9c-8f54-13b765ed4401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_93957866-123e-4e95-9ef3-19725df574b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cebb52e2-22fd-4c0a-8434-494fa94adac7" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_93957866-123e-4e95-9ef3-19725df574b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_6b6d9b1f-f5aa-4637-b491-86e41f361891" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cebb52e2-22fd-4c0a-8434-494fa94adac7" xlink:to="loc_us-gaap_TaxesPayableCurrent_6b6d9b1f-f5aa-4637-b491-86e41f361891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cc424741-c8db-4fc3-8547-7bebf16921f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cebb52e2-22fd-4c0a-8434-494fa94adac7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cc424741-c8db-4fc3-8547-7bebf16921f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_ab16492f-12de-47dc-98d1-ba1137d5841f" xlink:href="lgnd-20241231.xsd#lgnd_CurrentPortionOfLiabilityForContingentValueRights"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cebb52e2-22fd-4c0a-8434-494fa94adac7" xlink:to="loc_lgnd_CurrentPortionOfLiabilityForContingentValueRights_ab16492f-12de-47dc-98d1-ba1137d5841f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_55775ab1-4c01-4690-be1e-b3a1b151856a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cebb52e2-22fd-4c0a-8434-494fa94adac7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_55775ab1-4c01-4690-be1e-b3a1b151856a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_b001de0d-8123-4eff-a852-5f348f30c41c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cebb52e2-22fd-4c0a-8434-494fa94adac7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_b001de0d-8123-4eff-a852-5f348f30c41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cc8336c3-b730-4cd3-b42a-a1532b8b0752" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_cebb52e2-22fd-4c0a-8434-494fa94adac7" xlink:to="loc_us-gaap_LiabilitiesCurrent_cc8336c3-b730-4cd3-b42a-a1532b8b0752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeNoncurrent_1305fb4e-5510-49cf-ba8b-a4de4603cdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c87b7231-379b-4ffd-87ef-c5493d5fee89" xlink:to="loc_us-gaap_DeferredIncomeNoncurrent_1305fb4e-5510-49cf-ba8b-a4de4603cdf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LiabilityForContingentValueRights_76ee7140-d2ff-4e33-b6bf-760cf26ebb41" xlink:href="lgnd-20241231.xsd#lgnd_LiabilityForContingentValueRights"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c87b7231-379b-4ffd-87ef-c5493d5fee89" xlink:to="loc_lgnd_LiabilityForContingentValueRights_76ee7140-d2ff-4e33-b6bf-760cf26ebb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2ef29027-54df-408a-b940-fc9ac750ff6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c87b7231-379b-4ffd-87ef-c5493d5fee89" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2ef29027-54df-408a-b940-fc9ac750ff6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3cc1d6b5-bb92-47b8-abec-ee50a09737dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c87b7231-379b-4ffd-87ef-c5493d5fee89" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3cc1d6b5-bb92-47b8-abec-ee50a09737dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_fe0e4bcf-fc71-42e4-883a-1b23ee2d135b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c87b7231-379b-4ffd-87ef-c5493d5fee89" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_fe0e4bcf-fc71-42e4-883a-1b23ee2d135b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_52595f81-79ba-457b-b343-0bbf8da7b0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c87b7231-379b-4ffd-87ef-c5493d5fee89" xlink:to="loc_us-gaap_Liabilities_52595f81-79ba-457b-b343-0bbf8da7b0cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_03b51674-cbc6-4244-83eb-98cd3737cc19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c87b7231-379b-4ffd-87ef-c5493d5fee89" xlink:to="loc_us-gaap_CommitmentsAndContingencies_03b51674-cbc6-4244-83eb-98cd3737cc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2984352b-fb6b-4033-b2a8-29c51166817d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c87b7231-379b-4ffd-87ef-c5493d5fee89" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2984352b-fb6b-4033-b2a8-29c51166817d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a8be56fe-b007-413f-a9dd-55fdc1b98766" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2984352b-fb6b-4033-b2a8-29c51166817d" xlink:to="loc_us-gaap_PreferredStockValue_a8be56fe-b007-413f-a9dd-55fdc1b98766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b3159389-cb3e-4910-bed1-e503efb52087" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2984352b-fb6b-4033-b2a8-29c51166817d" xlink:to="loc_us-gaap_CommonStockValue_b3159389-cb3e-4910-bed1-e503efb52087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_7831f601-ab1f-4aea-b40a-c9561c9cf06d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2984352b-fb6b-4033-b2a8-29c51166817d" xlink:to="loc_us-gaap_AdditionalPaidInCapital_7831f601-ab1f-4aea-b40a-c9561c9cf06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5b293571-1d12-4185-9880-4123ee73925d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2984352b-fb6b-4033-b2a8-29c51166817d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5b293571-1d12-4185-9880-4123ee73925d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c0bba647-8a95-43b1-a99e-3ad83f0284ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2984352b-fb6b-4033-b2a8-29c51166817d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c0bba647-8a95-43b1-a99e-3ad83f0284ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fcb8e0ec-4ee0-4ac8-88b5-365ca9eb6ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2984352b-fb6b-4033-b2a8-29c51166817d" xlink:to="loc_us-gaap_StockholdersEquity_fcb8e0ec-4ee0-4ac8-88b5-365ca9eb6ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1cacd206-f9c5-4a11-9d95-ee15fd190fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c87b7231-379b-4ffd-87ef-c5493d5fee89" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1cacd206-f9c5-4a11-9d95-ee15fd190fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="lgnd-20241231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7783695a-d4df-4a76-ac80-408e9ef2f778" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5596abdd-5228-471c-8cf8-6ea6fbef8a62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7783695a-d4df-4a76-ac80-408e9ef2f778" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5596abdd-5228-471c-8cf8-6ea6fbef8a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_876385b6-3693-450e-aa7f-2eabb2bb8050" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7783695a-d4df-4a76-ac80-408e9ef2f778" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_876385b6-3693-450e-aa7f-2eabb2bb8050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7c5eaa05-0e1e-425d-aa05-eb1d58601195" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7783695a-d4df-4a76-ac80-408e9ef2f778" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7c5eaa05-0e1e-425d-aa05-eb1d58601195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_adddd965-3b1c-462b-ba73-9b529644dfcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7783695a-d4df-4a76-ac80-408e9ef2f778" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_adddd965-3b1c-462b-ba73-9b529644dfcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_fb4447f7-a6f2-45f6-a480-a8e36c9e444d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7783695a-d4df-4a76-ac80-408e9ef2f778" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_fb4447f7-a6f2-45f6-a480-a8e36c9e444d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1eb1e504-062a-47d3-9f9b-ab82ca6e3268" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7783695a-d4df-4a76-ac80-408e9ef2f778" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1eb1e504-062a-47d3-9f9b-ab82ca6e3268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a166a850-055a-4dc6-88bb-6cc6e7fe7aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7783695a-d4df-4a76-ac80-408e9ef2f778" xlink:to="loc_us-gaap_CommonStockSharesIssued_a166a850-055a-4dc6-88bb-6cc6e7fe7aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2f208115-4340-419a-9f28-bd7d2faacee4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7783695a-d4df-4a76-ac80-408e9ef2f778" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2f208115-4340-419a-9f28-bd7d2faacee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="lgnd-20241231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_fc235eaa-a177-4595-8ebb-4defa40c3d40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_ec366523-c2fd-455a-b09a-9e269b6d0ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fc235eaa-a177-4595-8ebb-4defa40c3d40" xlink:to="loc_us-gaap_StatementTable_ec366523-c2fd-455a-b09a-9e269b6d0ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0fad5cdd-f19c-4613-b4ec-3c4cee759a0a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ec366523-c2fd-455a-b09a-9e269b6d0ee4" xlink:to="loc_srt_ProductOrServiceAxis_0fad5cdd-f19c-4613-b4ec-3c4cee759a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eb2bcab4-04a1-45ad-88ca-62afd73f62cb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0fad5cdd-f19c-4613-b4ec-3c4cee759a0a" xlink:to="loc_srt_ProductsAndServicesDomain_eb2bcab4-04a1-45ad-88ca-62afd73f62cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_e941b5ef-388f-4e5f-bd81-47f8fedaa68d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eb2bcab4-04a1-45ad-88ca-62afd73f62cb" xlink:to="loc_us-gaap_RoyaltyMember_e941b5ef-388f-4e5f-bd81-47f8fedaa68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IntangibleRoyaltyAssetsMember_40c5f2cd-16e9-4068-8fef-5f837c821165" xlink:href="lgnd-20241231.xsd#lgnd_IntangibleRoyaltyAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_e941b5ef-388f-4e5f-bd81-47f8fedaa68d" xlink:to="loc_lgnd_IntangibleRoyaltyAssetsMember_40c5f2cd-16e9-4068-8fef-5f837c821165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsMember_72d4d273-0994-471b-9ee2-9b69de8c8821" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_e941b5ef-388f-4e5f-bd81-47f8fedaa68d" xlink:to="loc_lgnd_FinancialRoyaltyAssetsMember_72d4d273-0994-471b-9ee2-9b69de8c8821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_dbe3d144-927d-4df4-8d08-8f91340ee5f1" xlink:href="lgnd-20241231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eb2bcab4-04a1-45ad-88ca-62afd73f62cb" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_dbe3d144-927d-4df4-8d08-8f91340ee5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueAndOtherIncomeMember_3e8a4a6f-5e4b-442b-b767-1e1062ac38be" xlink:href="lgnd-20241231.xsd#lgnd_ContractRevenueAndOtherIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_eb2bcab4-04a1-45ad-88ca-62afd73f62cb" xlink:to="loc_lgnd_ContractRevenueAndOtherIncomeMember_3e8a4a6f-5e4b-442b-b767-1e1062ac38be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_ec366523-c2fd-455a-b09a-9e269b6d0ee4" xlink:to="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_685b96e0-8eec-48de-a36f-407a4e55a701" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_RevenuesAbstract_685b96e0-8eec-48de-a36f-407a4e55a701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_35934040-568f-468c-89e0-ed3a4ff2d9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_685b96e0-8eec-48de-a36f-407a4e55a701" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_35934040-568f-468c-89e0-ed3a4ff2d9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpensesAbstract_342aac4c-ca2f-4f6d-848e-3b2557432bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_OperatingCostsAndExpensesAbstract_342aac4c-ca2f-4f6d-848e-3b2557432bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostDirectMaterial_29d8897d-8f84-4540-b7ad-ed78ce8d37e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostDirectMaterial"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_342aac4c-ca2f-4f6d-848e-3b2557432bfb" xlink:to="loc_us-gaap_CostDirectMaterial_29d8897d-8f84-4540-b7ad-ed78ce8d37e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_18505dcd-ebe3-4103-84ae-ce02e4c580ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_342aac4c-ca2f-4f6d-848e-3b2557432bfb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_18505dcd-ebe3-4103-84ae-ce02e4c580ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_558a2660-a0ce-4110-95f5-24d849edad0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_342aac4c-ca2f-4f6d-848e-3b2557432bfb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_558a2660-a0ce-4110-95f5-24d849edad0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_cc8cd605-24a8-4ae1-b758-d412e379e52c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_342aac4c-ca2f-4f6d-848e-3b2557432bfb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_cc8cd605-24a8-4ae1-b758-d412e379e52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c877132f-1fcd-4b77-a80f-a917b6c8aaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_342aac4c-ca2f-4f6d-848e-3b2557432bfb" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_c877132f-1fcd-4b77-a80f-a917b6c8aaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_3384e06c-21bf-41f6-bd84-980b66d9f5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_342aac4c-ca2f-4f6d-848e-3b2557432bfb" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_3384e06c-21bf-41f6-bd84-980b66d9f5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_0950f046-f818-44b1-af80-d700bad7f315" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingCostsAndExpensesAbstract_342aac4c-ca2f-4f6d-848e-3b2557432bfb" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_0950f046-f818-44b1-af80-d700bad7f315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_3005550d-a81d-4be3-871b-db649b6aab0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_3005550d-a81d-4be3-871b-db649b6aab0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_74941871-ffe0-4f97-b9bb-2ba1bb8d48d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_OperatingIncomeLoss_74941871-ffe0-4f97-b9bb-2ba1bb8d48d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_97cc24fb-25bb-485c-9045-c02d3ea1e544" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_97cc24fb-25bb-485c-9045-c02d3ea1e544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_096e9d5e-1de3-4c52-8621-a04b1bb79ada" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_97cc24fb-25bb-485c-9045-c02d3ea1e544" xlink:to="loc_us-gaap_GainLossOnInvestments_096e9d5e-1de3-4c52-8621-a04b1bb79ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_89495922-f4af-4919-bfa4-68c52f247997" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_97cc24fb-25bb-485c-9045-c02d3ea1e544" xlink:to="loc_us-gaap_InvestmentIncomeInterest_89495922-f4af-4919-bfa4-68c52f247997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_e811ae35-195a-4ad3-92cc-8d1446db02ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_97cc24fb-25bb-485c-9045-c02d3ea1e544" xlink:to="loc_us-gaap_InterestExpenseNonoperating_e811ae35-195a-4ad3-92cc-8d1446db02ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6a19f033-f94b-4012-a5f8-e15e9630fbeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_97cc24fb-25bb-485c-9045-c02d3ea1e544" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6a19f033-f94b-4012-a5f8-e15e9630fbeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8de67a66-99f1-4f90-8a30-3fe6077a9387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_97cc24fb-25bb-485c-9045-c02d3ea1e544" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8de67a66-99f1-4f90-8a30-3fe6077a9387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_730ad9af-a391-4418-b3d6-44dd8a3a0855" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_730ad9af-a391-4418-b3d6-44dd8a3a0855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a8669c98-b4a3-47b0-8b05-bc83fe849f29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a8669c98-b4a3-47b0-8b05-bc83fe849f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_0f854bc0-3c01-4c46-b8cf-880143c2f3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_0f854bc0-3c01-4c46-b8cf-880143c2f3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b7d6c9db-edc2-46fc-9bb8-bd7028742f35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_b7d6c9db-edc2-46fc-9bb8-bd7028742f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_319b5f7b-1ae4-42d8-a038-a5adc080e30f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_NetIncomeLoss_319b5f7b-1ae4-42d8-a038-a5adc080e30f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b0658d0b-79d5-49d6-bbad-3822e2fdcddb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b0658d0b-79d5-49d6-bbad-3822e2fdcddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_cd0d5516-862d-4c03-93d2-422760d17de9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_cd0d5516-862d-4c03-93d2-422760d17de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7b8a96aa-556f-4124-9964-1d711a99b996" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_EarningsPerShareBasic_7b8a96aa-556f-4124-9964-1d711a99b996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_581e1a8a-2c8f-4281-af30-827b5db38ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_581e1a8a-2c8f-4281-af30-827b5db38ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_7e020a7d-b135-488f-98c7-ead42f15dd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_7e020a7d-b135-488f-98c7-ead42f15dd3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_1a81cb7b-e0ac-48f1-a226-db044ad5bd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_1a81cb7b-e0ac-48f1-a226-db044ad5bd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6829d89a-de6f-450a-a435-4b03fc7d51c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6829d89a-de6f-450a-a435-4b03fc7d51c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_03e2b33b-ffe2-4e3f-a991-054dcd6e48b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_776f3f7e-9f15-4ca8-9a29-0dbea11343a2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_03e2b33b-ffe2-4e3f-a991-054dcd6e48b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="simple" xlink:href="lgnd-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_59b44000-7e6d-456d-8dd4-1c800ebab522" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b37f40a2-9f26-4854-8b7f-2dc86a2fae9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_59b44000-7e6d-456d-8dd4-1c800ebab522" xlink:to="loc_us-gaap_NetIncomeLoss_b37f40a2-9f26-4854-8b7f-2dc86a2fae9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b78e9aa2-5b85-4504-8d83-0c06b3914c10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_59b44000-7e6d-456d-8dd4-1c800ebab522" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_b78e9aa2-5b85-4504-8d83-0c06b3914c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_584b4c71-a3b5-49ab-b773-553787c8fe56" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_59b44000-7e6d-456d-8dd4-1c800ebab522" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_584b4c71-a3b5-49ab-b773-553787c8fe56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_054f127c-91a3-4329-bf81-eb435ae36df3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_59b44000-7e6d-456d-8dd4-1c800ebab522" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_054f127c-91a3-4329-bf81-eb435ae36df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="lgnd-20241231.xsd#CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_51b000f5-904a-4c14-bc04-c8e1e8dd3472" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4fb5a648-e8f3-4025-94a1-91fd991505b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_51b000f5-904a-4c14-bc04-c8e1e8dd3472" xlink:to="loc_us-gaap_StatementTable_4fb5a648-e8f3-4025-94a1-91fd991505b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6d1fd264-c0aa-4753-bdcd-5b51cc4a8f20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4fb5a648-e8f3-4025-94a1-91fd991505b1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6d1fd264-c0aa-4753-bdcd-5b51cc4a8f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_76e4c569-4d7c-446e-b243-9d7775e6954c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6d1fd264-c0aa-4753-bdcd-5b51cc4a8f20" xlink:to="loc_us-gaap_EquityComponentDomain_76e4c569-4d7c-446e-b243-9d7775e6954c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e968c2ce-1f59-462c-b02d-90288aceb7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_76e4c569-4d7c-446e-b243-9d7775e6954c" xlink:to="loc_us-gaap_CommonStockMember_e968c2ce-1f59-462c-b02d-90288aceb7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_d4abef03-2180-4868-93cb-19bb1a04563e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_76e4c569-4d7c-446e-b243-9d7775e6954c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_d4abef03-2180-4868-93cb-19bb1a04563e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_172781f6-b056-4b46-8f8e-f144af5b4506" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_76e4c569-4d7c-446e-b243-9d7775e6954c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_172781f6-b056-4b46-8f8e-f144af5b4506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_100679af-0242-48fd-9b1b-4e0c3919678b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_76e4c569-4d7c-446e-b243-9d7775e6954c" xlink:to="loc_us-gaap_RetainedEarningsMember_100679af-0242-48fd-9b1b-4e0c3919678b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cefb75b0-536d-47ad-a46c-3976f39def60" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4fb5a648-e8f3-4025-94a1-91fd991505b1" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cefb75b0-536d-47ad-a46c-3976f39def60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c27bc332-df51-414d-b61c-b890ff65ca50" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_cefb75b0-536d-47ad-a46c-3976f39def60" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c27bc332-df51-414d-b61c-b890ff65ca50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4025b45a-7b38-4eca-afc5-38a223cde0d5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_c27bc332-df51-414d-b61c-b890ff65ca50" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_4025b45a-7b38-4eca-afc5-38a223cde0d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_4f289711-1f24-42d6-bfc1-dc4d47d93cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4fb5a648-e8f3-4025-94a1-91fd991505b1" xlink:to="loc_us-gaap_StatementLineItems_4f289711-1f24-42d6-bfc1-dc4d47d93cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_4f289711-1f24-42d6-bfc1-dc4d47d93cbe" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8c26cdc7-a7c4-4be5-ad46-d62a78ceeffd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8c26cdc7-a7c4-4be5-ad46-d62a78ceeffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3582ff2a-bb0c-4ab6-bd9f-20bc156d5a58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_StockholdersEquity_3582ff2a-bb0c-4ab6-bd9f-20bc156d5a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_33f6a3da-84c2-495f-8cfc-060774d95982" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_33f6a3da-84c2-495f-8cfc-060774d95982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c0bcaf32-c518-4ee6-a3f2-28ca5a9b038f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_c0bcaf32-c518-4ee6-a3f2-28ca5a9b038f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2433e666-254f-4679-8137-35f5fcc19687" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2433e666-254f-4679-8137-35f5fcc19687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6fa062db-06ef-40db-9d61-5d450d339401" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6fa062db-06ef-40db-9d61-5d450d339401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0db395f7-aa0f-452e-94f4-af4a41beb42a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0db395f7-aa0f-452e-94f4-af4a41beb42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_967d6a2c-85e2-4d9c-98ae-d8831c61becb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_967d6a2c-85e2-4d9c-98ae-d8831c61becb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d9d467d8-333b-4f8e-a4d9-d52de9819751" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d9d467d8-333b-4f8e-a4d9-d52de9819751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction_4a06e686-2c71-4997-b7de-c0f38a6fe673" xlink:href="lgnd-20241231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction_4a06e686-2c71-4997-b7de-c0f38a6fe673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation_33fd9c2d-263e-4178-a54c-f06b651069e0" xlink:href="lgnd-20241231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation_33fd9c2d-263e-4178-a54c-f06b651069e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation_35e82f8a-75cc-40ee-854c-e74ca5f1c68a" xlink:href="lgnd-20241231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation_35e82f8a-75cc-40ee-854c-e74ca5f1c68a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision_f3ddce9a-b53e-413b-8635-303117b9ae1a" xlink:href="lgnd-20241231.xsd#lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision_f3ddce9a-b53e-413b-8635-303117b9ae1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3855f016-2d2a-4695-b3c3-28a692d8764f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_NetIncomeLoss_3855f016-2d2a-4695-b3c3-28a692d8764f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9b1c3f5c-65d8-4c07-b785-8557d5dc39b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_StockholdersEquity_9b1c3f5c-65d8-4c07-b785-8557d5dc39b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8e4ef09f-eac3-42c1-83d6-75c59e01d308" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_900f7c04-36dc-4cc9-9a2a-8d0af08a97d8" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8e4ef09f-eac3-42c1-83d6-75c59e01d308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="lgnd-20241231.xsd#CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3223989b-e1bc-4577-8504-e7ce7b488479" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_05901b77-fe4c-411d-9d00-335c3ef57419" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3223989b-e1bc-4577-8504-e7ce7b488479" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_05901b77-fe4c-411d-9d00-335c3ef57419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="lgnd-20241231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e03070b1-6256-4f84-a289-fc81e331674d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_bd8ed404-59d7-4453-a0c8-2ec5f690ef79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e03070b1-6256-4f84-a289-fc81e331674d" xlink:to="loc_us-gaap_StatementTable_bd8ed404-59d7-4453-a0c8-2ec5f690ef79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_af317fc1-7316-4725-a8f5-40ffbf3bd3ee" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bd8ed404-59d7-4453-a0c8-2ec5f690ef79" xlink:to="loc_srt_OwnershipAxis_af317fc1-7316-4725-a8f5-40ffbf3bd3ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_7668555f-f2a8-4959-ac8b-db32df494097" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_af317fc1-7316-4725-a8f5-40ffbf3bd3ee" xlink:to="loc_srt_OwnershipDomain_7668555f-f2a8-4959-ac8b-db32df494097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NucorionMember_4f706fa7-1061-451f-a376-907638bd78e0" xlink:href="lgnd-20241231.xsd#lgnd_NucorionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_7668555f-f2a8-4959-ac8b-db32df494097" xlink:to="loc_lgnd_NucorionMember_4f706fa7-1061-451f-a376-907638bd78e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember_ebe068f4-1fac-40ad-90a3-e2912065e368" xlink:href="lgnd-20241231.xsd#lgnd_PrimroseBioMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_7668555f-f2a8-4959-ac8b-db32df494097" xlink:to="loc_lgnd_PrimroseBioMember_ebe068f4-1fac-40ad-90a3-e2912065e368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1853032e-425b-410a-918e-9b950e7979f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bd8ed404-59d7-4453-a0c8-2ec5f690ef79" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1853032e-425b-410a-918e-9b950e7979f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36c3465f-adb2-40d8-b1a2-dab8ad46f1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1853032e-425b-410a-918e-9b950e7979f8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36c3465f-adb2-40d8-b1a2-dab8ad46f1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_APEIRONMember_78ce6ef9-36f6-4963-9690-e4018a03bd04" xlink:href="lgnd-20241231.xsd#lgnd_APEIRONMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36c3465f-adb2-40d8-b1a2-dab8ad46f1c8" xlink:to="loc_lgnd_APEIRONMember_78ce6ef9-36f6-4963-9690-e4018a03bd04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanIncMember_091e3885-40cd-4020-81e1-e0520da596f2" xlink:href="lgnd-20241231.xsd#lgnd_NovanIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_36c3465f-adb2-40d8-b1a2-dab8ad46f1c8" xlink:to="loc_lgnd_NovanIncMember_091e3885-40cd-4020-81e1-e0520da596f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_bd8ed404-59d7-4453-a0c8-2ec5f690ef79" xlink:to="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9a57d541-4ad1-443a-933d-15a7363b1169" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9a57d541-4ad1-443a-933d-15a7363b1169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fed767c0-c2ad-4c3a-bc18-4fb473741316" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9a57d541-4ad1-443a-933d-15a7363b1169" xlink:to="loc_us-gaap_NetIncomeLoss_fed767c0-c2ad-4c3a-bc18-4fb473741316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9a57d541-4ad1-443a-933d-15a7363b1169" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_043acf63-b498-40aa-b575-14b8a850ac41" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_043acf63-b498-40aa-b575-14b8a850ac41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_0b6fbd5f-290f-4009-9341-80c55a846fd2" xlink:href="lgnd-20241231.xsd#lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights_0b6fbd5f-290f-4009-9341-80c55a846fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_f84e687c-2d82-4543-b542-f67df8cdba82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_f84e687c-2d82-4543-b542-f67df8cdba82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_GainLossOnShortTermInvestments_9c60540b-6959-49e5-9917-c266d214bc14" xlink:href="lgnd-20241231.xsd#lgnd_GainLossOnShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_lgnd_GainLossOnShortTermInvestments_9c60540b-6959-49e5-9917-c266d214bc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ca1c0886-6c63-41ed-a846-6a244902fd2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_ca1c0886-6c63-41ed-a846-6a244902fd2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4ea2efea-5bf5-48d4-aa7e-1649a4253f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_4ea2efea-5bf5-48d4-aa7e-1649a4253f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_064be873-89f6-4324-aeb4-a2e696892cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_064be873-89f6-4324-aeb4-a2e696892cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_db70070d-f9a6-455e-9ab7-9f1c96f70f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_db70070d-f9a6-455e-9ab7-9f1c96f70f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NonCashIncomeFromFinancialRoyaltyAssets_740de040-7f14-47a4-b1bd-dd7427a7b04b" xlink:href="lgnd-20241231.xsd#lgnd_NonCashIncomeFromFinancialRoyaltyAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_lgnd_NonCashIncomeFromFinancialRoyaltyAssets_740de040-7f14-47a4-b1bd-dd7427a7b04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CurrentAndExpectedCreditLossAdjustment_dbf6f8f8-fc57-4c97-9384-9e95e6ff4466" xlink:href="lgnd-20241231.xsd#lgnd_CurrentAndExpectedCreditLossAdjustment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_lgnd_CurrentAndExpectedCreditLossAdjustment_dbf6f8f8-fc57-4c97-9384-9e95e6ff4466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ImpairmentLossOnFinancialRoyaltyAssets_4a5c84b3-56df-43bd-afae-51f9ce067148" xlink:href="lgnd-20241231.xsd#lgnd_ImpairmentLossOnFinancialRoyaltyAssets"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_lgnd_ImpairmentLossOnFinancialRoyaltyAssets_4a5c84b3-56df-43bd-afae-51f9ce067148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization_b961f09c-0095-449d-a3cd-fb0b25072a12" xlink:href="lgnd-20241231.xsd#lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization_b961f09c-0095-449d-a3cd-fb0b25072a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_59cabd7c-2458-4992-bfe9-9b429a97ebd7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_ShareBasedCompensation_59cabd7c-2458-4992-bfe9-9b429a97ebd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_38c7c1aa-aa42-4454-8618-2949862d881f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_38c7c1aa-aa42-4454-8618-2949862d881f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_bc536292-d94a-4300-9449-83cca512640e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_bc536292-d94a-4300-9449-83cca512640e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_0c9c8231-a40a-43bf-8284-98b77e42bb24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_0c9c8231-a40a-43bf-8284-98b77e42bb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_45ecb04a-2847-4e5f-b859-7ac6174e2803" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_45ecb04a-2847-4e5f-b859-7ac6174e2803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e11cfe06-c6cd-4283-beba-da0f1ffef8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_917ee1e5-5092-404f-98b2-19641f40a830" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e11cfe06-c6cd-4283-beba-da0f1ffef8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cc8f714a-9670-4e3f-971e-277556f7cce4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e11cfe06-c6cd-4283-beba-da0f1ffef8ab" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cc8f714a-9670-4e3f-971e-277556f7cce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_38bff757-2f53-4c05-b064-2954e4924cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e11cfe06-c6cd-4283-beba-da0f1ffef8ab" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_38bff757-2f53-4c05-b064-2954e4924cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_2514b1d0-42e1-45e3-9618-6b0490db6559" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e11cfe06-c6cd-4283-beba-da0f1ffef8ab" xlink:to="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_2514b1d0-42e1-45e3-9618-6b0490db6559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ec7cde7f-a566-4944-a279-a4e606c2f736" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e11cfe06-c6cd-4283-beba-da0f1ffef8ab" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_ec7cde7f-a566-4944-a279-a4e606c2f736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_6cec93d1-c497-4c08-bc66-536ee030c612" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e11cfe06-c6cd-4283-beba-da0f1ffef8ab" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_6cec93d1-c497-4c08-bc66-536ee030c612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e7b0da38-f430-4963-9985-8b30f4c8fc38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e11cfe06-c6cd-4283-beba-da0f1ffef8ab" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_e7b0da38-f430-4963-9985-8b30f4c8fc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_fdc0b892-cd60-47b8-947f-7f0b8b7f6d60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_e11cfe06-c6cd-4283-beba-da0f1ffef8ab" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_fdc0b892-cd60-47b8-947f-7f0b8b7f6d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8ae574-00f2-4283-98e2-7518854e8139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9a57d541-4ad1-443a-933d-15a7363b1169" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0e8ae574-00f2-4283-98e2-7518854e8139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToAcquireFinancialRoyaltyAssets_c98a8bd6-93c1-4fd0-acbd-aeb39479b9d5" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsToAcquireFinancialRoyaltyAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_lgnd_PaymentsToAcquireFinancialRoyaltyAssets_c98a8bd6-93c1-4fd0-acbd-aeb39479b9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProceedsFromFinancialRoyaltyAssets_b875bb58-777c-4a83-a6e9-512650068a02" xlink:href="lgnd-20241231.xsd#lgnd_ProceedsFromFinancialRoyaltyAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_lgnd_ProceedsFromFinancialRoyaltyAssets_b875bb58-777c-4a83-a6e9-512650068a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9373d096-bcaa-4d04-ac13-b7101994f131" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9373d096-bcaa-4d04-ac13-b7101994f131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_e0f77ed0-4f37-4542-946f-c32f4d524e74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_e0f77ed0-4f37-4542-946f-c32f4d524e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_a092d61d-dec5-4b48-b1fe-8f91d52e5759" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_a092d61d-dec5-4b48-b1fe-8f91d52e5759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_c8b8750d-c3a8-4cd2-90b1-f55ecefa81c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_c8b8750d-c3a8-4cd2-90b1-f55ecefa81c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_da16297d-d423-432c-b145-c1209dee8907" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_da16297d-d423-432c-b145-c1209dee8907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_4e6ae19b-0a58-4d5f-88c3-768f45edaf78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_4e6ae19b-0a58-4d5f-88c3-768f45edaf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_fb3f20a8-132c-4655-8b76-95eaf922b11f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_fb3f20a8-132c-4655-8b76-95eaf922b11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForDerivativeInstrumentInvestingActivities_e398a77e-fecd-4370-ba4e-35940c79ab91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForDerivativeInstrumentInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_PaymentsForDerivativeInstrumentInvestingActivities_e398a77e-fecd-4370-ba4e-35940c79ab91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_8cbe4544-d053-40a0-a133-d1d41a2e5bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired_8cbe4544-d053-40a0-a133-d1d41a2e5bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_ab97978d-54c6-44b6-8be2-a70095a3f4a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_ab97978d-54c6-44b6-8be2-a70095a3f4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_c080c07e-2f15-4d0e-8d95-6e9118df7318" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities_c080c07e-2f15-4d0e-8d95-6e9118df7318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6fa5de85-f501-4e74-b5df-c1be10c6981f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6fa5de85-f501-4e74-b5df-c1be10c6981f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0bb9819-216e-4b7f-ae8b-aad4a05936ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1fa656eb-a1d1-490a-85be-7a83e652b725" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c0bb9819-216e-4b7f-ae8b-aad4a05936ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_aa854855-f30d-4d37-ac3c-26d75c55434e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_aa854855-f30d-4d37-ac3c-26d75c55434e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsForSeparation_06cc7831-9334-4412-b685-f224227c27b3" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsForSeparation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_lgnd_PaymentsForSeparation_06cc7831-9334-4412-b685-f224227c27b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_3cfd7234-3b46-4622-94bf-7074806f1ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_3cfd7234-3b46-4622-94bf-7074806f1ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_beb8abed-72ad-495d-b3ed-16ec3e799db1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_beb8abed-72ad-495d-b3ed-16ec3e799db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_3e5ca1f3-84a3-47b4-8d5e-7b8972edac53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_3e5ca1f3-84a3-47b4-8d5e-7b8972edac53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_4f3c26a2-c444-4e45-b90c-cb9ab99741e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_4f3c26a2-c444-4e45-b90c-cb9ab99741e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromHedgeFinancingActivities_0fcf35d9-bb87-45f3-9fd3-e61f8ffb519b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromHedgeFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_us-gaap_ProceedsFromHedgeFinancingActivities_0fcf35d9-bb87-45f3-9fd3-e61f8ffb519b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ac8915bb-36b5-4595-be3b-3465dc2ec493" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ac8915bb-36b5-4595-be3b-3465dc2ec493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5fe9a709-5d14-4275-ac64-293eef771fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5fe9a709-5d14-4275-ac64-293eef771fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_63e57fea-9889-402f-b35a-5897f2313fa0" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_63e57fea-9889-402f-b35a-5897f2313fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92d51198-f981-406f-8d22-0a68311a216b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c710b5c6-3189-4171-8a76-4528cd0a405f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_92d51198-f981-406f-8d22-0a68311a216b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2e26903b-77ac-4fce-bbd3-5567b9d75763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2e26903b-77ac-4fce-bbd3-5567b9d75763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3573b3dc-13ec-4dd4-93ba-afc1763f5e7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3573b3dc-13ec-4dd4-93ba-afc1763f5e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f83bc288-526f-43d5-b247-abdffe8772ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f83bc288-526f-43d5-b247-abdffe8772ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f67f8e4b-90f2-49f0-a06c-df124943e9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f67f8e4b-90f2-49f0-a06c-df124943e9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6fcc5328-5d0c-4055-a0fc-e2b07c59ef7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6fcc5328-5d0c-4055-a0fc-e2b07c59ef7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_48ad26b2-e7bb-48aa-81dd-86960e949792" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6fcc5328-5d0c-4055-a0fc-e2b07c59ef7b" xlink:to="loc_us-gaap_InterestPaidNet_48ad26b2-e7bb-48aa-81dd-86960e949792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_f560c9c9-ecc8-41be-aa18-8307dd84a3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6fcc5328-5d0c-4055-a0fc-e2b07c59ef7b" xlink:to="loc_us-gaap_IncomeTaxesPaid_f560c9c9-ecc8-41be-aa18-8307dd84a3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_713413b9-9e48-42cf-8786-351f594b2068" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_713413b9-9e48-42cf-8786-351f594b2068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived_8d8b819a-3316-437d-b719-1d0f4b5f8f32" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_713413b9-9e48-42cf-8786-351f594b2068" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived_8d8b819a-3316-437d-b719-1d0f4b5f8f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_245f2fe3-c97a-4a74-a355-671b6de75ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_713413b9-9e48-42cf-8786-351f594b2068" xlink:to="loc_us-gaap_Goodwill_245f2fe3-c97a-4a74-a355-671b6de75ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9b021f66-2afc-47bf-9a4e-32e251f82903" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_713413b9-9e48-42cf-8786-351f594b2068" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9b021f66-2afc-47bf-9a4e-32e251f82903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets_ff45db59-2000-49b2-8a09-224aa57b3228" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_713413b9-9e48-42cf-8786-351f594b2068" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets_ff45db59-2000-49b2-8a09-224aa57b3228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3116f9cb-d158-4e55-aa6b-f32eaa746e86" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_713413b9-9e48-42cf-8786-351f594b2068" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_3116f9cb-d158-4e55-aa6b-f32eaa746e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d47a8be6-a4ed-4e16-aba8-f53eb578dca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract_713413b9-9e48-42cf-8786-351f594b2068" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d47a8be6-a4ed-4e16-aba8-f53eb578dca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7f10b06b-4ebe-4e6c-89ce-42dd4dfca0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_26030052-c144-45ca-ac63-4aed671bb244" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7f10b06b-4ebe-4e6c-89ce-42dd4dfca0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid_89fca591-4a27-4931-8aba-10a6f4d5994a" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7f10b06b-4ebe-4e6c-89ce-42dd4dfca0e2" xlink:to="loc_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid_89fca591-4a27-4931-8aba-10a6f4d5994a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2d64cf1a-b447-4e7d-9526-bbfb78857109" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7f10b06b-4ebe-4e6c-89ce-42dd4dfca0e2" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_2d64cf1a-b447-4e7d-9526-bbfb78857109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid_ffa65098-11f9-4fed-a53c-21c661cc617c" xlink:href="lgnd-20241231.xsd#lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7f10b06b-4ebe-4e6c-89ce-42dd4dfca0e2" xlink:to="loc_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid_ffa65098-11f9-4fed-a53c-21c661cc617c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid_c1cd5e66-5aeb-4fdd-9236-4ca017804455" xlink:href="lgnd-20241231.xsd#lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7f10b06b-4ebe-4e6c-89ce-42dd4dfca0e2" xlink:to="loc_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid_c1cd5e66-5aeb-4fdd-9236-4ca017804455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid_3e870d76-0064-4387-afbb-4e0eaee1c023" xlink:href="lgnd-20241231.xsd#lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7f10b06b-4ebe-4e6c-89ce-42dd4dfca0e2" xlink:to="loc_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid_3e870d76-0064-4387-afbb-4e0eaee1c023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1cf69463-8519-4316-98cc-ae37362161ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7f10b06b-4ebe-4e6c-89ce-42dd4dfca0e2" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1cf69463-8519-4316-98cc-ae37362161ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_8fa32fe2-e2eb-46b9-83da-061fecf475a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7f10b06b-4ebe-4e6c-89ce-42dd4dfca0e2" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_8fa32fe2-e2eb-46b9-83da-061fecf475a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b4ae5184-baa6-4e4e-a4fe-fe5e4eec120b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_36b5010e-378a-485f-a920-f20de958c05b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b4ae5184-baa6-4e4e-a4fe-fe5e4eec120b" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_36b5010e-378a-485f-a920-f20de958c05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AgenusTransaction" xlink:type="simple" xlink:href="lgnd-20241231.xsd#AgenusTransaction"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AgenusTransaction" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c090ab04-bcd2-40cf-9f34-c8062d47a123" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTextBlock_21975826-05be-4a3c-9eb0-37b41dc8ffc2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c090ab04-bcd2-40cf-9f34-c8062d47a123" xlink:to="loc_us-gaap_AssetAcquisitionTextBlock_21975826-05be-4a3c-9eb0-37b41dc8ffc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/Acquisitions" xlink:type="simple" xlink:href="lgnd-20241231.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_47b6afc9-332e-4dc5-962a-6d14703d3cda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_0f851433-7dca-42a9-88e1-085bf0ab2c81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_47b6afc9-332e-4dc5-962a-6d14703d3cda" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_0f851433-7dca-42a9-88e1-085bf0ab2c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBio" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SaleofPelicanBusinessandInvestmentinPrimroseBio"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBio" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_584c3d65-3272-44fb-93b5-46fd2067972b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_8d541708-1a8d-4ead-a25f-852b79c5bbc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_584c3d65-3272-44fb-93b5-46fd2067972b" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_8d541708-1a8d-4ead-a25f-852b79c5bbc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SpinoffofOmniAb" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SpinoffofOmniAb"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SpinoffofOmniAb" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_a23286b8-7f57-4dde-8b8f-567191ae9cda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_995156df-6f61-4abc-b60e-a3581a96a4be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_a23286b8-7f57-4dde-8b8f-567191ae9cda" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_995156df-6f61-4abc-b60e-a3581a96a4be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRights" xlink:type="simple" xlink:href="lgnd-20241231.xsd#FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRights"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRights" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a8a5c29b-97ab-4e75-9a55-3fe635c7d788" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsTextBlock_5436e68c-0545-4dd2-9e6e-b5e1a97273a4" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a8a5c29b-97ab-4e75-9a55-3fe635c7d788" xlink:to="loc_lgnd_FinancialRoyaltyAssetsTextBlock_5436e68c-0545-4dd2-9e6e-b5e1a97273a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_43d84c0f-f316-416f-a81e-502bf16fb8bd" xlink:href="lgnd-20241231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_6a25040e-b798-4c0c-9e84-dad3fdc12e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_43d84c0f-f316-416f-a81e-502bf16fb8bd" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_6a25040e-b798-4c0c-9e84-dad3fdc12e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="lgnd-20241231.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_baf63f9d-82bc-402c-aa80-a1adb0487710" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_c3284721-820a-4f38-a90c-e7def40c48fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_baf63f9d-82bc-402c-aa80-a1adb0487710" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_c3284721-820a-4f38-a90c-e7def40c48fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/Leases" xlink:type="simple" xlink:href="lgnd-20241231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9b066006-c9ed-465e-a11e-9c26598927ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_3dc0291f-b3bf-4577-bad8-6d4bcb380141" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9b066006-c9ed-465e-a11e-9c26598927ec" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_3dc0291f-b3bf-4577-bad8-6d4bcb380141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_d1a0ccc7-3144-4c50-8fda-05a8464a7ce7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9b066006-c9ed-465e-a11e-9c26598927ec" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_d1a0ccc7-3144-4c50-8fda-05a8464a7ce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/Debt" xlink:type="simple" xlink:href="lgnd-20241231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cfcce25a-8881-4612-bd95-18f7451b858a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_56c8906b-8af5-40e1-b6b3-5bb32efe373a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cfcce25a-8881-4612-bd95-18f7451b858a" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_56c8906b-8af5-40e1-b6b3-5bb32efe373a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquity" xlink:type="simple" xlink:href="lgnd-20241231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9dec96e0-44e5-4fac-a8eb-e5842df4f1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f9123d6d-8072-4085-9ac8-d3db6ba1788c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9dec96e0-44e5-4fac-a8eb-e5842df4f1dd" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f9123d6d-8072-4085-9ac8-d3db6ba1788c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings" xlink:type="simple" xlink:href="lgnd-20241231.xsd#CommitmentandContingenciesLegalProceedings"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c53fd137-0fcb-4d30-bdef-6f6b4214d6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_38d46092-ac4e-4108-beff-3da39653e4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c53fd137-0fcb-4d30-bdef-6f6b4214d6f6" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_38d46092-ac4e-4108-beff-3da39653e4a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxes" xlink:type="simple" xlink:href="lgnd-20241231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_58a367fa-2784-45a1-ab6c-9be87c1aeec6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_bca79bcf-b614-4ed4-9cdc-4e26040b004f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_58a367fa-2784-45a1-ab6c-9be87c1aeec6" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_bca79bcf-b614-4ed4-9cdc-4e26040b004f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SubsequentEvent" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SubsequentEvent"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_99c68ac9-2384-4f21-a5cd-2a3f83f07d43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_d0aeee14-376e-4412-965f-a3f4506607fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_99c68ac9-2384-4f21-a5cd-2a3f83f07d43" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_d0aeee14-376e-4412-965f-a3f4506607fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock_1b130cde-4500-4832-9859-09c447b79474" xlink:href="lgnd-20241231.xsd#lgnd_BusinessSpinOffAndMigrationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock_1b130cde-4500-4832-9859-09c447b79474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8e688b5e-2406-4708-ad52-905d75e067b3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8e688b5e-2406-4708-ad52-905d75e067b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_a62583c1-6284-44c0-a2ac-72a61e5157dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_a62583c1-6284-44c0-a2ac-72a61e5157dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_6023fd28-3980-46c6-bda8-e116786c801e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_6023fd28-3980-46c6-bda8-e116786c801e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_f8f7609a-2f48-4967-88ce-b7b55091d80e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_DiscontinuedOperationsPolicyTextBlock_f8f7609a-2f48-4967-88ce-b7b55091d80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_e7a3dc07-0d8f-4221-86c5-57fdb4430e91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_UseOfEstimates_e7a3dc07-0d8f-4221-86c5-57fdb4430e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_45196b1e-b925-4302-be88-8d050375c81a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_45196b1e-b925-4302-be88-8d050375c81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_9968f5c7-99ee-4c88-aea8-71c868f7a793" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_9968f5c7-99ee-4c88-aea8-71c868f7a793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_f1b10646-1af4-4b55-a904-b48439b8a81a" xlink:href="lgnd-20241231.xsd#lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock_f1b10646-1af4-4b55-a904-b48439b8a81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_a7106ec5-b78f-4cd9-8c8f-2db3258a581c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditLossFinancialInstrumentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock_a7106ec5-b78f-4cd9-8c8f-2db3258a581c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_f94df291-b735-4fa1-bc16-c9986e75e152" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_f94df291-b735-4fa1-bc16-c9986e75e152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7014b5a3-9ccb-4a77-86af-85bd682995ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7014b5a3-9ccb-4a77-86af-85bd682995ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_f7c14016-0417-4406-93e7-313af2d55afe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_f7c14016-0417-4406-93e7-313af2d55afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsPolicyTextBlock_e56643c9-10a8-43ff-ba36-16649a3f711d" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_lgnd_FinancialRoyaltyAssetsPolicyTextBlock_e56643c9-10a8-43ff-ba36-16649a3f711d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_d5aa3e7e-58f6-441e-a34f-2bf4fbafa7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_d5aa3e7e-58f6-441e-a34f-2bf4fbafa7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_4f3825b9-79ce-4ed5-84f0-7347e053b55b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_4f3825b9-79ce-4ed5-84f0-7347e053b55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherInvestmentsPolicyPolicyTextBlock_95b3c307-97b1-4f93-aa0a-08ad67d58b5d" xlink:href="lgnd-20241231.xsd#lgnd_OtherInvestmentsPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_lgnd_OtherInvestmentsPolicyPolicyTextBlock_95b3c307-97b1-4f93-aa0a-08ad67d58b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_8a3d0572-75d0-4960-8318-2ba66e310dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_8a3d0572-75d0-4960-8318-2ba66e310dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5f07f015-7d3b-47b4-9d1e-d37c0e0525f0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_5f07f015-7d3b-47b4-9d1e-d37c0e0525f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7cf82841-77a1-40d0-9444-baf8c83d48e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_7cf82841-77a1-40d0-9444-baf8c83d48e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_91e4d2d3-b1e9-4ced-90e0-d2dfc35d19a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_91e4d2d3-b1e9-4ced-90e0-d2dfc35d19a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_d3a31c17-218c-4795-90d9-66c207f73f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_d3a31c17-218c-4795-90d9-66c207f73f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8f1f11c9-bbe1-4a1f-b2ee-02b772061872" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_8f1f11c9-bbe1-4a1f-b2ee-02b772061872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_5df99931-b567-422d-8bb7-9c03c006f5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_5df99931-b567-422d-8bb7-9c03c006f5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_85f594bc-ffde-41ca-87d6-fd5cf9cb9744" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef67cc77-28e7-4e73-9cc8-18788c069ebe" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_85f594bc-ffde-41ca-87d6-fd5cf9cb9744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_825e6bbd-5307-41e0-9c08-7dba62027fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_22841bd1-0115-4d50-8901-6eff8fd4342d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_825e6bbd-5307-41e0-9c08-7dba62027fe4" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_22841bd1-0115-4d50-8901-6eff8fd4342d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_753daa92-b68b-4062-a151-3049950733bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_825e6bbd-5307-41e0-9c08-7dba62027fe4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_753daa92-b68b-4062-a151-3049950733bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_615d3b14-27cd-496e-879e-513e905b7bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_825e6bbd-5307-41e0-9c08-7dba62027fe4" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_615d3b14-27cd-496e-879e-513e905b7bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_d53628bb-71b7-4cec-899c-6acc51e9bca4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_825e6bbd-5307-41e0-9c08-7dba62027fe4" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_d53628bb-71b7-4cec-899c-6acc51e9bca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="lgnd-20241231.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d23c0dd2-bf78-4f60-90b3-913340d40763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_c321a1d4-69a1-48a3-aa44-25f07af73a62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_d23c0dd2-bf78-4f60-90b3-913340d40763" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_c321a1d4-69a1-48a3-aa44-25f07af73a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioTables" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SaleofPelicanBusinessandInvestmentinPrimroseBioTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bbfc42dc-307c-4a00-af77-e1c8b0744359" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_a46c17a2-4d5d-40e9-b157-3d6ee555b28a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bbfc42dc-307c-4a00-af77-e1c8b0744359" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_a46c17a2-4d5d-40e9-b157-3d6ee555b28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock_883e8e48-d9f3-4183-afba-f7b96c5cbca5" xlink:href="lgnd-20241231.xsd#lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_bbfc42dc-307c-4a00-af77-e1c8b0744359" xlink:to="loc_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock_883e8e48-d9f3-4183-afba-f7b96c5cbca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SpinoffofOmniAbTables" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SpinoffofOmniAbTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SpinoffofOmniAbTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ccac41fe-750a-4fef-8bc2-09bccc0f0086" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_e36c92af-1d43-4e73-b568-3f8f1028cea4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_ccac41fe-750a-4fef-8bc2-09bccc0f0086" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_e36c92af-1d43-4e73-b568-3f8f1028cea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsTables" xlink:type="simple" xlink:href="lgnd-20241231.xsd#FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca37c4ec-be84-4ba1-9791-5ac7971627ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleOfFinancialRoyaltyAssetsTableTextBlock_44daba3c-f6bc-44d2-9e21-30c9877f8ff7" xlink:href="lgnd-20241231.xsd#lgnd_ScheduleOfFinancialRoyaltyAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ca37c4ec-be84-4ba1-9791-5ac7971627ca" xlink:to="loc_lgnd_ScheduleOfFinancialRoyaltyAssetsTableTextBlock_44daba3c-f6bc-44d2-9e21-30c9877f8ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsTables" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_d761dadc-1a4e-4e3e-900c-bfa6e4029dfe" xlink:href="lgnd-20241231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_3024c385-d565-48ae-9aea-6c60439a601b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_d761dadc-1a4e-4e3e-900c-bfa6e4029dfe" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_3024c385-d565-48ae-9aea-6c60439a601b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_02aea6f6-8a25-4657-a00a-f2ded60086f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_d761dadc-1a4e-4e3e-900c-bfa6e4029dfe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_02aea6f6-8a25-4657-a00a-f2ded60086f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_c53b751c-e313-4c90-ad93-062cf23e69b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_d761dadc-1a4e-4e3e-900c-bfa6e4029dfe" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_c53b751c-e313-4c90-ad93-062cf23e69b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5cc0054f-25da-410d-b40b-9aedd931ba5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_d761dadc-1a4e-4e3e-900c-bfa6e4029dfe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5cc0054f-25da-410d-b40b-9aedd931ba5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_e9f57b1b-1bba-402b-ae80-c87f850fc31c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_d761dadc-1a4e-4e3e-900c-bfa6e4029dfe" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_e9f57b1b-1bba-402b-ae80-c87f850fc31c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_5959a926-d3f8-4a5c-8a48-79794834f83b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_d761dadc-1a4e-4e3e-900c-bfa6e4029dfe" xlink:to="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_5959a926-d3f8-4a5c-8a48-79794834f83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryInvestmentHoldingsTextBlock_c4a48fa3-2129-4f0b-b4e6-2ad825c3e8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryInvestmentHoldingsTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_d761dadc-1a4e-4e3e-900c-bfa6e4029dfe" xlink:to="loc_us-gaap_SummaryInvestmentHoldingsTextBlock_c4a48fa3-2129-4f0b-b4e6-2ad825c3e8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_386b5a32-51ef-4950-99a9-99bf05e9a555" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_d761dadc-1a4e-4e3e-900c-bfa6e4029dfe" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_386b5a32-51ef-4950-99a9-99bf05e9a555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9f8040c5-0406-42a5-a7be-9f2a2a022343" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_d761dadc-1a4e-4e3e-900c-bfa6e4029dfe" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9f8040c5-0406-42a5-a7be-9f2a2a022343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_2faad2f5-2562-424b-b59b-f1fdc16a6936" xlink:href="lgnd-20241231.xsd#lgnd_ScheduleofContingentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_d761dadc-1a4e-4e3e-900c-bfa6e4029dfe" xlink:to="loc_lgnd_ScheduleofContingentLiabilitiesTableTextBlock_2faad2f5-2562-424b-b59b-f1fdc16a6936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_8715d0e5-e7ca-41c2-9a36-1186d7f9c028" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_d761dadc-1a4e-4e3e-900c-bfa6e4029dfe" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_8715d0e5-e7ca-41c2-9a36-1186d7f9c028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="lgnd-20241231.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b75eca92-e9f3-4247-84c8-ac31e34e3e02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_2084e5da-f81b-443d-a01e-7a2592323b09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b75eca92-e9f3-4247-84c8-ac31e34e3e02" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_2084e5da-f81b-443d-a01e-7a2592323b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_604059f7-8b20-48f7-933a-872d9700efe9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b75eca92-e9f3-4247-84c8-ac31e34e3e02" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_604059f7-8b20-48f7-933a-872d9700efe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_0a1795e8-dddf-4885-8686-e7ee01faf3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b75eca92-e9f3-4247-84c8-ac31e34e3e02" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_0a1795e8-dddf-4885-8686-e7ee01faf3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesTables" xlink:type="simple" xlink:href="lgnd-20241231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4ede6241-4ca3-4964-a064-f7e82a43f964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_dc6bed11-2952-49a6-b4a5-c2b0876a61dd" xlink:href="lgnd-20241231.xsd#lgnd_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4ede6241-4ca3-4964-a064-f7e82a43f964" xlink:to="loc_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock_dc6bed11-2952-49a6-b4a5-c2b0876a61dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5d955779-ee11-4225-806e-7c9a600200a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4ede6241-4ca3-4964-a064-f7e82a43f964" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_5d955779-ee11-4225-806e-7c9a600200a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_d7fedd80-5c20-4c36-b795-bef327fce0eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4ede6241-4ca3-4964-a064-f7e82a43f964" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_d7fedd80-5c20-4c36-b795-bef327fce0eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="lgnd-20241231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_95fefa85-c73e-4454-97af-9e40cbfd87dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_8f79dce4-4bca-42ec-9361-b4ef20ccdea0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_95fefa85-c73e-4454-97af-9e40cbfd87dc" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_8f79dce4-4bca-42ec-9361-b4ef20ccdea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7f8fffcb-bd52-4ca1-9d45-5710d7831f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_95fefa85-c73e-4454-97af-9e40cbfd87dc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7f8fffcb-bd52-4ca1-9d45-5710d7831f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_cbe09888-6726-4ec3-92fc-20407550d546" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_95fefa85-c73e-4454-97af-9e40cbfd87dc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_cbe09888-6726-4ec3-92fc-20407550d546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f03e37dc-a26b-4adb-ac0b-4a1d1801598f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_95fefa85-c73e-4454-97af-9e40cbfd87dc" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f03e37dc-a26b-4adb-ac0b-4a1d1801598f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_d6d2d36a-eff5-4b9b-a038-8a130fc72e85" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_95fefa85-c73e-4454-97af-9e40cbfd87dc" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_d6d2d36a-eff5-4b9b-a038-8a130fc72e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="lgnd-20241231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e04781ab-7619-4f31-9819-283e405c5446" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6f9342f0-590d-426d-95e9-062c5bc5abab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e04781ab-7619-4f31-9819-283e405c5446" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6f9342f0-590d-426d-95e9-062c5bc5abab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_46b99f3b-5216-45de-b85d-3d8b40a4cc01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e04781ab-7619-4f31-9819-283e405c5446" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_46b99f3b-5216-45de-b85d-3d8b40a4cc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a344fc23-7eb1-4f52-9cea-45ce10ca842a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e04781ab-7619-4f31-9819-283e405c5446" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_a344fc23-7eb1-4f52-9cea-45ce10ca842a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_b81e5708-9ade-47be-a068-a4325cfe76cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e04781ab-7619-4f31-9819-283e405c5446" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_b81e5708-9ade-47be-a068-a4325cfe76cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46bb17f3-ad5f-4a43-a708-9b84deb4ac38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_0d8f319d-a69a-48aa-afd6-58371402dd03" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_46bb17f3-ad5f-4a43-a708-9b84deb4ac38" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_0d8f319d-a69a-48aa-afd6-58371402dd03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d59da3a9-39b9-412c-8919-f5b98724ac44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_0d8f319d-a69a-48aa-afd6-58371402dd03" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d59da3a9-39b9-412c-8919-f5b98724ac44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_23e30a27-dfba-4a92-a9de-26e091700be7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d59da3a9-39b9-412c-8919-f5b98724ac44" xlink:to="loc_us-gaap_SegmentDomain_23e30a27-dfba-4a92-a9de-26e091700be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember_f4e86cf1-f152-449c-83b1-40eb4bce35f7" xlink:href="lgnd-20241231.xsd#lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_23e30a27-dfba-4a92-a9de-26e091700be7" xlink:to="loc_lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember_f4e86cf1-f152-449c-83b1-40eb4bce35f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e63fc92d-daa2-4e34-9945-a0b36513f4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_0d8f319d-a69a-48aa-afd6-58371402dd03" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e63fc92d-daa2-4e34-9945-a0b36513f4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5f04af90-421d-49b4-a694-7c9ed885cf01" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e63fc92d-daa2-4e34-9945-a0b36513f4fb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5f04af90-421d-49b4-a694-7c9ed885cf01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_20578c2d-c4a4-4c8a-aaf2-2aa891577cc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e63fc92d-daa2-4e34-9945-a0b36513f4fb" xlink:to="loc_us-gaap_ShareBasedCompensation_20578c2d-c4a4-4c8a-aaf2-2aa891577cc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_b972aed1-f0ac-405d-b98e-0a80487751dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e63fc92d-daa2-4e34-9945-a0b36513f4fb" xlink:to="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_b972aed1-f0ac-405d-b98e-0a80487751dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_042d065d-d8f7-41be-ac15-783254437e94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_b972aed1-f0ac-405d-b98e-0a80487751dd" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_042d065d-d8f7-41be-ac15-783254437e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_753d159c-54ce-4c8c-bf4f-5f69673c482e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_b972aed1-f0ac-405d-b98e-0a80487751dd" xlink:to="loc_us-gaap_Depreciation_753d159c-54ce-4c8c-bf4f-5f69673c482e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_db6b95ab-bbc0-40ca-a04e-89e6986c448e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_b972aed1-f0ac-405d-b98e-0a80487751dd" xlink:to="loc_us-gaap_InterestIncomeOperating_db6b95ab-bbc0-40ca-a04e-89e6986c448e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseNonoperating_c6ed7b42-1a66-49d7-8486-a5044a13c603" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_b972aed1-f0ac-405d-b98e-0a80487751dd" xlink:to="loc_us-gaap_InterestExpenseNonoperating_c6ed7b42-1a66-49d7-8486-a5044a13c603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_bbbbe2bf-8420-4c59-9cad-22db6ebbea1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract_b972aed1-f0ac-405d-b98e-0a80487751dd" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_bbbbe2bf-8420-4c59-9cad-22db6ebbea1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_83ba56e6-ca42-4e13-b707-a94a1cca00a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e63fc92d-daa2-4e34-9945-a0b36513f4fb" xlink:to="loc_us-gaap_OperatingIncomeLoss_83ba56e6-ca42-4e13-b707-a94a1cca00a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherExpenseItemsNet_b8b8cbb3-cb40-42db-ada6-99f26fd0ba23" xlink:href="lgnd-20241231.xsd#lgnd_OtherExpenseItemsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_e63fc92d-daa2-4e34-9945-a0b36513f4fb" xlink:to="loc_lgnd_OtherExpenseItemsNet_b8b8cbb3-cb40-42db-ada6-99f26fd0ba23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bb0bb918-751d-4fd8-82b1-5f4ccc564610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:href="lgnd-20241231.xsd#lgnd_BasisOfPresentationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bb0bb918-751d-4fd8-82b1-5f4ccc564610" xlink:to="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_50d897f4-7f55-4fcc-ab36-ebe1977c83b3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:to="loc_srt_ProductOrServiceAxis_50d897f4-7f55-4fcc-ab36-ebe1977c83b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4c00eb70-992d-4cd1-80d1-f8f9995aadde" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_50d897f4-7f55-4fcc-ab36-ebe1977c83b3" xlink:to="loc_srt_ProductsAndServicesDomain_4c00eb70-992d-4cd1-80d1-f8f9995aadde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_4b6c10dc-2417-4967-9967-5dd8d4ef5470" xlink:href="lgnd-20241231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4c00eb70-992d-4cd1-80d1-f8f9995aadde" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_4b6c10dc-2417-4967-9967-5dd8d4ef5470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d4cc9eba-db1a-4114-b4e0-d52c46281dcc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:to="loc_srt_RangeAxis_d4cc9eba-db1a-4114-b4e0-d52c46281dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_728f9e9d-70ff-4787-9b86-8680531a67fd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d4cc9eba-db1a-4114-b4e0-d52c46281dcc" xlink:to="loc_srt_RangeMember_728f9e9d-70ff-4787-9b86-8680531a67fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_99d781ab-9828-4812-b69c-8fa50756b16f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_728f9e9d-70ff-4787-9b86-8680531a67fd" xlink:to="loc_srt_MinimumMember_99d781ab-9828-4812-b69c-8fa50756b16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_facc2ead-c3eb-45b4-ac07-bc643a7906c2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_728f9e9d-70ff-4787-9b86-8680531a67fd" xlink:to="loc_srt_MaximumMember_facc2ead-c3eb-45b4-ac07-bc643a7906c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f62955a4-5e93-42d4-9c12-cc2d6b8fe2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f62955a4-5e93-42d4-9c12-cc2d6b8fe2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f6e7057-369b-4fd0-a81d-1606d5345745" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f62955a4-5e93-42d4-9c12-cc2d6b8fe2f6" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f6e7057-369b-4fd0-a81d-1606d5345745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_1dc82361-d398-4148-90f1-004850fb2ddb" xlink:href="lgnd-20241231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4f6e7057-369b-4fd0-a81d-1606d5345745" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_1dc82361-d398-4148-90f1-004850fb2ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2b94a76e-fbd4-4b0c-889e-5bb859dd5e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:to="loc_us-gaap_AwardTypeAxis_2b94a76e-fbd4-4b0c-889e-5bb859dd5e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95fa2ed5-6420-4191-b75a-dbcd1fa05c8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2b94a76e-fbd4-4b0c-889e-5bb859dd5e8f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95fa2ed5-6420-4191-b75a-dbcd1fa05c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_ad242745-fd79-47ff-8532-245b8c84ab9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95fa2ed5-6420-4191-b75a-dbcd1fa05c8f" xlink:to="loc_us-gaap_PerformanceSharesMember_ad242745-fd79-47ff-8532-245b8c84ab9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d9bf4b58-e4b4-4e74-b705-01c0025f7ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95fa2ed5-6420-4191-b75a-dbcd1fa05c8f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d9bf4b58-e4b4-4e74-b705-01c0025f7ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_50f53d0c-7666-45bc-8542-6f4f50a76392" xlink:href="lgnd-20241231.xsd#lgnd_RestrictedStockUnitsAndPerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95fa2ed5-6420-4191-b75a-dbcd1fa05c8f" xlink:to="loc_lgnd_RestrictedStockUnitsAndPerformanceSharesMember_50f53d0c-7666-45bc-8542-6f4f50a76392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_18798fe9-c0bd-4e90-8ebd-6b32d756bc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_18798fe9-c0bd-4e90-8ebd-6b32d756bc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0d523f04-5f7e-4dfd-a43b-13f39656400e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_18798fe9-c0bd-4e90-8ebd-6b32d756bc8a" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0d523f04-5f7e-4dfd-a43b-13f39656400e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_feaec0e6-2074-4180-8117-cd01060b3370" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0d523f04-5f7e-4dfd-a43b-13f39656400e" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_feaec0e6-2074-4180-8117-cd01060b3370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_653187a2-6e2d-4c38-8b32-e9bda2b507c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:to="loc_us-gaap_PlanNameAxis_653187a2-6e2d-4c38-8b32-e9bda2b507c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_89980042-a423-4e9a-89f0-9aa28812166d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_653187a2-6e2d-4c38-8b32-e9bda2b507c9" xlink:to="loc_us-gaap_PlanNameDomain_89980042-a423-4e9a-89f0-9aa28812166d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_5429c535-ea54-46f8-8f0b-e8f3e6fd80a4" xlink:href="lgnd-20241231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_89980042-a423-4e9a-89f0-9aa28812166d" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_5429c535-ea54-46f8-8f0b-e8f3e6fd80a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7aeeea15-534f-4569-8377-0068d17f8010" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:to="loc_us-gaap_VestingAxis_7aeeea15-534f-4569-8377-0068d17f8010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_3e956301-cc9d-4aa5-aac2-5dae2cf55270" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_7aeeea15-534f-4569-8377-0068d17f8010" xlink:to="loc_us-gaap_VestingDomain_3e956301-cc9d-4aa5-aac2-5dae2cf55270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodOneMember_a0bdfa21-7f46-4a63-8113-a96013d2ee8f" xlink:href="lgnd-20241231.xsd#lgnd_VestingPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_3e956301-cc9d-4aa5-aac2-5dae2cf55270" xlink:to="loc_lgnd_VestingPeriodOneMember_a0bdfa21-7f46-4a63-8113-a96013d2ee8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VestingPeriodTwoMember_5edbed73-1af6-4af9-a074-2d0b693f8ad2" xlink:href="lgnd-20241231.xsd#lgnd_VestingPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_3e956301-cc9d-4aa5-aac2-5dae2cf55270" xlink:to="loc_lgnd_VestingPeriodTwoMember_5edbed73-1af6-4af9-a074-2d0b693f8ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6248ca3b-8360-4cdc-80b6-3e2d688eaf63" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:to="loc_srt_CounterpartyNameAxis_6248ca3b-8360-4cdc-80b6-3e2d688eaf63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_caefe348-4708-4e94-8d80-1d30a8704d10" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6248ca3b-8360-4cdc-80b6-3e2d688eaf63" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_caefe348-4708-4e94-8d80-1d30a8704d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AgenusPartneredProgramMember_76addeb8-3d6c-427e-9d9c-b68251a7ae4c" xlink:href="lgnd-20241231.xsd#lgnd_AgenusPartneredProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_caefe348-4708-4e94-8d80-1d30a8704d10" xlink:to="loc_lgnd_AgenusPartneredProgramMember_76addeb8-3d6c-427e-9d9c-b68251a7ae4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_db1d494a-e4f5-4488-a009-5ce40a501f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_db1d494a-e4f5-4488-a009-5ce40a501f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_2ffce470-a328-4836-92c4-741a1a9f0df9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_db1d494a-e4f5-4488-a009-5ce40a501f2a" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_2ffce470-a328-4836-92c4-741a1a9f0df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimordialGeneticsMember_9ed685eb-cae8-4fa8-b1a1-59c7d10c3bea" xlink:href="lgnd-20241231.xsd#lgnd_PrimordialGeneticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_2ffce470-a328-4836-92c4-741a1a9f0df9" xlink:to="loc_lgnd_PrimordialGeneticsMember_9ed685eb-cae8-4fa8-b1a1-59c7d10c3bea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:href="lgnd-20241231.xsd#lgnd_BasisOfPresentationLineItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationTable_9ae64cc2-a5a2-43e0-94a6-54d41f7f2dd0" xlink:to="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_0a279ed5-4a73-4a75-b69c-e6f92f8bc979" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_NumberOfOperatingSegments_0a279ed5-4a73-4a75-b69c-e6f92f8bc979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_b725e81f-ccab-48f7-b3ba-e3e276153e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_NumberOfReportableSegments_b725e81f-ccab-48f7-b3ba-e3e276153e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_539776b1-c70d-480d-83e1-16cf1495536e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_539776b1-c70d-480d-83e1-16cf1495536e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_d907db82-15d2-4177-9afa-9ce772f45a67" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_InventoryWriteDown_d907db82-15d2-4177-9afa-9ce772f45a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_6dcf92f6-cfda-40a0-b609-0a210eb03ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_InventoryNet_6dcf92f6-cfda-40a0-b609-0a210eb03ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5a12aa6f-12c3-4a6c-bea5-44b21eb018a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_5a12aa6f-12c3-4a6c-bea5-44b21eb018a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeInstrumentAdditionalMaximumInvestment_9e40a8e3-8458-4d40-87b1-594dfe370016" xlink:href="lgnd-20241231.xsd#lgnd_DerivativeInstrumentAdditionalMaximumInvestment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_lgnd_DerivativeInstrumentAdditionalMaximumInvestment_9e40a8e3-8458-4d40-87b1-594dfe370016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneCompensationRate_13a5ae32-07d3-464a-91ed-547e2c774990" xlink:href="lgnd-20241231.xsd#lgnd_MilestoneCompensationRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_lgnd_MilestoneCompensationRate_13a5ae32-07d3-464a-91ed-547e2c774990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContracts_f2e6d9cc-1cda-47e9-b7ae-e4a0416e1d0e" xlink:href="lgnd-20241231.xsd#lgnd_NumberOfContracts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_lgnd_NumberOfContracts_f2e6d9cc-1cda-47e9-b7ae-e4a0416e1d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsIssued_57f812e2-ed1a-4efc-a153-26ea7aca5f4e" xlink:href="lgnd-20241231.xsd#lgnd_NumberOfContingentValueRightsIssued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_lgnd_NumberOfContingentValueRightsIssued_57f812e2-ed1a-4efc-a153-26ea7aca5f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5998eb79-b753-40fa-b37e-acbb86c44941" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_5998eb79-b753-40fa-b37e-acbb86c44941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e91ce11f-05ed-4986-b9b3-7de611826119" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e91ce11f-05ed-4986-b9b3-7de611826119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ffe9b4ac-0ae7-4e0c-b2f2-6f80ac949c2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ffe9b4ac-0ae7-4e0c-b2f2-6f80ac949c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_6e0e184a-484d-4f36-93b8-e8065d0b2b06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiMeasurementInput"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_EquitySecuritiesFvNiMeasurementInput_6e0e184a-484d-4f36-93b8-e8065d0b2b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_e0129b6c-f2be-4fa1-8104-6bc786ff1201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_e0129b6c-f2be-4fa1-8104-6bc786ff1201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_296f31c1-05be-46a2-9d34-7c4c50a200b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BasisOfPresentationLineItems_598bbfed-da1b-4bd7-97df-82b452bbf56b" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_296f31c1-05be-46a2-9d34-7c4c50a200b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ba71ff11-50ff-4ff6-87ba-9defbfe9a7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fa192bc2-bc54-4ac0-9ba3-88d6b54320f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ba71ff11-50ff-4ff6-87ba-9defbfe9a7f3" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fa192bc2-bc54-4ac0-9ba3-88d6b54320f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_9ac41b23-c579-44bc-82c4-48116a2e14f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fa192bc2-bc54-4ac0-9ba3-88d6b54320f9" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_9ac41b23-c579-44bc-82c4-48116a2e14f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_f71864fe-d95b-47d7-a027-aa6771551b7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9ac41b23-c579-44bc-82c4-48116a2e14f1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_f71864fe-d95b-47d7-a027-aa6771551b7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_c4d29a7a-edc4-41a7-86f6-9ccbd69bbe6e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_f71864fe-d95b-47d7-a027-aa6771551b7d" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_c4d29a7a-edc4-41a7-86f6-9ccbd69bbe6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1f1794c5-106a-4a6c-977e-259c47f2a62d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fa192bc2-bc54-4ac0-9ba3-88d6b54320f9" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1f1794c5-106a-4a6c-977e-259c47f2a62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f82137d2-3883-44a9-b72f-bfdbc4b21121" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1f1794c5-106a-4a6c-977e-259c47f2a62d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f82137d2-3883-44a9-b72f-bfdbc4b21121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_cef178cc-8c5a-4abe-9b14-1f7b5c780366" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_f82137d2-3883-44a9-b72f-bfdbc4b21121" xlink:to="loc_us-gaap_SalesRevenueNetMember_cef178cc-8c5a-4abe-9b14-1f7b5c780366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_11b30854-654b-4012-8fbf-93901dd559f1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fa192bc2-bc54-4ac0-9ba3-88d6b54320f9" xlink:to="loc_srt_MajorCustomersAxis_11b30854-654b-4012-8fbf-93901dd559f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b5320e7d-ec79-4d5b-89be-53baffa7fc32" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_11b30854-654b-4012-8fbf-93901dd559f1" xlink:to="loc_srt_NameOfMajorCustomerDomain_b5320e7d-ec79-4d5b-89be-53baffa7fc32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerAMember_18458d6d-591b-422a-8949-c34d1368ea82" xlink:href="lgnd-20241231.xsd#lgnd_PartnerAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b5320e7d-ec79-4d5b-89be-53baffa7fc32" xlink:to="loc_lgnd_PartnerAMember_18458d6d-591b-422a-8949-c34d1368ea82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerBMember_0f869856-743e-4ce8-9bb9-7b40c2927e7d" xlink:href="lgnd-20241231.xsd#lgnd_PartnerBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b5320e7d-ec79-4d5b-89be-53baffa7fc32" xlink:to="loc_lgnd_PartnerBMember_0f869856-743e-4ce8-9bb9-7b40c2927e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerCMember_54bad47a-b98a-4b7c-ae42-8a71a0b93c8c" xlink:href="lgnd-20241231.xsd#lgnd_PartnerCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b5320e7d-ec79-4d5b-89be-53baffa7fc32" xlink:to="loc_lgnd_PartnerCMember_54bad47a-b98a-4b7c-ae42-8a71a0b93c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RecordatiMember_f8f2552e-9b82-4dca-bf8a-8f60e02cfe75" xlink:href="lgnd-20241231.xsd#lgnd_RecordatiMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b5320e7d-ec79-4d5b-89be-53baffa7fc32" xlink:to="loc_lgnd_RecordatiMember_f8f2552e-9b82-4dca-bf8a-8f60e02cfe75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6f68a72f-c9b8-4d75-9388-9134bbf2bb04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_fa192bc2-bc54-4ac0-9ba3-88d6b54320f9" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6f68a72f-c9b8-4d75-9388-9134bbf2bb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_0db3d63a-1c30-479d-831a-0ad9b15aa4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6f68a72f-c9b8-4d75-9388-9134bbf2bb04" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_0db3d63a-1c30-479d-831a-0ad9b15aa4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d171206d-38bf-469a-a6cb-2437fbea33d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_dd5d33db-3112-4e6a-8cbb-276974a31c74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d171206d-38bf-469a-a6cb-2437fbea33d2" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_dd5d33db-3112-4e6a-8cbb-276974a31c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b395cef8-6aed-496c-84fd-553fdf38d1ff" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_dd5d33db-3112-4e6a-8cbb-276974a31c74" xlink:to="loc_srt_ProductOrServiceAxis_b395cef8-6aed-496c-84fd-553fdf38d1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0ec5e294-8485-4f88-be6e-77ff5177d1eb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b395cef8-6aed-496c-84fd-553fdf38d1ff" xlink:to="loc_srt_ProductsAndServicesDomain_0ec5e294-8485-4f88-be6e-77ff5177d1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0ec5e294-8485-4f88-be6e-77ff5177d1eb" xlink:to="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyKyprolisMember_bc19278d-1c7f-4a0d-8720-27254b6085bd" xlink:href="lgnd-20241231.xsd#lgnd_RoyaltyKyprolisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:to="loc_lgnd_RoyaltyKyprolisMember_bc19278d-1c7f-4a0d-8720-27254b6085bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyRylazeMember_b794d98e-131b-444d-a19d-56a00b7c7300" xlink:href="lgnd-20241231.xsd#lgnd_RoyaltyRylazeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:to="loc_lgnd_RoyaltyRylazeMember_b794d98e-131b-444d-a19d-56a00b7c7300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FilspariMember_0bcc6079-d313-4091-9daa-60591376e4c6" xlink:href="lgnd-20241231.xsd#lgnd_FilspariMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:to="loc_lgnd_FilspariMember_0bcc6079-d313-4091-9daa-60591376e4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyEvomelaMember_c5cef263-4223-4262-8d02-64080c838e4b" xlink:href="lgnd-20241231.xsd#lgnd_RoyaltyEvomelaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:to="loc_lgnd_RoyaltyEvomelaMember_c5cef263-4223-4262-8d02-64080c838e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyTeriparatideInjectionMember_165ca026-2444-4060-8546-dadaca8ea3b8" xlink:href="lgnd-20241231.xsd#lgnd_RoyaltyTeriparatideInjectionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:to="loc_lgnd_RoyaltyTeriparatideInjectionMember_165ca026-2444-4060-8546-dadaca8ea3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VaxneuvanceMember_56cf6884-815e-42ab-be79-11fc9471fe21" xlink:href="lgnd-20241231.xsd#lgnd_VaxneuvanceMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:to="loc_lgnd_VaxneuvanceMember_56cf6884-815e-42ab-be79-11fc9471fe21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyOtherMember_397db251-4dfd-4ea3-965b-a7df242af34d" xlink:href="lgnd-20241231.xsd#lgnd_RoyaltyOtherMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:to="loc_lgnd_RoyaltyOtherMember_397db251-4dfd-4ea3-965b-a7df242af34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IntangibleRoyaltyAssetsMember_17f6804a-b351-4595-8505-8ec52a903ca1" xlink:href="lgnd-20241231.xsd#lgnd_IntangibleRoyaltyAssetsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:to="loc_lgnd_IntangibleRoyaltyAssetsMember_17f6804a-b351-4595-8505-8ec52a903ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsMember_c229d865-ef82-4ec6-8cba-88d825f0d198" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RoyaltyMember_903604a5-0cd6-483c-88b9-b103e689ec43" xlink:to="loc_lgnd_FinancialRoyaltyAssetsMember_c229d865-ef82-4ec6-8cba-88d825f0d198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_7e6e72d2-5cc2-47b1-bdd7-cbc946ba460e" xlink:href="lgnd-20241231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0ec5e294-8485-4f88-be6e-77ff5177d1eb" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_7e6e72d2-5cc2-47b1-bdd7-cbc946ba460e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolCoreMember_2f951190-78fd-4512-be5c-1102600df182" xlink:href="lgnd-20241231.xsd#lgnd_MaterialSalesCaptisolCoreMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_MaterialSalesCaptisolMember_7e6e72d2-5cc2-47b1-bdd7-cbc946ba460e" xlink:to="loc_lgnd_MaterialSalesCaptisolCoreMember_2f951190-78fd-4512-be5c-1102600df182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolCOVIDMember_a28e7cdc-f763-4fb1-9851-f498c92fefac" xlink:href="lgnd-20241231.xsd#lgnd_MaterialSalesCaptisolCOVIDMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_MaterialSalesCaptisolMember_7e6e72d2-5cc2-47b1-bdd7-cbc946ba460e" xlink:to="loc_lgnd_MaterialSalesCaptisolCOVIDMember_a28e7cdc-f763-4fb1-9851-f498c92fefac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_c4ac1cef-262c-4440-885a-da09220771a3" xlink:href="lgnd-20241231.xsd#lgnd_ContractRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0ec5e294-8485-4f88-be6e-77ff5177d1eb" xlink:to="loc_lgnd_ContractRevenueMember_c4ac1cef-262c-4440-885a-da09220771a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_0a796fd7-5dc7-4178-a40d-f6dbebaafc23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContractRevenueMember_c4ac1cef-262c-4440-885a-da09220771a3" xlink:to="loc_us-gaap_ServiceMember_0a796fd7-5dc7-4178-a40d-f6dbebaafc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseFeesMember_67f926aa-1197-4a1f-9c8f-7fbdf558c066" xlink:href="lgnd-20241231.xsd#lgnd_LicenseFeesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContractRevenueMember_c4ac1cef-262c-4440-885a-da09220771a3" xlink:to="loc_lgnd_LicenseFeesMember_67f926aa-1197-4a1f-9c8f-7fbdf558c066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f8998d28-3517-4d0a-9340-4615bbf7f05f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_dd5d33db-3112-4e6a-8cbb-276974a31c74" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_f8998d28-3517-4d0a-9340-4615bbf7f05f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e1a298dd-cede-4af6-886e-2308c1917f79" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f8998d28-3517-4d0a-9340-4615bbf7f05f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e1a298dd-cede-4af6-886e-2308c1917f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7affe5a5-563e-4273-88a0-fb3f42aeb859" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_7c456c21-2112-4f4e-a33c-ca2a0aa2b50a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7affe5a5-563e-4273-88a0-fb3f42aeb859" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_7c456c21-2112-4f4e-a33c-ca2a0aa2b50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dd834177-e36a-411c-bba5-46aa3bcc0610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_7c456c21-2112-4f4e-a33c-ca2a0aa2b50a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dd834177-e36a-411c-bba5-46aa3bcc0610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f2bff3a7-ab1e-4598-9bc7-ea799c1489f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dd834177-e36a-411c-bba5-46aa3bcc0610" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f2bff3a7-ab1e-4598-9bc7-ea799c1489f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d9a28991-b6e9-4b43-ab6c-02be8f7dd2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f2bff3a7-ab1e-4598-9bc7-ea799c1489f3" xlink:to="loc_us-gaap_RestrictedStockMember_d9a28991-b6e9-4b43-ab6c-02be8f7dd2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_cfe2c28e-df5e-440a-ade1-ee7cf0efb4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f2bff3a7-ab1e-4598-9bc7-ea799c1489f3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_cfe2c28e-df5e-440a-ade1-ee7cf0efb4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_dd59891a-c2cf-40b3-9138-b03374ae0d71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f2bff3a7-ab1e-4598-9bc7-ea799c1489f3" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_dd59891a-c2cf-40b3-9138-b03374ae0d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_4f066fac-b19b-4dc3-90e7-bf771575f540" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_7c456c21-2112-4f4e-a33c-ca2a0aa2b50a" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_4f066fac-b19b-4dc3-90e7-bf771575f540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_85597d54-81ab-463a-8d44-70b682c8d382" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_4f066fac-b19b-4dc3-90e7-bf771575f540" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_85597d54-81ab-463a-8d44-70b682c8d382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1e5e4b4e-1dda-45b7-b032-a69f818959b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_4f066fac-b19b-4dc3-90e7-bf771575f540" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_1e5e4b4e-1dda-45b7-b032-a69f818959b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3019cf1f-8b02-4c76-a7c4-55122be3e1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_4f066fac-b19b-4dc3-90e7-bf771575f540" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3019cf1f-8b02-4c76-a7c4-55122be3e1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_51b68657-e30c-4d71-9578-9b48b815d8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_4f066fac-b19b-4dc3-90e7-bf771575f540" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_51b68657-e30c-4d71-9578-9b48b815d8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AgenusTransactionDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#AgenusTransactionDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AgenusTransactionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_64c3b6db-7bce-429d-b154-0e1f4cb62c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_fafa6d1f-a6f8-4c6f-9f1e-da59e1b2159e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_64c3b6db-7bce-429d-b154-0e1f4cb62c9b" xlink:to="loc_us-gaap_AssetAcquisitionTable_fafa6d1f-a6f8-4c6f-9f1e-da59e1b2159e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_26ec8753-4dc7-43ca-8345-095a09489b4f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_fafa6d1f-a6f8-4c6f-9f1e-da59e1b2159e" xlink:to="loc_srt_CounterpartyNameAxis_26ec8753-4dc7-43ca-8345-095a09489b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92330c18-512f-464c-a83e-6eddfb5834f0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_26ec8753-4dc7-43ca-8345-095a09489b4f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92330c18-512f-464c-a83e-6eddfb5834f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AgenusInc.Member_a6e934b3-f143-4f5d-8a11-f05eacbec924" xlink:href="lgnd-20241231.xsd#lgnd_AgenusInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92330c18-512f-464c-a83e-6eddfb5834f0" xlink:to="loc_lgnd_AgenusInc.Member_a6e934b3-f143-4f5d-8a11-f05eacbec924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AgenusPartneredProgramMember_025f0987-1acc-42fd-ba72-8aaeb65367cb" xlink:href="lgnd-20241231.xsd#lgnd_AgenusPartneredProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_92330c18-512f-464c-a83e-6eddfb5834f0" xlink:to="loc_lgnd_AgenusPartneredProgramMember_025f0987-1acc-42fd-ba72-8aaeb65367cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_39fb2c5b-8ee0-4083-8e39-f4f0172bd6b3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_fafa6d1f-a6f8-4c6f-9f1e-da59e1b2159e" xlink:to="loc_srt_ProductOrServiceAxis_39fb2c5b-8ee0-4083-8e39-f4f0172bd6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8c445437-13b2-43b2-86d9-bc7c83abbde5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_39fb2c5b-8ee0-4083-8e39-f4f0172bd6b3" xlink:to="loc_srt_ProductsAndServicesDomain_8c445437-13b2-43b2-86d9-bc7c83abbde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BMS986442Member_cb56b2c7-4c6a-4409-8aa6-b8f49da7cf3e" xlink:href="lgnd-20241231.xsd#lgnd_BMS986442Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8c445437-13b2-43b2-86d9-bc7c83abbde5" xlink:to="loc_lgnd_BMS986442Member_cb56b2c7-4c6a-4409-8aa6-b8f49da7cf3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AGEN2373Member_75cb8b14-fca7-443b-80ae-02f8676781a1" xlink:href="lgnd-20241231.xsd#lgnd_AGEN2373Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8c445437-13b2-43b2-86d9-bc7c83abbde5" xlink:to="loc_lgnd_AGEN2373Member_75cb8b14-fca7-443b-80ae-02f8676781a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_INCAGN2385Member_b107e762-8679-47ac-a438-dab0e4229c46" xlink:href="lgnd-20241231.xsd#lgnd_INCAGN2385Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8c445437-13b2-43b2-86d9-bc7c83abbde5" xlink:to="loc_lgnd_INCAGN2385Member_b107e762-8679-47ac-a438-dab0e4229c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_INCAGN2390Member_ad980790-1b98-4e83-b804-8b33ffffc79b" xlink:href="lgnd-20241231.xsd#lgnd_INCAGN2390Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8c445437-13b2-43b2-86d9-bc7c83abbde5" xlink:to="loc_lgnd_INCAGN2390Member_ad980790-1b98-4e83-b804-8b33ffffc79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MK4830Member_d08a5dfd-327d-4ba8-a57a-fa51ec1d341e" xlink:href="lgnd-20241231.xsd#lgnd_MK4830Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8c445437-13b2-43b2-86d9-bc7c83abbde5" xlink:to="loc_lgnd_MK4830Member_d08a5dfd-327d-4ba8-a57a-fa51ec1d341e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_UGN301Member_1b70c612-c8eb-419e-94b7-b19bd573ceea" xlink:href="lgnd-20241231.xsd#lgnd_UGN301Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8c445437-13b2-43b2-86d9-bc7c83abbde5" xlink:to="loc_lgnd_UGN301Member_1b70c612-c8eb-419e-94b7-b19bd573ceea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BOTBALMember_4110a2ec-37e1-48dc-8b0f-ae3054ec0151" xlink:href="lgnd-20241231.xsd#lgnd_BOTBALMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8c445437-13b2-43b2-86d9-bc7c83abbde5" xlink:to="loc_lgnd_BOTBALMember_4110a2ec-37e1-48dc-8b0f-ae3054ec0151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_19dcec56-9e80-461b-ab5d-f9917e3dd674" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_fafa6d1f-a6f8-4c6f-9f1e-da59e1b2159e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_19dcec56-9e80-461b-ab5d-f9917e3dd674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7ba8b8b6-47e2-489f-9d8c-e467a2a832e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_19dcec56-9e80-461b-ab5d-f9917e3dd674" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7ba8b8b6-47e2-489f-9d8c-e467a2a832e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_2b325ff0-c00a-4af7-8b2b-e5e6de6a862e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7ba8b8b6-47e2-489f-9d8c-e467a2a832e7" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_2b325ff0-c00a-4af7-8b2b-e5e6de6a862e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_43e4b8b9-ab84-41bb-b24e-e064d2d2ff9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7ba8b8b6-47e2-489f-9d8c-e467a2a832e7" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_43e4b8b9-ab84-41bb-b24e-e064d2d2ff9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_d254ad0f-320f-419d-a987-ede817bba468" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7ba8b8b6-47e2-489f-9d8c-e467a2a832e7" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_d254ad0f-320f-419d-a987-ede817bba468" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_b43449f4-e925-40ca-9411-0dd90065122d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7ba8b8b6-47e2-489f-9d8c-e467a2a832e7" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_b43449f4-e925-40ca-9411-0dd90065122d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_fafa6d1f-a6f8-4c6f-9f1e-da59e1b2159e" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsNet_f1649d78-adf8-4223-bd29-6f0f50b86f7e" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_lgnd_FinancialRoyaltyAssetsNet_f1649d78-adf8-4223-bd29-6f0f50b86f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceRoyaltyAgreementRoyaltyRate_8af6138c-4a33-48c0-a877-c6cbedb81d55" xlink:href="lgnd-20241231.xsd#lgnd_FinanceRoyaltyAgreementRoyaltyRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_lgnd_FinanceRoyaltyAgreementRoyaltyRate_8af6138c-4a33-48c0-a877-c6cbedb81d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate_1fd716dc-16e7-4ea1-be5c-f0045b449a8b" xlink:href="lgnd-20241231.xsd#lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate_1fd716dc-16e7-4ea1-be5c-f0045b449a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales_c030c36d-37fc-4056-9b42-63438b9ea3a1" xlink:href="lgnd-20241231.xsd#lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales_c030c36d-37fc-4056-9b42-63438b9ea3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeInstrumentAdditionalMaximumInvestment_8c30ccbd-f89d-44b6-ac39-724f5e94e7a4" xlink:href="lgnd-20241231.xsd#lgnd_DerivativeInstrumentAdditionalMaximumInvestment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_lgnd_DerivativeInstrumentAdditionalMaximumInvestment_8c30ccbd-f89d-44b6-ac39-724f5e94e7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyMaximumCapitalSourcing_4d05a07f-873d-4a71-8e3d-79fe506a9eee" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyMaximumCapitalSourcing"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_lgnd_FinancialRoyaltyMaximumCapitalSourcing_4d05a07f-873d-4a71-8e3d-79fe506a9eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaximumFinancingRoyaltyAsset_46f2c2e1-4789-42db-9ed2-12c9448ed8e6" xlink:href="lgnd-20241231.xsd#lgnd_MaximumFinancingRoyaltyAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_lgnd_MaximumFinancingRoyaltyAsset_46f2c2e1-4789-42db-9ed2-12c9448ed8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_bf5be6eb-8bb8-4143-ba95-f372fcd81650" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_bf5be6eb-8bb8-4143-ba95-f372fcd81650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1f2f98fb-2b1e-4281-9a0c-6f1a1e11ab93" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1f2f98fb-2b1e-4281-9a0c-6f1a1e11ab93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3ff0f89c-ce9a-4655-bc03-d1358e1e633d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3ff0f89c-ce9a-4655-bc03-d1358e1e633d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeNet_dfcc54ce-3e94-412e-bbf3-bb0ccd966293" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeNet_dfcc54ce-3e94-412e-bbf3-bb0ccd966293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_a41492eb-638c-4f94-916c-722f8cc258f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_5e880e22-499f-4ac7-aaac-e97aed4b9a5a" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_a41492eb-638c-4f94-916c-722f8cc258f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_18e555d3-6746-42c7-a713-9a9f54aaaf30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_509c2a1a-6022-4c63-ab93-e5ba0effce2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_18e555d3-6746-42c7-a713-9a9f54aaaf30" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_509c2a1a-6022-4c63-ab93-e5ba0effce2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_173fdc17-0ce1-415e-a19d-a6b6e927c64f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_509c2a1a-6022-4c63-ab93-e5ba0effce2d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_173fdc17-0ce1-415e-a19d-a6b6e927c64f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d7b06bd-6483-463f-8331-19fd9f18469d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_173fdc17-0ce1-415e-a19d-a6b6e927c64f" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d7b06bd-6483-463f-8331-19fd9f18469d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_APEIRONMember_1cb8c37c-044b-4f6c-80f6-4f2090dade6f" xlink:href="lgnd-20241231.xsd#lgnd_APEIRONMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d7b06bd-6483-463f-8331-19fd9f18469d" xlink:to="loc_lgnd_APEIRONMember_1cb8c37c-044b-4f6c-80f6-4f2090dade6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanIncMember_7fd1c172-0edf-4dce-9ea5-ed8c1a9d830e" xlink:href="lgnd-20241231.xsd#lgnd_NovanIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6d7b06bd-6483-463f-8331-19fd9f18469d" xlink:to="loc_lgnd_NovanIncMember_7fd1c172-0edf-4dce-9ea5-ed8c1a9d830e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_06dec5cf-55df-4f6d-81d8-0082a325919f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_509c2a1a-6022-4c63-ab93-e5ba0effce2d" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_06dec5cf-55df-4f6d-81d8-0082a325919f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_fde8c3d8-1993-40f0-8074-45547c545962" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_06dec5cf-55df-4f6d-81d8-0082a325919f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_fde8c3d8-1993-40f0-8074-45547c545962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvIOsHoldingAGMember_35dfea52-b4cb-4c7c-90c0-c514a2b5e39b" xlink:href="lgnd-20241231.xsd#lgnd_InvIOsHoldingAGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_fde8c3d8-1993-40f0-8074-45547c545962" xlink:to="loc_lgnd_InvIOsHoldingAGMember_35dfea52-b4cb-4c7c-90c0-c514a2b5e39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b7a185d-9280-4774-9ced-1276fc1bc52e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_509c2a1a-6022-4c63-ab93-e5ba0effce2d" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b7a185d-9280-4774-9ced-1276fc1bc52e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_1a2b0aa7-8610-4ded-babf-ba6cda06869a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1b7a185d-9280-4774-9ced-1276fc1bc52e" xlink:to="loc_us-gaap_RelatedPartyDomain_1a2b0aa7-8610-4ded-babf-ba6cda06869a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestorMember_f65c102c-e187-4568-bf20-28f5105e3022" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_1a2b0aa7-8610-4ded-babf-ba6cda06869a" xlink:to="loc_us-gaap_InvestorMember_f65c102c-e187-4568-bf20-28f5105e3022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2c16a918-c0c5-48e0-87c0-a314b7d1ddf7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_509c2a1a-6022-4c63-ab93-e5ba0effce2d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2c16a918-c0c5-48e0-87c0-a314b7d1ddf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4a1d1dc1-c823-4ce7-a5ec-8f57b09ca809" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2c16a918-c0c5-48e0-87c0-a314b7d1ddf7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4a1d1dc1-c823-4ce7-a5ec-8f57b09ca809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BridgeLoanMember_cee44ae9-078e-4e9f-b9f1-c4ffa3ed92b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BridgeLoanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4a1d1dc1-c823-4ce7-a5ec-8f57b09ca809" xlink:to="loc_us-gaap_BridgeLoanMember_cee44ae9-078e-4e9f-b9f1-c4ffa3ed92b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_92e8e5d6-ac27-4efb-aba8-2fba53d58e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_509c2a1a-6022-4c63-ab93-e5ba0effce2d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_92e8e5d6-ac27-4efb-aba8-2fba53d58e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fbd8a2c4-ffc3-45ba-a5d3-9483a94ce195" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_92e8e5d6-ac27-4efb-aba8-2fba53d58e8c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fbd8a2c4-ffc3-45ba-a5d3-9483a94ce195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_0615d781-15dd-4ad5-8f96-050202aeb584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_fbd8a2c4-ffc3-45ba-a5d3-9483a94ce195" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_0615d781-15dd-4ad5-8f96-050202aeb584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_36cfe184-ca3c-4826-8a31-6323060c50df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_509c2a1a-6022-4c63-ab93-e5ba0effce2d" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_36cfe184-ca3c-4826-8a31-6323060c50df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_07bac1bb-bf08-47b9-baba-66ff7675bed3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_36cfe184-ca3c-4826-8a31-6323060c50df" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_07bac1bb-bf08-47b9-baba-66ff7675bed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_9ea1e819-b606-4bee-9e25-a88bf957cccd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_07bac1bb-bf08-47b9-baba-66ff7675bed3" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_9ea1e819-b606-4bee-9e25-a88bf957cccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_8b8e6af1-b295-4732-bf2d-1eff02f5ee3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_509c2a1a-6022-4c63-ab93-e5ba0effce2d" xlink:to="loc_us-gaap_ValuationTechniqueAxis_8b8e6af1-b295-4732-bf2d-1eff02f5ee3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_3131c4cb-2a36-4c8e-ad54-2a3300bbd4e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_8b8e6af1-b295-4732-bf2d-1eff02f5ee3f" xlink:to="loc_us-gaap_ValuationTechniqueDomain_3131c4cb-2a36-4c8e-ad54-2a3300bbd4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_a91376c1-2b50-42ca-b1f5-1eb20a4b4599" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_3131c4cb-2a36-4c8e-ad54-2a3300bbd4e1" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_a91376c1-2b50-42ca-b1f5-1eb20a4b4599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_509c2a1a-6022-4c63-ab93-e5ba0effce2d" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f5358406-0c10-4323-aead-78a7ed76e352" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_f5358406-0c10-4323-aead-78a7ed76e352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5eae43a4-ad99-461a-95f3-b0f883e99a34" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_5eae43a4-ad99-461a-95f3-b0f883e99a34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_86f41374-6f40-49ca-a48b-f2d81bc17d1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_86f41374-6f40-49ca-a48b-f2d81bc17d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_f0b51771-3af7-43ca-a4d1-3509a6f3625a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_f0b51771-3af7-43ca-a4d1-3509a6f3625a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_61c12336-40af-467a-9ef6-874fe001d3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireEquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi_61c12336-40af-467a-9ef6-874fe001d3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EquityIssuanceCost_f167f3ce-0345-4ba1-ade5-00130b647650" xlink:href="lgnd-20241231.xsd#lgnd_EquityIssuanceCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_lgnd_EquityIssuanceCost_f167f3ce-0345-4ba1-ade5-00130b647650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_ef616604-d767-44c9-8182-ba013d6d5d98" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_ef616604-d767-44c9-8182-ba013d6d5d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6e8ce1fc-96b3-47e2-af6c-90b1301c7ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_6e8ce1fc-96b3-47e2-af6c-90b1301c7ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_cd0e2106-0e7e-434d-9b7c-ca0424a7a145" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_cd0e2106-0e7e-434d-9b7c-ca0424a7a145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationAcquiredPercentage_cdeff4a4-ff5e-4dda-99e9-4e3f6d992e10" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationAcquiredPercentage"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_lgnd_BusinessCombinationAcquiredPercentage_cdeff4a4-ff5e-4dda-99e9-4e3f6d992e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_08d830b5-87c4-4660-a732-0e64761c9531" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_08d830b5-87c4-4660-a732-0e64761c9531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_93e787c5-56d3-4a0e-ba80-df09b73a88a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_93e787c5-56d3-4a0e-ba80-df09b73a88a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_beed2651-1164-4240-b551-98c27bcfed17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_beed2651-1164-4240-b551-98c27bcfed17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_d247ab07-dbd1-4c10-aa81-205cb3c05867" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate_d247ab07-dbd1-4c10-aa81-205cb3c05867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_f7f68861-917f-46c7-8d76-a6812427836f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_f7f68861-917f-46c7-8d76-a6812427836f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_5834fafb-5eb2-4dc7-8179-e052779c927f" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_5834fafb-5eb2-4dc7-8179-e052779c927f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentMilestonePurchaseAgreement_739f616c-01cf-463d-8c4d-1aa1541f66a7" xlink:href="lgnd-20241231.xsd#lgnd_ContingentMilestonePurchaseAgreement"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_lgnd_ContingentMilestonePurchaseAgreement_739f616c-01cf-463d-8c4d-1aa1541f66a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_3c383fc3-44a4-4fbf-a1bd-4e89eb2cf8ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1e69b9aa-673a-463b-8ae3-00adf64742e8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_3c383fc3-44a4-4fbf-a1bd-4e89eb2cf8ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9055afb3-c9e5-4013-b450-f95b4bb5096a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0b51deff-b04e-419c-b6f8-8a6f4b788dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9055afb3-c9e5-4013-b450-f95b4bb5096a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0b51deff-b04e-419c-b6f8-8a6f4b788dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_01afd8bf-86a9-418c-9284-6d69d792497d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0b51deff-b04e-419c-b6f8-8a6f4b788dbf" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_01afd8bf-86a9-418c-9284-6d69d792497d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3d17ed30-24e3-4b99-ba0a-c2212d93832b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_01afd8bf-86a9-418c-9284-6d69d792497d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3d17ed30-24e3-4b99-ba0a-c2212d93832b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_APEIRONMember_3f61a630-5f90-418a-9083-ece430aa2f0c" xlink:href="lgnd-20241231.xsd#lgnd_APEIRONMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3d17ed30-24e3-4b99-ba0a-c2212d93832b" xlink:to="loc_lgnd_APEIRONMember_3f61a630-5f90-418a-9083-ece430aa2f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_b18d9e11-5bd4-45e1-aa0a-338b25edd3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0b51deff-b04e-419c-b6f8-8a6f4b788dbf" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_b18d9e11-5bd4-45e1-aa0a-338b25edd3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_edcb9b67-73c0-4cd7-baad-0568d9e45069" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b18d9e11-5bd4-45e1-aa0a-338b25edd3ab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_edcb9b67-73c0-4cd7-baad-0568d9e45069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets_8e93b9dc-6348-455c-827e-5fc41269ebf1" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b18d9e11-5bd4-45e1-aa0a-338b25edd3ab" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets_8e93b9dc-6348-455c-827e-5fc41269ebf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_de617cc0-525a-4c08-80ff-ba6497453442" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b18d9e11-5bd4-45e1-aa0a-338b25edd3ab" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_de617cc0-525a-4c08-80ff-ba6497453442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_a29ca3a1-ec58-415b-997c-bf3fbbefea0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b18d9e11-5bd4-45e1-aa0a-338b25edd3ab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_a29ca3a1-ec58-415b-997c-bf3fbbefea0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable_0dc6f12e-9c46-4fed-9b6e-3cdb4629a3ff" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b18d9e11-5bd4-45e1-aa0a-338b25edd3ab" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable_0dc6f12e-9c46-4fed-9b6e-3cdb4629a3ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ee810d47-c1ca-4cd1-909f-099378141424" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b18d9e11-5bd4-45e1-aa0a-338b25edd3ab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_ee810d47-c1ca-4cd1-909f-099378141424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2b058a0d-31df-45c7-b19e-15040ab69dab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_b18d9e11-5bd4-45e1-aa0a-338b25edd3ab" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_2b058a0d-31df-45c7-b19e-15040ab69dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b0ce9534-d25e-4788-8c7e-3209e45a35c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_55d863eb-a5d4-4436-8564-72fcd648f075" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b0ce9534-d25e-4788-8c7e-3209e45a35c5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_55d863eb-a5d4-4436-8564-72fcd648f075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ef505f1b-e899-480b-aa8c-38510a209307" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_55d863eb-a5d4-4436-8564-72fcd648f075" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ef505f1b-e899-480b-aa8c-38510a209307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04f01989-d8cd-4dab-916f-4e0fa5578266" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ef505f1b-e899-480b-aa8c-38510a209307" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04f01989-d8cd-4dab-916f-4e0fa5578266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NovanIncMember_02b8389e-4091-4011-a6ba-af465476fb52" xlink:href="lgnd-20241231.xsd#lgnd_NovanIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_04f01989-d8cd-4dab-916f-4e0fa5578266" xlink:to="loc_lgnd_NovanIncMember_02b8389e-4091-4011-a6ba-af465476fb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_55d863eb-a5d4-4436-8564-72fcd648f075" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6ef24731-6bf0-4a46-bfd0-17e3c2653488" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6ef24731-6bf0-4a46-bfd0-17e3c2653488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_b0f111a6-c7f7-476b-9e18-e30de9ce84f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_b0f111a6-c7f7-476b-9e18-e30de9ce84f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_2f3a6fcb-5157-4f98-9cc0-b6d061366709" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_2f3a6fcb-5157-4f98-9cc0-b6d061366709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_65416db6-e9d1-4897-8b2e-9cb64bb33487" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets_65416db6-e9d1-4897-8b2e-9cb64bb33487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_2cdb29fd-e68c-450d-b2c5-794d89a362e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets_2cdb29fd-e68c-450d-b2c5-794d89a362e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_691dd7c5-da63-4021-aff8-190b845cef4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_691dd7c5-da63-4021-aff8-190b845cef4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_83149b9a-0f05-4695-9c38-320873f40448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_us-gaap_Goodwill_83149b9a-0f05-4695-9c38-320873f40448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_662e2ed4-0cbd-4890-847c-db6d74f3ef99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_662e2ed4-0cbd-4890-847c-db6d74f3ef99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_6cca5e4a-a431-4604-9242-fa96e7ad696a" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities_6cca5e4a-a431-4604-9242-fa96e7ad696a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_7a98c77f-9a91-4a48-8dc5-1cda666b3c0d" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities_7a98c77f-9a91-4a48-8dc5-1cda666b3c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_cb29aca2-9f52-4f77-98da-320646d00c1b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_cb29aca2-9f52-4f77-98da-320646d00c1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationLoanFeesAndInterest_7fa799bc-c022-4948-a08f-c7d1661233b9" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationLoanFeesAndInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_lgnd_BusinessCombinationLoanFeesAndInterest_7fa799bc-c022-4948-a08f-c7d1661233b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_27e16252-3df5-4c95-80ff-d21a7eeeb73b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_546c2463-ace6-44dc-932e-c2b467bbf595" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_27e16252-3df5-4c95-80ff-d21a7eeeb73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6de211bb-c926-4234-9246-8303b40e760c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_6de211bb-c926-4234-9246-8303b40e760c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_ecff4c64-82aa-4255-aee1-f91a44a73df3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_ecff4c64-82aa-4255-aee1-f91a44a73df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_315f5527-f04c-4ae5-9ee6-4b38cc50f77e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_ecff4c64-82aa-4255-aee1-f91a44a73df3" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_315f5527-f04c-4ae5-9ee6-4b38cc50f77e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimordialGeneticsMember_3904cbcf-0676-4add-ab80-4d91ffba4565" xlink:href="lgnd-20241231.xsd#lgnd_PrimordialGeneticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_315f5527-f04c-4ae5-9ee6-4b38cc50f77e" xlink:to="loc_lgnd_PrimordialGeneticsMember_3904cbcf-0676-4add-ab80-4d91ffba4565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_9b0d01a5-3f82-494d-a55f-c249297868ad" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_srt_StatementScenarioAxis_9b0d01a5-3f82-494d-a55f-c249297868ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_f00eae3c-1c8b-492e-a428-391e0ccbe7fb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_9b0d01a5-3f82-494d-a55f-c249297868ad" xlink:to="loc_srt_ScenarioUnspecifiedDomain_f00eae3c-1c8b-492e-a428-391e0ccbe7fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_1a5ae47f-fc43-4704-a87c-c53913608f5b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_f00eae3c-1c8b-492e-a428-391e0ccbe7fb" xlink:to="loc_srt_ScenarioForecastMember_1a5ae47f-fc43-4704-a87c-c53913608f5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_36fc4a41-3a57-435d-a89b-52ea3b03a90c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_srt_CounterpartyNameAxis_36fc4a41-3a57-435d-a89b-52ea3b03a90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_594cd391-43f2-4835-98d8-798bb0f537bd" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_36fc4a41-3a57-435d-a89b-52ea3b03a90c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_594cd391-43f2-4835-98d8-798bb0f537bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember_cb7ab2bc-56fb-4658-8a6a-cc4f396da537" xlink:href="lgnd-20241231.xsd#lgnd_PrimroseBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_594cd391-43f2-4835-98d8-798bb0f537bd" xlink:to="loc_lgnd_PrimroseBioMember_cb7ab2bc-56fb-4658-8a6a-cc4f396da537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AgenusPartneredProgramMember_50bb83cf-963c-4acb-bc43-7c3e5c736100" xlink:href="lgnd-20241231.xsd#lgnd_AgenusPartneredProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_594cd391-43f2-4835-98d8-798bb0f537bd" xlink:to="loc_lgnd_AgenusPartneredProgramMember_50bb83cf-963c-4acb-bc43-7c3e5c736100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_318bdb39-d995-49b9-b301-1ec39edba7c2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_srt_ProductOrServiceAxis_318bdb39-d995-49b9-b301-1ec39edba7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e16b8691-ccdf-4d48-a5e5-5998869e6a11" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_318bdb39-d995-49b9-b301-1ec39edba7c2" xlink:to="loc_srt_ProductsAndServicesDomain_e16b8691-ccdf-4d48-a5e5-5998869e6a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PeliCRM197Member_a5b8eb9c-6755-4d85-8175-9c7be9989ee5" xlink:href="lgnd-20241231.xsd#lgnd_PeliCRM197Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e16b8691-ccdf-4d48-a5e5-5998869e6a11" xlink:to="loc_lgnd_PeliCRM197Member_a5b8eb9c-6755-4d85-8175-9c7be9989ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneAxis_d0337a49-db9d-4917-813e-eb70f11938d2" xlink:href="lgnd-20241231.xsd#lgnd_MilestoneAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_lgnd_MilestoneAxis_d0337a49-db9d-4917-813e-eb70f11938d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneDomain_57b979ec-d759-459a-801a-eb77589344ca" xlink:href="lgnd-20241231.xsd#lgnd_MilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_MilestoneAxis_d0337a49-db9d-4917-813e-eb70f11938d2" xlink:to="loc_lgnd_MilestoneDomain_57b979ec-d759-459a-801a-eb77589344ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BelowMilestoneMember_fb7999ea-01bc-49d9-b3f8-13a311f5ce6f" xlink:href="lgnd-20241231.xsd#lgnd_BelowMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_MilestoneDomain_57b979ec-d759-459a-801a-eb77589344ca" xlink:to="loc_lgnd_BelowMilestoneMember_fb7999ea-01bc-49d9-b3f8-13a311f5ce6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AboveMilestoneMember_551212d4-030e-4690-98a5-0c3cf4f05da5" xlink:href="lgnd-20241231.xsd#lgnd_AboveMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_MilestoneDomain_57b979ec-d759-459a-801a-eb77589344ca" xlink:to="loc_lgnd_AboveMilestoneMember_551212d4-030e-4690-98a5-0c3cf4f05da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_03476b5d-834a-4666-9133-ac1fdfb4feef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_03476b5d-834a-4666-9133-ac1fdfb4feef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_521dddda-8ff7-4773-9bb1-c7bcd7d7ec19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_03476b5d-834a-4666-9133-ac1fdfb4feef" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_521dddda-8ff7-4773-9bb1-c7bcd7d7ec19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_4e0dc57e-5133-4229-a379-75cc9b4b1ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_521dddda-8ff7-4773-9bb1-c7bcd7d7ec19" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_4e0dc57e-5133-4229-a379-75cc9b4b1ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3806be3b-3b49-4816-8b14-9455b1561705" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3806be3b-3b49-4816-8b14-9455b1561705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4a246384-5d37-4015-a1a1-d45c092dce37" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_3806be3b-3b49-4816-8b14-9455b1561705" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4a246384-5d37-4015-a1a1-d45c092dce37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PelicanTechnologyHoldingsIncMember_d2f48674-eb65-4357-b9e3-bf45d332e14e" xlink:href="lgnd-20241231.xsd#lgnd_PelicanTechnologyHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4a246384-5d37-4015-a1a1-d45c092dce37" xlink:to="loc_lgnd_PelicanTechnologyHoldingsIncMember_d2f48674-eb65-4357-b9e3-bf45d332e14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e24a1398-5cb2-4667-8fee-daacbf20f08b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e24a1398-5cb2-4667-8fee-daacbf20f08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3cb0fdbc-43cb-460f-a889-c466e7ac4be0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e24a1398-5cb2-4667-8fee-daacbf20f08b" xlink:to="loc_us-gaap_ClassOfStockDomain_3cb0fdbc-43cb-460f-a889-c466e7ac4be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c6b40ba8-0f9b-4c2d-91e1-0448a97728cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3cb0fdbc-43cb-460f-a889-c466e7ac4be0" xlink:to="loc_us-gaap_CommonStockMember_c6b40ba8-0f9b-4c2d-91e1-0448a97728cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_7e92b4f4-a4b0-4b71-80c0-923505df8d27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3cb0fdbc-43cb-460f-a889-c466e7ac4be0" xlink:to="loc_us-gaap_PreferredStockMember_7e92b4f4-a4b0-4b71-80c0-923505df8d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_050e9b69-b552-4fd1-9fbb-1e9a9ea0e0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_us-gaap_AwardTypeAxis_050e9b69-b552-4fd1-9fbb-1e9a9ea0e0e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d493c89-2ddb-4104-b6b7-33513a7de101" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_050e9b69-b552-4fd1-9fbb-1e9a9ea0e0e8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d493c89-2ddb-4104-b6b7-33513a7de101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_e7f67d82-af33-4147-8837-06ee2418a9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d493c89-2ddb-4104-b6b7-33513a7de101" xlink:to="loc_us-gaap_RestrictedStockMember_e7f67d82-af33-4147-8837-06ee2418a9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5015dcaa-51e1-499f-aab3-01746fba35ab" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5015dcaa-51e1-499f-aab3-01746fba35ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_3ce50969-e66e-4ba9-9f21-7b2e453d3524" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5015dcaa-51e1-499f-aab3-01746fba35ab" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_3ce50969-e66e-4ba9-9f21-7b2e453d3524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember_fa5ece35-7bc5-4747-8496-5e15dd2e24d4" xlink:href="lgnd-20241231.xsd#lgnd_PrimroseBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_3ce50969-e66e-4ba9-9f21-7b2e453d3524" xlink:to="loc_lgnd_PrimroseBioMember_fa5ece35-7bc5-4747-8496-5e15dd2e24d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e360e7b2-ee54-444e-8bf7-b3f017e16461" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration_235958bb-49e8-4110-b786-c286ca6d562f" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration_235958bb-49e8-4110-b786-c286ca6d562f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_cac12d7d-bd9b-4566-be30-ddb503958b2a" xlink:href="lgnd-20241231.xsd#lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_cac12d7d-bd9b-4566-be30-ddb503958b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneCompensationRate_4f6897fa-0bef-43de-a380-58f286aead84" xlink:href="lgnd-20241231.xsd#lgnd_MilestoneCompensationRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_lgnd_MilestoneCompensationRate_4f6897fa-0bef-43de-a380-58f286aead84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContracts_f892ab2a-d54f-423a-acc6-830d7bdac7c9" xlink:href="lgnd-20241231.xsd#lgnd_NumberOfContracts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_lgnd_NumberOfContracts_f892ab2a-d54f-423a-acc6-830d7bdac7c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SalesRevenueMilestone_d81bf852-7e1d-4a57-9140-7ba9d87ee407" xlink:href="lgnd-20241231.xsd#lgnd_SalesRevenueMilestone"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_lgnd_SalesRevenueMilestone_d81bf852-7e1d-4a57-9140-7ba9d87ee407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SalesContractInterestInSalesRevenue_646367f5-bbfa-4988-ab49-1fc69e5c594c" xlink:href="lgnd-20241231.xsd#lgnd_SalesContractInterestInSalesRevenue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_lgnd_SalesContractInterestInSalesRevenue_646367f5-bbfa-4988-ab49-1fc69e5c594c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_f0022e18-e66e-47c3-98ad-3aa1f61d2b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_f0022e18-e66e-47c3-98ad-3aa1f61d2b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_dc6e8030-22a9-4b5f-af01-9861af253acd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_dc6e8030-22a9-4b5f-af01-9861af253acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_12bd0306-e2b8-4c80-a087-5cb12053f71e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_us-gaap_BusinessExitCosts1_12bd0306-e2b8-4c80-a087-5cb12053f71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_08750b65-5b51-44e9-bee9-2464d766f00b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_08750b65-5b51-44e9-bee9-2464d766f00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_adc8107d-a0d4-4446-9570-d17621a89479" xlink:href="lgnd-20241231.xsd#lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_adc8107d-a0d4-4446-9570-d17621a89479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_a3a02416-3b09-4099-8c2d-56a855ae8f90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_a3a02416-3b09-4099-8c2d-56a855ae8f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_3e5509ed-9e78-49d3-899e-55183d28ef45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment_3e5509ed-9e78-49d3-899e-55183d28ef45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0dcc3191-06d6-4e28-ac6a-517f45dd99d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_0dcc3191-06d6-4e28-ac6a-517f45dd99d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_0926fcf6-a296-4929-8a01-2a6056b96d69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_094fa439-6376-485d-be3e-796c906a7099" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount_0926fcf6-a296-4929-8a01-2a6056b96d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_164640c2-b0a7-466f-b982-baab4c3121fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f964d8d6-3959-45cb-8050-3950d6622083" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_164640c2-b0a7-466f-b982-baab4c3121fa" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f964d8d6-3959-45cb-8050-3950d6622083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_998b6a26-1da5-4071-8f88-c768344c150e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f964d8d6-3959-45cb-8050-3950d6622083" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_998b6a26-1da5-4071-8f88-c768344c150e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_27d2d933-33a1-4fe8-9656-95ce8618cddc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_998b6a26-1da5-4071-8f88-c768344c150e" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_27d2d933-33a1-4fe8-9656-95ce8618cddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_266fd6b1-ae4b-4b06-8944-f7c5efac2f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_27d2d933-33a1-4fe8-9656-95ce8618cddc" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_266fd6b1-ae4b-4b06-8944-f7c5efac2f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_725175b5-633d-47a9-a9f9-4c11a0d8cb99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f964d8d6-3959-45cb-8050-3950d6622083" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_725175b5-633d-47a9-a9f9-4c11a0d8cb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4fb3c57e-61fd-4b54-a7bf-5924ef26b5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_725175b5-633d-47a9-a9f9-4c11a0d8cb99" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4fb3c57e-61fd-4b54-a7bf-5924ef26b5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PelicanTechnologyHoldingsIncMember_3c40f5e0-eef7-48c8-8ac6-d6590db0fb3c" xlink:href="lgnd-20241231.xsd#lgnd_PelicanTechnologyHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_4fb3c57e-61fd-4b54-a7bf-5924ef26b5a1" xlink:to="loc_lgnd_PelicanTechnologyHoldingsIncMember_3c40f5e0-eef7-48c8-8ac6-d6590db0fb3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_f964d8d6-3959-45cb-8050-3950d6622083" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_92ffc6f7-e4b1-482d-9203-666b5a4f507b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_92ffc6f7-e4b1-482d-9203-666b5a4f507b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_2e12e289-6b20-4df0-92e6-8c01618f7405" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets_2e12e289-6b20-4df0-92e6-8c01618f7405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_8fa7cc54-fbc5-4fb4-b7a7-6b4bd28bc937" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_8fa7cc54-fbc5-4fb4-b7a7-6b4bd28bc937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_67a366a1-5192-4748-9827-a083f1c1faae" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset_67a366a1-5192-4748-9827-a083f1c1faae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset_b088a7b0-7e18-4445-af15-de3074840fd4" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset_b088a7b0-7e18-4445-af15-de3074840fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_c64b3db9-cc5f-4ccf-a076-75bdfeed534f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities_c64b3db9-cc5f-4ccf-a076-75bdfeed534f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_7007cca8-8f79-418b-a4d7-1909fde57365" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue_7007cca8-8f79-418b-a4d7-1909fde57365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities_6eecc6d1-f711-4958-9fbd-70c0a3d7ece2" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities_6eecc6d1-f711-4958-9fbd-70c0a3d7ece2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_4a987cad-52a3-4c0f-abbf-c5d6bd407e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities_4a987cad-52a3-4c0f-abbf-c5d6bd407e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_f0499e04-18ad-4ed3-aad8-4eb146e8ccfa" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset_f0499e04-18ad-4ed3-aad8-4eb146e8ccfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_c58902ac-1948-4fa6-9e0a-a7f3d2eeeee6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_c58902ac-1948-4fa6-9e0a-a7f3d2eeeee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_043c0868-741d-4a96-970f-d4fda5eff8e9" xlink:href="lgnd-20241231.xsd#lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_043c0868-741d-4a96-970f-d4fda5eff8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_71504b95-63e5-4cbf-860b-b98112a76881" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ac088f8e-f3a3-4188-b2c2-c71b34419dcc" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions_71504b95-63e5-4cbf-860b-b98112a76881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_54e97071-c17b-48fe-a252-6f56eb4e37ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ade1da6c-2748-47c8-9e8a-a40f18e418ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_54e97071-c17b-48fe-a252-6f56eb4e37ae" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ade1da6c-2748-47c8-9e8a-a40f18e418ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_8ea74014-8c6f-4078-a1d4-8c5919d2376c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ade1da6c-2748-47c8-9e8a-a40f18e418ad" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_8ea74014-8c6f-4078-a1d4-8c5919d2376c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e997a2ee-bd5c-4526-9466-061c69c253f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_8ea74014-8c6f-4078-a1d4-8c5919d2376c" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e997a2ee-bd5c-4526-9466-061c69c253f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e33db3b1-bcc2-4c8f-9d90-edcea782a9a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_e997a2ee-bd5c-4526-9466-061c69c253f2" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_e33db3b1-bcc2-4c8f-9d90-edcea782a9a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102c2a5-ac5c-4bde-9f04-76c8a88d639d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ade1da6c-2748-47c8-9e8a-a40f18e418ad" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102c2a5-ac5c-4bde-9f04-76c8a88d639d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cd129850-fe48-4624-854e-899417433d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1102c2a5-ac5c-4bde-9f04-76c8a88d639d" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cd129850-fe48-4624-854e-899417433d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PelicanTechnologyHoldingsIncMember_f29c261e-9050-4cc0-8f96-9c404f694ccd" xlink:href="lgnd-20241231.xsd#lgnd_PelicanTechnologyHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_cd129850-fe48-4624-854e-899417433d3e" xlink:to="loc_lgnd_PelicanTechnologyHoldingsIncMember_f29c261e-9050-4cc0-8f96-9c404f694ccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationClassficationAxis_9fc1318b-89ab-439e-8781-3dbc76dcdd79" xlink:href="lgnd-20241231.xsd#lgnd_ConsiderationClassficationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ade1da6c-2748-47c8-9e8a-a40f18e418ad" xlink:to="loc_lgnd_ConsiderationClassficationAxis_9fc1318b-89ab-439e-8781-3dbc76dcdd79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationClassficationDomain_a3bb084b-cd9c-4dfb-9a26-bd0c840389bb" xlink:href="lgnd-20241231.xsd#lgnd_ConsiderationClassficationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ConsiderationClassficationAxis_9fc1318b-89ab-439e-8781-3dbc76dcdd79" xlink:to="loc_lgnd_ConsiderationClassficationDomain_a3bb084b-cd9c-4dfb-9a26-bd0c840389bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EquityMethodInvestmentsAllocationMember_796bfb25-8c50-4897-8031-a4121dbf5ac1" xlink:href="lgnd-20241231.xsd#lgnd_EquityMethodInvestmentsAllocationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ConsiderationClassficationDomain_a3bb084b-cd9c-4dfb-9a26-bd0c840389bb" xlink:to="loc_lgnd_EquityMethodInvestmentsAllocationMember_796bfb25-8c50-4897-8031-a4121dbf5ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EquitySecuritiesAllocationMember_a6a7d904-bbaa-475b-9388-97cf087d925f" xlink:href="lgnd-20241231.xsd#lgnd_EquitySecuritiesAllocationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ConsiderationClassficationDomain_a3bb084b-cd9c-4dfb-9a26-bd0c840389bb" xlink:to="loc_lgnd_EquitySecuritiesAllocationMember_a6a7d904-bbaa-475b-9388-97cf087d925f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeAssetsMember_c1c978f1-face-4fd6-8d40-099a723b04b9" xlink:href="lgnd-20241231.xsd#lgnd_DerivativeAssetsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ConsiderationClassficationDomain_a3bb084b-cd9c-4dfb-9a26-bd0c840389bb" xlink:to="loc_lgnd_DerivativeAssetsMember_c1c978f1-face-4fd6-8d40-099a723b04b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e9b9d945-ad88-4315-9a61-a74aab7624c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ade1da6c-2748-47c8-9e8a-a40f18e418ad" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e9b9d945-ad88-4315-9a61-a74aab7624c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_bac6d76a-6b5d-425c-8cea-c9daf3833f74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e9b9d945-ad88-4315-9a61-a74aab7624c7" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_bac6d76a-6b5d-425c-8cea-c9daf3833f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SpinoffofOmniAbNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e52f5cc5-5620-4abb-949f-04ff3cf9ac3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cc59c8f7-91e3-425f-b408-d835e84f9e17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_e52f5cc5-5620-4abb-949f-04ff3cf9ac3c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cc59c8f7-91e3-425f-b408-d835e84f9e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_7f54708a-853d-4da7-b4d6-c92cd22bbeb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cc59c8f7-91e3-425f-b408-d835e84f9e17" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_7f54708a-853d-4da7-b4d6-c92cd22bbeb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_b3260f29-debf-4c38-9bf8-f6106408a769" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_7f54708a-853d-4da7-b4d6-c92cd22bbeb7" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_b3260f29-debf-4c38-9bf8-f6106408a769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_dc319cf6-1abd-4715-948d-8727956bb0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_b3260f29-debf-4c38-9bf8-f6106408a769" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_dc319cf6-1abd-4715-948d-8727956bb0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_96245b7f-3721-4e68-90a0-c672ff1c1ec6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cc59c8f7-91e3-425f-b408-d835e84f9e17" xlink:to="loc_srt_StatementScenarioAxis_96245b7f-3721-4e68-90a0-c672ff1c1ec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7d758e1b-b446-4168-a216-fb83887e47ef" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_96245b7f-3721-4e68-90a0-c672ff1c1ec6" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7d758e1b-b446-4168-a216-fb83887e47ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScenarioAdjustmentMember_d2d84b71-727e-46c6-aca2-3437eb91ab58" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScenarioAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_7d758e1b-b446-4168-a216-fb83887e47ef" xlink:to="loc_us-gaap_ScenarioAdjustmentMember_d2d84b71-727e-46c6-aca2-3437eb91ab58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3465aee0-9c5f-4f1b-b767-eedf6c8f8697" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_dece00f0-c8e2-4039-baee-5d526f7f9d23" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_719c49d6-3c3b-4895-aad0-dbc510381a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_cc59c8f7-91e3-425f-b408-d835e84f9e17" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_719c49d6-3c3b-4895-aad0-dbc510381a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed_68ed47dc-e0e1-4598-b0f0-f9fb12efe971" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_719c49d6-3c3b-4895-aad0-dbc510381a9e" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed_68ed47dc-e0e1-4598-b0f0-f9fb12efe971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_7205a04c-332f-444c-ac2e-a2fbefc21e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_719c49d6-3c3b-4895-aad0-dbc510381a9e" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_7205a04c-332f-444c-ac2e-a2fbefc21e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_a492e300-6759-4db6-ba11-57194495c022" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2d25b822-8394-42b0-a758-162278ff69cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_a492e300-6759-4db6-ba11-57194495c022" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2d25b822-8394-42b0-a758-162278ff69cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_26cd54fa-11b1-4837-a608-972bb7decdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2d25b822-8394-42b0-a758-162278ff69cf" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_26cd54fa-11b1-4837-a608-972bb7decdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_4e452300-7b82-4c08-8d8d-2c77065d859c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_26cd54fa-11b1-4837-a608-972bb7decdc3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_4e452300-7b82-4c08-8d8d-2c77065d859c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_87791f03-ebc5-45d0-9a65-b830801fb37c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_4e452300-7b82-4c08-8d8d-2c77065d859c" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_87791f03-ebc5-45d0-9a65-b830801fb37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_99859ea6-a282-4262-9491-d9e2e0d0f05b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2d25b822-8394-42b0-a758-162278ff69cf" xlink:to="loc_srt_ProductOrServiceAxis_99859ea6-a282-4262-9491-d9e2e0d0f05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0d867e6d-9043-4e8b-bbbb-5b013cdc918e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_99859ea6-a282-4262-9491-d9e2e0d0f05b" xlink:to="loc_srt_ProductsAndServicesDomain_0d867e6d-9043-4e8b-bbbb-5b013cdc918e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_c8960038-6fa3-4743-a346-0beb5b02254a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0d867e6d-9043-4e8b-bbbb-5b013cdc918e" xlink:to="loc_us-gaap_RoyaltyMember_c8960038-6fa3-4743-a346-0beb5b02254a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContractRevenueMember_9b607db4-b5ea-420a-9ca3-7fed9ec1c699" xlink:href="lgnd-20241231.xsd#lgnd_ContractRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0d867e6d-9043-4e8b-bbbb-5b013cdc918e" xlink:to="loc_lgnd_ContractRevenueMember_9b607db4-b5ea-420a-9ca3-7fed9ec1c699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_2d25b822-8394-42b0-a758-162278ff69cf" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_088847ff-23f0-4696-ba84-54f1297c640b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_088847ff-23f0-4696-ba84-54f1297c640b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_5262f459-4a2f-4322-a342-b2957e6cb11a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_088847ff-23f0-4696-ba84-54f1297c640b" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_5262f459-4a2f-4322-a342-b2957e6cb11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_9ed86156-1066-470b-8425-00e4f68e048a" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_9ed86156-1066-470b-8425-00e4f68e048a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_dfff7126-4024-48af-ab2f-edcc9960fc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_9ed86156-1066-470b-8425-00e4f68e048a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization_dfff7126-4024-48af-ab2f-edcc9960fc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_440bb73d-e947-425b-9e1a-f394bf949307" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_9ed86156-1066-470b-8425-00e4f68e048a" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment_440bb73d-e947-425b-9e1a-f394bf949307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_96d12c58-ab4c-4719-9d03-bbc1f91630a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_9ed86156-1066-470b-8425-00e4f68e048a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_96d12c58-ab4c-4719-9d03-bbc1f91630a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_62fefbdf-0283-4419-bcc8-d68102435421" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract_9ed86156-1066-470b-8425-00e4f68e048a" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_62fefbdf-0283-4419-bcc8-d68102435421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_dec421be-dd44-41bc-9de6-fb81ebc58a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_dec421be-dd44-41bc-9de6-fb81ebc58a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_62339bc6-9c23-42b5-bdfc-ad521e9c7b05" xlink:href="lgnd-20241231.xsd#lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:to="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_62339bc6-9c23-42b5-bdfc-ad521e9c7b05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments_52966caf-6731-465c-9900-0202aa432767" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_62339bc6-9c23-42b5-bdfc-ad521e9c7b05" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments_52966caf-6731-465c-9900-0202aa432767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_68932c48-7f50-4e28-a721-530efd74899d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_62339bc6-9c23-42b5-bdfc-ad521e9c7b05" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_68932c48-7f50-4e28-a721-530efd74899d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_360962d0-70f8-452b-8fc5-a2def0eace19" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract_62339bc6-9c23-42b5-bdfc-ad521e9c7b05" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense_360962d0-70f8-452b-8fc5-a2def0eace19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_3d591630-6f1c-4406-b008-4cc6a4a7e70c" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense_3d591630-6f1c-4406-b008-4cc6a4a7e70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_f76efe2e-87ff-44cc-b241-7cbe9e3335d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_f76efe2e-87ff-44cc-b241-7cbe9e3335d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_a54bdae7-7773-4f6a-9061-910a0de6f739" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:to="loc_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation_a54bdae7-7773-4f6a-9061-910a0de6f739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6fceecc4-d2bf-4a3a-a266-0d7ef71a0fb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_ccc59df1-73bc-44f4-ad36-8cfe61dc8008" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_6fceecc4-d2bf-4a3a-a266-0d7ef71a0fb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9ccc78d3-42b6-4fdd-aa42-10e3679c991c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_dc2c6870-060e-43c7-baa3-f0f5ea5059db" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_9ccc78d3-42b6-4fdd-aa42-10e3679c991c" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_dc2c6870-060e-43c7-baa3-f0f5ea5059db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_76a46369-f4a4-4307-9f5d-6ae15ae7741d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_dc2c6870-060e-43c7-baa3-f0f5ea5059db" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_76a46369-f4a4-4307-9f5d-6ae15ae7741d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_520f583c-c79f-464f-ae09-3c7233dd380e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_76a46369-f4a4-4307-9f5d-6ae15ae7741d" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_520f583c-c79f-464f-ae09-3c7233dd380e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDiscontinuedOperationsMember_352b0e9a-b410-42c0-b7b7-c2b3f6a09341" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_520f583c-c79f-464f-ae09-3c7233dd380e" xlink:to="loc_us-gaap_SegmentDiscontinuedOperationsMember_352b0e9a-b410-42c0-b7b7-c2b3f6a09341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_10b39894-9650-4b5f-8e88-85e41f0d978c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_dc2c6870-060e-43c7-baa3-f0f5ea5059db" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_10b39894-9650-4b5f-8e88-85e41f0d978c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_c746cfa5-6557-4e54-bbad-19da0fdc3bd9" xlink:href="lgnd-20241231.xsd#lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_10b39894-9650-4b5f-8e88-85e41f0d978c" xlink:to="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_c746cfa5-6557-4e54-bbad-19da0fdc3bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration_24641f7a-69f0-4dbd-9eed-b8b83e6fdf25" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_c746cfa5-6557-4e54-bbad-19da0fdc3bd9" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration_24641f7a-69f0-4dbd-9eed-b8b83e6fdf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_d8644bc4-ac6d-4485-9b0e-82f9706353b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_c746cfa5-6557-4e54-bbad-19da0fdc3bd9" xlink:to="loc_us-gaap_DepreciationAndAmortizationDiscontinuedOperations_d8644bc4-ac6d-4485-9b0e-82f9706353b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense_d36eaf12-df1b-4ca8-8664-22a96e7e0477" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract_c746cfa5-6557-4e54-bbad-19da0fdc3bd9" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense_d36eaf12-df1b-4ca8-8664-22a96e7e0477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_ec46a937-ed13-4834-91a5-6a17e1a222f5" xlink:href="lgnd-20241231.xsd#lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_10b39894-9650-4b5f-8e88-85e41f0d978c" xlink:to="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_ec46a937-ed13-4834-91a5-6a17e1a222f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired_d7ce6f73-074f-443b-9116-e7360d1c7979" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_ec46a937-ed13-4834-91a5-6a17e1a222f5" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired_d7ce6f73-074f-443b-9116-e7360d1c7979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpenditureDiscontinuedOperations_c79b68b3-a886-47b6-b480-872fb1901fec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_ec46a937-ed13-4834-91a5-6a17e1a222f5" xlink:to="loc_us-gaap_CapitalExpenditureDiscontinuedOperations_c79b68b3-a886-47b6-b480-872fb1901fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity_269a83d4-8bdb-42bf-bb16-e42a0e5a87d0" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsToContingentValueRightHoldersInvestingActivity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract_ec46a937-ed13-4834-91a5-6a17e1a222f5" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity_269a83d4-8bdb-42bf-bb16-e42a0e5a87d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract_69a344f9-4155-4e17-97c0-8fd3eb9343b9" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_10b39894-9650-4b5f-8e88-85e41f0d978c" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract_69a344f9-4155-4e17-97c0-8fd3eb9343b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_37f97fc2-ab16-4aa8-905f-da34eefc9573" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsToContingentValueRightHoldersFinancingActivity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract_69a344f9-4155-4e17-97c0-8fd3eb9343b9" xlink:to="loc_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity_37f97fc2-ab16-4aa8-905f-da34eefc9573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2a220a10-59ed-44c3-b4b1-b51b55485d92" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_10b39894-9650-4b5f-8e88-85e41f0d978c" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2a220a10-59ed-44c3-b4b1-b51b55485d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid_a6eea7a4-2cab-4963-86c8-53de362785cd" xlink:href="lgnd-20241231.xsd#lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_2a220a10-59ed-44c3-b4b1-b51b55485d92" xlink:to="loc_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid_a6eea7a4-2cab-4963-86c8-53de362785cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56f8d53b-1df3-40a5-9de3-ce6d4b85cab1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e8f68082-d37d-4765-a6a8-b8b5dca60390" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_56f8d53b-1df3-40a5-9de3-ce6d4b85cab1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e8f68082-d37d-4765-a6a8-b8b5dca60390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1004c702-709f-4a03-95a8-1fffd663c8b2" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e8f68082-d37d-4765-a6a8-b8b5dca60390" xlink:to="loc_srt_CounterpartyNameAxis_1004c702-709f-4a03-95a8-1fffd663c8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1004c702-709f-4a03-95a8-1fffd663c8b2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_QARZIBAMember_e5f712b8-b38b-4951-bd6c-1e3340c0c9c9" xlink:href="lgnd-20241231.xsd#lgnd_QARZIBAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:to="loc_lgnd_QARZIBAMember_e5f712b8-b38b-4951-bd6c-1e3340c0c9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AgenusInc.Member_2e35b4bc-a813-4fce-bcc1-7f5dc385aede" xlink:href="lgnd-20241231.xsd#lgnd_AgenusInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:to="loc_lgnd_AgenusInc.Member_2e35b4bc-a813-4fce-bcc1-7f5dc385aede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ToleranceTherapeuticsMember_62458815-9355-4a8c-966c-0017bcbaea98" xlink:href="lgnd-20241231.xsd#lgnd_ToleranceTherapeuticsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:to="loc_lgnd_ToleranceTherapeuticsMember_62458815-9355-4a8c-966c-0017bcbaea98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EnsifentrineMember_180465a5-71a1-4c8f-9c2c-b15d2692b53b" xlink:href="lgnd-20241231.xsd#lgnd_EnsifentrineMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:to="loc_lgnd_EnsifentrineMember_180465a5-71a1-4c8f-9c2c-b15d2692b53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ElutiaAndCorMatrixMember_38ef31df-38c0-49fd-96ad-b6cf61f05845" xlink:href="lgnd-20241231.xsd#lgnd_ElutiaAndCorMatrixMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:to="loc_lgnd_ElutiaAndCorMatrixMember_38ef31df-38c0-49fd-96ad-b6cf61f05845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvIOsMember_aee05cf6-af41-4b47-b87c-099281f53b89" xlink:href="lgnd-20241231.xsd#lgnd_InvIOsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:to="loc_lgnd_InvIOsMember_aee05cf6-af41-4b47-b87c-099281f53b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisMember_ca73e043-e5fb-47d8-91f6-70719315bad0" xlink:href="lgnd-20241231.xsd#lgnd_SelexisMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:to="loc_lgnd_SelexisMember_ca73e043-e5fb-47d8-91f6-70719315bad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OvidTherapeuticsMember_22e10280-160b-4c3e-a802-8131afa91fcd" xlink:href="lgnd-20241231.xsd#lgnd_OvidTherapeuticsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4d625697-9537-4772-b688-7ee980f4d135" xlink:to="loc_lgnd_OvidTherapeuticsMember_22e10280-160b-4c3e-a802-8131afa91fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_35ad0854-d938-4345-b206-5be53202071d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e8f68082-d37d-4765-a6a8-b8b5dca60390" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_35ad0854-d938-4345-b206-5be53202071d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsGross_95f6234c-0cf8-4cf1-9bc0-b3719e6181e9" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_35ad0854-d938-4345-b206-5be53202071d" xlink:to="loc_lgnd_FinancialRoyaltyAssetsGross_95f6234c-0cf8-4cf1-9bc0-b3719e6181e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsAllowance_e59a0c34-2518-4bb4-aab6-3e60b78023aa" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_35ad0854-d938-4345-b206-5be53202071d" xlink:to="loc_lgnd_FinancialRoyaltyAssetsAllowance_e59a0c34-2518-4bb4-aab6-3e60b78023aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsNet_1d711f13-40c4-4458-8356-c15249621706" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_35ad0854-d938-4345-b206-5be53202071d" xlink:to="loc_lgnd_FinancialRoyaltyAssetsNet_1d711f13-40c4-4458-8356-c15249621706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsNetCurrent_fbcd1ac5-8244-4bcd-ad7d-07dec1596200" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_35ad0854-d938-4345-b206-5be53202071d" xlink:to="loc_lgnd_FinancialRoyaltyAssetsNetCurrent_fbcd1ac5-8244-4bcd-ad7d-07dec1596200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c7f680b3-62fc-47ba-97a6-0dd9240ef1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f209a7b3-7a95-49ca-8f57-ff5f6c90b4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c7f680b3-62fc-47ba-97a6-0dd9240ef1ee" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f209a7b3-7a95-49ca-8f57-ff5f6c90b4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_71626936-8dc6-4b7a-9494-0f7d7bdd8460" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f209a7b3-7a95-49ca-8f57-ff5f6c90b4c0" xlink:to="loc_srt_CounterpartyNameAxis_71626936-8dc6-4b7a-9494-0f7d7bdd8460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41fd63bc-39bf-4586-9153-36c96341fe79" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_71626936-8dc6-4b7a-9494-0f7d7bdd8460" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41fd63bc-39bf-4586-9153-36c96341fe79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OvidTherapeuticsMember_765c9ca9-dda1-466c-9505-0954f890da38" xlink:href="lgnd-20241231.xsd#lgnd_OvidTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41fd63bc-39bf-4586-9153-36c96341fe79" xlink:to="loc_lgnd_OvidTherapeuticsMember_765c9ca9-dda1-466c-9505-0954f890da38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SelexisMember_aa366eb3-d37a-4770-b58d-cc410f4abaf2" xlink:href="lgnd-20241231.xsd#lgnd_SelexisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41fd63bc-39bf-4586-9153-36c96341fe79" xlink:to="loc_lgnd_SelexisMember_aa366eb3-d37a-4770-b58d-cc410f4abaf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ElutiaAndCorMatrixMember_f257581f-b06a-4fd4-8e92-57e91acd6196" xlink:href="lgnd-20241231.xsd#lgnd_ElutiaAndCorMatrixMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41fd63bc-39bf-4586-9153-36c96341fe79" xlink:to="loc_lgnd_ElutiaAndCorMatrixMember_f257581f-b06a-4fd4-8e92-57e91acd6196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EnsifentrineMember_c18961fe-2e44-4f63-9f52-1cdcca9297e7" xlink:href="lgnd-20241231.xsd#lgnd_EnsifentrineMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_41fd63bc-39bf-4586-9153-36c96341fe79" xlink:to="loc_lgnd_EnsifentrineMember_c18961fe-2e44-4f63-9f52-1cdcca9297e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_21ca4897-b923-4116-9ecf-675ec19a3ca6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f209a7b3-7a95-49ca-8f57-ff5f6c90b4c0" xlink:to="loc_srt_ProductOrServiceAxis_21ca4897-b923-4116-9ecf-675ec19a3ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d0c197b9-45d8-4578-beea-cd84d39e89b9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_21ca4897-b923-4116-9ecf-675ec19a3ca6" xlink:to="loc_srt_ProductsAndServicesDomain_d0c197b9-45d8-4578-beea-cd84d39e89b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SoticlestatMember_d6b1ad6c-4301-4f06-a2c6-59b9b6a192a4" xlink:href="lgnd-20241231.xsd#lgnd_SoticlestatMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d0c197b9-45d8-4578-beea-cd84d39e89b9" xlink:to="loc_lgnd_SoticlestatMember_d6b1ad6c-4301-4f06-a2c6-59b9b6a192a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvIOsMember_ca814099-5e74-43c5-9bba-6faf9414af48" xlink:href="lgnd-20241231.xsd#lgnd_InvIOsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d0c197b9-45d8-4578-beea-cd84d39e89b9" xlink:to="loc_lgnd_InvIOsMember_ca814099-5e74-43c5-9bba-6faf9414af48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_QARZIBAMember_51c92dc1-4277-4ec2-9efb-4e009c575488" xlink:href="lgnd-20241231.xsd#lgnd_QARZIBAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d0c197b9-45d8-4578-beea-cd84d39e89b9" xlink:to="loc_lgnd_QARZIBAMember_51c92dc1-4277-4ec2-9efb-4e009c575488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d680904d-6a64-4173-89ae-63d2ebe99fb1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f209a7b3-7a95-49ca-8f57-ff5f6c90b4c0" xlink:to="loc_srt_RangeAxis_d680904d-6a64-4173-89ae-63d2ebe99fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_23eee21f-9510-4ffe-aaf0-151a26c5e779" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d680904d-6a64-4173-89ae-63d2ebe99fb1" xlink:to="loc_srt_RangeMember_23eee21f-9510-4ffe-aaf0-151a26c5e779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4894b216-3d20-4d7d-bb2a-c764696412fc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_23eee21f-9510-4ffe-aaf0-151a26c5e779" xlink:to="loc_srt_MaximumMember_4894b216-3d20-4d7d-bb2a-c764696412fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_d5308f75-c4b2-462d-98af-04a7c6f69849" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f209a7b3-7a95-49ca-8f57-ff5f6c90b4c0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_d5308f75-c4b2-462d-98af-04a7c6f69849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_85c0aa40-9cd9-490c-8514-5d8018be4dae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_d5308f75-c4b2-462d-98af-04a7c6f69849" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_85c0aa40-9cd9-490c-8514-5d8018be4dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ToleranceTherapeuticsMember_f2cb78ff-2d79-404f-a432-b8856902d00b" xlink:href="lgnd-20241231.xsd#lgnd_ToleranceTherapeuticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_85c0aa40-9cd9-490c-8514-5d8018be4dae" xlink:to="loc_lgnd_ToleranceTherapeuticsMember_f2cb78ff-2d79-404f-a432-b8856902d00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_APEIRONMember_accf0e56-5883-438f-8258-a477a43f211f" xlink:href="lgnd-20241231.xsd#lgnd_APEIRONMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_85c0aa40-9cd9-490c-8514-5d8018be4dae" xlink:to="loc_lgnd_APEIRONMember_accf0e56-5883-438f-8258-a477a43f211f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_f209a7b3-7a95-49ca-8f57-ff5f6c90b4c0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ImpairmentLossOnFinancialRoyaltyAssets_a05398a5-176b-47c7-8393-59bd174daf50" xlink:href="lgnd-20241231.xsd#lgnd_ImpairmentLossOnFinancialRoyaltyAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_lgnd_ImpairmentLossOnFinancialRoyaltyAssets_a05398a5-176b-47c7-8393-59bd174daf50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets_5d32ae45-29c1-4cf8-8dab-d5a0ae4b0840" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets_5d32ae45-29c1-4cf8-8dab-d5a0ae4b0840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_c9112d76-dd3c-4d01-bc8d-be0300c69aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_c9112d76-dd3c-4d01-bc8d-be0300c69aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ProductRoyaltyPercentage_c0cb5ccc-405f-443d-ad93-2bfb4eacf132" xlink:href="lgnd-20241231.xsd#lgnd_ProductRoyaltyPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_lgnd_ProductRoyaltyPercentage_c0cb5ccc-405f-443d-ad93-2bfb4eacf132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_40678b35-b716-4b96-ba8a-66c65d329dca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_40678b35-b716-4b96-ba8a-66c65d329dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsGross_e112a74b-9f0c-48c5-aca4-eb43206e109b" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_lgnd_FinancialRoyaltyAssetsGross_e112a74b-9f0c-48c5-aca4-eb43206e109b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_c2048395-78ae-4604-8a56-96071f2c7879" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_c2048395-78ae-4604-8a56-96071f2c7879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_5239267a-89fd-49f8-bda6-d2c3b22e4232" xlink:href="lgnd-20241231.xsd#lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_5239267a-89fd-49f8-bda6-d2c3b22e4232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CommercialLicenseRightsCreditLossAdjustment_220ea29d-41ae-4518-a434-a8952e463144" xlink:href="lgnd-20241231.xsd#lgnd_CommercialLicenseRightsCreditLossAdjustment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_lgnd_CommercialLicenseRightsCreditLossAdjustment_220ea29d-41ae-4518-a434-a8952e463144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_8b5ea1db-4aca-4892-812f-a16885e4769d" xlink:href="lgnd-20241231.xsd#lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone_8b5ea1db-4aca-4892-812f-a16885e4769d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SalesContractInterestInSalesRevenue_e3bf8f10-8204-4b62-bd8e-80b2be9a8caa" xlink:href="lgnd-20241231.xsd#lgnd_SalesContractInterestInSalesRevenue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c477c6c-4a43-4020-9478-af4e1198bdf5" xlink:to="loc_lgnd_SalesContractInterestInSalesRevenue_e3bf8f10-8204-4b62-bd8e-80b2be9a8caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsInvestmentCategoriesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_4ec2d5cf-5cef-4dcb-b5a3-aedf00cb1066" xlink:href="lgnd-20241231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7d32c418-0930-4813-8ca2-7d5c3b89e1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_4ec2d5cf-5cef-4dcb-b5a3-aedf00cb1066" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7d32c418-0930-4813-8ca2-7d5c3b89e1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a5024319-aa57-4035-a370-ba3d4278fb19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7d32c418-0930-4813-8ca2-7d5c3b89e1bf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a5024319-aa57-4035-a370-ba3d4278fb19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e853239-99b4-483e-a1bb-2efb866727c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a5024319-aa57-4035-a370-ba3d4278fb19" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e853239-99b4-483e-a1bb-2efb866727c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_663a39b2-8eaa-48b2-ae16-04ceb336c70e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e853239-99b4-483e-a1bb-2efb866727c5" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_663a39b2-8eaa-48b2-ae16-04ceb336c70e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MutualFundMember_9306fc34-9499-4cb0-b13f-9632dea7dbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MutualFundMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e853239-99b4-483e-a1bb-2efb866727c5" xlink:to="loc_us-gaap_MutualFundMember_9306fc34-9499-4cb0-b13f-9632dea7dbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a514d6cc-2f92-46f8-83ce-f8fbec8e7fce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e853239-99b4-483e-a1bb-2efb866727c5" xlink:to="loc_us-gaap_CommercialPaperMember_a514d6cc-2f92-46f8-83ce-f8fbec8e7fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_36e2fc2c-04ef-4816-ad13-2a1a9ca07cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DemandDepositsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e853239-99b4-483e-a1bb-2efb866727c5" xlink:to="loc_us-gaap_DemandDepositsMember_36e2fc2c-04ef-4816-ad13-2a1a9ca07cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_cb927720-a9b0-40c5-9f01-66522b08c668" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e853239-99b4-483e-a1bb-2efb866727c5" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_cb927720-a9b0-40c5-9f01-66522b08c668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_b8d9484b-ad77-4bb1-bdc3-330996df0efa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e853239-99b4-483e-a1bb-2efb866727c5" xlink:to="loc_us-gaap_EquitySecuritiesMember_b8d9484b-ad77-4bb1-bdc3-330996df0efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_f07eb9ea-cf79-4e3f-bda4-cadece2b0d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3e853239-99b4-483e-a1bb-2efb866727c5" xlink:to="loc_us-gaap_MunicipalBondsMember_f07eb9ea-cf79-4e3f-bda4-cadece2b0d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e61fa37e-1628-4776-afc9-1ea706638760" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_7d32c418-0930-4813-8ca2-7d5c3b89e1bf" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e61fa37e-1628-4776-afc9-1ea706638760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2a32ab0d-b1f8-43c0-9e2a-a675a7020734" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e61fa37e-1628-4776-afc9-1ea706638760" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2a32ab0d-b1f8-43c0-9e2a-a675a7020734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8064a3e3-4340-4960-94ba-2297caa07628" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e61fa37e-1628-4776-afc9-1ea706638760" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_8064a3e3-4340-4960-94ba-2297caa07628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f5a881af-7454-4fd3-8022-10637aab089b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e61fa37e-1628-4776-afc9-1ea706638760" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f5a881af-7454-4fd3-8022-10637aab089b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_825d074b-c9d3-4d16-992a-052b021a9ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_e61fa37e-1628-4776-afc9-1ea706638760" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_825d074b-c9d3-4d16-992a-052b021a9ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_c522a842-5762-4afa-8869-4d9dfbad0535" xlink:href="lgnd-20241231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_f0d9a9c6-9ca5-41df-a1cf-82acbc0e1ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_c522a842-5762-4afa-8869-4d9dfbad0535" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_f0d9a9c6-9ca5-41df-a1cf-82acbc0e1ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_29e3242f-1c92-408d-abf5-6dddee55bcf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_f0d9a9c6-9ca5-41df-a1cf-82acbc0e1ff0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_29e3242f-1c92-408d-abf5-6dddee55bcf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_b07c9450-e668-4fcf-8425-2330214d92e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_f0d9a9c6-9ca5-41df-a1cf-82acbc0e1ff0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_b07c9450-e668-4fcf-8425-2330214d92e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_3f5f84fc-6f0a-4df6-b900-75e42ff9e934" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract_f0d9a9c6-9ca5-41df-a1cf-82acbc0e1ff0" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_3f5f84fc-6f0a-4df6-b900-75e42ff9e934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_deb7643e-eecb-46b5-a9e5-1ab6ca9fdc19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_c522a842-5762-4afa-8869-4d9dfbad0535" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_deb7643e-eecb-46b5-a9e5-1ab6ca9fdc19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5006573d-ec3e-4b2c-86d6-28bd5a503857" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_deb7643e-eecb-46b5-a9e5-1ab6ca9fdc19" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_5006573d-ec3e-4b2c-86d6-28bd5a503857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_17f6fe41-855c-4f15-9506-39a5284e6e04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_deb7643e-eecb-46b5-a9e5-1ab6ca9fdc19" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_17f6fe41-855c-4f15-9506-39a5284e6e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_9fc5fc5d-fb4a-4b81-8afe-f51ee0e2c4cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_deb7643e-eecb-46b5-a9e5-1ab6ca9fdc19" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_9fc5fc5d-fb4a-4b81-8afe-f51ee0e2c4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_3add1fea-239e-4447-9ce5-fc798279d501" xlink:href="lgnd-20241231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_e6b039a5-de8b-4dba-bc92-b69fa1db10bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_3add1fea-239e-4447-9ce5-fc798279d501" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_e6b039a5-de8b-4dba-bc92-b69fa1db10bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a3a5bbe0-f29c-4e22-853d-4b7cc34717c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_e6b039a5-de8b-4dba-bc92-b69fa1db10bf" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a3a5bbe0-f29c-4e22-853d-4b7cc34717c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75e127fa-0374-40f3-b6bc-3c90140bbe7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a3a5bbe0-f29c-4e22-853d-4b7cc34717c1" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75e127fa-0374-40f3-b6bc-3c90140bbe7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DemandDepositsMember_0714bb33-ebba-4987-9fbb-5a7800034f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DemandDepositsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75e127fa-0374-40f3-b6bc-3c90140bbe7d" xlink:to="loc_us-gaap_DemandDepositsMember_0714bb33-ebba-4987-9fbb-5a7800034f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_97863994-007e-4eec-9189-642deed5a0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75e127fa-0374-40f3-b6bc-3c90140bbe7d" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_97863994-007e-4eec-9189-642deed5a0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_bf76f93b-bc71-4866-b087-a9d854a177ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75e127fa-0374-40f3-b6bc-3c90140bbe7d" xlink:to="loc_us-gaap_CommercialPaperMember_bf76f93b-bc71-4866-b087-a9d854a177ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_3a044963-1349-4e6e-98fd-214df50cedfb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75e127fa-0374-40f3-b6bc-3c90140bbe7d" xlink:to="loc_us-gaap_MunicipalBondsMember_3a044963-1349-4e6e-98fd-214df50cedfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_5b0bb8da-769d-41c2-b112-4e6057d4471d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_75e127fa-0374-40f3-b6bc-3c90140bbe7d" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_5b0bb8da-769d-41c2-b112-4e6057d4471d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_c335594e-72ad-4b98-bc47-688dd66c8070" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable_e6b039a5-de8b-4dba-bc92-b69fa1db10bf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_c335594e-72ad-4b98-bc47-688dd66c8070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_3a89d610-3c09-496e-9b9e-8629d246a441" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_c335594e-72ad-4b98-bc47-688dd66c8070" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_3a89d610-3c09-496e-9b9e-8629d246a441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b9f970fc-bc01-4137-aa6a-58ff57e2edb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_3a89d610-3c09-496e-9b9e-8629d246a441" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_b9f970fc-bc01-4137-aa6a-58ff57e2edb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b7135532-8f9e-45f9-ab72-6e1e7e4f4c19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_3a89d610-3c09-496e-9b9e-8629d246a441" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b7135532-8f9e-45f9-ab72-6e1e7e4f4c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_26e30e73-f4c5-4c29-a17e-eb58dadc8743" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_3a89d610-3c09-496e-9b9e-8629d246a441" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_26e30e73-f4c5-4c29-a17e-eb58dadc8743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_75947f6f-44df-43e4-b845-d89d8c6eee44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract_c335594e-72ad-4b98-bc47-688dd66c8070" xlink:to="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_75947f6f-44df-43e4-b845-d89d8c6eee44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f168b3e2-2600-41b8-bc93-a6dcc0c53d74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_75947f6f-44df-43e4-b845-d89d8c6eee44" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_f168b3e2-2600-41b8-bc93-a6dcc0c53d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_b34540b4-46b4-487b-b739-fba8fa98f917" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_75947f6f-44df-43e4-b845-d89d8c6eee44" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_b34540b4-46b4-487b-b739-fba8fa98f917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f5cf5e5a-5aa0-4e4e-aef7-529ea48425b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract_75947f6f-44df-43e4-b845-d89d8c6eee44" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_f5cf5e5a-5aa0-4e4e-aef7-529ea48425b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_fe806df1-6802-4165-82a4-e0cc7abbbb85" xlink:href="lgnd-20241231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_fe806df1-6802-4165-82a4-e0cc7abbbb85" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7ba36316-804e-4fd3-b5ee-bd1f6fe36b2d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:to="loc_srt_RangeAxis_7ba36316-804e-4fd3-b5ee-bd1f6fe36b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_faa7fb93-ec89-44dd-9a3a-1f761acdf72e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7ba36316-804e-4fd3-b5ee-bd1f6fe36b2d" xlink:to="loc_srt_RangeMember_faa7fb93-ec89-44dd-9a3a-1f761acdf72e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_dd05dfcd-d508-48c3-9131-d0de75697451" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_faa7fb93-ec89-44dd-9a3a-1f761acdf72e" xlink:to="loc_srt_MinimumMember_dd05dfcd-d508-48c3-9131-d0de75697451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c7df9769-e391-40ab-92fb-110a2753e581" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_faa7fb93-ec89-44dd-9a3a-1f761acdf72e" xlink:to="loc_srt_MaximumMember_c7df9769-e391-40ab-92fb-110a2753e581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_93530d59-96f5-4ee1-889a-4ccf1c1fe859" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:to="loc_srt_OwnershipAxis_93530d59-96f5-4ee1-889a-4ccf1c1fe859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_f590c60e-e014-4406-a624-3b8665f4cc0d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_93530d59-96f5-4ee1-889a-4ccf1c1fe859" xlink:to="loc_srt_OwnershipDomain_f590c60e-e014-4406-a624-3b8665f4cc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VikingTherapeuticsInc.Member_ef8c5dba-049f-4806-8165-9226f3d46708" xlink:href="lgnd-20241231.xsd#lgnd_VikingTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_f590c60e-e014-4406-a624-3b8665f4cc0d" xlink:to="loc_lgnd_VikingTherapeuticsInc.Member_ef8c5dba-049f-4806-8165-9226f3d46708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5c16ec17-0630-4ba8-8228-75c6df9acfe7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:to="loc_srt_CounterpartyNameAxis_5c16ec17-0630-4ba8-8228-75c6df9acfe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83ddffc1-2070-4892-975d-f6287d900081" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5c16ec17-0630-4ba8-8228-75c6df9acfe7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83ddffc1-2070-4892-975d-f6287d900081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember_1da0a7bd-77e3-4534-8099-24b44c0860b3" xlink:href="lgnd-20241231.xsd#lgnd_PrimroseBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83ddffc1-2070-4892-975d-f6287d900081" xlink:to="loc_lgnd_PrimroseBioMember_1da0a7bd-77e3-4534-8099-24b44c0860b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PalvellaTherapeuticsIncMember_0c171526-80e4-4b71-9822-ac9ac6cc21a0" xlink:href="lgnd-20241231.xsd#lgnd_PalvellaTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83ddffc1-2070-4892-975d-f6287d900081" xlink:to="loc_lgnd_PalvellaTherapeuticsIncMember_0c171526-80e4-4b71-9822-ac9ac6cc21a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AgenusInc.Member_8c767161-1e1d-4cfa-96c3-efb93a20a2b1" xlink:href="lgnd-20241231.xsd#lgnd_AgenusInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_83ddffc1-2070-4892-975d-f6287d900081" xlink:to="loc_lgnd_AgenusInc.Member_8c767161-1e1d-4cfa-96c3-efb93a20a2b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_cb72b054-456e-4058-ac5d-ceeec8001556" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_cb72b054-456e-4058-ac5d-ceeec8001556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_b649751f-9d9c-4718-84fe-3d93c0d74a10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_cb72b054-456e-4058-ac5d-ceeec8001556" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_b649751f-9d9c-4718-84fe-3d93c0d74a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherDerivativesMember_401aaab1-6ccf-46d5-a308-e1993f739411" xlink:href="lgnd-20241231.xsd#lgnd_OtherDerivativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b649751f-9d9c-4718-84fe-3d93c0d74a10" xlink:to="loc_lgnd_OtherDerivativesMember_401aaab1-6ccf-46d5-a308-e1993f739411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerProgramsMember_077e48c3-30a4-42b6-9d6d-915d82cf34ab" xlink:href="lgnd-20241231.xsd#lgnd_PartnerProgramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b649751f-9d9c-4718-84fe-3d93c0d74a10" xlink:to="loc_lgnd_PartnerProgramsMember_077e48c3-30a4-42b6-9d6d-915d82cf34ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CollarsMember_f557d911-9e26-4073-98da-a06706101147" xlink:href="lgnd-20241231.xsd#lgnd_CollarsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_b649751f-9d9c-4718-84fe-3d93c0d74a10" xlink:to="loc_lgnd_CollarsMember_f557d911-9e26-4073-98da-a06706101147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e1c13cb1-c322-4326-a875-b595a49c81b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e1c13cb1-c322-4326-a875-b595a49c81b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60b51c27-82c7-4f43-8581-19c5e2b19d48" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e1c13cb1-c322-4326-a875-b595a49c81b4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60b51c27-82c7-4f43-8581-19c5e2b19d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyAgreementsMember_66d76e78-52cb-41f1-afec-3f79cf5314a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RoyaltyAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_60b51c27-82c7-4f43-8581-19c5e2b19d48" xlink:to="loc_us-gaap_RoyaltyAgreementsMember_66d76e78-52cb-41f1-afec-3f79cf5314a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_128e7406-08f7-4f0e-a4da-d3e09468794a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_128e7406-08f7-4f0e-a4da-d3e09468794a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_09281e94-0bbe-4f28-b7fd-18aecf9dcb82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_128e7406-08f7-4f0e-a4da-d3e09468794a" xlink:to="loc_us-gaap_EquityComponentDomain_09281e94-0bbe-4f28-b7fd-18aecf9dcb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2998a279-b3f0-4230-b572-4ed9e843ebed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_09281e94-0bbe-4f28-b7fd-18aecf9dcb82" xlink:to="loc_us-gaap_CommonStockMember_2998a279-b3f0-4230-b572-4ed9e843ebed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1bacccb4-4fb6-4ecb-9565-08a6e656c4e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1bacccb4-4fb6-4ecb-9565-08a6e656c4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cb475dba-90d9-419b-8b99-a78273b616e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1bacccb4-4fb6-4ecb-9565-08a6e656c4e6" xlink:to="loc_us-gaap_ClassOfStockDomain_cb475dba-90d9-419b-8b99-a78273b616e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_ddc1ccf4-1926-4598-b6fd-ce3fccbe0127" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_cb475dba-90d9-419b-8b99-a78273b616e1" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_ddc1ccf4-1926-4598-b6fd-ce3fccbe0127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7faab6f1-72c9-4d78-946a-9756f6b57e01" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7faab6f1-72c9-4d78-946a-9756f6b57e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_9b078588-95f5-4061-9f33-d35bd99cc900" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7faab6f1-72c9-4d78-946a-9756f6b57e01" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_9b078588-95f5-4061-9f33-d35bd99cc900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_VikingsMember_7f612c5d-c465-47b0-80ad-77097f54d931" xlink:href="lgnd-20241231.xsd#lgnd_VikingsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_9b078588-95f5-4061-9f33-d35bd99cc900" xlink:to="loc_lgnd_VikingsMember_7f612c5d-c465-47b0-80ad-77097f54d931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_87d2253c-560d-4b43-9148-427f8f11b3fb" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_d8b703fd-449b-42d7-8710-2780ccf69e78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_d8b703fd-449b-42d7-8710-2780ccf69e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_7467e7b7-2216-496f-a4a5-b7bc1c114894" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_7467e7b7-2216-496f-a4a5-b7bc1c114894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtSecuritiesAvailableForSaleAmortization_5b22481b-56a8-47c1-8147-2e7a31c4e3cb" xlink:href="lgnd-20241231.xsd#lgnd_DebtSecuritiesAvailableForSaleAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_lgnd_DebtSecuritiesAvailableForSaleAmortization_5b22481b-56a8-47c1-8147-2e7a31c4e3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_8b499e36-4342-4609-a712-24075a69d383" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff_8b499e36-4342-4609-a712-24075a69d383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_b2627603-d3c8-4acf-9f1c-cf3c2a056d39" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_CommonStockValueOutstanding_b2627603-d3c8-4acf-9f1c-cf3c2a056d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_a1fa8a34-8f29-482f-b7c6-dac2eb1cb5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_a1fa8a34-8f29-482f-b7c6-dac2eb1cb5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_7bfc4849-29e2-439d-a236-c8bc67244e55" xlink:href="lgnd-20241231.xsd#lgnd_NumberOfSharesSoldOfEquityMethodInvestee"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_lgnd_NumberOfSharesSoldOfEquityMethodInvestee_7bfc4849-29e2-439d-a236-c8bc67244e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_7459d788-9bd2-4ca8-9bb6-014962ff7403" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_GainLossOnInvestments_7459d788-9bd2-4ca8-9bb6-014962ff7403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b7f57c94-105e-4e71-9815-6395e1e2d307" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_b7f57c94-105e-4e71-9815-6395e1e2d307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b923a64e-7432-4f9a-8833-d7764c1e0b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_Depreciation_b923a64e-7432-4f9a-8833-d7764c1e0b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7dfbe655-c27d-4b5f-8c1c-06bfb9f5c051" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7dfbe655-c27d-4b5f-8c1c-06bfb9f5c051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_50df5e9f-478e-4d76-9083-346c9da457bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_50df5e9f-478e-4d76-9083-346c9da457bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_bac86fa4-5fd4-462f-b324-ea8991c9a105" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_bac86fa4-5fd4-462f-b324-ea8991c9a105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_fff5b6bb-0ff8-48a5-8ca9-4da0a204494d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_fff5b6bb-0ff8-48a5-8ca9-4da0a204494d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2e188ec8-9f96-44b9-b01a-e3738d3eeaff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2e188ec8-9f96-44b9-b01a-e3738d3eeaff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_37baa425-eb88-4712-b234-2287ce891191" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_37baa425-eb88-4712-b234-2287ce891191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_57c4e4ff-7285-40fb-9e41-26d39c4338d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_57c4e4ff-7285-40fb-9e41-26d39c4338d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_4f769986-abaa-4af4-bedc-b7cdb426e172" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_4f769986-abaa-4af4-bedc-b7cdb426e172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5b05957b-6430-40b1-a214-8554827f818d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_5b05957b-6430-40b1-a214-8554827f818d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_640a075a-a0c7-4473-acd8-d98c954bc375" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_640a075a-a0c7-4473-acd8-d98c954bc375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ac1dad27-9f4d-40a0-84cf-a6d37d546021" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ac1dad27-9f4d-40a0-84cf-a6d37d546021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4f15f220-bad9-426a-86c3-5e8741e38774" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4f15f220-bad9-426a-86c3-5e8741e38774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_5847c4b4-6136-4181-9035-7ef6f0e4e581" xlink:href="lgnd-20241231.xsd#lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones_5847c4b4-6136-4181-9035-7ef6f0e4e581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SalesContractInterestInSalesRevenue_aecf9b04-ed37-4943-ad90-e07a3cdee80b" xlink:href="lgnd-20241231.xsd#lgnd_SalesContractInterestInSalesRevenue"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_lgnd_SalesContractInterestInSalesRevenue_aecf9b04-ed37-4943-ad90-e07a3cdee80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_b73be4fc-9dbc-47c6-bd7d-180b7cc360cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_b73be4fc-9dbc-47c6-bd7d-180b7cc360cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetNoncurrent_e5d916b8-f80e-43ed-b12e-5ef4c5c15e9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetNoncurrent"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_us-gaap_AccountsReceivableNetNoncurrent_e5d916b8-f80e-43ed-b12e-5ef4c5c15e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableTerm_6da463ae-0766-40e6-8da0-d980b56888c5" xlink:href="lgnd-20241231.xsd#lgnd_AccountsReceivableTerm"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_lgnd_AccountsReceivableTerm_6da463ae-0766-40e6-8da0-d980b56888c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount_274b5e0f-0636-46d4-8fc0-3f3edf500b8d" xlink:href="lgnd-20241231.xsd#lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount_274b5e0f-0636-46d4-8fc0-3f3edf500b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued_b60d2ecb-cd61-4103-8861-0f2bc013db6a" xlink:href="lgnd-20241231.xsd#lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued_b60d2ecb-cd61-4103-8861-0f2bc013db6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice_ef0264dc-c112-451a-94de-3b98a94d1c28" xlink:href="lgnd-20241231.xsd#lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice_ef0264dc-c112-451a-94de-3b98a94d1c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsNetCurrent_423109f3-b082-4b74-aa59-13a9412b8f96" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsNetCurrent"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_96019ea3-bf20-4f2f-91b0-7ba5c78c5342" xlink:to="loc_lgnd_FinancialRoyaltyAssetsNetCurrent_423109f3-b082-4b74-aa59-13a9412b8f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_d6d43e54-5cdb-445c-8adf-78a6f318ae76" xlink:href="lgnd-20241231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5371cb65-6b3c-4c00-a410-a5da0f83865c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_d6d43e54-5cdb-445c-8adf-78a6f318ae76" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5371cb65-6b3c-4c00-a410-a5da0f83865c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_58930ade-cf92-4ebf-8484-47a749d9c3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5371cb65-6b3c-4c00-a410-a5da0f83865c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_58930ade-cf92-4ebf-8484-47a749d9c3c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b499efde-c6b3-4e5d-b749-7e2b4bcb553d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_58930ade-cf92-4ebf-8484-47a749d9c3c5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b499efde-c6b3-4e5d-b749-7e2b4bcb553d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_a6d703bb-cc63-4c07-a900-1ccd3f9f2aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b499efde-c6b3-4e5d-b749-7e2b4bcb553d" xlink:to="loc_us-gaap_OfficeEquipmentMember_a6d703bb-cc63-4c07-a900-1ccd3f9f2aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_97068b44-ba24-4e57-834f-138e18025829" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b499efde-c6b3-4e5d-b749-7e2b4bcb553d" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_97068b44-ba24-4e57-834f-138e18025829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ComputerEquipmentAndSoftwareMember_bdb55889-ba3d-4f7b-a93e-006dd0fe1215" xlink:href="lgnd-20241231.xsd#lgnd_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b499efde-c6b3-4e5d-b749-7e2b4bcb553d" xlink:to="loc_lgnd_ComputerEquipmentAndSoftwareMember_bdb55889-ba3d-4f7b-a93e-006dd0fe1215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_2de0f136-3015-4678-9d06-53dbd321e51a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b499efde-c6b3-4e5d-b749-7e2b4bcb553d" xlink:to="loc_us-gaap_ConstructionInProgressMember_2de0f136-3015-4678-9d06-53dbd321e51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_44877795-c7ab-4fb2-909c-b467b9df2025" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5371cb65-6b3c-4c00-a410-a5da0f83865c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_44877795-c7ab-4fb2-909c-b467b9df2025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b3a4e2d1-662f-434a-8474-bc06414e8112" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_44877795-c7ab-4fb2-909c-b467b9df2025" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b3a4e2d1-662f-434a-8474-bc06414e8112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_32c43f9d-a784-42be-b0a0-fce06112c6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_44877795-c7ab-4fb2-909c-b467b9df2025" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_32c43f9d-a784-42be-b0a0-fce06112c6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a1731633-8366-4d3e-8e43-d937333b53de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_44877795-c7ab-4fb2-909c-b467b9df2025" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a1731633-8366-4d3e-8e43-d937333b53de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_5515f50e-e564-4be8-b909-e43e20b26b00" xlink:href="lgnd-20241231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_58b5e3f0-4bda-4b6d-9520-650157567f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_5515f50e-e564-4be8-b909-e43e20b26b00" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_58b5e3f0-4bda-4b6d-9520-650157567f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8e73e4be-46a5-423f-9796-b2f6ac34b3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_58b5e3f0-4bda-4b6d-9520-650157567f9a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8e73e4be-46a5-423f-9796-b2f6ac34b3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89fae857-1452-47db-ae6a-2af229050e36" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_8e73e4be-46a5-423f-9796-b2f6ac34b3d7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89fae857-1452-47db-ae6a-2af229050e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentedTechnologyMember_3446c553-976c-4001-afef-fd0722cb3c07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PatentedTechnologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89fae857-1452-47db-ae6a-2af229050e36" xlink:to="loc_us-gaap_PatentedTechnologyMember_3446c553-976c-4001-afef-fd0722cb3c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_6bd44dba-1277-4f32-8bbd-2e03b1ff3eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89fae857-1452-47db-ae6a-2af229050e36" xlink:to="loc_us-gaap_TradeNamesMember_6bd44dba-1277-4f32-8bbd-2e03b1ff3eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_053c5144-15d3-4e5d-9f26-7dc3f7a3ca49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89fae857-1452-47db-ae6a-2af229050e36" xlink:to="loc_us-gaap_CustomerRelationshipsMember_053c5144-15d3-4e5d-9f26-7dc3f7a3ca49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_67fcc97c-dcee-4537-910a-f77f5a520c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89fae857-1452-47db-ae6a-2af229050e36" xlink:to="loc_us-gaap_ContractualRightsMember_67fcc97c-dcee-4537-910a-f77f5a520c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_29758cd8-72c3-4885-af1a-3c493e0cb700" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_58b5e3f0-4bda-4b6d-9520-650157567f9a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_29758cd8-72c3-4885-af1a-3c493e0cb700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5c573623-f692-4d98-b435-b33a11331b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_29758cd8-72c3-4885-af1a-3c493e0cb700" xlink:to="loc_us-gaap_Goodwill_5c573623-f692-4d98-b435-b33a11331b9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d00e9556-73d7-4d3c-8ad8-80fe59e35220" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_29758cd8-72c3-4885-af1a-3c493e0cb700" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d00e9556-73d7-4d3c-8ad8-80fe59e35220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_28906b56-4067-437e-a4f0-203baa874018" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_29758cd8-72c3-4885-af1a-3c493e0cb700" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_28906b56-4067-437e-a4f0-203baa874018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_5beda22a-ddba-47d8-bb7e-9f354ce338e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_29758cd8-72c3-4885-af1a-3c493e0cb700" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_5beda22a-ddba-47d8-bb7e-9f354ce338e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f805186d-59e8-452d-bf03-f57a1bc9aa9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_f7756c4c-cc08-41ed-b1de-048508af3c20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f805186d-59e8-452d-bf03-f57a1bc9aa9d" xlink:to="loc_us-gaap_DerivativeTable_f7756c4c-cc08-41ed-b1de-048508af3c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d4ba61b4-127e-4a4e-931c-521d20c8b5da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f7756c4c-cc08-41ed-b1de-048508af3c20" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d4ba61b4-127e-4a4e-931c-521d20c8b5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_dc130610-93ac-4b8f-be30-f9a7e9eaacbe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d4ba61b4-127e-4a4e-931c-521d20c8b5da" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_dc130610-93ac-4b8f-be30-f9a7e9eaacbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PartnerProgramsMember_8289264b-eca0-4a8b-9696-abccf6cef03f" xlink:href="lgnd-20241231.xsd#lgnd_PartnerProgramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc130610-93ac-4b8f-be30-f9a7e9eaacbe" xlink:to="loc_lgnd_PartnerProgramsMember_8289264b-eca0-4a8b-9696-abccf6cef03f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_e67ec2e2-bda4-4c31-8947-b7ca06f19da8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_dc130610-93ac-4b8f-be30-f9a7e9eaacbe" xlink:to="loc_us-gaap_StockOptionMember_e67ec2e2-bda4-4c31-8947-b7ca06f19da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_fe2f35a5-f413-4efd-83f7-33a312c4dbad" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f7756c4c-cc08-41ed-b1de-048508af3c20" xlink:to="loc_srt_CounterpartyNameAxis_fe2f35a5-f413-4efd-83f7-33a312c4dbad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdc35a56-e724-4fc3-a334-45bf7f31e261" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_fe2f35a5-f413-4efd-83f7-33a312c4dbad" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdc35a56-e724-4fc3-a334-45bf7f31e261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember_e9fd924e-b830-4ec4-bc6b-eac551581f8d" xlink:href="lgnd-20241231.xsd#lgnd_PrimroseBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdc35a56-e724-4fc3-a334-45bf7f31e261" xlink:to="loc_lgnd_PrimroseBioMember_e9fd924e-b830-4ec4-bc6b-eac551581f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AgenusInc.Member_1ef782ec-2630-4ec3-bc63-68ae22e5aead" xlink:href="lgnd-20241231.xsd#lgnd_AgenusInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bdc35a56-e724-4fc3-a334-45bf7f31e261" xlink:to="loc_lgnd_AgenusInc.Member_1ef782ec-2630-4ec3-bc63-68ae22e5aead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_3235b9e6-c632-4261-81bf-ae6cc8a5d6df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_f7756c4c-cc08-41ed-b1de-048508af3c20" xlink:to="loc_us-gaap_DerivativeLineItems_3235b9e6-c632-4261-81bf-ae6cc8a5d6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_d6999858-99c6-4ee1-a3e1-c7c5f1c6deff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_3235b9e6-c632-4261-81bf-ae6cc8a5d6df" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_d6999858-99c6-4ee1-a3e1-c7c5f1c6deff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_318f3023-f0f8-4be8-b304-59985dc042b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_3235b9e6-c632-4261-81bf-ae6cc8a5d6df" xlink:to="loc_us-gaap_DerivativeTermOfContract_318f3023-f0f8-4be8-b304-59985dc042b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsOtherInvestmentDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsOtherInvestmentDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsOtherInvestmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3f326075-af4a-406a-a8c9-5fb4c8d04a26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsTable_f7596038-6ae3-44c9-a1da-3f907ce756ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3f326075-af4a-406a-a8c9-5fb4c8d04a26" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsTable_f7596038-6ae3-44c9-a1da-3f907ce756ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_f323904c-3a44-4d99-9503-8d9e56a27f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_f7596038-6ae3-44c9-a1da-3f907ce756ff" xlink:to="loc_us-gaap_InvestmentTypeAxis_f323904c-3a44-4d99-9503-8d9e56a27f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5ba2365c-9ec7-4965-a27e-c9a769e8c3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_f323904c-3a44-4d99-9503-8d9e56a27f6b" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5ba2365c-9ec7-4965-a27e-c9a769e8c3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_f35644ca-ef80-4f29-a7a7-141770871867" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5ba2365c-9ec7-4965-a27e-c9a769e8c3aa" xlink:to="loc_us-gaap_EquitySecuritiesMember_f35644ca-ef80-4f29-a7a7-141770871867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_2a16a18c-73b4-4a6c-8352-d7e6dbf2230f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5ba2365c-9ec7-4965-a27e-c9a769e8c3aa" xlink:to="loc_us-gaap_WarrantMember_2a16a18c-73b4-4a6c-8352-d7e6dbf2230f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d4790d48-a5a7-45a6-a535-91697e58832f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5ba2365c-9ec7-4965-a27e-c9a769e8c3aa" xlink:to="loc_us-gaap_PreferredStockMember_d4790d48-a5a7-45a6-a535-91697e58832f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_efd2d502-b922-47af-968e-cda394b13f79" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_f7596038-6ae3-44c9-a1da-3f907ce756ff" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_efd2d502-b922-47af-968e-cda394b13f79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f747c3a2-c977-463f-b67b-056b3ec6fa88" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_efd2d502-b922-47af-968e-cda394b13f79" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f747c3a2-c977-463f-b67b-056b3ec6fa88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimroseBioMember_8319055c-7613-4647-9b99-466b85001914" xlink:href="lgnd-20241231.xsd#lgnd_PrimroseBioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f747c3a2-c977-463f-b67b-056b3ec6fa88" xlink:to="loc_lgnd_PrimroseBioMember_8319055c-7613-4647-9b99-466b85001914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_InvIOsMember_bd790d13-30ad-4aac-b60b-811d189e8c1d" xlink:href="lgnd-20241231.xsd#lgnd_InvIOsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_f747c3a2-c977-463f-b67b-056b3ec6fa88" xlink:to="loc_lgnd_InvIOsMember_bd790d13-30ad-4aac-b60b-811d189e8c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cddd925b-5ad7-444f-81b5-0adef82033f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfInvestmentHoldingsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsTable_f7596038-6ae3-44c9-a1da-3f907ce756ff" xlink:to="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cddd925b-5ad7-444f-81b5-0adef82033f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestments_66a06ec4-2bd8-46d6-95bd-18203f9fb492" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SummaryOfInvestmentHoldingsLineItems_cddd925b-5ad7-444f-81b5-0adef82033f1" xlink:to="loc_us-gaap_OtherInvestments_66a06ec4-2bd8-46d6-95bd-18203f9fb492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsInventoryinOtherAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9c81c899-cd53-4819-9b23-4c71dc0bf31d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_a5a842f6-1aea-4d24-b5b6-718d7cefe1df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9c81c899-cd53-4819-9b23-4c71dc0bf31d" xlink:to="loc_us-gaap_InventoryCurrentTable_a5a842f6-1aea-4d24-b5b6-718d7cefe1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryAxis_50bd9e45-cb28-47e0-8fef-c6734d5bc867" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PublicUtilitiesInventoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_a5a842f6-1aea-4d24-b5b6-718d7cefe1df" xlink:to="loc_us-gaap_PublicUtilitiesInventoryAxis_50bd9e45-cb28-47e0-8fef-c6734d5bc867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_06d55be6-9084-44c3-a97c-13e0d3efd87e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PublicUtilitiesInventoryTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryAxis_50bd9e45-cb28-47e0-8fef-c6734d5bc867" xlink:to="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_06d55be6-9084-44c3-a97c-13e0d3efd87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ZelsuvmiMember_861126ae-1f44-4e92-8c6c-a71149f3e7e0" xlink:href="lgnd-20241231.xsd#lgnd_ZelsuvmiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PublicUtilitiesInventoryTypeDomain_06d55be6-9084-44c3-a97c-13e0d3efd87e" xlink:to="loc_lgnd_ZelsuvmiMember_861126ae-1f44-4e92-8c6c-a71149f3e7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_0dd05d4c-f3f6-4c07-8a45-eb12471ab97c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_a5a842f6-1aea-4d24-b5b6-718d7cefe1df" xlink:to="loc_us-gaap_InventoryLineItems_0dd05d4c-f3f6-4c07-8a45-eb12471ab97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c00bba22-a05d-412c-be14-b2b8187b5ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_0dd05d4c-f3f6-4c07-8a45-eb12471ab97c" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_c00bba22-a05d-412c-be14-b2b8187b5ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_6a79b36e-de5f-4086-9699-7770ba75a88d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_0dd05d4c-f3f6-4c07-8a45-eb12471ab97c" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_6a79b36e-de5f-4086-9699-7770ba75a88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f24148c9-c078-4250-8375-945756ec1451" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_0dd05d4c-f3f6-4c07-8a45-eb12471ab97c" xlink:to="loc_us-gaap_InventoryNet_f24148c9-c078-4250-8375-945756ec1451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_5c99bf7a-205e-4424-97e1-9464654be1f2" xlink:href="lgnd-20241231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_511ed571-5c43-490b-ad85-76f96a05181b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_5c99bf7a-205e-4424-97e1-9464654be1f2" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_511ed571-5c43-490b-ad85-76f96a05181b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4506cec5-8a38-42f9-b81c-4bc46b3412d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_5c99bf7a-205e-4424-97e1-9464654be1f2" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4506cec5-8a38-42f9-b81c-4bc46b3412d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ValueAddedTaxReceivableNetCurrent_92b148f9-941c-4cbf-b25a-d007e37da2f0" xlink:href="lgnd-20241231.xsd#lgnd_ValueAddedTaxReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_5c99bf7a-205e-4424-97e1-9464654be1f2" xlink:to="loc_lgnd_ValueAddedTaxReceivableNetCurrent_92b148f9-941c-4cbf-b25a-d007e37da2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_593e347f-bd21-4e46-a125-677a8f47fa59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_5c99bf7a-205e-4424-97e1-9464654be1f2" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_593e347f-bd21-4e46-a125-677a8f47fa59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSubcontractorExpensesCurrent_99ae67a9-d405-48f3-ab34-f48e7e4b58a8" xlink:href="lgnd-20241231.xsd#lgnd_AccruedSubcontractorExpensesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_5c99bf7a-205e-4424-97e1-9464654be1f2" xlink:to="loc_lgnd_AccruedSubcontractorExpensesCurrent_99ae67a9-d405-48f3-ab34-f48e7e4b58a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedCustomerDepositsCurrent_37b4114e-d3a9-45da-9ee5-1d085e76046f" xlink:href="lgnd-20241231.xsd#lgnd_AccruedCustomerDepositsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_5c99bf7a-205e-4424-97e1-9464654be1f2" xlink:to="loc_lgnd_AccruedCustomerDepositsCurrent_37b4114e-d3a9-45da-9ee5-1d085e76046f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AccruedSupplierExpensesCurrent_53b3eb1c-327b-4a41-816b-68e9f4cafdb4" xlink:href="lgnd-20241231.xsd#lgnd_AccruedSupplierExpensesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_5c99bf7a-205e-4424-97e1-9464654be1f2" xlink:to="loc_lgnd_AccruedSupplierExpensesCurrent_53b3eb1c-327b-4a41-816b-68e9f4cafdb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LicenseeAccrualCurrent_e08df9bf-908f-417d-9d3e-5025edd31243" xlink:href="lgnd-20241231.xsd#lgnd_LicenseeAccrualCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_5c99bf7a-205e-4424-97e1-9464654be1f2" xlink:to="loc_lgnd_LicenseeAccrualCurrent_e08df9bf-908f-417d-9d3e-5025edd31243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6eda6ab0-8b09-4988-a7aa-023a0401289e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_5c99bf7a-205e-4424-97e1-9464654be1f2" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6eda6ab0-8b09-4988-a7aa-023a0401289e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b714119f-ee57-429c-94b7-6402d2d9b67b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_5c99bf7a-205e-4424-97e1-9464654be1f2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b714119f-ee57-429c-94b7-6402d2d9b67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsContingentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_42fa2f11-ffb6-484e-a331-8ece5e55903f" xlink:href="lgnd-20241231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98339afc-3484-4ddd-8a7a-c303b4268314" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_42fa2f11-ffb6-484e-a331-8ece5e55903f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98339afc-3484-4ddd-8a7a-c303b4268314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_87d858c6-e59f-4bda-bf8a-613caee99eef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98339afc-3484-4ddd-8a7a-c303b4268314" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_87d858c6-e59f-4bda-bf8a-613caee99eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac6e91c5-7ac3-4aeb-9209-d326112c5f11" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_87d858c6-e59f-4bda-bf8a-613caee99eef" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac6e91c5-7ac3-4aeb-9209-d326112c5f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CydexPharmaceuticalsIncMember_d66e16b0-8431-48ce-bbc0-1941ecaf1782" xlink:href="lgnd-20241231.xsd#lgnd_CydexPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac6e91c5-7ac3-4aeb-9209-d326112c5f11" xlink:to="loc_lgnd_CydexPharmaceuticalsIncMember_d66e16b0-8431-48ce-bbc0-1941ecaf1782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisTherapeuticsMember_e7490c23-2b9d-4cdf-b069-ad5bfcad78f0" xlink:href="lgnd-20241231.xsd#lgnd_MetabasisTherapeuticsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac6e91c5-7ac3-4aeb-9209-d326112c5f11" xlink:to="loc_lgnd_MetabasisTherapeuticsMember_e7490c23-2b9d-4cdf-b069-ad5bfcad78f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_95aec6db-e179-4ab5-9628-d87d19d214ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_98339afc-3484-4ddd-8a7a-c303b4268314" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_95aec6db-e179-4ab5-9628-d87d19d214ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilityRollForward_7c22b456-47a6-4513-996a-6c84189dd132" xlink:href="lgnd-20241231.xsd#lgnd_ContingentLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_95aec6db-e179-4ab5-9628-d87d19d214ae" xlink:to="loc_lgnd_ContingentLiabilityRollForward_7c22b456-47a6-4513-996a-6c84189dd132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_7ab616d0-25a1-4c76-88f5-71d65671ca1c" xlink:href="lgnd-20241231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_7c22b456-47a6-4513-996a-6c84189dd132" xlink:to="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_7ab616d0-25a1-4c76-88f5-71d65671ca1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders_072233d1-c979-492e-bf69-d528383071c1" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_7c22b456-47a6-4513-996a-6c84189dd132" xlink:to="loc_lgnd_PaymentsToContingentValueRightHolders_072233d1-c979-492e-bf69-d528383071c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_92cef78e-71e5-4a1a-ba1b-bc5c80e7ec4d" xlink:href="lgnd-20241231.xsd#lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_7c22b456-47a6-4513-996a-6c84189dd132" xlink:to="loc_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities_92cef78e-71e5-4a1a-ba1b-bc5c80e7ec4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_e5dceed6-167f-4be6-ade2-301f5ea1dee5" xlink:href="lgnd-20241231.xsd#lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_ContingentLiabilityRollForward_7c22b456-47a6-4513-996a-6c84189dd132" xlink:to="loc_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod_e5dceed6-167f-4be6-ade2-301f5ea1dee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherBalanceSheetDetailsAbstract_07a3e44d-c073-4508-a390-c092eecf8f6a" xlink:href="lgnd-20241231.xsd#lgnd_OtherBalanceSheetDetailsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_059bdad5-d9ea-4d22-b5c3-72af19c63f77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_07a3e44d-c073-4508-a390-c092eecf8f6a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_059bdad5-d9ea-4d22-b5c3-72af19c63f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_UnrecognizedTaxBenefitsNoncurrent_06e1437e-c379-4d6f-9098-8bfae020c3a2" xlink:href="lgnd-20241231.xsd#lgnd_UnrecognizedTaxBenefitsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_07a3e44d-c073-4508-a390-c092eecf8f6a" xlink:to="loc_lgnd_UnrecognizedTaxBenefitsNoncurrent_06e1437e-c379-4d6f-9098-8bfae020c3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_666a7374-2a03-4872-88aa-69858bf1d867" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherSundryLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_07a3e44d-c073-4508-a390-c092eecf8f6a" xlink:to="loc_us-gaap_OtherSundryLiabilitiesNoncurrent_666a7374-2a03-4872-88aa-69858bf1d867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_494374de-3425-4534-801c-01e930f8e9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_OtherBalanceSheetDetailsAbstract_07a3e44d-c073-4508-a390-c092eecf8f6a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_494374de-3425-4534-801c-01e930f8e9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_89e31506-df6a-4f8b-b42f-73cf357d7a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_89e31506-df6a-4f8b-b42f-73cf357d7a2e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8830ed81-a86f-4fff-9424-2bd1eb53f462" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8830ed81-a86f-4fff-9424-2bd1eb53f462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_264e2c3c-b916-4cf6-a3f3-b6cddc8d4b12" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_8830ed81-a86f-4fff-9424-2bd1eb53f462" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_264e2c3c-b916-4cf6-a3f3-b6cddc8d4b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0f5975cc-1969-4232-9f19-80c29b9f29bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_264e2c3c-b916-4cf6-a3f3-b6cddc8d4b12" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0f5975cc-1969-4232-9f19-80c29b9f29bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a797a2a0-0c3e-46a8-a53d-f4f011d967b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a797a2a0-0c3e-46a8-a53d-f4f011d967b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7a75974-9466-4d38-bad0-7fc8f60f64de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a797a2a0-0c3e-46a8-a53d-f4f011d967b1" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7a75974-9466-4d38-bad0-7fc8f60f64de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5f05a6d5-6211-4c67-8b57-fe56ab785634" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7a75974-9466-4d38-bad0-7fc8f60f64de" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5f05a6d5-6211-4c67-8b57-fe56ab785634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7949cade-02b3-4c21-a7eb-26dc958cf092" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7a75974-9466-4d38-bad0-7fc8f60f64de" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7949cade-02b3-4c21-a7eb-26dc958cf092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8b67fc34-7741-4364-9285-a3a2b6fca557" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c7a75974-9466-4d38-bad0-7fc8f60f64de" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8b67fc34-7741-4364-9285-a3a2b6fca557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_37047524-c1ba-4ac3-925f-fb6eccb701a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_37047524-c1ba-4ac3-925f-fb6eccb701a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf4153a6-be75-413d-8d94-2a1bf7e29dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_37047524-c1ba-4ac3-925f-fb6eccb701a0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf4153a6-be75-413d-8d94-2a1bf7e29dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_dc4bbcb0-1e2e-49b9-9f46-bb653171b967" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf4153a6-be75-413d-8d94-2a1bf7e29dc0" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_dc4bbcb0-1e2e-49b9-9f46-bb653171b967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ContingentLiabilitiesMember_04fe4217-c2de-40be-905d-52efc15bc987" xlink:href="lgnd-20241231.xsd#lgnd_ContingentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cf4153a6-be75-413d-8d94-2a1bf7e29dc0" xlink:to="loc_lgnd_ContingentLiabilitiesMember_04fe4217-c2de-40be-905d-52efc15bc987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ed746267-2c5e-4ba3-b1c8-c9b46bd8e201" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ed746267-2c5e-4ba3-b1c8-c9b46bd8e201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47ec1724-f6f0-43e2-ac95-87b175dd7ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ed746267-2c5e-4ba3-b1c8-c9b46bd8e201" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47ec1724-f6f0-43e2-ac95-87b175dd7ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CyDexMember_1b207c1d-94fe-45c3-8fb2-4e6f2c62a08f" xlink:href="lgnd-20241231.xsd#lgnd_CyDexMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47ec1724-f6f0-43e2-ac95-87b175dd7ee8" xlink:to="loc_lgnd_CyDexMember_1b207c1d-94fe-45c3-8fb2-4e6f2c62a08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MetabasisMember_5c8f7afa-5c50-4b30-a358-f3e3d19a1bf6" xlink:href="lgnd-20241231.xsd#lgnd_MetabasisMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47ec1724-f6f0-43e2-ac95-87b175dd7ee8" xlink:to="loc_lgnd_MetabasisMember_5c8f7afa-5c50-4b30-a358-f3e3d19a1bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9dd042ba-1245-43bb-8f7f-98373e4b6d81" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_srt_RangeAxis_9dd042ba-1245-43bb-8f7f-98373e4b6d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4d4bb288-3f1f-4d33-af7c-c58108ff0732" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9dd042ba-1245-43bb-8f7f-98373e4b6d81" xlink:to="loc_srt_RangeMember_4d4bb288-3f1f-4d33-af7c-c58108ff0732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_558e52c5-3662-4990-a7d3-e7b580c718e3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4d4bb288-3f1f-4d33-af7c-c58108ff0732" xlink:to="loc_srt_MaximumMember_558e52c5-3662-4990-a7d3-e7b580c718e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_da044070-074f-405d-80d7-34e389844b1c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4d4bb288-3f1f-4d33-af7c-c58108ff0732" xlink:to="loc_srt_MinimumMember_da044070-074f-405d-80d7-34e389844b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_caf30ac1-f736-4331-99e0-27e3faa5c663" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_caf30ac1-f736-4331-99e0-27e3faa5c663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_80126a06-8634-434c-ab85-88127ea7ae4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceAxis_caf30ac1-f736-4331-99e0-27e3faa5c663" xlink:to="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_80126a06-8634-434c-ab85-88127ea7ae4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransferredOverTimeMember_0b3f4fe1-f46a-492a-8e53-58d1b2506b23" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransferredOverTimeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TimingOfTransferOfGoodOrServiceDomain_80126a06-8634-434c-ab85-88127ea7ae4c" xlink:to="loc_us-gaap_TransferredOverTimeMember_0b3f4fe1-f46a-492a-8e53-58d1b2506b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_721ba9fe-a1e5-435b-add2-cc6ffc415d55" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_srt_ProductOrServiceAxis_721ba9fe-a1e5-435b-add2-cc6ffc415d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_de10a7dc-c891-4b30-953c-21e8e30145bf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_721ba9fe-a1e5-435b-add2-cc6ffc415d55" xlink:to="loc_srt_ProductsAndServicesDomain_de10a7dc-c891-4b30-953c-21e8e30145bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_b27c10f7-0195-4df0-9611-fdde041f4e80" xlink:href="lgnd-20241231.xsd#lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_de10a7dc-c891-4b30-953c-21e8e30145bf" xlink:to="loc_lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember_b27c10f7-0195-4df0-9611-fdde041f4e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_Phase3ClinicalTrialMember_2fc5a933-65f7-4690-812a-30739e14855b" xlink:href="lgnd-20241231.xsd#lgnd_Phase3ClinicalTrialMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_de10a7dc-c891-4b30-953c-21e8e30145bf" xlink:to="loc_lgnd_Phase3ClinicalTrialMember_2fc5a933-65f7-4690-812a-30739e14855b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_d25f8b3d-3078-47be-8aed-1bb6152c819b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesByIndustryAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_d25f8b3d-3078-47be-8aed-1bb6152c819b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_9fdc92bf-5c7c-4c56-9567-927c291ef3da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesIndustryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_d25f8b3d-3078-47be-8aed-1bb6152c819b" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_9fdc92bf-5c7c-4c56-9567-927c291ef3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PrimordialGeneticsMember_51a6bf9d-59c7-445e-85cd-621d9a8b7789" xlink:href="lgnd-20241231.xsd#lgnd_PrimordialGeneticsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_9fdc92bf-5c7c-4c56-9567-927c291ef3da" xlink:to="loc_lgnd_PrimordialGeneticsMember_51a6bf9d-59c7-445e-85cd-621d9a8b7789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_10dd9916-cf42-4d2b-9570-93a0160a728a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_srt_CounterpartyNameAxis_10dd9916-cf42-4d2b-9570-93a0160a728a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76b7eede-d8bb-4d95-a716-cbe8bfd43c5e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_10dd9916-cf42-4d2b-9570-93a0160a728a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76b7eede-d8bb-4d95-a716-cbe8bfd43c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AgenusPartneredProgramMember_4613bc45-69ef-4978-811b-4b35daa4cf82" xlink:href="lgnd-20241231.xsd#lgnd_AgenusPartneredProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_76b7eede-d8bb-4d95-a716-cbe8bfd43c5e" xlink:to="loc_lgnd_AgenusPartneredProgramMember_4613bc45-69ef-4978-811b-4b35daa4cf82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f6a41a3a-a495-4fed-83ee-bd953fe22868" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f6a41a3a-a495-4fed-83ee-bd953fe22868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e9762ebb-f29f-4f36-b884-45b384ae8214" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f6a41a3a-a495-4fed-83ee-bd953fe22868" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e9762ebb-f29f-4f36-b884-45b384ae8214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_27fff6f0-5b1b-44e3-bdbb-9f1475b4f440" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_e9762ebb-f29f-4f36-b884-45b384ae8214" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_27fff6f0-5b1b-44e3-bdbb-9f1475b4f440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_aa92c9ba-4cf8-4cd3-90e3-f1d6dc58f40e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_29ada7f5-4991-4df4-8378-218037b9a892" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_29ada7f5-4991-4df4-8378-218037b9a892" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_9efda20b-7882-4446-a1e9-7a6b7682e091" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent_9efda20b-7882-4446-a1e9-7a6b7682e091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_97d29cc4-5223-44dc-a345-cbeeeee89d77" xlink:href="lgnd-20241231.xsd#lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_97d29cc4-5223-44dc-a345-cbeeeee89d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_2cd9f74a-56c7-4094-b1b8-f8b2187dc6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_us-gaap_DerivativeAssets_2cd9f74a-56c7-4094-b1b8-f8b2187dc6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d0f2f74b-76e6-4a75-aec7-a8e1c1dbb152" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_d0f2f74b-76e6-4a75-aec7-a8e1c1dbb152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_a552d1d9-a7bd-4dfc-bd86-c318dbe0deef" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure_a552d1d9-a7bd-4dfc-bd86-c318dbe0deef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_0b9fb021-2001-4bd0-9370-51c62abdc623" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_0b9fb021-2001-4bd0-9370-51c62abdc623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MilestoneCompensationRate_45dc849b-dab7-4b81-8591-9c4c649c97d9" xlink:href="lgnd-20241231.xsd#lgnd_MilestoneCompensationRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_lgnd_MilestoneCompensationRate_45dc849b-dab7-4b81-8591-9c4c649c97d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContracts_b317c155-c395-403f-b2cb-e8307b5b0c28" xlink:href="lgnd-20241231.xsd#lgnd_NumberOfContracts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_lgnd_NumberOfContracts_b317c155-c395-403f-b2cb-e8307b5b0c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetMeasurementInput_aadde2cf-ca41-4319-98cd-2210ed45bbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DerivativeAssetMeasurementInput"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_us-gaap_DerivativeAssetMeasurementInput_aadde2cf-ca41-4319-98cd-2210ed45bbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare_5526425f-bbb1-447c-bfa7-229b1589bdec" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare_5526425f-bbb1-447c-bfa7-229b1589bdec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries_12b64e1e-523a-4665-8b44-594727d9658c" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries_12b64e1e-523a-4665-8b44-594727d9658c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NumberOfContingentValueRightsSeries_702e02c4-f510-46cf-9f2b-cf11fe1464ab" xlink:href="lgnd-20241231.xsd#lgnd_NumberOfContingentValueRightsSeries"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_lgnd_NumberOfContingentValueRightsSeries_702e02c4-f510-46cf-9f2b-cf11fe1464ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders_5eca65c8-9e06-460b-8506-cc4a757f1e98" xlink:href="lgnd-20241231.xsd#lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders_5eca65c8-9e06-460b-8506-cc4a757f1e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Investments_ca15d998-24c4-4447-8471-2d9112299e50" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Investments"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_us-gaap_Investments_ca15d998-24c4-4447-8471-2d9112299e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_43059917-e110-4781-9540-35b410ca65e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerAssetGross"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7af66918-f965-4cc4-8882-977c2fb2c28e" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_43059917-e110-4781-9540-35b410ca65e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dccb1370-c62b-40f1-a333-7b637760d376" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01e0d686-5a65-4f63-9ed4-38a0e6d4f43d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dccb1370-c62b-40f1-a333-7b637760d376" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01e0d686-5a65-4f63-9ed4-38a0e6d4f43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_efdf2134-4060-41fc-9aff-b912cf6f98f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01e0d686-5a65-4f63-9ed4-38a0e6d4f43d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_efdf2134-4060-41fc-9aff-b912cf6f98f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_0c9576c1-60cd-47aa-a557-d90a54a0b9eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01e0d686-5a65-4f63-9ed4-38a0e6d4f43d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases_0c9576c1-60cd-47aa-a557-d90a54a0b9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_888b133c-9cf0-4856-b5ac-0fc839bc3038" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01e0d686-5a65-4f63-9ed4-38a0e6d4f43d" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_888b133c-9cf0-4856-b5ac-0fc839bc3038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_ba79b6d0-dc40-4d15-a988-ad2f692906ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01e0d686-5a65-4f63-9ed4-38a0e6d4f43d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1_ba79b6d0-dc40-4d15-a988-ad2f692906ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_f92308af-6fcd-43d8-994c-f822bc0565d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01e0d686-5a65-4f63-9ed4-38a0e6d4f43d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_f92308af-6fcd-43d8-994c-f822bc0565d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_ac984fae-7e0d-45c3-8853-28805d29e80e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_01e0d686-5a65-4f63-9ed4-38a0e6d4f43d" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_ac984fae-7e0d-45c3-8853-28805d29e80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_3bbdb396-b8e6-47dc-b419-1e1af152d2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dccb1370-c62b-40f1-a333-7b637760d376" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList_3bbdb396-b8e6-47dc-b419-1e1af152d2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_11601423-92e0-4079-b1aa-51d78eb66a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dccb1370-c62b-40f1-a333-7b637760d376" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_11601423-92e0-4079-b1aa-51d78eb66a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7954e283-6ca1-48cb-b78a-ed34d44b97ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_11601423-92e0-4079-b1aa-51d78eb66a8b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_7954e283-6ca1-48cb-b78a-ed34d44b97ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsToContingentValueRightHolders_0ca64e49-4028-4f82-b351-461ac36a019f" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsToContingentValueRightHolders"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_11601423-92e0-4079-b1aa-51d78eb66a8b" xlink:to="loc_lgnd_PaymentsToContingentValueRightHolders_0ca64e49-4028-4f82-b351-461ac36a019f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8e98735c-6d23-4303-a354-355c57e78d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_11601423-92e0-4079-b1aa-51d78eb66a8b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8e98735c-6d23-4303-a354-355c57e78d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8a0c3cb3-cc15-4f14-a275-553d4d31f4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_11601423-92e0-4079-b1aa-51d78eb66a8b" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_8a0c3cb3-cc15-4f14-a275-553d4d31f4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_81a13d6b-d208-4591-95ee-98a5a8fb6e25" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dccb1370-c62b-40f1-a333-7b637760d376" xlink:to="loc_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList_81a13d6b-d208-4591-95ee-98a5a8fb6e25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/FairValueMeasurementNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#FairValueMeasurementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/FairValueMeasurementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_39a87405-de17-45fe-b9e1-9c8d874e8084" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e9c483c-a572-4b41-8a3a-5b50309d5cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_39a87405-de17-45fe-b9e1-9c8d874e8084" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e9c483c-a572-4b41-8a3a-5b50309d5cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_63877f66-c56c-42be-8250-cefab65056a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e9c483c-a572-4b41-8a3a-5b50309d5cbd" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_63877f66-c56c-42be-8250-cefab65056a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b0daa886-42a4-4549-a748-810e71bd5213" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_63877f66-c56c-42be-8250-cefab65056a6" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b0daa886-42a4-4549-a748-810e71bd5213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53b6194a-06ff-45a6-9693-fb0ef998077a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_b0daa886-42a4-4549-a748-810e71bd5213" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53b6194a-06ff-45a6-9693-fb0ef998077a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_4ef9ab0b-d1a8-40fd-a773-7a5707bbe560" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53b6194a-06ff-45a6-9693-fb0ef998077a" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_4ef9ab0b-d1a8-40fd-a773-7a5707bbe560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_bd7abc7f-0538-4918-9250-51a01a555bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_53b6194a-06ff-45a6-9693-fb0ef998077a" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_bd7abc7f-0538-4918-9250-51a01a555bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1240e084-83b4-4656-9231-1d4a2c7a1331" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e9c483c-a572-4b41-8a3a-5b50309d5cbd" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1240e084-83b4-4656-9231-1d4a2c7a1331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1d800e0b-05b2-47d8-b3db-0fd184ec9687" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1240e084-83b4-4656-9231-1d4a2c7a1331" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1d800e0b-05b2-47d8-b3db-0fd184ec9687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_4dd7e6ed-6b82-43fc-a0c3-4a8b29c31582" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1d800e0b-05b2-47d8-b3db-0fd184ec9687" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_4dd7e6ed-6b82-43fc-a0c3-4a8b29c31582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_df65c29f-940f-45ab-8941-936d489cd3e0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e9c483c-a572-4b41-8a3a-5b50309d5cbd" xlink:to="loc_srt_RangeAxis_df65c29f-940f-45ab-8941-936d489cd3e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_11673f93-741c-4a72-b9e9-d77cb76178c8" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_df65c29f-940f-45ab-8941-936d489cd3e0" xlink:to="loc_srt_RangeMember_11673f93-741c-4a72-b9e9-d77cb76178c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_703288a6-1ba4-4ba2-8a8d-9ae663cd2d34" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_11673f93-741c-4a72-b9e9-d77cb76178c8" xlink:to="loc_srt_MinimumMember_703288a6-1ba4-4ba2-8a8d-9ae663cd2d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_14f2d1c4-9e78-453a-9555-a585076b84bc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_11673f93-741c-4a72-b9e9-d77cb76178c8" xlink:to="loc_srt_MaximumMember_14f2d1c4-9e78-453a-9555-a585076b84bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aac8ead-b25c-45f2-a725-c2b6312228bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_8e9c483c-a572-4b41-8a3a-5b50309d5cbd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aac8ead-b25c-45f2-a725-c2b6312228bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_6b6e77f3-9a22-4105-9581-fb6f58954a4f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aac8ead-b25c-45f2-a725-c2b6312228bb" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_6b6e77f3-9a22-4105-9581-fb6f58954a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_a8689a4e-d3d3-4bc5-98e2-a31cd81f2650" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aac8ead-b25c-45f2-a725-c2b6312228bb" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_a8689a4e-d3d3-4bc5-98e2-a31cd81f2650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_934c152b-dec0-497a-993b-10a56d9f5397" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aac8ead-b25c-45f2-a725-c2b6312228bb" xlink:to="loc_us-gaap_OtherLiabilitiesFairValueDisclosure_934c152b-dec0-497a-993b-10a56d9f5397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetsFairValueDisclosure_291fffb2-038a-4fa8-bc77-ca0f74ab0ec1" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aac8ead-b25c-45f2-a725-c2b6312228bb" xlink:to="loc_lgnd_FinancialRoyaltyAssetsFairValueDisclosure_291fffb2-038a-4fa8-bc77-ca0f74ab0ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinancialRoyaltyAssetMeasurementInput_f6369fbc-6050-4578-976b-278fb89efa75" xlink:href="lgnd-20241231.xsd#lgnd_FinancialRoyaltyAssetMeasurementInput"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1aac8ead-b25c-45f2-a725-c2b6312228bb" xlink:to="loc_lgnd_FinancialRoyaltyAssetMeasurementInput_f6369fbc-6050-4578-976b-278fb89efa75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9e7c1bc5-d820-4e9f-abd5-8de3df0976f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_aeafd35e-9a45-4ade-a967-f899d21405bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9e7c1bc5-d820-4e9f-abd5-8de3df0976f8" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_aeafd35e-9a45-4ade-a967-f899d21405bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f19d1723-c9e2-4c51-b111-c07672641902" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aeafd35e-9a45-4ade-a967-f899d21405bc" xlink:to="loc_srt_ProductOrServiceAxis_f19d1723-c9e2-4c51-b111-c07672641902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2eb9c994-ea17-40cc-b61a-26b2d8575be6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f19d1723-c9e2-4c51-b111-c07672641902" xlink:to="loc_srt_ProductsAndServicesDomain_2eb9c994-ea17-40cc-b61a-26b2d8575be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_MaterialSalesCaptisolMember_3de9dc50-35b0-45b5-87e8-bd860d37d233" xlink:href="lgnd-20241231.xsd#lgnd_MaterialSalesCaptisolMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2eb9c994-ea17-40cc-b61a-26b2d8575be6" xlink:to="loc_lgnd_MaterialSalesCaptisolMember_3de9dc50-35b0-45b5-87e8-bd860d37d233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6272099e-afa8-4b98-a1fc-297aeae2cfbe" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aeafd35e-9a45-4ade-a967-f899d21405bc" xlink:to="loc_srt_RangeAxis_6272099e-afa8-4b98-a1fc-297aeae2cfbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_39124bd0-206e-4188-aabc-f8da378b2ec4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6272099e-afa8-4b98-a1fc-297aeae2cfbe" xlink:to="loc_srt_RangeMember_39124bd0-206e-4188-aabc-f8da378b2ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_97fd45ed-ea5e-4e18-bb04-6c1c75675071" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_39124bd0-206e-4188-aabc-f8da378b2ec4" xlink:to="loc_srt_MaximumMember_97fd45ed-ea5e-4e18-bb04-6c1c75675071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_6871b503-f9fb-4119-a5f8-82b9f46a42ed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aeafd35e-9a45-4ade-a967-f899d21405bc" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_6871b503-f9fb-4119-a5f8-82b9f46a42ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_bf11dfb4-53f5-42c3-b80a-e0cb9370f7ed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_6871b503-f9fb-4119-a5f8-82b9f46a42ed" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_bf11dfb4-53f5-42c3-b80a-e0cb9370f7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OfficeInBostonMassachusettsMember_fa56947d-3a0b-4b76-a86c-503cb085a1ab" xlink:href="lgnd-20241231.xsd#lgnd_OfficeInBostonMassachusettsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_bf11dfb4-53f5-42c3-b80a-e0cb9370f7ed" xlink:to="loc_lgnd_OfficeInBostonMassachusettsMember_fa56947d-3a0b-4b76-a86c-503cb085a1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OfficeInJupiterFloridaMember_39d4e839-1f72-468b-add9-b722fadea03b" xlink:href="lgnd-20241231.xsd#lgnd_OfficeInJupiterFloridaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_bf11dfb4-53f5-42c3-b80a-e0cb9370f7ed" xlink:to="loc_lgnd_OfficeInJupiterFloridaMember_39d4e839-1f72-468b-add9-b722fadea03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_aeafd35e-9a45-4ade-a967-f899d21405bc" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate_62f9a87d-a288-482f-8b2f-94d362e6cc21" xlink:href="lgnd-20241231.xsd#lgnd_PurchaseCommitmentConsiderationPaidToDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_lgnd_PurchaseCommitmentConsiderationPaidToDate_62f9a87d-a288-482f-8b2f-94d362e6cc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_ad8c6a76-af53-401e-9ef0-6c71ce27ed24" xlink:href="lgnd-20241231.xsd#lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory_ad8c6a76-af53-401e-9ef0-6c71ce27ed24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_e81836c6-7b9e-4bb2-9f06-0462437824ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_e81836c6-7b9e-4bb2-9f06-0462437824ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseImpairmentLoss_a462a0c4-0d96-4be1-8097-3ef2d3df6c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_FinanceLeaseImpairmentLoss_a462a0c4-0d96-4be1-8097-3ef2d3df6c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_2adc313c-160b-4fbe-b36e-1593b4056a9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_2adc313c-160b-4fbe-b36e-1593b4056a9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_cb3d53a0-c637-4936-8347-3c5327cac4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_cb3d53a0-c637-4936-8347-3c5327cac4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_6eea99ec-d84a-48b8-80a7-1ac705b01729" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_AssetImpairmentCharges_6eea99ec-d84a-48b8-80a7-1ac705b01729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_fd7abb75-1a56-4f18-9dad-3a4955e7d1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_fd7abb75-1a56-4f18-9dad-3a4955e7d1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c3552b56-9272-4503-aae5-2180a39a4368" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_c3552b56-9272-4503-aae5-2180a39a4368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification_e9b79aa2-4e48-4d7f-9436-ccb87afdaff6" xlink:href="lgnd-20241231.xsd#lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification_e9b79aa2-4e48-4d7f-9436-ccb87afdaff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_df4c223f-db84-4d8f-bfc6-58dc9b0c635a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_df4c223f-db84-4d8f-bfc6-58dc9b0c635a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3f12688c-a105-4bf0-a430-c4885fe91ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3f12688c-a105-4bf0-a430-c4885fe91ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_58aecaca-ae0d-4bd8-96bd-12e022390a97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_58aecaca-ae0d-4bd8-96bd-12e022390a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_eba1b99f-c4c7-484e-8f0a-f9aac534442c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_OperatingLeasePayments_eba1b99f-c4c7-484e-8f0a-f9aac534442c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_2e73d68b-79e4-48ca-8280-24779c756ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_OperatingLeaseExpense_2e73d68b-79e4-48ca-8280-24779c756ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_622275f3-46f0-460e-9edd-0ff6ca16dcc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_SubleaseIncome_622275f3-46f0-460e-9edd-0ff6ca16dcc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_839d4404-2d27-4786-b3fc-0c751cf7751c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_839d4404-2d27-4786-b3fc-0c751cf7751c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_0d8d3425-8b51-4be1-ab8a-bf7b7ce48df9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_0d8d3425-8b51-4be1-ab8a-bf7b7ce48df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_6159b62c-0fdc-459d-ab2a-c1d5ff6c4598" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_6159b62c-0fdc-459d-ab2a-c1d5ff6c4598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_ea8d77c0-413f-4519-b7bf-e2d4a798d8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_2ad9eae8-bef7-4092-9b13-9781cdbcc60d" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_ea8d77c0-413f-4519-b7bf-e2d4a798d8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_feffa430-b39c-4183-b61a-e721597efc29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_02677f86-9855-4e86-9fc6-73fa5495fb22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_feffa430-b39c-4183-b61a-e721597efc29" xlink:to="loc_us-gaap_AssetsAbstract_02677f86-9855-4e86-9fc6-73fa5495fb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6fc70f3b-560f-4ebe-92c2-af29db6398e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_02677f86-9855-4e86-9fc6-73fa5495fb22" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6fc70f3b-560f-4ebe-92c2-af29db6398e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_4a13e42b-cb53-4cb9-9b37-b08726f3a4df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_02677f86-9855-4e86-9fc6-73fa5495fb22" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_4a13e42b-cb53-4cb9-9b37-b08726f3a4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseRightOfUseAsset_3ad59a54-de30-4de2-a0b0-c53366b4b0b4" xlink:href="lgnd-20241231.xsd#lgnd_LeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_02677f86-9855-4e86-9fc6-73fa5495fb22" xlink:to="loc_lgnd_LeaseRightOfUseAsset_3ad59a54-de30-4de2-a0b0-c53366b4b0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_41849fc6-29c1-4ec7-9db8-b64454eef0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_feffa430-b39c-4183-b61a-e721597efc29" xlink:to="loc_us-gaap_LiabilitiesAbstract_41849fc6-29c1-4ec7-9db8-b64454eef0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_bc76e518-09d3-4c15-88bf-dc639906cd78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_41849fc6-29c1-4ec7-9db8-b64454eef0e3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_bc76e518-09d3-4c15-88bf-dc639906cd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a71efeec-9480-4a71-973b-baeb050fc25e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc76e518-09d3-4c15-88bf-dc639906cd78" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a71efeec-9480-4a71-973b-baeb050fc25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_e9865af3-b9a7-4fc5-95fb-a854cb820952" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc76e518-09d3-4c15-88bf-dc639906cd78" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_e9865af3-b9a7-4fc5-95fb-a854cb820952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiabilityCurrent_ba8dac95-89f2-4769-9e49-ba762df044f7" xlink:href="lgnd-20241231.xsd#lgnd_LeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_bc76e518-09d3-4c15-88bf-dc639906cd78" xlink:to="loc_lgnd_LeaseLiabilityCurrent_ba8dac95-89f2-4769-9e49-ba762df044f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_8749765a-90d3-49e2-b708-bd6fd6f3e0f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_41849fc6-29c1-4ec7-9db8-b64454eef0e3" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_8749765a-90d3-49e2-b708-bd6fd6f3e0f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_982e5859-69cf-42ae-a9c9-046a1b74e213" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8749765a-90d3-49e2-b708-bd6fd6f3e0f7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_982e5859-69cf-42ae-a9c9-046a1b74e213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_95484225-0e44-40dd-b09a-d5797fe55080" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8749765a-90d3-49e2-b708-bd6fd6f3e0f7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_95484225-0e44-40dd-b09a-d5797fe55080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_LeaseLiability_f7b05253-fb9c-4d7c-8b6a-bba18d34caba" xlink:href="lgnd-20241231.xsd#lgnd_LeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_41849fc6-29c1-4ec7-9db8-b64454eef0e3" xlink:to="loc_lgnd_LeaseLiability_f7b05253-fb9c-4d7c-8b6a-bba18d34caba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_b805cff2-561c-4ee7-8dea-c0fbafc661c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_feffa430-b39c-4183-b61a-e721597efc29" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_b805cff2-561c-4ee7-8dea-c0fbafc661c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_55c9eec1-baa4-4527-9d82-c79e99026aea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3797246-4ccf-4931-9ba3-9e5de9326734" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_55c9eec1-baa4-4527-9d82-c79e99026aea" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3797246-4ccf-4931-9ba3-9e5de9326734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8a3147d9-b859-4b92-adfe-24d9540853a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3797246-4ccf-4931-9ba3-9e5de9326734" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8a3147d9-b859-4b92-adfe-24d9540853a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d63ff926-4fba-42ec-b178-eb3e2375dd30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3797246-4ccf-4931-9ba3-9e5de9326734" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_d63ff926-4fba-42ec-b178-eb3e2375dd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c9f434cb-8a45-4cb9-80e5-6a9a1357877f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3797246-4ccf-4931-9ba3-9e5de9326734" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c9f434cb-8a45-4cb9-80e5-6a9a1357877f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3ab848dd-d83f-4279-82c0-fa73ef2a4a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3797246-4ccf-4931-9ba3-9e5de9326734" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_3ab848dd-d83f-4279-82c0-fa73ef2a4a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9a05fce6-950a-41a1-9190-ff4597e9c5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3797246-4ccf-4931-9ba3-9e5de9326734" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9a05fce6-950a-41a1-9190-ff4597e9c5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_875b7cf9-a862-4677-851f-cf809734d7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3797246-4ccf-4931-9ba3-9e5de9326734" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_875b7cf9-a862-4677-851f-cf809734d7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_937e302b-cd31-4850-988f-cec47fcb1764" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3797246-4ccf-4931-9ba3-9e5de9326734" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_937e302b-cd31-4850-988f-cec47fcb1764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance_e92a64a9-0e8f-482d-a09b-82e3d12e8251" xlink:href="lgnd-20241231.xsd#lgnd_OperatingLeaseLiabilityTenantImprovementAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3797246-4ccf-4931-9ba3-9e5de9326734" xlink:to="loc_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance_e92a64a9-0e8f-482d-a09b-82e3d12e8251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cf2e05f0-f166-4c6b-9def-631702cda12f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3797246-4ccf-4931-9ba3-9e5de9326734" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_cf2e05f0-f166-4c6b-9def-631702cda12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5761cf1e-cc26-4a92-b71e-55a6a03acddb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_b3797246-4ccf-4931-9ba3-9e5de9326734" xlink:to="loc_us-gaap_OperatingLeaseLiability_5761cf1e-cc26-4a92-b71e-55a6a03acddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_71e4065e-6fc8-4940-a23d-8d8253c15b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_55c9eec1-baa4-4527-9d82-c79e99026aea" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_71e4065e-6fc8-4940-a23d-8d8253c15b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_75007fe2-5348-41f1-b11c-1f9b89896693" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_71e4065e-6fc8-4940-a23d-8d8253c15b8a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_75007fe2-5348-41f1-b11c-1f9b89896693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_336ce51d-8b98-4e15-977a-2ffdae74633e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_71e4065e-6fc8-4940-a23d-8d8253c15b8a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_336ce51d-8b98-4e15-977a-2ffdae74633e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_4139312c-d3a3-45b7-bc80-252bcd2c4ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_71e4065e-6fc8-4940-a23d-8d8253c15b8a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_4139312c-d3a3-45b7-bc80-252bcd2c4ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_cad1854f-8308-4879-ab70-49545841dbc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_71e4065e-6fc8-4940-a23d-8d8253c15b8a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_cad1854f-8308-4879-ab70-49545841dbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_9c7ccaf7-92ac-4538-abe9-48cc45f79e35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_71e4065e-6fc8-4940-a23d-8d8253c15b8a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_9c7ccaf7-92ac-4538-abe9-48cc45f79e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_005aaf64-c8da-4278-a7c5-0bdf7c194305" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_71e4065e-6fc8-4940-a23d-8d8253c15b8a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_005aaf64-c8da-4278-a7c5-0bdf7c194305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_c8e220df-70b3-4991-8e6e-e557be5c0b82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_71e4065e-6fc8-4940-a23d-8d8253c15b8a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_c8e220df-70b3-4991-8e6e-e557be5c0b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_28c14e4a-7d69-4c3b-8382-48155a9e90dc" xlink:href="lgnd-20241231.xsd#lgnd_FinanceLeaseLiabilityTenantImprovementAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_71e4065e-6fc8-4940-a23d-8d8253c15b8a" xlink:to="loc_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance_28c14e4a-7d69-4c3b-8382-48155a9e90dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_4f96115b-0cd3-49b6-8340-09a5c8bcc622" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_71e4065e-6fc8-4940-a23d-8d8253c15b8a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_4f96115b-0cd3-49b6-8340-09a5c8bcc622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_31b3598f-865d-4a0c-aa96-1db4b9946562" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_71e4065e-6fc8-4940-a23d-8d8253c15b8a" xlink:to="loc_us-gaap_FinanceLeaseLiability_31b3598f-865d-4a0c-aa96-1db4b9946562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d85ea268-7917-4d89-bf21-41fa4c437d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_7c2e3bea-d23f-4541-b49e-ee82843c93e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d85ea268-7917-4d89-bf21-41fa4c437d6b" xlink:to="loc_us-gaap_DebtInstrumentTable_7c2e3bea-d23f-4541-b49e-ee82843c93e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_61e2e278-8d31-4414-a7b5-7154fcbbaacb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7c2e3bea-d23f-4541-b49e-ee82843c93e5" xlink:to="loc_us-gaap_DebtInstrumentAxis_61e2e278-8d31-4414-a7b5-7154fcbbaacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0ecce62a-f3d9-48c5-a04f-b4a1c3578b15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_61e2e278-8d31-4414-a7b5-7154fcbbaacb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0ecce62a-f3d9-48c5-a04f-b4a1c3578b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ConvertibleSeniorNotesDue2023Member_5256dd61-6a16-47ab-bbbd-c521da261140" xlink:href="lgnd-20241231.xsd#lgnd_ConvertibleSeniorNotesDue2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0ecce62a-f3d9-48c5-a04f-b4a1c3578b15" xlink:to="loc_lgnd_ConvertibleSeniorNotesDue2023Member_5256dd61-6a16-47ab-bbbd-c521da261140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5e516867-70eb-4c6a-9ea0-2bd7ae711dda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7c2e3bea-d23f-4541-b49e-ee82843c93e5" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5e516867-70eb-4c6a-9ea0-2bd7ae711dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_696b3308-de7f-49bc-a2ed-00d56f758f44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5e516867-70eb-4c6a-9ea0-2bd7ae711dda" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_696b3308-de7f-49bc-a2ed-00d56f758f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleNotesPayableMember_b496246a-98d1-49e3-a017-a85b06d26e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_696b3308-de7f-49bc-a2ed-00d56f758f44" xlink:to="loc_us-gaap_ConvertibleNotesPayableMember_b496246a-98d1-49e3-a017-a85b06d26e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_e707a22c-23ef-4933-a949-bf09fe760ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_696b3308-de7f-49bc-a2ed-00d56f758f44" xlink:to="loc_us-gaap_LineOfCreditMember_e707a22c-23ef-4933-a949-bf09fe760ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAxis_31d27bc8-891c-460e-8430-ecf7ab6ea077" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7c2e3bea-d23f-4541-b49e-ee82843c93e5" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAxis_31d27bc8-891c-460e-8430-ecf7ab6ea077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_78d3d0cc-01b4-4bc8-bcd4-fcb14d8121f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAxis_31d27bc8-891c-460e-8430-ecf7ab6ea077" xlink:to="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_78d3d0cc-01b4-4bc8-bcd4-fcb14d8121f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember_5d1d7628-1297-4b49-8813-647a2ac97f7a" xlink:href="lgnd-20241231.xsd#lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ExtinguishmentOfDebtTypeDomain_78d3d0cc-01b4-4bc8-bcd4-fcb14d8121f6" xlink:to="loc_lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember_5d1d7628-1297-4b49-8813-647a2ac97f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_266d9c19-f2e7-472f-95dd-7f72a34b36ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7c2e3bea-d23f-4541-b49e-ee82843c93e5" xlink:to="loc_us-gaap_CreditFacilityAxis_266d9c19-f2e7-472f-95dd-7f72a34b36ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9a7e5920-6f2e-43b5-a013-4fb04fab81a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_266d9c19-f2e7-472f-95dd-7f72a34b36ba" xlink:to="loc_us-gaap_CreditFacilityDomain_9a7e5920-6f2e-43b5-a013-4fb04fab81a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_8f94fbe3-a5d8-42af-a312-c0e5e8bd8e06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_9a7e5920-6f2e-43b5-a013-4fb04fab81a1" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_8f94fbe3-a5d8-42af-a312-c0e5e8bd8e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_90dd15cb-27df-4ead-a70a-9dff62779bd4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7c2e3bea-d23f-4541-b49e-ee82843c93e5" xlink:to="loc_srt_RangeAxis_90dd15cb-27df-4ead-a70a-9dff62779bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_41a74ee3-9b35-4d69-9658-225eec77dbed" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_90dd15cb-27df-4ead-a70a-9dff62779bd4" xlink:to="loc_srt_RangeMember_41a74ee3-9b35-4d69-9658-225eec77dbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_000150fc-ebad-4430-aba9-d5a10646e6e4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_41a74ee3-9b35-4d69-9658-225eec77dbed" xlink:to="loc_srt_MinimumMember_000150fc-ebad-4430-aba9-d5a10646e6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e3df17d4-e8e9-4160-a500-66bbfd516140" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_41a74ee3-9b35-4d69-9658-225eec77dbed" xlink:to="loc_srt_MaximumMember_e3df17d4-e8e9-4160-a500-66bbfd516140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_94b68f74-ca49-4772-b8b7-0cfa06f9f399" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7c2e3bea-d23f-4541-b49e-ee82843c93e5" xlink:to="loc_us-gaap_VariableRateAxis_94b68f74-ca49-4772-b8b7-0cfa06f9f399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_e819bd9b-089e-4309-b67f-db5fc8ebc68b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_94b68f74-ca49-4772-b8b7-0cfa06f9f399" xlink:to="loc_us-gaap_VariableRateDomain_e819bd9b-089e-4309-b67f-db5fc8ebc68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_17c4c560-7fdf-4e99-bfce-cf144da7a542" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_e819bd9b-089e-4309-b67f-db5fc8ebc68b" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrMember_17c4c560-7fdf-4e99-bfce-cf144da7a542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_d9c73f1e-bda3-41d8-836b-095631d13711" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_e819bd9b-089e-4309-b67f-db5fc8ebc68b" xlink:to="loc_us-gaap_BaseRateMember_d9c73f1e-bda3-41d8-836b-095631d13711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_7c2e3bea-d23f-4541-b49e-ee82843c93e5" xlink:to="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_52e78a12-5e53-4ceb-92ec-22aac8d156a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_52e78a12-5e53-4ceb-92ec-22aac8d156a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_35d54e4b-5543-4cf6-b33d-e74aa2dc5b18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_35d54e4b-5543-4cf6-b33d-e74aa2dc5b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_6de9e039-b8ae-4112-9021-a57f728c56a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_6de9e039-b8ae-4112-9021-a57f728c56a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_f6580e3f-9103-4ebc-a539-47d7f7e6b6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_f6580e3f-9103-4ebc-a539-47d7f7e6b6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_2bec4dab-35d8-4ce2-a7ea-dab386431e99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_DebtInstrumentTerm_2bec4dab-35d8-4ce2-a7ea-dab386431e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_8431c95f-556f-4131-975b-f0b5e4e674fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_8431c95f-556f-4131-975b-f0b5e4e674fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_7ef0a56b-635a-4111-a007-96cfc3ab183d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_InterestPaid_7ef0a56b-635a-4111-a007-96cfc3ab183d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_df280f59-5884-45b7-9bbc-7736ae7bce05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_df280f59-5884-45b7-9bbc-7736ae7bce05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_2972013d-cf2e-418d-ab67-411f77b39620" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_InterestExpenseDebt_2972013d-cf2e-418d-ab67-411f77b39620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebtExcludingAmortization_c805bc3b-8042-4c6c-a56a-886863f5fffe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebtExcludingAmortization"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_InterestExpenseDebtExcludingAmortization_c805bc3b-8042-4c6c-a56a-886863f5fffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_60e1fd01-471e-46fd-8b55-e115a435973b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_60e1fd01-471e-46fd-8b55-e115a435973b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_09183971-c360-42e4-abd7-9a68106da451" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRepurchaseAmount"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_09183971-c360-42e4-abd7-9a68106da451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_26bbe26a-70db-4d9e-94c3-1f612c9bc03e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_26bbe26a-70db-4d9e-94c3-1f612c9bc03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c8113cde-1bfb-454f-8201-4f77e39e1a40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_c8113cde-1bfb-454f-8201-4f77e39e1a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncreaseDecreaseInDebtDiscount_90eda8cb-c45a-4481-8a45-02159f7557c6" xlink:href="lgnd-20241231.xsd#lgnd_IncreaseDecreaseInDebtDiscount"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_lgnd_IncreaseDecreaseInDebtDiscount_90eda8cb-c45a-4481-8a45-02159f7557c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_efb016a8-8914-402c-800a-2b830ba3c1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_efb016a8-8914-402c-800a-2b830ba3c1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c460417d-e534-4ddd-baaf-1333b0012e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_c460417d-e534-4ddd-baaf-1333b0012e0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PaymentsforConvertibleBondHedges_d5dd6528-3972-46fe-8781-0296a877e83a" xlink:href="lgnd-20241231.xsd#lgnd_PaymentsforConvertibleBondHedges"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_lgnd_PaymentsforConvertibleBondHedges_d5dd6528-3972-46fe-8781-0296a877e83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d35202cf-2f97-4263-abe3-195398bf4972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_d35202cf-2f97-4263-abe3-195398bf4972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_63a9d460-140a-40fd-b488-fa8226059953" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_63a9d460-140a-40fd-b488-fa8226059953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod_db480ef7-6cfa-4ea8-93a4-e54f05311e53" xlink:href="lgnd-20241231.xsd#lgnd_DebtInstrumentRepurchasedAmountDuringPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod_db480ef7-6cfa-4ea8-93a4-e54f05311e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_213d5838-dbfd-48d8-b775-98f69bf24e99" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_213d5838-dbfd-48d8-b775-98f69bf24e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_003f8dc0-881a-4248-bfe7-9f3fbdc7ae70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_003f8dc0-881a-4248-bfe7-9f3fbdc7ae70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_f46d277c-0785-4e60-8d56-d14f9efb4e63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_f46d277c-0785-4e60-8d56-d14f9efb4e63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_e8593c6b-a2b7-415a-a477-860a9d24f328" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_e8593c6b-a2b7-415a-a477-860a9d24f328" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_9fb1689a-d339-4bbe-b6b2-1a6bb6805b84" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_25d74716-8468-447d-947e-7acf011b9fa3" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_9fb1689a-d339-4bbe-b6b2-1a6bb6805b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#StockholdersEquityShareBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3e299fa0-8c59-4ebd-b157-cda5edcf31b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f04f8c2f-94ef-4b67-82f5-41d98406699e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3e299fa0-8c59-4ebd-b157-cda5edcf31b0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f04f8c2f-94ef-4b67-82f5-41d98406699e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6652e6a1-75ae-498d-ad14-51f078baa14f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f04f8c2f-94ef-4b67-82f5-41d98406699e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6652e6a1-75ae-498d-ad14-51f078baa14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_eb98ff9f-3627-4bab-b7be-c4b89a29af35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6652e6a1-75ae-498d-ad14-51f078baa14f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_eb98ff9f-3627-4bab-b7be-c4b89a29af35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_868bda6e-0c45-4d01-8448-0f1f1954070b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_eb98ff9f-3627-4bab-b7be-c4b89a29af35" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_868bda6e-0c45-4d01-8448-0f1f1954070b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_30208e09-3483-4a58-a30c-ab16eab389dd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_eb98ff9f-3627-4bab-b7be-c4b89a29af35" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_30208e09-3483-4a58-a30c-ab16eab389dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0ba5cdd-a114-43aa-90a3-bd2801f7eca6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f04f8c2f-94ef-4b67-82f5-41d98406699e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0ba5cdd-a114-43aa-90a3-bd2801f7eca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_03857e91-c78d-49b0-8649-d7378c22a160" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f0ba5cdd-a114-43aa-90a3-bd2801f7eca6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_03857e91-c78d-49b0-8649-d7378c22a160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6fb51331-91ca-4e88-b323-990e63904829" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_481e8d34-22ee-42d6-bb2c-1d36ffea3ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6fb51331-91ca-4e88-b323-990e63904829" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_481e8d34-22ee-42d6-bb2c-1d36ffea3ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_9ce0c698-4b26-4665-b500-5a42e1766bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_481e8d34-22ee-42d6-bb2c-1d36ffea3ba5" xlink:to="loc_us-gaap_PlanNameAxis_9ce0c698-4b26-4665-b500-5a42e1766bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7181244e-1874-4194-8d28-c441f36d8f62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_9ce0c698-4b26-4665-b500-5a42e1766bbc" xlink:to="loc_us-gaap_PlanNameDomain_7181244e-1874-4194-8d28-c441f36d8f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_f216b3de-eef7-476a-ad57-3b6fd39f4a40" xlink:href="lgnd-20241231.xsd#lgnd_TwoThousandTwoStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7181244e-1874-4194-8d28-c441f36d8f62" xlink:to="loc_lgnd_TwoThousandTwoStockIncentivePlanMember_f216b3de-eef7-476a-ad57-3b6fd39f4a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OmniabSeparationMember_467d05e0-f47d-4004-8ab7-2301427e224e" xlink:href="lgnd-20241231.xsd#lgnd_OmniabSeparationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7181244e-1874-4194-8d28-c441f36d8f62" xlink:to="loc_lgnd_OmniabSeparationMember_467d05e0-f47d-4004-8ab7-2301427e224e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AmendedESPPMember_e0dec66a-e6e4-4376-88e9-d1101c4bd751" xlink:href="lgnd-20241231.xsd#lgnd_AmendedESPPMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7181244e-1874-4194-8d28-c441f36d8f62" xlink:to="loc_lgnd_AmendedESPPMember_e0dec66a-e6e4-4376-88e9-d1101c4bd751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_73d00295-e159-4bee-bc79-f2351c0bdf33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_481e8d34-22ee-42d6-bb2c-1d36ffea3ba5" xlink:to="loc_us-gaap_AwardTypeAxis_73d00295-e159-4bee-bc79-f2351c0bdf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad197081-e277-433e-9f65-fe4b8d24386b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_73d00295-e159-4bee-bc79-f2351c0bdf33" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad197081-e277-433e-9f65-fe4b8d24386b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_38169ec9-d4d0-44b7-9a2e-940d8a7ef011" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad197081-e277-433e-9f65-fe4b8d24386b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_38169ec9-d4d0-44b7-9a2e-940d8a7ef011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_d1592916-bdd3-4ad5-8215-184c31a062e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ad197081-e277-433e-9f65-fe4b8d24386b" xlink:to="loc_us-gaap_RestrictedStockMember_d1592916-bdd3-4ad5-8215-184c31a062e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_646b1f1e-ee0d-4c80-afe3-93a412a33c81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_481e8d34-22ee-42d6-bb2c-1d36ffea3ba5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_646b1f1e-ee0d-4c80-afe3-93a412a33c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c1ecc432-361f-4531-b66e-8228af170c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_646b1f1e-ee0d-4c80-afe3-93a412a33c81" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c1ecc432-361f-4531-b66e-8228af170c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_AtTheMarketEquityOfferingMember_d47dabe7-ace1-4fdb-a4c0-8a6046d5247c" xlink:href="lgnd-20241231.xsd#lgnd_AtTheMarketEquityOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c1ecc432-361f-4531-b66e-8228af170c3f" xlink:to="loc_lgnd_AtTheMarketEquityOfferingMember_d47dabe7-ace1-4fdb-a4c0-8a6046d5247c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_481e8d34-22ee-42d6-bb2c-1d36ffea3ba5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_4ff402d2-5160-4fad-89b7-61a359cb8952" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_4ff402d2-5160-4fad-89b7-61a359cb8952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4a6bb64b-7640-4ebc-aef6-baf9eb7c606f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_4a6bb64b-7640-4ebc-aef6-baf9eb7c606f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2155a81b-8295-43dc-b21d-98e9572c060e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2155a81b-8295-43dc-b21d-98e9572c060e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1ecc2c54-6aff-4ffd-83dc-83df1f714c0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1ecc2c54-6aff-4ffd-83dc-83df1f714c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8867b531-6bd9-4ec6-8cd5-7d8a2dc15a6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8867b531-6bd9-4ec6-8cd5-7d8a2dc15a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_48de8285-ee1c-4327-ab39-69714e667164" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_48de8285-ee1c-4327-ab39-69714e667164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_57e7c035-f520-45f6-b6a6-a8d6cdaa9110" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_57e7c035-f520-45f6-b6a6-a8d6cdaa9110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f11f9345-ae6d-499f-95f6-067f84207528" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_f11f9345-ae6d-499f-95f6-067f84207528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1f247d53-e20f-4af1-9e7c-e8b457b3e610" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1f247d53-e20f-4af1-9e7c-e8b457b3e610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EmployeeStockPurchasePlanAbstract_4e1ce780-21cc-4595-835b-28b7c73543d8" xlink:href="lgnd-20241231.xsd#lgnd_EmployeeStockPurchasePlanAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_lgnd_EmployeeStockPurchasePlanAbstract_4e1ce780-21cc-4595-835b-28b7c73543d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_d3330967-29af-4755-8019-fff5f9ff34cb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_4e1ce780-21cc-4595-835b-28b7c73543d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee_d3330967-29af-4755-8019-fff5f9ff34cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7d90fdb7-44e3-405e-b026-a9a92d98d1e7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_4e1ce780-21cc-4595-835b-28b7c73543d8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7d90fdb7-44e3-405e-b026-a9a92d98d1e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ShareBasedCompensationInitialOfferingPeriod_15ed1ff7-53b6-442e-a2c7-af7506ff35fb" xlink:href="lgnd-20241231.xsd#lgnd_ShareBasedCompensationInitialOfferingPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_4e1ce780-21cc-4595-835b-28b7c73543d8" xlink:to="loc_lgnd_ShareBasedCompensationInitialOfferingPeriod_15ed1ff7-53b6-442e-a2c7-af7506ff35fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_8aad1935-3b12-40a1-b626-2f4f0670315d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_EmployeeStockPurchasePlanAbstract_4e1ce780-21cc-4595-835b-28b7c73543d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_8aad1935-3b12-40a1-b626-2f4f0670315d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CorporateShareRepurchaseAbstract_b7588697-93d4-4016-b93e-909d89f4f709" xlink:href="lgnd-20241231.xsd#lgnd_CorporateShareRepurchaseAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_590ccea9-ab91-44d6-b970-6715b6a47327" xlink:to="loc_lgnd_CorporateShareRepurchaseAbstract_b7588697-93d4-4016-b93e-909d89f4f709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_a4334695-28dd-4088-9b87-d91bc453f113" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_b7588697-93d4-4016-b93e-909d89f4f709" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_a4334695-28dd-4088-9b87-d91bc453f113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_e64367bb-193e-41f5-9d9c-527f62ecd115" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_b7588697-93d4-4016-b93e-909d89f4f709" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_e64367bb-193e-41f5-9d9c-527f62ecd115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_SaleOfStockAuthorizedOfferingAmount_60a2bb31-6d9f-4bed-b020-90e27f7e508b" xlink:href="lgnd-20241231.xsd#lgnd_SaleOfStockAuthorizedOfferingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_b7588697-93d4-4016-b93e-909d89f4f709" xlink:to="loc_lgnd_SaleOfStockAuthorizedOfferingAmount_60a2bb31-6d9f-4bed-b020-90e27f7e508b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1a9b1acb-03f9-483c-8b5b-9b7f25ed50f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_b7588697-93d4-4016-b93e-909d89f4f709" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_1a9b1acb-03f9-483c-8b5b-9b7f25ed50f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_723397b1-a2ed-44cc-8bc4-11b2962c2832" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lgnd_CorporateShareRepurchaseAbstract_b7588697-93d4-4016-b93e-909d89f4f709" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_723397b1-a2ed-44cc-8bc4-11b2962c2832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#StockholdersEquityStockOptionPlanActivityDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ef60035a-87be-4ab6-9f27-85a596acde95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f1fb7cd2-817f-4965-b44a-c6d84f537160" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ef60035a-87be-4ab6-9f27-85a596acde95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f1fb7cd2-817f-4965-b44a-c6d84f537160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_02339953-5023-4699-bfb6-c031fd3c3a10" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f1fb7cd2-817f-4965-b44a-c6d84f537160" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_02339953-5023-4699-bfb6-c031fd3c3a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_aaeb5ea9-ccb5-447d-9b29-89a03b0e268a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f1fb7cd2-817f-4965-b44a-c6d84f537160" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_aaeb5ea9-ccb5-447d-9b29-89a03b0e268a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_460e4b4b-c0ba-4012-bb15-1e6946132b91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f1fb7cd2-817f-4965-b44a-c6d84f537160" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_460e4b4b-c0ba-4012-bb15-1e6946132b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_95d8d62c-8399-4f1c-b73c-c3d03ab455de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f1fb7cd2-817f-4965-b44a-c6d84f537160" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_95d8d62c-8399-4f1c-b73c-c3d03ab455de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7bf48862-f79a-4be8-a6d1-a3dc43c6bdf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f1fb7cd2-817f-4965-b44a-c6d84f537160" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7bf48862-f79a-4be8-a6d1-a3dc43c6bdf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1ea92943-2b73-4dd2-9e14-9b5df48c3d35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ef60035a-87be-4ab6-9f27-85a596acde95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1ea92943-2b73-4dd2-9e14-9b5df48c3d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_7d0309da-8e95-4a0c-8a38-236d580ca3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ef60035a-87be-4ab6-9f27-85a596acde95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_7d0309da-8e95-4a0c-8a38-236d580ca3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4e73ed67-da62-49c3-9375-cf17b229bdfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ef60035a-87be-4ab6-9f27-85a596acde95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4e73ed67-da62-49c3-9375-cf17b229bdfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_df9cfce2-a26f-4b77-8173-89c651356a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4e73ed67-da62-49c3-9375-cf17b229bdfa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_df9cfce2-a26f-4b77-8173-89c651356a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_39f3b1c0-4cf6-43f5-b178-53541c663120" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4e73ed67-da62-49c3-9375-cf17b229bdfa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_39f3b1c0-4cf6-43f5-b178-53541c663120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_26296a68-59f1-4906-a7cd-46ff189e81e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4e73ed67-da62-49c3-9375-cf17b229bdfa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_26296a68-59f1-4906-a7cd-46ff189e81e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0e894dab-0be7-4097-b775-c122727f8bad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4e73ed67-da62-49c3-9375-cf17b229bdfa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0e894dab-0be7-4097-b775-c122727f8bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0a518d83-76b5-4284-bb5d-e17242e9f6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4e73ed67-da62-49c3-9375-cf17b229bdfa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0a518d83-76b5-4284-bb5d-e17242e9f6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_19fd419b-ebb0-4803-a130-ec2bb77a6d02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ef60035a-87be-4ab6-9f27-85a596acde95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_19fd419b-ebb0-4803-a130-ec2bb77a6d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_cf96eaf4-a88b-4341-9597-7742ccbd0df9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ef60035a-87be-4ab6-9f27-85a596acde95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_cf96eaf4-a88b-4341-9597-7742ccbd0df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0a61256f-9eb4-4402-8a56-6aec06eceb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ef60035a-87be-4ab6-9f27-85a596acde95" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0a61256f-9eb4-4402-8a56-6aec06eceb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e29befd0-b157-4afa-a727-265496449633" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ef60035a-87be-4ab6-9f27-85a596acde95" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_e29befd0-b157-4afa-a727-265496449633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_182c628f-6eff-4043-b06c-bcfd3714639c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ef60035a-87be-4ab6-9f27-85a596acde95" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_182c628f-6eff-4043-b06c-bcfd3714639c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b293b178-a0fa-4649-9375-711850c4dd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ef60035a-87be-4ab6-9f27-85a596acde95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b293b178-a0fa-4649-9375-711850c4dd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_84949c3d-7163-4bfc-8fc4-aeb03e18c321" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ef60035a-87be-4ab6-9f27-85a596acde95" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_84949c3d-7163-4bfc-8fc4-aeb03e18c321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_019d34e2-1b28-4d0c-bb8d-f6012511faf3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ef60035a-87be-4ab6-9f27-85a596acde95" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_019d34e2-1b28-4d0c-bb8d-f6012511faf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#StockholdersEquityBreakdownofOptionsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d366bb00-0e23-42fa-b05e-a826547b7dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9579d046-3482-4c91-bace-5e20765359de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d366bb00-0e23-42fa-b05e-a826547b7dd5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9579d046-3482-4c91-bace-5e20765359de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0ed196d9-e9b4-45af-ab2a-3c3be60d180f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9579d046-3482-4c91-bace-5e20765359de" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0ed196d9-e9b4-45af-ab2a-3c3be60d180f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_0ed196d9-e9b4-45af-ab2a-3c3be60d180f" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeOneMember_7af95dda-130f-42b5-a011-dd976a72a916" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeOneMember_7af95dda-130f-42b5-a011-dd976a72a916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTwoMember_39c68177-6a46-4615-bffa-af7cfe2f110b" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeTwoMember_39c68177-6a46-4615-bffa-af7cfe2f110b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeThreeMember_61038d75-4b85-4481-944c-7af4b0f8bf42" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeThreeMember_61038d75-4b85-4481-944c-7af4b0f8bf42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFourMember_f66989e7-303f-4f97-b169-ff8c69a466bb" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeFourMember_f66989e7-303f-4f97-b169-ff8c69a466bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeFiveMember_728e9bc5-c66e-4ca9-87c0-7f2bad2fce8c" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeFiveMember_728e9bc5-c66e-4ca9-87c0-7f2bad2fce8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSixMember_9a5fbbc2-d922-48f5-8364-a7a3b99fb3ab" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeSixMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeSixMember_9a5fbbc2-d922-48f5-8364-a7a3b99fb3ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeSevenMember_d1b4951c-98e3-488b-a058-676053f1f837" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeSevenMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeSevenMember_d1b4951c-98e3-488b-a058-676053f1f837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeEightMember_057dedd1-dd85-4be0-bc6d-9808edc89269" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeEightMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeEightMember_057dedd1-dd85-4be0-bc6d-9808edc89269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeNineMember_0fab30f9-8f99-4765-bd0d-127304811f94" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeNineMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeNineMember_0fab30f9-8f99-4765-bd0d-127304811f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_ExercisePriceRangeTenMember_f353c223-5992-4cb9-b812-962ca5f15010" xlink:href="lgnd-20241231.xsd#lgnd_ExercisePriceRangeTenMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_4c0806a5-8683-4f95-ac7c-8c98153a58f7" xlink:to="loc_lgnd_ExercisePriceRangeTenMember_f353c223-5992-4cb9-b812-962ca5f15010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5eac6c4-ba6d-4a82-8fe3-06a6f02eeba3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9579d046-3482-4c91-bace-5e20765359de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5eac6c4-ba6d-4a82-8fe3-06a6f02eeba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_7f7785ef-7913-447d-ba91-fcfdaa5a4592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5eac6c4-ba6d-4a82-8fe3-06a6f02eeba3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_7f7785ef-7913-447d-ba91-fcfdaa5a4592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_763df597-da87-4501-a6fc-41e300f01e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5eac6c4-ba6d-4a82-8fe3-06a6f02eeba3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_763df597-da87-4501-a6fc-41e300f01e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_f51ef6b7-a43e-4de7-bc10-5bb2d4f559c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5eac6c4-ba6d-4a82-8fe3-06a6f02eeba3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_f51ef6b7-a43e-4de7-bc10-5bb2d4f559c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_c78cd117-f0ec-49ff-b2ed-bca511414c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5eac6c4-ba6d-4a82-8fe3-06a6f02eeba3" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_c78cd117-f0ec-49ff-b2ed-bca511414c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_52b50f05-8e7f-4ede-91e7-b6de9a62f767" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5eac6c4-ba6d-4a82-8fe3-06a6f02eeba3" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_52b50f05-8e7f-4ede-91e7-b6de9a62f767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_3d0f6837-7038-4f88-8865-69c42e20be7d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5eac6c4-ba6d-4a82-8fe3-06a6f02eeba3" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_3d0f6837-7038-4f88-8865-69c42e20be7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_d7a98251-829a-40f6-b509-2b815debb94f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b5eac6c4-ba6d-4a82-8fe3-06a6f02eeba3" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_d7a98251-829a-40f6-b509-2b815debb94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#StockholdersEquityAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_02d9e10a-1d97-4152-b408-f65b5e05fb06" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a881c79-4f48-42fc-abc9-4bbc3b682ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_02d9e10a-1d97-4152-b408-f65b5e05fb06" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a881c79-4f48-42fc-abc9-4bbc3b682ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd63df32-a6e2-4948-89cc-d2e78179daeb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a881c79-4f48-42fc-abc9-4bbc3b682ab7" xlink:to="loc_srt_RangeAxis_fd63df32-a6e2-4948-89cc-d2e78179daeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0008e6c-2c89-44d3-a830-1ccec42e905b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fd63df32-a6e2-4948-89cc-d2e78179daeb" xlink:to="loc_srt_RangeMember_d0008e6c-2c89-44d3-a830-1ccec42e905b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6cc571b9-433e-4987-b2aa-320e8123a467" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d0008e6c-2c89-44d3-a830-1ccec42e905b" xlink:to="loc_srt_MinimumMember_6cc571b9-433e-4987-b2aa-320e8123a467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f316f2ad-246d-4d57-9cbc-66213902bcec" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d0008e6c-2c89-44d3-a830-1ccec42e905b" xlink:to="loc_srt_MaximumMember_f316f2ad-246d-4d57-9cbc-66213902bcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d348455e-2a0a-4a4f-b2e1-db5626e37a68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a881c79-4f48-42fc-abc9-4bbc3b682ab7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d348455e-2a0a-4a4f-b2e1-db5626e37a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4a5c5837-2f28-42d0-95f2-b83e8b70a53f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d348455e-2a0a-4a4f-b2e1-db5626e37a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4a5c5837-2f28-42d0-95f2-b83e8b70a53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40c328d6-d05f-4f0f-bd99-e031739f7413" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d348455e-2a0a-4a4f-b2e1-db5626e37a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_40c328d6-d05f-4f0f-bd99-e031739f7413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8842a378-272c-468b-8453-72781ae66d75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d348455e-2a0a-4a4f-b2e1-db5626e37a68" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_8842a378-272c-468b-8453-72781ae66d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#StockholdersEquityRestrictedStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_29fd92b5-1d3a-40a1-8918-83fb80ed9f22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_225674b6-1e8f-4093-a6d0-60c48a8671f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_29fd92b5-1d3a-40a1-8918-83fb80ed9f22" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_225674b6-1e8f-4093-a6d0-60c48a8671f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8977cf70-965e-4396-b13d-882a370735e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_225674b6-1e8f-4093-a6d0-60c48a8671f6" xlink:to="loc_us-gaap_AwardTypeAxis_8977cf70-965e-4396-b13d-882a370735e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e2460dd-3078-4b31-bd1f-7ba1f985776b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8977cf70-965e-4396-b13d-882a370735e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e2460dd-3078-4b31-bd1f-7ba1f985776b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_11aa212f-ad28-45a1-8c39-92a4492f144b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e2460dd-3078-4b31-bd1f-7ba1f985776b" xlink:to="loc_us-gaap_RestrictedStockMember_11aa212f-ad28-45a1-8c39-92a4492f144b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dca12d26-0812-427b-a728-7fdea7de3ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_225674b6-1e8f-4093-a6d0-60c48a8671f6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dca12d26-0812-427b-a728-7fdea7de3ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4f7ade80-0aec-4b4e-9ee2-522a3d22e96a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dca12d26-0812-427b-a728-7fdea7de3ebb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4f7ade80-0aec-4b4e-9ee2-522a3d22e96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_566613fa-a357-4769-8698-611c539db4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4f7ade80-0aec-4b4e-9ee2-522a3d22e96a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_566613fa-a357-4769-8698-611c539db4bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_deb6e4c6-d1cb-4949-9ee8-9635aa753752" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4f7ade80-0aec-4b4e-9ee2-522a3d22e96a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_deb6e4c6-d1cb-4949-9ee8-9635aa753752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_492b0a7c-e3d7-4559-baca-971cac26d840" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4f7ade80-0aec-4b4e-9ee2-522a3d22e96a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_492b0a7c-e3d7-4559-baca-971cac26d840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c3258b68-d4f7-4d76-98b7-67d2fbe4d3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4f7ade80-0aec-4b4e-9ee2-522a3d22e96a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c3258b68-d4f7-4d76-98b7-67d2fbe4d3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1d77dc8b-c543-426b-b37c-ec5fcc36a672" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4f7ade80-0aec-4b4e-9ee2-522a3d22e96a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1d77dc8b-c543-426b-b37c-ec5fcc36a672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a569f00f-731a-42dd-9232-42533e6679a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dca12d26-0812-427b-a728-7fdea7de3ebb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a569f00f-731a-42dd-9232-42533e6679a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2124647f-0254-4ab9-9e54-cd4f72634c89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a569f00f-731a-42dd-9232-42533e6679a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2124647f-0254-4ab9-9e54-cd4f72634c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5cc14d68-6697-4935-9133-375b05b6db3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a569f00f-731a-42dd-9232-42533e6679a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5cc14d68-6697-4935-9133-375b05b6db3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cafb332d-418d-4cbb-a36f-63ffeec1bad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a569f00f-731a-42dd-9232-42533e6679a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_cafb332d-418d-4cbb-a36f-63ffeec1bad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c1429205-30ca-40cf-997a-475efae5e9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a569f00f-731a-42dd-9232-42533e6679a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c1429205-30ca-40cf-997a-475efae5e9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a00da48c-d4a8-4ac1-b4ea-2864d0127d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a569f00f-731a-42dd-9232-42533e6679a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a00da48c-d4a8-4ac1-b4ea-2864d0127d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#CommitmentandContingenciesLegalProceedingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d1aea064-ed37-480d-81b5-eea0ab39206a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_088f9163-0ceb-4a87-99d1-4ab5e2d50072" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d1aea064-ed37-480d-81b5-eea0ab39206a" xlink:to="loc_us-gaap_LossContingenciesTable_088f9163-0ceb-4a87-99d1-4ab5e2d50072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_235ed266-8a5a-41b6-8457-eac5fcf6ac7c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_088f9163-0ceb-4a87-99d1-4ab5e2d50072" xlink:to="loc_srt_LitigationCaseAxis_235ed266-8a5a-41b6-8457-eac5fcf6ac7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4056aea2-4b2e-469a-a397-61c0d53e600b" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_235ed266-8a5a-41b6-8457-eac5fcf6ac7c" xlink:to="loc_srt_LitigationCaseTypeDomain_4056aea2-4b2e-469a-a397-61c0d53e600b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_55dde826-aca8-4d07-ae0c-d2247922cbf0" xlink:href="lgnd-20241231.xsd#lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4056aea2-4b2e-469a-a397-61c0d53e600b" xlink:to="loc_lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember_55dde826-aca8-4d07-ae0c-d2247922cbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_acd675ef-bb6a-4e44-957d-aac934490e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_088f9163-0ceb-4a87-99d1-4ab5e2d50072" xlink:to="loc_us-gaap_LossContingenciesLineItems_acd675ef-bb6a-4e44-957d-aac934490e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b708a673-cefa-44ee-82e3-8a59017fe535" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_acd675ef-bb6a-4e44-957d-aac934490e2a" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_b708a673-cefa-44ee-82e3-8a59017fe535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesIncomeBeforeIncomeTaxFromContinuingOperationsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#IncomeTaxesIncomeBeforeIncomeTaxFromContinuingOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesIncomeBeforeIncomeTaxFromContinuingOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1e2b44bc-f6ca-46c1-b8b1-215186e2dd60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_6a66ba43-d03e-40ce-800b-a9db3e1f89cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1e2b44bc-f6ca-46c1-b8b1-215186e2dd60" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_6a66ba43-d03e-40ce-800b-a9db3e1f89cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_36562b1c-72da-42e3-9b25-8eeb014243bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_6a66ba43-d03e-40ce-800b-a9db3e1f89cf" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_36562b1c-72da-42e3-9b25-8eeb014243bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_42b0e471-3708-4db1-bda3-4a01f37e4b47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_36562b1c-72da-42e3-9b25-8eeb014243bd" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_42b0e471-3708-4db1-bda3-4a01f37e4b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_e1904c49-debb-49e5-b667-825bd4f64bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_42b0e471-3708-4db1-bda3-4a01f37e4b47" xlink:to="loc_us-gaap_DomesticCountryMember_e1904c49-debb-49e5-b667-825bd4f64bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_b6965b0f-a531-423c-a96e-f7a4b49784b7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_42b0e471-3708-4db1-bda3-4a01f37e4b47" xlink:to="loc_us-gaap_ForeignCountryMember_b6965b0f-a531-423c-a96e-f7a4b49784b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_0dd8be9e-ea93-48cc-b5c2-dd44adfbf192" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_6a66ba43-d03e-40ce-800b-a9db3e1f89cf" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_0dd8be9e-ea93-48cc-b5c2-dd44adfbf192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_031aff1a-8597-43a8-919e-0972ae1f6b44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0dd8be9e-ea93-48cc-b5c2-dd44adfbf192" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_031aff1a-8597-43a8-919e-0972ae1f6b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_348f7a9a-a08b-43e1-a4e5-480905c683fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f9533f33-3a3e-496f-a1e9-45f2a3c0a985" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_348f7a9a-a08b-43e1-a4e5-480905c683fe" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f9533f33-3a3e-496f-a1e9-45f2a3c0a985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_346c9dc5-e49e-4716-b5c4-7cc4085d0d14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f9533f33-3a3e-496f-a1e9-45f2a3c0a985" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_346c9dc5-e49e-4716-b5c4-7cc4085d0d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4a455e11-3d7a-4f1c-b4a2-97e385a90e59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f9533f33-3a3e-496f-a1e9-45f2a3c0a985" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_4a455e11-3d7a-4f1c-b4a2-97e385a90e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_f7bbd4a9-b211-476e-9d12-c2e6953d0048" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f9533f33-3a3e-496f-a1e9-45f2a3c0a985" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_f7bbd4a9-b211-476e-9d12-c2e6953d0048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2428fa7c-75fb-4a06-b5fe-9cf8d78f9f62" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_f9533f33-3a3e-496f-a1e9-45f2a3c0a985" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2428fa7c-75fb-4a06-b5fe-9cf8d78f9f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b5365952-194c-4fb3-a4fb-9f943084224d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_348f7a9a-a08b-43e1-a4e5-480905c683fe" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b5365952-194c-4fb3-a4fb-9f943084224d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ebc09d27-c123-49db-811f-4a6f8a93dacc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b5365952-194c-4fb3-a4fb-9f943084224d" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ebc09d27-c123-49db-811f-4a6f8a93dacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_90e10a9e-cead-4cd3-94c1-84088d96a79a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b5365952-194c-4fb3-a4fb-9f943084224d" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_90e10a9e-cead-4cd3-94c1-84088d96a79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_7a25c2f9-60ac-48de-9df0-8a78e5d75ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b5365952-194c-4fb3-a4fb-9f943084224d" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_7a25c2f9-60ac-48de-9df0-8a78e5d75ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bd721c6e-eccb-4ea8-8ea5-e05a376e487f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_b5365952-194c-4fb3-a4fb-9f943084224d" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bd721c6e-eccb-4ea8-8ea5-e05a376e487f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6beb3263-1530-41a1-9324-37e04867b6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_348f7a9a-a08b-43e1-a4e5-480905c683fe" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6beb3263-1530-41a1-9324-37e04867b6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_13c89c60-d4bb-435f-a341-3299a70f0ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e58288f1-29da-4322-a63b-e89689289f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_13c89c60-d4bb-435f-a341-3299a70f0ea4" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e58288f1-29da-4322-a63b-e89689289f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2b143485-4e96-428e-80f3-4123df46e387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e58288f1-29da-4322-a63b-e89689289f7a" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_2b143485-4e96-428e-80f3-4123df46e387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome_543f07a9-1d4f-43b0-b5e0-277a5aed30bb" xlink:href="lgnd-20241231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e58288f1-29da-4322-a63b-e89689289f7a" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome_543f07a9-1d4f-43b0-b5e0-277a5aed30bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount_00b8c530-a3f9-4d53-928c-4578c898af8f" xlink:href="lgnd-20241231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e58288f1-29da-4322-a63b-e89689289f7a" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount_00b8c530-a3f9-4d53-928c-4578c898af8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_7ba02cfa-0e10-464f-aab9-74e509e1f55a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e58288f1-29da-4322-a63b-e89689289f7a" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_7ba02cfa-0e10-464f-aab9-74e509e1f55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_0bf11143-459d-424b-a24c-ab21ff52f922" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e58288f1-29da-4322-a63b-e89689289f7a" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_0bf11143-459d-424b-a24c-ab21ff52f922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_e9dcbe67-e7f5-4919-9b45-6158e01c5138" xlink:href="lgnd-20241231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e58288f1-29da-4322-a63b-e89689289f7a" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount_e9dcbe67-e7f5-4919-9b45-6158e01c5138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_b9669583-e757-47ad-9b89-b80504ac1013" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e58288f1-29da-4322-a63b-e89689289f7a" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_b9669583-e757-47ad-9b89-b80504ac1013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_IncomeTaxReconciliationContingentValueRights_0db6b4c1-bb47-4594-8f6e-31ad7c80bee1" xlink:href="lgnd-20241231.xsd#lgnd_IncomeTaxReconciliationContingentValueRights"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e58288f1-29da-4322-a63b-e89689289f7a" xlink:to="loc_lgnd_IncomeTaxReconciliationContingentValueRights_0db6b4c1-bb47-4594-8f6e-31ad7c80bee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_3e8f0492-32c7-432a-be98-95e7fac6368a" xlink:href="lgnd-20241231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e58288f1-29da-4322-a63b-e89689289f7a" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions_3e8f0492-32c7-432a-be98-95e7fac6368a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount_6fd01a03-9dc2-4d90-a9b2-613efd1bb1c1" xlink:href="lgnd-20241231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e58288f1-29da-4322-a63b-e89689289f7a" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount_6fd01a03-9dc2-4d90-a9b2-613efd1bb1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_797b8da2-f9cc-4b7c-844e-b6e8f796fa89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e58288f1-29da-4322-a63b-e89689289f7a" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_797b8da2-f9cc-4b7c-844e-b6e8f796fa89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_71ac48b2-a3f6-453a-b51e-59e47794f507" xlink:href="lgnd-20241231.xsd#lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e58288f1-29da-4322-a63b-e89689289f7a" xlink:to="loc_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch_71ac48b2-a3f6-453a-b51e-59e47794f507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_8ea18921-ad09-40da-aa13-4b01dee5aec2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e58288f1-29da-4322-a63b-e89689289f7a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount_8ea18921-ad09-40da-aa13-4b01dee5aec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_d8c3e97f-2b6d-49d0-b7df-21273eaee04a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e58288f1-29da-4322-a63b-e89689289f7a" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_d8c3e97f-2b6d-49d0-b7df-21273eaee04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_09dfd449-5da9-4634-bdd2-6897847f85df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsForeign"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e58288f1-29da-4322-a63b-e89689289f7a" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsForeign_09dfd449-5da9-4634-bdd2-6897847f85df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_94001e5a-f551-4288-b7a6-b45879cb24d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e58288f1-29da-4322-a63b-e89689289f7a" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_94001e5a-f551-4288-b7a6-b45879cb24d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a5b12840-c921-41d0-acdf-60d93829492e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_e58288f1-29da-4322-a63b-e89689289f7a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a5b12840-c921-41d0-acdf-60d93829492e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6dbbde09-8560-4575-a8c6-45e4004936f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_d5d43038-29ef-4315-8866-cb19078e8fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6dbbde09-8560-4575-a8c6-45e4004936f5" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_d5d43038-29ef-4315-8866-cb19078e8fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_0f02055f-4067-4fb9-9b88-326f1e628925" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d5d43038-29ef-4315-8866-cb19078e8fa0" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_0f02055f-4067-4fb9-9b88-326f1e628925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1af08f46-c773-4531-8659-a77cfebe71cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_0f02055f-4067-4fb9-9b88-326f1e628925" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1af08f46-c773-4531-8659-a77cfebe71cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_6ab45732-371e-454b-97a0-f11117a81a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1af08f46-c773-4531-8659-a77cfebe71cc" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_6ab45732-371e-454b-97a0-f11117a81a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5477fa2b-3542-4b2d-bfa7-2af4a7b0a6f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1af08f46-c773-4531-8659-a77cfebe71cc" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_5477fa2b-3542-4b2d-bfa7-2af4a7b0a6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_2b7a9aa1-747d-4b00-bae6-3a47021543bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1af08f46-c773-4531-8659-a77cfebe71cc" xlink:to="loc_us-gaap_ForeignCountryMember_2b7a9aa1-747d-4b00-bae6-3a47021543bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_388f718a-5358-481a-840e-c3bd822531da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d5d43038-29ef-4315-8866-cb19078e8fa0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_388f718a-5358-481a-840e-c3bd822531da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_36ee8aab-2a32-4477-acb0-472f82bf8fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_388f718a-5358-481a-840e-c3bd822531da" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_36ee8aab-2a32-4477-acb0-472f82bf8fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_f47df681-2449-4e77-a783-343e46de022f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_36ee8aab-2a32-4477-acb0-472f82bf8fe3" xlink:to="loc_us-gaap_ResearchMember_f47df681-2449-4e77-a783-343e46de022f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_f497fd44-03e9-40f9-bb51-2b39cbfce757" xlink:href="lgnd-20241231.xsd#lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_36ee8aab-2a32-4477-acb0-472f82bf8fe3" xlink:to="loc_lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember_f497fd44-03e9-40f9-bb51-2b39cbfce757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalLossCarryforwardMember_afbb7066-f0e3-43f6-b017-1f8dd7d61246" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CapitalLossCarryforwardMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_36ee8aab-2a32-4477-acb0-472f82bf8fe3" xlink:to="loc_us-gaap_CapitalLossCarryforwardMember_afbb7066-f0e3-43f6-b017-1f8dd7d61246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6827b21-d6ab-4fff-b174-a6bc865f500f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_d5d43038-29ef-4315-8866-cb19078e8fa0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6827b21-d6ab-4fff-b174-a6bc865f500f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_ef6f3750-5285-46a6-8933-cc53086e98fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6827b21-d6ab-4fff-b174-a6bc865f500f" xlink:to="loc_us-gaap_OperatingLossCarryforwards_ef6f3750-5285-46a6-8933-cc53086e98fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_80d224ed-598c-4c4d-a4cf-0c06f97bd144" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6827b21-d6ab-4fff-b174-a6bc865f500f" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_80d224ed-598c-4c4d-a4cf-0c06f97bd144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1eb154bc-60ba-48d2-9fa6-1f9b084aec54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_f6827b21-d6ab-4fff-b174-a6bc865f500f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_1eb154bc-60ba-48d2-9fa6-1f9b084aec54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#IncomeTaxesDeferredTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0238c93a-feb2-4ba9-99ba-09bcb62d667a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_661759c1-d88b-43fd-bce3-42bae1e17f80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0238c93a-feb2-4ba9-99ba-09bcb62d667a" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_661759c1-d88b-43fd-bce3-42bae1e17f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ed808729-f79d-4745-804f-8830b84ada42" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_661759c1-d88b-43fd-bce3-42bae1e17f80" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ed808729-f79d-4745-804f-8830b84ada42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_032158e6-0971-4256-b073-8c01265e0ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_661759c1-d88b-43fd-bce3-42bae1e17f80" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_032158e6-0971-4256-b073-8c01265e0ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment_66cab2e5-db0b-4dfd-94d0-b9668694ff6c" xlink:href="lgnd-20241231.xsd#lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_661759c1-d88b-43fd-bce3-42bae1e17f80" xlink:to="loc_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment_66cab2e5-db0b-4dfd-94d0-b9668694ff6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2f2dcf01-0440-4737-9e4b-bf8fbfb37b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_661759c1-d88b-43fd-bce3-42bae1e17f80" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2f2dcf01-0440-4737-9e4b-bf8fbfb37b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_5630467b-441e-4dc3-a6e0-f8c17d00927d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_661759c1-d88b-43fd-bce3-42bae1e17f80" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_5630467b-441e-4dc3-a6e0-f8c17d00927d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_8f4c7942-97ff-4e65-ad41-759283cc11d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_661759c1-d88b-43fd-bce3-42bae1e17f80" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_8f4c7942-97ff-4e65-ad41-759283cc11d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fa55ceed-fd47-4bd3-9f90-50e2216286af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_661759c1-d88b-43fd-bce3-42bae1e17f80" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_fa55ceed-fd47-4bd3-9f90-50e2216286af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_f9041271-1388-4a48-a150-35518c05985f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_661759c1-d88b-43fd-bce3-42bae1e17f80" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_f9041271-1388-4a48-a150-35518c05985f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4093ac1e-c812-4048-9199-c29309a08a55" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0238c93a-feb2-4ba9-99ba-09bcb62d667a" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4093ac1e-c812-4048-9199-c29309a08a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_bb77277d-04ea-4e09-be94-9a4067dc6599" xlink:href="lgnd-20241231.xsd#lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4093ac1e-c812-4048-9199-c29309a08a55" xlink:to="loc_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets_bb77277d-04ea-4e09-be94-9a4067dc6599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_60d9397d-8dc4-4afa-b40a-e3d42922773b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4093ac1e-c812-4048-9199-c29309a08a55" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_60d9397d-8dc4-4afa-b40a-e3d42922773b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_199527e5-a028-48b6-9ed0-6318d903217d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_4093ac1e-c812-4048-9199-c29309a08a55" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_199527e5-a028-48b6-9ed0-6318d903217d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_cb95cab4-91ec-402f-9719-d15fb803053f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0238c93a-feb2-4ba9-99ba-09bcb62d667a" xlink:to="loc_us-gaap_DeferredTaxLiabilities_cb95cab4-91ec-402f-9719-d15fb803053f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b57a81a8-1b2d-497e-a0a2-a1662c174995" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_23c6816c-458f-4b15-a73b-6eb2c9a5ad59" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b57a81a8-1b2d-497e-a0a2-a1662c174995" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_23c6816c-458f-4b15-a73b-6eb2c9a5ad59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e304bc03-75ff-4a42-8689-12bcfdc1de69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_23c6816c-458f-4b15-a73b-6eb2c9a5ad59" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e304bc03-75ff-4a42-8689-12bcfdc1de69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_2a80f900-5836-4a95-84d3-bfe6a439cd0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_23c6816c-458f-4b15-a73b-6eb2c9a5ad59" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_2a80f900-5836-4a95-84d3-bfe6a439cd0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_52c5133f-1128-4fc1-a566-36aac3db1531" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_23c6816c-458f-4b15-a73b-6eb2c9a5ad59" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_52c5133f-1128-4fc1-a566-36aac3db1531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_48ba5021-2853-4712-a6bd-90ab64ba0036" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_23c6816c-458f-4b15-a73b-6eb2c9a5ad59" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_48ba5021-2853-4712-a6bd-90ab64ba0036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_56c6c40c-8217-47f9-92fd-3325aa0c17c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_23c6816c-458f-4b15-a73b-6eb2c9a5ad59" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_56c6c40c-8217-47f9-92fd-3325aa0c17c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ligand.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="lgnd-20241231.xsd#SubsequentEventDetails"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_47908dee-bdc5-4093-8259-b5cb0ce464e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_0c2a28f2-68ca-4ca5-9bbc-8a498661a55b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_47908dee-bdc5-4093-8259-b5cb0ce464e4" xlink:to="loc_us-gaap_SubsequentEventTable_0c2a28f2-68ca-4ca5-9bbc-8a498661a55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_9958bfa3-6c7b-4590-ba18-2884b68a5d04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0c2a28f2-68ca-4ca5-9bbc-8a498661a55b" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_9958bfa3-6c7b-4590-ba18-2884b68a5d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_adb1a9db-93ba-4476-8ab5-30017830af0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_9958bfa3-6c7b-4590-ba18-2884b68a5d04" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_adb1a9db-93ba-4476-8ab5-30017830af0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_ebe65841-5ea5-44f4-b81d-0cbaa1512c14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_adb1a9db-93ba-4476-8ab5-30017830af0f" xlink:to="loc_us-gaap_SubsequentEventMember_ebe65841-5ea5-44f4-b81d-0cbaa1512c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_beebe1c8-ceaa-4a9e-b822-7389310ac6d4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0c2a28f2-68ca-4ca5-9bbc-8a498661a55b" xlink:to="loc_dei_LegalEntityAxis_beebe1c8-ceaa-4a9e-b822-7389310ac6d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0119f749-86e1-460a-8a30-741ca13ff0f5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_beebe1c8-ceaa-4a9e-b822-7389310ac6d4" xlink:to="loc_dei_EntityDomain_0119f749-86e1-460a-8a30-741ca13ff0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_PurchasersMember_483a4642-955f-4ea1-b073-de2c47026ca9" xlink:href="lgnd-20241231.xsd#lgnd_PurchasersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0119f749-86e1-460a-8a30-741ca13ff0f5" xlink:to="loc_lgnd_PurchasersMember_483a4642-955f-4ea1-b073-de2c47026ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_OtherPurchasersMember_fde5dab0-1e74-45c1-ae30-e0ec41ac6c2d" xlink:href="lgnd-20241231.xsd#lgnd_OtherPurchasersMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0119f749-86e1-460a-8a30-741ca13ff0f5" xlink:to="loc_lgnd_OtherPurchasersMember_fde5dab0-1e74-45c1-ae30-e0ec41ac6c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f23271dd-3293-4ae0-af63-ea239a89e219" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0c2a28f2-68ca-4ca5-9bbc-8a498661a55b" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f23271dd-3293-4ae0-af63-ea239a89e219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_69d45c00-e9ee-48fd-9a6b-a1c1b314ff78" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f23271dd-3293-4ae0-af63-ea239a89e219" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_69d45c00-e9ee-48fd-9a6b-a1c1b314ff78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lgnd_FCX007Member_66f1d839-d491-4d6c-bea8-01ce65840537" xlink:href="lgnd-20241231.xsd#lgnd_FCX007Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_69d45c00-e9ee-48fd-9a6b-a1c1b314ff78" xlink:to="loc_lgnd_FCX007Member_66f1d839-d491-4d6c-bea8-01ce65840537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_1a753b4d-c8e5-4f43-b255-16cfa99ce352" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_0c2a28f2-68ca-4ca5-9bbc-8a498661a55b" xlink:to="loc_us-gaap_SubsequentEventLineItems_1a753b4d-c8e5-4f43-b255-16cfa99ce352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_a4d57451-d031-4f60-b758-edea51022e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1a753b4d-c8e5-4f43-b255-16cfa99ce352" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_a4d57451-d031-4f60-b758-edea51022e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableWithImputedInterestFaceAmount_b46c5d2b-dae1-4811-b398-cf269bab549e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivableWithImputedInterestFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1a753b4d-c8e5-4f43-b255-16cfa99ce352" xlink:to="loc_us-gaap_ReceivableWithImputedInterestFaceAmount_b46c5d2b-dae1-4811-b398-cf269bab549e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireNotesReceivable_c4031943-c58f-426c-9658-25caaf8b6856" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireNotesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1a753b4d-c8e5-4f43-b255-16cfa99ce352" xlink:to="loc_us-gaap_PaymentsToAcquireNotesReceivable_c4031943-c58f-426c-9658-25caaf8b6856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>lgnd-20241231_g1.jpg
<TEXT>
begin 644 lgnd-20241231_g1.jpg
M_]C_X  02D9)1@ ! 0$ P #   #_X1#H17AI9@  34T *@    @ ! $[  (
M   *   (2H=I  0    !   (5)R=  $    4   0S.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QI+"!*96YN
M>0  !9 #  (    4   0HI $  (    4   0MI*1  (    #.#   )*2  (
M   #.#   .H<  <   @,   (E@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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M?Z* /H#_ (2SX$_] #_R3;_&C_A+/@3_ - #_P DV_QKY_HH ^@/^$L^!/\
MT /_ "3;_&C_ (2SX$_] #_R3;_&OG^B@#Z _P"$L^!/_0 _\DV_QH_X2SX$
M_P#0 _\ )-O\:^?Z* /H#_A+/@3_ - #_P DV_QH_P"$L^!/_0 _\DV_QKY_
MHH ^@/\ A+/@3_T /_)-O\:/^$L^!/\ T /_ "3;_&OG^B@#Z _X2SX$_P#0
M _\ )-O\:/\ A+/@3_T /_)-O\:^?Z* /H#_ (2SX$_] #_R3;_&C_A+/@3_
M - #_P DV_QKY_HH ^@/^$L^!/\ T /_ "3;_&C_ (2SX$_] #_R3;_&OG^B
M@#Z _P"$L^!/_0 _\DV_QH_X2SX$_P#0 _\ )-O\:^?Z* /H#_A+/@3_ - #
M_P DV_QH_P"$L^!/_0 _\DV_QKY_HH ^@/\ A+/@3_T /_)-O\:/^$L^!/\
MT /_ "3;_&OG^B@#Z _X2SX$_P#0 _\ )-O\:/\ A+/@3_T /_)-O\:^?Z*
M/H#_ (2SX$_] #_R3;_&C_A+/@3_ - #_P DV_QKY_HH ^@/^$L^!/\ T /_
M "3;_&C_ (2SX$_] #_R3;_&OG^B@#Z _P"$L^!/_0 _\DV_QH_X2SX$_P#0
M _\ )-O\:^?Z* /H#_A+/@3_ - #_P DV_QH_P"$L^!/_0 _\DV_QKY_HH ^
M@/\ A+/@3_T /_)-O\:/^$L^!/\ T /_ "3;_&OG^B@#Z _X2SX$_P#0 _\
M)-O\:/\ A+/@3_T /_)-O\:^?Z* /H#_ (2SX$_] #_R3;_&C_A+/@3_ - #
M_P DV_QKY_HH ^@/^$L^!/\ T /_ "3;_&C_ (2SX$_] #_R3;_&OG^B@#Z
M_P"$L^!/_0 _\DV_QH_X2SX$_P#0 _\ )-O\:^?Z* /H#_A+/@3_ - #_P D
MV_QH_P"$L^!/_0 _\DV_QKY_HH ^@/\ A+/@3_T /_)-O\:/^$L^!/\ T /_
M "3;_&OG^B@#Z _X2SX$_P#0 _\ )-O\:/\ A+/@3_T /_)-O\:^?Z* /H#_
M (2SX$_] #_R3;_&C_A+/@3_ - #_P DV_QKY_HH ^@/^$L^!/\ T /_ "3;
M_&C_ (2SX$_] #_R3;_&OG^B@#Z _P"$L^!/_0 _\DV_QH_X2SX$_P#0 _\
M)-O\:^?Z* /H#_A+/@3_ - #_P DV_QH_P"$L^!/_0 _\DV_QKY_HH ^@/\
MA+/@3_T /_)-O\:/^$L^!/\ T /_ "3;_&OG^B@#Z _X2SX$_P#0 _\ )-O\
M:/\ A+/@3_T /_)-O\:^?Z* /H#_ (2SX$_] #_R3;_&C_A+/@3_ - #_P D
MV_QKY_HH ^@/^$L^!/\ T /_ "3;_&C_ (2SX$_] #_R3;_&OG^B@#Z _P"$
ML^!/_0 _\DV_QH_X2SX$_P#0 _\ )-O\:^?Z* /H#_A+/@3_ - #_P DV_QH
M_P"$L^!/_0 _\DV_QKY_HH ^@/\ A+/@3_T /_)-O\:/^$L^!/\ T /_ "3;
M_&OG^B@#Z _X2SX$_P#0 _\ )-O\:/\ A+/@3_T /_)-O\:^?Z* /H#_ (2S
MX$_] #_R3;_&C_A+/@3_ - #_P DV_QKY_HH ^@/^$L^!/\ T /_ "3;_&C_
M (2SX$_] #_R3;_&OG^B@#Z _P"$L^!/_0 _\DV_QH_X2SX$_P#0 _\ )-O\
M:^?Z* /H#_A+/@3_ - #_P DV_QH_P"$L^!/_0 _\DV_QKY_HH ^@/\ A+/@
M3_T /_)-O\:/^$L^!/\ T /_ "3;_&OG^B@#Z _X2SX$_P#0 _\ )-O\:/\
MA+/@3_T /_)-O\:^?Z* /H#_ (2SX$_] #_R3;_&C_A+/@3_ - #_P DV_QK
MY_HH ^@/^$L^!/\ T /_ "3;_&C_ (2SX$_] #_R3;_&OG^B@#Z _P"$L^!/
M_0 _\DV_QH_X2SX$_P#0 _\ )-O\:^?Z* /H#_A+/@3_ - #_P DV_QH_P"$
ML^!/_0 _\DV_QKY_HH ^@/\ A+/@3_T /_)-O\:/^$L^!/\ T /_ "3;_&OG
M^B@#Z _X2SX$_P#0 _\ )-O\:/\ A+/@3_T /_)-O\:^?Z* /H#_ (2SX$_]
M #_R3;_&C_A+/@3_ - #_P DV_QKY_HH ^@/^$L^!/\ T /_ "3;_&C_ (2S
MX$_] #_R3;_&OG^B@#Z _P"$L^!/_0 _\DV_QH_X2SX$_P#0 _\ )-O\:^?Z
M* /H#_A+/@3_ - #_P DV_QH_P"$L^!/_0 _\DV_QKY_HH ^@/\ A+/@3_T
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M%_S?@'UGR,RBM/ ]*,#TH^HO^;\ ^L^1F45IX'I1@>E'U%_S?@'UGR,RBM/
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MWH *TQT%9E:8Z"O1P.\OD<>*Z"T445Z1QA1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-;[C?2G
M4UON-]*3V&MS-HHHKYT]<^P/@9_R1?0O^WC_ -*)**/@9_R1?0O^WC_THDHH
M X?Q'_R:/8?]<;?_ -'"OG>OHCQ'_P FCV'_ %QM_P#T<*^=Z "M,=!696F.
M@KT<#O+Y''BN@M%%%>D<84444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !36^XWTIU-;[C?2D]AK<S
M:***^=/7/L#X&?\ )%]"_P"WC_THDHH^!G_)%]"_[>/_ $HDHH X?Q'_ ,FC
MV'_7&W_]'"OG>OHCQ'_R:/8?]<;?_P!'"OG>@ K3'05F5ICH*]' [R^1QXKH
M+1117I'&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4UON-]*=36^XWTI/8:W,VBBBOG3US[ ^!
MG_)%]"_[>/\ THDHH^!G_)%]"_[>/_2B2B@#A_$?_)H]A_UQM_\ T<*^=Z^B
M/$?_ ":/8?\ 7&W_ /1PKYWH *TQT%9E:8Z"O1P.\OD<>*Z"T445Z1QA1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %-;[C?2G4UON-]*3V&MS-HHHKYT]<^P/@9_P D7T+_ +>/
M_2B2BCX&?\D7T+_MX_\ 2B2B@#A_$?\ R:/8?]<;?_T<*^=Z^B/$?_)H]A_U
MQM__ $<*^=Z "M,=!696F.@KT<#O+Y''BN@M%%%>D<84444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !36^XWTIU-;[C?2D]AK<S:***^=/7/L#X&?\D7T+_MX_P#2B2BCX&?\D7T+
M_MX_]*)** .'\1_\FCV'_7&W_P#1PKYWKZ(\1_\ )H]A_P!<;?\ ]'"OG>@
MK3'05F5ICH*]' [R^1QXKH+1117I'&%%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UON-]*=36^
MXWTI/8:W,VBBBOG3US[ ^!G_ "1?0O\ MX_]*)**/@9_R1?0O^WC_P!*)**
M.'\1_P#)H]A_UQM__1PKYWKZ(\1_\FCV'_7&W_\ 1PKYWH *TQT%9E:8Z"O1
MP.\OD<>*Z"T445Z1QA1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1)11\#/^2+Z%_P!O'_I1)10!P_B/_DT>P_ZXV_\ Z.%?.]?1'B/_ )-'L/\
MKC;_ /HX5\[T %:8Z"LRM,=!7HX'>7R./%=!:***](XPHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "NL^%O_)4M _Z^A_(UR==9\+?^2I:!_P!?
M0_D:BI\#]"H?$C[ KA/C5_R1_6_^V'_I1'7=UPGQJ_Y(_K?_ &P_]*(Z\.E_
M$CZH].I\#/DZBBBO?/*"BBB@ HHHH **** "BBB@ HHHH **** "OL?X=?\
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M6G(#]DD_?VC'O$Q.!]005_"N5KW8R4E='EM-.S"BBBF(**** "BBB@ HHHH
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M -*(Z\.E_$CZH].I\#/DZBBBO?/*"BBB@ HHHH **** "BBB@ HHHH ****
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MP^'5GMS@ZI&&QZ>5+_7%>105ZL3T*OP,^:J***]T\L**** "BBB@"?[#=_\
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M?Q $HWXC(S[+7-@ZG+/E?4VQ$+QYNQX=1117K' %%%% !1110 4444 3V/\
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MX=?\DU\/?]@^+_T$5P8WX$=6&^)G2U\4^*_^1SUK_L(3_P#HQJ^UJ^*?%?\
MR.>M?]A"?_T8U9X'XF7B=D9-%%%>F<04444 %>F_ &X$/Q.5">9[*5!SU^ZW
M_LM>95UGPMU(:5\4-"N&.%:Y$!/_ %T!C_\ 9JSJJ]-KR+INTTS[ KS;X]6I
MN/A;/*,XMKJ&4X]"=G_L]>DUSWCW2#KOP_UK3T4O)+:.T:CNZ_,H_P"^E%>)
M2ERS3/2FKQ:/C2BBBO?/*"BBB@ HHHH ^HO^%]>"?^>][_X"G_&C_A?7@G_G
MO>_^ I_QKY=HKC^ITO,Z/K$SZB_X7UX)_P">][_X"G_&C_A?7@G_ )[WO_@*
M?\:^7:*/J=+S#ZQ,^HO^%]>"?^>][_X"G_&O0[*\BU#3[>\MB3#<1++&2,':
MPR./H:^&J^UO"G_(F:+_ -@^#_T6M<N)H1I).)O1J2FW<OWW_(.N?^N3?R-?
M#5?<M]_R#KG_ *Y-_(U\-5K@=I?(C%= HHHKT3C"BBB@ HHHH *]N_9X\*>=
M>WGBBZC^2 &VM"P_C(R[#Z#"_P# C7BUI:S7U[!:6D9EGGD6*)%ZLS' 'YFO
ML[PEX>A\*^%+#1K?!%M$ [@8WN>6;\6)-<>+J<L.5=3HP\.:5^QLUX'^T1XJ
M\VZLO#%J_P L(%U=8/\ $00BGZ#)_%:]YE<QPNZHTA520B]6QV&>]?+6O_#K
MXB>(?$%[JU[X?F,UW,TC#SH\*#T4?-T P/PKCPJCS\TGL=-=OELCSNBNS_X5
M#X[_ .A>F_[^Q_\ Q5'_  J'QW_T+TW_ ']C_P#BJ]7VM/\ F1P\DNQQE%=G
M_P *A\=_]"]-_P!_8_\ XJC_ (5#X[_Z%Z;_ +^Q_P#Q5'M:?\R#DEV.,K8\
M)^()O"WBO3]9M\DVLH9T!^^AX=?Q4D5M_P#"H?'?_0O3?]_8_P#XJC_A4/CO
M_H7IO^_L?_Q5)U*;5FT"C-.Z1]:6MU#>V<-U:N)()XUDC<=&5AD'\C6;XJT"
M#Q1X6O\ 1KG 6ZB*JQ_@<<JWX, ?PKG/A';>(-,\%)I/BC3Y;2:QD*0,[JWF
M1'D=">AR/IBNZKPY+DGH]CTU[T=3X9O;2?3[Z>SNXS'/;R-%*A_A93@C\Q4-
M>M?'_P *?V5XKAUVU3%MJBXEQT691@_3*X/U#5Y+7NTYJ<%)'ESCRR:"BBBK
M)"BBB@ HHHH GL?^0C;?]=5_F*^Y:^&K'_D(VW_75?YBON6O-QV\?F=F&ZF%
MXY_Y)WXC_P"P5=?^BFKXPK[/\<_\D[\1_P#8*NO_ $4U?&%7@?A8L3N@HHHK
MO.0*[3X9?$"X\">(A)*7ETNZ(2\@'IV=1_>7]1D>XXNBIE%27*QQDXNZ/N:T
MNX+^SAN[.5)K>=!)'(ARKJ1D$4W4+"UU33Y['4(5GMKA#'+&XX937SY\$OB5
M_8UXGAG6Y\6%P^+25SQ!(3]WV5C^1^IKZ+KQ*M.5*=CTX34XW/D#XB^!+KP)
MXD:T?=+83YDL[@C[Z?W3_M+T/X'O7)5]G>,_"5CXT\-S:5J VEOG@F RT,@Z
M,/Y$=P37R#KVA7_AO7+G2M5A,5S;MM8=F'9@>X(Y!KT\/6]I&SW1Q5J?([K8
MSZ^F_P!GS_DFLG_80E_]!2OF2OIO]GS_ ))K)_V$)?\ T%*6,_A#P_QGJ-?(
MWQ>_Y*SKO_75/_1:U]<U\C?%[_DK.N_]=4_]%K7+@OXC]#?$_"CC****]4X
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MCH*S*TQT%>C@=Y?(X\5T%HHHKTCC"BBB@ HHHH **** "BBB@ HHHH ****
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MNN$^-7_)'];_ .V'_I1'7ATOXD?5'IU/@9\G4445[YY04444 %%%% !1110
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M;_KJO\Q7W+7PU8_\A&V_ZZK_ #%?<M>;CMX_,[,-U,+QS_R3OQ'_ -@JZ_\
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M%:D!1110 45OZ)X%\3^(F7^R-$NYD;I*T>R/_OML+^M>L^%/V=U1TN/&-^)
M.?L=F2 ?9I",_@!^-93K4X;LTC3E+9'D_@_P3K/C;5!::/;DQJ1Y]RXQ'"/5
MCZ^@')KZI\$^"=,\#:&MAIJ^9*^&N+IEP\[>I] .P[?7).QI>E6&BZ?'8Z3:
M0VEM&/EBB7:/K[GW/)JW7E5L1*KILCNITE#7J%>-_'+XC)INGR>%M'F!O;I<
M7LB'_4QG^#_>8=?0?45L?%/XL6_A"UDTO19(Y]<D7!_B6U!'WF]6YX7\3QP?
MF.YN9[VZEN;N5YIYF+R22-EG8\DD]S6V%P[;YY;&=:K9<L2.BBBO4.$****
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M?_"K?!/_ $+=E_WR?\:Z7[=:?\_4/_?P4?;K3_GZA_[^"L^>:V;*Y8]CFO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *:WW&^E.IK?<;Z4GL-;F;1117SIZY]@? S_DB^A?]O'_
M *4244? S_DB^A?]O'_I1)10!P_B/_DT>P_ZXV__ *.%?.]?1'B/_DT>P_ZX
MV_\ Z.%?.] !6F.@K,K3'05Z.!WE\CCQ706BBBO2.,**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M IK?<;Z4ZFM]QOI2>PUN9M%%%?.GKGV!\#/^2+Z%_P!O'_I1)11\#/\ DB^A
M?]O'_I1)10!P_B/_ )-'L/\ KC;_ /HX5\[U]$>(_P#DT>P_ZXV__HX5\[T
M%:8Z"LRM,=!7HX'>7R./%=!:***](XPHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:O\ PTYK'_0O6/\ W^>@#R?_ (1#Q+_T+VJ_^ 4G_P 31_PB'B7_ *%[5?\
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M]'_#3FL?]"]8_P#?YZ /)_\ A$/$O_0O:K_X!2?_ !-'_"(>)?\ H7M5_P#
M*3_XFO6/^&G-8_Z%ZQ_[_/1_PTYK'_0O6/\ W^>@#R?_ (1#Q+_T+VJ_^ 4G
M_P 31_PB'B7_ *%[5?\ P"D_^)KUC_AIS6/^A>L?^_ST?\-.:Q_T+UC_ -_G
MH \G_P"$0\2_]"]JO_@%)_\ $T?\(AXE_P"A>U7_ , I/_B:]8_X:<UC_H7K
M'_O\]'_#3FL?]"]8_P#?YZ /)_\ A$/$O_0O:K_X!2?_ !-'_"(>)?\ H7M5
M_P# *3_XFO6/^&G-8_Z%ZQ_[_/1_PTYK'_0O6/\ W^>@#R?_ (1#Q+_T+VJ_
M^ 4G_P 31_PB'B7_ *%[5?\ P"D_^)KUC_AIS6/^A>L?^_ST?\-.:Q_T+UC_
M -_GH \G_P"$0\2_]"]JO_@%)_\ $T?\(AXE_P"A>U7_ , I/_B:]8_X:<UC
M_H7K'_O\]'_#3FL?]"]8_P#?YZ /)_\ A$/$O_0O:K_X!2?_ !-'_"(>)?\
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M!2?_ !-'_"(>)?\ H7M5_P# *3_XFO6/^&G-8_Z%ZQ_[_/1_PTYK'_0O6/\
MW^>@#R?_ (1#Q+_T+VJ_^ 4G_P 31_PB'B7_ *%[5?\ P"D_^)KUC_AIS6/^
MA>L?^_ST?\-.:Q_T+UC_ -_GH \G_P"$0\2_]"]JO_@%)_\ $T?\(AXE_P"A
M>U7_ , I/_B:]8_X:<UC_H7K'_O\]'_#3FL?]"]8_P#?YZ /)_\ A$/$O_0O
M:K_X!2?_ !-'_"(>)?\ H7M5_P# *3_XFO6/^&G-8_Z%ZQ_[_/1_PTYK'_0O
M6/\ W^>@#R?_ (1#Q+_T+VJ_^ 4G_P 31_PB'B7_ *%[5?\ P"D_^)KUC_AI
MS6/^A>L?^_ST?\-.:Q_T+UC_ -_GH \G_P"$0\2_]"]JO_@%)_\ $T?\(AXE
M_P"A>U7_ , I/_B:]8_X:<UC_H7K'_O\]'_#3FL?]"]8_P#?YZ /)_\ A$/$
MO_0O:K_X!2?_ !-'_"(>)?\ H7M5_P# *3_XFO6/^&G-8_Z%ZQ_[_/1_PTYK
M'_0O6/\ W^>@#R?_ (1#Q+_T+VJ_^ 4G_P 31_PB'B7_ *%[5?\ P"D_^)KU
MC_AIS6/^A>L?^_ST?\-.:Q_T+UC_ -_GH \G_P"$0\2_]"]JO_@%)_\ $T?\
M(AXE_P"A>U7_ , I/_B:]8_X:<UC_H7K'_O\]'_#3FL?]"]8_P#?YZ /)_\
MA$/$O_0O:K_X!2?_ !-'_"(>)?\ H7M5_P# *3_XFO6/^&G-8_Z%ZQ_[_/1_
MPTYK'_0O6/\ W^>@#R?_ (1#Q+_T+VJ_^ 4G_P 31_PB'B7_ *%[5?\ P"D_
M^)KUC_AIS6/^A>L?^_ST?\-.:Q_T+UC_ -_GH \G_P"$0\2_]"]JO_@%)_\
M$T?\(AXE_P"A>U7_ , I/_B:]8_X:<UC_H7K'_O\]'_#3FL?]"]8_P#?YZ /
M)_\ A$/$O_0O:K_X!2?_ !-'_"(>)?\ H7M5_P# *3_XFO6/^&G-8_Z%ZQ_[
M_/1_PTYK'_0O6/\ W^>@#R?_ (1#Q+_T+VJ_^ 4G_P 31_PB'B7_ *%[5?\
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M]'_#3FL?]"]8_P#?YZ /)_\ A$/$O_0O:K_X!2?_ !-'_"(>)?\ H7M5_P#
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M_H7K'_O\]'_#3FL?]"]8_P#?YZ /)_\ A$/$O_0O:K_X!2?_ !-'_"(>)?\
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%10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>lgnd-20241231_g2.jpg
<TEXT>
begin 644 lgnd-20241231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *0!/$# 2(  A$! Q$!_\0
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M XZGN:C^T2?WOT%1T4K(+L"<G)ZFBI7411*I'SM\Q]AV%-B<(_S#*G@_2G<
M69T& <#Z4Y;J16!##(YY IDL9B<J>?0^HIM*R8:HFN?G83#I)R?8]Q4-/CD
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M>GZB $KT..U&">Q_*BG+(RC 8@>QH ;M/H?RJ:7]S&(OXF^9_;T%,$\@.0[
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MM@2*&P2A(# 8)QD'Z-^._P#P4<\=>)/%L]K\-]0_X1/P?9MY5F(K2,W%RBX
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MQMT:X\/_ !D\<:?JHN1?P:U>"8R1A"Y,S'?CT8$,#T(((XKCU2-X'%N':0D
MAASCVQ[XKT(8+#NBHN-[]>OK<Y)8FJJCES6MTZ?<>^>)OC_HOPA_:&U_QC\
MPVE:->6S6J1:C9+Y2[V5I1#&22L99%90<$9(P  *^R?BM^U1X^\)?L7_  W^
M(^G7MG'XJU[4(K:[FDM$:)E:*Z8@(>!S"G-?E?7W9^T+_P HT?@O_P!ABW_]
M$7U98K#T^:BFKZI7>[5GN70K3M4:=M+_ (GSV/C)XF^.?[1O@?Q+XLG@N-5&
MJ:=:[K>!85$:7"D#:.^6/->O_P#!4J-YOVD])CC5GD?P[:JJJ,DDW%Q@ 5\Y
M_"40?\+>\#;]XG_MNQWA<8W>>E?5_P#P4%U*PT7]M#P)J&HLRV=I8:9/.< K
MY:WLS-G/L#5RM#$TU%:*+T^XF-Y49\SW:/4/$&NZ!_P3<^ &AV6EZ5::K\4O
M$<7[ZYG7<K2J TK.PPQAB+A40$;B<]2QKY;TS_@HI\<[#7QJ4WBFWOX [.=,
MN--MQ;,#T0[$5P![.#QR3S7K/_!671=03XA^!=::5I-&N=)DM8%"?(DR3%Y#
MN[EEEBX_V/K7PA48+#TJU'VU5*4I;M_UH5B:LZ=3V<'91/K7]L#]H#X4_M$^
M O"OB+3-)NM*^*?"ZDD5O^Z2(95HY93CS.0K1LH8A<AMI.![5\%-3U/X)?\
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M_*Z,Y\[A+EGS+K?=>9\DO)YBKD?,!C/J.U$<GEAB!\Q& ?3UIE%>[8\L**E
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M-U'HW>HJ-&&Q89C=6^2298NYZE?_ *U5Z=%*89 XZCL>X]*1L%CM&!G@&DM
M>I/;?N5:<]5X0'NW_P!;_"HO/D)_UC_]]&B67S B@;508 _F:90EU8-]A3([
M=78_4TA!'44^&/S'P3A0,L?04DLGF.6Q@= /04_(!N#C/;UIPE<?QM_WT:?
M0Q,;'"OW/8]C4;*58J1@C@B@"2*ZDBD#;F8="K'(([BDN(A%)\IS&PW*?45'
M3S+F 1D9VG*GT]12M9W07T& $D #)/:K,\AMU%NC$;>7*GJW_P!;I4,,ODOO
MQE@/E]CZTRBUV%[(=YTG_/1_^^C299SW8_G25+CR8<_QR=/9?_KT]@(@,G Y
M-*&9>A(^AI*EF'F*)1WX;V;_ .O0 SSI/^>C_P#?1J;<;JWPQS+%R,]2O?\
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M ;V]*(I?*#X'S,-H/IZTM;!I<DN+@@K%$Y$<? P>I[FH3-(>LC_]]&FT4))
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M^1^(%%?M_P#\,7_ [_HF.@?^ Y_QH_X8O^!W_1,= _\  <_XT_[:H_RO\/\
M,/[-J?S(_$-;>1NBYJ6.RD))=2L:C+$$=*_;?_AB_P"!W_1,= _\!S_C0/V,
M/@>O(^&>@J<8R("#_.D\ZI?RO\/\QK+9]U_7R/Q"ED,LA8C&>@'8>E-K]O\
M_AB[X'?]$RT#_P !S_C1_P ,7_ [_HF.@?\ @.?\:?\ ;5'^5_A_F+^S:G\R
M/Q):)[I!*BY;[K\XY]?QJ(VTJ]4/YU^W?_#&'P/VX_X5GH.,YP8#C^='_#%_
MP._Z)CH'_@.?\:2SJDOLO\/\Q_V;4[H_$%E*G!I*_;__ (8O^!W_ $3'0/\
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M7^'^8?V;4[K^OD?B/<+Y $&,,.7^OI^%05^WY_8P^![')^&>@D].8"?ZT?\
M#%_P._Z)CH'_ (#G_&A9U17V7^'^8/+:G\R/Q'ME\\&#^)CE/K_]>FFSF'5/
MU%?MVO[&'P/4Y7X9Z"I]H"/ZTG_#%_P._P"B8Z!_X#G_ !H_MJE?X7^'^8_[
M-J=T?B$T;)U&*;7[?_\ #%_P._Z)CH'_ (#G_&C_ (8O^!W_ $3'0/\ P'/^
M-/\ MJC_ "O\/\Q?V;4_F1^( &3@5(MO(W1<_C7[=_\ #%_P._Z)CH'_ (#G
M_&C_ (8O^!W_ $3'0/\ P'/^-']M4?Y7^'^8?V;4[H_$F*V:+=+*N$3G'J>P
MJNS%V+$Y)Y)K]OA^QA\#P"!\,]! /7$!&?UH_P"&+_@=_P!$QT#_ ,!S_C26
M=4>L7^'^8?V;4[H_$%6*,&4X(.0:L26SR@2Q)\C\XR!@]Q7[;?\ #%_P._Z)
MCH'_ (#G_&@_L8? \@ _#/02!P,P$X_6AYU1Z1?X?YC_ +-J=T?B(UM(O5,?
MC49&#@]:_;__ (8O^!W_ $3'0/\ P'/^-'_#%_P._P"B8Z!_X#G_ !I_VU1_
ME?X?YB_LVIW1^(%*L;/]T9K]OO\ AB_X'?\ 1,= _P# <_XT?\,7_ [_ *)C
MH'_@.?\ &C^VJ/\ *_P_S#^S:G\R/Q%%K*1]S]13IU-N@A(PY^9_Z"OVX_X8
MO^!W_1,= _\  <_XT']C#X'MC/PST$X&!F G _.E_;5'K%_A_F/^SJG='X@5
M-;#S283_ !_=/HW;\^E?MS_PQ?\  [_HF.@?^ Y_QI5_8P^!Z,"OPST%2.X@
M(_K0\ZHO[+_ 2RVI_,C\139S#.4Z>XJ-HF3[PQ7[>_\ #%_P._Z)CH'_ (#G
M_&C_ (8O^!W_ $3'0/\ P'/^-']M4OY7^'^8?V;4[K^OD?B!0!DU^W__  Q?
M\#O^B8Z!_P" Y_QH_P"&+_@=_P!$QT#_ ,!S_C3_ +:H_P K_#_,/[-J?S(_
M$06\C=%)J6*T9,R2IB-!D\]?05^VW_#%_P #O^B8Z!_X#G_&@?L8? \9Q\,]
M!&1@X@(S^M)YU2_E?X?YC66S[K^OD?B"[F1RS'))R:0$J00<$<@U^W__  Q?
M\#O^B8Z!_P" Y_QH_P"&+_@=_P!$QT#_ ,!S_C3_ +:H_P K_#_,7]FU/YD?
MB3);-.HFB7*M]X#C![U$UM*O5"*_;P_L8_ \J ?AGH) Z P$X_6D_P"&+_@=
M_P!$QT#_ ,!S_C4K.J2^R_P_S&\NJ=U_7R/Q ((.#UHK]O\ _AB_X'?]$QT#
M_P !S_C1_P ,7_ [_HF.@?\ @.?\:K^VJ/\ *_P_S%_9M3^9'XA+&S]!FGBT
MF/\ !^HK]NO^&+_@=_T3'0/_  '/^-'_  Q=\#O^B8Z!_P" Y_QI?VU2_E?X
M?YA_9M3NOZ^1^(\ZF!!#T;[S_7L/PJ"OV_/[&'P/8Y/PST%CC',!/]:/^&+_
M ('?]$QT#_P'/^-"SJBOLO\ #_,'EM3^9'XCVP\T&#NYROLW_P!>D-G,.J?J
M*_;D?L8? ]3E?AGH*GU$!']:/^&+_@=_T3'0/_ <_P"-']M4>D7^'^8_[-J=
MT?B$T3)]X8IM?M__ ,,7_ [_ *)CH'_@.?\ &C_AB_X'?]$QT#_P'/\ C3_M
MJC_*_P /\Q?V;4_F1^( &3@5(MO(W1,U^W?_  Q?\#O^B8Z!_P" Y_QH_P"&
M+_@=_P!$QT#_ ,!S_C1_;5'^5_A_F']FU.Z/Q)CMGA!FD3Y$[9ZGL*K,Q9B2
M<D\DU^WX_8P^!X! ^&>@@'KB C/ZT?\ #%_P._Z)CH'_ (#G_&DLZH]8O\/\
MQ_V;4_F1^(*L48,IP0<BK$EJ\H$L29C?G /0]Q7[;?\ #%_P._Z)CH'_ (#G
M_&@_L8? \@ _#/02!P,P$X_6AYU1Z1?X?YA_9U3NC\1&MI%ZIC\:C(P<'K7[
M?_\ #%_P._Z)CH'_ (#G_&C_ (8O^!W_ $3'0/\ P'/^-/\ MJC_ "O\/\Q?
MV;4[H_$"G+&S]!FOV]_X8O\ @=_T3'0/_ <_XT?\,7_ [_HF.@?^ Y_QH_MJ
MC_*_P_S#^S:G\R/Q%%I,W1#^8IUP/) @'5>7]V_^M7[<?\,7? [_ *)CH'_@
M.?\ &@_L8? ]CD_#/06/J8"?ZTO[:I7UB_P_S'_9M3NC\0*GMU-PI@ZM]Y/K
MW'XU^W'_  Q?\#O^B8Z!_P" Y_QI5_8P^!ZG*_#/05XQQ 1_6AYU1?V7^'^8
MEEM3^9'XB&TF'5/U%,:-D'S#%?M[_P ,7_ [_HF.@?\ @.?\:/\ AB_X'?\
M1,= _P# <_XT?VU2_E?X?YA_9M3NOZ^1^(% &3@5^W__  Q?\#O^B8Z!_P"
MY_QH_P"&+_@=_P!$QT#_ ,!S_C3_ +:H_P K_#_,/[-J?S(_$1;>1NB9_&I8
M[=H 9I%PJ_=&>K=J_;;_ (8O^!W_ $3'0/\ P'/^-'_#&'P/ ('PST$ ]0("
M,_K4O.J3^R_P_P Q_P!FU.Z_KY'X@$EB2>2:5',;JR\$'(K]OO\ AB_X'?\
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MZMXATK0?)_M/4[/3O.)$7VN=(MY&,A=Q&>HZ>M))R=D-M15V:%%%%(84444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 45B^&?&>B^,8IY-&U"._2!@LC1@C:3TZ@>E;55*,H/EDK
M,F,E-<T7=!1114E!1110 4444 %%%% !1110 445D^)/%6E>$;%+S6+V.PMG
MD$*R2 D%R"0. >RG\JJ,7)VBKLF4E%7D[(UJ*BM;F*\MHKB%Q)#*@D1QT92,
M@_E3;^^@TRQN+RZD$-M;QM-+(W1$498GZ &E9WL.ZM<GHK,\/>)=,\5Z?]NT
MF[2]M-YC\V,$#<.HY ]:@3QGHLGB5_#ZZA&=91=S6F#N VAO3'W2#UJO9SNU
M9W6_D3SPLG?1[&U1114%A1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !15+
M6=9LO#VF3ZAJ-PMK90 &29P<+D@#I[D4:-K-EXATR#4-.N%NK*<$QS(#AL$@
M]?<&JY9<O-;0GFCS<M]2[1114E!1110 4444 %%%% !1110 455U+5+/1K*6
M\O[J&SM8AEYIW"*OU)JIX=\4:5XMLGO-(O8[^V20PM)%G < $CGV(_.JY9<O
M-;0GFBGRWU-6BBJ6LZS9>'M,GU#4;A;6R@ ,DS@X7) '3W(I)-NR&VDKLNT5
MAIXX\/MH]KJKZS96^G71(@N;F984D()! WXST-;4<BRQJZ,'1@&5E.00>A!I
MN,H[JPE*,MF.HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH PO'?_
M "(_B'_L'7'_ **:O.OV6/\ DFUQ_P!A&7_T".O1?'?_ "(_B'_L'7'_ **:
MO,?V8=3L[+X=3I<7<$#G4)2%ED53C9'S@FO4I)O!5+?S+]3S*C2QD+]G^AM?
MM%3Z7;^ H&U>TN;RU^W1@1VLXA?=L?!W%6XZ\8JSK'Q0T7X:_#WP]=3Q32&Y
MLH19V*L&D8"-?O-@# !&6QWX%<]^T[?6U[\-(3;W$5P%U&($Q.&Q\DGI7 ?$
MOR]+USX7ZMJD#SZ''I=D)5V;E;80T@QW.UEX[UVX;#QK4:<9WWEIWLMCCQ&(
ME1JU)0MM'7M=[G7I^U.+>!I=0\)7EDKH6MV-QE93Z9,8P,=QGM]:[B#XS:5'
M\,[3QCJ,#V4%TSQQ6:MYDCNKN@4' SG83VP*Y?XZ_$+PGJWPTNK6#4[+5+N[
M\MK6*WD61T8,#O('*8&X<X/)'K7)V_C^'P5^SMX9@;3;;5+C47NHXX;V,/"H
M6>0LS+W(RN![^W+^JTZU.$XTG%N5K7>UF^HOK-2E4E&5522C>]EO=+H=%'^T
MZ]N;6YU+P=J%AH]PV([[S2P<=RH**&^@:NP^(OQCLO >CZ+J<-I_:UGJF3%)
M'-Y8";0P;[ISD'IQ7CWQ;L?'UOX%AN/%6N::MA++&(M*M8U#[NHY"#[HST8B
MJ?Q5_P"2+?#C_KF__H(K:.#P]25-I*S;3LVUM?=_IH8RQF(IQJ)MW235TD]T
MMD=U)^U/!;WD3S^%KZ'2)7Q'>M+AG7^\$*X/';?^->D^*?B=H7A3PI;Z_<W)
MFM+I5:U2$9>X+#("CZ=2>E<G^TE:PP_":6..)$CAN(!&H'" ' QZ<<5XMXU2
M0>#OA?<7P9]'$#JXSD9$PWC'NNW\O:L:6%P^*C"<8\JNTU>][*_4VJXJOAI3
MA*7,[)IVM:[L=]J'[2XU32+R&\\*WEAI]Y!)!'?";S%RRD X**",GL3^-;G[
M*/\ R3O4?^PK)_Z)AKL?B#K/A\_"W5)YKBUDTBXL72WV$;)#M(C5 .^X#&.F
M.V*X[]E'_DG>H_\ 85D_]$PUG-TY8.HZ<.75=6_S-(*I'&052?-H^B7Y'41_
M%F-_BS)X'_LQA(B[OMOG<']R)?N;??'6G^,_BK'X/\:^'_#S::UTVKR1H+@3
M;1%ODV9V[3G'7J*\SFN8=-_:UDENI4MXI%55>1@ 2;-5 S[GBI?C+>P7'QV\
M!0Q3))+!<6HE1&!*$W((!]#CG%$<)2=6G'ET<+O?>S!XJHJ=1\VJG9;;71S?
MQ;^+VN-\18X;(ZEI-IIEPULUO!=R(M[LF(+8&!A@ ,<_4UU7Q,\>:9XU^$MC
MJVMZ%?6]N=7$*VD-T(Y PBDPQ9HSQ@GC'IS5#]H_]Q\2O!L\A"0@)EV. ,3
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M9]-V>U9SPV%;C96]ZS2YGI\UOZ&D,1B4I7_ENF[+7Y/;U-ZP_:3\J\LO[?\
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M\[<2/4*4 /T#5R?QD\JR\2_#?^W4=H8K"U^WHXRQ4./,!'KC=7L_Q8U30/\
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M1589+ERRDM]W=N1" ?7D=.W-5/B[\0;Y?'FD>%O#^FV$^N K)'?7\2N8';.
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MU2QDT&TL9FBD2=BY("H0P^4=2^ ,=17!3_M3*\DTUCX1O;O2XF(-XT^W ]2
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MR]U;V?6W76W_  0U[XB3>/\ X'>*6GTN?3GLH[:(M<2%S,3(F6Y4>GOUKG_
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M:KVBBNFEB:U!-4Y6N<]7#TJ[3J1O8\KA_9S\-0>&KK1%OM5-I<7,=T[F6+S
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MS<5=Z'B:_LI>&1J'FG4M2:TSG[.63/TW;>F?;_&O7]&T6Q\/:9!I^G6R6EG
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 45\K?MS?M5>+/V9?^$)_X1?3]&O\
M^V_MWVC^UX)9-GD_9]FSRY4QGSFSG/0=._RK_P /5/BQ_P!"]X,_\ KO_P"2
MJ]&E@*U:"J0M9G)4Q5.G)QEN?JG17Y6?\/5/BQ_T+W@S_P  KO\ ^2J/^'JG
MQ8_Z%[P9_P" 5W_\E5M_9>)[+[S/Z[1/U3HK\K/^'JGQ8_Z%[P9_X!7?_P E
M4?\ #U3XL?\ 0O>#/_ *[_\ DJC^R\3V7WA]=HGZIT5^5G_#U3XL?]"]X,_\
M KO_ .2J/^'JGQ8_Z%[P9_X!7?\ \E4?V7B>R^\/KM$_5.BORL_X>J?%C_H7
MO!G_ (!7?_R51_P]4^+'_0O>#/\ P"N__DJC^R\3V7WA]=HGZIT5^5G_  ]4
M^+'_ $+W@S_P"N__ )*H_P"'JGQ8_P"A>\&?^ 5W_P#)5']EXGLOO#Z[1/U3
MHK\K/^'JGQ8_Z%[P9_X!7?\ \E4?\/5/BQ_T+W@S_P  KO\ ^2J/[+Q/9?>'
MUVB?JG17Y6?\/5/BQ_T+W@S_ , KO_Y*H_X>J?%C_H7O!G_@%=__ "51_9>)
M[+[P^NT3]4Z*_*S_ (>J?%C_ *%[P9_X!7?_ ,E4?\/5/BQ_T+W@S_P"N_\
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MCW_H$>'/_ :X_P#C]=G]E8GLOO.;Z_1\S[KHKX4_X;L\>_\ 0(\.?^ UQ_\
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MLOO#^UL-W?W'U=17RC_PU=XM_P"@=HO_ 'XF_P#CM'_#5WBW_H':+_WXF_\
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M/^?#2/\ OS+_ /'*/^&FO%'_ #X:1_WYE_\ CE'L9A[2)]-45\R_\-->*/\
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MHHH _/#_ (*X?\TI_P"XM_[9U^>%?H?_ ,%</^:4_P#<6_\ ;.OSPK[;+O\
M=8?/\V?-XS^/+Y?D%%%%>D<84444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >B?LY?\G"_"
M_P#[&G2__2N*OW:K\)?V<O\ DX7X7_\ 8TZ7_P"E<5?NU7R^<?'#T/;R_P"&
M05^0]?KQ7Y#UODO_ "\^7ZF.9?8^?Z!1117TQXH4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %?=?["?_ "2/5_\ L.3?^D]O7PI7W7^PG_R2/5_^PY-_Z3V]>/FO^[/U
M1Z& _C?(^C:^=/VO?^93_P"WO_VC7T77SI^U[_S*?_;W_P"T:^?RK_?(?/\
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MM*=:I/VW+K;;[B9TX1]G?2^_WGLJ?L51)/'I=Q\1M'A\2O%YG]DB$%CQU&9
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M **** /T6HHHK\J/U ^*/B!_R/GB3_L)7/\ Z-:L"M_X@?\ (^>)/^PE<_\
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M-]0HHHK8S"BBB@ K[K_83_Y)'J__ &')O_2>WKX4K[K_ &$_^21ZO_V')O\
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M&05^0]?KQ7Y#UODO_+SY?J8YE]CY_H%%%%?3'BA1110 4444 %%%% !1110
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MZ/\ AGOX6?\ 1-?!_P#X(;7_ .-UW]%'M:G\S^\.2/8X#_AGOX6?]$U\'_\
M@AM?_C='_#/?PL_Z)KX/_P#!#:__ !NN_HH]K4_F?WAR1[' ?\,]_"S_ *)K
MX/\ _!#:_P#QNC_AGOX6?]$U\'_^"&U_^-UW]%'M:G\S^\.2/8X#_AGOX6?]
M$U\'_P#@AM?_ (W1_P ,]_"S_HFO@_\ \$-K_P#&Z[^BCVM3^9_>')'L<!_P
MSW\+/^B:^#__  0VO_QNC_AGOX6?]$U\'_\ @AM?_C==_11[6I_,_O#DCV.
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M?_$5U=%'M:G\S^\.2'9'*?\ "IO _P#T)OA__P %<'_Q%'_"IO __0F^'_\
MP5P?_$5U=%'M:G\S^\.2'9'*?\*F\#_]";X?_P#!7!_\11_PJ;P/_P!";X?_
M /!7!_\ $5U=%'M:G\S^\.2'9'*?\*F\#_\ 0F^'_P#P5P?_ !%'_"IO _\
MT)OA_P#\%<'_ ,175T4>UJ?S/[PY(=D<I_PJ;P/_ -";X?\ _!7!_P#$4?\
M"IO _P#T)OA__P %<'_Q%=711[6I_,_O#DAV1RG_  J;P/\ ]";X?_\ !7!_
M\11_PJ;P/_T)OA__ ,%<'_Q%=711[6I_,_O#DAV1RG_"IO __0F^'_\ P5P?
M_$4?\*F\#_\ 0F^'_P#P5P?_ !%=711[6I_,_O#DAV1RG_"IO __ $)OA_\
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M\36]11[:I_,_O#V5/^5?<8/_  @'A?\ Z%O2/_ &+_XFC_A /"__ $+>D?\
M@#%_\36]11[:I_,_O#V5/^5?<8/_  @'A?\ Z%O2/_ &+_XFC_A /"__ $+>
MD?\ @#%_\36]11[:I_,_O#V5/^5?<8/_  @'A?\ Z%O2/_ &+_XFC_A /"__
M $+>D?\ @#%_\36]11[:I_,_O#V5/^5?<8/_  @'A?\ Z%O2/_ &+_XFC_A
M/"__ $+>D?\ @#%_\36]11[:I_,_O#V5/^5?<8/_  @'A?\ Z%O2/_ &+_XF
MC_A /"__ $+>D?\ @#%_\36]11[:I_,_O#V5/^5?<8/_  @'A?\ Z%O2/_ &
M+_XFC_A /"__ $+>D?\ @#%_\36]11[:I_,_O#V5/^5?<8/_  @'A?\ Z%O2
M/_ &+_XFC_A /"__ $+>D?\ @#%_\36]11[:I_,_O#V5/^5?<8/_  @'A?\
MZ%O2/_ &+_XFC_A /"__ $+>D?\ @#%_\36]11[:I_,_O#V5/^5?<8/_  @'
MA?\ Z%O2/_ &+_XFC_A /"__ $+>D?\ @#%_\36]11[:I_,_O#V5/^5?<8/_
M  @'A?\ Z%O2/_ &+_XFC_A /"__ $+>D?\ @#%_\36]11[:I_,_O#V5/^5?
M<8/_  @'A?\ Z%O2/_ &+_XFC_A /"__ $+>D?\ @#%_\36]11[:I_,_O#V5
M/^5?<8/_  @'A?\ Z%O2/_ &+_XFC_A /"__ $+>D?\ @#%_\36]11[:I_,_
MO#V5/^5?<8/_  @'A?\ Z%O2/_ &+_XFC_A /"__ $+>D?\ @#%_\36]11[:
MI_,_O#V5/^5?<='11161J<3J'@_0;J_N9IM$TZ6:25G>1[2-F9B2222.234'
M_"$>'?\ H :7_P" <?\ \36]<_\ 'S+_ +Y_G4=.[%9&+_PA'AW_ * &E_\
M@''_ /$T?\(1X=_Z &E_^ <?_P 36U11=]PLC%_X0CP[_P! #2__  #C_P#B
M:/\ A"/#O_0 TO\ \ X__B:VJ*+ON%D8O_"$>'?^@!I?_@''_P#$T?\ "$>'
M?^@!I?\ X!Q__$UM447?<+(Q?^$(\._] #2__ ./_P")H_X0CP[_ - #2_\
MP#C_ /B:VJ*+ON%D8O\ PA'AW_H :7_X!Q__ !-'_"$>'?\ H :7_P" <?\
M\36U11=]PLC%_P"$(\._] #2_P#P#C_^)H_X0CP[_P! #2__  #C_P#B:VJ*
M+ON%D8O_  A'AW_H :7_ . <?_Q-'_"$>'?^@!I?_@''_P#$UM447?<+(Q?^
M$(\._P#0 TO_ , X_P#XFC_A"/#O_0 TO_P#C_\ B:VJ*+ON%D8O_"$>'?\
MH :7_P" <?\ \31_PA'AW_H :7_X!Q__ !-;5%%WW"R,7_A"/#O_ $ -+_\
M ./_ .)H_P"$(\._] #2_P#P#C_^)K:HHN^X61B_\(1X=_Z &E_^ <?_ ,31
M_P (1X=_Z &E_P#@''_\36U11=]PLC%_X0CP[_T -+_\ X__ (FC_A"/#O\
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M/X_TH SJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Z.BBB@# N?^/F7_?/
M\ZCJ2Y_X^9?]\_SJ.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -'1_P#EM^']
M:TJS='_Y;?A_6M*@ HHHH **** "BBB@#-UC_EC^/]*SJT=8_P"6/X_TK.H
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MJ>'IKF]7\K"5:3M\CZ<\:^-=&^'GAF]\0>(+U=/TJS4-+,P+')("JJ@$LQ)
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MO;"[T^Y-G?Z9JEN;>[LY@H;;)&2<95@002I!X)K!\;_'O1O!_BI_#-EHNO\
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MD]&<]\0? VF_$KP5K'A?5_.73M4MVMY7MV"RQYY#H2" RD!@2",@<&N2\:_
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M.&5@588R.!CLJ*S]I._-?4KDC:UCS?P%\%(/"7B0^)=7\2ZYXR\2"V:SBO\
M6IDVVT+,&9(8HT1$W$+N."QV]<<5K?$KX5Z3\3K33_ML][IFJ:7.;G3=8TN;
MR;NRE(VDQO@@AAPRL"K#&1P,=E6?_P )#IO_  D']A_;8?[8^R_;?L6[]YY&
M_9YF/[N[C/K3]I-RYKZH.6*7*<+X'^"4/A7Q!)XCU7Q1KOB[Q*;5K*'4=7FC
M(M(6(++#$B*BY(4DD$G:.<<54_X9O\+-\/+CPJ]SJDDMQJ/]L2>(&G3^U#?^
M9O%UYP3:)0> =N HQC%>JT4_;3O>XO9QVL<#<_!7P]J=]XQN=4:ZU8>++"TT
M[4X;ID",ENLBHR!%4JY\UB2#U"E0N*P?#O[.\&EZ_HM_K'C7Q1XLM-"F%QI.
MFZQ<Q-#;2B-HUD8I&K2NJLP4N3C)ZDYKURBA59I6O_6P>SCV.$U?X166H_$R
MS\<6FLZOHNK1P16EW!I\T8M]0@C=G2.='1LX+-RI5L$C/I1U+X">']4\-^+=
M$EO-26U\3:['X@O'26,/'<(]NX6,E,!,VL>00QY;GD8])HI*K-6L]A\D7T.;
M\:^ M/\ 'G]@_P!H37,/]C:M;ZQ;_9F5=TT.[:KY4Y0[CD#!]Q7AOQOL_#>C
M?%*75]9TSQQX0>YLHHQXQ\%23,FH8R/LUS'"CD,F!M++R#U 4"OI:BJIU7!^
M0IP4D?/7[*O@!/#^M>._$UCH6IZ!H&N/90:=%KC.=0O%@64R7<X?YP97G;&\
M[L*. ,"O7M/^'VG:;\1-7\91373:IJ=C;Z?-"[KY*QPL[(5&W<&)D;.6(X'
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MRW#13+:-+G&P7)3R2?8/7>OXPT>/Q='X7>^1->DLCJ*6;*P9[</L+@XVG#$
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M-1>'O%VN0ZI?W^CK'JEY=>=-;B>2!#&IP/W0!X0Y&"0<YKUK0/A?JS?"'5/
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MQ!?26HM(=-TZU-EIUNN[<7\K>QDD) ^=CP"P P:;JP=/S[>=]]OU\A*$E/\
MK;[_ -#B?B_:Z]XJ^/\ X'\*6'B[6?"^C7FBZA=WRZ-.(I)_+DA"@,00IRWW
M@,XW 8S4>IV.N_$_XM:C\/K?Q9KGA_POX-TJQ>_N=-NC#J.J7-PK^7ON ,A
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M8$'&#7G'[5.NV&L>!-.\#6FOQ7GQ9^WV$ND6^FX2Y2]5U)N3%EC%%L:5B6)
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MI[K'?MXSU@6[MT63;'M)_'%>T6MK#8VT-M;0QV]O"@CCBB4*B*!@*H'  '
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M,B"Y(W'#194D$CUKDOV9O![^"_@AXZU6R\0:Y,\,^MVL%M=7I>& PSS!947
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M/$)&W9YY!P,5U%?,-Q\/=8^'W[3?PI@?Q;JWB7P[<1:LUK!KL_VFZM)A:@2
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MR6TP"EDD,/\ $VU7 !/!S7UI6=>G&FUR[?UY(NE-S6H4445S&P4444 %%%%
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MT_2HY-5TFXU0G^RY-:TJXL8=1&,Y@DE15?(Z#()["O&SJEGXZ_9,^'9T1?\
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MXJ_;^NXW4DK-OO\ GZGV)1117GG6%%%% !1110 4444 %%%% !1110 4444
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M(M*_X2#4?#GBS1;UBM^+"S>PFTP[25:(M(XG3( ((5N01P#7-ZO^SMJFN?\
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M)>VVG7VD>&HM1,UK>@NYFG6 0NB;2IVF)B=Q&,J1D].6_P"&=KY_!7BWX?\
M]I00^"IYH[[PU,"TEWH\PE$PAV,NUH4E4%/GSM9D/&#4*=*48<V_7TN]%_6W
MXURU$Y<OR];(Y*#]HW4/!^L:%=ZQ\3OAWXYT[5;^"RO=(\.2I'=:>9F"+) P
MGD,\:,1NWJIVY/&,59\%V7Q''[6GBV"[\5:9<:?%IUC<W%J-/< VC2SB.*/]
MYA9!M^:0@[L]!@5UVA^%OB?J6M:5;ZOI/@?P[IUC<1RWNJ:2C7,^H(N3LBBD
MB @#$#+%F*Y^7/6MRX\ >)-*^.\OC/1FTJYT;5M,MM-U2"^FDCN(/)DD99(
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M UR62!))H5"17$$J*VUMF%92,$*#UQB(SA)7=N;7HK=/EM<J49)V5[?U_P
MI^%_&7BW3=<\:?#KQQ>6NM:G9Z(=7TW7+.U^S"^LWWQ-YL8)5)$D7&%X(8'
M[\-\/O'GB*P^"GP.\#>#)K.S\3^)M($G]IWJ>;'IUI!&K33>5D;W.]513@$D
MYX!KTKP1\*?$LFL^*?&/C2^TZX\8:WIHTJWM=-#_ &/3;1=S+"CO\SDNY9V(
M&3T&*P+7X >)M#^''PP_L35M-L_B#X%M/L\,TWF2:?>(Z*EQ!)\H?8X52&"[
ME*@@>E\U+9VZ>E[/\+_U8GEGO_P]KK]"RVN?$'X-^-_"=KXJ\4Q>._"?B2_&
MD?;'TR*SO+"\=&:'B'"/$Y1E.5!7(Y/<7Q!X^^,GCSQ=8^$_%4/@CPMX7O\
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MZ+G&[ YVYXW#CWKP;X8^'/"LG[&OB)=>N#H&E:M-K"ZKJUI"S2J#J-Q$LK;
M2P4! <C&T'.!FM_P5JVH:/\ %;P+I'BJ'PEXJN[O3;J/0/%7AQ3!/';QQ@N)
M8,LHC=1@,C%0PQ@9I2H07,HWTO\ A_7_  X*I+W;];?B7)_VH]!^'?@SP$_C
M/Q'H6J:[K\D*37.C7!6T$+M(K7:%U!\E2F"2!S7HND^,9-=^(=G#I^MZ->>&
M[SP\FIV]K"[->RL\P"7"\;3 4( .<[CTQ7S1X<M+ ?LP_L[7M[#;B*+Q'I:S
M7$ZKM2(RS AF/122!SQDBO1/B%'?S?&SQ+'X7P-4?X67*Z7]FZ><;EO)V;?]
MK;C%:SHPNTM]?31D1J2M=^1ZDOQQ^'S>,#X5'C+1?^$A$GD_V?\ ;$\SS.GE
M]<;\\;<Y]JN>.?BSX,^&CVJ>*O$VF:#)=']Q'>W"H\@S@D+UP#U/0>M?*>G6
M%UJ_[+EMIUQXQ^&ND^#&TY(Y'DT6Z-[9W)4*7.+LG[8LF3G:6+CH>E>F:WI%
M]%\3X;[PSXST&?Q[!X6M;'5]'\56<PM[^T!=_/C?(:/+>9O"[U'&\ CF'AZ:
M=KOK^'RT_&Q2JR:V_K[SZ%L;ZVU2R@O+.XBN[2=!)%/ X>.1",AE8<$$=Q4]
M><_L\Z[I?B/X0:#?:-H</ANP)N(AIEK)YD,+I<2))Y;@ ,A=696'!#"O1JXI
MQY)./8Z8OF284445!04444 %%%% !1110 4444 %%%% !1110 4444 26W_'
MS%_OC^=;]8%M_P ?,7^^/YUOT %<Y71USE !1110 4444 %%%% !1110 444
M4 %%%% !7*>.OA1X.^)L=NOBKPUINNFW.87O+=7>/V5_O 'N <&NKHJHR<7>
M+L)I-69S,WPS\*3^"9/!Y\/Z>GA>2,1-I44 C@*Y#?=7'< YZYYK4\.^&]*\
M(:-;:1HFG6NDZ9;+MAM+.(1QH,Y.%'')))/<DDUI44.4FK-A9+6P4445(PHH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "M;2?^/9O]\_R%9-:VD_
M\>S?[Y_D* +M9NL?\L?Q_I6E6;K'_+'\?Z4 9U%%% !1110 5X3:_ ;QMX2L
MKCPUX)^(R^'O!$SR&&SFTI;B]TU'8LT=K/Y@ 7+';O4E,\9P*]VHK2%24-O\
MR)04MSR[QG\&K_4+WP]KOA7Q3<Z#XNT2Q_LU-4OHA?+?VIVEHKI"5,F60/O!
M#!B3SFJ_A+X+ZM'KNJ^)_&?B=?$OBN\TU])MYK>Q%K::=;,=S)#%N8DLV"SL
MV3@#@"O6:*KVT[6O_7J+V<;W/)+SX"?:_P!FU?A/_;NS&DQZ7_:_V//W<?/Y
M/F=\=-_XT_Q?\(_$</C?4?%_P_\ %,'AK5]6BABU6SU*Q^V6=Z8EV12[0Z,D
MBI\N0<$  CC->L44*M-=>_X_\,'LXG@%E^RWJ+:/\5(=8\=SZWJWC^PM[2ZU
M&?3E06SQ+,NY(UDP4VRJ F1M"?>;.1VGC/X2:CKFJ>"-8T/Q''H>M^%XIK:.
MXN-/^UQ7$,T<:2HT?F)@GRD(8-QCOFO2Z*;KU&[M_@NUOR$J44K6_K<\HUW]
MGW3O$]S\23J>I3/!XQN+*Z06T?E3:=+:P11QR1R;CN8/$K@X&.F".3D3?!#Q
MMXRDL=-^('Q"@\1>%+*XAN7TVPT=;.34FB8/&+J3S&&T.JL410&([=*]NHH5
M>HNOY>F@.G%G'^&/A[_PCGQ#\:^*/M_VC_A)/L7^B>3M^S_9X3']_<=^[.>@
MQTYKC(?@9KV@6%])X9\<W&D:Q)XBU'7XW-IOLY5NY"[6UQ!YG[U5R '#*P(W
M #I7L=%2JLT[W[?AH-PBSSWX7?#74O!^L>)_$.OZO;:OXB\1RP27CV%E]DM8
MEA0I&D:%W8X!.69B3QZ"O0J**B4G-W922BK(****DH**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#HZ*** ,"Y_X^9?]\_SJ.I+G_CYE_P!\_P Z
MCH *SKCP[IUUJD6HRVJO>QXVRDGC'3C."?>M&BJ4G'9V)<5+=!7E7[0.B_$R
M^T71]2^&&K00:MI5X+FXT:Z"+#JL7_/)I#RN.>-R@[CDY"UZK6?J_B'3=!DT
M]-1O8;-]0NELK19FVF>=E9EC7U8A&./]DU5.3C)-*X22DK-V/D[0/AU\1OC)
M^T#X*\>>(_ASI_PPM?#+2R7EU'>1W%UJDA4 *=F"5!S@L. [_,W2J7@GPI\<
MOV7M.\0>!?!G@BR\<Z!>7DMSH>MG4(X#9F0 8GC<@MM !Q\HSG#$<#Z^\0>(
M=-\*:-=ZMK%[#IVF6B>9/=7#;8XUSC+'L.16A76\5)JSBN7:VMM->]^O<Y_8
M).ZD[]SXU^.OPF^*WB^;X::IXKT&+XF:7IUI(OB#PQHFHG3H9;LEBDO)&X*#
M&"1U,;<*KUQ7AK]F#XCVMC\:]O@"S\-0^)=%AMM&TFPU*WDB1Q)&WD[S)]Y5
M!W.V 6#$$@BOO^LZ?Q'IEMKUKHDM]!'JUU"]Q!9L_P"\DC0@.X'< LN3[BJC
MC:D8\L4OQ[WVO;_@"EAX-\S?]6L?$GC+X"?$!-6^&L_B#P!/\3/"NE>$K#2C
MX7AUQ+1+#48X$61GPVUQN5AO&0>,G"J#S]I^RG\48_@O\7="_P"$,M-/U/7]
M8T^\TS3+#4+?R!#'+(SK&S2?*J!E WD,<=SFOT,HIK'U$DDET[]'?N)X6#=[
MO^E8^+_'GASX^_'#P98?"?6O!&F^%]*#V\>K^*8]12:"YAA965HH@=P)*JVW
MDY&#MYQK^(OV5]<\6?%?XI6SV[:=X1USPE::-I>KR3QR$SPBV*!HU;?@-#R2
MH! .#R*^N:S++Q+I>HZ]J>BVUY'-JFF)#)>6JYW0K*&,1/\ O;'Q_NFH6+FO
M@BDO+U6OX(IT(OXG?^GH?"7A#]G;Q=!%HGA2_P#V>_"AU"SDCBO_ !A?ZIYE
MI<P*<-)Y*,'WLO/!SG/R#H/OJSLX=/M(+6VB6&W@C6**)!A451@ >P J:BL:
M^(E7MS?K^K9I3I*EL%%%%<QL%%%% !116=KWB/3/"]G'=ZM?0:?;231VZRSO
MM4R2,%1 ?5F( 'J::3>B#8T:***0!1110 4444 %%%% !1110 4444 %%%%
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M+(J$#)')%*#IR2<K7MK][Z>G:S[=1R4UM?\ K^O0^CJ***\XZPHHHH ****
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M/A'\+Y_BC\%O%$'_  D1U'46\9W&MZ5XFFM@8;NYA:/%P(@<&!Y$E3:#]PD
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MN5\$?M*:9X>UKQ_H^O7.M>(=8LO%%^D-AI.FSW\MG8J4"%Q$I$<8P^-QR<'
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M#;@Y.1CFN'\5_M$^#_".NWNE3MJNI2Z<1_:<^CZ3<7T&F@C/^D21(P3CG')
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M6-$DQC=#L9"F<C.0.2:^C:ANK*WOD5+F"*X16#A94# ,.AY[T/$*2<9+1_\
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MAUIK7>BZW>Z?,^IM=QP2+'+,@6V\IP3F3=L+=$Y^M>^>&K_4=4T*SNM7TO\
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M0 4444 %%%% !1110 4444 %%%% !14:7,4LTL22H\L6/,16!9,\C([9J2@
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MQ=\/M0U+7M1DOK33Y4C2[B-U)Y4H26-O+<QE0)$QD '!QFN]5%R.T]=-?O\
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MU*PRK $9!!Y[$5A55/E?*K6:_%,U@Y77,^YZK1117&= 4444 %%%% !1110
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M/_'S+_OG^=1T %%%% !117DW[07[1&F?L^6&A7.HZ+J.MMK%TUI!!IH4R;P
M0,,1G.< #G-7"$JDE&*NR924%S2V/6:*\"^%_P"UE_PLSQUIGAK_ (5MXPT#
M[;YO_$QU6Q\NVBV1/)\[=L[-H]V%>^U52G.D^6:L*$XS5XA117G'QX^--G\"
M?"%GK][IL^JQ7.HPZ<(;>0(RM(&(;)[#;^M3"+G)1CNQRDHJ[/1Z**\,U7]J
MG3]+U[XG:6/#6IWLW@5+9YULV61[SSF4 1IV(W9.?0TX4Y5/A7];"E.,/B/<
MZ*S?#6M+XD\.Z5JRV\MHM_:170MYQB2(.@;:P]1G!]Q6E4-6=F7N%%%%( HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH T='_Y;?A_
M6M*LW1_^6WX?UK2H **** "BBB@ HHHH S=8_P"6/X_TK.K1UC_EC^/]*SJ
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MMIE<,R*S_O0NW[N,\5]!7>N:;X1\(-JNJ7;V&E:?9B:>YU!R7CC5,DR$Y);
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MS_(4 7:S=8_Y8_C_ $K2K-UC_EC^/]* ,ZBBB@ HHHH **** "BBB@ HHHH
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M9\;_ !WEO_@=XN\9> M(NUCMKI+>WU2]T\^3<QEXDEO8XL[YHT1F.2!N\ON
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M_C;_ "$J=FFWV_"_^9\L^-/ VH_$#6?VG?#6AD1:GJ5EI/D(&""67[(3M)/
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MO#.G-#;:A&)H59Y+A2YC;*E@ 0&(R,G&,THTJ?*YW=M>G:WGY@ZD[J/I^O\
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M !1110 4444 %%%% '1T444 8%S_ ,?,O^^?YU'4ES_Q\R_[Y_G4= !1110
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M%604445!04444 %%%% !1110 4444 %:VD_\>S?[Y_D*R:UM)_X]F_WS_(4
M7:S=8_Y8_C_2M*LW6/\ EC^/]* ,ZBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** .CHHHH P+G_CYE_WS_.HZDN?^/F7_?/\ZCH ***Y'5-1\11>,[6WMH&;
M26*;V$0*[3]XEL<$<\9["M:=-U&TG;U,YS5-)M7.NKF_B'\1/#_PK\)WOB3Q
M-J":=I5J!ND8%F=CPJ(HY9B>@'\@3725\I?MTM:Q:U\%I=?./!:>*HSJ_F?Z
MG&4VF3_9V>=GVW5="FJM10>PJLW"#DBY!^WOX?MWL[_7/ 7C7P[X2O7"6WB2
M_P!,(M7!)PQ()R,?W"Q]J^F--U&UUC3K6_LITNK*ZB2>">(Y22-@&5@>X((-
M8?CV;PH/ VHR^+6TYO"?DJUV=0VM:F/<NW=G@C.W'X5\P?$2>3XV_M'Z%\)-
M-\33^%_AU9Z NL(GAJ=8/[3S@HL;H-I0*RD  C".1S@C94X5M8+E2O?KHOU,
MG*5/XG>_R/L2BOAW3M2UWX'_ !1^)_PHLO$^K>(O#+^#;S6;%]1N?-N=+F$#
M$#S."!UX&/O(<9R3YEJWA'7_  Y^R=X9^-UG\0O%1\91W$6T2Z@6MTA\]X1&
M$(YZ DDD-E@0<UK'!7M[^CM;3>^WH0\3;[.U[_(_2^BOB%O"&J_ 3X^?!&ZT
MKQKXCUD>.//AUN'6;PSQW#JD3,X'&,F?(!R5*#GDUP7@_P"'&K?$_P""/Q<\
M>7WCWQ5;ZKX4U75&TJWM]3=8(OL\2W!)'));=M&"-NT8I+!Q:YN?33IYM?H-
MXAIVY=?7RN?HW17YQ^(M-\3>$_@K\-_CI%X_\2WGC35-4MDNTNKS=:/&YD C
M$0  4", @Y!!/%;/CGQ-KWQG_:$^(FE:OI7CK7]!\,SC3]/TCP;>);+;'+*9
MY=S#<S;"0<'J1T !?U&^JEHKW]4[?J+ZS_=U_P S] Z*_.KQEXD^+6D_LY>'
M--\2WGB#P_J5OX]M+'2]7O)=MY/9/!<%1*58^858<[B0< <[:[[XK>$M3\$>
M,OAI\#=#\<>(M.T;Q7=W.H:OX@N[[S+^X(0 PK+@;0WEGY>06D7.1P9^IV=N
M==?N6[']8OKR]OQ/L7Q+K2^&_#NJZLUO+=K86DMT;> 9DE"(6VJ/4XP/<UD_
M#'QW'\3/ FD^)HM-O-(CU!&<65^H6>+:[)AAV/RY^A%>%)\$KWX'Z9\0WT/X
MEZQ?Z"_A:[N$\-ZM<?:+F&?RI,7,<FY3& 5 !"\G.3\HKQA?&L.O? 'X+:'K
M'BSQM>ZKJD5U//X;\)QF;4-819Y0IDF+ JJE>Y;@,=OR@@CAHSC[KOKO9]F]
MOZ]1RK.+]Y=/U1]L_%;X@0?"OX>:[XLN;22_@TJW^T/;1,%:09 P">!UKAO"
M_P"TGIWBCXB>"?"<6BW,$_BCPM!XIBN7E4K!'('(B88R6&SJ..:^.M&\6ZY:
M_#S]HKP)>'7H-$TW28;RQTSQ)="XO+ LZ;HV89'(<' /&!QDFNP\+>'%\7_&
MOX.Z(US-9?VA\%[2W6ZMY"DD+-%,%=6!!#*<$?2NA82$(RY_/7Y)HR^L2DUR
M_P!:V/OFBOSP3XV>+-=^ >C?!J/5+RW^*<WBD^%[BX$SBY2WBE#M.7R&P,I&
M3GE5<D^OTM^U#\/]6_X9ONK;PIJFHV>L>%H(;^TN8+AQ/,MNN) [ Y<M'O)!
MSN8 FN2>%=.48RE:[M\NYO&OS1<HK9?TCWFBOB_P;\8;K]I;X\^ KNQU2YT[
MPIX2\/+KVO+#.88FO9%!,4F#AE5A&<-D863IFO$/B%XGN+GPKK_Q"\+Z]\4/
M$6JVFH^=#XYN"+#1XT$P18DBW?,OS!< +\S ;0/E.L,#)RY9.ST_'8SEB4E=
M*Z/N/Q+^T18^&_BUJO@-M$O+N\L/#TOB$W,#J1*B GRE3KO.,#MS7:?#'QW'
M\3/ FD^)HM-O-(CU!&<65^H6>+:[)AAV/RY^A%?&FN>)+S7/VAM0\0/(UOJ%
MY\'I+\R0MM*2O;E\J1C&">,5A^%_%/B?XJ>'O@#\+)_%NIZ%I7B/3[V_U;58
M+EA=WFR>XVPB5CG.(<8.?OC(. #I+"1<$UIM=_)M_D2L0U)WU[?>K'V1XF^-
M5GX9^-G@[X<2:9//>>)+:XN8KY) (X1#'(Y#+U.1&1QZUZ/7PM;?":W^"O[<
MOPITVV\3ZMK6DS:=J-W#%KEWY\ED/LER' ?CY&*[N@P=W6O-/B7XD.M:-XN\
M=^&->^)_BG4K._::U\:HPT_1K1%=0(D3=\R_,5P OWE^7J"OJ<:CBH2T:6MN
MK;7R_JP?6)13<EU_1'Z(>(_B/X;\(^(O#^@ZOJD=EJ^OR/%IMJR.S7#)MW $
M @8WK]XCK725^>OQD^'\7Q,^)O[.?BB_UW7+/5/B%80OJ#V-VD7V,K:VIW6N
M$_=EC*Y;.03T K:^-VN:YKG[0=G\*S%XSU[PCX8T&WD_LSPW>+%>ZC)L0>?/
M(2N\#>,D?Q+P!N)J/J:DHVEK9M_)V*^L-7NNJ2^9]X5P_P ;/BG;?!3X8ZSX
MSO+&74[;3/)WVL#A'?S)HXA@G@8,@/X5\<V'Q+^+'P-^"WQ5,NF>)++0[1K=
M/#-]XF9);NP\Z412(S@L&V!@5[ @<#=BL[X_?LX#P5^RU+XW3XB^(]9U6\M[
M&?4XK[43+9ZF)I8CM5#S\KLDBDEN(R?<5#!Q52*G+1M+3KM]VXI8AN+Y5K:_
MH?H!X?U==?T'3=42,PI>VT5RL;')4.@;!/MFK]<[\./^2>>%_P#L%6O_ *)6
MNBKS)*S:.U:H****D9HZ/_RV_#^M:59NC_\ +;\/ZUI4 %%%% !1110 4444
M 9NL?\L?Q_I6=6CK'_+'\?Z5G4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!);
M?\?,7^^/YUOU@6W_ !\Q?[X_G6_0 5SE='7.4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 5K:3_Q[-_OG^0K)K6TG_CV;_?/\A0!=K-UC_EC^/]*TJS=8_P"6
M/X_TH SJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH,8YSU'QI^!'ACX[:)9V/B!;JWN;"7[18:GI\OE75G)QEHWP1SM7(((^4'J
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ML;@?O'.2<U]!MXX\.IX4/B<Z[IW_  C@A\_^UOM2?9?+SC=YF=N,\=>O%5?
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M']:TJ "BBB@ HHHH **** ,W6/\ EC^/]*SJT=8_Y8_C_2LZ@ HHHH ****
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M 4444 9NL?\ +'\?Z5G5HZQ_RQ_'^E9U !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 26W_ !\Q?[X_G6_6!;?\?,7^^/YUOT %<Y71USE !1110 4444 %%%%
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M:/[.M_\ GG_X\:LT4 5O[.M_^>?_ (\:/[.M_P#GG_X\:LT4 5O[.M_^>?\
MX\:/[.M_^>?_ (\:LT4 5O[.M_\ GG_X\:/[.M_^>?\ X\:LT4 5O[.M_P#G
MG_X\:/[.M_\ GG_X\:LT4 5O[.M_^>?_ (\:/[.M_P#GG_X\:LT4 5O[.M_^
M>?\ X\:/[.M_^>?_ (\:LT4 5O[.M_\ GG_X\:/[.M_^>?\ X\:LT4 5O[.M
M_P#GG_X\:/[.M_\ GG_X\:LT4 5O[.M_^>?_ (\:/[.M_P#GG_X\:LT4 5O[
M.M_^>?\ X\:/[.M_^>?_ (\:LT4 5O[.M_\ GG_X\:/[.M_^>?\ X\:LT4 5
MO[.M_P#GG_X\:/[.M_\ GG_X\:LT4 5O[.M_^>?_ (\:/[.M_P#GG_X\:LT4
M 5UL($8,$P0<CDU8HHH *K?V=;_\\_\ QXU9HH K?V=;_P#//_QXT?V=;_\
M//\ \>-6:* *W]G6_P#SS_\ 'C1_9UO_ ,\__'C5FB@"M_9UO_SS_P#'C1_9
MUO\ \\__ !XU9HH K?V=;_\ //\ \>-']G6__//_ ,>-6:* *W]G6_\ SS_\
M>-']G6__ #S_ /'C5FB@"M_9UO\ \\__ !XT?V=;_P#//_QXU9HH K?V=;_\
M\_\ QXT?V=;_ ///_P >-6:* *W]G6__ #S_ /'C1_9UO_SS_P#'C5FB@"M_
M9UO_ ,\__'C1_9UO_P \_P#QXU9HH K?V=;_ ///_P >-']G6_\ SS_\>-6:
M* *W]G6__//_ ,>-']G6_P#SS_\ 'C5FB@"M_9UO_P \_P#QXT?V=;_\\_\
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M ./&C^SK?_GG_P"/&K-% %;^SK?_ )Y_^/&C^SK?_GG_ ./&K-% %;^SK?\
MYY_^/&C^SK?_ )Y_^/&K-% %;^SK?_GG_P"/&C^SK?\ YY_^/&K-% %;^SK?
M_GG_ ./&C^SK?_GG_P"/&K-% %;^SK?_ )Y_^/&C^SK?_GG_ ./&K-% %;^S
MK?\ YY_^/&C^SK?_ )Y_^/&K-% %;^SK?_GG_P"/&C^SK?\ YY_^/&K-% !1
M110!7:P@=BQ3))R>32?V=;_\\_\ QXU9HH K?V=;_P#//_QXT?V=;_\ //\
M\>-6:* *W]G6_P#SS_\ 'C1_9UO_ ,\__'C5FB@"M_9UO_SS_P#'C1_9UO\
M\\__ !XU9HH K?V=;_\ //\ \>-']G6__//_ ,>-6:* *W]G6_\ SS_\>-']
MG6__ #S_ /'C5FB@"M_9UO\ \\__ !XT?V=;_P#//_QXU9HH K?V=;_\\_\
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*:** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>lgnd-20241231_g3.jpg
<TEXT>
begin 644 lgnd-20241231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0+Z17AI9@  34T *@    @ ! $[  (
M   0   !2H=I  0    !   !6IR=  $    @   "TNH<  <   $,    /@
M   <Z@    $
M
M
M
M
M
M2&5R;6%N+"!-96QA;FEE   %D ,  @   !0   *HD 0  @   !0   *\DI$
M @    ,R-0  DI(  @    ,R-0  ZAP !P   0P   &<     !SJ     0
M
M
M
M
M
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M-#+M;'7T/K0 E.!RA7TY%-H!(.10 4Y?E4M^ IM!)('M0 444#GI0 JKG.>
M!S24]_E&P<X/)]33* %9=N.X(R*2GI\XV'U^4^],Z4 %.8[E![C@TV@$@$=C
MUH *<3M0+Z\FFT$EB2>IH ***5%W-CIZGTH -OR;CZX'O2  L,\#UI7;<>.
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MZ4]_D78.N?F/O0 RE9=N.X(R*2GI\PV'N>#[T ,HH(P<&B@!S?,H8?0_6FT
MD9]Z* ',=J!!]6IM!.>M% !2[?EW>^![T*I=L#\_2E=MQ '0# H ;]:5EVMC
M_)I*?G>F#]Y>GN* &4 D$$=1110 YP,[EZ-^E- R<#K1DXQVH!(.10 YST5>
MB_J:;110 4I7"@GOVI47=DG[HY-(S;FST]O2@ 5=S8Z>E)13G^8;QUZ-]: &
MTY&VMST/!IM% "LNUB*$7<W/ ')I"2<9[=*,D CL>M "NV]L_D/2DHHH *5E
MVMCOWIR#8OF'_@(]_6F4 *%RI([=J2E5MK T,,-QT/(H 2GH=RE#WY'UIE%
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MDH D2;8X.U?RICKM;U'4'UI*<#O7:>HY'^% QM*B[VQT]3Z4E.)V+M'4]?\
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M=O0G.,&N\OD;_AD^W7'/R\?]O->%>4_]W]:RH4HJ<G?:3+G4DX1TW1]!>!?
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M*<XVX7N.OUIXC,2[W'.?E^M1=:-QBJ0&^89'>AEVMBDJ15:5< 9*_P J (Z
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M!/B\ZKJL-S- ;9XMMLJLV21CAF QQZUD>,-9@\0>+]3U2R21+>ZN&EC64 ,
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MS'4 AB-LB,%P&!SN8?WO>O,R<DT1B_;SET:7Y"NO91CUNST?X$M_Q=*T4_\
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M?AR]M[V2\U S>4\*(8UWQ!!N)8'J.P-:XB+E2:7]:F="2C5BWL>?0;5O8).
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M$+_Q9PO^-,H **>!OC/JG/X4R@ !*L"."*?( <.O1OT-,I5;&0W0_I0 E.C
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ME1]C9ZCH1ZBAUVL1^5(8E2QKYL14D IR"?Y5%3Y#M41KT'WO<T,$'E?[:?\
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MC /I3:*4;<?-G/M0 E.0#EF^ZO7W]J!Y??=^E*^W8NS..^?6@8PDDDGJ:<C
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M;HOZF@!I&#BE R"1VI*53M8&@!**5UVMCJ.Q]:2@!ZG<I0_5?K3**"2QR>M
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MRB@ IR 9W-]U?U]J:26.3UHR< =A0 ,2S$GJ:*** !1N.!13CE8Q_M<_A3:
M C !]:*>GS90]^GUIG2@ I[?.@;^)>#]*90"0<B@ IZ_(A;N>!_C3*"23S0
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M@_\ BZ)/@QX]*JJ>'RO7(^V0?GG?7U=11]<J=E_7S']7@?)W_"E?B!_T /\
MR<M__BZ/^%*_$#_H ?\ DY;_ /Q=?6-%'UVIV0OJT#Y1'P9\>F( ^'MQ!/6\
M@&/;[]!^"_CS_H7<?]OT'_Q=?5U%'URIV7]?,?U>!\GGX*^/^WA_'_;[!_\
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M!@8^V0<?^/U]844?7*G9?U\P^KP/D[_A2OQ _P"@!_Y.6_\ \71_PI7X@?\
M0 _\G+?_ .+KZQHH^NU.R#ZM ^4O^%,^/&1?^*>W$#DF]@'_ +/33\%_'IZ>
M'<?]OT'_ ,77U?11]<J=E_7S']7@?)Q^"OC_ +>'\?\ ;[!_\71_PI7X@?\
M0 _\G+?_ .+KZQHH^NU.R%]6@?)W_"E?'_\ T /_ "=M_P#XNG#X+>/>_AW/
M_;]!_P#%U]7T4?7:G9?U\P^K0/E)?@QX\5@?^$=QCO\ ;8#C_P ?J/\ X4MX
M_//]@?\ DY!_\77UC11]<J=D'U>!\G?\*5^('_0 _P#)RW_^+H'P7\?HP)T$
MC!ZB[@./_'Z^L:*/KM3L@^K0/E)O@QX[+$CPYQ_U_0?_ !=-/P6\>]O#N/\
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MKZPHH^N5.R_'_,/J\#Y._P"%*_$#_H ?^3EO_P#%T?\ "E?B!_T /_)RW_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MV7RKB%([.2<E9E)&')5L@Y_E6UJ7C.^T3PKX=A\.^')K^\U*VC%O!'N$$ V
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$_CB+Q1J&G3Z986%L]O86]TNV:5GQOD9?X1@8 /-=Q6<^E]^O]>EBH[NVW_
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MTKQ)X<UB34K2,1![&T,\5UM& R..!G&2#C%-)I-+?03=[/IK_7YB67BG5_\
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M6\66&D>(-*TB=E:XU*1T4!U'E!5W;F'IVJKXAUN[L/$WABULID%MJ-S+'/\
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MOS3B1ESN5^JXXP!QQ6/=>)=2O/A?X1M[B2]G?5Y_L]Y)9@M/+$F[<J\YW,%
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MJ>A%3S72N]4_\O\ @CY4GIV_S_X!Q&C#P;<^)=-6TTJZ\):W Q*6YM/LIN5
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MJXMXM4L$>+RKL'RKB)\91BO(.1D$5*E;E3??\>;_ #'RWYFEV_"W^14\6?\
M)1O!/_7>Z_\ 1)K-T?2;3QSXPU_4/$D*WUOI=Z;"RL9QF*(* 6<IT+,3U-6E
M\.>+-5\9Z'KVO3Z9!#IK2YLK5G;:'C*[MQ'S,3CC@ #O5J_\-Z[I'B2[UOP;
M/9,-0VF]T^^W+&[J,"1'4$JV.O&#3344E?6S^^_^0Y:_A^O]?(O:;X&TC1]2
MO)],5[:RO8/*GTV,@6SD]7V=CCCC Q7,>"?">@P^//$[Q:3:HVG7L(M"$_U&
M8@3M].374:!I_B0ZI-J?B?4( 7C$46G6.3!$,YW%F&6?WX'UJK!H&N:1XWOM
M2TF2QFTS5I(Y+R.Y+K+"RKM)CP"&R!T..:49--IOI^J_X(I)-;=?T(? ?_(<
M\8_]AIO_ $6E9R_\CM\0?^P;;_\ HF2K]QH'B30_$FH:EX2?3[FUU1UEN;._
M9X_+E V[T90>" ,@BH]$\(:[;:AXGOM9OK.YN-;MHXT\D,JQL$9=N".%&X '
M))P2<4G9Q;O]FWST_P BXZ2^=_QN1?#7PSHFE^!]*UG[/&E])8B26_E.9%!7
MD;CT4#C'0 5@)9>#[W2KE-*\):MXE>X+LVKR6PW2,<_,)Y2O3L5XXKN;#PO(
M/AK#X8U"95D_L_['++ 20#LVDKD G\<5D6FC^.$\/Q>'FET>TMH8!;?VC"TC
M2M&!M!6(J K8[Y('H:N<KRFT_3TU,X1M&*:]3G4OKG4?AQ\/KF^E::=M9ME:
M1SEFVLZC)[G '->B>+9M/A\*WQUG49M-LVCV27$#[9%SV4@$Y/3 &:YBT\!Z
MG;^"_"NCM/:&?1M1BNIV#MM9%9B0IVY)PPZ@5O\ C3PW-XET6&&RN$M[NTNH
M[NW:52T;.AR%<#JIHJ.+EY<S^[0=--)=^5??J>9^*4T6P\)-?>%?!6I:9/8&
M.6WU=[9;8H0P&2682.".#D'.:[>=B_QETACU;1)B?^_B50\4^'/&_C3P[/IE
M]+I&EQG:PC@EDD\]@0<,Q4;5XS@ D\=*Z-_#]TWCZPUL20_9K;39+1TW'>79
ME((&,8X/>GS+2[[_ /I(K::>7YHX*'5KW2?AAK3Z9-]GN;GQ!/:K<?\ /'S)
M]I;\ 3781_"[PFFDBS.E1/-MR;X_\?!?^_YGWMV>>M06OA"VL_ ^MZ9XKGMQ
M97=W<7;RI(0(D9]ZMN(&&7@^F1WJ"UTSQG)I,<$'B[2Y=):+*:F+4FY,6.#G
M=LSC^+\:ER]W1VV_)?EJ.VNOG^?_  QQ^FP/;? ?QA!+.UP\5_<HTS')D(90
M6/N>M=3J_P //#T'P_N)H+)4U&WLS<QZD#_I'G*NX.9.I.1]*R?!_AF;5O@U
MK>DZ7*NV_O;@6<]PQPZ;P%<D GG:><5Z3J.GRW?A>ZTV-D$TUFT"LQ.T,4VY
M/&<9]J=635[/73\A4HIM76EW^9YOJ5NOB[4/AM_;+-(+RTEEN0K%?-_<JQ!Q
MV)ZCN"14GC/PAI.F>(_#D>BP?V5#JUW]AOXK$^4MQ#C=M8+],9Z\UT-EX.U"
MVNO!<CS6Q&@6LD-UAF^=FB"#9\O(R.^.*T?$_AZ[UK6/#UW:R0I'IE_]IF$C
M$%EVD87 .3SWQ5.:4URO2[_-_H+E?)KO;]/\SF_%7AW2_"6H>'=7\,V<.EW/
M]J0V<OV9=BSPR'#*X'!Z Y-4-5U"VUKXEZK;Z_HFI:U8:.L4=K9VUMYT*NZ[
MFD=<@$\X&<\9KM?%^@77B"VTN.SDA0V>IP7<GFL1E$;) P#SZ?SJKJ_A[5K7
MQ&_B'PG/:K=W$2Q7EG>;A%<JOW6W+DJX!(S@C%1&>GO;Z_I_P?O+E'MY?F_^
M <WI:_8O'VFS^%/#&K:/876^+4X9;/R;<C;E) H. P(QD <&GZ'X6TG7?B1X
MPN=:M([Y8+J%(H)QOC4F%<MM/!;H,GI73Z19^*KG6DU#Q%>6EG;1(RQZ=IY+
MK(3_ !2.P!)'8 #ZU+H&@W6E>(_$6H7$D+1:I<QRPJC$LH6,*=V0,'([9HYK
M?=^J)<;_ '_HSF] T*PM/&GB7PH(%DT*6V@NUL)/FCC9BVX*.P)4'%-^%7AS
M1[:UU#48-.MX[R'5+N".94PRQA\!0?3%=-9Z#=6_C_4]<>2$VUW9PVZ("=X9
M"Q)(QC'([U2\-Z!KGAS6KVVBDL;C0KJZENP[%UN(F?DIC&TC=WSTH4[K?I_7
MX XZ[=?T_P SK:***P-0HHHH **** "BBB@ IDTT=O$TL\BQQJ,LSG 'XUA:
M]XMM-'W0PXN+O_GF#PG^\?Z=?I7GVIZQ>ZO-YE[,7 /RH.%7Z"J46SGJ8B,-
M%JSM=4\>VEN6CTV(W3CCS&^5!_4_I7*7_BG5]0)$EVT2'_EG#\@_3D_B:QZG
M@L[BY_U,3,/[W0?G5I)'#*M4GU(223D\FDK8AT!SS/,%]D&?UJY'HMFGWE9_
M]YO\*=R%3DSFZ*ZI=.M%Z6Z?B,T[[!:?\^\?_?(HN5[)G)T5U+:99OU@7\,C
M^55Y-"MF^XSH?8Y%%Q>RD8,4TD$@DAD:-QT9&((_&M[3_&NJV1"S2+=QCM*.
M?^^AS^>:I3:%.G,+K(/3H:SY89(&VS(R'W%&C$G.&VAZ9I7C'3-2*QRM]DF/
M\$IX/T;I^>*WZ\0K;T7Q5?Z.5CW?:+8?\L9#T_W3V_E4./8ZJ>*Z3/5**S](
MUNSUJW\RTD^=?OQ-PR?4?UK0J#N335T%%%% PHHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIKND4;22,J(H+,S'
M '4DT -N+B&TMI+BZE2&&)2\DCMA54<DD]A7SE\3?C'<^(FETCPS+):Z5RLL
MX^62Y_JJ>W4]_2JWQ8^*<WBN\DTC193'HL+<LN0;MA_$?]D'H/Q/;'F->C0P
M]O>F<=6K?2(4](V?IT]:?%#NY;IZ>M6 ,<"N^QS$:0JO7D^IJ6BBF(*6BEH
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M$UM=6LFR6!QW4X(Z<8((JN9*WJ*S=_0P_B-"]A:Z=XIM5)GT*Y$LH4<O;O\
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M^\>P_$UY!>WDM_>RW5PVZ25MQ]O;Z545<Y<15Y(\JW9!6EI>F_:6\Z8?N5/
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M444 %%%% !1110 4444 %%%% !1110 4444 %%%0W=RMG9S7$GW8D+'WQVH
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MX7C_ 'AR/TS7=5SS5F:Q=T%%%%04%%%% !1110 4444 %%%% !1110 4444
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M;_:-QX?\'W5HDT<<QL]SLF]@H."H'4C\Z<*[6F_S%*DGJ?/M+7;?%VQM=/\
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M "BBB@ HHHH **** "BBB@ KY*^+D_VCXKZX_7$J)US]V-5_I7UK7Q_\2_\
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MK6C+EJ)D5(\T6CY3K0C;=&K>HK/JU:/E2GIR*]H\TLT44M, HHHI >@_!?\
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MV7V_7+:(C**V]_H.?_K?C7IU3,UPD='(****@[@HHHH **** "BBB@ HHHH
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M=&)&YFZ/QVJ>H(64W,X$QD((RA'W.*GH **** "BBB@ HHHH **** "BBB@
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M:DA6'JD1ZO[GV_G6EH?A**S*W&H[99QRL?54_P 372U#EV.NCA_M3     8
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M'ZU]=T$!E*L 01@@]ZWCBIK?4RE0B]CXFHKZA\2_"3POXB5Y$M!IMVV3Y]F
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MH *GM+26]N%A@7+'J>P'J:9!!)<SI#"NYW. *[?3-.CTVU$:?,[<N_\ >/\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 7Z***
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M(8N"Y'4U?+6&EZ3=16]X+B6X7;\OY=OJ: .>HHHH **** "BBB@":S.+R/\
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MI5G]YHR17=E=&ZL7;:Z$]* .<HK4U^S2UU - ,13*)% ' ]?\^]9= !1110
M4444 3V0W7D8]\UMUDZ8FZY+?W5K6JD)FUI(Q9GW<G^57:KV";+&,>HS^=6*
M3&%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &33)!"\LK;
M4098UB6?B&VEU!U8SJLQ 3?C:O;MTS6M?VOVRPEMPVTNN ?0US%KX;OC>*)U
M5(E8$ON!R/:@#KZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** .#^)?A;0I?!NOZM)I%FVH
MBT=Q=&$>9N"X!W=<C%9WPH\+Z#)\.]'U>72+-]0"._VDQ#S-P=@#NZ]!73_$
MC_DFGB#_ *\9/Y5F_";_ ))#I'_7&7_T8];<S5"6O5?DS)I.K'Y_H<CX2\;0
M:/\ "C7=>T;0+2Q-G?!#;1RNR2$[ 6)))SAOTJ2X^+7C&/0H/$*>#4&AE%,D
M[S'<V>"0 <JN>A(/:N/T+_DWCQ9_V$D_G%7HU]_R;6O_ &!(_P#T%:Z*BC&\
MFKZI?@A1NVHW[_F9UY\6?%%QI;>(- \'F7P]$,O<W,N'8#AB #P <C.".*ZF
MY^)VD6OPX@\7.DABN!MBM@1O:7)!3/L0>?09K&\/_P#)MI_[!%Q_)Z\\O=&N
M]1_9TT*\M(Y)8]/O9I9UC^\$+N"WX<?3-2Z<&W&UK-+\Q1E)QC/>Z>GRN=U=
M?$CQOHEA%K?B+P;%#HKLN\PW&9HE8\%AGW[@>^*[R^UFYN/![:OX6MUU*>:!
M9K2)CM$N[&,\C'!KQ*^/P_E\/+-<>//%%ZLX56L!<[Y#DC(*,F./?CCC->X>
M%=+M=%\*Z?8:>UP]M#"/+-R,28//S# P>>F*BK&*CM9W\PIR;DM>AXO\*O$/
MC$>)M4ACTK^T(YK]%U"22?\ X\LNV[:"W09;@9^[7<^)/B9J$?BJ3PUX(T3^
MVM3@7-PS/MCB]NWKR20,\<US7PRUS3_#/Q!\5Z-KD_V2]OM2 MD=#B4EWP 0
M.^Y<9ZYIOAW6;3X;_%?Q-;>+"UK#JTOGVMXR$HR[V8#([?/CV*\UI)*4D[=+
MKST7Y"3<8O7K;TU>IU/A?XEWUSXH7PSXTT4Z+JTJ[H"K[HYO8=?0X()!P1UJ
M3XS^);OPYX#;^S9&BN;Z9;994."@()8@]C@8_&N2U?5K;XC_ !D\.CPJ7N+7
M1F$US>JA5<!PQ'../EP/4M7:_%OPI<^+/ \D&G*7O;247,,8/^L(!!7ZX)Q[
MXK*48IPE)6ONO*_ZFD6[R2=^WK8C\*_";PQH^@00ZAI5KJ-X\8:XN+J,2%G(
MYVY^Z/3%3^%_AM9^$/%E]JNC7T\-C=1A?[- S&I]<G).#T],GFLCPS\:?#<^
MBQ1^([I]+U.W39<PS0N<LO!((!Z^AYJWX7^)=UXOUS55T;19)=&LX2T5\Y*&
M20#A=N.<]AU Z]:<_;)R;_X%OZV(AR.,5_P]RG=>/_&VHZA??\(IX+:6QL9#
M&\E\_E22$==JDJ>G..>WTJ[I_P 6+"\^&UYXIELI(I+%O)GL]W/FD@ !L=#N
M'...?2O.M(U^'Q;I5_JWCCQ_?Z7)%*X72K&<0':!D +@[O3H>G)I_P .KS3+
M+X/>)I-;TZZU'3VO0LT,(!< JN&)R,8.#GM5NDE!IK56_'SV_P @4[S5MFW_
M %W.QL/B)XT2/3]2U?P<'T?4&7RY+"0RS(K<JQ0$D\>P_I7.^(M7U#1_VB)I
M]%TM]4OI;%8H;8-LR2@Y)/0  FL>ZU.V\$QZ;>_#?QK<:G%<3JG]B3GS#@\X
M*_P^GW0>>#786Q+?M/2EAM)TP$CT^057*E*Z6EI?E_6I/,W&S?;\_P"M#2\*
M_$K5[KQH/"WC/0UTK49D+P&)\JV 3CJ>P/(/;%4OVA?^1"LL_P#003_T!Z3Q
M3_R<=X3_ .O-_P"4M+^T+_R(5E_V$$_] >LXI.=.25K_ .=C;5.<6^GYHG@F
M^#WV>/S!X=W[!NS&F<X^E9FM6]O:?M$^$K>QB2*VCT_;%'&,*JA9< #TKMK;
MX;^#6M8F;PY8$E%)/E>U<?XD4+^TIX751@"R( ]/EFJH23J63?7\F9V?LF_)
M?FC3UWXFZI+XHN/#W@/0O[:O+3/VF:1]L<9'5>H^F21SQS5CPE\2;O4O$C^&
M?%FD'1=;V;HDW;HYN,\?AD]2#@\UR/@S7;+X;^/_ !-I7BYC9?;[CS[>[="4
MD7<Q'('0ANO3((-22:G!\1/CIH]YX9#S6&C1[KB]"%5."QQSV).!ZY/:E&G%
MV5M&KW^7]*P2DUS.^J>B^?Z[G:^!?'<_B2[URPUFUAL;W1Y]DB1L2I3D;N?=
M3^E4/A[\5%\;^)-3TM[6.W6 &2U96),L8;!)SWP5/XFN$^+'V_P;\0+N_P!'
M4A/$FGM;N!_?.%;'OPI_$U-XRT.Z^&6D^%->T>-1<V=L]E=D=&=U+9/_  )G
M_(4*$'%2[Z+UUO\ C;[QRE)2<5TU^6GZ7^X]%\(>.+KQ7XNUVQ@LXDTO2Y/*
M2Y!):5\X^F/E8_E7:UP7P:T$Z+\.K668?Z3J3&\E)ZG=]W_QT _C7>UC5BHR
MY5T_IETVY+F?4****R+"BBB@ HHHH \_^+NG?:/#UK?(N6M9MK'T5QC^87\Z
M\>KZ1UW3%UG0;S3WQ^_B*J3V;JI_ @&OG"6-X9GBE4HZ,593U!'45ZF#G>'+
MV.'$1M*X].5IU1QG!Q4E=IS!2T44 %+110,[SPNB/X N@$,B+JD37JHNYOLX
MV$\#J.#^M2^(=,T;Q!KD^HOXMLXQ+@)&8R=B@8 ZUQNDZS?Z'=_:=,N&AD(P
MV "&'H0>#6__ ,+)UP]5L_\ P'%<DJ<U-RC_ %^!NIQ<;,/^$2T/_H<++_OR
M?_BJO:/HFCZ/K-K?Q>+K-F@D#%?*(W#N/O=QD52_X61KG]RR_P# <4?\+(US
M^Y9?^ XH<:S5G^G^0TZ:U_K\S=UQ8KKPCJ+1Q2/;7.K"33U"D-)NQNV C.#\
M^.*Q[CPOX<>3$/B"73W'WK?4+8K(O\JP]3\3:MJ][%=7MXYD@;=#L^41GKD
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ME0 WQ).CWZ01'(@C"$^_^<5CTI)9B6)))R2>])0 4444 %%%.1#(ZJO5C@4
M:>F1[;=G/5S^@J^BEW51U8X%1QH(XU1>BC%7],B\R[#'H@S^-7LB3910B*HZ
M*,"EHHJ"@HHHH **** "BBB@ HHHH ***IZOJEMHFCW6IWQ86]K&99"BY.T=
M<"@"Y17FZ_'CP4S &>\4'N;4\5U3>--#/A&7Q+;W@N=,B7<\D*DL.0,;3@@\
M]#S5RISBKM$J46[)F]15+1M6MM=T:UU2P+FVND\R,NN#CW%7:EIIV8TTU=!1
M7.^'O&VG>)=<U?2["&ZCGTB7RIVF10K'<P^4AB2/E/4"NBH::W'<***S?$&O
M67AG0Y]6U0R"U@V[S&NX\L ./J:0&E17G$?QW\$O(%:YO(P3RS6K8'Y9-=[I
MNIV6L:=#?Z9<QW5K,-T<L9R&_P ^E7*G.*NT2I1;LF6J***@H**** "BBB@
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M%% !1110 4444 %%%% !6%XW_P"1!U[_ +!\_P#Z :W:PO&__(@Z]_V#Y_\
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MNPJ[0$ )!Q]58?A7)S>.O$FH_"+5O$^I1V4D;7R1V4$UJKH$WX)(/WN3C/\
MLUD?%72]3\/^/+N#0@1;^+84B= /O2;UW >Y./P<UV'Q0T:'P]\!QI-M]RT^
MSQYQ]X[QEOQ.3^-3:%E.WQ-+TUU+]Y-P[7?X:?UY')?%YO$-YX,T"^FEM4T.
M2"W98(D"L+AHR2< <*!G S^%=3K>M?$7PI\/_P"V-0N-.EFM[E-Z01;E-NP
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MR;GYD;K[>U5L(FMK=;:$(O)ZL?4U+114%!1110 4444 %%%% !1110 4444
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M'^"K3PO:^8VVXU"0?O)\?=']U?0?S_0=/117E2DY.[.^,5%604445(PHHHH
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M6,MS@@;4_O&MBWM8[9<1CD]6/4T7$165BML-[_-(>_I5NBBI*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBD==\;*21N!&5."/H: .#M-&\4^"9+J+PU;6>
MM:-+.\\=E+-Y$\!8Y958@JRYR1G%:-MXM@U[0=;B2WN=-U.PMW%S9W VR0DH
M2K C@@XX(-4[&?Q=X4B;3I]*F\36B,?LU]#=(L^TG(659",D9QN!.:ET+P]J
M=_K&LZ[XCMX[";5+9;..RBE\PPQ 'EV'!8D]N!ZUK)7B[]M^I,7:2?F:7@2>
M6Y^'NAS7$KRRR6,;/([%F8[>I)ZFO/I]2U0_ ..ZMKV?[>=0V),TK;O^/LJ
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MEX=UR]^QZ1K%I>7&TOY44F6P.IK;IJQHIRJ*#Z@4ZL';H:J_4****0PHHHH
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M'@]U(_&G^$?#M]I$VJZCK$UN^H:M<">:.U!\J+"[0JYY/'4G&:GFO#5_U?\
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M<@8 VCUJHP<I6)<DE<]1HKGPSQ^(-:9=:$^VTC*Z>/O6IPWS]?XOIVJO\/\
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M#OL(I9+Z7:8G%NTD2+N 8LPX'!XYZD5T&D^(K#5])DU&%I8;>$D2/=0M!MP
M2<.!Q@]>E'*^7FZ!S+FMU(] \*:5X;,[Z;#(9[D@S7%Q,TLLF.@+L2<#TZ5L
MUR ^)WA[B4_V@M@6VC46L)1;'G&?,VXQ[]*V]9\1Z7H.EQZCJ=TL5I+(D:S
M;ERWW3D=O?I3DIW]X2Y>AJ45REI\2/#]UJ-O:%KRV%V^RVN+JSDBAG8] KL
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MX[8X"X YXI1E%*_D_P!0DF]%Y?H4?AO_ ,S1_P!C!=?^RUVM9>B:!:Z#]O\
ML<DS_;[R2\E\U@<.^,@8 XX[Y^M:E9R:;7HOR+6[]7^84445(PHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ K,E\-:+/K:ZQ/I=I)J*XVW3Q N,< Y]1ZUIT4TVM@W"BBB
MD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% $-K96MC&Z65M#;H[F1EBC"!F
M)R6..I/<U-110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>lgnd-20241231_g4.jpg
<TEXT>
begin 644 lgnd-20241231_g4.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" <##/@# 2(  A$! Q$!_\0
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MZI_\DT?\.N/V8O\ HF?_ )7]4_\ DFOJJB@#Y5_X=<?LQ?\ 1,__ "OZI_\
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MG_Y7]4_^2:^JJ* /E7_AUQ^S%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]4_\
MDFOJJB@#Y5_X=<?LQ?\ 1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)KZ
MJHH ^5?^'7'[,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?\
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M^J?_ "31_P .N/V8O^B9_P#E?U3_ .2:^JJ* /E7_AUQ^S%_T3/_ ,K^J?\
MR31_PZX_9B_Z)G_Y7]4_^2:^JJ* /E7_ (=<?LQ?]$S_ /*_JG_R31_PZX_9
MB_Z)G_Y7]4_^2:^JJ* /E7_AUQ^S%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]
M4_\ DFOJJB@#Y5_X=<?LQ?\ 1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\
MY)KZJHH ^5?^'7'[,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^
M5?\ AUQ^S%_T3/\ \K^J?_)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?^'7'[,7
M_1,__*_JG_R31_PZX_9B_P"B9_\ E?U3_P"2:^JJ* /E7_AUQ^S%_P!$S_\
M*_JG_P DT?\ #KC]F+_HF?\ Y7]4_P#DFOJJB@#Y5_X=<?LQ?]$S_P#*_JG_
M ,DT?\.N/V8O^B9_^5_5/_DFOJJB@#Y5_P"'7'[,7_1,_P#ROZI_\DT?\.N/
MV8O^B9_^5_5/_DFOJJB@#Y5_X=<?LQ?]$S_\K^J?_)-'_#KC]F+_ *)G_P"5
M_5/_ ))KZJHH ^5?^'7'[,7_ $3/_P K^J?_ "31_P .N/V8O^B9_P#E?U3_
M .2:^JJ* /E7_AUQ^S%_T3/_ ,K^J?\ R31_PZX_9B_Z)G_Y7]4_^2:^JJ*
M/E7_ (=<?LQ?]$S_ /*_JG_R31_PZX_9B_Z)G_Y7]4_^2:^JJ* /E7_AUQ^S
M%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]4_\ DFOJJB@#Y5_X=<?LQ?\ 1,__
M "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)KZJHH ^5?^'7'[,7_1,_\ ROZI
M_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?\ AUQ^S%_T3/\ \K^J?_)-'_#K
MC]F+_HF?_E?U3_Y)KZJHH ^5?^'7'[,7_1,__*_JG_R31_PZX_9B_P"B9_\
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MUQ^S%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]4_\ DFOJJB@#Y5_X=<?LQ?\
M1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)KZJHH ^5?^'7'[,7_1,_\
MROZI_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?\ AUQ^S%_T3/\ \K^J?_)-
M'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?^'7'[,7_1,__*_JG_R31_PZX_9B_P"B
M9_\ E?U3_P"2:^JJ* /E7_AUQ^S%_P!$S_\ *_JG_P DT?\ #KC]F+_HF?\
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M31_PZX_9B_Z)G_Y7]4_^2:^JJ* /E7_AUQ^S%_T3/_ROZI_\DT?\.N/V8O\
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M,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?\ AUQ^S%_T3/\
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M1_PZX_9B_P"B9_\ E?U3_P"2:^JJ* /E7_AUQ^S%_P!$S_\ *_JG_P DT?\
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MJB@#Y5_X=<?LQ?\ 1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)KZJHH
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MZI_\DT?\.N/V8O\ HF?_ )7]4_\ DFOJJB@#Y5_X=<?LQ?\ 1,__ "OZI_\
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MG_Y7]4_^2:^JJ* /E7_AUQ^S%_T3/_ROZI_\DT?\.N/V8O\ HF?_ )7]4_\
MDFOJJB@#Y5_X=<?LQ?\ 1,__ "OZI_\ )-'_  ZX_9B_Z)G_ .5_5/\ Y)KZ
MJHH ^5?^'7'[,7_1,_\ ROZI_P#)-'_#KC]F+_HF?_E?U3_Y)KZJHH ^5?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!\J_\ !4?_ ),3^)O_ '#/_3I:44?\%1_^3$_B
M;_W#/_3I:44 '_!+C_DQ/X9?]Q/_ -.EW7U57RK_ ,$N/^3$_AE_W$__ $Z7
M=?55 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9/4GC.#CTCP%XRM/B)X,T?Q-I]K>V=AJMLMW;Q:C 8)_+890LAY7(P<'G!%
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MG&9;F^OIEAAA0?Q,[$ #ZU<L[R'4+."ZMI%FMYXUECD7HRL,@CZ@T 34444
M%%%>(^+?VPOAUX*^/>D?![4[G4%\::HT"VT4=F6@)F!*9DS@=.?2@#VZBBB@
M HKY+^(?_!3[X'?"_P =:[X2UR_UN/6-%O)+&[6#2VD02HQ5@K9Y&1UKGO\
MA[Q^SS_T$O$ _P"X._\ C0!]JT5\O>#/^"F'[.?C;6(],MOB%%IMU*0L;:Q8
MW%G"Q)Q_K9(Q&O;[S#K]:^G;>XBNH(YX)$FAD4.DD;!E92,@@CJ".] $E%%%
M !116;XB\2:3X/T.\UG7-2M-'TFSC,MS?7TRPPPH/XF=B !]: -*BH;.\AU"
MS@NK:19K>>-98Y%Z,K#((^H-34 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!\J_P#!4?\ Y,3^)O\ W#/_ $Z6E%'_  5'_P"3$_B;
M_P!PS_TZ6E% !_P2X_Y,3^&7_<3_ /3I=U]55\J_\$N/^3$_AE_W$_\ TZ7=
M?55 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRP7=!YLL7)Q_K40ICWW5\1_MH^+/%?[9G[;VC_LX^']7FTSP9I-Q'%J7D/\
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MQSJ82V!N4,<#(Q]?_P#!1SX<_&;XO?!NS\'?"&S6Z74;ESKNS4(K.62V5,K
M&D905D8_,,C[@!^5C0!V_BW]O#]G_P $:J^FZK\5-!^V1DJZ6,CWJHP."K-
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M ()3_ KQ)\-M2TWPIX7D\+>(XK5SIVKVU_=3NLP&5\Q))&6120 01G!.TJ:
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M?]K/X?6GQF^/-W?_ !"U&^3^RM&L;R\EB@M[.T/V<.WEE"SEXY.^T\LP9V)
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M75-,NHK[3;[P]<W-M=0,&CFB>V9D=2.JE2"#Z&O@+_@A]_R(/Q3_ .PG9?\
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MC_L7(6X([ K7Z@_$#QKIWPW\#>(/%>KR>5I>BV$^H7+9P?+B0N0/<XP!W)%
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M9M\6/^P,_P#Z&E>%?\$8?^34-;_[&V\_]);2@#Z9^'O[)7P?^%'BFV\2>$?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y5_P""
MH_\ R8G\3?\ N&?^G2THH_X*C_\ )B?Q-_[AG_ITM** #_@EQ_R8G\,O^XG_
M .G2[KZJKY5_X)<?\F)_#+_N)_\ ITNZ^JJ "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7QS_ ,$3-(N;;X$^.]1D21;:Z\1"*(L,*QCMHRQ'_?P#\/:O.?BI_P -=?\
M!0>.R\&7GPWD^$GP_:Y2:^.K126H?:V4:8S 2R[",A(XP"<$] 1^BW[//P-T
M/]G+X1:!X"T M-::;$3-=R+B2[N'):69AS@LQ) R=HPHX H _.__ ();0HW[
M:OQ_E*@R*MZH;N =2R1^@_*OU7K\ZO\ @GG\ ?B'\+?VJ?C3XB\5^$]0T+1-
M8^U?8+ZZ4".XW7QD7;@GJO/TK]%: /RK_P""&/\ S6S_ +@G_M_7ZJ5^=7_!
M(?X _$/X&_\ "V/^$]\)ZAX7_M3^R?L7VY0OG^5]L\S;@G[OF)G_ 'A7Z*T
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M[!?72@1W&Z^,B[<$]5Y^E?HK0!%<SBUMY9F5W6-"Y6-2S' S@#N?:O'OV?\
M]KOX9?M.7VNVGP_UF?4YM%CADNUN;.6V(64N%VB0 M@QG.!@97UKV:ORY^*'
M['_QI_9!_:"U'XN_LY6*>(_#NI2.UUX95C))''(P:2W>$E3+#O *%&WKQ_=W
M$ _4:OR-_P"";*I=_P#!1GXS7/AQU7PT(=;9-A!1K=M3B\@ CC/W2#Z UVGC
MS]IK]LO]H#0;OP-X4^ ^J?#NYU!#:7FM75K/ 5C8%7\J>Y$<<8(S\PW,!]T@
MD&OJ#]@K]C6V_9"^&=W::A=6^J>-=<D2XUB_M@?*7:"([>(D E$W.=Q +,['
M &  #Z>HHHH *_(C_@D;"B_M>?%TA%!32[M5XZ#^T(N!^0_*OUWK\T?^":?[
M.OQ)^$G[3'Q.U_QAX/U+P_HVI6%Q%:7EXBA)F:]C<!<$]5!/X4 ?I=7Y%?\
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M_@GO^S[\1?A?^UU\8O$WBOPCJ&AZ#JT5\MC?W2 1W!>_21=N#W0%OI0!W/\
MP5T^")^)7[-:^+K&W\W6?!-V+\,HRYLY<1W"CV!\J0^T1KP/]K7]L2?XB_\
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M_?L,^*_A/XTUSXQ?%^\6^^)>M";RK3SEG-IYS!IYI9%RK3.<KA#M52PR=V%
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M-^U5^SOH_P"U!\%];\$ZGY<%W*OVG2[]ER;.\0'RI?IR58#JKL.]?(/_  3
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !115&WUS
M3KK5+G3(=0M9M1M55I[..96FB# %2Z Y4$$$9'.10!>HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /E7_@J/_P F)_$W_N&?^G2THH_X*C_\F)_$W_N&
M?^G2THH /^"7'_)B?PR_[B?_ *=+NOJJOE7_ ()<?\F)_#+_ +B?_ITNZ^JJ
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN_X*EZKX?^(MKX'_ &AOAS<_"S4;LKY.J>7-%;IN8A6EBE&Y8B1CS59UR#D
M D 'Z%454O\ 5K+2]*N=3O+N&VTZVA:YFNI7"QQQ*I9G+= H4$Y]*_//5/\
M@IS\1?BSXNU72OV>O@M>>.=(TV1HY-<OHYFCDYX8HFT1!@"5#R;F!'R@@B@#
M]%Z*_.?PM_P5,\6?#GX@:?X3_:&^$UU\//MS#;JUJLJQQ(6V^889 3)&#]YX
MW)&#A2>*_12">.ZACFAD66&10Z21L&5E(R"".H(H DK\_P#]L+]L[XD_!?\
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M'!.5H_\ P51\>_"KQM9:'^T'\&KSP397KD1ZE8PSQ%$! :18I<B= 3R8WX[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#Y5_X*C_\ )B?Q-_[AG_ITM**/^"H__)B?Q-_[AG_ITM** #_@
MEQ_R8G\,O^XG_P"G2[KZJKY5_P""7'_)B?PR_P"XG_Z=+NOJJ@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,URQ9FLD*A0&/55D,R#J $"C@8 !\Y?\$@?^2_?'G_MG_P"E4U=K_P %N/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!\J_\ !4?_ ),3^)O_ '#/_3I:44?\%1_^3$_B;_W#/_3I
M:44 '_!+C_DQ/X9?]Q/_ -.EW7U57RK_ ,$N/^3$_AE_W$__ $Z7=?55 !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(K[\HH R=7\*:-KWABZ\.:AI=K=:#=6ILIM-DB'D/ 5VF/9TV[>,5\$^(/\
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M;#YT$4CDES"%EB>)3D_('*C/  &*U_AU_P $L?!NF^*M/\1_$_QMXC^,>I6
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M110!6T[3K31]/MK"PMH;*QM8EA@MK>,)'%&H 5%4<!0   . !5FBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /E7_@J/_P F)_$W_N&?^G2THH_X*C_\F)_$W_N&?^G2THH /^"7'_)B?PR_
M[B?_ *=+NOJJOE7_ ()<?\F)_#+_ +B?_ITNZ^JJ "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /E7_ (*C
M_P#)B?Q-_P"X9_Z=+2BC_@J/_P F)_$W_N&?^G2THH /^"7'_)B?PR_[B?\
MZ=+NOJJOE7_@EQ_R8G\,O^XG_P"G2[KZJH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWC#(J;0J%>N<+V/_  6DTN_M_P!GWX;/)+YT%KKHM[B3L\QM)-I_$))7V_\
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M0X#'AMKL,^C&@#ZW_;&\06/BS]AWXCZYIDOVC3=3\*O>VLV,;XI(U=&QVRK
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M?_["?[:6O_'S6K7P%J7PFU+P78Z-X:6YCUVZO9)H[LPM;PA%1K:, N)"_#G
M0C!Z@ ^TJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ^5?^"H__ "8G\3?^X9_Z=+2BC_@J/_R8G\3?
M^X9_Z=+2B@ _X)<?\F)_#+_N)_\ ITNZ^JJ^5?\ @EQ_R8G\,O\ N)_^G2[K
MZJH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ K\C?^"MVB^)1^U;\._$&A^'-2UQ-+T"TGS:6DLL9DCOKE
M]C,BG';WP:_7*B@#\JO^'LGQO_Z('_Y OO\ XBLSQU^T-^V9^UYH\_@GPO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#Y5_P""H_\ R8G\3?\ N&?^G2THH_X*C_\
M)B?Q-_[AG_ITM** #_@EQ_R8G\,O^XG_ .G2[KZJKY5_X)<?\F)_#+_N)_\
MITNZ^JJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ^5?\ @J/_ ,F)_$W_ +AG_ITM**/^"H__
M "8G\3?^X9_Z=+2B@ _X)<?\F)_#+_N)_P#ITNZ^JJ^5?^"7'_)B?PR_[B?_
M *=+NOJJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%:3\(?VAM6_X2GPOKDD<6G^)IY?-:(2-LCN$G(#/%O\ ED67YD^\" ,/^H5
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M /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\
M_P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_
M  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\
M!C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &
M-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8W
MW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??
M_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\
MAT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'
M1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='
M_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\
M.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY
M4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3
MXW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C
M?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-_
M_0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]
M#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-
M/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_
M#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/
M_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__
M /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\
M\&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P
M8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C
M??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]
M_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_
M ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\
MR'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(
M= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT
M ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!
M^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[
M4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M3
M17XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%
M?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^
M*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK
M?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_
MPY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#
ME3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5
M/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^
M-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW
M_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_
M -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\
MT-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0
MT_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3
M\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P
M_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_
M /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\
M_P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_
M  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\
M!C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &
M-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8W
MW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??
M_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\
MAT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'
M1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='
M_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\
M.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY
M4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3
MXW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C
M?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-_
M_0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]
M#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-
M/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_
M#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/
M_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__
M /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\
M\&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P
M8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C
M??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]
M_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_
M ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\
MR'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(
M= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT
M ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!
M^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[
M4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M3
M17XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%
M?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^
M*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK
M?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_
MPY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#
ME3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5
M/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^
M-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW
M_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_
M -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\
MT-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0
MT_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3
M\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P
M_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_
M /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\
M_P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_
M  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\
M!C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &
M-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8W
MW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??
M_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\
MAT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'
M1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='
M_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\
M.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY
M4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3
MXW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C
M?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-_
M_0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]
M#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-
M/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_
M#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/
M_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__
M /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\
M\&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P
M8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C
M??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]
M_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_
M ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\
MR'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(
M= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT
M ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!
M^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[
M4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M3
M17XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%
M?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^
M*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK
M?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_
MPY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#
ME3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5
M/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^
M-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW
M_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_
M -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\
MT-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0
MT_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3
M\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P
M_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_
M /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\
M_P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_
M  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\
M!C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &
M-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8W
MW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??
M_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\
MAT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'
M1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='
M_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\
M.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY
M4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3
MXW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C
M?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-_
M_0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]
M#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-
M/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_
M#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/
M_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__
M /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\
M\&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P
M8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C
M??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]
M_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_
M ,AT ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\
MR'0!^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(
M= '[4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT
M ?M317XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!
M^U-%?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[
M4T5^*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M3
M17XK?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%
M?BM_PY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^
M*W_#E3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK
M?\.5/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_
MPY4^-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#
ME3XW_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5
M/C?_ -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^
M-_\ T-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW
M_P#0T_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_
M -#3\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\
MT-/P_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0
MT_#_ /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3
M\/\ _P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P
M_P#_  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_
M /\ !C??_(='_#E3XW_]#3\/_P#P8WW_ ,AT ?M317XK?\.5/C?_ -#3\/\
M_P &-]_\AT?\.5/C?_T-/P__ /!C??\ R'0!^U-%?BM_PY4^-_\ T-/P_P#_
M  8WW_R'1_PY4^-__0T_#_\ \&-]_P#(= '[4T5^*W_#E3XW_P#0T_#_ /\
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M "=-XI_[$RZ_]+K&OVIK\5O^"*G_ "=-XI_[$RZ_]+K&OVIH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q6_:6_P"4R6D?]CGX
M3_\ 1.G5^U-?BM^TM_RF2TC_ +'/PG_Z)TZOVIH **** "BBB@#Y5_X*C_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ6_:6_Y3):1_V.?A/_T3IU?M37XK?M+?\IDM(_['/PG_ .B=.K]J: "BBB@
MHHHH ^5?^"H__)B?Q-_[AG_ITM**/^"H_P#R8G\3?^X9_P"G2THH /\ @EQ_
MR8G\,O\ N)_^G2[KZJKY5_X)<?\ )B?PR_[B?_ITNZ^JJ "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q6_X(J?\
M)TWBG_L3+K_TNL:_:FOQ6_X(J?\ )TWBG_L3+K_TNL:_:F@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH _%;]I;_E,EI'_8Y^$_\ T3IU?M37XK?M+?\
M*9+2/^QS\)_^B=.K]J: "BBB@ HHHH ^5?\ @J/_ ,F)_$W_ +AG_ITM**/^
M"H__ "8G\3?^X9_Z=+2B@ _X)<?\F)_#+_N)_P#ITNZ^JJ^5?^"7'_)B?PR_
M[B?_ *=+NOJJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@#\5O^"*G_)TWBG_ +$RZ_\ 2ZQK]J:_%;_@BI_R=-XI
M_P"Q,NO_ $NL:_:F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/_R8G\3?^X9_Z=+2B@ _X)<?\F)_#+_N)_\ ITNZ^JJ^5?\ @EQ_R8G\,O\
MN)_^G2[KZJH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _%;_ ((J?\G3>*?^Q,NO_2ZQK]J:_%;_ ((J?\G3>*?^
MQ,NO_2ZQK]J: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHK(\4>+M%\$Z/-JNO:I:Z1IT7WKB[E"+GT&>I/8#DT;%PA.I)0@KM[);FO7,
M^/OB5X8^&&CMJGBC6;72+3G9YS9>4C^&-!EG/LH)KY#^-'_!1!5\_3/AM8;C
MRO\ ;FI1\?6*$_S?_OFOC'Q7XPUOQSK$NJ^(-4NM7U"7[UQ=2%VQZ#LH'8#
M%<-3%1CI#4_8,A\-\=CK5LR?L8=OMOY;1^=WY'U=\:/^"A6L:YY^F?#VR.B6
M1RIU:]57NG'JB<K']3N/^Z:^1=8UF_\ $&I3ZAJE[<:C?SMOENKJ5I))#ZLS
M$DUJ>"? 'B+XCZTFD^&M'NM8OFZQVZ9"#^\['Y47_:8@5]K?!?\ X)XV&G>1
MJ?Q&OAJ5QPPT73W*PK[2R\,WT7:,C[Q%<5JN(?\ 5C]:J8CAS@>AR1M&36R]
MZI+UZ_>U'L?'7PU^$/B[XN:K]@\+:+<:BRD"6XQL@@]Y)#\J_3.3V!K[C^"_
M_!/_ ,->$O(U+QS<+XIU1<,+"+*6,1]^C2_\"POJIKZDT'P_IGA;2H-,T?3[
M;2]/@&V.UM(ECC7Z "M"N^GA80UEJS\7S[Q"S+-+T<'^YI^3]Y^LNGRMZL@L
M;&VTNSAM+.WBM+6%0D4$"!$11T"J. /85/1178?E;;D[L****!!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'XK?M+?\IDM(_['/PG_P"B=.K]J:_%;]I;
M_E,EI'_8Y^$__1.G5^U- !1110 4444 ?*O_  5'_P"3$_B;_P!PS_TZ6E%'
M_!4?_DQ/XF_]PS_TZ6E% !_P2X_Y,3^&7_<3_P#3I=U]55\J_P#!+C_DQ/X9
M?]Q/_P!.EW7U50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!^*W_!%3_DZ;Q3_P!B9=?^EUC7[4U^*W_!%3_DZ;Q3
M_P!B9=?^EUC7[4T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'XK?M+?\IDM(_['/PG
M_P"B=.K]J:_%;]I;_E,EI'_8Y^$__1.G5^U- !1110 4444 ?*O_  5'_P"3
M$_B;_P!PS_TZ6E%'_!4?_DQ/XF_]PS_TZ6E% !_P2X_Y,3^&7_<3_P#3I=U]
M55\J_P#!+C_DQ/X9?]Q/_P!.EW7U50 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!^*W_!%3_DZ;Q3_P!B9=?^EUC7
M[4U^*W_!%3_DZ;Q3_P!B9=?^EUC7[4T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% 'XK?M+?\IDM(_P"QS\)_^B=.K]J:_%;]I;_E,EI'_8Y^
M$_\ T3IU?M30 4444 %%%% 'RK_P5'_Y,3^)O_<,_P#3I:44?\%1_P#DQ/XF
M_P#<,_\ 3I:44 '_  2X_P"3$_AE_P!Q/_TZ7=?55?*O_!+C_DQ/X9?]Q/\
M].EW7U50 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110!^*W_!%3_DZ;Q3_V)EU_Z76-?M37XK?\$5/^3IO%/_8F77_I
M=8U^U- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%</\ %#XU>#O@_IOVOQ1K,-E(R[H;-/WE
MS/\ [D8Y(SQDX [D5\,?&C]OKQ7XV\_3O!L3>$M';*_:@P:^E7_?'$7_  #D
M?WJPJ5H4]WJ?8Y'PIFF?-2P]/EI_SRTC\N_ROYV/M#XO?M'>!O@K;.-=U59M
M4V[H])L<2W3^F5SA ?5R!]:^$/C1^V]XX^)_GZ?H\A\(Z ^5^SV,A^TRK_TT
MFX/([+M'8YKYYNKJ:]N);BXEDGGE8O)+*Q9G8]22>2:]"^$O[/\ XV^-%X$\
M.:0[6*MMEU2ZS%:Q>N7(^8C^ZH)]J\V=>I5?+$_?LKX-R3AJE]<QTE.4=Y3L
MHKT6WI>[['G+,68DG)/))KU_X-_LL^._C0\5SIVG_P!F:&Q^;6-1!CA(_P"F
M8QND/^Z,9ZD5]I_!?]A;P7\.?(U'Q&%\8:ZF&!NH\6<+?[$7.[ZOGU %?2D<
M:Q1JB*$11A548  Z "M:>$>\SYG/?$RG3O0R>',_YY+3Y1W?J[>C/"?@O^QO
MX$^$?D7TUM_PDWB"/#?VCJ48*QMZQ1<JGU.YA_>KWBBBO2C&,%:*/P?'9CB\
MSK.OC*CG+N_T6R7DM HHHJCS@HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@#\5OVEO^4R6D?]CGX3_]$Z=7[4U^
M*W[2W_*9+2/^QS\)_P#HG3J_:F@ HHHH **** /E7_@J/_R8G\3?^X9_Z=+2
MBC_@J/\ \F)_$W_N&?\ ITM** #_ ()<?\F)_#+_ +B?_ITNZ^JJ^5?^"7'_
M "8G\,O^XG_Z=+NOJJ@ HHHH ^4?VSOV_?#_ .RG>:=X9T_19O&?Q!U2(2VN
MC6\NQ(%9MJ-,P!;+-G:BJ2VT\KD$^"WG[8?[;NB:6_B?4OV>]*_X1M(O.>WB
ML;G[4D8!)8H+II <9SF/@#H._K?AC]@_6(?V[-6^/?B?7])U[3)I9KBPTSR)
M!/:R")(;8G.58QQ@\YX95('I]FT ?-O[&?[<'A3]L#0+Y;&RE\/>+=*1'U+0
M[F0285N!+"XQYD>>"2 5) (Y4GJOVJ_VJ/"G[)OPY/B?Q&LE_>7,GV?3-'MG
M"SWTV,D GA44<LY! &."2 ?SR_9KELA_P6"\7CP+'%_PC+7.KK>_9 /)"" ^
M:1MXV_:PN,<<C':MG]L"W3]HS_@J7\-OA;J9:Z\.:&MG'<Z>W,;@QF^N>/\
MII$(T8^B#TH Z&V_;I_;)\6>'5\=>&_@)I3>!WC-Q#YFGW4TTL!^8.N+A'D&
MT<.D>TYS@\5]0?L4_MS>&OVO]#O[>.Q/AOQII*!]0T.27S 8R0HGA? +1[B
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MDD<^I8G)KI?AM\(?%OQ<U;[!X7T6XU%E($MP!L@A]WD/RK],Y/8&OL/X+_\
M!/&RT_R-3^(]\-1G&&&BZ>Y6%?:67AF^B[1_M$5]AZ!X=TOPKI4&F:-I]MI>
MGP#;';6D0CC7\ .OO54\+*6L]#ESSQ(P6!3P^4Q]I):7V@O3K+Y679GRW\%_
M^"?WAOPGY&I>.KA?%&J+AA8192RC/H>C2_C@>JFOJZQL;;2[.&TL[>*TM85"
M100($1%'0*HX ^E3T5Z4*<::M%'X#FF=8_.:OM<=5<GT71>BV7]7"BBBM#Q
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M+_HT#Q!_X4\/_P C5\0?\$5/^3IO%/\ V)EU_P"EUC7[4T ?*O\ PU)\=O\
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M]544 ?*O_#4GQV_Z-1\0?^%38?X4?\-2?';_ *-1\0?^%38?X5]544 ?*O\
MPU)\=O\ HU'Q!_X5-A_A1_PU)\=O^C4?$'_A4V'^%?55% 'RK_PU)\=O^C4?
M$'_A4V'^%'_#4GQV_P"C4?$'_A4V'^%?55% 'RK_ ,-2?';_ *-1\0?^%38?
MX4?\-2?';_HU'Q!_X5-A_A7U510!\J_\-2?';_HU'Q!_X5-A_A1_PU)\=O\
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M4V'^%?55% 'RK_PU)\=O^C4?$'_A4V'^%'_#4GQV_P"C4?$'_A4V'^%?55%
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M_#4GQV_Z-1\0?^%38?X4?\-2?';_ *-1\0?^%38?X5]544 ?*O\ PU)\=O\
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M]544 ?*O_#4GQV_Z-1\0?^%38?X4?\-2?';_ *-1\0?^%38?X5]544 ?*O\
MPU)\=O\ HU'Q!_X5-A_A1_PU)\=O^C4?$'_A4V'^%?55% 'RK_PU)\=O^C4?
M$'_A4V'^%'_#4GQV_P"C4?$'_A4V'^%?55% 'RK_ ,-2?';_ *-1\0?^%38?
MX4?\-2?';_HU'Q!_X5-A_A7U510!\J_\-2?';_HU'Q!_X5-A_A1_PU)\=O\
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M4V'^%?55% 'RK_PU)\=O^C4?$'_A4V'^%'_#4GQV_P"C4?$'_A4V'^%?55%
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M^(/_  J;#_"OJJBMCY@^5?\ AJ3X[?\ 1J/B#_PJ;#_"C_AJ3X[?]&H^(/\
MPJ;#_"OJJB@#Y5_X:D^.W_1J/B#_ ,*FP_PH_P"&I/CM_P!&H^(/_"IL/\*^
MJJ* /E7_ (:D^.W_ $:CX@_\*FP_PH_X:D^.W_1J/B#_ ,*FP_PKZJHH ^5?
M^&I/CM_T:CX@_P#"IL/\*/\ AJ3X[?\ 1J/B#_PJ;#_"OJJB@#Y5_P"&I/CM
M_P!&H^(/_"IL/\*/^&I/CM_T:CX@_P#"IL/\*^JJ* /E7_AJ3X[?]&H^(/\
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M_P G3>*?^Q,NO_2ZQK]J: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV-_ GPC\B^GMO^$F\0QX;^T=2C!2-O6*+E4]B=S#^]7N\<:Q1JB*$11A548
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M^EUC7[4U^*W_  14_P"3IO%/_8F77_I=8U^U- !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ7=?55?*O_!+C_DQ/X9?]Q/_ -.EW7U50 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!^*W_!%3_DZ;Q3_ -B9=?\
MI=8U^U-?BM_P14_Y.F\4_P#8F77_ *76-?M30 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)7C'QF_:R\!_
M!E9[2ZOO[:U],@:1IK!Y%;TE;[L?OGYL<A37P;\:/VO/'GQC\^R>\_X1_P /
M29']E::Y4.OI+)]Z3W'"\?=%<U3$0IZ;L_0,AX)S3/+5%'V=)_:EU_PK=_@O
M,^U?C1^VQX%^%GGV&F3#Q;KZ97[)I\@\B)O22;E1]%W'(P0*^#_C!^TKXZ^-
M4SQZWJAMM(W931[#,5LOIN&<N?=R<=L5Y97O'P7_ &-_'?Q<\B^GMO\ A&/#
MTF&_M'4HR'D7UBBX9_8G:I_O5YTJM6N^5'[Q@>'L@X/H_6\1)<R^W/>_]U=/
M^W4Y>;/"(XVED5$4N['"JHR23T %?2_P7_84\9_$00:CXDW>#]#?##[5'F\F
M7_9BXV9]7P>A"D5]I?!O]EOP)\%HXKC3=._M/7%'S:QJ($DX/?RQC;&.OW1G
M!P2:]>KIIX1;S/@,^\3*E2]#)X<J_GEO\H[+U=_1'G7PF^ /@GX+V0C\-Z0B
M7K+MEU2ZQ+=R^N9". ?[JA5]J]%HHKT%%15D?B&)Q5?&577Q,W.;W;=V%%%%
M,Y0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBLGQ)XLT/P;8I>Z_K.GZ'9R2"%+C4KJ.WC:0@D(&<@%L*QQUP#Z4%P
MA*I)0@KM]$:U%<-_PO;X:_\ 10_"G_@[MO\ XNC_ (7M\-?^BA^%/_!W;?\
MQ=3S1[G;_9V-_P"?,O\ P%_Y'<T5PW_"]OAK_P!%#\*?^#NV_P#BZO:'\6?
M_B;5(=-T?QEX?U749]WE6=CJD$TTFU2S;45R3A02<#H":.:/<F6 Q<(N4J,D
ME_=?^1U=%%%4<(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+2/^QS\)_P#HG3J_:F@ HHHH **** /E7_@J/_R8G\3?^X9_Z=+2BC_@J/\
M\F)_$W_N&?\ ITM** #_ ()<?\F)_#+_ +B?_ITNZ^JJ^5?^"7'_ "8G\,O^
MXG_Z=+NOJJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#\5O^"*G_ "=-XI_[$RZ_]+K&OVIK\5O^"*G_ "=-XI_[
M$RZ_]+K&OVIH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ KY4_X*/?\D/T/_L8H/\ TFNJ^JF8*I). .237Q=_P4&^)WA3Q#\-]*\.
M:5X@T_4];@UN*YFL[.<2M%&L$ZL6*Y"D,ZC!.>>E<^(:5-GVW!E&I4SW"RA%
MM1E=V6RUU?8^":***\(_LT*]R_8D_P"3GO!G_;[_ .D4]>&U[E^Q)_R<]X,_
M[??_ $BGK2E_$CZH^>XB_P"1-C?^O53_ -(9^JU%%%?0G\.A1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !163XH\6:-X+T>;5=>U.UTG3H?OW%W*$7/8#/
M4GL!R>U?&OQH_P""B"1^?IGPVL/,;E3KFI1X'UBA/7V,GXI652K"G\3/H\GX
M?S+/*G)@J3:ZR>D5ZO\ 17?D?7?CSXD>&?AEHS:IXGUFUTBSYVF=OGD(_A1!
MEG/LH)KXE^-'_!0O5=8\_3/AW9'1K,Y4ZQ?(KW+CUCCY6/ZG<>?X37R?XL\9
M:YX[UJ;5O$.JW6KZC+]ZXNI"Y _NCLJCLHP!V%2^#/ ?B'XB:U'I/AO2+K6+
M]_\ EE;)D*/[S-T1?]IB![UYM3$SGI#0_H#)O#_+,HA]:S22JRCJ[Z0C\GOZ
MRT\D9VLZUJ'B+4I]1U6^N-2O[AM\MU=2M)(Y]2S$DUT/PX^$OBSXM:M_9_A;
M1;C4Y%($LRC;#"#WDD.%7\3D]@:^Q/@O_P $\;.Q\C4_B/?B^FX<:)ITA6(>
MTLHPS>X3'^\17V)X?\-Z5X3TF#2]%TZVTK3H!B.VM(A&B_@!U]^IIT\+*6L]
M#FSSQ'P6 3P^4Q]I):7V@O3K+Y679GRS\%_^"?GAWPKY&I>.[I?$VIKAAI\&
MY+*,^AZ-+^.T=BIKZPT_3[72;*&SL;:&SM(5"16]O&$CC4= JC@#V%6**]*%
M.--6BC\ S3.L?G57VN.JN79=%Z+9?U<****T/$"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH _%;]I;_ )3):1_V.?A/_P!$Z=7[4U^*W[2W_*9+2/\
ML<_"?_HG3J_:F@ HHHH **** /E7_@J/_P F)_$W_N&?^G2THH_X*C_\F)_$
MW_N&?^G2THH /^"7'_)B?PR_[B?_ *=+NOJJOE7_ ()<?\F)_#+_ +B?_ITN
MZ^JJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** /Q6_P""*G_)TWBG_L3+K_TNL:_:FOQ6_P""*G_)TWBG_L3+K_TN
ML:_:F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO2ITH4_A1_/^<\29EGT[XRI[O2*TBOEU]7=^84445L?,!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110!^*W[2W_*9+2/\ L<_"?_HG3J_:
MFOQ6_:6_Y3):1_V.?A/_ -$Z=7[4T %%%% !1110!\J_\%1_^3$_B;_W#/\
MTZ6E%'_!4?\ Y,3^)O\ W#/_ $Z6E% !_P $N/\ DQ/X9?\ <3_].EW7U57R
MK_P2X_Y,3^&7_<3_ /3I=U]54 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 ?BM_P14_Y.F\4_]B9=?^EUC7[4U^*W
M_!%3_DZ;Q3_V)EU_Z76-?M30 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117F'Q!_:6^&WPS\
MV/6?%-FU['D&QL6^TW&X?PE(\[3_ +V!4RDHJ[9UX7"8C&U/98:FYR[13;_
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M45F^(/$FE>$])GU36M1MM+TZ 9DNKN41HOXGN>PZF@J,95)*$%=OH:5<K\0_
MBCX6^%6BG4_%&L6^E6W/EK(<RS$?PQH,LY^@^M?)GQL_X*&10^?I?PUL_/?E
M3KNH1$(/>*$\G_>?'^Z:^*O%/B[6O&^LS:MK^J76KZC-]^XNY"[8[ 9Z =@.
M!VKAJ8J,=(:L_8<@\.,;CK5LS?L:?;[;^6T?GKY'U#\;/^"@'B#Q5]HTOP';
MOX:TMLH=2FPU[*/5>JQ9]MS=PPKY.O;ZXU*[FNKNXENKJ9B\DTSEW=CU+,>2
M?<UO> _AOXE^)VM+I7AC1[G5[PX+"%?DB!_B=SA4'NQ K[C^"?\ P3ZT7P[Y
M&J?$&Z37]0&'72K5F6TC/H[<-*?;Y5Z@AA7$HU<0[GZU6QO#O ^']E!*,G]E
M:SEZ]?FVEV/CWX2? 'QK\:KX1>'-*9K)6VS:I=9BM(?7+XY/^RH+>U=;_P ,
M2?&G_H3/_*K9?_'J_4W3=-M-'L8+*PM8;*S@4)%;V\8CCC4= J@8 ^E6:[%@
MX6U9^5XCQ2S.5:4L-1@H=%+F;^]2COZ'Y4_\,2?&G_H3/_*K9?\ QZC_ (8D
M^-/_ $)G_E5LO_CU?JM13^IT^[.?_B*.<_\ /JE_X#/_ .3/RI_X8D^-/_0F
M?^56R_\ CU?I7\)M#O?#/PK\&Z/J4/V;4=/T6RM+F'>K^7+' B.NY20<,",@
MD>E=716U.C&DVXGRO$'%V.XDI4Z6+A"*@[KE36^FMY,****Z#X@**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q6_X(J?\G3>*?\
ML3+K_P!+K&OVIK\5O^"*G_)TWBG_ +$RZ_\ 2ZQK]J: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM]^D?Q;/S>\,>#M=\:Z@+'0-'OM9NSC]S8V[2L/<[0<#W/%?1?P]_P"">_Q
M\4"*?Q%=6/A*T;!*3-]IN<>HC0[>G8N#[5^BVBZ#IGAO3X['2=.M=+LH_N6U
MG L,:_15  J_77#!Q7Q.Y^;9GXGYAB+PP%)4EW?O2_1+[F?.7P^_8/\ AEX-
M\N;4[6Z\5WR\F34Y<0@^T28&/9MU>_Z/H>G>';".QTK3[73+*/[EM9PK%&OT
M50 *O45V1A&'PH_+,?FV/S27/C:TI^KT7HME\D%%%%6>2%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'XK?M+?\IDM(_P"QS\)_^B=.K]J:_%;]I;_E,EI'_8Y^$_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!V\U>L1^O&> QKRYT:E%\T3^B<JXJR7BRC]2QD5&<MX3V;_NOKY;2\NI]_?
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M11_P5'_Y,3^)O_<,_P#3I:44 '_!+C_DQ/X9?]Q/_P!.EW7U57RK_P $N/\
MDQ/X9?\ <3_].EW7U50 4444 %%%?.W[7W[;7@[]C_2M%?6[2XU[6M6E(M]&
ML)46<0J#NG;=]U V%&?O$G'W6P ?1-%%>:?M"?M!>%?V9_AV_C/QA]M.DK=1
M6833X1+,\DF=H"EE'16)YZ"@#TNBOA7_ (?)? 3_ )\_&'_@KB_^/UW7P/\
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M]K+C)CEC;E6P?H1R"1S0!Z)13)IH[>&265UBBC4L\CD!54#)))Z"OA[XG?\
M!8#X(^ O$5QI&DV_B#QJ;=MDFH:/;1+9DC((1Y9$9\$=0NTYR&- 'W)17SY^
MS/\ MT?"O]JF:;3_  IJ-UI_B*"(S2:#K,*P7?EC&73:S)(H)YV,2.,@9%?0
M= !1110 4444 ?BM_P $5/\ DZ;Q3_V)EU_Z76-?M37XK?\ !%3_ ).F\4_]
MB9=?^EUC7[4T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM[&!88Q_P%0!6E17;&G&'PH_*\PSC,,UES8VM*?DWI\ELOD@HHHJSQPHHHH
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MTA'H-J]?O"N)1JXAW/UNMC.'>!\/[*"49/[*UG+UZ_>TNQ\?_"7X!^-/C3J
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M9<JS*<'D,1T-?"FN?\$>=6\;6[ZWXI^.NMZQX\F)FDU*XLFGB$I'0%YO,(!
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MT&RL/$/@WQAK'BA8_P!\OA?21?K(!U?:KAA^6*[S_AX=X8_Z)1\8/_"-E_\
MBZ\RO0J8:HZ556:/'Q.&JX2JZ-96DCZJHKY5_P"'AWAC_HE'Q@_\(V7_ .+H
M_P"'AWAC_HE'Q@_\(V7_ .+KG.4^JJ*^5?\ AX=X8_Z)1\8/_"-E_P#BZ/\
MAX=X8_Z)1\8/_"-E_P#BZ /JJBOE7_AX=X8_Z)1\8/\ PC9?_BZ/^'AWAC_H
ME'Q@_P#"-E_^+H ^JJ*^5?\ AX=X8_Z)1\8/_"-E_P#BZ/\ AX=X8_Z)1\8/
M_"-E_P#BZ /JJBOE7_AX=X8_Z)1\8/\ PC9?_BZ/^'AWAC_HE'Q@_P#"-E_^
M+H ^JJ*^5?\ AX=X8_Z)1\8/_"-E_P#BZ/\ AX=X8_Z)1\8/_"-E_P#BZ /J
MJBOE7_AX=X8_Z)1\8/\ PC9?_BZ/^'AWAC_HE'Q@_P#"-E_^+H ^JJ*^5?\
MAX=X8_Z)1\8/_"-E_P#BZ/\ AX=X8_Z)1\8/_"-E_P#BZ /JJBOE7_AX=X8_
MZ)1\8/\ PC9?_BZ/^'AWAC_HE'Q@_P#"-E_^+H ^JJ*^5?\ AX=X8_Z)1\8/
M_"-E_P#BZ/\ AX=X8_Z)1\8/_"-E_P#BZ /JJBOE7_AX=X8_Z)1\8/\ PC9?
M_BZ/^'AWAC_HE'Q@_P#"-E_^+H ^JJ\E^-?[,?@KXX6[RZK9?V?K@7;%K-B
MDXP. _:1?9N<="*\O_X>'>&/^B4?&#_PC9?_ (NC_AX=X8_Z)1\8/_"-E_\
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M\X#RW/*?US*Y*G.6J:UA+Y+;UC]S/VJHKXB\!_\ !2C2['PV?^$[\-:E+J<
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M9?\ XN@#ZJHKY5_X>'>&/^B4?&#_ ,(V7_XNC_AX=X8_Z)1\8/\ PC9?_BZ
M/JJBOE7_ (>'>&/^B4?&#_PC9?\ XNC_ (>'>&/^B4?&#_PC9?\ XN@#ZJHK
MY5_X>'>&/^B4?&#_ ,(V7_XNC_AX=X8_Z)1\8/\ PC9?_BZ /JJBOE7_ (>'
M>&/^B4?&#_PC9?\ XNC_ (>'>&/^B4?&#_PC9?\ XN@#ZJHKY5_X>'>&/^B4
M?&#_ ,(V7_XNC_AX=X8_Z)1\8/\ PC9?_BZ /JJBOE7_ (>'>&/^B4?&#_PC
M9?\ XNC_ (>'>&/^B4?&#_PC9?\ XN@#ZJHKY5_X>'>&/^B4?&#_ ,(V7_XN
MC_AX=X8_Z)1\8/\ PC9?_BZ /JJBOE7_ (>'>&/^B4?&#_PC9?\ XNC_ (>'
M>&/^B4?&#_PC9?\ XN@#ZJHKY5_X>'>&/^B4?&#_ ,(V7_XNC_AX=X8_Z)1\
M8/\ PC9?_BZ /JJBOE7_ (>'>&/^B4?&#_PC9?\ XNC_ (>'>&/^B4?&#_PC
M9?\ XN@#ZJHKY5_X>'>&/^B4?&#_ ,(V7_XNC_AX=X8_Z)1\8/\ PC9?_BZ
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M9?\ XN@#ZJHKY5_X>'>&/^B4?&#_ ,(V7_XNC_AX=X8_Z)1\8/\ PC9?_BZ
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M'T^/I#;)C<?[S'JS?[3$GWK=KY5_X>'>&/\ HE'Q@_\ "-E_^+H_X>'>&/\
MHE'Q@_\ "-E_^+KNVT1^,U*DZTW4J2;D]V]6_F?55%?*O_#P[PQ_T2CXP?\
MA&R__%T?\/#O#'_1*/C!_P"$;+_\73,SZJHKY5_X>'>&/^B4?&#_ ,(V7_XN
MC_AX=X8_Z)1\8/\ PC9?_BZ /JJBOE7_ (>'>&/^B4?&#_PC9?\ XNC_ (>'
M>&/^B4?&#_PC9?\ XN@#ZJHKY5_X>'>&/^B4?&#_ ,(V7_XNC_AX=X8_Z)1\
M8/\ PC9?_BZ /JJBOE7_ (>'>&/^B4?&#_PC9?\ XNC_ (>'>&/^B4?&#_PC
M9?\ XN@#ZJHKY5_X>'>&/^B4?&#_ ,(V7_XNC_AX=X8_Z)1\8/\ PC9?_BZ
M/JJBOE7_ (>'>&/^B4?&#_PC9?\ XNC_ (>'>&/^B4?&#_PC9?\ XN@#ZJHK
MY5_X>'>&/^B4?&#_ ,(V7_XNC_AX=X8_Z)1\8/\ PC9?_BZ /JJBOE7_ (>'
M>&/^B4?&#_PC9?\ XNC_ (>'>&/^B4?&#_PC9?\ XN@#ZJHKY5_X>'>&/^B4
M?&#_ ,(V7_XNC_AX=X8_Z)1\8/\ PC9?_BZ /JJBOE7_ (>'>&/^B4?&#_PC
M9?\ XNC_ (>'>&/^B4?&#_PC9?\ XN@#ZJHKY5_X>'>&/^B4?&#_ ,(V7_XN
MC_AX=X8_Z)1\8/\ PC9?_BZ /JJBOE7_ (>'>&/^B4?&#_PC9?\ XNC_ (>'
M>&/^B4?&#_PC9?\ XN@#ZJHKY5_X>'>&/^B4?&#_ ,(V7_XNC_AX=X8_Z)1\
M8/\ PC9?_BZ /JJBOE7_ (>'>&/^B4?&#_PC9?\ XNC_ (>'>&/^B4?&#_PC
M9?\ XN@#ZJHKY5_X>'>&/^B4?&#_ ,(V7_XNC_AX=X8_Z)1\8/\ PC9?_BZ
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M9?\ XN@#ZJHKY5_X>'>&/^B4?&#_ ,(V7_XNC_AX=X8_Z)1\8/\ PC9?_BZ
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M9?\ XN@#ZJHKY5_X>'>&/^B4?&#_ ,(V7_XNC_AX=X8_Z)1\8/\ PC9?_BZ
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M_5=C\3SW"8;!XMPPTKKJOY7V_K8^JJ*^5?\ AX=X8_Z)1\8/_"-E_P#BZ/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%%%:'BA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %>??&[XV^'?@1X+N/$/B"XV@96VM4(\RXDQPJC_ #BMSX@?$KPO
M\+- EUKQ9K=IH>FQ_P#+6Z?!<_W4099V_P!E03[5^4O[;G[4'AK]H[Q)I)\.
MZ)>6MMI"O"FJ7LY5[E6.<" $J@SSN)W'/(&,5[.69?+&U5S)\G5GT&3Y7/,:
M\>:+]GU?Z?\ #'EGQZ^._B+]H#QM+KVNS,(8]T=E8JQ\JUB)SM4>IXR>^/:O
M-J**_4Z=.-**A!62/VNE2A1@J=-6BMD:GA?Q/JG@SQ!8:YHM[+IVJV,HFM[F
M$X9&'],9!'0@D5^NG[(?[7FF?M!:(NF:D\5CXRM(@;BU'RB<#K(@_H.E?CO7
MJ?[-/Q0\/_!WXO:+XJ\1Z/>:O96+[U6PN?*EA?H) .!)C^X2H/<]CY.:8"&,
MHMV]];6W]#P\ZRRGF&';Y??BM+;^A^Y%%</\*?C5X,^-F@C5?!^N6^J1*!YU
MN#LN+<G^&6(_,IZ]1@XX)'-=Q7Y9.$J<G&:LT?BE2G.E)PJ*S71A1114&844
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '/\
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MPA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 45XI\=/VO?AQ\!(IK?6=6_M+7
MU'R:'I>)KG/;?SMB'^^0<= >E?G1\>/V^OB-\9/M&G:=<_\ "&>&Y,K]@TN4
MB>5?26?AFXX(7:I'4&O:P>4XG&6DERQ[O].Y]#E^1XO,+2C'EAW?Z=_R\S]
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M8'S'W/-;=%=D:<(?"C\JS'.\RS9WQM>4_)O3Y16B^X****T/$"BBB@ HHHH
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MH1LEM&>F8HCAI#_M-M''1@:^'/C%^T%XZ^.VK?;?%VN37D*,6@TZ']U:6_\
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M6]A@:3F^O9>KV7S/I77O$&F>%]*GU/6+^VTS3[==TMU=RB.-![DFOC;XV?\
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MTNZ^JJ^5?^"7'_)B?PR_[B?_ *=+NOJJ@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\5O^"*G_)TWBG_ +$RZ_\
M2ZQK]J:_%;_@BI_R=-XI_P"Q,NO_ $NL:_:F@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW'YUB\=B<=/GQ$[_ )+T04445QG %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,T(PKCU9,' ^ZQK]!/ _Q \.?$O0(=;\+:S9ZYI<O N+20,%.,[6'5&&>58
MCN*_!_QEX)U_X>Z]<:)XETB[T358#\]K>1%&QV8=F4]F&0>QK1^&WQ7\6_"'
M7TUGPCKEUHM\,!_);,<RC^&2,Y5U]F!%7C,BH8E>TPSY6_N?^7R^XTS#AK#8
MQ>UP;4&__ 7_ )?+3R/WOHKX@_9]_P""F'AWQ=]FT?XEVT?A?5V(1=7M@6L)
MCZN.6A)]]R]22HXK[7T_4+75K&"]L;F&\LYT$D5Q;R"2.13R&5@<$'U%?#8G
M!U\'+EK1M^3^9^:XS XC SY,1"WY/T98HHHKC. **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%1_^3$_B;_W#/_3I:44?\%1_^3$_B;_W#/\ TZ6E% !_P2X_Y,3^&7_<3_\
M3I=U]55\J_\ !+C_ ),3^&7_ '$__3I=U]54 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 ?BM_P $5/\ DZ;Q3_V)
MEU_Z76-?M37XK?\ !%3_ ).F\4_]B9=?^EUC7[4T %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIR7VZEM_[JVOVLG+S/$J]3^$W[,_C_XR/%+HFC-;:4YYU;4<P6H'JK$9?_@
M:OO'X2?L1_#WX:>3>:C:GQ=K*8/VK5$!A1O5(.5'_ MQ'8BOH)%6-555"JHP
M%48 'I6U/!O>;/D<Z\3Z<+TLHI\S_GEM\H[OYV]#YA^$G[ W@CP1Y-]XHD;Q
MCJJX;R[A/+LT;VB!._\ X&2#_=%?3-E8V^FVD5K:6\5K;0J$CAA0(B*.@"C@
M#Z5/17HQA&FK11^'YEF^/S>I[7'57-^>R]%LOD@HHHJSQPHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8"NWHKXC&9EB<:_WDM.RV_KU/SG'YMB\P?[Z7N]EHO\ @_,****\P\8****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q6_:6_Y
M3):1_P!CGX3_ /1.G5^U-?BM^TM_RF2TC_L<_"?_ *)TZOVIH **** "BBB@
M#Y5_X*C_ /)B?Q-_[AG_ *=+2BC_ (*C_P#)B?Q-_P"X9_Z=+2B@ _X)<?\
M)B?PR_[B?_ITNZ^JJ^5?^"7'_)B?PR_[B?\ Z=+NOJJ@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\5O^"*G_)TW
MBG_L3+K_ -+K&OVIK\5O^"*G_)TWBG_L3+K_ -+K&OVIH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M*P_&'CCP_P" -)?4_$>L6FC6*_\ +6[E";CZ*.K'V )I7MJS2G3G6FJ=.+<G
MLEJV;E9^N^(-,\+Z7-J6L:A:Z7I\(S)=7DRQ1K]68@5\;?%O_@HM:VOG6'P\
MTC[8_*_VOJRE8_K'""&/L7*].5-?''C[XH>*OBAJG]H>*=<N]8G!)19GQ%%G
MJ(XQA4'LH%<=3%0CI'4_6,E\.,RQ]JN.?L8=GK)_+I\W==C[C^+?_!0WPYX?
M\ZQ\":>WB2^7*C4+L-#9J?4+P\G_ (Z/0FOB_P")WQR\;?%^\,OB?7;B\MPV
MZ.QC/E6L7IMB7Y<_[1R?4FN,T_3[O5KV&SL;6:]NYFV16]O&9))&/0*H&2?I
M7T]\(_V ?&?C/R;[Q;.OA#2VPWD2*);UQ_US!PF?]HY']TUPN57$.R/V"CEO
M#?!=)5JC49?S2]Z;]%O_ . I>9\MQQO-(D<:-)(Y"JJC))/0 >M?1'PD_8<^
M('Q'\B\U: >#]&?#>?J2'[0Z_P"Q!PW_ 'V5'UK[O^$_[-_@+X-QQR:#HL<F
MIJ,-JU]B:Z;UPY&$SZ(%'M7I]=5/!K>;/SS.O$^K4O2RBGRK^>6K^4=E\[^A
MXO\ "/\ 9(^'GPC\FZM=+_MK6H\'^U-5 ED5O6-<;8_8@;O<U[1117?&*BK1
M1^*XW'XK,:KKXNHYR[MW^[LO)!1115' %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45P'Q<^._
M@?X':/\ VAXOUV#3BZEH+)3YEU<8[1Q#YFYXW?='<BOSH^/W_!2+QE\1/M.D
M^!8I/!.@ME#=*X.HSK[R#B+Z)\P_OFO5P>6XC&N]-6CW>W_!/;R_)\7F+O2C
M:/=[?\'Y'W=\=OVMOAY\ +>2'6]4_M#7MN8]#TTB6Z)QQO&<1+[N1D= >E?F
MU\?OVZOB'\</M&G6]S_PB7A>3*_V5I<K!YD/:>;AG]U&U3_=[U\ZW%Q+>7$D
M\\KS3R,7>21BS,Q.223U)->N? O]E/XA?M 72/X>TDVNBA]LNN:AF*T3GD*V
M,R,/[J D<9QUK[C#Y7@\MC[6L[M=7^B_IGZ1A,EP&40]O7:;7VI;+T7_  [/
M'Z^D?@#^PA\0_C=]GU*[MSX0\+R8;^U-4B(DF7UAAX9^.C':I[,>E?>7P!_8
M)^'OP6^S:GJ, \8^*(\/_:&I1#R87'>&#E5P>C-N8$9!'2OIBO*QO$.\,(OF
M_P!%_G]QXF8\5;T\"O\ MY_HO\_N/&O@3^R9\//V?[>.70=*^W:[MVR:YJ6)
M;IL]0AQB-3Z(!D8SGK7LM%%?&5:M2M)SJ2NS\^K5ZN(FZE:3DWU84445D8!1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!\N?M!?\ !/\ \ _&+[3JNAQKX+\429;[581#[+</U_>P# R3U9-I
MYR=W2OS9^-G[-/C[X ZCY/BG1F&GN^V#6+/,MG/Z8D ^4G^ZX5O;%?N3535=
M)L==TVXT_4K.WU"PN$,<UK=1+)%(IZJRL""/8U]#@<ZQ&$M&?O1[/?Y,^JR[
MB+%8&T*GOP[/=>C/Y]]/U"ZTF^@O;&YFL[R!Q)%<6\ACDC8<AE8'((]17VM^
MS[_P4P\1^$?LVC_$NVD\4Z2N$75[8*M_"/5QPLP'OM;J2S'BO5?V@O\ @F7H
MGB3[5K/PPNT\/:D<NVAWC,UG*>N(WY:(GT.Y>@^45^>?Q"^&/BGX4^()-%\6
MZ'=Z'J*Y(CN4^61<XW1N,JZ_[2DBOL8U<#G%/E>K[/1K^O+0_0(5LMX@I<CU
M?9Z27I_P-#]Q_AK\5_"7Q>\/IK/A'7+76K$XW^2V)(6/\,D9PR-[,!76U^ G
M@?Q_XC^&OB"#6_"^LW>AZI#PMQ:2%21W5AT93CE6!![BOT#_ &??^"G6GZM]
MFT;XJV:Z5=<(OB#3XF:W<],S1#+(?5DR,G[JBOE\=D-:A>>']Z/;K_P?E]Q\
M5F/#&(PUZF%]^/;[2_S^7W'WQ15#0M?TSQ1I-MJFCZA;:IIMTGF07=G*LL4B
M^JLI(-7Z^6::=F?%M.+LPHHHI""BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ KR7XU_LQ^"OCA;O+JME_9^N!=L6LV("3C X#]I%]
MFYQT(KUJBIE%25FCMP>-Q.7UEB,+4<)KJOZV\MC\FOC=^ROXU^",TMS>6O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% 'XK?M+?\IDM(_['/PG_ .B=.K]J:_%;]I;_ )3):1_V.?A/_P!$Z=7[
M4T %%%% !1110!\J_P#!4?\ Y,3^)O\ W#/_ $Z6E%'_  5'_P"3$_B;_P!P
MS_TZ6E% !_P2X_Y,3^&7_<3_ /3I=U]55\J_\$N/^3$_AE_W$_\ TZ7=?55
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'XK?\$5/^3IO%/\ V)EU_P"EUC7[4U^*W_!%3_DZ;Q3_ -B9=?\ I=8U
M^U- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** /Q6_:6_P"4R6D?]CGX3_\
M1.G5^U-?BM^TM_RF2TC_ +'/PG_Z)TZOVIH **** "BBB@#Y5_X*C_\ )B?Q
M-_[AG_ITM**/^"H__)B?Q-_[AG_ITM** #_@EQ_R8G\,O^XG_P"G2[KZJKY5
M_P""7'_)B?PR_P"XG_Z=+NOJJ@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#\5O\ @BI_R=-XI_[$RZ_]+K&OVIK\
M5O\ @BI_R=-XI_[$RZ_]+K&OVIH **** "BBB@ HHHH **** "BBB@ HHHH
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M^-U^1%%'^LF*_DC^/^8?ZW8S_GW'\?\ ,_7?_ALSX,?]#U:?^ UQ_P#&Z/\
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MI_X#7'_QNOR(HH_UDQ7\D?Q_S#_6[&?\^X_C_F?KO_PV9\&/^AZM/_ :X_\
MC='_  V9\&/^AZM/_ :X_P#C=?D111_K)BOY(_C_ )A_K=C/^?<?Q_S/UW_X
M;,^#'_0]6G_@-<?_ !NC_ALSX,?]#U:?^ UQ_P#&Z_(BBC_63%?R1_'_ ##_
M %NQG_/N/X_YGZ[_ /#9GP8_Z'JT_P# :X_^-T?\-F?!C_H>K3_P&N/_ (W7
MY$44?ZR8K^2/X_YA_K=C/^?<?Q_S/UKUC]MCX/Z?I-Y<VOC"WOKF*)GBMH[>
M<-*X'"@F/C)P*_+CXA>.+_XA>.-7\2WTK-=WUPTP/38,_*!Z8 %<W17E8[-*
MV/48U$DEV/%S+.<1FBC&JDE'M?\ S9^JO[)_[26A?$#X7:;;Z[KVG6/B2P'V
M6XM[JZCBDE 'RR*K$$@@'ITQ7T/#/'<Q+)#(LL;='1@0?Q%?A'5[2]>U+0YO
M-TW4;K3Y<YWVL[1-^:D5[.'XBG2A&%2GS6ZW_P" ?0X7BRI1IQIUJ7-96O>W
MZ,_=*BOQIT/]I;XJ^'=OV/Q_KQ5?NI<WKW"CIP%D+#''3_&O0-#_ &_/C'I.
MT7&MV.KJO&+[3H1^9C"$UZD.(\-+XXM?<_U/9I\6X.7QPDON?ZGZK45^=.B?
M\%-O&-OC^U_"&AW_ *_8Y)K8GK_>:3V_(_AZ!H?_  4[\.7&W^V/!&J6/][[
M#>1W./IN$>:[X9W@9_;MZIGIT^(LMJ?\O+>J?^5C[6HKYIT/_@H5\(-6V_:K
MW5M%SU^W:<S8Z=?),GKV]#[5Z!HG[57PC\0;?LOC_18MW3[=/]D_]&A<5WPQ
MV%J?#5C]Z/3IYE@JOP5HOYH]6HK)T7Q=H7B0 Z3K6GZH#T-E=1S>O]TGT/Y5
MK5VJ2DKH]",E)7B[A1113*"BBB@ HHHH **** "BBB@ KYV_:"_8=^'WQV^T
M:DMM_P (MXJDRW]L:;& )F]9XN%D^ORM_M8XKZ)HK>C7JX>?/2E9G3A\36PL
M_:4).+\C\2_CQ^R7\0OV?[F2;7-,^WZ!OVQ:[IP,EJV3P'.,Q,?1P,G.">M>
M-PS26\R2Q.T4L;!D="0RD'(((Z&OZ$[JUAOK:6WN88[BWE4I)#*H9'4C!!!X
M(([5\:_M!?\ !-GPGX^-SK'P^FB\&ZXV7;3V4G3IV] HYA_X!E>/N=Z^WP7$
M$)VABE9]UM\T?HV7<50J6IXY6?\ ,MOFNG];'SO^S[_P4@\8_#G[+I'CI)?&
MOA],(+IW U&!?:0\38]'^8_WP.*_1OX2_'+P5\<-$_M+P?KD&IJ@'GVI.RYM
MR>TD1^9?KC!QP37XJ_%3X,^,O@OKITKQ?H5SI,Y)\F9EW07 '\44@^5QTZ'(
MSR >*Y_POXLUGP3K=MK&@:I=Z/JEN=T5W93-%(OJ,@]#W'0]ZZ\7DV&QL?:X
M=\K?5;/^O([\=P_@\QC[;"M1;ZKX7\O\OQ/Z!J*_.[]GW_@IX\?V;1OBQ9;U
MX0>)--BY'O/ O7W:/_OCO7WSX3\8:'X\T.WUGP[JUIK6EW S'=64HD0^H)'0
MCN#R.XKX7%X&O@I6K1T[]&?FN.RW%9?+EKQT[]'\_P"F;%%%%<!Y84444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,FACN(7BE198I
M%*NC@%6!&""#U%/HH ^3OCK^P3X>\:?:-6\"O#X8UELNVGL#]AG;T ',)_W0
M5_V1UKX-\??#?Q+\+]<?2/$^D7&E7JY*^:N4E4?Q1N/E=?=2:_:.N?\ &W@'
MP]\1]#ET?Q+I-OJ^GR?\LYUY0_WD8?,C?[2D&N*KA8SUCHS]9X>\0L=E?+0Q
MUZU+S^->CZ^C^]'X[>"?'WB'X<:Y%K'AK5KC2-0C_P"6D#<./[KJ?E=?]E@1
M7W;\"_V_=$\4?9](^($47A[5#A%U6$'[%,?5QR8B?7E>IRO2O+_CI^P%K?A?
M[1J_P_EE\0Z6,NVE38^VPCT0\"4#\&Z##=:^1[JUFL;B6WN(9(+B)BDD4JE6
M1@<$$'D$'M7"I5<.['[)6P?#_'6&]K!J4E]I:3CY/_)IKMW/V_M;J&^MXKBW
MECGMY5#QRQ,&5U(R""."".]2U^2/P4_:<\:_ ^X2+2[W^T-#+9ET:^)> Y/)
M3O&WNO&>H-?H5\$?VJ?!7QNABMK.Z_L?Q#MR^C7S@2$]_*;I*/ISCDJ*]&EB
M(5--F?@O$/!.99%>JE[2C_-%;?XET]=5YGLE%%%=1^>!1110 4444 %%%% !
M1110 445YU\6OC]X*^"M@9O$>JJMZR[H=+M<274WT3/ _P!IB%]Z3DHJ[.K#
M86OC*JH8:#G-[)*[/1:\0^-?[77@;X,B>R>Z_M_Q$@(&DZ>X)1O263E8_IRW
M^R:^-?C9^W!XT^)WVC3M"9O"/A]\J8K.0_:IE_Z:3#! /]U,#G!+5\X$EB2>
M37G5,7TIG[GD'AG*5J^<RLOY(O7_ +>E^D?O1Z_\9_VI?'/QJDEM]1O_ .R]
M")^31]/)2$CMYASF0]/O'&>@%>0HK2,JJI9F. JC))]*]F^"O[)_CGXT-#=V
MMG_8OAYR"=8U!2L;+_TR3[TAZ]/E]6%???P5_91\#?!5(;NTL_[9\0(/FUC4
M%#2*W?RE^[$.O3YL<%C7/"C4K/FD?;YEQ3D?"='ZGA(J4X_8A;1_WGT??>7D
M?&WP3_85\8?$7[/J7B;?X0T%L,!<1YO)E_V8C]P'U?'KM(K[R^%7P-\&_!G3
M?LOAG2([>=E"S:A-^\NI_P#?D/./]D84=@*[VBO3IT84]MS^?\]XMS//FXUY
M\M/^2.B^?5_/Y)!1116Y\6%%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<7\4/C+
MX,^#.B_VGXPU^UT>!@?*BD;=/.1VCB7+.?H..^*N$)5)*,%=LTITYU9*$%=O
MHCM*\Z^,'[07@/X%Z7]K\7:]!8S,I:#3XOWMW<?[D0^8C/&XX4=R*^"_CQ_P
M4X\1>*/M&E?#2Q;PQIK90ZO>JLE](/5$Y2+_ ,>;H05-?%6LZUJ'B+5+C4M5
MOKG4]1N&WS7=Y*TLLC>K,Q))^M?68/A^I4M/$OE79;_\ ^YR_A6K5M/&/E79
M;_Y+\3Z\^/'_  4I\:>/OM&E^ X6\%:(V5^V!@^HRKZ[Q\L7_ ,L/[]?'E[>
MW&I7<UU=SRW5U,YDEFF<N[L>2S,>23ZFNV^$_P #?&_QNUC^S_!^@7.J%& F
MN\;+:W]Y)6PJ\<XSD]@:_0CX#_\ !,WPIX-^SZK\1+M?%^K+AAIL&Z/3XF]^
MCS8_VMJGH5-?13Q& R>')'1]EJWZ_P#!/JZF*RS(:?LXI)]EK)^O_!9\$_!G
M]F_X@?'C4!#X4T*6:R5MLVJW68;.'UW2D8)']U=S>U?HA\!_^"<'@7X;_9]3
M\9.OCC7DP_E7";-/A;K\L7_+3'3,A(/7:*^L],TNST73X+'3[2"PL;=!'#;6
ML:QQQJ.BJJ@ #V%6J^0QF>8C%7C3]R/EO]_^1\'F'$>+QEX4O<AY;_-_Y6([
M>WBL[>."")(8(U")'&H554#   Z "I***^=/DPHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH _%;]I;_E,EI'_ &.?A/\ ]$Z=7[4U^*W[2W_*9+2/^QS\)_\ HG3J
M_:F@ HHHH **** /E7_@J/\ \F)_$W_N&?\ ITM**/\ @J/_ ,F)_$W_ +AG
M_ITM** #_@EQ_P F)_#+_N)_^G2[KZJKY5_X)<?\F)_#+_N)_P#ITNZ^JJ "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /Q6_X(J?\G3>*?^Q,NO\ TNL:_:FOQ6_X(J?\G3>*?^Q,NO\ TNL:_:F@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJMJ6IV>C6,U[J%W!8V
M<*[Y;BYD6..-?5F)  ^M?+WQ:_X* ^#O!_GV/A"V?Q=J:Y7[0"8;)#Z[R-SX
M/]T8/]ZLYU(TU>3/9RS)L?G%3V>!I.;ZOHO5O1?-GU/-,EO$\LKK'$BEF=S@
M*!R23V%?.GQ;_;G\ ?#OSK/1I6\8ZPF1Y6G2 6R-_M3X(/\ P -^%?!_Q6_:
M+\>_&29U\0:W(-.+972K+,-HO<?(#\V.Q<L?>O-:\^IBWM!'[EDOAC1IVJYO
M4YG_ "1T7SEN_E;U/9/BU^UE\0_B]YUM>ZJ=(T:3(_LK2B88F7T=L[I/HQ(]
M *\;KW?X1_L9_$/XJ>1=RV'_  C&B28/V_5E*,Z^L</WVXY!(53_ 'J^UOA'
M^Q=\//A=Y%W<61\4ZU'AOMVK*&1&]8X?NKSR"=S#^]6,:-6L[R_$^IQW%/#W
M"U)X7").2^Q3MO\ WGM?O=N7D?!WPE_99^(/QB,-QI>D-I^CO@_VMJ>88"/5
M.-TG_  1ZD5]J_"/]@_P)X!\F]\0AO&6KKAO],39:(W^S#D[O^!E@?05]+*H
M50 , < "EKOIX:$-7JS\4SKC[-\VO3I2]C3?2._SEO\ =9>1%;6T-G;QP6\2
M001J$2*-0JJHZ  < 5+1176?F[;>K"BBB@04444 %%%% !1110 4444 %%%%
M !17#>./CCX!^&_F+XD\6Z7ID\?+6K3A[C_OTF7/_?-?/7CG_@I/X&T7S(O#
M.B:IXEG7[LTV+.W/T+;G_-!7#6QV&P_\6HE^?W;GFXC,L'A/XU5)]MW]RU/K
MZH+R^M]-M9+F[GBM;:,;GFF<(BCU)/ K\Q/'/_!0SXH^*/,BTAM.\*6S<#[#
M;B6;'N\NX9]U5:\ \6?$#Q-X\NA<>(]?U+7)0<J;^Z>4+_NACA?PKP*W$="&
ME&+E^"_S_ ^7Q'%N&IZ4(.3\]%^K_ _57QQ^V7\(_ OF)/XK@U>Z7/\ HVBJ
M;LG';>O[L'ZL*^>O''_!3@_O(O!W@S'79=:Y/^688C_[4KX0KIO!OPQ\7?$*
M81>&O#>J:V<X+V=J[QI_O.!M7ZDBO"J9YCL0^6EIZ*[_ %/FJW$F8XI\E'W;
M_P JN_QO^!Z)XX_;(^+?COS([CQ;<:5:M_R[:,HM% /;>GSD?5C7C5W>3ZA<
MR7%U/)<W$AW/+,Y=V/J2>2:^H_ __!.GXE^(_+EUV?3/"EN?O+<3_:9P/9(L
MK^;BOH3P/_P3?^'N@^7+XBU/5/%,X^]'O%G;M_P%"7'_ '\K..6YEC7S5$_6
M3_3?\#*.3YOF+YJR?K-_IO\ @?FHB-(ZHBEF8X"J,DGTKU7P1^RS\4_B J2Z
M9X.U""T;G[9J2BSAV_W@TI7</]W-?JUX)^#_ ()^'**/#7A;2](D QY]O;+Y
MQ^LA!<_B:S?CT/%TWPMUJS\#Z6VK>(KV/[+#&MQ%!Y:OP[EI'4<+D<'.2/>O
M4AP[&G!SKS;MTBOZ_(]JGPI&E3=3$5'*RVBORW_(_'+Q#HK^'=:O-,DN;>[E
MM9#$\UJQ:-F'7:2 3Z=.U9U>\R?L-_'&21G?P66=CDL=6L<D^O\ KZ3_ (89
M^-__ $)/_E6L?_C]?,/ XJ^E&7_@+_R/C)9;C6W;#SM_A?\ D>#U]??L%P^
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M/Y%]R#ZGAO\ GW'[D>:?\,S_  H_Z)[X=_\ !?'_ (4?\,S_  H_Z)[X=_\
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MA9?IPW7Y>]?0]?$UJ%7#SY*L;,_.<1AJV%FZ=>+B_,****P.8**** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%8OB[QIH/@'0Y]9\2:O9Z)I</W[J]F$:9[*,]6..%&2>PII.3
MLEJ5&+DU&*NV;5<S\0/B7X6^%>@OK/BS7+/0M.7($EU)AI& SM1!\SMC^%03
M[5\/_'C_ (*A00?:-)^%6F?:'Y3_ (2#5HB$'O# >3[-)CIRAKX+\<_$+Q+\
M3->EUGQ3K5YKFI2<&>\D+;1_=4=$7_94 #TKZG!Y!6K6E7?(OQ_X']:'VF7\
M+XC$6GBGR1[?:_X'S^X^V_CQ_P %0+_4/M.D_"S3/[-@Y3^WM4C#3-[Q0\JO
ML7W<?P@U\,^*/%FM>-M:N-8\0:K>:SJEP<RW=],TLC>@R3T'8=!VJSX)\ ^(
M_B1KT.C>%]&O-<U.7D6]G$7(']YCT51W9B .YK[R^ __  2]CC^SZK\5=3\P
M\,/#^DRD+])IQS]5CQ[/7U%\!D\.S^^3_K[C[-RROA^G;1/[Y/\ KY(^&OAQ
M\*?%OQ<UQ=(\(Z#=ZW>\;Q;IB.('^*20X5![L0*^_P#X#_\ !,'1]$^SZK\4
M-177;P8<:)IKM':H?227AY/HNT>["OM7P?X)T#X?:'#HWAK1[/1-+A^Y:V4(
MC7/=CC[S'NQR3W-;=?*XS/J]>\:'N1_'[^GR^\^)S#B;$XF\,/[D?Q^_I\OO
M,[P_X<TKPGI%OI6B:;:Z3IENNV&SLH5BB0>RJ !6C117S#;;NSXUMR=WN%%%
M%(04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 45SWC7X@^&_ASI+:EXFUJTT:S&</<R ,Y'9%^\Y]E!-?'WQ<_X*+*O
MGV'P[TC>>5_MC5EP/K'"#^1<_5:RG5A3^)GTN4<.YGGDK8*DW'^9Z17S?Y*[
M\C[/\1^)](\(:3-J>N:G:Z3I\0^>YO)EC0>V2>2>PZFODSXM_P#!1'0]%\^Q
M\ Z8VNW8RHU/4%:*U4^JQ\._X[/QKXA\<_$?Q/\ $K53J/B?6[O6;KG:;A_D
MC![(@PJ#V4 5BZ7I-]KFH0V.FV=QJ%[,VV*VM8FDD<^BJH))^E>=4Q<I:0T/
MW3)_#7 8)*MFD_:R6MEI!>O5_@NZ.K^)7QG\9?%R^^T>*-=N=016W1V@.RWB
M_P!R)<*#CC.,GN37'6]O+=SQPP1/--(P5(XU+,Q/0 #J:^J_A)_P3[\6^+/)
MOO&5VGA/3F^;[(N)KUQ] =L>?<DCNM?:7PK_ &>_ GP=@3_A'=$B6_VX?5+O
M]]=OZ_O#]T'T4*/:HAAZE1WEH>EF?'629#3^JY?%5'':,+*"_P"WMO\ P%,^
M$/A'^PGX]^(/DWNO(O@W2'P=U\A:[=?]F#((_P"!E?H:^UOA+^RK\/?@^(;C
M3M)74]9CY_M;5,33AO5!C;'_ ,! /J37L%%>C3H0I[+4_#<ZXSS?.KPJ5.2F
M_LQT7S>[^;MY!11170?#!1110 4444 %%%% !1110 44C,(U+,0JJ,DDX %>
M5>.OVIOA9\//,35?&6GR74?!M-/<W<P;^Z5B#;3_ +V*RJ5:=%<U222\]#&K
M7I4(\U62BO-V/5J*^)/'7_!331;3S(?"'A*\U%^BW6K3+;H#Z^6F\L/JRFOG
MKQU^W3\7/&WF11:Y%X<M'_Y8:) (2/I*VZ0?@PKPZ^>X.CI%N3\O\W8^:Q'$
MV7T-(R<WY+]78_4WQ!XGT?PG8M>ZWJMEH]FO6XO[A((Q_P "8@5X3XY_;T^$
MO@[S8[75;KQ-=IQY.CVQ=<]OWC[4(]U)K\MM:U[4_$E\][JVHW>J7C_>N+V=
MII&^K,2:HUX%?B.M+2C!+UU_R/E\1Q=7GIAZ:CZZO]%^9]H^./\ @IEXDO\
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MQAEG#].[LG]\G_7R1\8_#WX9^*?BMK\>B^$]#N]<U%N3';)E8UZ;I'/RHO\
MM,0*_07X ?\ !,?1]!^S:Q\4;U=<OQAUT+3W9;2,]<2R<-(?9=J\=6%?9?@+
MX<^&?A?H$6B^%-$L]#TR/GR;6/!<XQN=C\SM_M,23ZUTE?*XW/J]>\*'N1_'
M_@?+[SXK,>)L1BKPPWN1_P#)G\^GR^\HZ)H>G>&M+MM,TFPMM,TZV79#:6<2
MQ11KZ*J@ #Z5>HHKYAMMW9\8VV[L****0@HHHH **** "BBB@ HHHH ****
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M;+-],X'8"NRHKT:=&%/X4?A6<<49KGC:Q=7W/Y5I'[NOSNPHHHK8^4"BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%>0?'/\ :J^'O[/]JZ^(M6%QK)7=%HFG
MXENY.,C*YQ&#_><J#VSTK\W/C]^WQ\0OC1]ITW39V\&^&),K_9^FRGSYE])I
M\!FR.JKM4CJ#UKV<%E.)QMI15H]W^G<^@R_(\7F%I17+#N_T[_EYGWE\?_V[
M/AY\$/M&FVUQ_P )=XHCRO\ 9>F2@I"P[33<JGN!N8=U%?FU\=OVM/B'^T!<
M20Z[JGV'0=^Z/0]-S%:K@\%QG,C#U<G!Z =*\9KZ(^ /[#OQ$^.GV;43:?\
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MOCYU)U).<W=L^!J5)UIN=23;?5A11169F%%%% !1110 4444 %%%% !1110
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M9=!VK#XVNKE!P5OK>"XS]2Z%OUKT#1/^"D'Q0TW:M]8>']63NTUI)&_?H4D
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MCOYX?>__ )$_)BBOU9_X8'^#'_0O7?\ X,[C_P"+H_X8'^#'_0O7?_@SN/\
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MI%Y#I<."/H0:_0O_ (=E^!/^AI\1?G!_\;IDO_!,OP0T;"/Q7X@23'RLP@8
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M?$.Y23LSZ2K ?4><,_G1_9.9]G_X$O\ ,/[#SG^5_P#@2_S/C_\ X7[\3O\
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M$[_H.^$O_ RZ_P#D:CV.<=Y_>_\ ,/J^?]ZG_@3_ ,S@_P#AN;XW_P#0[?\
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M?PR_[B?_ *=+NOJJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7M1C&"Y8JR/H80C3CRP5EY!1115%A1110 4444 %%%% !1110 4444 %%%%
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M$6G3,0/7A:VK/]G_ .)U^4\CX>>*&5QN5VT>X52,9SN* ?K2_M;,Y_"W_P"
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MO_Z$G_RK6/\ \?H_X89^-_\ T)/_ )5K'_X_7ZT45Y?^KF$_FE]Z_P CQ?\
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M)_\ ITNZ^JJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%F^RT0_[4Q!W?\ ##W%?%7Q:_:F^(/QA,UOJFKMI^COD?V3IF88"/1^=TG_
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M"/VG2/AM:)XJU9<H=6N0R6$3>J#AIL>VU>A#-7PM\;?VFOB!\?;]I/%&LO\
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MV&)KR3/3Y,X0'^\Y4>]?G7\>/^"B'Q!^*GVC3?#3-X&\//E?+L92;V9?]N?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJUE5@I6[JYSUL/1Q"2K04K=TG^9X/_PPS\$/^A)_\JU]_P#'Z/\ AAGX(?\
M0D_^5:^_^/U[Q17/]1PG_/F/_@*_R.7^S,#_ ,^(?^ K_(\'_P"&&?@A_P!"
M3_Y5K[_X_7HOPR^#WA'X.Z?=V'A#2WTFSNI!+-";R>=2X&-P\UVVG'7&,X&>
M@KLZ*TIX7#TI<U.FD_))&M+!86C+GI4HQ?=))_D%%%%=1VA1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17,?$+XG>%?A3H+ZS
MXMUVST+3UR%DNGPTA'\,:#+.W^RH)]J^!/CQ_P %0-1U+[1I7PLTTZ7;G*'7
MM4C5YS[Q0G*I[%]QP?NJ:]'"9?B,:_W4=._0]; Y7BLP=J$=.[T7W_Y'W9\4
MOC1X+^#&BG4_&&OVNCQ,"8H7;=/.1VCB7+/^ P.^*_/KX\_\%-O$GBK[3I7P
MVL3X7TMLI_:UX%DOI!ZHO*19'^\W<,#7QIXF\5:SXTUJXU?7]4N]8U.X.9;N
M]F:61O;)/0=AT%:_PW^%'B[XN:XND>$-!O-<O>"XMTQ'$#QNDD.%1?=B!7V^
M%R3#81>TQ#YFN^R_KS/T;!<.X/ Q]MBGS-=](KY?Y_<<_K&LW_B'4[C4=4O;
MC4M0N'WS75W*TLLC>K,Q))^M=A\)_@;XW^-VK_8/!^@7.J;&"S7>-EM;Y[R2
MMA5XYQG)[ U]X? ?_@F%HVA_9M5^)^HC7;T8<:'IKLEJA]))>'D^B[1GNPK[
M>\/^'-*\)Z1;Z5HFFVNDZ9;KMAL[*%8HD'LJ@ 5CC.(*5%<F%7,^_3_@G/C^
M**%!>SP:YGW^ROU?X(^.O@-_P3.\*>#/LVJ_$2[7Q?JZX?\ LV'='I\3>_1Y
ML?[6U3R"IK[,TS2[/1=/@L=/M(+"QMT$<-M:QK''&HZ*JJ  /85:HKXG$XNO
MBY<U:5_R^X_.L7CL3CI\^(G?\EZ(****XS@"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** /Q6_:6_Y3):1_V.?A/_T3IU?M37XK?M+?\IDM(_['/PG_ .B=.K]J: "B
MBB@ HHHH ^5?^"H__)B?Q-_[AG_ITM**/^"H_P#R8G\3?^X9_P"G2THH /\
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M+[RYO%OBRQTJ/JUMI<+7,A'H7;8JGW 85Q<N:9AOS-/Y+]$>-RYUFN_,T_\
MMV/Z(^*JT-#\/:KXFOEL]'TR\U6\;I;V-N\TA^BJ":_4GP/^P?\ "3P;Y<EQ
MH]SXENEY\[6;@R+G_KF@5"/JIKW;0O#>D^%[%;+1M+LM(LUZ6]C;I#&/^ J
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP_%?+K\ON/M*BH;2[@O[6*YMIH[BWF4/'-"P9'4C(8$<$$=Q4U?,GQX4444
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M_P F)_#+_N)_^G2[KZJKY5_X)<?\F)_#+_N)_P#ITNZ^JJ "BBB@ KCOB?\
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M_P"+O@[I/C?XQ65]XK\4^*K==5$$FH7%NMG%,-\>3$ZM)*RL'8N>"VW'RDL
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M]?O>H4445W'I!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117GWQL^-WAKX#^";
MOQ%XBN<*BD6UG%@S74F/EC0>Y[G@=35PA*I)0@KMFE.G.M-4Z:NWLA?C7\;O
M#7P(\&W/B#Q%<X501;V<9'G7,F.$0'^?:CX*?&_PS\=_!MMX@\.76Y77%Q9R
M$":VD[HX]CWZ&OQM^._QX\1_'[QE/KFNSLD )%I8*Y,5M'GA5]_4]ZC^"/QX
M\4_ 3Q4FM>'+A2#Q/93Y,$X]& (_,5]I_J[_ +-\7[S\/3_@GZ'_ *IOZG\7
M[[?R]/\ @G[F:EJ=GHNGSWVH7<%C96Z&2:YN9%CCC4=69F( 'N:^,_CS_P %
M,?"G@S[3I7P[M%\7ZNN4.I3;H]/B;U'1IO\ @.U3U#&O@CXS?M)?$#X\:@9O
M%>N2362OOATFUS#90>FV,'DC^\Q9O>O-[2SGU"ZBMK6"2YN9F"1PPH7=V)P
M .23Z"NC!\/TZ?OXI\S[+;_@G5E_"M*E:IC9<S[+;YO=_@=M\6/CIXX^-VK_
M &_QAK]SJFQBT%IG9;6^>T<2X5>.,XR<<DUQ^D:/?^(-2M].TNQN-2U"X;9#
M:VD32RR-Z*J@DGZ5]<_ ;_@FSXV^(7V;5/'$K>"-#?#_ &5U#ZC,OM&>(O\
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M-PMW'9ZI;K/&DP5E$@5A@,%=QGT8UYY_PQ3\!/\ HD/@_P#\%,7^% 'Y1_\
M!(;Q]X8^'/[2?B74O%GB/2?#&G2^$KFWCO-9OHK2%Y3>63",/(R@L51CC.<*
M3V-?KO\ \-3?!?\ Z*]X#_\ "FLO_CM?CQ_P2A^$G@[XS?M$>(M%\;^';'Q-
MI5OX5N+R*TOTWHDRW=F@<#/4+(X_X$:_5S_A@W]GS_HDOAO_ ,!C_C0!W?\
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MX6?]%+\'_P#@^M?_ (Y7*?\ #%/P$_Z)#X/_ /!3%_A1_P ,4_ 3_HD/@_\
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M%M?+\SX+_"F[V=?.\,@;_KMD7],5B^'L8MK/Y_\  ,)<*Y@MG%_/_@'[%_\
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MOQD=Z4ON9A+*L?'>A+_P%GUS_P -"?"S_HI?@_\ \'UK_P#'*/\ AH3X6?\
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MBE^#_P#P?6O_ ,<H_P"&A/A9_P!%+\'_ /@^M?\ XY7*?\,4_ 3_ *)#X/\
M_!3%_A1_PQ3\!/\ HD/@_P#\%,7^% '5_P##0GPL_P"BE^#_ /P?6O\ \<H_
MX:$^%G_12_!__@^M?_CE<I_PQ3\!/^B0^#__  4Q?X4?\,4_ 3_HD/@__P %
M,7^% '5_\-"?"S_HI?@__P 'UK_\<H_X:$^%G_12_!__ (/K7_XY7*?\,4_
M3_HD/@__ ,%,7^%'_#%/P$_Z)#X/_P#!3%_A0!U?_#0GPL_Z*7X/_P#!]:__
M !RC_AH3X6?]%+\'_P#@^M?_ (Y7*?\ #%/P$_Z)#X/_ /!3%_A1_P ,4_ 3
M_HD/@_\ \%,7^% '5_\ #0GPL_Z*7X/_ /!]:_\ QRC_ (:$^%G_ $4OP?\
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M4_ 3_HD/@_\ \%,7^%'_  Q3\!/^B0^#_P#P4Q?X4 =7_P -"?"S_HI?@_\
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MP?\ ^#ZU_P#CE'_#0GPL_P"BE^#_ /P?6O\ \<KE/^&*?@)_T2'P?_X*8O\
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M&A/A9_T4OP?_ .#ZU_\ CE'_  T)\+/^BE^#_P#P?6O_ ,<KE/\ ABGX"?\
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M_@^M?_CE'_#0GPL_Z*7X/_\ !]:__'*Y3_ABGX"?]$A\'_\ @IB_PH_X8I^
MG_1(?!__ (*8O\* .K_X:$^%G_12_!__ (/K7_XY1_PT)\+/^BE^#_\ P?6O
M_P <KE/^&*?@)_T2'P?_ ."F+_"C_ABGX"?]$A\'_P#@IB_PH ZO_AH3X6?]
M%+\'_P#@^M?_ (Y1_P -"?"S_HI?@_\ \'UK_P#'*Y3_ (8I^ G_ $2'P?\
M^"F+_"C_ (8I^ G_ $2'P?\ ^"F+_"@#J_\ AH3X6?\ 12_!_P#X/K7_ ..4
M?\-"?"S_ **7X/\ _!]:_P#QRN4_X8I^ G_1(?!__@IB_P */^&*?@)_T2'P
M?_X*8O\ "@#J_P#AH3X6?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P 'UK_\<KE/
M^&*?@)_T2'P?_P""F+_"C_ABGX"?]$A\'_\ @IB_PH ZO_AH3X6?]%+\'_\
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M_ABGX"?]$A\'_P#@IB_PH_X8I^ G_1(?!_\ X*8O\* .K_X:$^%G_12_!_\
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M_1(?!_\ X*8O\*/^&*?@)_T2'P?_ ."F+_"@#J_^&A/A9_T4OP?_ .#ZU_\
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MP?\ ^#ZU_P#CE'_#0GPL_P"BE^#_ /P?6O\ \<KE/^&*?@)_T2'P?_X*8O\
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M&A/A9_T4OP?_ .#ZU_\ CE'_  T)\+/^BE^#_P#P?6O_ ,<KE/\ ABGX"?\
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M\-"?"S_HI?@__P 'UK_\<KE/^&*?@)_T2'P?_P""F+_"C_ABGX"?]$A\'_\
M@IB_PH ZO_AH3X6?]%+\'_\ @^M?_CE'_#0GPL_Z*7X/_P#!]:__ !RN4_X8
MI^ G_1(?!_\ X*8O\*/^&*?@)_T2'P?_ ."F+_"@#J_^&A/A9_T4OP?_ .#Z
MU_\ CE'_  T)\+/^BE^#_P#P?6O_ ,<KE/\ ABGX"?\ 1(?!_P#X*8O\*/\
MABGX"?\ 1(?!_P#X*8O\* .K_P"&A/A9_P!%+\'_ /@^M?\ XY1_PT)\+/\
MHI?@_P#\'UK_ /'*Y3_ABGX"?]$A\'_^"F+_  H_X8I^ G_1(?!__@IB_P *
M .K_ .&A/A9_T4OP?_X/K7_XY1_PT)\+/^BE^#__  ?6O_QRN4_X8I^ G_1(
M?!__ (*8O\*/^&*?@)_T2'P?_P""F+_"@#J_^&A/A9_T4OP?_P"#ZU_^.4?\
M-"?"S_HI?@__ ,'UK_\ '*Y3_ABGX"?]$A\'_P#@IB_PH_X8I^ G_1(?!_\
MX*8O\* .K_X:$^%G_12_!_\ X/K7_P".4?\ #0GPL_Z*7X/_ /!]:_\ QRN4
M_P"&*?@)_P!$A\'_ /@IB_PH_P"&*?@)_P!$A\'_ /@IB_PH ZO_ (:$^%G_
M $4OP?\ ^#ZU_P#CE'_#0GPL_P"BE^#_ /P?6O\ \<KE/^&*?@)_T2'P?_X*
M8O\ "C_ABGX"?]$A\'_^"F+_  H ZO\ X:$^%G_12_!__@^M?_CE'_#0GPL_
MZ*7X/_\ !]:__'*Y3_ABGX"?]$A\'_\ @IB_PH_X8I^ G_1(?!__ (*8O\*
M.K_X:$^%G_12_!__ (/K7_XY1_PT)\+/^BE^#_\ P?6O_P <KE/^&*?@)_T2
M'P?_ ."F+_"C_ABGX"?]$A\'_P#@IB_PH ZO_AH3X6?]%+\'_P#@^M?_ (Y1
M_P -"?"S_HI?@_\ \'UK_P#'*Y3_ (8I^ G_ $2'P?\ ^"F+_"C_ (8I^ G_
M $2'P?\ ^"F+_"@#J_\ AH3X6?\ 12_!_P#X/K7_ ..4?\-"?"S_ **7X/\
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M%\<+Q<RZ#IUB=H.)]5@//I\C-S^E=+8_\$M_BW=9\[5O"ED 1_K;Z=B?7&V
M]/?%/FR>G_)^##FR"E_S[_!_YGD>H_MD?&O5-_G?$;64W8!^SND'3TV*,?A7
MG?C'XC>*OB'=1W/BCQ'JGB">/B-M2O))_+'HH8G:/I7V-I__  2A\8R$?;O'
M&AVXW8/V>WFE^7UY"\^WZURWQN_X)O\ BSX4>!9_$FCZZGC$68:2\L[6P:&6
M*(<F11O8N .2  0*UHX[+%-1I.*;[*WXV-Z&99/&HH4914GM:-OQL?(%%!R.
M#P:!D\#DU[I],/A\OSH_.W&+<-^S&[;GG&>]?K!^RS-^S;\-? ^CZYH&N>&]
M(UV]M@]Q<^(M7M?[4C8C#(VYQY?0_*@4$8.#7C'[%_[!=OXDTZV\:_$W2C)I
MUP@DL-#NU($R$<22KUVD<A3U!!Z5]:_\,4_ 4\GX0^#R?^P3%_A7P&>YC&JU
MAZ,GIO9Z/R\S\NXES:%=K"X>3T^)IZ/R\SJO^&A/A9_T4OP?_P"#ZU_^.4?\
M-"?"S_HI?@__ ,'UK_\ '*Y3_ABGX"?]$A\'_P#@IB_PH_X8I^ G_1(?!_\
MX*8O\*^./@#J_P#AH3X6?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P 'UK_\<KE/
M^&*?@)_T2'P?_P""F+_"C_ABGX"?]$A\'_\ @IB_PH ZO_AH3X6?]%+\'_\
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M_ABGX"?]$A\'_P#@IB_PH_X8I^ G_1(?!_\ X*8O\* .K_X:$^%G_12_!_\
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M_1(?!_\ X*8O\*/^&*?@)_T2'P?_ ."F+_"@#J_^&A/A9_T4OP?_ .#ZU_\
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MP?\ ^#ZU_P#CE'_#0GPL_P"BE^#_ /P?6O\ \<KE/^&*?@)_T2'P?_X*8O\
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M&A/A9_T4OP?_ .#ZU_\ CE'_  T)\+/^BE^#_P#P?6O_ ,<KE/\ ABGX"?\
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M_@^M?_CE'_#0GPL_Z*7X/_\ !]:__'*Y3_ABGX"?]$A\'_\ @IB_PH_X8I^
MG_1(?!__ (*8O\* .K_X:$^%G_12_!__ (/K7_XY1_PT)\+/^BE^#_\ P?6O
M_P <KE/^&*?@)_T2'P?_ ."F+_"C_ABGX"?]$A\'_P#@IB_PH ZO_AH3X6?]
M%+\'_P#@^M?_ (Y1_P -"?"S_HI?@_\ \'UK_P#'*Y3_ (8I^ G_ $2'P?\
M^"F+_"C_ (8I^ G_ $2'P?\ ^"F+_"@#J_\ AH3X6?\ 12_!_P#X/K7_ ..4
M?\-"?"S_ **7X/\ _!]:_P#QRN4_X8I^ G_1(?!__@IB_P */^&*?@)_T2'P
M?_X*8O\ "@#J_P#AH3X6?]%+\'_^#ZU_^.4?\-"?"S_HI?@__P 'UK_\<KE/
M^&*?@)_T2'P?_P""F+_"C_ABGX"?]$A\'_\ @IB_PH ZO_AH3X6?]%+\'_\
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M_ABGX"?]$A\'_P#@IB_PH_X8I^ G_1(?!_\ X*8O\* .K_X:$^%G_12_!_\
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M@5_P42\:?L9>%+?X3_'#X<:Y)<:#&;72[J,B&?R%'R1-O^25%^4+(C8V8X;
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M'/%OC'PI=>#_ ()^&92\%I>*VR>,.K20H[*IFEF**KNH"HBXZ@;OUG50BA5
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MJYS^ZLEC/YK@UCWG[#_P-OF=I/A[8*7&#Y-Q<1#IC@+(,?45LN),/UA+\/\
M,WCQ=A/M4Y?A_F?BO17[&7?_  3S^ ]RJB/P;-:D=3#J]X<_7=*:Q;S_ ()J
M_!6Z\SR['6;3=T\G4V.SZ;@WZYK5<18-[J7W+_,WCQ9@'O&2^2_S/R-K2L_$
MNKZ?Y?V75;VV\OA/)N'3;],'BOU&N_\ @EM\([EE,>K>+;4#J(;ZW.?KNMS6
M)>?\$I? +J_V7QAXDA8GY#,+>0 9[@1KGCZ5K_;V!ENW]QM_K-ELOB;^X_.V
MT^+7CC3U9;7QEX@ME8Y(AU2=0?KAZW+/]I/XLV+JT7Q-\7?*,!9-;N74#_=9
MR*^W;K_@DWH+R VWQ$U&*/'*RZ;&YS]1(O\ *L*Z_P""2=PD8-M\48Y9,_=E
MT$H,?47+?RH_M7*Y[M?^ O\ R#^V\FJ?%)?.+_R/E>U_:^^,]G'LC^(^O,,Y
M_>W'F'\V!-;MI^WA\=[.0O'X_N&)&/WVGVD@_)H2*]SO/^"3OBB-G^R^/M(F
M7'RF:REC)..A +8Y^M8=W_P2I^)B*OV7Q1X3F/\ %YT]S'CZ8@;-'UO*)[\O
M_@/_   ^O9#4WY/G'_-' V?_  44^.MJL8D\46EV5.2TVDVH+\YP=L:_3C%;
M=G_P4T^,UMO\Q] N]V,>=IQ&WZ;7'ZU9O/\ @F#\8;7S/+NO#-WLZ>3J$@W_
M $W1+^N*Q;O_ ()O_&^W91'HFFW0/4PZI",?7<11?)Y_R?@@OD%3_GW^".LL
M_P#@JA\58?+%QX?\(W*+PQ%I<H[>^1<8!_"MFU_X*N^-D5OM/@K0)FSP8I9X
MP/S9J\?O/V OCS9J[MX#:5%.,PZI9.3SC(439_2L:Z_8M^-MG($D^'>JLV,_
MNC%(/S5R*/JV43VY/_ O^"'U/(:FW)\I+_,^E;/_ (*T:BCJ;KX:6LR8^80Z
MRT9)]B8&Q6S:?\%:;!X\W7PRN87S]V'6ED&/7)@7^5?&EU^R_P#%ZSC#R?#/
MQ4RYQ^ZTB>0_DJDUCWGP/^(VG,ZW?@#Q1;,@W,LVC7*%1C.3E..*/[+RN>R7
M_@3_ ,P_L;)9[17RD_\ ,^_[3_@J]X+>0BY\$Z]"F.&AF@D.?H67^=;-G_P5
M2^%DRQBX\.^+K>1CAMMK:NB\]<_: 3Q[5^9=WX)\16"J;G0-4MPW"F:SD7/T
MRM9$T,EO*T4L;12*<,CJ01]0:/[#P$OA3^\/]6LLG\*?RD?K/:?\%-?@U<;O
M,;Q!:[>GG:<#N^FUS^M;5G_P46^!=UY?F>)KRTW]?.TFY.SZ[4;],U^/=%9O
MA[!O9R7S7^1E+A3 /9R7S7^1^SUI^WE\"+U6:/Q_ H4X/G:?>1G\ T(S6W:?
MM@_!>]D5(_B/H:EAD>=.8Q^)8 "OQ&HK)\-X;I.7X?Y&$N$<']FI+\/\C]TK
M3]I;X2WT>^+XF^$0,[<2:W;1MGZ,X-;MK\7/ U](4MO&GAZX<#)6+58&('K@
M/7X(45B^&J72H_N,)<(4?LUG]R/Z![/Q1HVH+&UIJ]C<K(=J&&Y1PQSC P>>
M>*U*_GDJQ9ZC=Z?N-K=36V[[WDR%,XZ9P:R?#/:M_P"2_P#!,)<'_P M?_R7
M_P"V/Z$Z*_ :S^)'BW3S&;7Q1K5L8^$\G4)DV?3#<5M6GQ^^)^GJRVOQ'\6V
MRL<E8=<NE!/KQ)6+X:J=*J^XPEP?5^S67W?\$_=^BOP\M/VL?C'9.K1_$GQ&
MQ48'G7SR#\0Q.:V+3]MSXX64>R/XAZBPSG]]#!(?S:,G\*R?#>(Z3C^/^1A+
MA'%_9J1_'_(_:NBOQQM/^"A7QYMY"TGC.*Z!&-LVD60 ]_EA!K9L_P#@I1\:
M[58Q)J.CW94Y)FTQ!OYS@[2OTXQ6+X=QBZQ^]_Y'/+A/'K:47\W_ )'ZZT5^
M4MG_ ,%2/B[;;_,TKPG=[L8\ZPN!M^FV<?K6W9_\%6OB#'Y?VKPAX:FQ]_R1
M<1[OIF1L?K63R#&K9+[S"7"^8K:*?S/TO\0:]I_A?1;W5]5NXK'3K.)II[B9
M@J1H!DDDU^2G[8G[8VI?'G69-#T.66P\%VDG[N)3AKMP>)']O0?C7/?M&?MG
M>,_VB]/M]*OX+?0M"B82-IU@[E9G'(:0L?FP>0.F>:\ KZ/*<G^J_OL1K/HN
MW_!/KLCR!8)_6,4KU.BZ+_@_D?H9^QG^WI;66G0>#_B;JP@BM8B+37+Q\C:H
MX21NI.. >^/6IOC_ /\ !3Y(_M.C_"BP\QN4/B/4XN!_M0P-U]FD_%*_.VK.
MFZ=<ZQJ%M8V4+7-W<2+%%#&,L[$X 'XUVRR;!NLZ\H_+I_7X'HRX?P#Q#Q,H
M_+[-^]OZ1H^,/&FO?$#79]9\2:O=ZUJD_P!^ZO)3(^.P&>BCLHP!V%:?PU^$
M_B[XOZ\FC^$="NM:O3C?Y*8CA4G&Z20X5%]V(K[4_9__ ."8=S>"VUGXJW_V
M2$X=?#VER@R-[33CA?=8\]?OBOOSP7X$\/?#G08-%\,:/9Z)I</W;:SB"*3W
M9CU9CW8DD]S7#C,]H8=>SPRYFON7^?R^\\S'\38;"+V6#7.U_P" K_/Y:>9\
M=? '_@F7X>\+"VU?XF7:>)M47#C1[1F2QB/7#MPTI_[Y7J"&%?;.EZ79:'I]
MO8:=9V^GV-N@CAM;6)8XHE'1550 !["K5%?#8G&5\9+FK2O^2^1^;XS'XG'S
MY\1._ET7H@HHHKC//"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8;A?$UL/*I4?+/HO\^WD?NA17GWP/^-GASX\>![;Q%X>NTD!_=W5H6'FVLP
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M_9/^,>I &'X;>(TRN[_2+!X>/^!@<^W6G_9F54_B2^<G_F/^Q\EI?$E\Y/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^7_!-X\59@M^5_+_ ()^.5W_ ,$\_CQ;,HC\&PW0/4PZO9C'UW2BL2\_8?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O/_C+\"_"/QX\
M.)HWBNQ:>*.020W-NPCGA(()VO@X!Z$8Z&O0**N%25.2G!V:-*=2=&:J4W9K
MJC*\+^%]*\%Z#9Z+HEE%IVF6<8CAMX1A5 _F?<UJT45+;D[LB4G)W;U"BBBD
M(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH _%;]I;_ )3):1_V.?A/_P!$Z=7[4U^*W[2W_*9+2/\ L<_"?_HG3J_:
MF@ HHHH **** /E7_@J/_P F)_$W_N&?^G2THH_X*C_\F)_$W_N&?^G2THH
M/^"7'_)B?PR_[B?_ *=+NOJJOE7_ ()<?\F)_#+_ +B?_ITNZ^JJ "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q6
M_P""*G_)TWBG_L3+K_TNL:_:FOQ6_P""*G_)TWBG_L3+K_TNL:_:F@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _%;]I;_E,EI'
M_8Y^$_\ T3IU?M37XK?M+?\ *9+2/^QS\)_^B=.K]J: "BBB@ HHHH ^5?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH _%;]I;_E,EI'_ &.?A/\ ]$Z=
M7[4U^*W[2W_*9+2/^QS\)_\ HG3J_:F@ HHHH **** /E7_@J/\ \F)_$W_N
M&?\ ITM**/\ @J/_ ,F)_$W_ +AG_ITM** #_@EQ_P F)_#+_N)_^G2[KZJK
MY5_X)<?\F)_#+_N)_P#ITNZ^JJ "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** /Q6_X(J?\G3>*?^Q,NO\ TNL:_:FO
MQ6_X(J?\G3>*?^Q,NO\ TNL:_:F@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH _%;]I;_E,EI'_8Y^$__1.G5^U-?BM^TM_RF2TC
M_L<_"?\ Z)TZOVIH **** "BBB@#Y5_X*C_\F)_$W_N&?^G2THH_X*C_ /)B
M?Q-_[AG_ *=+2B@ _P""7'_)B?PR_P"XG_Z=+NOJJOE7_@EQ_P F)_#+_N)_
M^G2[KZJH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH _%;_@BI_P G3>*?^Q,NO_2ZQK]J:_%;_@BI_P G3>*?^Q,N
MO_2ZQK]J: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /Q6_:6_P"4R6D?]CGX3_\ 1.G5^U-?BM^TM_RF2TC_ +'/PG_Z)TZOVIH
M**** "BBB@#Y5_X*C_\ )B?Q-_[AG_ITM**/^"H__)B?Q-_[AG_ITM** #_@
MEQ_R8G\,O^XG_P"G2[KZJKY5_P""7'_)B?PR_P"XG_Z=+NOJJ@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\5O\
M@BI_R=-XI_[$RZ_]+K&OVIK\5O\ @BI_R=-XI_[$RZ_]+K&OVIH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /Q6_:6_Y3):1_V.
M?A/_ -$Z=7[4U^*W[2W_ "F2TC_L<_"?_HG3J_:F@ HHHH **** /E7_ (*C
M_P#)B?Q-_P"X9_Z=+2BC_@J/_P F)_$W_N&?^G2THH /^"7'_)B?PR_[B?\
MZ=+NOJJOE7_@EQ_R8G\,O^XG_P"G2[KZJH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _%;_@BI_R=-XI_P"Q,NO_
M $NL:_:FOQ6_X(J?\G3>*?\ L3+K_P!+K&OVIH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNZ^JJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /Q6_X(J?\ )TWBG_L3+K_TNL:_:FOQ6_X(J?\ )TWBG_L3+K_T
MNL:_:F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M _%;]I;_ )3):1_V.?A/_P!$Z=7[4U^*W[2W_*9+2/\ L<_"?_HG3J_:F@ H
MHHH **** /E7_@J/_P F)_$W_N&?^G2THH_X*C_\F)_$W_N&?^G2THH /^"7
M'_)B?PR_[B?_ *=+NOJJOE7_ ()<?\F)_#+_ +B?_ITNZ^JJ "BBB@ HHHH
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M/4 =!1110 4444 ?BM_P14_Y.F\4_P#8F77_ *76-?M37XK?\$5/^3IO%/\
MV)EU_P"EUC7[4T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% 'XK?M+?\IDM(_P"QS\)_^B=.K]J:_%;]I;_E,EI'_8Y^$_\ T3IU
M?M30 4444 %%%% 'RK_P5'_Y,3^)O_<,_P#3I:44?\%1_P#DQ/XF_P#<,_\
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MM_X*U?!?Q#8ZEX"_: \'VK7&I^#98HM1,:,[0Q1S^?:W! _@24R!CV\Q.P)
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M% 'RK_PQ#XG_ .CF/C!_X.(O_C='_#$/B?\ Z.8^,'_@XB_^-U]544 ?*O\
MPQ#XG_Z.8^,'_@XB_P#C='_#$/B?_HYCXP?^#B+_ .-U]544 ?*O_#$/B?\
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M% 'RK_PQ#XG_ .CF/C!_X.(O_C='_#$/B?\ Z.8^,'_@XB_^-U]544 ?*O\
MPQ#XG_Z.8^,'_@XB_P#C='_#$/B?_HYCXP?^#B+_ .-U]544 ?*O_#$/B?\
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M% 'RK_PQ#XG_ .CF/C!_X.(O_C='_#$/B?\ Z.8^,'_@XB_^-U]544 ?*O\
MPQ#XG_Z.8^,'_@XB_P#C='_#$/B?_HYCXP?^#B+_ .-U]544 ?*O_#$/B?\
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M% 'RK_PQ#XG_ .CF/C!_X.(O_C='_#$/B?\ Z.8^,'_@XB_^-U]544 ?*O\
MPQ#XG_Z.8^,'_@XB_P#C='_#$/B?_HYCXP?^#B+_ .-U]544 ?*O_#$/B?\
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M% 'RK_PQ#XG_ .CF/C!_X.(O_C='_#$/B?\ Z.8^,'_@XB_^-U]544 ?*O\
MPQ#XG_Z.8^,'_@XB_P#C='_#$/B?_HYCXP?^#B+_ .-U]544 ?*O_#$/B?\
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M% 'RK_PQ#XG_ .CF/C!_X.(O_C='_#$/B?\ Z.8^,'_@XB_^-U]544 ?*O\
MPQ#XG_Z.8^,'_@XB_P#C='_#$/B?_HYCXP?^#B+_ .-U]544 ?*O_#$/B?\
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M% 'RK_PQ#XG_ .CF/C!_X.(O_C='_#$/B?\ Z.8^,'_@XB_^-U]544 ?*O\
MPQ#XG_Z.8^,'_@XB_P#C='_#$/B?_HYCXP?^#B+_ .-U]544 ?*O_#$/B?\
MZ.8^,'_@XB_^-T?\,0^)_P#HYCXP?^#B+_XW7U510!\J_P##$/B?_HYCXP?^
M#B+_ .-T?\,0^)_^CF/C!_X.(O\ XW7U510!\J_\,0^)_P#HYCXP?^#B+_XW
M1_PQ#XG_ .CF/C!_X.(O_C=?55% 'RK_ ,,0^)_^CF/C!_X.(O\ XW1_PQ#X
MG_Z.8^,'_@XB_P#C=?55% 'RK_PQ#XG_ .CF/C!_X.(O_C='_#$/B?\ Z.8^
M,'_@XB_^-U]544 ?*O\ PQ#XG_Z.8^,'_@XB_P#C='_#$/B?_HYCXP?^#B+_
M .-U]544 ?*O_#$/B?\ Z.8^,'_@XB_^-T?\,0^)_P#HYCXP?^#B+_XW7U51
M0!\J_P##$/B?_HYCXP?^#B+_ .-T?\,0^)_^CF/C!_X.(O\ XW7U510!\J_\
M,0^)_P#HYCXP?^#B+_XW1_PQ#XG_ .CF/C!_X.(O_C=?55% 'RK_ ,,0^)_^
MCF/C!_X.(O\ XW1_PQ#XG_Z.8^,'_@XB_P#C=?55% 'RK_PQ#XG_ .CF/C!_
MX.(O_C='_#$/B?\ Z.8^,'_@XB_^-U]544 ?*O\ PQ#XG_Z.8^,'_@XB_P#C
M='_#$/B?_HYCXP?^#B+_ .-U]544 ?*O_#$/B?\ Z.8^,'_@XB_^-T?\,0^)
M_P#HYCXP?^#B+_XW7U510!\J_P##$/B?_HYCXP?^#B+_ .-T?\,0^)_^CF/C
M!_X.(O\ XW7U510!\J_\,0^)_P#HYCXP?^#B+_XW1_PQ#XG_ .CF/C!_X.(O
M_C=?55% 'RK_ ,,0^)_^CF/C!_X.(O\ XW1_PQ#XG_Z.8^,'_@XB_P#C=?55
M% 'RK_PQ#XG_ .CF/C!_X.(O_C='_#$/B?\ Z.8^,'_@XB_^-U]544 ?*O\
MPQ#XG_Z.8^,'_@XB_P#C='_#$/B?_HYCXP?^#B+_ .-U]544 ?*O_#$/B?\
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M% 'RK_PQ#XG_ .CF/C!_X.(O_C='_#$/B?\ Z.8^,'_@XB_^-U]544 ?*O\
MPQ#XG_Z.8^,'_@XB_P#C='_#$/B?_HYCXP?^#B+_ .-U]544 ?*O_#$/B?\
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M% 'RK_PQ#XG_ .CF/C!_X.(O_C='_#$/B?\ Z.8^,'_@XB_^-U]544 ?*O\
MPQ#XG_Z.8^,'_@XB_P#C='_#$/B?_HYCXP?^#B+_ .-U]544 ?*O_#$/B?\
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M% 'RK_PQ#XG_ .CF/C!_X.(O_C='_#$/B?\ Z.8^,'_@XB_^-U]544 ?*O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 ?BM^TM_RF2TC_L<_"?_ *)TZOVIK\5O
MVEO^4R6D?]CGX3_]$Z=7[4T %%%% !1110!\J_\ !4?_ ),3^)O_ '#/_3I:
M44?\%1_^3$_B;_W#/_3I:44 '_!+C_DQ/X9?]Q/_ -.EW7U57RK_ ,$N/^3$
M_AE_W$__ $Z7=?55 !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'XK?\$5/^3IO%/_ &)EU_Z76-?M37XK?\$5/^3I
MO%/_ &)EU_Z76-?M30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 ?BM^TM_RF2TC_L<_"?\ Z)TZOVIK\5OVEO\ E,EI'_8Y^$__
M $3IU?M30 4444 %%%% 'RK_ ,%1_P#DQ/XF_P#<,_\ 3I:44?\ !4?_ ),3
M^)O_ '#/_3I:44 '_!+C_DQ/X9?]Q/\ ].EW7U57RK_P2X_Y,3^&7_<3_P#3
MI=U]54 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?BM_P14_Y.F\4_P#8F77_ *76-?M37XK?\$5/^3IO%/\ V)EU
M_P"EUC7[4T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% 'XK?M+?\IDM(_P"QS\)_^B=.K]J:_%;]I;_E,EI'_8Y^$_\ T3IU?M30
M 4444 %%%% 'RK_P5'_Y,3^)O_<,_P#3I:44?\%1_P#DQ/XF_P#<,_\ 3I:4
M4 '_  2X_P"3$_AE_P!Q/_TZ7=?55?*O_!+C_DQ/X9?]Q/\ ].EW7U50 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!^*W_!%3_DZ;Q3_V)EU_Z76-?M37XK?\$5/^3IO%/_8F77_I=8U^U- !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^*W[2W_ "F2
MTC_L<_"?_HG3J_:FOQ6_:6_Y3):1_P!CGX3_ /1.G5^U- !1110 4444 ?*O
M_!4?_DQ/XF_]PS_TZ6E%'_!4?_DQ/XF_]PS_ -.EI10 ?\$N/^3$_AE_W$__
M $Z7=?55?*O_  2X_P"3$_AE_P!Q/_TZ7=?55 !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'XK?\ !%3_ ).F\4_]
MB9=?^EUC7[4U^*W_  14_P"3IO%/_8F77_I=8U^U- !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!^*W[2W_*9+2/^QS\)_\ HG3J
M_:FOQ6_:6_Y3):1_V.?A/_T3IU?M30 4444 %%%% 'RK_P %1_\ DQ/XF_\
M<,_].EI11_P5'_Y,3^)O_<,_].EI10 ?\$N/^3$_AE_W$_\ TZ7=?55?*O\
MP2X_Y,3^&7_<3_\ 3I=U]54 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 ?BM_P14_Y.F\4_\ 8F77_I=8U^U-?BM_
MP14_Y.F\4_\ 8F77_I=8U^U- !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#8F77_ *76-?M30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ?BM^TM_RF2TC_ +'/PG_Z)TZOVIK\5OVEO^4R6D?]CGX3_P#1
M.G5^U- !1110 4444 ?*O_!4?_DQ/XF_]PS_ -.EI11_P5'_ .3$_B;_ -PS
M_P!.EI10 ?\ !+C_ ),3^&7_ '$__3I=U]55\J_\$N/^3$_AE_W$_P#TZ7=?
M55 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% 'XK?\$5/^3IO%/_8F77_I=8U^U-?BM_P14_Y.F\4_]B9=?^EUC7[4
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'XK?M
M+?\ *9+2/^QS\)_^B=.K]J:_%;]I;_E,EI'_ &.?A/\ ]$Z=7[4T %%%% !1
M110!\J_\%1_^3$_B;_W#/_3I:44?\%1_^3$_B;_W#/\ TZ6E% !_P2X_Y,3^
M&7_<3_\ 3I=U]55\J_\ !+C_ ),3^&7_ '$__3I=U]54 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?BM_P $5/\
MDZ;Q3_V)EU_Z76-?M37XK?\ !%3_ ).F\4_]B9=?^EUC7[4T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'XK?M+?\IDM(_['/PG
M_P"B=.K]J:_%;]I;_E,EI'_8Y^$__1.G5^U- !1110 4444 ?*O_  5'_P"3
M$_B;_P!PS_TZ6E%'_!4?_DQ/XF_]PS_TZ6E% !_P2X_Y,3^&7_<3_P#3I=U]
M55\J_P#!+C_DQ/X9?]Q/_P!.EW7U50 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!^*W_!%3_DZ;Q3_P!B9=?^EUC7
M[4U^*W_!%3_DZ;Q3_P!B9=?^EUC7[4T %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!^*W[2W_*9+2/\ L<_"?_HG3J_:FOQ6_:6_Y3):1_V.
M?A/_ -$Z=7[4T %%%% !1110!\J_\%1_^3$_B;_W#/\ TZ6E%'_!4?\ Y,3^
M)O\ W#/_ $Z6E% !_P $N/\ DQ/X9?\ <3_].EW7U57RK_P2X_Y,3^&7_<3_
M /3I=U]54 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 ?BM_P14_Y.F\4_]B9=?^EUC7[4U^*W_!%3_DZ;Q3_V)EU_
MZ76-?M30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?BM^TM_P IDM(_['/PG_Z)TZOVIK\5OVEO^4R6D?\ 8Y^$_P#T3IU?M30
M4444 %%%% 'RK_P5'_Y,3^)O_<,_].EI11_P5'_Y,3^)O_<,_P#3I:44 '_!
M+C_DQ/X9?]Q/_P!.EW7U57RK_P $N/\ DQ/X9?\ <3_].EW7U50 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^*W_
M  14_P"3IO%/_8F77_I=8U^U-?BM_P $5/\ DZ;Q3_V)EU_Z76-?M30 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?BM^TM_RF2T
MC_L<_"?_ *)TZOVIK\5OVEO^4R6D?]CGX3_]$Z=7[4T %%%% !1110!\J_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW7U57RK_ ,$N/^3$_AE_W$__ $Z7=?55 !1110 4444 %%%% !1110!^;/\
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M (;B'_Y!H_X:6_X*&?\ 0(^('_AN(?\ Y!H _:FBOQ6_X:6_X*&?] CX@?\
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M_P -Q#_\@T ?M317XK?\-+?\%#/^@1\0/_#<0_\ R#1_PTM_P4,_Z!'Q _\
M#<0__(- '[4T5^*W_#2W_!0S_H$?$#_PW$/_ ,@T?\-+?\%#/^@1\0/_  W$
M/_R#0!^U-%?BM_PTM_P4,_Z!'Q _\-Q#_P#(-'_#2W_!0S_H$?$#_P -Q#_\
M@T ?M317XK?\-+?\%#/^@1\0/_#<0_\ R#1_PTM_P4,_Z!'Q _\ #<0__(-
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M (;B'_Y!H_X:6_X*&?\ 0(^('_AN(?\ Y!H _:FBOQ6_X:6_X*&?] CX@?\
MAN(?_D&C_AI;_@H9_P! CX@?^&XA_P#D&@#]J:*_%;_AI;_@H9_T"/B!_P"&
MXA_^0:/^&EO^"AG_ $"/B!_X;B'_ .0: /VIHK\5O^&EO^"AG_0(^('_ (;B
M'_Y!H_X:6_X*&?\ 0(^('_AN(?\ Y!H _:FBOQ6_X:6_X*&?] CX@?\ AN(?
M_D&C_AI;_@H9_P! CX@?^&XA_P#D&@#]J:*_%;_AI;_@H9_T"/B!_P"&XA_^
M0:/^&EO^"AG_ $"/B!_X;B'_ .0: /VIHK\5O^&EO^"AG_0(^('_ (;B'_Y!
MH_X:6_X*&?\ 0(^('_AN(?\ Y!H _:FBOQ6_X:6_X*&?] CX@?\ AN(?_D&C
M_AI;_@H9_P! CX@?^&XA_P#D&@#]J:*_%;_AI;_@H9_T"/B!_P"&XA_^0:/^
M&EO^"AG_ $"/B!_X;B'_ .0: /VIHK\5O^&EO^"AG_0(^('_ (;B'_Y!H_X:
M6_X*&?\ 0(^('_AN(?\ Y!H _:FBOQ6_X:6_X*&?] CX@?\ AN(?_D&C_AI;
M_@H9_P! CX@?^&XA_P#D&@#]J:*_%;_AI;_@H9_T"/B!_P"&XA_^0:/^&EO^
M"AG_ $"/B!_X;B'_ .0: /VIHK\5O^&EO^"AG_0(^('_ (;B'_Y!H_X:6_X*
M&?\ 0(^('_AN(?\ Y!H _:FBOQ6_X:6_X*&?] CX@?\ AN(?_D&C_AI;_@H9
M_P! CX@?^&XA_P#D&@#]J:*_%;_AI;_@H9_T"/B!_P"&XA_^0:/^&EO^"AG_
M $"/B!_X;B'_ .0: /VIHK\5O^&EO^"AG_0(^('_ (;B'_Y!H_X:6_X*&?\
M0(^('_AN(?\ Y!H _:FBOQ6_X:6_X*&?] CX@?\ AN(?_D&C_AI;_@H9_P!
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M_P -Q#_\@T?\-+?\%#/^@1\0/_#<0_\ R#0!^U-%?BM_PTM_P4,_Z!'Q _\
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M_P#(- '[4T5^*W_#2W_!0S_H$?$#_P -Q#_\@T?\-+?\%#/^@1\0/_#<0_\
MR#0!^U-%?BM_PTM_P4,_Z!'Q _\ #<0__(-'_#2W_!0S_H$?$#_PW$/_ ,@T
M ?M317XK?\-+?\%#/^@1\0/_  W$/_R#1_PTM_P4,_Z!'Q _\-Q#_P#(- '[
M4T5^*W_#2W_!0S_H$?$#_P -Q#_\@T?\-+?\%#/^@1\0/_#<0_\ R#0!^U-%
M?BM_PTM_P4,_Z!'Q _\ #<0__(-'_#2W_!0S_H$?$#_PW$/_ ,@T ?M317XK
M?\-+?\%#/^@1\0/_  W$/_R#1_PTM_P4,_Z!'Q _\-Q#_P#(- '[4T5^*W_#
M2W_!0S_H$?$#_P -Q#_\@T?\-+?\%#/^@1\0/_#<0_\ R#0!^U-%?BM_PTM_
MP4,_Z!'Q _\ #<0__(-'_#2W_!0S_H$?$#_PW$/_ ,@T ?M317XK?\-+?\%#
M/^@1\0/_  W$/_R#1_PTM_P4,_Z!'Q _\-Q#_P#(- '[4T5^*W_#2W_!0S_H
M$?$#_P -Q#_\@T?\-+?\%#/^@1\0/_#<0_\ R#0!^U-%?BM_PTM_P4,_Z!'Q
M _\ #<0__(-'_#2W_!0S_H$?$#_PW$/_ ,@T ?M37S_^R=\4O$_Q,U;XW0^)
M-3_M*+PY\0]3T+2U^SQ1?9[*)8C'%\BKOQN;YFRQSR37YK?\-+?\%#/^@1\0
M/_#<0_\ R#7*>!/B)^W+\,[CQ+-X;\*?$#39?$>K3:[JC?\ " "7[1>RA1)+
M\]FVS.U?E7"C' % '[J45^*W_#2W_!0S_H$?$#_PW$/_ ,@T?\-+?\%#/^@1
M\0/_  W$/_R#0!^U-%?BM_PTM_P4,_Z!'Q _\-Q#_P#(-'_#2W_!0S_H$?$#
M_P -Q#_\@T ?M317XK?\-+?\%#/^@1\0/_#<0_\ R#1_PTM_P4,_Z!'Q _\
M#<0__(- '[4T5^*W_#2W_!0S_H$?$#_PW$/_ ,@T?\-+?\%#/^@1\0/_  W$
M/_R#0!^U-%?BM_PTM_P4,_Z!'Q _\-Q#_P#(-'_#2W_!0S_H$?$#_P -Q#_\
M@T ?M317XK?\-+?\%#/^@1\0/_#<0_\ R#1_PTM_P4,_Z!'Q _\ #<0__(-
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M_P#(-'_#2W_!0S_H$?$#_P -Q#_\@T ?M317XK?\-+?\%#/^@1\0/_#<0_\
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M $"/B!_X;B'_ .0:/^&EO^"AG_0(^('_ (;B'_Y!H _:FBOQ6_X:6_X*&?\
M0(^('_AN(?\ Y!H_X:6_X*&?] CX@?\ AN(?_D&@#]J:*_%;_AI;_@H9_P!
MCX@?^&XA_P#D&C_AI;_@H9_T"/B!_P"&XA_^0: /VIHK\5O^&EO^"AG_ $"/
MB!_X;B'_ .0:/^&EO^"AG_0(^('_ (;B'_Y!H _:FBOQ6_X:6_X*&?\ 0(^(
M'_AN(?\ Y!H_X:6_X*&?] CX@?\ AN(?_D&@#]J:*_%;_AI;_@H9_P! CX@?
M^&XA_P#D&C_AI;_@H9_T"/B!_P"&XA_^0: /VIHK\5O^&EO^"AG_ $"/B!_X
M;B'_ .0:/^&EO^"AG_0(^('_ (;B'_Y!H _:FBOQ6_X:6_X*&?\ 0(^('_AN
M(?\ Y!H_X:6_X*&?] CX@?\ AN(?_D&@#]J:*_%;_AI;_@H9_P! CX@?^&XA
M_P#D&C_AI;_@H9_T"/B!_P"&XA_^0: /VIHK\5O^&EO^"AG_ $"/B!_X;B'_
M .0:/^&EO^"AG_0(^('_ (;B'_Y!H _:FBOQ6_X:6_X*&?\ 0(^('_AN(?\
MY!H_X:6_X*&?] CX@?\ AN(?_D&@#]J:*_%;_AI;_@H9_P! CX@?^&XA_P#D
M&C_AI;_@H9_T"/B!_P"&XA_^0: /VIHK\5O^&EO^"AG_ $"/B!_X;B'_ .0:
M/^&EO^"AG_0(^('_ (;B'_Y!H _:FBOQ6_X:6_X*&?\ 0(^('_AN(?\ Y!H_
MX:6_X*&?] CX@?\ AN(?_D&@#]J:*_%;_AI;_@H9_P! CX@?^&XA_P#D&C_A
MI;_@H9_T"/B!_P"&XA_^0: /VIHK\5O^&EO^"AG_ $"/B!_X;B'_ .0:/^&E
MO^"AG_0(^('_ (;B'_Y!H _:FBOQ6_X:6_X*&?\ 0(^('_AN(?\ Y!H_X:6_
MX*&?] CX@?\ AN(?_D&@#]J:*_%;_AI;_@H9_P! CX@?^&XA_P#D&C_AI;_@
MH9_T"/B!_P"&XA_^0: /VIHK\5O^&EO^"AG_ $"/B!_X;B'_ .0:/^&EO^"A
MG_0(^('_ (;B'_Y!H _:FBOQ6_X:6_X*&?\ 0(^('_AN(?\ Y!H_X:6_X*&?
M] CX@?\ AN(?_D&@#]*?VP_BEXG^%FD_"F;POJ?]ERZY\0]&T+4&^SQ3>=93
MM()HOWBMMW;1\RX88X(KZ K\*_B#\1/VY?BG;Z%#XH\*?$#4XM#U:WUW3U_X
M0 0^3>P%C#+^[LUW;=Q^5LJ<\@UU?_#2W_!0S_H$?$#_ ,-Q#_\ (- '[4T5
M^*W_  TM_P %#/\ H$?$#_PW$/\ \@T?\-+?\%#/^@1\0/\ PW$/_P @T ?M
M317XK?\ #2W_  4,_P"@1\0/_#<0_P#R#1_PTM_P4,_Z!'Q _P##<0__ "#0
M!^U-%?BM_P -+?\ !0S_ *!'Q _\-Q#_ /(-'_#2W_!0S_H$?$#_ ,-Q#_\
M(- '[4T5^*W_  TM_P %#/\ H$?$#_PW$/\ \@T?\-+?\%#/^@1\0/\ PW$/
M_P @T ?M317XK?\ #2W_  4,_P"@1\0/_#<0_P#R#1_PTM_P4,_Z!'Q _P##
M<0__ "#0!^U-%?BM_P -+?\ !0S_ *!'Q _\-Q#_ /(-'_#2W_!0S_H$?$#_
M ,-Q#_\ (- '[4T5^*W_  TM_P %#/\ H$?$#_PW$/\ \@T?\-+?\%#/^@1\
M0/\ PW$/_P @T ?M317XK?\ #2W_  4,_P"@1\0/_#<0_P#R#1_PTM_P4,_Z
M!'Q _P##<0__ "#0!^U-%?BM_P -+?\ !0S_ *!'Q _\-Q#_ /(-'_#2W_!0
MS_H$?$#_ ,-Q#_\ (- '[4T5^*W_  TM_P %#/\ H$?$#_PW$/\ \@T?\-+?
M\%#/^@1\0/\ PW$/_P @T ?M317XK?\ #2W_  4,_P"@1\0/_#<0_P#R#1_P
MTM_P4,_Z!'Q _P##<0__ "#0!^U-%?BM_P -+?\ !0S_ *!'Q _\-Q#_ /(-
M'_#2W_!0S_H$?$#_ ,-Q#_\ (- '[4T5^*W_  TM_P %#/\ H$?$#_PW$/\
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MHAK>K%=T$;?>6&-0%3(X+<L>1N )%?4% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\
MJ_\ !4?_ ),3^)O_ '#/_3I:44?\%1_^3$_B;_W#/_3I:44 '_!+C_DQ/X9?
M]Q/_ -.EW7U57RK_ ,$N/^3$_AE_W$__ $Z7=?55 !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7@?[:G[4]E^R7\&+GQ2;6/4M?O)A8:-I\N?+FN64MND
MP0?+159C@@G 4$%@1[Y7BO[2_P"R/X%_:OT_1+/QPVK"'1WFDM/[+O/(VM($
M#,P*L&.(P!D<9;UH ^)?AI\!OVP?VKO"]M\0/$?QTU+X:6&LH+S3=+TR:>V8
MPL,QL8;=HPB$$$;F9B,%N>3G']I#]H/_ ()[_&+0_#GQPUW_ (6-\-]<DS'K
M;;IYEB#!9)(9"!)YD89&:&3<""-I^;=7ZF:;I\&DZ=:V-JGE6UK$L,2#^%%
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MT&QD\/K#9VJG'_'_ "99F.2[$\EF))/))K]A: "BBB@ HHHH **** "BBB@
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M%WP")UMKU=8DFN1&7;Y1,LI,D08@!9$D(#$*>H#?I!\"_C%HWQ^^$OAOQ]H
MDCTW6K;S1#+]^"16:.6)O4I(CKD<';D<&OFK_@K'\7M"\!?LHZSX6O9(YM=\
M7RPV6GV9PS;8YHYI9BN<[45 -W9WCKIO^"8G@/6/ /[&W@RWUJ.2WN=2>XU6
M*WE!#1032LT7';<FV3_MI0!]5T444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 )G')X%?EOX@_:@^.O[=WQV
MUSP%^S_KB>"? &AOFX\2+F*26(-L$\DN"XWD,8XHPI(&6Z$K^GNL:9'K>D7V
MG3/+%#=P/;N\+[)%5U*DJW8X/!KR3]FW]DOP%^RG9^(+7P+'J$<.N313W7]H
M7(G(,:LJ*IV@@#>QYSR30!\3?$3]FW]L/]F[PO=>._"_Q[U;XBC28_MM_H]]
M<7%PYC0;I-D5PTJ2* .0"K$9VC/%?5W["?[7D'[7?PGFU>[M(=,\6Z/,+36;
M&V#>2'8$QRQ;B3L=0>"2058<@ GT_P#: ^+VA? KX/\ B?QIXBEB6QTZS<QV
M\A&;J9@1% H/5G8A<>Y)X!-?!/\ P1%\!ZQIOA#XF>,+E9(=%U:ZL]/LU;@3
M26ZS-*X]0//10?7<.U '5_MG?MA_$KQ%\=[']G7X %8?%T^(M5UM-A>%FC\Q
MHXV8%8A''EY),%AT7#+SP_Q _93_ &R/@GX7G\>^'_C_ *SXWU72XFO+O0O[
M0NIU91R_DPW!>*; R=I120"%!. <C_@E21\3OVOOCE\2+]%FOI%GD1V.?+:\
MO6D.W\(=H/8<=Z_5V@#YG_8)_:\C_:X^$<NIZA!;V'C'19EL]:L[;(C+,N8[
MB,$DA) &X)X9''( )X3_ (*&_MN:W^SJ?#O@'X=6<>H_$[Q.%>W\R#SQ:0.Y
MBC98^CRR2 JBG(^1L@\ _.?_  3Y8_"__@I%\;O =DIAT2X;5H8;:,_*H@OE
M: D?[,;.O_ Z^[/''[&_P]^(7Q\T'XP:P-5D\7Z));R6FR\Q;#R<F-3&5/ 8
MEN".30!\E:3^Q'^U_P"*M'BU[7OVE]4T#Q)(@E_L:VU*[-M&Q).R0PNL8('7
M;&PSP,@9JQ^RI^V5\5?AK^T2O[/?[0YCO=8GE%MI?B (#*\S@-"K.H"RQ2#A
M7VA@Q ;OM_2"OR#^.7B*']J+_@K!X"L? <@NH?"MYI]I=:G:\HPL;A[JZE##
MLFYHP>A9 !D$9 /M_P#;Z_; 7]D7X46U_IEK#?\ C'797M-&M[D$PH4 ,L\@
M!!*H&7Y0>6=!TR1\O^!?V4_VPOCEX5M?'/B;]H36/ NI:K&+ZUT.WO+J (C@
M,@EBMVCCBR,'8%; ." <@?=WQC_9E^&7[0%QI<_Q \*6_B.;2\_8Y)KB:(P@
ML&(!C=>"57(/!P <BI?BU^TA\,O@3Y<?COQGI?AJ>2 W,5K=2$SRQ@D;DB4%
MW&01\H/(H ^)_P!E']KSXL?"W]I1OV=OV@;F/6-3GD%OI7B# +^:R;X@9 %\
MZ*4<*Y7>'(5NX3](J_([P4VJ?M_?\%&M&^*'A+1K^P^''@ZZLY&UJYB,:R):
M,98U)X_>2R'B/)8(<GH17ZXT %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% 'G7[0GQNT;]G7X/^(O'VNH
M\]II4(,=K$</<SNP2*)3VW.R@GL,D\"OSO\ A+H?[7/[?6EW'CY_BK-\)/!-
MS*\6G0Z*\UJ)0CX8PI"RNR*P*EY),D@@9&<?H5^T#^S[X5_:6\!KX0\8G4/[
M&%VEZ5TZY\AVD175<G!R!O)QTR!Z5T?PP^'6D?"/X>Z!X,T$3#1]$M$LK7[0
MX>4HHZNP !8]2<#DT ?F1\1/'7[5/_!./Q#HNM^+/&;?&#X;:A.MI+)J4LD_
MS 9\MGDS+!*5#E6#.AP<AB,5^F7@_P"*7AWQM\+]-^(-A?"/PQ?::NK+=7 V
M>5!LWL7'\)4 Y'8@U\2_\%E/B]H7A[X"Z9\/GDCN/$GB+4(;R*V&"UO;0,6:
M8\Y7<^U%X^;]YC[IJ+QY8Z_\ O\ @CJ=*U19+;79- @M)H)LAXDO[U=T3#J&
M6&X92.Q7% 'FFE_&3]HK_@I!\2_$%O\ "CQ/<?"?X5Z)+Y8U*&9[>=L@A/,D
MB_>/,ZY;RT8(@QDYVLU+XC:K^U3_ ,$X_$&D>*]>\?WGQA^&UW=+;WIU2ZFN
M1D_\LW\XM);NR@E'1BF1AL_=;Z=_X)+^%;;P[^Q7X:OX8PDNNZCJ&H3MW9UN
M'M@3_P  MD'X5Z;^WEX7MO%_['GQ9LKJ,2)!H4VH+D='ML7"'\&B% 'JGPS^
M(>C_ !:^'WA_QEH$QGT?6[*.]MF; 95<9*,!T93E6'8J17YZ?'#]K3XR_M-_
MM):I\#?V=KZ+P]IVCO)!JOB;&R3="^R>4RD,8H5<A%\M=[GD$A@!Z9_P1V\7
M3^)/V19--GD9AH/B&\T^%6.=L;)#<<>VZX?]:]R_9]_8X^'W[-/BCQ-K_@_^
MUGU'Q"B)>OJ=Y]H'RNSDK\H(+,Q)R3T'2@#Y!\7?L??MB?"W0;KQ5X2_:)UC
MQMK5HOVJ30[F\N6$VW+%(4G:2)SZ(RJ#T]!7O'_!/7]M>X_:Q\&ZOIWB:S@T
M[Q]X=9%U".UC9(;F%\A)U4D[6W*RLF>" 1@-@?2_Q"\?:)\+? ^M^+?$=XMA
MHFCVKW=U.Q'"J/NJ">68X55ZEF ')K\QO^"/NB:MXR^.7QA^*"6;6'AZ\CDM
M%C Q$;BXN1<>6O8F-$YQT$B^M 'ZMU^:?_!5/]N;4OAXT/PE^'&NW6E>)6\N
M[U[6-+N&AGL8\AHK:.1"&1W^5F(((4J.=Y ^JOVVOVK--_90^#=WKN8;GQ7J
M6ZST#39.?.N".9&'7RXP=S>ORKD%A7YW?%7]E?4OA+_P3_\ &7Q,^( EO?BO
MXXU6POM0N+P9GM()+E9!"2>1(['S).G.U<?)D@'Z-?L)^)-7\7_LC_#36-=U
M2]UK5[O3F>XU#4;A[B>9O.D&7D<EF. !DGM7O-?.O_!/'_DRWX5?]@QO_1\M
M?15 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'RK_ ,%1_P#DQ/XF_P#<,_\ 3I:44?\ !4?_
M ),3^)O_ '#/_3I:44 '_!+C_DQ/X9?]Q/\ ].EW7U57RK_P2X_Y,3^&7_<3
M_P#3I=U]54 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% &)XT\::%\._"^H^(_$NJVVBZ'I\1FNKZ[?9'
M&H_F2<  <DD  DXK\I_BQ\:OB=_P5)^([_#'X46=SX=^$MA.DFJ:K>*4690W
MRSW1';C,=N"2Q&YNF8_.?VP/VK=+_:X_:4MO!7B#QNW@CX&Z%J+PF]AMYKC[
M3Y61)=>7"CL\CX98LKM16!.,OG[:^#_[<G[&GP(\"V/A'P7XVBTC1[49VKH&
MJ&2>0@!I97^S9>1L#+'T &    ?2?[._[/OA3]F?X8Z?X+\)6[+:PDS75Y-@
MSWMPP >>4CJQP!@<   <"OSH_9YC_L7_ (+(?$&VNBR375SJYB63JV^(3+CV
MV9(]A7W=\(?VX/@G\>/&4?A3P+XU_MS7Y(9+A;3^RKVWS&@RQWS0HO /3.:^
M'OV]-)U3]DO]N?P)^T=I^FSWOAO4Y(DU+[.<'SXX3;3P^BM):X*YX+*_H: /
MU6K\G?VA(5US_@LC\/[6$LTEK<:2T@4<@I$9C^&W!K[:_P"'@G[/_P#PK_\
MX2[_ (69HOV7R/._LSSQ_:6=N[R_LG^MW]ONXSWQS7QO^P9H^L?M8?MP>.OV
MDM0TZXT_PUI\DT6E_:%!S,\ MH8=W0M':\OMZ,R?WJ /U0KYU_X*'?\ )EOQ
M5_[!B_\ H^*OHJOG7_@H=_R9;\5?^P8O_H^*@#S3_@D-_P F;:=_V&K_ /\
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M=;Z;;;_O&.&-8U)]\**WJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M57U#4+72+"YOKZYALK*VC::>YN)!''%&H)9V8G"J "23P *L5^/_ /P4\_:\
MN/B5\7/^%&:1XC7POX$TN[BMO$>K,DKI/<[@7$BQ*TCQ0?W%!+.K<':A !UG
M[3W[9'C7]M/QM+\"/V<[2YNM%NRT6K^(H]T0O(0</\__ "QM!GYG/S29"@8.
MV3[4_8W_ &0?#G[(OPY.CZ>ZZIXEU'9-K6MLFUKF0#A$'58DR=J^Y)Y)KYZ_
M9J_:J_8M_9;\ P^&_"/C\>?(%?4=7G\/:F;K4)@/OR-]FZ#)VH/E4$XY))][
M\ ?\%"OV?_BAXRTGPIX8\??VGK^JS"WL[3^QM0B\V0@D#?);JJ]#R2!0!\4_
MM&;M"_X+&?#B[N!Y<5Y/I'E,W 8.C0C'_ @1]:_6"OS1_P""N7PMU[PUXF^&
MW[0/ABW:>Y\*W$%I?NJEO(\JX^T6<K8Z)YAE4GC!>,=Z^FOAG_P4-^!7Q"^'
M=KXGN_'VB^%KCR%>\T76KU(+VVDZ,@C)W2X(.#&&!&#[4 ?&G_!7P'6/VCO@
M?HT/S7+P\*O+?O;Q$7]4-?J_7Y(^!]7N?^"B?_!1[2O'.C6-U'\-? 1MIH[J
MZB(!BMI&EA# \!Y[@LP0\^6#D90U]G?\%!_VL)/V4_@FU]HYC;QGKTK:?HJR
M*&6%MN9+EE/!$:D8!R"[H"",T 9'[;W_  4!\-?LKZ7)H&C+!XE^)MW%_HNC
MJQ:*RW#Y9KHJ<@<@B,$,_'W0=U>(_L1_L,>+/&7Q"'[0/[0;W&H^++R<:AI>
MB:B,R1R<&.XN$QA"@QY<( V84D J%'S]^PCX\_9L^'VK3?%;XV_$7^W/BI=W
M<EU!:7VDZC>+ISEB?/=U@99;AC\P;)" C'S<C[\_X>C?LQ?]%,_\H&J?_(U
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MC5[M\(?C-X.^//@V/Q7X%UC^W- DFDMUN_LLUOF1#AALF1&XSUQB@#M:***
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M.D_%7_@KA\6(-2U..Y\$_ K0;LA$1LC('S+&2,3W3*<%\;(E;WQ)^K7P_P#
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M7C4<#WKZ)_X=<?LQ?]$S_P#*_JG_ ,DU\S_\%$OV&?@C\"OV8M8\6^!_!/\
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M# @[6*GGT(Y'X4ZB@#Y5_P"'7/[,1Y/PSR?^P_JG_P DT?\ #KC]F+_HF?\
MY7]4_P#DFOJJB@#PKX0_L/?!/X#^,H_%?@7P5_8>OQPR6ZW?]JWMQB-QAALF
MF=>0.N,UZUXT\$Z!\1?#=[X?\3Z/9Z]HEZFRXL;^$2Q..H.#T(/((Y! (P:V
MZ* /D0?\$I_V;AKAU#_A#+PPYS_9_P#;-W]GSG.?]9O]L;L8[5]1>$/!NA?#
M_P .V6@>&M(L]"T6R39;V%A"L448SDX51U)))/4DDGDULT4 %<Y\1/A[X?\
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M/5W.!EF)8XY)KIZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#*H97 WQ,K@94=&&>AX)%=)10!\J_P##KC]F+_HF?_E?U3_Y)H_X=<?LQ?\
M1,__ "OZI_\ )-?55% 'EGP-_9A^&?[-L6LQ_#CPU_PCJ:PT+7P^WW5UYQBW
MB/\ U\K[<>8_W<9SSG KU.BB@#R?QI^RO\+OB%\6M$^)OB#PQ]O\;Z*UNUAJ
MG]H74?DF"0R1?NDE$;;7)/S*<YYR*]8HHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX_:0L-*LOB+X=/B&UTN5YK2/[?<VHC=P Q_<2)NX4?>SCMU->1_\.N/V8O\
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M.S\Z2;RD+%L;Y&9CRQZD]:Z.BB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y5_X*C_\F)_$
MW_N&?^G2THH_X*C_ /)B?Q-_[AG_ *=+2B@ _P""7'_)B?PR_P"XG_Z=+NOJ
MJOE7_@EQ_P F)_#+_N)_^G2[KZJH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Y5_X*C_\F)_$
MW_N&?^G2THH_X*C_ /)B?Q-_[AG_ *=+2B@ _P""7'_)B?PR_P"XG_Z=+NOJ
MJOE7_@EQ_P F)_#+_N)_^G2[KZJH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HKPS2]+\7_$SXC_%"*+XH>)O">F^'M?M])L=.T.STAHA$=(T
M^[9F:ZL9Y&<RW<O._&-H &.=[_A3?B[_ *+M\0/_  !\/?\ RJH ]5HKRK_A
M3?B[_HNWQ _\ ?#W_P JJ/\ A3?B[_HNWQ _\ ?#W_RJH ]5HKRK_A3?B[_H
MNWQ _P# 'P]_\JJ/^%-^+O\ HNWQ _\  'P]_P#*J@#U6BO*O^%-^+O^B[?$
M#_P!\/?_ "JH_P"%-^+O^B[?$#_P!\/?_*J@#U6BO*O^%-^+O^B[?$#_ , ?
M#W_RJH_X4WXN_P"B[?$#_P  ?#W_ ,JJ /5:*\J_X4WXN_Z+M\0/_ 'P]_\
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MC_A3?B[_ *+M\0/_  !\/?\ RJH ]5HKRK_A3?B[_HNWQ _\ ?#W_P JJ/\
MA3?B[_HNWQ _\ ?#W_RJH ]5HKRK_A3?B[_HNWQ _P# 'P]_\JJ/^%-^+O\
MHNWQ _\  'P]_P#*J@#U6BO*O^%-^+O^B[?$#_P!\/?_ "JH_P"%-^+O^B[?
M$#_P!\/?_*J@#U6BO*O^%-^+O^B[?$#_ , ?#W_RJH_X4WXN_P"B[?$#_P
M?#W_ ,JJ /5:*\J_X4WXN_Z+M\0/_ 'P]_\ *JC_ (4WXN_Z+M\0/_ 'P]_\
MJJ /5:*\J_X4WXN_Z+M\0/\ P!\/?_*JC_A3?B[_ *+M\0/_  !\/?\ RJH
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MP]_\JJ /5:*\J_X4WXN_Z+M\0/\ P!\/?_*JC_A3?B[_ *+M\0/_  !\/?\
MRJH ]5HKRK_A3?B[_HNWQ _\ ?#W_P JJ/\ A3?B[_HNWQ _\ ?#W_RJH ]5
MHKRK_A3?B[_HNWQ _P# 'P]_\JJ/^%-^+O\ HNWQ _\  'P]_P#*J@#U6BO*
MO^%-^+O^B[?$#_P!\/?_ "JH_P"%-^+O^B[?$#_P!\/?_*J@#U6BO*O^%-^+
MO^B[?$#_ , ?#W_RJH_X4WXN_P"B[?$#_P  ?#W_ ,JJ /5:*\J_X4WXN_Z+
MM\0/_ 'P]_\ *JC_ (4WXN_Z+M\0/_ 'P]_\JJ /5:*\J_X4WXN_Z+M\0/\
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MQ _\ ?#W_P JJ/\ A3?B[_HNWQ _\ ?#W_RJH ]5HKRK_A3?B[_HNWQ _P#
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M_HNWQ _\ ?#W_P JJ/\ A3?B[_HNWQ _\ ?#W_RJH ]5HKRK_A3?B[_HNWQ
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MWQ _\ ?#W_RJH ]5HKRK_A3?B[_HNWQ _P# 'P]_\JJ/^%-^+O\ HNWQ _\
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M#W_RJH_X4WXN_P"B[?$#_P  ?#W_ ,JJ /5:*\J_X4WXN_Z+M\0/_ 'P]_\
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MC_A3?B[_ *+M\0/_  !\/?\ RJH ]5HKRK_A3?B[_HNWQ _\ ?#W_P JJ/\
MA3?B[_HNWQ _\ ?#W_RJH ]5HKRK_A3?B[_HNWQ _P# 'P]_\JJ/^%-^+O\
MHNWQ _\  'P]_P#*J@#U6BO*O^%-^+O^B[?$#_P!\/?_ "JH_P"%-^+O^B[?
M$#_P!\/?_*J@#U6BO*O^%-^+O^B[?$#_ , ?#W_RJH_X4WXN_P"B[?$#_P
M?#W_ ,JJ /5:*\J_X4WXN_Z+M\0/_ 'P]_\ *JC_ (4WXN_Z+M\0/_ 'P]_\
MJJ /5:*\J_X4WXN_Z+M\0/\ P!\/?_*JC_A3?B[_ *+M\0/_  !\/?\ RJH
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MP]_\JJ /5:*\J_X4WXN_Z+M\0/\ P!\/?_*JC_A3?B[_ *+M\0/_  !\/?\
MRJH ]5HKRK_A3?B[_HNWQ _\ ?#W_P JJ/\ A3?B[_HNWQ _\ ?#W_RJH ]5
MHKRK_A3?B[_HNWQ _P# 'P]_\JJ/^%-^+O\ HNWQ _\  'P]_P#*J@#U6BO*
MO^%-^+O^B[?$#_P!\/?_ "JH_P"%-^+O^B[?$#_P!\/?_*J@#U6BO*O^%-^+
MO^B[?$#_ , ?#W_RJH_X4WXN_P"B[?$#_P  ?#W_ ,JJ /5:*\J_X4WXN_Z+
MM\0/_ 'P]_\ *JC_ (4WXN_Z+M\0/_ 'P]_\JJ /5:*\J_X4WXN_Z+M\0/\
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MQ _\ ?#W_P JJ/\ A3?B[_HNWQ _\ ?#W_RJH ]5HKRK_A3?B[_HNWQ _P#
M'P]_\JJ/^%-^+O\ HNWQ _\  'P]_P#*J@#U6BO*O^%-^+O^B[?$#_P!\/?_
M "JH_P"%-^+O^B[?$#_P!\/?_*J@#U6BO*O^%-^+O^B[?$#_ , ?#W_RJH_X
M4WXN_P"B[?$#_P  ?#W_ ,JJ /5:*\J_X4WXN_Z+M\0/_ 'P]_\ *JC_ (4W
MXN_Z+M\0/_ 'P]_\JJ /5:*\J_X4WXN_Z+M\0/\ P!\/?_*JC_A3?B[_ *+M
M\0/_  !\/?\ RJH ]5HKRK_A3?B[_HNWQ _\ ?#W_P JJ/\ A3?B[_HNWQ _
M\ ?#W_RJH ]5HKRK_A3?B[_HNWQ _P# 'P]_\JJ/^%-^+O\ HNWQ _\  'P]
M_P#*J@#U6BO*O^%-^+O^B[?$#_P!\/?_ "JH_P"%-^+O^B[?$#_P!\/?_*J@
M#U6BO*O^%-^+O^B[?$#_ , ?#W_RJH_X4WXN_P"B[?$#_P  ?#W_ ,JJ /5:
M*\J_X4WXN_Z+M\0/_ 'P]_\ *JC_ (4WXN_Z+M\0/_ 'P]_\JJ /5:*\J_X4
MWXN_Z+M\0/\ P!\/?_*JC_A3?B[_ *+M\0/_  !\/?\ RJH ]5HKRK_A3?B[
M_HNWQ _\ ?#W_P JJ/\ A3?B[_HNWQ _\ ?#W_RJH ]5HKRK_A3?B[_HNWQ
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MWQ _\ ?#W_RJH ]5HKRK_A3?B[_HNWQ _P# 'P]_\JJ/^%-^+O\ HNWQ _\
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M#W_RJH_X4WXN_P"B[?$#_P  ?#W_ ,JJ /5:*\J_X4WXN_Z+M\0/_ 'P]_\
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M% !1110 4444 %%%% !1110 4444 %%%8/C+Q[X9^'.D#5?%GB+2?#&EM*L
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M<\#?$-]GA7QGX>\3/@MMT?58+LX&03^[<^A_*@#K**** "BBB@ HI&8*I).
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MLZ?X=TF\U35;ZVTS3+.%KBZO;R98H8(U!+.[L0JJ "22< "O-O\ AK'X(?\
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MEQ_R8G\,O^XG_P"G2[KZJH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ,FL_&3_ +$S6?\ TAFKRL7@J^"DHUE:^QXF.R[$9=-0Q$;7VZW/C7_@B/\
M\D7^(?\ V,$?_I,E?H_7YP?\$1_^2+_$/_L8(_\ TF2OT?KA/-*NJ6*ZIIMW
M9LQ1;B%X2R]0&4C/ZU\^_L<_L7Z+^QSIOBBST;Q'?^(5UZ:WFD:^A2,Q&)9
M NWKGS#U]*]V\6?\BKK/_7E-_P"BVK\UO^"'/_(J_%O_ *_=-_\ 1=Q0!^G]
M9-OXLT.\U0Z9!K.GSZD!N-G'=1M, .IV Y_2OSA_;^^/'Q"^,?[1V@_LP?"C
M59M&ENFA36[VUE:)I))(_.*/(GS""* ^8X7ELL"#M .NG_!%7P-8^$8O[/\
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MHI5/SK]X)V#E0 ?L545S=0V<#SW$L<$*#+22,%51ZDGI7R)_P5@_Y,E\7_\
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MEQ_R8G\,O^XG_P"G2[KZJH ^%?\ @LE_R:/9_P#8S67_ **N*\D_9-_X)?\
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MK_%#PIXP^".K>)/&?@W5KKR;WP])&\[RNHR8;A(4"2!TW;) BLA4^@)^L/\
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M0)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#T.T ?/@?J;6-#X+\/6OB.Y\00Z%ID6O7043ZHEG&MU*%4(H>4+N;"@*,G@
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M\%>*?AMXHO\ 4]"UB*25+;4V"_:1"R">UN1'M65")8R&"J1OX *AC]%>$O\
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M"2OA+X5_"7Q#X\^&7B_Q)::[X8LI=7:WU:>*59HH(_,<1O%'&T<FU&8'Y@2
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M8):@#[L_8(^/FI?M&_LS^&_%&N-YGB&W>73-3F"A1//"<>;@< NA1B, ;F;
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M -CG=?\ I#8U]^NZQJS,P55&2S'  ]:^ O\ @BI_R:SXI_['.Z_](;&O8O\
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MG\RWR9;=I#\TJ&,&6-VYVH1D@J  <=\??^4R7PY_[AO_ *)DK]5:_*KX^_\
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ME7P?I-S;^1K.K1?VYJ8(PWGW 5@K#^\D0BC/O'7TA0!^>O\ P6P_Y-M\&_\
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MO9<NR6WZGQG_ ,$1_P#DB_Q#_P"Q@C_])DK]'Z_#']B/]M[7/V-_!?B'0/\
MA4^H>+_[6U!;[[1]ODLO*Q&J;-OV:3=]W.<CKTKZ/_X?1:Y_T;UJ'_A0R?\
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M2/A9X9,>J:UJVHKB6[D#B.&$B,LGWI PC#.25#':$H ^XO\ @EQ_R8G\,O\
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M%^SQ:?M3? +7/!HFCAU-@NH:->,WR17D8)B+$9^1@S(QP<+(2.0*^!_V<_\
M@H%XB_8F\-1?![X\_#_Q%$V@;H=,O+*-&N/(W$B,K*Z)+&I.$D1\;=HP< T
M?JCXB\5Z)X/LH[S7M8T_1+2258$N-1NDMXVD;)5 SD L<' ZG!K\G?\ @M-=
M?VY\0_A#);WMN^D7.F736UYYF^WRTT>Y\KG*[?+)(SQCK2?&#XG^.O\ @K%X
M[\,>"/AYX3U+PU\+M&OA=ZAKFJ1A@DA4J9I2I*!D1I%2%79F+L2<?=^JOV\/
MV&_^%X?LY^%_#W@6&./Q%X"@6/0K69PBW-LL21R6VXX"LRQ1%6/&Z, X#%@
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MDC,0X/W6 Q\N2 >[_P#!;!A_PS?X-&>?^$LB./\ MSNJ^MOV3O\ DUGX-_\
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MBO;?C5\*-)^.7PI\3^!-<+)INN6;6S2Q_>A?(:.5?4HZHX!X)49XK\N?V?\
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M'[1/PWU/XN?!WQ!X3T>>TMM1U#[/Y4M\[)"/+N(I6W%58_=0XP#SCZU\5?\
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M8E9NP$G3FOT%_;;_ &0=*_:\^%Z:.;B'2?%>ER-<Z+J\R%EA<@!XI,<^5(
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M_P )]\ O[1_Y!_G:A]H_ZY^;9;_TS1KVDWS?\%N-.O197!L_W?\ I'E-Y?\
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M^"@7B?\ 8E\/P?![X[_#[7T&@[H=.O+1$^TK!O)";9'5)HUSA)$?&W Y !H
M^V?^"C36:_L4?%0WPS!]@A"_]=#=0B+_ ,?V5XQ_P3'^'^F?%+_@G_>>$O%-
MJ;_P_K.HZC:R6[$J?)8J"5/\)#AF!'1AFOGGX_\ [2WQ%_X*;7&F?"[X.^ ]
M4T[P:M['<ZEJ6I':&=0=IN9$)CAB3=NV;F9F"XR0%/VKXZ_8WN;/]AE?@GX&
MUN:PUW2[&.2QU2.9K7[3>K+YTI<H?E69VD7!)"AP>=M 'R7XB_X):?'#X%:Y
M>:Q\ _BM,;5VWBS:_ETN\< G:CE,PS8'=R@/]T51T+_@H!^TK^R7XPTC0OVB
M?",NK:%<L5:[FM(8KQHUP&:WN("()BF02IR3D99<YJ?]FS_@I!J?[)'@VV^$
M_P =O /BF'4=!+QVE[;Q+]K: NS*DD4[QA@I)"R*Y!7:,?+EN<_:5^/OB7_@
MJ+KGA3X<_"'X?:K;Z#INH&]NM:UA%7RG*&,/,T99(8U5V)&]F<E0!D , ?8'
M_!2[Q%8>+O\ @GSXIUW2YOM.F:I'I%[:S 8\R&2\MG1OQ5@:Z?\ X)E_\F.?
M##_KC??^E]S7&_\ !0'X?CP+_P $W]3\%Z4)]0BT*PT/2H&6,F21(+FUC#%1
MGG"9-=O_ ,$U;6>Q_8C^&4%Q#);S+#>[HY5*L/\ 3[D\@T ?(W_!+7_D]#]H
M'_M\_P#3B:Q?^"WBW,OC[X31R/Y5@VGWPCD?=L5S+#YAX!Z#R\XYZ>U>?>%_
MC5K?_!./]M+XL7GBKP3>:IIVOW%ZMJJS>09K>2[\Z"XBD*LKJ5X([$D'!4BO
MN']L3X"_\-[_ +)OA+Q1X7LQ;^+EL+?Q#H5K<2J-RW$*/-:.YPH+*5^8X&^)
M<X!- 'C]O^R?^WA]GB\C]H+PYY&T>7Y>JW6W;CC&+'IBN5^)W_!//]L3XT>'
MX=#\;_&'PGXETF&Y6\CM+[4[QD29595<8L1R%=Q]&-2_ ?\ X*GW_P"S_P"%
M[3X<?'GP)XFC\0^'HELDO;.!!=RPH-J>?#.\?S  #S Q##G&>3RWQ0^-7Q6_
MX*A_$;PWX4^%7A_6/!?P\T>\\^YURX=E$<I!!GN)(R%5E0L$A5F8EF.3GY0#
MZ8^+/@/]J_X6_LZ_!?P=\%[FSO/$V@Z>=-\0SZ>^GO T<4<26^QM0521A6^Z
MH/'/:O#_ /C9U_G_ (1BOT\\&^&;?P5X1T7P_:37%Q:Z590V44UU*9)I%C0(
M&=SRS$#))ZDFMB@#$\$?VS_PA>@?\)%_R,']GV_]H_<_X^?+7S?N?+]_=]WC
MTXKR_P#;6_Y-'^+W_8LWW_HIJ]KKQC]M""2Z_9-^+<4,;2ROX:OE6-%+,Q\I
MN !UH ^7/^")_P#R;;XR_P"QMF_]([6OT*K\_?\ @B[IMWIG[.7C".\M9K21
MO%<S!)XRA(^QVO.".E?H%0!^3'_!*G9_PVM\</[0!&M_9+[(/7']I1^=UY^]
MY=?K/7Y4?M3_  1^)?[&G[5ES^T=\+-$D\1^%=2GEO-7L+>-W%N\P/VJ.=4^
M;RI&)D60#".1D#:N[L]0_P""V'@FY\+XT/X<^)+GQ?,FR#3[B2#[)YQ&%'FH
MYD8;CT$0)]L\ 'GGQL\N3_@L]X/&FDK=K=Z7]K*]2WV,%O\ R#M%:?\ P5^_
MY+]\!O\ MI_Z50UU/_!/G]EGXA^+?CIK7[2GQBL)M(UG4'N+C2=,NXC'.TLX
M*-,8V^:*)(B8XT;YB"#P%4M3_P""RWP_\2_:?A=\2='TF;4=)\//<0ZA<1(7
M2U8R0R0F0#D(Q60;N@( )!9<@'Z1>*O%&E^"?#.K>(=;NTL-'TJUEO;RZDR5
MBAC4N[$#DX / YK\U+/]NS]I;]KGQ=J]A^SKX'L=(\+Z;*4?6-42)Y I)V-+
M),PB5F SY2*[#)Y8#->O_"[]I>V_X*6_ +XR>"M(\/2^#]9AT9+-&O+WSHI)
M[B.;RSN5 0BO" W!.&Z=C\G_ +%/[9"?L 6?BGX4?&'P+K^E22:HVI1SV=JG
MVB.1HXXF#H[H'B(A5ED1FSDXR"" #TGXL?LU_M?^(OA#XV\1?%?X\VVG:%IF
MA7NHW>CZ&S W4<5N\C6\J0101[7"E3RXP>AZ5WW_  1/_P"3;?&7_8VS?^D=
MK7+?&#]K3Q]^WYX-U;X9_L__  ZUNW\/ZFAAUGQ;X@5+>%(!RT*E"Z*7QC[Q
M<J2 @R2-/_@BIJ+6/PO^(OAJ\M;FRU&UUF'4#'<Q-'NCE@$8*Y'.&@;/IE?6
M@#B_^"9__)_7[0O_ '%/_3JM?JI7Y:_\$V=)OK+]O+]H&>XLKB""3^T]DDL3
M*K9U12,$CGBOU*H *_&#_@FE\*/!OQ<_:H^*^G>-/#.E^*+"VLKJXAMM4MEG
M2.3[=&N\!AP<,1GW-?L_7Y+_ /!)G1[_ $_]K;XNS75C<VT3Z;=!9)H616_T
M^,\$CF@#[1^)_P#P3H^ GQ*\)W>CQ^ =+\+WDB-]FU;0(!:7%M(1@.-N%<#^
MZX*GTSS7PI^S#^T!XH_X)X_M"7WP/^*T=HW@N:Z$4>LI;)&UNLC9AO%E W26
M[ _,K$E.<8*,K?L%7Q;_ ,%//V1A^T-\(3XI\/V7F^//"44EQ;+$N9+ZS^]-
M;<<LPQO0<_,&4?ZPT ?6?CB2XD\!^()-.8O=-IMPULT9))?RFV$8YZXZ5^&G
M_!/[X2?'3XG-XX?X(_$32O MQ9"S&JI?W<T$ERK>=Y)7R[>7(4K)GD8+#KFO
MOG_@E3^TYJ?Q*^&;?#3QA%=Q>*/"ENHL+F\C=3>Z<"%09(Y>$E4/JIC/)#&O
MGOXC^ _B-_P3'_:<UKXF^!O#-QXB^#^N,WVFWAW&"*!V#M;RLH)A:-\^7(P(
M*X'.76@#TO\ X9/_ &]?^C@O#_\ X-;O_P"0:Z+]BG]@_P",OP!_:5U?XF^/
M/%/A?7DUJQO(-3DTV[N9+JXFGECF,A#VT:G,D88G/X5@^+/^"T_A&_\ "SVW
M@3X>^)+_ ,:W2F&TM=46%;5)FX0YBD>27!(.P(I;ID9S79_\$S?V=/B9X/F\
M4?%;XLWVK0>(/%&_[)H>HS2!X5DE\V:XFA)PDDCA-JD!E56SC=@ 'CW_  5^
M_P"2_? ;_MI_Z50U^GWBS_D5=9_Z\IO_ $6U?F]_P66^'_B7[3\+OB3H^DS:
MCI/AY[B'4+B)"Z6K&2&2$R <A&*R#=T! !(++GZ5_8O_ &VM)_;6TWQ=!%X4
MG\-RZ'':I=0W%VMPEP+@3 ["%7@>41S_ 'A0!\O?\$.)E;P[\7HAG>MWICGT
MP4N0/_037W;^UDP7]ECXR$G'_%&:R/\ R1FK\K/A'\1O%W_!*/\ :#\:Z#XM
M\(ZEJ_@3791#%=QJ$:\AA=S;7-O(?W;MLE8/'D8+X)!7%>P?&']M?QE^WAX'
MUWX;_!+P!J^EZ!<VLC^(O%&MA0MM:1CS'B C+(K.% QO+,"5"\[@ =__ ,$3
M_P#DVWQE_P!C;-_Z1VM>2_\ !->UCD_X*+?'B9E#210:T$)[9U:#)^O'ZFO8
MO^"+NFW>F?LY>,([RUFM)&\5S,$GC*$C[':\X(Z5Y;_P3=TB^LO^"@WQYN+B
MRN(()(=8V2RQ,JMG5H2,$C!XH _4G5O^05>_]<7_ /037Y<_\$-;&'R?C)>%
M,W&[28@WHN+PD#ZG'Y"OU&U;G2[P#D^2_P#Z":_,O_@B'I-]I>E_&$7MG<6A
M>;2=OGQ,F["W><9'/44 ?>G[37_)MOQ7_P"Q2U;_ -(Y:^-?^")?_) O'7_8
MS'_TE@K[-_:6B>;]G+XJQQHTDC^%-55449+$V<N !ZU\=_\ !%G3;O3/@-XX
MCO+6:T=O$I8+/&4)'V6#G!% 'Z&4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !6=XDT*V\4>'=4T:\W&SU&UELYMO79(A1L?
M@36C12:4E9B:4E9GY7^+/V ?B[HFNW5II&BV_B+3D<^3?VU_;PB1>Q*2R*RG
M'48(SG!/6L?_ (89^-__ $)/_E6L?_C]?K117R\N'<(W=2DOFO\ (^,EPG@)
M-M2DOFO\C\E_^&&?C?\ ]"3_ .5:Q_\ C]'_  PS\;_^A)_\JUC_ /'Z_6BB
ME_JYA/YI?>O\B?\ 5+ _SS^]?_(GX]>-_P!E'XI_#?PS>>(?$?AE-,T>S"F:
MY?4[-]NY@J@*LI9B20, $\UY)7ZJ_M@? SQ_\?=+T30_#&I:+IVAVLC75XNI
M7$T<D\V-L8 2)QM52QY/);IP#7R]_P .T?B=_P!!WPE_X&77_P C5\[C<GJT
MZSAAH2<5U=O^ ?)YCD%:C7<,'3E*"ZNVK\MCY+KUOP1^RC\4_B1X9L_$/ASP
MRFIZ/>!C#<IJ=FF[:Q5@5:4,I!!&" >*]9_X=H_$[_H.^$O_  ,NO_D:OJ']
MC_X&>/\ X!:7K>A^)]2T74=#NI%NK-=-N)I)()L;9 0\2#:RA3P>"O3DFC!9
M/5J5E#$PDHOJK?\ !#+L@K5JZAC*<HP?56T?GOH?$7_##/QO_P"A)_\ *M8_
M_'Z/^&&?C?\ ]"3_ .5:Q_\ C]?K117T7^KF$_FE]Z_R/K/]4L#_ #S^]?\
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MDCC=(P!( )^/O^"@]QXD_9M_;V\&?'3_ (1N?5_#*PVDB3*2D,LL2/%+;F0
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MX-_\E%^.W_8YVW_J/:-7JM>5?!O_ )*+\=O^QSMO_4>T:O5: "BBB@ HHHH
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MT44 %%%% !1110 4444 %%%% &=8^'=*TR\FN[/3+.TNIO\ 63P6Z([]!\S
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M31K+$XVM&ZAE8>A!ZU4TO0=,T-773=.M-/5R2PM8%B#$DDD[0,\DG\35^B@
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M!]ZU? O@G1OAOX-T7PMX>LUL-$T>TCLK.W5BVR-%"C)/+'C)8\DDD\FMVB@
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M_0?%.HVKV=U=:>ABCDC9U=CY0/EJQ9 2RJ">Y->GT44 %%%% !1110 4444
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MA'K<^L^#? &@^'M6F#*U[962+,JGJJ-C**>ZK@>U>ET %%%% !1110 4444
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M6/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\
M\=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_
MX:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^
M"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_1
M9/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A_
M_P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%
M18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__
M !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO
M5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:*
M/*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^
M&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@
MA_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T6
M3X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_
M /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A4
M6/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\
M\=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_
MX:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^
M"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_1
M9/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A_
M_P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%
M18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__
M !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO
M5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:*
M/*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^
M&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@
MA_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T6
M3X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_
M /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A4
M6/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\
M\=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_
MX:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^
M"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_1
M9/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A_
M_P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%
M18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__
M !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO
M5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:*
M/*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^
M&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@
MA_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T6
M3X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_
M /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A4
M6/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\
M\=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_
MX:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^
M"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_1
M9/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A_
M_P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%
M18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__
M !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO
M5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:*
M/*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^
M&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@
MA_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T6
M3X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_
M /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A4
M6/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\
M\=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_
MX:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^
M"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_1
M9/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A_
M_P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%
M18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__
M !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO
M5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:*
M/*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^
M&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@
MA_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T6
M3X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_
M /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A4
M6/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\
M\=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_
MX:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^
M"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_1
M9/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A_
M_P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%
M18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__
M !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO
M5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:*
M/*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^
M&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@
MA_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T6
M3X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_
M /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A4
M6/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\
M\=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_
MX:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^
M"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_1
M9/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A_
M_P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%
M18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__
M !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO
M5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:*
M/*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^
M&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@
MA_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T6
M3X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_
M /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A4
M6/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\
M\=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_
MX:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^
M"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_1
M9/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A_
M_P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%
M18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__
M !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO
M5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:*
M/*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^
M&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@
MA_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T6
M3X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_
M /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A4
M6/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\
M\=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_
MX:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^
M"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_1
M9/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A_
M_P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%
M18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__
M !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO
M5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:*
M/*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^
M&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@
MA_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T6
M3X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_
M /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A4
M6/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\
M\=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_
MX:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^
M"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_1
M9/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A_
M_P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%
M18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__
M !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO
M5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:*
M/*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^
M&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@
MA_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T6
M3X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_
M /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A4
M6/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\
M\=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_
MX:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^
M"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_1
M9/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A_
M_P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%
M18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__
M !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO
M5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:*
M/*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^
M&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@
MA_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T6
M3X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_
M /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A4
M6/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\
M\=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_
MX:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^
M"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_1
M9/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A_
M_P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%
M18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__
M !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO
M5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:*
M/*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^
M&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@
MA_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T6
M3X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_
M /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A4
M6/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\
M\=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_
MX:Q^"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^
M"'_19/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_1
M9/A__P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A_
M_P"%18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%
M18__ !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__
M !VO5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO
M5:* /*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:*
M/*O^&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /*O^
M&L?@A_T63X?_ /A46/\ \=H_X:Q^"'_19/A__P"%18__ !VO5:* /F#]IK]I
MKX/^(/V;_BOI>E_%?P1J6IWWA/5K:ULK/Q'9RS7$SV<JI'&BR%F9F( 4 DD@
M"OI^BB@ HHHH ^5?^"H__)B?Q-_[AG_ITM**/^"H_P#R8G\3?^X9_P"G2THH
M /\ @EQ_R8G\,O\ N)_^G2[KZJKY5_X)<?\ )B?PR_[B?_ITNZ^JJ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH ^5?^"H__)B?Q-_[AG_ITM**/^"H_P#R8G\3?^X9_P"G2THH
M _$ZS^/GQ/\ ATL_ASPK\2?&'AS0+"XFCM-,TO7[NWMX%,K,0D:2!1EF9C@<
MDDGDU8_X:Q^-_P#T63X@?^%1??\ QVBB@ _X:Q^-_P#T63X@?^%1??\ QVC_
M (:Q^-__ $63X@?^%1??_':** #_ (:Q^-__ $63X@?^%1??_':/^&L?C?\
M]%D^('_A47W_ ,=HHH /^&L?C?\ ]%D^('_A47W_ ,=H_P"&L?C?_P!%D^('
M_A47W_QVBB@ _P"&L?C?_P!%D^('_A47W_QVC_AK'XW_ /19/B!_X5%]_P#'
M:** #_AK'XW_ /19/B!_X5%]_P#':/\ AK'XW_\ 19/B!_X5%]_\=HHH /\
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M!_X5%]_\=HHH /\ AK'XW_\ 19/B!_X5%]_\=H_X:Q^-_P#T63X@?^%1??\
MQVBB@ _X:Q^-_P#T63X@?^%1??\ QVC_ (:Q^-__ $63X@?^%1??_':** #_
M (:Q^-__ $63X@?^%1??_':/^&L?C?\ ]%D^('_A47W_ ,=HHH /^&L?C?\
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M ,=HHH /^&L?C?\ ]%D^('_A47W_ ,=H_P"&L?C?_P!%D^('_A47W_QVBB@
M_P"&L?C?_P!%D^('_A47W_QVC_AK'XW_ /19/B!_X5%]_P#':** #_AK'XW_
M /19/B!_X5%]_P#':/\ AK'XW_\ 19/B!_X5%]_\=HHH /\ AK'XW_\ 19/B
M!_X5%]_\=H_X:Q^-_P#T63X@?^%1??\ QVBB@ _X:Q^-_P#T63X@?^%1??\
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M'XW_ /19/B!_X5%]_P#':** #_AK'XW_ /19/B!_X5%]_P#':/\ AK'XW_\
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M'XW_ /19/B!_X5%]_P#':/\ AK'XW_\ 19/B!_X5%]_\=HHH /\ AK'XW_\
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MW_QVBB@ _P"&L?C?_P!%D^('_A47W_QVC_AK'XW_ /19/B!_X5%]_P#':**
M#_AK'XW_ /19/B!_X5%]_P#':/\ AK'XW_\ 19/B!_X5%]_\=HHH /\ AK'X
MW_\ 19/B!_X5%]_\=H_X:Q^-_P#T63X@?^%1??\ QVBB@ _X:Q^-_P#T63X@
M?^%1??\ QVC_ (:Q^-__ $63X@?^%1??_':** #_ (:Q^-__ $63X@?^%1??
M_':/^&L?C?\ ]%D^('_A47W_ ,=HHH /^&L?C?\ ]%D^('_A47W_ ,=H_P"&
ML?C?_P!%D^('_A47W_QVBB@ _P"&L?C?_P!%D^('_A47W_QVC_AK'XW_ /19
M/B!_X5%]_P#':** #_AK'XW_ /19/B!_X5%]_P#':/\ AK'XW_\ 19/B!_X5
M%]_\=HHH /\ AK'XW_\ 19/B!_X5%]_\=H_X:Q^-_P#T63X@?^%1??\ QVBB
M@ _X:Q^-_P#T63X@?^%1??\ QVC_ (:Q^-__ $63X@?^%1??_':** #_ (:Q
M^-__ $63X@?^%1??_':/^&L?C?\ ]%D^('_A47W_ ,=HHH /^&L?C?\ ]%D^
M('_A47W_ ,=H_P"&L?C?_P!%D^('_A47W_QVBB@ _P"&L?C?_P!%D^('_A47
MW_QVC_AK'XW_ /19/B!_X5%]_P#':** #_AK'XW_ /19/B!_X5%]_P#':/\
MAK'XW_\ 19/B!_X5%]_\=HHH /\ AK'XW_\ 19/B!_X5%]_\=H_X:Q^-_P#T
M63X@?^%1??\ QVBB@ _X:Q^-_P#T63X@?^%1??\ QVC_ (:Q^-__ $63X@?^
M%1??_':** #_ (:Q^-__ $63X@?^%1??_':/^&L?C?\ ]%D^('_A47W_ ,=H
MHH /^&L?C?\ ]%D^('_A47W_ ,=H_P"&L?C?_P!%D^('_A47W_QVBB@ _P"&
ML?C?_P!%D^('_A47W_QVC_AK'XW_ /19/B!_X5%]_P#':** #_AK'XW_ /19
M/B!_X5%]_P#':/\ AK'XW_\ 19/B!_X5%]_\=HHH /\ AK'XW_\ 19/B!_X5
M%]_\=H_X:Q^-_P#T63X@?^%1??\ QVBB@ _X:Q^-_P#T63X@?^%1??\ QVC_
M (:Q^-__ $63X@?^%1??_':** #_ (:Q^-__ $63X@?^%1??_':/^&L?C?\
M]%D^('_A47W_ ,=HHH /^&L?C?\ ]%D^('_A47W_ ,=H_P"&L?C?_P!%D^('
M_A47W_QVBB@ _P"&L?C?_P!%D^('_A47W_QVC_AK'XW_ /19/B!_X5%]_P#'
M:** #_AK'XW_ /19/B!_X5%]_P#':/\ AK'XW_\ 19/B!_X5%]_\=HHH /\
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M!_X5%]_\=HHH /\ AK'XW_\ 19/B!_X5%]_\=H_X:Q^-_P#T63X@?^%1??\
MQVBB@ _X:Q^-_P#T63X@?^%1??\ QVC_ (:Q^-__ $63X@?^%1??_':** #_
M (:Q^-__ $63X@?^%1??_':/^&L?C?\ ]%D^('_A47W_ ,=HHH /^&L?C?\
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M ,=HHH /^&L?C?\ ]%D^('_A47W_ ,=H_P"&L?C?_P!%D^('_A47W_QVBB@
M_P"&L?C?_P!%D^('_A47W_QVC_AK'XW_ /19/B!_X5%]_P#':** #_AK'XW_
M /19/B!_X5%]_P#':/\ AK'XW_\ 19/B!_X5%]_\=HHH /\ AK'XW_\ 19/B
M!_X5%]_\=H_X:Q^-_P#T63X@?^%1??\ QVBB@ _X:Q^-_P#T63X@?^%1??\
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M'XW_ /19/B!_X5%]_P#':** #_AK'XW_ /19/B!_X5%]_P#':/\ AK'XW_\
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M'XW_ /19/B!_X5%]_P#':/\ AK'XW_\ 19/B!_X5%]_\=HHH /\ AK'XW_\
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MW_QVBB@ _P"&L?C?_P!%D^('_A47W_QVC_AK'XW_ /19/B!_X5%]_P#':**
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MW_QVC_AK'XW_ /19/B!_X5%]_P#':** #_AK'XW_ /19/B!_X5%]_P#':/\
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M (:Q^-__ $63X@?^%1??_':** #_ (:Q^-__ $63X@?^%1??_':/^&L?C?\
M]%D^('_A47W_ ,=HHH /^&L?C?\ ]%D^('_A47W_ ,=H_P"&L?C?_P!%D^('
M_A47W_QVBB@ _P"&L?C?_P!%D^('_A47W_QVC_AK'XW_ /19/B!_X5%]_P#'
M:** #_AK'XW_ /19/B!_X5%]_P#':/\ AK'XW_\ 19/B!_X5%]_\=HHH /\
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M!_X5%]_\=HHH /\ AK'XW_\ 19/B!_X5%]_\=H_X:Q^-_P#T63X@?^%1??\
MQVBB@ _X:Q^-_P#T63X@?^%1??\ QVC_ (:Q^-__ $63X@?^%1??_':** #_
M (:Q^-__ $63X@?^%1??_':/^&L?C?\ ]%D^('_A47W_ ,=HHH /^&L?C?\
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M ,=HHH /^&L?C?\ ]%D^('_A47W_ ,=H_P"&L?C?_P!%D^('_A47W_QVBB@
M_P"&L?C?_P!%D^('_A47W_QVC_AK'XW_ /19/B!_X5%]_P#':** #_AK'XW_
M /19/B!_X5%]_P#':/\ AK'XW_\ 19/B!_X5%]_\=HHH /\ AK'XW_\ 19/B
M!_X5%]_\=H_X:Q^-_P#T63X@?^%1??\ QVBB@ _X:Q^-_P#T63X@?^%1??\
MQVC_ (:Q^-__ $63X@?^%1??_':** #_ (:Q^-__ $63X@?^%1??_':/^&L?
MC?\ ]%D^('_A47W_ ,=HHH HZQ^T!\4?B!8_\(_XG^)7C#Q%H5[+$MSINJ:_
9=W-O,%D5EWQO(5;#*K#(X*@CD4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719804173728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 25, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIGAND PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0160744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">555 Heritage Drive, Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Jupiter<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">550-7500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LGND<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-Known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,255,353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Portions of the Proxy Statement for the Registrant&#8217;s 2025 Annual Meeting of Stockholders to be filed with the Commission within 120 days of December&#160;31, 2024 are incorporated by reference in Part&#160;III of this Annual Report on Form&#160;10-K.&#160;With the exception of those portions that are specifically incorporated by reference in this Annual Report on Form&#160;10-K, such Proxy Statement shall not be deemed filed as part of this Report or incorporated by reference herein.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000886163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719800319504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young&#160;LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719801534736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 72,307<span></span>
</td>
<td class="nump">$ 22,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">183,858<span></span>
</td>
<td class="nump">147,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">38,376<span></span>
</td>
<td class="nump">32,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">14,114<span></span>
</td>
<td class="nump">23,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income taxes receivable</a></td>
<td class="nump">4,073<span></span>
</td>
<td class="nump">6,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">1,934<span></span>
</td>
<td class="nump">1,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">16,897<span></span>
</td>
<td class="nump">2,657<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">331,559<span></span>
</td>
<td class="nump">237,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">266,648<span></span>
</td>
<td class="nump">299,606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">105,250<span></span>
</td>
<td class="nump">103,370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsNonCurrent', window );">Long-term portion of financial royalty assets, net</a></td>
<td class="nump">185,024<span></span>
</td>
<td class="nump">62,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="nump">10,583<span></span>
</td>
<td class="nump">3,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">15,133<span></span>
</td>
<td class="nump">15,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">6,907<span></span>
</td>
<td class="nump">6,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">2,766<span></span>
</td>
<td class="nump">3,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investment in Primrose Bio</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Other investments</a></td>
<td class="nump">10,908<span></span>
</td>
<td class="nump">36,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes, net</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">6,924<span></span>
</td>
<td class="nump">6,392<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">941,774<span></span>
</td>
<td class="nump">787,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,233<span></span>
</td>
<td class="nump">2,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">27,906<span></span>
</td>
<td class="nump">12,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income tax payable</a></td>
<td class="nump">1,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">1,278<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CurrentPortionOfLiabilityForContingentValueRights', window );">Current contingent liabilities</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">1,266<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current finance lease liabilities</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">37,112<span></span>
</td>
<td class="nump">16,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeNoncurrent', window );">Long-term deferred revenue</a></td>
<td class="nump">2,246<span></span>
</td>
<td class="nump">1,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_LiabilityForContingentValueRights', window );">Long-term contingent liabilities</a></td>
<td class="nump">3,475<span></span>
</td>
<td class="nump">2,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">5,815<span></span>
</td>
<td class="nump">5,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes, net</a></td>
<td class="nump">32,524<span></span>
</td>
<td class="nump">31,622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">30,163<span></span>
</td>
<td class="nump">27,758<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">111,335<span></span>
</td>
<td class="nump">86,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2024 and 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 60,000 shares authorized; 19,106 and 17,556 shares issued and outstanding at December&#160;31, 2024 and 2023, respectively</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">337,377<span></span>
</td>
<td class="nump">198,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(5,942)<span></span>
</td>
<td class="num">(817)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">498,984<span></span>
</td>
<td class="nump">503,016<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">830,439<span></span>
</td>
<td class="nump">700,913<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 941,774<span></span>
</td>
<td class="nump">$ 787,216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CurrentPortionOfLiabilityForContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current portion of liability for contingent value rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CurrentPortionOfLiabilityForContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinancialRoyaltyAssetsNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Royalty Assets, Non Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinancialRoyaltyAssetsNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LiabilityForContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability for contingent value rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LiabilityForContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481174/470-10-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719802175840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock authorized (in shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock authorized (in shares)</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued (in shares)</a></td>
<td class="nump">19,106<span></span>
</td>
<td class="nump">17,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding (in shares)</a></td>
<td class="nump">19,106<span></span>
</td>
<td class="nump">17,556<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719802323136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues and other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">$ 167,133<span></span>
</td>
<td class="nump">$ 131,314<span></span>
</td>
<td class="nump">$ 196,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostDirectMaterial', window );">Cost of Captisol</a></td>
<td class="nump">11,074<span></span>
</td>
<td class="nump">10,512<span></span>
</td>
<td class="nump">52,827<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization of intangibles</a></td>
<td class="nump">32,959<span></span>
</td>
<td class="nump">33,654<span></span>
</td>
<td class="nump">34,237<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">21,425<span></span>
</td>
<td class="nump">24,537<span></span>
</td>
<td class="nump">36,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">78,654<span></span>
</td>
<td class="nump">52,790<span></span>
</td>
<td class="nump">70,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Financial royalty assets impairment</a></td>
<td class="nump">30,572<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Fair value adjustments to partner program derivatives</a></td>
<td class="nump">15,055<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">189,739<span></span>
</td>
<td class="nump">121,493<span></span>
</td>
<td class="nump">193,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of Pelican</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,121)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income (loss) from continuing operations</a></td>
<td class="num">(22,606)<span></span>
</td>
<td class="nump">11,942<span></span>
</td>
<td class="nump">3,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Non-operating income and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain from short-term investments</a></td>
<td class="nump">75,024<span></span>
</td>
<td class="nump">46,365<span></span>
</td>
<td class="nump">28,540<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">8,055<span></span>
</td>
<td class="nump">7,711<span></span>
</td>
<td class="nump">2,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(3,037)<span></span>
</td>
<td class="num">(656)<span></span>
</td>
<td class="num">(1,799)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other non-operating (expense) income, net</a></td>
<td class="num">(54,918)<span></span>
</td>
<td class="num">(1,702)<span></span>
</td>
<td class="nump">4,187<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total non-operating income, net</a></td>
<td class="nump">25,124<span></span>
</td>
<td class="nump">51,718<span></span>
</td>
<td class="nump">32,974<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income tax from continuing operations</a></td>
<td class="nump">2,518<span></span>
</td>
<td class="nump">63,660<span></span>
</td>
<td class="nump">36,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(6,550)<span></span>
</td>
<td class="num">(9,841)<span></span>
</td>
<td class="num">(41,230)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(4,032)<span></span>
</td>
<td class="nump">53,819<span></span>
</td>
<td class="num">(5,219)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net loss from discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,665)<span></span>
</td>
<td class="num">(28,142)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss):</a></td>
<td class="num">$ (4,032)<span></span>
</td>
<td class="nump">$ 52,154<span></span>
</td>
<td class="num">$ (33,361)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Basic net income (loss) from continuing operations (in USD per share)</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="nump">$ 3.11<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Basic net loss from discontinued operations (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.10)<span></span>
</td>
<td class="num">(1.67)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income (loss) per share (in USD per share)</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="nump">$ 3.02<span></span>
</td>
<td class="num">$ (1.98)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in basic per share calculation (in shares)</a></td>
<td class="nump">18,290<span></span>
</td>
<td class="nump">17,298<span></span>
</td>
<td class="nump">16,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Diluted net income (loss) from continuing operations (in USD per share)</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="nump">$ 3.03<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Diluted net loss from discontinued operations (in USD per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.09)<span></span>
</td>
<td class="num">(1.67)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income (loss) per share (in USD per share)</a></td>
<td class="num">$ (0.22)<span></span>
</td>
<td class="nump">$ 2.94<span></span>
</td>
<td class="num">$ (1.98)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in diluted per share calculation (in shares)</a></td>
<td class="nump">18,290<span></span>
</td>
<td class="nump">17,757<span></span>
</td>
<td class="nump">16,868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues and other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">$ 108,773<span></span>
</td>
<td class="nump">$ 84,959<span></span>
</td>
<td class="nump">$ 72,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_IntangibleRoyaltyAssetsMember', window );">Revenue from intangible royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues and other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">95,329<span></span>
</td>
<td class="nump">83,910<span></span>
</td>
<td class="nump">72,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_FinancialRoyaltyAssetsMember', window );">Income from financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues and other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">13,444<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember', window );">Captisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues and other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">30,883<span></span>
</td>
<td class="nump">28,372<span></span>
</td>
<td class="nump">104,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueAndOtherIncomeMember', window );">Contract revenue and other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues and other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">$ 27,477<span></span>
</td>
<td class="nump">$ 17,983<span></span>
</td>
<td class="nump">$ 18,838<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostDirectMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of material used for good produced and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostDirectMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 17: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479836/810-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_IntangibleRoyaltyAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_IntangibleRoyaltyAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_FinancialRoyaltyAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_FinancialRoyaltyAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueAndOtherIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_ContractRevenueAndOtherIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719936405008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (4,032)<span></span>
</td>
<td class="nump">$ 52,154<span></span>
</td>
<td class="num">$ (33,361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized net gain (loss) on available-for-sale securities, net of tax</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment, net of tax</a></td>
<td class="num">(5,170)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (9,157)<span></span>
</td>
<td class="nump">$ 52,321<span></span>
</td>
<td class="num">$ (33,428)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719800482672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Retain earnings</div></th>
<th class="th">
<div>Retain earnings </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at beginning of period at Dec. 31, 2021</a></td>
<td class="nump">$ 821,159<span></span>
</td>
<td class="num">$ (15,997)<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 372,969<span></span>
</td>
<td class="num">$ (51,130)<span></span>
</td>
<td class="num">$ (917)<span></span>
</td>
<td class="nump">$ 449,090<span></span>
</td>
<td class="nump">$ 35,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes</a></td>
<td class="num">(5,004)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,004)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">60,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized net gain (loss) on available-for-sale securities, net of tax</a></td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction', window );">Bond hedge transaction</a></td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation', window );">OmniAb Distribution</a></td>
<td class="num">(229,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(229,732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(33,361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(33,361)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2022</a></td>
<td class="nump">597,485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">147,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(984)<span></span>
</td>
<td class="nump">450,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes</a></td>
<td class="nump">17,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">17,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">25,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized net gain (loss) on available-for-sale securities, net of tax</a></td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation', window );">Final OmniAb Distribution</a></td>
<td class="nump">1,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision', window );">Final tax impact of OmniAb Distribution</a></td>
<td class="nump">5,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">52,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2023</a></td>
<td class="nump">$ 700,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">198,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(817)<span></span>
</td>
<td class="nump">503,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2023</a></td>
<td class="nump">17,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes</a></td>
<td class="nump">$ 60,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">60,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of commissions and fees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of commissions and fees</a></td>
<td class="nump">37,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">41,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized net gain (loss) on available-for-sale securities, net of tax</a></td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation adjustment, net of tax</a></td>
<td class="num">(5,170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,170)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(4,032)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,032)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at end of period at Dec. 31, 2024</a></td>
<td class="nump">$ 830,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 337,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,942)<span></span>
</td>
<td class="nump">$ 498,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2024</a></td>
<td class="nump">19,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid In Capital, Bond Hedge Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Decrease Due To Separation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid in Capital, Increase Due To Separation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments To Additional Paid In Capital, Tax Return To Provision</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719805995648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">Accounting Standards Update 2020-06 [Member]<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 80: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719803047408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (4,032)<span></span>
</td>
<td class="nump">$ 52,154<span></span>
</td>
<td class="num">$ (33,361)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of Pelican</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,121)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights', window );">Change in estimated fair value of contingent liabilities</a></td>
<td class="nump">683<span></span>
</td>
<td class="num">(265)<span></span>
</td>
<td class="num">(748)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation of fixed assets and amortization of intangible assets</a></td>
<td class="nump">35,239<span></span>
</td>
<td class="nump">36,521<span></span>
</td>
<td class="nump">51,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_GainLossOnShortTermInvestments', window );">Gain from short-term investments</a></td>
<td class="num">(67,901)<span></span>
</td>
<td class="num">(46,365)<span></span>
</td>
<td class="num">(28,540)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization/accretion of premium (discount) on investments, net</a></td>
<td class="num">(1,331)<span></span>
</td>
<td class="num">(1,318)<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance fees</a></td>
<td class="nump">486<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="nump">734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Loss (gain) on derivative instruments</a></td>
<td class="nump">20,010<span></span>
</td>
<td class="num">(250)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,192)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_NonCashIncomeFromFinancialRoyaltyAssets', window );">Non-cash income from financial royalty assets</a></td>
<td class="num">(5,467)<span></span>
</td>
<td class="num">(878)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CurrentAndExpectedCreditLossAdjustment', window );">CECL adjustment to financial royalty assets</a></td>
<td class="num">(4,315)<span></span>
</td>
<td class="nump">3,595<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ImpairmentLossOnFinancialRoyaltyAssets', window );">Impairment loss of financial royalty assets</a></td>
<td class="nump">30,572<span></span>
</td>
<td class="nump">924<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization', window );">Lease amortization expense</a></td>
<td class="nump">2,126<span></span>
</td>
<td class="nump">1,735<span></span>
</td>
<td class="nump">5,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">41,089<span></span>
</td>
<td class="nump">25,743<span></span>
</td>
<td class="nump">60,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Losses from equity method investment in Primrose Bio</a></td>
<td class="nump">12,821<span></span>
</td>
<td class="nump">1,829<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Fair value adjustment to Primrose Bio securities investments</a></td>
<td class="nump">25,788<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes, net</a></td>
<td class="num">(15,800)<span></span>
</td>
<td class="nump">11,696<span></span>
</td>
<td class="nump">20,723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">7,723<span></span>
</td>
<td class="nump">739<span></span>
</td>
<td class="nump">365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of acquisitions and dispositions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable, net</a></td>
<td class="num">(6,459)<span></span>
</td>
<td class="num">(2,601)<span></span>
</td>
<td class="nump">55,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">9,619<span></span>
</td>
<td class="num">(10,870)<span></span>
</td>
<td class="nump">12,058<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent', window );">Other economic rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">13,903<span></span>
</td>
<td class="num">(4,704)<span></span>
</td>
<td class="num">(3,340)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income taxes receivable and payable</a></td>
<td class="nump">2,310<span></span>
</td>
<td class="num">(1,781)<span></span>
</td>
<td class="nump">1,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(1,308)<span></span>
</td>
<td class="nump">419<span></span>
</td>
<td class="num">(6,281)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other assets and liabilities</a></td>
<td class="nump">1,291<span></span>
</td>
<td class="num">(9,865)<span></span>
</td>
<td class="nump">6,342<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">97,047<span></span>
</td>
<td class="nump">49,577<span></span>
</td>
<td class="nump">137,850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsToAcquireFinancialRoyaltyAssets', window );">Acquisition of financial royalty assets</a></td>
<td class="num">(17,819)<span></span>
</td>
<td class="num">(50,328)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ProceedsFromFinancialRoyaltyAssets', window );">Proceeds from financial royalty assets</a></td>
<td class="nump">7,429<span></span>
</td>
<td class="nump">418<span></span>
</td>
<td class="nump">92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,821)<span></span>
</td>
<td class="num">(3,521)<span></span>
</td>
<td class="num">(17,923)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(226,384)<span></span>
</td>
<td class="num">(126,764)<span></span>
</td>
<td class="num">(51,226)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale of short-term investments</a></td>
<td class="nump">229,367<span></span>
</td>
<td class="nump">148,765<span></span>
</td>
<td class="nump">209,561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Proceeds from maturity of short-term investments</a></td>
<td class="nump">33,131<span></span>
</td>
<td class="nump">45,402<span></span>
</td>
<td class="nump">24,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireNotesReceivable', window );">Cash paid for Palvella notes receivable</a></td>
<td class="num">(2,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for Novan acquisition, net of restricted cash received</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,405)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForDerivativeInstrumentInvestingActivities', window );">Cash paid for the Agenus transaction</a></td>
<td class="num">(75,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired', window );">Cash paid for Apeiron acquisition, net of cash received</a></td>
<td class="num">(91,996)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Cash paid for InvIOs investment</a></td>
<td class="num">(4,196)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities', window );">Net proceeds from Viking Share Collar and Viking Share Put</a></td>
<td class="nump">7,123<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(960)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in (provided by) investing activities</a></td>
<td class="num">(143,664)<span></span>
</td>
<td class="num">(11,682)<span></span>
</td>
<td class="nump">163,624<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock issuance, net of commissions and fees</a></td>
<td class="nump">37,140<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsForSeparation', window );">Net cash transferred to OmniAb at OmniAb Separation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,840)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment at maturity/repurchase of 2023 Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(76,854)<span></span>
</td>
<td class="num">(260,949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments under finance lease obligations</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities', window );">Cash paid for transaction costs related to OmniAb Transactions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Cash paid for debt issuance costs</a></td>
<td class="num">(426)<span></span>
</td>
<td class="num">(949)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromHedgeFinancingActivities', window );">Proceeds from bond hedge settlement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from stock option exercises and ESPP</a></td>
<td class="nump">65,588<span></span>
</td>
<td class="nump">22,448<span></span>
</td>
<td class="nump">3,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(5,136)<span></span>
</td>
<td class="num">(4,547)<span></span>
</td>
<td class="num">(8,236)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity', window );">Payments to CVR Holders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,545)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used) in financing activities</a></td>
<td class="nump">97,141<span></span>
</td>
<td class="num">(59,947)<span></span>
</td>
<td class="num">(275,990)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(1,171)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">49,353<span></span>
</td>
<td class="num">(22,052)<span></span>
</td>
<td class="nump">25,484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">22,954<span></span>
</td>
<td class="nump">45,006<span></span>
</td>
<td class="nump">19,522<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">72,307<span></span>
</td>
<td class="nump">22,954<span></span>
</td>
<td class="nump">45,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="nump">1,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Taxes paid</a></td>
<td class="nump">19,206<span></span>
</td>
<td class="nump">8,770<span></span>
</td>
<td class="nump">11,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract', window );"><strong>Acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived', window );">Fair value of tangible assets acquired, net of cash and restricted cash received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">105,250<span></span>
</td>
<td class="nump">103,370<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets', window );">Financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,405<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid', window );">Accrued Primrose transaction costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">998<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Addition of right-of-use assets and lease liabilities</a></td>
<td class="nump">1,769<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid', window );">Accrued royalty from financial royalty assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid', window );">Accrued purchases of financial royalty assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">347<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid', window );">Accrued debt issuance costs</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued fixed asset purchases</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain (loss) on available-for-sale investments, net of tax</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_APEIRONMember', window );">APEIRON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for Novan acquisition, net of restricted cash received</a></td>
<td class="num">(91,996)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract', window );"><strong>Acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived', window );">Fair value of tangible assets acquired, net of cash and restricted cash received</a></td>
<td class="nump">8,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets', window );">Financial royalty assets</a></td>
<td class="nump">106,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities assumed</a></td>
<td class="num">(23,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for acquisitions</a></td>
<td class="nump">91,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember', window );">Novan, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for Novan acquisition, net of restricted cash received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,405)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract', window );"><strong>Acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived', window );">Fair value of tangible assets acquired, net of cash and restricted cash received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets', window );">Financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,891)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid for acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=lgnd_NucorionMember', window );">Nucorion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Cash paid for equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(750)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=lgnd_PrimroseBioMember', window );">Primrose Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Cash paid for equity method investment</a></td>
<td class="num">$ (998)<span></span>
</td>
<td class="num">$ (15,249)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Commercial License Rights Purchases Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Debt Issuance Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Royalty From Commercial License Rights Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Acquisition Cost Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired Net of Cash And Restricted Cash Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CurrentAndExpectedCreditLossAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current And Expected Credit Loss Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CurrentAndExpectedCreditLossAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease And Operating Lease, Right-of-Use Asset, Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_GainLossOnShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Short-Term Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_GainLossOnShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ImpairmentLossOnFinancialRoyaltyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Loss On Financial Royalty Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ImpairmentLossOnFinancialRoyaltyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Change In Estimated Fair Value Of Contingent Value Rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NonCashIncomeFromFinancialRoyaltyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash Income From Financial Royalty Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NonCashIncomeFromFinancialRoyaltyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsForSeparation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Separation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsForSeparation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToAcquireFinancialRoyaltyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Financial Royalty Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToAcquireFinancialRoyaltyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Contingent Value Right Holders, Financing Activity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToContingentValueRightHoldersFinancingActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ProceedsFromFinancialRoyaltyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Financial Royalty Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ProceedsFromFinancialRoyaltyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in intangible assets (for example patents and licenses).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForDerivativeInstrumentInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for derivative instruments during the period, which are classified as investing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForDerivativeInstrumentInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for financing costs associated with business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow provided by derivative instruments during the period, which are classified as investing activities, excluding those designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromHedgeFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromHedgeFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_APEIRONMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_APEIRONMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=lgnd_NucorionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=lgnd_NucorionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=lgnd_PrimroseBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=lgnd_PrimroseBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719800272544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. We do this by providing financing, licensing our technologies or both.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating and one reportable segment: development and licensing of biopharmaceutical assets. The Company's Chief Operating Decision Maker (&#8220;CODM&#8221;) is Todd Davis, our Chief Executive Officer. The CODM uses net income (loss) from continuing operations as a single segment profit or loss measure to evaluate our single segment performance, and in deciding whether to reinvest into the existing assets, or to new potential opportunities. Our CODM relies on internal management reporting processes that provide information on segment operating income (loss) for making financial decisions and allocating resources. CODM does not evaluate, manage or measure performance of segments using asset information.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information on significant segment expenses that are regularly provided to the CODM, and other segment items included within the reported segment profit or loss measure, is presented in a table below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total revenues and other income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,089)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,743)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60,285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other segment items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,959)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33,654)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,905)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,841)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other *</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(99,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(103,348)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income (loss) from continuing operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,032)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,819&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,219)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">* Other items for the years ended December 31, 2024, 2023, and 2022, include the amount of other general, administrative, research and development expenses of $56.7 million, $48.7 million, and $42.0 million (net of share-based compensation and depreciation expenses), respectively, and additional income and expense items that are presented in consolidated statements of operations such as financial royalty assets impairment, Fair value adjustments to partner program derivatives, cost of Captisol and other non-operating income and expenses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to the previously issued audited consolidated financial statements to conform with the current period presentation. Specifically, within the consolidated balance sheet as of December 31, 2023, our commercial license and other economic rights line has been reclassified to long-term portion of financial royalty assets, net, and to other assets, and a portion of other investments has been reclassified from other assets. Moreover, noncurrent derivative assets as of December 31, 2023, have been reclassified from other assets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, within the consolidated statements of operations for the years ended December 31, 2023 and 2022, royalties have been reclassified to revenue from intangible royalty assets, and a portion of the contract revenue has been reclassified to income from financial royalty assets.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued operations</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the spin-off of the OmniAb Business in November 2022 in connection with the OmniAb Transactions met the criteria for classification as a discontinued operation in accordance with ASC Subtopic 205-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 205-20&#8221;). For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (5), Spin-off of OmniAb&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All disclosures have been adjusted to reflect continuing operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they incurred. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Business Risk</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue and other income from significant partners, which is defined as 10% or more of our total revenue, was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;10%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;10%</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to credit risk through our counterparties, including risks associated with royalty assets, receivables, and financial instruments such as derivatives and available-for-sale debt securities. Most of our royalty assets and receivables come from contractual agreements that generate royalties based on sales of pharmaceutical products across the United States, Europe, and other regions. This risk is primarily mitigated by the broad range of marketers responsible for paying royalties and the geographic diversity of product sales. Our royalty portfolio includes products marketed by leading biopharmaceutical </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">companies such as Amgen, Merck, Jazz, Recordati, and Sanofi. As of December&#160;31, 2024, Recordati was the largest individual marketer and payor of our financial royalty assets, representing 54% of the financial royalty asset balance.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively monitor the financial performance and creditworthiness of counterparties to our royalty agreements, derivative financial instruments, and available-for-sale debt securities to assess and respond to changes in their credit profiles. So far, we have not incurred any significant losses related to the collection of income or revenue from royalty assets, available-for-sale debt securities, or the settlement of derivative financial instruments. However, if a counterparty faces bankruptcy or financial difficulties and fails to meet its obligations under a derivative financial instrument, we could face substantial delays in recovering amounts owed during bankruptcy or reorganization.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtain Captisol primarily from two sites related to a single supplier, Hovione.&#160;If this supplier were not able to supply the requested amounts of Captisol from each site, and if our safety stocks of material were depleted, we would be unable to continue to derive revenues from the sale of Captisol until we obtained material from an alternative source, which could take a considerable length of time.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments with maturities of three months or less from the date of acquisition. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Investments</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments primarily consist of investments in debt and equity securities. We classify our short-term investments as &#8220;available-for-sale&#8221;. Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statements of comprehensive income (loss), net of tax, and unrealized gains and losses on equity securities included the consolidated statements of operations. We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and include net realized gains and losses as a component of non-operating income and expenses within the consolidated statements of operations. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of certificates of deposit, corporate debt securities, and securities of government-sponsored entities. Debt securities have effective maturities greater than&#160;three months and less than thirty-six months from the date of acquisition. Debt securities available-for-sale in an unrealized loss position are assessed for current expected credit losses. We start by assessing whether we intend to sell the security, or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity securities consist of bond funds, investments in privately held companies (non-marketable equity securities), and companies that have completed initial public offerings (marketable equity securities). Bond funds are valued at their publicly quoted net asset value (&#8220;NAV&#8221;) price on the last day of the period. Our non-marketable equity securities without readily determinable market values are initially measured at cost and adjusted to fair value for observable transactions for identical or similar investments of the same issuer or impairment. Our marketable equity securities are measured at fair value. Equity investments are classified as short-term investments, equity method investment in Primrose Bio, or other investments, based on the nature of the securities and their availability for use in current operations. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Balance Sheet Account Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During the years ended December&#160;31, 2024, 2023 and 2022, we considered the current and expected future economic and market conditions and concluded a decrease of $0.1&#160;million, an increase of $0.2&#160;million, and a decrease of $0.3&#160;million of allowance for credit losses, respectively. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, which consists of finished goods (Captisol), is stated at the lower of cost or net realizable value. We determine cost using the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements. During the years ended December&#160;31, 2024, 2023 and 2022, we recorded an obsolete inventory charge of $0.2&#160;million, $0.2&#160;million and $1.1&#160;million, respectively. In addition to finished goods, as of December&#160;31, 2024 and 2023, inventory included prepayments of $3.1&#160;million and $4.6&#160;million, respectively, to our supplier for Captisol.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from <span style="-sec-ix-hidden:f-611">one</span> to nine years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Balance Sheet Account Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at the reporting unit level at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment at the reporting unit level during the fourth quarter of 2024, noting no impairment. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles at December&#160;31, 2024.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Balance Sheet Account Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Royalty Assets, net (formerly known as Commercial License Rights)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial royalty assets represent a portfolio of future milestone and royalty payment rights acquired that are passive in nature (i.e., we do not own the intellectual property or have the right to commercialize the underlying products).</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we account for financial royalty assets under ASC 310, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is recalculated in each reporting period as the difference between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by accrued interest income (except for assets under the non-accrual method) and decreased by cash receipts in the period to arrive at the ending balance.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate financial royalty assets for recoverability on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the total amount of expected undiscounted cash flows is below the amortized cost basis, we measure and record an allowance for the change in expected cash flows. This allowance is measured as the difference between the financial royalty asset&#8217;s amortized cost basis and the net present value of the expected future cash flows, calculated using the original effective interest rate. In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance in part or in full.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above allowance, we recognize an allowance for current expected credit losses under ASC 326, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our financial royalty assets. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the credit loss provision.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of financial royalty assets is presented net of the cumulative allowances for changes in expected future cash flows and expected credit losses. The initial amount and subsequent revisions in allowances for changes in expected future cash flows and expected credit losses are recorded as part of general and administrative expenses on the consolidated statements of operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we are reasonably certain that a part of a financial royalty asset&#8217;s net carrying value (or all of it) is not recoverable, we recognize an impairment which is recorded in financial royalty assets impairment on the consolidated statements of operations. To the extent there was an allowance previously recorded for this asset, the amount of such impairment is written off against the allowance at the time that such a determination is made. Any future recoveries from such impairment are recognized when cash is collected in a respective period earnings.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of financial royalty assets represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter. This portion is presented in other current assets on our consolidated balance sheets, net of the allowance for expected credit losses.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (6), Financial Royalty Assets, net (formerly known as Commercial License Rights)&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Assets</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative assets include instruments used for risk-management purposes, and other instruments. Derivative assets which are not used for risk management purposes, include: (a) acquired rights in future milestone and royalty payments from Agenus Partnered Programs (as defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (2), Agenus Transaction&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), (b) Agenus Warrant (as defined </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (2), Agenus Transaction&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), (c) option to invest up to $25 million to milestone and royalty rights which expires on June 30, 2025 (&#8220;Upsize Option&#8221;), and (d) rights to receive from Primrose Bio 50% of milestones on two contracts previously entered into by Primordial Genetics.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2024, we entered into a collar arrangement to hedge against the fluctuation risk in Viking's share price (the &#8220;Viking Share Collar&#8221;). However, because the Viking stock investment is remeasured at fair value through earnings under ASC 321, the Viking Share Collar is not eligible for hedge accounting, but is considered as an economic hedge. The Viking Share Collar was fully exercised during three month period ending December 31, 2024. During the three months ended December 31, 2024, we entered into a put arrangement to hedge against the fluctuation risk in Viking's share price (the &#8220;Viking Share Put&#8221;) which expired within the same quarter.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivatives are measured at fair value on the consolidated balance sheets. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (8), Fair Value Measurement&#8221; and &#8220;Note (7), Balance Sheet Account Details&#8221;.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investment</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments that we do not consolidate but in which we have significant influence over the operating and financial policies of the investee are classified as equity method investments and are accounted for using the equity method of accounting.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In applying the equity method of accounting, investments are initially recorded at cost and are subsequently adjusted based on our proportionate share of net income or loss of the investee, net of any distributions received from the investee and any impairment.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (4), Sale of Pelican Business and Investment in Primrose Bio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Investments</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other investments represent our investments in equity securities of third parties in which we do not have control or significant influence. Our equity securities investments do not have a readily determinable or estimable fair value and are measured using the measurement alternative, which is cost less impairment, if any, and adjustments resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. The amount of such impairment or adjustment recognized during the period is presented in other non-operating (expense) income, net in our consolidated statements of operations. For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Balance Sheet Account Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Liabilities</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of CyDex in January 2011, we recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any change in fair value is recorded in other non-operating (expense) income, net in our consolidated statements of operations. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (8), Fair Value Measurement&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Balance Sheet Account Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue and Other Income</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, income from financial royalty assets, and contract revenue for license fees, technical, regulatory and sales-based milestone payments. Other operating income is primarily related to milestone income received for financial royalty assets that have been fully amortized or where there is no underlying asset recognized on the consolidated balance sheets. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the following five-step model in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Intangible Royalty Assets</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalty revenue from intangible royalty assets on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than when the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted in the period in which they become known, typically the following quarter.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Financial Royalty Assets</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2024, we introduced a new line item &#8220;income from financial royalty assets&#8221;, which was included in &#8220;contract revenue&#8221; in prior periods. Accordingly, the prior year period amounts have been reclassified to align with the current period presentation.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. Income is calculated by multiplying the carrying value of the financial royalty asset by the periodic effective interest rate.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for financial royalty assets related to developmental pipeline or recently commercialized products on a non-accrual basis. Developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. Newly commercialized products typically do not have an established reliable sales pattern, and thus have uncertain cash flows.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Captisol Sales</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Captisol sales is recognized when control of Captisol material is transferred or intellectual property license rights are granted to our customers in an amount that reflects the consideration we expect to receive from our customers </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in exchange for those products or rights. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. For Captisol material or intellectual property license rights, we consider our performance obligation satisfied once we have transferred control of the product or granted the intellectual property rights, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost of freight and shipping when control over Captisol material has transferred to the customer as an expense in cost of Captisol in our consolidated statements of operations. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Revenue and Other Income</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers often include variable consideration in the form of contingent milestone payments. We include contingent milestone payments in the estimated transaction price when it is probable a significant reversal in the amount of cumulative revenue recognized will not occur. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone payment is based on sales, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some customer contracts are sublicenses which require that we make payments to an upstream licensor related to license fees, milestones and royalties which we receive from customers. In such cases, we evaluate the determination of gross revenue as a principal versus net revenue as an agent reporting based on each individual agreement.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income is primarily related to milestone income received for financial royalty assets that have been fully amortized or where there is no underlying asset recognized on the consolidated balance sheets.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue and certain service revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue. During the year ended December&#160;31, 2024, the amount recognized as revenue that was previously deferred at December&#160;31, 2023 was $1.3 million. During the year ended December&#160;31, 2023, the amount recognized as revenue that was previously deferred at December&#160;31, 2022 was $0.1 million. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties for 2024, 2023 and 2022 for continuing operations are reported as below (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rylaze </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filspari</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Teriparatide injection </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from intangible royalty assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,773&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,959&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,912&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregation of Captisol and contract revenue and other income for continuing operations (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Captisol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Captisol - Core</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Captisol - COVID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Captisol</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,883&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,372&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,495&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract revenue and other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total contract revenue and other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,477&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,983&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,838&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(a) Captisol - COVID represents revenue on Captisol supplied for use in formulation with remdesivir, an antiviral treatment for COVID-19.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, contract research organization (&#8220;CRO&#8221;) costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur share-based compensation expense related to restricted stock, ESPP, and stock options.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit (&#8220;RSU&#8221;) and performance stock unit (&#8220;PSU&#8221;) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment. A limited amount of PSUs contain a market condition dependent upon the Company&#8217;s relative and absolute total stockholder return over a three-year period, with a range of 0% to 200% of the target amount granted to be issued under the award. Share-based compensation expense for these PSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the market conditions.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock purchases under our ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatility of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income (Loss) Per Share</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares consist of shares issuable under the 2023 Notes, stock options and restricted stock. Although we paid off the 2023 Notes in May 2023, it would have a dilutive impact when the average market price of our common stock exceeded the maximum conversion price during the year ended December 31, 2023. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (11), Stockholders&#8217; Equity&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, if a company had a discontinuing operation, the company uses income from continuing operations, adjusted for preferred dividends and similar adjustments, as its control number to determine whether potential common shares a dilutive. The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:62.189%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dilutive potential common shares:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;2023 Convertible Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares used to compute diluted income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,290&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,757&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,868&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Potentially dilutive shares excluded from calculation due to anti-dilutive effect</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,530&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,357&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,241&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Euro is the functional currency of Apeiron and the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Translation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented for unrealized gains and losses on available-for-sale debt securities and foreign currency translation adjustments. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Updates, Recently Adopted</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have adopted the updated accounting guidance in our Annual Report on the Form 10-K for the year ended December&#160;31, 2024. We have updated our segment disclosure (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (1), Basis of Presentation and Summary of Significant Accounting Policies&#8221;) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including, among other required items, the information on significant segment expenses that are regularly provided to the CODM and included within the reported segment profit or loss measure.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December 15, 2024, with early adoption permitted. We have not yet completed the assessment of the impact of ASU 2023-09 on our consolidated financial statements.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income (Subtopic 220-40): Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update requires entities to disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. We are currently evaluating the new guidance to determine the impact it may have on our consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719798139616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agenus Transaction<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTextBlock', window );">Agenus Transaction</a></td>
<td class="text">Agenus Transaction<div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 29, 2024, we closed the transactions pursuant to the $75&#160;million purchase and sale agreement (the &#8220;Agenus Agreement&#8221;), dated May 6, 2024, among us and Agenus Inc., </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agenus Royalty Fund, LLC, and Agenus Holdings 2024, LLC </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(collectively, &#8220;Agenus&#8221;). Under the terms of the Agenus Agreement, we received (i) 18.75% of the licensed royalties and 31.875% of the future licensed milestones paid to Agenus on six-partnered oncology programs, including BMS-986442 (Bristol Myers Squibb), AGEN2373 (Gilead Sciences), INCAGN2385 and INCAGN2390 (Incyte), MK-4830 (Merck), and UGN-301 (UroGen Pharma) (collectively referred as &#8220;Agenus Partnered Programs&#8221;), and (ii) a synthetic 2.625% royalty on future global net sales of Agenus&#8217; novel immuno-oncology botensilimab in combination with balstilimab (&#8220;BOT/BAL&#8221;) program, collectively subject to certain events which may adjust the royalty and milestone percentages paid to us. In addition, we received the option to commit an additional $25&#160;million in the same assets on a pro rata basis which expires on June 30, 2025 (&#8220;Upsize Option&#8221;). We have also agreed to allow Agenus to raise up to an additional $100&#160;million bringing the total syndicated purchase price up to an aggregate of $200&#160;million. As part of the Agenus Agreement, Agenus granted us security over certain assets related to the programs included in the Agenus Agreement, subject to certain customary exceptions. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with entry into the Agenus Agreement, Agenus issued us a 5-year warrant (&#8220;Agenus Warrant&#8221;) to purchase 867,052 shares of its common stock, at an exercise price equal to $17.30.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for all Agenus Partnered Programs, Agenus Warrant and Upsize Option as derivative assets. All derivatives, except for Upsize Option, were presented in noncurrent derivative assets line in our consolidated balance sheets. Agenus Partnered Programs were recognized as derivative assets under ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as they have different underlyings (milestone payments and royalties). The commercial milestones and royalties are dependent on the development milestones and the commercial milestone and royalties underlyings are not determined to be predominate. The derivative assets were recorded at fair value as of May 29, 2024, and are marked to fair value at each subsequent reporting period. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Agenus Partnered Programs derivative assets is determined as a present value of expected future cash flows adjusted for the level of risk appropriate for a respective program stage. As of Agenus Transaction date, it was $21.3&#160;million. During the three months ended September 30, 2024, certain Agenus partners discontinued development of their partnered programs. These programs may be relicensed at a later date, and Ligand would retain its economic interest upon any relicense activity. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Agenus Warrant is determined using a Black-Scholes model. The following assumptions were used as of May 29, 2024, and December&#160;31, 2024, respectively: expected term of 4.0 years and 3.4 years, volatility of 84% and 102%, risk-free rate of 4.7% and 4.3%, Agenus stock price of $15.03 and $2.74. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Upsize Option was determined using the binomial option pricing model under which we assessed and considered the possible upwards and downwards scenarios through the expiration date of the Upsize Option. The fair value of the Upsize Option was written down to zero as of December&#160;31, 2024.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the Agenus Partnered Program derivative assets, Agenus Warrant, and Upsize Option, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (8), Fair Value Measurements&#8221;.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accounted for the acquired BOT/BAL rights as a financial royalty asset which is currently put under the non-accrual method as management cannot reliably estimate future cash flows from this program. The amount of BOT/BAL financial royalty asset was determined as a residual value from the $75&#160;million aggregate investment amount, less fair value of all acquired derivative assets as of May 29, 2024. For additional information on the Agenus BOT/BAL rights, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (6), Financial Royalty Assets, net (formerly known as Commercial License Rights)&#8221;.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719803576736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Apeiron </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2024, we acquired all the outstanding shares of Biologics AG (&#8220;Apeiron&#8221;), including the royalty rights to Qarziba (dinutuximab beta) for the treatment of high-risk neuroblastoma (the &#8220;Apeiron Acquisition&#8221;) for $100.5&#160;million base consideration. We funded the Apeiron Acquisition from our available cash on hand. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to base consideration, we would also pay Apeiron shareholders an additional consideration based on future commercial and regulatory events, including up to $28&#160;million if Qarziba royalties exceed certain predetermined thresholds by either 2030 or 2034, and pay additional earn-outs on specific future events, primarily related to Qarziba regulatory approval and commercialization in the USA.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluated this acquisition in accordance with ASC 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to discern whether the assets and operations of Apeiron met the definition of a business. We accounted for this transaction as assets acquisition.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred $4.9&#160;million of transaction costs related to the Apeiron Acquisition, which were included in the amount of total purchase consideration. All assets acquired (except for contract assets) and liabilities assumed in the Apeiron Acquisition were recognized at their fair values. Contract assets acquired were recognized on a relative fair value basis. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract assets (financial royalty assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,740)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total fair value of net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,433&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets acquired are accounted for as financial royalty assets, similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30. The acquired contracts assets include Qarziba and other development phase contract assets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As Qarziba is a commercial phase program, we are able to reasonably estimate future cash flows and, as such, we recognize income from Qarziba financial royalty assets starting from the Apeiron Acquisition effective date, which is calculated by multiplying the carrying value of the financial royalty asset by the periodic effective interest rate. As described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (1), Basis of Presentation and Significant Accounting Policies&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is recalculated in each reporting period as the differences between expected cash flows and actual cash flows are realized and as </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">there are changes to expected future cash flows. We account for other Apeiron development phase financial royalty assets on a non-accrual basis as there is a higher level of uncertainty over the related expected cash flows.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For tax purposes this transaction is treated as a stock purchase. As a result, we will not obtain a tax stepped-up basis in Apeiron&#8217;s underlying assets and will assume the carryover tax basis. As part of the tax purchase price accounting, deferred tax liabilities of $18.1&#160;million have been recorded to reflect the difference between the book and tax basis of the acquired assets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for the earnout liabilities in the Apeiron Acquisition in accordance with ASC450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and will recognize respective liability when the contingency is resolved, and the liability becomes payable. No earnout liability is recognized as of the acquisition date or as of December&#160;31, 2024.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Apeiron Acquisition, we have also invested $4.2&#160;million (including $0.2&#160;million transaction costs) in InvIOs Holding AG (&#8220;InvIOs&#8221;) common shares, a privately held spin-off of Apeiron. This investment was part of an &#8364;8 million (approximately $8.8&#160;million) round with other investors which would help finance the research and development of three innovative early-stage immuno-oncology assets. Apeiron has previously outlicensed these assets to InvIOs and is entitled to future royalties and milestone payments.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the result of this investment, we did not obtain control or significant influence in InvIOs. We determined that common stock of InvIOs did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. When fair value becomes determinable, from observable price changes in orderly transactions, our investment will be marked to fair value.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novan</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 27, 2023, we closed the transaction to acquire certain assets of Novan, Inc. (&#8220;Novan&#8221;) pursuant to the agreement we entered into with Novan on July 17, 2023 for $15 million in cash (which agreement contemplated Novan filing for bankruptcy relief) and provided up to $15 million in debtor-in-possession (&#8220;DIP&#8221;) financing inclusive of a $3 million bridge loan funded on the same day. Novan filed for Chapter 11 reorganization on July 17, 2023. On September 27, 2023, the bankruptcy court approved our $12.2 million bid to purchase from Novan its lead product candidate berdazimer topical gel, 10.3%, all other assets related to the NITRICIL technology platform and the rights to one commercial stage asset. The remaining commercial assets of Novan will be sold to other parties. The approved $12.2 million bid was credited to the $15 million DIP financing, with the balance of $2.8 million and accrued interest repaid to us. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition was accounted for as business combination. We recorded $3.1 million of acquisition-related costs for legal, due diligence and other costs in connection with the acquisition within operating expenses in our consolidated statement of operations for the year ended December 31, 2023. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have finalized purchase accounting for the Novan acquisition. The following table sets forth an allocation of the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets acquired </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for Novan, including restricted cash received</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DIP loan fees and interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,150&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the goodwill is deductible for tax purposes. Acquired intangible assets of $10.7&#160;million related to core technology. The fair value of the core technology was based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the licensing of the related technologies. These projected cash flows were discounted to present value using a discount rate of 29%. The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of 15 years. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquired other liabilities of $13.7&#160;million related to a royalty and milestone payments purchase agreement, entered by Novan in 2019 and assumed as part of the acquisition, which previously provided Novan $25&#160;million of funding used primarily in the clinical development of berdazimer topical gel, 10.3%. Pursuant to the purchase agreement, Novan will pay ongoing quarterly payments, calculated based on an applicable percentage per product of any upfront fees, milestone payments, royalty payments or equivalent payments received by Novan pursuant to any out-license agreement, net of any upfront fees, milestone payments, royalty payments or equivalent payments paid by Novan to third parties pursuant to any agreements under which Novan has in-licensed intellectual property with respect to such products. If Novan decides to commercialize any product on its own following regulatory approval, as opposed to commercializing through an out-license agreement or other third-party arrangement, Novan will be obligated to pay a low single digits royalty on net sales of such products. This contract liability was fair valued based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the related programs mentioned above, by applying a discount rate of 14% (revenue risk-adjusted discount rate).</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 3, 2024, we announced the creation of Pelthos Therapeutics to focus on the commercialization of innovative, safe, and efficacious therapeutic products for patients suffering from conditions with limited treatment options. ZELSUVMI (berdazimer topical gel, 10.3%), its first product, is the FDA-approved prescription medicine for the treatment of the highly transmissible molluscum contagiosum (molluscum) viral skin infection in adults and pediatric patients one year of age and older. ZELSUVMI received a Novel Drug designation from the FDA in January 2024 to treat molluscum viral skin infection. ZELSUVMI was developed using Pelthos' proprietary nitric oxide-based NITRICIL technology platform. The rights to ZELSUVMI and all assets related to the NITRICIL technology platform were acquired from Novan in September 2023 in the Novan acquisition described above.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719806031264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Pelican Business and Investment in Primrose Bio<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Sale of Pelican Business and Investment in Primrose Bio</a></td>
<td class="text">Sale of Pelican Business and Investment in Primrose Bio<div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 18, 2023, we entered into a merger agreement, pursuant to which our subsidiary, Pelican Technology Holdings, Inc. (&#8220;Pelican&#8221;) became a wholly owned subsidiary of Primrose Bio. Primrose Bio is a private company focused on synthetic biology. Pelican has developed technology related to PET (protein expression technology) and PelicCRM197 (vaccine material), and has property and equipment, as well as leased property in San Diego, CA. As part of the transaction, we received 2,146,957 common shares, 4,278,293 preferred shares and 474,746 restricted shares of Primrose Bio. Simultaneous with the merger, we entered into a Purchase and Sale Agreement with Primrose Bio and contributed $15 million in exchange for 50% of potential development milestones and certain commercial milestones from two contracts previously entered into by Primordial Genetics. In addition, starting January 1, 2025, we will receive 25% of sales revenue of PeliCRM197 above $3 million and 35% of all PeliCRM197 licensing revenue in perpetuity.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We retained contractual relationships utilizing the Pelican Expression Technology, including the commercial royalty rights to Jazz&#8217;s Rylaze, Merck&#8217;s Vaxneuvance and V116 vaccines, Alvogen&#8217;s Teriparatide, Serum Institute of India&#8217;s vaccine programs, including Pneumosil and MenFive vaccines, among others.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the sale of Pelican meets the definition of a deconsolidation of a business. Net assets sold together with allocated goodwill and cash consideration paid were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net assets sold</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocated goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash consideration paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">47,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the consideration received includes the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">49,184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill allocated to the selling business based on the relative fair value of the Pelican business and Ligand that was written off was $4.1&#160;million, resulting in a $2.1&#160;million gain on sale of Pelican recorded to income (loss) from operations for the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs of $1.2&#160;million were allocated to the equity method investment and equity securities based on the relative fair value.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, we will receive 25% of sales revenue of PeliCRM197 above $3.0&#160;million and 35% of all PeliCRM197 licensing revenue in perpetuity. The considerations were recognized as contingent consideration under the loss recovery model and they will be measured based on the gain contingency model under ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and thus, will be recognized as the underlying contingencies are resolved.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we will receive 50% of potential development milestones and certain commercial milestones from two contracts previously entered into by Primordial Genetics. The considerations were recognized as derivative assets with a fair value of $3.2&#160;million, at the disposition date, which was included in noncurrent derivative assets in our consolidated balance sheets. They are recognized as derivative assets under ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as they have two underlyings (development and commercial milestones) and (i) the commercial milestones are dependent on the development milestones and (ii) the commercial milestone underlying is not determined to be predominate. The derivative assets are recorded at fair value as of September 18, 2023, and will be marketed to fair value at each reporting period going forward. During the year ended December&#160;31, 2024, an adjustment of $(0.1)&#160;million was recorded to market the derivative assets to fair value and was included in fair value adjustments to partner program derivatives in our consolidated statement of operations. During the year ended December&#160;31, 2023, an adjustment of $0.3&#160;million was recorded to market the derivative assets to fair value and was included in other non-operating (expense) income, net in our consolidated statement of operations. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (8), Fair Value Measurement&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Balance Sheet Account Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Primrose Bio</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. Since the preferred stock and restricted share investment in Primrose Bio has a substantive liquidation preference, it is not substantially similar to the common stock investment and is therefore recorded as an equity security under ASC 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our common stock investment in Primrose Bio under the equity method as we have the ability to exercise significant influence over Primrose Bio's operating and financial results. In applying the equity method, we record the investment at fair value. Our proportionate share of net loss of Primrose Bio is recorded in our consolidated statements of operations. Our equity method investment is reviewed for indicators of impairment at each reporting period and is written down to fair value if there is evidence of a loss in value that is other-than-temporary. In June 2024, Primrose Bio received an equity </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment from an equity firm. In July 2024, Primrose Bio raised additional funds from another equity firm. As a result, we recognized an impairment loss on our equity method investment in the amount of $5.8&#160;million during the year ended December&#160;31, 2024. There was no impairment to our equity method investment during the year ended December&#160;31, 2023. Our share of the net loss of Primrose Bio for the years ended December&#160;31, 2024 and 2023 was $7.0&#160;million and $1.8&#160;million, respectively, which reduced Ligand's equity method investment accordingly. Any income or loss from our equity method investment (including the impairment) is presented in other non-operating (expense) income, net in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the Series A preferred stock and reserve stock investments in Primrose Bio did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investments at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. When fair value becomes determinable, from observable price changes in orderly transactions, our investments will be marked to fair value. Our investments in Series A preferred stock and reserve stock have been reduced by $25.8&#160;million during the year ended December&#160;31, 2024 in connection with the above mentioned equity funding received by Primrose Bio in June and July 2024. There were no no observable price changes or impairment to our investments in Series A preferred stock and reserve stock during the year ended December&#160;31, 2023. Any income or loss from our investments in Series A preferred stock and reserve stock (including the impairment) is presented in other non-operating (expense) income, net in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Former President and Chief Operating Officer Matt Korenberg served as a board member of Primrose Bio beginning in the fourth quarter of 2023. His employment with Ligand concluded in October 2024, after which Lauren Hay, Vice President of Strategic Planning &amp; Investment Analytics, succeeded him as a board member of Primrose Bio. </span></div>Spin-off of OmniAb<div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2022, we entered into the OmniAb Separation and Distribution Agreement to separate our OmniAb Business and the OmniAb Merger Agreement, pursuant to which Merger Sub would merge with and into OmniAb, with OmniAb continuing as the surviving corporation and wholly owned subsidiary of New OmniAb following the effectiveness of such merger, resulting in New OmniAb&#8217;s acquisition of our OmniAb Business, in a Reverse Morris Trust transaction (collectively, the &#8220;OmniAb Transactions&#8221;). </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the final closing date of the OmniAb Transactions on November 1, 2022, the historical financial results of OmniAb have been reflected in our consolidated financial statements as discontinued operations under GAAP for all periods presented through the date of the OmniAb Distribution. Pursuant to the OmniAb Separation and Distribution Agreement, Ligand contributed to OmniAb cash and certain specific assets and liabilities constituting the OmniAb Business. Pursuant to the OmniAb Distribution, Ligand distributed on a pro rata basis to its stockholders as of October 26, 2022 shares of the common stock of OmniAb representing 100% of Ligand&#8217;s interest in OmniAb. Immediately following the OmniAb Distribution, Merger Sub merged with and into OmniAb, with OmniAb continuing as the surviving company in the OmniAb Merger and as a wholly owned subsidiary of New OmniAb. The entire transaction was completed on November 1, 2022, and following the OmniAb Merger, New OmniAb is an independent, publicly traded company whose common stock trades on NASDAQ under the symbol &#8220;OABI.&#8221; After the OmniAb Distribution, we do not beneficially own any shares of common stock in OmniAb and no longer consolidate OmniAb into our financial results for periods ending after November 1, 2022. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued operations</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the OmniAb Merger, the Company determined its OmniAb Business qualified for discontinued operations accounting treatment in accordance with ASC 205-20. We recognized a $1.7 million tax provision adjustment related to deferred taxes during the year ended December 31, 2023 that was attributable to the discontinued operations. The following table summarizes revenue and expenses of the discontinued operations for the year ended December 31, 2022 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,564&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,132)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain from short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,578)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,142)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the significant non-cash items, capital expenditures of the discontinued operations, and financing activities that are included in the consolidated statements of cash flows for the year ended December 31, 2022 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(554)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for acquisition, net of cash acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(960)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719802748432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-off of OmniAb<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Spin-off of OmniAb</a></td>
<td class="text">Sale of Pelican Business and Investment in Primrose Bio<div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 18, 2023, we entered into a merger agreement, pursuant to which our subsidiary, Pelican Technology Holdings, Inc. (&#8220;Pelican&#8221;) became a wholly owned subsidiary of Primrose Bio. Primrose Bio is a private company focused on synthetic biology. Pelican has developed technology related to PET (protein expression technology) and PelicCRM197 (vaccine material), and has property and equipment, as well as leased property in San Diego, CA. As part of the transaction, we received 2,146,957 common shares, 4,278,293 preferred shares and 474,746 restricted shares of Primrose Bio. Simultaneous with the merger, we entered into a Purchase and Sale Agreement with Primrose Bio and contributed $15 million in exchange for 50% of potential development milestones and certain commercial milestones from two contracts previously entered into by Primordial Genetics. In addition, starting January 1, 2025, we will receive 25% of sales revenue of PeliCRM197 above $3 million and 35% of all PeliCRM197 licensing revenue in perpetuity.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We retained contractual relationships utilizing the Pelican Expression Technology, including the commercial royalty rights to Jazz&#8217;s Rylaze, Merck&#8217;s Vaxneuvance and V116 vaccines, Alvogen&#8217;s Teriparatide, Serum Institute of India&#8217;s vaccine programs, including Pneumosil and MenFive vaccines, among others.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the sale of Pelican meets the definition of a deconsolidation of a business. Net assets sold together with allocated goodwill and cash consideration paid were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net assets sold</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocated goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash consideration paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">47,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the consideration received includes the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">49,184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill allocated to the selling business based on the relative fair value of the Pelican business and Ligand that was written off was $4.1&#160;million, resulting in a $2.1&#160;million gain on sale of Pelican recorded to income (loss) from operations for the year ended December 31, 2023.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction costs of $1.2&#160;million were allocated to the equity method investment and equity securities based on the relative fair value.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described above, we will receive 25% of sales revenue of PeliCRM197 above $3.0&#160;million and 35% of all PeliCRM197 licensing revenue in perpetuity. The considerations were recognized as contingent consideration under the loss recovery model and they will be measured based on the gain contingency model under ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and thus, will be recognized as the underlying contingencies are resolved.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we will receive 50% of potential development milestones and certain commercial milestones from two contracts previously entered into by Primordial Genetics. The considerations were recognized as derivative assets with a fair value of $3.2&#160;million, at the disposition date, which was included in noncurrent derivative assets in our consolidated balance sheets. They are recognized as derivative assets under ASC 815, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as they have two underlyings (development and commercial milestones) and (i) the commercial milestones are dependent on the development milestones and (ii) the commercial milestone underlying is not determined to be predominate. The derivative assets are recorded at fair value as of September 18, 2023, and will be marketed to fair value at each reporting period going forward. During the year ended December&#160;31, 2024, an adjustment of $(0.1)&#160;million was recorded to market the derivative assets to fair value and was included in fair value adjustments to partner program derivatives in our consolidated statement of operations. During the year ended December&#160;31, 2023, an adjustment of $0.3&#160;million was recorded to market the derivative assets to fair value and was included in other non-operating (expense) income, net in our consolidated statement of operations. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (8), Fair Value Measurement&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Balance Sheet Account Details</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Primrose Bio</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#8217;s common stock. Since the preferred stock and restricted share investment in Primrose Bio has a substantive liquidation preference, it is not substantially similar to the common stock investment and is therefore recorded as an equity security under ASC 321, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for our common stock investment in Primrose Bio under the equity method as we have the ability to exercise significant influence over Primrose Bio's operating and financial results. In applying the equity method, we record the investment at fair value. Our proportionate share of net loss of Primrose Bio is recorded in our consolidated statements of operations. Our equity method investment is reviewed for indicators of impairment at each reporting period and is written down to fair value if there is evidence of a loss in value that is other-than-temporary. In June 2024, Primrose Bio received an equity </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment from an equity firm. In July 2024, Primrose Bio raised additional funds from another equity firm. As a result, we recognized an impairment loss on our equity method investment in the amount of $5.8&#160;million during the year ended December&#160;31, 2024. There was no impairment to our equity method investment during the year ended December&#160;31, 2023. Our share of the net loss of Primrose Bio for the years ended December&#160;31, 2024 and 2023 was $7.0&#160;million and $1.8&#160;million, respectively, which reduced Ligand's equity method investment accordingly. Any income or loss from our equity method investment (including the impairment) is presented in other non-operating (expense) income, net in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the Series A preferred stock and reserve stock investments in Primrose Bio did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investments at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. When fair value becomes determinable, from observable price changes in orderly transactions, our investments will be marked to fair value. Our investments in Series A preferred stock and reserve stock have been reduced by $25.8&#160;million during the year ended December&#160;31, 2024 in connection with the above mentioned equity funding received by Primrose Bio in June and July 2024. There were no no observable price changes or impairment to our investments in Series A preferred stock and reserve stock during the year ended December&#160;31, 2023. Any income or loss from our investments in Series A preferred stock and reserve stock (including the impairment) is presented in other non-operating (expense) income, net in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Former President and Chief Operating Officer Matt Korenberg served as a board member of Primrose Bio beginning in the fourth quarter of 2023. His employment with Ligand concluded in October 2024, after which Lauren Hay, Vice President of Strategic Planning &amp; Investment Analytics, succeeded him as a board member of Primrose Bio. </span></div>Spin-off of OmniAb<div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 23, 2022, we entered into the OmniAb Separation and Distribution Agreement to separate our OmniAb Business and the OmniAb Merger Agreement, pursuant to which Merger Sub would merge with and into OmniAb, with OmniAb continuing as the surviving corporation and wholly owned subsidiary of New OmniAb following the effectiveness of such merger, resulting in New OmniAb&#8217;s acquisition of our OmniAb Business, in a Reverse Morris Trust transaction (collectively, the &#8220;OmniAb Transactions&#8221;). </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the final closing date of the OmniAb Transactions on November 1, 2022, the historical financial results of OmniAb have been reflected in our consolidated financial statements as discontinued operations under GAAP for all periods presented through the date of the OmniAb Distribution. Pursuant to the OmniAb Separation and Distribution Agreement, Ligand contributed to OmniAb cash and certain specific assets and liabilities constituting the OmniAb Business. Pursuant to the OmniAb Distribution, Ligand distributed on a pro rata basis to its stockholders as of October 26, 2022 shares of the common stock of OmniAb representing 100% of Ligand&#8217;s interest in OmniAb. Immediately following the OmniAb Distribution, Merger Sub merged with and into OmniAb, with OmniAb continuing as the surviving company in the OmniAb Merger and as a wholly owned subsidiary of New OmniAb. The entire transaction was completed on November 1, 2022, and following the OmniAb Merger, New OmniAb is an independent, publicly traded company whose common stock trades on NASDAQ under the symbol &#8220;OABI.&#8221; After the OmniAb Distribution, we do not beneficially own any shares of common stock in OmniAb and no longer consolidate OmniAb into our financial results for periods ending after November 1, 2022. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued operations</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the OmniAb Merger, the Company determined its OmniAb Business qualified for discontinued operations accounting treatment in accordance with ASC 205-20. We recognized a $1.7 million tax provision adjustment related to deferred taxes during the year ended December 31, 2023 that was attributable to the discontinued operations. The following table summarizes revenue and expenses of the discontinued operations for the year ended December 31, 2022 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,564&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,132)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain from short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,578)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,142)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the significant non-cash items, capital expenditures of the discontinued operations, and financing activities that are included in the consolidated statements of cash flows for the year ended December 31, 2022 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(554)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for acquisition, net of cash acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(960)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719806012976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Royalty Assets, net (formerly known as Commercial License Rights)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsTextBlock', window );">Financial Royalty Assets, net (formerly known as Commercial License Rights)</a></td>
<td class="text">Financial Royalty Assets, net (formerly known as Commercial License Rights)<div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, financial royalty assets consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross carrying value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Allowance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross carrying value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Allowance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Qarziba</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(484)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agenus (Bot/Bal)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tolerance Therapeutics (Tzield)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ensifentrine inventors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Elutia (CorMatrix)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">InvIOs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selexis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ovid (Soticlestat)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,538)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195,049&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,073)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) The amounts of allowance include accumulated allowance for changes in expected cash flows and current expected credit losses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(2) The amounts include $10.0 million current portion of financial royalty assets which represents an estimation for current quarter royalty receipts that are collected during the subsequent quarter. This portion is presented in other current assets on our consolidated balance sheet as of December&#160;31, 2024.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial royalty assets represent a portfolio of future milestone and royalty payment rights acquired in the Apeiron Acquisition in July 2024, from Agenus in May 2024, Selexis, S.A. (&#8220;Selexis&#8221;) in April 2013 and May 2015, CorMatrix Cardiovascular, Inc. (&#8220;CorMatrix&#8221;) in May 2016, which was later acquired by Aziyo (Aziyo changed its corporate name to Elutia Inc. (&#8220;Elutia&#8221;) in September 2023) in 2017, Ovid Therapeutics Inc. (&#8220;Ovid&#8221;) in October 2023, Tolerance Therapeutics, Inc. (&#8220;Tolerance Therapeutics&#8221;) in November 2023, and from certain ensifentrine inventors in March and August 2024.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, we recorded a $30.3 million impairment loss for Ovid (Soticlestat) financial royalty asset and a $0.3 million impairment loss for Selexis financial royalty asset. During the year ended December&#160;31, 2023, we recorded a $0.9 million impairment loss for Selexis financial royalty asset as a result of reduced programs.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Apeiron Financial Royalty Assets</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (3), Acquisitions&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we acquired certain financial royalty assets within the Apeiron Acquisition, including Qarziba and certain InvIOs programs, recorded at $104.9 million and $1.3 million, respectively as of Apeiron Acquisition date. As Qarziba is a commercial phase program, we are able to reasonably estimate future cash flows and, as such, we recognized income from Qarziba financial royalty assets starting from the Apeiron Acquisition effective date. We accounted for InvIOs financial royalty assets using the non-accrual method until we are able to reliably estimate future cash flows.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tzield Agreement</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we acquired Tolerance Therapeutics for $20 million in cash. Tolerance Therapeutics is a holding company, owned by the inventors of Tzield (teplizumab), and is owed a royalty of less than 1% on worldwide net sales of Tzield. Tzield is marketed by Sanofi, starting in 2023. For tax purposes this transaction was treated as a stock deal, so there is no step-up in basis and tax attributes. Therefore, during the year ended December&#160;31, 2024, a deferred tax liability (DTL) of $5.5 million was recognized on the book basis and tax basis difference and recorded to the book value of the Tolerance Therapeutics&#8217; financial royalty asset. Due to the early stages of Tzield's commercialization, management has placed the investment on the non-accrual method until we are able to reliably estimate future cash flows.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ensifentrine Inventors Agreements</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and August 2024, we acquired future milestone and royalty rights related to ensifentrine from certain ensifentrine inventors for a total of $3.8 million and $13.6 million, respectively. On June 26, 2024, Verona Pharma plc received FDA approval for ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease (&#8220;COPD&#8221;). During the third quarter of 2024, Verona started commercial sales of ensifentrine (marketed as Ohtuvayre) in the U.S. Due to the early stages of Ohtuvayre's commercialization, management has placed the investment on the non-accrual method until we are able to reliably estimate future cash flows.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Elutia Agreement</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2016, Ligand entered into a purchase agreement to acquire certain financial royalty assets from CorMatrix. In 2017, CorMatrix sold its marketed products to Elutia where Elutia assumed the Ligand royalty obligation. In 2017, we amended the </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">terms of the royalty agreement with Elutia where we received $10 million to buydown the royalty rates on the products CorMatrix sold to Elutia (the &#8220;CorMatrix Asset Sale&#8221;). Per the amended agreement with Elutia, we will receive a 5% royalty, with certain annual minimum payments, on the products Elutia acquired in the CorMatrix Asset Sale and up to $10 million of milestones tied to cumulative net sales of these products. The royalty agreement will terminate on May 31, 2027. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, due to Elutia's nonpayment of the minimum payments under the amended royalty agreement over several quarters, we placed the Elutia asset on the non-accrual method. In January 2024, we executed an amendment to our agreement with Elutia which will allow us to reliably estimate future cash flows. As such, the Elutia asset was switched from the non-accrual method to the effective interest method during the first quarter of 2024. We further considered the current and expected future economic and market conditions, current company performance and recent payments received from Elutia. During the years ended December&#160;31, 2024 and 2023, we recorded a reduction of $5.2 million and an increase of $3.2 million, respectively, to Elutia allowance of expected credit loss. The credit loss adjustments were included in general and administrative expense in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Soticlestat Agreement</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, we made an investment of $30 million to acquire a 13% portion of the royalties and milestones owed to Ovid Therapeutics related to the potential approval and commercialization of soticlestat. </span></div>In June 2024, Takeda announced topline results of the phase 3 clinical trial of soticlestat, narrowly missing its primary endpoint to reduce convulsive seizure frequency compared to placebo in patients with Dravet syndrome, and missing its primary endpoint to reduce major motor drop seizure frequency compared to a placebo in patients with Lennox-Gastaut syndrome. In January 2025, Takeda announced its decision to discontinue its soticlestat program. As a result, in the year ended December&#160;31, 2024, we recognized a full impairment of the soticlestat financial royalty asset.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinancialRoyaltyAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Royalty Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinancialRoyaltyAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719803576736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Account Details</a></td>
<td class="text">Balance Sheet Account Details<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Investments</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2024 and 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">gains</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">losses</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,187&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,626)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,618&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bond fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(537)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,874&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,783)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,170&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain (loss) from short-term investments on our consolidated statements of operations includes both realized and unrealized gain (loss) from our short-term investments in public equity and warrant securities, and realized gain (loss) from available-for-sale debt securities. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,233&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12 months or greater</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of Deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,370&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,790&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,160&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of Deposit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,809&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,949&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,758&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy is capital preservation and we only invested in U.S.-dollar denominated investments. We held a total of 45 securities which were in an unrealized loss position with a total of $0.03 million unrealized losses as of December&#160;31, 2024. We believe that we will collect the principal and interest due on our debt securities that have an amortized cost in excess of fair value. The unrealized losses are largely due to changes in interest rates and not to unfavorable changes in the credit quality associated with these securities that impacted our assessment on collectability of principal and interest. In July 2024, we sold certain securities before the recovery of the amortized cost basis to fund the Apeiron Acquisition. Accordingly, we wrote down the amortized cost of $0.05&#160;million during the second quarter of 2024. We do not intend to sell these securities and it is unlikely that we will be required to sell these securities before the recovery of the amortized cost basis as of December&#160;31, 2024. Accordingly, there was no credit loss recognized for the year ended December&#160;31, 2024. There was no credit losses recognized for the year ended December&#160;31, 2023. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Investments: Investment in Viking</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We held 1.0 million shares of Viking common stock as of December&#160;31, 2024, and we account for it as an investment in available-for-sale equity securities, which is measured at fair value, with changes in fair value recognized in net income. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and December&#160;31, 2023, our investment in Viking was $40.2 million and $32.2 million, respectively, and was included in short-term investments on the consolidated balance sheets. During the year ended December&#160;31, 2024, we sold 0.7 million shares of Viking common stock and recognized a total realized gain of $60.0 million. During the year ended December&#160;31, 2023, we sold 5.0 million shares of Viking common stock and recognized a total realized gain of $44.4 million. There were no sales of Viking common stock during the year ended December 31, 2022. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment, net</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lab and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,655)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which ranges from <span style="-sec-ix-hidden:f-1090">one</span> to nine years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $2.3 million, $2.9 million, and $3.8 million was recognized for the years ended December&#160;31, 2024, 2023, and 2022, respectively, and was included in general and administrative and research and development expenses in our consolidated statements of operations.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and intangible assets, net</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and identifiable intangible assets consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Completed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,710)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,894)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,843)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,710)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contractual relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122,638)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total goodwill and other identifiable intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371,898&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402,976&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in a goodwill carrying value for the year ended December 31, 2024, relates to finalization of Novan Acquisition purchase accounting in the first quarter of 2024. Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of up to 20 years. Amortization expense of $33.0 million, $33.7 million, and $34.2 million were recognized for the years ended December&#160;31, 2024, 2023, and 2022, respectively. Estimated amortization expense for the years ending December&#160;31, 2025 through 2029 is $32.7 million per year. For each of the years ended December&#160;31, 2024, 2023, and 2022, there was no impairment of intangible assets with finite lives.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Assets</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative assets consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Primrose mRNA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agenus Partner Programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agenus Warrant (5 years contractual term)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total noncurrent derivative assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,583&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the fair value of Agenus Partner Programs and Primrose mRNA derivative that amounted to $(15.0) million and $(0.1) million, respectively, for the year ended December&#160;31, 2024, was included in fair value adjustments to partner program derivatives in the consolidated statement of operations. A net increase in fair value of Viking Share Collar and Viking Share Put that amounted to $7.1 million for the year ended December 31, 2024, was recognized in gain from short-term investments in the consolidated statements of operations. A change in the fair value of other derivatives that amounted to $(12.1) million for the year ended December&#160;31, 2024, was recognized in other non-operating (expense) income, net in the consolidated statements of operations. We acquired the Primrose mRNA derivative on September 18, 2023 with the sale of Pelican business and investment in Primrose Bio transaction. A change in the fair value of the Primrose mRNA derivative that amounted to $0.3 million during the year ended December&#160;31, 2023 was included in the consolidated statements of operations. We did not have any other derivative instruments during the years ended December&#160;31, 2023 and 2022.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Investments</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other investments consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities in Primrose Bio</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">InvIOs investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuritek warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palvella Series C preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total other investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,908&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,726&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2024, we recognized a full impairment for our investment in Neuritek warrants. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 13, 2024, Palvella Therapeutics, Inc. (&#8220;Palvella&#8221;) announced the completion of its previously announced merger with Pieris Pharmaceuticals, Inc. (&#8220;Pieris&#8221;). The combined company will operate under the name Palvella Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market on December 16, 2024, under the ticker symbol &#8220;PVLA&#8221;. In conjunction with the transaction, the Series C Preferred Shares we held were converted to common shares using an exchange ratio of approximately 0.3095, converting the 189,112 Series C preferred shares into 58,524 common shares. We account for the Palvella common shares as a short-term investment included in our consolidated balance sheet. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Assets and Other Current Assets</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets include economic rights related to the 2023 expansion of our strategic partnership with Palvella to accelerate Phase 3 development of Qtorin rapamycin for the treatment of Microcystic Lymphatic Malformations (&#8220;Microcystic LM&#8221;). According to the terms of the second amendment to our development funding and royalties agreement with Palvella (the &#8220;Palvella Second Amendment&#8221;), Palvella received an upfront payment of $5 million from Ligand. In return for the upfront payment, among other contractual changes, the tiered royalty payable by Palvella to Ligand was increased to between 8.0% and 9.8% based on annual aggregate worldwide net sales of Qtorin rapamycin. We are not obligated to provide additional funding to Palvella for development or commercialization of Qtorin.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined the economic rights related to Palvella should be characterized as a funded research and development arrangement, because the contract designated the funds usage for research and development activities, and thus we account for them in accordance with ASC 730-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We reduce our asset as the funds are expended by Palvella. As of December&#160;31, 2024, of the $5 million upfront funding related to the Palvella Second Amendment, $1.2 million of the funding to Palvella was expended. Our CEO and director, Todd Davis, is a director of Palvella. Mr. Davis recused himself from both board's consideration of the agreement between us and Palvella, including any financial analysis, the terms of the Palvella Second Amendment and the vote to approve the Palvella Second Amendment and the related transactions.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, we funded Palvella $2.5 million in exchange for a convertible note with a maturity of three years, which is included in other assets in the consolidated balance sheets. In conjunction with Pavella's merger with Pieris as discussed above, the convertible note automatically converted into Pavella common shares. The $2.6 million principal and interest converted into 184,595 shares, using a conversion price of $13.9965 per share. We account for the Palvella common shares as a short-term investment in our consolidated balance sheet. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets primarily include $10.0 million current portion of financial royalty assets (disclosed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (6), Financial Royalty Assets, net (formerly known as Commercial License Rights)&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), and $4.5 million inventory (raw materials and work in process related to the manufacturing of finished goods) for the preparation of commercial supplies of ZELSUVMI by Pelthos Therapeutics, a wholly owned subsidiary of Ligand. For additional information on ZELSUVMI, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (3), Acquisitions&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Below is a summary of the ZELSUVMI related inventory included in other current assets (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Pelthos inventory in other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,526&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued liabilities</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalties owed to third parties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UK value-added tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subcontractor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer deposit </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplier</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts owed to former licensees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,906&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,467&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent liabilities</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes roll-forward of contingent liabilities as of December&#160;31, 2024 and 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:20.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cydex</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metabasis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,513</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(50)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(265)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(200)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">683</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,681</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other long-term liabilities</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novan (Pelthos) contract liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,163&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,758&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Balance Sheet Details [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719804104112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">Fair Value Measurement<div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We measure certain financial assets and liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described in the below with level 1 having the highest priority and level 3 having the lowest:</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - Observable inputs such as quoted prices in active markets </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments, excluding Viking</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194,441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,811&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent liabilities - CyDex</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,681&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,298&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments, excluding Viking</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent liabilities - CyDex</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,198&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) Excluding our investment in Viking, corporate equity securities, and US government securities, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in bond funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we had investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and were at level 3 of the fair value hierarchy, based on Black-Scholes value estimated by management on the last day of the period. This investment in warrants expired in January 2024.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(2) Derivative assets include instruments used for risk-management purposes, and other instruments. Derivative assets which are not used for risk management purposes include: (a) acquired rights in future milestone and royalty payments from Agenus Partnered Programs, (b) Agenus Warrant, (c) Upsize Option, (d) Viking Share Collar (e) and rights to receive from Primrose Bio 50% of milestones on two contracts previously entered into by Primordial Genetics. The considerations were recognized as derivative assets included under current derivative assets and noncurrent derivative assets in our consolidated balance sheet. They are recognized as derivative assets under ASC 815, Derivatives and Hedging. The fair value of the Agenus Partnered Programs and the Primrose Bio derivative assets was determined using a discounted cash flow approach, utilizing the mostly-likely cash flows which considered the probability of success for the underlying clinical programs. The discount rate used contemplates the underlying credit and business risk of the partnered programs. At December&#160;31, 2024, the discount rates used range between 15% and 28%. At December&#160;31, 2023, the discount rate used was 25%. The fair value of the Agenus Warrant was determined using a Black-Scholes-Merton model. The fair value of the Upsize Option was determined using a binomial option pricing model.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(3) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">significantly based upon quoted market prices and actual amounts paid under the agreements may be materially different than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#946; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10 million payment upon initiation of a Phase 3 clinical trial. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2024 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions to derivative assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,888&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1303">Fair value adjustments to derivative assets</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,010)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of derivative assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,826)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2024</span></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,583&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments to CVR holders and other contingent payments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1309">Fair value adjustments to contingent liabilities</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2024</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2023 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1313">Fair value adjustments to equity security warrants</span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(135)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions to derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value adjustments to derivative assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments to CVR holders and other contingency payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1320">Fair value adjustments to contingent liabilities</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets Measured on a Non-Recurring Basis</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to our goodwill, intangible assets with estimated useful lives and long-lived assets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate goodwill annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate intangible assets with estimated useful lives whenever circumstances occur indicating that intangible assets may not be recoverable. An impairment evaluation is based on an undiscounted cash flow analysis at the lowest level at which cash flows of the long-lived assets are largely independent of other groups of assets and liabilities.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no impairment of our goodwill, intangible assets, or long-lived assets recorded during the years ended December&#160;31, 2024 and 2023. Other than the finance lease equipment discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (9), Leases&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there was no impairment of our goodwill, intangible assets, or long-lived assets recorded during the year ended and December&#160;31, 2022. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and cash equivalents, accounts receivable, other current assets, financial royalty assets, accounts payable, accrued liabilities, deferred revenue, current operating lease liabilities, current finance lease liabilities and Novan (Pelthos) other long-term liabilities are financial instruments and are recorded at cost in the consolidated balance sheets. The estimated </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair value of the Novan (Pelthos) other long-term liabilities is $19.1&#160;million compared to a carrying value of $15.9&#160;million. The estimated fair value of the remaining financial instruments approximates their carrying value.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Assets Not Measured at Fair Value</span></div>Financial royalty assets are measured and carried on the balance sheet at amortized cost using the effective interest method or on a non-accrual basis. Management calculates the fair value of financial royalty assets using a forecasted royalty receipts. The projected future cash flows derive from royalty payments and milestones, then discounted using appropriate individual discount rates. The fair value of financial royalty assets and other economic rights assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. The estimated fair value and related carrying values of financial royalty assets as of December&#160;31, 2024 were $196.6&#160;million and $195.0&#160;million, respectively. The estimated fair value and related carrying value of the financial royalty assets as of December&#160;31, 2023 were $75.9&#160;million and $62.3&#160;million, respectively. To determine the fair value of long-term financial royalty assets, we estimated future underlying product sales, applied a probability of technical and regulatory success for development stage programs, estimated a timeline for any development and regulatory milestones, and applied a discount rate based on the level of partner execution and commercialization risk, in the range of 15-30% and 10-45% as of December 31, 2024, and 2023, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719802469936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance lease</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020 and January 2021, we entered into an agreement and the first amendment with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol, respectively. The agreements are considered to include an embedded finance lease under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as it provides the Company the right to use the underlying equipment to exclusively manufacture Captisol. As of December 31, 2021, we had fully paid consideration of $69.1 million for prepaid inventory and capacity ramp-up fee. We allocated consideration in the agreements between lease and non-lease components using relative standalone prices. Since the inception of the agreements, we have allocated $50.2 million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and being amortized to cost of Captisol based on the usage. The remaining balance of $18.9 million was recognized as a right of use asset. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, given the COVID status, our forecast for COVID-related Captisol had been significantly reduced, which triggered an indicator of impairment of the right of use asset. We performed a recoverability test at the asset group level by comparing the sum of the estimated undiscounted future cash flows attributable to the asset group to its carrying value and identified the asset was impaired. We recorded a $9.8&#160;million of impairment charge based on the fair value of the right of use asset which has been recognized in cost of Captisol in our consolidated statement of operations for the year ended December 31, 2022. As of December 31, 2022, the remaining right of use asset balance was $4.0&#160;million which will be amortized straight-line over the remaining 6 years lease term. During the years ended December&#160;31, 2024 and 2023, no impairment to this asset group was recorded as there were no indicators of impairment. As of December&#160;31, 2024 and 2023, the remaining right of use asset balance is $2.7&#160;million and $3.4&#160;million, respectively.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating lease </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease certain office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to eight years, some of which include options to extend the leases for up to five years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, we entered into lease agreements for our offices located in Boston, Massachusetts, and Jupiter, Florida, which resulted in a $1.6&#160;million and $0.1&#160;million, respectively, increase in both operating lease assets and operating lease liabilities at lease commencement. During the year ended December 31, 2023, we entered into an amendment to the lease agreement for our office located in San Diego, California, which resulted in a $1.1&#160;million increase in both operating lease assets and operating lease liabilities at lease commencement.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease assets and liabilities (in thousands) are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,673&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,455&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1373"><span style="-sec-ix-hidden:f-1374">Long-term finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities   </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,154&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,184&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of operating and finance lease liabilities as of December&#160;31, 2024 are as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,983)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,081&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, our operating leases had a weighted-average remaining lease term of 5.8 years and a weighted-average discount rate of 7.5%. As of December&#160;31, 2023, our operating leases had a weighted-average remaining lease term of 7.4 years and a weighted-average discount rate of 7.7%. Cash paid for amounts included in the measurement of operating lease liabilities was $1.3 million and $1.4 million, respectively, for the years ended December&#160;31, 2024 and 2023. Operating lease expense was $1.3 million (net of sublease income of $0.1 million) and $1.4 million (net of sublease income of $0.3 million) for the years ended December&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, our finance leases had a weighted-average remaining lease term of 3.3 years and a weighted-average discount rate of 6.6%. As of December&#160;31, 2023, our finance leases had a weighted-average remaining lease term of 3.4 years and a weighted-average discount rate of 6.8%. We excluded the Hovione equipment lease in the calculation of weighted average remaining lease term and weighted average discount rate because the Hovione lease was fully paid off as of December 31, 2021. Cash paid for amounts included in the measurement of these finance lease liabilities was $0.02&#160;million and $0.05&#160;million, respectively, for the years ended December&#160;31, 2024 and 2023. Finance lease expense was $0.5 million and $0.7 million, respectively, for the years ended December&#160;31, 2024 and 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Finance lease</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020 and January 2021, we entered into an agreement and the first amendment with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol, respectively. The agreements are considered to include an embedded finance lease under ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as it provides the Company the right to use the underlying equipment to exclusively manufacture Captisol. As of December 31, 2021, we had fully paid consideration of $69.1 million for prepaid inventory and capacity ramp-up fee. We allocated consideration in the agreements between lease and non-lease components using relative standalone prices. Since the inception of the agreements, we have allocated $50.2 million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and being amortized to cost of Captisol based on the usage. The remaining balance of $18.9 million was recognized as a right of use asset. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, given the COVID status, our forecast for COVID-related Captisol had been significantly reduced, which triggered an indicator of impairment of the right of use asset. We performed a recoverability test at the asset group level by comparing the sum of the estimated undiscounted future cash flows attributable to the asset group to its carrying value and identified the asset was impaired. We recorded a $9.8&#160;million of impairment charge based on the fair value of the right of use asset which has been recognized in cost of Captisol in our consolidated statement of operations for the year ended December 31, 2022. As of December 31, 2022, the remaining right of use asset balance was $4.0&#160;million which will be amortized straight-line over the remaining 6 years lease term. During the years ended December&#160;31, 2024 and 2023, no impairment to this asset group was recorded as there were no indicators of impairment. As of December&#160;31, 2024 and 2023, the remaining right of use asset balance is $2.7&#160;million and $3.4&#160;million, respectively.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating lease </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease certain office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to eight years, some of which include options to extend the leases for up to five years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, we entered into lease agreements for our offices located in Boston, Massachusetts, and Jupiter, Florida, which resulted in a $1.6&#160;million and $0.1&#160;million, respectively, increase in both operating lease assets and operating lease liabilities at lease commencement. During the year ended December 31, 2023, we entered into an amendment to the lease agreement for our office located in San Diego, California, which resulted in a $1.1&#160;million increase in both operating lease assets and operating lease liabilities at lease commencement.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease assets and liabilities (in thousands) are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,673&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,455&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1373"><span style="-sec-ix-hidden:f-1374">Long-term finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities   </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,154&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,184&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of operating and finance lease liabilities as of December&#160;31, 2024 are as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,983)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,081&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, our operating leases had a weighted-average remaining lease term of 5.8 years and a weighted-average discount rate of 7.5%. As of December&#160;31, 2023, our operating leases had a weighted-average remaining lease term of 7.4 years and a weighted-average discount rate of 7.7%. Cash paid for amounts included in the measurement of operating lease liabilities was $1.3 million and $1.4 million, respectively, for the years ended December&#160;31, 2024 and 2023. Operating lease expense was $1.3 million (net of sublease income of $0.1 million) and $1.4 million (net of sublease income of $0.3 million) for the years ended December&#160;31, 2024 and 2023, respectively.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, our finance leases had a weighted-average remaining lease term of 3.3 years and a weighted-average discount rate of 6.6%. As of December&#160;31, 2023, our finance leases had a weighted-average remaining lease term of 3.4 years and a weighted-average discount rate of 6.8%. We excluded the Hovione equipment lease in the calculation of weighted average remaining lease term and weighted average discount rate because the Hovione lease was fully paid off as of December 31, 2021. Cash paid for amounts included in the measurement of these finance lease liabilities was $0.02&#160;million and $0.05&#160;million, respectively, for the years ended December&#160;31, 2024 and 2023. Finance lease expense was $0.5 million and $0.7 million, respectively, for the years ended December&#160;31, 2024 and 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719801240768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">0.75% Convertible Senior Notes due 2023</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we issued $750 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually. The net proceeds from the offering, after deducting the initial purchasers' discount and offering expenses, were approximately $733.1 million. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the issuance of the 2023 Notes, we incurred $16.9 million of issuance costs, which primarily consisted of underwriting, legal and other professional fees and was being amortized to interest expense using the effective interest method over the five years expected life of the 2023 Notes. On May 15, 2023, the 2023 Notes maturity date, we paid the remaining $76.9 million principal amount and $0.3 million accrued interest in cash. The effective interest rate for the year ended December 31, 2023 was 0.5%. During the year ended December 31, 2023, we recognized a total of $0.6 million in interest expense, including $0.4 million in contractual interest expense and $0.2 million in amortized issuance costs. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, we repurchased $266.4 million in principal amount of the 2023 Notes for $261.4 million in cash, including accrued interest of $0.5 million We accounted for the repurchase as a debt extinguishment, which resulted in a gain of $4.2 million reflected in other non-operating (expense) income, net, in our consolidated statement of operations for the year ended December 31, 2022, and a $1.3 million reduction in debt discount. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Convertible Bond Hedge and Warrant Transactions</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the 2023 Notes, in May 2018, we entered into convertible bond hedges and sold warrants covering 3,018,327 shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the 2023 Notes. The convertible bond hedges have an exercise price of $206.65 per share and are exercisable when and if the 2023 Notes are converted. We paid $140.3 million for these convertible bond hedges. If upon conversion of the 2023 Notes, the price of our common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below are separate transactions entered into by us and are not part of the terms of the 2023 Notes. Holders of the 2023 Notes and warrants did not have any rights with respect to the convertible bond hedges.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants covering 3,018,327 shares of common stock with an exercise price of $315.38 per share, subject to certain adjustments. We received $90.0 million for these warrants. The warrants have various expiration dates ranging from August 15, 2023 to February 6, 2024. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. The common stock issuable upon exercise of the warrants will be in unregistered shares, and we do not have the obligation and do not intend to file any registration statement with the SEC registering the issuance of the shares under the warrants.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, in connection with the repurchases of $227.8&#160;million in principal of the 2023 Notes for $223.7&#160;million in cash, including accrued interest of $0.4&#160;million made during the six months ended June 30, 2022, we entered into Bond Hedge Unwind Agreements with Barclays Bank PLC, Deutsche Bank AG, and Goldman Sachs &amp; Co. LLC to unwind a portion of the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, there are no warrants that remain outstanding. The warrants expired on February 6, 2024.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Facility</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 12, 2023, we entered into a $75 million revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) with Citibank, N.A. as the Administrative Agent (as defined in the Credit Agreement). We, our material domestic subsidiaries, as Guarantors (as defined in the Credit Agreement), and the Lenders (as defined in the Credit Agreement) entered into a credit agreement (the &#8220;Credit Agreement&#8221;) with the Administrative Agent, under which the Lenders, the Swingline Lender and the L/C Issuer (each as defined in the Credit Agreement) agreed to make revolving loans, swingline loans and other financial accommodations to us (including the issuance of letters of credit) in an aggregate amount of up to $75 million. Borrowings under the Revolving Credit Facility accrue interest at a rate equal to either Term Secured Overnight Financing Rate (&#8220;Term SOFR&#8221;) or a specified base rate plus an applicable margin linked to our leverage ratio, ranging from 1.75% to 2.50% per annum for Term SOFR loans and 0.75% to 1.50% per annum for base rate loans. The Revolving Credit Facility is subject to a commitment fee payable on the unused Revolving Credit Facility commitments ranging from 0.30% to 0.45%, depending on our leverage ratio. During the term of the Revolving Credit Facility, we may borrow, repay and re-borrow amounts available under the Revolving Credit Facility, subject to voluntary reductions of the swing line, letter of credit and revolving credit commitments.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Revolving Credit Facility are secured by certain of our collateral and that of the Guarantors. In specified circumstances, additional guarantors are required to be added to the Credit Agreement. The Credit Agreement contains customary affirmative and negative covenants, including certain financial maintenance covenants, and events of default applicable to us. In the event of violation of the representations, warranties and covenants made in the Credit Agreement, we may not be able to utilize the Revolving Credit Facility or repayment of amounts owed thereunder could be accelerated. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amendment to Revolving Credit Facility</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 8, 2024, we entered into the first amendment (the &#8220;Amendment&#8221;) to the Credit Agreement, which amends the Credit Agreement to, among other things, increase the aggregate revolving credit facility amount from $75 million to $125 million.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had $124.4&#160;million in available borrowing under the Revolving Credit Facility, after utilizing $0.6&#160;million for letter of credit. As of December&#160;31, 2023, we had $74.5&#160;million in available borrowing under the Revolving Credit Facility, after utilizing $0.5&#160;million for letter of credit. The maturity date of the Revolving Credit Facility, as amended, is October 12, 2026. As of December&#160;31, 2024 and 2023, there were no events of default or violation of any covenants under our financing obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719806012976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense from continuing operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense as a component of:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,089&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,881&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion and Modification of Equity Awards Outstanding at Separation Date</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the OmniAb Separation on November 1, 2022, under the provisions of the existing plans, we adjusted our outstanding equity awards in accordance with the OmniAb Merger Agreement to preserve the intrinsic value of the awards immediately before and after the OmniAb Distribution. Upon the OmniAb Distribution, employees holding stock options, restricted stock units and performance restricted stock units denominated in pre-OmniAb Distribution Ligand stock received a number of otherwise-similar awards either in post-OmniAb Distribution Ligand stock or in a combination of post-OmniAb Distribution Ligand stock and OmniAb stock based on conversion ratios outlined for each group of employees in the OmniAb Merger Agreement. The equity awards that were granted prior to March 2, 2022 were converted under the shareholder method, wherein employees holding outstanding equity awards received equity awards in both Ligand and OmniAb. For equity awards granted after March 2, 2022, for Ligand employees, the number of awards that were outstanding at the OmniAb Separation were proportionately adjusted into post-OmniAb Distribution Ligand stock to maintain the aggregate intrinsic value of the awards at the date of the OmniAb Separation; for OmniAb employees, the number of awards that were outstanding at the OmniAb Separation were proportionately adjusted into post-OmniAb Distribution OmniAb stock to maintain the aggregate intrinsic value of the awards at the date of the OmniAb Separation. The conversion ratio was determined based on the relative values of Ligand common stock in the &#8220;regular way&#8221; and &#8220;ex-distribution&#8221; markets during the five-trading day period prior to the closing of the business combination.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These modified awards otherwise retained substantially the same terms and conditions, including term and vesting provisions. Additionally, we will not incur any future compensation cost related to equity awards held by OmniAb employees and directors. We will incur future compensation cost related to OmniAb equity awards held by our employees.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Plans</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, our stockholders approved the amendment and restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan (the &#8220;2002 Plan&#8221;). The amended and restated 2002 Plan, which is referred to herein as the &#8220;Restated Plan&#8221; was amended to increase the shares available for issuance by 1.0 million. In June 2024, our stockholders approved the amendment and restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan, which increased the shares available for issuance by 1.3 million.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, our board of directors (the &#8220;Board&#8221;) approved the Ligand Pharmaceuticals Incorporated 2022 Employment Inducement Plan (the &#8220;2022 Inducement Plan&#8221;). The terms of the 2022 Inducement Plan are substantially similar </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to the terms of the Restated Plan with the exception that incentive stock options may not be issued under the 2022 Inducement Plan and awards under the 2022 Inducement Plan may only be issued to eligible recipients under the applicable Nasdaq Listing Rules. The 2022 Inducement Plan was adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Board has initially reserved 300,000 shares of the Company&#8217;s common stock for issuance pursuant to awards granted under the 2022 Inducement Plan. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, there were 1.6 million shares available for future option grants or direct issuance under the Restated Plan and the 2022 Inducement Plan.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of our stock option plan activity and related information:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,199,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">863,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,069)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at October 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,987,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at October 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,769,629&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options vested and expected to vest as of October 31, 2022, before the OmniAb Separation and Regrant</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,987,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancellation due to OmniAb Separation, Before Regrant</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,987,833)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at November 1, 2022, Before Regrant</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,584,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50,449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(542,838)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,991,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,559,662&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.51</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,991,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">537,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(489,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(399,371)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,784,209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">783,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,080,135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,226,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,229,294&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.02</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,226,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) Options granted primarily relate to the modifications in connection with the OmniAb Separation which resulted in new stock option grants at the modification date fair value. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant-date fair value of all stock options granted during 2024, 2023 and 2022 was $37.81, $36.65, and $28.90 per share, respectively. The total intrinsic value of all options exercised during 2024, 2023 and 2022 was approximately $38.6 million, $12.0 million, and $4.6 million, respectively. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash received from options exercised, net of fees paid, in 2024, 2023 and 2022 was $65.2 million, $22.2 million and $2.6 million, respectively. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a further breakdown of the options outstanding as of December&#160;31, 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of exercise prices</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">remaining life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">in&#160;years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">exercise price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">exercisable</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">exercise&#160;price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$32.78-$52.84</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281,644&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.78</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.02&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$54.81-$63.62</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$64.65-$68.74</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$69.39-$73.76</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.66</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$73.92-$75.09</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$78.56-$88.27</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.57</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$89.20-$89.20</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$89.86-$103.42</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.64</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$104.30-$114.15</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$122.70-$122.70</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.92</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,226,273&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,229,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5%-4.5%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7%-4.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4%-4.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44%-46%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45%-54%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49%-55%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1 to 4.8 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7 to 5.3 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0 to 6.5 years</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:27pt"><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, there was $34.0 million of total unrecognized compensation cost related to non-vested stock options under the 2002 Plan. That cost is expected to be recognized over a weighted average period of 2.5 years.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, there was $0.1 million of total unrecognized compensation cost related to non-vested OmniAb stock options received in connection with the OmniAb Transactions described above. That cost is expected to be recognized over a weighted average period of 0.5 years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Activity</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our restricted stock activity and related information:&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:69.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">348,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.60&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(181,246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,054)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350,905&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(167,308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64,313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437,872&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, unrecognized compensation cost related to non-vested stock awards under the 2002 Plan amounted to $19.6 million. That cost is expected to be recognized over a weighted average period of 1.4 years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, 24,493 shares of our common stock are available for future issuance under the Amended Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase up to 1,250 shares of Ligand common stock per calendar year at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first of a <span style="-sec-ix-hidden:f-1686">six</span> month offering period or purchase date, whichever is lower. There were 6,308, 5,080 and 8,479 shares issued under the ESPP in 2024, 2023 and 2022, respectively. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, our Board of Directors has approved a stock repurchase program authorizing, but not requiring, the repurchase of up to $50 million of our common stock from time to time through April 2026. We expect to acquire shares, if at all, primarily through open-market transactions in accordance with all applicable requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. During the years ended December&#160;31, 2024, 2023 and 2022, we did not repurchase any common stock, respectively. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the Market Equity Offering Program</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, we filed a registration statement on Form S-3 (the &#8220;Shelf Registration Statement&#8221;), which became automatically effective upon filing, covering the offering of common stock, preferred stock, debt securities, warrants and units. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2022, we also entered into an At-The-Market Equity Offering Sales Agreement (the &#8220;Sales Agreement&#8221;) with Stifel, Nicolaus &amp; Company, Incorporated (the &#8220;Agent&#8221;), under which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $100&#160;million in &#8220;at the market&#8221; offerings through the Agent (the &#8220;ATM Offering&#8221;). The Shelf Registration Statement included a prospectus covering the offering, issuance and sale of up to $100&#160;million of our common stock from time to time through the ATM Offering. The shares to be sold under the Sales Agreement may be issued and sold pursuant to the Shelf Registration Statement. During the year ended December&#160;31, 2024, we issued 360,325 shares of common stock in the ATM Offering, generating proceeds of $37.4&#160;million, net of commissions and other transaction costs. During the year ended December&#160;31, 2023 and 2022, we did not issue any shares of common stock in the ATM Offering.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719806011952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies: Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitment and Contingencies: Legal Proceedings</a></td>
<td class="text">Commitment and Contingencies: Legal Proceedings<div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record an estimate of a loss when the loss is considered probable and estimable. Where a liability is probable and there is a range of estimated loss and no amount in the range is more likely than any other number in the range, we record the minimum estimated liability related to the claim in accordance with ASC 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As additional information becomes available, we assess the potential liability related to our pending litigation and revises our estimates. Revisions in our estimates of potential liability could materially impact our results of operations. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2019, we received three civil complaints filed in the U.S. District Court for the Northern District of Ohio on behalf of several Indian tribes. The Northern District of Ohio is the Court that the Judicial Panel on Multi-District Litigation (&#8220;JPML&#8221;) has assigned more than one thousand civil cases which have been designated as a Multi-District Litigation (&#8220;MDL&#8221;) and captioned In Re: National Prescription Opiate Litigation. The allegations in these complaints focus on the activities of defendants other than the Company and no individualized factual allegations have been advanced against us in any of the three complaints. We reject all claims raised in the complaints and intend to vigorously defend these matters. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 22, 2024, CyDex Pharmaceuticals, Inc. filed a Verified Complaint in the Delaware Court of Chancery against Bexson Biomedical, Inc. (&#8220;Bexson&#8221;), asserting claims for declaratory relief and breach of contract arising out of a Captisol In Vivo Agreement (the &#8220;In Vivo Agreement&#8221;) between the parties, pursuant to which CyDex provided Bexson with research-grade Captisol and related confidential and proprietary information for a potential new formulation of ketamine being developed by Bexson. CyDex alleges that Bexson breached its obligations under the In Vivo Agreement, including by misusing confidential information and materials provided by CyDex and by using CyDex&#8217;s confidential information and materials to file patent applications that purport to cover formulations that are &#8220;not ketamine.&#8221; CyDex also asserts that Bexson failed to return and destroy Cydex&#8217;s confidential information and materials as required by the Agreement. CyDex seeks relief including specific performance of certain co-ownership provisions of the Agreement and disgorgement from Bexson for any benefits obtained in violation of the In Vivo Agreement. On September 27, 2024, Bexson filed a Motion to Dismiss the Verified Complaint. A Verified Amended Complaint was filed by CyDex on November 6, 2024, and a Motion to Dismiss the Verified Amended Complaint was filed by Bexson on January 17, 2025. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719800290256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2024, 2023, and 2022, the Company has the following income before income tax from continuing operations (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,855)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,518&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,660&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,011&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:66.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred expense (benefit):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,767)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,800)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,029&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,488&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total income tax expense (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,841&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,230&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:66.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax at federal statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subpart F income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Officer compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign tax differential on income/loss of foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision to return adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate change for changes in federal, foreign or state law</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(535)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt repurchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(405)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FDII</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,638)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,841&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,230&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of our deferred tax assets and liabilities as of December&#160;31, 2024 and 2023 are shown below. We assess the positive and negative evidence to determine if sufficient future taxable income will be generated to realize the existing deferred tax assets. Our evaluation of evidence resulted in management concluding that the majority of our deferred tax assets will be realized. However, we maintain a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of December&#160;31, 2024, 2023 and 2022. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a non-current deferred income tax asset or liability (as applicable). Deferred tax assets (liabilities) are comprised of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,649)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57,699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identified intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69,150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66,966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,991)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,504)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,141)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77,470)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,452)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,408)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had federal net operating loss carryforwards set to expire through 2037 of $21.4 million and $162.8 million of state net operating loss carryforwards that begin to expire in 2028. We also have $6.2 million of federal research and development credit carryforwards, which expire through 2040. We have $29.5 million of California research and development credit carryforwards that have no expiration date. In addition, we have approximately $98.4 million of non-U.S. net operating loss carryovers and approximately $14.4 million of non-U.S. capital loss carryovers that have no expiration date.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we had federal net operating loss carryforwards set to expire through 2037 of $48.0 million and $165.1 million of state net operating loss carryforwards that begin to expire in 2028. We also had $8.5 million of federal research and development credit carryforwards, which expire through 2040. We had $29.4 million of California research and development credit carryforwards that have no expiration date. In addition, we had approximately $95.5 million of non-U.S. net operating loss carryovers and approximately $16.5 million of non-U.S. capital loss carryovers that have no expiration date. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, utilization of our net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December&#160;31, 2024 are net of any previous limitations due to Section 382 and 383.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Our remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying consolidated balance sheet.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2024, 2023 and 2022 is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:66.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,783)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(512)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,363&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,096&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the balance of unrecognized tax benefits at December&#160;31, 2024 is $20.7 million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2024 and December&#160;31, 2023, we recognized an immaterial amount of interest and penalties. We file income tax returns in the United States, various state jurisdictions, Austria, and United Kingdom with varying statutes of limitations. The federal statute of limitation remains open for the 2021 tax year to the present.&#160;he United Kingdom statute of limitation remains open for the 2020 tax year to the present. The Austrian statute of limitation remains open for the 2020 tax year to the present.&#160;Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized. The Company's 2019 and 2020 California tax returns are under examination by the California Franchise Tax Board. The Company does not anticipate that the examination will result in a material adjustment to its financial statements. No other income tax returns are currently under examination. We believe our reserve for unrecognized tax benefits and contingent tax issues is adequate with respect to all open years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719805970976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">Subsequent Event<div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 24, 2025, we entered into a Purchase and Sale Agreement (the &#8220;Agreement&#8221;) with Castle Creek Biosciences, Inc., Castle Creek Biosciences, LLC (collectively, &#8220;Castle Creek&#8221;) and a syndicate of co-investors for which Ligand acted as representative (collectively, including Ligand, the &#8220;Purchasers&#8221;), to support Castle Creek&#8217;s autologous human fibroblast cell-based gene therapy genetically modified to express COL7, also known as FCX-007 (dabocemagene autoficel) (&#8220;D-Fi&#8221;) Phase 3 clinical study, its lead candidate for patients with dystrophic epidermolysis bullosa (&#8220;DEB&#8221;). </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Agreement, we and the other Purchasers obtained, for an aggregate purchase price of $75&#160;million, $50 million of which was paid by Ligand and $25&#160;million of which was paid by the other Purchasers collectively, (i) a high single digit royalty on worldwide sales of D-Fi and (ii) warrants to purchase shares of Castle Creek Biosciences, Inc. Series D-1 Preferred Stock. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the transaction we also acquired an unsecured subordinated promissory note issued by Castle Creek Biosciences, LLC with an aggregate principal amount of $8.3&#160;million, which is due and payable upon Castle Creek&#8217;s receipt of U.S. Food and Drug Administration approval of D-Fi for treatment of DEB and certain other conditions to payment. We paid $1.8&#160;million for the unsecured subordinated promissory note.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719798188336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (4,032)<span></span>
</td>
<td class="nump">$ 52,154<span></span>
</td>
<td class="num">$ (33,361)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719801655840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719801251584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719802627120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. Our cybersecurity risk management program includes a cybersecurity incident response plan. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We design and assess our program based on the National Institute of Standards and Technology (&#8220;NIST&#8221;), the International Organization for Standardization (&#8220;ISO&#8221;) and other applicable industry standards. This does not imply that we </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">meet any particular technical standards, specifications, or requirements, only that we use the NIST, ISO and other standards as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk management program is integrated into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk management program includes:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise information technology environment;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a security team principally responsible for managing (i) our cybersecurity risk assessment processes, (ii) our security controls, and (iii) our response to cybersecurity incidents;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cybersecurity awareness training of our employees, incident response personnel, and senior management; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a third-party risk management process for service providers, suppliers, and vendors.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity risk management program is integrated into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#8220;Committee&#8221;) oversight of cybersecurity and other information technology risks. The Committee oversees management&#8217;s implementation of our cybersecurity risk management program. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee receives regular reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also receives briefings from senior management on our cyber risk management program. Board members receive presentations on cybersecurity topics from senior management, or external experts as part of the Board&#8217;s continuing education on topics that impact public companies.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior management team, including the Senior Director, IT and Facilities, is responsible for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. The Senior Director, IT and Facilities has over 20 years of industry experiences leading and overseeing cybersecurity programs at public and private companies.</span></div>Our senior management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information technology environment.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#8220;Committee&#8221;) oversight of cybersecurity and other information technology risks. The Committee oversees management&#8217;s implementation of our cybersecurity risk management program.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also receives briefings from senior management on our cyber risk management program. Board members receive presentations on cybersecurity topics from senior management, or external experts as part of the Board&#8217;s continuing education on topics that impact public companies.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#8220;Committee&#8221;) oversight of cybersecurity and other information technology risks. The Committee oversees management&#8217;s implementation of our cybersecurity risk management program. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee receives regular reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also receives briefings from senior management on our cyber risk management program. Board members receive presentations on cybersecurity topics from senior management, or external experts as part of the Board&#8217;s continuing education on topics that impact public companies.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior management team, including the Senior Director, IT and Facilities, is responsible for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. The Senior Director, IT and Facilities has over 20 years of industry experiences leading and overseeing cybersecurity programs at public and private companies.</span></div>Our senior management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information technology environment.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#8220;Committee&#8221;) oversight of cybersecurity and other information technology risks. The Committee oversees management&#8217;s implementation of our cybersecurity risk management program.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">The Senior Director, IT and Facilities has over 20 years of industry experiences leading and overseeing cybersecurity programs at public and private companies.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">The Committee receives regular reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719804130624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock', window );">Business</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. We do this by providing financing, licensing our technologies or both.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has one operating and one reportable segment: development and licensing of biopharmaceutical assets. The Company's Chief Operating Decision Maker (&#8220;CODM&#8221;) is Todd Davis, our Chief Executive Officer. The CODM uses net income (loss) from continuing operations as a single segment profit or loss measure to evaluate our single segment performance, and in deciding whether to reinvest into the existing assets, or to new potential opportunities. Our CODM relies on internal management reporting processes that provide information on segment operating income (loss) for making financial decisions and allocating resources. CODM does not evaluate, manage or measure performance of segments using asset information.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain reclassifications have been made to the previously issued audited consolidated financial statements to conform with the current period presentation. Specifically, within the consolidated balance sheet as of December 31, 2023, our commercial license and other economic rights line has been reclassified to long-term portion of financial royalty assets, net, and to other assets, and a portion of other investments has been reclassified from other assets. Moreover, noncurrent derivative assets as of December 31, 2023, have been reclassified from other assets.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, within the consolidated statements of operations for the years ended December 31, 2023 and 2022, royalties have been reclassified to revenue from intangible royalty assets, and a portion of the contract revenue has been reclassified to income from financial royalty assets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsPolicyTextBlock', window );">Discontinued operations</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discontinued operations</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the spin-off of the OmniAb Business in November 2022 in connection with the OmniAb Transactions met the criteria for classification as a discontinued operation in accordance with ASC Subtopic 205-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Discontinued Operations</span> (&#8220;ASC 205-20&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they incurred. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.</span></div>Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Business Risk</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Business Risk</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock', window );">Cash Equivalents &amp; Short-term Investments</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of highly liquid investments with maturities of three months or less from the date of acquisition. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Short-term Investments</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments primarily consist of investments in debt and equity securities. We classify our short-term investments as &#8220;available-for-sale&#8221;. Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statements of comprehensive income (loss), net of tax, and unrealized gains and losses on equity securities included the consolidated statements of operations. We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and include net realized gains and losses as a component of non-operating income and expenses within the consolidated statements of operations. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities consist of certificates of deposit, corporate debt securities, and securities of government-sponsored entities. Debt securities have effective maturities greater than&#160;three months and less than thirty-six months from the date of acquisition. Debt securities available-for-sale in an unrealized loss position are assessed for current expected credit losses. We start by assessing whether we intend to sell the security, or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.</span></div>Equity securities consist of bond funds, investments in privately held companies (non-marketable equity securities), and companies that have completed initial public offerings (marketable equity securities). Bond funds are valued at their publicly quoted net asset value (&#8220;NAV&#8221;) price on the last day of the period. Our non-marketable equity securities without readily determinable market values are initially measured at cost and adjusted to fair value for observable transactions for identical or similar investments of the same issuer or impairment. Our marketable equity securities are measured at fair value. Equity investments are classified as short-term investments, equity method investment in Primrose Bio, or other investments, based on the nature of the securities and their availability for use in current operations.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock', window );">Accounts Receivable and Allowance for Credit Losses</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable and Allowance for Credit Losses </span></div>Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div>Inventory, which consists of finished goods (Captisol), is stated at the lower of cost or net realizable value. We determine cost using the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from <span style="-sec-ix-hidden:f-611">one</span> to nine years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Balance Sheet Account Details</span>.&#8221;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill, Intangible Assets and Other Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill, Intangible Assets and Other Long-Lived Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at the reporting unit level at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment at the reporting unit level during the fourth quarter of 2024, noting no impairment. </span></div>Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#8217; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsPolicyTextBlock', window );">Financial Royalty Assets, net (formerly known as Commercial License Rights)</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Royalty Assets, net (formerly known as Commercial License Rights)</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial royalty assets represent a portfolio of future milestone and royalty payment rights acquired that are passive in nature (i.e., we do not own the intellectual property or have the right to commercialize the underlying products).</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we account for financial royalty assets under ASC 310, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Imputation of Interest</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is recalculated in each reporting period as the difference between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gross carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by accrued interest income (except for assets under the non-accrual method) and decreased by cash receipts in the period to arrive at the ending balance.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate financial royalty assets for recoverability on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the total amount of expected undiscounted cash flows is below the amortized cost basis, we measure and record an allowance for the change in expected cash flows. This allowance is measured as the difference between the financial royalty asset&#8217;s amortized cost basis and the net present value of the expected future cash flows, calculated using the original effective interest rate. In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance in part or in full.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above allowance, we recognize an allowance for current expected credit losses under ASC 326, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our financial royalty assets. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the credit loss provision.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of financial royalty assets is presented net of the cumulative allowances for changes in expected future cash flows and expected credit losses. The initial amount and subsequent revisions in allowances for changes in expected future cash flows and expected credit losses are recorded as part of general and administrative expenses on the consolidated statements of operations.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we are reasonably certain that a part of a financial royalty asset&#8217;s net carrying value (or all of it) is not recoverable, we recognize an impairment which is recorded in financial royalty assets impairment on the consolidated statements of operations. To the extent there was an allowance previously recorded for this asset, the amount of such impairment is written off against the allowance at the time that such a determination is made. Any future recoveries from such impairment are recognized when cash is collected in a respective period earnings.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current portion of financial royalty assets represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter. This portion is presented in other current assets on our consolidated balance sheets, net of the allowance for expected credit losses.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (6), Financial Royalty Assets, net (formerly known as Commercial License Rights)&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Assets</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Assets</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative assets include instruments used for risk-management purposes, and other instruments. Derivative assets which are not used for risk management purposes, include: (a) acquired rights in future milestone and royalty payments from Agenus Partnered Programs (as defined in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (2), Agenus Transaction&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), (b) Agenus Warrant (as defined </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (2), Agenus Transaction&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), (c) option to invest up to $25 million to milestone and royalty rights which expires on June 30, 2025 (&#8220;Upsize Option&#8221;), and (d) rights to receive from Primrose Bio 50% of milestones on two contracts previously entered into by Primordial Genetics.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investment</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Method Investment</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments that we do not consolidate but in which we have significant influence over the operating and financial policies of the investee are classified as equity method investments and are accounted for using the equity method of accounting.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In applying the equity method of accounting, investments are initially recorded at cost and are subsequently adjusted based on our proportionate share of net income or loss of the investee, net of any distributions received from the investee and any impairment.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (4), Sale of Pelican Business and Investment in Primrose Bio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_OtherInvestmentsPolicyPolicyTextBlock', window );">Other Investments</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Investments</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other investments represent our investments in equity securities of third parties in which we do not have control or significant influence. Our equity securities investments do not have a readily determinable or estimable fair value and are measured using the measurement alternative, which is cost less impairment, if any, and adjustments resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. The amount of such impairment or adjustment recognized during the period is presented in other non-operating (expense) income, net in our consolidated statements of operations. For additional information, see &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note (7), Balance Sheet Account Details</span>.&#8221;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue and Other Income</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue and Other Income</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, income from financial royalty assets, and contract revenue for license fees, technical, regulatory and sales-based milestone payments. Other operating income is primarily related to milestone income received for financial royalty assets that have been fully amortized or where there is no underlying asset recognized on the consolidated balance sheets. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply the following five-step model in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Intangible Royalty Assets</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalty revenue from intangible royalty assets on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than when the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted in the period in which they become known, typically the following quarter.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income from Financial Royalty Assets</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2024, we introduced a new line item &#8220;income from financial royalty assets&#8221;, which was included in &#8220;contract revenue&#8221; in prior periods. Accordingly, the prior year period amounts have been reclassified to align with the current period presentation.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. Income is calculated by multiplying the carrying value of the financial royalty asset by the periodic effective interest rate.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for financial royalty assets related to developmental pipeline or recently commercialized products on a non-accrual basis. Developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. Newly commercialized products typically do not have an established reliable sales pattern, and thus have uncertain cash flows.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Captisol Sales</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from Captisol sales is recognized when control of Captisol material is transferred or intellectual property license rights are granted to our customers in an amount that reflects the consideration we expect to receive from our customers </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in exchange for those products or rights. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. For Captisol material or intellectual property license rights, we consider our performance obligation satisfied once we have transferred control of the product or granted the intellectual property rights, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost of freight and shipping when control over Captisol material has transferred to the customer as an expense in cost of Captisol in our consolidated statements of operations. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Revenue and Other Income</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with customers often include variable consideration in the form of contingent milestone payments. We include contingent milestone payments in the estimated transaction price when it is probable a significant reversal in the amount of cumulative revenue recognized will not occur. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone payment is based on sales, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some customer contracts are sublicenses which require that we make payments to an upstream licensor related to license fees, milestones and royalties which we receive from customers. In such cases, we evaluate the determination of gross revenue as a principal versus net revenue as an agent reporting based on each individual agreement.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income is primarily related to milestone income received for financial royalty assets that have been fully amortized or where there is no underlying asset recognized on the consolidated balance sheets.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div>Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue and certain service revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div>Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, contract research organization (&#8220;CRO&#8221;) costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur share-based compensation expense related to restricted stock, ESPP, and stock options.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock unit (&#8220;RSU&#8221;) and performance stock unit (&#8220;PSU&#8221;) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment. A limited amount of PSUs contain a market condition dependent upon the Company&#8217;s relative and absolute total stockholder return over a three-year period, with a range of 0% to 200% of the target amount granted to be issued under the award. Share-based compensation expense for these PSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the market conditions.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock purchases under our ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatility of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.</span></div>Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Income (Loss) Per Share</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income (Loss) Per Share</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive common shares consist of shares issuable under the 2023 Notes, stock options and restricted stock. Although we paid off the 2023 Notes in May 2023, it would have a dilutive impact when the average market price of our common stock exceeded the maximum conversion price during the year ended December 31, 2023. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded. For additional information, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (11), Stockholders&#8217; Equity&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 260, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Earnings per Share</span>, if a company had a discontinuing operation, the company uses income from continuing operations, adjusted for preferred dividends and similar adjustments, as its control number to determine whether potential common shares a dilutive.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Euro is the functional currency of Apeiron and the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Translation of Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div>Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented for unrealized gains and losses on available-for-sale debt securities and foreign currency translation adjustments.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Accounting Standards Updates, Recently Adopted and Not Yet Adopted</a></td>
<td class="text"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Updates, Recently Adopted</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have adopted the updated accounting guidance in our Annual Report on the Form 10-K for the year ended December&#160;31, 2024. We have updated our segment disclosure (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Note (1), Basis of Presentation and Summary of Significant Accounting Policies&#8221;) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including, among other required items, the information on significant segment expenses that are regularly provided to the CODM and included within the reported segment profit or loss measure.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting Standards Not Yet Adopted</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December 15, 2024, with early adoption permitted. We have not yet completed the assessment of the impact of ASU 2023-09 on our consolidated financial statements.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU No. 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement&#8212;Reporting Comprehensive Income (Subtopic 220-40): Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This update requires entities to disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. We are currently evaluating the new guidance to determine the impact it may have on our consolidated financial statements and related disclosures.</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessSpinOffAndMigrationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Spin-Off And Migration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessSpinOffAndMigrationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinancialRoyaltyAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Royalty Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinancialRoyaltyAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherInvestmentsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Investments Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherInvestmentsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479515/805-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditLossFinancialInstrumentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.M.2.Q4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483530/326-20-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479391/326-20-30-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479366/326-20-35-8A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-3D<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479175/326-30-30-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-3D<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 13A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479148/326-30-35-13A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479391/326-20-30-4A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479148/326-30-35-7A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-21<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditLossFinancialInstrumentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480781/205-20-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719804079136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Revenue from Significant Partners</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue and other income from significant partners, which is defined as 10% or more of our total revenue, was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Partner C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;10%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&lt;10%</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties for 2024, 2023 and 2022 for continuing operations are reported as below (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kyprolis</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,377&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,116&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rylaze </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filspari</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Evomela</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,197&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Teriparatide injection </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vaxneuvance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from intangible royalty assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83,910&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,527&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income from financial royalty assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total royalties</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,773&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,959&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,912&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents disaggregation of Captisol and contract revenue and other income for continuing operations (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Captisol</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Captisol - Core</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,883&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Captisol - COVID</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(a)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Captisol</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,883&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,372&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,495&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract revenue and other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone and other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,838&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,944&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total contract revenue and other income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,477&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,983&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,838&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(a) Captisol - COVID represents revenue on Captisol supplied for use in formulation with remdesivir, an antiviral treatment for COVID-19.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Income (Loss) per Share</a></td>
<td class="text">The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:62.189%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dilutive potential common shares:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Restricted stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;2023 Convertible Senior Notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares used to compute diluted income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,290&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,757&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,868&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Potentially dilutive shares excluded from calculation due to anti-dilutive effect</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,530&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,357&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,241&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information on significant segment expenses that are regularly provided to the CODM, and other segment items included within the reported segment profit or loss measure, is presented in a table below:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total revenues and other income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,314&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,245&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,089)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,743)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(60,285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other segment items:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,959)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33,654)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,237)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,905)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,841)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,799)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other *</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(99,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,248)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(103,348)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income (loss) from continuing operations</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,032)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,819&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,219)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">* Other items for the years ended December 31, 2024, 2023, and 2022, include the amount of other general, administrative, research and development expenses of $56.7 million, $48.7 million, and $42.0 million (net of share-based compensation and depreciation expenses), respectively, and additional income and expense items that are presented in consolidated statements of operations such as financial royalty assets impairment, Fair value adjustments to partner program derivatives, cost of Captisol and other non-operating income and expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-16<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719798968816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract assets (financial royalty assets)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,740)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total fair value of net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,433&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have finalized purchase accounting for the Novan acquisition. The following table sets forth an allocation of the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets acquired </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,508)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,700)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for Novan, including restricted cash received</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,988&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DIP loan fees and interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total consideration </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,150&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719802640464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Pelican Business and Investment in Primrose Bio (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Carrying Amounts of Major Classes of Assets and Liabilities Related to Assets Held for Sale</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the sale of Pelican meets the definition of a deconsolidation of a business. Net assets sold together with allocated goodwill and cash consideration paid were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net assets sold</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocated goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash consideration paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">47,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The following table summarizes revenue and expenses of the discontinued operations for the year ended December 31, 2022 (in thousands):<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,564&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,132)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain from short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,578)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,142)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the significant non-cash items, capital expenditures of the discontinued operations, and financing activities that are included in the consolidated statements of cash flows for the year ended December 31, 2022 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(554)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for acquisition, net of cash acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(960)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock', window );">Schedule of Fair Value of the Consideration</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the consideration received includes the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">49,184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Fair Value Of The Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5D<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719918993520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-off of OmniAb (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of Carrying Amounts of Major Classes of Assets and Liabilities Related to Assets Held for Sale</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the sale of Pelican meets the definition of a deconsolidation of a business. Net assets sold together with allocated goodwill and cash consideration paid were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">717&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(495)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,445)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net assets sold</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Allocated goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,132&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash consideration paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">47,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The following table summarizes revenue and expenses of the discontinued operations for the year ended December 31, 2022 (in thousands):<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalties</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,564&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,383&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating costs and expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,696&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36,132)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain from short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expense, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income tax</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(35,578)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,142)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the significant non-cash items, capital expenditures of the discontinued operations, and financing activities that are included in the consolidated statements of cash flows for the year ended December 31, 2022 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(554)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for acquisition, net of cash acquired</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,572)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(960)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments to CVR Holders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,545)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,310&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5D<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719915766560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Royalty Assets, net (formerly known as Commercial License Rights) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ScheduleOfFinancialRoyaltyAssetsTableTextBlock', window );">Schedule of Financial Royalty Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, financial royalty assets consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.605%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross carrying value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Allowance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross carrying value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Allowance </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net carrying value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Qarziba</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(484)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,845&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agenus (Bot/Bal)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(408)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tolerance Therapeutics (Tzield)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,613&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,512&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,709&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ensifentrine inventors</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Elutia (CorMatrix)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,268)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,304&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">InvIOs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selexis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ovid (Soticlestat)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,310&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,007&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial royalty assets, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">198,587&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,538)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195,049&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70,364&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,073)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) The amounts of allowance include accumulated allowance for changes in expected cash flows and current expected credit losses.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(2) The amounts include $10.0 million current portion of financial royalty assets which represents an estimation for current quarter royalty receipts that are collected during the subsequent quarter. This portion is presented in other current assets on our consolidated balance sheet as of December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ScheduleOfFinancialRoyaltyAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Financial Royalty Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ScheduleOfFinancialRoyaltyAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719799098704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Investment Categories</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2024 and 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">gains</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross unrealized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">losses</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">fair value</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,442&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,595)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,187&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,626)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,618&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bond fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,763&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(537)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,226&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of Deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper  </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,578&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,586&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,736&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,003&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,235)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,874&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,783)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,170&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available-for-Sale Debt Securities by Contractual Maturity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Within one year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,296&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">After one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,928&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,233&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">140,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Available-for-Sale Debt Securities in an Unrealized Loss Position</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 12 months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12 months or greater</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of Deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,965&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,370&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,790&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,160&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificates of Deposit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate notes/bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,857&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,809&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,949&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,758&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost and consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lab and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,363&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,268)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,655)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,133&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Goodwill and Other Identifiable Intangible Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill and identifiable intangible assets consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indefinite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,370&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Definite-lived intangible assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Completed technology</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,710)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,894)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trade name</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,843)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,710)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Customer relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,652)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contractual relationships</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122,638)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(93,782)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total goodwill and other identifiable intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371,898&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">402,976&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock', window );">Schedule of Derivative Assets at Fair Value</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative assets consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Primrose mRNA</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,451&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agenus Partner Programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Agenus Warrant (5 years contractual term)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total noncurrent derivative assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,583&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryInvestmentHoldingsTextBlock', window );">Summary Investment Holdings</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other investments consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity securities in Primrose Bio</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,712&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,726&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">InvIOs investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,196&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuritek warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Palvella Series C preferred stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total other investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,908&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,726&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current</a></td>
<td class="text">Below is a summary of the ZELSUVMI related inventory included in other current assets (in thousands):<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Pelthos inventory in other current assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,526&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consist of the following (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalties owed to third parties</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UK value-added tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,858&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subcontractor</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,756&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Customer deposit </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplier</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts owed to former licensees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,906&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,467&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ScheduleofContingentLiabilitiesTableTextBlock', window );">Schedule of Contingent Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes roll-forward of contingent liabilities as of December&#160;31, 2024 and 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:20.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.734%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.739%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payments</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Adjustment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cydex</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Metabasis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,429&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,513</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(50)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(265)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,198</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(200)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">683</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,681</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Schedule of Other Long Term Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novan (Pelthos) contract liability</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,938&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrecognized tax benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other long-term liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,163&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,758&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Balance Sheet Details [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ScheduleofContingentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Contingent Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ScheduleofContingentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative assets at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryInvestmentHoldingsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the summary of investment holdings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryInvestmentHoldingsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719918644240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023 (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments, excluding Viking</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,811&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,240&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">194,441&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61,811&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,583&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent liabilities - CyDex</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,681&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,298&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements at Reporting Date Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Active Markets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">for Identical</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Observable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments, excluding Viking</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> (1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,170&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment in Viking common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Derivative assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,476&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,879&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent liabilities - CyDex</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent liabilities - Metabasis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,198&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) Excluding our investment in Viking, corporate equity securities, and US government securities, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in bond funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we had investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and were at level 3 of the fair value hierarchy, based on Black-Scholes value estimated by management on the last day of the period. This investment in warrants expired in January 2024.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(2) Derivative assets include instruments used for risk-management purposes, and other instruments. Derivative assets which are not used for risk management purposes include: (a) acquired rights in future milestone and royalty payments from Agenus Partnered Programs, (b) Agenus Warrant, (c) Upsize Option, (d) Viking Share Collar (e) and rights to receive from Primrose Bio 50% of milestones on two contracts previously entered into by Primordial Genetics. The considerations were recognized as derivative assets included under current derivative assets and noncurrent derivative assets in our consolidated balance sheet. They are recognized as derivative assets under ASC 815, Derivatives and Hedging. The fair value of the Agenus Partnered Programs and the Primrose Bio derivative assets was determined using a discounted cash flow approach, utilizing the mostly-likely cash flows which considered the probability of success for the underlying clinical programs. The discount rate used contemplates the underlying credit and business risk of the partnered programs. At December&#160;31, 2024, the discount rates used range between 15% and 28%. At December&#160;31, 2023, the discount rate used was 25%. The fair value of the Agenus Warrant was determined using a Black-Scholes-Merton model. The fair value of the Upsize Option was determined using a binomial option pricing model.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(3) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate </span></div>significantly based upon quoted market prices and actual amounts paid under the agreements may be materially different than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#946; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10 million payment upon initiation of a Phase 3 clinical trial.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Reconciliation of Level 3 Financial Instruments, Assets</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2024 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions to derivative assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,888&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1303">Fair value adjustments to derivative assets</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,010)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of derivative assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,826)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2024</span></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,583&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments to CVR holders and other contingent payments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1309">Fair value adjustments to contingent liabilities</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2024</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2023 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1313">Fair value adjustments to equity security warrants</span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(135)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions to derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value adjustments to derivative assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments to CVR holders and other contingency payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1320">Fair value adjustments to contingent liabilities</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Reconciliation of Level 3 Financial Instruments, Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2024 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions to derivative assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,888&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1303">Fair value adjustments to derivative assets</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,010)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of derivative assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,826)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2024</span></div></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,583&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments to CVR holders and other contingent payments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1309">Fair value adjustments to contingent liabilities</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2024</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the level 3 financial instruments as of December&#160;31, 2023 is as follows (in thousands):</span></div><div style="text-align:center;text-indent:45pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1313">Fair value adjustments to equity security warrants</span></span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(135)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions to derivative assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value adjustments to derivative assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,531&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2022</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments to CVR holders and other contingency payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1320">Fair value adjustments to contingent liabilities</span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of level 3 financial instruments as of December&#160;31, 2023</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719803941008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Operating and Finance Lease Assets and Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating and finance lease assets and liabilities (in thousands) are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,673&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,455&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,266&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,815&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-1373"><span style="-sec-ix-hidden:f-1374">Long-term finance lease liabilities</span></span></span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease liabilities   </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,154&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,184&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of operating and finance lease liabilities as of December&#160;31, 2024 are as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,983)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,081&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Finance Lease Liabilities</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturity of operating and finance lease liabilities as of December&#160;31, 2024 are as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.391%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturity Dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance <br/>Leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,637&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,560&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less tenant improvement allowance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(418)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,983)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,081&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets and Liabilities, Lessee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719803390496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense from continuing operations (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense as a component of:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,970&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,089&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,881&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Plan Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a summary of our stock option plan activity and related information:</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.244%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Term in</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(In thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,199,598&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.34</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">863,245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,941)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38.56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40,069)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78.46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at October 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,987,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at October 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,769,629&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options vested and expected to vest as of October 31, 2022, before the OmniAb Separation and Regrant</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,987,833&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancellation due to OmniAb Separation, Before Regrant</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,987,833)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at November 1, 2022, Before Regrant</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,584,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50,449)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(542,838)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,991,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,559,662&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.51</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,991,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">537,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(489,076)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(399,371)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,784,209&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.90&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,640,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.63</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">783,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,080,135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117,114)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,226,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December&#160;31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,229,294&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.02</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options vested and expected to vest as of December&#160;31, 2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,226,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,538&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1) Options granted primarily relate to the modifications in connection with the OmniAb Separation which resulted in new stock option grants at the modification date fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of Stock Option Plan Activity by Exercise Price Range</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a further breakdown of the options outstanding as of December&#160;31, 2024:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.212%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of exercise prices</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">remaining life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">in&#160;years</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">exercise price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">exercisable</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">exercise&#160;price</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$32.78-$52.84</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281,644&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.78</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49.42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">195,152&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.02&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$54.81-$63.62</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228,498&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">191,316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$64.65-$68.74</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312,067&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">245,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$69.39-$73.76</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233,288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.66</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$73.92-$75.09</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288,134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,797&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$78.56-$88.27</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.57</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$89.20-$89.20</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">444,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.35</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$89.86-$103.42</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.64</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$104.30-$114.15</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">114.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$122.70-$122.70</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.92</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,226,273&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.58</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,229,294&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Option Weighted-Average Assumptions</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.227%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5%-4.5%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7%-4.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.4%-4.3%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44%-46%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45%-54%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49%-55%</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1 to 4.8 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7 to 5.3 years</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.0 to 6.5 years</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our restricted stock activity and related information:&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:69.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.830%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant&#160;Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">348,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75.60&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">203,752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(181,246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,054)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350,905&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85.23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(167,308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84.28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64,313)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77.28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437,872&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719802700416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Benefit</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2024, 2023, and 2022, the Company has the following income before income tax from continuing operations (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25,855)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,339&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,373&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,672&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,518&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,660&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,011&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:66.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">718&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,350&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred expense (benefit):</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17,767)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,374&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15,800)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,029&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,488&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total income tax expense (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,841&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,230&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:66.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.062%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.063%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax at federal statutory rate</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subpart F income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">853&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Officer compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,869&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign tax differential on income/loss of foreign subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,241&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision to return adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rate change for changes in federal, foreign or state law</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(535)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in uncertain tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debt repurchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State, net of federal benefit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(324)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(405)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FDII</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,037)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,638)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">876&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,841&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,230&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">Deferred tax assets (liabilities) are comprised of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,702&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research credit carryforwards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized R&amp;D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,090&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,761&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance for deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55,649)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57,699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,689&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identified intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69,150)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66,966)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,991)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,504)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(73,141)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(77,470)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32,452)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,408)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2024, 2023 and 2022 is as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:66.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.048%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,363&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,096&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,550&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,783)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(512)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,471&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,363&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,096&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719801070560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Segment Profit or Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">$ 167,133<span></span>
</td>
<td class="nump">$ 131,314<span></span>
</td>
<td class="nump">$ 196,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="num">(41,089)<span></span>
</td>
<td class="num">(25,743)<span></span>
</td>
<td class="num">(60,285)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Other segment items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization of intangibles</a></td>
<td class="num">(32,959)<span></span>
</td>
<td class="num">(33,654)<span></span>
</td>
<td class="num">(34,237)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="num">(2,300)<span></span>
</td>
<td class="num">(2,900)<span></span>
</td>
<td class="num">(3,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(3,037)<span></span>
</td>
<td class="num">(656)<span></span>
</td>
<td class="num">(1,799)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net income (loss) from continuing operations</a></td>
<td class="num">(22,606)<span></span>
</td>
<td class="nump">11,942<span></span>
</td>
<td class="nump">3,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_OtherExpenseItemsNet', window );">Other expense items, net</a></td>
<td class="nump">56,700<span></span>
</td>
<td class="nump">48,700<span></span>
</td>
<td class="nump">42,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember', window );">Development and Licensing of Biopharmaceutical Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">167,133<span></span>
</td>
<td class="nump">131,314<span></span>
</td>
<td class="nump">196,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="num">(41,089)<span></span>
</td>
<td class="num">(25,743)<span></span>
</td>
<td class="num">(60,285)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract', window );"><strong>Other segment items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization of intangibles</a></td>
<td class="num">(32,959)<span></span>
</td>
<td class="num">(33,654)<span></span>
</td>
<td class="num">(34,237)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property and equipment</a></td>
<td class="num">(2,300)<span></span>
</td>
<td class="num">(2,905)<span></span>
</td>
<td class="num">(3,841)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">8,055<span></span>
</td>
<td class="nump">7,711<span></span>
</td>
<td class="nump">2,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(3,037)<span></span>
</td>
<td class="num">(656)<span></span>
</td>
<td class="num">(1,799)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other</a></td>
<td class="num">(99,835)<span></span>
</td>
<td class="num">(22,248)<span></span>
</td>
<td class="num">(103,348)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Net income (loss) from continuing operations</a></td>
<td class="num">$ (4,032)<span></span>
</td>
<td class="nump">$ 53,819<span></span>
</td>
<td class="num">$ (5,219)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherExpenseItemsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Expense Items, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherExpenseItemsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-39<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719799812128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2007 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>May 29, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 18, 2023 </div>
<div>contract</div>
</th>
<th class="th">
<div>Jan. 31, 2010 </div>
<div>right</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease', window );">Increase (decrease) of allowance for credit loss</a></td>
<td class="num">$ (100)<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="num">$ (300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-downs related to obsolete inventory</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">14,114<span></span>
</td>
<td class="nump">23,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividend declared (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusPartneredProgramMember', window );">Agenus Partnered Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DerivativeInstrumentAdditionalMaximumInvestment', window );">Additional maximum investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_MilestoneCompensationRate', window );">Percentage of milestones (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusPartneredProgramMember', window );">Agenus Partnered Program | Primordial Genetics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_NumberOfContracts', window );">Number of contracts | contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiMeasurementInput', window );">Measurement input (as a percent)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2002 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award expiration period (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2002 Stock Incentive Plan | Vest 1/8 on the six month anniversary of the date of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting right (as a percent)</a></td>
<td class="nump">12.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2002 Stock Incentive Plan | Vest 1/48 each month for forty-two months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">42 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting right (as a percent)</a></td>
<td class="nump">2.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=lgnd_RestrictedStockUnitsAndPerformanceSharesMember', window );">RSUs and PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember', window );">Metabasis Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_NumberOfContingentValueRightsIssued', window );">Number of contingent value rights | right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life (in years)</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting right (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life (in years)</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting right (as a percent)</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember', window );">Captisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">$ 4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DerivativeInstrumentAdditionalMaximumInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Instrument, Additional Maximum Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DerivativeInstrumentAdditionalMaximumInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_MilestoneCompensationRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Compensation Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_MilestoneCompensationRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfContingentValueRightsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Contingent Value Rights Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfContingentValueRightsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_AgenusPartneredProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_AgenusPartneredProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByIndustryAxis=lgnd_PrimordialGeneticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByIndustryAxis=lgnd_PrimordialGeneticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=lgnd_VestingPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=lgnd_VestingPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=lgnd_VestingPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=lgnd_VestingPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=lgnd_RestrictedStockUnitsAndPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=lgnd_RestrictedStockUnitsAndPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719799132944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details) - Customer Concentration Risk - Revenue<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Partner A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenues (as a percent)</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Partner B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenues (as a percent)</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Partner C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenues (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Recordati</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Total revenues (as a percent)</a></td>
<td class="nump">54.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lgnd_PartnerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lgnd_PartnerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lgnd_PartnerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lgnd_PartnerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lgnd_PartnerCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lgnd_PartnerCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=lgnd_RecordatiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=lgnd_RecordatiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719802771904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">$ 167,133<span></span>
</td>
<td class="nump">$ 131,314<span></span>
</td>
<td class="nump">$ 196,245<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">108,773<span></span>
</td>
<td class="nump">84,959<span></span>
</td>
<td class="nump">72,912<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyKyprolisMember', window );">Kyprolis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">38,377<span></span>
</td>
<td class="nump">35,640<span></span>
</td>
<td class="nump">30,116<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyRylazeMember', window );">Rylaze</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">13,743<span></span>
</td>
<td class="nump">13,520<span></span>
</td>
<td class="nump">8,796<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_FilspariMember', window );">Filspari</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">12,179<span></span>
</td>
<td class="nump">2,655<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyEvomelaMember', window );">Evomela</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">8,680<span></span>
</td>
<td class="nump">10,212<span></span>
</td>
<td class="nump">10,197<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyTeriparatideInjectionMember', window );">Teriparatide injection</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">8,221<span></span>
</td>
<td class="nump">11,061<span></span>
</td>
<td class="nump">15,785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_VaxneuvanceMember', window );">Vaxneuvance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">5,184<span></span>
</td>
<td class="nump">4,062<span></span>
</td>
<td class="nump">1,083<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_RoyaltyOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">8,945<span></span>
</td>
<td class="nump">6,760<span></span>
</td>
<td class="nump">6,550<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_IntangibleRoyaltyAssetsMember', window );">Revenue from intangible royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">95,329<span></span>
</td>
<td class="nump">83,910<span></span>
</td>
<td class="nump">72,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_FinancialRoyaltyAssetsMember', window );">Income from financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">13,444<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember', window );">Captisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">30,883<span></span>
</td>
<td class="nump">28,372<span></span>
</td>
<td class="nump">104,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolCoreMember', window );">Captisol - Core</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">30,883<span></span>
</td>
<td class="nump">28,372<span></span>
</td>
<td class="nump">16,429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolCOVIDMember', window );">Captisol - COVID</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">88,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember', window );">Contract revenue and other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">27,477<span></span>
</td>
<td class="nump">17,983<span></span>
</td>
<td class="nump">18,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Milestone and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">25,533<span></span>
</td>
<td class="nump">17,983<span></span>
</td>
<td class="nump">18,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMember', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues and other income</a></td>
<td class="nump">$ 1,944<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyKyprolisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyKyprolisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyRylazeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyRylazeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_FilspariMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_FilspariMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyEvomelaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyEvomelaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyTeriparatideInjectionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyTeriparatideInjectionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_VaxneuvanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_VaxneuvanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_RoyaltyOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_RoyaltyOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_IntangibleRoyaltyAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_IntangibleRoyaltyAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_FinancialRoyaltyAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_FinancialRoyaltyAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolCoreMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolCoreMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolCOVIDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolCOVIDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_ContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_LicenseFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_LicenseFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719800343920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">18,290<span></span>
</td>
<td class="nump">17,298<span></span>
</td>
<td class="nump">16,868<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used to compute diluted income per share (in shares)</a></td>
<td class="nump">18,290<span></span>
</td>
<td class="nump">17,757<span></span>
</td>
<td class="nump">16,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares)</a></td>
<td class="nump">1,530<span></span>
</td>
<td class="nump">4,357<span></span>
</td>
<td class="nump">6,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">255<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive potential common shares (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719799461984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Agenus Transaction (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>May 29, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsNet', window );">Royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195,049<span></span>
</td>
<td class="nump">$ 62,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusInc.Member', window );">Agenus, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsNet', window );">Royalty assets</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 40,407<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinanceRoyaltyAgreementRoyaltyRate', window );">Royalties right to receive (as a percent)</a></td>
<td class="nump">18.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyMaximumCapitalSourcing', window );">Maximum capital sourcing</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_MaximumFinancingRoyaltyAsset', window );">Maximum financing royalty asset</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued in public offering (in shares) | shares</a></td>
<td class="nump">867,052<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in USD per share) | $ / shares</a></td>
<td class="nump">$ 17.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusInc.Member', window );">Agenus, Inc. | Expected Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusInc.Member', window );">Agenus, Inc. | Option Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.84<span></span>
</td>
<td class="nump">1.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusInc.Member', window );">Agenus, Inc. | Risk Free Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input</a></td>
<td class="nump">0.047<span></span>
</td>
<td class="nump">0.043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusInc.Member', window );">Agenus, Inc. | Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Derivative liability, measurement input | $ / shares</a></td>
<td class="nump">15.03<span></span>
</td>
<td class="nump">2.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusInc.Member', window );">Agenus, Inc. | BMS-986442</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate', window );">Future milestones right to receive (as a percent)</a></td>
<td class="nump">31.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusInc.Member', window );">Agenus, Inc. | AGEN2373</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate', window );">Future milestones right to receive (as a percent)</a></td>
<td class="nump">31.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusInc.Member', window );">Agenus, Inc. | INCAGN2385</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate', window );">Future milestones right to receive (as a percent)</a></td>
<td class="nump">31.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusInc.Member', window );">Agenus, Inc. | INCAGN2390</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate', window );">Future milestones right to receive (as a percent)</a></td>
<td class="nump">31.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusInc.Member', window );">Agenus, Inc. | MK-4830</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate', window );">Future milestones right to receive (as a percent)</a></td>
<td class="nump">31.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusInc.Member', window );">Agenus, Inc. | UGN-301</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate', window );">Future milestones right to receive (as a percent)</a></td>
<td class="nump">31.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusInc.Member', window );">Agenus, Inc. | BOT/BAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales', window );">Future royalties (as a percent)</a></td>
<td class="nump">2.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusPartneredProgramMember', window );">Agenus Partnered Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DerivativeInstrumentAdditionalMaximumInvestment', window );">Additional maximum investment</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Fair value of derivative assets</a></td>
<td class="nump">$ 21,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DerivativeInstrumentAdditionalMaximumInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Instrument, Additional Maximum Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DerivativeInstrumentAdditionalMaximumInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Royalty Agreement, Milestone Proceeds Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinanceRoyaltyAgreementRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Royalty Agreement, Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinanceRoyaltyAgreementRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinancialRoyaltyAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Royalty Assets, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinancialRoyaltyAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinancialRoyaltyMaximumCapitalSourcing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Royalty, Maximum Capital Sourcing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinancialRoyaltyMaximumCapitalSourcing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_MaximumFinancingRoyaltyAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Financing Royalty Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_MaximumFinancingRoyaltyAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Financing Agreement, Percentage Of Global Net Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_AgenusInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_AgenusInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_BMS986442Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_BMS986442Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_AGEN2373Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_AGEN2373Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_INCAGN2385Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_INCAGN2385Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_INCAGN2390Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_INCAGN2390Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MK4830Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MK4830Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_UGN301Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_UGN301Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_BOTBALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_BOTBALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_AgenusPartneredProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_AgenusPartneredProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719799737584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 15, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 15, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 27, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Cash paid for InvIOs investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,196,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lgnd_InvIOsHoldingAGMember', window );">InvIOs Holding AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Cash paid for InvIOs investment</a></td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_EquityIssuanceCost', window );">Equity issuance cost</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lgnd_InvIOsHoldingAGMember', window );">InvIOs Holding AG | Investor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi', window );">Cash paid for InvIOs investment</a></td>
<td class="nump">8,800,000<span></span>
</td>
<td class="nump">&#8364; 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_APEIRONMember', window );">APEIRON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">100,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent earn-out payment</a></td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Deferred transaction costs</a></td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="nump">$ 18,109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember', window );">Novan, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash payments for acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Liabilities incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationAcquiredPercentage', window );">Acquired (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired from acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill acquired that is expected to be deductible for tax purposes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate', window );">Discount rate used to value intangible assets acquired (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average estimated useful life of finite-lived intangible assets acquired (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ContingentMilestonePurchaseAgreement', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember', window );">Novan, Inc. | Discount Rate | Valuation Technique, Discounted Cash Flow</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent liability measurement input (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember', window );">Novan, Inc. | Core Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember', window );">Novan, Inc. | Bridge Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Liabilities incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationAcquiredPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Acquired Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationAcquiredPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ContingentMilestonePurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Milestone Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ContingentMilestonePurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EquityIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Issuance Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EquityIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lgnd_InvIOsHoldingAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lgnd_InvIOsHoldingAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_APEIRONMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_APEIRONMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_BridgeLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_BridgeLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719806522400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Fair Values of Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 15, 2024</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets', window );">Contract assets (financial royalty assets)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_APEIRONMember', window );">APEIRON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets', window );">Contract assets (financial royalty assets)</a></td>
<td class="nump">$ 106,156<span></span>
</td>
<td class="nump">106,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets', window );">Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable and accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable', window );">Income tax payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,109)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total fair value of net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Income Tax Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_APEIRONMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_APEIRONMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719798955552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,250<span></span>
</td>
<td class="nump">$ 103,370<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for Novan, including restricted cash received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">10,405<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember', window );">Novan, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Restricted cash</a></td>
<td class="nump">$ 583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">13,054<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use asset</a></td>
<td class="nump">3,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets', window );">Other assets</a></td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets', window );">Deferred tax asset</a></td>
<td class="nump">1,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets acquired</a></td>
<td class="nump">10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(4,508)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(3,683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities', window );">Other liabilities</a></td>
<td class="num">(13,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for Novan, including restricted cash received</a></td>
<td class="nump">10,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationLoanFeesAndInterest', window );">DIP loan fees and interest</a></td>
<td class="nump">1,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="nump">$ 12,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationLoanFeesAndInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Loan Fees And Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationLoanFeesAndInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_NovanIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719798090384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Sale of Pelican Business and Investment in Primrose Bio - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 18, 2023 </div>
<div>USD ($) </div>
<div>contract </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,121,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="nump">$ 10,583,000<span></span>
</td>
<td class="nump">3,531,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag', window );">Derivative Asset Noncurrent, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">consolidated balance sheets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) on derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (20,010,000)<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Losses from equity method investment in Primrose Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,821,000<span></span>
</td>
<td class="nump">1,829,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lgnd_PrimroseBioMember', window );">Primrose Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment', window );">Impairment of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Losses from equity method investment in Primrose Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount', window );">Decrease in value of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Pelican Technology Holdings, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone', window );">Consideration paid for an interest in potential development milestone</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill written off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain on sale of business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Business exit costs</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Pelican Technology Holdings, Inc. | Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration', window );">Shares received as consideration | shares</a></td>
<td class="nump">474,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Pelican Technology Holdings, Inc. | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration', window );">Shares received as consideration | shares</a></td>
<td class="nump">2,146,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposal Group, Disposed of by Sale, Not Discontinued Operations | Pelican Technology Holdings, Inc. | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration', window );">Shares received as consideration | shares</a></td>
<td class="nump">4,278,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PrimroseBioMember', window );">Primrose Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone', window );">Consideration paid for an interest in potential development milestone</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,451,000<span></span>
</td>
<td class="nump">3,531,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusPartneredProgramMember', window );">Agenus Partnered Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_MilestoneCompensationRate', window );">Percentage of milestones (as a percent)</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Primrose Bio | PeliCRM197</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_SalesRevenueMilestone', window );">Sales revenue milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Primrose Bio | PeliCRM197 | Below 3 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_SalesContractInterestInSalesRevenue', window );">Interest in sales revenue (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Primrose Bio | PeliCRM197 | Above 3 million</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_SalesContractInterestInSalesRevenue', window );">Interest in sales revenue (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByIndustryAxis=lgnd_PrimordialGeneticsMember', window );">Primordial Genetics | Agenus Partnered Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_NumberOfContracts', window );">Number of contracts | contract</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain (loss) on derivative instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (100,000)<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration Paid For An Interest In Potential Development Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Asset Noncurrent, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Share Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_MilestoneCompensationRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Compensation Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_MilestoneCompensationRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_SalesContractInterestInSalesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Contract, Interest In Sales Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_SalesContractInterestInSalesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_SalesRevenueMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Revenue Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_SalesRevenueMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lgnd_PrimroseBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lgnd_PrimroseBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PelicanTechnologyHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PelicanTechnologyHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_PrimroseBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_PrimroseBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_AgenusPartneredProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_AgenusPartneredProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_PeliCRM197Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_PeliCRM197Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_MilestoneAxis=lgnd_BelowMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_MilestoneAxis=lgnd_BelowMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_MilestoneAxis=lgnd_AboveMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_MilestoneAxis=lgnd_AboveMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByIndustryAxis=lgnd_PrimordialGeneticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByIndustryAxis=lgnd_PrimordialGeneticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719799788320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Sale of Pelican Business and Investment in Primrose Bio - Net Asset (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations - Pelican Technology Holdings, Inc.<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 18, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment', window );">Property and equipment, net</a></td>
<td class="nump">$ 8,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">19,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Other assets</a></td>
<td class="nump">717<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">8,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(630)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(495)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities', window );">Long-term operating lease liabilities</a></td>
<td class="num">(8,445)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities', window );">Other liabilities</a></td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset', window );">Net assets sold</a></td>
<td class="nump">27,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Allocated goodwill</a></td>
<td class="nump">4,132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone', window );">Cash consideration paid</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions', window );">Total</a></td>
<td class="nump">$ 47,063<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration Paid For An Interest In Potential Development Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Financing Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Long-term Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Net Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Net Contributions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred revenue attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PelicanTechnologyHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PelicanTechnologyHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719799755856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Sale of Pelican Business and Investment in Primrose Bio - Fair Value of the Consideration (Details) - Disposal Group, Disposed of by Sale, Not Discontinued Operations - Pelican Technology Holdings, Inc.<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 18, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Cash consideration paid</a></td>
<td class="nump">$ 49,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Cash consideration paid</a></td>
<td class="nump">13,706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Cash consideration paid</a></td>
<td class="nump">32,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Derivative assets</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Cash consideration paid</a></td>
<td class="nump">$ 3,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PelicanTechnologyHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=lgnd_PelicanTechnologyHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ConsiderationClassficationAxis=lgnd_EquityMethodInvestmentsAllocationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ConsiderationClassficationAxis=lgnd_EquityMethodInvestmentsAllocationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ConsiderationClassficationAxis=lgnd_EquitySecuritiesAllocationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ConsiderationClassficationAxis=lgnd_EquitySecuritiesAllocationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ConsiderationClassficationAxis=lgnd_DerivativeAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ConsiderationClassficationAxis=lgnd_DerivativeAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719801654624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Spin-off of OmniAb - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax asset adjustment</a></td>
<td class="nump">$ 40,689<span></span>
</td>
<td class="nump">$ 46,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember', window );">Scenario, Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax asset adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed', window );">Percentage of voting interests disposed (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Percentage Of Voting Interests Disposed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719809577600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-off of OmniAb - Schedule of Revenue and Expenses of the Discontinued Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net loss</a></td>
<td class="num">$ (1,665)<span></span>
</td>
<td class="num">$ (28,142)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization', window );">Amortization of intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,383<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating costs and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,696<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,132)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments', window );">Gain from short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense', window );">Other income (expense), net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax', window );">Loss before income tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,578)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation', window );">Income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,436<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,142)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations | Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations | Contract revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,275<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Browse Taxonomy Disposal Group, Including Discontinued Operation, Other Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Gain (Loss) On Short-Term Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Nonoperating Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Operating Costs and Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Other Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Research and Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480781/205-20-S99-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_ContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_ContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719800343632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Spin-off of OmniAb - Schedule of Non-cash Items and Capital Expenditures of the Discontinued Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity', window );">Payments to CVR Holders</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (1,545)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration', window );">Change in fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(554)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,218<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid for acquisition, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpenditureDiscontinuedOperations', window );">Purchase of property, plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,572)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity', window );">Payments to CVR Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(960)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity', window );">Payments to CVR Holders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property, plant and equipment included in accounts payable and accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,310<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Change in Amount of Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Payments to Acquire Businesses, Net of Cash Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Share-Based Payment Arrangement, Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operations, Capital Expenditures Incurred but Not yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Cash Provided by (Used in) Discontinued Operations, Investing Actives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Cash Provided by (Used in) Discontinued Operations, Operating Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToContingentValueRightHoldersFinancingActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Contingent Value Right Holders, Financing Activity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToContingentValueRightHoldersFinancingActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToContingentValueRightHoldersInvestingActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to Contingent Value Right Holders, Investing Activity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToContingentValueRightHoldersInvestingActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpenditureDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capital expenditure attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpenditureDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortizationDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719806518288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Royalty Assets, net (formerly known as Commercial License Rights) - Schedule of Financial Royalty Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>May 29, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsGross', window );">Gross carrying value</a></td>
<td class="nump">$ 198,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsAllowance', window );">Allowance</a></td>
<td class="num">(3,538)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,073)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsNet', window );">Net carrying value</a></td>
<td class="nump">195,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsNetCurrent', window );">Financial royalty liability current</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_QARZIBAMember', window );">Qarziba</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsGross', window );">Gross carrying value</a></td>
<td class="nump">105,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsAllowance', window );">Allowance</a></td>
<td class="num">(484)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsNet', window );">Net carrying value</a></td>
<td class="nump">104,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusInc.Member', window );">Agenus (Bot/Bal)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsGross', window );">Gross carrying value</a></td>
<td class="nump">40,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsAllowance', window );">Allowance</a></td>
<td class="num">(408)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsNet', window );">Net carrying value</a></td>
<td class="nump">40,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_ToleranceTherapeuticsMember', window );">Tolerance Therapeutics (Tzield)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsGross', window );">Gross carrying value</a></td>
<td class="nump">25,613<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsAllowance', window );">Allowance</a></td>
<td class="num">(101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsNet', window );">Net carrying value</a></td>
<td class="nump">25,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,709<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_EnsifentrineMember', window );">Ensifentrine inventors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsGross', window );">Gross carrying value</a></td>
<td class="nump">15,969<span></span>
</td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsAllowance', window );">Allowance</a></td>
<td class="num">(157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsNet', window );">Net carrying value</a></td>
<td class="nump">15,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_ElutiaAndCorMatrixMember', window );">Elutia (CorMatrix)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsGross', window );">Gross carrying value</a></td>
<td class="nump">9,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,304<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsAllowance', window );">Allowance</a></td>
<td class="num">(2,268)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,490)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsNet', window );">Net carrying value</a></td>
<td class="nump">7,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_InvIOsMember', window );">InvIOs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsGross', window );">Gross carrying value</a></td>
<td class="nump">1,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsAllowance', window );">Allowance</a></td>
<td class="num">(62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsNet', window );">Net carrying value</a></td>
<td class="nump">1,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_SelexisMember', window );">Selexis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsGross', window );">Gross carrying value</a></td>
<td class="nump">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsAllowance', window );">Allowance</a></td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(179)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsNet', window );">Net carrying value</a></td>
<td class="nump">147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_OvidTherapeuticsMember', window );">Ovid (Soticlestat)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsGross', window );">Gross carrying value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsAllowance', window );">Allowance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(303)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsNet', window );">Net carrying value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,007<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinancialRoyaltyAssetsAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Royalty Assets, Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinancialRoyaltyAssetsAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinancialRoyaltyAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Royalty Assets, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinancialRoyaltyAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinancialRoyaltyAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Royalty Assets, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinancialRoyaltyAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinancialRoyaltyAssetsNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Royalty Assets, Net Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinancialRoyaltyAssetsNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_QARZIBAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_QARZIBAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_AgenusInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_AgenusInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_ToleranceTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_ToleranceTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_EnsifentrineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_EnsifentrineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_ElutiaAndCorMatrixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_ElutiaAndCorMatrixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_InvIOsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_InvIOsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_SelexisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_SelexisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_OvidTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_OvidTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719802376048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Royalty Assets, net (formerly known as Commercial License Rights) - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Jul. 15, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Oct. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ImpairmentLossOnFinancialRoyaltyAssets', window );">Impairment loss of financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,572,000<span></span>
</td>
<td class="nump">$ 924,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets', window );">Financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsGross', window );">Gross carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,587,000<span></span>
</td>
<td class="nump">70,364,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_ToleranceTherapeuticsMember', window );">Tolerance Therapeutics (Tzield)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash payments for acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_APEIRONMember', window );">APEIRON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets', window );">Financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,156,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,109,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_InvIOsMember', window );">InvIOs | APEIRON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets', window );">Financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_QARZIBAMember', window );">Qarziba | APEIRON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets', window );">Financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_OvidTherapeuticsMember', window );">Ovid (Soticlestat)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ImpairmentLossOnFinancialRoyaltyAssets', window );">Impairment loss of financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsGross', window );">Gross carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,310,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_OvidTherapeuticsMember', window );">Ovid (Soticlestat) | Soticlestat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone', window );">Consideration paid for an interest in potential development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_SalesContractInterestInSalesRevenue', window );">Interest in sales revenue (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_SelexisMember', window );">Selexis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ImpairmentLossOnFinancialRoyaltyAssets', window );">Impairment loss of financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsGross', window );">Gross carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,000<span></span>
</td>
<td class="nump">940,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_ElutiaAndCorMatrixMember', window );">Elutia (CorMatrix)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ProductRoyaltyPercentage', window );">Product royalty (as a percent)</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsGross', window );">Gross carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,418,000<span></span>
</td>
<td class="nump">13,304,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Proceeds from royalties received</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CommercialLicenseRightsCreditLossAdjustment', window );">(Reduction) credit loss adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,200,000)<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_ElutiaAndCorMatrixMember', window );">Elutia (CorMatrix) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones', window );">Additional royalties receivable under sales-based milestones</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_EnsifentrineMember', window );">Ensifentrine inventors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsGross', window );">Gross carrying value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,969,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Royalties Receivable Under Sales-based Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CommercialLicenseRightsCreditLossAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial License Rights, Credit Loss Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CommercialLicenseRightsCreditLossAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration Paid For An Interest In Potential Development Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinancialRoyaltyAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Royalty Assets, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinancialRoyaltyAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ImpairmentLossOnFinancialRoyaltyAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment Loss On Financial Royalty Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ImpairmentLossOnFinancialRoyaltyAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ProductRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product Royalty Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ProductRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_SalesContractInterestInSalesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Contract, Interest In Sales Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_SalesContractInterestInSalesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_ToleranceTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_ToleranceTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_APEIRONMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_APEIRONMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_InvIOsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_InvIOsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_QARZIBAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_QARZIBAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_OvidTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_OvidTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_SoticlestatMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_SoticlestatMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_SelexisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_SelexisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_ElutiaAndCorMatrixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_ElutiaAndCorMatrixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_EnsifentrineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_EnsifentrineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719800780352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Investment Categories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">$ 150,187<span></span>
</td>
<td class="nump">$ 120,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(6,626)<span></span>
</td>
<td class="num">(5,783)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">143,618<span></span>
</td>
<td class="nump">115,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">78,442<span></span>
</td>
<td class="nump">6,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">78,448<span></span>
</td>
<td class="nump">6,751<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember', window );">Bond fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(537)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,226<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">23,483<span></span>
</td>
<td class="nump">11,578<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">23,482<span></span>
</td>
<td class="nump">11,586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DemandDepositsMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">22,812<span></span>
</td>
<td class="nump">17,165<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">22,820<span></span>
</td>
<td class="nump">17,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">15,496<span></span>
</td>
<td class="nump">14,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">15,509<span></span>
</td>
<td class="nump">14,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember', window );">Corporate equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="nump">9,954<span></span>
</td>
<td class="nump">5,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(6,595)<span></span>
</td>
<td class="num">(5,235)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="nump">$ 3,359<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,003<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MutualFundMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DemandDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DemandDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719799361152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Within one year</a></td>
<td class="nump">$ 127,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">After one year through five years</a></td>
<td class="nump">12,937<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total</a></td>
<td class="nump">140,233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Within one year</a></td>
<td class="nump">127,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">After one year through five years</a></td>
<td class="nump">12,928<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total</a></td>
<td class="nump">$ 140,259<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-5<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719799459936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">$ (15)<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">46,370<span></span>
</td>
<td class="nump">17,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">7,790<span></span>
</td>
<td class="nump">2,949<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">54,160<span></span>
</td>
<td class="nump">20,758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DemandDepositsMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">6,195<span></span>
</td>
<td class="nump">4,175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">6,195<span></span>
</td>
<td class="nump">4,175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate notes/bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">866<span></span>
</td>
<td class="nump">1,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">3,026<span></span>
</td>
<td class="nump">1,447<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">3,892<span></span>
</td>
<td class="nump">2,857<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">9,344<span></span>
</td>
<td class="nump">10,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">9,344<span></span>
</td>
<td class="nump">10,222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember', window );">U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Gross Unrealized Losses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">Less than 12 months</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">12 months or greater</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">Less than 12 months</a></td>
<td class="nump">29,965<span></span>
</td>
<td class="nump">998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">12 months or greater</a></td>
<td class="nump">4,764<span></span>
</td>
<td class="nump">1,502<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total</a></td>
<td class="nump">$ 34,729<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479081/326-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DemandDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DemandDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719809615552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>position </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 16, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of positions in an unrealized loss position | position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Unrealized losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DebtSecuritiesAvailableForSaleAmortization', window );">Amortized cost</a></td>
<td class="nump">$ 50,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff', window );">Credit losses related to available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,200,000<span></span>
</td>
<td class="nump">32,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain from short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,024,000<span></span>
</td>
<td class="nump">46,365,000<span></span>
</td>
<td class="nump">$ 28,540,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization of intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,959,000<span></span>
</td>
<td class="nump">33,654,000<span></span>
</td>
<td class="nump">34,237,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated amortization expense for 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated amortization expense for 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated amortization expense for 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated amortization expense for 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Estimated amortization expense for 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment loss of financial royalty assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Fair value adjustments to partner program derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,055,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Received amount expended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,425,000<span></span>
</td>
<td class="nump">$ 24,537,000<span></span>
</td>
<td class="nump">$ 36,082,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsNetCurrent', window );">Financial royalty liability current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lgnd_VikingsMember', window );">Vikings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Vikings common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3095<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,524<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lgnd_OtherDerivativesMember', window );">Other Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Fair value adjustments to partner program derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lgnd_CollarsMember', window );">Collars | Vikings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Fair value adjustments to partner program derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PrimroseBioMember', window );">Primrose Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Fair value adjustments to partner program derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetNoncurrent', window );">Convertible note</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AccountsReceivableTerm', window );">Convertible note maturity period (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount', window );">Preferred stock shares, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued', window );">Shares issued upon conversion of preferred stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice', window );">Debt conversion price per share (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.9965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember', window );">Palvella | Royalty Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones', window );">Additional royalties receivable under sales-based milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Received amount expended</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusInc.Member', window );">Agenus, Inc. | Partner Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Fair value adjustments to partner program derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_OwnershipAxis=lgnd_VikingTherapeuticsInc.Member', window );">Viking Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_NumberOfSharesSoldOfEquityMethodInvestee', window );">Stock sold of equity method investee (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">5,000,000.0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain from short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="nump">$ 44,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Palvella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_SalesContractInterestInSalesRevenue', window );">Interest in sales revenue (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Palvella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_SalesContractInterestInSalesRevenue', window );">Interest in sales revenue (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, after Allowance for Credit Loss, Converted Instrument Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, after Allowance for Credit Loss, Converted Instrument , Conversion Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, after Allowance for Credit Loss, Converted Instrument Shares Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccountsReceivableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccountsReceivableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Royalties Receivable Under Sales-based Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DebtSecuritiesAvailableForSaleAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Amortization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DebtSecuritiesAvailableForSaleAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinancialRoyaltyAssetsNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Royalty Assets, Net Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinancialRoyaltyAssetsNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfSharesSoldOfEquityMethodInvestee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Shares Sold Of Equity Method Investee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfSharesSoldOfEquityMethodInvestee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_SalesContractInterestInSalesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales Contract, Interest In Sales Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_SalesContractInterestInSalesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of writeoff of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479106/326-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column B)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B)(Footnote 10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lgnd_VikingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lgnd_VikingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lgnd_OtherDerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lgnd_OtherDerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lgnd_CollarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lgnd_CollarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_PrimroseBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_PrimroseBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_PalvellaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_RoyaltyAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_AgenusInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_AgenusInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lgnd_PartnerProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lgnd_PartnerProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=lgnd_VikingTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=lgnd_VikingTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719936369248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">$ 23,401<span></span>
</td>
<td class="nump">$ 22,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(8,268)<span></span>
</td>
<td class="num">(6,655)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">15,133<span></span>
</td>
<td class="nump">15,607<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Lab and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">6,868<span></span>
</td>
<td class="nump">7,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">10,464<span></span>
</td>
<td class="nump">10,363<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lgnd_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">1,850<span></span>
</td>
<td class="nump">716<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment , gross</a></td>
<td class="nump">$ 4,219<span></span>
</td>
<td class="nump">$ 4,115<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=lgnd_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=lgnd_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719800461120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 105,250<span></span>
</td>
<td class="nump">$ 103,370<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Total goodwill and other identifiable intangible assets, net</a></td>
<td class="nump">371,898<span></span>
</td>
<td class="nump">402,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentedTechnologyMember', window );">Completed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="nump">39,249<span></span>
</td>
<td class="nump">42,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(19,710)<span></span>
</td>
<td class="num">(20,894)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="nump">2,642<span></span>
</td>
<td class="nump">2,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(1,843)<span></span>
</td>
<td class="num">(1,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="nump">29,600<span></span>
</td>
<td class="nump">29,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">(20,652)<span></span>
</td>
<td class="num">(19,161)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember', window );">Contractual relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Definite-lived intangible assets</a></td>
<td class="nump">360,000<span></span>
</td>
<td class="nump">360,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less: Accumulated amortization</a></td>
<td class="num">$ (122,638)<span></span>
</td>
<td class="num">$ (93,782)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719799902368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details - Schedule of Derivative Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 18, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Total noncurrent derivative assets</a></td>
<td class="nump">$ 10,583<span></span>
</td>
<td class="nump">$ 3,531<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_PrimroseBioMember', window );">Primrose Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Total noncurrent derivative assets</a></td>
<td class="nump">3,451<span></span>
</td>
<td class="nump">3,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=lgnd_PartnerProgramsMember', window );">Partner Programs | Agenus, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Total noncurrent derivative assets</a></td>
<td class="nump">6,326<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option | Agenus, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Total noncurrent derivative assets</a></td>
<td class="nump">$ 806<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Derivative, term of contract (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_PrimroseBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_PrimroseBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=lgnd_PartnerProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=lgnd_PartnerProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_AgenusInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_AgenusInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719802557312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Other Investment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Summary of Investment Holdings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Total other investments</a></td>
<td class="nump">$ 10,908<span></span>
</td>
<td class="nump">$ 10,908<span></span>
</td>
<td class="nump">$ 36,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities | Primrose Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Summary of Investment Holdings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Total other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,712<span></span>
</td>
<td class="nump">32,726<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember', window );">Equity Securities | InvIOs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Summary of Investment Holdings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Total other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,196<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember', window );">Neuritek warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Summary of Investment Holdings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Total other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_PreferredStockMember', window );">Palvella Series C preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfInvestmentHoldingsLineItems', window );"><strong>Summary of Investment Holdings</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherInvestments', window );">Total other investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfInvestmentHoldingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478297/946-220-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfInvestmentHoldingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lgnd_PrimroseBioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lgnd_PrimroseBioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lgnd_InvIOsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lgnd_InvIOsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719802100720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Inventory in Other Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total Pelthos inventory in other current assets</a></td>
<td class="nump">$ 14,114<span></span>
</td>
<td class="nump">$ 23,969<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PublicUtilitiesInventoryAxis=lgnd_ZelsuvmiMember', window );">Zelsuvmi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">3,923<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">603<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total Pelthos inventory in other current assets</a></td>
<td class="nump">$ 4,526<span></span>
</td>
<td class="nump">$ 615<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PublicUtilitiesInventoryAxis=lgnd_ZelsuvmiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PublicUtilitiesInventoryAxis=lgnd_ZelsuvmiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719803247680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Royalties owed to third parties</a></td>
<td class="nump">$ 6,500<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Compensation</a></td>
<td class="nump">5,522<span></span>
</td>
<td class="nump">4,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ValueAddedTaxReceivableNetCurrent', window );">UK value-added tax</a></td>
<td class="nump">5,159<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">4,858<span></span>
</td>
<td class="nump">2,394<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AccruedSubcontractorExpensesCurrent', window );">Subcontractor</a></td>
<td class="nump">1,756<span></span>
</td>
<td class="nump">1,756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AccruedCustomerDepositsCurrent', window );">Customer deposit</a></td>
<td class="nump">621<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_AccruedSupplierExpensesCurrent', window );">Supplier</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_LicenseeAccrualCurrent', window );">Amounts owed to former licensees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">3,490<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 27,906<span></span>
</td>
<td class="nump">$ 12,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedCustomerDepositsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Customer Deposits, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedCustomerDepositsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedSubcontractorExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Subcontractor Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedSubcontractorExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_AccruedSupplierExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Supplier Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_AccruedSupplierExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LicenseeAccrualCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensee Accrual, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LicenseeAccrualCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Balance Sheet Details [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ValueAddedTaxReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value Added Tax Receivable Net, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ValueAddedTaxReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719800021456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Account Details - Contingent Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights, beginning of period</a></td>
<td class="nump">$ 3,198<span></span>
</td>
<td class="nump">$ 3,513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="nump">683<span></span>
</td>
<td class="num">(265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights, end of period</a></td>
<td class="nump">3,681<span></span>
</td>
<td class="nump">3,198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_CydexPharmaceuticalsIncMember', window );">Cydex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights, beginning of period</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights, end of period</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">320<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember', window );">Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ContingentLiabilityRollForward', window );"><strong>Contingent Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights, beginning of period</a></td>
<td class="nump">2,878<span></span>
</td>
<td class="nump">3,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities', window );">Fair Value Adjustment</a></td>
<td class="nump">420<span></span>
</td>
<td class="num">(551)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod', window );">Commercial rights, end of period</a></td>
<td class="nump">$ 3,298<span></span>
</td>
<td class="nump">$ 2,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Contingent Consideration Potential Cash Payment at End of Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ContingentLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ContingentLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToContingentValueRightHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to contingent value right holders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToContingentValueRightHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_CydexPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_CydexPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719800504112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Account Details - Other Long-term Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_OtherBalanceSheetDetailsAbstract', window );"><strong>Other Balance Sheet Details [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Novan (Pelthos) contract liability</a></td>
<td class="nump">$ 15,938<span></span>
</td>
<td class="nump">$ 13,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_UnrecognizedTaxBenefitsNoncurrent', window );">Unrecognized tax benefits</a></td>
<td class="nump">14,160<span></span>
</td>
<td class="nump">14,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total other long-term liabilities</a></td>
<td class="nump">$ 30,163<span></span>
</td>
<td class="nump">$ 27,758<span></span>
</td>
<td class="nump">$ 27,758<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OtherBalanceSheetDetailsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Balance Sheet Details [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OtherBalanceSheetDetailsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_UnrecognizedTaxBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits - Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_UnrecognizedTaxBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719809625168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2010 </div>
<div>cvr</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 18, 2023 </div>
<div>contract</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag', window );">Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Derivative assets(2)<span></span>
</td>
<td class="text">Derivative assets(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_NumberOfContingentValueRightsSeries', window );">Number of CVR Series | cvr</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusPartneredProgramMember', window );">Agenus Partnered Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_MilestoneCompensationRate', window );">Percentage of milestones (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=lgnd_AgenusPartneredProgramMember', window );">Agenus Partnered Program | Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetMeasurementInput', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByIndustryAxis=lgnd_PrimordialGeneticsMember', window );">Primordial Genetics | Agenus Partnered Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_NumberOfContracts', window );">Number of contracts | contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember', window );">Transferred over Time | Phase 3 clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGross', window );">Gross contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Agenus Partnered Program | Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetMeasurementInput', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Transferred over Time | Development, regulatory, &amp; commercial milestones and tiered royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Investments', window );">Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 375,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Agenus Partnered Program | Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetMeasurementInput', window );">Discount rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisMember', window );">Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare', window );">Number of CVRs issued per acquiree share | cvr</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries', window );">Number of CVRs issued from each CVR series | cvr</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders', window );">Frequency of cash payments to CVR holders</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,240,000<span></span>
</td>
<td class="nump">32,185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,583,000<span></span>
</td>
<td class="nump">3,531,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,441,000<span></span>
</td>
<td class="nump">150,886,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,681,000<span></span>
</td>
<td class="nump">3,198,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,618,000<span></span>
</td>
<td class="nump">115,170,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Contingent liabilities | CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,000<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Contingent liabilities | Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,298,000<span></span>
</td>
<td class="nump">2,878,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,240,000<span></span>
</td>
<td class="nump">32,185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122,047,000<span></span>
</td>
<td class="nump">39,476,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;1 | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,807,000<span></span>
</td>
<td class="nump">7,291,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;1 | Contingent liabilities | CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;1 | Contingent liabilities | Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,811,000<span></span>
</td>
<td class="nump">107,879,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,298,000<span></span>
</td>
<td class="nump">2,878,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2 | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,811,000<span></span>
</td>
<td class="nump">107,879,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2 | Contingent liabilities | CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;2 | Contingent liabilities | Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,298,000<span></span>
</td>
<td class="nump">2,878,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent', window );">Investment in Viking common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,583,000<span></span>
</td>
<td class="nump">3,531,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,583,000<span></span>
</td>
<td class="nump">3,531,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;3 | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;3 | Contingent liabilities | CyDex</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,000<span></span>
</td>
<td class="nump">320,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Level&#160;3 | Contingent liabilities | Metabasis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration, Liability, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Frequency of Cash Payments to Contingent Value Rights Holders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Number of Contingent Value Rights Issued from Each Contingent Value Right Series</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Number of Contingent Value Rights Issued per Acquiree Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_MilestoneCompensationRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Compensation Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_MilestoneCompensationRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfContingentValueRightsSeries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Contingent Value Rights Series</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfContingentValueRightsSeries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_NumberOfContracts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_NumberOfContracts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479319/326-20-50-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H)(Footnote 7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column H))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 30: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(h))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=lgnd_AgenusPartneredProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=lgnd_AgenusPartneredProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByIndustryAxis=lgnd_PrimordialGeneticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByIndustryAxis=lgnd_PrimordialGeneticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TimingOfTransferOfGoodOrServiceAxis=us-gaap_TransferredOverTimeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_Phase3ClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_Phase3ClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=lgnd_ContingentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=lgnd_ContingentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=lgnd_CyDexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=lgnd_CyDexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719808763040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Beginning balance</a></td>
<td class="nump">$ 3,531<span></span>
</td>
<td class="nump">$ 135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases', window );">Additions to derivative assets</a></td>
<td class="nump">35,888<span></span>
</td>
<td class="nump">3,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustments to equity security warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1', window );">Fair value adjustments to derivative assets</a></td>
<td class="num">(20,010)<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Exercise of derivative assets</a></td>
<td class="num">(8,826)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Ending balance</a></td>
<td class="nump">$ 10,583<span></span>
</td>
<td class="nump">$ 3,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Gain from short-term investments<span></span>
</td>
<td class="text">Gain from short-term investments<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">$ 84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsToContingentValueRightHolders', window );">Payments to CVR holders and other contingent payments</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Fair value adjustments to contingent liabilities</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 383<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList', window );">Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Non-Cash Change In Estimated Fair Value Of Contingent Value Rights<span></span>
</td>
<td class="text">Non-Cash Change In Estimated Fair Value Of Contingent Value Rights<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsToContingentValueRightHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments to contingent value right holders</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsToContingentValueRightHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 102<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-102<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from asset measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719801654176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Tangible asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill and intangible asset impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetMeasurementInput', window );">Financial royalty assets, measurement input (percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetMeasurementInput', window );">Financial royalty assets, measurement input (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimate of Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Other liabilities, fair value disclosure</a></td>
<td class="nump">$ 19,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsFairValueDisclosure', window );">Financial royalty assets, fair value disclosure</a></td>
<td class="nump">196,600,000<span></span>
</td>
<td class="nump">$ 75,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Reported Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesFairValueDisclosure', window );">Other liabilities, fair value disclosure</a></td>
<td class="nump">15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinancialRoyaltyAssetsFairValueDisclosure', window );">Financial royalty assets, fair value disclosure</a></td>
<td class="nump">$ 195,000,000<span></span>
</td>
<td class="nump">$ 62,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinancialRoyaltyAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Royalty Asset, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinancialRoyaltyAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinancialRoyaltyAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Financial Royalty Assets, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinancialRoyaltyAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719803030496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">$ 2,766<span></span>
</td>
<td class="nump">$ 3,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification', window );">Increase in operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Increase in operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term of operating leases</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate of operating leases (as a percent)</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease payments</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term of finance leases</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate of finance leases (as a percent)</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Cash paid for amounts included in finance lease liabilities</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Finance lease expense</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=lgnd_OfficeInBostonMassachusettsMember', window );">Office in Boston, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification', window );">Increase in operating lease assets</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Increase in operating lease liability</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=lgnd_OfficeInJupiterFloridaMember', window );">Office in Jupiter, Florida</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification', window );">Increase in operating lease assets</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Increase in operating lease liability</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term of operating leases</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember', window );">Captisol</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PurchaseCommitmentConsiderationPaidToDate', window );">Consideration paid to date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory', window );">Portion of consideration allocated to inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Right-of-use asset recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseImpairmentLoss', window );">Finance lease, impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">3,400<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term of finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Increase (Decrease) In Operating Lease Assets Due To Modification</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Commitment, Consideration Paid, Allocated to Inventory</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PurchaseCommitmentConsiderationPaidToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase Commitment, Consideration Paid to Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PurchaseCommitmentConsiderationPaidToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479365/842-20-25-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=lgnd_OfficeInBostonMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=lgnd_OfficeInBostonMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=lgnd_OfficeInJupiterFloridaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=lgnd_OfficeInJupiterFloridaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=lgnd_MaterialSalesCaptisolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719799880560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Operating and Finance Lease Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 6,907<span></span>
</td>
<td class="nump">$ 6,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease assets</a></td>
<td class="nump">2,766<span></span>
</td>
<td class="nump">3,393<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_LeaseRightOfUseAsset', window );">Total lease assets</a></td>
<td class="nump">9,673<span></span>
</td>
<td class="nump">9,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">1,266<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current finance lease liabilities</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_LeaseLiabilityCurrent', window );">Current lease liabilities</a></td>
<td class="nump">1,290<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">5,815<span></span>
</td>
<td class="nump">5,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease liabilities</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_LeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 7,154<span></span>
</td>
<td class="nump">$ 6,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_LeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Right-of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_LeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719799258784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Operating and Finance Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 1,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">1,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">1,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">1,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">1,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">2,005<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">9,482<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance', window );">Less tenant improvement allowance</a></td>
<td class="num">(418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(1,983)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">7,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance', window );">Less tenant improvement allowance</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 73<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_FinanceLeaseLiabilityTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, Tenant Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_FinanceLeaseLiabilityTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_OperatingLeaseLiabilityTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Liability, Tenant Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_OperatingLeaseLiabilityTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719801356064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 12, 2023</div></th>
<th class="th"><div>May 15, 2023</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jul. 08, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 76,854,000<span></span>
</td>
<td class="nump">$ 260,949,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss (gain) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,192,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit facility, interest rate (as a percent)</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Minimum | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate (as a percent)</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Minimum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate (as a percent)</a></td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit facility, interest rate (as a percent)</a></td>
<td class="nump">0.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Maximum | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate (as a percent)</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Maximum | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate (as a percent)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Revolving Credit Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Available borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,400,000<span></span>
</td>
<td class="nump">74,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2023Member', window );">2023 Convertible Senior Notes | Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest on debt instrument (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of 2023 notes outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds from debt issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">733,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Term of debt instrument (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Accrued interest portion of repurchased amount of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Contractual interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Repurchased amount of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss (gain) on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_IncreaseDecreaseInDebtDiscount', window );">Reduction in debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued in public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,018,327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt conversion price per share (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_PaymentsforConvertibleBondHedges', window );">Payments for convertible bond hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 315.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrant derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2023Member', window );">2023 Convertible Senior Notes | Convertible Notes | Notes Repurchased During Current Period, Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayments of notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod', window );">Repurchased amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 227,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DebtInstrumentRepurchasedAmountDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Repurchased Amount During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DebtInstrumentRepurchasedAmountDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_IncreaseDecreaseInDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Debt Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_IncreaseDecreaseInDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_PaymentsforConvertibleBondHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments for Convertible Bond Hedges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_PaymentsforConvertibleBondHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=lgnd_ConvertibleSeniorNotesDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719803939904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Share-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based compensation expense</a></td>
<td class="nump">$ 41,089<span></span>
</td>
<td class="nump">$ 25,743<span></span>
</td>
<td class="nump">$ 50,881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based compensation expense</a></td>
<td class="nump">3,544<span></span>
</td>
<td class="nump">6,248<span></span>
</td>
<td class="nump">10,970<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based compensation expense</a></td>
<td class="nump">$ 37,545<span></span>
</td>
<td class="nump">$ 19,495<span></span>
</td>
<td class="nump">$ 39,911<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719802509600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jul. 29, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share of stock options (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.81<span></span>
</td>
<td class="nump">$ 36.65<span></span>
</td>
<td class="nump">$ 28.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,600,000<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CorporateShareRepurchaseAbstract', window );"><strong>Corporate Share Repurchase</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares repurchased in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=lgnd_AtTheMarketEquityOfferingMember', window );">At-The-Market Equity Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_CorporateShareRepurchaseAbstract', window );"><strong>Corporate Share Repurchase</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_SaleOfStockAuthorizedOfferingAmount', window );">Sale of stock, authorized offering amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">360,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Common stock aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Cash received from options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,200,000<span></span>
</td>
<td class="nump">$ 22,200,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember', window );">2002 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period in which cost is expected to be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember', window );">2002 Stock Incentive Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Increase the number of shares under the 2002 Stock Incentive Plan (in shares)</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future option grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember', window );">2002 Stock Incentive Plan | Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period in which cost is expected to be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost, restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lgnd_OmniabSeparationMember', window );">Omniab Separation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period in which cost is expected to be recognized (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=lgnd_AmendedESPPMember', window );">Amended ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future option grants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_EmployeeStockPurchasePlanAbstract', window );"><strong>Employee Stock Purchase Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee', window );">Shares allowed to purchase in employee stock purchase plan per employee (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Proportion of fair market value of common stock at which stock is purchased under ESPP (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_ShareBasedCompensationInitialOfferingPeriod', window );">Initial offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock issued under amended ESSP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,308<span></span>
</td>
<td class="nump">5,080<span></span>
</td>
<td class="nump">8,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_CorporateShareRepurchaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Corporate Share Repurchase [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_CorporateShareRepurchaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EmployeeStockPurchasePlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EmployeeStockPurchasePlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_SaleOfStockAuthorizedOfferingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Authorized Offering Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_SaleOfStockAuthorizedOfferingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_ShareBasedCompensationInitialOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation, Initial Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_ShareBasedCompensationInitialOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The highest quantity of shares an employee can purchase under the plan per period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=lgnd_AtTheMarketEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=lgnd_AtTheMarketEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lgnd_TwoThousandTwoStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lgnd_OmniabSeparationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lgnd_OmniabSeparationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=lgnd_AmendedESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=lgnd_AmendedESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719916043808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Option Plan Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at beginning of period (in shares)</a></td>
<td class="nump">2,987,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,199,598<span></span>
</td>
<td class="nump">2,640,458<span></span>
</td>
<td class="nump">2,991,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,584,760<span></span>
</td>
<td class="nump">863,245<span></span>
</td>
<td class="nump">783,064<span></span>
</td>
<td class="nump">537,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,449)<span></span>
</td>
<td class="num">(34,941)<span></span>
</td>
<td class="num">(1,080,135)<span></span>
</td>
<td class="num">(489,076)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(2,987,833)<span></span>
</td>
<td class="num">(542,838)<span></span>
</td>
<td class="num">(40,069)<span></span>
</td>
<td class="num">(117,114)<span></span>
</td>
<td class="num">(399,371)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,991,473<span></span>
</td>
<td class="nump">2,987,833<span></span>
</td>
<td class="nump">2,226,273<span></span>
</td>
<td class="nump">2,640,458<span></span>
</td>
<td class="nump">2,199,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,559,662<span></span>
</td>
<td class="nump">1,769,629<span></span>
</td>
<td class="nump">1,229,294<span></span>
</td>
<td class="nump">1,784,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest at end of period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,991,473<span></span>
</td>
<td class="nump">2,987,833<span></span>
</td>
<td class="nump">2,226,273<span></span>
</td>
<td class="nump">2,640,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at beginning of period (in USD per share)</a></td>
<td class="nump">$ 102.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106.00<span></span>
</td>
<td class="nump">$ 65.70<span></span>
</td>
<td class="nump">$ 61.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.10<span></span>
</td>
<td class="nump">91.34<span></span>
</td>
<td class="nump">86.91<span></span>
</td>
<td class="nump">72.69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.24<span></span>
</td>
<td class="nump">38.56<span></span>
</td>
<td class="nump">60.64<span></span>
</td>
<td class="nump">45.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.20<span></span>
</td>
<td class="nump">78.46<span></span>
</td>
<td class="nump">74.58<span></span>
</td>
<td class="nump">66.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at end of period (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61.31<span></span>
</td>
<td class="nump">102.92<span></span>
</td>
<td class="nump">75.14<span></span>
</td>
<td class="nump">65.70<span></span>
</td>
<td class="nump">$ 106.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.83<span></span>
</td>
<td class="nump">102.38<span></span>
</td>
<td class="nump">72.15<span></span>
</td>
<td class="nump">64.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest at end of period (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.31<span></span>
</td>
<td class="nump">$ 102.92<span></span>
</td>
<td class="nump">$ 75.14<span></span>
</td>
<td class="nump">$ 65.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term in Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 25 days<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">6 years 6 months 29 days<span></span>
</td>
<td class="text">5 years 7 months 17 days<span></span>
</td>
<td class="text">6 years 4 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, exercisable (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months 3 days<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">5 years 7 days<span></span>
</td>
<td class="text">4 years 3 months 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, vested and expected to vest (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 25 days<span></span>
</td>
<td class="text">0 years<span></span>
</td>
<td class="text">6 years 6 months 29 days<span></span>
</td>
<td class="text">5 years 7 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value (In thousands)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,477<span></span>
</td>
<td class="nump">$ 14,835<span></span>
</td>
<td class="nump">$ 71,538<span></span>
</td>
<td class="nump">$ 8,784<span></span>
</td>
<td class="nump">$ 113,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,951<span></span>
</td>
<td class="nump">13,722<span></span>
</td>
<td class="nump">43,120<span></span>
</td>
<td class="nump">7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,477<span></span>
</td>
<td class="nump">$ 14,835<span></span>
</td>
<td class="nump">$ 71,538<span></span>
</td>
<td class="nump">$ 8,784<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719802391040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Breakdown of Options Outstanding (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">2,226,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">6 years 6 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 75.14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">1,229,294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 72.15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeOneMember', window );">$32.78-$52.84</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">32.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 52.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">281,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">5 years 9 months 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 49.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">195,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 48.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTwoMember', window );">$54.81-$63.62</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">54.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 63.62<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">228,498<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 58.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">191,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 58.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeThreeMember', window );">$64.65-$68.74</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">64.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 68.74<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">312,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">5 years 1 month 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 67.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">245,199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 67.67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFourMember', window );">$69.39-$73.76</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">69.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 73.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">233,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">7 years 7 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 70.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">125,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 71.02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFiveMember', window );">$73.92-$75.09</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">73.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 75.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">288,134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">7 years 8 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 74.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">105,797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 74.88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSixMember', window );">$78.56-$88.27</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">78.56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 88.27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">155,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">8 years 6 months 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 82.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">32,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 81.71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSevenMember', window );">89.2</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">89.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 89.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">444,229<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">8 years 4 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 89.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">103,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 89.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeEightMember', window );">$89.86-$103.42</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">89.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 103.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">244,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">4 years 7 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 98.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">218,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 98.24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeNineMember', window );">$104.30-$114.15</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">104.30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 114.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">28,290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">6 years 8 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 110.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">12,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 114.15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTenMember', window );">$122.70-$122.70</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower range of exercise prices (in USD per share)</a></td>
<td class="nump">122.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper range of exercise prices (in USD per share)</a></td>
<td class="nump">$ 122.70<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in shares) | shares</a></td>
<td class="nump">10,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining life in years</a></td>
<td class="text">9 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 122.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Weighted average exercise price (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=lgnd_ExercisePriceRangeTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719802542528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
<td class="text">4 years 8 months 12 days<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (as a percent)</a></td>
<td class="nump">46.00%<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719804158960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Restricted Stock Activity (Details) - Restricted stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">350,905<span></span>
</td>
<td class="nump">348,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">318,588<span></span>
</td>
<td class="nump">203,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(167,308)<span></span>
</td>
<td class="num">(181,246)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(64,313)<span></span>
</td>
<td class="num">(20,054)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">437,872<span></span>
</td>
<td class="nump">350,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant&#160;Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at beginning of period (in USD per share)</a></td>
<td class="nump">$ 81.22<span></span>
</td>
<td class="nump">$ 75.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in USD per share)</a></td>
<td class="nump">85.23<span></span>
</td>
<td class="nump">83.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in USD per share)</a></td>
<td class="nump">84.28<span></span>
</td>
<td class="nump">74.62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in USD per share)</a></td>
<td class="nump">77.28<span></span>
</td>
<td class="nump">65.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding at end of period (in USD per share)</a></td>
<td class="nump">$ 83.55<span></span>
</td>
<td class="nump">$ 81.22<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719806000496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies: Legal Proceedings - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>complaint</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember', window );">US District Court for the Northern District of Ohio</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of civil complaints filed against entity</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719918647216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Before Income Tax From Continuing Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income tax from continuing operations</a></td>
<td class="nump">$ 2,518<span></span>
</td>
<td class="nump">$ 63,660<span></span>
</td>
<td class="nump">$ 36,011<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income tax from continuing operations</a></td>
<td class="num">(25,855)<span></span>
</td>
<td class="nump">62,140<span></span>
</td>
<td class="nump">33,339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income tax from continuing operations</a></td>
<td class="nump">$ 28,373<span></span>
</td>
<td class="nump">$ 1,520<span></span>
</td>
<td class="nump">$ 2,672<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719798126000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 18,277<span></span>
</td>
<td class="num">$ (1,186)<span></span>
</td>
<td class="nump">$ 10,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">718<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">3,355<span></span>
</td>
<td class="nump">780<span></span>
</td>
<td class="nump">452<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current expense (benefit)</a></td>
<td class="nump">22,350<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="nump">10,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred expense (benefit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(17,767)<span></span>
</td>
<td class="nump">9,374<span></span>
</td>
<td class="num">(3,656)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">655<span></span>
</td>
<td class="nump">34,144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">1,890<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred expense (benefit)</a></td>
<td class="num">(15,800)<span></span>
</td>
<td class="nump">10,029<span></span>
</td>
<td class="nump">30,488<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense (benefit)</a></td>
<td class="nump">$ 6,550<span></span>
</td>
<td class="nump">$ 9,841<span></span>
</td>
<td class="nump">$ 41,230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719799095440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="nump">$ 529<span></span>
</td>
<td class="nump">$ 13,448<span></span>
</td>
<td class="nump">$ 7,562<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome', window );">Subpart F income</a></td>
<td class="nump">5,649<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="nump">853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount', window );">Officer compensation</a></td>
<td class="nump">3,921<span></span>
</td>
<td class="nump">844<span></span>
</td>
<td class="nump">5,869<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign tax differential on income/loss of foreign subsidiaries</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">602<span></span>
</td>
<td class="nump">1,241<span></span>
</td>
<td class="nump">1,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount', window );">Provision to return adjustments</a></td>
<td class="nump">293<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">2,232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Rate change for changes in federal, foreign or state law</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">342<span></span>
</td>
<td class="num">(535)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_IncomeTaxReconciliationContingentValueRights', window );">Contingent liabilities</a></td>
<td class="nump">88<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions', window );">Change in uncertain tax positions</a></td>
<td class="nump">94<span></span>
</td>
<td class="num">(7,206)<span></span>
</td>
<td class="num">(158)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount', window );">Debt repurchases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State, net of federal benefit</a></td>
<td class="num">(85)<span></span>
</td>
<td class="nump">397<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch', window );">Research and development credits</a></td>
<td class="num">(324)<span></span>
</td>
<td class="num">(405)<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount', window );">FDII</a></td>
<td class="num">(832)<span></span>
</td>
<td class="num">(1,037)<span></span>
</td>
<td class="num">(2,395)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(1,638)<span></span>
</td>
<td class="num">(1,184)<span></span>
</td>
<td class="nump">24,799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign', window );">Foreign tax credits</a></td>
<td class="num">(3,232)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">876<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax expense (benefit)</a></td>
<td class="nump">$ 6,550<span></span>
</td>
<td class="nump">$ 9,841<span></span>
</td>
<td class="nump">$ 41,230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Debt Repurchases, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Officer Compensation, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Other Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_IncomeTaxReconciliationContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Reconciliation, Contingent Value Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_IncomeTaxReconciliationContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax benefit from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719802115872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">$ 20.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">6.2<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">21.4<span></span>
</td>
<td class="nump">48.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">162.8<span></span>
</td>
<td class="nump">165.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction | California and New Jersey Research Tax Credit Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">29.5<span></span>
</td>
<td class="nump">29.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforward</a></td>
<td class="nump">98.4<span></span>
</td>
<td class="nump">95.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign | Capital Loss Carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward</a></td>
<td class="nump">$ 14.4<span></span>
</td>
<td class="nump">$ 16.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_CapitalLossCarryforwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719805977232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 40,385<span></span>
</td>
<td class="nump">$ 45,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Research credit carryforwards</a></td>
<td class="nump">24,404<span></span>
</td>
<td class="nump">26,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized R&amp;D</a></td>
<td class="nump">7,090<span></span>
</td>
<td class="nump">4,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">10,726<span></span>
</td>
<td class="nump">11,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">13,733<span></span>
</td>
<td class="nump">15,012<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">96,338<span></span>
</td>
<td class="nump">103,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(55,649)<span></span>
</td>
<td class="num">(57,699)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">40,689<span></span>
</td>
<td class="nump">46,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets', window );">Identified intangibles</a></td>
<td class="num">(69,150)<span></span>
</td>
<td class="num">(66,966)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="num">(3,991)<span></span>
</td>
<td class="num">(10,504)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">(73,141)<span></span>
</td>
<td class="num">(77,470)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred income taxes, net</a></td>
<td class="num">$ (32,452)<span></span>
</td>
<td class="num">$ (31,408)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Capitalized Research And Development</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Finite-Lived Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lgnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719799122576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at beginning of year</a></td>
<td class="nump">$ 22,363<span></span>
</td>
<td class="nump">$ 29,096<span></span>
</td>
<td class="nump">$ 29,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="nump">477<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(396)<span></span>
</td>
<td class="num">(6,783)<span></span>
</td>
<td class="num">(512)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at end of year</a></td>
<td class="nump">$ 22,471<span></span>
</td>
<td class="nump">$ 22,363<span></span>
</td>
<td class="nump">$ 29,096<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45719801807184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 24, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireNotesReceivable', window );">Payments to acquire notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivableWithImputedInterestFaceAmount', window );">Receivable with imputed interest</a></td>
<td class="nump">$ 8,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireNotesReceivable', window );">Payments to acquire notes</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | FCX-007</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive asset</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Purchasers | FCX-007</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive asset</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Other Purchasers | FCX-007</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive asset</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivableWithImputedInterestFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The principal amount of the receivable or note before consideration of the discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivableWithImputedInterestFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lgnd_FCX007Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=lgnd_FCX007Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lgnd_PurchasersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lgnd_PurchasersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=lgnd_OtherPurchasersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=lgnd_OtherPurchasersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>106
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M:%/X;EJ93@O2.IC]O1#Z:-@#NMZ=_0502P,$%     @ 0X!<6CG.K#7'!P
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M[.N4S.8XGI*++XLXOB0#\A1'Y.+=)7E'<D8>,[Z5E*5R9"H,2DN;21/ ;1V
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MR5*MN?JOJ:_UY-F2K-CR@>WE&B_.[<</H%-AZIHN2%.=;:@VH32O3P=\:,H
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MY[]?J/+-[F7O=WE5Y>O=QQ6+EZRH&_"_W^=Y]7VA?G_\\;\J7/T?4$L#!!0
M   ( $. 7%K;NK^C8 (  !(%   8    >&PO=V]R:W-H965T<R]S:&5E=#@N
M>&ULG51M;]HP$/XK5B;M1=J:$"B;.HC$6]6JI;!"-TU5/YCD(%8=.[6/TO[[
MG1W(F$3YL"^Q[WSWW/,X=^YLM'FT.0"RET(JVPURQ/(L#&V:0\'MB2Y!T<E2
MFX(CF685VM( SWQ2(<,XBMIAP84*DH[W34W2T6N40L'4,+LN"FY>^R#UIALT
M@IWC5JQR=(XPZ91\!3/ NW)JR IKE$P4H*S0BAE8=H->XZS?<O$^X*> C=W;
M,Z=DH?6C,RZS;A Y0B A18? :7F& 4CI@(C&TQ8SJ$NZQ/W]#OW<:R<M"VYA
MH.4OD6'>#;X%+(,E7TN\U9L+V.HY=7BIEM9_V::*;3<#EJXMZF*;3 P*H:J5
MOVSO82^A=?I&0KQ-B#WOJI!G.>3(DX[1&V9<-*&YC9?JLXF<4.ZGS-#0J: \
M3 :3F]GD^G+8FX^&;#:G93RZF;/).1F3P=7%Y'HXNIU]8*,?=Y?SW^SCE!M0
MF .*E,M/G1")@T,*TVV]?E4O?J->(V9C30"6C50&V;\ (9&O%<0[!?WX*.(0
MTA/6;'QF<10WCN UZQMI>KSF&W@SY C4=LCTDLU0IX^YEAD82Y?PM!;XRNY[
M"XN&^NGAD/X*O748W<W8F2UY"MV ALB">88@>?^NT8Z^'^'>JKFWCJ$GO335
M:X5"K8@Y5QDWF65W94:*V/WH!=TP+22P:V$/D_]_>+K]Z$O49O=C*!9@'@ZI
M"??ZM "S\M-HF0>M6K;VU@/?J_K\;WCU6HRY60EEF80EI48G7VE<3#6!E8&Z
M]%V_T$@SY+<Y/5I@7 "=+[7&G>$*U,]@\@=02P,$%     @ 0X!<6NLDA _<
M$   P&L  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6S%G6USG#@2Q[\*
MY=NZ2JIV8I 0#[G$5<Z0[+HJ&[OB[.YKS&@\7!B8 \8/^^E/8AZ$I$8,%WGO
M36*/FX9_2T@_M1KFW6-5?V]6E+;.T[HHF_=GJ[;=O#T_;[(57:?-FVI#2_:7
M956OTY;]6M^?-YN:IHONH'5QCEPW.%^G>7EV\:[[[*:^>%=MVR(OZ4WM--OU
M.JV?/]"B>GQ_YIT=/OB:WZ]:_L'YQ;M->D]O:?O[YJ9FOYT?O2SR-2V;O"J=
MFB[?GUUZ;Q//#?@1G<D?.7UL>C\[7,M=57WGOUPMWI^Y_))H0;.6^TC9?P]T
M3HN"NV(7\I^]U[/C2?F!_9\/WC]UZIF:N[2A\ZKX,U^TJ_=GT9FSH,MT6[1?
MJ\=?Z5X1X?ZRJFBZ?YW'O:U[YF3;IJW6^X/9%:SS<O=_^K2/1.\ +Q@X .T/
M0.H!_L !>'\ /O4 ?W^ WT5F)Z6+0Y*VZ<6[NGIT:F[-O/$?NF!V1S/Y><D;
M_K:MV5]S=EQ[,;_^<GO]^2JY_/8Q<6Z_L?]^^_CEVZUS_<F97][^ZGSZ?/WG
MK3-S?K]-G%<_O79^<O+2^;:JMDU:+IIWYRV[!N[I/-N?[\/N?&C@?!YR?JO*
M=M4X'\L%7<@.SMG%'Q6@@X(/R.@QH=D;!WL_.\A%/G!!\],/Q\#AR>F'(X,:
M?&P/W/G#0^V1-BMGR6['QEG6U=IA=WB=MGEYO[M#\C:GS5LH[#NW/NR6#Q]O
MFTV:T?=G;'QH:/U SR[^^0\O</\%A<RFL\22,RF<_C&<OLG[Q1<V=.9E5JVI
M\ZJHFN8U%+J=B[!SP0?*AXN9[V+6F@_]F.A6!'G$EZT2P!?&./".9I(,<I1!
MC+WB<O%O-A2P\;9MG+9B VY6E5E>4*=4]?$_\P\SWH\V=?60L[O,N7L^O2,1
MFQW)IK/$DC.I!8)C"P3&CO0+FT,=-D\U*8MZM71N:)%G:0D%<.<HZ'4!5^E*
MNL4,><A3NI+)CZ0A/&H(C1KFJ[2\IWP ITV;LSF3]8QEFM?.0UIL.U6L6_$N
MPOJ94^3I75YTW002&6H7%T18D:G;S%! %)6 4>A'L-#H*#0R"DTHZP%9GG9D
MP60M\R<F-6T:RNX?-F\YZ;JJV_ROHT%>MBPT^1UKVYT5)#G2KA03A&-%-& 5
M$*UM=2OB$>S#LN.C['B\CW:S1K-B^F8MK==,V@/=#QV0J%@/?Q#&KG*]<\#,
M#[#6F( 9BH@_T&\]5T"*:U1VV6NO\S3+:GIH.=;0ZWR[=EXM\B:KMF7[FM^E
M/=$_\^$0Y!17OU@/8U4Y;.9%BG+ S L&9/?8S#M9-A>[H'>M<Q#:=>2\:;9I
MF5%G2>'[='^&_G7Y4:!JU(V0[ZH*=:-PJ,=Z2$A$1HF?V:3EO+IG/;=KN 6M
M\X>4+P58&S9MO1WLN'N_TC6[KJ<.M8#9#!%-FVXUU&<%R'E&L#G.&%VCT2<^
MKF[S9L4%@7KPZ+0Q;I( )C/?B]& &(%1W@A'5>6L0XH];'2CS#(O6=_+T\*I
MJ^>T:)\-@^?>OW1AQ ]"52)@%H7:S098><%07Q20Y1D)XF+^<?[928^HQ5%J
MDD0"Q!Y[1)6HFV$2JR,I8#74(P7">&:&N5IOV&S?2>.LN)L9)^C3@02[)%0Y
M&3"+D8K)@-&0/$$WGAEO/E.V_I>G=OJTH65#034Z># &TT9&W<H+L=98NA7I
MS_FR($$QGAEC;E=I36<\J[%@9+;F4CI9H!R=*'S/C50Z <P0"7VL"M+- I?-
MY .*!*!X9D+AHSW=KVSI?[8YZV]KVJZJ16_&YGQZ4^?KNF*M^2&O0+4Z:'@H
M4BEK#IE%*%;%ZE8#?1$)8$%F8/DDL%H>4/K*G(9FV[I#[#%,0SI>L':+E(%Q
M#IBI,X311%8K. 69.26A2UK7='&8'=KTB0Z#%])!8N:1R%6G.\#.\X(X4 4!
M\.*&" ^($F2"S&1RW:YH#5Z_#@MA_WS[JP>LU,5" ACUH5J^<D$>:"2'U*WS
M>)_JK_K%ZJ>WM.L:B4\$:<9NQR;GP\O.B&'FIMI_ .8)D-6,DU5OB2UO<@,(
M6D)F6KK,.D)O>**&,IYEZ\KANP%@F< GZL -F:% 7:<E@!DAV(L'NI1 (V1&
MHRLV/)5M53^#$G16B0-/4P#@$9NA0FV TNT\Y)*!E  2](/,]-/=SP[/G%7K
MG!W!-P3@L78\@0.8S(BKCF")T9,L0U .,E/.L6]MTN>T2UCP? 9;$F_I8BQI
M@P":P;&K#5U 3L8/797A(#.,AQ;[2& /,F//56\2Z=U!G="]:% <@#986P\"
M5C,OC+3[2#?S2#AT&PG^06;^.4Z4-67WTQ;6 211/.QJ4[UNYJOW7 +Y"E T
M0*98X TVX\WN7H*G%'!S LB.H%C%-<!J%D=:D@DP"[ _L,3% F*P&6*^G)HU
M!P7J$!*S.T9=W@)F?DS"4%4(D \.(S)P:V'!-!A-VEW:4><INTM&5IJ\O633
M6V++FQS3WH:=.<]S*<AIZHH: ]D:/ABI4R=D1UR,U+P(8#?4903+8#/+W-15
M1NFBF9[RP3J+A+ZZ^IH#5KZ6706,AG):6# --C/-S;;.5BE?CW9Y9'ZK<SUL
M-.-+T\U0H@Y#'*.O/2$SK&\$@-[">&CY@@7N8#/N2.I.WP_ T-X4"G#DJ_H
M0P\%8:!B F1(/(0&LN-8D! VDY#<,P\;<Q.D AD@%&,M)PG8>7X4ZO,2X,^-
MR=#>+Q9 A,U ) M=IRU/&CQ/% OL2V%/V^T S'SBNTB5"K"6'^&AP4;P$3;S
M43<_;=)\X2RKVKE)BP=:%*E35JV$@J! :.^):$D%P$RE=J.)7(4@@,DW Y,L
M[$OUD);])?=Q&<XFJ+;.,[XSV['(3K-:)[-3[(\F>^: "5MS^:[:=8VN9,F"
MIWPS3\F2&3 ZE_>,>1NGK=.R2;.A3*8/I(="?7$U!^S4EC2:R+($0OGFM) L
MZW)#\[J"VW*\ 8&]J=B+U0S7'+#3E)Z\@>4+L/'-8",KO2H?KJ[[>4I0$;S]
MI D:W\@RFLB">K5 X\5 &VDL_2/_SN&W2[0[\XJ--74' -+G-UM8*X WGI8&
M!*PTJ2836:I@&]_,-H/)2]^TK[2_Y%&3!#"9Q<'050MF\<W,<ER";9LNF>R\
MZJW%7H.K%5 CA"8^#E0TF8.&7A"ITQU@YP4X0 ,[CKY &#^<M![;X_7X>LPW
MHM'4]9A5;XDM;W),!2WY4V@IJ]9K7K;55MGW8[6$&*+97]F'QZ3W4!6%#]!3
MZ*DE$G/ 3+MS3":R8D%-OIF:CK=--[/N,TQMY5ROR_SRSDG;PT^W=)/6@UN(
M_B@:S<=-$L"$+8^&LH)$$!0Q$]17=NW/W2X:TW-@X/.:;O;K'-Z<O(27P54+
M-R(9YR7 9!8&D5;E"=FAP(W]@0PA$=1$S-1TLQ/9.-MR0>O]@$"=HMO;KNZ*
M_+YK/U@@0$Y(+3^ C'R5!R$C,C#:$8%.9 HZ]3"0W8=-MUM2=#6)HNM^$S:P
MXE$RFH^;)(#)+.CO1\IZ!4"1*0#5U0$=Z[4ZQ: D"*&TN@3(JM_[]L).AB@B
M((I,R0?=56S47-'%/74:VK8%'2)#,LI!\W&3!#!![D BB/2*J\VPI'/A;KJH
M-OLB$EIG.<^D\"GBX^W-#2A01Z* $&V''C!#R/?5A!=@AA$>4BH BY@!ZUNW
MI])UR=[-QB?#ID-=T89\.-U7:*2/:0T_ZD' U [6.BM@YA,U.9Y 9A'" WDB
M(B"+C.2)#D,JDSK_XZOS:U6PH146I*=PM%XZ:I( )C./^ /[^D20#3&3#;A#
M\8JS,F=C$!Y!D3J"Q QFU%008#8C<:PW&V"'0F8Y--0(KB%FKOFX7-)LUQ.?
MLEWM.J,7-G;NZQOXQ,'#P6_+[@?>81_28B@'1B T\4)-^#CD&$WDYPL$X 1F
MP-D_JE)W,_VK!=W]U+7L))6!SB9^C(FZ, 7,9@BY1%W[ ':(^-$ # 0"=((3
MTD.0)LYW=_0^+TO>E5GC/],47,H&0.$/BE56FP-F/G%=M8P(,/-B@@:&W$!
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MT"_QI?&CSASK#0P18 M$<Q7C]OZM$# 7@#RM5:WDEM=!719BP-'L7A  J5B
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MY+A5CS!(K[:?_1/IE]41JXK,]Q:8PWD+L*%P>H)WBWP)Q%%3E!1?(IF%"@Z
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M(>*5FU.R1!P]P! ZQQ UA2!" X0-FU;H[:L;3BJ0Q#]21Q@UC%K% E@"5IT
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M&YPRF=4=("?]N@+-W37X 'R_J.M._\ %MG7SB;;WXG\!4$L#!!0    ( $.
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MP!,_ 6'9)$3\J) PB#H8G':'?0\.GJ:Z\J'%5$JP8$_R0^-&-"[0T";LB&5
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M@5=*O("S\]>(2].VIN*?&R7A%+0 SU<&2!8NZ(#T>>KK?P%02P,$%     @
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MQ%Q%,E4X=K,R2;(59I.!E88VB]J2H[LKE8;<8IWK!UDH$9ET+;.M6!B$-:@
MDNP6 :$*'8FY9KZZ-:\K:0$N#P#--=86#>>Y2D M)FGO7G\4G75N"@5UJB]D
M!<;*9O4%ZYUIWGRX[5]-1.=!1A%, @R!7K5,+@)>0^>!%+R^V/(7ZO=2KYV&
M\=,&L$E_)DH2[_5*''P/;E]IM32!N)EUQ0QT9%Z09B";0)!D5C("LSES%2G
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M;%OUL&"3^7=-[&-*ZNQ.Z1KU7I #\TU#5ORI6?X@K$],S.X1E<A^LU-9AVY
M#N#V,#G'.N8\PLA*SBUCC7"I3I0TM]HK;YJTP;>9*O:#[+JB0..+W9FKDG"@
M3QSDD92NH&PL2K;',=02 M%L(!")&W1L6VI'A[E.2DL6!'?XBQMKV]9TPQEU
M3@I@[M=(OZI>1[K/N<IO7P:X^04A%@H%  $^5*FTS9GW?TNW,-K:4N4PSTKM
ME+9S18:V.QH,?HRI@-VDS<!.A[#7'[A W;/U'_ 2]H"Y4ED=8&A\S\,?P"17
MQV69O^JN[SK<M(1XP]>J'MP0ZKJIB$=WWW W*=%G!.*Y!O,:^.A_0#[\=U*_
M9-L#8/QQ37TW<CX&.3]^_'\ )M$3!"ZKE.6@82YO5EHM6E/L]PL48UAU*XM"
M_ UXD4$[2\&BN$I3S W5Z:G3VWXVF:NESC(_L'33W#*'*_U>HEUTZYV:WU*]
MD:X3LVTNQ_QL%/(T?=C[J#!TD.]^%T3$I91?): K$V\EDLPG\IQ&,NK7$90%
MF(G$'9HAYN@GF:Z?MJ^09Z@?MM1EH/<JHT@I.G.ETV_+V:7KYEN9@PWJ3,%<
M>'@=2.*_3S,]F]/T0/J)GW\+X"[]Z(OFAI"PUBU4;%B_>><&O$7TUEUDSQZ[
MR/9K[LNYV)@RB=W=I1]G99Y11R]PWWKB_AT#U]MN%HA,\: ?W"@PI\*O%N>1
MJ^W?U*:BV,SUN3I?+%R-P)+1R+8$N]7-ZL[<NZ%1=W,R @S9^H;IB+("-S'_
MH-!*P&:W)D='*3[FI2W:>"TZ$=AJJA5BS3?4GF!K_&VK6WV@!#LB.[BF*C0"
M4!"[L2SJDNL( :HO?P.@ND%2Y3BT> 67,#DGLH/>A@AZ8FW 7_A,?@P&&AHM
M0*#I8/N%2NLJP+5P;V:S.\ZJ- 5W+40;G(I5;LJERPM'!&U[=9>NPFM?_*.1
M$+2@H+X=KQW57?VUQ\54;U(764_SLMTK-%(-7Y-6WK?G+">Y;;-7,Q577[H)
M/+W/H,:DD#25USQ<TG251L"/R(!BK1\BUF V=J9OO3LX:/T;FZ.K<R8@[OL]
M-TYWO-0!H1EX+.<$MPUM5)HJ!&(!Q]X+OJ/2M:""PS#^MU'"O5;QB6 7M(@J
MH^QW88>;VI(&\IWW(-R-T#F)\L8X#"Z>%AR3_M9C30NBM'73I'HZ39 Z3W3D
MBKR8'Q(XJ<"WW;,8KW A/KM_-?OOUES$;M.Y26IDF;U\UZU&> V2'+4*DDIL
MN-J? RKAXVYH1(T\L=$XT-ZPIJ)&XJ/,2DQ&:F]A1"USYFNK0]@A)*A00+EZ
MSR7@?2UWQ:L3N/+N>%6Y9P+ZZL8KMM4W413MYT 4$@E"W4]$3L&9GV2QQ=$>
MU;V[:RYY.,J\4)<3]D9/PIY_+M+,!JBIG=15="&_4)@_:'X2TAI#MQY3Q541
MB,743'Q?Q=E<!:/D8KMS,>QQZ(2 +B!:;LU[W+-8L-]<??)=JZL=:Y@YI;3O
MN X.#^[D_Y<6OSZQ^(/CPEZ+#_P^AK#X'$X33J_X.I(FO36KX2@()R/QT13L
M@FXG0>5H/&Q5J.X*NBW7M9BE-/;Z6C\NT?7[#0O #*;#"5BQBNLU1O#69=-@
M&@S'8[XBS*6[<I4Q_(^BT'7#_4$PF X\8^811L0X#,978_%KTS0TVNT,QO1X
MHGJ$4=W,5X7]M7A#F8QWV17$<:\ZVAT'@WU(%:S'>K^W_N$X9=<KC$;#2@(W
M(W._-C\RTW,W(_ DR.D[@U$PFDPOZ)5C]9U#HD),@N%@S*]'N$TZ%YUP&O2'
MD/$;WLF0V)K\4K/#25VC5$'I%LFU)E:9R1B)._^F]P;ML3 !%95TK<L&-\9O
M^HKJ-<J)QHFY6? #HC\_+!IG;KB\1BO&C_UV+]T8V$^\'8"^83AZ&H3Z ,!=
M%U6R'0[PWK _13^$O/#$/1N@' ;CN]\K)[H*AKVA[XX.6"-M\!,?+@Z;XMNY
M3Z4O_H$ \+QVR?I!)+T \"^O:!PD6^] 7!QVR,_@.G=R6]\QWGSZP.]LJ8+J
M7(U[%_X5U3Y_I_9 0_U@1"^?[LLUB@1:1,5Z95QV)O@N^==US:O]-K-M3_*Y
MAAZM;MG1V03^(5<-#><B# ;]GCCV/ONR]?B>2R_Z)P94V("L>X=??UO_*X:9
M>[S?+'?_! (]*1IP>F6[P-9>=S(Z<V_-J@^%6?-3_KDI"I/R7U<*=4M."_#[
MPIBB^D 'U/^VX\6_ %!+ P04    " !#@%Q:0ERXQ" 1  "=,0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q-"YX;6S-6_MOV[B6_E>(W.RL ZB.+3^3/@ W
M[;2=G4RS3;<7B\7^0$NTS5M)](A27/>OW^\<4@^_TLS<6> "@VDMD4?G^9T'
MV1<;DW^U*Z4*\2U-,OOR;%44Z^O+2QNM5"IMUZQ5AC<+DZ>RP,]\>6G7N9(Q
M;TJ3R[#7&U^F4F=GKU[PL[O\U0M3%HG.U%TN;)FF,M^^5HG9O#SKGU4//NGE
MJJ 'EZ]>K.52W:OBO]9W.7Y=UE1BG:K,:I.)7"U>GLWZUZ^'M)X7?-%J8UM_
M%R3)W)BO].-#_/*L1PRI1$4%49#XXT'=J"0A0F#C=T_SK/XD;6S_O:+^,\L.
M6>;2JAN3_%W'Q>KEV?1,Q&HARZ3X9#;OE9=G1/0BDUC^O]BXM:/1F8A*6YC4
M;P8'J<[<G_*;UT-KP[1W8D/H-X3,M_L0<_E&%O+5B]QL1$ZK08W^PJ+R;C"G
M,S+*?9'CK<:^XM7]6F?/S&(AS$)\3#,]F[^X+$"7WEY&GL9K1R,\0:,?BEN3
M%2LKWF:QBG<)7(*AFJNPXNIU^"C%-RKJBD$_$&$O'#Y";U!+.6!Z@U/TM(W
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MM0'*83"^>U\YT54P[ U]=W3 &FF#K_AP<=@4W\Y]*GWQ"P+ \]HEZPN1= /
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M5R^UVC%-JT&-+IRJ;C>$DP4YY<YJO)789Z_>R8(7B>09^TWM>6;W[-H884W
M"D3$D+PN=+9G'PNU@PT->Z-R/'$[?I8)O".8\Z09O;RP$(C(7B0U\]>>^>0,
M\VC"?E&%W1KV8Y&*])# !31IU9DTZKR>/$GQK4C&+(X"-@DGTR?HQ:UY8D<O
M/D/O1F]X(3]SBJ  NA=&93+E/J"*E-UJ841A_0.U9ITY[_!0('JM8?^\7AFK
M$7__.F4B+\#TM "4D\]-R1/Q:E 2+WTO!E???1/-PQ=/J#=MU9L^1?U_[?TG
MF9]6[2^4"#O))0@)D:^$;L/".0X7<<#6+3==<^..&TO@:6DL[;=;P=8J WK)
M8L.&LL 351D0,:/G)Z@?/XG9W[0R(,FUWA.)>YY5@@TG$)"H0@#<12/V*Q0\
ML>CD[B_N_ ?7G^6*LV<L"F=!/+G$U7"ZG([<DVFPG,YP]=TWRTDT>7'RZGHC
MBLJPX6ME+U[S;,2F8;",9J 2+MW--%RTBX__/ZA,:"??ARTN2E%9F8#8A\]2
M9.F(36;!/(HA?!BYFQF@ '_+*.R>+<)+X(*1:R211NPP6=SC4FG#HEEP.;_$
MTMEB1#=+;#\GRH\9>',V?*/T+QR$'D;L,IA&2Q@WF,RARB*(9B&+XB .IVRX
M"*:7X8@1S2E[7]R_OP&[8!)C_1S>B()H,3_+ZP[5YD$:N!UVFH%V-%VPRRDI
MM;@$IWG$;NYERH9W"O;(A %(C,Y2B\,@)H/$83RBFQ &_Z LHO5<W/HL@8<O
ME\%LN2"?Q\$L7CJO7\Z"<$IQL #=^91>+H-P$=/+.6QQ&;E@@L,8SU5%R(7P
MYVVDR2+)JA0ODZ3*JPSPEO;>(C-9LN7%1ABL9.*A1-W%BH2;+5MCE7%YEU1:
MPXF]]UJDTK(,02[,V$5\7X*&Z;,H'(<H@%E&2-M0*95ND/=L*N^V,MFB?R@]
M5),8#(:7N0=M)W=-[E/%M47F-A0T4EF6V&*WW#*N!7 AR[S<::4IVP@=3+4R
MXE/5HS"&#@B#1CRZ]-RQ$<91V-5QK>4D-2KMD,?7&*Q=\<P9U_=G_#2>C7M5
MYTCW5FO&G3# ,:F<M2I;01W8$Z90R"WR3;.YY'LJ7$P['(6_/U52>\E)W>M2
M2 UIK^FYD5[#@OU4 99)'L"J5GF#'WCS"V]>U/F!B_$U?$V!/@E?U$_=7?1B
M1%NN2RTS; )&D&2> A*=M5G,WG"=2G7/38)8U %R->E(MLOZ1&LJ\Z".B1T,
M2F&L.Q57J#>?Y5ZQH?_S$0W574W0L"'6LX+G@EG50,L!9_^LS_9.E-9[C*J!
M>P0I%H&'@@-\/*!$K_MT;A*K&BK!&80],L/I17VBOZK[3K; &=MY+Q':<LKC
MTP#LK*EA0]IP76W0J-:Q^+;+B[W@&@30V3T.6OA 4'XI3:]1I^)P'+?Y+?.2
M2^V"D(#!)>D)X#R3\TXHD/P2Q0:MSY#Y6EWB1[J$X\O_AC$E.@=!@\F"DA6!
M626@7&JUT3P'2C8I>*Y;HM8GE<@,W+F\K>/A5X7H'<:CH)^\33PPIT>;"DT$
MG =6:;?G(2&HH9L,V#0CK@#49.O2VN@4] QH">VG/1O2OF=1YTU:;*A^8*#+
M]C4NGH(E0M$Q&:.10))EDZYE++>8Z!HAO/Z 1;[*7'YCRC6JP-V^J1BB0<[#
MLA:0#*9*MFTH;# U.-.#F? IU<APUJ (:M0+V,LM/P>U8KWVFM?:_>DJ,E5+
M\*/HJBU[EDUEFJ N5/$#]NH*BW*!MC9E( /@?62'3'[!"JAXKK4#[&OAYA[(
M<8PN_? ZTR&2 L\F7:5'I!"3\;GUSJ%;E;DX@ZU+7NP#AMG @SEIV:$6HJ26
M<FA%F<G/5<Y7(X]Z(*1V+GT;<V$U@,85_X)%WU*!WBF=I1C0A>NS#,?[CFAK
M I#*N?XHK)?ACA=J+8/.O:X 3&+4;2AK^0,K*U06M#]@A;T8%0O#_:$%E2B+
M,'2]%JF*:IU\9*G@&0@JT@]NP*9"X94H?ZA*(K_B1OI^B\AS"_A>59;Z*S*>
M@)%%T.]@GD9J3L<<0I/7B!S%@LPD+#1\^^'G$1G@V6P\:UU&,O=20'F(H(.9
M([G\72H1T&B$DKH):6# JFZ?GVGJ8>Q\48L6+YX"<]'0A+8(9OACT_??]Z:'
M#.W,G_,"RUQ  RM8F7&"XB:NC'5O:AW_TGPZ&'W>MS'<YA=U"Z>+\&&B/=GJ
MU2T>!'(A!MD."O[7M *4L1P[:2ZA4(C'RR/@CL?ST\@]9C?4-X+<9-X$VQ\"
M@,?9[9;K'$UKEO@N_![2O7M[S7@)L+ZG$4CI(UDIF> $.HFTHG !XE+'>VB-
MMM9*9S<J7.CLP$<F3-'93.4!M:RR',SUGHJGH,K0]I,WMV^;MNF@+T#&ZK0=
M',#E0 N7\E1+NXK3@L:!\,,6,!!C-UM;W?.]%J.FY?Y]?/=D +<[_M]BV#?(
M!S7!=^ _RPT%!XU$?K0 24Y F+B*S-L=]-R'\I<[$A>N;>L_KKDM^E,#9BO?
MS;<&1SRAO:(AKVWH=PY5ZQO0KO+:7+74;85897A -N[Q(COE'DM=@ B=FP:Z
M6GE;]5PL'K#U#82/>/1!;2Y!O%6U3^G8JT^*!A+3.*_5Y4CA3K4A+3L>DGS7
MB$*5B2[(;X7/IT:9DS([=7>0L)$93IQ]VP@7U*E6^XT7A8LJ6<B\RILQ$ZW?
ML?2-Y8\&SU/R.HA!T8.&?6/!WBW@P;/28UM];D%B'M1O$#<=>U<D3[H*:I([
M$7X(=^4'RKI,+EI4\*U.6O4FQ.^I/A?-6%W'PK$9D&;ID<D?RX!^2C,C\ M#
MUJACG!-Z2=T%KG@BK5W(_L3A$KWORH9X$$GE<*CP8C1)2&<3Y\+6#=-D'7<<
MA ;SJP'BNFF;'\E-780!FV0KTJXA/H%.#22V;;%TF():6"_H]3EKJ8T]1FO7
M0J\K[0]EZ. W=9A$&]HS&L*JYLBJU@.-2J%RE!!ZZ>&$MJ=^J K:O757RDJA
MW4>T7J?CSK :_[=9[[3UQG@T@YIS;5KO5/MP&G738W-*AD9M<E"=.;78B7;%
MSE?OR>E:'?1 I#OUHSIVXB3/IU#O >/IORM?:%!_7<_J#_9<<F]$X0+:"912
M8M#W$N=,HDYG^O+$Z9CI/K% #@7[.BP&]]XIP6'Q.3Q#V5&W0">:Q4$A)#,<
MX&Y3@#B+XF_[AXX=$$OA^]H>ZKAQ KL?'_/TVBV'>YC*46+) $UWXR;EXT).
M'$VGV9B=^@)TT?L6B.T;]\63N@)4<?]9L'W:?E2]]M\2N^7^BRR:RXTL#*:@
M-;:&X\5LX!O&YL:JTGU97"EK5>XNMP(&U;0 []<*FM4WQ*#]U'SU'U!+ P04
M    " !#@%Q:+;;+A$P3  #>-P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6RM6VMSV[B2_2LH7]][Y2I&YEMD)DF5XV1FLYMDO/%,4K5;^X$B(8DW
M%*D!23O:7[^G&^!#SS@[4Y58? "-1J,?IQO@B\=*?:U74C;BV[HHZY<7JZ;9
M/+^^KM.57"?UM-K($F\6E5HG#6[5\KK>*)EDW&E=7+NV'5ZOD[R\>/6"G]VI
M5R^JMBGR4MXI4;?K=:*VKV51/;Z\<"ZZ!Y_RY:JA!]>O7FR2I;R7S>^;.X6[
MZYY*EJ]E6>=5*91<O+RX<9Z_]JD]-_B<R\=Z="UH)O.J^DHW[[*7%S8Q) N9
M-D0AP<^#O)5%083 QA^&YD4_)'4<7W?4?^:Y8R[SI):W5?$ESYK5RXOH0F1R
MD;1%\ZEZ_#=IYA,0O;0J:OXK'G5;+[X0:5LWU=IT!@?KO-2_R3<CAU&'R#[1
MP34=7.9;#\1<ODF:Y-4+53T*1:U!C2YXJMP;S.4E+<I]H_ V1[_FU>ND2,I4
MBGO6@)LTK=JR$6]DD^1%_>*ZP1#4\#HUY%YK<NX)<HXK/E1ELZK%VS*3V2Z!
M:_#6,^AV#+YVSU)\(].I\!Q+N+;KGZ'G]1/VF)YW@MZOS4HJL3MM,UWQWS?S
MNE%0E/\Y-G--US].EXSG>;U)4OGR M912_4@+U[]XV].:/]TAFN_Y]H_1_W'
ME^DLN>/,GAT#3RO5/&ND6HMWY8.L&UAF@V7^EA9MEI=+4;5*Y*,W>2D^YU_Q
MQA(0N5A4!1P -6R2>2&-%\C_5];\^@'755N/*(@T:>2R4CE:),1'*M=S+%VG
M"R(I,[KPQ 1#-2OTQI/ZZKFXK>I&_**JNA9M"4]58)1,+.&AZL/'!>XQPMNZ
MR6'C>+!(<@5VBE8>&7,DA?%<?Y_>3\5OH%FWS.^EF$66[[NX<&+\F3C>5?<P
M G_KM51IGA1BDVQ WO4L/_)$(";AE;YQQ:U43;[(20BUJ!;@95/5>2-<UXI@
M9?@W\:_XSK5!46TJA::BK-#^>EY!$L()+#\.A>N(271%=X$=CYK*/]J\V8I:
MIF"Z(;9C*PY\\8^_1:[C_@1FK" .KH1G>0%-P@ELRXEFN KH#UZ';DC3<GS/
M"IWH0%S>*7&]!GMBT>+/I0@]:Q9ZN.B&!>7 FUWI5ZX;GI2$,[.<,&!).%=\
M-PM/2<*WHL 6OBTF[A7?14>6P7&L8!:)6-/#310>K&QHS;Q08+(3K"AN D=\
M:,L\S3<@8P:S;'LV2!&K1$^\LY(/K-DL&/H$ENM!\@$8AGA=VXIF/ND/ZQ+:
M1JQ.#I;4F=GB%VBVF) B7XF%JM:B/BYV!$$RTK0JZZK(,];VNL&/>;T0B/5@
M$-&2#)$,&ZS-JV8E>G,AH]LSJIVA:8 3PZ/EIIT7>=K-GV@])DHE,/9!%A8_
M/SU"\@!_1"[D&2#)LSJ!+\GD?$P!"W;>X1"3WR<CYEN2%0>$%JL+]T!OM@?^
MYM!-W*PA 6:??='/Y%(^LTOYDC<K=*]**;8R4;R\,\N%F>HKSW/$S0*R&YHT
M*U6URY58 +[P$ZB8:\7>C'_<2/Q6-6"/[-"&WGC=%8SVKY$#^$W*?9\IV @)
M6.V+X[VLR:>C"TQSK=' <%4IL00AFJ'F6WODP?]^[_Y0VJ<<Q"4;'_R(Y<3!
MCH<9^9I1B^.^@YQ!%(9B,B-7:,,AD3?UK"AV#UT(.?#8\OS!BP[>M'NS[U+8
MC\/UPI=-XBOAPQ_Z.F)XN';C?GTG3D#,^J'ES6R^9_<[LV8QWWH.W08^W*)]
MQ!F?$1-W1+_923&-6IP6DV/YCMU=^3-VM@A0"!>'@B*W""5UW4-)#:_V76OG
M3(^(MW^S+]ZN11QKIPV_;KM\Y>+*'DG79J<ZLR([[C4#%N;K"*YO;;C\2/RZ
M@W5@"O!J6Y'7P"R;G,@95)7HS(/\G(1!%UO3"VH,HR%.GV4P3QAY)LL*\#[1
MKWJG.15?I%C) HY7-,PH%LX/QM;YN,K3%>@K^3U#?83O&=.YM*<(2^N\*.CM
M(29*C)KLV1OS-)=%+N&/8.<-3>X15. M"\JV&-!M%"((+QU-/R]A\)B4R%K9
MQ:%]-\.D5@F(8A))[T%3\J"8F?R6DF,!1P-"TY[^".<0!J2ZE) XC=A4(H5#
M6FIGUC.CV!2(/V@R-6K+1?( W28_.>I \TF5S& L?R 2<.RJZPKJ3,O%8D63
M6A[,)E\#9%,;]K3$6LT* PD8627SG.EA6L<E-@7<%O_>8B(D>XMDC>@-L<":
M*32.XY6$"Y?,K9)I]2 5TZ7[/7$BCX6R8L(,PJC!S4;F"FS=I(C-6E^FG ,H
M O?%E@=^5#!XD56/Y3&B1J."7J,R,$9A9\6"(<P'Z2F.;8M!D[**I4_S)5XJ
MM(4J'<B39=*0C;5(9[[2RN[HWIPF#=ZQ3*>)_*B$3EK CF0HHP07:%Q6G9ZP
MY=$8RY*)8EP>AB.ZI-SX&-G?3E"2/TK+FYY(V)Z/;H84K?<RSM3NEZ]>P8Q8
M *91"B=.SYLJ_7I*-%;G[1*3/Q*SF$5"*SCVF>2K#J'' 3*VC'_#8JS9I1,&
M;48NP-+V-[+640(W$AI>E)*&Q2S@-VZ.L\_<'PC3VDMN1X*CM;KT[:G;BXTH
M7'KN\,0"&_5&<OF)U$7#WAYA,VNG$3O[GC%BGYLTG6L^"!!O!BL[IUR#Y["G
MLZ>N,0/Q7H1=Z-C%YF3VH3WHS5,Y\@:.@J=KW5,Y\OVI/W!D[(K^P+!(TTZ.
MD#V)>7<J[A1E2R:-(;W=T)I9K&7'WW%8XH2+=9C]##6@Y<VU ]VME'P_T6!@
M]SZ9,YUJ 70G1^,1L(W"B#&BC=_WL""Y(HDC,"FX/ZUE %L^("=^O)#2U/6F
M)2<]XAO$ZVK1/-($'$ZE9P[EVF7=J%:75RF[4Q6@/?R>;[E.3&C1";B<83M4
MJ'!#5^<&< WMNBU8#ID$5*) VIF.\</ZP21"+Z!MJC4$#'XIY=4I3F"%2+/?
MC/M#@ /3A,;T5)"QUGT@0CI'A=IG5!*#2X%X(3@$ GXK^RRCK>6B+40!FZW[
M$ %'W'2 2VE_HY->D/JEJC(.1"9XXW5.,$)WTFJQVP:0C_ X@XV##G]:*=Y!
M;Q=YF3?R&4WB"$\#.Y"F'2!AY&J#[7%Z\>9[O4E/"DFR:F2Z*JNB6FZ%%ULN
M\+(/V.PXO-K/*5;VR[V[NDYLS0AU3ZC"$0-@_Z:2#"::K"6 =^B[YN]WZ5B1
M#SR/7R9WRV5S2$3)0E<S5OFFIAPK!-XW/]^C"9;"P+UB)IT0*<WMJ!2P2]@+
M;60>=O_[779A#*%':AU[UBS"(#H'68[5H^(Z]7DET5IU*;P9)!"3G?LV)#\+
MQ8T)B!QF!\)IHM26E$B'QZ> $DM/5FJXB REZ.8!S?Q8/20[F%%L6H61ZS[^
MTV &02]R53>'$/!F+!M"]^?5[B\RZX7<L6JZ:3<T1=?6-98]QN2WC2QK[G3I
M>4.\LOAV-MSJ\.^/  &'G1/PK3XM=ATB39';W041TU$])#G&YL$8)*C]08*^
MM(2;F"1+N&4 !Y2G$X&I^!GD9 *O9V3V@ZSO &3*B7*ETZ#%D05F.*>50+M?
M  JI<LJED1K>Z$:C)W^1O[Q3^5I5$-WZT\<;LBG+#QS^#:@DMY1E6XL[Z&Z)
MKG<4Z9(UE8,]-^Q+#*;5%U/3G 1&4.,J(F&\*Q'90R]M_&55 O,J$DMV,#ER
MRU80>0,_(_OFZ0Z8%P(XQ2VMR.X\1T-Q-@5E@M'J%.IRX@"87>T"VXD]=:Y.
M(=NG^9-][#OB/<G^U7;8%QQLS 0V>@(C;H>T_&@Q>[>6#5/NL#^5A>3>H ,0
MO"?L"4?/%1F:[L[SN[8Y(J39U.DE]/3Y[R8FC%K/5>[/3K8^G.TYY="!92S*
M8ROOCI;Y_STO/10T^YEAC\S1N*@KDXI99FE^9()?*+QTN3ZZG=1I\'XO-XWF
MU(E,(;0KV' B0+3O9)&G"&1S"BB,4,ML+]WKAWB=5P+&7-9):HHD9Z5]EKU#
MP=M3[UCYY%P:=6!//R;(+-?5+U-XVQ[H!T@2RM?]]W@Z%0.\WOE/A=YP'^\9
MZR=C_?ZSSOOMP8;:_I)1*C1S:$/6<ZT9?#88>O?KSGXS\I5X\,H?)9&27[L=
MJJ&0[#'(NTL*.+TB@8)QF?F6:KX+J10+G#+)KKW#[;67KPZFSJX]M@F\>2%S
M-DJ?FU6N#JIFG#?O),& -,4XKI*]'E8L#F:$M2D'B3I>9\C]U"AM3C:R;?(4
M6/-=F4[%A&;EVC]U;?C6^>D*"UY"CU-CD:E.#@RDRS%/2.>!=OB+[:@I0/H2
M0[-!WN40)((6?.TZ27G0I#@8EAMU@^KR+\::PVPS'I0TF*&N5G,J#F<&!7):
M<69NEJDQUET-@IP^>:O46.=<+DD=D:/P>0=M:1^3.DO^$+>F\/\A45\E%W@'
MP8:=8 =>,.I77-;;];PJ1#>YS^]OS-2XZ@NK^!?D--3NN>?@>_3!BE[_[GK]
MN]?\/YJB'@-0$ ,<-C/I*AZZG8;1"9?8M2MC!T$KEVP0>[\QTL3"P3O9<6!U
MM#HM=2*D2+"M8Y:@1P#*JT0060$,=F=LX\N'4B'[RVZ-=MFD$N+Q +GC_@ZV
MN'<*9IT_,CB25EP_N#7@R[S0#[N<0Y,75,2NUGDJ%.4:M<F,6*+$-[LB*$RB
MCZR1KZ7=\(;T<(E>!LY0TFA4OILH"$ (LM J>\<)E <?C+?5I@,T_]E4< Q8
MFTVRWJ;Y$)8;VD_M6GW(4U6E6Z0'J7B_76\08G#U(3$'^'AOO[.FG;8?!JOJ
MJ]O=S$C>?1G$U/)A367&HZ*1WL\9V*5]!:U4F5#5-BET#7^II,9GN].?$-D]
MQP)MXF%NNF$Z]D;^"4Y0<II(NUX; "C:BTNVG2@NAZT(!E?O\R7X8=-2LFG5
M(,&]SA8%93)Q5H(Q>C=E9LL8L20=U_/;4F=.T^?;G875HW91F@&H\2;-HY2E
MB*;VWUE.\33Z.Y\PS 2C[9(&3):0V9*TXK%2!;)XJH_ P?0US'VMT!;%A4X(
M85[DRTY%J>)'W9,LXUP=U+MEPMN>99+)CN8IMD.]>SO*T_7 &D-(4A#VP9QN
MGS:3?A38<0O7-.=]-I*N5#J8U1S/&%70'FJBD'62=,8L<?Q:2KU4<YDF2.L[
MV,-+A=9UOM2[J0PH6MH]!HI8ZM3X-&7*94;'4)I56^_O9H#@FNLJ;"7L6EB=
M;^YOQ<RSG[FV)3Z-!W@S&N!F8%VP[*!!+2AT&X2\4S*PW(4@EL=(L4YN8%B=
ME8Z4O]/N;K7WW-9)B[/$I3.J8W3@[(C.D')W;$YY=_SV[:]:N #I*33% @#*
M((KD(8=H:6NM?\4(O)_7!S75K<BZ6S*&5;ZN9;'0-LRGD>95HK)_&MB8&3C;
MUW-Z)]-96&LR7S.&9?RY]D];+FJ5?#0A@4ULZ[PS[['3.RDDHR92/-#>*#GR
M#9?6G]BK7XLAK-=FR[>4 ]PS%M'3NW2GP_KFH\A-"IKT 9K<$1W2Z+;^^R-,
M/"O(2:/XT2;;3B3=C8'?WXHZAEGN$N;XG_4QL >UR?(:RTSKG,PA-JL;99?_
MI&TJBEZ A,5VA&486)@A]I$%84/(*1SJ6<>/).Q1<R*?SCT:,E:'CDRSVA!*
M=2G0\:8Q'=RA4AEW^,L S1-Q3%<S,JL$SNAP%Q\TT9CETAGMS?7--U0S[.NM
M1OV[0&9H36AIBJK6RF#"\T=:C4F(*/QSW^^3Z7<S*DI/"&Y(!4:^EG1>(*G'
M9X#>0WY4IN1O .HK$]K%E2F?^CO*_0"&*[45$Y4\D@9#<Y 8Z&W42GTU.T]\
M.&3/LZV3LEU0Y.:$RM26(;Z,*^)TH- L$  KP%GO1H9X)^IVLRER'6K_Z^W[
M^]\_?WC'CE@6R$OKO30"GG!5D89BRH1^VSG\4Y[H4P8=_*!BZB@&YV6/S"CN
M=X-8P%ER5^H>Y#.JM7=I$.((?URAO:KYNJ+S6SW/G6@&>1Z:^IXR/3'Y_K*W
M"%2CC%W>HX,9?=I9M-#VA.]VV7 GQ#%/QUFALV>!2X<D0R<@?*I:.NV3Z^,S
MM#['GOW9LL*G'KE6CYU644).0%X?\P[Y"-FEB&V;-\2@U7HE [#K@NDP<L7O
M_Z'K0<^PZD0F^8;73A#W%8([52T@.8/)I*0=U"B(A&MYL2_NVWF':Z YCC4+
M0O.WW^C*S%&^T'7X_[W66C74+"#W&RXT#7/1%@J!L2V.3LKY@7$NGN7'-HT5
MAF;%DB-2OA3NS(IM?8+5\L,9;Y5!S+1^XX;?.8VJ\(I.@CPBN&LK/$KEQ,&3
MTY\#'.S=PQ]O=?%E=##WIB\]'ZEF_6 '7]QN,_D- HE\/K'-)PO=*.3R$Y_5
M=&W]C(^^>Y$G/D@(A \=0>IN/#H+'CA\BG(6#0L$&I[EQL/17\\*'&\8:N*&
MO%ON60YO"W;#A68+(8P<L\0%\AP=?<8R/O?NSQJ5WC.<&-N_&C![-\A6[^['
M'G'N>-8,MO5[.2IXD0'-92D75*MQ]'%7_-A>?)9Q^E8@WJG#'6\' =F@Z6G%
MIN.>QS[@N1Y]<\7(AKXL(^G QO3G5_W3_N.U&_W-UM!<?_GV(5%+^C:ED MT
MM:>SX$*G3MU-4VWX"RZ 7]@[7ZYD N!+#?!^42$^F!L:H/^D[]7_ 5!+ P04
M    " !#@%Q:ZL^/YC .  #]*0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6S=6EESVS@2_BLH3S)K5U&R3EMVCBHGF>QD-]?&.;9J:Q\@$I*PI@@&
M("UK?OU^W0 /69(]GDW-P[[8(@DT^NZOFWRZ,O;*+90JQ,TRS=RS@T51Y.?'
MQRY>J*5T79.K#$]FQBYE@4L[/W:Y53+A3<OT>-#KG1POI<X.GC_E>Q_M\Z>F
M+%*=J8]6N'*YE';]0J5F]>R@?U#=^*3GBX)N'#]_FLNYNE3%E_RCQ=5Q3271
M2Y4Y;3)AU>S9P47__,6(UO."KUJM7.NW($FFQES1Q9ODV4&/&%*IB@NB(/'O
M6KU4:4J$P,;W0/.@/I(VMG]7U%^S[)!E*IUZ:=)O.BD6SPXF!R)1,UFFQ2>S
M^E4%><9$+S:IX[]BY=<.1P<B+EUAEF$S.%CJS/^7-T$/K0V3WIX-@[!AP'S[
M@YC+5[*0SY]:LQ*65H,:_6!1>3>8TQD9Y;*P>*JQKWC^6FHKOLJT5.*=DJZT
M"AHOGAX7H$TKCN- YX6G,]A#IS\0[TQ6+)SX)4M4LDG@&$S5G TJSEX,[J3X
M2L5=,>Q'8M ;C.Z@-ZPE'3*]X?V2OM(N3@T)Z\2_+J:NL'".?^\2VI,<[29)
M 7/N<AFK9P>("*?LM3IX_O-/_9/>DSL8'M4,C^ZB_@#3_!$ZXIL22W\I8F4+
MQ*^8Z4QFL9:ID,ZIP@F9)2+5<JI376@H2Q9B1M2NF1H%%0(S+JW5V9R"0[NN
M>-TLT-@!9[57JNA0Z"35B<Q L0 YMS!EFHBI0B@5RL+#L:IT1 \\E,N<8M?Y
MM9Z2R*4M=*QSF8'#%6\O'0[+1&YQGW9F7@!A;,W^NDL2*U?(::K= HP5"ZM4
M)U77*A4+K:RT\6(M"D-DC(7 ORFL(<)YB9-*XA^'>!'HF$857?$9"YD41+8D
MC(NMGOH=1&1*Z0^Q72S\,M$7"WE-5.CI KD#K%4GK[WB>=VPO0XTL.Q<O TD
M.N+#E-P.,M5\NC*&=$Y\+TV!\TDGL)RN$F#0H@LT!J#QQF\T.,&2ICW']^UG
MDY"LIF%!:::1:'A%D:Y)_SJKK]X&@3KB2V:V^,8)JX4&[T2"?0=6*_ <1#)3
M&3]!DHO"0JN^EZ#-W+XT2S@$FR^A8TPN-,FTRC;\B,PT,RGTR"KE\W-KKG5"
MWEV5)F%F3'1/%-22!V].?D=<D$5 %4E-+:=04978F#A^#,4A>XHI'>ZXHW.Q
M.VPY!C^IW" &0!LY7XDO'"[;I/_A+?BQMN"%M^"[8$&4=/$F 5$=(^0OO+"7
M>I[I&>X@0C^P-5LN%CREO6;#E.'Y9U. X&'PTJ/JUZ#^-3P*QYV+RP5$Z5#H
M@\-K>#=+&0EU$Z=E0H)]U5?T[Q"$'HG^:!B=]"?X->E'D]XI?IS@1[^/'S__
M-!GT!T_ 146'A [;8[-<PC HJ/&5&/6BP:A7_:OV5?]?*:NO):LJ>, A6._W
MHO%DN+4XW/8BA^5@\VP4C4;$5'\PB'JC#3[#EK>-2YW#?S,R*/'<=K6.>+E^
MI6ZP:8@=C8CM7_1D[_9W"D[.#G@(I0^CP=FDWKIYY25H[P;IZ&32WSR,]_A#
M_U</'?Y_>FA_'/5/>_AU"EUY>Y]&D].S!WGH<!#U)^/JW^_ST&$T'O:WUOJ[
MM_USW(LFDQ,RY%DT.CW9X-+O>*![#GK[W!-/?J=[#L! XY";5[O=L\_.V!SF
M]_A#R1R_U#8RI6V9KU%[!+U;."NY*=43%%]'J9O/B#@]?[D4<W.M;,8[VT^)
MJ-OI'HP4V(O9[1(U+9C6UA%<2.(4EH&_4BG!G6NI4]K6@?]WG,3^UGH/I R1
MS] VT6E_H>,*"A.J<70,$448IJ'&AWK6JE$UX(GH1#QD!%6KYQ9_O"<)1Y<Y
M#M]$!Q2GNHY37#B]A BD<8#K\I9&6A4T,T7 %5[52Y.H-&!%.E1RZU:H>)'I
M[V4XR5=_F:8XI@GS=IF_!4L"!O.G=_<$-*V:&O P*U& VV)+PJH*JLM4$8"E
M5^+A^XNO1V0*QF;2$3RIP4..&#4)HTX@N T;MQRCI6@&AX!_<Z#P%&N*Z@$(
MSM%P%Q4Z,YD2:P7MPG)[O*]E*?+1 (%9Q=Y3""@1:B;,Q X#;3+CQJD]_&&'
M@SW<;.WEA4%T0E0SI1+FDHXBU$/T#>1GZZ$E> - E& IKH#=2!_)K5A<26L9
MSZ.-0C_-Z-J:I;A4@'(,VZS,50G_<J"&QA#NA>VDB5RNO<SL5"O"CK 0@"-C
M;[>0U.4E'K%S$&@+0WTOT45 H>!ZT.N?L0YX;QTUP[NCI@[#%ZF,KSJ7\<*
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M:&<:R*/(2%TE?AY9 2F&-IP.FA*8@ZAP<)!/]&RF;)B]>BAR'[M RV1PF3[
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MQP=^0EU=%";G#_RFIBC,DG\NE 0NH@5X/C,(]7!!!]1??#[_+U!+ P04
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M9D]J)O[U>I,["^?_^Y22GL7\- L*B!=Y)D/UZ@*(SY6]5Q>WWWTS68Z_?T+
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M CR?5QA8XA<2T/[/"9?_!5!+ P04    " !#@%Q:3-P)T_(0  !F,   &0
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MM4*'_ P@T@B9P 773=UOZ;"]T//J,?LP&83F%M9MX H["=VOFZ0BN6Z;'"?
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MUB4ND8#_24S.6NT#KV,8>CR+^ 83:Y-4K<EDFS;YDKA;@M\_43;67C;7^SM
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MJ\1LJ6JUUNT%#&9.,) 0!59U%OW#MKGJC($PCSD_$V]5 68E+!3D7IAE9+[
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M%ER@A>B!,U5*])5ED/V;[VJS02\XZJV#4> ]I!,4^C<H\(+I""\<R@TM+[S
M.U?F#=J_H@W+R(%D#:;GJNZ@T_-0\]TL98U3B!W]84@0!W"2CQ_\N?=E1'DZ
M*$_'Z,FNH8!\;S^[]4^UT2KCM?K_D#O=<6".J801L=D@-AOE_.#L]@JY<>A[
M<O-!;G[5J3V!T%\1ON VSGS/;3&X+:X^N'&_<>Y%/_>D/U0@"ML%)4IYPU37
M*H;5H=&NNO[R-[SKT@]8%(1)1"'7J=YDH5^GZ#I?-U&\MMUFSY7N7798ZI\%
M"!.@G^><J^/$;##\?I(W4$L#!!0    ( $. 7%H\I3,X$0(  -T$   9
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M;"]W;W)K<VAE971S+W-H965T,C<N>&UL[5I9;QM'$OXK#08('( K'K9EQ3H
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M()G;\#UG.,'9B[^AQ''"FYP/%T!?<] #>']FT/WQA!347]6>_0%02P,$%
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M-$DCUDH>]SB+?*XF=NS@)JL$%Y,M'K[L, +R^!HT.AY%!$MVZZI81YKLR2A
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M9BR\&60@[&+-" ]YB4@N6V^R JT0 $:4@;-(<%HVB$D$E/V#&0CU7K)LR[Z
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MXS&=JDDBJ]3<!9D'>\[M?24&_AU;/86(OU2C'V_F!&RQ:N[8)>RS!O?OLN/
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M(,O>B'?>;P4[&5T&K^)@=CAV:KCDQ6CD6 E BLH;P"!!5&VPWU!<6DM-++9
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MK"E\S-F/C%\>K;K05D+"LK-LE.8&I(R4%B[A-DK[TR1+D'$ALN^>CA%9?')
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MH?\'<"4.B>JP:S?TX]KD(-KQ ?C[L@4[2OZ!$^Q:^X66]^K_ %!+ P04
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M#"<TW=\/]2]6=>Y.YDY9JQHW7 D.^V@!OB\4]J'AA01,EW3G_P-02P,$%
M  @ 0X!<6H.6RSU-!   >@D  !D   !X;"]W;W)K<VAE971S+W-H965T,S N
M>&ULC59K;]LV%/TK%UHQV( :/?R(D]D&G&2/#.L:)%G[8=@'6KJRB5*D2E)V
MTE_?2^H1.TV"?4E$D??PG',/1<_W2G\Q6T0+#Z609A%LK:W.H\AD6RR9.5$5
M2IHIE"Z9I:'>1*;2R')?5(HHC>-I5#(N@^7<O[O1R[FJK> 2;S28NBR9?KQ
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M2W>U?]S2CR/4;@'-%TK9;N VZ']N+;\#4$L#!!0    ( $. 7%IO*A-]$P8
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M+D53Z/?J]G?9'B@D>IDJ:O/+;NW<&).SIM9JTRX&!YN\M%?QM17$8$'BWK.
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MY/BQ:^Y-3(B=.#6WOD>W80"L=D<BQ(28S$*LB^\5TV#&_6+RG,!S=Z,@-A$
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MXCYA/W*!CVYW?9!=N$GDD\&GJ!L2;&*1<C4T#V7,<MI('%9*\G\_A@120H#
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M=362N!YE-THT-GO4\B2F$TA=+W)C/G2!.RE&P ]5(W8]]^;]&YHM,W?E2X]
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M\QMV[59YR&[/Z<K-R4C/'. -';PL ]D47H+<)_PB=A&D;7@>#DR_\>.O]5T
MCD'+1W0__F $%S\-[CN$?Y#Y1L%,I%2:Q#S9=B)25BGO*9G$ *(M)VHEH("A
M-9W&(ME6Y#&">3=:'JF,K) B5#@B*LD\7\QFCQWYE &/M(8G4Q'4-)*I6!/.
M\"RR&+S<EW]>N8VY-*!.2=(@$W%JMPVEC(V2+"5K*$W:;5E*(IEDYE,A3>.4
M[[,48#Y*D1]*4_*E.@8(ZS@ES4R4&?6<H22%//PI$@KY5,4V@:%$2CHC<Y._
M8*=G5=N8*3,2^4UP8=+8\FTS44U((B[UZ^#&])N0XO EY\H# [QK]AD*13$2
M N7*>RW3,5?PFE<M0ZP@T9^QE(*EA+"1L"HXE&L<)R'O*AEQ\5=,];QR>XI@
M.A3!]/]0!-G-U\=UY2JOYCL[I+WR7E0<9^L&B(C[ .Y!M]/ZOB+E""/KWI:X
M_K0=+$D4W['=<5"0UMQ&\14IW@X>V>8R5,F\KY+-4"7+8N:H,G[UE?')QF^Y
M#\S=5MP\1W,@19R9HP,M8B2 ,!P9HA!&&;E:V5@!N*R.N/9A97QX:14;?G20
MRAA@)H1!VV20HYP 6*-4(C"!1I*GX9OP!GF<:I"8.%.PDT!Z99#"/1AFL<H8
MBC 5[?"-Q8/4QM(>'60RSE(F),JT,0Q+'@D24I"C,9/<^ICTBF&O%2!!%EB<
MQ2!/%4A"#"OBPQ/T<C8+W^!WD%%I/SHP)A89XUH#+@W#'&TQ(@:V2F2"(B&&
MQQGPVEC4BJ/P8DHIRD%02.HAPB1/D'XV&;YIKX$0S),]!6BDT;"8AQ@+:4 F
M#FV3-'PC_;!9Q1)R ">4V+"RL-3%^,-PGL26#!!9;X]^TP$7\"81^3?UP )E
MT5+)QJ8PN2FA!\/H(=4W*>[S_2FZ[,GY;,CY['_+^4V@'FUZQ?,6C6J(Z%VI
MOE\,W7OR!P9L3>"-3L*G<@L(+&:%H^9V53<=91KN-44];3U&TA[@ V[_M *0
M+-#W.I_K]QLM-^D4VI(IM:NSO&C8G>]4P2W<K7R3W>LP#]7EQ3>EJZ*]/9HU
MCA"@<PV!=4-R9*Q?':&ZO,(HHU'ZBO%8T4B^\O='#_!W-35E)2&HHD7L4B#4
M"F^+M][:VU$'CA"BJH"\Z/$&&4,3.I;]A(@3FD"4A(D]\6"&># OC@=<\]#P
M>X5":.R[!^UE^Y++\*Z[4/.@0;@6_>FKT!"^OI=@;\EA[RDPPA7FXW;UV-4E
M2@4XU7W11>YN6A(!3,D\"!L)7&2?0TD_Y$!LH=*^XP >;W4C K<4[9L1]#K
MIV>$2R;1+=M$!ZP3#Y<D"7#2A);,Z!C[!N$IM62^@S;HT<RV\!0@QZ77*Z.E
M9X0K]"RX#V3]"?5NL!EO_0Y;NF;N?_JU;%*OJR[\&1MFA_^*Y^%WVL/V\%/R
ME[R9XW+)2C<#*>H)+M9-^-$7/KIZY7^NW=1=5R_]<.'RJ6MH ]9G==UM/DC
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M /K^DG/U=F(>4._*S_X&4$L#!!0    ( $. 7%I#7CSH6 L  '"'   9
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M.,(';L*(\;W$[WL_M>/O1+?,2^T3\Z;0)S7GASUZKH N+$.AV93N=6) MF+
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MS^LL!ZA?"Z4E4!J%TAB*9JNF-76C,TPF@OJY4%H,I250&H72&(IFBZ4U?2/
MQE,_H[-2H YN=.C@!J'K+O\$VBZ%TAB*9C]+JS5RAT?O/S6)YJ9(9PM!_I3<
M.6[X65W5 *7%4%H"I5$HC:%HMF):#W>(V8TZA'JO4%H,I250&H72&(IFBZ6U
M8X=^._;8W69^3&>Q0!W9X:$C&SD].&BS%$IC*%JM@_[>XV57HEA43PY6I/+,
MZL=][H[NGDY\73V3]\7QF^#B-G <3X(+5C][N,77CT+^R(M%FBN2B;EI:G!R
M:M;S1?UTX?J-ENOJX;8/4FNYJEXN!9^)HBQ@/I]+J9_?E WLGO$\^1=02P,$
M%     @ 0X!<6N/;0F&D P  J1   !D   !X;"]W;W)K<VAE971S+W-H965T
M-#8N>&ULM9AK4]LX%(;_BL;M[,!,P=<X"9MX!N)VRLZV98!V/RO.,=94ME))
M3N#?5[(=$P>C)3O>+\2ZO*]TGEC*.<RVC/\4&8!$CSDMQ-S*I%Q?V+9(,LBQ
M.&=K*-1(RGB.I6KR!UNL.>!5)<JI[3E.:.>8%%8TJ_IN>#1CI:2D@!N.1)GG
MF#]= 67;N>5:NXY;\I!)W6%'LS5^@#N0W]<W7+7LUF5%<B@$807BD,ZM2_<B
M=CTMJ&;\(+ 5>\](A[)D[*=N7*_FEJ-W!!02J2VP^MC  BC53FH?OQI3JUU3
M"_>?=^Z?JN!5,$LL8,'H/V0EL[DUL= *4EQ2><NVGZ$):*3]$D9%]1=MF[F.
MA9)22)8W8K6#G!3U)WYL0.P)W. 5@=<(O+<*_$;@OU40-(*@(E.'4G&(L<31
MC+,MXGJV<M,/%<Q*K<(GA?[>[R17HT3I9'29_"J)(/H[$.@,?<*$HQ^8EB 0
M2]&E$" %JB9Q6"%<K-#?!"\)50HU18V7N>H_B4%B0L6ILOA^%Z.3]Z?H/2(%
MNL]8*91*S&RI=JO7M)-F9U?USKQ7=A9#<HY\]P/R'"_HD2_,\K]*>H[<T:OR
M^.VK>UVYK1"WG+V6LU?Y^:_X795"]8B&90V\CTGM$O2[Z$O@0JQQ G-+G7(!
M? -6],<[-W3^[",TI%D\D%F'GM_2\TWNT8(5DJLK N'ZA3Q)28&+A&"*.'O"
M5#XU(Z=]3(W>QS(=TBRNS<:5F;ZA-Y$SLS<]H((65& $=7GS\?KVV]<^"D;A
ML12&-(L',NL &[7 1H.<R]&0](8TBP<RZ] +6WJA^5QBD54_"HE^ $5P@RD4
MLO>Z-UH=BS!\<7)</_#'[>FIV0RT9(?-N&4S_A_OK/'+^)S0'87= !?UM/!?
MIL7&G?Y'#I.6P\3(X9O,@#>A]D5J5!_[6DQ>\)A,P]$!C8%6[-"8MC2FY@LZ
M25BI#@A:XR>\I%"='IPDO%1I%'U.K?I(&9V/)35]0>K,'P?. :J!ENR@<IWG
MW-0QPKHN$I8#DOAQAZLWC32:',NE<>N <;WQX8D::M$NF;VLW362B2$%KC-R
MS6;OM?F "I"]D(Q^1T-R>R!-7&=Z2&F@5;N4GG-NUYB41O=,JMLVU37-1M<T
MNJ11?'8W,F[*FEY>@R;BC5OW.A\%OG_(:] DV]XK"W41_P7S!Z+*/ JILG?.
MQRIUX'5=7#<D6U>5XI))57=6CQG@%7 ]08VGC,E=0Q>?[7\GHM]02P,$%
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M"?EMR50 \L(DY^VFA;ZYA6J\?E<NHYA=#>2 7#*Q9H/K?_S-F8S^:8H-)"Q
MPD(DC()@6LSXVYCQ;?3K]S(+$IEJRF9 >FP&(I.V5E)?;3>P:0U3>7A]/;H<
MKG<%ZY9P'=<9C?;*A4=)%-1PK8/'VPX>6SOX$R_BE1!J,$^82->;L3LJ2U89
M.WG<.1M/3E<Z9WW7+>>,QC.O4S#8%)SL L>>H1NMI]$WI$$PK<<GVQZ?6'L\
M:+OY1G4S:24X:P='\MN<T+20PV,JQ[Q[7M;#XAD)OU9J O<H+X>P6.7-6'<F
M(=7+B"D'09I%"Y-ZUI;UO43LIRE'Y))G:2+/)Y&SO,U 7\](3'$5(%L6(F$4
M!--B9;J-E>GQX>^-U+3\18V".U=H6I256*E(,5ZF5FQ?H:>=:_FMO.:=[E4?
M3#L7LSON%@N[Q?:'1%#[M4Z?;3M]9NWT?\ONEG..N> Y87^LTNH;R5GUQ!/9
MZ8=FOB8-K$?IJ\&LTV6..S.DF\!0<.9>=#68'4U+H/9K&EQL-;BP:G"L;ZVU
M^_8M$A8@82$21D$P34]GU-Y1CDY^]M\T$10V4%H I850&D71]-#9,2,<ZV#P
M(5]&J:B'77D+<&A(-@IN!?<6W.F,K>.98?(;& KN#[_0EE$431?(;05R?TK&
MM!^FMUQN1X7IR"A7MZ!CTC6$MH^B:+IHK1OC6&_<E5LD6%2JJ2191]FJOK\^
M<CE![9.&MMOM;]T#%Q34'8'2*(JFR]@:)([=(=$SXUF3*64J5&[)-Z*<W/;N
MT) GR?>MR_L?%C\5/..+;^17GJGDNDFTY\98@-HM4%H I850&D71]'!I[1YG
M?/K3,*27<P>E!5!:"*51%$T/G=:W<NR.SIV4,TT:88F<DB5DSH6,&)DU*B:/
M6.?X):]D6"G3*F%KEO%EG?SS-)/?\X(9XV'2S;]C4Z:^L[>PM]90TPE*HRB:
MKG7K.SE'C"?.D^<TR\BS2"LIJ,PF<Z-T4*,)2@N<KLWD.\9I'?*P%$73E6O-
M*\?N7O7YQ<2.ZJT>DA8X72/+-:N'/"Q%T73U6MO+L?M>VQ_:V=>T(C$OS?9N
M0]%^7C'^#&,_7&]-H.86E$91-'UY06MON58/Y*=,PV69SS*+BC16OZG(=!I_
M,06'O:5]KVHH+8#20BB-HFAZ!+4NE^N<_,S<A?IE4%H I850&D71]-!I_3?7
M[K\]U,N7B& Q2]=2Y*A42YMV)NO?#Z]PNG6[[I<_E?\F>ZG$WH;>:B)I(91&
M431=S=:8<X\8<S\GE=SQ/)>A\7 PC4#-/B@M@-)"*(VB:'KTM'Z@ZY]^&H%Z
M@U!: *6%4!I%T?30:;U!U[X6[,?22'<AE^OXDXOQ=#^/0/TZ*"V$TBB*ILO9
M^G7ND85F/R>/W LV9T+(JH=3"73=&9060&DAE$91-#V 6A/0G9Y^*H$:C%!:
M *6%4!I%T?30:5U(U^Y"_E@JZ5I_OCN=N1?>?BJ!.HY06@BE411-E[.U)=T?
M6XYGK][[*H6:EE!:"*51%$U_'J<U+;W37Y/G0=U**"V TD(HC:)H>NBT;J5G
M7Y/WE_T8W!Q7^VG#_&.PO86]M8;:BU :1=%TK5M[T;/;BWV?$;+C>E_277_2
M\\>&E>^F@L9'B:#MHRB:+L[.0Y5VM_!FP8I52>XC415,W87="[X046X4!OOX
M(_;Y1^P#D-@G(/\*2\]K+3WO]"T]#VKI06D!E!9":11%TT.GM?0\NZ5WST0L
M(R9:U&M!MHFW)&_D'5E$EINO30^)WS9DQ]D93T?GX_TD#'7SH+002J,HFJYD
MZ^9Y=C>/<GDS'<EIU7=]RX6-27?W^:-S,37*"/7>H+0 2@NA-(JBZ7*WWIMW
M^MZ;!_7>H+0 2@NA-(JBZ:'3>F_>$>\MRFKK;2TGANS(S19T 2"4%D!I(91&
MO>[3L][>/:HN7NNT>7:G[37#O'Q3;_Y$/*5N)B]?H[903PY*"Z"T$$JC*)J^
MWTGKR?FG[\GY4$\.2@N@M!!*HRB:'CJM)^<?>4YVQWDKM21P?+9O1_>6'&K-
M06DAE$8;VMY=DCLVYP&_]=Q\N^?VRCQP\\C7S)X'[ ?JK2QT%2"4%D)I%$73
M Z#U]?S3WRW-A_J%4%H I850&D71]-#9V3/-:BK]6!Z ^GQ06@"EA5 :;6A[
M>< [E =: \\_8N#)P9^+1/V$]IX5K$ICM2ZKC^EO/T!O1:%^'Y060FD41=.%
M;_T^?W+ZXS_4.X32 B@MA-(HBJ:'3NL=^O:'=S^M\D<FE.'_LL&M&C->7AN%
M-FS<MF?TVX_96SVH?0>E411-5Z^U[_Q7/,#[_^SY9^?VOEJ[%M=;T_.W@:&@
M9WI.%]H\BJ)M1!KN;)6=,[&H-S572Q971;799'K[Z7;C])MZN_"]S^^<=^%F
M^_,6L]F-_6,D%E) DK&Y1([.IS*]B,T&YYLW%5_6&W(_\JKB>?WRB452?E5
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MN6;U(]-K3FV)P!65!4<C^F[JNO^K!U855<]UI2QU<-5E1CTS:K> YE=*V=W
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MS7:_;_:#:R7^O<ZNB3=Y1]R)ZY//3Q'Y\0?3ABWLF$@L)<;1,62;EW&[V_Q
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MLX#\_Y<\K[Z_:2IXRXLO[6K?_1=02P,$%     @ 0X!<6O]$6?*D P  (Q$
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M<&V@[F\8DX\#?4[NOXLDOP!02P,$%     @ 0X!<6@B%=<%=!   31D  !D
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MGN!*':#.;SB7SSOZ!7GS#\KR/U!+ P04    " !#@%Q:;#\VRK0#  !L$@
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M >-%1US<2';(F\H-DZI%S2_W0&+@.D ]WS(FGV_T!-7_)9;? 5!+ P04
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M,N\/;F>0I\7ZW^1''XBM YQXQP%N?X#[Y #7W7& UQ_@'7J WQ_@/SW VW%
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MN]ADL2_DAYU*9@M<IP+7:01W'L?,N+<B6F#P2[:@)JL0>O!>"GO=+:11%.U
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M2,H+)& ^#<[Q68+'QL%:?*&PEEO7R*1RS_E7T_@UFP:1B0@8I,I $/WS )?
MF$'2<?RU 0WJ,8WC]O4S^I5-7B=S3R1<<O8GS=1R&IP&*(,Y63%UR]>_P":A
M@<%+.9/V/UIO;*, I2NI>+YQUA'DM*A^R>.&B"T'/-SC$&\<XEV'_AZ'WL:A
M]U:'_L:A;YFI4K$\)$21V43P-1+&6J.9"TNF]=;IT\+,^YT2^B[5?FIV1:A
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MF7[54+RTI]SW7"F>V\LED R$,=#WYYRKYX89H/ZR,OL'4$L#!!0    ( $.
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M#@A>&>!W _RW#@BZ <%;!TR[ =/# =-7!LRZ ;.W_I;FW8#Y6P><=P/.WSK
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MZI\O\WH7TWW33/"4%[^U#^?J?U!+ P04    " !#@%Q::Z5SMTL#  #P#0
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M2094&HCO"T+XOB,GJ!YY_G]02P,$%     @ 0X!<6E_S,)1G"@  $W,  !D
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MZ*I5T9511;?%Q:]K?O&9B6^\>)N4^F6YE#)*5SH9&7'GR@@)<Y$P#PGSD;
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M"*51%$W56N=I66932WZP-JD3!9K.9;]97F7X$+-4*S"HAP6EN5":!Z7Y4%H
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M>J/(-M7C^9ZRHLB2ZN6:,ZGLLH!\?YEEQ=M&64'[',S9_P%02P,$%     @
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M8JWHSFQ_XD[/J<<KC'+A"]O>]SR)H%@[,GH7S RT;/M5/.[J<!"03HX$I+N
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M9?0$10QE6UIMF%YJW:74O;RK>-?]$H37NOHQ5-*CL[_[KC5H<'6 @M!(<.H
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M*;YK+K>,0JW7 'B_YER]WN@!^K.\Y?]02P,$%     @ 0X!<6J+1WPX2!
M7!4  !D   !X;"]W;W)K<VAE971S+W-H965T.#4N>&ULM5AK;]LV%/TKA%8,
M#=!)HBP_DMD&5@?#4JQ=8"_;9T:ZMHE*I$?2=C+LQY>4%#UBF:T+SA]L/>X]
MO(?WB#[B],C%9[D%4.@ISYB<>5NE=C=!(),MY$3Z? =,WUESD1.E3\4FD#L!
M)"V2\BR(PG 4Y(0R;SXMKMV+^93O5489W LD]WE.Q/-[R/AQYF'OY<*2;K;*
M7 CFTQW9P K4P^Y>Z+.@1DEI#DQ2SI" ]<S[!=\LHB*AB/B+PE&VCI&A\LCY
M9W-RE\Z\T%0$&23*0!#]<X %9)E!TG7\4X%Z]9@FL7W\@OYK05Z3>202%CS[
MFZ9J._,F'DIA3?:96O+C;U 1&AJ\A&>R^$;'*C;T4+*7BN=5LJX@IZS\)4_5
M1+02<'PF(:H2HF]-&%0)@X)H65E!ZY8H,I\*?D3"1&LT<U#,39&MV5!FVKA2
M0M^E.D_-[UC"<T!_DB>0Z"?TB0A!S,2BM[>@",WDE;[ZL+I%;]]<H3>(,O21
M9IEN@)P&2H]O4(*D&NM].59T9JQ;2'PTP.]0%$9Q3_KBV],'W?1 LZZI1S7U
MJ, ;G,'[8P>&*]N@W[F4:*&I/^OGXDA$VDNN1(O[T<SC=B-W)(&9IY\G">(
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M2AM@GJ^$T*\->W3N/I7R_P%02P,$%     @ 0X!<6J#($BXE P  &0H  !D
M  !X;"]W;W)K<VAE971S+W-H965T.#<N>&ULK5;1;MHP%/T5*ZNF5EJ;D(1
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M,6/4Y'!4\D97YK!C1G<5P>\FF&IT*_<LA(6ERXT$<0!K^?-/[L3YM<M<3%B
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MF3F]2\379J]0^C[9O);#,T_+>V9IC@9)GC4K-'!U@XI/4NH\$CYTQX2SB6#
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MCF .P .&!$'U'-QZ'GGKYY37_*ME]!=02P,$%     @ 0X!<6I>*NQS
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MLQVF>"XN.R/]*$SU>]P73-/];RL<%&@I\U&Z V::UGAT*(,RE06;JOV'W5&
MY2%8'BW6:':[F%U/QX/E9,R&@^O![6C"%E\FD^4" /81P'YK@.QLS@&DCT#Z
MOQ%RL70O-Y-;!SB[8K/YY Y !@ADT!KD:'8S!Y A AFV 5DQ+I:ST5< &2&0
M48N0*P] Q@ADW-[M'BR^ ,@/".0'6L@AM](RO6%S(ZP[M3Z#<96R19GGL'?W
M+K"Q^X)X\+X7JK1L:;BR/#D:O7NH5:BUDGPOW9?6^R$3II0>L5,6/!/U/169
M"RP4&Y96*F%M?5^GC:;#Q-(C-LO"A27G[NP*=98K.5A#,LPF/6*=7$G%52)Y
MQN[T,\^*9S:PUH5*?S'EOO$,8F(^Z1$+9<@SARE8'0BR09+H4A5L+ HNL\;#
MB/FD1RR4*RX-^\:S4K ;P6UI1/4!2(>)I$=LDFN')!IMA1FC1ZR,L5@W6@83
M0X_8#(M")P];G:7"V#_8Q(URQ3,,F3$=>,0Z&.D\ET5U4CVDC5Q:Y3(<X;JL
ML"MV#3$Q-WC$;IBJ1.>"+?F/QB/FH>D&M1O*M17?RZKI)H_-CNAA,O"(93#G
MS^S1.F69^N/5L#:6-LET-6) 2,P+'K$7ILI*UQ^J."1U#QP;&!>0W-<#6N,&
M8U+PB*5PS#C7+@AP_:+N*7.8C'N8%CSJ/.-Y[086D93&C2OL3MH'=L,5WS<F
M@X&GA_G!(_8#&A\W,@T/$X='+ X<LP\Q,:=XQ$Z!P3([6W+W[?9/6.; I-(G
ME@H:-3=N=1^32I]8*F^CYI,MB3FF3^P8-'QNMB1:V")6#AH^-Z+\/B:=/G4R
M<C* /GG3,>_TB;VSCZ1/8F&>Z1-[YE08>Q(2LTR?V#(P4#P)A[FEWZI;?(B)
MN:7?9B5K%< Z-689G]@R.&8(,3'+^,26P3$CB(F9QB<V#8X90TS,-#ZQ:=Z6
M+]G9BV=@-_?1&11BS31BLW-VRUUN4\TJOI!"3$PS/K%FCC!_R;%^# 80$]..
M3ZR=(\Q]_,/JO4:D#&)BXO&)Q8/'O#!O\#$%^<0*PC&A@GQ,03YUR0S%A H*
M, 4%U(G.VPP"]G>(B2DH^/V)SCE;N NG9=7,$!-34$!=4,,P&\E.@"DH(%80
MGI/!GAY@%@K:G'EI]/0 G<EO<^:%G4-,S$(!L850S.:SB5DH("^R89B-9Q.S
M4$">"&&8C6<3LU! G@AAF-!"(6:AD#P1PC!A(A1B%@K)$R$,$R9"(6:AD#P1
MPC!A(A1B%@K;++FM/D!,S$(AL84PS%6]$.85$[-0V**%5O6JF%=,=$59BQ9:
M]:"%0LQ"(;&%WJFS'I(WB(E9*"2VT+N8=R+1*H&8F(5"8@N]B[E/-. Z0LQ"
M$;&%7JK6;^L=S<I,A"DH(E;0*^-L)RI&=5\GE/M0N9&O19B"(F(%O6+>\**:
MU97[DLP!&F)B"HJ(%52ML?GO^XW9)R*VS\DI"Y=3;KD1YT,X-1YA]HF([?,.
MYJ%A(29FGZB-"2#7FM5N]W!"3'1%,W4E[C3FT C^D.HGB(G9)Z*NQ)W&=(HL
M\UT!J\019I^HA<5KM2)M860"[1-C]HG;7,?67,>."2C^C>O87"N^; Z%NYAH
MKB>.,0'%Q (ZPG2-N].J6II5::B)B0DH)A;0$>8^;).9W,]=P;IFC%DH)E_K
MUL!$YH-BS$(Q^7*W!N98;(2I9EA>YM(A)F:AF-A"Z$UO]G3,0C&UA8Y6AYX,
MCF+T3S6U@+KUR?;SIU1LI!+IK;NZ=?L3GB5SPZJ7ZDH]SP^J1<Z;,LM&;M],
M76N>'OZI>/B7Y>=_ 5!+ P04    " !#@%Q:PR792)0"  #?,P  &@   'AL
M+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=I-;J- $(;AJU@<(+BKNJK;HSBK
MV60;Y0+(:?\HMD' *,GMQW(6]H=F,9N(;X4:1/&N'B'HQY=R;,9#>Q[VAVY8
M?)Z.YV%=[<>Q^U77PV9?3LWPT';E?+FR;?M3,UZ6_:[NFLU[LRNU+)=>]_<S
MJJ?'^YF+UZ^N_,_$=KL];,KO=O/G5,[C/P;7'VW_/NQ+&:O%:]/ORKBNZL_C
M[?107P_AX3*Y6CR_K:O^^2U4]=Q! D$R?Y!"D,X?%"$HSA]D$&3S!SD$^?Q!
M"8+2_$$9@O+\02L(6LT?%)8HXY(@:8(U@=8!N0X$7@<$.Q"('9#L0&!V0+0#
M@=H!V0X$;@>$.Q#('9#N0&!W0+P#@=Z">@N!WH)Z"X'>,GG9)M!;4&\AT%M0
M;R'06U!O(=!;4&\AT%M0;R'06U!O(=!;4&\AT%M1;R706U%O)=!;46\ET%LG
M'TL(]%;46PGT5M1;"?16U%L)]%;46PGT5M1;"?16U%L)](ZH=R30.Z+>D4#O
MB'I' KTCZAT)](Z3C]T$>D?4.Q+H'5'O2*!W1+TC@=X1]8X$>D?4.Q+H;:BW
M$>AMJ+<1Z&VHMQ'H;:BW$>AMJ+<1Z&V3GY4$>AOJ;01Z&^IM!'H;ZFT$>AOJ
M;01Z.^KM!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>COJ[01Z^V2S"8'>CGH[@=Z.
M>CN!WHYZ.X'>"?5.!'HGU#L1Z)U0[T2@=T*]$X'>"?5.!'HGU#L1Z)U0[T2@
M=YIL%B30.Z'>B4#OA'HG KTSZIT)],ZH=R;0.Z/>F4#OC'IG KTSZIT)],ZH
M=R;0.Z/>F4#OC'IG KWS9+/W3^H]C%_',MQZOM?X_)^D>KS<6VZ/ORZ_3Z*$
MJRO.]7W%\/074$L#!!0    ( $. 7%J-G,NK- (  %8R   3    6T-O;G1E
M;G1?5'EP97-=+GAM;,W;36[;,!"&X:L8V@:6+%*DU"+.INVVS:(78"4Z%JP_
MD$SJW+Z4G 1HD1H)7*#OQH)-<KX1!WAVOO[^.%F_.O;=X+?)/H3I8Y;Y>F][
MX]-QLD-<V8VN-R%^=7?99.J#N;.9V&QT5H]#L$-8A[E&<G/]V>[,?1=67X[Q
M9]^.PS9QMO/)ZM-IXYRU3<PT=6UM0ES/'H;FCY3U4T(:3RY[_+Z=_%7<D&2O
M)LPK?P]X.O?MP3K7-G9U:USX:OJX*SMVF0^/G?7I^1*O]#CN=FUMF[&^[^.1
MU$_.FL;OK0U]EYZ*7IU/#O&&[>DSOSA_*7,N,.Z\=>/DX\2<?7_<\TCFT^LI
M%K(NM.=?\24QEK[X_>P\[<8V;\R.U_MS=(=E'CY;'I??\>\S?JG_SCX$I \)
MZ:. ]*$@?6A('R6DCPK2QP=('_F&T@A%U)Q":DXQ-:>@FE-4S2FLYA17<PJL
M.45609%54&05%%D%159!D5509!44605%5D&155!DE119)45629%54F25%%DE
M159)D5529)44625%UH(B:T&1M:#(6E!D+2BR%A19"XJL!476@B)K09%54615
M%%D5159%D5519%44615%5D6155%D5119-45639%54V35%%DU159-D5539-44
M635%5DV1M:3(6E)D+2FREA192XJL)476DB)K29&UI,A:4F2M*+)6%%DKBJP5
M1=:*(FM%D;6BR%I19*W^IZP_QO'PC^.79]J;=GC.SY:_D]S\ E!+ 0(4 Q0
M   ( $. 7%H'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ 0X!<6O.&LL?N    *P(  !$
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M970R+GAM;%!+ 0(4 Q0    ( $. 7%HYSJPUQP<  (@C   8
M  " @>82  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " !#
M@%Q:L(^6-OX"   7"@  &               @('C&@  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ 0X!<6JATE0VI"   &S(  !@
M         ("!%QX  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( $. 7%J$.UXA1P,  %0)   8              " @?8F  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !#@%Q:4A0NJ> )  !A80
M&               @(%S*@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ 0X!<6MNZOZ-@ @  $@4  !@              ("!B30  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( $. 7%KK)(0/W!
M ,!K   8              " @1\W  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " !#@%Q:$QJ0K.TH  !1A@  &0              @($Q
M2   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( $. 7%KK
M\TU'^0@  ( 5   9              " @55Q  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ 0X!<6FM#?PX8$   JBH  !D
M     ("!A7H  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M" !#@%Q:[)^B&1H1  #G,0  &0              @('4B@  >&PO=V]R:W-H
M965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( $. 7%I"7+C$(!$  )TQ   9
M              " @26<  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L!
M A0#%     @ 0X!<6IC3+$('"P  =AX  !D              ("!?*T  'AL
M+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !#@%Q:+;;+A$P3
M  #>-P  &0              @(&ZN   >&PO=V]R:W-H965T<R]S:&5E=#$V
M+GAM;%!+ 0(4 Q0    ( $. 7%KJSX_F, X  /TI   9              "
M@3W,  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ 0X!<
M6IVR5W]'"P  :3L  !D              ("!I-H  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " !#@%Q:HNK%R)<+  "H(   &0
M        @($BY@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( $. 7%I,W G3\A   &8P   9              " @?#Q  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 0X!<6B2_C2-C!P  J1$
M !D              ("!&0,! 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " !#@%Q:).*ZEBD,  "4(0  &0              @(&S"@$
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( $. 7%IL5<L
MK@0  %(*   9              " @1,7 0!X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ 0X!<6K:HSR!B @  A@8  !D
M ("!^!L! 'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " !#
M@%Q:+'5HOD,"  "*!@  &0              @(&1'@$ >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( $. 7%H\I3,X$0(  -T$   9
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M970S,"YX;6Q02P$"% ,4    " !#@%Q:;RH3?1,&   *#@  &0
M    @(%U90$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M $. 7%I\27>_I04  (0,   9              " @;]K 0!X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ 0X!<6KG!*9&6!   _@D  !D
M             ("!FW$! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " !#@%Q:T3&C2G(*  #R'@  &0              @(%H=@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( $. 7%K%,M*3! H
M )<C   9              " @1&! 0!X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ 0X!<6F<9T+ZB P  /PL  !D              ("!
M3(L! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " !#@%Q:
MV9U/:TP(  !Y%0  &0              @($ECP$ >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( $. 7%IXFE!U*@<   P2   9
M      " @:B7 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ 0X!<6O2PA\L:!0  H1<  !D              ("!"9\! 'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !#@%Q:0UX\Z%@+  !PAP
M&0              @(%:I $ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( $. 7%K@<04W> ,  %@2   9              " @>FO 0!X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 0X!<6FF7\AM#
M!P  FCP  !D              ("!F+,! 'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    " !#@%Q: ;T<@D($  #A$P  &0
M@($2NP$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( $.
M7%H%L;E,B@<  )\^   9              " @8N_ 0!X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ 0X!<6L"'E OC"   [UD  !D
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M=#0Y+GAM;%!+ 0(4 Q0    ( $. 7%I>J^>I,@,  )$+   9
M  " @6;G 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
M0X!<6F%Y TX] P  ?PX  !D              ("!S^H! 'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    " !#@%Q:CYJ;;>X$  "8&0  &0
M            @(%#[@$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( $. 7%H%@X>VDP0  *(6   9              " @6CS 0!X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ 0X!<6D.X+A+P!P
MMT\  !D              ("!,O@! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    " !#@%Q:AN?1U+P*  ".B   &0              @(%9
M  ( >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( $. 7%H$
M22M<%08  )LG   9              " @4P+ @!X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ 0X!<6EWKIRJF @  5 <  !D
M     ("!F!$" 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $. 7%IL/S;*M ,  &P2   9              "
M@4HP @!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ 0X!<
M6K 8B]Z& P  $Q0  !D              ("!-30" 'AL+W=O<FMS:&5E=',O
M<VAE970V,RYX;6Q02P$"% ,4    " !#@%Q:87"LD;P"  #F"   &0
M        @('R-P( >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0
M   ( $. 7%IJL<H"6@,  +D*   9              " @>4Z @!X;"]W;W)K
M<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ 0X!<6LB%/U'* P  HQ
M !D              ("!=CX" 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q0
M2P$"% ,4    " !#@%Q:U^>E+L\"   %"0  &0              @(%W0@(
M>&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( $. 7%K'+W%'
M&0T  %64   9              " @7U% @!X;"]W;W)K<VAE971S+W-H965T
M-C@N>&UL4$L! A0#%     @ 0X!<6G<@J)UJ!   <Q   !D
M ("!S5(" 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " !#
M@%Q:8+7W#DL$  !E&0  &0              @(%N5P( >&PO=V]R:W-H965T
M<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( $. 7%H"AG5P!0<  (LV   9
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M970W-2YX;6Q02P$"% ,4    " !#@%Q:7_,PE&<*   3<P  &0
M    @(%7>P( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    (
M $. 7%J.>Y9P:0<  ,$L   9              " @?6% @!X;"]W;W)K<VAE
M971S+W-H965T-S<N>&UL4$L! A0#%     @ 0X!<6C4<.EG["   O4$  !D
M             ("!E8T" 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"
M% ,4    " !#@%Q:T#2P_H<#  !W#P  &0              @(''E@( >&PO
M=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( $. 7%JR$S_FH@,
M "\-   9              " @86: @!X;"]W;W)K<VAE971S+W-H965T.# N
M>&UL4$L! A0#%     @ 0X!<6LI^#^]  @  !04  !D              ("!
M7IX" 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4    " !#@%Q:
M(]'CS3D#  "M#0  &0              @('5H ( >&PO=V]R:W-H965T<R]S
M:&5E=#@R+GAM;%!+ 0(4 Q0    ( $. 7%I2DNSCIP,   4.   9
M      " @46D @!X;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%
M  @ 0X!<6MA2U\%)!0  UQ,  !D              ("!(Z@" 'AL+W=O<FMS
M:&5E=',O<VAE970X-"YX;6Q02P$"% ,4    " !#@%Q:HM'?#A($  !<%0
M&0              @(&CK0( >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+
M 0(4 Q0    ( $. 7%IK(5K?O0,  #8-   9              " @>RQ @!X
M;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @ 0X!<6J#($BXE
M P  &0H  !D              ("!X+4" 'AL+W=O<FMS:&5E=',O<VAE970X
M-RYX;6Q02P$"% ,4    " !#@%Q:K/1O=/D#  !8&P  &0
M@($\N0( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    ( $.
M7%K>]K:3CP,  '<9   -              "  6R] @!X;"]S='EL97,N>&UL
M4$L! A0#%     @ 0X!<6I>*NQS     $P(   L              ( !)L$"
M %]R96QS+RYR96QS4$L! A0#%     @ 0X!<6JO[O.5O!@  Z3D   \
M         ( !#\(" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $. 7%K#
M)=E(E (  -\S   :              "  :O( @!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( $. 7%J-G,NK- (  %8R   3
M      "  7?+ @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !@ &  5QH
' -S- @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>454</ContextCount>
  <ElementCount>651</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>173</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Agenus Transaction</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AgenusTransaction</Role>
      <ShortName>Agenus Transaction</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBio</Role>
      <ShortName>Sale of Pelican Business and Investment in Primrose Bio</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Spin-off of OmniAb</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SpinoffofOmniAb</Role>
      <ShortName>Spin-off of OmniAb</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Financial Royalty Assets, net (formerly known as Commercial License Rights)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRights</Role>
      <ShortName>Financial Royalty Assets, net (formerly known as Commercial License Rights)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Balance Sheet Account Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetails</Role>
      <ShortName>Balance Sheet Account Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Commitment and Contingencies: Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings</Role>
      <ShortName>Commitment and Contingencies: Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/Acquisitions</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioTables</Role>
      <ShortName>Sale of Pelican Business and Investment in Primrose Bio (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBio</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Spin-off of OmniAb (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SpinoffofOmniAbTables</Role>
      <ShortName>Spin-off of OmniAb (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/SpinoffofOmniAb</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Financial Royalty Assets, net (formerly known as Commercial License Rights) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsTables</Role>
      <ShortName>Financial Royalty Assets, net (formerly known as Commercial License Rights) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRights</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Balance Sheet Account Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsTables</Role>
      <ShortName>Balance Sheet Account Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BalanceSheetAccountDetails</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/FairValueMeasurement</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/Leases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/StockholdersEquity</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ligand.com/role/IncomeTaxes</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Segment Profit or Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Segment Profit or Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Agenus Transaction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AgenusTransactionDetails</Role>
      <ShortName>Agenus Transaction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ligand.com/role/AgenusTransaction</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Acquisitions - Fair Values of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions - Fair Values of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Acquisitions - Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Acquisitions - Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails</Role>
      <ShortName>Sale of Pelican Business and Investment in Primrose Bio - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio - Net Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails</Role>
      <ShortName>Sale of Pelican Business and Investment in Primrose Bio - Net Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio - Fair Value of the Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails</Role>
      <ShortName>Sale of Pelican Business and Investment in Primrose Bio - Fair Value of the Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Spin-off of OmniAb - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails</Role>
      <ShortName>Spin-off of OmniAb - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Spin-off of OmniAb - Schedule of Revenue and Expenses of the Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails</Role>
      <ShortName>Spin-off of OmniAb - Schedule of Revenue and Expenses of the Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Spin-off of OmniAb - Schedule of Non-cash Items and Capital Expenditures of the Discontinued Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails</Role>
      <ShortName>Spin-off of OmniAb - Schedule of Non-cash Items and Capital Expenditures of the Discontinued Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Financial Royalty Assets, net (formerly known as Commercial License Rights) - Schedule of Financial Royalty Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails</Role>
      <ShortName>Financial Royalty Assets, net (formerly known as Commercial License Rights) - Schedule of Financial Royalty Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Financial Royalty Assets, net (formerly known as Commercial License Rights) - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails</Role>
      <ShortName>Financial Royalty Assets, net (formerly known as Commercial License Rights) - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Balance Sheet Account Details - Investment Categories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails</Role>
      <ShortName>Balance Sheet Account Details - Investment Categories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails</Role>
      <ShortName>Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails</Role>
      <ShortName>Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Balance Sheet Account Details - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails</Role>
      <ShortName>Balance Sheet Account Details - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Balance Sheet Account Details - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails</Role>
      <ShortName>Balance Sheet Account Details - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails</Role>
      <ShortName>Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Balance Sheet Account Details - Schedule of Derivative Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails</Role>
      <ShortName>Balance Sheet Account Details - Schedule of Derivative Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Balance Sheet Account Details - Other Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsOtherInvestmentDetails</Role>
      <ShortName>Balance Sheet Account Details - Other Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Balance Sheet Account Details - Inventory in Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails</Role>
      <ShortName>Balance Sheet Account Details - Inventory in Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Balance Sheet Account Details - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Account Details - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Balance Sheet Account Details - Contingent Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Account Details - Contingent Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Balance Sheet Account Details - Other Long-term Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Account Details - Other Long-term Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails</Role>
      <ShortName>Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Fair Value Measurement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/FairValueMeasurementNarrativeDetails</Role>
      <ShortName>Fair Value Measurement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Leases - Operating and Finance Lease Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails</Role>
      <ShortName>Leases - Operating and Finance Lease Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Operating and Finance Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Stockholders' Equity - Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails</Role>
      <ShortName>Stockholders' Equity - Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Stockholders' Equity - Stock Option Plan Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails</Role>
      <ShortName>Stockholders' Equity - Stock Option Plan Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Stockholders' Equity - Breakdown of Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails</Role>
      <ShortName>Stockholders' Equity - Breakdown of Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Stockholders' Equity - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityAssumptionsDetails</Role>
      <ShortName>Stockholders' Equity - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Stockholders' Equity - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails</Role>
      <ShortName>Stockholders' Equity - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - Commitment and Contingencies: Legal Proceedings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails</Role>
      <ShortName>Commitment and Contingencies: Legal Proceedings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955565 - Disclosure - Income Taxes - Income Before Income Tax From Continuing Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesIncomeBeforeIncomeTaxFromContinuingOperationsDetails</Role>
      <ShortName>Income Taxes - Income Before Income Tax From Continuing Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955566 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Components of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955567 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9955568 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9955569 - Disclosure - Income Taxes - Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails</Role>
      <ShortName>Income Taxes - Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9955570 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="lgnd-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9955571 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ligand.com/role/SubsequentEvent</ParentRole>
      <Position>88</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="lgnd-20241231.htm">lgnd-20241231.htm</File>
    <File>lgnd-20241231.xsd</File>
    <File>lgnd-20241231_cal.xml</File>
    <File>lgnd-20241231_def.xml</File>
    <File>lgnd-20241231_lab.xml</File>
    <File>lgnd-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>lgnd-20241231_g1.jpg</File>
    <File>lgnd-20241231_g2.jpg</File>
    <File>lgnd-20241231_g3.jpg</File>
    <File>lgnd-20241231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="1466">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>113
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "lgnd-20241231.htm": {
   "nsprefix": "lgnd",
   "nsuri": "http://www.ligand.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "lgnd-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "lgnd-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "lgnd-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lgnd-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "lgnd-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lgnd-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 527,
   "keyCustom": 124,
   "axisStandard": 49,
   "axisCustom": 2,
   "memberStandard": 70,
   "memberCustom": 91,
   "hidden": {
    "total": 16,
    "http://fasb.org/us-gaap/2024": 11,
    "http://xbrl.sec.gov/dei/2024": 4,
    "http://www.ligand.com/20241231": 1
   },
   "contextCount": 454,
   "entityCount": 1,
   "segmentCount": 173,
   "elementCount": 1133,
   "unitCount": 12,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 1466,
    "http://xbrl.sec.gov/dei/2024": 38,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://www.ligand.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.ligand.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "9952151 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "longName": "9952153 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostDirectMaterial",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
     "longName": "9952154 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
     "longName": "9952155 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-24",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical",
     "longName": "9952156 - Statement - CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "shortName": "CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R9": {
     "role": "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "9952157 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "longName": "9952158 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.ligand.com/role/AgenusTransaction",
     "longName": "9952159 - Disclosure - Agenus Transaction",
     "shortName": "Agenus Transaction",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.ligand.com/role/Acquisitions",
     "longName": "9952160 - Disclosure - Acquisitions",
     "shortName": "Acquisitions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBio",
     "longName": "9952161 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio",
     "shortName": "Sale of Pelican Business and Investment in Primrose Bio",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R14": {
     "role": "http://www.ligand.com/role/SpinoffofOmniAb",
     "longName": "9952162 - Disclosure - Spin-off of OmniAb",
     "shortName": "Spin-off of OmniAb",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R15": {
     "role": "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRights",
     "longName": "9952163 - Disclosure - Financial Royalty Assets, net (formerly known as Commercial License Rights)",
     "shortName": "Financial Royalty Assets, net (formerly known as Commercial License Rights)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:FinancialRoyaltyAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:FinancialRoyaltyAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetails",
     "longName": "9952164 - Disclosure - Balance Sheet Account Details",
     "shortName": "Balance Sheet Account Details",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.ligand.com/role/FairValueMeasurement",
     "longName": "9952165 - Disclosure - Fair Value Measurement",
     "shortName": "Fair Value Measurement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.ligand.com/role/Leases",
     "longName": "9952166 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.ligand.com/role/Debt",
     "longName": "9952167 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.ligand.com/role/StockholdersEquity",
     "longName": "9952168 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings",
     "longName": "9952169 - Disclosure - Commitment and Contingencies: Legal Proceedings",
     "shortName": "Commitment and Contingencies: Legal Proceedings",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.ligand.com/role/IncomeTaxes",
     "longName": "9952170 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.ligand.com/role/SubsequentEvent",
     "longName": "9952171 - Disclosure - Subsequent Event",
     "shortName": "Subsequent Event",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-454",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-454",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:BusinessSpinOffAndMigrationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:BusinessSpinOffAndMigrationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.ligand.com/role/AcquisitionsTables",
     "longName": "9955513 - Disclosure - Acquisitions (Tables)",
     "shortName": "Acquisitions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioTables",
     "longName": "9955514 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio (Tables)",
     "shortName": "Sale of Pelican Business and Investment in Primrose Bio (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:ScheduleOfFairValueOfTheConsiderationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.ligand.com/role/SpinoffofOmniAbTables",
     "longName": "9955515 - Disclosure - Spin-off of OmniAb (Tables)",
     "shortName": "Spin-off of OmniAb (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R33": {
     "role": "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsTables",
     "longName": "9955516 - Disclosure - Financial Royalty Assets, net (formerly known as Commercial License Rights) (Tables)",
     "shortName": "Financial Royalty Assets, net (formerly known as Commercial License Rights) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:ScheduleOfFinancialRoyaltyAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:ScheduleOfFinancialRoyaltyAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsTables",
     "longName": "9955517 - Disclosure - Balance Sheet Account Details (Tables)",
     "shortName": "Balance Sheet Account Details (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.ligand.com/role/FairValueMeasurementTables",
     "longName": "9955518 - Disclosure - Fair Value Measurement (Tables)",
     "shortName": "Fair Value Measurement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.ligand.com/role/LeasesTables",
     "longName": "9955519 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:AssetsAndLiabilitiesLesseeTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.ligand.com/role/StockholdersEquityTables",
     "longName": "9955520 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.ligand.com/role/IncomeTaxesTables",
     "longName": "9955521 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails",
     "longName": "9955522 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Segment Profit or Loss (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Segment Profit or Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:OtherExpenseItemsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9955523 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails",
     "longName": "9955524 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Revenue from Significant Partners (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-70",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-70",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
     "longName": "9955525 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Royalty Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-87",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
     "longName": "9955526 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Calculation of Earnings per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.ligand.com/role/AgenusTransactionDetails",
     "longName": "9955527 - Disclosure - Agenus Transaction (Details)",
     "shortName": "Agenus Transaction (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "lgnd:FinancialRoyaltyAssetsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleOfFinancialRoyaltyAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-142",
      "name": "lgnd:FinanceRoyaltyAgreementRoyaltyRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
     "longName": "9955528 - Disclosure - Acquisitions - Narrative (Details)",
     "shortName": "Acquisitions - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsToAcquireEquitySecuritiesFvNi",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-160",
      "name": "us-gaap:PaymentsToAcquireEquitySecuritiesFvNi",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
     "longName": "9955529 - Disclosure - Acquisitions - Fair Values of Assets Acquired and Liabilities Assumed (Details)",
     "shortName": "Acquisitions - Fair Values of Assets Acquired and Liabilities Assumed (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-159",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
     "longName": "9955530 - Disclosure - Acquisitions - Assets Acquired and Liabilities Assumed (Details)",
     "shortName": "Acquisitions - Assets Acquired and Liabilities Assumed (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-41",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-166",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
     "longName": "9955531 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio - Narrative (Details)",
     "shortName": "Sale of Pelican Business and Investment in Primrose Bio - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GainLossOnSaleOfBusiness",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails",
     "longName": "9955532 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio - Net Asset (Details)",
     "shortName": "Sale of Pelican Business and Investment in Primrose Bio - Net Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-175",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-175",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails",
     "longName": "9955533 - Disclosure - Sale of Pelican Business and Investment in Primrose Bio - Fair Value of the Consideration (Details)",
     "shortName": "Sale of Pelican Business and Investment in Primrose Bio - Fair Value of the Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-175",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleOfFairValueOfTheConsiderationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-175",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleOfFairValueOfTheConsiderationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails",
     "longName": "9955534 - Disclosure - Spin-off of OmniAb - Narrative (Details)",
     "shortName": "Spin-off of OmniAb - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-187",
      "name": "us-gaap:DeferredTaxAssetsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails",
     "longName": "9955535 - Disclosure - Spin-off of OmniAb - Schedule of Revenue and Expenses of the Discontinued Operations (Details)",
     "shortName": "Spin-off of OmniAb - Schedule of Revenue and Expenses of the Discontinued Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-190",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails",
     "longName": "9955536 - Disclosure - Spin-off of OmniAb - Schedule of Non-cash Items and Capital Expenditures of the Discontinued Operations (Details)",
     "shortName": "Spin-off of OmniAb - Schedule of Non-cash Items and Capital Expenditures of the Discontinued Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:PaymentsToContingentValueRightHoldersFinancingActivity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-190",
      "name": "lgnd:DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails",
     "longName": "9955537 - Disclosure - Financial Royalty Assets, net (formerly known as Commercial License Rights) - Schedule of Financial Royalty Assets (Details)",
     "shortName": "Financial Royalty Assets, net (formerly known as Commercial License Rights) - Schedule of Financial Royalty Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "lgnd:FinancialRoyaltyAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleOfFinancialRoyaltyAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "lgnd:FinancialRoyaltyAssetsAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleOfFinancialRoyaltyAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
     "longName": "9955538 - Disclosure - Financial Royalty Assets, net (formerly known as Commercial License Rights) - Narrative (Details)",
     "shortName": "Financial Royalty Assets, net (formerly known as Commercial License Rights) - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:ImpairmentLossOnFinancialRoyaltyAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-212",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-6",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails",
     "longName": "9955539 - Disclosure - Balance Sheet Account Details - Investment Categories (Details)",
     "shortName": "Balance Sheet Account Details - Investment Categories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails",
     "longName": "9955540 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "shortName": "Balance Sheet Account Details - Available-for-Sale Debt Securities by Contractual Maturity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
     "longName": "9955541 - Disclosure - Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)",
     "shortName": "Balance Sheet Account Details - Available-for-Sale Debt Securities in an Unrealized Loss Position (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
     "longName": "9955542 - Disclosure - Balance Sheet Account Details - Narrative (Details)",
     "shortName": "Balance Sheet Account Details - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "position",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "unitRef": "position",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
     "longName": "9955543 - Disclosure - Balance Sheet Account Details - Property and Equipment (Details)",
     "shortName": "Balance Sheet Account Details - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
     "longName": "9955544 - Disclosure - Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)",
     "shortName": "Balance Sheet Account Details - Goodwill and Other Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:IntangibleAssetsNetIncludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails",
     "longName": "9955545 - Disclosure - Balance Sheet Account Details - Schedule of Derivative Assets (Details)",
     "shortName": "Balance Sheet Account Details - Schedule of Derivative Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DerivativeAssetsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-257",
      "name": "us-gaap:DerivativeAssetsNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherInvestmentDetails",
     "longName": "9955546 - Disclosure - Balance Sheet Account Details - Other Investment (Details)",
     "shortName": "Balance Sheet Account Details - Other Investment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:OtherInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-275",
      "name": "us-gaap:OtherInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryInvestmentHoldingsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails",
     "longName": "9955547 - Disclosure - Balance Sheet Account Details - Inventory in Other Assets (Details)",
     "shortName": "Balance Sheet Account Details - Inventory in Other Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:InventoryNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-285",
      "name": "us-gaap:InventoryWorkInProcessNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails",
     "longName": "9955548 - Disclosure - Balance Sheet Account Details - Accrued Liabilities (Details)",
     "shortName": "Balance Sheet Account Details - Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AccruedRoyaltiesCurrentAndNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
     "longName": "9955549 - Disclosure - Balance Sheet Account Details - Contingent Liabilities (Details)",
     "shortName": "Balance Sheet Account Details - Contingent Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleofContingentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:ScheduleofContingentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails",
     "longName": "9955550 - Disclosure - Balance Sheet Account Details - Other Long-term Liabilities (Details)",
     "shortName": "Balance Sheet Account Details - Other Long-term Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ContractWithCustomerLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ContractWithCustomerLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "longName": "9955551 - Disclosure - Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurement - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "lgnd:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails",
     "longName": "9955552 - Disclosure - Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)",
     "shortName": "Fair Value Measurement - Reconciliation of Level 3 Financial Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-41",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails",
     "longName": "9955553 - Disclosure - Fair Value Measurement - Narrative (Details)",
     "shortName": "Fair Value Measurement - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetImpairment",
       "us-gaap:GoodwillAndIntangibleAssetImpairment",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetImpairment",
       "us-gaap:GoodwillAndIntangibleAssetImpairment",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.ligand.com/role/LeasesNarrativeDetails",
     "longName": "9955554 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:FinanceLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "lgnd:LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails",
     "longName": "9955555 - Disclosure - Leases - Operating and Finance Lease Assets and Liabilities (Details)",
     "shortName": "Leases - Operating and Finance Lease Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "lgnd:LeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "lgnd:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails",
     "longName": "9955556 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)",
     "shortName": "Leases - Maturities of Operating and Finance Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.ligand.com/role/DebtNarrativeDetails",
     "longName": "9955557 - Disclosure - Debt - Narrative (Details)",
     "shortName": "Debt - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-358",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails",
     "longName": "9955558 - Disclosure - Stockholders' Equity - Share-Based Compensation (Details)",
     "shortName": "Stockholders' Equity - Share-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
     "longName": "9955559 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails",
     "longName": "9955560 - Disclosure - Stockholders' Equity - Stock Option Plan Activity (Details)",
     "shortName": "Stockholders' Equity - Stock Option Plan Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-379",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-382",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails",
     "longName": "9955561 - Disclosure - Stockholders' Equity - Breakdown of Options Outstanding (Details)",
     "shortName": "Stockholders' Equity - Breakdown of Options Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails",
     "longName": "9955562 - Disclosure - Stockholders' Equity - Assumptions (Details)",
     "shortName": "Stockholders' Equity - Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-406",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-406",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
     "longName": "9955563 - Disclosure - Stockholders' Equity - Restricted Stock Activity (Details)",
     "shortName": "Stockholders' Equity - Restricted Stock Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-418",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-416",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails",
     "longName": "9955564 - Disclosure - Commitment and Contingencies: Legal Proceedings - Narrative (Details)",
     "shortName": "Commitment and Contingencies: Legal Proceedings - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-430",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "unitRef": "complaint",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-430",
      "name": "us-gaap:LossContingencyNewClaimsFiledNumber",
      "unitRef": "complaint",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.ligand.com/role/IncomeTaxesIncomeBeforeIncomeTaxFromContinuingOperationsDetails",
     "longName": "9955565 - Disclosure - Income Taxes - Income Before Income Tax From Continuing Operations (Details)",
     "shortName": "Income Taxes - Income Before Income Tax From Continuing Operations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-431",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
     "longName": "9955566 - Disclosure - Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "shortName": "Income Taxes - Components of Income Tax Expense (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails",
     "longName": "9955567 - Disclosure - Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)",
     "shortName": "Income Taxes - Reconciliation of Income Tax Expense (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.ligand.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9955568 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails",
     "longName": "9955569 - Disclosure - Income Taxes - Deferred Taxes (Details)",
     "shortName": "Income Taxes - Deferred Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails",
     "longName": "9955570 - Disclosure - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-28",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.ligand.com/role/SubsequentEventDetails",
     "longName": "9955571 - Disclosure - Subsequent Event (Details)",
     "shortName": "Subsequent Event (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PaymentsToAcquireNotesReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-452",
      "name": "us-gaap:ReceivableWithImputedInterestFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "lgnd-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "lgnd_AGEN2373Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AGEN2373Member",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AGEN2373",
        "label": "AGEN2373 [Member]",
        "documentation": "AGEN2373"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_APEIRONMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "APEIRONMember",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "APEIRON",
        "label": "APEIRON [Member]",
        "documentation": "APEIRON"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AboveMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AboveMilestoneMember",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Above 3 million",
        "label": "Above Milestone [Member]",
        "documentation": "Above Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingStandardsUpdateExtensibleList",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Update [Extensible List]",
        "label": "Accounting Standards Update [Extensible Enumeration]",
        "documentation": "Indicates amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r339",
      "r340",
      "r341",
      "r405",
      "r406",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r516",
      "r517",
      "r526",
      "r692",
      "r693",
      "r694",
      "r695",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r714",
      "r715",
      "r716",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r730",
      "r731",
      "r732",
      "r742",
      "r743",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r768",
      "r769",
      "r785",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r1382"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r1182"
     ]
    },
    "lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock shares, amount",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Converted Instrument Amount",
        "documentation": "Accounts Receivable, after Allowance for Credit Loss, Converted Instrument Amount"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt conversion price per share (in USD per share)",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Converted Instrument , Conversion Price",
        "documentation": "Accounts Receivable, after Allowance for Credit Loss, Converted Instrument , Conversion Price"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued upon conversion of preferred stock (in shares)",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Converted Instrument Shares Issued",
        "documentation": "Accounts Receivable, after Allowance for Credit Loss, Converted Instrument Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1393"
     ]
    },
    "us-gaap_AccountsReceivableNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible note",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Noncurrent",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r858",
      "r1393"
     ]
    },
    "lgnd_AccountsReceivableTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AccountsReceivableTerm",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible note maturity period (in years)",
        "label": "Accounts Receivable, Term",
        "documentation": "Accounts Receivable, Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization/accretion of premium (discount) on investments, net",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "lgnd_AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued purchases of financial royalty assets",
        "label": "Accrued Commercial License Rights Purchases Incurred But Not Yet Paid",
        "documentation": "Accrued Commercial License Rights Purchases Incurred But Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AccruedCustomerDepositsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AccruedCustomerDepositsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer deposit",
        "label": "Accrued Customer Deposits, Current",
        "documentation": "Accrued Customer Deposits, Current"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AccruedDebtIssuanceCostsIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AccruedDebtIssuanceCostsIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued debt issuance costs",
        "label": "Accrued Debt Issuance Costs Incurred But Not Yet Paid",
        "documentation": "Accrued Debt Issuance Costs Incurred But Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties owed to third parties",
        "label": "Accrued Royalties",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "lgnd_AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued royalty from financial royalty assets",
        "label": "Accrued Royalty From Commercial License Rights Incurred But Not Yet Paid",
        "documentation": "Accrued Royalty From Commercial License Rights Incurred But Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AccruedSubcontractorExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AccruedSubcontractorExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subcontractor",
        "label": "Accrued Subcontractor Expenses, Current",
        "documentation": "Accrued Subcontractor Expenses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AccruedSupplierExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AccruedSupplierExpensesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplier",
        "label": "Accrued Supplier Expenses, Current",
        "documentation": "Accrued Supplier Expenses, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r290",
      "r881"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r158",
      "r299",
      "r875",
      "r922",
      "r926"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r17",
      "r33",
      "r734",
      "r737",
      "r811",
      "r917",
      "r918",
      "r1362",
      "r1363",
      "r1364",
      "r1379",
      "r1380",
      "r1381",
      "r1384"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average estimated useful life of finite-lived intangible assets acquired (in years)",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r1114"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r1182",
      "r1581"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r938",
      "r1379",
      "r1380",
      "r1381",
      "r1384",
      "r1505",
      "r1582"
     ]
    },
    "lgnd_AdditionalRoyaltiesReceivableUnderSalesbasedMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AdditionalRoyaltiesReceivableUnderSalesbasedMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional royalties receivable under sales-based milestones",
        "label": "Additional Royalties Receivable Under Sales-based Milestones",
        "documentation": "Additional Royalties Receivable Under Sales-based Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1273"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1273"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1273"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1273"
     ]
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bond hedge transaction",
        "label": "Adjustments to Additional Paid In Capital, Bond Hedge Transaction",
        "documentation": "Adjustments to Additional Paid In Capital, Bond Hedge Transaction"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "OmniAb Distribution",
        "label": "Adjustments to Additional Paid in Capital, Decrease Due To Separation",
        "documentation": "Adjustments to Additional Paid in Capital, Decrease Due To Separation"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Final OmniAb Distribution",
        "label": "Adjustments To Additional Paid in Capital, Increase Due To Separation",
        "documentation": "Adjustments To Additional Paid in Capital, Increase Due To Separation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r77",
      "r616"
     ]
    },
    "lgnd_AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Final tax impact of OmniAb Distribution",
        "label": "Adjustments To Additional Paid In Capital, Tax Return To Provision",
        "documentation": "Adjustments To Additional Paid In Capital, Tax Return To Provision"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant derivative",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r64",
      "r198"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AgenusInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AgenusInc.Member",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agenus, Inc.",
        "verboseLabel": "Agenus (Bot/Bal)",
        "label": "Agenus, Inc. [Member]",
        "documentation": "Agenus, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AgenusPartneredProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AgenusPartneredProgramMember",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agenus Partnered Program",
        "label": "Agenus Partnered Program [Member]",
        "documentation": "Agenus Partnered Program"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1318"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1231",
      "r1242",
      "r1252",
      "r1285"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1234",
      "r1245",
      "r1255",
      "r1288"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1319"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1273"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1280"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1246",
      "r1256",
      "r1280",
      "r1289",
      "r1293",
      "r1301"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) of allowance for credit loss",
        "label": "Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1415"
     ]
    },
    "lgnd_AmendedESPPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AmendedESPPMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended ESPP",
        "label": "Amended ESPP [Member]",
        "documentation": "Amended ESPP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization issuance costs",
        "label": "Amortization of Debt Issuance Costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r571",
      "r1372",
      "r1524"
     ]
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount and issuance fees",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r1148",
      "r1149",
      "r1372",
      "r1524"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive shares excluded from calculation due to anti-dilutive effect (shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r363"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionLineItems",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Line Items]",
        "label": "Asset Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "us-gaap_AssetAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionTable",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Table]",
        "label": "Asset Acquisition [Table]",
        "documentation": "Disclosure of information about asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "us-gaap_AssetAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetAcquisitionTextBlock",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransaction"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agenus Transaction",
        "label": "Asset Acquisition [Text Block]",
        "documentation": "The entire disclosure for asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1499"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset impairment charges",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r60"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r235",
      "r294",
      "r329",
      "r366",
      "r371",
      "r395",
      "r398",
      "r443",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r725",
      "r728",
      "r773",
      "r869",
      "r986",
      "r1135",
      "r1136",
      "r1182",
      "r1209",
      "r1445",
      "r1446",
      "r1533"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSETS",
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating and Finance Lease Assets and Liabilities",
        "label": "Assets and Liabilities, Lessee [Table Text Block]",
        "documentation": "Assets and Liabilities, Lessee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r304",
      "r329",
      "r443",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r725",
      "r728",
      "r773",
      "r1182",
      "r1445",
      "r1446",
      "r1533"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r755",
      "r1169"
     ]
    },
    "lgnd_AtTheMarketEquityOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AtTheMarketEquityOfferingMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-The-Market Equity Offering",
        "label": "At-The Market Equity Offering [Member]",
        "documentation": "At-The Market Equity Offering"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.ligand.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r1214",
      "r1215",
      "r1238"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.ligand.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r1214",
      "r1215",
      "r1238"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.ligand.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r1214",
      "r1215",
      "r1238"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrealized gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r409",
      "r471",
      "r868"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValueAbstract",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position [Line Items]",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r1141"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After one year through five years",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1403"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After one year through five years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r863"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAmortizedCostAbstract",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r1400",
      "r1401",
      "r1545"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within one year",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1402"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within one year",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r416",
      "r862"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated fair value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r471",
      "r754",
      "r857",
      "r1169",
      "r1173",
      "r1394",
      "r1509",
      "r1510",
      "r1511"
     ]
    },
    "us-gaap_AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsAbstract",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Number of Positions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1296"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1297"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r619",
      "r620",
      "r621",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1295"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1294"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1293"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1293"
     ]
    },
    "lgnd_BMS986442Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BMS986442Member",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BMS-986442",
        "label": "BMS-986442 [Member]",
        "documentation": "BMS-986442"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BOTBALMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BOTBALMember",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BOT/BAL",
        "label": "BOT/BAL [Member]",
        "documentation": "BOT/BAL"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BaseRateMember",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Rate",
        "label": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Principles of Consolidation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BasisOfPresentationLineItems",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Presentation [Line Items]",
        "documentation": "Basis of presentation."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BasisOfPresentationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BasisOfPresentationTable",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation [Table]",
        "label": "Basis of Presentation [Table]",
        "documentation": "Basis of Presentation."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BelowMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BelowMilestoneMember",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Below 3 million",
        "label": "Below Milestone [Member]",
        "documentation": "Below Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BridgeLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BridgeLoanMember",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge Loan",
        "label": "Bridge Loan [Member]",
        "documentation": "Financing which is expected to be replaced by a medium to long-term loan. The loan \"bridges\" the gap in time when otherwise no financing would be in place."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BrowseTaxonomyDisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenseAbstract",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Browse Taxonomy Disposal Group, Including Discontinued Operation, Other Income (Expense) [Abstract]",
        "documentation": "Browse Taxonomy Disposal Group, Including Discontinued Operation, Other Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r712",
      "r1161",
      "r1162"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r712",
      "r1161",
      "r1162"
     ]
    },
    "lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Commercial rights, beginning of period",
        "periodEndLabel": "Commercial rights, end of period",
        "label": "Business Acquisition Contingent Consideration Potential Cash Payment at End of Period",
        "documentation": "Business Acquisition Contingent Consideration Potential Cash Payment at End of Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred transaction costs",
        "label": "Business Acquisition, Transaction Costs",
        "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill acquired that is expected to be deductible for tax purposes",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "lgnd_BusinessCombinationAcquiredPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BusinessCombinationAcquiredPercentage",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired (as a percent)",
        "label": "Business Combination, Acquired Percentage",
        "documentation": "Business Combination, Acquired Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BusinessCombinationAcquisitionCostIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BusinessCombinationAcquisitionCostIncurredButNotYetPaid",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Primrose transaction costs",
        "label": "Business Combination, Acquisition Cost Incurred But Not Yet Paid",
        "documentation": "Business Combination, Acquisition Cost Incurred But Not Yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition related costs",
        "label": "Business Combination, Acquisition Related Costs",
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration transferred",
        "verboseLabel": "Total consideration",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r16"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities incurred",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r2",
      "r88",
      "r718"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent earn-out payment",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r211",
      "r719",
      "r756",
      "r757",
      "r758"
     ]
    },
    "lgnd_BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contingent liabilities",
        "label": "Business Combination, Contingent Consideration, Liability, Fair Value Disclosure",
        "documentation": "Business Combination, Contingent Consideration, Liability, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent liability measurement input (as a percent)",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "documentation": "Value of input used to measure contingent consideration liability from business combination."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r757",
      "r758"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.ligand.com/role/Acquisitions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r713"
     ]
    },
    "lgnd_BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Frequency of cash payments to CVR holders",
        "label": "Business Combination, Frequency of Cash Payments to Contingent Value Rights Holders",
        "documentation": "Business Combination, Frequency of Cash Payments to Contingent Value Rights Holders"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BusinessCombinationLoanFeesAndInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BusinessCombinationLoanFeesAndInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DIP loan fees and interest",
        "label": "Business Combination, Loan Fees And Interest",
        "documentation": "Business Combination, Loan Fees And Interest"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of CVRs issued from each CVR series",
        "label": "Business Combination, Number of Contingent Value Rights Issued from Each Contingent Value Right Series",
        "documentation": "Business Combination, Number of Contingent Value Rights Issued from Each Contingent Value Right Series"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of CVRs issued per acquiree share",
        "label": "Business Combination, Number of Contingent Value Rights Issued per Acquiree Share",
        "documentation": "Business Combination, Number of Contingent Value Rights Issued per Acquiree Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Restricted cash",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial royalty assets",
        "verboseLabel": "Contract assets (financial royalty assets)",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract Assets",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Contract Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts payable and accrued liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred revenue",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue",
        "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset",
        "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets",
        "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability",
        "negatedTerseLabel": "Deferred tax liabilities, net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax payable",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Income Tax Payable",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Income Tax Payable"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate used to value intangible assets acquired (as a percent)",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Discount Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Intangible assets",
        "terseLabel": "Intangible assets",
        "verboseLabel": "Intangible assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Liabilities assumed",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "documentation": "Amount of liabilities assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total fair value of net assets acquired",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82"
     ]
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating lease liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Liabilities",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use asset",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Right-of-Use Assets",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Operating Lease Right-of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "verboseLabel": "Other assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other liabilities",
        "negatedLabel": "Other liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Liabilities",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Other Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82"
     ]
    },
    "lgnd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of tangible assets acquired, net of cash and restricted cash received",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired Net of Cash And Restricted Cash Received",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets Acquired Net of Cash And Restricted Cash Received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationsPolicy",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Business Combinations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209"
     ]
    },
    "us-gaap_BusinessExitCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessExitCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business exit costs",
        "label": "Business Exit Costs",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "lgnd_BusinessSpinOffAndMigrationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "BusinessSpinOffAndMigrationPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business",
        "label": "Business Spin-Off And Migration [Policy Text Block]",
        "documentation": "Business Spin-Off And Migration"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California and New Jersey Research Tax Credit Carryforward",
        "label": "California and New Jersey Research Tax Credit Carryforward [Member]",
        "documentation": "California and New Jersey Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpenditureDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpenditureDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchase of property, plant and equipment",
        "label": "Capital Expenditure, Discontinued Operations",
        "documentation": "Amount of capital expenditure attributable to discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued fixed asset purchases",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44",
      "r45"
     ]
    },
    "us-gaap_CapitalLossCarryforwardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CapitalLossCarryforwardMember",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital Loss Carryforward",
        "label": "Capital Loss Carryforward [Member]",
        "documentation": "Deductions derived from capital losses that cannot be utilized on the tax return during a period that have been carried forward to reduce taxable income or taxes payable in a future year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reported Value",
        "label": "Reported Value Measurement [Member]",
        "documentation": "Measured as reported on the statement of financial position (balance sheet)."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105"
     ]
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAcquiredFromAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash acquired from acquisition",
        "label": "Cash Acquired from Acquisition",
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business)."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r288",
      "r1118"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at beginning of year",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r173",
      "r326"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r173"
     ]
    },
    "lgnd_CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash Equivalents &amp; Short-term Investments",
        "label": "Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]",
        "documentation": "Cash, Cash Equivalents, and Short-term Investments [Policy Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental schedule of non-cash investing and financing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1271"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1268"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1266"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r296",
      "r297",
      "r298",
      "r329",
      "r354",
      "r358",
      "r360",
      "r362",
      "r368",
      "r369",
      "r443",
      "r540",
      "r542",
      "r543",
      "r544",
      "r547",
      "r548",
      "r579",
      "r580",
      "r584",
      "r587",
      "r595",
      "r773",
      "r931",
      "r932",
      "r933",
      "r934",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r974",
      "r995",
      "r1014",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1324",
      "r1375",
      "r1385"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price of warrants (in USD per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued in public offering (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r596"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "lgnd_CollarsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "CollarsMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collars",
        "label": "Collars [Member]",
        "documentation": "Collars"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_CommercialLicenseRightsCreditLossAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "CommercialLicenseRightsCreditLossAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Reduction) credit loss adjustment",
        "label": "Commercial License Rights, Credit Loss Adjustment",
        "documentation": "Commercial License Rights, Credit Loss Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r539",
      "r1199",
      "r1200",
      "r1201",
      "r1202"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments and contingencies",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r224",
      "r872",
      "r973"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedings"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment and Contingencies: Legal Proceedings",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r530",
      "r531",
      "r1109",
      "r1433",
      "r1438"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend declared (in USD per share)",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r198"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1195",
      "r1196",
      "r1197",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1379",
      "r1380",
      "r1384",
      "r1505",
      "r1579",
      "r1582"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value (in USD per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r974"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r149"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock outstanding (in shares)",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "periodEndLabel": "Balance at end of period (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r149",
      "r974",
      "r992",
      "r1582",
      "r1583"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, $0.001 par value; 60,000 shares authorized; 19,106 and 17,556 shares issued and outstanding at December\u00a031, 2024 and 2023, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r874",
      "r1182"
     ]
    },
    "us-gaap_CommonStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValueOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vikings common stock outstanding",
        "label": "Common Stock, Value, Outstanding",
        "documentation": "Value of common shares held by shareholders. Excludes common shares repurchased and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r974"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1277"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1276"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1278"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1275"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income (loss)",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r308",
      "r310",
      "r315",
      "r859",
      "r888",
      "r889"
     ]
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Income (Loss)",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ComputerEquipmentAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ComputerEquipmentAndSoftwareMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Computer equipment and software",
        "label": "Computer Equipment And Software [Member]",
        "documentation": "Computer equipment and software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r106",
      "r107",
      "r404",
      "r1108"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r106",
      "r107",
      "r404",
      "r928",
      "r1108"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r106",
      "r107",
      "r404",
      "r1108",
      "r1333"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Concentrations of Business Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r248"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenues (as a percent)",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r106",
      "r107",
      "r404"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r106",
      "r107",
      "r404",
      "r1108"
     ]
    },
    "lgnd_ConsiderationClassficationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ConsiderationClassficationAxis",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration Classfication [Axis]",
        "label": "Consideration Classfication [Axis]",
        "documentation": "Consideration Classfication"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ConsiderationClassficationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ConsiderationClassficationDomain",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration Classfication [Domain]",
        "label": "Consideration Classfication [Domain]",
        "documentation": "Consideration Classfication [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration paid for an interest in potential development milestone",
        "verboseLabel": "Cash consideration paid",
        "label": "Consideration Paid For An Interest In Potential Development Milestone",
        "documentation": "Consideration Paid For An Interest In Potential Development Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ContingentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ContingentLiabilitiesMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent liabilities",
        "label": "Contingent Liabilities [Member]",
        "documentation": "Contingent Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ContingentLiabilityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ContingentLiabilityRollForward",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Liability",
        "label": "Contingent Liability [Roll Forward]",
        "documentation": "Contingent Liability [Roll Forward]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ContingentMilestonePurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ContingentMilestonePurchaseAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Contingent Milestone Purchase Agreement",
        "documentation": "Contingent Milestone Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ContractRevenueAndOtherIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ContractRevenueAndOtherIncomeMember",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract revenue and other income",
        "label": "Contract Revenue And Other Income [Member]",
        "documentation": "Contract Revenue And Other Income"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ContractRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ContractRevenueMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contract revenue and other income",
        "netLabel": "Contract revenue",
        "label": "Contract Revenue [Member]",
        "documentation": "Contract Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerAssetGross",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross contract asset",
        "label": "Contract with Customer, Asset, before Allowance for Credit Loss",
        "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r460",
      "r1450",
      "r1451"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r599",
      "r602"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novan (Pelthos) contract liability",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r598",
      "r599",
      "r602"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r603"
     ]
    },
    "us-gaap_ContractualRightsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractualRightsMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual relationships",
        "label": "Contractual Rights [Member]",
        "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements)."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1428",
      "r1429",
      "r1430",
      "r1431"
     ]
    },
    "us-gaap_ConvertibleDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtSecuritiesMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Debt Securities",
        "label": "Convertible Debt Securities [Member]",
        "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r1454"
     ]
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes",
        "label": "Convertible Notes Payable [Member]",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r219"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock (in shares)",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r68",
      "r148",
      "r196",
      "r590"
     ]
    },
    "lgnd_ConvertibleSeniorNotesDue2023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ConvertibleSeniorNotesDue2023Member",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Convertible Senior Notes",
        "label": "Convertible Senior Notes due 2023 [Member]",
        "documentation": "Convertible Senior Notes due 2023"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate notes/bonds",
        "verboseLabel": "Corporate notes/bonds",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r1158",
      "r1160",
      "r1169",
      "r1183",
      "r1192",
      "r1576"
     ]
    },
    "lgnd_CorporateShareRepurchaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "CorporateShareRepurchaseAbstract",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Share Repurchase",
        "label": "Corporate Share Repurchase [Abstract]",
        "documentation": "Corporate Share Repurchase [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostDirectMaterial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostDirectMaterial",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Captisol",
        "label": "Cost, Direct Material",
        "documentation": "Cost of material used for good produced and service rendered."
       }
      }
     },
     "auth_ref": [
      "r1366"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangibles",
        "negatedLabel": "Amortization of intangibles",
        "label": "Cost, Amortization",
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service."
       }
      }
     },
     "auth_ref": [
      "r1366"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r331",
      "r332",
      "r553",
      "r582",
      "r814",
      "r834",
      "r865",
      "r1124",
      "r1126"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r1443"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r539",
      "r1443",
      "r1444"
     ]
    },
    "us-gaap_CreditLossFinancialInstrumentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditLossFinancialInstrumentPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable and Allowance for Credit Losses",
        "label": "Credit Loss, Financial Instrument [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit loss on financial instrument measured at amortized cost basis, net investment in lease, off-balance sheet credit exposure, and available-for-sale debt security. Includes, but is not limited to, methodology used to estimate allowance for credit loss, how writeoff of uncollectible amount is recognized, and determination of past due status and nonaccrual status."
       }
      }
     },
     "auth_ref": [
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r460",
      "r462",
      "r463",
      "r464",
      "r465",
      "r467",
      "r468",
      "r469",
      "r470",
      "r472",
      "r473",
      "r474",
      "r481"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment",
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "documentation": "Increase (decrease) to financial statements for cumulative-effect adjustment in period of adoption of amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r277",
      "r338",
      "r344",
      "r351",
      "r447",
      "r453",
      "r517",
      "r691",
      "r692",
      "r706",
      "r708",
      "r733",
      "r734",
      "r735",
      "r737",
      "r738",
      "r739",
      "r745",
      "r748",
      "r750",
      "r751",
      "r809"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]",
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "documentation": "Information by cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r277",
      "r338",
      "r344",
      "r351",
      "r447",
      "r453",
      "r517",
      "r691",
      "r692",
      "r706",
      "r708",
      "r733",
      "r734",
      "r735",
      "r737",
      "r738",
      "r739",
      "r745",
      "r748",
      "r750",
      "r751",
      "r809"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]",
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "documentation": "Cumulative-effect adjustment to financial statements in period of adoption of amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r277",
      "r338",
      "r344",
      "r351",
      "r447",
      "r453",
      "r517",
      "r691",
      "r692",
      "r706",
      "r708",
      "r733",
      "r734",
      "r735",
      "r737",
      "r738",
      "r739",
      "r745",
      "r748",
      "r750",
      "r751",
      "r809"
     ]
    },
    "lgnd_CurrentAndExpectedCreditLossAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "CurrentAndExpectedCreditLossAdjustment",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CECL adjustment to financial royalty assets",
        "label": "Current And Expected Credit Loss Adjustment",
        "documentation": "Current And Expected Credit Loss Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1335",
      "r1378",
      "r1494"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1335",
      "r1378"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current expense (benefit)",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r690",
      "r1378"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current expense (benefit):",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_CurrentPortionOfLiabilityForContingentValueRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "CurrentPortionOfLiabilityForContingentValueRights",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current contingent liabilities",
        "label": "Current Portion of Liability for Contingent Value Rights",
        "documentation": "Current portion of liability for contingent value rights."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1335",
      "r1378",
      "r1494"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r404"
     ]
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Customer relationships",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1427",
      "r1428",
      "r1430",
      "r1431"
     ]
    },
    "lgnd_CyDexMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "CyDexMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CyDex",
        "label": "CyDex [Member]",
        "documentation": "CyDex"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1223",
      "r1312"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1223",
      "r1312"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1225",
      "r1314"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1225",
      "r1314"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1227",
      "r1316"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1225",
      "r1314"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1218",
      "r1307"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1219",
      "r1308"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1219",
      "r1308"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r1217",
      "r1306"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1217",
      "r1306"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r1217",
      "r1306"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1220",
      "r1309"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1222",
      "r1311"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1222",
      "r1311"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1223",
      "r1312"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1226",
      "r1315"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1224",
      "r1313"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1221",
      "r1310"
     ]
    },
    "lgnd_CydexPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "CydexPharmaceuticalsIncMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cydex",
        "label": "Cydex Pharmaceuticals, Inc [Member]",
        "documentation": "Cydex Pharmaceuticals, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.ligand.com/role/Debt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r327",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r538",
      "r539",
      "r549",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r565",
      "r572",
      "r573",
      "r575",
      "r783"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r137",
      "r138",
      "r219",
      "r223",
      "r334",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r561",
      "r562",
      "r563",
      "r564",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1180",
      "r1376",
      "r1434",
      "r1435",
      "r1436",
      "r1523",
      "r1525"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate (as a percent)",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt conversion price per share (in USD per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r552"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount of 2023 notes outstanding",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r783",
      "r784",
      "r1146",
      "r1147",
      "r1180"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective rate (as a percent)",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r576",
      "r783",
      "r784",
      "r1180"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on debt instrument (as a percent)",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r551"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r561",
      "r562",
      "r563",
      "r564",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r574",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1180",
      "r1376",
      "r1523",
      "r1525"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r334",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r561",
      "r562",
      "r563",
      "r564",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1180",
      "r1376",
      "r1434",
      "r1435",
      "r1436",
      "r1523",
      "r1525"
     ]
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRepurchaseAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchased amount of debt instrument",
        "label": "Debt Instrument, Repurchase Amount",
        "documentation": "Fair value amount of debt instrument that was repurchased."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DebtInstrumentRepurchasedAmountDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DebtInstrumentRepurchasedAmountDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchased amount",
        "label": "Debt Instrument, Repurchased Amount During Period",
        "documentation": "Debt Instrument, Repurchased Amount During Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r68",
      "r69",
      "r109",
      "r195",
      "r197",
      "r334",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r556",
      "r561",
      "r562",
      "r563",
      "r564",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r574",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1180",
      "r1376",
      "r1523",
      "r1525"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of debt instrument (in years)",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit losses related to available-for-sale debt securities",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss, Writeoff",
        "documentation": "Amount of writeoff of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "lgnd_DebtSecuritiesAvailableForSaleAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DebtSecuritiesAvailableForSaleAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized cost",
        "label": "Debt Securities, Available-for-Sale, Amortization",
        "documentation": "Debt Securities, Available-for-Sale, Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "12 months or greater",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r480",
      "r1141"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "12 months or greater",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r480"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than 12 months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r480",
      "r1141"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less than 12 months",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r480"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-Sale Debt Securities by Contractual Maturity",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1395",
      "r1396",
      "r1397",
      "r1398",
      "r1399",
      "r1400",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1407"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r477",
      "r1141"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total",
        "terseLabel": "Unrealized losses",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Accumulated Loss",
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r478"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTable",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table]",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r1141"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-Sale Debt Securities in an Unrealized Loss Position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r1141",
      "r1416"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of positions in an unrealized loss position",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r479"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1378",
      "r1493",
      "r1494"
     ]
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsGross",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs",
        "label": "Debt Issuance Costs, Gross",
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r1523",
      "r1525"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1378",
      "r1493"
     ]
    },
    "us-gaap_DeferredIncomeNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term deferred revenue",
        "label": "Deferred Income, Noncurrent",
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r1330"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes, net",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r663"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred expense (benefit)",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r253",
      "r1378"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred expense (benefit):",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r220",
      "r682"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes, net",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r663",
      "r870"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1378",
      "r1493",
      "r1494"
     ]
    },
    "lgnd_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized R&amp;D",
        "label": "Deferred Tax Assets, Capitalized Research And Development",
        "documentation": "Deferred Tax Assets, Capitalized Research And Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r683"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset adjustment",
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1487"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1491"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1491"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research credit carryforwards",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1491"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1491"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Valuation allowance for deferred tax assets",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Deferred income taxes, net",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1487"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DeferredTaxLiabilitiesFiniteLivedIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DeferredTaxLiabilitiesFiniteLivedIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Identified intangibles",
        "label": "Deferred Tax Liabilities, Finite-Lived Intangible Assets",
        "documentation": "Deferred Tax Liabilities, Finite-Lived Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1491"
     ]
    },
    "us-gaap_DemandDepositsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DemandDepositsMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificates of Deposit",
        "verboseLabel": "Certificates of Deposit",
        "label": "Demand Deposits [Member]",
        "documentation": "Accounts that may or may not bear interest and that depositor is entitled to withdraw at anytime without prior notice. Checking and negotiable order of withdrawal (NOW) accounts are the most common forms of demand deposits."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Depreciation of property and equipment",
        "verboseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r61"
     ]
    },
    "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortizationDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation and Amortization, Discontinued Operations",
        "documentation": "Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r1372"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation of fixed assets and amortization of intangible assets",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r366",
      "r376",
      "r398",
      "r1135",
      "r1136"
     ]
    },
    "us-gaap_DerivativeAssetMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssetMeasurementInput",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate (as a percent)",
        "label": "Derivative Asset, Measurement Input",
        "documentation": "Value of input used to measure derivative asset."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r757",
      "r758",
      "r1173"
     ]
    },
    "lgnd_DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Asset Noncurrent, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag",
        "label": "Derivative Asset Noncurrent, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag",
        "documentation": "Derivative Asset Noncurrent, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag",
        "label": "Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag",
        "documentation": "Derivative Asset Statement Of Financial Position Extensible Enumeration Not Disclosed Flag"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative asset",
        "label": "Derivative Asset",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r306",
      "r754",
      "r755",
      "r764",
      "r772",
      "r950",
      "r951",
      "r952",
      "r954",
      "r955",
      "r957",
      "r958",
      "r960",
      "r962",
      "r963",
      "r980",
      "r981",
      "r1068",
      "r1070",
      "r1072",
      "r1073",
      "r1074",
      "r1075",
      "r1126",
      "r1169",
      "r1173",
      "r1197",
      "r1509",
      "r1510",
      "r1511",
      "r1580"
     ]
    },
    "lgnd_DerivativeAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DerivativeAssetsMember",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative assets",
        "label": "Derivative Assets [Member]",
        "documentation": "Derivative Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent derivative assets",
        "verboseLabel": "Total noncurrent derivative assets",
        "label": "Derivative Asset, Noncurrent",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r960",
      "r963",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r987",
      "r988",
      "r989",
      "r990",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1068",
      "r1069",
      "r1072",
      "r1074",
      "r1195",
      "r1197",
      "r1512",
      "r1513",
      "r1514",
      "r1515",
      "r1516",
      "r1517",
      "r1519",
      "r1520"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeFairValueOfDerivativeNet",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of derivative assets",
        "label": "Derivative, Fair Value, Net",
        "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives."
       }
      }
     },
     "auth_ref": [
      "r772"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Fair value adjustments to partner program derivatives",
        "terseLabel": "Fair value adjustments to partner program derivatives",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r1503"
     ]
    },
    "lgnd_DerivativeInstrumentAdditionalMaximumInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DerivativeInstrumentAdditionalMaximumInvestment",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional maximum investment",
        "label": "Derivative Instrument, Additional Maximum Investment",
        "documentation": "Derivative Instrument, Additional Maximum Investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r98",
      "r99",
      "r215",
      "r960",
      "r963",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r987",
      "r988",
      "r989",
      "r990",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1068",
      "r1069",
      "r1072",
      "r1074",
      "r1126",
      "r1195",
      "r1197",
      "r1512",
      "r1513",
      "r1514",
      "r1515",
      "r1516",
      "r1517",
      "r1519",
      "r1520"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability, measurement input",
        "label": "Derivative Liability, Measurement Input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r757",
      "r758"
     ]
    },
    "us-gaap_DerivativeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeLineItems",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Line Items]",
        "label": "Derivative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "us-gaap_DerivativeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeTable",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Table]",
        "label": "Derivative [Table]",
        "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r92",
      "r93",
      "r94",
      "r95",
      "r97",
      "r98",
      "r100",
      "r102",
      "r103",
      "r740"
     ]
    },
    "us-gaap_DerivativeTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativeTermOfContract",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, term of contract (in years)",
        "label": "Derivative, Term of Contract",
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Assets",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r92",
      "r93",
      "r95",
      "r101",
      "r333",
      "r350"
     ]
    },
    "lgnd_DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and Licensing of Biopharmaceutical Assets",
        "label": "Development And Licensing of Biopharmaceutical Assets [Member]",
        "documentation": "Development And Licensing of Biopharmaceutical Assets"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development, regulatory, &amp; commercial milestones and tiered royalties",
        "label": "Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties [Member]",
        "documentation": "Development, Regulatory, &amp; Commercial Milestones and Tiered Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r601",
      "r1151",
      "r1152",
      "r1153",
      "r1154",
      "r1155",
      "r1156",
      "r1157"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1452"
     ]
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Expense",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r70"
     ]
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax",
        "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r127",
      "r162",
      "r1546"
     ]
    },
    "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income tax benefit",
        "label": "Discontinued Operation, Tax Effect of Discontinued Operation",
        "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r120",
      "r121",
      "r127",
      "r132",
      "r664",
      "r697",
      "r699"
     ]
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DiscontinuedOperationsPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued operations",
        "label": "Discontinued Operations, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r30"
     ]
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r283"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r23"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accrued liabilities",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities",
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r113",
      "r130",
      "r188"
     ]
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of contingent consideration",
        "label": "Disposal Group, Including Discontinued Operation, Change in Amount of Contingent Consideration",
        "documentation": "Disposal Group, Including Discontinued Operation, Change in Amount of Contingent Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash consideration paid",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred revenue",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Revenue",
        "documentation": "Amount classified as deferred revenue attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r113",
      "r130",
      "r188"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangibles",
        "label": "Disposal Group, Including Discontinued Operation, Depreciation and Amortization",
        "documentation": "Amount of depreciation and amortization expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationFinancingActivitiesAbstract",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities:",
        "label": "Disposal Group, Including Discontinued Operation, Financing Activities [Abstract]",
        "documentation": "Disposal Group, Including Discontinued Operation, Financing Activities"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease right-of-use assets",
        "label": "Disposal Group, Including Discontinued Operation, Financing Lease, Right-of-Use Asset",
        "documentation": "Disposal Group, Including Discontinued Operation, Financing Lease, Right-of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain from short-term investments",
        "label": "Disposal Group, Including Discontinued Operation, Gain (Loss) On Short-Term Investments",
        "documentation": "Disposal Group, Including Discontinued Operation, Gain (Loss) On Short-Term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allocated goodwill",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill",
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r113",
      "r130",
      "r188"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets",
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r113",
      "r130",
      "r188"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense",
        "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r30",
      "r128"
     ]
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Long-term operating lease liabilities",
        "label": "Disposal Group, Including Discontinued Operation, Long-term Operating Lease Liabilities",
        "documentation": "Disposal Group, Including Discontinued Operation, Long-term Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationNetAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net assets sold",
        "label": "Disposal Group, Including Discontinued Operation, Net Asset",
        "documentation": "Disposal Group, Including Discontinued Operation, Net Asset"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationNetContributions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationNetContributions",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Disposal Group, Including Discontinued Operation, Net Contributions",
        "documentation": "Disposal Group, Including Discontinued Operation, Net Contributions"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expense, net",
        "label": "Disposal Group, Including Discontinued Operation, Nonoperating Income (Expense)",
        "documentation": "Disposal Group, Including Discontinued Operation, Nonoperating Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingCostsAndExpensesAbstract",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating costs and expenses:",
        "label": "Disposal Group, Including Discontinued Operation, Operating Costs and Expenses [Abstract]",
        "documentation": "Disposal Group, Including Discontinued Operation, Operating Costs and Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating costs and expenses",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "label": "Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset",
        "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease, Right-of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets",
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r113",
      "r130",
      "r188"
     ]
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense), net",
        "label": "Disposal Group, Including Discontinued Operation, Other Income (Expense)",
        "documentation": "Disposal Group, Including Discontinued Operation, Other Income (Expense)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other liabilities",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities",
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r113",
      "r130",
      "r188"
     ]
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash paid for acquisition, net of cash acquired",
        "label": "Disposal Group, Including Discontinued Operation, Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "Disposal Group, Including Discontinued Operation, Payments to Acquire Businesses, Net of Cash Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of voting interests disposed (as a percent)",
        "label": "Disposal Group, Including Discontinued Operation, Percentage Of Voting Interests Disposed",
        "documentation": "Disposal Group, Including Discontinued Operation, Percentage Of Voting Interests Disposed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails": {
       "parentTag": "lgnd_DisposalGroupIncludingDiscontinuedOperationNetAsset",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment",
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r113",
      "r130",
      "r188"
     ]
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Disposal Group, Including Discontinued Operation, Research and Development",
        "documentation": "Disposal Group, Including Discontinued Operation, Research and Development"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails": {
       "parentTag": "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenues",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r284"
     ]
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Disposal Group, Including Discontinued Operation, Share-Based Payment Arrangement, Expense",
        "documentation": "Disposal Group, Including Discontinued Operation, Share-Based Payment Arrangement, Expense"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationShareConsideration": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationShareConsideration",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares received as consideration",
        "label": "Disposal Group, Including Discontinued Operation, Share Consideration",
        "documentation": "Disposal Group, Including Discontinued Operation, Share Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Purchases of property, plant and equipment included in accounts payable and accrued expenses",
        "label": "Disposal Group, Including Discontinued Operations, Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Disposal Group, Including Discontinued Operations, Capital Expenditures Incurred but Not yet Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues:",
        "label": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBio",
      "http://www.ligand.com/role/SpinoffofOmniAb"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Sale of Pelican Business and Investment in Primrose Bio",
        "terseLabel": "Spin-off of OmniAb",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r185"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r1161",
      "r1162"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r1214",
      "r1215",
      "r1238"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r1214",
      "r1215",
      "r1238",
      "r1281"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1259"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r1212"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesIncomeBeforeIncomeTaxFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1270"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Basic net income (loss) per share (in USD per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r352",
      "r354",
      "r360",
      "r361",
      "r362",
      "r365",
      "r710",
      "r724",
      "r751",
      "r752",
      "r860",
      "r890",
      "r1129"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Diluted net income (loss) per share (in USD per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r354",
      "r360",
      "r361",
      "r362",
      "r365",
      "r710",
      "r724",
      "r751",
      "r752",
      "r860",
      "r890",
      "r1129"
     ]
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDilutedLineItems",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method",
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r358",
      "r360"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income (Loss) Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r364"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Change in uncertain tax positions",
        "label": "Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions",
        "documentation": "Effective Income Tax Rate Reconciliation, Change in Uncertain Tax Positions"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt repurchases",
        "label": "Effective Income Tax Rate Reconciliation, Debt Repurchases, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Debt Repurchases, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development credits",
        "label": "Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research",
        "documentation": "Effective Income Tax Rate Reconciliation, Expired Tax Credits, Research"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationFdiiAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "FDII",
        "label": "Effective Income Tax Rate Reconciliation, FDII, Amount",
        "documentation": "Amount of reported income tax benefit from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)."
       }
      }
     },
     "auth_ref": [
      "r1168",
      "r1483",
      "r1485"
     ]
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Officer compensation",
        "label": "Effective Income Tax Rate Reconciliation, Officer Compensation, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Officer Compensation, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationOtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subpart F income",
        "label": "Effective Income Tax Rate Reconciliation, Other Income",
        "documentation": "Effective Income Tax Rate Reconciliation, Other Income"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Provision to return adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Provision to Return Adjustments, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ElutiaAndCorMatrixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ElutiaAndCorMatrixMember",
     "presentation": [
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Elutia (CorMatrix)",
        "label": "Elutia and CorMatrix [Member]",
        "documentation": "Elutia and CorMatrix"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average period in which cost is expected to be recognized (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrecognized compensation cost, restricted stock",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1481"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrecognized compensation cost",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1481"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_EmployeeStockPurchasePlanAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "EmployeeStockPurchasePlanAbstract",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan [Abstract]",
        "documentation": "Employee Stock Purchase Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_EnsifentrineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "EnsifentrineMember",
     "presentation": [
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ensifentrine inventors",
        "label": "Ensifentrine [Member]",
        "documentation": "Ensifentrine"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1211"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1211"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1211"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1321"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1211"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1211"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1211"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1211"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-Known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1322"
     ]
    },
    "us-gaap_EntityWideRevenueMajorCustomerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EntityWideRevenueMajorCustomerLineItems",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Major Customer",
        "label": "Revenue, Major Customer [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1264"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1317"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1317"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1317"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r277",
      "r312",
      "r313",
      "r314",
      "r335",
      "r336",
      "r337",
      "r340",
      "r346",
      "r348",
      "r350",
      "r367",
      "r447",
      "r453",
      "r517",
      "r597",
      "r691",
      "r692",
      "r706",
      "r707",
      "r708",
      "r711",
      "r723",
      "r724",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r739",
      "r750",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r785",
      "r788",
      "r811",
      "r886",
      "r917",
      "r918",
      "r919",
      "r938",
      "r1014"
     ]
    },
    "lgnd_EquityIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "EquityIssuanceCost",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity issuance cost",
        "label": "Equity Issuance Cost",
        "documentation": "Equity Issuance Cost"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherInvestmentDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r702",
      "r1326",
      "r1327",
      "r1328",
      "r1495",
      "r1496",
      "r1497",
      "r1498"
     ]
    },
    "us-gaap_EquityMethodInvestmentOtherThanTemporaryImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentOtherThanTemporaryImpairment",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Impairment of equity method investment",
        "label": "Equity Method Investment, Other-than-Temporary Impairment",
        "documentation": "Amount of other-than-temporary decline in value that has been recognized against investment accounted for under equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r1412"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investment in Primrose Bio",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r381",
      "r398",
      "r439",
      "r1355",
      "r1413"
     ]
    },
    "lgnd_EquityMethodInvestmentsAllocationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "EquityMethodInvestmentsAllocationMember",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investment",
        "label": "Equity Method Investments Allocation [Member]",
        "documentation": "Equity Method Investments Allocation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment",
        "label": "Equity Method Investments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r108",
      "r441"
     ]
    },
    "lgnd_EquitySecuritiesAllocationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "EquitySecuritiesAllocationMember",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity securities",
        "label": "Equity Securities Allocation [Member]",
        "documentation": "Equity Securities Allocation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesByIndustryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesByIndustryAxis",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Industry Sector [Axis]",
        "label": "Industry Sector [Axis]",
        "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate."
       }
      }
     },
     "auth_ref": [
      "r952",
      "r956",
      "r959",
      "r1029",
      "r1043",
      "r1064",
      "r1094",
      "r1140",
      "r1169",
      "r1171",
      "r1173",
      "r1197"
     ]
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in Viking common stock",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r770",
      "r1120"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in Viking common stock",
        "label": "Equity Securities, FV-NI",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r754",
      "r770",
      "r865",
      "r866",
      "r1169",
      "r1191",
      "r1194",
      "r1509",
      "r1510",
      "r1511"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiMeasurementInput",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement input (as a percent)",
        "label": "Equity Securities, FV-NI, Measurement Input",
        "documentation": "Value of input used to measure investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r757",
      "r758"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 25.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Fair value adjustment to Primrose Bio securities investments",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r891",
      "r1411"
     ]
    },
    "us-gaap_EquitySecuritiesIndustryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesIndustryMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Industry Sector [Domain]",
        "label": "Industry Sector [Domain]",
        "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate."
       }
      }
     },
     "auth_ref": [
      "r952",
      "r956",
      "r959",
      "r1029",
      "r1043",
      "r1064",
      "r1094",
      "r1169",
      "r1171",
      "r1173",
      "r1197"
     ]
    },
    "us-gaap_EquitySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate equity securities",
        "verboseLabel": "Equity Securities",
        "label": "Equity Securities [Member]",
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r1183",
      "r1203",
      "r1204",
      "r1205",
      "r1584"
     ]
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Decrease in value of investment",
        "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount",
        "documentation": "Amount of impairment loss on investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r438"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1274"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1231",
      "r1242",
      "r1252",
      "r1285"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1228",
      "r1239",
      "r1249",
      "r1282"
     ]
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimate of Fair Value",
        "label": "Estimate of Fair Value Measurement [Member]",
        "documentation": "Measured as an estimate of fair value."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r772",
      "r1146",
      "r1147"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1280"
     ]
    },
    "lgnd_ExercisePriceRangeEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ExercisePriceRangeEightMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$89.86-$103.42",
        "label": "Exercise Price Range Eight [Member]",
        "documentation": "Exercise Price Range Eight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ExercisePriceRangeFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ExercisePriceRangeFiveMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$73.92-$75.09",
        "label": "Exercise Price Range Five [Member]",
        "documentation": "Exercise Price Range Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ExercisePriceRangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ExercisePriceRangeFourMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$69.39-$73.76",
        "label": "Exercise Price Range Four [Member]",
        "documentation": "Exercise Price Range Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ExercisePriceRangeNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ExercisePriceRangeNineMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$104.30-$114.15",
        "label": "Exercise Price Range Nine [Member]",
        "documentation": "Exercise Price Range Nine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ExercisePriceRangeOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ExercisePriceRangeOneMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$32.78-$52.84",
        "label": "Exercise Price Range One [Member]",
        "documentation": "Exercise Price Range One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ExercisePriceRangeSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ExercisePriceRangeSevenMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "89.2",
        "label": "Exercise Price Range Seven [Member]",
        "documentation": "Exercise Price Range Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ExercisePriceRangeSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ExercisePriceRangeSixMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$78.56-$88.27",
        "label": "Exercise Price Range Six [Member]",
        "documentation": "Exercise Price Range Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ExercisePriceRangeTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ExercisePriceRangeTenMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$122.70-$122.70",
        "label": "Exercise Price Range Ten [Member]",
        "documentation": "Exercise Price Range Ten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ExercisePriceRangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ExercisePriceRangeThreeMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$64.65-$68.74",
        "label": "Exercise Price Range Three [Member]",
        "documentation": "Exercise Price Range Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ExercisePriceRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ExercisePriceRangeTwoMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "$54.81-$63.62",
        "label": "Exercise Price Range Two [Member]",
        "documentation": "Exercise Price Range Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExtinguishmentOfDebtAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ExtinguishmentOfDebtAxis",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extinguishment of Debt [Axis]",
        "label": "Extinguishment of Debt [Axis]",
        "documentation": "Information by type of debt extinguished."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_ExtinguishmentOfDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ExtinguishmentOfDebtTypeDomain",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extinguishment of Debt, Type [Domain]",
        "label": "Extinguishment of Debt, Type [Domain]",
        "documentation": "Type of debt extinguished."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "lgnd_FCX007Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "FCX007Member",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FCX-007",
        "label": "FCX-007 [Member]",
        "documentation": "FCX-007"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value adjustments to equity security warrants",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r11"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r755",
      "r764",
      "r1169"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r755",
      "r764",
      "r1169"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1507",
      "r1508",
      "r1519"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Level 3 Financial Instruments, Assets",
        "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset."
       }
      }
     },
     "auth_ref": [
      "r759",
      "r762",
      "r765",
      "r1171"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r753",
      "r755",
      "r756",
      "r757",
      "r758",
      "r763",
      "r764",
      "r766",
      "r821",
      "r822",
      "r823",
      "r1146",
      "r1147",
      "r1158",
      "r1159",
      "r1160",
      "r1169",
      "r1173"
     ]
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementBasisAxis",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Basis [Axis]",
        "label": "Measurement Basis [Axis]",
        "documentation": "Information by measurement basis."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r1146",
      "r1147"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r755",
      "r756",
      "r758",
      "r1169",
      "r1510",
      "r1521"
     ]
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosureItemAmountsDomain",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement [Domain]",
        "label": "Fair Value Measurement [Domain]",
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r1146",
      "r1147"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Level\u00a01",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r605",
      "r610",
      "r755",
      "r764",
      "r821",
      "r1158",
      "r1159",
      "r1160",
      "r1169"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Level\u00a02",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r605",
      "r610",
      "r755",
      "r756",
      "r764",
      "r822",
      "r1146",
      "r1147",
      "r1158",
      "r1159",
      "r1160",
      "r1169"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Level\u00a03",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r755",
      "r756",
      "r757",
      "r758",
      "r764",
      "r823",
      "r1146",
      "r1147",
      "r1158",
      "r1159",
      "r1160",
      "r1169",
      "r1173"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of Level 3 Financial Instruments, Liabilities",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r759",
      "r762",
      "r765"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r754",
      "r755",
      "r756",
      "r758",
      "r1169",
      "r1510",
      "r1521"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value adjustments to derivative assets",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r765",
      "r1171",
      "r1172"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions to derivative assets",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases",
        "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r761",
      "r765",
      "r1171"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercise of derivative assets",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements",
        "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r761",
      "r765",
      "r1171"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value",
        "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r759",
      "r765",
      "r1171"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value adjustments to contingent liabilities",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r765"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r759",
      "r765"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r753",
      "r755",
      "r756",
      "r757",
      "r758",
      "r763",
      "r764",
      "r766",
      "r821",
      "r822",
      "r823",
      "r1146",
      "r1147",
      "r1158",
      "r1159",
      "r1160",
      "r1169",
      "r1173"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r1169",
      "r1507",
      "r1508",
      "r1509",
      "r1510",
      "r1511",
      "r1521"
     ]
    },
    "lgnd_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Adjustment",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities",
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Fair Value Adjustment, Contingent Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from asset measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r765"
     ]
    },
    "us-gaap_FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from liability measured at fair value using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r765"
     ]
    },
    "lgnd_FilspariMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "FilspariMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Filspari",
        "label": "Filspari [Member]",
        "documentation": "Filspari"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease amortization expense",
        "label": "Finance Lease And Operating Lease, Right-of-Use Asset, Amortization",
        "documentation": "Finance Lease And Operating Lease, Right-of-Use Asset, Amortization"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease, impairment charges",
        "label": "Finance Lease, Impairment Loss",
        "documentation": "Amount of impairment loss from right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease expense",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r797",
      "r1181"
     ]
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in finance lease liabilities",
        "label": "Finance Lease, Interest Payment on Liability",
        "documentation": "Amount of interest paid on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r794",
      "r799"
     ]
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Leases",
        "label": "Finance Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of lease liabilities",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r790",
      "r803"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "lgnd_LeaseLiabilityCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current finance lease liabilities",
        "verboseLabel": "Current finance lease liabilities",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturity of Finance Lease Liabilities",
        "label": "Finance Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1529"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "lgnd_LeaseLiability",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term finance lease liabilities",
        "label": "Finance Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "label": "Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of financial position that includes noncurrent finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Finance Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "lgnd_FinanceLeaseLiabilityTenantImprovementAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "FinanceLeaseLiabilityTenantImprovementAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less tenant improvement allowance",
        "label": "Finance Lease, Liability, Tenant Improvement Allowance",
        "documentation": "Finance Lease, Liability, Tenant Improvement Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less imputed interest",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments under finance lease obligations",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r793",
      "r799"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "lgnd_LeaseRightOfUseAsset",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease right-of-use assets",
        "verboseLabel": "Finance lease assets",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate of finance leases (as a percent)",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r1181"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term of finance leases",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r801",
      "r1181"
     ]
    },
    "lgnd_FinanceRoyaltyAgreementMilestoneProceedsRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "FinanceRoyaltyAgreementMilestoneProceedsRate",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future milestones right to receive (as a percent)",
        "label": "Finance Royalty Agreement, Milestone Proceeds Rate",
        "documentation": "Finance Royalty Agreement, Milestone Proceeds Rate"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_FinanceRoyaltyAgreementRoyaltyRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "FinanceRoyaltyAgreementRoyaltyRate",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties right to receive (as a percent)",
        "label": "Finance Royalty Agreement, Royalty Rate",
        "documentation": "Finance Royalty Agreement, Royalty Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r458",
      "r459",
      "r460",
      "r461",
      "r466",
      "r475",
      "r481",
      "r482",
      "r574",
      "r593",
      "r740",
      "r767",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r887",
      "r1141",
      "r1169",
      "r1171",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1183",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1506",
      "r1509",
      "r1510",
      "r1511",
      "r1518",
      "r1521"
     ]
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement",
        "label": "Financial Instruments Disclosure [Text Block]",
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_FinancialRoyaltyAssetMeasurementInput": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "FinancialRoyaltyAssetMeasurementInput",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial royalty assets, measurement input (percent)",
        "label": "Financial Royalty Asset, Measurement Input",
        "documentation": "Financial Royalty Asset, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_FinancialRoyaltyAssetsAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "FinancialRoyaltyAssetsAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails": {
       "parentTag": "lgnd_FinancialRoyaltyAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Allowance",
        "label": "Financial Royalty Assets, Allowance",
        "documentation": "Financial Royalty Assets, Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_FinancialRoyaltyAssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "FinancialRoyaltyAssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial royalty assets, fair value disclosure",
        "label": "Financial Royalty Assets, Fair Value Disclosure",
        "documentation": "Financial Royalty Assets, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_FinancialRoyaltyAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "FinancialRoyaltyAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails": {
       "parentTag": "lgnd_FinancialRoyaltyAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross carrying value",
        "label": "Financial Royalty Assets, Gross",
        "documentation": "Financial Royalty Assets, Gross"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_FinancialRoyaltyAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "FinancialRoyaltyAssetsMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income from financial royalty assets",
        "verboseLabel": "Income from financial royalty assets",
        "label": "Financial Royalty Assets [Member]",
        "documentation": "Financial Royalty Assets"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_FinancialRoyaltyAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "FinancialRoyaltyAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty assets",
        "totalLabel": "Net carrying value",
        "label": "Financial Royalty Assets, Net",
        "documentation": "Financial Royalty Assets, Net"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_FinancialRoyaltyAssetsNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "FinancialRoyaltyAssetsNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial royalty liability current",
        "label": "Financial Royalty Assets, Net Current",
        "documentation": "Financial Royalty Assets, Net Current"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_FinancialRoyaltyAssetsNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "FinancialRoyaltyAssetsNonCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term portion of financial royalty assets, net",
        "label": "Financial Royalty Assets, Non Current",
        "documentation": "Financial Royalty Assets, Non Current"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_FinancialRoyaltyAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "FinancialRoyaltyAssetsPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Royalty Assets, net (formerly known as Commercial License Rights)",
        "label": "Financial Royalty Assets [Policy Text Block]",
        "documentation": "Financial Royalty Assets"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_FinancialRoyaltyAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "FinancialRoyaltyAssetsTextBlock",
     "presentation": [
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRights"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Royalty Assets, net (formerly known as Commercial License Rights)",
        "label": "Financial Royalty Assets [Text Block]",
        "documentation": "Financial Royalty Assets"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_FinancialRoyaltyMaximumCapitalSourcing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "FinancialRoyaltyMaximumCapitalSourcing",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum capital sourcing",
        "label": "Financial Royalty, Maximum Capital Sourcing",
        "documentation": "Financial Royalty, Maximum Capital Sourcing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finite-lived intangible asset, useful life (in years)",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r490",
      "r510",
      "r1143"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Estimated amortization expense for 2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r1114",
      "r1143"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated amortization expense for 2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r1114",
      "r1143"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated amortization expense for 2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r1114",
      "r1143"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated amortization expense for 2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r1114",
      "r1143"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated amortization expense for 2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r511",
      "r1114",
      "r1143"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r505",
      "r506",
      "r507",
      "r509",
      "r510",
      "r512",
      "r513",
      "r854",
      "r855",
      "r1114"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetIncludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Definite-lived intangible assets",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r510",
      "r855",
      "r1143"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r510",
      "r512",
      "r513",
      "r515",
      "r854",
      "r1114",
      "r1143"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r505",
      "r506",
      "r507",
      "r509",
      "r510",
      "r512",
      "r513",
      "r1114"
     ]
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesIncomeBeforeIncomeTaxFromContinuingOperationsDetails",
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r666"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1246",
      "r1256",
      "r1289"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1246",
      "r1256",
      "r1289"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1246",
      "r1256",
      "r1289"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1246",
      "r1256",
      "r1289"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1246",
      "r1256",
      "r1289"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1269"
     ]
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain from short-term investments",
        "label": "Gain (Loss) on Investments",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r168",
      "r1323"
     ]
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnSaleOfBusiness",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Gain on sale of Pelican",
        "negatedTerseLabel": "Gain on sale of Pelican",
        "verboseLabel": "Gain on sale of business",
        "label": "Gain (Loss) on Disposition of Business",
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant."
       }
      }
     },
     "auth_ref": [
      "r727",
      "r1372"
     ]
    },
    "lgnd_GainLossOnShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "GainLossOnShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain from short-term investments",
        "label": "Gain (Loss) on Short-Term Investments",
        "documentation": "Gain (Loss) on Short-Term Investments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on debt extinguishment",
        "terseLabel": "Loss (gain) on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r65",
      "r66"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r998"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r492",
      "r856",
      "r1136",
      "r1142",
      "r1170",
      "r1182",
      "r1419",
      "r1420"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and intangible asset impairment",
        "label": "Goodwill and Intangible Asset Impairment",
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, Intangible Assets and Other Long-Lived Assets",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r502",
      "r1142"
     ]
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill written off",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "documentation": "Amount of divestiture of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r1142"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Held-to-Maturity, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date",
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r1406",
      "r1544"
     ]
    },
    "lgnd_INCAGN2385Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "INCAGN2385Member",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCAGN2385",
        "label": "INCAGN2385 [Member]",
        "documentation": "INCAGN2385"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_INCAGN2390Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "INCAGN2390Member",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCAGN2390",
        "label": "INCAGN2390 [Member]",
        "documentation": "INCAGN2390"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r1214",
      "r1215",
      "r1238"
     ]
    },
    "lgnd_ImpairmentLossOnFinancialRoyaltyAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ImpairmentLossOnFinancialRoyaltyAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss of financial royalty assets",
        "label": "Impairment Loss On Financial Royalty Assets",
        "documentation": "Impairment Loss On Financial Royalty Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial royalty assets impairment",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r504",
      "r514"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss of financial royalty assets",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r1372",
      "r1432"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss) from continuing operations",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r161",
      "r178",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r359",
      "r362",
      "r724"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/IncomeTaxesIncomeBeforeIncomeTaxFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before income tax from continuing operations",
        "terseLabel": "Income before income tax from continuing operations",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r229",
      "r234",
      "r861",
      "r884",
      "r1131",
      "r1135",
      "r1387",
      "r1389",
      "r1390",
      "r1391",
      "r1392"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic net income (loss) from continuing operations (in USD per share)",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r230",
      "r316",
      "r339",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r354",
      "r360",
      "r361",
      "r710",
      "r724",
      "r752",
      "r860",
      "r1547"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted net income (loss) from continuing operations (in USD per share)",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r161",
      "r316",
      "r339",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r354",
      "r360",
      "r361",
      "r362",
      "r724",
      "r752",
      "r860",
      "r1547"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss from discontinued operations",
        "totalLabel": "Net loss",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r127",
      "r132",
      "r213"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic net loss from discontinued operations (in USD per share)",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r316",
      "r358",
      "r360",
      "r361",
      "r1542",
      "r1547"
     ]
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted net loss from discontinued operations (in USD per share)",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r358",
      "r360",
      "r361"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Losses from equity method investment in Primrose Bio",
        "negatedLabel": "Losses from equity method investment in Primrose Bio",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r160",
      "r228",
      "r366",
      "r378",
      "r398",
      "r439",
      "r883"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Statement of Operations:",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r1161",
      "r1162"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r23",
      "r29",
      "r113",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r131",
      "r133",
      "r134",
      "r189"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r518",
      "r525",
      "r527",
      "r760",
      "r762",
      "r765",
      "r912",
      "r914",
      "r999",
      "r1114",
      "r1172",
      "r1549"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r527",
      "r760",
      "r762",
      "r765",
      "r912",
      "r914",
      "r999",
      "r1114",
      "r1172",
      "r1549"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r665",
      "r666",
      "r675",
      "r687",
      "r1168",
      "r1490"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r665",
      "r666",
      "r675",
      "r687",
      "r1168",
      "r1490"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameAxis",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesIncomeBeforeIncomeTaxFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name [Axis]",
        "label": "Income Tax Authority, Name [Axis]",
        "documentation": "Information by name of taxing authority."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r1490"
     ]
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityNameDomain",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesIncomeBeforeIncomeTaxFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority, Name [Domain]",
        "label": "Income Tax Authority, Name [Domain]",
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r1490"
     ]
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesIncomeBeforeIncomeTaxFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Line Items]",
        "label": "Income Tax Contingency [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxContingencyTable",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesIncomeBeforeIncomeTaxFromContinuingOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Contingency [Table]",
        "label": "Income Tax Contingency [Table]",
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months."
       }
      }
     },
     "auth_ref": [
      "r1486"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r657",
      "r665",
      "r672",
      "r673",
      "r674",
      "r680",
      "r686",
      "r696",
      "r698",
      "r700",
      "r701",
      "r936",
      "r1168"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/IncomeTaxesComponentsofIncomeTaxExpenseBenefitDetails",
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "totalLabel": "Total income tax expense (benefit)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r244",
      "r254",
      "r349",
      "r350",
      "r366",
      "r379",
      "r398",
      "r664",
      "r665",
      "r697",
      "r892",
      "r1168"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r660",
      "r661",
      "r680",
      "r681",
      "r685",
      "r689",
      "r930"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r1168",
      "r1483"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInEnactedTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rate change for changes in federal, foreign or state law",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates."
       }
      }
     },
     "auth_ref": [
      "r659",
      "r665",
      "r670",
      "r1168"
     ]
    },
    "lgnd_IncomeTaxReconciliationContingentValueRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "IncomeTaxReconciliationContingentValueRights",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent liabilities",
        "label": "Income Tax Reconciliation, Contingent Value Rights",
        "documentation": "Income Tax Reconciliation, Contingent Value Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign tax differential on income/loss of foreign subsidiaries",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r666",
      "r669",
      "r1168",
      "r1483"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax at federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r1168"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1168",
      "r1483",
      "r1485"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1168",
      "r1483",
      "r1484"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State, net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r1168",
      "r1483"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCreditsForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit."
       }
      }
     },
     "auth_ref": [
      "r1483",
      "r1485"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Taxes paid",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r177",
      "r1374",
      "r1488",
      "r1489"
     ]
    },
    "us-gaap_IncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes receivable",
        "label": "Income Taxes Receivable, Current",
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r1359"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable, net",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r851",
      "r1371"
     ]
    },
    "lgnd_IncreaseDecreaseInDebtDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "IncreaseDecreaseInDebtDiscount",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reduction in debt discount",
        "label": "Increase (Decrease) in Debt Discount",
        "documentation": "Increase (Decrease) in Debt Discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred income taxes, net",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income taxes receivable and payable",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInIntangibleAssetsCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other economic rights",
        "label": "Increase (Decrease) in Intangible Assets, Current",
        "documentation": "The increase (decrease) during the reporting period in intangible assets (for example patents and licenses)."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities, net of acquisitions and dispositions:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in operating lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1334",
      "r1371"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other assets and liabilities",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive potential common shares (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r362",
      "r618"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1246",
      "r1256",
      "r1280",
      "r1289",
      "r1293",
      "r1301"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1216",
      "r1305"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1216",
      "r1305"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1216",
      "r1305"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r1428",
      "r1429"
     ]
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total goodwill and other identifiable intangible assets, net",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "documentation": "Amount, after impairment and amortization, of goodwill, indefinite-lived, and finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1417"
     ]
    },
    "lgnd_IntangibleRoyaltyAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "IntangibleRoyaltyAssetsMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from intangible royalty assets",
        "verboseLabel": "Revenue from intangible royalty assets",
        "label": "Intangible Royalty Assets [Member]",
        "documentation": "Intangible Royalty Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r569",
      "r577",
      "r1148",
      "r1149"
     ]
    },
    "us-gaap_InterestExpenseDebtExcludingAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebtExcludingAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual interest expense",
        "label": "Interest Expense, Debt, Excluding Amortization",
        "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r570",
      "r1148",
      "r1149"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r1368"
     ]
    },
    "us-gaap_InterestIncomeOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOperating",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Interest Income, Operating",
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r996",
      "r1090",
      "r1091",
      "r1135",
      "r1206",
      "r1207",
      "r1365",
      "r1585"
     ]
    },
    "us-gaap_InterestPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest portion of repurchased amount of debt instrument",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities."
       }
      }
     },
     "auth_ref": [
      "r1373"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r322",
      "r324"
     ]
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InternalRevenueServiceIRSMember",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Internal Revenue Service (IRS)",
        "label": "Internal Revenue Service (IRS) [Member]",
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_InvIOsHoldingAGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "InvIOsHoldingAGMember",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "InvIOs Holding AG",
        "label": "InvIOs Holding AG [Member]",
        "documentation": "InvIOs Holding AG"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_InvIOsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "InvIOsMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherInvestmentDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "InvIOs",
        "label": "InvIOs [Member]",
        "documentation": "InvIOs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Current [Table]",
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "terseLabel": "Inventory",
        "totalLabel": "Total Pelthos inventory in other current assets",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r1119",
      "r1182"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r287",
      "r300",
      "r484",
      "r485",
      "r487",
      "r852",
      "r1127"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r1123"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r1122"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Write-downs related to obsolete inventory",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r374",
      "r398",
      "r1135",
      "r1367"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type [Axis]",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r953",
      "r954",
      "r957",
      "r961",
      "r1020",
      "r1029",
      "r1043",
      "r1051",
      "r1064",
      "r1076",
      "r1094",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1197"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments [Domain]",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r953",
      "r954",
      "r957",
      "r961",
      "r1020",
      "r1029",
      "r1043",
      "r1051",
      "r1064",
      "r1076",
      "r1094",
      "r1098",
      "r1099",
      "r1100",
      "r1101",
      "r1197"
     ]
    },
    "us-gaap_Investments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Investments",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments."
       }
      }
     },
     "auth_ref": [
      "r865",
      "r867",
      "r1191",
      "r1194"
     ]
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, fair value",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r1507",
      "r1508",
      "r1518"
     ]
    },
    "us-gaap_InvestorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestorMember",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investor",
        "label": "Investor [Member]",
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value."
       }
      }
     },
     "auth_ref": [
      "r1530",
      "r1531"
     ]
    },
    "lgnd_LeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "LeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease liabilities",
        "label": "Lease, Liability",
        "documentation": "Lease, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_LeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "LeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "lgnd_LeaseLiability",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current lease liabilities",
        "label": "Lease, Liability, Current",
        "documentation": "Lease, Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_LeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "LeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease assets",
        "label": "Lease, Right-of-Use Asset",
        "documentation": "Lease, Right-of-Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r804"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease term of finance leases",
        "label": "Lessee, Finance Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r1527"
     ]
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeFinanceLeasesTextBlock",
     "presentation": [
      "http://www.ligand.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Finance Leases [Text Block]",
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "lgnd_LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in operating lease assets",
        "label": "Lessee, Increase (Decrease) In Operating Lease Assets Due To Modification",
        "documentation": "Lessee, Increase (Decrease) In Operating Lease Assets Due To Modification"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r805"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r796",
      "r805"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturity of Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1529"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining lease term of operating leases",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r805",
      "r1527"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1528"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.ligand.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letters of credit outstanding",
        "label": "Letters of Credit Outstanding, Amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r137",
      "r138",
      "r139",
      "r142",
      "r143",
      "r144",
      "r147",
      "r329",
      "r443",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r726",
      "r728",
      "r729",
      "r773",
      "r972",
      "r1130",
      "r1209",
      "r1445",
      "r1533",
      "r1534"
     ]
    },
    "us-gaap_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities",
        "label": "Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r225",
      "r877",
      "r1182",
      "r1377",
      "r1414",
      "r1522"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r286",
      "r329",
      "r443",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r726",
      "r728",
      "r729",
      "r773",
      "r1182",
      "r1445",
      "r1533",
      "r1534"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current liabilities:",
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r755",
      "r1507"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncurrent liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_LiabilityForContingentValueRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "LiabilityForContingentValueRights",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-term contingent liabilities",
        "label": "Liability For Contingent Value Rights",
        "documentation": "Liability for contingent value rights."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_LicenseFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "LicenseFeesMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "License Fees [Member]",
        "documentation": "License Fees"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_LicenseeAccrualCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "LicenseeAccrualCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts owed to former licensees",
        "label": "Licensee Accrual, Current",
        "documentation": "Licensee Accrual, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r141"
     ]
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available borrowing",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r141",
      "r539"
     ]
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, interest rate (as a percent)",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]",
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]",
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r1434",
      "r1435",
      "r1436"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r63",
      "r1434",
      "r1435",
      "r1436"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r533",
      "r534",
      "r537",
      "r653",
      "r1144",
      "r1439",
      "r1440"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r533",
      "r534",
      "r537",
      "r653",
      "r1144",
      "r1439",
      "r1440"
     ]
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyNewClaimsFiledNumber",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of civil complaints filed against entity",
        "label": "Loss Contingency, New Claims Filed, Number",
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period."
       }
      }
     },
     "auth_ref": [
      "r1439",
      "r1440"
     ]
    },
    "lgnd_MK4830Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "MK4830Member",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MK-4830",
        "label": "MK-4830 [Member]",
        "documentation": "MK-4830"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r1153",
      "r1185",
      "r1189",
      "r1452",
      "r1548",
      "r1550",
      "r1551",
      "r1553",
      "r1554",
      "r1555",
      "r1556",
      "r1557",
      "r1558",
      "r1559",
      "r1560",
      "r1561",
      "r1562",
      "r1563",
      "r1564",
      "r1565",
      "r1566",
      "r1567",
      "r1568",
      "r1569",
      "r1570",
      "r1571",
      "r1572",
      "r1573",
      "r1574",
      "r1575",
      "r1577",
      "r1578"
     ]
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investment Categories",
        "label": "Marketable Securities [Table Text Block]",
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_MaterialSalesCaptisolCOVIDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "MaterialSalesCaptisolCOVIDMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Captisol - COVID",
        "label": "Material Sales, Captisol, COVID [Member]",
        "documentation": "Material Sales, Captisol, COVID"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_MaterialSalesCaptisolCoreMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "MaterialSalesCaptisolCoreMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Captisol - Core",
        "label": "Material Sales, Captisol, Core [Member]",
        "documentation": "Material Sales, Captisol, Core"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_MaterialSalesCaptisolMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "MaterialSalesCaptisolMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Captisol",
        "verboseLabel": "Captisol",
        "label": "Material Sales, Captisol [Member]",
        "documentation": "Material Sales, Captisol [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_MaximumFinancingRoyaltyAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "MaximumFinancingRoyaltyAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum financing royalty asset",
        "label": "Maximum Financing Royalty Asset",
        "documentation": "Maximum Financing Royalty Asset"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r273",
      "r274",
      "r533",
      "r534",
      "r535",
      "r536",
      "r612",
      "r653",
      "r758",
      "r850",
      "r911",
      "r913",
      "r927",
      "r962",
      "r963",
      "r1023",
      "r1042",
      "r1047",
      "r1048",
      "r1086",
      "r1112",
      "r1113",
      "r1139",
      "r1150",
      "r1163",
      "r1173",
      "r1174",
      "r1178",
      "r1179",
      "r1186",
      "r1447",
      "r1535",
      "r1536",
      "r1537",
      "r1538",
      "r1539",
      "r1540"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount Rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1509",
      "r1510",
      "r1511"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividend yield",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r1509",
      "r1510",
      "r1511"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Term",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r1509",
      "r1510",
      "r1511"
     ]
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Volatility",
        "label": "Measurement Input, Option Volatility [Member]",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r1509",
      "r1510",
      "r1511"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk Free Interest Rate",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r1509",
      "r1510",
      "r1511"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Price",
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1509",
      "r1510",
      "r1511"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AgenusTransactionDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r757",
      "r758",
      "r1173"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/AgenusTransactionDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r757",
      "r758",
      "r1173"
     ]
    },
    "lgnd_MetabasisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "MetabasisMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Metabasis",
        "label": "Metabasis [Member]",
        "documentation": "Metabasis"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_MetabasisTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "MetabasisTherapeuticsMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Metabasis Therapeutics",
        "verboseLabel": "Metabasis",
        "label": "Metabasis Therapeutics [Member]",
        "documentation": "Metabasis Therapeutics [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_MilestoneAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "MilestoneAxis",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone [Axis]",
        "label": "Milestone [Axis]",
        "documentation": "Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_MilestoneCompensationRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "MilestoneCompensationRate",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of milestones (as a percent)",
        "label": "Milestone Compensation Rate",
        "documentation": "Milestone Compensation Rate"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_MilestoneDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "MilestoneDomain",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone [Domain]",
        "label": "Milestone [Domain]",
        "documentation": "Milestone [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r273",
      "r274",
      "r533",
      "r534",
      "r535",
      "r536",
      "r612",
      "r653",
      "r758",
      "r850",
      "r911",
      "r913",
      "r927",
      "r962",
      "r963",
      "r1023",
      "r1042",
      "r1047",
      "r1048",
      "r1086",
      "r1112",
      "r1113",
      "r1139",
      "r1150",
      "r1163",
      "r1173",
      "r1174",
      "r1178",
      "r1186",
      "r1447",
      "r1535",
      "r1536",
      "r1537",
      "r1538",
      "r1539",
      "r1540"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1300"
     ]
    },
    "us-gaap_MunicipalBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MunicipalBondsMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Municipal bonds",
        "verboseLabel": "Municipal bonds",
        "label": "Municipal Bonds [Member]",
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MutualFundMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MutualFundMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bond fund",
        "label": "Mutual Fund [Member]",
        "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective."
       }
      }
     },
     "auth_ref": [
      "r1454"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r1153",
      "r1185",
      "r1189",
      "r1452",
      "r1548",
      "r1550",
      "r1551",
      "r1553",
      "r1554",
      "r1555",
      "r1556",
      "r1557",
      "r1558",
      "r1559",
      "r1560",
      "r1561",
      "r1562",
      "r1563",
      "r1564",
      "r1565",
      "r1566",
      "r1567",
      "r1568",
      "r1569",
      "r1570",
      "r1571",
      "r1572",
      "r1573",
      "r1574",
      "r1575",
      "r1577",
      "r1578"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1273"
     ]
    },
    "lgnd_NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "NetCashProvidedByUsedInDiscontinuedOperationsInvestingActivesAbstract",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities:",
        "label": "Net Cash Provided by (Used in) Discontinued Operations, Investing Actives [Abstract]",
        "documentation": "Net Cash Provided by (Used in) Discontinued Operations, Investing Actives"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "NetCashProvidedByUsedInDiscontinuedOperationsOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities:",
        "label": "Net Cash Provided by (Used in) Discontinued Operations, Operating Activities [Abstract]",
        "documentation": "Net Cash Provided by (Used in) Discontinued Operations, Operating Activities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used) in financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in (provided by) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r178"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income (loss):",
        "terseLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r178",
      "r231",
      "r284",
      "r307",
      "r309",
      "r314",
      "r329",
      "r339",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r349",
      "r350",
      "r359",
      "r443",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r710",
      "r724",
      "r752",
      "r773",
      "r885",
      "r994",
      "r1012",
      "r1013",
      "r1207",
      "r1445"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Standards Updates, Recently Adopted and Not Yet Adopted",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_NonCashChangeInEstimatedFairValueOfContingentValueRights": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "NonCashChangeInEstimatedFairValueOfContingentValueRights",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in estimated fair value of contingent liabilities",
        "label": "Non-Cash Change In Estimated Fair Value Of Contingent Value Rights",
        "documentation": "Non-Cash Change In Estimated Fair Value Of Contingent Value Rights."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_NonCashIncomeFromFinancialRoyaltyAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "NonCashIncomeFromFinancialRoyaltyAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-cash income from financial royalty assets",
        "label": "Non-cash Income From Financial Royalty Assets",
        "documentation": "Non-cash Income From Financial Royalty Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1235",
      "r1246",
      "r1256",
      "r1280",
      "r1289"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1263"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1262"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1280"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1300"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1300"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental cash flow disclosures:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumedAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions:",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-operating income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "lgnd_NotesRepurchasedDuringCurrentPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "NotesRepurchasedDuringCurrentPeriodTwoMember",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Repurchased During Current Period, Two",
        "label": "Notes Repurchased During Current Period, Two [Member]",
        "documentation": "Notes Repurchased During Current Period, Two"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_NovanIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "NovanIncMember",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Novan, Inc.",
        "label": "Novan, Inc. [Member]",
        "documentation": "Novan, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_NucorionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "NucorionMember",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nucorion",
        "label": "Nucorion [Member]",
        "documentation": "Nucorion"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_NumberOfContingentValueRightsIssued": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "NumberOfContingentValueRightsIssued",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of contingent value rights",
        "label": "Number of Contingent Value Rights Issued",
        "documentation": "Number of Contingent Value Rights Issued"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_NumberOfContingentValueRightsSeries": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "NumberOfContingentValueRightsSeries",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of CVR Series",
        "label": "Number of Contingent Value Rights Series",
        "documentation": "Number of Contingent Value Rights Series"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_NumberOfContracts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "NumberOfContracts",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of contracts",
        "label": "Number of Contracts",
        "documentation": "Number of Contracts"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r1136",
      "r1388"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segment",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r1132",
      "r1138",
      "r1388"
     ]
    },
    "lgnd_NumberOfSharesSoldOfEquityMethodInvestee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "NumberOfSharesSoldOfEquityMethodInvestee",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock sold of equity method investee (in shares)",
        "label": "Number Of Shares Sold Of Equity Method Investee",
        "documentation": "Number Of Shares Sold Of Equity Method Investee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lab and office equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_OfficeInBostonMassachusettsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "OfficeInBostonMassachusettsMember",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office in Boston, Massachusetts",
        "label": "Office in Boston Massachusetts [Member]",
        "documentation": "Office in Boston Massachusetts"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_OfficeInJupiterFloridaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "OfficeInJupiterFloridaMember",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office in Jupiter, Florida",
        "label": "Office in Jupiter Florida [Member]",
        "documentation": "Office in Jupiter Florida"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_OmniabSeparationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "OmniabSeparationMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Omniab Separation",
        "label": "Omniab Separation [Member]",
        "documentation": "Omniab Separation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating costs and expenses",
        "label": "Operating Costs and Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingCostsAndExpensesAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating costs and expenses:",
        "label": "Operating Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating income (loss) from continuing operations",
        "terseLabel": "Net income (loss) from continuing operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r1131",
      "r1387",
      "r1389",
      "r1390",
      "r1391",
      "r1392"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1526"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leases",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "lgnd_LeaseLiabilityCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current operating lease liabilities",
        "verboseLabel": "Current operating lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "lgnd_LeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liabilities",
        "verboseLabel": "Long-term operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "lgnd_OperatingLeaseLiabilityTenantImprovementAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "OperatingLeaseLiabilityTenantImprovementAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/LeasesMaturitiesofOperatingandFinanceLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less tenant improvement allowance",
        "label": "Operating Lease, Liability, Tenant Improvement Allowance",
        "documentation": "Operating Lease, Liability, Tenant Improvement Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r795",
      "r799"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "lgnd_LeaseRightOfUseAsset",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/LeasesOperatingandFinanceLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate of operating leases (as a percent)",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r1181"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term of operating leases",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r801",
      "r1181"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforward",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r179",
      "r180",
      "r212"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r138"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r1182"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r293"
     ]
    },
    "lgnd_OtherBalanceSheetDetailsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "OtherBalanceSheetDetailsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Balance Sheet Details [Abstract]",
        "documentation": "Other Balance Sheet Details [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized net gain (loss) on available-for-sale securities, net of tax",
        "verboseLabel": "Unrealized net gain (loss) on available-for-sale securities, net of tax",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r17",
      "r213"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMELOSS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment, net of tax",
        "verboseLabel": "Foreign currency translation adjustment, net of tax",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r17",
      "r213"
     ]
    },
    "lgnd_OtherDerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "OtherDerivativesMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Derivatives",
        "label": "Other Derivatives [Member]",
        "documentation": "Other Derivatives"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_OtherExpenseItemsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "OtherExpenseItemsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense items, net",
        "label": "Other Expense Items, Net",
        "documentation": "Other Expense Items, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherInvestmentDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other investments",
        "verboseLabel": "Total other investments",
        "label": "Other Investments",
        "documentation": "Amount of investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r1356"
     ]
    },
    "lgnd_OtherInvestmentsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "OtherInvestmentsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Investments",
        "label": "Other Investments Policy [Policy Text Block]",
        "documentation": "Other Investments Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities, fair value disclosure",
        "label": "Other Liabilities, Fair Value Disclosure",
        "documentation": "Fair value portion of other liabilities."
       }
      }
     },
     "auth_ref": [
      "r1507",
      "r1508",
      "r1518"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other long-term liabilities",
        "totalLabel": "Total other long-term liabilities",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Long Term Liabilities",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other non-operating (expense) income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-operating income and expenses:",
        "label": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Operating Activities, Cash Flow Statement",
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1272"
     ]
    },
    "lgnd_OtherPurchasersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "OtherPurchasersMember",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Purchasers",
        "label": "Other Purchasers [Member]",
        "documentation": "Other Purchasers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherSundryLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherSundryLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Sundry Liabilities, Noncurrent",
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r222"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1233",
      "r1244",
      "r1254",
      "r1287"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1236",
      "r1247",
      "r1257",
      "r1290"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1236",
      "r1247",
      "r1257",
      "r1290"
     ]
    },
    "lgnd_OvidTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "OvidTherapeuticsMember",
     "presentation": [
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ovid (Soticlestat)",
        "label": "Ovid Therapeutics [Member]",
        "documentation": "Ovid Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Axis]",
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership [Domain]",
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PalvellaTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "PalvellaTherapeuticsIncMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Palvella",
        "label": "Palvella Therapeutics, Inc. [Member]",
        "documentation": "Palvella Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PartnerAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "PartnerAMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partner A",
        "label": "Partner A [Member]",
        "documentation": "Partner A [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PartnerBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "PartnerBMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partner B",
        "label": "Partner B [Member]",
        "documentation": "Partner B [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PartnerCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "PartnerCMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partner C",
        "label": "Partner C [Member]",
        "documentation": "Partner C [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PartnerProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "PartnerProgramsMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Partner Programs",
        "label": "Partner Programs [Member]",
        "documentation": "Partner Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentedTechnologyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PatentedTechnologyMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Completed technology",
        "label": "Patented Technology [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patented technology to exploit the technology for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1427",
      "r1428",
      "r1430",
      "r1431"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "us-gaap_PaymentsForDerivativeInstrumentInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForDerivativeInstrumentInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash paid for the Agenus transaction",
        "label": "Payments for Derivative Instrument, Investing Activities",
        "documentation": "The cash outflow for derivative instruments during the period, which are classified as investing activities, excluding those designated as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r1369"
     ]
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r1331",
      "r1369"
     ]
    },
    "lgnd_PaymentsForSeparation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "PaymentsForSeparation",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net cash transferred to OmniAb at OmniAb Separation",
        "label": "Payments For Separation",
        "documentation": "Payments For Separation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash paid for debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfMergerRelatedCostsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash paid for transaction costs related to OmniAb Transactions",
        "label": "Payments of Merger Related Costs, Financing Activities",
        "documentation": "The cash outflow for financing costs associated with business combinations."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash paid for Apeiron acquisition, net of cash received",
        "label": "Payments to Acquire Business Two, Net of Cash Acquired",
        "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r1369"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payments for acquisition",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r717"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 7.0
      },
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash paid for Novan acquisition, net of restricted cash received",
        "terseLabel": "Net cash paid for acquisitions",
        "totalLabel": "Cash paid for Novan, including restricted cash received",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash paid for equity method investment",
        "label": "Payments to Acquire Equity Method Investments",
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireEquitySecuritiesFvNi",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash paid for InvIOs investment",
        "terseLabel": "Cash paid for InvIOs investment",
        "label": "Payments to Acquire Equity Securities, FV-NI",
        "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity."
       }
      }
     },
     "auth_ref": [
      "r242",
      "r320"
     ]
    },
    "lgnd_PaymentsToAcquireFinancialRoyaltyAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "PaymentsToAcquireFinancialRoyaltyAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition of financial royalty assets",
        "label": "Payments To Acquire Financial Royalty Assets",
        "documentation": "Payments To Acquire Financial Royalty Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireNotesReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireNotesReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash paid for Palvella notes receivable",
        "verboseLabel": "Payments to acquire notes",
        "label": "Payments to Acquire Notes Receivable",
        "documentation": "The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to acquire productive asset",
        "label": "Payments to Acquire Productive Assets",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r1500",
      "r1501",
      "r1502"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of short-term investments",
        "label": "Payments to Acquire Short-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "lgnd_PaymentsToContingentValueRightHolders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "PaymentsToContingentValueRightHolders",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails",
      "http://www.ligand.com/role/FairValueMeasurementReconciliationofLevel3FinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments",
        "negatedLabel": "Payments to CVR holders and other contingent payments",
        "label": "Payments to Contingent Value Right Holders",
        "documentation": "Payments to contingent value right holders"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PaymentsToContingentValueRightHoldersFinancingActivity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "PaymentsToContingentValueRightHoldersFinancingActivity",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments to CVR Holders",
        "negatedTerseLabel": "Payments to CVR Holders",
        "label": "Payments to Contingent Value Right Holders, Financing Activity",
        "documentation": "Payments to Contingent Value Right Holders, Financing Activity"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PaymentsToContingentValueRightHoldersInvestingActivity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "PaymentsToContingentValueRightHoldersInvestingActivity",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments to CVR Holders",
        "label": "Payments to Contingent Value Right Holders, Investing Activity",
        "documentation": "Payments to Contingent Value Right Holders, Investing Activity"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PaymentsforConvertibleBondHedges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "PaymentsforConvertibleBondHedges",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for convertible bond hedges",
        "label": "Payments for Convertible Bond Hedges",
        "documentation": "Payments for Convertible Bond Hedges"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1271"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1271"
     ]
    },
    "lgnd_PeliCRM197Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "PeliCRM197Member",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PeliCRM197",
        "label": "PeliCRM197 [Member]",
        "documentation": "PeliCRM197"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PelicanTechnologyHoldingsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "PelicanTechnologyHoldingsIncMember",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioFairValueoftheConsiderationDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNetAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pelican Technology Holdings, Inc.",
        "label": "Pelican Technology Holdings, Inc. [Member]",
        "documentation": "Pelican Technology Holdings, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1263"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1280"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1273"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1262"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PSUs",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_Phase3ClinicalTrialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "Phase3ClinicalTrialMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase 3 clinical trial",
        "label": "Phase 3 Clinical Trial [Member]",
        "documentation": "Phase 3 Clinical Trial"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1455",
      "r1456",
      "r1457",
      "r1458",
      "r1459",
      "r1460",
      "r1461",
      "r1462",
      "r1463",
      "r1464",
      "r1465",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473",
      "r1474",
      "r1475",
      "r1476",
      "r1477",
      "r1478",
      "r1479",
      "r1480"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1455",
      "r1456",
      "r1457",
      "r1458",
      "r1459",
      "r1460",
      "r1461",
      "r1462",
      "r1463",
      "r1464",
      "r1465",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473",
      "r1474",
      "r1475",
      "r1476",
      "r1477",
      "r1478",
      "r1479",
      "r1480"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1264"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1320"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1263"
     ]
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Portion at Fair Value Measurement",
        "label": "Portion at Fair Value Measurement [Member]",
        "documentation": "Measured at fair value for financial reporting purposes."
       }
      }
     },
     "auth_ref": [
      "r771"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionRatio",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange ratio",
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherInvestmentDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "verboseLabel": "Palvella Series C preferred stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r1195",
      "r1196",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1579",
      "r1582"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in USD per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r579"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r974"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r579"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r974",
      "r992",
      "r1582",
      "r1583"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at December 31, 2024 and 2023",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r873",
      "r1182"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r302",
      "r488",
      "r489",
      "r1121"
     ]
    },
    "lgnd_PrimordialGeneticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "PrimordialGeneticsMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Primordial Genetics",
        "label": "Primordial Genetics [Member]",
        "documentation": "Primordial Genetics"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PrimroseBioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "PrimroseBioMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherInvestmentDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Primrose Bio",
        "label": "Primrose Bio [Member]",
        "documentation": "Primrose Bio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r1353"
     ]
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from debt issuance",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r317"
     ]
    },
    "us-gaap_ProceedsFromDerivativeInstrumentInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromDerivativeInstrumentInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from Viking Share Collar and Viking Share Put",
        "label": "Proceeds from Derivative Instrument, Investing Activities",
        "documentation": "The cash inflow provided by derivative instruments during the period, which are classified as investing activities, excluding those designated as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r1331"
     ]
    },
    "lgnd_ProceedsFromFinancialRoyaltyAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ProceedsFromFinancialRoyaltyAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from financial royalty assets",
        "label": "Proceeds From Financial Royalty Assets",
        "documentation": "Proceeds From Financial Royalty Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromHedgeFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromHedgeFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from bond hedge settlement",
        "label": "Proceeds from Hedge, Financing Activities",
        "documentation": "The cash inflow from a financial contract that meets the hedge criteria as either cash flow hedge, fair value hedge or hedge of net investment in foreign operations."
       }
      }
     },
     "auth_ref": [
      "r323",
      "r1370"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from common stock issuance, net of commissions and fees",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash received from options exercised",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r22"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from maturity of short-term investments",
        "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments",
        "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r170"
     ]
    },
    "us-gaap_ProceedsFromRoyaltiesReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromRoyaltiesReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from royalties received",
        "label": "Proceeds from Royalties Received",
        "documentation": "Cash received for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176"
     ]
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from sale of short-term investments",
        "label": "Proceeds from Sale of Short-Term Investments",
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from stock option exercises and ESPP",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r22"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r271",
      "r402",
      "r853",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r1116",
      "r1151",
      "r1184",
      "r1186",
      "r1187",
      "r1190",
      "r1193",
      "r1352",
      "r1441",
      "r1442",
      "r1452",
      "r1548",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1555",
      "r1556",
      "r1557",
      "r1558",
      "r1559",
      "r1560",
      "r1561",
      "r1562",
      "r1563",
      "r1564",
      "r1565",
      "r1566",
      "r1567",
      "r1568",
      "r1569",
      "r1570",
      "r1571",
      "r1572",
      "r1573",
      "r1574",
      "r1575",
      "r1577",
      "r1578"
     ]
    },
    "lgnd_ProductRoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ProductRoyaltyPercentage",
     "presentation": [
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product royalty (as a percent)",
        "label": "Product Royalty Percentage",
        "documentation": "Product Royalty Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r271",
      "r402",
      "r853",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r1116",
      "r1151",
      "r1184",
      "r1186",
      "r1187",
      "r1190",
      "r1193",
      "r1352",
      "r1441",
      "r1442",
      "r1452",
      "r1548",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1555",
      "r1556",
      "r1557",
      "r1558",
      "r1559",
      "r1560",
      "r1561",
      "r1562",
      "r1563",
      "r1564",
      "r1565",
      "r1566",
      "r1567",
      "r1568",
      "r1569",
      "r1570",
      "r1571",
      "r1572",
      "r1573",
      "r1574",
      "r1575",
      "r1577",
      "r1578"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r804"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment , gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r289",
      "r882"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails",
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r804",
      "r864",
      "r882",
      "r1182"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r249",
      "r252",
      "r880"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r186",
      "r804"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, useful life (in years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PublicUtilitiesInventoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PublicUtilitiesInventoryAxis",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory [Axis]",
        "label": "Inventory [Axis]",
        "documentation": "Information by type of inventory held."
       }
      }
     },
     "auth_ref": [
      "r1360"
     ]
    },
    "us-gaap_PublicUtilitiesInventoryTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PublicUtilitiesInventoryTypeDomain",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory [Domain]",
        "label": "Inventory [Domain]",
        "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale."
       }
      }
     },
     "auth_ref": [
      "r1360"
     ]
    },
    "lgnd_PurchaseCommitmentConsiderationPaidAllocatedToInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "PurchaseCommitmentConsiderationPaidAllocatedToInventory",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Portion of consideration allocated to inventory",
        "label": "Purchase Commitment, Consideration Paid, Allocated to Inventory",
        "documentation": "Purchase Commitment, Consideration Paid, Allocated to Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PurchaseCommitmentConsiderationPaidToDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "PurchaseCommitmentConsiderationPaidToDate",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consideration paid to date",
        "label": "Purchase Commitment, Consideration Paid to Date",
        "documentation": "Purchase Commitment, Consideration Paid to Date"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_PurchasersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "PurchasersMember",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchasers",
        "label": "Purchasers [Member]",
        "documentation": "Purchasers"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "lgnd_QARZIBAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "QARZIBAMember",
     "presentation": [
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Qarziba",
        "label": "QARZIBA [Member]",
        "documentation": "QARZIBA"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r273",
      "r274",
      "r533",
      "r534",
      "r535",
      "r536",
      "r604",
      "r612",
      "r644",
      "r645",
      "r646",
      "r653",
      "r758",
      "r824",
      "r833",
      "r850",
      "r911",
      "r913",
      "r927",
      "r962",
      "r963",
      "r1023",
      "r1042",
      "r1047",
      "r1048",
      "r1086",
      "r1112",
      "r1113",
      "r1139",
      "r1150",
      "r1163",
      "r1173",
      "r1174",
      "r1178",
      "r1179",
      "r1186",
      "r1197",
      "r1437",
      "r1447",
      "r1510",
      "r1536",
      "r1537",
      "r1538",
      "r1539",
      "r1540"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/DebtNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
      "http://www.ligand.com/role/LeasesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r273",
      "r274",
      "r533",
      "r534",
      "r535",
      "r536",
      "r604",
      "r612",
      "r644",
      "r645",
      "r646",
      "r653",
      "r758",
      "r824",
      "r833",
      "r850",
      "r911",
      "r913",
      "r927",
      "r962",
      "r963",
      "r1023",
      "r1042",
      "r1047",
      "r1048",
      "r1086",
      "r1112",
      "r1113",
      "r1139",
      "r1150",
      "r1163",
      "r1173",
      "r1174",
      "r1178",
      "r1179",
      "r1186",
      "r1197",
      "r1437",
      "r1447",
      "r1510",
      "r1536",
      "r1537",
      "r1538",
      "r1539",
      "r1540"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Axis]",
        "label": "Name of Property [Axis]",
        "documentation": "Information by name of property."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r1110",
      "r1111",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1586",
      "r1587",
      "r1588",
      "r1589",
      "r1590",
      "r1591",
      "r1592",
      "r1593"
     ]
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name of Property [Domain]",
        "label": "Name of Property [Domain]",
        "documentation": "Name of the property, for example, but not limited to, ABC Shopping Center."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r268",
      "r1110",
      "r1111",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1586",
      "r1587",
      "r1588",
      "r1589",
      "r1590",
      "r1591",
      "r1592",
      "r1593"
     ]
    },
    "us-gaap_ReceivableWithImputedInterestFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivableWithImputedInterestFaceAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivable with imputed interest",
        "label": "Receivable with Imputed Interest, Face Amount",
        "documentation": "The principal amount of the receivable or note before consideration of the discount or premium."
       }
      }
     },
     "auth_ref": [
      "r783",
      "r784",
      "r1180"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized Tax Benefits",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_RecordatiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "RecordatiMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recordati",
        "label": "Recordati [Member]",
        "documentation": "Recordati"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1228",
      "r1239",
      "r1249",
      "r1282"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r611",
      "r812",
      "r813",
      "r871",
      "r879",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r991",
      "r993",
      "r1019"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r611",
      "r812",
      "r813",
      "r871",
      "r879",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r991",
      "r993",
      "r1019",
      "r1532"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment at maturity/repurchase of 2023 Notes",
        "terseLabel": "Repayments of long-term debt",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r934"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of notes",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r331",
      "r332",
      "r553",
      "r582",
      "r814",
      "r834",
      "r865",
      "r1125",
      "r1126"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "verboseLabel": "Received amount expended",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r655",
      "r1114",
      "r1135",
      "r1541"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Tax Credit Carryforward",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1490"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1229",
      "r1240",
      "r1250",
      "r1283"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1230",
      "r1241",
      "r1251",
      "r1284"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1237",
      "r1248",
      "r1258",
      "r1291"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "lgnd_RestrictedStockUnitsAndPerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "RestrictedStockUnitsAndPerformanceSharesMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs and PSUs",
        "label": "Restricted Stock Units and Performance Shares [Member]",
        "documentation": "Restricted Stock Units and Performance Shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r198",
      "r876",
      "r921",
      "r926",
      "r935",
      "r975",
      "r1182"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retain earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r335",
      "r336",
      "r337",
      "r340",
      "r346",
      "r348",
      "r350",
      "r447",
      "r453",
      "r517",
      "r691",
      "r692",
      "r706",
      "r707",
      "r708",
      "r711",
      "r723",
      "r724",
      "r733",
      "r735",
      "r736",
      "r739",
      "r750",
      "r785",
      "r788",
      "r917",
      "r919",
      "r938",
      "r1582"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenues and other income",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r366",
      "r372",
      "r373",
      "r393",
      "r398",
      "r402",
      "r403",
      "r404",
      "r600",
      "r601",
      "r853"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue and Other Income",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r997",
      "r1115",
      "r1128"
     ]
    },
    "us-gaap_RevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Revenues and other income:",
        "label": "Revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving Credit Facility",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset recognized",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r800",
      "r1181"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Addition of right-of-use assets and lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r800",
      "r1181"
     ]
    },
    "us-gaap_RoyaltyAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyAgreementsMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Agreements",
        "label": "Royalty Agreements [Member]",
        "documentation": "Contractual arrangement, generally for a defined period of time, entitling the entity to use the rights and property of another party. Examples include, but not limited to, licensing the use of copyrighted materials and leasing the extraction of natural resources."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r656",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1427",
      "r1428",
      "r1430",
      "r1431",
      "r1482"
     ]
    },
    "lgnd_RoyaltyEvomelaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "RoyaltyEvomelaMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Evomela",
        "label": "Royalty, Evomela [Member]",
        "documentation": "Royalty, Evomela"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_RoyaltyFinancingAgreementPercentageOfGlobalNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "RoyaltyFinancingAgreementPercentageOfGlobalNetSales",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future royalties (as a percent)",
        "label": "Royalty Financing Agreement, Percentage Of Global Net Sales",
        "documentation": "Royalty Financing Agreement, Percentage Of Global Net Sales"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_RoyaltyKyprolisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "RoyaltyKyprolisMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Kyprolis",
        "label": "Royalty, Kyprolis [Member]",
        "documentation": "Royalty, Kyprolis"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties",
        "verboseLabel": "Royalties",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r1453"
     ]
    },
    "lgnd_RoyaltyOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "RoyaltyOtherMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Royalty, Other [Member]",
        "documentation": "Royalty, Other"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_RoyaltyRylazeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "RoyaltyRylazeMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rylaze",
        "label": "Royalty, Rylaze [Member]",
        "documentation": "Royalty, Rylaze"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_RoyaltyTeriparatideInjectionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "RoyaltyTeriparatideInjectionMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Teriparatide injection",
        "label": "Royalty, Teriparatide Injection [Member]",
        "documentation": "Royalty, Teriparatide Injection"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1300"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1300"
     ]
    },
    "lgnd_SaleOfStockAuthorizedOfferingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "SaleOfStockAuthorizedOfferingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, authorized offering amount",
        "label": "Sale Of Stock, Authorized Offering Amount",
        "documentation": "Sale Of Stock, Authorized Offering Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock aggregate offering price",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of common stock (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_SalesContractInterestInSalesRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "SalesContractInterestInSalesRevenue",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest in sales revenue (as a percent)",
        "label": "Sales Contract, Interest In Sales Revenue",
        "documentation": "Sales Contract, Interest In Sales Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_SalesRevenueMilestone": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "SalesRevenueMilestone",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales revenue milestone",
        "label": "Sales Revenue Milestone",
        "documentation": "Sales Revenue Milestone"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r1332"
     ]
    },
    "us-gaap_ScenarioAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScenarioAdjustmentMember",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario, Adjustment",
        "label": "Scenario, Adjustment [Member]",
        "documentation": "Domain member used to indicate figures that are adjustments during a period or as of a point in time. This domain member would never be expected to appear in a relationship group without the \"Scenario, Previously Reported\" Member with the same parent."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r613",
      "r1343",
      "r1383"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r351",
      "r613",
      "r1325",
      "r1383"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsFairValuesofAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsContingentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r712"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Benefit",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1492"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1487"
     ]
    },
    "us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDerivativeAssetsAtFairValueTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Derivative Assets at Fair Value",
        "label": "Schedule of Derivative Assets at Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of derivative assets at fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioTables",
      "http://www.ligand.com/role/SpinoffofOmniAbTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Carrying Amounts of Major Classes of Assets and Liabilities Related to Assets Held for Sale",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r23",
      "r29",
      "r113",
      "r122",
      "r123",
      "r124",
      "r125",
      "r126",
      "r131",
      "r133",
      "r134",
      "r189"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Computation of Basic and Diluted Net Income (Loss) per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1386"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]",
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]",
        "documentation": "Disclosure of information about diluted earnings per share by class of stock. Includes, but is not limited to, two-class method."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r49",
      "r354",
      "r358",
      "r360"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r1168",
      "r1483"
     ]
    },
    "us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRevenuefromSignificantPartnersDetails",
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "label": "Schedule of Revenue by Major Customers, by Reporting Segments [Table]",
        "documentation": "Disclosure of information about the extent of the entity's reliance on its major customers."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherInvestmentDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r440",
      "r441",
      "r442",
      "r702",
      "r1326",
      "r1327",
      "r1328",
      "r1495",
      "r1496",
      "r1497",
      "r1498"
     ]
    },
    "lgnd_ScheduleOfFairValueOfTheConsiderationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ScheduleOfFairValueOfTheConsiderationTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Consideration",
        "label": "Schedule Of Fair Value Of The Consideration [Table Text Block]",
        "documentation": "Schedule Of Fair Value Of The Consideration"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_ScheduleOfFinancialRoyaltyAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ScheduleOfFinancialRoyaltyAssetsTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Financial Royalty Assets",
        "label": "Schedule of Financial Royalty Assets [Table Text Block]",
        "documentation": "Schedule of Financial Royalty Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Asset, Finite-Lived [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r503",
      "r510",
      "r512",
      "r513",
      "r515",
      "r854",
      "r1114",
      "r1143"
     ]
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Goodwill and Other Identifiable Intangible Assets",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class."
       }
      }
     },
     "auth_ref": [
      "r1418",
      "r1421"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory, Current",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r155",
      "r156",
      "r157"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInvestmentsLineItems",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments",
        "label": "Schedule of Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1077",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097"
     ]
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInvestmentsTable",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Investments [Table]",
        "label": "Schedule of Investments [Table]",
        "documentation": "Disclosure of information about investments owned by investment company."
       }
      }
     },
     "auth_ref": [
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1063",
      "r1064",
      "r1065",
      "r1066",
      "r1067",
      "r1077",
      "r1078",
      "r1079",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1092",
      "r1093",
      "r1094",
      "r1095",
      "r1096",
      "r1097"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Restricted Stock Activity",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r202"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r804"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Allocation of Consideration / Recognized Identified Assets Acquired and Liabilities Assumed",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails",
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r617",
      "r619",
      "r620",
      "r621",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Plan Activity by Exercise Price Range",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Stock Option Plan Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r199"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Weighted-Average Assumptions",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r676",
      "r1167"
     ]
    },
    "lgnd_ScheduleofContingentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ScheduleofContingentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contingent Liabilities",
        "label": "Schedule of Contingent Liabilities [Table Text Block]",
        "documentation": "Schedule of Contingent Liabilities [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue from Significant Partners",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r53",
      "r106",
      "r216"
     ]
    },
    "us-gaap_SecuredOvernightFinancingRateSofrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredOvernightFinancingRateSofrMember",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Overnight Financing Rate (SOFR)",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral."
       }
      }
     },
     "auth_ref": [
      "r1504"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1210"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1213"
     ]
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDiscontinuedOperationsMember",
     "presentation": [
      "http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofNoncashItemsandCapitalExpendituresoftheDiscontinuedOperationsDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbScheduleofRevenueandExpensesoftheDiscontinuedOperationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discontinued Operations",
        "label": "Discontinued Operations [Member]",
        "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, classified as held-for-sale or disposed of by sale or by means other than sale, and business and nonprofit activity on acquisition and upon joint venture formation, classified as held-for-sale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r114",
      "r115",
      "r116"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r366",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r404",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r515",
      "r528",
      "r529",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r1134",
      "r1135",
      "r1136",
      "r1142",
      "r1188",
      "r1548",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1555",
      "r1556",
      "r1557",
      "r1558",
      "r1559",
      "r1560",
      "r1561",
      "r1562",
      "r1563",
      "r1564",
      "r1565",
      "r1566",
      "r1567",
      "r1568",
      "r1569",
      "r1570",
      "r1571",
      "r1572",
      "r1573",
      "r1574",
      "r1575",
      "r1577",
      "r1578"
     ]
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r366",
      "r384",
      "r385",
      "r398",
      "r1135"
     ]
    },
    "us-gaap_SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherSignificantReconcilingItemConsolidatedAbstract",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment items:",
        "label": "Segment, Reconciliation of Other Items from Segments to Consolidated [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r401",
      "r403",
      "r1133",
      "r1134",
      "r1137"
     ]
    },
    "lgnd_SelexisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "SelexisMember",
     "presentation": [
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selexis",
        "label": "Selexis [Member]",
        "documentation": "Selexis"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C Preferred Stock",
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1357",
      "r1358",
      "r1448"
     ]
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone and other",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r1151"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "negatedTerseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r634"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r631",
      "r632"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding at beginning of period (in USD per share)",
        "periodEndLabel": "Outstanding at end of period (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r631",
      "r632"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant\u00a0Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Risk-free interest rate (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails",
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
      "http://www.ligand.com/role/StockholdersEquityShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r617",
      "r619",
      "r620",
      "r621",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares allowed to purchase in employee stock purchase plan per employee (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee",
        "documentation": "The highest quantity of shares an employee can purchase under the plan per period."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase the number of shares under the 2002 Stock Incentive Plan (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1166"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares available for future option grants (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercisable at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercisable at end of period (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r625"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average grant date fair value per share of stock options (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r637"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate Intrinsic Value (In thousands)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "periodEndLabel": "Balance at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r624"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period (in USD per share)",
        "periodEndLabel": "Balance at end of period (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r624"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate intrinsic value, vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options vested and expected to vest at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options vested and expected to vest at end of period (in USD per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock issued under amended ESSP (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityRestrictedStockActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r619",
      "r620",
      "r621",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercised (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r628"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r629"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in USD per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r627"
     ]
    },
    "lgnd_ShareBasedCompensationInitialOfferingPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ShareBasedCompensationInitialOfferingPeriod",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial offering period",
        "label": "Share Based Compensation, Initial Offering Period",
        "documentation": "Share Based Compensation, Initial Offering Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r614",
      "r622",
      "r641",
      "r642",
      "r643",
      "r644",
      "r647",
      "r649",
      "r650",
      "r651",
      "r652"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range [Axis]",
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]",
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lower range of exercise prices (in USD per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options outstanding (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upper range of exercise prices (in USD per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting right (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1455"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award expiration period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1165"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate intrinsic value, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average remaining contractual term, exercisable (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted Average Remaining Contractual Term in Years",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average remaining contractual term, vested and expected to vest (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r639"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proportion of fair market value of common stock at which stock is purchased under ESPP (as a percent)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price (in USD per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average exercise price (in USD per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r201"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityBreakdownofOptionsOutstandingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining life in years",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r227",
      "r1361"
     ]
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermInvestmentsMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Short-term investments",
        "label": "Short-Term Investments [Member]",
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet."
       }
      }
     },
     "auth_ref": [
      "r1099",
      "r1100",
      "r1101",
      "r1117"
     ]
    },
    "lgnd_SoticlestatMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "SoticlestatMember",
     "presentation": [
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soticlestat",
        "label": "Soticlestat [Member]",
        "documentation": "Soticlestat"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and Local Jurisdiction",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r665"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesSegmentProfitorLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r281",
      "r366",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r404",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r515",
      "r519",
      "r528",
      "r529",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r1134",
      "r1135",
      "r1136",
      "r1142",
      "r1188",
      "r1548",
      "r1550",
      "r1551",
      "r1552",
      "r1553",
      "r1554",
      "r1555",
      "r1556",
      "r1557",
      "r1558",
      "r1559",
      "r1560",
      "r1561",
      "r1562",
      "r1563",
      "r1564",
      "r1565",
      "r1566",
      "r1567",
      "r1568",
      "r1569",
      "r1570",
      "r1571",
      "r1572",
      "r1573",
      "r1574",
      "r1575",
      "r1577",
      "r1578"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r296",
      "r297",
      "r298",
      "r329",
      "r354",
      "r358",
      "r360",
      "r362",
      "r368",
      "r369",
      "r443",
      "r540",
      "r542",
      "r543",
      "r544",
      "r547",
      "r548",
      "r579",
      "r580",
      "r584",
      "r587",
      "r595",
      "r773",
      "r931",
      "r932",
      "r933",
      "r934",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r974",
      "r995",
      "r1014",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1324",
      "r1375",
      "r1385"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r149",
      "r152",
      "r153",
      "r277",
      "r312",
      "r313",
      "r314",
      "r335",
      "r336",
      "r337",
      "r340",
      "r346",
      "r348",
      "r350",
      "r367",
      "r447",
      "r453",
      "r517",
      "r597",
      "r691",
      "r692",
      "r706",
      "r707",
      "r708",
      "r711",
      "r723",
      "r724",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r739",
      "r750",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r785",
      "r788",
      "r811",
      "r886",
      "r917",
      "r918",
      "r919",
      "r938",
      "r1014"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r367",
      "r788",
      "r853",
      "r929",
      "r949",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r974",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r993",
      "r997",
      "r998",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1014",
      "r1198"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Condensed Balance Sheet:",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails",
      "http://www.ligand.com/role/SpinoffofOmniAbNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r351",
      "r613",
      "r1325",
      "r1329",
      "r1383"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r335",
      "r336",
      "r337",
      "r367",
      "r407",
      "r788",
      "r853",
      "r929",
      "r949",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r974",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r993",
      "r997",
      "r998",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1014",
      "r1198"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1232",
      "r1243",
      "r1253",
      "r1286"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of commissions and fees (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r148",
      "r149",
      "r198",
      "r931",
      "r1014",
      "r1103"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock compensation plans, net (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r148",
      "r149",
      "r198"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityStockOptionPlanActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r148",
      "r149",
      "r198",
      "r628"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of commissions and fees",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r148",
      "r149",
      "r198",
      "r938",
      "r1014",
      "r1103",
      "r1208"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under employee stock compensation plans, net of shares withheld for payroll taxes",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r148",
      "r149",
      "r198"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsScheduleofDerivativeAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Option",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchase program, authorized amount",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1449"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares repurchased in period",
        "label": "Stock Repurchased During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r148",
      "r149",
      "r198",
      "r938",
      "r1014",
      "r1105",
      "r1208"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 equity",
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r152",
      "r153",
      "r183",
      "r976",
      "r992",
      "r1015",
      "r1016",
      "r1182",
      "r1209",
      "r1377",
      "r1414",
      "r1522",
      "r1582"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r328",
      "r578",
      "r580",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r591",
      "r592",
      "r594",
      "r597",
      "r741",
      "r1017",
      "r1018",
      "r1107"
     ]
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r798",
      "r1181"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r816"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r816"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r816"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r816"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEventDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r782",
      "r816"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.ligand.com/role/SubsequentEvent"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r815",
      "r817"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryInvestmentHoldingsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryInvestmentHoldingsTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Investment Holdings",
        "label": "Summary Investment Holdings [Table Text Block]",
        "documentation": "Tabular disclosure of the summary of investment holdings."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfInvestmentHoldingsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfInvestmentHoldingsLineItems",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Investment Holdings",
        "label": "Summary of Investment Holdings [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r964",
      "r965",
      "r995",
      "r1197"
     ]
    },
    "us-gaap_SummaryOfInvestmentHoldingsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfInvestmentHoldingsTable",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Holdings [Table]",
        "label": "Investment Holdings [Table]",
        "documentation": "Disclosure of information about summary of investment holding, including, but not limited to, investment with value exceeding one percent of net asset value of registrant."
       }
      }
     },
     "auth_ref": [
      "r937",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r964",
      "r965",
      "r995",
      "r1197"
     ]
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Account Details",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r1354"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplemental disclosure of cash flow information",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1279"
     ]
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TangibleAssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tangible asset impairment charges",
        "label": "Tangible Asset Impairment Charges",
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r187"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforward",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r688"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138"
     ]
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Core Technology",
        "label": "Technology-Based Intangible Assets [Member]",
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1427",
      "r1428",
      "r1430",
      "r1431"
     ]
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TimingOfTransferOfGoodOrServiceAxis",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service [Axis]",
        "label": "Timing of Transfer of Good or Service [Axis]",
        "documentation": "Information by timing of transfer of good or service to customer."
       }
      }
     },
     "auth_ref": [
      "r1156",
      "r1452"
     ]
    },
    "us-gaap_TimingOfTransferOfGoodOrServiceDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TimingOfTransferOfGoodOrServiceDomain",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Timing of Transfer of Good or Service [Domain]",
        "label": "Timing of Transfer of Good or Service [Domain]",
        "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time."
       }
      }
     },
     "auth_ref": [
      "r1156",
      "r1452"
     ]
    },
    "lgnd_ToleranceTherapeuticsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ToleranceTherapeuticsMember",
     "presentation": [
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsNarrativeDetails",
      "http://www.ligand.com/role/FinancialRoyaltyAssetsnetformerlyknownasCommercialLicenseRightsScheduleofFinancialRoyaltyAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tolerance Therapeutics (Tzield)",
        "label": "Tolerance Therapeutics [Member]",
        "documentation": "Tolerance Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1271"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1278"
     ]
    },
    "us-gaap_TradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TradeNamesMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsGoodwillandOtherIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Trade name",
        "label": "Trade Names [Member]",
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1428",
      "r1429",
      "r1430",
      "r1431"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1299"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1301"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ligand.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransferredOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransferredOverTimeMember",
     "presentation": [
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transferred over Time",
        "label": "Transferred over Time [Member]",
        "documentation": "Contract with customer in which good or service is transferred over time."
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails",
      "http://www.ligand.com/role/FairValueMeasurementAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r574",
      "r593",
      "r740",
      "r767",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r887",
      "r1169",
      "r1171",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1183",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1506",
      "r1509",
      "r1510",
      "r1511",
      "r1518",
      "r1521"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1302"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1303"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1303"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1301"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1301"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1304"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1302"
     ]
    },
    "lgnd_TwoThousandTwoStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "TwoThousandTwoStockIncentivePlanMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ligand.com/role/StockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2002 Stock Incentive Plan",
        "label": "Two thousand Two Stock Incentive Plan [Member]",
        "documentation": "Two thousand two Stock Incentive Plan."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_UGN301Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "UGN301Member",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UGN-301",
        "label": "UGN-301 [Member]",
        "documentation": "UGN-301"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_USDistrictCourtForTheNorthernDistrictOfOhioMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "USDistrictCourtForTheNorthernDistrictOfOhioMember",
     "presentation": [
      "http://www.ligand.com/role/CommitmentandContingenciesLegalProceedingsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US District Court for the Northern District of Ohio",
        "label": "US District Court for the Northern District of Ohio [Member]",
        "documentation": "US District Court for the Northern District of Ohio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAvailableforSaleDebtSecuritiesinanUnrealizedLossPositionDetails",
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInvestmentCategoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasuries",
        "verboseLabel": "U.S. Treasuries",
        "label": "US Government Debt Securities [Member]",
        "documentation": "Debt securities issued by the United States government."
       }
      }
     },
     "auth_ref": [
      "r1543"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1298"
     ]
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ligand.com/role/SaleofPelicanBusinessandInvestmentinPrimroseBioNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Loss (gain) on derivative instruments",
        "terseLabel": "Gain (loss) on derivative instruments",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1071"
     ]
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrealizedGainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on available-for-sale investments, net of tax",
        "label": "Unrealized Gain (Loss) on Investments",
        "documentation": "Amount of unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of year",
        "periodEndLabel": "Balance at end of year",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r676",
      "r1167"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Reductions for tax positions of prior years",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r1167"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions based on tax positions related to the current year",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r678",
      "r1167"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesReconciliationofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions for tax positions of prior years",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r677",
      "r1167"
     ]
    },
    "lgnd_UnrecognizedTaxBenefitsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "UnrecognizedTaxBenefitsNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherLongtermLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits - Noncurrent",
        "documentation": "Unrecognized Tax Benefits - Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.ligand.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r1167"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r246",
      "r247",
      "r250",
      "r251"
     ]
    },
    "us-gaap_ValuationTechniqueAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueAxis",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Axis]",
        "label": "Valuation Approach and Technique [Axis]",
        "documentation": "Information by valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r757",
      "r1173",
      "r1511"
     ]
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Technique, Discounted Cash Flow",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "documentation": "Valuation technique calculating present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1173",
      "r1509",
      "r1510",
      "r1511"
     ]
    },
    "us-gaap_ValuationTechniqueDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationTechniqueDomain",
     "presentation": [
      "http://www.ligand.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Approach and Technique [Domain]",
        "label": "Valuation Approach and Technique [Domain]",
        "documentation": "Valuation approach and technique."
       }
      }
     },
     "auth_ref": [
      "r756",
      "r757",
      "r1173",
      "r1511"
     ]
    },
    "lgnd_ValueAddedTaxReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ValueAddedTaxReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "UK value-added tax",
        "label": "Value Added Tax Receivable Net, Current",
        "documentation": "Value Added Tax Receivable Net, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.ligand.com/role/DebtNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_VaxneuvanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "VaxneuvanceMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesRoyaltyRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vaxneuvance",
        "label": "Vaxneuvance [Member]",
        "documentation": "Vaxneuvance"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1455",
      "r1456",
      "r1457",
      "r1458",
      "r1459",
      "r1460",
      "r1461",
      "r1462",
      "r1463",
      "r1464",
      "r1465",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473",
      "r1474",
      "r1475",
      "r1476",
      "r1477",
      "r1478",
      "r1479",
      "r1480"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1455",
      "r1456",
      "r1457",
      "r1458",
      "r1459",
      "r1460",
      "r1461",
      "r1462",
      "r1463",
      "r1464",
      "r1465",
      "r1466",
      "r1467",
      "r1468",
      "r1469",
      "r1470",
      "r1471",
      "r1472",
      "r1473",
      "r1474",
      "r1475",
      "r1476",
      "r1477",
      "r1478",
      "r1479",
      "r1480"
     ]
    },
    "lgnd_VestingPeriodOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "VestingPeriodOneMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vest 1/8 on the six month anniversary of the date of grant",
        "label": "Vesting Period One [Member]",
        "documentation": "Vesting Period One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_VestingPeriodTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "VestingPeriodTwoMember",
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vest 1/48 each month for forty-two months",
        "label": "Vesting Period Two [Member]",
        "documentation": "Vesting Period Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_VikingTherapeuticsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "VikingTherapeuticsInc.Member",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Viking Therapeutics, Inc.",
        "label": "Viking Therapeutics, Inc. [Member]",
        "documentation": "Viking Therapeutics, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "lgnd_VikingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "VikingsMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vikings",
        "label": "Vikings [Member]",
        "documentation": "Vikings"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1267"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsOtherInvestmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Neuritek warrants",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r1195",
      "r1196",
      "r1199",
      "r1200",
      "r1201",
      "r1202"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.ligand.com/role/AgenusTransactionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants term (in years)",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1509",
      "r1510",
      "r1511"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares used in diluted per share calculation (in shares)",
        "totalLabel": "Shares used to compute diluted income per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r362"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ligand.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCalculationofEarningsperShareDetails",
      "http://www.ligand.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Shares used in basic per share calculation (in shares)",
        "terseLabel": "Weighted-average common shares outstanding - basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r362"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1265"
     ]
    },
    "lgnd_ZelsuvmiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ligand.com/20241231",
     "localname": "ZelsuvmiMember",
     "presentation": [
      "http://www.ligand.com/role/BalanceSheetAccountDetailsInventoryinOtherAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zelsuvmi",
        "label": "Zelsuvmi [Member]",
        "documentation": "Zelsuvmi"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "7",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-7"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "8",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479637/805-30-30-8"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1D",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1D"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-13"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-6"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-7"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-3"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481244/470-50-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "37",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-37"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-5"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "25",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-18"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "25",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1A"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1C"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r198": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r199": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r200": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r201": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r202": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r203": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r204": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r205": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r206": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r207": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r208": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r209": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4"
  },
  "r210": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r211": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1"
  },
  "r212": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r213": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r214": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 5.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479836/810-10-S99-5"
  },
  "r215": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r216": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r217": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r218": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r219": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r220": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r221": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r222": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r223": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r224": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r225": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r226": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r227": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r228": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r229": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r230": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r231": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r232": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r233": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r234": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r235": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r236": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-7A"
  },
  "r237": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r238": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r239": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r240": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-6"
  },
  "r241": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-7"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-27"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-4A"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479391/326-20-30-5A"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479366/326-20-35-8A"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-5"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-17"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-21"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3C"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-3D"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.M.2.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483530/326-20-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479175/326-30-30-1B"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "13A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-13A"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479148/326-30-35-7A"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3A"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3C"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-3D"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-5"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-15"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1B"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479365/842-20-25-5"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(h))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-9"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "SubTopic": "320",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479294/326-20-55-12"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-39"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481174/470-10-25-2"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/210/tableOfContent"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1394": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1395": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1396": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1397": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1398": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1399": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1400": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r1407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r1412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r1413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r1416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r1417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r1418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r1451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r1452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r1505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r1532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r1543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r1545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r1548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>114
<FILENAME>0000886163-25-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000886163-25-000012-xbrl.zip
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M<P8G#'<_ WI/,UYO =PB70O>(>N\XX^?"I&$^AD!K-<MLQ,\XQ%SC+0LZ)"
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M,_L#!K4(DFOD:G#04C#!F"7+1^)ATN]1Q]E^B;+*P%9$F8%6V&T0EV"+XVR
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M19K$TF@"97::)F'>H>FS012**>P&!J'@1]#^R)DI+3FP&X,L"Y*"+\TCV(L
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MQ^V9U<+J4\RIQ]"2]D5L1-\Z:!(5Y!H"#1:&N(.DZGT*EJN85>UET_HJ^_"
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M!FL$AUC+@"*7PG#$N_++V F\<RI/XL0)'2?@<(>JI=)!-YEGVW'6::D,Q;L
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M-2>M^T]T]H^Y+XCS,14BL0:ZCT96T<@7^VCDET0C6R*2=PKG?.0-!R/JTGX
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MHM[AAGXV9Y!#E.6^S%M0A7+&>NBL/UQ8KIQ;P/I2(V:X&WOA!+/BW["*3Z3
M8Q:PE:/K]YV>_XZ25RY<,+F[WM7$[[H]_*4[& T'(W(546J[/_'9D:B2YCM&
MQCSESWM88TPW>)?#WN"C!]=3Z?@I52(?=7L>^CGP&5AUB8, *Z)Y-3N.FX09
M3AO(-U3MBNH:9'<1B;G3HUY\^D:0,P=O3]X<.F].WAY]?_+ZS9>Y!C[#$'MB
M'\,#5K/\[S0-U_#/HEC&/_]_4$L#!!0    ( $. 7%KIO/70N*4#  5<*0 1
M    ;&=N9"TR,#(T,3(S,2YH=&WLO6ESXDBV,/S]_@H]GJ6K(@S%ZJ6JNY[
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M7$]++^>"5I.P\?'>U__P8)IC)]]+M=)/+>C:G[FY%J\U=PCT_!"^^2,2R$W
M1!TL69)4:!@\PUU53(I-?D4U=K.H32PIP#%>QAJ[)W$-B'D2MF^GC-]\-_)"
M)JFR2@9)=7P)N6\!@E@W=A>S4R_B961 6?,)ZZ''*>T[25V?K0]E'1/I@2!
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M3?:JCJA2*Q7+I=-"&6A_I0)N,3R\9+28+6=>43=&121!C[MN4N[Q8;*F?*(
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MTBI7]JF,9Q^_9WV<30"F(P-5T;46LC)M/0\!GBG"8,+4I&=^BQB>W^S+P/H
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M> #KS',1?--?(CZ$%_'I[P/.?\P\82!]B[1,<L&7\34&S['%8.+%<%5A-Q!
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MC?AX1P0#%^B*BH2HS)ER8[K>5?<*S7FN@SZZI6H^5<$9T.DTD/"UCL_UA?X
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MW,4LN,:]<& \1RAYX3']5&^:AH^J:P9,\PY 4E ;,]:J^P]6TK4 ?X&M!4^
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MP"&RAJ[C&3NO2"]/YBVFF"SN_0LLL%LD&#C^(U@_/P7JS$+2?.I@0D6YJ-!
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M2VDSW)H(R6H\'-MA+SH+']0Y'4K5@2R+@O%@G20/1 #55].G*,1>@;H4'\F
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MIJ=Y=#.F>5+'V@A +X'J?[7H_VFB$CE=R%]0/L5S]@8X2GI4 DT1Y8I(//Z
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M[VX5,@^6,,,L[W!>B#\@K9R;AOMC.8FUX./'M0?5$^BZA5=B9WB0%.0 !%,
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M?_MYF*' P7]?H!O.M_M^8?>\X[V9\X1H[(B-C*.S]TLF3S:-8Z&C&BQ&"'8
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M[^R"Z1B&>']!:1,)N2#3C/7]S/L5J$BDZ$^%RY_B^X^C*)[QA3\5R;?7,)E
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M[6 19HF1*SB<Q6%X_@DO$ZDQH+)_&^_2,30= C75P_H2=#Q>"<,FDC-^AK<
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M-+[2O FLJ[]'C0IBN.I)2V/P$>1B9%O&40NAA!K'=+S/4;&/NK56RSM4TU
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M&/G&I$R6ML)'6!SELOO*['72./H:(YW4.<HCW?H9A,@<!#=,[YMIT5QY@6[
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MRU5Q Z_4\E(?CDY7'E-2G2$!;?L9#G&]!5>"YM#QB1KZ:'2DI]:1EN]]VY
M63K5T%!!!B[R%IR&A135^9DE[Z^&Y"+K2J73'(-#A2ZM:[U!B\<T3:Z"NH%
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M"2_06X4F,P8GC Y=$(,#H^/JER<$>SHHT8H.N%6C;9JZL)H=5%(?;I9.W:!
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M_R!D+3-"3-EKTZX,YU[=%EGIP :&9;!T^QBA1S*]5!N"-I;;[Y7P0L)( ]]
M(>F/X^K*W&$-AJ8H^4L*-_OAS!_"K@XO5IT.G(E(N6:7TM20^VP=_78R_:(H
MZ$FCIH;%4-+!G>PN&9+4=G<KI*_LV,@E"\,FXH)-VE)+R $BO"0TU@Q(L9C!
MWX0#0X@>$BIC"A# )5E,*R<]XWPXV2WC=[[XX8[]NG"6W "EFS+N"X*B27[.
M09?*S2+I&TJ@908-9H)-R<JQTT41[^AU_>(6*-(B%*^+8$IO*%C6PGV1'?FF
MHZ;M&T;B?%,Q.[@X!/=Q 3@ EWY HQ[5/0<0*9^#?&6A%6R]-%Z0U!S=YC2$
MJ=8@XCDF(3;FEO\GVN<;1[=P71.),F*B>80"@W6!GB9N\1U)/ZQZ!^DS0HN4
MLWRV93X^PG:NY%6G.K?W/G6Y^/#C&#RF]?XWXP.]1VA@/!MM0C'B6YG!9'$F
M3!:@6LG):5*P7;)]PSI,RVQ5&.!V&XYA*;P>XYV(.@_FJO9*'J-&P96R6@^9
M,9?Z]OX3]NG=I->?:#:4?UQ*X;H^^% $N!1EA;:[*ANJ+# <_^5UN:,&GZ=/
M(8E9#R%NX_\]J#3:R^!Z &A0;LF77AEB_:NR^4#T'V$)\C4PEO\S,HP[O?\?
M]);9C\"<-&5Q?"QH 6Z9RSKIZG#2"#NBV%V]N:HIR)$X*F$038AZ,L8R4QSA
M)(L67FEPY4Y9X7DIV-9L,H+?(V)M@(A1E=,UD;FM"Z!UM0*P]WL6K;%8DO)
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M"'/SNA+AW<HIL5JY7BJ;I>/ZV%#Z*NU"3*JAED).RK;6>!=E).,IC\0!?"L
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MS_YB6HU^$%$UJ^EA6X9F&K#XJBTW4FP*80KPTPO";B#)W)SYET!+C>N!9[%
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MK*5+7VG4M'0W::H/9W3;[0A#(KJV'GD8AL>*,E&\P)-UG5Y4]0.W%UNED65
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MZ(@;-]+H+=5,*Y!8T&CO_OYZE+HE/4@T=K;2NBS%8OH/ZOV3W \Y0B=H 5)
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MHB7-DH2[+IF(\-BMD?[M/3GE'$Y%FRJLO*H-2)M:(-C*IE/]M.,D!I@)Q2U
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M)LBJ6#O7=QWTHAHD;9Y^\>+KYIJ.G["@WI7KL.Y1 Z!]FD[[:W#RUN29@:)
M#)WRWW,J0_OPPL_(Q0M.#YHFW!H#5*QFTO4^/H^Z"E9\L72B+V%YN[+NXY31
M,F&\S\88KI*I<9J\M(!E9Z8? N@RWA82![S$,:9F3$BV^ONS[]_I@<%>PC==
M<.6)=-Z6[:LWW^BJ15Z.R'Q+F;1782F C(&ZFVEVV(&:774*;:,X1"F+PN]K
M[0+TWXN"ZIMO6!,\++.G3S3T(">O,OUENH;C%-0+*!AC"S5=Q>&NH""P[$+P
M4-9GM+M9L3LV?(:;\F?0W7'4NQDOY^><$Y#GWY^'Q3\$AX+R3HS=X FG*5E\
MJ/8ZZ7H@:IF29_W'<77E-!U+(!D;-_'\DD?M Z U]&X)A#J5LE;]]1_T'"7V
MYZ6 1)AWDTQ[&"%)S/':(*1C)Z)H8-J&M0E_)3-BK-M5P_6,PV>*Y_9,3/!_
M)99_9ET7&C 01H"_Q5+2:##MP:0TDX#G0P(8=G\<I@C.*M)>"=R=,WF:J?:4
M1BPP9*6%IE2TXZPY[1552V4IN/Q1S #CZ=Z!EMUTATSFD<,\_^CD8?,V@4()
M^ 2)<\F.4$P"N'=5"'YT RJ84FJ66G;!V#:@2C?O*=>K%U@<<]XJ.$"%DK2(
MZMJ_8;@J!ZM,NCYHMY#I.;X#S&LUWO%5&PXD W^OX4G+1&?3)!2TD3V9.'+6
M9!1[I5.!*;7V*6$3""N3LF.\B.@%V,KBQLQB;_P'I+^=N3;_%?X[!&S6[+\"
MF&3L*F?J$Z>BT!B1F3)3)RV]Z8S_>H4N<SG-)$O3TR-I(P/ *C&\=Z!-WRQ:
M2MA:3DK$RL <9HO]8N<%/_WB^8NG?SC_?.H&E[-NKHV,N,;B*(N''-7,B3]&
MGRCQ)C7U'/*2G7OQ])D>,6R*@C,Q5$V?'4C+$LCZF!Y[5$[YML*/(T;FL:B6
MT3_2<!WRLNY^/AUX-VR\VRK9N>!($'H+WA(:7*:X]L0:',"RNO3;X2*_*XB#
M)-F,M2603K&#1]*K6VCCTG!_\_XE[SRTB4E52%2^T0Q=)4%D*6966==MCF7,
M/I#J)I&-D1>#R$"\ ,31DP0.D55+YZ;^#9AX;#JM16N#0"1\%+$U.Z"FA=_X
MZVAR]<Z>5/O(+6@CQT9=7G-C$VY+.006\;9H,<0NL?2EX@RT@@1E3<VGN.?G
M:DYIW"^(%^Z;\)[J)!ST1#Y4U2Y6H]2)GRLB<8X4H+!($%7IBY=+!JC%#^#B
M>N0<$TCY%#AK7_"H?&P?(4G,]R";=2XRONR]?"8[!+VPR7H3R&M@0A',!S4E
M05J6\4%^U8T+<4]JA0)AIF2PU;NY:3<C@^PLO9[H*M"6WJPD@T#;QTR_N$C$
M!4 4AX:2BF!);FB,U)5#VVYZ66AD.U,0%[<Z+&[&#7DDR$L"FYTR+-T=)S)E
M:Y06+7(1V6YC1^N-;*V4P1)U3;7OU3ER':35/*XFK&?J)^*/]SH3;N>UL8J=
MHS&2W:B]K+?599@IUYE&.B4FQY.\#\BR79>;_!2G N7]3\_XOHQIM&,XP"D4
MX5"*52LH\/"H'*]&I)4.RK9AE)7W?DSMB/W-"%^5&T2;1XM=00#\VM5/U&Z"
M&I3VN^4@<%E&6$-^Y522$ /N,^EB<^(A61.B+=XIQKR.'799=CD%4L$&<F7/
MLMB<X>?VSX\#K(Y"HU3 S\]2!%PG/LA#F?[YLX<R_<^U'2@-)-!V*F_ZFL"_
MPU^9N&K6/W*D@RLR*3L-1;0^LK;@;KPDUTG)0N_4BC=3)A/[-=.B=XH \/?7
MU<(W5B!TXM9BKN";E_3J(@\M3:\DPK DW=5<#==$KE=OU0E04%G=$)X/EBR1
MHA'B0M\7F'1#.1WYJ(HHN,JY]V=(,C<MQT[8(H4%.RB:TPD3$<,3C(O0E:-
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MJANG2I$\FH;>S =C5';:U8KO(!9<I $*_HXE^E@-+F*Z7E-3PR*,=$^GC>$
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M1!-)S2OU3_(?-:?*F?-ZXP>+(CO@FH2G*H&LLX-(L872Z4MN?>);T]_$],C
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MG3%I7$DV+7O\20+I*3WWIB+ 3>]6AV$@>;RM:.0"Y7@8&\50ZH2E?@N"QQA
MNP*.%D0ISR5A+#1.^*7N3R/YZ<^(EYHC'*(K.+/S:)=7S17$=*0VK.F8N?'A
M:.LG$FRHG"U6[K(TL;;6%%?%56CSXS0O2'_^6PBEFB2A9M8'('1!MDZ6QZ/8
M=_W_?_W7=]__][>OO5/,#S5,S67E^N8C6<[?7K]_^_KEZ[\NAFIYW5"SZ)Z2
MUP/9C\?VFJ74 "7]('D7JQ7Y!3:S=%[_<BLS1D&^"LZY?+/05EOE S'5QY,S
M602NTC:S8687GB_>D7U);PK?XV/>L4 1-GM^+)D^.IYL0E^6(1(.'FM2?,\9
M3+EV+L7IMSC8LI+D5_KK[](0(ES&J+4PMN\IH[UX0ZYZ,)!:V?[-5V"_PSK#
M5__ITY'R_I__.,43Q:%E7;T5/I)ZAVDG7:P:?*BXNT"3=).[Q*(3$N7,MAJ+
M5)RR:6=? %F<#9%)$@"!<XB1<IQ<$U+M8;1E93FBX$"?8/:&IB#&Q%Q50U#\
M#\Q+/;C1IT.',V,Z"<>F3?75]#GF-*,Q5#1O#U!\;(4342B4Z/;2XRHNK002
MC@R$^4C)Y)N:=OL+R+@\T(0?H@D'BM7J_H84IE8Q'$W_M:?^X#K,YM<W[38<
M(IZ71R$)?1L]#CUX?PGJ_H=I.S9MDH",FVF.4M>XND.<F(B)ZW^$2;SJRFW_
MH"3_*T]7Y+ P'VXW=LOK4M/8(S.6S?6[>L?61!4>)NR?,F$\_OT I 'R0Q01
M,=K!Z@XUE"4YMYX4R68%)R=,W9*BB1T^G,BF<*N5=NS@#W#.*R$YP=;UT VA
MX6=#3D0_0E;PL+U_Q=7",@TUD\/Z7F8F(G"X!6@9"%O[5 3=P18 ^9.0.H;9
M86E 3.5A,G]%?2O%H:%J*$WV+%MKJ@A.70%X,'>MI*%/,?=%^<3EN!TWOH'*
MU<7%L9\@LC94"4PCA(PY3EO2,5IWC&X8Y<L\3(*0IR##-R!,GI"_&2*;LMZ(
M)=U6U>!@*#&'8TTO!.0P]$49]N9>L%ILZ]LNMJ +(IT254X>/@)7_;>XZ'7N
M\?,/"O_!/P$ZLB5"@7[HLPA7LU-<O/+TKLDO9J]&2';/M^)2$J#9T?$$<0B#
MMGD&5G V*U_OWNPE*59Z>+==R;_CH!*L'EH/X-XC<"7LO= KESB(\'9 8LN-
MOT$8_O&LP&\F,Z,\K*03T*X0YVN7KU^QT1 9MM53;7)"T;7PZZB19OM58\+@
MCNGL]P*T_R;WB(3)[.+=5PIX*#?$_19&^$?B(%,-6XYUV^ZJ;,11@V"V*A?U
MZ&]-3@N0R&^J!$B<\U0JCVQS9)#3=KHPT=^&B7GVY.EG!;^V5*%1!YC,.^S4
MS/2>7<1KWQG^^:5;4XOW[:Y>+KYX\D6Q^)4/YX.;8'X.WWHQK9>4/"JM(^)E
M,.!M<*C[3YGSA?V]>/>2!N],6O^H6ZI:4?Z?@@A%#,[,C)DK!MZ;\9*&[MY5
M8K%S\<._1XFQ<=<V7!RAXA]DJMH5]S<J'S*7<V6D%B"FURX$:29>;RHFFG%8
MS12-H)R@*#NO6&!*HP[4N,G$3!Z=?=-E.)JVZF*0LP$SUE/8&Q;XEZ?H/7V/
MHHM,?K'X:WT%H%K/.#=A5FU;HE"Q?)OG#Q>W2!IO/-M65T%14?-R6G1"E6>S
M=S100&F81M , YV<C'0-\_#&9)ZO_C,M>Z9%%_$828)P[C$)11J!;&00N&=>
M3A\%UT<?[_5Z]KL-X\D/51\G4W7;H/!//Y L"],'FB\@G\PH7'UVG!W?EN$(
M#83Q%GZDZ['1QZ1HAU]BU<XAK/Y7 M_^\#L OOWFO$>R-^5/S(W0IK1,!A_0
MEOD(Z>3F^;MWBD>,>X@_KD-@V-X6<Z!VD9/]??B7=!L=VT*XY=%',&Y<.T&M
M*KIMM^*&:=]:V)0X;TL.=LA)91^0^"]92Y$-Z)+;[/7ZU\U:M"7?5B!/#?_K
M@B0]B,0$T#L'Y)?W*1=//__7!?'3;L<M7ISEEG!$P>1N<= H>(AC_&"(=ZW'
M"X3;_"N=_X34DIM$=36^MI)XCPC\)-WM$'G6/?H/CITCG8GR)50'%9TCNLNN
M"N<'<])P#)6/-;4W QB&D>7TK=U86)#X?GJ[(@_(#N&A"0$HE#)[A9<8L8WL
M'V  (S2Z\&FF.)HT4)TIUTA;0T)5VH1HF5@/.X"&PN4,ZQ$J[?(GNUAYF?60
M+*PW8\4+*7+C&N ^\C*\#W=F%;^P%K;<&*2,%A=OOWZ'-9ARYN'=*^0TG21J
MD<1(T;K$&"F!K](GSGY>S/OXWH80TYTA[A/$.G]D6.%@K_3%;[J7?N<IY@B^
M2UM3%4_1 -2L*2D (I=EU^W#--S&YE=5"N5N'QK58>CJRU%0H.UZW5.SCHV4
M:+G!3DSE7<UL4!5?P]G3,^H7.)=>!8.[O:PZYL9\_K0(,<JSSPK.3JU8:F M
M<I<J+%)]?-@?"4#K;]_]M5?^&^3=J$KTDW;'_,NSI^>?+2(AYVKQ+T^_>';^
MI?Y3H3@U="ESQY2^#-U99+4,E??LR?,_&*$OORDNNPS[L1%$? T>(/K*+]'G
M0WB,<:A!IWN^^'[& M 6]P\E"60A;=.UPDHHE4A\D+=F [O@,7WZ!T'IT3 M
M9)S04[PF=3M\WIUFQ$^&XQ4YV/Q"RWU)F>0AFZ+I;'QQ_BR=C&=_//_\T%Q0
MR*OO<O^'QXE0;GQ1_[.9_.S)S/2\3QF%#G?\\#,_.N(\W4;%]/S+9[C5\R^?
MT_"\UL*DYF:(@(G^\/2/7WZ1' T)XU.XR)8\-9)YSX*/F*L6X:G^HKT5-*<>
MP,:T<YVX)5'$/#6$U. 73O$SR53P(G5(%OM+:OIBM[>-8YPO;JT7RXA>5F&&
M;?M!;R<6$N=J^5-EBA0";\*1SR2+F^+(Y^K7,AV_I/B%LL?7;.RIC*2SNX1S
M6>X<O#[P @C<. YC.0AI;;_X_ E5-\C+)')'5F1@R96PGEK&[X=56%5>RNY\
M\4[5"4!S"+AKB"7VXC*PK5$W#ZD*1T^"LS]V)[H#*1L)2YI0KR_&%3]5?/\!
MY\#GO&WN[[\E*<]*SN<5;0RA;521 Y)&%!D]292LK!:,5_3O[;_4%8(G'^MD
MUUWKIJ2IP>4Q'1_?.Z+GM6]YD<4!KQP^8>,:-U3+0N%W6N&<NA79%G)CC>PD
M38<L^9:T@\2+HU,Q\QYTD,@+U4%R@TH(^&%&_CT559US2S=./F0@XAL5 L,B
M9-9H(3B5%O)2155Q&B)5)G*9TZ.*Q$ADYVH3JX8:][G_H9,0&,N&4GEL7[Y\
M\J_J_*;C)[51V?G<_\)@ T%YEO%LUA''M$#2#\N#WVDE3 -AL7(E._)+Q*^0
MCIIUV\W<E !-"#D7F"U2H<2M763E'$)=$O=:6WEX-:/'-YMKX+M-T:TGZ.:+
MNM)WVZ:^N%R\(H$9.JR89:6]8NX#IB<P)D@Q?MX,//)E0;N=Z &%*QX7*)VS
MS?R?D3P*4W/PU3#9>M%!^/QS=A"^^/)1^?C1T\>/7CTVRD:P,PIUC#SQVW#6
M5]W/>98\(KVY45V)"(CG^:!M&9O[3C#)]!W5 .G$>O8<+N^SPF@J86'"Z#VJ
M'Y,?<7'554S717/Q9E,BX)>Q]JY8.@OVLTC(R<DC+F<4,FG%XN(FK+MR\88;
M#2]<']++X(R%P_%U 5*_??CFQ>L0Z#<K93A$18GK6!H"7;RY>.F>&-[XN^ZV
M"HZIO-:[,3SR=;,\IYO>!M>%[.(MG;"$,*A7-0DXA.^C^]A-XV_36S^J:8C<
M2L>_^GWD1F]FJ.[TP^/CAQ_2RYXOWJA8+XX]JX<A8]&N9S;*(SCG(*[8M+?A
M ?CH;7W5J8,#=T;$K]AHTTYZ%8S +52.G:MM,6A8G_R8Z)8WXNXD+-8+\FV,
M+VNEC<AS+VICD;)\SAJ;(R-)2[R0T^0^PQ0F68NAG2HQ!%_GC. HE^UJ;XV[
M>]<=-YUM[92*$QKMIOFH"@%B,VMKLA;V+;G5T;5DXVY+-"6F@+]/LP#Y$XE/
M5@LJ8=#SX^0A^DDP.=H0*"7)\$+ROY*^PYFW\Q.B[P?'7;B!&WN-^)%(^?N,
MDM(.ZPF>MUA3=7FHAW'(3J*OK)?NFY:(1P\>5):TG#T1P]__%F89SM53-9HS
M:YO;BA.MU)^QU MGL4A;YTHY/#CG:,-4\+_JF'%K(=Q!KKWW8W?###HF&4^T
M[;!\9W.6+V[@A9+QK0?QB.>WR_8C9T&<\*0SW3U(_%V$OC$_W92,L4GNR=9;
M@TT2CC.R8(8M^-?TC+G)*YUB"O']W)(MYM8JGWNI$:.F#L=U?V?OCG/]Z;1Z
M\EFS-L)'+<N;NGQW+8L7USMEL*&ZSJYN'#* N[@(1Q2<\-0J<]!V>*/.?3A[
M?'6U^F7\R_P-9#"C%#WW&IH7^?GGCZKD%CA$D;HX>%Z%P^C0%!Y]_*6$HG?Y
MUAG_EM-[.ANWZ/W=U#>'>#61' L!6X1$9"\%JQ+N<@DA+S!/S)!^Z4HC '!?
M'-Z$_WO0"5\^H!-^KD%T=&ZHHE(6KAE<31E[8 !%NG0D4O'4 @_R=NFR>!#-
M(5Q)XTX]!LL42KI#Z1V-;$?84*).IR;Q<Q)FWA9;8KU5%8!&I4,%($_UQ2-?
MB.@W^4)8X(AQ(L$4$FL(E_=D$B-I;,JFK#"O(=H#TW:)Y1WGW\T)"?CH."EC
MN9R.CYBGE*YJBD0#Y[(6#7M^L==OWVFT'QX/VCAZMW EF2= 5762[!OT=XHD
M5]096=>14K*Y??7GFA)&)#F$\!5GZ^"@Y<:V7J,S6I^@&!B;T;O,YV0Z6Z5!
MRD:'+:RI3L;91F[XLJJ:Q4W=\DFN5$&'/K*_MK-$4H%KIUE;]GC1N"<R,J$R
MI_Z3B@$'"ZVP@+C$<O0D9U[&U+[G7C1C^G.9<1J$X[F>XN!*GI._.K1Z#^6"
M[K+:3S W..MM'O2[R*PP!XJ+#2.132*:*P5=D$BMI9@#FRICN.["[APWS O:
MW%1[5H-0%1XFT(7B4872"U+4:*@ZP3S<_88Y6ZHB&LVNGI9V[S.@(2(^/-BQ
M)&$]/VS5*$U(:7;0%E6BKX'@FZBEZ;";?R(:<9!-N:[T'II8Z7U0OZ**+5,&
M,R79FG1H4O!XJP8*Q/VT"&Y*/)#1/8AFPAG=O(AID/C8/RW(&Z[IU7LB3*;D
M)AM)']=&!#PT=#OHD< ]UA\)2$DO?+%X=/D8Y9RQ<2_7;TM4QG>T^=B=%L/>
M2KV<#/L027]>T!,?+1\+37+/F@=+U@.74B>X.%!RY[\073I5@_9MPW&T*X:$
MDX9:2(DZ!5=Q:H#HGLF+H9H*-<"5]4IJE4#&N8DN648]O.5E=5UNUFS[[5J7
M_U<EEUB< <W2V ^5M*Q>AE^<$8\HJEH]<S:%BXAOE;CWE^!*]$F(3DV*(, ,
MD>V\*Y\H>\P5R(Y;KE77*$Q!=<4NPL&H\D HECQWO@1BJ2<4MCZ^%T3W":X,
M)9"J';=*$(D_O:BZ>+738B+C6BZ:$0DH<"-OPP14R0$]'?]B<=/6^%N:F>7D
M'LLQJS"ZII;9IJ:_R0[.5K:7SP$"Z&DRO4@^03<@RRHE&47I/+JIRT-'?R'$
M?#?\%?(PT?K!!\!G(?7E*&BG7^0>2ZO,>E2(,]'2#8KR1#?)<$L.U#"ASK0V
ME9C^C%;:!A2&2GHBV1#-V)69-7:B)]<V&#F0_:S-*"[WS,NK]5MU@ ^?,S!B
M-Y1]7%6[RKQ^-I$_CL%=H,9<C\@)/P->A?'EYXL_ZTE5.*-E61*=Q\1R!X]=
M3R+QPGGNJ#$$?K"!1.O!SJ;PS(T(/DC!V717Z"KOY3B;R#E9Z,&Z*QZ_B(?2
MSWP#1B*UE[@Z4:IH4F,O))=\0#"*2)(B0M!*Q\ *+T35 M '0.DF/34L;+W7
MA[K?T<ZO@9T(1CH]A/C(JV_P^(^<H&L)!*-LJJX6ALVP7[)"?4&^A (O@B>T
M8[B2FNFTMU%ML.B2::HN!HMN76LPE?[&=S.5P]U.+G]<<=A^P VA'R)FNN(<
MOF9&V]^9(9D[=E5!]9##RXYN+!>L_(\5^N]!IE:W%'N! K/6+Z&2F*('#3A#
M^T ##G;&B*K*GX?2]TLF1>(:7!*,X":XY(\(JR0[.*R4L=>E_)A7??TXP>$U
MK9#*\L\+?TNZ$Z.7>ML'TNX(!%WMDP86) %+%L[*3E,"L#G+"MO6_=RI+LO*
M-:$.57DXL.Y@=9%)8FY>??7;N2V8[B(R_^!I([1^OIUFG(JYI]_"8H3I78^;
M4XVV@<@T;OPP/.50AD]L=V$^:7&3+':GR2P6JLK02NS]"%>%,?AK3-"$\>=3
MEYQ#=AMCYX((!CA%!#A>!H(A!NK%![A80WE0(B-\P4!LUL1LPK<^Y4ZL'YB>
M]V;<D+V0="D/LE,+BJ)AO79Y,E?T.KBU=%YAQ+ M&CKK2@Q/>+FS;;FJ;&8=
M0CCLQ.$Z>*@?N.K?-25%Q.'O).5)(-=2CE.M)5-'$&F7TG,)M$8XQO4&G=/P
MS 5.J_(Q4*XC#1<3S3%U3V6Y7E42P8@*#P39= VJ2"U6;)'#.E5M;UXDG::"
M>3=87E;.:>0N@V$+OQWV47=+E-S=21^>KQ)M<45'UBK-;0LK.FN*_#_VWH2Y
M;21;%_PKB+JNVW($Q!8W+>7NCE!YJ5:_\G(M=]6\F)BX 1))"6408&.1S/KU
M<[9< ((4*6LA)+Z8N5VF2""7DR?/^GU8;XRCD4I*#F"2ZL/9FPUPL(5EP=PX
M7^,8<A,IEW#Q#.NC,/8E'6IN3:X=KQF5L,#2L 0!DUV/G-':1YIU28#HX3<@
M?%(%Z0Q.'E'!C<>^_BN16[XQ&?]+#\+@W//>U#=FS4I(3:*N*78<.6 N>(-1
MEY=D79F6<)?G#DY#B3%RPKVR_+-\LM!PGT@4O(:7G"OWIYD84YK/B%@75AZZ
M!N(#=WMK:8KKYIYXG*RN:V5LAK2"Y&,;+4R_ON\L"_6_UPO''02W0/,A.GJ&
MY23**N#-;FB>37XCV0L<A$ZUJVF;O_>>\VU[SO/),I_LLLQW9ZPYT!@NUH4#
M89_/X=A-S<G%BF1B7-1T'>.Y7[W*"-^$*"3F8 ?/<M.>NO(%U=P<O&@\Q]B@
M>9)F[<YM7ZQ@,=UT79L*JKB-K(\?W:E0E%^36L8ZR$3]&XDW1M*.,79,,2WQ
M-UU>IS+[O?7W@,$U5;'/.5KS#4R0E\0&5*$='DL]@#7'##HG&^+R#XR;E(D&
MZB)[2>]:GIJX(C+Q\ LY-:Z*ZS3[FC,0]K646MIDO[U\);TCB'0ZCU2!7C&X
M/\$X(PNQ0C!JN27QDHXTO[/I#C<"*?%"83!<O:Y2 97:LV#N6_X+<@KP!&1T
MSD06S7;L_,$N)6V^FWW61Y#L$CI ^_S=G(6B1#/A*LI*7;HQ1;4(S]]3G8N.
MAY'J=(H?O/3M1%&+CB]QHF42E#"+#%LJ*=*/QI0V21S;'T<"W\JG8&9@QWZA
M8E79=Q8)K.'+"-17E HRPL)@"?$</,7\DG0!3\ )O1$/7(RA,9 ^Q2Q4,, I
M_EXS3>+N3:B28!KE)2+<7)98=$\C\SF$BY"T2<365(B$EZ&SR[P+9O5R=%U-
MZ3C3SNW;]*3[P;X<#UHCC5G8L'2>H!N/"#4QYR8T!H(OJ]!JG#:0[W"V@)^
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ML%,93%9K(%6^=CR$#_;Y(]ITR+H>&5XI>:WVIB3\89JQA 65J1LKZ&].%-A
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M3U@<(BX%HR)J[*+-A8KDQF&0O-*1(!1WWX$S001\LABIBT<'C/ [M;HK?'*
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MT(Q,$MD:C%D>M5*6*N2')*)$:Y4D:LPJ&\'-<1=\BX8-[T+K@.X7LWG"R.4
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M24KLM/#>J#$A-W)6N-_U)1%SK3B;,(/;ZELT!2<\GB-DUF$5< MQ"7W&:T0
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MK&J6$5 A9]D$]U1FV<+]_IV#=T0;K-?0K?195/[7ERJ1@Q!Q6DJ'P.4D2$Z
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M;!A-!;ZJ9)&WW80]8\P5W535P%Q?P5AK7^YJ1X&Y=;TP-S2++&<+ &K0##Y
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MFK\Y[&')&R9LF*)GF<!>*5.A.>QA/8ZIRYI2N^'#L32!:JT%P>B]^4^T#"4
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M1OA!I8%*761N"*8X$FW1:#ID$7MHM1,BQ7WT]K;C+O(>Q7U%Z\3 P?,>%Z5
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M:FD:I6"Q4V"QUHS<,O2F1FX)_A+\U9I]MW#DEM%M8.36/IALWWG.A\3)GUY
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ML%\_B-XN![W]6ACC*]*'%\OQJ*=MPT->:7<E<+K#*)AO'TD_"V.U;,'HGUY
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M#8]M6\&$;$%%Q%X# H=LO))I%2]]P ;RV# ^MWE?G?OXM;U1CY"K&G3^UW1
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MW0T_0_AO=XX4S;(R8^_*EHC1&79-63=T$3DY73CO)G+2<F3W: ZG8M09T2=
MW5Y0-VD;M1S*V&?0D+N#VO/]1.RFB7X)>983]@U^)B^.Y^$]DC^6WHD5G%>T
MI@I#]G;(CY79:T UA9G3=4RXQ4>/M.XN[?/*4*,M$&5%64WK$U [>JAI@_9
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M$\;6B$TM%1I_(!RX:&IL9$H9Y<2,68'<\)&8!'L&L?7VL5($@(N^.%A)!X(
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M"Q^U&[LK^)49&Q%/%P2X_M.C]_./$7627M"'\:;L8O@9AYT"[BF;R%DS[B7
M2W]@1=#S*%]6?G<ZIR;S>.[97*I@$AN-F+,L*YM0[J*+G%KH"Z$)BBS%S%[\
MRO(&DRGJU*@=+] <O>%,>">@EB[?-I=97XA-+<(;]FKIS@.)1,/RUWPC+& ?
M?XH#VCD9J=*&S8.CX803(-?+'"0;XH"+#S0K403!WT'V9@"V ?*6DX6M+=VM
M-2:\I:'KP#;AN-_I+&>0HYGG6T&LJ5FJ ][I.N2-,"D_A8_CN]S(^H$VP"L
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M$MB(7*XRY;W<*Y<MZ56UO$\)$;SAA.[CBE]$!7@NK5LQHSMH-K=5_E+I)@_
MXZMK7W9)EBVJ?AGTGCQ%L^IMUI2Y[Y3YN *8K5%F>ULE,"]!F:^];J&PJUC4
MYLJ^4=$T9O0R31FH)-UTRJVK6RKBS8[]>_5<N<:*.8>CEB>M$<,_B1OB^8YH
M7?),IUS?VSGU0E=F51SM:/<ZSU#9N^I^#\!U?<N4NLZRV0VI=H_.NG;GZ>9.
M3:JOB537F#J[(=7>T5G?;G=;^T^JZ9&XN2;Y1PPA_!Q&<)_!!\(7FRRO(Z %
MWGU\'DSIGVQCQ"4X6X-F'F<+_G:H.%OB/"QY()9Q!(>'>80-\9\648B() R2
M&4P$ULA$;C"<6>=SUXL$> X#%<!G\3QD\*="2$'")AH3P*TX( J@@1%*PS ^
M8H\ZX[X6@5$,.\W3SM[A41A7C:?R6>W[2NU[IW@FUGDY/J]Q"SAN!H12.#L5
M"$&,D_MPZ_FN'#?-#TF/KDT]0;8%9F%]<TA@*=P_-0 (O)'PSP(L]A020HW-
MCMCLW<PI'1XVNT1A+_B8-<&N9/_*@Y_[#F+I,EP1"<@4 QA3KY@'U,0N-<S1
M0-I-#-%A(+'(\<CLMO/81C!@PD ,E 39R,]PY6AJ_#AR;W$$]+V;!AG9[@3W
M#^:+&%V2-7RIGL^#L,#?#E7/I[9OI= U7^V0#[ZNS-;3.#;&B-<\X&9N_J"
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M1TWK&-3?,G'A.U__Z[0[[,!?OKK1Y,\3UC&__?KMM--L6<>_1>&O;F!]OW5
MTY]8*2EOJ4DYX%BFU?)WM;WO8E=:/^/SCSV0Z8X5+P,XO02,R\IT-%I%1X*
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M1FB,Z)DZRX8F#I'K_'#KS!&QM]4"V@BC&R>0$ -9%FE8)9Q-$1%-8A,0RXG
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MIGJ)D1G&@R\ 6L$;"C66&&!8%127!TN%O I,K*)VC2-AA'"!1-W 13<.C%)
M[0J&-E*GH@_[0%&NZ#$4X'70R!&Z$)EICP&!Z+>XS, /)L'7PE1(%;EH"^/<
M%E"=$CU;!8@4UN@9LD,59@UHG.+"#W3Q(HWY\>6+GLE^N(/4ZZ:S9T/^P^E4
M&MFPH9%-.E-%+AB9""SEK $2ZB\$+3)E=A79;FYX&F,S)])?,?\,X22%J.
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M U&\DY%UWU?.,NN>D2NN]'G6/<^ZYUGWS6;=GQ5!=LRMO]"I5\J3OX0<Y0\
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MCX,X=3S(F!E;;/2D%Z]<6)<R%Z14=C5#=(>HJO_1Q\)M@^.<7[R(8J)<8+G
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M,U9+^*N!$8VJIZ=19:H["6T:V&&F$9T@<9#0)/_(?CA);;,MM;G+N+,,5\V
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MO-RS6<@]46TG76'G576$_ZIB+J2$N2@1WF##)ISF,#9+/'?231L, 52<@:/
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MRDU"QX^)I3\4<,RB4P'PD48X__3T#P?HJPZ0HL:T7]4DJD_"'7P33DDW/:J
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MU='.NM8^6,V=@D)@7@F+9:]SLOK3*\TQ9.FMZ.?<BKV]I/R88S?.NE8=2>2
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MI$1MO40]SF&HAN97'0:]M,?0-T&TFFK7.#D64Y%H?='T C427X":Q#T20+J
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MLL!B&)K'>7C,)IB9I\ Y-P-QY_R0R=]/- IP'?QL'(- Q<HWC#ICCCW_ZNQ
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MAU3RLN3ERP E5\#,7:RQZ%DO@O0JF5DR\ZMDYH.PGRM@YM[5P-)5PVR':BY
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MLX.E\X\=>]P9]^9@VJ0V1V+R*1L^_P8*[H:83@L%\!'^ UGV27TQ)F33F6-
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M[1YP&!P.B8BS@'[+%MP=:JXX5QN//-'>THV#1 8)OF3=+VN8]+1.SSH"6=!
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M$#PLYO,=(R?-2$\WCVF X8QE_PU1_("0!\Z8TL#5!!)(=%#")(MH)0H_#.C
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M)RUUE8YF[Z0ES53:]F[$LQ5K1XJR%;V]^DC6DG2>#HXA1R^BR%TZYVFU6ZE
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M*(9#&!$*<S-!(0Q80*<X^?\GT^N*HZ(!C60[E1 K93L6?Z3%DDVR'<EV-(U
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MHQ5F#K^G4X>L,'&Q6F,M&,:F^A"V5O.*#3O7DXYOB3OCDS:ZV=AFAG5S^K'
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MKY(]HJD;27>,'%:EXZ?W6EO]Q/=?RM_+/:B[D>9K4'*-/8#_^GQ]!C[PZ@D
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MI/;]P'9\KF][V \)I!\X.0O/K"Q!BU*T(I+LMPQ1*Z5JQ63WR/[=.42A/R$
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MUR#]">XZ#I^G@3<"KC- 496Y*XR<+]"9P\QC!95#3G.$.NIXT:%(1:1K2'D
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MPPBQBQ,KR]^-GTRK]&T9F*G3;KPKGF&2<<TKC)POT)G7Q!WD@,8>Q3'+I-F
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M<_;/SL-P6OGZKMP=6'-_6HWA3BM#48AQM=>M"HS<4C2D[FSREMEBL/6]_IT
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MM3BV//A<?;_^$<G _^U/_Q]02P,$%     @ 0X!<6KC85^"HVP  9+T) !4
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M+0-8(XAUY;A><(0' 3]PT$Y;QV.J?:JQ =*?Y*JJM!Z**A10TX(*$-?;[T4
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MHY]!,I1K(F$H"5X"$<I)&HWSP?5UI- =Y8LA64^*JYEYOG%>?/FCN3LQ; R
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M*(N4<I5-J-XT=BV8/_E325&UW;:KGF$MKM]1+>4&=QW9T<%0HK21-+I$[JN
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MMUIS5)>EU9>Q-<NV/[@P#:S/F@GDL/1"(*4C)=X:0Z*. 5*P+*ENG;8WO^N
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MPIGJDEVA^YZN$^X-+KK3P$I$846;/EI.9F0.F7@6$I%@'3(Z9NMKEZ>H /L
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MZIB)*"/(J.K\ &[(-. *O-(Z<FVX9:U' QUF92\VW7J;[@2YU; ]U<JW_SG
M][-[.L ^A,'8'?)QS,A39-&F Z!G"O1M>VP!7X7:E,(IT%G:.OA#0^"!0U8Z
M,2]RPL?)/N?%W&?LV3,F[C::[R,TF<+H,Z:OH_%P_.7[OXV'%?3T;B)-%D4Y
M8Q5@-+IFW=%YY5%"+(H 2X'\<9O>#<'*S<\ZLBW;E\X>!S@;"KP'(_;V'9N;
M]N_+I]DX_?.FQ%.HP*5WH!/9,.0S6C+PD2RL$%(L@A7F6O<96@OFQ51<;RJV
MT6##]HU+8/?Q+#,%.B#JR7![BN8X-EDC=8U[D74/%M(*9#)%5G*-6=%7M:UH
M@>"<AT0@T8:D(K(?5/O/V#4'4_XV(NY#Z>/+R_%H#FB9H&VB8C$X8,43H"0R
M>(X<:AOPX*T5+K4^39Z .+S!L:]F'BMZ+['V8#U\F"SZ7=_'9-&+J(J"H"(#
M%2T'QQ(#+Z1F.A>716O?9A6.'U[;>PNWAQ?[U9]ADC_3+]^$%31#'XV'J.>=
M4S,'7V($CCYX# P9MAZ9\ # BUFXWBS<75,]M$G^]#5,\'688J8M[(K$>Q.:
MFDS"Z,M<A"2?N]]9=.^=K^!N&:-<!^_=\\JZK*DG8[*/]1S''-V#)H_]D%/1
M<0_;7C]KR\K+1(>!R)G.!LX41!,M2*FY##8C9ZW;1/XXO'W&D#YUVFZAVA[H
M^A&GL\D@S1Z:#FB+L=D)"*6&2[DB%\-)"\P@>1^<[,42&O-M)9##&V;'U_&X
MM8):-\A*7S%?#_%]N6D+]CO.OH[OM4U^^E/$VTIMS;C.*030U?50WI.1&Z($
MLE&4*3%('=JT1]D=XXNEN*;=UJ'TWG)P0@6^#M@R)Z4#M(9EE9O1'*%!U\'4
M.NY5)8T+,9]!*!-JYLF,0'+.R;<.GLP(P8'>*U1:9JF%^D')LJFMUPER91M-
M]-^9HP2-":6FQR<-RM9S67D#&FGQ6=#9G!_QXC0[<[04^N9V'-M(K'5IRH/3
M<_/A.;?Y'HSTN!!2>^UB;7"&CFPPSB!:9R )9U(P61O1K?QH+QB'-Y%/O>/^
M@57;FI0/D'P(@_SK>/)JM!Q ]';T83RKPTE(OO@-A^.KJH/;HJ&+%!(7V9*8
M<KWEU\94@3$@QT,S61<ENE4Q[@7CA90K27DXU?96+'O?*_Y(PKY0Q3AO2P 6
ML8"2&2%(QT"[0B]+P)!=MQ-O[2->R+223&U4TK %\AS5N^LJVO>%J#Z;A#2;
M7A3G12!J0M:*T @9(*1DP$F6;<PAV=1M'MV3CWXAQDIB[*>"AHTPYVAJ=<9T
M,>/X;B_+CL?BM "+/(.J;?L\5XR,P."SLXB*=>M@M_+C7XBQDAC[JZ)AKZL[
M1$N>WIV#]X%>&&6DL45#C+2E*>\<A)J#RTLR'G6JG>.Z4V7SPUZ(LYXX#=74
ML!'+4H[_&(_SGX/A\#\F@QD94>]+^8A#$FK^/*XPWY?EB+\_2*.U0;40R-W"
M?[5)UJ+Z##($7@S/(C9/6-T*X L/UX5#^M-S#_7L_R#)_S:>3M^/'F*[R,F@
M8V2["Q$\J*@+A,(X@3,\%*%E2)W:^&[#OS587JBVEFHMM-=#*=P2QR]_#69O
MQM/9E%]P$3,!,H#$:%")C/W G*T9HEPP+8OEK0=1/47QPJ1U3-I38STDW/\=
M)X-O\WFVKZ93G$W?C4?I>C(A(5X0"LUJ@8F.FH-2Z&FA](=01F5K#.VIK<_&
M]6A>.+6VJ*R-!AMF\-W<NSZ$=8?J5J+ORZ^#$<ET$(8?QC<SN'^IXY.G@SC$
M7T;7EPLY+4KZYV-(?QV&+Q<A)\>9S?2BY'G@VH#7ED'FU@@>G%>VVT5"?QA?
MZ+KZ,OXT2-$RL6 I_S]&$PS#P7]COC,7[I8[O0@R5/X9D)&1K4 2 E=3[[4)
M3NN KOC6!2S/0'KAZ+HMM:4N5W"MT332QT'W][.O./G\M9:.7EZ-)V'R_>WE
M51A,ZM]=2-2:><S@T;K:^$^"\QY!:^YD%@Z+:MT19'N4+XQ<Q\B>-;Z"I#O?
M_C\4;7UY?B6QKUX "26G)+GGP$PFH:!P$)*IN2&V%C-G[W,_<^^? ?9"Q754
M;*_7%>S;.=3P\(6YFU3['P-">#W[B"$/AM__CC.<7)*A04;%K_3"_'L87N/=
MNU,7]VHTN@[#5Y=U2@G)2YB2BH$@O*ES[&C##^3HBV"8-M'3&ELWC6NZ@!<V
M;]Y8C\&3%:Q?Q%#^U[\^4A,M]9_SOYC_O*KA(Y9_J?__X^/;6Y7]^>>??QL.
MOH11_AO)_E_GVJH75N.R:"FQO'V@W[A[50>C>ZE8[T@[U3"G=8?!</H0ZG1P
M>35\MI''GD_\U[MU/ES_XK$/2-KWBK%Z'AGS_SCUIF]W[T)(S+GB$(H,M1[
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MB>Q4M!SHO$)0)AD(*0B02EJ,GDXU[5I;$FNP',Y\:*BJQR9#"SD?Q$Z0RNB
MR,#/NWR6NEYK+"#F8NB0<\9WNA39WTYHM7=U6='ACZY6J\N8D+%">Y!# 8I)
M#Y%6"SIK88HMM;CK%%>U;2N0#V3V$5W"%WQ?_GU<6R0N>]A,EV5#%\9A5C8G
M0(:T/6OO(%;1%%\B%UC0V^9-7SK@.N]0Y"ZWU\=6?A_C8Q8=9S^'OVY"_>]P
M=F$%TX&I!%**4OM^)]K=!=*Y42*6)#CZYH..5N!X(>#:6Y]]M;;6)NLOSOTI
M?<5\7=OK++H;TR__\M<5&;4XG;?/62VP=E'Q/0&TCJ&WE,</&'%/]?8A%[(@
M94S$UJ(@9%GG#A4T/"?'6&M+_27B_N0*2&2AHQ,"G/0*E(@, KD+P(T0UI5B
M?&H]).$EXGZ0=^98$?=M&/6C1-R%25FK$H#S^8@_:2$85C-918R67)F<.CDK
M+Q'W7EBT9<1]&VT>)7#:!>!+Q'UGE6X=0=U%'T<ACD*EA60,++T[M5N] Y<=
M6<7)6F9T=MH?L/_9"4?<^^7+-FHX4L3=6>MY81)P/D51D]_I@]$0G62.\1*E
M;<V4'S3BOI4R=XBX;Z.)QC?I'R;C?)UF[R>?</)MD/ F5N1I11@,!%'7*XP
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M)7:://#<_>'R@6=LY>XFU,9>S1S$[=[]/(R6D82[1Q_>?-U1^(_5MX?D6H<
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MZHPS)05$Y[3Q3&3&NM7_GD1]=T_ZZ%K;O8TPFS=C^/#+VX_OWRTCTRD5AMJ
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M5GKH)[(VKWB^#L./@R]?;X.]9.NGY&V"G)".42TM>,X"%&N+#N04I.;]WM=
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M&YGU$,"\7=I_C"?_G$^E2CBM76O>EX\XQ0FY5!>)L1B#$!#(Q )2%?G0R.F
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M?8[KOJYKKO,XM^,XO\?W/$\WM9,Z !Q45U%3 6AH:(!R\!] '3PXKNQJ_@
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MXB4$GV]"*B/\#; ?4ILFM:/D15$FPYC]:H/0HQ:<2K-BA-/C'%2 5>,+)/L
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M;6D?27?D$Z3SB_QT,!>W\&E"LL%U];+L'&'34E,9RI<?TI0Z.[4(6A?^!2)
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M3?,9N.>RE([^M]#1$&OYX,L/C%'T+VAQ[M=Y?<+K'P.A^GOQ@HNML]4@ZLA
M"!!ZE<$H@C,(&GD\@VN<[>^(>)^D=U92EUIF.!S-K+281W=;#%L<,4N*GJ6_
M+J[VPFZ]W:G_F;S4/>9NR4UQB&GQ,TB=3/QBE%V7P/?XDHT;I/Z!8,D[7UI-
MRD+1/V(2]SE0@5U;H93'$',7]/I'W2""W@W=>T3^(AM)2IP* -=OLR.T15T\
MI<<RZ?$M*?W6^,HA@\DHVZX[*C#S![9O/3P],PCRGO,SL]KZ<A4G!I_]0&J%
MVM;#)Z*QQ93YL4XG'&\[6373-6QN1G8T06$:2Q@M^(*=31U$ \+BQ1.&O-PF
M&3*F3^V;90^$J4;KAB%,0SL_2'!%\J?Q%R8W*3N_J?B_]F_8_S?%<0)TJ<(4
M4D?5^G5:S8YE#BT5NOL_ IE)C-*;PM:09[$*WLXI3[DP*S-Q#FLO)*NTKD]4
MS(:JV]^1*()SHKP4(6!(%_$&0E8V-4!IS"<MA,(#H*V0M6$HR,;>WB^T$+@Q
MD!\(D<=J6V;4O9YX5E!P^.YE]Y)O^I@A"TZ!C./_[N3PWTG^7J>8_SO+S_VG
MR2TBHNVQW_I!DS+;8DJVI_>OK./7/2G EK*=<BPOJ6[;F +8DF69ZK/$&A$)
MWGU(7@Q;HYY ?"GOL_]JR_L[RXY7_%UDQRO^/K+C%7\7V?&*OX_\'_(*W>HN
MH]F\&_%Y*;J.<U\N3=1X1,$ZL;T6/R\IRE;+1:7U%-RNL>[#&UFJ6Y<;XPE3
M3A[^;0-W-^ZCG5*W+NDQK)[6.-OUDKW8AYJS>9"MBTX\)JMM%H+P=I@)V&Q/
MV+JD.VJ!V@B31%'/''A1Z]:E[5H@K #QT=. OB&??U4/LW5):U)MGUQESB@O
M7*FB3&EM76[*"JSW&@PNN[+_N6Z0.QD]L)VJ[51MIVH[5?O_0]64G'TO=_4*
M);'BP;P>>^A9M>XF_YL9GCOCN[X%Y+U?C(VAE63KS/["6W'/BKG4&0<<#%BV
MME@#T.,&;6@BDR;E="DS 0)9UMSG>I^@[',I-U9.X(DE[Y?R=PW:]!94@'#-
M$K($O44%^L?>,O-3@2=*565+4(LR$CWX<%B5?)+G%!6(\[A)!<H%X:3H90S)
M_*L1Q7<*LD%>0N]DWLF\DWDG\T[FG<P[F7<R[V3>R;R3>2?S3N:=S#N9=S+O
M9/Y;9=8E04T=#(G^ROGX@L@NQ\75:G%6D_H%EN=N7 ?-<()4P.]-.WS<((<*
ME#4H VCJ]_\'4$L#!!0    ( $. 7%J3,%V8IT@" &") @ 4    ;&=N9"TR
M,#(T,3(S,5]G,BYJ<&><NW585/_V-CQ((QT"TETBW3$BTL+0("B-E+02$B,@
M"$@(" A2TMU=0[<TTMW=,##!,_@]YSGG]U[O=;WO\^R9__;,_GSNM>[[7FOM
M/7,W<[<"(%955%$$H*&A <Q0+\#=/$ >@/[@P?T;=6"@WI@XF)@8&)AXV-A8
M./AX^/@/\1X^)" D)28@)"%\^)#X$3$)&3D%!04^$275(W(J4G(*\ON+H*&C
MOH.!B8N)B4M.\)" _/_XN&L#D. \^(9QBH[&#'A @H9.@G;7!6   - PT?X>
M@'\=: ]0>\3"QL'%>XCZ0 TQX $:.OH##/3[7:/.^J'. S!(,$F9!.2PR+3,
ML9E=R04#8G[AL#RO:*?0'CMA%;)P"\3%>T1)1?V8C9V#DXM;6$143%Q"4OZ%
M@J*2LHJJCJZ>OH'A*R-+*^NW-K9V]N[O/WAX>GE_#/H<'/(E-"P\-NY[?$+B
MCZ3DS*SLG-R\_(+"RJKJFMJZ^H;&CLZN[I[>OOZ!\8G)J3_3,[-SJVOK&YM;
MVSN[>Z=GYQ>75]?0F]M[7&@ =+1_'_^ON$A0N!Y@8*!C8-_C0GO@>?\!$@Q,
M)@$L4CDM;'-7,F;! !SRYS&_*MIQ682T3R@LW,;P'K$*K[*=WD/[B^S_'[#
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M(\YAI/;[P-7MO!\F/,)=8"9U3K*S_/Y6Y$,ZB3\A='Z5=T$?R7_2DY4AO*#
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M<3K\P%-4!"*P'2T9SARE(!TPC*'E]IZO#V$K]]*)(,6Y&B'VGP8"6G'MS^R
M^/[X=B9,<1HQ)=-O6LX2A^;\X>Z2:D_"08IL[NV[X1'R>=HM\6(2;'4*X#=/
M]=C$QYO2N<$^L.AGB#@DKSVD%M)I2N\K#DUW?%1N7F-0^R>XLN?&KTT KPFC
M0K1'7Q,7^YN+"G3P2AG*P'"(>UJD?-(]+_R1K=DY?R]$=.[0F5IS(*_BK>V$
M3!#9'.0YT")Z;K ;6-T;WOS*$9QA]YCR2[6Q(3W.^\MO?:SQ,X"CW]41+!=Z
M<(>M,B@;89Z-\VE9M[YV*9_3^T=>K(Q^D_5?/VZ7:FR*TWFD7%!T4P]_=J6M
MV+3CL#IVR"K4BC10/+IN;3GX *P!'4[DP[E/"7H[4.:J?PL.J880@3,6[#7G
M>IE>??LT.I_U(#Q?GD6(RV*^HLYI:UT6#=RN!'?.\:I=UH"F>Q.%-[/Y(M4W
MNQ*TLJ]"%R@?L&DQH\7VZ<8*1<N?*_4L/EY']274TJYY>YD;INTE)K@1,9^?
MOASR7!\+P"=ZCL,2OC[%XD5K_,4.%Q!"NSY/#RU[3O5$*C-SW>=R?]\]UC"Y
M,"M1I&0B;\%G.ZP5N /! =LZ@GN @$X[(Y'-*J-LH\C8&[66^!SB'A4>:BM]
M31=%Y38 'HQCK>Y0:_T8U[\;U>PC67:G:UVA12:3S+5-R6HO;).,>'(9F5;<
M\=Q-XR^O;0X?W@$XQZ!\=P#SKV $B=\KB_*+F_S<LD(#GQJ;AO<\&E.//<;O
M &'G,]#^-><H<+5S %QMK7^E?DJQ(,_HJ"[ 7.OQ:RYTV^,$Z>DRE(]H9WE#
M[&38Q:?2E$X."POS^UD77INAF4K V8C!'4LGHH@U\&$3W:IKY-)'@ZE[$WFC
MVJF J);&S;=_,FAC9YX+DFCCV2PY&)H=*1=QJQ80GM0/YP/5_UC2M1FZMKTD
M(G9HQ(:3N:]@?;'.V=5/+NOF(^F&[2=-NU47HJL.=^*;A];K/E-<<Y^L*$NX
M&(%RYO5*$?C:ZWCE+B$!!]LOZR<<NZO0QPB[#  ^XM)N(!%4R=-_0ZD)"O7'
M_).L'Z?8,&Y5$_#<-TSPI8E\4X-UPE/@S.UT!P75$QGN2;\:W1PNI^7+7X;)
M57DZL^VS+VZGK]H0&;+DR#'9!R=EH=6_V?=5H7D=>RH4D*-8IGC;S>_K0QL\
MB@-4P7V.V2L^!NWJ(!TH&\I3EIM/ESL/9876'][8)%_=."+'6+GKHM&^ETDK
MX6&A!>CU6^ ,@R6>OZ!0N\DH[VNC JK>/KRR050T&\!$Y'DC4]#?G.0L_&9M
MU+O2TU?/$))GW*0YLC(/H+IQ<S<PQ9G"F<@IU+CR,["P,V@QD$Q^8[2?ES1Q
M/VD$AOGJGAB$'Y3YOBI162<B&EAU%I[_ZJ4%+X:/D!46$$JT<=AML_RBMX;I
M>PVNW@&BD,+VR=>=QC2I0/DFO=@/R6AX:A\2SMG"^=WR.^W:VQ<,5]ZV-HPC
M!9&H<:A&HX$P>)T(C0'+*T\WAOF+3@C;U]^I2-T'6_B/)!B))$0O1G)\PV Z
M_B/3P"K/;I_TARV[D]6S&<:'DJ?3#OU.!P/H 3V75A_$5PZ'L5P>48]?+:-_
M/JQ3;#62(JPL.$ ^M5WVSS][->G*',%R=2'3[5^)'#'!G@3;W0%F'X).\KJ/
M"1=GY[HJ>K/W#IE+?G?A0.H;HR6L/F"_-32?3O\A41:**BO1GY,->HCFT$'E
MTR7K+6/53=XB=L6;U&HA$869_$=-B[C8C,'M5"*S_HO@:A3O?;5.B[1/6F.*
M36U;Z4]2S]H=G<TYXEN/R,XUNI79$IX]/P_&P0'$V@O8&X87$8&4Z)SG1XME
M\MNGT@IVG;;SD'.FE,R(9#@%0UO9%W^RGQVW(I>YL!8+D\1OXEU?R:P2W_9,
MQPP_PWRV07(*[G3^U J$MMODFWA)=5(F+Z8&%;Y^_4*+)3*4]>FV&6Y;/[HX
MA@TUQ36X Q2V1(1*9B"</W$5TJ5%$=TE(TK&&U7T.%-% B5H!N+H8WPB4;Y&
M)1;T(VOD'UG^":#E\NRU/)1A)0S_XU:-[?A><BS[M"W58;*VF\LYOQ5Z:GXQ
M%G]-"'UUOC$!%?*RQ;D*>?F;>R(2M"SA$V:'5-I^,_XCAS\5TLBFT8N/.\)*
MTDZ_'@Y+1^(*W '8Q'J!5]A?[P!*>% ]4:>;:S3DB!&L"8DKSH*:;9/6(X/[
MD7U?C]'N #+!'ZFC8=G3EPV#GY'2+XEFKJ^20)_!M'"ME672!:X3L3 1M=!-
MF)+ ["(U7G&>-(;K9]\(OW$7\NUY:0Z4;"['I>E@ZO8F?),YG^#\XS$?4F7G
MO,FY1QI^]L4AD^3K_$$85.V+Y]/;H&@X!/I26FTC8>0JM3>IJ53Z3X],T;RO
M*<P%VM2]7*7X\Z1Q-1?VL:%V4J3GQTV=!U=U-^YQ_5DI:$GW];:/@<@[D5=J
MZ82'O[,A(Y-SJ;:<9U,&FU/@F#T=Y/BY_UAZG7/G=E7\1(>D8F7MK3 VB]>V
M[P&PA5U0AIQQ/]:;#\I-"4\9 E\]0%%H=+.,$X$JX!O;2!KPC 7?O@FJ><*D
M@52.0QS\Z&]/V1)H' 4[["PC=8\4DI\_PRY])F.KNRY/C2-GFWD'X'?_X'+V
M/:U4J<A!<BL&%8(-1+JTC$..W:/$Y4?-!I0_W3W?!W>]^_7RYP^S'VM/\_-Q
M%KKJKHNV'#F0> ]/1U[^R9RT.HV^^O1*K"5^,;*A-AY<KZ>ES' 4+[O6>H:H
M!-J54*Z@NJU@UBE_ZAFOLPG#NJ3#LM)24B#G+_4^,3D.S9T%DND<W\4[ !';
MB2F"9C@852JIP#=X]2<#'^Q@*IK;;GMS" ])'K<.WYBB@40UX.@4HN ] Z'_
M!+"*/0DF!_54?0P*.Q!M+YY_]BOBZQ:.%>&S0:J9(IXTWUH).M$=5,V0 =HS
MT/O*08.SX9)_^)YLG/3$K)[3%0L8<2L_P@P7KUR/"][??\W0E0[EW$I?=_Z\
MQ'8B&G^2/-*I/_<[.V'I0VUQ"2U;&R8\I_99;[367 5P)1%I"A>N6JE%C<L\
MQ=M4L%/]V%^<*WO<HS5E@SY2?-H4RLTOZ"2<'2X:U*X2$=6R'%Y?WD"_GNR=
M:Y8[X]\![);LTK0-,P<WE%P&LL"O5[%%CB$G&HLV*B?I!XFG',:GF'5S%WYB
MN@V0QCI.AJ$H'G':THEV#F? B1O/JFE4YC22LJP+R(^R1!;VK!1+AM-+-C]G
M&)_3'>"+GZ_7\O0A98OD_2!8ROZ=)22"L?AG](["X]@/*=G'5B/LIV)P<L]U
MDZJU)!$9L3<UH^_'.&W?^SC@L 80TY,DOW@Z2TM6[]FS%+03'3ZW% >S\^_T
MA! ?O]]78W@,?=DW/@@0#U<.%][)/M_L)^,)9EVM/?/80#I,+RU7)BQ#/<MZ
MU6]FMY>VG4VAYX'5W:N[FA'<VM$\ZN\4\*H*-W&;<I,&[S,BB^;EW.WF%;>6
M%[5>^[.CE7R!.>0"Z]-PS$VE&J<T11A>"CVN"_A+LBD5<"4GG;19;RWL#K"*
MT_"U?>EQH+ZQH65-N$/2^DZ)4%\QFOCP) !_):$'5(@<_ ;N>(,B\3XTY]<.
MKMA5L:#]PR=:/;FOP@*Y^#,8?KX',XY(8'A0W,PR1J.;N^_7X[TOZ"0++> >
M@)?VRWY%XNBFY(]_MFLRU1\9C9YUN-IL@G:6=IY4K8OD_EPCD#+%&IC735YD
M/F=[=QCBU8;C>5(X0!XRW[[8X.^(R+X#O(65!4.J/\*EQK!3'8I&G.:(DZ*,
MI))$%8N])5Z)L?L<C/@:I,/QQCX0$</M3IZFYSP)03K:CPS8)KJ^?%EL2A^.
M9CF/YW ,FAOI:F1+/T2<R#W-DN?]44E)]DZG>M"3\;. -+SD'.;4E_]=GXS,
MGD?IT=SNA^F+QTXM#$LR.JK('$@$F,(7B K $=0F RX#]<F9,_5:UZFC]$P.
MGMNP//J9](GI1Q462:Y'OOX%6JOU22*<W&#=/W)-O.P8KN9<9ECD]%.C9:)D
MG-)DA2J&SB_4>;C1&<I-&.EN"5.<6S9Y&&3CESG_\Q6&UTN6OM* IF_+ G2*
MIWL\&Z^D(94,C!4W$&](6=VJWN?.L0(YC6SO'%[CC^$M]M\*URFMZ6*!)B(,
M#%"==>P#RU.A7B35A/EXJ<@RT;)HB0/QFWYONBJ6,!QT=[0Z_&=/F@A\?Z-@
M%)PDQ!5!]WL:$8LI!LG#898/=EN=<".&K$@%@\8J'I<>M<^ *=X#*YV^YMLM
MGX#X(@WJM)KUC3X;%=<&A&"$UZK0U,OT;/)<RIM2PJFA+6LC@?0B7[J0Q W$
MIATA$ID)0JQD'4-"M$4]FJDM[=@8Q"X.R0G4 VG,P6+3H#,$0:%^]:Y>\BX"
MG+3?RHAH1LKNIDFVIIUWQ>Y2BEY'L8UF3_PR=!RH&,*/^%DNN]N_>)SFH'-5
MC<AN9?"__QU6,TT1>[!LZJD^VN:>^WP'9F.'&#J)F]M*[2Q9R,Q#+@D.V>;T
MNO3VLHBO%%]Z&((UJ[>O.71K0Z3:J1@?M$?U9]'W&9Y(3B<BI],K\SY+8ZZD
M$JWE=1(HHL9$@(-3*&]2LFEE58% 914<1CB>#1PJ^:0R3&GO%%N$J9U8E:CV
M#EX:L3V\^O35^=.Z1>]TUN8TBU*E(2RA/2DMVC1#"^PA1;2+RUPMD\/H)YP%
MSX)HDX0.,%5PJL\I7>.HCR/\A4NE2.K/+!["G0=]"#MO)VVWQ/ EP]_/PZ>7
MK\]_"P:7"ZK\_=]Q)P^2@NY5D'DM6+S\)?SGQ^T6_J^^)];P8-P+&GGFN$$.
M%NY.?*[ONZ)6[Y[X>>(Y"BH-LI\!J/2H'B1I1+_5.&L#5VFC.:>]K+_%,\:W
M$OAB87S$.>C'5;HY4W&LSW[677@C57MT<_UAQ+FC2+-FDCZ93%%Z)QQ,"A\\
MDHK>UYS(7-S*'8'$1)<8UC]*<W 4!+>Y1L!\M'P$YG:*0+$@ 0.6+72,VUN=
M"NQBR+?\@B.FT_[-D+:;T#;9M.H!;DW&7MZG_H&1G\)SOGD+8"!%;W[.>% \
M>3#Q^TV/1K,3.O7U5>'9D6#K'0 2EU["LQAMQ2R@B"\9% -*!3!-'P%9YB=U
M/[Q=-J^+&QZ)3T]T?K.T'$RD_J)FM$0C',1;%5% 9;['_9P71@UFTNK?/"VO
MN%P,%R,(2;?WC76> W3DMY$/O/<1.D] 1R1;T(!"@ (WJ]A/_#"E'_J>H4(H
M"WIBE,[A(>8+NX7YT]F):K\@!?[8K(B6V^$Z)9(48C@E2@+GYQ?H>%S.IMZL
MTU<?9GS.+%EX:"I\SGZ\-H.U<-TM'PILX=O@XG"Q=>AOH639,KE//WF:R7KT
MCPCTW9>9J8&K"JH85-2"-C-XL21V6T_/GPH-NX8;E!M&?HG',5WW!Y4? $L4
MHRQ=.O/S0)!AOSL 6'J"TQB=-?5!N34L2E"FI5"RRGGSIYWTX9*)_YL63QV<
MNOL'0]GI<C-6VMZ.L8+99M%:+_/^#=Y:BV73;_/9O_/O[_;O_$.^Y91?4^-;
M*$G5*U!;'JJP)-%6K,NT<'=E"OPOUMXZ+*I^:Q\?!"5$2E!ZD)"6$) >$!D8
M$$:Z106DI+M#">D0!*0[1;J[NT.Z>^B.X3?#H\\YSW/.][SO>Z[?']M+KHO/
MWI^UUKWN>ZW-WFL;"'HVFUZM;-?.^JCG/!][Y7B?ZB"9\=+P@*U\FXG46>!R
M:1\.M\]:?> )GM#;G"2^9*B).A%7=PYS\(  V8GIQP9C7Q#/=20D_@I_SAOG
MYC= T9EHI.F;;$L,XQC9ANCA>,&GDRMF9J+R(JS.(QWA?(NV/*NE1M55U:VS
M)T5]HY%;3E2!W:;$V(L%.])<[YZ=.8!)%& O<U[Y]B0]C<0B.W%R7*V;%QN2
M8[5F&EH(?S\'5O+&R @UB\=&X&[I9^B/ B!,KOP#3P)+O(XY>^);B<1TA92?
MX=4_#B?]WI')BQ*_4ZM=P"ZK2\SXPQT9?45;'4O;^_MVVYM5UX 12*T7K8K=
MDY9@!?G\G23F$>3KYW[>"2@6G!\NSA9\?H1T,G4W#G6;>&OJEW+(A=[!P8X^
MN>7OY=U!'UV<4!-P?_,YI "(NF+Z=$U@B"'C3;F<_ *NFMLC!8V[VMP.X7:[
MVZU3QWV+D*K;OGJ4+]^Q.+>MF*TQAD*6RVEUK6F&Y2%53F:]6P<)ZE*V_4^$
M#2XS6BTS0ES$.?.H B888\MFA%_WEN^<*NIJ''/"GX?I&.A:FF"GZJE:GVP9
M?B0A69\E7.?17V*1N%"<T(UT'<"]O CN]<L3?Z(HX$["2QX3^7X"362W1G)[
M>H/*W+"+K/Q,L:Q? :5X+86SG= B/J/?<? J7OMLY1IPTI$5)Y-*IDH4^3KQ
M2 GY/J;9#[JIX^#QC&9^J!?("(1F5-F;89AJR#.D&6U6@CF(H7-G5$^^MYEI
M*81/2)*PKG2F*NTTXSANK[0@V<C6L3?"CK7 \P):#ID+-\EEFM3"5/#$F#O.
MOY<%DPRWQC:GO<@8J'+SLJID5#X^63=K7>E,6[]@MJDXEK@DW&R;(=X[:8;>
MF3K5:7:$^L+F!E.##(N_K7T/XWE*0!3P081W]4XMIQ^4262\?4TB<YNQQYB3
M@)0>S7;", _;#Y.A'F=)(4F*BY$),OU(*7-#IB='\^(9',MNL0_[]&0!^-'4
M^>D"*WVS;;^A/&V1X;,!+=H/[VGO<!0 %F-)%Z\!<_'7 -(\83QG,SQCQ\#:
M;_/!>!K<7K"6I2Y"O/;$#NSO/>X JG0( %/&N4%<CYQ6F6RC9UJ]I7+?IJ90
M/<'8K4$<_O14Y[5__>R]2Y2L]1B?3];,HK:P%,TV"R/:!C_BIB0:CM;\5K?E
M,N[]AQ\%M;/M45MB)'P/-<(-L]?M&&U,&'I1LWHQMC.2*#!H*>_IGA%< _J>
M70-J92"W8\- O0&A05J^:\Q27&^?AZ557G9DR2L9624DQ].9>0)W7U&028V8
M"4)PFT!^%I-YU:%:A2A\P*:23O]/:#R#N=]1SGQ$U2C)KKS@^)</1N;W@"T@
M?W79@E3U@DA6:FYI"^NN,"+WB!DYCP36A_3IDG-P-RA;'.,'$XI;YSB-49CR
M&+PT(>(6N122;6%QRBF3,D*4*SOXF,*&#<]FX2@[LR7Z,/P4YS>G X8+4$Q[
MQS;)P6(K4G5IN@!CUC,PFK1Y>1/N%Z84?2QVQU!MF=//PEC(OZ]=\B4;$=C'
MC,V7M0A(ZQ8Y&2?[T;5"(S.[DZW1'9X'D(B>^1A=[L8_*)>S(" @V_$BF4 T
M-L(EZ*%LEP=N%TNCA8TMK5BQL9JV;JM37J^EY*U4Y*>NJ$ZA%_R7[%>!@M*X
MS=K 2X4AFT#IE][:6U5WZ3"6HTE(/KV=7A'0S 3<UOI)GP3$=K8^_4;?&NP/
M9]@++>7QSWE-\J@,Y$"MA-^<UW%62KU*KL_['<];S!,K04P2!Y=<J;^)W\I&
M_XDAMS$L(XF;V:KE.4>AQ%J^EPT(T6N52FQUS"7XQ)P$L0K>701AM-S+9;4?
M^$@?CNG+R5R(*9>"XJN,G1N[*VR&>0J==\.!]\V607T.':J-TS;@P $SPHX%
M%7N8B:I0J%4D)^?WL9!65ZO.8T'<*&4>M\JTVH]<.T6(@E]P%G[&C==HR=@
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M7AU8S)M0=]>GIR87$JZ=/, [SE8+W[0Q[8-?5$RGS\Q&+6(W2ACH^CLH63X
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MMWU['4,_W<X/CV]1<9KS<25%.Q((>X>E13GXT5&<FKV_!FSVHPJN@U93$(H
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M\C9PYF,- D,;#_LM8L1&P:!=&IGE0H1K_&*TIUIIX#0'H$/"XUMXF+RHC_^
MD($R4X-' SK5<'CBF:YV^54-KH4(]D$JHAP*1JI,_'/3O,M&*Q;G9Y7'H*']
M[.%3/?9VLLR;O]4BZ&F;,U?C&I#2.G1H5@4<J[ADJFB5Y5<,EUZ) )B($RL=
MWLR-OO_;8>G@FSQCDJ3!^6E6GL+BDK7VT9(3X2TPQC]#**-1<(3#;J-.&]H:
MA*2FE!_7  _2R+MAA>_ [P.]1]%6_1 (BM)TWB.FTZ7G79.P&!^2(Y50E(ND
MOQ6_?Q9*'7K AE)3P^"GS2",WMUD(!Q?7/+#T%+:WQ.KY7XHN3,V949%YLM!
MRD+DGHI?A8F,5Q?0ASG%B""\0C^1;K'4?!_YH,/;<44I!(#F@L2Y,P&VR*(
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M;T4^"AG\^C"&HCGQEBSZXP0F+^?\:1KJ.,Q]CZ^G/G>1T)@5*>!N:JI&!SL
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M(0Z3N%S$ A6=%\^N :]#?G;S9VS\:BY^T<8+-#?UOU6OP$E%1_%?1#EP^FF
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MJ9>)E4)I9=ELB*NC_[3$@XM-?Q3IP1[$TL(580/VT]ZI044^"O!F&A_)4:@
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MT*!6+\DDB06*$;QWOIFS-7*['V/9O$,>&=$A2<Z58>BZ-:TF#].FA$UEP7A
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MU&21;L@3'$,?7F=B6?8$_9X;DKX'75-QT%(TP^H\NH;18U\N',^=Y#716C>
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M_IB&3+C./+[2M!AA\?*D/,(T)[F[W ! )6YD'U#:B971<\M<K643FO7!2S<
MR2V:-<CM[?\E;ICM$7RP=B2VR-$]VH.;'EJM^(>XM8 E>OC>6@J*8C4P%B4X
MUT^LL7:$5^7F(A@6K&B",[QIKW2;<.W=KJZ"VZ9 MJT9%>6(KCD6,:;'"(Q)
M,NK*XI<0_GPA$OQGT7^ WNN+ B/!J#_[+^3T_LAJR1/-P+.S/X<?7T>8^F_D
M_PI+^D(E43LL(0TURBRE+#Q9W5\5C'S2/E8@92V<.RS5"2'BASY!=RB@7DYV
M;;C/68PP"QOBJ< &0O_".!,L^0+S&M[,/*\K76A@]"8N;#AP;$R1 R"R4+)C
M&$#^H.EC+8S3M";2+D#D%0O#+PA? LJX8XBAVX\F2'9B/4K92N9"(PL<)ZC^
MI76=JEO^O3.\$".(MOR$'%!MJ"JKKZO73VB< D7545("3$@F9]25Y[7.[.*%
MZB])9\:WM$5\-R>.;@#4/CAC/OIK]UU_0Z$NOW;J$DHHP<XA=FVT3Y8)$OV^
M74FB;Z<6-JE8=\%&RK9<+"B!EW=PUK82D\#RIP>/A(#.>:=*9]F@T\G)N0%\
MQ'N90V+G)^L[$N\R@K/3\LA/S&->>9*H[T'VL3P3*6RLL_R+G#1!(".>.U01
M"=E?7(42VD3N/AEP+AHA)/C)5?UC+.AM%8FJKZI$T?@JO+@$RM00.+S$7B!-
M*OHN8YF%A0-?[9F?MDT]NP5Y;LPGYBRS8F=XJ\:W/XDJBPUI8AC(N,F4))<'
M??N.\MPB_VNE])484&@QKZB#BKV^7W\S99#&DSY(_H@5C0/,4CKM<YMS>"YI
MD_?=X5AS3V?RSC.WXP49Z3#=%SHN;;UMC(RI'D5:S2TZ_*NJT8X5E<<,$]9*
MV;O:BHL+F^) Y+0\RO+["G(C$T3,BR\7RJ&489C^!7_S4Y@ON_<[^*=1%WUB
MWL64E8J:L#G!&/\N=1E_!8 E[JCV'/O7B>2LWJ4DS/"FZJ-X4;U]S[_>\+!0
M(P+-A<3'11M:$[,_]0!7_Z[$]D<>7>/TI)//>N"N!@8AE^ ?3_(-MY+HP8L=
M^+&MB @ [@R.(9B\$>6Z^W9V&)Q%^<E*,ZTJY+%EN+'?8"I]FE;JVKC&Q,F\
MXCRO[GQO@U=:S&-> @D24!Y2J&V(</6@SKU@A]?(,_[A!3[5ADXHD,WC0GI8
MZW8(NFMIIO(V*1PI@3/>WI=Y_.?69:S'^)DS<OH73,25,KL6;O?']]@WIB!,
MQBLEVT'QY)GK>N*V'QV&>;29NH?/NHCC/#I?U^Y P?K>7I4)@$)\Q8MHBWQ.
M79-#VW/\3"-ID]:AZI.4-27[;=N&WO;E#G;0#'_#KSXX8G)AL9[GKC0NC;:O
M=3/=;8M%6W;70W\B[+B96B:^_^+X:U!X%Z6DLS+&4O:) \UEWT)U5#6<IO0O
MXO(U@X/5T6Y'XDE=:9600(Q\X4#^O)IKU@C?TTC.!Q=FJ=FO:"UGUN?J(0 ,
MZZ@DO:[!VT^X!BI.#2QU]<^79+&';^Y<X9P.N6GI1'5-)TLDY^Z_<ZAZ_A?*
M5+%"[* ??6-+(HA.7AU>DB<2!U]L"SD>-3,C-4T\@1"@I=XC!7\^C<UY-Z;_
MG$NY>LM-0C?<R4&*;3XS]KV*S=B' N;1G=5\>'3RBV@1AA_&1/S&/W7<4#9%
M_,[Z49_JJDTJF+W"I/%H2>XA/EBEW:^28&]M008;<"2F)@\.=V_1U#Q)]D\'
MM^V$@6"9&<#"]((",1;77<T,Q:&A+L-MCT1LOQ$5=5"B*Z=B"5]:9=S[:R'P
M3IH]"FH\5J7/0&H=87WI6J&GV]I@&BSY!<+K.\)<.J:M_T2O7BD[J9R_;,)*
M<*=[6GR^9_G.B3T=Z)ONE>&?^(*((J:I8IYGN( (>0)**H+T'6T7^]GI#CTN
M:,YNI.&ND_''P1IZL^CG3X1-G&X +*JB=Z0D01/;11\'9?S]D\JY[TL/I+09
MK&!?^%"/2C(IQ0L5<>:F_RHSG(N@"C)I]:<D'5FJTS>>-6XOWSG$.T^,&:\,
MO%)2^-&/[_=!,/);JM/]=7\1J$7F#U,>LK6,^U41>=\Z)J*3TY-$((\PPF/B
MP-5?8%*-@*WJZG<*S$1X8[$?,KZ9EA*(FUP"TZQ;*FH".;E>>B<A9,YXBPMH
M>)GATC@_"?OHY&W#I&F!56-*J5Q-K+7M8&8M9!5;GY*#2E8RDN%KL22]E?&L
MJ,LTG[YGB>!>KHY/-5]_/N4ZO.#MK6P,6F/"\NG_ZBA\GT3]>&<#9_,'FL;=
M11UC""K+K#B;%,EAW^/$#$F$2G[LGI.W9^R!MEBHD:H5JCE:%]AX@;,1"1R(
M#<,FM?[[5+BI00+C:)J5/P'(<X.&B9,$;O&!'S[?B([8Y8IBQ7W2M]A$HY<:
M"MFMU]DGPIERYW@#'W]_.43)-"* .FR5(D&??P1K>'(5<V?/,7OK&%:LAT2T
M'G\-"?$3@*X;?Y\C#3LI$I.0$]%1YG_4YDYX-T&+R%3X61B:\:AT.#BM>,J@
M^?C<[8A]=\)8J+X)@1EA0M;LSZZVD.Z6+2\N&.X];FW+#-[.__%HG(U@*%S&
M<1\TM9V96>(5N[BKM*F1H>H/$YYA_XX.0#J_10<YDF_VI79H_I0I063==2)X
MTQI"ZW9X:+A(SK\['%.WT\"[JQGP\6C(D-YSA=1?C_L+3&Y28VU/<U(IED+(
MCJ15CF24P, Q.JT]>HVA%8&[QI4N0)-75S[A]MT:\?%3ZTZ=@DCK.B-=$_L8
M:XD?S'C.V\A]:*%GM\HWK6+3("\1W;(B&;#6R]^XL#BS9#V%FNMRQ^4Z#\6G
M@% R>85 E :_G9DC^WT3=:&GNH<O(I2FF<T6GU.V/LM8,:T1/Q4WG;8J"A-Z
M1'E4T/"$@YY>XX\#4-ST["OJ:4+N4/8L:(E<M#J2W4XT2DE[99=*$_"I7I#0
MY))^26)M!"TC0"<Y+8=DCH9X%QNI-I1R27,5S0E0[2I2"6^+3L\ =2*,]1LI
M7O<XXH;P:Z2;?SH@Q<_?27TZYJ*8"!93*"N+;3Z)J^ZC82CXP%Y)&AYP[V7_
M0>-B6J$PBI(*F.33/S*@O3U(Y4=C77_>@6#I2-RXXVAI321I!@X*A;_.B6QP
MP8""QR'F:<1ZQMDUP,O0ZV)P#"QV4BMDBTCKCGPIC]&(K.-;"J-$FR?6?-4>
M2N34SL'@1_/ZLI;V9 _ERMH>XX7Q4VI_> V@^T)^%-X!":PW[FRA].@?T8CR
MH+Z?J&!18T+UL7\]0AK/97T^'UI<F),;;?J)HV)N=GY>F?NR)_"EG!\F0J2H
M8RTG*&3"/1:&** ,X7!\_"UNK#EE1 ))T4I*XD&AJ:+ ?YF"D>=1=*VQE9_4
M(FG>DIPIF6VFM-;T>?>M&^SH(:#P(;.=3MQ?O)*!T>X@!/+K5NOI\'9.)2=O
MLKB5'.V#: 4H9>5XQL0P5PE&S,CNI'5B>C"?=K5^D:(GFP=;1]:KW7NGY)L/
M_VI_X1^.C34F<F $4I8<7VXGNY??G::*8)=R[7P6:B?KUT6!6;H%6L&V?WRD
M:>F)D9P37A;^B;$Y*<V3\*P51084R5M+?\5>IN.)Q(M*Y6D_,D4K5SKECO.I
MN4*SZEB\TJF#]=S[ME^\_3VVOAD;3$E,?W,AW.MP=\[8J:%X=\ W8$TCZ>O^
M*'E:E8:"FDW)>O%4=1ERZIST)" 62(%?7"\ V3L2MSQS1[Z_#/^&T17,PHO3
MH7]N7-G-V%X37_UF,($ ]_P[[K=S+V )FK1UBH&4GWL_11244-(XE>0ZSBZI
M3[6I1>2X8_@X7_9!.MO7+X#6.W%EG9_S?B0GC0EY>UF%YG_*D.%1UHG#UE?V
M"JC-9KUIG+)LJIJ <7+1!')REA0'4T1'D46V;F4,LV<AI=I""5;/?W )@)F5
MQ_BGEBU>#[VH^J0HHW [_3^X2@RYQZAS6+QPW(A9#*)]>4\Y]350^'8-7[Y5
MLH$W@#FIV7B*Z.NFR<TK_2R3TOV_MNWU:?YE$@P'W(=OW1#8>59#$66\*R,;
M)Y)"I-PT.3Q*]J@_Q"R5O2*SPG6WKZ\.=-LER1\XJBM)D2S),PAU$+/9_XCP
M&"KEQB]X0/;Q;5Z$?)SI!GAQ+!SE6FK9>0.H+/U:NGMLHP.,3Z0]CAI_F81#
M\V3BBSR5^,KM+EBD#B32MN)?9\FLZ?WY*7](@/7@\%@$ O 1&</26D?I[BBR
M4_T6'Q^>SXX(2VC%Q4T%'&IX[+52RW=*/'>YUA-B#?\CR\_Q5&&>LC^*U'34
M7^JYX4ORM.H"A 14J&EA>E9SX\R@^= T! EL;V)L2WW2A$1:"X@1]J7J3B%?
M+=9I.WXAH)0]'U8;_]%T'2O.XYCO.6I#'5I2+B+8WSNS%5$,?.;K;#0I"Z:U
M>/'8*61QZ0]O^X=D+?.[YN6AJVKW=OP>C*V-\R=]LK=-CDZN"EW\?<YR YC\
MJHX>:?.R#.<7@L.L%A$#/\FSP%":D-68RY5(=.)B9MUU]L5USO7!'^PP;>KP
MG)OX]%LT::95ZI,IC&3\W/=JK\HL94;1^P\9S652:A%]C&DVNU7<=S^B(6T%
MJT6>=O1MGZ)PF(IS#4L_1D>D6_X17JM_P*ZXQC:!WO2U/YX9IO32PE+.*_O4
M"+?<]6$>Q9!FVHBJE-=.<$#G75#+%9*'\907VAY=CL"TBI; O&9KSE,Z)?C8
M# 4,J$/GA<^>?,MX7-;ZWQAO*-^7<52/(8_KE@H09\GU8)?]I0P'=S450WCZ
M!L3HBWOJ;JN+",#>BG%>36*@Q,*1VY?!#;J+^I\PU7,=3X=;O^W>(T!"<]@*
MX,6)&*,D,6<O_+M]/WW:NB7/^,:#BR79M"Q%PW7&@<>^BM# 4"NYQ#'FE,;X
MMWTN4K/.[9=&V35"0&!]LL*LOO6L-NG5_!N6$Z@*BB* 'TINY61-'9NI]GD%
MAY+&[=%H 8-+V Q6&RIKKOE$KS@FCWEN!IY*'7JK$UZQU*TY_$==AK 30NQB
M_P@M*D5$%J\&SWI5SA%<Q#4>Z=]6GYH=DKB;7W@K-N1R1&K /P,?!_!/F,2>
M\XD+I.NC]:7+X6!Z7<[BM4=RXP\-ONZ^P94*</#CNDX3%UI;?BA8 5_Z:#CP
M+,K1=J_B[<)JS$J:^@4P;TQW'*H3D[S*+F@M2E8H*^-8+T^#(ERUB$8Q&_*<
MBOWJ)4DUS+QBS#Q8KA2K88<XN/1X;<,0^!V=<UJ7=GFV\6[.(>+VEP^]_"5D
MK=0U$996W3< DB59;U8CU>6G6,N?:;/*'2P?CN5R"@C?;^U?14NIS'M9SF-
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M=N#3.#$"42QYCG4;.MT+J=+Q\G=VA@X@PT)<>N:]U?ANPQL(+% 1G-FY7/#
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MO^"@D'MU#\7'4C]IQ%XRC,O$IG23QV9Z]5?):%W3L9K9W5W$[&SX.Q<K2._
M[>Q@.%LH2#U( ND6:LZ2T)G#W#1>;[FI:/A\;G;ZM]QMR5)9=MZOOO* ]:(!
MF]9SS<V U?&!B$CHO3<$'N^7W'I%2>HMO2'TS"OQ4UT!6"N8M0]P5_B70'+
M;%#PF]6SI)"+PU,+%W&)VAP!?U#[7^L_ZSKBM-;ZM.[RSW:N:][JD_S" :!]
MZZ^P% C46K^#SOZSY>Q_UUKH]:S;L]!0L";ACZHR*<6;C"E+%&YN.N>W<I_4
M[O^>SG'\_# O.X(,F^.$78Q154SKYN5C$,QQ>7DL?KQD<4GN[7KRGI$VHSGD
M\\A'%Q:W[77<=>,P]I?+^I*-640 / WE9WT9)XI4<4 V9Z'B LT;1R:\;OYN
M>SIRZZ:)^OGO #3/67HI*B><"*"3'J3?D@MPB+4^>1[."A$?Z-=9D^>^<^F2
M<P/&-RYOFPBH<DVV*]\"3RLZ]_ %EK7Z)OKPD0O%ZU+ZNW6H78( VQ=XY *H
M2#[4RC#(/+?P3ZPU7!>BENIF61\I54Q9Y3!,JD[7%!<//E;:&HE3O/?1L=NT
MT/>HJ<&R#U>,!-)!]*W$H0IEY=5UC%66++^BW83#[ZH^Z/(,.#.A IOC$* :
M4"R,;MCEJR'$M>YV[,M*-@Z>K93US@UE-:PSX1KICWVZ7>>*[^BS4"9-L89@
M3\47;*U40N1PIY%XQ<*JZ%CNK(QY\3N3-HI3[%X]O98EFRY!;W*\5@-$%_:4
M9?(A)L<A/VMJ,(WUZ.(HUQ>CZ(?H.M_GVFBWCT4*+0)D/P.HCZQH=+ ,<65N
M.U /9)Q@W],4AFED^ .!X4S,5<IP=T^.IZT\"LM.OSXZ%O6E/4F>%X+;C?6F
M6HG$ZZV-R]:Z.,X?JDKD-G_ /9N!A:LR0&K/#D 11E921I]3%3Y =V+H^S.Y
MH2V<-2ZH4G <[ K4Q*MTD[7VI/XQDS;M!WJ65,D-PVR3W:78?=6?I:DJ7:"Y
M$P/-AI/]F_(LM^&P!:=-B[K/!^(LA\$9JI\Q4DC9*!2-BPB/MO4$J]SYX^5=
M-]!=VB/JRY<O2_J72Z"H.A,8H.H8]W/?T&,PJ]@G[5(CLDLAJ@?7?X;0T#4N
MQ:Y5A]_QL=LU<)6KV3OSE<IF95[>&],R;BH[.U%.BCZ_N=@R@V@?I'<\@X5(
M#P@ZC_QJ;A[KNYQ8N=&8F12X1 ]06 Z]R,73,>#YSF!1!94UHS6=*3>;+1Z=
M__(37I<_C12Y"Y(74J'T&NE'&N>&F,O9E2-D1M:./*='OJTM%%MM%O8<J7KE
M1HO.*+OG1M\&_!LC/S2/O@WO31ACB%:] ?M]B@*=7[4D C8FOE,O_L/4^Y@%
M?]0NRQ810$-@V;"6P 01ZKX[R1E?=?;$2CW>*"HJBONY:W"Q;*T'?H"_/I(W
MJ4H/B0&E;K[)^]60+OC3(Y'];F</1<*:B(ALWE=W$WME(H"\405%P_4-DQ U
MJ==49[5VU8K[;FO+K?NS28I+">N6DWC1()5@A@'4YUL-.OH*C7ED=HP,BQ0*
M5@U5H=L3#8M7-ZV9<<*R!:5SD))%LV;9->;JVBF!5I&I*9YX3:.5)3)#N 18
M_R+3AZL'8/*SR=&4_FW-D-#IA.5@WLA&*7^;XWV!MY<UT>!'D,L'X!I,<#+;
M^T8.NH:G-%;@K:3;FC_/EVG+9W^AW]Z]K"&=PQJK>FD"?P^%DVXP/3)8NS5.
MJK<EB?V0GANT*6)SRT()6J,SSL[7^PH&^;!U[4T&+:*%63KHJ852Y5=4]J)U
MKGZVM$%(*Z'VQ; 9^QJD\^!U2+)!VK/A+Y[1+\B]7KRU$)#SJ@9<%3HZS(EO
M5DQ[//3F35A84\N$N*!&ZGV_1_M%O43 (JS NAJ7*($7_MP(NOCLN/88J?J;
M;#]A+U4Y9U F1SG3Y#.TLD'U]3BJ*L*X*0'T>5>,R<_"WY;=(?;>5,<+SR<,
M#PY+?/:L::VD[F-<J[ B1,"SZ)/G#?6I%H'NEZ?DM*M%U@O[=2W*J7@. EL7
M[E7@UM+#W\$W68<L\\55FCI_*MR_8GUUY>Y<$\9_B5Y4-]![F+%O#;JG'L2X
M5%N)<6BC,S[1JPC5=Y$D&$WUWMT7BX[JH8J;4AW;"\L6"NTV494=/]*1G'HL
M[I*"3O035M?\H7!T*<+ SR4TS<YKW5QT$QZA*EN-:W H=:SO"G/@*?BDR23-
ME>8H1$[UE2L@_M>&2%T[ CB--ZL?5Y8IVI#]X%CZQBY$OOLJN\A/U5B:2]3+
M[,<#$J_'=VN!(KO0>?4@&DR@;OA@F_D49FO*$O*#IBXVZW[0&.VEPQ7AYT^[
MN9I3?D.=QNZXEGE73S2*20=!70_<D';[#GI=;!SS4_N>34KCP@O&%9EOROUU
MF/7,K_VO[K$%+NY4$@%2:A>DKH%V.JG'@/[=':7U<=ST.$,8);.>&>N_- F&
MP/YVNPCQB A8*@<>:,%VQ4G)W^<4"79)@]6WKY]6K6%SNM/Z]JG/W0A78[!4
M;0MD6&""'58MRCN!7L/+\76%:AF,I>AC1#+?LU@YQL3,@&A<4O0V7-/DVV:=
M\R?]HDT='6_5QHLP-<=/>)[E+(U6(N":C(?7$N)ZR\0!Z/N<:UW-)V% PU/W
MROK4)X,<MW4!,G/0R[C/F/-C&]PXE@I9FX?243/'.: &(D"3WMN_=[_4&M/G
M*F0+OD*(A<N^@MPKO<82!:0<-C5L>YB7W/0QM;G48<N1<S]:N^[(YE #F;"S
MC'$X=L>N(CHNP,NZ">4;Z0Z?_?*G'@]]SK^EV_;,4^%SBN[]N,L65&_O@94L
M@\?BU-"?5.]9/+B5FGF6_Q(]Y>KUXJ:%/2W9^1KE'P6RRDEN_)XU]EP,;X_S
MP03L6=5CU]].=J4QU53/&#8;ZDYX/K$5\Q+2Z<Q3X.CZDT(?&I*B62<[7B].
M8V28'ALT'H@?_(%8RN-5&&EF@W+ J"'!MW=\@+Q;+D%!Q^YZ^5$4+M+O8SUW
M;ACD-!9$R,NOPVSW.#8Y$3O!S?08C0X>!N1ZQZ?=;ZG'V\_O"91E)"W83YXO
MM=GH+/'DD[6R8/W0+-@#LXM< C\(E65.61'VRL)"7%%8KB"?)NF:[&64V>>8
M%[9U]P'D_:*<$. Q9#2YJNE\^RQ-&;1GB:JN21@!QO.J8FH*=S2789<'L1&Z
MN(1ETUUTV$!'>I+RB63&K.-GEV4',>Q-;CM)!/\AW]M]^,Q!=S8'5F*G"D.C
M.:*LGK]57_ZY8*8[R,8NB'ETIJ(R3*LWNO-#.,6U%L\K\-B-LLVE99W"@2JW
M/6.I;+X!&==4/&@H9\9\&SF)UL.0MUM+CP;?W S@K4+R</K;8HY6$B^^.9K+
M'[CJ99F9]EPQ>L$NN_/6\S81$&(/:6OOMF;%NK4E,%I\*[!QD58\2FG<LKK[
MH[O1JX5&I&4IH(%W_!0-ME,_]X0\0JZW%1^ZA2'H^3"%L3+BJDKBCRQGF2CM
M=+X934GQV_ZRFKTO),";,FA!=WOXF'EW]W!V?F*M>EO(8$9;1^9 N?L8B?NA
M*DX85KU97_=1N^#UCK0SDU3(AU3Z>7\Z4:V66'?C)ACA:O=?0X0*L][%WJB!
MLN)OWP>;FY;E.J5A+;A"BOU_/N$)WY<K]\ATY<UM%LAM< B/+0JDV*G&TT,F
M/$K1 5E"X<'\N(S6>K9(:9?K9K]&O9N"YUU\E%ZS4_Z*Y Y3MO6CB&7B^(CI
M ):KV0U&JK)BB("=1]B<A^/*VGF;]:M$P''"U&%?'R[WUZ_YETSPM.MW'?HN
MY0%60D11BB+;S^-,9UT,SJ,*C4;]5,]Q;LNP"+6:B)WV+U !;$(TNI$.M4=7
MK5EHM2"9+^6O-=S1]RO%MM]5+]G=9?$NJN;-$3@\I\*M%<'IF Z,?P/UQ_)W
M?#BE.::+K4"R/[9BF7L2><M!*4/B Q5[]WH02S_&L?97CJA?'9ZWJ_3:"$*B
MR=GR7&HY)T%9JI0(:%53O0[Q[>XPU]F+%*MY*E _XK*7F[0[_UCN;54'>_U;
MJ\M/@9" Z(8\J#;F.(T(H)C.>!C:<?9,52+"4#O2.Z>V\WC(1%^3_ J-VXW;
M\R<>[[)3L#(L,*,$D;CCM'NJ\_,-WI5GQ8%8U[[C,HQ;A ^,'.\&?D\0JHEP
M+<L%20*Z5^=\E;[RF>)_W'E 2]:ZN;^(KD-E22HQT$- SW#=W_%ZO^K<JIV*
M/:2]3#O=B_1LXX9>W%N\,<5Q'-KG .\Y--1O?1(["E+_\0-_(O*-;RPN??R,
MH+$![!9-B #7".UT+I'RW S^T0A>"25Q:4.J[TZHGYB]_^K^3>.ZJ3]QJ4E7
MQKDO<<$>/B77[IB): ?&Y%#"[!&4S@LJ0V+?79K[9V;BS"F3AF^.VMIP+\K?
M<_4V_3'%E^G7 O]3(BS&DZ3E]F1F_R>ATG<V_ACQ^\+D(M<;1!( G'BV7(CH
M@XLO>(8E-<K-RES9!$<O1_>JCRV14D%E=R,!;39P@20V=G 5NCNTD1$#ZU:C
M:>;%FV-VDY?[7!ZD2[#TWV!<%-[/U.;\S&,%;1K"?Y^](AZ[K/:IVMB9['6@
M:I#<M-OZXIK)1--NL%40^)!$XJ[AEMNSF2]2584A!AU KD-$9+9\?56]8W:0
MN21T(E)DUKP+?,O$@4\M+N.M+E5*<.^" $:H$S8MU0FC:-18II&@=#;Q(_C4
M#!P6Y1H=\*7+WE\U&OS,:'Q_MO(WOS)46/UUA>:#[@R+PB!IY]]I4:Z:L]JF
MY_ EDT@\#V;QV(9$4CD\EH,NKYV@%;.R/PW :$$EN;/L>:E7^I*V^2S+1Z;_
MD,F4+B%8\0H7%3![,#7^+E8B5AQ/MJQ&?86O*OWT@[H[7V1'[-?IQ^]REXI>
M]/9EFW AU#9*4NED5P?VK$\.:MY7T@F4%7P/?@_>1M#!7@'?6DMA"B.@SC;+
M\,AFX2CT2HXN8^*5VWHT)57O32<T7I1W--Q;(N]F.=>$$ 'MG'L[4ABW!Z-0
MC7PG3O3["?N]9S7-T189[K7)HOZ)HJS/F,A^<W\01?7>CF<4%NXU2=E=#!(3
MBG21+[!S!CK.XTB'H"/U__X?F HL[P?HL_IWOL/JAV 7FHO<O61Z-&[FD0./
MPB:854_=>R2_V,ML=_:\OU!."9Q;^9]X(.CXKP>"CG[\KQX("GJ>?06GC=UN
M2Q>KYX470I6P/)DWN3*N7B+CVYJF[;5K[6&Z+$1%*T]FBVM')=!"%2YR7N%L
M"G'I:JQ;^T_?K=?9^=09?=+R"FD%S##?T5R9[/4VR:P(WF^<C?;3'ISTJD1)
M^T;KE(()9"<D-G,5,]BVR"R.EWM9@OLVV7:V<ZUJNL?7Y TVJV'267+W1I$R
M=\(SSOW!2%X!C%_+XCO2.%JDW:Z )%B/SUW4KLVG#,NYF'%4/ 6E7!*Q3<S,
M7CF5ZW:+5\/4KP^M$#H(783^,&3W#)X(D/.P#D8M[YX?P<7*W\A2.V6RF"D)
M!5O)(;R<IC[]ZADU;[H3U%X(U:K#K2^IT&XL,G:_53:RX^W;UO!1_[1T6<DL
M?/7WW/?\I7L4#H7I>$]L+DYDL3TUP*]C_E'7V7S!G(G)\>!-3;MFH85\]/EW
M'L,W<]V Y-!8_+"Z&XB,TZL^>,]98M!+&%4@/UT6.$_0F.95P4R^A3DE["0P
M;1)DJS$352PEK7YV0359ADP//SH\I*ZZ.R=)K^YA8(87Q3!TY414X$!F;,!7
M/Q^5.OU8$#7+I ?ZG_KQ:L[,4I%S_%%]DUO"+D?9@P;>*98 ]^MW"*NZJ@>O
MSP0SXF*6,D SW5UG<6MEA<I^QZF5CO5U,XQE)U?XF&Y\Y/F2="_S2%\JFT%O
M2=P.RK*L73K( [4?E>DIYX.@Q5AWE0)?CU78B)8O?6U^7J)D5Z$+P3%%=_E[
MVQ7*/:ZU4O*5CK]7YA]0=Y)C C'IRN:MP]W#9G=9^3V+/B8"C,8$JFH#?W>D
MB?QN,)<1ND,OSZ\ OXQ30 'I( [=9T'K,=Z1-7$TG]:B#0\HS#8%_R14'QED
M7UW*-&%1]WU$QRY<B@>OVF0;969:U:K6)2P)M3<@V%J7)>BAH-'J,FJE@B;9
M4C&M8]R+-1G8O6<V'P!VO2%2Z8NCP7(04 <14'-SRV-K0M9<,.MK7V&<[O'C
M$(75 [^L\A6[X#>T1^V,K0-0 W4O90:5B_S9D3X7B=,,,1.)5N::7X=RK? H
M3H90-4?$=:?Z++S>IF+*P%&UR5;K5ZY=\KQ4[C=*P2>@3[R9D]H%<Q"+)3#Z
MNAU<(N:-#)JKXR&Z,'L\I;GE1X7M';T,=_%WV?(]:+"(GOD@%8=FLPMGU<%-
M^0CFE%H_C5E.B?:$B.:KN#^J-[6Q0MK.%K/%NSL[YBC&\YYW<\\:,'K0+A4J
MHQ["(1% KWH#HJ(J@]<7ACNFIG\KPM!)F?@G(A,?R_,!E309JE,&!^)QRRAJ
M4:JT@\)!V<,ZG>1?N9W[-7W,-8B-H%/,08=O-E7#! I;UXF6ZC ?F".W90CB
M-C[^_6N#AI)^MIN=BEKQG37'.1]DN3T8Z,:QH7IS_.5PLE5-M+SKKJ4&^\PM
M8\K9MQZW^97=G=>=1%(OB5R/2>MTC7*92HN&#CM"Y? @>#-@!F*S!$]0]LE;
M@,P^::R3E46)GMYY]>X6;(%5O?\]J^7;^T)E7C!R* PIP0'E'0MF@;0;Z% H
M54V#>UOY%3X\E>Q8DNQ)#GW;LEP&[5.W:!7VTM+W\_4[L'I<>4=62U%T<V6P
M$LKX%4=UK!]J@J5;CWV#-T!QH)^QIOJJ&_4R<;EV^G6M/4A[ [A,!=V_BSO0
M'E>SE6 U6W!6],1%$P&&<AJZYP_%=LUWV5Y5.OC>9<<HDF^"I?4T7R1##Y(]
MZ_T.-QBNV_6Q3YO!&\^TEQRB#W7XCSUP&=_ SHI!J05^/"VU53_KGZYER+;0
M13X53^XF+_,F FBERR1!-!MI8#I5DNYM$_6M#"W9.%OID:Q^O_KI\91>;$IO
M.;O+"O?ZBI/P(%7_REB97U"RA87];92"OLZ;[X$GZ*AE,"V.-$#UANZ4^2AE
M:#_BV<US"&7NUS5Z%/+(A6/%EJ[%(32!+#=Z.T_S^;?BPD!VPXQ2.;FQV[G1
M4_W_EV?MW=JR/+O;P=>JK4#Z.3L3LOM5VG>Z7+[DT4=?54X<,B0".)0?%>+@
MJ"?PDDT3H%/%SWWH+U])UUEJ8>1;_A3^Q)F?]:(,-D 7=/W,8MS 17536N5F
M((%5"?C>_"(BC'!SX^Q;H=KT=Y>91V(-',=K0GIM(2 !;Q:'[F#I<'",7_:M
MH5W*#DT_EH'& @YRM-'6%2H."D9+<>:L*XK-XWO._A8>)?N&%TDS)P?-W4,S
M:S68AF7R&6?%A6(_)-K\]F._:\)=&(9G.R^FUBE>+,7&OW7 Y:%\DU$P9@BP
M794S;/3!J(RH?E)]BF2%C]$,@SR@3B@)M(XDR=6[N&S2M5X;$XK1JALK_&5X
MY:!6.:GA%SO'NI]R?$JK&'4A5]M^75O&,!C?^&=CV4K3W#?NQ-%I)Z"N8Q H
MUYZ0D%I?^G"2M>Q;-V6_9MP E]3U.F7;:X6+[,L*^;\:<"9^W[51PE"+XIK&
M>'L7 6W)8J\Q%YI&VH/8Y45NDS!(5:=Y1)S,=A;8X*.FCP+'E;N17UZ(Q+<P
M$)HU!2LWPJU_\?G+"'Q'3Y[M7N]N]C<7[FPH/20T\-9@UE''&4N#O$XG0+MZ
M5<ZQW['=RMG>6)'DRBBAM1;QQ.1V'_GU@MHJG#@RH[BF8TQPPBBE7_%9XF<6
M3:JW!52ZH?[+H9E+DV_U+ 8IKVJG2WK4:T[ON:Y=Z]*ZM_K1H+9DV_E810I)
MU:$CU IDW).QB#'^,2+!GSIO$UF=8__$Q^?DA2S9]L(/59$9B#%=D .FO%"V
MP,6;TQ\_?N/Q3D<8AY%\ZUZ2TH&E$<N/]BZ9H!^NQW7)]WQ6-@,%4^ PZ4"Z
MP81J#C4'"Q"M^+%/Q\<J\U-)=]61P9-C]'D^;\WRF)[)D]C7!YY'+A<KXV4B
M<XWS3&"/0[>H8'&(P7-<QE*0^:+1@?2%K&A8?<;.?H)8-<2:VG;EC-S:"\7
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M475X;@&4<B4"JAY6[G9Y9))EVA)\$&;U:OA:O%J9H_Z_?0,%V3]7)&.?U]O
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MW$:EC@5V\#0<*=21Y=9:E[9O\>#%27IPC(_<C'AUC[%4:J2JJ;" $M\KA 3
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MTXQI?,Y&0OBC!_K*1:KU[,>X44IAVM\:?\_KYBN=TZ1T^8.9$S&*  AV/"Z
MNA::-U!'QTG*#];7:V]Q%/NXS/<8-T2_&HF4V22NKWVA=U73*1C4KK;7SATK
M<0.@=$X9(&J-J?.$B>F*:ZH8.TF[$+@M=-:.'+^3K7V 6+NF_]*M'/!RRC9O
MI<\"%J46$=$_T:F,3((XR:1L&W_WIMQE:U&R+9MJ4A+MB[L@T"RX6QU$-_T'
MP((TD=%.W@Z[PZT]:U!:7#B'$=.IFTARDJK-&X(9S5XK[F3X"?0>,*PXL]76
M%/QY[M1NK:$*;OU.^>OHI?N3E>@=YZBD(&7';@)<9Q"-G!2L#I]BK2@IXWE%
MU6^E\+TI1>.SSB/KTF<I V_L?8?N-L ^4O^3"HY6/J52/F>;LGB0OT!NXE[D
MBGWXA3)112YB+OCS916;6US9J"@X^*IIRM#9&VA345,4$#C9J;':I6$SU:1/
MZ\PL!_[]'39Q?SIF5O3#FA"6B:6'YR_=TQSZ<*#.A?2ED0XD_/P&T'_ F,^Z
M!"P)6]GQL?CJW9 K/=SKB8_;(PNA48VX@/-M=-&C/$',&'+<]P<1%.<B\<2J
MB-%09:L[_\@.E]BO#9H%KF)3;P#2-6LL?*L9^\H>IN+NZ3/9?Y3A+Y">P4AB
M>%99F%<^\Z+9;I98Y/'OHIS;%<KF(_=EOYIK!5JHZ %6'=S7:@3"NY6<@$(X
MM<RH P5YM WICER\NTYI$JU3WQ^Q.<E%-#_5RA.;+T7@CQZQ _BA-; #ZJ!G
ME/OUQ)((15+9GZ6=.M!IVA2&[U'#$@LL_D'>%][DSVI0_]US_CK</(ID4ND!
M/AQM5%LO#'26-D0@O1JSM<(&66+YGO,"!@GXA(YF/KQ5E7RP[G(#"#NN-RQ'
M3\$@_6<K#$%3%LR1S37.PV+4^'SKQHF_A\V!-NK309,.93]4]AJDL/V5WS_\
MKFGB<C/C9H,Y+HS?V56F0F//HDZL@S5Q1.N=C<Y9@4E(GCRDYKI]&,$/E]P6
M8H(&BK.UT6L>_" <2(:#)$GJ$J/O56!A"$$/D?D@EKF:J8U?%NEV=V71H:$B
M_&15W0)+TT(D SXVK)U&X@'*>($U:CIDL*T&&"TJ9C1GD-SBU+%79DJ-,#;1
M,A;W>_^APN"3E8WHP;7-7'][BK/V17#^2=L"?OXT?**3M +J\:I[LO.%5S7H
M5-??OM3,">&?L=#H^3%DW8IXB#BTN0&Z68(MZT^0'UA^,'LL[V^YJZBCW5C?
MV1YY2LN:X)*,E$1H+2NT4%"_V 5"*G>\+<XP+[#31M]_Q)[V'?3YI8\VCVBX
M:[$/?1S>\0\KI@FD=%C!7[S BUUH0L>.$*:36W+ZL9X)3X^7]+886U)T;)I$
MZID1!$F2EH2)2LU)#7$)A5V[-KC6OTYCTQU^P)6H?WDE99>FV*OC//$C 7\2
MA8>NX!.=[&92.EJR$7,]O3>\B=!-!5-:^PL3Z+NU/9_,+.+88P@E\-7G!6BV
MT10;IYSJ)LG"&?/+=^J<DV_^>@"?$DH'LP7=6FSBOKE69G=GBSUI)I,#UD2=
MGX61L]C*-9DLF;'%^&2>DSJ;EJNJ;G;G=J5T<$D7HK5ZJ?.)!DJ'_,$9=JCM
MN6E$6/1E=\F7"'9Q:NW)"0.D*.S7RQO ^/Y#8T@-S%I[A?8&X!AHTQO,I2"[
MBE?@KEMQG$8N=HV.EF9O2NZ%WG]_\711F@_X]HCZ78_WYNQQ$J<3<CXA0 WE
M[Y7C;,$@E;KT[!MM^@\ZEE..O_E+4N[W9':!ICCX )MIR+7,)1^..UK,;LJ3
M1;2Y2JN9/3[Z0889)MX1$R\($<7E=>@:PG"G45B;T\^XW,WXNJ()SWR&;3:[
M[?;<"6$P7P;,T?R=6#PQEW,+*4>@L[6DC$:&W,*!SPW@_M&/H:7MX [](_DE
MA[7!R&-1^L&LDA'3C85>C[C 5WQ"YE\*90XC#[Z\4]M-//[%G=3-D=]KT1H'
MV3O))8;/L9,!G<\]%JZ:;:XL+0O^_:70CF!__C"*8WZ4[2"F)L >JW%:-%?-
M9&#G6RF\T#39!.8+=F@AY3$!1'C=B51!1?AG8NQ0@2\L\%X%5MMQ%>2!Q#;U
MLW7T+V.E.RS-XH@=#6;3\Q3[5*3R3P*%<DG4$.([-X#;-3<02G%JG@RJNTQ8
MH0R:\%-J18O*J\\J**/UB1=W2E)?I?;[05MB__7M_V&O^D[=^CFI.5&&%=VE
MWJUQ81.BQ O-[#U7R[PEZ!R7JEUR75V7;%YQ?WZ*<C$=,:%7:PI9BE0!'[]#
ML@'T66?Y#+?Z#[G<X>%?<JDWIZ!H]WA%3+=Y6N)?4139'?@O MDAHC:[7S1/
MG@@+-14QM?NM7-9:\2,#@]9@A97;4JU,<L:YS4M[6>DS3XK=ET>BDUQ1*DZL
MKXF(HODB !180)4QPO,_+D$VN?^.D#)Q2;H!B,*H=RW> /[_8J7<NY_A/<J@
M!Z;8YM,2-V]Z.#)Z5A1SWXMFU+7\%[LV68JWBTB']M&\Y*R!KC2S)W_J9,Y9
M/S>!$XRND[$::F-ZE*DW*XI<-FVU;1C,>U' $S*L8JO)R^,*2L'5]?A3,]EL
MLXV613>/4^$;7S4RT>*C7OU0:_L1'F:(,B?3+NG^R(B*X67<GC%&%!=@&ZQX
M12=[H/2KW7&K'9QN+BYUE_H5H!UZTYF3/Y^.@-]4PZ0 1&9]C8#8;[9GM00F
M5^G5-9W/ @L7\(,#1W@I>9\G4 U,;\WW>R:4%PH;4:V9L D'#E.8@4G5C-X9
M?1E3C5VO$M<E2]0@=Z,^/)>X7[ 2[V$Y)5+C JZMB6F&3;LDDU!(4U3 GPC!
M">F3K<7"E1U^<9/C#Z<1R*18A1?H)(;G]H_S()*6T<,2CX<77CJQ?2)[D]S*
MT4'?P<N5X(_FE-:;/5YZO'/*(LFI,W+!V=C"%2SJH]7D@R3A;Q(<;M8(_)A[
M Z 5<C,Y5%C0Q9.BKL3@0723#SIGLN;A<GMY/(T^&>*'5O*+LN8DKQA&9[X
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M3>/.=%1DGX[OMQ_+]1+5;+*TYDHO/Q"%$#LA=)4=Y*52OWL@3B%&DZPO*DP
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M  LEO@&0]A)+1A4&0'#QL,:N'ZWMV=?TY/F,-X ^9OM*YY8=_IBL@R&M?5Y
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M!@Y3REA:(!(-TE05$$)W3/E:T/^I30,05/>\RM[PZ[BZD@LJT1;?M*K253J
M'<M21RHQX*@QY"AU?&C5I0I./VJL2K%W2F*<>B4P946_50LH<S;8>C;%^17R
MC#?'UM@&F8^:JRH/&I=[=<V/,RGPK=WR\2:71*2LV+5TI5CN0CN'WK(2)9NE
MRP*>B@#&B,V)>^K8H/R;AO5X7]Q=;BJHI4%'QMYVYKGJLE+.8<LV977$/)E9
M/<EJA$"WKA>7 %XDCQ?_:(6Z&,=5)A+V2 K4'GY5N37*,"2G??&=^RP:)D;
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MPM+UWK2[PLXNU+^_*J4<LUP;Q'Q5EQ5M;9PBC0_5NA'%U$3"G"]MKACOD'O
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M)@X3PFY-<E-.+I08G&%O::'?-@%.='HHU/=WXOTI&3GHS;Y)1Y1FZ_&6_RU
MS4\/^\B, ;#VP/L[KFBV6V1F^5VZZ\:C7\6X<#51Q">KA&']C$R4%CS-V1$G
M<MF"K!:_NW@"D>#=T2VO94_5M^%>S^.TG KCPBX@5&X!B6?7AB^ARLWS8F,F
M6Q=A)0[U(_PB[*V<WKTJ&5R4\D#(]6<8ZPT1]A&JRF2DCW%C@OCO:B7M@FDQ
M(J)7KMM1Y4=?B0O_XL86M%93X"2@9=1F:I4O\(JL?*<F+XS.W&V-\3J_ZBH0
MR98@4QE<786H""F9$V_12F01+XJWD*8D%MQF^DC9E^6^S5UG)9B,*KOB1'D!
M5D$A?8J4,"7G2J#>KDP&/+'*65OP7#J*3 1'I"03$>%(42U,SP@DWMA(7QZ*
MJG+(L82^,9+,^K![GKYJ-5R[W,VDQ5_]MK1<1.,<8!KYOS?G9<BC:)E%+"=*
MB!0;.\@X4.7*'"A)*XE6%S@:*XU+\_+E37I%L$)_:#T2X28/T7ZJ9:U(V;JL
M713"FEZ^N-]FG%]<LC(89!=$:&6Y\F(98K:JS%GV^R%[U)%)Q=8$#M:Y7X'F
M.IG?4XZF?%^F*_Z,C.27C7E_B$]#4QD0U-+O1@\H, SKD]X0LLA9UVDILKYZ
M;JE-A61++,ISWY0IB8*!T^7/T:8.=0R1G\XARO<%8]GM@N=D&#5*OMYTOC .
MT/8,95()DCRD0#+)L[V8.A22\RX%2? M]]30QKLL,.87);S_)-#,)R,1 -DK
M>K?B++X%)P#[EIO=A9S^&^H6&*:HC1P]-.^>FL+I-\O^V>%97?+&-2)N4QW^
MT]'=:"#JH_0,4WFAH.$> :=&H<N&,6B%QM'N@]+>P]+*2H_&$;-#]T-D8W.<
MW:-WN!QDSPO?V;+OA#%AZJZS#CKYA?K@U!,H(A;B_<3["\N-NYSQQ#$, IC8
M5<;7#93]\=(L?%,P4Z00.=@:FXC0O>\:?';Q7BP12E*2( X<>PIK'TK;H!CT
MHBYBX_=<,8^5^H&26^Y=7-12";F*-_:L\=K-KT&2L5E@0P99J="C\S-:_DBA
MIC]4CY@X+N5>J*[F!^'?HYDU'95D(_-/C84WPGL^L?6WM<2#9;UI*^=K@0W7
MW_:F[=SN1^BH;JOB/22!$.8'U914\-8F40=9_^XRL>+:##D-_TI8*38BW@5$
MN (Z'(['?B:#>[I65Y-02Y539HS1_UG3BW^O]^![W-0(Q9Y[74P<4^,$_/O^
M^_2_I"XC1$O_O>=#O3\;[4Z;3E?Q3E9;<55U37D\2?+'^NC,#55)C;K@O"\;
M,QH=T2&,L_HJCZ*I39PZD-9"O12+&N4V:@Y9+6]_639^OMXX;OZ%HO\]^O9I
MT5J<A-A.Y9U'"79J"BJS,+-5"O3]-BIPQ!%_/*EN)*S&DC)OF/J"3S4F>T62
M\$GE $8P,Y\[M7<LB'Z^J!%XVK =],Y:O^CTA[,^-H'2Z_6OF:\)H^B%>+\N
M^AV3X/G$(-:"XC6>SU[^M $_6SDY%955\JI95?.H34)+XOR6KYWUICV.['(,
M9Z:?"A[J-W 1/;%GL/LE,3!8/:,2,?DUX2E W^@L[\U([Y+\>469%?>W//O[
M6::2E*&_OJKP'X1&W+^A4=/%Y,=7 "EV3;*3#/=$7#%[B9ZM*QX.;\J$=-LT
M:Z^>+C:%$.[;NR4\*1+^;X2*!B&P5O'NTOGGKRMK:J1E9473YDO-@:_J\$32
M;GZ?3ESV-.XN?B%\\O7#_SQ5+"QW%WHZ1<R)T.7VGUE_[G\7F0+0=(,F4"T1
M-ZQ[@3)><7(J#_)*NYD-Q M5.(=[#'KDXQ)>O3\((Z<ZSDTX FXY+\">?@E;
ME6G,9\^>GS""]C37[IJ:)I4G;)D3QU6N$#"HL?PTO5>&_S6)>KGCU'1RN"C7
MP[/R?"(63G/%@]&9WPLGVM?;"W?P9AEE8F58MY_4H$ZH_GSG*YWQ64B\%?$Z
M>57(#C"%H,%!F5,]04&2^6+P< 1RRTCI!X.4L1Y@",4@'DM:_ V4>MX]\QO\
M5+YC^1?($\E&N;JHSBC:9G8S0AT-$L&M)R?@$OIG4RHK:;FWJ\&VQX.#1/0E
MK'.AJ:S*PTM.@R&$B,!@"VF<]Z-;D- .P*O%^K7-F+[)H04XYRITW)K:&-B^
M&S[YEZF;C5F. L/0=']2O+\=JAM[2"<Q8ZGM):,R<237JF]5PP;"E?']6<V&
M4#MT1"@FW*7S-AG4MP!':T&D;IUT9.A"0%U?]<D'/?=N@6BY#SB#XMTNP=^^
MP9N.WAWX>S'OWCR;^SIY)M04[NA:YDI2+AP/X3!1$]2P_N6$ JQ[UCS',H4#
M\?N[D@,HK7I9+K$)#"9SN02:3/3"W<'KZR<S49I&KCTB 5XO%^">\)(_D672
MXOM>O;-;G;3@T!9L%V;;M+$! VM>$H1*1VFB#SNS7[AY)UI/ZXI-T)[UUO%&
ME/RMNVB8*,(.GJ=AO=99@E$J\U>Z-)W%;N4+PMT>\H.+[Q@>.,4SO$%!<Q-Z
ML!2W &XAE-=UTE3X+DF'+[3^SL6((J QV<T9-7N,8>DH)A:=/U=&V1_+[D_X
MS+0S%*V%.;@,TX SEN%1.F^C/(H.(%.6Y?#72440[;TC+'C"<:Z3&VOY$JV.
MB5YK=<JGYZ-*-I$\8>?C2F04=IS RU,-)CY) 4)UEW@0(R!K.76PL4LVT1Z^
MEO6+EVF/@.\H<EZ_*>0<P6L)G?FU,'8A$=#256_:9\Y?I0F2-<#T&>X(RR E
M9N!&#6P<'YXQJ?,XLB;Q+=T"7$E$IH^/UC>+YJ>TW.0"W[SDCWJ]# PP3<DE
M5^2%VFG+ROZ^!=R'PDNO*[/;#KJHWDR<%V"M0[ZY20XA]UT*:QTT$*V1+IXB
MVP3U^$I<.>WNAOESLU@B9%9T)X\K'2,TIBFNB4G+E=B402U&G9DX R*-V\;L
M>X)CXX]A>SFS?5VN0&8[Y$R<!5W,7OHS'M',J?4F]Q90[YC.FC-1Y9@Q?7H+
M6*)#$;D1<<D8K9'70O4NN5Y-RZ0V\77.XGT^)R;&!0&,VHPVF08NFFX!3)9V
M)V.RLEY>/=N!".B2*&(B24[C0501-I\I3Q/Q62!C/?M)]6<?]1A3)>:BU]<#
M;J<)?X1Z&0\'>P]%$2F?_MX"HCN?7LFVS?E=*RH+>=;N+85(#GD($YIS"=\"
MJ#Q, 53=8Z&NY@LEC!X^A]=!'+O:8_^T&O!E^G_3#NG_D[2(BF\@WL?'EO&%
MD8_F-E^7*U(9S$LF7$ET/IWNS]'Q2/C)94K4_N'AAH-S645D(L0@X*7VD,KW
MB@8;:4J7N:FH0N(8PP]J=27&+%1:VE2:S74:C,;1 4>>)7>OV*+#D._Q89U^
MN^8E5/Y*Z/KK*9STB@SK6@XZ,NIH7P!K./.]0)MW]"WX/MI\\;(H4_8C %\Q
M+Z YO#$PLAK&5[D_;07_I?Q5FYBQ*>\&*D87[*O9K3=&],31,/=W-_W][:A4
M0BP+X]"WF^&0CQ*KBN9V:;EL#6<U6@M@OA)LUWDF!AI[A" I 2J2>7QI5P$$
MO:L11*V$FCU=/Z.GV34JUM!>5:BY!3P&'DLAI(\K@H1ZMJNP-8.,NE'<4V]F
MMT%;\_X/&]N?H)+:-60CG__8 9APMP$(Q/M!L><9:-U8\>07PZ[^ELNA(KI\
MAG-^JX^W]GIUP_;E, 4O.>62\CHP-I:7BA/58'5L5)$2THR+\HIOIGC*&:+2
ML^)6?4CP61=#5M]7!;6,2D#<L+CMHUM^M+!28VP'/'2[&;?2!48#\UFRU&8V
M0C*#K&$CX2*+^9M.Q,SD5A#L!'4FX]/O'1;77HL*F9<#^QJ+5="SU7#UOX&#
MX2S@1V@,3"X[;[-_-)\]P;RQ]'1$0X@5S9Z4QMA'7\=AQ,FBQ//E<6V3[I)]
M+\65# 8_OO&7N%9[%4MRTWS*7X?=$ \?O7JN21K2"-016Q;#=I05_ONK9T"$
M$.O-N(5*Z>Q="%):>'G/(MX>EDP<$&VB8D,3V;Q"&O&FV<M]NP-[@8$,#$L$
MU8#IWMQ_AMG6NLF,3ULYB="MTJTO:N_L^B/>]>AD[!9@8RI+%@UG.U5D 7.G
M#BP5I/?.-S?K392-E%H.>=TW$-,\VA2+"$K;K*UL71T0T1:*5G05P@,U6,^<
MEF[,^>4DZT$/6L6K>)$#+"_MI2,U](V/98@C0P@Q#>7FV/WS5]@ OSLX\CY;
M"%^C0 .I33E'-&XPQ7FIW:ZJJE7&E&"?]VE;O %3@AQ\KR 'LE5%AT>(NX"U
MD!77MKKMC<"'JSE:9IZ4YH+%W.$^M.+^?VH7P8"@\G,*G[#]U:L.OYL/'940
MBZK.DWF/3CFLP262!A[IOFS0B<'+^]G4%K.@G6]V&*_R]GBX7)\\!O'IW8=0
M$D/T+>"0>SV5$MC,Z%$U7D@M\W%@67O.\W0D3NQ:];7ZLVZ?'4K5X0_"08,,
MU2'K WV8H\'8$!/8O;ZG;:O4HJ_PWK.QWX_P_=DMM05K^+$F,PU[%+B>S/9C
M322<TF5!IK\C#>N/E*6'&T_IYP:E5'^'"#7\_GER3Q '9^)!L5Y4F\9.%K)F
M^>]O20/-L<Y; +3LG)M:WR9H_O].]/A_LO^ZR0FK$K(KRH:S$;-6AF*+S1>(
M[67,;Z#6WYMG3,D7XJ]A%%]F7E;F4V.W$2&EQTE;:ZSL)% KNY+%D$5?N2)9
MM 9\0)%JF3?'F[ /20$'M%.X)G@O$H8?O.WERCZ%-O:?IS;\*=L^@&]Z,C5O
M,PQ:.7=H6(:X+O(=7NPVMW^^E%I!6\(C.A4Q-I!.&DQ@/U4EB(^(9=1D27-Y
M3^8]7^K*A'='#*GP:#E#ZQ"#^(YD.!$B!YD: [/V C77NF1KCV>P?LJ\!?#Q
M5U$0L[U=HE9);M?QG7W3GOW$_]LM )%EW6V8(+43QOK'EE[PRO^Z -KHHK<#
M?7T<=I3ES;_F];D]]T][P"'*TW<<7VC]*#*[)NH YOA5!?GI-YBO6OST/)/2
M]8NNO?A,@[0H@6)P1(.=9M3$&BK_]\3 7^U;0+*_$&&O:'-#R9)RB#=%4K19
ML;/1HS9*34F6.LO9$(U!M<U; $#ZS9E:YCX4=WVA$V=7D81GGCMNMRTTNDBF
M41@ 7M9],BCTT2R2Z"7!"_7N@9 %\1 TT\":Y *,NQ*TC*3I.,UGG"N8/?2[
MYE._E&^,)GO\:MCLI]HPDY2>)6&@4\=:@G>-U,$M &_!6\;;^0.H9GTA[E N
ML!PTB-A.M$,/E%3V4P<WQ126)([P#20'#$I,#D_]I$N*B@$X!%9G=<-)/$^]
M"($6MG$P_3)0_9W3#[+Y^W<C+@/<]\M@C5RSEUZ_)^E8@^O\4$@05=N0O_7F
MI?# M/0]KB<,BL,-8!;DF.Q@&.WTE7*1YHEK\$<B7P_. E4'NP^:^6J3DWO:
M@T-!H4O)+Y[F^R+@D?D<,PI4T'LVV//-Z0%9D)BUK6;#)<G<Q[<>Q^\_I66Z
MN^OY %Z3JDD7HP=[V&BMP$I3,'-4#;TY*&;[><(6BR")J#HMW^6F49"3/6<F
MMZH$\1.YC87J*;7F_,XPK=(0J=V-(&B_5[1%5^*5!J*&!F1O&_L<HQJ1);P\
M%.)ZWN[Z-9<]C55^6.D/#G$1ZR!''9@;364^$\8.M!'#D"4S]3'.UQ5(),L(
MYK-' JQ$/AE)+R5&'>="S#^U2-4X?854B;,:W24ZI+F6[?_H2DE>0R_ENWKN
M'$.X:&#LYF174]A8:A>1RM8?RTO/\=7KNORS/&37NRS3PI[LKAB8^@T+!AIS
MBOEFN=?E8+[>WK)4@,C'A8M0OHNAIY&+!,Z7%IAD!W:=]B[V5YAAV,C >!@Y
M. U8&D,TP"K+^+NF2,47U_4\VZ6Y07TS[MNOV$^:S3I;3BN6A IZ?,NE7[_Y
M<QNLK.+3/W&_6_-.9O]3TO ?S*0Y_1; .G8'8U[4_X?NQ,_I@/^JSZGB_>^T
ML"?W9/YI)SA!L0]$K'*$;,674*P_G$5Q?9 YW]=&C\/RN:;M.]0M2/K*DE/>
M*AV$S']$J_A2J8BY\K\2_KG'H'[Q $($JK(S*TA^%*]*PZE7KA!ADA7+775D
M&\XIJYM_,;T<!#']>0N@.%T^BLN^!?0I)EAH=O1/](Z, '7)RE&43+0G3?RD
M-\Z?N>3\CS$32F<VS>+W"FV3>7[>S%[*01TN#6D2QY<"O-@IZ0)$GO,PK"_$
M8CG/A;'>W[!:FBT8W1BQ(PK0Q^=597OUGQFJJRVW,H[5N6AY&.XEF:JROBT)
MNAN_=4@P>'1OP+#10.C* MN*S)&=B*X#RT2]FH4.&&K6W0+<\(_!T/K/$ .]
MWX11V^P^W9I)5-D",'L,$2(\!2Q4A-W7F[K2_P+*W]F=_UO]^<V\J-G:I[67
M\2@1*= OSO+:1^\8Q#<['V.!*%N<O7 \.<XB(*-C9\4W4)2Y#,W&5XTW$GQ
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M3IP3E;:L$)^H&3!SVM*K%W ->#Z^H)$G#\(JP$CPX=T7AZ$\TU*!V>3:#0E
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M<(PRB\<5S<)Q+DU<!!7<ZGF&]3]4K$]_;CAP[KV-.5]@KYB\JGHB!8NX37#
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MQ1%Z/DTMOBE23"H!QQ,A_+$PER\@)WRJ=%18[79+ 1$6LBB#6[$9YCKM*OG
M$$.I8?_A<#7G">DSN7/R-H64#Q'$':U9(00FU'9Y9L*H<(XQY>3 1IJ.8UK8
M-%F?2(>*V/TQ\32M/_Y]"Z:6![N?L3)J'I^\FW8.[FRS1D#<T]ZQ2BATIS_D
M(!(?/LQSX4%T=I\V-S:GGP;A,@=Z7V?K-S'-^U.2O-OD-XOZ<6J_3JVD=:"'
M1>Y.H"[9UI^I4'F76A@_*_!N?.79DDWS)J5+(?7=8JJ6-9W!ZK"^8"*2".2!
MT0ZX5$ S#5" [P!-^S:%BLL6W2A<^$IP'-.75:H\-XO>U3][P9R\R##_VRA3
M/U#H =]EX/8UX%;O4QUVB'>:K$]\(<W!U4-".'RCL4V>/U$22318[293I'.9
M]4=,G^'MEH.WHY/<'_,-=C,:7,3P )+EBAD8@^9*#M"&R9#&%$/AQUXWG55$
M#A!?DP]Q,>!<D.')GQO>Y5(G*00A)+[C&H#-N^R^LK=;[+8_!&]C)H] $T@L
M1T?X$2(EH9L&C'('*<[!Q$ZO ;O=T#]VVQ$&^8V.H_PK*VV3WP,Y_'68,UG4
MQA"G!Y?@3SH):=GY5^'):J<%.+%XD,1Z/C&,HT*S;&?ABA<>\,OI,]' 6D"O
MM!:-,6\BAI2EEV$<CY@:MKLA+'G JHTC-<*5Y;5'05HZ2ST86[;I4U?T/X:T
M?.4UHN#1*N&S,)"#^"!VGJ0/VA)C:U,9!B<^=^*"4KV]=_$Y*TH]1MR<W]M&
ME&(KP2AM('P0$9WI@R,=SKKBP<YG!C/LACI%?VSQ @MK!N@%7"S?-R=9C"3A
M*8@TAOLFR;9)>71L5R^/$V*D^*4SSP-E#9A!KY1%\;GH5=:SH;\>3S\&-5X*
MWRO&UKY7VEC(YI8*>9 3V/+9Q+C5D+;WGB-6W0R&[\!TAJ$X"[)"Y];RT<2X
MN>R8>SB&R?CYO[%\P]A;45:$\0OQ!L (@$4M\:;0/$@36SR \$D,!-\%J>#4
M"V/VF^M9Y@(NS?0OG$H.OX:XR7L%N&[<IF>G@S0Y.CIGG:V7%=< C?K/O>LP
M;!,.1G"8MAM:(4G_<(5+"96G8Y_\J$>-96@.T#*]5)6I(Z#I78@-C:C19V #
MJ^R ?VR_KN_ @[&_";; !MV+#@6W<J^P@7=*L8LB[8:T2<_<PRC9J4N.[.2!
M8>BUHB)@=T\V:_  #3UP3VK5DDK&7#[ZW3SB\=%<I(>%'BS"PA10%1,^7JAF
MIPTRQ!+7#:K$G".C?+R=&Z"SZX=) P"FI+>4D/>]-S*<#&XY!M=)=^/9,(6L
M'A%TLXIV.)+)32[*W_/G^2WY):[=SN\V!@DO]S\G'Y(1N9&W^60V/,YG@3<&
M<E[9855&VE/S%\1._OJ*SWWXF.$(WB9\%)I9417'9(0/K.NOUB:-$0X4D5)!
M<78UC/U1__D8M(NYGY)3$_6M.#E860K?;S7=Q=M9%TNP^1N[=U':B+-(KGH\
M@<^CYZUFIC83VEA9I 712A5!T;?RYW[@Q]=]$F%ZK] TE.4#Q.F]K,=IS1.U
MD++<Y0NMC==35)W].B236B]_#3U.O/O6ZHH;[XO1U?,Z(#!A N!>HB+<C:TS
M@1=\LUX.BZ6,KH L"38,BW6FWPV>!?U0,P.##O@XX1I )^?R-V9<F"*DR.-3
M<(5FTY+(&$[6[,'IP4 TA=R!E HCWD$[_86(#^T+UGEZ[2=NENIL8YD&G]Z>
MJ6MBMX9"AZ 8H6O S6W;QSCO3M2EKG:6AQV=!RME2S9"?4P\*=K"ZZNV6C7C
MRQ<?C=@W.[2N 2[JTZ [ZQ,*_6L\A3HXL0^)!^4>2>YIU2RC,G?&29Y^*IE:
MN<6 Z-!:MA&+!#%A.!2L6^<)3IC[M3:=W4M?X)(=:B[ER[5[@X2&_1FM-R2;
MWB1/.+;E9EZ NL %*3X+5Q2&N5G="YASSE<7C$!-PVE%KIHU:V"QT1R$NK$2
M\2!J/7$H.3N-I-"OXO5!8HLV"S_ ;/IDJY"BB^DW%Z7/"?[^ J8+.W%Y,E3D
M4MJ</%JS46 D'#FUR?78;R+RQ9T"[3JU6O<C$T$Y_K;FAX>]ZO^=]LD_%JGF
M/Z(+XG]KA]3^#ZS%/RFND(,A<+1\]L"J0K^#)HXR@G5.4L19Q'GMT.I&:.D,
M2_%M!W%^PNFD/T%)#O.CHBHQCTM2.\,X\S.&=:K7@!6_U2=_#8A1=,&Q(BV^
MS7IAK/Q?H8X;PMPP.7(.&85R _&4]LPC-][R2-D>K<<DP9S0W:0[:X]Q>_G3
MV,F2[--S[_3BW# W'!N/9&Z9\Q';F[^N4F.=:7/D]%S(R=;#(WR<$'MJ",;N
MKBO>Q];"^VR9<<GI8+'3DY18*1L#XP+DR.$1QW)C<Y=,_B*E69!&.#$(4HLO
M5,U%)5T#WN]UB0*3T0-J#Z(*^W>2!'@6-NQ+-%_Q%H'Z.=?I/\KIRZ"[?E5T
MC=,@(J9_\B.D0R*\I[N]_:%*O@6^9OH=[[TM3[:O#+!\ 6UIN@8[L[C%*XH=
MM?X"XKDF)2^0"*:35/6]5E:(U^ JY#NW)-)',BPCD^Z>_5A/Y90UNH,F)H(:
M)QT57.E>((SS+."9$WOWL*49>B$2E2/ZYEM_6[(VOW\CW1OY&_%[OVI*35^:
M@A>^-]_*GQX&&J ."-Q7"KBI.)4F9?@U@$QIHG1X"99?Z'PH\I+2>R5X?ZE#
MUMJ%_:2&BFD]^U2SQ\L#!3U=R+TL]:A:!KM=9OMDGR[QAZ^9'N471#QN]5Y>
M5@QNWXH+F*+ZN]^O 6YKFBZG%ZV[(J#O5Z?!DR-#"GE<8TW;8=H'VWC7]VDJ
M"Y_1AP1:G$R,HAYUQWHWX^)V]@*K>D%"19*5MHQONU4TF>1])S4VT/ &;R5&
M26YBYAK@M+0+(JL!1NP,!;.6KI6C1Q3-I"L#7W<Y:"5Y3]PQ>4.-\8YX%5G4
M@P@Z.C VN7Q=#NX-8&J(<4C R?2[$K1Q,KT18FDX!V76]R_B1%A75/(6A.CV
M:5H]!;F5DH.#AA5+NANS"ODR,5PTM=4BW1^:ES-F/8\[@$':Q4A2.LGYF?V^
MRE135<[O)*N3S/$[Q^"X(!E.YIF3).^9@[YRPUGJS\19=7?B_>5:@:]M6J\!
M65%J ONUY9U!])VE6F[AW9K@[W*O1 P$?W1Q$C1S[68V<9H#KG5-2:*OQ"U_
M(5[49[^POVW7K/*IIT[N87S5 .4QY#%VV!#>);8&A&OB;@5)AT(@S2WU)5/V
M_!=F2P2D ";WN]&=FR]IQGHPS:$,#*(UA3\;N+C)'WYMD/R?S<G[/Y-+_%_,
MWOM/K/]$$\_->(&/$QQ]/G'SST;9/FXXLG/-L@+"_T>T.0.K]:#PS$!:\3BC
MXH I<;IB8O)2Y?^Z6O3_J *;WBQ^^,(:S[@^Y@51- BG]QLE*X#W0_V??4\V
M?-<^I-HOP,[YM2E*;@IEQFV4&,$79L*0CYH(10ZR,B1#W#@&3!=2A:=+9ZDH
MBPR>C/2(%[Z6L)2BLEC*_@>/$_E?"?T:*I<AA',4NIL:'[1=RIK<>9I2_^%Y
MT2$/#1]F^2</9W.W7AG$U^;1U[8#(N"!+CZF>*IRF\2Y.?H0/?A]M!ZVZ.BZ
M@8'[Y7&>_/@!3VB\!3=355>5.FENGNB$0>^H*_6^HM1?ERRA_/CE\,T-?HYJ
M(5U<678-L-$&N]I4BZA-8&A:2/TT8FS1_RG6.T;9Z'@[)51XK2C ^Y]$D^'*
M2K^+C\C@0.6M._?3M!WMJ^))=.F  &K_)W2&S^.-"WBS^"UX BEK8^Z__:6Z
M+_ ?Z&QS3@5<RV?L5E_V&O<\JPF\YC2DC'[M&J 8G_ 6N>EK=;R[YVMCVZO.
M0#QX"<EKP1GX4]*MJ&23:Z$L-8:"*I3T;\AR9D0;_*==#?!@N-/ =!:FAKT&
M].0$U0>BQNT8D"N:X*K%[FR_;ZI$.J^B#=9#;@,>;0 6ZU[7FJ%5^FUXT-$Q
MC/E5N=5N(N6Z'4IJ!I]Z@YWDPY=>?0R?9U'^\DZ5I+GT 4NYV,X5<UP9QC&$
MI!.E?EEP=0^DT(HM@U2W)*&5'%TML]Y6_#:R'>3_3)\F,AOA+Z'Q:_IG?![M
M8L_!!($2KT0Z6$>#3[? V<6#="O:@3'&+7 ()+ ZP?QX3C?[QD<-3,#GT?$-
M8D% 3YT-%MR3$$XQ:%KP8(%@5 =$6GW3YH%O+O"EC-=3/]JC-_SZ,,@NH^U6
MZC##3SM2L(N219.>'P%8/(BD::;2M9UU[&J"_]2:V><)Y,]\J.W@(_+=Z4GJ
MXX\W>H<\.HVMD^$+>A'7@,*I8SEK+O&S@ 6#UBV8&IJ&$?@>Y1R#JE1\%>Y5
MO5UX-[W/8>#'-ZO<6,-54\UA*CYV =)W(V2CFQTJL;9$*:<ARLPXGP\G>^")
M=*L&>+.-BO'<5F>":3S:\*Y$S?=>9YO>3#@S M@K%8;AZM%[?,4*).W)84P-
M\RU20^?*B27!DN&Q*3DN;6F&1]XK%XF?UPM6S$R*(J8>6>+3=>=@FA@5.ORB
M*_RR7*=Q?M_AD>78#0HA8=<NSWBR_B[?-$V^&%-&/26IF>5K@%V,ZD.=TY9V
MC\6-8Z[;8GNDF&XN6WRCV=Q0*FK/Z5A)X@D\4*#F=<Q8LK3,RQ#1FD,%9>/Z
MGA>/J('K, \TUYUM+K*(1T .F%[E6G=4X"7CE!Z.K/!2TFK5&J']4[$X&SB0
M&)7RXHVF^YD*,X@4NJ!H%((VH,&7VV*5&RNX-2O&BR:8X_'W^II2M9*[7B<3
M15++;A9T-TY%WT5!#M[-AQOL9I]-NP<C,K*Y=7?&2PKD"$M.@?<_Y]"3_KR
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M-(B45?K<1HK L/N"RZE6E"3KB[V0%#I+_/OU[L&)X*$<NYAF&@:\[J"AU37
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M^XETV58>/VN% HN?OK5.' H&=5(_J2W#K$>4UA)$X""1.GQ];7,2ZR9%)]<
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M=U'8T>PBCBGE"D 7X_OURP9+JM8D/8/*2"I 0IM)*B IH<Y/Z!+HY=K;1=8
MI3<RVTNVRW (H8EX&PZR?";287'/^NZS0<V/5N$X5QE;'>8H^KZ>:U),?9F7
MKUP@TUZ.X$=S,Z] PW:#PRVG,8_^K]&C<0>C:1.;)H(YMO'<F79\IJ#2[#,L
MWLXXYWR"^=??I>=Q&)FN.P',&"DSU-  "X79C[V+U :QUR9[FX6SNHFM.:PM
MK#A'?>0/<H\#PO6W^'*[,QVCZ"/"L=)K-X!0F""JI)$)2UIE=\T%"A@JZ6T%
MD=_]CLM,\/6'QP?\,?6 ;#V#93:"9D^H(P_$!;4T7/P^3TN!:I.IY_]@,_^_
MV7]=;>F_:?_Y]9*G'B'KXZ1KFH/'45\P)VBW)QWJWI"*7:/E/:KF]C#(O!!^
M!AY._YNX6!=Y*_=MF\$; --F%X8)>4SG1:1\VS@UR2NK;SIG)E-<Z;R2C;\C
M)WX7OK*68'4XN?P _E%S<'B,>/:CAZF??6.(&T\'0Y_1EFT@6K1>D^WV;2A9
M13@GXYJK7X8++1I5X[6/4)Z6>>(5@G0_]6H;-!Z.Z6\S_<3;[9?8'YG\7%R7
M5_GUU3U/>M*!+D(LWU5Y@! TNDB=9%4[4\5 9"GRNW%]22X)9.7%L[B('WE)
MN9G3L+R&NN8O,2--P3Q>)\96RI169^)47[U<$5F2+'%^WE 34\Y\TN@:/G[Z
M$6,GZM6O3?'$16E2IYM'$WA"\<X92_L/D^W4U(S1FHU=. +OV6<TH3O825;4
M4,P&NGE -K*+$DA6"BO/!ZU0FG*/!#Y-$FG'Y!@.I6?1Z(X,M+?:WWU!BTJ(
MN0$\O(6P-->3/JF;JP,0SP'8\X[:>+4$HEVR(?![BP =[DE"A4YRWF=C":/<
MZ!3S_"<Q]-R/0Q5H"0L!I*KQ1#R^(.LTVL?1*O&[3 _O;L]%[F.FPSF?I8OQ
MSS>/;OXV<"G8J ZXG9_&?M<C _OY*!#IA_X%8)G'S6[3F3WC8,Z*1R *#3XO
MU6'.;QZ%D._&M<[)=T0*:>*$_]1Q:]#_<,:"JY$QGX+@@;R$&)LTR9\[GT>^
MTC*J^M17Z[CR4.A#R HLW,V0+&E6\EF/'AVN#_W[QBI1)UY1-/O#TN5X$<+"
MG7LVAX7O2\J- Z=7RP/&5_T%7-<AKGU&:9VH]/Z%C,#SSQ'RF.8RNU]]BG'L
M'=139E_9O;3F4K/%[@/@WO&-L(4UTL@5#E1 TGMTX)#L0Z@&U#$0+_O=N0N1
M4EC'0$L+CVWXDV\?&'@9MKIQMV M919US8W>9K2/P[8@)\*VE.T^6>ZR1EU5
MN\VE9^_\$W+/?N4H7&KM7(1M![L1FXVJYQHUH;8C[=U'KP07<4;=P41BGRI"
M_08\\9=61VOPUQ,&90G\?#%@KB _G'(E9"ZE5[BQUZ%%??1+N)=A$GS/-6@C
M,GA[BW4;APF\1Q_^CYICWFW_R9-E,),^EGQ3?;A=FGD[V4_]!I 2CN&[ 3A#
MK]A5ZR]U,,9OT!'=DV0&MN<)Y::#$"A)-BWNBM*]?E<5@J\2O+5? "X:^!(]
M9]'<5/HT]SE0-X#,]^*F*C)=FY8#>5>5,HS@;[O4/AP#DU'N,9>1[V+ZX/Z9
MTC^).UVF^[^3$<!.A1[BK=Q'?LE$BD5</PCX=MOK-M U>3G,M6B.DL^>Q7LT
M'ZH[NX-IHFW[/W6[BTMILC^#YK'5-T=O&8<&"[=\O,->\4%J/2AE%IFV-4TT
MH- 2+C%'*QGU\)D>$\%DH$^Q=D:;ED= 0$)S$C^Y!V2O(R$KX)[=^E N*4S*
M?#>MF4-$EL(N?)KNG56:+ICH+=WW%VQ.\!=LLL^J)X.OGTYWN%[R&>Q<$._9
M&=6D(PS<,O>?!)U6'\V/*7YK>T@ &5&46H_^Y?,BC_P%("4E_N>FH>J%N^81
MP8P=//?QWHKP%%#W$D_)LMCNN9G93H9H7*F=WF@21_&8BS';P.-$PB]6;S$^
M^E5&CW.7B/1<"IU0')^(XU](ALT')F(KOP=_4 '<U="0FOZV7Y*AYGLM>@-X
MQ.T!:EY"=?W.Y<7,=,,3^HEMSK-1\^&OC'**WQ?])J!E33.OHVA(Z5YY^(AK
MH=H(#3T40*B[KFTU(I;X<'0=J4U 0J#CM=V&5F3RU!AO;%WMBRAR$K6CP6]2
M:',U,V/_N@G?0%%EX/=%X'=C<(FB8&DMDQST02=&!*VO]ZT$%9"/5EQ9[]5Y
M!2F9#?^HV"S22FN;X?ALJ 4Z\GZQ92/+NBG,0&-E1LVXRZI=9@FT9_-$59;4
M^-KS>,L>@_.J RUV$(;H9-%,'^Z:!1)!0([\+Q;9,WPJLG)?*CC+$M\ 0)H1
MUX08J0*,K\&I\#&E+=S-QW0A1*&P\?+'8+!HM+C']:DWW0,9G?9DB:$I2<XX
M$&*9ND]U!D%]3BV*AB_UWW_$ID!8F;(#H)(R-.Z<-A4F$QGA'_B4MT+SC;FE
M2KK*=#9UQG-EL"-9#[0/9KZ#%NI_Z">#&5TSCX(]FCDZ]&/A#'$N'.=-=)!D
M&JM3X!X6+#D,2C5Z/**,Z^(\SR<_Z",[Y!@?2/(>Q?=MWMZ/2V3SNAH*9V.P
M)3=V)8=7=?!TQ':GXB)TI".A!8;RY7J <EK67V6'$-;:((NF<"DO?2G+J)=E
MP\/=S#_GK))GWF2LJCO.;'&IK_J+R4BA5^.!TFMQ-D-&T#"L;SE6"AV\8C+I
MN>;OL\A?[>Z;]=8J^BX1F7.C$UIB0@D'5S\?ZXCF 96C9 ?-.#_LZ.EEC'E*
MMH]46<ZL&-/IVT?0O6:'? ;BQ")A0<G3]TO#O1_%;47(F,3FU5E9'$K722*+
MWI,4&]PML@A9J5RJ+!UM_FW<O.WLRU53.A'(>+:*:^(UVGO1>0.($<F-:(O-
MT!DMQ"![OAF8*K#QB%2F/4A()%>OJ<PA8$>;0@^6UJO-AU;NS_&?@;^*A#;,
M\_-6N>^#Y<',4/L@PF6"BP?UDN1=3Y\G\\P>0=YV!.6W1'&%7?]T*7LO^]I.
MX74TU0M"/ !3!8>NI%_:->QX?N")B PX1H%2__F7_P(]X.[_@)'$_\DS(,K%
M_$Z_.L7N22;_'PK;_[JDAX2Q8^72NSUAA,$\PNW,K&A<29[Z5G,.,[HB01()
MMF$<ED-]L!G=I:[!'OU'<\)JMVK-2P:M],'SF'LW@,7YP$>P8>_PDZ7P"WIX
M[)NM%*&R'Y9NGJNTUZRCJ';$U7'D6KW:;[XC^\-^<HD7?I=E>5RLS,':*Y@!
M.Y#D/-1[7?;A;K.1E>B%PD=1J&5 NO*)24>P/'?#BZ.$MV]Z+,0<_E2P.;Q\
MA:%!,L>A*DY.33&Y-X#[U*G,A<6_X8Y8MO-SF(<[D457AR)OR[OJ(=.68UT8
MWWX&-!PK?ZFT1\\W=BY6:[O"H-?1Q-+1%):#L$EU7GX,HB6[@N^%$8S<5RA9
M-?4=\/9\GJI77(%MESV1*3(-_ -T9$&?FI\QZY#S7/(HU*=E<A2S0 5!OQ$8
MN &0>ZEB#;^#VO12WP>DSZA]:9\X*9=/^8"?]OP,BG=5?$V(Y40%'HQ6@HVH
M<K(+3/JL9.M%1FGN;EUM +P=GTG5X%88/!QH83^O@6TCH.$RCP/F5YXQ<TU!
M1'9X.X1*A47AH>]L=7/4PO@M[<LM[MR)_#H\**0J7'[2NKQDEEV]O452=%2X
M>W$#2/KY3O)K]$[/5+C\TZ]L\Y6@B\[XJKI,AB7?'@K[Q*61.GM'^9"><VAL
MXU*<9E\@$5!NK?.!%,:'-)JM#VS#7W!>SOR976O\W+P!XA$MFB9'_4+<\/D>
MN'$:QKB?0X-)7X/H*&/\UX[#!J56ZU9D4I& H3?USV$8XI;&2'56*:L'*F\W
M<TU"4<,\K3Z0Z\ M$</FVI\C=FG:)@3D1WA9]4_BWFOW0U=H)URD+EY?%'_4
M^4WJ>5>]0VFSH8+!F8XH]HPMD:>GR]HQ8H7Q>@D3@5R8.K1&<V$YVP[NEX_3
M>N?'FHHO,K"T$/ EMDRLYS32!/O=R]L/;$@?="1;M=5KFV@M6MFU4??-H^V^
M[8:)SYX??55D%YC 4\0'ZCE\?%,$K;O2/M[2+N=,:=J&_0!34WM^,9STA=S[
M<0/8J]Y(U5.1\JO0T$3H7)4(-/CGCFO*WOZ./$[+S>(3DNO2^UN:0>9X'??0
M.FO] 4_1\9]MD+(47A_47*OVC3[@[<VO2>''2Y"..SSF:<#EB6N<].(RF_T9
M&,YR/X#73HS"+-#2[(<M?5J^E(-O)[5O23!/%*E_;-JT3<N/96+COLJ6T@J/
MI9JNS7?^E7401^C7B^/#UU>E!]=V_H4VGS<=&,ZW&6H7Z-9%B&NJ+?U=G1TA
MOH[.SO9+7-%/=7/8=KH9RR\6QM?[?4ROX]".R*/.\]]NX"Y,B;#CP; 13UI]
MN#G;,QG%^8PC)59T7)FFSX8#4, 3M834[[F,T8S(H<> S[.=W7Z VO);9X_S
MP-Y^<RU/":NBKJO2;#Q(FW/4B8A]*_<OX(>.WYC ;M<UOF:9E_(@G\!@K#%2
MD_*36[LT1;\GG!&$XY#L'K[S(I8J<I3\3:*DOG.95_KK6P27V2?:9II=4UA@
M)PNZ="AH3@IQW,Q[?O#'EOIXJI1K,YTX-!GKCB"FZ9>MSQVHEM>9X8-"W2:9
M[0[? ]'A8%?.<OI6^247E'_E0H<E(ENL.Y<F@!#$3#<-J>*U7U^(J\FV+W@2
M(E+F@O^V]7NROTHUAV*N^M6Q.M5PG(K["=;P2,AN7O07ZONHKR/5P8B9E$WJ
MJWA\[<JLI)^EJWNB&;JM+9UMX1. %X*3K JX/^F ^OU=)!WW*_U4,3)^<A5^
M JBN*/>XMUQM[>CP4J1UR.OH-:G@GKA"D:YD?=M73C2CS!N_X+^"_!20EX[A
M1N&5-*'73_;;%#_< . RE+-G!'"&J4=QBOEWK-Y;_Q8]<E\ZS7IH]SX\]KV-
MP)_GEJ6(]2"F OM'V(2RI/E7^HHDL8)T&G+,#7LGJXO3Z_(R..VUWQHZU?K0
MH+;B\>R)J'+-;=%,IRJZM;@0P=_R3D\;UA\\CT_=TQT2/U'IWXG94@G[AR)E
MMWBR\"]\:_V7IM"_.WQ'U_9O %<O_F^:0K/_L93_BMWA^$L^R(#Z+]0+H)K0
M5S+9_!>,[=T<!Y/<#7B(?I7#V/ -J( <=R @W]N;[&L+A!-7:6@,)GU.4CP0
MI20?PH^V+K^4QTBI8 S!:#SCF%+4P0(9O)VC];1Z$^17HL(FSJUU0NM.*XX?
M^YLF#O:T>G7 G'9G11B37N8G./TS*C]&;5KXT[OH?=W0?I9)"J"+<&9676@"
MKB63NO<-("*J]2K]R&\'JA/8O_-+H2)Y02U;F[=J<9_K5_VJR)X2,;-!*W\E
M^G> $D75T>$VAD7-2_,\8@JHAMQG(5[9D6%'Y126*YZ (OJ-/!<M9^\2CSV6
MRMPB.H7X5\?/_HDVO_EPA7<8NR*RI5ZA26/=1\7GC??-B0V(<FMY'D"SQD8J
ME#>><$0>&@8V )6!<BB'M2<4I?%\A8;XKZM!GBTVWP[I+O0?K0E$KC!A2-=S
MHWRX$HXM4>/SU4B>.$_-.1'<IWB%(,&2[N0PN!%?.R%%TI 9^,E,:#K0TE_T
M]_=F":Z1U<D-R/7D*CDD@,M/%P,MWVWV3-Y5A;]Q@IM5]I\G$WE3VXYICMDS
M*;^-+^QTEV&]RFN0QD<R+01;3G7(5V&"YZ6\-R-49M1[V;6WR85PPG37GMO[
M(V)/XVG.[= >N>M=L;+T(H?<O;Y,DN?KJK;T2!RB'T^:W2D.6!^R.""2D@FD
M]TLP/M&!H*Y8DC<T] X?<"P3"4TW D).2K7)=%+GAT&_!&8?<:XS2"]=J3M2
M87VG_:21,9,DNQGXD1V6E=^YI;',C+4T=[^*CT29+E,^9SS ;9(8,#>/-WN8
M@O"?3$B^5OK&%Z3R(>AZBG&I/]#&5OD'QREA2:]0&E,\>+ORS4P @Y\B)N;M
MNGG4-2<&+%H*_0&6]%UJ+!*5#*OJ(11V48-P[E(P&S^U_U ^9+0TW0#%Z;N4
MQ2R\:35G\LKM-7LT#UOP+S,;HC=M8H\*;+ P2!8EPZ%T<5ALWYB8YLXF8&_>
M/85=FX56U$&PDV:HB"%3H0%)+)QJ(:)# >'O#F&^6-58J-*[[_CH)4[#/=.Y
MK[RMIDOABHH\21B:RY=V-P *K.\Z$X4.*J>UJ,>RK$%/VQ2TH@WO?:1XW^5R
M8M&@UJ)EI_=+ !%6N;4%4_L6X4^$9,'R08G42DQ,-,LT'<+WE=[;8HO3MD1T
M$]72& P<1FSRZ)8PLDB(T L,&FW31Y^*- 1?U#12Y[^U%.?^I7<#>!<CJ)04
MKE5[&C(XDZ%=3%M>8Y:^OWI,GYD2TV7^;7Y*UBZ0"!.AMB"BQD33/[TKR==X
M-G!>Y-;;-,7P^I#=# 2I?O1FY(/R[W1VQJ E3"'2(PDA$,$UV#SL!A</)HK[
M,D@/J1?D]BL*ROK:NCW? 48H11SYJ5U28Q*49O+)]^BSH5&0MW%*@FH<RWNL
M6!4M$X$!1SA%3P['5=I;U$IFF?1DU,J,1D/K5"@_O[W9TSP*[SW]7V\)GXTZ
M:0 F%&0K!]TE++(_5EW=.S1YZRV3+I.$24!GOL(X!I;NZACN9?R*=*<"\0E+
M$WY;-E.CO]H5W>#. U)[:/VFS\_S\YG"*A5Y!8--*?J?[V>0LZU@S/QEK2OR
MKQ$&:F_[7,/UN)V\:R@&<CAG8,37,YXP;G1HG"4"^A 3L*I>MV =F^DK@?B\
M>%CD).O!*.YD\$&9#>B\:TXBP^?EB<RIK!8+9VV%S52%:G5%4J^^SU[*[A]Z
M$(&GG?V501$Q*1);7M:CEMIH=3PS\_/(MN1'1M?7/[EW-X"&U(78 %*[:SZT
M>42COZ Z.?SB^GS#X+?'C,*#F>LC/+[3KU$/]1C]UA9*O?Y3?[,@=#>AT;+6
MFLQ8X=H61?1 <6DDA-]-_QX_J_>1PYCQQZ"^^Y:L\23'U:XL5%VVFGA>Z>>&
M$7T^#GF_9+A\U26GMQ4?MK36>I5\4-\N-U\.?=+'UR..(T$UQ2N9;:PHZ6J\
M8571TGOX$ZL9B#X^O)/OA3]$YO52G:6??CO2>F9&)WI4?B9N!DC,GI2V%@MY
MGG74O>FD(EZACF9XA=)H1D<8=<Z)C&* ,O/I]&&A+5[V0]\+G9JBC0N?DO0E
M9#7/5RZ6R3:15'UGB CB[9:^ 6P\<C<S1LM>R\DV#EWY?K\![);03U"NP1.2
MN\8+BB4X L4PG#XY29=:&!N=N9]@WSB*?KAH:O4?:1<VD2+JSWI*5Y1OH[TY
M]A\&CM?D(_GU/=4W@$A91F%S /@\A\54S! M&\7_]E+5=H6Y_E*]5SX9N##*
M_=C*DK>/J]B9I>%]!_CR.;RMH-)8,Q_(H0ALNG0OV/079P\04=-!J^=V0^%$
M@P&L:/?&#1E&-"0[J'8!T9",)#+D6[==F=?D4^-$OHI)"DF99'PR';H@K.\O
M!5_=QA!/:$W!X%>W'^=I3G+;!,1^:FC_[;"&2W5SS84#"/'R87BE%:2X\:Z"
M>GS1MO./JN>IW')XG:(P6\S[]4J!R!M XSRT!F1D.E>2N$)L[&OZ\F@Y#Z*@
M_=/ZO=*=IKL#=UAMWA[&^@L8Z >7LB<W1<Y_S$I=N@5ZK>,O_R,\_&L#CRK%
M"*Z)]16[W/Y-"&@W_+?0 *3WMP/U+^AF_P=$!O]OJ#]ZLI$=CXJ\:B#,IGHS
MA]H@FMWR[[G/9T9:WKCI_U9>#DL:9&#+R2+\7I !L0N=^_4<:XH@9AOR>0 7
M;06='XJ"'GU>.V4&=F@7U69_E4.LRR]D66R0<X<=!]L?\G=H5=N>B^:BDL%I
MSDN3?)<J')U#R<D$U*\F[I(^[X'?>13O&F0J33F;H0<+!DEKQKJS!-' >*>M
M47/IW?N:>&":,@@4^.JB2I_>(9<R]/YF78SOP['VX(H"JN5@YX5]-7.\G7,S
MOEF@)G'.N,OU/,^?ESQ.8 IXIVJF/6)I'%[@;B=[55?PV*5NZBA=7%=-4!;B
MI,H2^7%?:$:YM;K9\@L?DYNJ^%8LF0BII@M)/A9*[#]$"G>; -Z0A8R_\Q);
MPP\!$D,5J@T65U;L]/:F%B<K[?1I!D=$]Q*])U8,ANC,E-=2S&(4; XY4_1]
MTH<95@9EP_UNG2G)])+O\<Q!TA[-Z9XGVYCG*3^GRTG7F(;8<RX<@,?=.*Y>
M>L4P*+AM/*XTJ1R<K"":+_OI<!NHQ:N57938HJ!U$I1EM7%J3/GF5-K]1R7;
M2(?"Y3,_2;1,JW?YBNT"F30V'/)R>E2KM:D!YIJ08<N6I#7)F.6W.I!1BAY5
M6W#$$HOUY1)X/1*H:NP4^3DW2Z_\=N9GV=>37Y+4I!]U6N\^'=:*3ST0UJMH
MF-'0.(=O2#K7JZEE!62C2ON:NHBJL'?<WU+G([[RLLVLP"V<N;F#6M8VGK-Y
MK+FV9VUG;/]T7(1V&\G4ENP=W@;X&8.?G=*IC>*K*Y9-)QVT#+7(BA*1SVBQ
MN6XH9?:[TB^C4_7LSE-F_9(\OFWB]W81W@!Z1: 8_X;(C:FS_<S,<=5I0ROW
MEC1$S-@BK^J19=93@,> D#)&"Q%'AA4^G]=I@#'2L/V1MG6-1"H#4:]:0>R6
MG'+=*\:VW286^J8*FL#+A#3I!+Z%&X!U0L0U^_RQ"$,U_]ZCP$<9U[V3VBW-
M=;#$>#-;-J=X31>E<:QA]20=E@%5&D^A*M8D^'UY]^GF[@)<>BR-1A3T052)
MG;>J_ />2I9;#3P:"M;1]-[A5SY_YD>Q9DJ!6 G.D FRXK774_P<E+3IS6Z9
MEK0\;//.IYY<W5%+P7HII?TI>VKB/](8_2?7&7TX;N/H+"RDANNB?I_S*=,=
MJTG3TB;_"KO;X2J_K:X9IJ#VZ7&+@@7B_8ON9SO>QSK_BF8>+AL:KSXN'B,S
M>?S%J2[/@M8-^*N\K.##XZ:&X'%3""+^G@=_KS A78*V\^I*$9P(K_L'WIUC
M-04 %:5'HCQP9N@!2/C[*;ONG5P<'.?CH!D1/DK \%K\'DVT[;1!UMND6<$O
M/UG/"IXD$R0_2;*,H^0N>' /)P_G2^G4B_L->'Q!+;$4*X7QTP0V&5Z(.,Y,
M9JOH/*$U"P=IE*1U\;\QYTY7(W-(T"7%-=_!,$*TGP_?9@.QHVA*!3RS6A2M
MAO?@:U5-/"G#7'T\S[_()YE.\;GR"(T'T&%YY_PDD.K& RM\"PO],/[9P_4Z
MT.'A]3C8QCYV[(L<\Q8K];NQ,16NZ4[NZ*<C&@X';%145K?.EI/[CSN1?Q_D
MA_^NH0(P_1MCHZ'R;^N0>0_V_@>(@G^:I.3MX]E?A(T]M;\6(@&W4Q*3CA::
MTDRHL;DI*%/E7>;W5X2'LEYI0[BN@[Z$\]EB6@W9G7]LBZASSDVTM79%!I(!
M95'07D\8.UHT+\,CU0YOEY;:QK*WX,GFIYP/@:SJ;JDGZ8?3\[5@\WO%"Q-
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M_^&6-0YQ8P(^*]E*.SB7!>,PV:<GPYII7*M.CNGG<^Q8>Y<U\B+V$8M7+1O
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M5^JR]7A.Q;8MT1L_IXD,/"C.\Y-#?X3QSP#ED"QW,1G(1_>V\A&9J_4B&Q8
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M1XTT>'&1Y_.J#P\9>8)Q &-""P_\P48ZKS-2'CMOQ2CAK#F2>)DKH_D:;V%
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MN8PG=_^>F^6O%"+6T8#JOV=7^M\*_J<K$.%]742HB_=-PV?VX^L[6NJ.3(/
M@>7XK"3M?ZZN]K^%_Z/"_V7#P;2*U8-7ASTK1YWKGZUW_6\%_[@"@OSF^%49
MH\-),Y5RVW^=[V1O%O\?4$L#!!0    ( $. 7%I?X@!DR%T! %^, 0 4
M;&=N9"TR,#(T,3(S,5]G,RYJ<&?LNW5856_[+[@V#1*"&^F0WG1WBK2P:1"5
M1KH[-Z&@2(<H()L.::2[I)1&4$"ZN]GT;/#[ON^Y?G.NF7-FYIJ9/\X"+IZU
M]N*YZW-_[OM9/.OFU\T<<%]97DD> (% @#'R"[B91SF7\[)^!0"JJ@ K  !8
M !I(#$!!CNX# $@YS!I 0XY!R&^#U,^WOP%: $ 9V: $,)'7<)'GDL@?@'+C
M[UW_ZP  10L7>Q,'=EI5"SL3!VL+ $"/0;WS*!CIN?P8M'^/&^-B[\:HO (
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MUR2 BPI"!@^5$) "#I0A.T)XBQ,KU*&?C.2]%K+L[8Z/J2MYMQU$J"(9R1A
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M(:F^8_Q+_I$]/>*$&Q"Q:)E*K>R7)=(B5#(GN:.$[-8K[:TQ.?@R4GTI?WU
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M\A=;_K4"H\314'"3_ 4%9?3>36%^ABBV*=+[Q)//T#OZ*^_^/8$D_R:1?JN
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M%OV*@1)N4^C)SY=X-*)9)SZ/,V63B^EL,;_R^;]G/-XNV>3K8N,ZH'E?9+=
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MS:W&!/WG(Q/N PNUWQ8RFG\NW\'HVNI\OMMQ_!0DZP^5%XSI+-?.9K\QT#>
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M62SO7YO?=Z1&I,I57WHJ7&3A=3RO8S:=XIM1*.<G)^)]H67*AH&&NZ C^[/
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MV4SW,(%HU+OICVWUS>D;/);#3C"<I:($?0\*_'!?I>)=8T1\89*Y=:%AP9P
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M*\0 @OL> ZD"<CZX0]%>^TJX C_,^&_(;_ IU4G,?7#& T"FP)+S+GKY)?B
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MLYH/11,L1MI/CGAC?"V:?!S0!D$>1-L]-$RILJMWC0YJ>2O;.&)M4L= "O]
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M+P*SZN:1$X2_B==L GKTK$\^WJIH):MM4]#]?_#VUF%1=EW;^"@J(DA(@X2
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M2",)HBI40]P%IQDBY3^?7=A4:>!^O5HH)OL#FZ7/8FB'W=/5#R\K0NZ!VE>
MV[3R&:W.8\XUE:_M40<(YTS=YX/KAMEAB>YI:O-OY-<.Q1=3++7[GAD7:ER/
MXM2MI0@44BJ>;MJC\ZE^\; V5VZ#6Z[=8&>>%1Z'N>;#D #UNRPZY43INH J
MR?X'+XBX#8'M:C&UEK25IN>-9U_7><3Y/,!"U\H6T*B9>1=+I[OL17Q!N%D-
M&=4$<HI&OSW&IU2X9I7GR\T:^BZ3:V5UW>7.1FO==R1 9N\]C=D)SU66B9$X
M+;?]ISZ/AZ7&574:C=R6^(?]9'6W(N:=YA.W5-:6_*SF=1N9"Z2W&-T[00I,
M&*PNF;8HFC?\[D^-[GII<!0\<[6E#F[#^%(3/C,)SO8PUZ&ZE40"(A-+D8#I
MO6DCG#7/ $':%9XZ$2/U>L4#U!\?-6IG<*-P\?>$3S@9&9$?>%5 [S&'1,!@
MW;>3%$)T1_V91]!2*F>1]2N-'XLDHUE:[S<,$PBMWP<8DMI- ["X-C2[?W"Q
MW;XSUB[49R.]91J_Y2F><3ZT0-<8)V-2LW?)<=M[ZMYC&!AGNY8W;Y=R+=#%
M%%2UGNOY=3>78&W7NL%7D/3*(GW&M*$F5'?UL:O\F#8:*RYV.[=@.PD%QI$:
MU7&9.RL2\.%("I5:D "XG]&MT'',5@#4)^]-V<(.+ G"63WQ..9STH%@0&IW
MK;LM9]8S4M'XQ@@&[D;:;0T(SHZU,_&-'0)7BFZQ2,<T3N:LQ3#@WA:?RV>[
M$->S%*8A)&#ED[,^(G Q$97*AE&:6CO0YGY-YG&.QH'K:;NLOP K44-HDQ'?
MEQ5IW%.7'E)24IZ^Z6&'&)+\I43HJZPD"_W)8N8F@1/6=B='5^R(W&UU>%,A
M'6Z@S-%:-_^R<2L)]W=H_IO'['LB5SJKR7RRD+[ZVDD+^0\]W(*?M3KM@-BW
M# Z%NQ%[MII"^MD[7'B#-@[6<RH;G^9$6[<YM)-S--K7F%A)1;.U.C[532X[
MU'W>GR,-_'9S'$#96LP(B3G-S4E]UKZHLOO)W?388AX6O?AB?%[S!QF=4W@I
MB^4[$JOT>QZ\Y_S.4 _TDJMAZ1-@@+NI::9(L96A$>8"Y-K9+EP,"J '7,+T
M@8+*=4ZOM-7L:0HTIU'\544H_%>(*[F-WG@AH&IYK,"U>3CH+D?A'MAW6N?S
ME5*ZY' _)FCXY@D[*J^<@CR4CL6BCN,D>[?/UN8N2S6_M7JY)JX@:%LR@I@&
M^-[_B?SU:"HD9)K\>>1'"6$K*ON3[Q>%G(_KPZM:#,I[ Q]J^1Q"A(\4_AP[
MUO98W>&Z"E(:G@?IY)(BJK<YM[09D8"(A#T$BJ*DL9C+K-*XD=8$-YP^0XR4
M>)<5 ==@K*7GQ;-C&O%IJ/PG\IN1IBW[[(B# )9F3I>R_/(:DC6DLH370ENG
M!< Y8B3@; D)>*ISG*NVV#&U.72%C\&C0B$[/A1,>SL5!6)W?%9F9J\14S@S
M:&2L-R2N9RM^I"['^O,6R-'ZP.F.!PH87L38UQ6+>8BL *A.!['5"AY+[$H&
M*I+,DH3KO:$EH:RR),=_5^:1S&46*6+3!_#4,?,9M%H"YXJ?@@O7;U%>J[B[
MD1-GXX(7R9(N])W9)C5;P%?JD_BXPUUI<:5>8*C15':2!:%_5B06>X$WD+<_
M'>W76<UZO[5A<5[)'JE &5B]4E8;">B.;CT<U_#RT?9:P>"Z<N5$K%4@ZA'5
M6]"%*_JH])Z'R]+?/25!,K[6\]LF&4%;G']FNIIIKH)SH4?-P/&^$ZV]-)]2
MD/\+.YO7+OH.]RR4J-AM%G/^'*%I6NL>LSK!,D]YLB "?((BO@(NN6&MZT96
ML/48N?G-3C#6]QJM2SD&Q$LT:$E+/1_.]4,A)$ +_:RDHLJ8@@4%;%F_C\DF
M++7'N:5]FX3[,5G $VJ0]IC&G_L>2F+.358TQ"27D7@Y'E VK<'DC2)^1NQN
M[<<J3V%T$;O=I"(!VF;%8;&794TM>B)!CAO-X-Y\SE7I@N4+);33?!8D8%VY
M 0DHR;PN?N7C:.NTK58Q*E4]X<3*;T5FD.3!\*;?+U6U,3E924U,7AJ;HPMX
M1U9,[+A(]8@5&%\4Q&)M*U<=:I=N"Q[7O36M,.%X&+^<PB,1$J,P:"0B*];R
MZ3D[UYUIPM'W%[&NGZ=K9!N2+"B-7%#4P$XDCR;SE1_?V<7"$\S*@8CD, \W
M<,"6>+'Q?@WIUJ6.V[07*'5PI?&[S)VSVWQQCBO-JO9O20][#]G1H;3':6ZE
M$1 4T2'Q^W4HO/($L6<R-Q+P*;4_H5)."^OG ([SW+7LR_(>E0QWP2C' 'X#
M>+^WZ$A>*5\)RNFV;GU*@7MY"$5)?7ZN$^RV?U_O*5@R!8,R#UBWJ^X8!15?
MQ)VK"XXA@M\1F?R["^;K.D'A\-35V(:D,[O6U(MH+FAID2?JD@[;K77E#5?'
M7N )I$:CDVN]$7@AL=<&!*_KZJQP/P1.%VL5X"57,%P60G<S?5%2*PV%7E58
MYSC>2,"IH#AJ#/'!$NMO*-QDCQ?+L;.SAG3KOL*5IG_UO^9"2UJ76V\AD>!I
MWZ6Q)D29.$\OD'5B=(? @SS3.1),>F7+TT2,'?AXWI:X91PJEAS[PE(R77@D
M*6DM*<473YGEE8/6VUDIG<[!%9)S5=E*R5QAVL;:=P6J:Z436R&N+G'MC[&W
MI+Y=#2NT>KP4*4=G#WN\9,6,O2M#N>4U3(O?G<+?=)*3@_VX)AZ-JE(=;1Q>
MTZT,S!6:3['2=ZGKU@>;FBP<VJOG=AV8EJHZNXZ-2Y<IP^>-< ?:)QL-8-@I
MN<4.+=A7?C@A%B_&9X<E*DXH%Z8.[.Z8O))1^/[,ZZ(72KJNXCV>$2EF)*[K
M&"8VP\[[E) V7&C?W$5W>3*R/+*0#BIPIG7<&G*K],E>Z_U-VP61W$#D0DF2
M(3:Z15\[!0]IES5/"4X7Y>NR\C'@"MXQ\+#JVU5#H\+98JNG6VFKI\_&WKA)
M"F/JJI5/B3NK4Q[8V#S[CK@_H56,Z((E$B KV!02=,HB*=4T"F4HXJ0G6]Q\
M,'M2MTZU*W S99]9G#V>NZNYD;TV<="$@F4:UK!6U+!N0K>@VY0 %%H3=^M
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MR24";SB ZEQ $[Q<H8-X$?>OOZ96:Z7.=_;<E#:M?$K1,/^Z51N1$?L6*RP
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MM=J@8LU%Y8)XQ>++B&8"8\*?&L[FTC[W,TV_.454HL!*GCO3_W4$34984"9
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M.9?^FQI-\=FL&]8)HI$FIQ*%MJ;:F"^DP*CZ]9V&FVYE/6>9/L<8P3BIKP
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M5#I>M#50-!BMJX<9#I3@(@!2\B9.F39K=PR^)L<KP9+/K/-L$FF^S;ZJ#<[
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MO/;1LF4&@]WJOC&?>%>AA7C^=Z.7=9Z"$9!GF(1#>U^VPEUP@<SK=OJ>?,$
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M2JT5J<BDZO]M:F!@CQK?G(4IZ(<5EA7T7;?T\U;0$VM_AK$C'ELH7U>UDH]
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ML_0AGI$'>7JRV&/7LP7(*]]Y>*@;D?0\I&;8S1;%VK;(G8=M:!]WQU5]G,=
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MRLHA^84$0<CSP81]V$,E4^.Q4 O]?/^-JD7X0HY4U((.!2#>$/#1I8%GH%*
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MKA29K C&3:@:(F;-RLI_,X_U$<#Z8'/#\6#D?0GR&QJ0FA&^&AY>XU#PG6A
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M3_Z>""2'E\)FJY'$:4L=ZJI1$YPKDHN*QSA$V4>0@R5!QQ:[')F G>RVY:8
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MX)33ND@0OG;["Y>(O#;N./&/:__R[#_G6/S_(\_^#\?^AU^S  \+$R-X+/P
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M.-7E[4%03*V"6[XZ_-PQ$"QDEY/U27U';&#:O\+BT?,?SQ0GJ3NNC012^NO
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MP=\;M]S8,G_O>*JA5EL'0U7K<J.>20UJ6,L].6&A"":;Q9'L*<*KM/-S%^C
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MM],Z#H%=<A%RV=[B-[*%'B#FNG0$D*-"FU3Y^FS.(_706C[SI:;+H"Q>4VU
MQ&%V"*]Z.5O=6O0/GFGWG*W;"9%:B.TN$I1E:=?<Y*#U/Q B?/^GC/V!Y$A(
MXP1RY)I7A)D,69!=EH[\CI>1%'Y-FBN*VGD(D%J_.QV1JRYS8N3::@Z89_IZ
M@R6\VD<9GRWE7+7DY*:V)GDZ;*V=E,VI2DV!SN1A*_O7E@E"K0C62&.BDFU<
M0;KQIUZ/@G9+_/Z0<GO&V^:OV'?Y"0V?K@# ,TCMWGH_09[T&92BQN4LOSH
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M.8-Q5"O=@1T,=^#2BO^637#JI G7-8T?X2=K/_X<$TMLY>F_M9]&8TTAF+5
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MY2A*?UY,WJ_AR)F8_NMI+RCG$OWDPV3]^;\-.\"IX?VC5_7'0)]\L(=VTH=
M;MOCZR9!>6K"3^7GS6^G;-P^922@OI5H-?JZ%U$*YSIJVPR$S+]S"% OQ&.4
MD4\W]XVA+?('ZW0*195/"H%:>LJL[Y#5/&6SXZ='!$8NYD1?SQ43. G, (
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M6R1E"@I2]>T_KI^JUW[.RKOWO>RSBLK72;L;(M^K+I9WL-_BY=)MMF , 02
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MK(^Q-M(!T7J- HHY*=EE&K3'AII+-K@6><,UU6.PM_#6I3WSA\H]ML-_=%<
M05-Z_K&K<H09 VHJ;?\R37?PGGMU^>;-RI+HID\_6J(.R;]*3W&(?_@PXPV[
MP,XJOJH!54$'5K]D?"$(+D_/#36AN2=5TR2_&%>G=UV-K-X3U_!YPA)G!8^Y
M]>O\W:A@1$$/)!G+"793B<:6#*T*9%&.43,JH*0K<)5B(S%KY(O<Y*_WGT:7
M:CU]&]PM2 >2]))_FM9SL()VGYUGX[?JP.*OH\<N;A-M\#&1[TGZO3K&TRH1
MPC-]#O%@=64'\_P^-8?D>]\$A#(\6N9=S5FV!@1VPG-I[:C*W$CXB?03_=C[
M^R]=)CSH)&;ANXF?NJY_D*A*EDMX;K'QI%Q*XIL&H-C+Z):@L)7)431)V!B$
MI$A(';:&&W\7O+1_-B[+W%[IJN"M;(L=G@\O&Q/"KZ*FE!K$83WV#F0C"HR1
M8SMC0P/H0&S%Z]0U91T!Y4*'AVB_1U)[(V3D<F[-OA63=VYL103"E?%RJTCR
MXX7'%+U:4HT/OJ!INVO>L+1W3:Z,3W(-R'IXNBJQ6F!2*DG[Y6$'"?'\3:NY
M]2;3T<@9Z(H/6<\5S(&\[V%#.X3B7HXW$$1-N\YM6!^3>A S)2>AVHJ=BW/:
M25C? S33,O[NN\PQ8?*/Q-]@ TKV,)@!\2P)B<.."MTF==_Q<84[Y1=.SZQ:
MW3.^XR3UZ/)8XK'S9AMW>$_9CP0%07-NV]K;FQXIRJ[W4.KKFCJD9I;D[-
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M@MV'*1XX" ANB/\Q&4ZY\7YX>5=Y=#6U_?H3I^A/O!RXF(QPB5\<[T JO73
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MG0D2FNI^M@[7FU:<7*$>[79!><UIUVDP$D\%Q5-?SL6P!_Q"DSRP(9.;9^G
MG,(V'8CJ(7LP'/(CJ9LVCMVLY*)\*.;:FKMB6P)VPGWC^4**5$E7$3K;9O8F
MMG8Z\=6]W=;E@B5$ ;+9@R)(!S*Z&:YNA:4XQ_Z%Z-"<B4#WUN>TN&TL@;L4
MND.VH@-[PNF !*+T/KB2O0G,YY[J&YM#JEH]%Y/A=22['#Q2Y?K36&JOWG@/
M<+J%)YZ]*% &H0EG)/GQ4[^WAU76H@-7'-##NZO- XDWQV,[-8?"\&\UGF<:
M<QXW,CFSDQJHY>H8$B%?G+D1S$Q.F,D)D_^N_-[3NJPJWG_.\&ZT<7W\20L+
ML7BC!<6Y[FCQJO:G]:#YQ0E0--RN\(35*D?K@WM0/['.S6N@[6>7E_13ZU-6
MG%)TM30+5AZJO9VT_S*P@G%Q)7L>I ,\S3-@9 ER\8' CH7=4*M*],1I4ON'
MH(*6W:ZA1XJ>86W@'V,7:+,.43/1[4J!";;*L(HEA=):<&$U6**HN<:K:5HV
M^[A1YYB3CP!4IZJ4$6YKNFNT4$_ OVQUCR*'6W.1BU=]R.*0&/$]R-EJN#8C
M8D1>HP.]KY>)NI]LQ9NZ?TX*@"<?8J>0K\WT!!;$P]GXS<[_9Q'_LWCT9UG8
M][]A.;__5#7!Z2K*P1NT:V]:P419.^2B3_0?&>*_._;]KU&ZD F3OST"TUAA
M.N .9:&(\MWN#J363._M$+F6VOA#M->*7$+$4<;Q.3GF9E8)6OA;/)9.MZ\W
M]GF]64B>'_'_!'*5EI?&*\['1HM7#CW!"/GO(A+E"9Z8%$C9+4/=;KX (PTI
MM-,XK+$5;D% $:L)\VVFNM_<NU?$01@#XK745H$AQCEZ T.?T0%'JPBKM!M"
MO2GDRDM3KQS<1KK6J1V?P*N+B#ARMQFID6P$FY^Q:,ZIR5?')-2=6A0\&S'@
MW_%Y_H1!0;S! ZO7!J)?)0U$U.+/<N5G2B=\9UFVW\9#B*<(DZTH2=K:).T@
M%-091D9D"A^ZDEM_'?^U72(M/Y / J.(45_#.?&6\KF]WI-5RVXG=]LR7IQ0
MG70Y'.5#?B?F(_OQ&5<B2BVVL(M4)S45 +G1J'?%C'R@U(@.!-BHZ,S]$$=5
M(DNV6VHP1Y9TE5 7:BIM?%X4E3]B[<RS6X\[D/B$Q8GK<,F/T&?:#JDSX*G+
M%&,Z\-Y_&DLY9$L'" )D<3V?>K$ U8T(^^/.IWX27QU3_*1A:>TZ/T%SF0FG
MR*->(#=-M1G)9H@QBB892S(#'Z(#"^DP-"/")8,I>HCV'N.E1VM0.G#PAB@=
M.-]#'MG1PT-PV)8C*C-"3U2@<,YI=RTMCX FU[43:H%/8^0'I[BU3EU5".:4
MQ@/H@5'YXM2;B=*]+@V/5 X-3EOW+PWF9'2D]E358:^_CU#TFKG('.EFCG0S
M^>_"%$8>[H[W:_RAL8J0'[Q;%O>J_(P9[==/Y+:46%RZAIC\FIYLO\5(3WCS
M8.O-FP_QCQ-&9'QIAFON7V@JM-ZC^TB*GLO%2P5G"JJ\ _1B9&J15XL?!N_6
ML/:I$Y!ML6/SK>D:&YN3[)<G#O:,*1(3[PSUHHL)+1 \K\%VP5S=FP_H$S+5
MU8GSZ98JTJ6GG'WEI./]I8=0-P237H(?=,!5BZP'ROQ_&>Q($> 37^;\?L9F
M8-008QA-4L;\XN[E\*9SK'.([KO'R)<+Z(")+([&7>X5FKK3']^2T(G6)QF3
M=4F3,R8X4]Y%W@>L'LDW:[LLXP+F.G:>TY;"H&[D*AQV106'#M?5SYB6P)P<
MLMK_IIK@PHTL 6F5+.VLG+>>BSY7'>Z+B(SJUD2&RFLK[WV5/!Q6"B5W;R5@
MW5$"%%%JDK8?(>-]35\Y'5CYQ!G[M=#M?#NG^&:7@W<XM2=J2Q+SBZ1"%B/Q
M38'B@F2J*-*88['[J=D?]+G:)DKT/N>6:+U&!GP:5+O58\8O*=]@<1@(X/()
M4,/C<XM7*(JZ,V_[SGV2_S)BCG360;8J3^+J0_[HX7_\*]Q\9H^?"9/_6DJU
MS:97A1K/:8\6?\JW7A3QA@1,KUV/1%U(SR*R)NBW-O%]D.%0K"JU2=WJ(I&G
MK<)T#]]?S8=EWJ[H53X[,G_&WAP<IB;LHON9$_V2IH9LO"P IZI.583-?*8#
MGFYFA*T(/LHD;0<=!;>:V0]M/]=2BWZN;EP$N9Z\;FMG:%>RH"5_)+A!H/F&
MP.'%_:;#I\7W$X:7+;M0)>'02IJ-P;S?;) =(9/&)5#HGHY(P1,[%I(,%'S<
M!ZQJ'RV]^-R^I15+SL'H#:J_H0,'W&XLB62OMF4BM:!)2TN6\4:@ M5#)FXP
MN8:CDJ38(MF$J:*CR[<PGB5C.1=!ZUKBB4+4' FKT4DV.H!+/R/B%_>!HH\1
M26SG4;/3^=R$Z?W2K-'C&Q5;K_?(NO@8'; $6W]X/O6-/:-35-_DP:>E^*WE
M[8JC[>V0_8@#I+KIGP5$$/?]*I'(XWMLHAZ$@/REP0I4U81A$7(L#DOAHP/-
M]H=^J:N(C:M$^.@U<W.4)IT21T2K4+BYEW(P6=_AX!R8S970JSV;9 \5TV"/
MF,%>F1CU74#Q8MWBU-W]3@5@H>[ZBUUEQCV-M)^HA&U482V\:*E#Z8%'>9VF
MA]+J='G%LXMZ>SD.'C0XGZ_).GQST\PN?,ZC1NMW9#Y@IL</_!5@^;/WM]!_
MDBL#_&9Z?P!G/ ;9#/X8R&#<HH?=U'/69@84 7':5=-I*+49O+GHJ@>(XXUC
M=TZ!PR#;?+\'1'X$64 4Z$#C"?!L"TT8.<YX$EQ+]MFR^!?1_R@(162C 'AV
ML?X&';CG-$1+OC7T.XW_DX/_:6DF3/ZVF(W;ZKE I3<^OVP62?:7OI.??U8Z
MX?MUG<W+B::6@TK>1\X%4J_]FC0M>>+WQ<M'LET$9-Z"L^J:% %#H9PPH>Z^
M^F,BI+K;MA^J]14=^ *K?YJ^?XBL5YR"1D!$ZYT(L69DTQ=;*9Y3EC_V1T'J
M*L.I'>V,?NK]N=C'[C$YL@=ZW+K[3XN#-K0'!QX9#_>N#=53I7;K_&W)BC,&
M%'XI_>^_X_Q6ZO)0,R,<MSJ67UIZT6RTI65 ;L)(DIX0M%K%^2O"^BEFA>-+
M0V>U]A8]GV8G.5QX=F'EG>4^5.Z/I:&/(\.C7P/]5!]$3$RH2L>?6A XWPF^
MLMO^.UBNM^C*,V+E43N-L/+!YOWGQ@LF.G0._RIYM%Q3)R#0,&=U8 4Q8L#>
M7 ^Z-/HU[\M.>EER+J1&9GS'H1DC.E!O5W A>Z'69[ @K^O1D8HL?0,HG+>Y
M9D%Q!1)"!_"FH@58J1ND."11L_KN>]?>?:_(QB<[(.]=0K>?H#_2&($-CVH*
MDB.#FT:5,2E\@$R*_F*.5'V\6!E"CK52L;CX,^Q6^^TEQ T4+"&JS3[&2MP)
M]#/@*RUNQV[GM?U^O$HX[>A"R:*N:*^R=^!>.I!TIF1U'%G_=> --4>:/+C*
M;^4[*D7XG"AG[9EMI"%7%U"UP27_/N7U7RE&,V,U$R;_93Q]MC>=#89M@X[V
M-2#W#;H;1TZN?@K2_&/\V>;W^#,5]'4A!\-#ZB;;DC9FQ%$NRO-$4/BD%%G1
MY%[^\J(B=5$WG)O64>SV^OF-/E_$DY?X:Z[IUKDJ95FT_EHZ\,R3X90_@PH(
MF<01O$;3I&[SE5>P*LA5],@#Z:.737X/,LSZK-3%%BM.@:+$RU$Q"'7;<^X!
M&56]?LXZDNVG;%2TG;R2I08Z=5^CE=&!C+Z_,&E]>B@NR M*!SBPX;/-R/MN
MI^*D(Y?YM54#^2I,'>P?Y \4[YB1V]C#2<C0O$)[2>.4H)IUY%HQBKB$?:,M
MHCGA>DBS)RNNP\)"6#H]&&2]ZX##KLC-@)]#7/KA)G6-NU)3(>/M;SJMJ*^Q
MH4LD'6(JV1@WN?()9QK2TZJ;G(N\O^RFZ^%P?8_1QJ2+J(/X6G"0$=JV.!]V
MN2)EAQ8T[62=G)G0G(C4KMHQ<%I:7XC5)IGB08W@?4J7[45[I6((R0]J$[_)
MU+Y9/B8&(EIQK]J'ZPDL2+\OC&UYI)E/^ER,D?7T"JQ<:XJ0SWG\[/]A5H\Y
M\\>$R=^7AW2 7U<=IH6CO2%B^=U/CAA^J155H\YUT8$U_;-2VHXXWEFK9G%&
MNHL6((TQTEU1/IBQP0/T:.@^3")R4DR/#@"SR("/'ZSYMP-0#G'X'%>4NI*.
MKC6R6UGJU_HO;%ILN:X*HF=B'TGQP8S=@*7'#<^%S3=BQMZT%-LIEJW'[(.8
M Z0>,A0V,XU$Y2[\$N=8 "62=:+"5T^CJ6IO0CM6Z@P<4G=^+BVYC[WP/"$3
M[S]W[Y>QHJ"+0W^\O^PG[BF5%3HP XT6>J)]-DOK5L$_C?:6_)_1WI"@@J]I
M 8D0)=/)4LS^3DVWY*%3O3=>^;U:>?])<"*Y;L7_RREGZ;<)G;*?D(S863:#
MC08)?$O+I0/.]Q\@/!S,]FDR(D^.@V@6>"W*Y8, $=6('+9I1/+"HPU:[L+O
M%N<<%LW[8^A82 N#1EUG"SHNYL[O]CSCH+[ S3O .4#1&F90WYW2#;^:>VWS
M-,P+/!_?-W=DLJ J4UN.$<ZA.-.G"+W-P4E\ BQ$6X,8DWU8432@54@!=:,F
M?+M@0O[])_FVDY818/9V9\WZ;V7HJ+SY$^N;-C*SY8QL-F\CY'_Z6A36.?$Q
M+2(53P=6<OUS82ZF/<X$5,L1\V/*Q='0$RU/;E=F7FT0_'+&]_T'Y?)?-7M)
MRO.KX63/A50;$LJ<FKZ))NGWJIQ=G2ZI(9OKL\A$<.>\%',Y&QM\CI=6-14[
M#+X53EP9P.B04)!>G]73KL[5'_NT7^PEEG+$B][S2G00N[.1+GSSR2+1 X"/
MD85IXT?YJ1_5N.=*2I.;)Y1[X\3-OZ\Y'KIK\T3IQ*F?!NF<$@+2>\Z:!Z!'
MT<0\?.[*&_PL"=7B+L/P)Y1+GUJ@"[?.YG GD"[ __C;!< AQ)!]XPO1/:D#
MV7BGWEZ;6PR"CZKX5ER%=63MY)#0=16%C1$_5K>+1?D6H<;V_ #?[R8I0)JA
MSVI3W-&\]]U=CGQ+'V_#M4&+88PV&L?1$_L>= 58\,!ZHL;D6M./0([ H#C9
M5Q/LL*\MNLXH'[7>!L2=Y<BG_OMZFK,"KWF%M@9=(//3QB=$J.A-+3)LQ32,
MXIKU+NC2I7C(R<.=7'+/\-P&U<&/6<S/Z]RLZCO5]K*MI"W_^3N%_"B _3P;
MXCK%,&R2Z,RXFUB2.5GOA?</Q3;T?<\B!U%)9)5GQ4N<KP;GSS^V)<[3U2$,
MAN._--9B(^J-D4>3,US/K'KY^<@^?*X#S,8_W!-C),%K@O"U9O1Q],'WD:.L
M-P<\$0"%K[(?KIC[9>X-U?FX7%S'SL=O97HB-;;.ZB<:-.PO%&%)RBXM[F@0
MA0\/"5TMEGZBK5?0Z?4X[Z%LV #_"M3LIPF?PP![=A"*K$E1_DA2P:LTZO+V
MK2;]4/MQ8B_*#??E88>(OR@U-RXM=C!8UYJ:!,9E54T>T%5 -N60ODZQD?P(
MG'-D]3+]4CT/G<;9\SU7C%M6.$:2[NP !ZZ$D2NQI\&X\J-LX9?Z$(<I-WMO
MK!R5[-NZE%V9 8Q)P7.FQY.VHC->H<D_L9<P J0>A!3E)#X\\H!"<5V6M5O@
MC?<[W[->BYL,O^/-J8<0"ZCYVL?)LI2SNG($D4ZDOY?<R.;7HR--W4%G3I^7
M>Z8G5O;R_&%</ LQ@I))_:C<1XQB7/=LRAF2S8>D6OS/L,I'XXNK79X\SKOS
ML;NN!Z(/[TILON,-&R,N4DOAMZ<&"$-AM#VN)CB_J/%+/UVW;Y@HL?_DK:XV
M>.DA=LZ@?%Y3VZI?O,1T]>L4>I0.7,)6Q;20H&VI5]C[U<[*;+!$O7P/@P#E
M@<_9&2V<=< X2%7,E<==S"TO8D]^7@/@#5C-@5J>>S#")I2DR$BG5<IO)9OT
MUKL1PY8&3Y7*D7V7;_.R.SQ,AY+[679#9R:/W$?RU(L6D I:J@B+ 8()GD,:
M?N8N'*'?>8WD /G9>&!V:-X)3>%W((93WZF;6,[C0(U:'@9-M7#,;>S@O7A_
ML=@W/,MJ9@6);0[F*ZP^LR)CC,LQ"->O942*1C ;27=TVI"OQ;H^64,A?,]]
M#[-K;5M''7O.Z%P/L!JA V6Q36.@$#JPA\*'6]4=\>@SZ<49$8MYJGB>Y,9A
M1_V%AZGW6>?0(PXT+N,@ NMT+D4!&C5Q !*./) .*;-1<Y>V[!L_>GD_?U;]
MM8;H%&?02Y:]>= Z]PTI&O<%W"UO'8VIV%83&=W&:67PS7,V;@?VEVI\]E3N
MA-X:%;Y"!S#NFUI3D&BA:7 SB -6LB=_N58O)[?BG$H:E]&3S1\1P-+]_S-U
MP)S]8O+?@<)8?EB5/OY:[)D"M)MO[;4TT&1UW4O)^8_"2Z9WSNH4S)A&B^/-
MV"#@JR2/N]6_L&.IK^!!]Y[2 8W?WJ"0>-=TVJ5GEJ*3XE)Q]N3-XMK.18$E
M.J#G-QOD/]/]PEZ8Y)!9^6$ZR'G,L'P>^G92.PO))?'E+/&Z^_1OX>M%$.N-
MS>[P) .]LK.7"B;R/_7%I%R><]A-:Z?V0>1AZ#:1R1B?%SZ0 V[)UI@,E8GJ
MVI=U#M]]KVNQ!"M V4C<+9"#/EF]]>J9/]R%5NF TFK",?;MM-C/D;2^ SK+
M71]>I)D<RZ"R),"0B;/XW4$7&4NS@4E#E83)06M_*8U;@Q6@ TO_:EKLYY)E
MO(%N]HO.XN2IJB9Q08KM *9Q*DAPQLQ)POCAOHYCV_Z@S]BKL\1]F&:2"J,G
M2BCMHT2;3NO@^UT.WWV_N&8I0$RR%\9$EB/+]8+"W\'\C/'%B?M2,EV)H_8H
M8.Q(1=9%S2$\*_J3A;92=N'F6:_N0R=O\>-WK@9E)26/<O<58BSM4GY--B))
M<MMA%+E9-_MSU1!^M\@PP8-.2IFZX9G&)%S !W1!X?]E7FOQ1H_]J^-MJ>5F
M)%[7-(>-5,S0$8O.33NA]R-(*T;B6:Y]_K_H595_@+<5%#?&B&N,/X9^R8"8
MX*&X2)-IE1<B;\.OU?5[9ZL>T7DS=_)"E=9:X"'-6-3,8=MNDKS0:L+TJL.T
M0-7*/-Y@5176=S-.:<OC2L/T_52][I&[2-PQWD69CN%ZQP.M075$*>J3>A6R
M_/U'2[OA<0QIC;A[VS9.GVWVB:L)9H19: E)J&XW- 7S=)/D_%8N@IV@;';N
M&-E?:QAI6(B,2*@^N;>))TPP;[+%[VY:.%LPZ[%+XBG*PD,T[G=M7F$;MGO&
M'\+/^-)>HP<^4[*HM9S45#J RYSDT56U;Y3 ?\M3=JROC>9L?"YJ\_+40-*/
M]W>TYOE9=JL@KY!X,R<-<;QY]PA1$4JBWM\48!>>759=H7I!/HQ>J\E='M7)
M*<J%V$RZ^CTL^OIIKCYC*DE6-''@2:,YKQ<DT<"\C/J1<:JB@#,?IE[PW<8G
MA^SEP^1R>S[-?GF:4R"<S63\"7_,X0/-$4#)[ZV6-W1_X!U\X;$JM\9HQ =5
MB#?N6ZZWSH69"QMV2&6@N]$DI?FF,:P@G 4_&:54-#I5KY@?YU-A=&K,]IT^
MG+CG<C"RX5/!$F1$;L8^FK", X523+/M6[V\B!P>/IH'&P-M.F8L4C6$.[3"
M] ,*%+W56#94*(*)[\5+T>%[0T_ [[K.,5)5HM;D8NJN"_%LS'VD(QT(_:(Q
MJ<O7=_A1[*NQ8Q"*=P3)B\9%)G"!7DS(DESP6DWF.173(SYF/CYW'S1&J5YY
M+WIK[(CPT](SH&.^"<U<U*-X1'@N7('D]/Y^[X\++EDPJ&%(3W'N2P/^ZV--
M>78I'P4NYAAI _*LN>C/6OH^C$:V<.KM5/T04"4FOC\-FZ.X20>:,-KX[IB,
MZN1F>\E>^"6!.K94$X5=Q<07SSMX'!Q"'@;L6OT$K7XW71EB7,6CI+N$5"(G
M>YC/!7>9N?[[UWC.CXX_B2FL7.5CF=1\!QJHI63^KF9[O)KQ;Q*BN\0&V;YL
M\"Y/LUON-LIE.95ZK=?G*]B^9U7=X]SN!-FX[IFGQ[KR'(BGY.1X<2$OUTNO
M5$K^N434:CCC9.X]%:8\AJG=3^L/2*1M:=IXRR@]>6E8J*G@.<N1]; A3.PZ
M6RSIA%4*<3U4M&S6/Z!M<KO,J6YS#%)PI;'_],O/^A>.[$<$(1M== 5_D,IP
MH##*72?/H?U3=C<CB_*-8D;G]JC.?SPDS4IC6X68TSK!(IO06 @ %Y\.4B J
MOD%]O.3^H2&&>W3"0*2PI_K;A?'3J@.W;3+>@5*0N/*B ]1$N*:TL-<,MZD*
M=;UD@@Y<'>H#EW1Y72++48[>QNS@TU\W1\%S1KCHP$R653,*;S7Y_#K\&D&C
M&?QDXE"B.EKP2WYD00&W,\_=5(L#HVW#"UTR<1_]N<O3#ULMJC2O<U[ B;/
MW)L%LT0]A*Y6]MT;ZW,\I>2P:7;^R.^!RZ-(0D'[A!+);\K&SKAQ$H36E5YZ
M/)%=GVH133D#Y9<]>_B;/>15\.?(<B]R0Z ( 4)R,XV9W'33E6#<\IQFBN)2
MOCPK7I'&F4M0; -ST<XMUU:%($0GX-<'G/'CQ-)%08UE9WR39]&M;W9QC2QQ
M0I[@N7=GI[&,]'**X4_W57;50 >04Z8@.B!EU2*.US/=.0?EIP/#*8QFECVH
M3KYQ7ER!#C2;PWWI0*89@9TF<$9\RH"B+M<.W5479WSTQEV:P)8%/\LO]+\]
MR(_\BP]!+,R86DPMIA93BZG%U&)J,;686DPMIA93BZG%U&)J,;686DPMIA93
MBZG%U/K?JW7#UE;/=6]"M^0E'C>[V;B0_#SAWR5(("KP^]1/]5(X"/@:_JG[
M--7I<0YLO"C*9%WBGY83*<AI]EDEZ$25R;>[" 3%[$MXLSP2\"FYJWL Z8Z.
M%A%$Z="RR2>618*BN#$V;]!"KH1VD=VRDP"HR+\R@PZPJ0_Y*(O\U!(/P\.0
M-\\:SF(&!;<<=$Y;R@_8C($B=IJGD]M!PA3'?D3?=)"S39Y%U24'H;75.W3@
M\:FV1VTS23J=Q2JF?6L5[L,/5CQRZNM20O2@4&%_:8?O"C%&1(&?_:U7K"]=
MVAZ/;;:5/:BP4T_-2JHO,%2QJJ,()9P3?R[.5V]&,+YU#A6A_B;->CXMQ++E
M$2OEU+NF=\3KBN(7\&L?IHO,CVCH]Q57V%UT>+[Z8,K5$?H^3TY@"_Q[!GO^
M>;W%K)N]5BV49S$Z3 0N:D^\L!!0"(F9&<Y#5V/$X#)X5)/'/Z\D$OVW*XD^
M"O#C^_)V<C,6YL4"7\V^HGU(:KWYROO*N8M@=6P68A,!64"6Y;;J"+4<["R@
M\!(,7FSF[9R\M40\H^NZNE%7Q[8E>I,<L8MJ1(GH*E"T>AQZX1KD(VZC.B'(
M+XI0OEM[VLE=PU^JR%>-MM&E\N@K:?(W2&:D?5XM*4F!6C,*@9\DRR-V$,7K
M73M6-)&$F2JJ2.QS,/[#1SK !9[ZH*N%[,DCA3+^\P:$1^?G%<6^_ETI-"R+
MM$H']#.G012%!^"FV#^;&IK[RPDC^7_W.4S^/Q4>9<HQY9AR_VOEP%PT25BN
M'2&7(N#0E-K]HO[X(UR0YWP;XC!9/]3'YTA74IU>Q G'V#F/S_D4;UYV,TAM
MXG_Q#B*@KVA19*/P VW_&66_EMK8UE6]]:W(G2WN, ^!PSOQ'=_&4W;FHN\Q
M'L,QWN!=Q8!P&L<,'9C9VD7J ?!C9%5DH\(F>J1NQB^,)F4#UZL?<NY!]%69
M)E\QM(2<&[W%:WMEN"'9[]+;>YCWU RL"W0?K0\)<L&'1RO-IG9UG%!&*]O*
M?'V+.R#SXKG$&<[#$B&<>T4V1^59-^21C=*ZDJZ5JB0;0VIF1:0*RS4;WT2B
MS1/A&Q1ESZJ+<DLCVBY]Z;HMU$2PH\I>1*?NP9K>^A-EDTL!H4JI257(\O$?
MIZ,4*._V1C_V?;=8'6\D/53=<UXX718_F#RCPKMD+5CEP)N;N62Y[N[G\K N
M,U7.O# KX( )PG\9A3<Z FW$R&*Q)%4"UAZ_+QD^G&PJZQ1W(-VJ.^165P3+
M@WVV,T!)I_HNF'$9@LB_-_75@,N0-6 5%&C1\C;R !P^X9)< &F0C!C&3L!F
ME%9_'C \K9H0\E!(%I-"RL5YD]+P[:TTWJ35<E+]I<P)U_V^<3MA+-J@@P]K
M1"/6OYU6C:GH9R1 &HA6;$ET\@KT'0EUM8QPE29O]_BG:%)\H$SER1VW+\&L
ME5YU8]D!<JO[R5HP#>(;4B#XJ;:KB_2@\X5''OYN4R<>S -/E*Y>8/EHV+CW
M@*'$4$[/>?&42S3.8P0^DQ)4TZC!ZI'"VS"NQV/EZ-)QCL^H*7>?VH-@R\X9
MW;<$HMS*!_(QF!31"!_]+7'*)YT.W.@7=NROJ*/F_%Q\===J#I!V3ZA@-VF)
M-Y+]U!8!=!$TPLJQPC _\^\5=8=]=,3-JP)MZK2>_1#K.9?H)/4]Q'VCVY;1
M8 V7$?L)ZE3&54-%[VX'J]7];*GU5U5Z_O07!GZHS?$Z]YW3\X?98HS0/;OR
MK#/K(QHTSKHIE9&Z5O1,$!121PJ=^;FA_<F:QL)OV4K;:!=V@9X,N1#W]BU?
M<(TZ<?__O\J&N22,R3\@ M-T0!CK#F:A"-]>/0'%5FYM=HCHIS;.6FXFTE80
M.,I$A)N3C("_*I8MN-59/9%'1N,LY@4B*/G-=V+ SO*,P6H)#OH,$Q26?/*/
M6HZEB[] DHP8E)/P.'.A+O:PA%4K1 3LCCX*=]A8R:JG-> I*>(CY]P3K2!&
MCN3>(%XA:IR]C+W/5<@5E[414)A9=(&+*G9;D@YL?D#$T8&&6'-2(_D*;'GF
MYEKJ1)Y'>?189L^*ET#IKJ?M7,?6XT=C G.$M@W#DK;"M1:%_*AXT_-L@>V-
MR.&^=J0@)7(Y$DG2HX!E1<F7S*/"XX+NA8<A/XSFEEE-0/;1 :?)/7#!F..;
MG[3(!C9F&^XBSP^9II,UQP[3 6_6F*S! YGF93_CMFI00HYP%>,EF/R'*^![
M@D;@=6.G^?JZS.G?NZ!_1$71)/U%8E_XP<"7'IPYX?!UMH#6!6E$634>\8V#
M^%#D2&PX5 A14F7_(D=R89U3_UJ)\OA$S<L8%MI2,&9@X955]K6GQU=K2(+^
MK2,Y\''%[B34+P.]C24:4OIWP:_0Z;_U^JY_V'5?_\EWA)F5&9G\ S%%DZ.X
MXOT:J?]47;'4U^[[2.[Z"9??(RJ=PC-^7%IQ1A4"OMYW\5LE%@(B!_ZYNJ)B
M%T(%T8/Y8ZVL_8"EW>^ULI%*QMZ41XG?#HA;*>BH0H0H]ZF8>JN9WV-%CJ93
MRL=*L6[C(KL66Q.:D326>/ GB-(/.Y/ 1\JM+:6FVH7V1D[WNE8"XDW_=75%
M]+^MKK@0!")D$B<([2WK8-.>+-V#W\45[I2\I.98_ [F#_TW33+?B@U]BVI]
M'?_85#IUT_3I) #W(+S?-)CZ=&RBT^9!;?;@O?+(H=,'.\5_7/^Z"O&%"U&?
MP87QRQW]<*.J-I'IN^&CF:UOE6E=MNOM!;-^7/L?MZ59KZU01873\-O[KL.L
M.8\CI=43D!/(PC2R+:D*-[E2-8.-/JWW*&=Q<B155/S-K?X+,7NT=AQ$LW00
M"VWZG +;L8Q(/]F XJ!$+JYBIV0)/##HZI$K)\W/;$6<L-!Y,=Y,'E@CM)7H
MYT4<Y+]KH0^POMN39A^MK7U\N0[,U5T]K_8-?>4T\29J)'* #D388!O]V?C-
M[ SF+_R='\SL?[:1#/;/]GE4^Y<B-+_0?U% 1OPO2R  R']7/.9W(9I_5P/A
MYO]# 1R&S$V&3 [!E/HB&;)KY_#'%I1_<E3MKU5UAPF3/\&1E-F:JA'B[5]A
M%WBCHE=M 4%M'<\0T@W5,5IAEZL0%>*XDO7J_V/OS>.A_/O]\6E5% D),;)$
MA!!*S*2REB1KQ'R$)"3[-DN+)>N$HBB3?3?)OLU@+"$)V=>Q[V8L8YCM._K<
MYS[GW/=]?F<_G_MW3G^\_G ]7*_W=5US7>_W\_5\O5[/MW#!:,MC)S.ER8Y0
MH3_WE?7I%,\Z?L#XZ="Y->(\ECXF;'/L"G!I&'5T@P3,7=70I)ET(- \&9P<
M2]0CXQJ3%/K4O/+:<WU?F%3V;/+!-QM_! T)OO8V$7Q:*QCTY$>CENHUHTUJ
M" [JK=I3)+%D,[2,C>O<7IR"V?S46<QULH:_(ZQ]F2MUD/(*F#*K<%L\!<U#
M&#$_QTJG*75;BQ]JFMD&60OQ??R1--P_""UF/[BDE#Z.W4,.F3A3(A2+SQ=9
M-,?"H;EV7S3>/_8&2\E1;E[90I? V9@AK9IS'G2WI8R,30SFE_UPVER[^'.$
M8D#@T!=*@QE/S@1PTW:SI>]O""TBCM*/^Y9-].;34'B7$Y-WO(1OJ$9^NL+A
M)W;19(<K-FH/NARS.P 8>@D/$;U#'&DEHXSNG>_&#\?)ER7/==$OFQ4:08Q\
M$;A*2-"%MQ?:!6Z5=FW,'10M*0ZUC40 5"E;^?RKF4&!2G%Y5 B(R*;0+J?-
M0DF &XS"F2%$6:YTOR.ITN2ULK?I]X'!J\DB96418FY9<SS:@ #60DV>?KCQ
M4&S5L&1*V/X_7);(<%=1ZZ]1L=/?;%K[1TV;72FOOU2D,?QK5; K+'\E1V/6
MBOTK9;#_B*;.WV@'@?S-H_\MHCZ_[/^Z&?OP<EK4B77K_%EV\:"NV 8W!XQ3
MW+BGQ$F0Q2") ;A37=:]])O5VO"(7N%N0E,>P)$/;6="U4T"\ID:[7*])$:N
M-UYZMHGB?-_52/@?I!<188A3:@[$V-N[THNACS^:CAP-!%>5O-B57FP6B#+?
M.E.^<-_FZ(D\VK73! 9 L3W?['A-I$0/VF]'>]-[K8)DT(0D2VJ%?_3;<< M
M*O6A@XT7RL):'H;T< 7'$@<O/_\GVHLOLLFI=RMZ"OSZQ9VUCX%Q_$>D..SW
M5BP>!2V:U 1_:QUT:JMX*V9*(L;':*GOS9I"V4#,J+S,.!A.1C9::Z5/5L41
MFM[VVV3B2E;3(-=Z[D_V>7A+23]K+3C=3_L<Q1;B*Q12DF@8OW[C;ELWFKXW
M9@5:@F< V!>2I'L^=E]P49TU_N%P,:JWZTR,%A4POSJ(:?B]H;@&LZ8$?KDU
M4R]T\F&EY[,,4%>K0NX*EP_+ZCZ(#56%K(N7"ZPT("&"BBUA2B?WG%M0,;@D
M./5J.G'NUD'?O56L2YE!$5Y)F=.7MD(O?K6?FW8CW:8[Y(W- ]^,)9Q7XQT'
M<T!_)D.5TBSF2(<[WCB_E76+_#;F-_13?9'VS]07+^FNC.93Z\,D,Q[\T;/U
MKYG[E_VR_Z")^S8WN0ZVU2(.F@;<R%U=SH<I'(S.^.3'4R/N6@7$P)W=N?OJ
ML/Q@IXZ?E&_2.IV3 >#0C::]R:BXO3A_#N5OX%9/W-+T,&ZXFI18M'$DY+G'
MS;4>;M@'"5)Z'U7:ARRGN R)!)8V/X.?\"/QV^$:*W?LX2V97]1>)G;I5AAN
M6#6+[F<E@R=9EJ4GT9%&:OX_:>$!?2&<O*5<!OY]Q=9/5OC-*O  ,U!&"%+O
MK<EEEC( @;:X+AMLL9?D%S_>7LER!Y+$(]2JV0>I$B>,,9SX#+_TXL4<S953
M_"MF> N[969 \;KD5U0O&ID>;<A=55C_.[<,DR- 2-Q$5(/&P=0)_5&.[V-'
M0#U"KF<@I/N3#V 0EF1635@ZP95D29"H>SA1WNVYNJSNIMV>]TA8]Z(ZM3"R
M, KKZ<"R/V%S83XST/(K^0BEH?6-W#6)$"FZG^M:5%O/6*>0%R%QG.,YG&W@
M$%4E3<3Z\W*\<65#F?O.S-6++)0<'EANY\.4F@,\/';PTZ&-9DTF7D1%C\21
M,F_F?*;X^@]7 ?D;]FNKW%_VSRT/==RWZ!K!)<QZ<><;*GF@13A(5DDZ:WG2
M\9"8L(/PB?K"YGO[YC6>!.;H7F5=WM JX<$AZDED)P9 DZ,>1;[,_)PGYAB
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M'/V09WOX0+4-I_;'V^>E&KUPAP\0+Z/>S5A+/#!/;-YWZT(\(@P2A=J65N/
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MK["GSC]D !HJ_?/58M0L_S76"5U-!U+U"'V-,D>57(\\(NWDOZM%G)O0><L
M''D)MW.]?P"N0:;LIIQX%Y%IOBB=\BZTF3BTIU4OE9SJME9)R59B>5[M-\$1
M8K&DVAR\:1DI>AN95KK\%$<IR R!D,PY[W8W?$N<3LHL2GHB9)EDM#-S5_R6
M>\_%Q</0N-%"RCN*B2;T&4&:1.^LUB?!1">X#>?XW]7+YA\"V[[=^7))GFNQ
M=?.282/,P]'G "W/3+E;V\-5(23JH;F":O0KC5/'8)K^K[+YPX@.ZZ4N,9-K
M>J/-@OJ-&S!@Z@#=*5N)V]!"Z.0?7R[U;S3#X7N:3OMC]?_YSBYF;1 !L*LK
MFR]PF=_AA2VRL;)U6O_[_7,VKEO-"C0N)"GWTH]()3_%_C8%J+>;9?^XXR5,
M37SN +0C0TUC0D:N/N'F3E)1EJ6CO^<^SW@5]Y>="*ZQH1JH([&(SLIW (M*
MIRH74:Z_S^[S.O1%8Y5;(I:^/DGKAHA";Y)Q$ZOA@V5#5,.\]BP>,9PS>YNO
MXN#%YE;L/;O)&*=WG9[JV@T)Z9C$M/[A1Q9!.)>PWMXS,=J@9U=:T,H94G>Z
M^('?[_*&7#RWWU1".29;/+_T^>:BW(=XSS:X-#&X;/+#(Q?+!O[?$Z@%LFFR
M_4LL]OL^G=Q78DF0P*&.4_5[X_4(34B/W-'W)\QYIR+^G.;,_9GF5'?U A8M
MH#A7V5&NN,CC]5<>V/0=;U7@&I:]!0[5AY6,K^Z; W)LF!<CV1V5*T$HH(Y+
M[.-)VHSZ7>S@?=W-= .VLXOJ1XNPQSXOY8!-6E-R6APS7B%'L&F>ZR!S,A,2
M[-_NK 9//4(=*XBUQIZT21LLDDESH)7BTT!C4IO \^B"XA&%#JU/SYL-2H*;
M6D?V7G-U.1EU\8<GZ\??.&Q,'Z)O<4_J6TC2H>U%7W&7<Y?=>NY5R<1L6,IU
ME!MJ\B3C_^C:]5^U\+]JX?]<S]Y(7I\$/Z.?;&J?<.5RW+F7HP)[ES[V!#<H
MWH:JO>.B;>IZC<.22TDO\%3:CM@0)7K0$,)/O<H$"L@Y"T2BZW@'^[V%=?83
MZ\9NKNRPJ[)W0PHEG68,7H)+^AJ!+S%V9M9B\;J%B&WWSI !V^8G=V^1A+XV
M53B$90J6@'7:U"Y_*R2]>9@C3U_O8P#VF"%@NTUN0LQE5 5WLI\<W[ #?Z<0
M07O=,G./<_FX?<<T1/'GV*\>DD NV.=4%;<<'843%!.$R+F=EWWG< NW^VJ[
M=+J^?%NRZI]^%Z4KD7VFF'H9[^+0./B\?\Y??Z70=S@\0,#G'7$QB 7ISP1L
M[EVJP!Q[NL 4^1#E'G3$M*QJ&CG\@;YMOC'&O(<RYCV,VODDB2?>^'D/S<Q[
M2+:_O LWB5O>T>_>A2N>BF,"PWR8(H&R.S<1!1KA]P87[_KJM5> G5X9N"$-
M3]DAZ][IPY0(6R06LLLX R %LY>E6D++Q=%3:^-'EX]S-A?%91D[F?1"0N?,
M)D;Y\ N/HS@;2TB.XN22AW05\$4U%;RZ:Q/_T\+OQ>$C]PD,0!L;\Q::*UC9
M62K0R70@H@X,%R'GMJ&L8]KJ35U:> U(X1'^+R<O4OE^],V-OL"/2-?O^)L_
M'+1/BK5#>8^V'@B69S[MVP<>]MT[[P;AJM@NM9\(!M7@GZ9E%ZR.QL_%#W<D
M8I@8$W)4#3C=D7O-9Z*M9]8[]<R7/:30\X=([CT;["%XFAQ.%>JM"DIT3+^[
MR[1]-+>%I&3M+98L^%)_GFRX_0"LTCP3,]/4^YIF'=[IC-%A1GE%7_XG0I!+
M#(" +Q-$<VY<\D0<GU?>P: DJ$4?_*[1IFS611'%:?QD@W^U%AU[33+OD6&0
M02C0))JH;/_J%EEW5/#^9OBV)_S15^KE?[%0?0%U .&(Y*=R5.IL)*Z6/0PJ
MNY$*.4Y:3DJ_W#2Z&$%\Y6\V5]:$'4#604[)C%J9ME' ]]A*91XT['__VQ-@
M<?C2\&0RS_8\L8ID1D37\:575)?0^PFDI3-%]P.;6%R5_!O@U0Y/FZHK.K,U
MUZ_30UO+<\4G6L%WFC2UW$>Y!K K&(SEC;;LK:U:!F"PJ XBD,)<G&<IO W7
MH3M*Z\]$A>A&!'%!?YM/"L9F17WXKW>JCZ=%5VF+'&M=>&(<I<%2B,X%'8"/
M8D0(V@,;J%-BHY*=9H?*:I%E5S!+OJ\#Y(_2^Q[-IX<;Z(74$3F"2R37[RLX
MM .G M $# 8)4>[HS)%^2T80I7$0[N(+/=7RN4,+I0Y[J$6A(K94A=/;T34O
M>;K[/B8\FJ,JE_"_]8]Z8U[>\CBAR#J+^7H\T/C#Y\-_N>\'RXM]Z+J?RETD
M,R%H:&EH_WOI>_K&MN+:"]J,<$#7Z]<F SU!]7U-/<;GOWLD#HA[^YOX&C1U
M#+'5CK% *2=7P'@QXBD_R%(-Z,IU_?D+U3D!49:T!'+?I,-RX:1K6!+\0]J7
M42["^K1^?D3F,I<<[4+BBQ>TGL%+=2.0RWT?C'B[WE$*-/")WNCWK6/#X0Q
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M/A2[?RP7UN2*'QQ_&E!&Y9F<U-S"@0<*QG#^^CB+,7(KU;%;5^"-FP/_.PD
M<A4HI7 Y+^)R7Q8<A_V,#:3OH1XBM&:$.$B$;48J2[>[&B7QQ/@]2#C?P;[^
M7NM9V(&3^_?JM!V'7V8^S.F12Q5D19?W6ESFL0NZGX'=FTH[N?OEAZZ=DA?6
M2;W],O<[X/P! -P 47<#='P WC+&!Q> ^I)M;3E"T+)*9WA[O9VF+96&?U,M
MK:OETIY)S0(<2YL\UT#/)-]HB$M2(!1$3K#MU8_*M3]*JWB,N5>86X XR$-H
MIIY(&+R$L$<=;6TTU:F&.'V*;FG_,"Z, -=C$FE1#C&3) ,R:"V8@P$XE)&
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M1SLR\S.#EDZL3?,5Y-NQ?[$Z__2ZAO.F_<D9K!X#@)^S9DYT*3>(S$L][,L
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M5"WMFIA;^% N=FP(Z@IUR,&$UK&Q  <E^Y;AEY%$5=)0UOEL .";E\?)!#O
MBS:)F)N5)8F$IVY%36"J9/:KGP]U'E)-R1[WWQTRT6>[8>0_?Q7X&7.71]3
MZAS3H[O$ J%K_G4FMPJ+RMCPA7:[0PK_SGFKT?P_P8G_,/B'P3\,_F'P7V/P
MHYZ"QY=VA;YS!EI9$]JGI7_KX=H'.S..;-2M.TKQS+>;FN37R+L:;Z[GJ!_=
MX!U(A;D%#?B^4EP+:7,>]<5#!<5CA4WN, F]2K8*?FIO5O"_HW>U?/;]F:*(
M[_04?(^B2.XO*(KJU62F8&7VJ9PWZ.:%18;?9+@>LOM6S<%^U[27"\.=JK,D
M(XUIGN&*81A*[,-R\-DZ_N485+Q+FT_J]^%3>3V-AKR/E0''XBR!(725H0F1
M:/!)JLGT+_:Z725>R*8DI1=0FO1]:5?&<H4ZAW??>PN-$JA'TZR%>J,RLL#(
M7G=[MF RWF2!9]'V28UXVK3ZW4F]OH)GBK+7B!6:CHY<?^H-*X;\WKZU"14U
MI**\1IV*FZ-X6YMO3_1U7,IE+GY?']2SI\LR<A#<=,$^9CL1%0#E73GK/J:X
MD<J1J)O, DR^QMX@J&KM(8(Q__D=U$H1#?=$YT=8@##E LMY6X,]U7DR[G8,
M'98"B2(Y^Y<!0VK.F>F'*+RU!.NC,B^W1^%I73ZEO\F3C&,2D']']OQS[#I"
M_F[FDMY KOCW+6=CIMW?EPG(R_\O<O4_#/YA\ ^#?QC\P^"_W"",&:;_[P87
M4%Q>$;=)J1&>^0[#+E\7AHJ3Q5/O!1GQ;,O2'B&^UB3ANZWU]FND.(+WCW3&
M!]W/Q;HTQ.K?496:P5G8U#$P."?]?<PODQPF5[]8D[&!>6:6WL']=SZ%CTY,
M1?-+P)2KQMK!4C]R?D)$,=C/:U_;H*9Y]3_#"NL(_51GR5</BA.FMVO$*]99
M@ ">7"+RI .6G7PPNC(=IO=QL>)2P="6\;)1C#]#VQIXX 2';2_,NB^V%/IK
M[%T]Q30:%TV$.;QCMW(P3?/C8A0G>D;U/GY4UI#X[.+0C<9EGYD*QP45NCP5
MZ.S[P8MVG:S8EC 3E_FUIU20<&B^U.KVS7?+QPXUIH:(D7P$&")_F:&NU4UR
M:'"$NGQ@F-B0U;:.!#=.?[O05[.(2Z P*_[N\ZD6R/.=O/!MD[]YU/$!F)?S
M]P40@#\,_@\V^!+ZURBW3<C<TV?WB*RE\4%J]VPSEP2$RUF 2/K%DF:KDLM)
MQ4]Y+Z(OB>A8Q)^[,GLS=9.6^^^=\]*[\?!_[GO?O3ZH_1O^\BT+\)S 4#$S
M^)7M+YK>]Z).7=3V16@P;(M[#\PY[F?TNUW$KF\WNN+FPG8M.K, 3V4V[V*/
M[L[1CXAV%N $T@%(-8:2,&X1?B8T(.W>RH3?QN4)V'N*OAS(AF-D[=%"/VAC
MWU8A?'R:,%;:P.1@Y"@0_%-241@S:O3.-+O7IJFUOQO%?OK$-2-ZWTKU&^V.
M8Y=]76$WAO'HRNQE('#%")0TC69W>.WE.*T5!4YP]E5VX5B6UA6[>PG>6W+E
M7(FDV+,'5S]+[Z,(([1VGU333 Z,;+P!.4[U;,;,+0T5/Z&87#(7)APH1)[K
M..4A)10AKD^JDO"W"K&;1E$E>P+36HD&1 Z@8177X0SRN?[[ZFU?+E955W,E
M_LC'5ZT0Q&+]Y"EG&"_=T8%,E0&(+-U\^%XK[*0[\&+&B(R^<$P\EUB4#.!1
M<GS"YWV&O/L]7@#4^IGLGE,14;I$7+,^;RNW.C8F=WRA7V4#5H87S(6,E(M"
MF)M;N\LS6,@<?HMJ1 3RFMVJ/.YHIE=(<C^]+G:S"U@E%J!Z7/,N=8'D>)7Q
M <)##6Q B&DQNP<_K-&I+]=EL^X*7(F#MD3SA-A$@H[P;!.FP('(BJUEZ\I4
M+JJ[729=DV08=['$/CMH*@@M\4+[7*_N$:AWDOB%D2M7Q%ZZXTCF<OP:+,!1
M A$?<-H9:CA07CG(.W2Q1N]3$RFPS'5=L8<MEZT/NT&5F=I&@."")(F@QRP
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M%BZV[RU!S@[K$E99=IW<.T"IJ:ZWP0M^KN"S5_ F4B.:/A+963]I]]='*;@
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M_%@L;K.HE@AMF!2D.PVR *5T\ >+Q:!31XJ*2T8GF34WOQK-O+.3^*2XY=F
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M K1@FYL*10N*X8ABWA<8OMY$F$[N9XSMD$""TQN7R=4ZN^?LSOV8-8II(V&
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M#:E2R76R4U6T<UR20%2-.D-SCE;))TZI[]]P<)CAXFNCJ3SWXS9AL'=! QR
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M:CT6X\^UXNY<_MD?>N5'3G4?ZW32LY*'JSV-/=/90%\IMCUW2RX(E%(4_A!
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M>[+L#\QR=P+OYB*0MJ!F7:]X<]C!A7Q?PS'<D;'@''0PTW*@YH\!1;Q0!XT
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M.>R-/S<XPF7^0"5+EGV'"JR4^0G>3$(B"I]5LVNR'Q)_2HO5PZ0;VDDOD\8
M@Q2S9]0;C!,GUDS6X<(:71 &KE&'4*ZKE>NL@]X<R7,(EPY8-IW#R-XR9]7;
MS%12)QKLY'CX>&[BYF-M+!_<WB'07WU)W,%PW3K%600$9FZ"!M;6IO4*@HJY
M2-N3^&\I$GAB+9*NQ]#"N[,,@A\>E:^-B1^F !QM(FX11[V&"=7.IC@JU[ZK
MH$9;]WOS9V3^><^ ,I+_R"3<PX-AA=$$#)+,GM&Z&2?$US!3:%\GS*$:#U(Z
M80AVAECZH_80\4:JQE+]MD(#OJAU(6%Z)Z/]S=(ME)OWXY"G%0-4&\<%6T%T
MV3KO$I<=];U3H\-P;$$^H5J:GEKB.%C\E?"MYJ_#I$[LWTM&AQ$1-? /;P")
M#">I]3G=<AE"\W 1T-7Q"/1'X]>3MM1P+!6=!O8>(UXVL9RC$XYZ0SCJB'M_
M72$5R$L?=C6417/V7 8E>5V@Y9LY'/6F@*7+(E2XF^-0U/>- D"ZH9P]-7!K
M3BB@YE2=@CJ5&F/T[[(MS&>9LU],(F&2H][0[7YAXQJ+FO2'^,.+;)>L0)GU
M7T<6KQGU(]8N;+#7!&E:^%L3:P9C3"C[X#M2+=#7YX7</_]8)G]*7]T^QSO!
M%T^ELQ5_J,-'?"<[*TM58@ZUF'$AIU?R"HZU]D>Y<5Q775:_44S2WU8]M79.
MRO,\>@D:_,'ULL>NLU 1DVG@ZC!.[,'!]=3H#<14-\OR_RFOH@#9 B\1;NB*
M')>MIIVK)C7W>QLMA;DV];E?-RPZI-'0JF :JB^U;[R,0;,L_:=)%?9-[E;F
MF;@N8-O*I-^:Q!-<Z3MQ 0W7!G?EL=+Y;"+< -!%=T'YT$)LU0%=0\V0A*7]
MK<4]<OU(C+_:HVB@>J#N"N>Y%VZ;7R/9@SJ+]?+;D PR/3=TF>A9/_U=>(PS
M4N#+-P'WJ<$WP478MN2E<T)P6QJL*/_6EQ%RR/6Z5]X7G\"N__3X82&7]M'6
MB1E:MO&R ^F+/-9^\&/_8:FGBAU-#\:)HGOZ2$ZM.>B96\MZG:JWF(<'R2XJ
M#H%VCY&V)QR#E$OAMS&D2)@@Y@=H;21:3P!Z=ECJ! D9!CLPYSD'B/;"BTOG
MEZV6+Z.[3P\E)EXOGY? CND?[CS/)$X[M"X%T^(6- QH,V_>!O@[BT";/FW'
M'&FIX63!3DWPBZ NTHZL:,&N99VV9;G)0B_8K3 ;0^,*WW,A?!/-?K$("9.A
M>Z?,/\KTI+DN/W;\62O&2/>G1;=6O5KSI6 .C(E+6G?V%T ?K6NA70\M-J=.
MK^VJ'/ 6#..#M'O]_'U]J@]V(OR*R0IHW/J=I>S!/(AF\?"$/R=9#@R<RIXA
M*SX:Y5,,[9J]58$[H'LRAU\3+=^]],>Y@34\^2KTXJM%1,1!"Y7(K)XD"A<"
MF4TZ;/3S!^B_$R:AI14XF;HCSC,7/&C\#31=>R6) :7-.+5-WYDB=R[$!?O,
MQ[C<).*(HI0[IZ,U&4[[X4_'MU[A!:F9?P6IFX)23=DF1$'\B/UD5K*9?-Q1
MMS'=7,%*N%Z1E,6)V:4MJLO0K=8"A.WSP>W29SUPF!0#L2US_3N,Z$/T&/0L
M+X)?(D6/L6SC90O[!G(A.R49IJXS_A; L9J1WK:B&'<F,A%C8Z$TRS[83EK5
M9*J$U1B=75I4]Z&]9GJH>?3B>@B:GYH+TGQ1>0,#)3:G7HL>='C"#KV_QO;B
M&6DHT^3V!W64E44\X^3RLVI>Q/B2777-"*-7)KGAG*O(&K G4NWD(<(^$;7J
ML#0KI1?K^_="6^K.ES&<R:P913>2L3OI2=L!YUY5/F)H?BX<%*AD[RT36=)L
ME(2-NZ6;#.EFC*-.U#9F#S#P?9;*NT4.ORI.G_$T(R5LZ6->K*># U]L%O''
MW:=:O-B'GDWW/)W,I+ACKC3S8LE)J,N)$>4_=%6VB[5V(1_]%/X \X-F^>_$
M_7Q'"V <C?YRI&'EO(S7'RI=_H?9KBY$NBR#Z)>54"^BP,_?T:<D"T^XHL <
M0.I5$JA0QK:-46;V*!>BP(7$:U?C&0I)S=6Q==9./H.+T[=$<06S\*Q[ML X
MXHB[^ %&YGC?<N><5_4--$[=$4O-?46@FG A,;Y[&XRA)N6M%Y6S#G3U.FN4
M.()">9*1ZV7VO88ZECW=MH;/TC%Y.R+HN4Z.=A0%,,W\RA@S (U69,=M7Z-_
M8W2@CXLP%FB^KW%RX^,J[??MH:'WQM&]A$,JT1*PHZZ+E3XXN0TR9<3]3!"3
M6,D+&:OI!OYF4L9XU_A<!(TY47#\"_V[$:Z'%R!/UA[YR#+!GC[V<#W:Q'^7
MGK_WNP7_FDW0QOI"F RGHP/-T)C7A Z<XA@H^R)1W]Q1@>3 IS5\RD6/!MGC
M1<HUCF3!:4'/@@7+/?LF3U2_" ORUZ!S\&R1Y2'!H!RR;C&6M%IZ/9DYX]/Q
M5WR<+1=#<*&]*CDSTI6P0W6*N2J)=8$7K9UD&ZW$\[;YZSL64!ZL*<)W-C7>
M,O52O('S<?M7#[2.,Q.,\3W5*@PY7.-E5/EGHJ[IX\7-\.'\;DGJ_OMH[S+>
M1UQA&#S\'"_M,K?<^:#OC,?\Z@?*QLS'1X#&BL/:*5VEY':T^1I(/6A;4T3>
M(4(AIMXH:-PQ5*ZRRT3S9O5AIMM+=%F%(TN:+5ETQYYZ(GI_-29(O8<&:CW/
M+H+5T*,9Q;QW#"[D1;>,2$OMK!A/#_]ABB@N1Y3PG"V5;XQ TL!0;V<O)6EM
M?!_FR' )0PTT_$VNE]?MI/87"GW>[17M5;]!TAYH#UOT_D 0S=0]BE@R1WC"
M#YZRMM9:N7\2N2/ALV144VB<WB/%31%B@[98W$J)4Y5WW4KMM-6ERM:"G:ZG
M0J]#ODA!%!T:5?*1C8! MXPPQH4 &(&S9\-+&!AR^N46)5W-W#&)769MA8F;
M06=J!CIP7W"1VD_,W,#1-(O*GONQ^,Y&K*MR*!A1=M"B/>SCQB> DJD+-5JR
MP#SF0M1HWXCTVXP*O\.MX/LVMK6H$7OH=+5$?C5B,(=B3CD #<XQBP'HS %5
M+@1[17'C6]30HW')O&D&!OPR!QJ"/L6SX5_9.26<8+2:[<,U+T$=O4;YSKY)
MG:"X%F2OQJ^5FF44>8E^3VJDIZ7M,$;/(O6N#8Y@L] X4VMEF?K\49X2K/&S
M5+&NA*>"[OZ:.Q$02*<))=;UDDWV_CDTJ:_1&++5H/@8+ ['ET!+_1:-(SWJ
MHUH,M-BW+.?TQ:J^/E+TJUAS_-//4<FZGI &.U#""]*\42!B#@R%P9Q(W1Z=
M.JHXYJ_T!O%&TV<L1&S9[:]PS03G@_XR0TK8@;J^S/+;RMOAJRLTS(R70?CJ
MUR4#6M(6[M@PCYT J4Q<*2.Z6?2<W^IL^05L"Y\UR-S7",_*?[9<*!B=??.*
MO3?HW!M\SH?\=XF3[\J.>QF<:']7=ABG=QNH1^Q<NN*?<:2R>O@SS.?C8TVH
M6;G^['RSVQ#0 M]U^L][\.W#Y8TO9FUMC";JYD$ZHG]2= AN,' Q9;WHEJK@
MD_Y@\.LLN+\W_F<M-;7C2BN5=>'N:X#>?1^>YKB:WXYX"M^79R2)A##L1BO&
M5TM=';J( K;Y8L6-W7$_$(^U94,;6TG926V'7Z%W4V<ROKEY"2D/?EK:):G0
MR]<;.F]%M6YV%6G>ZWS0M5OV^AOT]O>9Y::F0]('8NRIN3L/FMZ\_L_2Q$,H
M[1TNK?5538!4;^='O%))M.*%8P9U]\Y4.CI<WZ:EI;=M!9%\I.+G;=J$5;\R
M?KGF2,_HZ+>>KTNY0R*W7F>@F!S;S)K7/M9&9SR\[_=76[-32#.W]:6ZFP=>
MQF/_)"ZD;*GP,A5HA%^9"K>X$!H33@I#\R(6":"EX0H%X(C\@Y9)0,%=>"HB
M "2:9B[D9B&\"UZ+696?/I3 .H3R[?8VLF8A=I5:GNLY752U0/_MZ;Z K0TF
M9E*GPX557Z4+R/9V)N$UB@5'+AXS++YS9O#^@QL"$H?U=J]8]UE^#&YW=EB^
M]C*-$(B)U\NK4'B76*E]-N'&W#!'!/2+:^U'_ZFWK-@$TP8&,?M@VULU"O(_
M<2&N?J$&[6_G_S1Z),Q1UQK9/[_Y]?P4'^(U%R(#1YI$<"%'8-TY0[:8!FE2
MY5G"T/#5O!.)02=P8>CS1WT^2M\DEH5\\SC?;JA\:Q.3XSGWF!TMD6QU1;=P
MF0NYQH4DI3"WT2CT*0:2"E\Z! 4-C&<Y3473F&+U%#%V^7JJG07<HUUXF3BK
MV8H9,2,;M#[X7%S=ARG4U3SZFU.5T6&*]WHBL%Y;+#"2\4<4]<HF-AA:A&G"
M8H60@0[97,A=/_<_! 8V')S(WAN1JE5VC%.\NPGJ>L)LG[;++KE4E_4#T4S'
MN>2'.<IM;Y=RU8=9-SCBZUW\^/=H/G0]X0"@$91F6E4&CNIBXXV[A-*R6X.&
MIV2H]8WP#_(N&1V(-_!M8">X<"@?T/%! \<^87<"*\3)S[V4)^LQ?MC_UM8<
M^@%T')_IVM;B<8C:H)+&$=_BM(8D>]A1O[0"XYA,+@3^F;H2#"_J:L0^R=TY
MGI3%0].(A(P5N+PQ>B0IE1QVKDF;\V7?/@&-9753A*1%V975V5Q%@MJD(OD4
M^<&"14+"&KAL15K_79@!PCH,#NV2\#.HH 9^_U>2^PTUH<PIAYD[?P2O3Q,F
M-1ACN0M)VC,??3_87>X9L[W2>^7G8R/5-ORP2B2!OT:6%FU26DA#OV*6I>>%
MW;HKGO#E[=<6RK3V\OGYUQ1Y:6-_(OM,5[TP4P2SFA_$A;0N3I<\K!!+OGE-
MY(IB-68*9>'_TM[S2I'7M-CN?%$D&O\ ;=2-R.<AX^^ _P6,O_DOP/C_+K5G
M@X3)32;,8,>YD*];^ TC:3:5!?IFQU X4'!O,KZC9"GS-9(8V)B:C>S7?:,G
MOK ^<R&!.7W$>7V_L#26&/M(]X:@*TMEMU[9=&GT:36#7,0N [/GC9N<"W@D
MON ;M9_J%13KDUX.TL%-;$U;H=_K7= %QJOTC%=U8V67%3*CZ,)^_W^<[7\B
MSO8IH+SH[AOG-<2";SG3.T;6JT+S1I['FXW33=LNF$8GF$95.WR+FEF0U/&7
M_YSXVU,-Y=6O]>8WO8]G0/ O>8E ]1?8)TE([=9Z'R0Y7_\QX6'2F:&C&SO8
MJV@(WU N>2(*4<H?5Z=JHTJ3J50OMZZ02W-CI=U<;[(/D^TO#EJ,RSZUO]NE
MJW<5(>QIT]FOJCC8NZ(2/2T-L* ^;!M.C2[_)%2[O;&YQB&WP/(0LKA;F&6V
MWQ?SA4_8 R&&LN)\K/N-?5?->B&UVIFI,X6Y/Y\2MET/FMZ#^=(F\\0R_M2K
M.Y\$[CV"++A. "+H)BYD?YV\OZ9O.8X:.8</H=>:[TY,ZO^-A&4+.NG%/OJ6
M9;7\E8,3:&1K-:B_DM]//,OR[)]@Y1(8YAP3W.(03 1H(^P'5/PU+:Q,>]2=
MSV#*-&P:154^*6L:;IAB;RBNJ#S#%1$;":$PXPFZ+_MX0)\??/A(<>2YBCP/
MRKU J4.@Y'J</S_)[,")I?ME),X['.1"EK;0+[@0S568!\.0M=>/CS21X)_7
M-*XZ( HZ'_;;AR0YR6<O<"'!K]B*<Y_O&OG%*[RPCSQX*G/O3KXGD)\GURW?
M'KZTI]N +!'F' LJL8=NEEK^/VL/M4\]C5)\2<MI1O*C=&(J(E'&67/Y,1$%
M!>8.R$W[SAGVMIR3+8*IU[ZNRI_OQ:J/):7T=R,4&+/ 'DTJI;'NOAVTN%_7
M_!'!YW(F2ZD2[+\--)PI876!M"[V04\R/ +UM0;ND,6P&.4,R48O6?(MK*+"
M 4X4S=7QUBEMSS6X$D::(#I;)'4QZ>XZ_747JPK00<O/HXK?JY;&:[<>B?W^
M_1%$N@TO1VM=NDO-(7$AR:G8F(?N!0G8XOEGXX;5K)SVO>#GJ=%'F_GUDEMC
MZHY=[B C1!=2OR54MU55/H@T8:G.N@ 0RY-V.]V/)_2$ZH Z'W0@U*9I4@C-
M[".)-5-<B#[@. 'P$![3G O]GS,NUF]JQG8KEZ4,B,D -P,CH515WH5Y]$E&
M-05S3I5\E,0"3:NDH'T'D!7S\F>QK.6:\(:ZG31HG#O03AKCOT&4Y]^ISK),
M0U:[\?.-$NL84$!@A6;6;&=3]?X()M3-.MY;\L7QS_0XI5&6JM4J4);ZX,B%
M-KR2^#C!PH]@V^EI?+)2@]/OL(GOQYU?J&H&JE&;J8E++>_\Y2<^5R5F\? J
M$\P5UP-YP3=CQ$XGP*9.GK@!/W"U]FZYH.,V^F_NGHPS^+<H82J4M-*(4:K1
M(0FI7,N 5WM/";CS<\J"ND"3W-)8!MIL[ONI#R/.075^A^^AN,)<5J^S$:0<
M,OJ&'Y3NP4BA2;8'"=97O:?W/*[P/1"4NEWOS_A$,X8HX@^&)"" (\<:M:<U
MH^5[UR]CY29,8@MFF"(^"K#)0GRWMN+XN\9!JX ^=Y-E1/@6SB2<9".FY%*A
MN:G2B&C::OTR4:C2@.3?>FPW3\Q0J+)#=5A-O>PJ]?AY0R]9([ U'"6?Z0=K
MNCUGI1<7ZP2?#@TM_AT7'VS59UEK('AQ7_X5 10VIW&2.FCN<K O2'SAH*F^
MM_0_WHS\W_$</7KA^.2>+5?Z$Y!"0D#6$Q[VJMVN3ZN(?/=-,E# 8.@W)-/U
M_-?C&&]-F=TZKMEA,@6G4"_M?;Q)A8FT!+K7;R"%Y;.@UQ:L$C-B[^K1WWKO
MC$VLDI"KK'QN(.6B7:+Z&T3/&&5)8P%['$B$W9R<RPPWIXQ3_4D*WJ[/V^Z*
M!KPA9;>6]\]=U$ IT2KHJ8Q@&IWSGG:IF L9^L0B=>>5"+V$)6/AJM#QQQTK
M=O;V]IZ?["XX.R*5QD:79:-V[Z_^VC1YZL-4?. >UD-QX=Z<%7+ZA#L.-CLW
MA!&\D>623/S.4JI#XB=KK^60?9M7Q-GVQ#1+&KK:.V]L5?:V]8'?<QCV,7>O
M!RK(;&!)</[%#!VBTCIRW[QFP,#'1Q[2^2_E#& Y?&^DVR9]\7@T!!3WZB@S
M"K)D8>* ^WUJ6-S@W>P&L3*!I FM6YA)Z[08,6G7=0,2LAZWBRW^HR5QDK-K
MY'+PD[7L"U6!3^%1AM:G9_%FP1EG%'/$TN\6>M!O>7\GNB5M3'E3/D?S/\$6
M-63)5:,49P&$/TWE"Y0A)X L<86*K=#CI/Q\C=)PFXZOT;E0SN9PW085&Z*N
M IE[Y#0NU?-PW59Y&ZO:6N&9D_!CCW[L8W^]#C=3A%!4ZSW5^%IGYY&<430R
M[GO1[6>5N=\6*_17@>3_O5O5_X>?G6X&QJ4#IQV+"65A]&^DO9[6HY>.Q^GK
MF;^,V1\DA#)A7<#4J]7HD;M*%Z%[E^VI+9^&7I0&9G;8GUQ\YFXE$@1SF(.8
M(AYUVR8_=$!)57[X-I&P)1,F#(WX8H(3UD&;]$.#N1 1F!BCA"0> =6G^81[
M9T[$O!0ML$^YT#(W)7%;?,Q0S* >K4T3;LP/$$(V:C?/1'ZZN*G\<%IA<#E_
MZ.6FV?/ *,X8C=@X(<2^^D.N6]<L<]@U]7[MG6JL3R]GVOU#8\G)'3X:6QN\
MH:INZ$G9+,+WK%A;EDKX_- 0V#[Z9C'"X?QM?I92*:T_$E]9/_M257&(;*F(
M\>1"5'#CZ(0DFK+DX=HX507>5A]A=6M^QAM:LL(^N-!UG:4<2[-J>RA__@)9
M2?O87?M%==F7F_>_MK$^*2Y/"/MAK] >8-URG5)C"_*S;0H8R-,SM^\]#SP;
M+X3>MIAZ*(N4;C%[M?^GLE?MI2&ZL;._J/YIM[EO7P[8XNM7L.-:#-&\H.H&
M[=$!T^I=GWNG.=-97:4O9 1:)<,.^QQ[)_G\1EYMMMAJW1A\$GW)/USP1Y.*
MZU,4OF((,[T%K3YH^94+X0W3NAYZ$-W^GO'%8!(G MNOUY32NRS)B31A%F.J
MY2"3N^P1U@;'OD;-U7>'73SY5;;/LI%\IJRP9"I?4FWMH<6^NCWHSAHMQ$;)
M@G:40H%9S#^S=',_./M8E<*,-]Z+/^="NG0B7NFS(PK$K3GIP&&_:#G6%YB,
MKWNQ?D[KKUB=?$Y^P FQU_-_Y+0>Y)C&7E%?F+]QDIF+TUO$%"+K\^T]PALK
MM&_&]O_TEFB=DDXQF+838/V);B+L@PFS=?I19DBR7L"N8 ^DLQ?U^XG$8K%M
MN]]O]UC\09S8V,)S(3MW@RZ!+64.)7D7MJ1V$4X8G% <E9&$+Z\SH[9JAL,$
MA<(2_R_VWCNLJ6W=%XZ"4E2P4$20J"!(%ZD*)#9 1$!$>LE2.@B(@+20*$@1
MA @(""@!J=(BO2=TI!EZ[T4Z))002/O"VOOYSG?7VL]WUCUWG[//O=<_Q@-S
MA$SF^(WQMC'>^?[4-=Q4N&('YZ"QWH'M."\-?7?+CFT#@\'Y4;<YGRM?, K@
M2TK@-V VPQE,1"[TJER8WVG?\7K>L#3QP-H?O1'Q/.2<Y14IXF7J5^$X B9$
M_KWMQMX-4PU$AK49-0:O'9UMMNB3GI%B*W;'PU&TDR/TN?Z'.</5N%IPJ $-
M<!;$;3=QZ6W?6"LP^N6KS>@KAU[OXR9QHON?XDZ\:;ZNA^)M=2CQ!3HVE"L?
M5?D1*\2=T._0/]BZ#3(_V#2R&/J"*('>+?^X/M>0)@[U<9-QVS UP. >()F$
M-HJ)&+,X$OKQ\PQ0A4&G7YRJWXM6W*D1Y P-T$$JG^.Q>OD%O4NU;>-"XK00
M@82U2G/3)FZ(I'RK-X!G9^\WIIT-4WDX3L?E#1<:$F^=8[ZVLN @KN#W,I B
M#='4-14O.G+^JU3Y8H1.7(N#- G!4$0)A+&:'!F?(E1X.-5E]*UCIVY^. QF
M'2VAO(>Q#0>=(K)K.XU#!V)UVMT^&7[K-A7GXE)ZA!B+")D?ND*6M?Q]ZUSY
MYR#=!3"V:6S!;32(NR(FEIY_!^/GY4IL<7&U(\X-]E-8=I./S6=:>Y*U4KN>
M*.87A@X_3#^?C)YS5S]Q&WS\])Z /+;!1RWII,F2@4$=[XL]^<5$;;?(UW5Y
MHE?RHC0MW3^X'T1QEO^R# 6Q'Z"KU*XD!B)GAE].T\BVO"%;57)ORM]([-E<
MDQ3XKJRKPKRA!^P4T<3!&:81=\SA^@F6;EX10LGS_7<Y*S_9+NT+=X#1COUU
M\Q\_.1?/VNWZPNOV^"<8A)M^LFVGVNWZ2!'! ANH<&0)L '[ZF6^LE:>V/*H
M0M.7H:>.K3*]<S]. C>NZVY /L/YP5-?@"=AHGZI6KA>A=?5RGL0R>9'+C80
MPD*M&/+NL45-PW9NS^AE[D=CXUJ7.SLZ+#0R7JRO:FL(;FKLR"T!C\)M-D*
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M[1_?$?[&ET L.BC 96*LO,(>[*,>58TB-.<FEPTHWJK=.=*ZJPNYX-7;,B%
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MM_2P'TAE&<6U-,#,*D</BHCQ%8Z/G;V +50MP1QNSKAN8/D.VN^R0E=B;#3
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MN)R]J[O(\5RTB<,PIS2$4-I]D(/[GU=)F.ZR2--=%D;BJ72_HJ:1.8/HRO4
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M\FB6>9WD7W5#[+Z7F8J(FUY&]*;&N9ZZ)W;M23%7FG8UA/<.:*S4[?X;N/(
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M"PX1(:F%68"7'$E_)[HOL)O@[G:1Z]36/B"Z;\MWK4"HZB89AS!4H$IA##1
MG=2.A-[J2%F3Q+TE@P5V2D#Z=]3SB9[.MLQRK1:F#1$4^N^L/I]9W.$'K#Y<
M25=-E!XWW*NU=(]X\3NK3PYWTA-<^_!TG SD!;4:O8D?TPRL0UF_,5M[V2-&
MID*\<;NU<.+E55=*H@$QY^M>7@/=5(/3V@/WM13G2+E>!!]2U;_+>>]NV/BT
M8.B=Y=^3?5S##Y)]4!:>YI52<=OUH5?R&3K^Y>_,_[5T8'N7O0>QD32 )?(-
M#;"M_1E2(O>/CA#_+<2+@?\I0OMS0G,RPY_BLQQZJ/?'G.:_W;5\@WY]5ID;
M![D38(1O>2NN+),QIBV14HZ)MHMZE.Y_95F;$\&0G,]+2*+D*Q\B"1-M!A_A
M8\8;X_;]VRGQ:4;U5N4U=O7KQ\A74GWF/[U28,L,)>M2"M$@J"XE0P[(3KZ)
M3XIV3?82I6KFN!RSG[W4_TA*#&O76A>#\>9:<@T"7ZG5RCY$.?Y(AO%1Q^TL
M'L%MCI*],KK@:A/[9Y <7K.UDT6>KR6M2ON@9EV@'$&GLA_&F9MY:\/!HHF1
M$SJ$VR_'F)D&]Y%K<3@I]4&V2$^\;;TT1.SC.+SDJ97:>?TTQB^1O8P1M\[G
M#&S7/&HW[5W;V%XIEUIU/JEQHC\W1_#1U\6VMGL7]D.)9;?H6-XA'RT@^K&%
M91LY5&:&H'^<=CDCF2HKPU/0GG;QG6C%G)C ;W1G.'H:4L >"M4C\5*'$S96
ML3/AUCLNK,O.&ZF=PNWGM)^2[LJHL2@Q%JRKWW3]Z;3@?X]I.=P[KE%GQ'$:
M7&_^<"E)BA@\O<;T&"!COVNX1/C E&+W6C)YP?\F$_+^YB3Q2N::")PD0_T1
M-U(:J#!,UL\SRT"D:P-<BKXO_]B:H@%>R$+AI7K*AC\F"[#DTS0 /;8)0[,M
M@12(3=9^,Q@.8O:XARYC0F!3Y7#3U4G^!]IY@KFYY\.2CCFUM&D"8/Y$[AEP
M($S8;G)DXB2>/V[&2>9E@T?:>(OKN;)=C=O/_1!RW8.SD\V(X!MQY-,HPD><
M2P24)1LR#I7!"^9QKD<K)PXU\$HA'2\N$HT9&N>L3M[ZT6.Z0VC>/W&_;6)S
M0+^\I#S<.M3HAW[W*]':_9.WDEF6>/Q%;"X^/A[EPVI"'J4#G0EUP.N$*KM.
MN0Q7U<9=,W4 2=H!]:/D1Q?$>_<,"*L-,5K?-X1)%Y6<&1E6*#J$=B)WZDKP
MO2IBT?195$R',V:DX)H 6W;/8=U[2_[J%R+Z5WPLOEKG+1%V]SW&N D*S()!
MRP/Z42*/MZVM!4_ZJ4)-D^DJ[B*5P8@,"E;M%Y<SUVN$V+(HO(W33>!Y-S3?
M<[*9TVR3,_(;@#%) X<:"FX"B5#":8!GG9X$6[Q:X7Y9H(>"9_?/Z/EP86F_
M+SRIC)_]C78%DA6WY+?J!!EVU*K;9X37Y'#(:<DL=RPW^0Z.$) -X"DFY6R3
M[C-T%=^,>^A6=X$!F^[M0N;0(WS 4.)I %O--=/;B:M4T8%\/?6>3(#"\)R'
MK3<.7G$.!!X521);<!E:H++ #][CFV1R1_*2GQ:B\9!0J+YS99:_UNV9\6<S
M'UT00L(&408&;$W8(Z6S\Y=?@6]!C^&!]9@SQ2YK+LQ>"$V\?'S5D\H>Y]GR
M<%-26HHBJ"5A<05_4$C[LR:5Q9#TP$NA!<38+[6.YB%&&83N:B1IK3X)C\.6
MO-^&BK^>>7&-^<*"O<0^R=+O:+JUB[>CZ)C)F%IAD[BMZ&(MYV]^S!>Z&+?_
MZW(*.#G[^^3E>\;,VG[G<]<X*YH=D1;=93B+:G'9DP2>I %6G_;!MS/N3TEF
M;*8JDEI>6V@]JY>U%&F[(25#X&MX]6W/0D]YECMB/I/9#3.^9]$^.5[#'4^R
MGIKDM8.<=%<L0;(YQ.ZCXP6N271666N*7$ \O,59 0E\*>-QVZ_)5)P[ZKD8
M'\B>3_6RKMHDF,@45U]]\<U,;D*2JR;O]\][T8%[@F5:6ZC'J_D)MNM:7BU-
MV)'1Z85Z\(V!E<?4D8'4[]3VGI!851<-7B7+?6EL :K3AI)<;>N(V]#&J235
M@)#3[9PQ!@,-NUH*\6+?)RP1\4%F^$^6?(:?0<GP0->=7+$%(Q^'UI7=)!43
M*#!2/_&'S+W^>>>N5&_YZ-[XYF6)G?#MT8_[D)G)M58\PXS"9]LT;>7SJ6!^
MM82%-4G,&O;5Y&ZM#G3P1QFWZ9RWT(?J=YHR2M8?D]+V$]I]WPHNM_"//?;8
MBBDJ$UY7HV+FGH3@,>)M(LH*Q^<_Y>QEK.TV*[S8^S&_BU8E)9<M/4 \CA(>
M^\HC$%GC"7!;] +?9L[*?>;LH92U]FQMOJKB_=J]WVZOMW0=:D79X!16+?%N
M+3#3AFGC8D?U%;<\Q>)CZ[H8+_7N$][MG!%-:!-#&J!,=\_">@9Q#G_,?<G0
M?8;:>79SE#IAB*0^\-:FNU&.9L41/;MZ%4G- A]SR?6E>'C%R7IA,B/K=U3U
MW\Z)53?G\8AW\1B,?4H=HLT>3AS_G6-J95KX%;E"HOJR4[:Y,-A^@*7ZJ>]Y
MU >FQ2]5]E9&(QL)J*KE=1K@&/*43K";\K-Q,\TBWPJELCVJ./DK#M% 5ZK[
ML]]Q"\$E$DY;Q92@_GE]&L#[53U5T+"+_R!QRI/\$*\0)UGH/LEJJB!>%G?8
M'K]\6J(!U-$.R90O_68TVN+B=/PE3DT^3?>*ONXB8.IQ_WKW=(>R7(ZP5!T<
M.>/'#WR#*]Y!*0CO2O53A;^C#XI<.7FQWZ$/1[(HVRO)@]3=K/JYRD]?$SPW
M@WZ# ]>!#Y$5'H-X<4EQZ0]J)"W+3H!GQ:RQ,XZE7VKV%?GD@<3'/60J!9O5
M,%^N+(RS%R3MD"925#D,79?^2R/&:_91$\*QAD:SJN(_%@[=/$A@W]N:W5VK
MPVU,Z8S(;GG2 "S@WRFC+)=>'-U,[/'V-JIID:!VPIZ1O2G?T)>@L 13)\-'
MU.^X%6#TG9YV=6=UEZL+[IF9$XK8"ZR[SXU! CSV<NW\&]OJO=;#1Z6 ]B6M
M;!O;YG I&?J,(B9QNEA&J"Q).V:J"='"?_%!2@*+=&;M1![=>3+>1@10IB&?
M)L]B[-C/0U_VHT=GUEXX#D6&W<IL(%5IPG<O\3%$*/ 5K&MYS]GUW/@BXFGY
M*OOWXL]QM4"B,"0"+7+ )&5# S 0/7!3YJJ)2X.H5I;F6GB-$/OS7+$UD2?/
MK]]529NHF: !I(A,BX^?&SO?T1GI3"/5F&[3 *^@!:EVE<$A)9I^"O<+*OI*
MCL4-GTA/TQ(O5/B2[:^Q;S@Z"0!/?=P?# &UYT(?UC@QZ"BZI@Q5ULP%9)W6
M:&MD3QX;5V]S7'<) !>A7J$9[)$VN-BWYTMZ,UIW-!$3$V9PC A/L]K+?.XN
MUNWLO3&7DX^_>CV)$]T8I![:]$9P].?Y>,FU5=70 %,PJ:YY]'FR%-W%]SMT
M0-SY,N%WXL[6K;9_<_$K$ZZ@HOY.W!GT3R+N_&_1REU"#UZJY\87W;D!>2<K
MYO=(CJFU7,"ZJ4)E]@.T?9N)B2_ O)/S^:>OK??9.L_I?;WQ2"]C=? QS(#:
M!<%IT4V^"LF@8$K$&I_T*M[-BN.$VI'M(<7$Y8^6E!\[^/ZFZE+/T[>4=8[C
M"]0C5$7;:J?\V6^?@-_>F4'R8ZQT@C'%C*?-'&^X$&Q#7LZH>&H=5DIB.JPM
M+;H]_5IQT0#=P-!X.CPEU-!\@ :0]5LW;](+_#JK/[@E075$M>/!XE1&V #X
M)-R6E#7;57+'-\5E7#(P*UHBQVKSH:UT 77S5)),4LR^/@E$'9MD1]^0*/TL
M]QV7&9I63P-8.3QZ571]C7%,/*GM91E)965KD/"*$D*]"&52.!=@0H_0M*;M
M6@6,>P4$U=!%3>VJ._/P$532RACJ59W--T+Q!"J;8KBW["<I+-:^50F;B#:$
M.X"S:0 5G47G4'+(P39+L@6(J$)P$K.(K+:?]L(A;= ?*-GC/K!EM^A7X,!=
MMJOR.Z@>%W]X<>8K&-@>#0_T"'3<-N]=XOX8NLF^FXKM (\\:M^ G IOPY^5
ML$+QK^RLPEP^6I575U1HN=W9BYT$M61UJW+.)C'_R\^-?V_>N\W8\(ES1/:I
M1,PIK] %UE#5DD]&,N8:B%A9_H6**0^YYV^R-6ZSKB7H9=[H?;R44U;(/0MI
MWC@!9<8Y84.45=T"']*#="OOP6N6;V["D0X@5J@+#ML"/SKJ%= 09QHSR,WU
MXJ10:72E(D%E_QS9B;B!GVV$ ZNM017Y/UH!@B9&8M&<Q=[3AI-]NUE49K(7
M7J=6AU.H9+H]\ )>Y</>56V5LX?!TA![:CX-4 2%5)-5P%/(%!H@VV49SKU1
MMDG73/ZPGPXFGY/",K%^6>9UEM;.01KYSE9&L^'J!C9/ ?P_T3+$+7J<)HW+
M# #UID.5BB'<RRL?;GP83>V=<='MSJ#KMC6]/FF4/T@&U@,Y"5)V..K"N1*E
M985"GQ<:O#I\:ZGTJK< J<.X9J5S37RA3_)+:8F_9F+\1\'G]8'C0Y\ @+GH
M1;%4IH;M)1(QLX,D@9GZ; QG[4EW^#CL!FIW21RG,CGA+6<S(T *#C2 "SX(
MXY;][&F7B:UU"=I7_?2T883,NT\OM%SWU1#PF1/W)[5[5IWE)&Y/E]YQM#^C
M*1Z^F)T<!8O9P=:Z$(6PX>B+?HF/\8UY4^$GZ/ZVM0=[5@>Z.^D2#?":W$ *
MPMQ!LU&QH,/$,QF4Q/H;Q^4])1-M^S(H:W,TP$:;=[/WR-74;YR#H3^N?KQ"
M$CT6GQ]F30='H(JG\2Q?):CE^(>$Q>+0/1H@$F=8"R<*Z;R%&A/\#&=4M[P,
M-9\I$+12C*7F(6K.CZ1:W#R.J,("R!)$J0,*9@6"R]\HF!DZXP]Y+PA41Y4:
MTP!G7@^QKF6A0IIMC#XY4N:*5TNI-3H_7/=*I:["T7%5PW:8*7)]Z!745;S_
MOUJM_N]T@LW0016!==( ;%1YKYR&<S1 !/0ZTUOG:GFA<QXU6S*F O<M);%L
M+UNI7Y_S<:XTP;SI$:5KWDQ1&?$\XRG!DW<K>]3Y'#AU;_;6 M@ #"6P7,-Y
M")E;B6J'I#33 (3Z5V!]L<TX@_=>.=1C;RT=W1_$$B3#6)'3F\5GKM( W^/!
MX; \PWE@^*L#VO8CQ5TEFK4"I0/69:3KT%>P[K1$Z1W*HLO\36!.S)XJR:\
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MZ<\6=_!L0+H<'C!:I("XX-V:.#B5/0].G'^!Q#6!#X$7WQ/!!T86'@C\PS7
M X[K0AX#+Z8?]# -8 [HA.QT I';C\A &B!@!4*];I9)EJ8;_GU!$/W9ZQY
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MO_S,O?'9;3^SK%T4%H*8Q#W4"0&>!?6F+[Y0\(?*"#T<6=I$EFC7@'T5Z^J
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M2IXII5&#+KWTQ9-- YRVHJ]'5J+!F+.@WQ>Q>)A%P]LX)+P'#>W%6,/?W<C
M"D]GOHU^>9.DEBA^7L7S-:*YTER)P$5<R7:Z2@95:34\)ZG.YP*3]M382X!Z
M;2(;[5MQ>]^HV.]9Z\DUUM1GZU*8J0PD#TIZ7B/9:(<&T,T\,TC9=8[I= #B
M'KI$[$YE$[LE3N;WE.[K?R2_>"H(3,D3 Q*%N5N.-754LGU^^C+@[8X1.P@I
MH !.=R\%XS3A89[&6R4NK,8 ]?W1I2&DF=.K[=TFT+,DY";L^/5"5LC6!@[^
MTYL_E60%=>Q7V)L\5?)A_!7LQQ*3CE:H--'P,[%E1B$4?7%<W6T&<6HYZ4(2
M2,#I_J8&N6 QY>T(*(8@?\"!F()_]\:OJN7<^?+Q (*O=_J>G_<Q;-F*65GS
M!E&(!@@#<7AQP4_;[2][-1H'16W^&*A+B;T2+*3*.U3.$ 5@9!V(4!+7TTV;
M25S-(PY-!%E'-W\)Y%'56+,;Q1=L'N'@BV _^CJZ=FZPTN\J$8JY 59R#7L^
M6<1;NO#)M@;V#=8N ^O$G("RIZXD'*V8KA$PKREE=W6;D; 8)#V2%S@>7M$2
MUT7.XC@5$& A3>*FUKVD"O;F53OB%>Y?LQ]D%OS6M=[W^MJIQBB4>=H+CAU&
M_I@=U,&)J5[KP:$Z?/4,-]&PUK;BG4-)<*IP!L$'+"6SN7ZY,\4\5Y)?1^=M
M9NKFU@W4/\&6H2) _QM:UE^^QR^$?B'T"Z%?"/U"Z!="OQ#ZA= OA'XA]'\A
M0F!QF+)7\'V\(9ESZV:_K)8VUJA74MEV&B)$J'=/XI%OR<QQ<K^LS7-/4?FD
MN@.E M6 >0=CZ0*=A]>95E^?WCAN1_!A"[:=!1_S0^I\>Z-ZW+2G;M(AXJAY
M/*+J'*7Q/[/&(^8J>*K4XLR@LN[!"\PD7K4^.;@ R;:3="*G<WZ=Q#8^>JOY
MN6M2N=P^7!7 B?,D<PP2M/ N31>G=<+ QR^45Q #I@@/G<3QA/BUGCNR.LQ4
MD4OOBQB7ZT9Y+C#LAG,<VGM]4%O/1G(;PQK.VSC)4J*!%C)5G].T=Y&*=)*M
MTS:._-#._53/T?-G)62(G>!$#)M%1)S;79/"Y]>;*S7ZA+RW&[&>.\KSOO7L
M.^P\_].[P;O2.=!&+N$OL91S7UXI"Q/Z*(F]A#3BD3PO>1[+TH$9CSYWW[?E
M=ZM#KMYL86)=QO(()+_P;A:;0KV&X'2ESL&:+3C*B#KXANGFBLO- 3PE/>NI
MEWC(@4!!+<Q<#/?\L4OR\I9!M<([^:$ <EQ7M0A>@<H:3KKKY=:$EL:E#P90
M68@VCW F%F+/DJXN]]R.:,NPM[F2O9XL>FDVBQ>C197V2GV,8Z>O2UXBXF9A
M*,FXVUUL[8Y.4910U/7,H/&YT&LA=ZZ*9\M_95P !)C3(=I$K#*1M*":E'2H
MP@QIXRV(JP!7,Q#CR2CO.K0T*.__V/UIX]NY%T.BU\^N6'C3 $?D*-%04_P]
M+[T9; .SI"3L E'E Z^FLE^&K_O[SC/UX-![:>)U-[Z];+X'H,RJ F"_V8%Q
MQF$U4O6I:GB%>J='+F]CN_=.CYBVSYEJ7=6+M;*^UC3T861\+S^.P$!)A%TB
MSLX&U9 TR8[?XK3Q_%\$S\G'>Q\*LKJF)B"SI_XQ\B*EPV%2^LC;Q72,6E8R
M.PNE!&RS3?D*.N1H<2+(:*VD_+/'>?X9YU-2EXZ?E*ZKKRQJOK?(E^0:2A2;
M,B1S:#8C"^("):AGR,^)KOD:KLG-3NY56=^#X!?56\^X[%U6W;O]/3S\X_0W
M%HKCEU?@R]M2K%"M@U4.Z^;GP[N\@XIX3!T4H.'Y4,T5%SHJ_.Y&\?O4PJ\)
MQJ&B55FL(>7+1S<&/!Z&<M[49P"P^<?^&Q<.V8#^-5%X:Z]7)K6Q'461+$"-
M)/S#SC]Q[/Z5)B(3H7,X-AE=&/:HH+SXD[3_C'SH+=Y"^0%&OFOO'T_M,)X:
M>>T##,/PR=V30[U+NE%3_$'+WC5_4NMX6'=D/I\_*#ET1FPG'?,$XR_9E%AG
M_/2%#J%DEP8 IOV13 <&-[W8//!5-.J#,WER#_CIIS>_8Z*EJ*6KW*4%!;_)
M+Q"V5F.!38O/O!_'KJY!<B=Q#6!&\*(&#=#V^_WHJMEV*IC" MXS0-/UYLX'
M+T\>KH1/L%VJ.C\PR$U<PLXP]9&HKGW&IV+'Q]33.D.!C<A".DK?Z0IGDB*1
M5--3@0K&L$%5<*@&UT7^LP5."O<BU&(D$GX:UQ?QE1Y_UWC8N]DU2L?-7,*/
M<K9-=I9G/:IB?T" TY37Q"M7M>+G6+I3_OAX=3YGG/>T.?=#0].\2_7S5DJ?
M;4K5C[M]^A3AG7=?S'UDJ$FCQ>:%(829?,SO0M1"'8R__+E\4-S]UR'\\2(;
M1H:0(O5ZS>_U&KB6>M$*['JQIAWV9]8)'WW.[#P#)0W*3WRC :)!'OT,/XH=
MVITJV5+2P,W>>=3 U/JF\8;EJS3+93&V#<()XBF?;$$<(RMWY-RR0B35UX8'
M!?M2:M3QX&6.5$UBR]5F]>F\RS2 "W@+9%M-!\&=?+QR2QESPL+$96EN>5#8
MMM>M;"6AJ8K^D17Y7+FU-.*DR>N^.UD!R/PYN9T8SNP.U\B17/26U\\AXIH%
MQ!=T[> N!F3Q&+-1K["FKGLM8I7+_=W>2X@B?_B-YDKZAP^)$G-'1YOWMZ5G
M8V+/6EW?^7YL;03]\TNI<>EU>/L@D;=%N2.UQ)8(C]S;\Z !&&,*O&I+B8FN
M'/'SZ=V<S2!_#ZH'@JXF&./Z4FU)PHU5QA_8/W2FREI]<K_P8&AA!9+J;I"C
MU(+:\R9*;2H@3MG0C44<Y@W\._G[P3!TO88Y89VSYH<MR1;N>BV(#,XBHS(D
M[CX-$/IM+]P%152;YUY'E(REEDTYX=AG(=FR!NV@%HDYY/<)99UX^L]68%0<
M'/< ^VZ@XXOB]K%DGX\>EZ1WQOP+I,!3G^'GG?0[8%PE5:+_#WMO'@YE__?_
MGU*4;2IKR"AK"9>0$C-:D%22(NLD10@A6\9,&T),*"HQ94E"8Y=ULI<E.UEG
M(;(,,]:3&3._<=W']_[=Q^>Z?M_C_GR/WWU?G_OZSA^/P^%]O([7S)SG^_UZ
MO9[G^5[NB.VUZ1&;_#"R?R.H 55G;O-I?Z-J#^(;"WA5&8B3*35'*S%=QK;U
MST)IH]\-X@*WD"+V;/1NI#]:M'["4.&;63D%MKM(!,&D9EK+FN9R*^O6#BCB
MO91S$W=?OU<+QZPE-47E8]W>H*&+<+YYN/-\U!$!LE<82HV+9^)&IYJ]0:/O
MYWW07,<1AA*M,>6C9Z44F?_:\($DTV3-I6:K^5#1CV2;*E=<Y:@>PI9BC@B&
M8VW;!:<'T:]6<M56AEKH3+^*]X1/QJ+)B(Z1*Q7=AY9Y+/Q<MWUS$&F3K(:]
M$BT@>RZA%[Q 'MH89.(="XA'KV0NCABBZ Y(32KJ[:=2!Y&..<M39?6#=]4D
M)H\=<PC*<<<-L(N1D*6'IM@PYJ[/SP0K,CIRKXYU*^KV>JO"BK"C=XV?'O!+
M92XSC4FBHO0'?G0%I%3E4WFL8*5>]AOF]#<G^&MBG_[D+)QZ9"TY'0R^EM$(
MB??VWCD5L^6KQC+[*YV#7S6EL@#-0)J_,,4BD<1T(5>)TO<$L/O*(@CQ^2A'
MO=V7[O?;]&HXW+[K=<-F3W5CB++[>\5>Y^X ,R4+I\*ISSHSKWN]Q03G,E;5
M%W4P8M=D:'%KZHMP.?>S[?7EU=B?&XE7JDH60#-%4K=7-V_DAM%FI[)%RI7=
MU)@>52WF_A"V/CPY4S[<IS#)V)WX10VW@I (C!-3&M?D#P+VS&UU3X&]P*VL
M\-B6KDJA<P9N5RLRQQ9+NLG],5K+-XMIB4]47\2<";^<?&*=-./3OA(/%EZ?
M[D2>IP4T_R9VWO-G#V35^BNNU!-/C+_'_U6PM/Z\D3*MN>5]XR3<?#\+.%B[
M.<1,AN6O#2'-8ZPU5V]VG!4(,6Q!'X07^Y3-]3.WL("O\)(%-ZQ(XG=U!N8%
M!>T^_W3%>Q9#AE76'=N@-+U$']G:1\FDD-C=\B0-9)(B)#96L*ZRC->[58;G
MX<3X:N5H[&PUK$O1#OG>_8"3_-@[H.38>M]> F-W)OGZP8W$!AGAERQ /%F_
M-7#].D\;U+99":_.Y&8! *SJ60\A?A*Z:,SMPL[S(N",6WZ$GKFK_^7QHL'S
M']2_W_%OQ%_0L/5'4RW,GO8-,9HZU%:=9/S?&!'>]T-SK3?OV#6&8S'[CN$$
M1F;9$6JW( LXWZD^$_E[B/)B>)7>W/7KM4>'_CG==#FH?;TY,@7]#92M/F'!
M#&%NGSFT^;('*NJXT- 4SI#SB:K;Y>H3,[HF+L%+S4U"@ ?GHV-M*3"^#L7;
MU.L)@5\8 ]E-\_!KZI@C;G.CW*[F%S2%LFZ,+SX-%7998O?G'Z5C'F\>R(,!
M'PN=X.4:9^#:/LKK)>;Z97"J.KAO62_L_3#V@/HB[,7FX>I%;LK3GM62-JTO
MUQ[KMAB9K"CR--P>1-?8W);1&T$>+@M=7'7L2SB!L7LIOF;5F(A@IZ2&F:-U
MWZCM#>?8 : H8AP>EZ6-":+"R4?>?"]% 33#0MGAEB/1/J%&FO'/QR+A!0ME
MLXG,K2R@%9Y?8$T178AGCX5YNAEX</7AZ$DUI##NY$O2N]<[A%"AB6M];5B&
MJ"GI1HO$9^I\5.ZX4]B0N]NORN7V02Z]8*L)>\)#I.&UCYYW!2\-Z_ Y%\;Z
M+C7WG>[XYJ5B>,A#)/+.U^D3T(NWF'5?3$EF\Y!E]T/86FRS\8Q^)KN )O8V
MSFM4GG OS4S.Y*Z8*FZ?L;5$4\V]'@0X(%Z1W5O.;R IBN.SZQ2C#4T$YJZE
M5WB>EXO"(F+\IIK(%_TWB6WH6+J^*ST(N;W*\A8#O27T*,P?&[2'P7U2T]8?
M6P*I"1X0E0,Q[[(<8R<O.$$CK@&X>C<5I;I SWCVF#?:39*&#F2IUS$P(RIF
M@[8DU:5@,IA$VJE9NMO=O[,$]9381\$UM',CSEP::DQA9]W#EJJ6/++WB/JH
M[>97JR4SNM+H3Q5J15!M+JMRZ[R%-*/H#X<\7+-_#.>$NTEXFM=)CW'SI@3F
MGF4&'6Q(20O(G#M2:F'K21\]%ZH9\ZHF!RNPDLL"XMBJX+=$MA9413,264 )
M_)VN"E6RG6P<=7=Q3S'-J/BV$TDO^>2-@:4Z;UM+++1::6JZQ9T&;2AI;E)P
M[%=[+CQ3_R**]#'Y(.YSK1W4:K8/$< 07D5%,O2*-G)0&@.Z1>C=2*,&(]YD
MY *D7N-8;I39D.]8Z/-@.3#\0]YW=(C ;FA;FA(U!RM(UKW 3A@2IH^]T<[I
M:.@"W.T7KDG*#%2V:DH*XC<9._KI@<30D=@;P.J:(T_);?88R8!*4BPU%-/2
M1EX<4_30X&'Z/BK"=3^U5 _WCLK9K*3T/IO)E#Q';+X87Y\Q1%UBA_::2S"U
M(:]%+=R.D;E&O1G^!Z53)=Z;VT8P1-W) BC$8.4^4E;^*B/66V;^_8W;J.+X
MKQK9-ZH7=]RIOEX2B=9<PM=+KF!)(6*K5KV>Y/SN'+)KYN=7#]-O\9C(]X]G
M4B+H3FX(&;]76OI"UK?UQ%V5YL@6815W F,WJGC'[%8I>^@N@>TK4=V4I6Q0
M=4F53W'WD>1K<Y8NTF'/\M?R@KC?!^$ 7%JS#_HCD[XK9UV-0#7[]'5AVT/T
MU0:5GE_EZB \=GT/?0]S-*'/YJX,!$S*WKZ_^$G4>1_:PI$/)'G/]+'[P6-]
M[T$6P Y=L#/,[C2&<MZBU'.87 ^9B"X6$.P?2&=<PA]W^YZ4:3<C&5H<_5S5
M-\![?X.(QM/"_*, 2GOH4!+/C.X"IB5S&91Y^AD-T"#"RHSJ-OK0NA'FJ9XK
M#FG0[]*'-,D>F;%A5\6HZ04+N;&\/;_2"IYR_;#$UB$>,]5 /$X10]K+-V-3
M=90P_EXNU*1Q2O[H983__NJ>#2S[UKT,T'DX9 UFHU?.7-B+U,]H%HBF:(V%
MKEY=[)^/I"_6H+925^N2>03%ZR3U4R(RZE8]<LC;TU>=]:TQ_O+QP_U"FOKO
MPAW:!<I>TQ/7&-6+K4VT(U+;JQ($?8M9P'W<XIKK!-*/RLO<D4B:Y^?W0)!O
M#@8F7;8[VDG9$]<HUR\TK)7)7'-X&R:Z\CTQ8^#6O9"JL&07K\P?0V]CI&RO
M)AQ-->^\<AG@S<N^;%5WW?L%+6XB5X5I.H[R>MI$]EZ<K+_ M!=/Y5-._=RN
M]W\B4_XG\1,EAU2E9C;@(=519(I0OVW>[1>VH6ODZQKE.A(WO/QD^R<QE&WL
MZJ6MGZ&ZDNQ$>M$-)IK:5=SJOYT=LG/FR5#H2[^QGY[W>?3ZIQI$IZXM2AOM
M8$[;^ ?+-')K-]SLVFBM&FWWFNE@!ONI'EDTPJ<T72Q*:5P9:?6UM6OL_"8E
M]+'90!9SRB&6:K;RG+;Z1?6,&<G^9E<-(:0Q-N#5[<GED3WP RS E:^T"E7&
MN+/QDL%%-W"=@ M/\96_?O]5.TG:, CR'LH;"!VYT])^KG^BB;*-OH4]0(A-
M@W[G]RO2L*%I+4D4F-S*$W%FDL'A+UR]B3[$&R^F$'ZA;7FO'H>\N.F\KH]-
M8[Y:OP#1^S*1MR+Q.$VIRQ9NS ($VDO0+@10&7J_^K>-I+/]R4AQ<L1O>)?J
MYR%QI'74M.^#.'3H2LH='3]<ELK:3UPJ"W A#"61(5_PA:X%=NC:*Z2K5/R
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MRNRZR@YG<,KK"A,Z[M.BWYI1Y0*J?X,>=&4!U//PAWV&R)GSGBR 5XDB&2]
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M3_1Z*5Y9OAS*#6WK7\1UP!^5V_Y";V?L>O\U6CKAWM[H"KF'>\[:ICX[,=^
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M"<IJC9:(&V[.]3UFR=VR>-J[03+V,U&#^QD>%W)4F@^P44Z]K\<"QJQJ6UA
M5(IH<><2"Y &XTF,#H>,@1Z&ND^>77.V=,1XX>$W[]0DGOH9+N%$64#8/AI\
M0[JI$<*0-F0!C6R-H,Q-56'NR*2B+< !6K]]QQ(6RO;2T( /FZSRL*I=/>_E
M>S"W]Z.$]8,])V\(&.>X3R$RT-1Y%B")[NQAL$="30^688\\P0YGE]GA[#W-
M;",B$;%N[X0HUN)BQS,-2 0+^#4!^PU-)*LS=8S_L0%QY=\VYZK;"6*9,4YC
MO$RA_>S?=1?]#PU^RU=$./XX_CC^./XX_CC^./XX_CC^./XX_CC^./XX_CC^
M./XX_CC^./XX_CC^./XX_CC^./XX_CC^./XX_OZ3_D KFO"75800G)@M(T*E
MS$<48R2&!\#V.JGEW'N.JI1&FI/LHC0@U$'BA?I9XOU4_J)#EZQZM.CV-HWD
MYO5!J2&5)X,'<N?D=AL?W/4P)_W:PZ.RO9'*W!,46^:.%OI1=YO4:7$HO];7
M24OG':Y^?AX0?;2?],?']P0K_7%WJ.IU! '&;]197<CC(D%XW6L]^0)KUY(9
M@6",Y3[C0\'YXZO:'9T&VP)Y8_#7T ,L@&S\)+W?CQ!F8U>>7A#4U7;ST(JI
M2GS<]V=G(L=33*[YCE8Q(X'Q:DF&(M6KA@")%JZ!278C-=][CG:X4K<S&IF+
MI:/^E+*(H^1R^U-FI;U%]"2IKY;DK@G%L%N(M+0M>\SRMT;F&P)!\[78@552
M_Y<I;1TJ]'$1"^"O3I>SK;N>HT>2H205F)V?9P$ADO.?5,GE#\\H12N&&2K3
MOKY[\?SISA/3VRF7V!?_F#N">J%]H-V!QNVN@^#7*JIT/G2IBSPQ.!S?O[KK
M;#YZK'@.)DB%AU?O!?W[3U"KHYQ(&Y(]UZ7VZHXX1H1<Z.667Y9?,%,L57Z[
MI9*["9$'GV4!-+GZ2^[E\W6J:O:7K/6FG L2@A5>?/OF<D;>T,=,/N_8O ,+
M, 1\$((HX4 =XGQX8P01*^A:O:=;Q^N6%K@5Y80.&IH_[C]<_\;;WN,_G/M"
M+F7LLF!>2&J KRC:HZ?\HG]?G_B'MH[_KH-H.'#X5X+WSQ;KXO]L!: 68&XH
MLLEF=A"%LL,JV6NC#KXTY6H(_<=YB0"Z1@W.CLY[T,/LX'TAD9T$D-E_,C'Q
M\O_R^9^%"\S]DPE!VG_:JO7/.N? X>\ UY^MU<7]R0K ?S_X<G-P_F/Q9/P/
M@QR _J%P0FS68?\XT/\/3MU$UXC"QZ<J+5C ]9O]S,2K_9N+$_^D\2\_()0#
MA[\"SL&T'#C\_?C7603TGY<+'#W-@</_%QP]S8'#WPN.GN; X>\$1T]SX/#W
M@Z.G.7#X.\'1TQPX_+W@Z&D.'/Y.</0T!PY_/SAZF@.'OQ,</<V!P]^+?S4]
M;:5 <R(GAE?S,8[W,=S)V>UYOVQ.R]Q=.#CG+Q]ZIC.XHO#@@^FZ#)0_Z+52
MOI'' MR->]BE]D/4MBZD-C')VD9"S:LR/,@Z:&#2+L\:FK_0<7!RZZ,V (7M
M1&#1A3H,$:4F<\:=*&(F19!DB^8+_#YQI22_)S>^V43)^^78"YW#NQ0-3)P\
MTE](3/JA'K+CGNCB).45W1$,7C$ @[VR"8,LP",0<]D_W+A3S.S0< %E43Z@
M9DB2Q^[-;E/EO3X [%$J7N-V]6'VSSU1Z4KZS A. ^6,"CI<,!3_==FB$NN,
M^T_#=K8<>$,]NC7\]E/N6,0I9BVZU -'N>F4_<MF+A8:!MM_RW4"X9J7L."Y
M?R2O;2?ZU9$ROJ_U+PY5OJ%R+2>+?D->!3-(\P_Q0LMX2?#CXJRN6"QOLEYD
M17+$ODM:#G.SS6_OY4TADJNE-C[A;\,'.Y?WHHG8!W>Q@H&*?99A_$GS^T8M
M'?R#^@^)&<\BB_C*:F07#:"92U:3A-DV]MW=0>M!2^\'#]!/!5H2:E,TRUYX
MY/BIW%B(,QEV/OKS?.MCDV>[KPZY*A@=&T&\??X?NA(GWG+@\+_C7RS>HFZS
MK3PJ@WW3D8= /]+V&W%'_=HN33#O9'+U]6E=S)W6L5=QZCU!0?@S!,$05VHF
MD?"0L<]E2XT0)GW(YG!HC:N8QL0Q%N"*]87Z:Z^QA_JVKR8\Q52_%M2OH>EW
M5GLEM-]?0(6B#VY<BS%\K1TKH?N;0$[E0\@I ^AK/-4&L3U:O79S&;'"5/J/
MF<$+>8-NB)-'ONJ\^QP^,;.@7U&P+NYE0U\EKD:;U6,?5_/1W#T(GWZ5W$MZ
M+,'U_H&\K-"/0X&X*#2Q.$YY(X&A_#AZLM$R7=UG6_0*^B5C9AKR8V+4U&L
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MYOY=3]X?%VM5F3/@_2ZUUPBBQ47/,D2I_#'K&/\Q-7'1+3BF'%..*<>48XJ
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MC$[L$>$R);4W0KD9#L55952SR"6LR-" ;I.OXHN[\3F'OKP0N$P]P[N :T.
MRMMRFV;[Z2BD&CBE4-05Z'4QV")$RR1.!C(\; 0?/-(:ZML_L3>;0AA06CE&
M;9]%IX)1YZE]Q=GNYNY6N^S.K6=%^6BY-6]9NU6YMRGWGG@C]J$#9.-M)6\
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M8$0BR0I]_\SMD#???8F7R+5MAU,>QIQ96(HVNFCSU9/8FF\I]@U13WP%2C9
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MX:[9 :X# -L8K [-X%J;*00N'8%%<[C43G=>F'3,NCX2&=C.5GA9KZ9=1 (
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M/-9LG_*B91[D%PU,QR[:7CPCBXC$LS&D&T->O)A74>@L%"'L$0O1Y1]4UC?
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MZN#)#53-/\=H)Z@5=E^JB^L:8LF\EVTTO"5.J"XU<6I\8+4$/+.,0=:.290
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M7SG9ZZ:)WWN4MW.FP?6>?4S_1P'QP8CJUL:?U^9?X]:N-5&TX1V\!\H(7CJ
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M0Y_/L_[JQ5%^OY<1<,,LV\:U7=;\-"_4Q56K(@/DG5[$:+/4M=9PE@.RF8%
M$=<31S 6D>@F2,I^9?6&9-[= DZN_^IQ>LS-*Y?@=C8SSD$]-^TI*^>/T&7=
MZY')/Q@$UXP0@P:2[N%GKJ1<((3!*6HXO_-.IMVA]R?J_#PUNRUM<;(A<I8.
MHKT:I6.M]O_F-=%"R2?CWR&]"T7'?FH;NE^J'PN>"?FNO;BSQJVN5J%_%#C(
M ]"FX::3&U-D\%6,=@G%!3]TOO)HO6.,Q=8#6=LK<.C<>]^.67T\IMM04CN
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M!#.$B]CPKPS(I<I8C?,M-H1)RDY7O]25N'6J'[O,+/51)N'%.G\1=1>#W(\
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MS*<,^Y:4G&?GE)HO>\E9%@=E9Y[FKC0TD?3='NID:%Q39'Q:T=G94P1D2D.
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M_!UY2J.01G7O-9\KOJ%XW5]\69^4B\N0/3!!W),!M#W?&)WX5B@&"SBF5>[
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MSP8=SOYO;1.X5%?X:6I%R&^4NOB!S= R.[#0,S:>[0I4BT/X>>=,K5.V[,Y
M]QSQH2)W7?V+5BYB=^JIM&1S0>6H3->"!X.QR;=936Q]D]]HN&'H+)*%,#X&
MY?%'XHB<:_^Z=RP78AY_V.B;^W9@Y:UB)ZA,/Z+*?<#1'1-^:8X']Y<)KTAA
M:/K7=P[Z7T]@-BC\ ?L\M!JGF;EI9*:%% E&D(II1\5D+\?O<;,+>32FGI<^
MY6KR0\1QYFT)39G(3%%O)@1002U2QZ#0 !@EW=Z+U$-N)-7W#("M7++W6M.+
M5L;&(<^ON%[^ 7F+OUM!W=;48OI\ZH8&T,T'1+ 7&_Z>R_GXSMC=A'=^5#"8
MK7'*Z";FTS&(5?.\)<(2"'P/8(W%M8MMXL3$?9Z\0E3IAHQV*.+M/)!W*)S4
M"H0'$=PQWG0APJM@5<BOOV<RTKI&J7>Q\7YY]=.X4"W;B%P]3]\5"'%[*VYN
M]R0QBW9B!K5MQ'L]@GU%;PJ64_%.AZ/KNJJNYNRJ_[AQT8H3WT'1,0BL +P[
M!FDILJ#F1<?_1[^^_WJ*KG*G (6MS9NHL<3FYB/TT'?9'1.:F!U)C1;ZSY-]
M5</2#,HYZ #FO/#)[W2.%1$7@Y4+ "NI\>7.FE[]*5B8PG ,.O&Q>IW'O_DH
MN@&CX#D]L G5DST8!/"?X)@.5)U>%]W@ D85Y7LP#OBP^6C7QJ<?UHPC$[>+
MJ.\VXWU[^B.ZW0[9@<"%<E6"<_A+%*\K^[+)R#Q/=Q7[33$=B>#24P^3E3B0
M#VD]-,APBQ4=F[2I>2_M'+Z+ZAF,.)&,"F<*UIIN? BY+9L/OL7"M\N5]M;L
MP^:;O<NOGM\Q5EC!?(!6*6[(%-!&Z-_<Q0C\/O"?_("N<A/R43%Z1PC[HA>2
ME+(:7,J^??HLRMWD0!F<""7+/,<<&DHAG>".]_\UBGMU#*K+Z$XM-O +(*9W
M,6F_"WLB'^>[U-]CM?$F_C.#E.%C\!6WW69R#:YNE&XZ$OCK++AF)J8!M0?9
MPK&V-_637):L+%]H,Y[1*W_@W/=O63G].O]^6?N]['<,*E!1WJ?+[K*^MD>Z
MAE>^,HRUGJ3CV"54;QE01.M1PU+/56(=Z&>2*2_HCEWX2 8HV1Q;^#:VMR=T
M*ML,'YE>RB(2Q!?U[''P96L0I1O XC<>DM>!=#H-6PW]R5[0)YJ_$SF\YYU8
M.M6E] '\V.-Q<PX#,#"&NX>:SX&*XO"!M.\TX;3-A9_C+2K0SWZB_5F.K-CT
M<YL!MQPE<\L@0XU00 K[U1 5@ZHR*O^#?8H.6?B8;M82[_1S30^F<'J@Y'7T
M,>C(W6V)?D,6E@U4-,IK0 S!.;H,KY$/"JBJ<DUFT \=>"(S$"CN;\M9?GZG
M"X1L&%_8[S8![D+G/QR#ZKLKB2E F@?XJQA70U-$;Z2GF:$YEZTQCYJ]U06U
M1SE1IJV1JNL<R ?(T6-0-:P;-H$B?QA!N8##K?W&OGQ<S>)YSE\WYK\1(%53
M_73FCCK;C@%C4N.^XLS HTME6IJQE?39TZ$-J&1;3_9_7-NO#LV;,RIM>)4Z
M@C]9I$&SISBT*@+[Q*PN*/$N+GF6BX3MP'+-K2+9QPI>N&_9GGKCX+13MGDK
M-)E5G]6@YHR!^,DWFAW$91J;FY.@(33V&,2^)5?Q04U!@:+V4O(@K,-A-J30
M^Z^3\MY^&W:2'CX6&U8!;A__WAR-SJ_HH*6>C:N8.%!U^>HS6!;!J;7J\.SK
MFI:H7H\BES6\F:P'1%2LK/<_*8%#[G^I?]9]S\=2?]58X[7%4@R%QXLL"O@=
M60#2W3?KDYS'"$U#?@(>'MT9_BG%N@G>TT(JO?W(S\BA04EHM4F7Y<*=Y&O$
MY)*2^,N\;#=>@':QL;CY6-2VH28=X'X_FSL&W18"K=5B@/-;;;)_;=;%SI$^
MOM$<XHK:JRG&F)O7]QZ>XMONI^*Z4( DND=>!.4V#:_'V]=+J&DUY]?A8L](
M/>22U'D96GJ*<5FVU_0[U*64X 7(CD=Z(+2/(+#G55^K;/_>_)*Q>)5K1Z_5
MI+H._)['Y^8+#2902!(>P^TZ>YFXF85UV3<(*5CUKYRUMNW9=XJ^PYFH$9_B
M%D<MT+QL36$"A!<41:=?S>2O;$G5^+S,7/J<HG<,.IF1$L*"%:$_5'O@PW(7
MI!(::KT)N^G&$%BTJ7%+S^]B$HKQ(I3U8(K&!B;=/ 9UUL]QT)C@7GX_L16S
M/<5VUMV!J6_ZO[S5FRAP-6!N.I<'CJ4S2@Q-$5 C%N$#-G0\?+U]BV% ^\:D
M0=QD]P7=V,I5Q,2Y5O-U+88Q'((F!BS< ][,P\! M6[6SZ':4@&OC1SQ=VGB
MC\'Y[//)G5SV'*1TLL'PWM;O9UOSW:FLT[8K-WD-"K^51J?19F['TKJM^"(@
M!M8MTK33$Z1?0/,\N9GXP_3M.Y-V"UU"KR3T2N6[!#Z&X@G5-QCM2W23PC!6
MFZ#(^7=_LJ+0)S/(+Y';SG9:_T7E[7BKZ2,F1AK? 8-W"<6$/A^UE)>CNW:J
ME@U$3!L*_%-2YO.!]VW+V%S]-C&_D3"K4,=:D/M+M59ZHH:_A7]?:\-4PCI9
MY#ZZ!9<;R+_\O(I:>CO.5?!CUZ6%#MEA%G3)P!A'=,+0L]OQRU6+<&5^^W.C
M7EX5DCU]]WQRG 1W3[(O4//7M#A_T8,\%5H]EO6AQRFP<"V[:[)"^$'3Z*+!
MZX6*WW6Z&JVP"K>EN<E@,AL)MJ[[@U0TKYC@%SE<X[SCM;[\8M_\02:#_Z-;
M \S77_KA ]6Z";B*41W8K_66!WFKUBJ%)V=<)Y-J,K,NJQJ<3[U[$^-0@.X.
M58>2I:C%[L<@-W"XO_T%%T(U22H1\WA<[@FCI,7=O"TM8T2]J6C0@I3/W72Z
MXX:ESA'U1.W7VJ$UJEW8F&.0BW\U[:=;9E*L>*^K_^=3AX3YW36 E>J=!X90
M*Z&+(YJ7Z4E26():D<LX"*// YX:B11&CF+8$$8$B)!)Q1U4D=N%=J["64F9
MI0,NW+E\][>-RYH9AZ@C!U3O)\03NLDW-#L&#5G);N?06.AVG^DD,6 ]@3C>
MB10F2<<H]S];>SCZ\[U(DV6,0U&Z2+#Q_L.W[]4Y":&:]21I"I?;_%C^$Z6_
MM ND:#1J*2/:2J%\\XG%^H!@F%7,9[^!3]A_.U10P%$/JFIN([6$UF\O,VI<
MGC?=[^W%B'2\IC+.PF#;I7ZB\4[FE?"(8C_IC.4A/RP@/]#Q]^4$1A\((-CT
M:S$LZ01[>WGQB'@WCA:(.XORCFO\NU$BT_B&X-$=>!$YAY39^.%'14UU2$3'
MI!/!P-ME6]>#TON!W?KBF$B/ .K-3L,"Z#/S#*J6>7W_/V583F^U,)4\'[>6
M*ASMY.<(=!5JB7=X,0^:]HV?!GB(F</S)NU0#CAK.\W#=%BG7H4T:RMN(,4T
ML:TU'[(YF[&31>&KIMVK[X20>>C_;!=>$4&^0JI[0QRGL:S,8\^ZF5ZS-H[#
M3[V[M?+*J:6AX,WOBYN=[">F4RXRK 9^-(3G6MDYQO%6J[UE8D@S6+\4C2;8
M270:R@S5VLC?NS7U5"6 1:'[GY _'%\,:)N+QO% YTMIUTG,":WGX?7WB7/M
M,V+$#M>"E:)]0UD%/%-3:K7/N5L[UY^IO7+$9#4!>_39*4^?-XE4H)VGG"(-
MQ,NKF^!_"QUL*"JD;_!T"6VF?\L\O7".6+ N'K/H_34//))-&0*F2&I=01@*
M7SZ^/KQ">6V<F)NC7-M5D5SE46=@_U/7E96=V3T]VCV%\Q0SWP;D,V9#7G6C
M]N@&''V;9#MKD? 2@-T9JY!_<'^ EW2SZV5I4DG?!RW=*TT7Q$%:D+>SUZEQ
M"%D\:FJY@PZ+\GLS#C#.5:CSCK(,.\P-IC13>+W=?3XQ9/;5B:,O5H<]L==P
MG%-L23:FU</RO5\SMU]&75W)% _@VP9W)MG<ID>4';)K9P+^;'.YD_]'L%1%
M'/7S_9JL+*G%OC ^;?W1IPC0U6I/75^8*O(GBFA,]25W$I>*NB'H7$T2WTQ/
M;-:&^5D57UT%CD;)_)HTV3+OSTL.22!6B]2W(/"H!]2T9K1LH;FR*7I[3/M5
M[JSV^<M[[)P<5MAO:#2L&IV,FW]]LQ5-LI@_!B4IVSW\NA4B6E%:\#R916ZJ
MKKS]0YE/]SP?N-9*H.*&.'K8A WA2QR(;V6<I%A&.\>T;[N4EW\; N<*I"EM
MEX*W+HP]W*PY,6<[H^/,T.\M]^+6VW_[ZR"FSS^B"1R*G9=K)LT+G8O;BSBD
MWJY<BDB[?#=]&O)M?!':C@(AZ 037DFY1X+&4;P(_7H=4-8:&^REJ;N5-VX_
M8Q]L8X7,O.%CK4F__NS@E2.["AE6@Z+P:"Z3'8BV&-[6$\!PUR\@H0/OU%B5
MZ1=<_%ZN9(.M3<19(MIEPE)I<R6T@&$3,E5*NW<,(LQ1$_8AWUL,_ZU2OJ1S
M)!J8=K-'R&V\[V?/"2W+*H/=4J024$Z )<X1[RD*P;.ZK3F68Q"/I*,W-_9D
M#7_(R*OV"\HLG[_._#14-O$%&Q_$OU6"&H%RFA.F_<:P;U+4RN%SID0<G0=6
ME;R&=S\S9B=1XI,7,*_63>0V7[0%7'QT\/H7\SHMB9 DW(GT(AMC'4L"]=PQ
MCHT&=5S)G$/>(TB_8ECR7)T>A6>!)E#?1H;QMW(!"YWWWXD="E1$[0Z6SWQ.
M#9<<[&?M/KW#6GSK;1SS=4;(+UP8E']+4YW6?=,DN98O\7E048QGU$J<?[[M
M;:EH<X;/BCPB_C\O,LR5JAJ1+J26VYIX%:UF6@Q/D:Z9C[-(Z-&(IOH4-^(R
MF1%X2.(GYPTB=(CYNB0$C15P<_5O&H_S7&<(^4 JO!,OZRG@R:BUR+"=>/6R
M Z]%'7($0[P;HC:OVO[N(0': 19V&R@!'+@^34^M^NA6":0\LSJ7R7LK,?\/
M**(]]2TA%&IS$9M)9ZX<%$09/<E#A@W5>G%-]WZ")^A^R='!X5XO;>9*&4BD
MHOVO&)UQ")03V,>FTHE#,0'&@_("3_YX!# 0YSH?PAWQ9+3D6-.7O;KY=#EF
MC[Z=5^<*M*4W\]$OS-58NM<_,:^JVU\:5% .&/HP)B<YRJ-69K["OB#J\V;F
MT+P<Z0U$T$X7$0_49<2) VCU!TZ$WZ^^?*'E_3)X[B12\3=-RL\V^7VOH'0N
MD\5_-IB.M&H.(J^XT74PJIMM94^1RU7>^VSZ)WM])TQ??6_F3 'TVB?'4Y8S
MC9.13\/S0-YS$-22$HP3M2E\#/KP%#MJ32D!Z'0DDP;X'H->S%%YI$+H7,*D
M1,76>DV@\<FI!8"F4T2/V*5,???->!:.C)8GB(D,??%6^VNVB8B^P*EXT.&:
M->E".K[!U,[&K&J(X!L9/!4997EXLM/Y$V5U_6J/'ZLA>X*<L:I<[/^YL>49
MY1Q]['IM)+6.L[0KP-H"FL\>6+:)M;>SGK#3E:Q5R(O,MEI(+<CPW7$$05X]
M9<?(DVAA)%D:BS0IN*,)$Z-N&$*8BQ3:79<<VOP=F2+S4$Y)>CKY17GCA7N>
M;=^^.N6!?\?GE[HU><5LT 9+GI]M<H?LC&WZQ:%4Q"U>45Y2"VI,(G'5FN6D
MH+Z*XB*4DTY(P?MO_#ZVC&?S]B?[+YWM.1<@-GJ /U*B=6E*TX<::C5->0:L
M+"3YU?3?)9@-E94]-<N\;=%1@W2HT@$]_O8I[N<0_*O<B<,)QQ"/XLD[?L[>
M?#-E^2]]M?"#/9^>M/%I(%60$Y@J2"+TR5QTTY?Q#HS@VLWQ=B_>BT.U,Q S
MV7/UJ:^OF3;<,;OQ%'273]"8=U%3]B]T8FO^ ^T7C*CO(=%6V2DULBE7:_CN
M:O*=Q9N%(Y]#@SV=3IOLVWUBV+T53]FGCU*9\M2+CP(>;Q6=ZT/5M$"03^OC
MC06LIC-?@-0IU7('N[,?OK#16,M)I30^Z'I1J:M*^H%U3^(%.VY0T9\SEQ5]
MYDQD[CG//M"".#Z _5OZH-'*@FJ/IV8@( 734P="/\OYR7\^GNX(W#]A*0O>
MDKQU<:#%;S<*A RB?]8=NCCUK^B"HSOT4,\/9D+K@FZ[T!4 :MV*;K<&#6&7
M4?_3SVB)C5M]!M+U&T>?#I\;E2L<R1<,OM:@HX0V#5U\J=%L@5]>/\+/Q:'X
M<*YS"3C65E$@HT74BY!DO;T,&S_'L3SUV\;NGN#]4H:8P-&[X6S<>9]-)PXM
M".,4+G3'H6+'C(DY$9*L?$3W_#9?IA\\IQEJ!YQ'3/%VQP]6@D(-O'($Z2!P
M7Z9*OU+WYSH7K].;9)#8Q]9_>[#NT ;MSP']Q.#.7$&2>:%?^?/9,\UAYT84
MI93ND@-8_TCZ0Z_RNCP3CCLJU"..1R%_B6D =)7(=(KZV0\22F,G,?7$:(K
M@UPW]FYL[ ?ZQ)XVS(D;U=_1RXE=N.6_7934&0H>-9+M$E)I]E87\BQW_&3B
MZ7W-OUY&]A_^>0/C2_L4'BC-9(T<=0QJ***],V]&\:#:)-QI G\K@=)Y3*<)
MKRN$>]=)5>7J\X?M3QI3 [>/00'< OL^+5D/4P3.&&#_+1727!/"Q**>#\1/
M5M05*N=LB!%6#ZRA<G&SAQ=2W&F0U[EJ+_/ X]^_C:H_R?L;D&JU>G/VW9,
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MAS7C&-4R]#[H&3_.H 4IGXO:-U),N*C&&-5^12>=.H>6R)6[_3[GC(\W84V
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M OX0XU>!;VD6T%-$>^. Y"K5*M+G2Q:YH<_V*'I:' ]&!2A]G3B89"O#(_F
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MG%1(?G#8D1$)6M ?H.\QHP+H.C&STAC9%</FJ"(V\-8K.Z,A,N2U=;29Y^2
M<T?^[=,&G$GC'*:N\WV@9FW)O);Q+R0O2_(>;*YD[9RW__NZR<D3OHA@'_X,
M)3=&PWU/J6N#$29XJ@[Y+Q$OB!FQ@U100?_?SU8=$B*.DZJO"Y5MIKK]C_%,
M*7C:V9YW]W"?3@XACG41:D[T@6';;1ODJQ>*)O\@*I?'OIL@=TWTS5*(5GXS
M8] .1*PTDN$+=M-20*N-2<_RH0T5X3Z.YP?T1MKW8!^1)LYZ+MKY_'RIW<<0
MW:(94>V[+E"6.Q$QY3T/YW$"YQ6SNOKGEI:FE8]U4&2W-&TD;KW-$O+_%GT+
MUJRQ)<(2B!O%4F(8:O9PZA']G<>0?1M":,./_SUJ2^" TM SP!+6[GH9?$O9
M[CAAHE]AI4C6??YF?\\QBH7RH%*;56#[+5:>YUM08@[)$$/0$OL9#^=0@LX@
M@C@36W&0?MHG?3+VF.0;#\[>'->(387)! E$X#D@7)\>5MH&-7_4]\* QR?I
MFQ$J'BM(LGAN%;C4V >JBGV:9+4C!#-#?^9$9223WT_#5W=L$>!AO<0Q; 4L
MN?0C><;+>%I7^<A!U\=85#_LM(83BZ_$^U3*FBGEFT"<6]V+VY^G98LA$QW^
M=4$:^"?#$GC%!G2M6/-8^FWD!]HHU6&JD^N04HPR;]QGL=,MG!1\#Q[4YLX(
M+\:V9='%,CMGLYDUA"_Q.%],:R+1OY]ENY-Y&IZ)@:3LLWDO @T2RI>Y2[&M
MGLW=;(!ONT6'#/_'\V\R=A*QBLMU)_SY(4W+0,]2G)(,_S@XRR"FV4!!J.4B
M1!5<*9\3 ^>JL,1ZOYJN!LI-9?JF:?'[O@_>1T_#2S+_[;[,Z4X?01M18O3A
MOTN#/U2;LEX\J9W=>;Z*;$50KC$M:*C^.Z _E0V0EN-]&*&D7^(]Y,F[,>>'
MK44U'QY-OP _(G7L8*#KEJ G9U^3! D>AZ!<1TP^/ ,FS:7L<PYQ(O;%O+CP
MT5ZFUOE\LMNFJP=@J5P&I W[7 <\#YX# G;KL74.SS-SFOFTQN^7?GO:M,S$
MCH]);;,!AU'"&8(GH8(-M$6"7DQH0*'1 "\&]$%V90Q1V5WUI]-OMK9[;1A7
M8]5B:=]*L=I7V,CU]</=[>/+/<GK1UK/N;[Y9)R6T:N_S".)CR)X(L%#$I"E
MN8.$M5+"Y@GMY'#NJ$]RAIL#(F0-[LVS/FDCJDD/GZ3!9?P, &F [LGBUQWU
MIHNBK^NW'PF/W$_XVS]]%F+L;II](K;U* O^&R=*(.*V\X2IEA\(%%;5^Y43
ME4X5A]%9A_FN,91/>G %W,[YMSS/!LA:5 D6OX]_(5H;-"*>NG:%<F^F^^&'
M>XYIDU+#<H5+YU5/WK&<JO7U\!!(3!5EELSCQV>6^FA2R$@,]^A2^5A H^1"
MQ8C2BU+,T*/*?X/9AS"V+R8OM"H?\@N=.@U7 9^R^+RH[42[AM"/D'XJ/5H3
M-*,YR7+1IK:HW3.XW'Z")_@0;/N"=3^!F ^OQJ]ES^]3.LM\@U;2+GWM7&'7
MF#,HB9?6:_&HJX^(4U5/O?0R(RW+>:F(F8L@%DCCUM*(4R@H3>6:..>>!\IQ
M-05EUU)U)B?WK'U+OV#4):FNK)FP(#9Y='.QH6_2?GXC'DM\_VDYVD26<1 ,
M+Y[Z9>B;C_*M*;TMABXZY H[?M$!TE#C:9]??+W*?5J0@\;#$&WLL)/7AO@#
M#1:Y#"[1K[PH-BVX.?F=V_B+6U-M *KSAO1O2%J]P&ZZX@01JTG;K.R?8[O+
M QP@QE@  JW988;$.[Z_O-4:^V"7'F<=<TM3:*A)/&J=Y_=";PI*>CT?SPIF
M'$OJC+]@UI:F?N/;S-T=3U8-QE&GX4K85BWLPA_$73@=#4%1_$<DJ#7WLV=^
MX\G %Y9ME-=VFP$\J/.AILEMHGQ43Z_!;_+-<!(VR7&6(9)"&P0K0N?P7#/W
M<H((_H]JBZM"N;U#M1F_M!532S0^W.1=,^?9:X:OQ]ZWBB!09MA )>I)DS4I
M["AJ;K&\CBH4[>U_.*G'G]]X-'F97T =^9R(BG\880F$, EK.'I(>)Z.$BV2
MLIQ6'8JY61)8YWNR2_/1G09D_"S%"C$E,F\:2^IGH*BQ;1B5P=L-3E_(.C5&
M7>=?V&8ZW^EX(/8S7')X%U&)'Z!4@C(FFFPBBPZEJ,6_I<)BWS@I?ZYZO/=G
M>?YD'OIX$_8( #MR5-"@*]2XKA.6A!0C$-]C#S3IDZRB;\)'C24H6Z9-6^N!
M/;'N![Z=X0Z+5SIHFRG %>WP/,LU _>,\W?*4Q-.9@E+G-5+V,N0H]Q<ZMWJ
MF!3*"YC=WU?4G$?1]3<5=EKS.7,]+1KU*9_:=X\"Y?'$V#\V\.0.P<I8AI2+
MW1MB>H'"+!B3$/]D^^R$M66@>KJ7N"ZOU,_-[Z>_JGU0K3W$*=(*GT)0HG_!
M*6G8+ZU,'(KY=ALQO]R#U%]'$[#!T_-#"9ML8,J)90F?VV8^U9_=42^97.U"
M^/ J?V)F8+0Z!7TT\:22Q1L#%L?AZO5 8#XL&T&$\&#3I_D8&ZBH13&5:O#]
MQ0PF%(K:O^L>>:XMSO-N:'E4IS79'^?*._8DI6)R*]+0_I<8@+F,;3T<A&WW
M1ONQ^KF\L6[-7T[Y,]_!7XWA/B^.K9["7,<,0X&)46%UX6K<^\ARE*KS&1T8
ML>&BK"W[\KJDGTY-+<QB@Q$3U.&+JA=2!9724D^4K?==_<^"B.IR&]C/D@73
MESNW5+_HTN,5Z&HO+XJ&OE^Z*)-R9K_:E#$0NMS5IVT%:FY'=>5<FBZ=R:95
M?K8(3Q2' -_HPNZ="$C" @'-S09J<3NV^P(1%"O<A.<<_"G&T!M97=2EP5>=
MY'DU[&F2VN7&N&XCBY.'AB2GEA*4XY[/7_P7IT 1L[@&/4D/&@'E.48";3[P
MYT6-G%I[G[_0:W]A"0N[8^>454\;\':ZR7S: RB+.T=@TD)*.J61D>CC)2&Q
M3HT6^^"7:K)HFRN7,Q,DAQLK.#,B8)PYC.$J9B/""S6YW#GY.79ME1@FI]2V
M<_\=_,:(L%JJNIJKA?)W1;M;QQ<5&P7S;@B.X1G:S'=D O$= 6@^%J)A1OG3
M#!N]/9#^0WISNS?!?%TIM\<HDX,7S[NO]:3OJQ3(&%58D5-QY7MQ"1A1]&V*
M-N&=N>K[R6</)R:+)I72WB:K"B7_DE<\:.=P(-?@Y!>%")@Y6$'78XVQ%,%S
M\Z@#:'MPRZ?HKJ-'=-C[Z5\[,D?TK3M]-_6:/G!=-:UIRS2N;_WUR#X<FE:K
MW:MOJ-G,I"KL;[G2![.2"&\K.&8V;]](L]1_K@BI:<3"5N[>'D4[S>VU"+'A
MZ#G[3N!-=I<)]4%!1)1R$@)4+'PSBA" _N^]S=&E'NN:T=O#@L%'=</>9G%(
M:J3U2G/W%=J/1IPD@*I8!FZ,#(&<OQ73L'1W00?/$/$T;ZYD-A'N2JUKEBE$
M6I%/I5N('*X-O*#$E1R"'RX&-*A1++YWE+>M! G$O92$G> DX^/OP#=MD]]6
MYF1\;"8\S1;H =Y-W+*R1Z6V]>@(9/KN92"OY"%,9)8V:_\(='WH(_*[[HQ;
MCO@%U!^PCROY+B<9#F4*Y4I*!$ZX22WX;3=13J=M.UTI/->N7T$\6WSP0,2\
MKU@+:S6R:,AXK U7!2-SS*6 :BEDOG *8JXZ*(G84/;$>E7]?EK-IR\3,51W
MSH"L-=CWC^97_",32^E[D5#LMEHAW&[3SZ$/FJA3F-FY\WU\%U0Z*SL:TG?Z
M-BQ]NC7;9?H?;G%;L\K[>48Q)]/GK#C 2$N#I],G<OU&?T@I9V_FWI9<+C.T
M)Q4Q1.@DM6ZK^!_SL: 25>021:LSM4JZ&#G]@RO[\$QPNGU/7?;!2U_S+@H(
M->";L<1,1/52$56#E(O6I3ZQ]P]YVY:UHJF-4@K4_^1W\*I;\DUA6UCQ\S[E
MH_@\EA((F]-GB,!I+T>;54&9=GUY11!1=CR\<$:NBS<_2&ATLS+R]MU9$^=$
M7HW'O2YW.0<A[93!!E#(G9,Z, B01S?80*KW&V8"]A8;2"0 6"\7Y!PJQ?@:
M*3Q4KT3FBYZ![E3C"^TRU;P;2\?VTP8^?$^+44-$WP*K6 )6)(CX!$[5/3:1
M!Z%9ZZJ[=+NZ9D1<K,8\]XE!@FFZL[!02X)3X<6'+CB&B#XM 'Q!_-=D376:
M^T$KY8DSMB:LY<B_U7U,<E#9\JC/$?9+-R.=^,"1:5N5- [([VZ1QK"!="9%
MAC6)_7U=;R?\?VYD1V%;W9OA8#89(="L_&OG\F1R!FFY/O9J?;S NQ*I@^DB
M"K)/[E3NF^8 A 6T,9G,IVS IU2--CJ$=N&Z*8IK?_#+?_+=L+Z$MU_V'N)E
MH3:Q$'EK6380<I6G9Y9R+CZSR8CZZ."KU>!"@S^M%JF(/R+((-;H90G:#?"+
M>3?#.N<+&_@J5;)918)WH"2PK8?8P%V$]"\3+4KRNQ)0Q.79.;&?]P[@#T;_
MG'*>^H(-(E?:P>0O"A!3[<76X))8'ZP49D:>9PPCPQ"F<./?_9(X48F(:[(N
MC1;P\9+<DE=0TDSH%15$:;9D"O02.6:A@!1A PM3:/?=LVNS.Z;>-RV@[!^K
M2;8"#]5UQ[\X9RXJW7\VS-,N2FVU>\5[G$!\^LEGY@7=(*3-J,>A5!DE]KU5
M+?&UTEI0$S$Y<Y% L9Q6W.EA\>^C+LW-?9OC58Z],:%9<:S$T^Y)HO"1D'S8
M\"LGUAE[PM].-@#U/1M!.><DB<8E9D<?]V\TC]-_,T=)-2F"I^*'?9Q>:5.$
MK* (V.'#?R> BO(9X>]^8R4OD%]UO@ZM?M6,OIQ;7A?:97KJ A#^FVZ)_5K+
ML-\M1@"YQ$$#[WDDJ(ADI.K(8<>_8_]D\=/U:5GQ2\R7S8>[I773$=%ZMM>M
MTSLF>B)X2M'!4)<=AGS_]$7,G$S>'/4V10EG"1B[\\'=HUX>. U__;^YP$#L
MU9PE_U2GO-R(KO>/KC[KFJQ>G\]!9M$R\,=Z;R^H/LM\GF-CY[F(?8JX!7_Z
M2;4QT*O@;BU+<2BM+P.:/11O6IAP^I>/17(7>7O]K!PA)Q0C!4+3=-:*9?L1
M"S(QU=9('6VY-OU =9T<-J TK](6PG=BN*#9FY'R%0O>QB5!XZK,!A9WOYHR
MP 8$CU,)K"<X1LD--D#=8=Y]D[W3\(3E%;[*@,#N>CFB#_$9NZDV/[:[& )/
MP.YC' ^=@Q\ W75_R']7SUG\:Z0_U1#YGK\RZXXY)R#R(U0%4\P:AW,:8ZG;
M%@.Z",%[CMJO7D]^&;-_^L'94C;C1U)%A+":C*V%O)7*)[]]Z,\050SL%F(Z
M,\N');J/08]LWSO_X%'UZLG;K]7$1J98')NAR6<<DX(%Y0PN"934XGM<%S[]
M)7!AOB%$6<HA'GT=)K*4;_<>G2*Z[OMV+\BKT5OLENT[P8+]%WEY$O[BP*"4
MCHT=(1"*6DYMPC_IYM?,%!9W" 1!XMFEOS!JP]4NIN<^I?E^'+.LSS%7R)5Q
MXS(V.U$9;2S/_V<AYXC#*<?,9T>/I#]=V7TS<&PMLN;>BN2W!XEP6Q]XW@[\
M +9=D(%B Z_5V,#A400#D_+?(SRV>D'L#W)E2>3?NVW\IDD5TZ:%#1BS_D(J
M!;=+.>T(",Q^F;.!;S4I; !>8HA:DZ$6[^Q(JE&JI0-LCMA]:AC1<CS9O?W<
M5.F$28(E!C]@Q71NP^HV_V6=<U9Y3.C^S_R(49"D:@0O1@(,:SOR,_RC5[E8
M.OJ6N4:CN1+'N$20PJ,[A&.$VQO_+FUWPW:85'W6RU&"8\EF+$UE8(.,)1;C
M9+0+*^MC1BWZA$5SS%Y85WWX('GGR .-WZ]YAQ*>!#G"7:^\]#JK2_R87OG'
M= I7N[U6<9MNCQ9K[A>['=5I&+1*YMZY##N\H+-3ZSOPC;MKS<2N]9#&UBS-
MBUFL,\]\AM%G]2'WRWO#A7_)BXU>.^^T]K%1J2Z[K^+^5K.BU#-LP!&B GZ\
MF &-<F0=IMN>FVRB'Z+:9IKE4XM1K:H\>R/=N'Z]+>7J>9OPJ_/9>AZQ'R!D
M$D,LC*(AE>;Z:HR5.C[V&-MJW60]!YN\1BNC8%OZ.-N9)6%OVJO6X@^_^8KU
MBW30/WKP=#)7X@(N^UC TN>W+#XC?%$;8?SMG'Y<S913KK>+4L>CF+>:6B*:
M>-E'@;G[$RZ:&YG)%R5LX4$51/N/L#D\&48]/H]/O%^4_._F]5KOYQ-GFIJ"
M0AV-:<D'J^0S.$[+J:850 ]V45=.M>=R>51[5JVXGTI-TX$D94W_-]&V\BT
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MFU.&AM ]54:(1>@[B^(9[IQ4ZHLER@MG"^%3(Z$XNVZ=_.I']#=4'9_5=*<
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M/9F!'J@"V?NV6('(EWD6Y ??CTI =N^&(H3.RRYZ/6:V2SMNNFQX1N-3GX5
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M$.G"5WD0<QV-$Z1ADF8R-RHI8DYR:I=I3] BJ- "+C/-[A<$.VV\0QNTQ&_
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M07YB93 P $G' :@&%L!2\P#:N_K-';WH/K4O-&$#N*'5,!F,=LJCYP.TM&[
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M29) AI@RNSG1)4F5.9F*0)F882 C$II6W+(E/K45OF$'=/S<#+$W2O\//-V
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M?)8@\7<&\MC75YTL#OS)@K\-(K[]A7F?CHK9"=MZ\;A]I(_J:A-#NO"8NO=
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MK1&JOUDT-$N?8FXL#<^C:1DW0NM1*]1__U7O$,Z42&/.U[/*E[&&TS8MQIZ
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M,Y].-)=I3PE:O&9_K?'Z'\WC[1\5KV_Y?[Y9;2,G#.\USKP^\9E:(]$\=GG
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MAZ5H__RR7-6*,>Y0OL807K,3LG_0[+:2#5Y;#FYF:6MB)[BGT[(AT5D/S'9
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MT"SLD]#A_NIS91&UC6C79/E%5/?1(A6YY())&%'=79"P$&+U7\BR.!<\"/*
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M@@HLHRSENC.B@$C0&%+,0B@#(2CG4DIB5??++WM37U+WS+:]?C1CO<MVDP8
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M(849@Q[-+5NHXZN[44$;SE#/&M*\-;D;FCMDV)L*94 KWZG0=FOS.R[JL#[
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M9AD3.(K3/ M9FJ5QZEP("6!D9./0C-H1NP2;OK2CY0/M@VQG-Z: #F9-X+E
M>XR]2B+006BF3P/:9^.M)@$=!.N,%*##ZSGV :O8HBZTJNLCRC=5/99"4_U:
MM/&(DLVO%O6J:DZ>M3&C]>%_ZG9N[<Q0)F6$"QH7F$2IQ%PE.29",E$0P5,F
M0*W#/#(WLNG;$$8[E!U])*_OQ,XJOA;2,$OI"#*\I]D(:/AJ@^:3M6D[IXT
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M_/?F>OQR(4WS56$"&$OST4[Z4A=^%(2J5*0<TS@-NY1!*3*]\[,TBN,B8R2
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M!\!Z4< [L+,?XR +,R8]#^B7GHN_&("W/;7[8HPQBD?A /AK:&A+>.JNAD!
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MDS"R]ZE/$!M9Y2]76)/'+7W4,K"IQ(3,BCL!F87#[1$(F'*W&*##&+AXX:?
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M#)[8>5M)?:"]6LC;<C57MHF<^T^-K)4-#?ODS&<2#6O;><+ %.NV8F:T]O,
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MFY1NF%6;_!=@9R/?\GN%6=Q=29KRWJTL7?+]SIO6;W<C#]H*A+82M3^&X5^
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M453%25%(:M>?^SPVIKC!K;9$ 0G([L@.*_]T> &/J=8->1M0=S@[V8;7)[B
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M"[IIS3^^_:9#VPM](NNXV#8'K2]S-07 ,4:1R'*$J<A0&5.E(>,D)(3+LDA
M\:IS!,<V;O_Q[1_!?6UNJ<!#><Z#52196JKS(XO2$F&68U248:G^%9>QR"6/
ME",+.DE\PN5T8(P+F)VB]PD"V)K?D@X.$H!'".;92NI)VYXE-ZE2M17^4'=:
MO^?:@+!YO%YP_0\]=>X[F9O:J57?H,Q<<<]HR62>EA&*"%-;/Z4I(C(5*!0Y
MC4212Y&7L*UO17?T_6^RP;2M8K+JQ)81:.]!&Q#MU(%W8& Z88.(^<,.!U<!
M4<YIQ\29!HT.#0<!0GMK,VA#<^+F@@ 87K<4A+SL6 S)'@5?ZTJH3]MAU_<Z
MRW^6Y;F424X193H73A"."IDPE$L<93C/>4)"4.GC25(C&U$]8>V6[) ._C+$
M@0EN X#9J0,_,,!T@"L"\&K%L\+YJDT\36C:2L2S K^J.SS_AL.E0.^:_U8O
MU\_*.YNO=7+*4<=,^6-,!S0?% M_+O4<QD\+M:L4*TV[BN"S-$L3Y2PE*-;7
M!I@G)2JH<J-*D<4"AXS3V*K<< 3>QL[\V7"@-\MWPT-0]4SHX)/A(OB%- '1
ML2;]-*35H.<O97'=\';XP[34)KQD&+T*-JR>"#:9^%+_L6YET#(<;#@.>I;?
M[NL ;C'>[BNY77%,_[5@%R'CX#EX2^*9Y'17*.-@M7>_,A*)RXK6/B[KNWK)
MA. FCFDZ ;>GLB)ZK6=X&;]\%E.&N<QTDWZNO&4I"D1RF:,4\T@J?SD5!/=E
M:W;&,) #J^V\7[,&._8,8;?B,UL0[<SC,8"YK !-W]S^TO-B+DE^#=HNW1M^
M@BU#_BO0@$AXKD&SI?XF56A :$[5H4&7<;#/^PJWF^43K19&S7U>DL5'(1KE
MXO?Z;<:21)9%FJ&T#)7=G2GCFZ:$H:0,"8O21(%EE3X/H#FR/?W^TUTP5U0#
MJ<B:.%1O3 .L,DOT+&QA_YC M,JFA'6'@:M LQ!H'@+%Q,8D\@\0P!SU#Y2;
MF>D%,)CE"!-]T"*T7&HZ2P\FVYX%!WP57BUW\Z@MO8^Z".]6WJY7#5?:=\'_
M6'QO5OS#OU<OUW_7O/FM7JP4M;NZ_M=FT*6%1KR(P,@Z4C=*0?I.")F&.C>/
MZB^%[BBV4W*JB^_^O3;)N[KNKE%N%UFLVL9C=W6E;!3];A/</Y)5H.<AW&YK
ME(S:_<,<:+;.\&7?8U@13_8I8*IYTJ_@\3+6"YQ.Y9+N5">KH;P8F-W"RLL7
M<QBSJ/QD]=V_D"<Q*P2+BC1-E3F(<V4=2HX*GC)$<"G#."IDFEGE<1^L.[)V
MZR@%FA1@P.*.W,/JY )I8 K"2A#8:,77;+L-5MQ99[JQBJ^9WQNJ>.2O'>\H
M=>*8J73:+36_KFNMH+5%^>YE^TCGTQGUW*KJ;>UD8SP[I9L7M\\F14TY?E)4
MJ[7ZZ/\4NN&QX-?J " /PNAUW>1NTQ5@EL5$D(1R%,J,(EPF,:)AG"*9XC 3
M3*9, E,F?@[!1L_)Z)C1ER87INC^'(#97O3^%,R.>*FLF>\J1_=Z0.R(&-"7
M8/>Y3LS6>KKJ;:D=4;O(VDH)&W327@4[\EX%O<1!)W)K@IF&E#N6FL<K[9_J
M,_JZ/O\YA)KVJO[GD/E46L#/Q9UC[N&ZKA4+;7;X/?GQX8>61+P3"R$K/1Y*
MW_0H5VB;)+Z9 U!D- WCO$!Y6N@!X@5&I.08)3%7IR['1,88- ?9F961S>&.
ML4"T# 6_T):E7_\3F*+HCK7=^34-@K SIP>O*UQ17 4?>AP[QGXU ^LZWG8K
M6,:8WW Y1KYR']T9F38A\F+ 7F5)7KZBF[+[C52+1I? B.9V\>&'OBM:5\VC
MUL&W4B=VS](L)*D,$Y3F$4,X+TI$9!2BE+%41)*641XZ=#L]2]CAMMBAPZEF
M(U#F'M=E!F*/#9@FLP!2*+AP&"*6TA)A+$M4)KJ!;%B$)"FQH&D*.1S\(.A^
M!FC2P2\/BHM?-8+[X.D@(P<W@SX/HIW6]PH-3+F;'U17BZA0^? *E<$6V6#=
M;2VI)Q5]GMZDFMA:_$.%:_^BIX[27W3/M>U,TEF)8T*2L$0I3U-E*L81*GC$
ME5Z(2(99+K"4/II(']"=1JON]XV^(_/O8CXG7=^Y>L/,A7VB#R'-<LEXH=2J
M2(52L#SGB"0T1C3)1)QS3K,BA<6VO*!Y2=1IMX$TZ1I(&Q0]0V>G5GW" =.J
MQQII&^([LZ%';)M]0LZQ.F4?DGO;YM@GA#_;#_O4>_ []7_5'Q:\N[$ZO*&Z
M^5[S?]6']UBP*W77]:>X41<+;GMW>Z/O?=4?S<WORM\5NC/\YV_0IT#>X0)]
M-- ]WYA?"I_3A;DST<GNRR^%9?>Z_.*U'.W'6C>%6;W<J1_G2BVM?W_/6K_^
MT0BYGG^NI)B%!<G#/*:(4]/G/R*H#'-=_ER6,J.X((G5!'D S9$U7L^!V3.B
M)W\5K T#P5QQ8*[?]# UZ&Q'&T0MS2"_. $MH8[X56#(&Z0^;)%J60@T#Q[M
M(7N!?9E$%A2GM8KL(7AE& %>G3BWH+M<V3FMOB[G\X_+6O_E#">2TC+)$9>1
M<E'+E*,B5G]*,QF7/%:.*P%V5AF'T=&]L':DYD2W_,/?9.1;>V\X3WX+O[EG
MWS6]_M+<!QW[/BO$1\7WK:_'AYG\OW'=;06TM^MK.VH7SG[:#L#0PR_:]OE-
M-X.H2"03I!0H3O5D79P52E4SB2AG699CQHO(JJ,UA.C(MN"._[4SX.;2B4Y#
M(-KI5M_0P#2E*RKNDYLLQ/0]L&F(Y-O,:;( X>1X)IMW+^B2U4V8TS5_U]O!
MC#,<A9'4??!*7>.KC+<"T8C'*!(AR=(,$Q*!G,,!6F/GFIC>3QWIMK_GS@1*
MAY98)Q"SV_Z><(#M^KWQD"T$UQ80N#6\&A;.9YNK$Y2F;VXU+/+1EE9G7H$'
MN:_Y?]\O[\12FQX?%]M!R)8Q[!.OC[PW%=5UV_TGN%\&=Q]N]\QWG?2Z7.G[
M*OM@\RD8SL>2/2  VY6VPGL>$FTAJU-<]]2:DX5MSPBU&Y4]]ZAC'&6EUFAM
M^>X&HV!"J&,S1%%:) C+7)G414I0&)>I3#(:$PI*Z'Q%8>3]V5U;M!2! 8Q7
M8%C&'BX1$;8!]Z0;H3/L25%\>>BOUI_6N3XEWBN_^.2##DTDOHFY^%%M6UU+
M690B0H+FVG&-"E26(D:D2##'DH=%0:Q[1>PM/?+.ZF@!VAOL"SZ\F2X3!QA\
M:\FX3$39%PG0F,%9-+?^"^<^%JRUPE'F!SLH[+\Q7:.$HYSN]4,X_H1CI*I:
M$,739T$:L9D]VJ>%S.(X#\.2Q2AF!4>XB$M4D(@K_U2$-$DD+=/,(>%MD.@T
MV6Z;Y*3U0H$5R):C8*Y9"I9T7CVT*=O D-4@FI:QJHO!<0M2=0@8NE?!=@YM
M3]ICF,I&0E_QJ4%:TP:F;,1^%9&R>LFAY8DRPJ_9:DWF\Y<[4O$_V^JM+CX)
M]F0MEQL[ZK1W#=6Q$VA^@N_-/[H*SXXG0#<22ZC.>[LCH 2,20$ &L$#!LKO
MUAK$DL9TC4!@0N^U_0"^ZCY2?3L*XOH[J>8Z]_/CLOY&YN*/12W(O/I?P77F
M_=VRC9EM N6F?_1V#\2BB)A4KD')$XHPRQ@B810A*K)0N0>TB")0ZW:/O(WM
M6^QT.M_PB>2R1IK35R-1JD5 %L%6@,!4YO0BP&>[^_J =C;*&WT6F+([@/SJ
MR&>Y.OD%KG9S2=MN]8%7?3@BE!Z'UOOB;/(Y]YXA/33+QB !-^+^;%:+A_>K
MHYFNUPMU7&P37F')]>"%1U:N?W;=;@]Z;9Q.\M89EG^VV=L'^=[V=A\<W?,6
MX*C PM2C1TP]9\@[@^1D,,*I368Z.@.Q:T2Z+^(0*/ZZ?"'SU<N]J)6?JJO>
MN?BT^&_!=FXD!$F$3 J)XDQWL\H+91U*&J$DCWG*9$I$7%A'C\_3&UDS[5)6
MVZ(C#0C'6B!F$7;VBP-,D72TKX(]+#;D76+4%J   M=^P7&+9I\!R5.4VU[2
MP="WQ3+3Q</M9=H+D@-><]!S-\OZ>:E6%2:W]*MX5I_]D31BT^DF*646A92C
M1&"&,$E25&0\1 3G:41QP<O0*KG3BMKH8;6.?)O+'6P9 &SILXA9:#F?.$ #
M9Z<@L.GNXX &0+WY1,5-N5V&#DS%V4H[J.#.+C*=>K.59T^Y6;_D%A&\;AJQ
M:F9)$=$XQ!@13A.$8\(13?,0E30B:<YEGI!XMEJNR-PNF-<N"U)6F\7M#3+]
M2D ,*5@8K9/:+@(&EP6F<*Z'!0"'F?;Y]10AZA:=-+BS+\AA7.;@;]U^_IN.
M7GOM-I1_DN5%C-4Y7F;*;Y$$%7%1()[1*"-10G)A-2%ED,K()WG7O6ZEB3KW
M=#D.C]VVN5AHV"[:=NO;ZSIR%72]V_SMKT'!/&VWXS0FW7V#8AYNQN&'7689
MD:9J;N6=^N*]C=(.P!5AP1BE&*4B*Y6UG>6HS"*"HHP6L> B3835M=,@E9'W
MIB&KHV^[A&&C@H=!LC"P?8@.VZ&C2PV9/.1!>L=90\=0^(>OJ4)GQ!J>(W3J
MY0DG!YWA?W]6T+F'/;6&.]D@8(:+,A228VTP1[I)G'+Z2\$1+V24E:F@+'$<
MV7B>N-4O]9)IC7>=HV%^K,]'.W]<V.7L-+!V%H9GL+QU/COH 7*UWP1DQ#YH
M9^4?JR/::<)OVQOM+"!GNZ2=7\%-RYCLGL\5H=7<W"M_41*VANHLCZ1("R&0
MR!E5JB7#B&8)15DFPRC*99*S'-;7XS0QR,9PZLW1YIG-EXL'I REIV"^Y0*F
M/08 XP7.HY*F*.)$N6LQ5H#1L$0Y3>.(%8DH<0@)7OB!RSF@L9P ,CL%ZP<(
MF$)M?S [1*^"+5E_NO.\:)YTY0"A277C>8$/=:'%&_ \EH^*_^5"*"=1)Q6\
MO%^+^^6?U7)NS+=;^5_*B[S1%?CURV?R]_73RC:-!;KNR!Y>QT[0\Q/PM= F
MPH8E;51IIH*.JT"Q=16TW0?L\U; : [O^[&!A&F"<3 $I:>X@N&4G0(F-EER
MBBL,N[DISFO =$Q3KV8WZZ>U7O>[^""E8*L[45=+?BNO^=(425[_J)I93#'E
M+,\1+8E$.$H)HFD2H;0HXCR7&#,J;92/+<&Q+VXW+ 0M#\KY,%R8).6.C^ O
MS8EEK,4:R6&=,@8^,#WB!1IKM0&5=\C,4&OMF!CJW[8*PYK,)$H"*G2O&,#O
M.3;B63X]5:83A)XBW8YK>1 +IHR:69+&6<XE57H@3!'.,H;*I%!_*FB<X"A+
M" ]AWM8 M='=K1W:)NK =JD#>_$,@&;G/G@" KC;#Q"XL4( WHKGO&R^6O$,
M4)JV%<]YD5^UXK%XQ24EZ^6]^-$G!Q(1RHCF2!))$$YBCDJ9E$AM6YP7643C
MLK3/OMHN//9YK2E!LHAV1+:XW7$4!+C5-!&7G,^][P?(?G(3RC'1:? # 1.9
M7C,^G+.T\_R$Z4FON=S/1#KR]SX;(K<=3)2>^*1X76B#0 ==F[OEO&(OLX3%
M/ RS HD"*WL]24M4AK%$@H<T+M1A'8G(1[?C02Y&/[]/==KUT=QX&%^[(WUD
MS&#ZYVB[X9V.Q'^U#(Q3S'<!$J,V$![FX"?H#FP%D5WK7[NE''545^1[*UNW
M1"V^27+Y2E8FD*$,F7FUO7C>EM:F6%D><8Q1+F*&,.,,%30O$2<XRB.!PR)F
MH+YD%S SLB&S6PR]86YW=JKF+]AG$*C-+OD2EFIM(GR!^LT!VE$+F'W Y$OY
M7<+*M%K0 VBOU*&/-2](&-]IJ;JC]$@H"I)05'+EA.%<A(B(HD#* \LP82G)
M0PY1>B<IC:S1KI6'NFZ">V5(- 10XW<>(3MEY$5NF*8Q)'=[%GON"&,MFL]L
M]:-TID]@'Q+W:$[[X OP&]?[FBNC^%[43]7"J -=!6Y[K7KTY9'WWPXU4[%N
M?QUZ7-3A7>=%2MAN4YK%C#_9]56LA0;=7PX*YG1)>7S%R6XB!P7:O6X<?M A
MYFAST)J,B?;O9SRB.,(D1WD1ZP;_.$<EB1BB!:<QC_,L$HEU7!)(?&R3?TV?
M2;T*/@:5(0>(_$%1M AUCH@-;%O;FNA77?.U3V.#!PBMC@BB6_C5,YBP>*TC
M&H,Q7>B:T\5]':7=BPV[KN&@B-^+NOIN[HN-M?1-_;!$.Q>^;:!9D7G?ANG#
MCY58-)7R?CXLU&^P-FQ\6:ZZD2^"?YR3AQF1<5G@)$&$,H%P5!:HD%1Y,%P0
M4N09X]@J6#,*=R.K\BV[0>L#;!@.;F6P87G3*RW8,AWL<*V'?0<;O@/-.$"O
M>?^B%J?&6WXGV+'R_\]/!#B;WO)3N1U>;_#)8 ?<6) .GH#>B4YW1(Z%U]X9
M.AJ1"P<;MH7VUPN^DPO>]:7EMXNONC5B79D!VU^6B[K_5U.=][E:F*EJS8SB
M+,N%4/X/9<H=2M,,%7E<(HPE+VE:)!FQ2M,8A;N1#]EMQ[VK5A^TF4D[#/>-
MF'F@=OV&9_/4+M>!8=MQM**7SV@7P7RSCP,[63U_E^ OS7-@F!YCTJ-/,'V/
MA/3"V]O,CO0)Z\DADUZ)N.GSST+Q(&Z?S6FQ>#!C!GIN7OJZQ_=KH;M\WO^]
MG"4X#VF>$Q27-$)8<(F*.,Y0QE,AN9 E+T#7.4#Z(^MD]5/.8(H4BI^=JAP1
M%9@R;!G1@[H[5OKQ(!MNKG3Q#15FAL!5VPQ6<>1/T3E"X4F50:E/JJP<H3E4
M1Z[+.$1IMH74FZS?E=&$7ZN'Q]5_+>=JG6:6E3)-,26(D[Q0MB#/$,U$C(HR
M+&+,98QS!A@Z9$_9:A]YFSP$<+3M<&-13J.RB!$-"X)P)IF"3*OJ-(I%20A+
M,V'7>&)4R-S0TFKFYL^OP6-+UUA;;4WTIIIA%3R/!:U%[,@?7!>WG-@RT+7T
M-BP$'0_>P0%$;;R#Y!:*V05KY^?SW8!5&[ >SX %"ZV Y!Z,E]BM-%T0!"39
M7F0#]J;K:!LI:F5-WY,?K;']6[ULFDV3U8**/"]I@FA2*&NVC(72G1RC/"XR
M9=6FLHBMRCWMR(T>M6^)Z^Y^7?_+_X3.D1E$R\YV]8<!-"+>B:_O!%O*5X&A
M[;4'+4Q,;Y-8!HE-/%S%1O#7\U*LWG+,/CP8O[(=S*+'M/Q.5OV8%JFVU>U"
MW#_6R_7#X\?JNS%JFXU#/F,$RRB*2A3K[H$XC#@B+%8654'#5-*88@8*2'KC
M;.SL1DT_T'T57K0'MVK9"*2^K-#_!=I)U]L'L=,Y;P(S5#U9#*/:C3UV7"L'
M^WINU%$W@>6;.BGG8O/7)B_L*B#F QKW6\D7= (&6D*/B9J^8?:5V.F-KVD3
M07W#^2IQU#N!2ZMF=.['PT(/QOK$=6V.K 3OHJ!M9S6^'PU5?Z?,>WY0OD%+
MDF/!.9))JK0TH[K;:X*1S K.12JRG&5NA31>^!L[T6YWT&"K&KJV-\J.;BK>
MWQ/_1["5)MB*TU]J] *]NMWH9'(MQ_'SB>WT_AM^.)CVW_UF%WV5B2IYO,+I
MO;C'#W=O5._C%=K3)4!^R;@/EOVT4":^"=&8MD#*#1!%K#NIQ+'RN!-6*MLZ
MPMK4)FF29S%C5F4(ITF,[F4K.VY+$=0\:0 76]_Z$FD=#%9[09WFGAZ7Q>/X
MT@,"DT\A/2[@L6&B)YYT[%9=+YD0O/FHF-J:>7>UZ /DNN\*F<^;6_GM<5FO
M=$?13XOOHFF[LLQ"SDH<*S<XEZ5$6)0"E2%.4<H2@6DJ8D9!4YPOY&?D+=US
M%^AO&#SUCI4ZJAO-3-MOM=JR VQP?>&WL-,,$R(,O)?8 W?+VE6PPUS;DTFS
MIU$W#")=I1-\LD =WB';#U:^VF9?R,VTO;3]0/>JP;:G99T&^?5W#YL[[Z_+
M^5QYS'KX[8S*#$<Y2Q%+=!=IF@E$22Y0DO(,9RFA1%JYFA:T1M9R.Y>"&^J@
M@76#.%E<D/J3'J:!C@D>_*5)!QUMV."^01Q 8_M\X>$ZM,\=%^C(/AM)SPSL
M&UQBRG%]-K(<#.NS>N6"?!H=WQ/ME%/UJY.,82F81%'.<^59<9U?+0N=$9)%
M>23CG&>N^3-[E*;)E_DB5@$CS6.PTKT7^CO.97#[M*BN:4!6_9^VC#FD..Q#
M:*'.W!&Y++]#T?,IJ4/RAK/$%R9K6$KNEIEQ5"BK3(S]-Z?/O#C*^=%,B^-/
MNKF8:E>V59N?ETTSRPM,""TQBB.F(_*,HD(I&Y1D.J@C.<,TAPS;V%L=9!C!
MYVMH_=*6K >_S!6Y7X%9$P=(<$)94H;*=<Z4ZTQCBDA$A:X;C7C!HS(6!.(Z
MNR/AIFGWD+@$"!(7><APB.)4A@@G68'*6/VKB'-9)$E2$LIAK1F=H7!JNN@5
M##LGWEE V%&B)>OJYW_1E'X-KE>KNJ+KE;E:4$?K'?$[5^6H8)[\Y_VU)_6&
MCXIUZ-L>?\BE8X_I#W-=UR9@;-VJ9_>MD?7'D18VEKKTB(##6^8RV6#[Y5AG
M'E_1\--R.#;BV5MJP@X\QT38;[US] D'I^>:,3T29&>DK X5SA@G82J90#*,
M&,)I42"2IQ(1(05/")9A6EA':H[3&#]"HTZJE2GX7BQ78AN*?FXG4_Q2+=IL
M+,NS: @N"P_G<A!@^ZRGMS>H69.\7%J EW.YU&YN#EQZF*,S+->@IW/BU>E<
MG6'>]WR=,X_"S]V[[\\'N2F61^^K%\>^QB(OP?=&3[&1R_J)*%3[-A'K6O^4
M[ >]'Q?[_(%\D<3@<,BAL&-DQ@Q*Y71"OUYMLD/ZI""[Y_3IA^!;Y\._5R_7
M?]>\N>;_W7SXP>8/?Y+YU^=ZQ3\MOJV?GNH7W;>[62WNZ;P;_&"YM^ KC[SY
M] 18=5!?ZXAN$RBNUMW=U%6@V5L; [(KQA+/RUIG\ZK3?+=O.72'.J![?@N/
M"RQLCSMBNGH41W ]/Y$$I!3<<7+2&@[D)E,K[E#LZIT+5H$I)BZJV8?%2OVR
M/E9S\65M-D:>*A\A57Z#S'*.,)$8E2PB*"UHQG&8ZV;]-KKIV.)C:QY#+M#T
M@I:@G0HYBL.P@KA4.N#VMQ?,>NL.23"P,=5K[<94?]ANS*.+3;+MAL3H-]7@
M,PYN]V^D6N@0UNW"I&#<'Z0I)4*$69'&B L9*?>;9(@*GB%.J"0YCC*:1-!+
MQV&2T]P^:A[:W*5+DL%L$+3PR#T XK05#0A=K%@=J, $+3 2 &_='R)N7OME
MR, \>#M9!SWY,TM,Y]';R;+GV5N^XG:=V8;H-]WU-C7/)2N8X#A'.<4APKJ=
M1L$*@>)4Q&D2$1'1%'*==X+.^)%%KLQA91]O>TXN9=_59[F %HJ?0FM8A7G$
M *:^NLNNK>QC%(2?D<K3;=<I*I/>>YT1]? &[-SCKO;[->?JHS?=/SY7"Q'-
MXI"&F!<YDI0QA(LT5(9\3%%<E))204.>6^W702K36/0=Q:O^#X&FK:M[H?;]
M,9QL#?T+I7>R^.&".]C_ X)=X @<6W5BCV! L->NP=##CE.UR7.E4W#407U#
MZOI%MEF.70"J*&D4"IPI[$+E9[-8':>TS%$:Y4R=L&DI&:A]X""UL0_5EG:@
MB0>[U($3M0<!LSM1O<$ VZ\G$? 8; .)Z&NX]B"M:<=KVXC]:L"VU4N.^WM=
MZ]R@CT+7F<_OR8\//W2D5;P3"R&KU2P-99**O$1E26*$E8VLY[T11/,")Z':
MX&JK@W;X,+V1]WA'%KBCST!DN:?]"0[<U2WAH*-L^BEUM(-?.NJG$Q#@&]M.
M3E];^PRU:3>WG>BOMK?E:VX;O!W:<BL__&"/.MU)CVRY7=R0YE'_O[Z3^4[F
MPMRP*SN^8BO!]5]<+_C^?]AY<L;#F#)*<R3RW)1^<T1RF2+E6.>"TS0L"ZNQ
M5R/R.+9-;SC63K?H> YJ/;>H_7.C8T>FQD$70IH_B"UK,.TSQO>STUAO_%6
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M:D$63'F:^CZUN5YPTQ!AO5@ULY Q)DL6(Y(D2BUP$2&21AF2D60YDQE/[3K
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M0!9F?ET RZ!5YK+N=,;:!5+OV7"7K..@N;?QP:ZHJ@T3=AX%8XDN$:>(EJ5
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MXQQ'41*C5.=-8DXP(I1&*"QUU3MGRE>W[U]G07!D3;+MD,XV/ 3?-1-!;;@
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MA#-)$94D1UDI$X[3E!:P<3\_DW CZ[Z>EX"TS 2BXZ9-HS;]A__X]CYX5NZ
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M,$*E)NW^V"T.B:5:P/[8SZM\M)7#K+-CD/$BEFCCXQ;(C(IYD*OJ[LRZ*MZ
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M-4/T)$^)1"G24..JE0M"D#(N(<\IUYG"F.9.I4L>,H=.Y-HJ427)V\FJ6SW
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MZZ/0_B5&PV/[]A*C$K8Y&W=T_/9=L5'LW55%$S;>GBDV/GL[HN@OC\A;_<F
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M_J6];74^T3C%1&8E5))(B%%F]E7($B=IS1!GBI:6#, ]->:$C(&38NX/4F'
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M!8^5!M6]BE6ARFFHLI!=DQK\<.WW[H.AY>>@FV[,][I.)E@!JX3]9ZT&J/4
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M.,(LE BG/$*$A1R1J,AC7F1Q'(.:B>V,/O9QJZ8%KH"T"T LHB1,\PRE*=<
M9%F""A9S%&$9Q3G#>F$@L-P#9PB<D@N\@&!GCYT%@UG6ELP((7]'!?!5%W1G
M[&G+>QX3ZZ!*Y]&'X 5*OJ[$]6IU+99UG-\[;9ALBY <OCGV/5]+*C"T[,N'
M')%P6#\N%PZF(%]7M(X#ZW>!MY,55./CM$A.=3R.##=9K8[3HO3K<0P\Y7CA
MW@;*F^B=FZ=JO7S85A%[^:39;MHXSU).691G%.4\-MW\E%Y_PY2C,)5I%O.(
M)K!CB"7=D=7OT_*9+H(W;1OKG[:Y*UWM0F#0NRV:=HO9"!C!M+ACH DK[%CH
MQ0I>!5LV/-ZAP^3V=7UN277:FW,8% >7YL#7W6R(&8A6][>K.[I:M_^HJ[)6
M91UH;RY_;M5A<=;-63N2*4O2'".>Q01AD0A4Y#Q$69*1F!1Q$6(.,2Z7,C1Z
M<,^&%:AGXV*H[2S/E #"3%++C.FB97@+NG_WN+MJ;K?KZ(+#<M.C.#1\X>7)
ME%W,SJ0VSA=X^\;/V[AN5O'#@J],/:=WLOGOAT53V>DK_2ZK;5C?+%=A&E-1
MH%@(4UD@#)$^SQ/$&->&,"HB)G.'(M&6Y*TT]>*"T&V+N[6A':QV0QH?Z8OY
M&68';<&U,W<^L7*R:AT#P9N.A9],[:D6MIJ-7B2H/[L%%-R3>;*E.JD5 D*Q
M;VR@KSM$K]RMEN*)KULOR9W4G])B3;_)6187(A,%1RE.M06AE"*:J1@1G)!(
MAERDN96#=)#*R'NBEFRP:CUK;V@5T."Q(0_I>7<2I6%3X$UVF.)W8G<.Q2U-
M'R(#8DI\B.X60.(  2Q2Y)QH@V$A)U^>+@;D'/\[ 1]G'W8P//4%4"_EH_7(
M4XFEPFF*>)R$"*>)WK-$"4-2<2D+;7F4L*IA,D!CDIOF'E6 TIT Q<+*7"XJ
MS,8<2'G^VL):7("%N5QL-_MB/\DPLS(LSZ!1.?'J="9EF/<=@W+F40=S\G:U
M_+,R&Z/E8OGP FUQT?4>-E7&Y<:M$6.F(BPS%&%3@25/*6+"=-I)LHC24/)0
M6KFGQV)P$D/6E)H.WLB&]D^6OJ71)L7"%KXRU#!#VC ;=-P&K@U[VF/=FY;Q
MGVQ<4M/,&,"<O_+,N:T%8\V@IR5E1$P'UZ,QZ$ZWF(V(VLY*."8=Q_A2_?G7
M=^M=2<,NBN_Z>UG-5,)8S#*,:"*$B<.6J(CB#.4%EH5>(G%14%#DZ!"UD1>X
M37CB'X:8I9FT@\G.1>A->-B28RLW/ 331AY?P96#M*8-F[01^R @TNHEAT9*
M]XMO'Q8_F^RXZ^I6_5ZMM0%9WZJ[U>IOJ_?_7+]<_[D2E?ZU^+"X>5Z)OZW:
M4Y=M2R7'\4?6Y9M[$Q)D_-O;5-2 5N:^[G=9U>V]36!+TX6M7*Z"OTFZJGN.
MK5^"ZS^IYKE^4"_,>HR;Y;,TJ:OF(4#_)5?HAZW%5*C#C,AX@'L,@/0!G5OS
M)E>BT[5QNA"6G89.EX[EW$67SY<F\?=6U<VCWIHDM'ZSL%ZD8/7V9?O,'7TQ
MOZL_PVU./B&IBJD^Y<?2=*KAC"!J2K\D0F582/U+!:IN[YF_L7=#O9(*-2>H
M9B78:;[6;C7!K7>]SI/=YNH5T8=9TBVC@]#WN0W8R\Z#+<>-71VU=,)(J/IK
MZ^N5NZE;_8X![9'VOZ.0<7#:OO\N5[RLI-X@</G9T+Q=R'9/5(0YE3@W749R
MTYJ*8$0H)B@BA<(X)HR$]A=! X1&MJK_GL1_R0OT[VG\EP(#''%#T%BX0#T)
M##-D'=&@IAK49 --U^5J:$A^@$/1$PYNCD%W/& >/@LA!SUU0^]/YW&SD&+'
M<V;SO&N0W;.>Z^7JY:,^F-?IK#.9"D6S)$%YKF(33!RB D<2);*(<KTS+*(0
M5&WKD,3(=FA#$!H2=P"%W>[K,@%A=F=#*_C#4&LRD#WN>4[+XBUV[8# Q&%J
MIP0\C$@[^>2E!79[%47*ZA^U%U6&*2\PERB,PD1K79$C%DF*HABK(L$B"W-0
M"/\0L9'UKU=DMU\UTL'Q/(B8Y='($P[ <XX+!!<4VCTMF_=2NT=(O5*QW=-"
MGRZW._ .W/]<GP[>?U_Q>EVV]2KOOC6R+N[NR^S]NWNBG??:NDL%TZSFV&\I
M%LAY>EP")Y?HWE"3.3J/B]!W7YYXPMDI:7N%^XM<Z)_FUPMQ+1[*16FN;XT^
MMDZV&2&28![KTV\>IJ9/"T$L#3E*XE"HG"M.!*S"O#?61E;0EGJ=R4%WZ(,=
MC[[FPMKG^ H(@]V-P/"4_G3L,GO6'^SB7_2,H#_7HB_&IO8J>@;TB$/1-P7'
MR)7V!N-6O9--J\VO]'M3(%93[.7DU?[Q[7T"2Z(P)OIP(9.$(1RG(2(B+E"4
MY!$6%&=4@DK^._(QX?U.QY<)6NOJ-1OM[O$&C(9QA-[.K$X *,R& K$<]4;F
M0G!\A>,X<C%MH,YE4!V$\%PXG)N5JPGT4H[KP6<T#/.0A3F*2"00CG*)J$KU
M%CQ51!9*;Q@34#VSHU1&ME US7[2?:LW0 ?)<8#L+,W%8@,/;F")P>9A4")/
MRG^<QJ2J/2CFON(./^QPD7DM_OY4K>L+TZ_+:R'J4>G\CI8FXH4^EFLZ?[M<
MB/^6XINL6X%37E]>8<%2ENL-1\A)B##/""IXI)#>DB14DI 1;+7UN(B+D=7:
MD SN#<U@O24*N MT1G=8YR?##&@3MAR9NJE;G@+#E#ZN!2U;5T&-;,U9\'5:
M9 %7L%,@['8_.Q[2L/O;2Q$:O-QU'GRZF]]+Y=^Y%KYX,-?2D.^>FC,NK"QD
M]];86ZM>R<2.)+0RY$; \XYO=]E@MO)81<BSXCD4@]R7Y()"D)NA)BX"N2_"
M80'(@R?<SB>MLV?QS;15NZ&KU8M:KNIX[YD4&<NH8B@+189PF,6(A'&*"DP)
MP4HRS'+((>4TJ9'5:4,XF&O* >^1AIU5!L"R.[#X@0"F=5OI#=%@AZJ_@\MY
MR3R=7@8(37J$.2_P_CG&X@TW'?XH]0E)-NWSY$=3>JC:^NP*+C.1,XFD2!G"
M,A:H4&F.B@@+F:8))7$$T>(A8B/K<4,-IK*#V-@IK2^)86K;4.WZE\J@(1S\
M,8I7TD9$3_H[2&I2#;81>E^'K=YQ+A:X?)!U=U/-ZDUS&V-Z+W37,=6=7)D^
M>;R.\9ZQ#+.PB'*DPJPPW>FT3L<D1A3+I""*AED*NF\&TA_;#6$(!0NYWI2T
M,&OW3TVG$KYA+EANN O>E(O@MR_O3,6PH#(L6M8,<YT .^LQ(JPP@](5+/BX
MQ7'+S?8"V718UP V^-<L>:TUZ(*%OYJ#(.I3UQYT@>9(#4*G85R+#VBS=[^<
MZS>J)E=T4T9$&Z DTF8(Q::0*>99A&A>2+T!(7F:9HHPK& -2TX3@^B,4_>2
M/NG_^+<BCO+_"F3- K0KU6G [*R)'Q!@AJ.A<Q5<K]>KDCVMZ\O1]=(47VY"
M0D?H#G563&]U"4X2FK@HP3F!#RL2G'W#-<:;K;^8OKQ-0>1G6L[-C/^\7'VA
M<]F:E.53]=MB)>F\_%\IC+FY6S:7,V:#]/6>+J+X5_WD?35+LARGL61($S,E
M2,)4&X(\1DF14X)5G!8),"K<)WNCGUCTB7NMZ051'#S4%*'AXUXGP\[(O![$
M,,-4]YW=,JHM5,<JTB=K9)B]"K;L!EM^&U=(Q_%5L#-/OP[/DT.,^QAP>HN*
M]\K<Q''T8P![&'D_"A5XB]W/>OCWE2E$8R+R.']Z>)J;8NSOY.-*\J:QXSM9
M\559=P8R!1W,Z4@O#'5VCE2)PE(BF2J.<,1R1*B(4(I#F2<\SP6S;LE[$2<C
MF]Q/]*$M8]*0!&7M7 [SL(6=%#R8,87B!NH<[$7F"SH-7T9_LL[$7F#J=S+V
M,Z#C/E(?1*MUR6],E_%5U\,QSS*I;4^,)&84X2*BB# >(<%XED<24\I!%>F.
M4AG9Q'0T@5NYHWA8[L@NE1*XL6K)U4&R_Z-7ODJ4O EX\][M<E T7YN<HS2F
MW:L,B7FPY1A\V#U-OHVTF!4Y$7&8A(CDQ.3'1PPQP@G"25(D.>4XH:#22;VQ
M1U:]'B5X:GPGOJWCUDDHJ%/VO#Q.&?![G'M,?>]&GCSG?4^D8\GN^X]<FIGR
MGJX6Y>*;<9K6_M)WY?Q)+Y]O7VZ6#_HX?S.G51,N/E,RS6.FE[2$IX7>7H<<
MT3 L$.49SL-,YG%AE5Y[ 0\CJU['1WT]4'-R%;2\7)D*5PT[0<U//T_MZY]+
M5/\R^%6N[Y?"+4S<94XL7:KC(@WTM4X%\@6)*V"8O">MV'/P2@DK8(A.)ZO
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M21BA1$2A$F&B6!2ZU"?<DAC9 &P"&:6F>$G-P1XH=GN RT2%:?%&2D-LK*J
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MUXY+7;TUTW-D$S+/]7*^+1^_W;&'5&3*N$CR+,L0IFF*"IQGJ(B52F46*<:
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MLXHH0R1+,>*1)$D<*LZ4E:H>'7UD)=V2 ZR4!PA8; XND0NF=%M*+KN  ]D
M2_\E,KJM]Q;3!UO:3XDPN)X?O#3=(GZ*WYV5^^1#;LOUVZ>J7,BJT@<^5BZZ
M>@3+;PN3@O1!Z$DL56FL3'._WL;(B^N%^-CV]BREJ5F@YUM\T#.^^%9N'KY=
MZ\W%UWNZ^&6Y%'^6\_DLE8*'IO!J1@MB-@*%2:\72!:Y5''&:8;5;"'7=MN
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MB0"@L_6-C ,(U$?2<-&4 &O:6QI&@EXE]I:7X$W+C<?H,1<0O#E. *0G=J#
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M&D4912%3)M$ASE"1XQ2%N:#Z!QH6=BD/%K1&-A)'\@8-9;=.K@.(V9U//>$
MLRB.$,"S)\\+YRMS<H#2M%F3YT4^R)BT>,55H8U_IC[(-K&[2N)"%5RA7"8Y
MPJ:6+=/+.^(R2^*<%:%(@5'<^R0@'ZU3*-O-CL_IW\._A&$4/-)5$V']7T$6
M7H5AV&0C50%]6M\O5Z;?P'\%$;F*PJSV247Y59IFW4-M-I/YPW(;<QA0<_SC
MM6%M0N>2Z"HP7U[]I/XAN0KTZX]-482YY3[]Y-S8V@MWO*%&H@;Z2P-T%TM7
M0^730AP7QYM9V!M^8EMP7+A# W#B.8<=?7NC1^>?ER]TOG[YE7XO'YX>;NAC
MN:;S+V:R];<]DT*(0A898B32AB W==QP7* HC4,5\B1CB54U& #-D9?UEFC
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M;AG_QLVGYLL_J\#,<IN9XN3HO@!J.X,T+GQ>7=@'!;PM/=5@^^2.B2<CY<#
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M33/<KJ,]6_6\4G,A;3DS97\-;Y%F+KI;1WOV9L+8X04]$]9^+]EI,7=[/P8
M:O =-V;]^=Y3 5 X>->$6"] HY!JN%*_,K]=KLW+<!];B7$ALB1. 9(D!TBA
M#!"A&(@3AHL$%AA2QSC76):FCW*UL_ ^R67)Z6K?V=N41=_6#=9K(]AXYS;E
M_483B'XKUR-ZB?AL3*[T/F1Q#E@.$4 <%8"*E ,2(R@Y83EAL4NB\IS;XC.@
M\*%<@;529F.:U_K,>-MYL>=$T>W-?MC%I;K<QL54]N\8C+Y.$FD,!=<4+5U\
MV'FYOBXCP!ML[C)F71]G;[FL]*NO;'-T,&1I08E^W62Y?OO (@$$*PP@S..<
M\HSI/UKG6AVN/;&^ZHBY.+H.9;=Q4'I+Y.@W;.GXY%P]D\K%J^8MG:>SZ]*6
M.;J:3K(_[ $Z?&1&Q\Q)7@_]):<_,E$6074AZ'38^/)OTA182/%&VWOTFSRH
MPUA@15DJ,@JD,@7;"@E $,YK^"%-A,($!DXF",?]Y,9NO_WQF,*O.7<T4$+!
MR^Q2^+R"RC:QX'F[XZNH$RIJI7I6N39CED'XS9@KV2 @YZ\KYR#\ECBG'DS
M@D\')_MNA]??#>NWJV8"X$>UCP'HGZI2M!];0$8X1(R '$D&$$TE8(H2@%*1
MI"*'699:M1*8B+^)C>.&"Z.(E(D![K+9^#[TQ_OLN#0V"K]7%H;XR^[ &$>
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M^_&A[%4NUY7*BX3QO&"4 )9D%*!8IH!D60(DI+G@4.",,Q<KSX;HQ"9?O^M
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MTCCYX'PJ8XCO X4Q^$$/=?%AO3*1_-L5UPN^TTR=B5<D0@F5B!P0:FX[.16
M,8)!EJ6Y3',D>2I=HV66M.>)EFEF #?I*F7-3F0V*$3,S!9@"]T4$B\O=;7#
MJ&$A,CR$")K98N2@U2; RD_1A<',30LZ"C^H&&W7FD]7.DIWH#Y=GW73J&;N
M^DW[+6G< <8;\$[_IEI G*DXQ00D)B,)I8AJ!<HAD)A2BA*9,[OD\P$:4X?
M6JH'GHZ:L-U1'T)G6/L%DMDQJ.0NKO4IM1!H()*CGV[<-?J'O9=F:,U9#J>%
M4-U9M/FHGP/WS0]:+DVYX[OUQO0PW^<9W4BV;?UR^E]?RM6WI>S\=#?::%@4
M-(ECD>5 *,X!8E0"DJ(,I"J3*5:(2DD66Q,=M'/H^K/B=)!W#%E_L^L(IYM?
M=P2L=G[>><!RU ":\D%VX8Y)H-8;8-B\VKEZ]5^7]8&7HDERKAG=>X(-J_UQ
M3^'\P>.A"^0?'L'(K/[B\8 ]]Q\'6-%SM(5>?E]9]X'>RYOU/2U7BRQFD'"I
MS8T$:F46:[7&:(8!S+-<7^-R3(E5;\5+A*:V.<P1W-.]B@SEZ&M#V['>[2Q6
M=AHJ! (>^L==>/<!!!<D"S58X!R9>0<&7!#V:!# I<][VBGU/6,W,&T_06#!
M"Y2P7%! <5H A!D$Q/3KSG*<IQE-$9;(R0PY1VD.*\/)7W(9&TM;(H3$;D>U
M(7DPSG%/-N"K_I)DH=[D9^G,^Z*^).[1>_CB WZGM>ES9&(TLM\%J8O7%054
MD*@$</W*-<T6I7[92@D$RS&A%-(X+EQ>ML/D)G[EUL3=#NP%>.Q.;3BAW8YN
MVPRM(=SOEQ8PI.DF8Z!#?('8K"?93O#GQ]GR*>]4KW(KWY<_3-^)K?Y&E/N>
M9_?KS;;\1^WH??O+Y '+VC^A/[O("):I2@1(F(#Z]0PA8#*7($$,X;A(42:L
MLC7&L3%UO+7:EO?-5;;'0R0;)NI\:/UU*YQSPWP M],>T\/HIE4:?D#-4+3G
MJ/'S7T6&CSKAO,_<5>MCU,\$S18; 4RXS#$?)N;.(AL!U(F,LC&K^<<=F@XZ
M;U>B=KZQF&*2<08H$;FV3 @%I$@QX%00F5(4J\0J2?4LA;EB#@W12%.M/6GN
M$8=#7.SC#=[2>D8;; 7UBC6<%&94I.%PQ=GC#"<%.A5E./U!SU:(CZPJ14DW
M3\;7]U%]V:[Y?]>MDZ@4N4H5!0SCI DA%!3K,Y>D-$GS!'/B5*YQEM+$QZZ;
M_EK3\VHN=1XCN_=Y$,G=CJ"3T.Y-]2X)%*H%WEDZ\S:LNR3N47NYBP],.[2H
M_6'U[7I=Z7?T2K2OYFI7L) C C,SGRAE9H9>;EJ,H!@"* HL.<:LP)8S](+S
MYG(H_+KV=QQ$W+!01[C:VT#U+].,N[F\(<.:Y$5!=GSY.X^TV>_']6X_.GYM
MBDXFWIEI1A %W:&YA@\-[=3\PX:L(0PU9N@RP5<Y8,@:)]_10O8$_&S4+IWM
MVT8V0P3;Q'"69HISD@)6Z%LA$E288B,)8I1DRG3=%JE30_TS=":V3W=9DSNR
M;M;I.73L;-, ,KN]'X[%G:"\^()4@<S3<U1F-4XOB/K<-+WT\7"EQD]=R 22
M'-&$, !Y*O1%,L> I4+_!#.>4(4$DTZMBH>(37Q66RIM+KV,EH:':+EWYX^O
M,-[#EK*BR+,,*)1 @%*HM5N<40"SC&5$<*1!=1MS'0HXO^ZO,T)G[68/ H>S
M,_U, 7;P")V-@!.64S^]2'3.1FB;DNFC9SS[M^LE/].MW/5 *5B>QPC$25+H
M>W>1@0)Q#N(T98Q3R#%TBJX?+C^Q]C/$HL_6'NLS$-@=3G_!W([C3J8)K)#3
M,H3JNWZX^+SMUD\*=M1E_?2GPK3+_5NY_;Y^W'Z65)3+IQMI>O7J4VS25KN,
MF=O[!_VC,7+,$*$WJ]4C73;5_0M.BACEL01I!E-]<Y ",$130'*>:6N%)4*Y
M],N<A$FK[_SH4L$;R3?UF[A<[<=VE[NFQ^.Z\8[;)#M%,3_F8?K[1C\;1J.6
MTZC/:B_W[BK:LQL9?J^BAN-V /1TW8"#(#E1V^!QO+UH?^$@L%YJ1!R&B.?X
M0UE54NZ<0H=65:\-S2(AF""8$) EDFMCB"C LD3K8X*%*HJ"%42X9 ?;$G8R
MDWR3A9O[S4-+U7$XHBV"=BIR"ES<M%_#0=^!/-1_*N!014?)0XU9M"4[[^!%
M1S".1C&Z/O_:AC-^6-=VC10?'NN;""T2H;5.#&0A8X!,_),(A$$F61P7&.>Y
MPHN'.MGBRY9NMG9::#;^78[K<RGL@Z6/VVI+5W58B&[U"?U6KDPS6F,F-HN^
MQLF-SW<:XH)F>2H!R2 &B%,)6,$0$#'%$JDTRV+8[O3;U8N/X1R]SYT,OKLL
M5^+/M;]V[\%7N6-N+]+YIG+N1-(_UD+]&69RGMF'5S^1\SG?_TOF<9[9COFF
M<9YCP'V @"92ZD_>;:A1DIJW]^5*WF[E_:4DP.&'I],4+<VH)=I7$%7TU3 0
MU1P$ZOM^642O=NX#R\[6I?VR:/WFZQ:?]LW4?7A8UOM'E[_1I0E8?/DNY79?
M&%CM!^_%J:09I1R0(B, J4R >@BYP+D0E!-)W,;#NA"?/ I1DX]J^J;6S;@L
MC/>,EDO'>[83I)8VQD1 .9H)/2ZB0\!ZC$1?@XXG' -!L(1A!](SYQ"[@W*<
M5NRQQHBI8VJ]N38OT,W6%/S\MEZ)OTKQ35:+HF TCX4"6*L9@ A!H,@@ X1A
MDF0Y)TK9=WF^1&UB=;(;!&4* ?F>@8AI#J+O-0L>,[/.8C>L1H(CXJ8W#L#H
MT8X,\>BOP<'PF!P6 I21(\-\P/$;%79)6*L986<7F7\XV"5Y3DX%N_C0M&$*
M4\]XIX&6"Y(PCFG. $)8JSW&.:"%RD"<0X8@I$+%3OFFSAQ,K KU5RB?)E"Q
MQS!LQ,(+F2E#%VW9<\W3_&&,(SAFCF?LZ;_*P,81/+X1CN.%_%30\U&QM9?C
MTZ;D7:Y4HF@*8T5!IJ $*#8I*E)KG$0P" G*!:3(1>-<(CBQ@JG)134]-SUS
M$2@[M1)2?#<M<C3$^2KJ@3%![IFMJ($TQ$5RLRH$6^&?GW_KYSQS01^K<J55
MS/7ZGI6KVOC\+/GZVZK\AQ2W0E,M54GWO16:6:CBS:K?,$;_3=NNHLU.[?^A
M\82803]F#:T[,*(R*P"'B.A+&L6 )4("D<)$_RU5(LT]<MQF%6*>'+B.J,G6
MJ+.O3%T;;9LH>6>HS[O;=@KP]6V>7])N*T;4D^,JVDL2]45IV]%W4YZ;CK8]
MKJ-6GET"_F'?K-V7HY4J8'KP2VQ&J.SC67F?-[GY);;E*'?Z19CP>ZW=KK0I
M**MM,XA@9STO2)Z;9@("<*[_AZ14@&#]*I(FM4__$*/"J8'(&3H3VZP=U7:6
MBML[X!PT=MHZ@,"N,<-6UH9B[](;3NM=$"J0?CI'959-<D'4YV?^TL>G'2+0
M=O(R,?AJNV]^@',*$Z( 5W$*D$((%"+.02Y$P1/&,%:QRQD>Q<W$)WU'L^YN
M,,U,@=,HVZF#V;!S4QI6DP4.L9UQP&P0T&:>*7":EU<Y5F 0-M_) L.+^JG!
MZ_6J7L841EP_5ENM83<[U]YG^4.N'N7>PEH4&#&MVK2V2TQJL-9^@"J9@ )F
M"*90$4J<\B?<R$^LZ%IZT69'T$W9.6)II]VF0\A-G75\U/594<?)@;N_P^_S
M9?R<]94?#($4E"/Q6362'S#/59#G*GXZY].F7&^:9HUZS26M*GUIXTURH_BO
MQZ;"\D96?%/6Z8H+RA(B10I!#HD$*(,(L)@A0(3,<)RD*83"1>NX,C"YWCGD
MP4WK.*-IIW>FQ,A-\SPG?U5G>---^^V,]NQ$7S^MER5_BB;)W_)%)) 2<B8_
MJQKR!>>Y(O)>Q[^;\MV&KJJR<24]: MKH2263*$<,)D2@&#. *5FPA+$<9:D
M<8*0571QB,C$*F77:GA/-VH(NW=5/L)G6(&$DMKQMN4NL%=WY7,2C6JP?+3H
M[#V6SXEUJLWRV<]ZYF_S[U(\FG:P;U=;K<__5@K96AR_/?U._VN]Z0R2ZK>G
MAF*Y^O9%?JNS#N[J*$]6T%@*)(#DH@ H806@C$! ] F&1- 49D[NF  \39TR
MT')HZM$ZNYL]135O.^N\NC*_V_$7=0Q&7VL67=L]!]@H.]MC9OC=-,VTR+MG
ME8?#*E2R>0".YLU!#P?A46IZP*7'JM<_5GO'QAW]]9M<255NJ\_KY?+=>F/J
MQFIZ^\H.F*I4) *!G!OK1]M H) ) HGD$D*>YIE;H,J?E1F5:9^U2/,6=<SY
M*DMGV%UUY)1@^JO&LSA&AK&HY:S5A]-<V,9#%%PC.C/R0HK0%[#S^L][18]"
MG8]*WQGE[>K?'Q]*K0[>+=>;4M V)9+$F"F,4Y 59K@7*A @629!2M,TYTE"
MA+!R)EVD-+'2:DB;_F0M\:NH)>]0B3*(U+ B"BJ_FYXY$KV3_'+"J",$#H4X
MH:#P*\(Y"TF@RAL;Z0:K;@87F*_BQD:.@VH;JP<\NT-W+<?:9*6#)*4VYU9\
M- E.CYN-*9I>B0]KHT:;?_Y&J[*]5B70>,'C1...%$"JP( QI4#&N)3*3"U)
MG!SDP3B;6 ?V1O'V<I2K.N>Q8:7.:NSSYG?W#;=5=M;=BVR FQ+NMV(< ;=[
M]^;0T(1J]1R,KWG[0H>&\ZB)=' ";MJVVFP79J3[1W5PWVXFO"\P(X3(- =2
M9-CX^F- <I8 C'F<<961&"8VFG.0RL1:L",6?6W(6>JV86"&]50P<=UTCKVD
MUFK%2I(A%:$7Z*D'_:^]:AA>>Y9C;B5>=V3M/NP>:6M\7VV^]=[+I4W<QVK!
M\Y2A)"N X*:$.$\0H)+JFUF6%@G!,<4JMXVV#1&:^! VI'>U$CW7;TW=/NPV
M"-;ET%LH"-P.IJ_T3C$X&]&\XG"#"\\6B[,1KQ^/L_J\YV0ITS5H)<5;NC%-
M+;O12;!(:"KC&.1,9OIE*1- 3 NE3)"$0$Q(QIS*;D^3F3S;QA"-9$O3<:C4
M:6#LC/KQXKH=RHY>U!&<8J+4H$RA!DJ=)C+O/*E!08_&20U_VN]4UEW\M&W,
MCPJ7G@=N9(9AG!> DU29B> IT*_8&*04TUAQE&;(*1QN2WC&,$W3FO/]6K]B
M[N3FOE^;Z':BK4&U.^-30.7H'*V1V;-P4-,Y9;C%5?1 RL&:[*SJPA6,YPK$
M^7G/*JBFI* 95ZF:>4_=P,H%1E)QTP<\568H$Q(8%/HE#SA6<2STW1CF3D.9
MAHA-K#KZI*.RJA[KSG_UG&/'@J8AP.Q41"@8W-3" 0):@=;E2;<=$M>#2+A7
M%UF(&*IX:(C4O+5!%D(?E?[8/.,1 7VKE.3;\H=LBB;OZ"\S<<ID\.OUEV5+
MST0V-@>]A9L)0TPI*/-$@;3 .4!*Y8!(JLT)FF"-#$V0G9T_GI598JBFO^&>
ML$/H<!S*P]IB7NP<;_L=6VU!=)W?40^+.V3M*NH [G-W=6E"4VB@'8*XLP'N
M%^6=&'BWD' 0K 9CQN,HS!=4#H+$0=0YS(J^?2M:DF\>M]_7I@+9^(3?_"JK
M1:ZX2DF>@225$B (&6 X8Z! >9[',B[BE+NUKCA':F+%WSL^.])7D2$>?37D
M'</# Y#9V81A@'#3XOX8>#2WN"1>L/X69PG-W.+BDL#'72XN/A%R;E3]VZJE
M]0\I_ECI%;]L]8VR&1'Q27]5JK>_Y(:75=/J[;,9D_#'PX/<U#^]+^_+[4)E
M>5;HVR#@A4H PEHUT#C#0%(!H> IC!.K\.D<S$ZL4FIJ43U,PMRO9,M.]&#X
MJ>II07]\N3'#@YJI04&&!@7:1CLE]5HVQTW-G1SYLQ_Z<=6.]KF*.A[;WI,U
M;U=1LZWU/Z*:TZGG_83%<](1/X%8?053?<*";C?()S!-W^DI]_=T\W2[FVS\
MU_72#&CI#?@H$&49DP3@G*< Q6D"BB1)@.)0$58DJHB)V\R42R2GCB,T#$1[
M#J*.!=<Y*1?!L]2L02%QU(_GT9BV.L-:YF!#4"X2G'GTB2T QP-/K)_TO@+6
MT\^[*>BWJUHO?==D]'%KQHOU*C<6,H;: (0Q2!,S^"1),2B,QLAX3(CD&99N
M*L*1_O27Q686_%\Z?O[9)-KW6?J_W?C K_WJ)O=;I!/JUE?+J;!TOF^&AM'G
M(NH#1KC;J1/UN:^L/M"<N,=Z+>,^>E";1OS1^,BNZ59^6V^>:G^+A98Y^_#4
M*8(=S:@C^B]V"N*\M,,J((B@CJ&!(QF#.9,N2N,U2?'TBK,-41P4J#\_<?B#
M/M/,] Y^UP=47TGT-<)8$=?K9D9C?3LQ4UONUC>:V )G&<RQ3(#$A $DB0 %
MD3$@&9$9U*]\'&/[L6:V9"<^C =4HP=-UHRK$9JPRR O:PPM@GV3(.-V>CL6
MHCT/IMM6'ZE/+5(W4R'E,OML"L0\AZ %0LYQ'IHK ,.#T:Q7FW%"FJN$AZ/2
MG)\>VV3#.'C6*U.$^%'M7/IO?QFGCVQKWH^2-7.5*"$!H0SINQ.F@.8Q RJ+
M(40L*W+LE&4U@I<9\S?WO)E_]4)1+6.^W3;<\;?TT,R#JJ/KQ@;0EK7H+RUS
M_SQ3SPUOG((WW7#GY(6Z;GA#=K[MAO^28Y('3!%*'5UYOVYZ-[9%A2+.F4QY
M 3*$M*[+4PP89@PD'&<X(4Q28C4@UXK:U-JLH]H[;QT#5[OATFXEF78H6OM]
MPF#CJ)/"P.*98G!!W*!9!N=HO4"BP06Q3^<:7'K(W2-SO?XBEY)OI6CKNDT*
M@ZU'YN3#DU\"[Q_HZBGJ*'==).HL&'O?S&FY+_MF1HOL=C3]I'7RSPQ*Y.6?
M.;WB;/Z908'Z_IGA#WI69S3SJ)JJSI6@&U']\6!<%!HA"#.GXD.KM:;[[NW)
M1SOZ4<- 9#@ ,)N@.M%)Z% %"58TYZU,<('AJ$3!Z>%S7_3^GK[7/_WK/W6_
MT?]C^HK^K__T/U!+ P04    " !#@%Q:CSW3? \T 0 960X %0   &QG;F0M
M,C R-#$R,S%?<')E+GAM;.R]6W=;.9(F^MZ_(D^=UX-*W"^UNGN6?,OR:J>E
M8SNKIN>%"Y> Q"F*5).4TZY?/X%-72B)E"@26QOIGE[53EF2B;A\"$0$ A'_
M^C^^G4]^^@KSQ7@V_;<_L3_3/_T$TSA+X^GIO_WIMR_OB/W3__CW?_F7?_U_
M"/F?KSY]^.G-+%Z>PW3YT^LY^"6DGWX?+\]^6I[!3W^?S?\Q_NI_.IGX99[-
MSPGY]^Z?O9Y=?)^/3\^6/W'*U?6O7?]T_A<;F9"))>(#C40*XXBSCI/DF X2
M- =A_K_3OW ;N%$@2(Z!$>EU))Y")DY! BJ# UA]Z&0\_<=?RA_!+^ G9&^Z
MZ/[Z;W\Z6RXO_O+SS[___ON?OX7YY,^S^>G/G%+Q\_5O_^GJU[\]^/W?1??;
MS#GW<_?3FU]=C#?](GXL^_E__OKA<SR#<T_&T\723V-98#'^RZ+[YH=9],M.
MZD_2]=/6WRA_(]>_1LJW".-$L#]_6Z0__?N__/332ASSV00^0?ZI_/>W3^_O
M+#D9G_II^G.<G?]<?OSSZQG" 0GM_N'R^P7\VY\6X_.+"5Q_[VP.^=_^-#F=
M)ER02\97R_V_JW_X\^VJ%W-8(%0Z+C_@-Z[^?5GEN13 MR5,$ZQXNO[\R2S>
M^:5)D>CLYE].?(!)]]U1@O&H^]2CL%C.?5R.@D;@.&!$9Y:)9,83%V(F#)A1
MY8?&I;L,%X(72'&G@ 7$/Y_.OOZ,'_QS$4+YHI-&)XD'RZVDLA_=USON"_[N
MR#IK+/!,;$"*91*<N)P$X=9(GI'N%.Q!9*^O=I?J=6T>S>-/LWF".9J,Z^7\
M/#[0[%VP7OW&SQ=^CA]$XMEX<B/C/)^=U]#5<E9!<BNU(+E_^@FYSC"?0_JP
MTLI6YCK.EFA(H?O-&AH_FDXO_>037,SFRY%FD4OO'*$BHYE,7A(O@B%&<6%#
M9"Y*J*+Y]55W0@!O'P%[2[(1))S ?#Q+;Z?I#9ZYHRQ5UB(R/"(C10;PX'-"
M4**X%S%QE4P25:!P9]F=L"#:Q\+^LAP8#*\OYT52[\:+Z"?_"7Y^S4,$;S@X
M3:1T@4C*0W&- HE&R:BXC$;KP\ZR+2OO! G9+B2J2+01$_%E[J>+<9']E9ES
MQBF?J4/*;2*22TJ\QJ\0U-$9H4SPM(ZK<&_EG5"AVD5%%8D.C(JWT^5X^?W=
M> (?+\\#S$>:"\F5M,38<NA!+.%3$"B6A!&6-X+Q>! :[J^X$PITNR@X2()-
M:/\3G(Z+$*;+C_X<1CHD&43PQ%N--DUC[(Q!LR:>9:&%,(PE4P$!=U?="06F
M=10<(,DFD/!^&F=S-&&=X#^C_.'U['*ZG']_/4LP$MQ&&RQZP3EP-&L,#SM'
M%<F2YI0H%][E"L!XE(B=<&);QTD].3<!FR_^V_N$XAOG\2I5=64)(P/OH^4D
M<P 4$M4D2,.)H590);UW254 S);E=X**:QTJ-63;!$B.4D(5+*[^\V$\!3:R
M'&+@3!!'\9245BMB$W+"DT/I6/P?8Q4 LF'IW5)6M'5T'"K4EI#Q&K\\GG^9
M_3X=L9P,.LD"T0P8;#,'>&9*AG_ED9>P6[C#$A=;%MX-%0UG,FL(M"5,=&?C
M\?QD/OLZGD8890#KM<90RFI+I,>@RFH9"7=!)(N,A'A8<O.QU7=#1\-9SFJB
M;0DB)[/%TD_^U_BB\YTLAMR,,X..ML"0RX1<O&U'M),60!H=XF$IKNUK[P:/
MAA.?E<0Z=/:S\# 'OW*E8_841"#.XPDHF:#$<8U'H_1,,*55E/(@.*ROMAL
M6DYS[BNZ@55>;L@G)V>SZ74*1B0#>+Q98KA+Z (Q1KR,GE@N1)19 _C#CHG[
M*^ZF^H9SF0>)<&#U?X9X.4?H,AZ^C)<3&#&-9YB(FN3H%)':JT(V)5%HH4L2
M3AVXZ^^ON)OZ&TYB'B3"@=7_9>Y+%=+G[^=A-AGIJ#P''@A5:+NDRHIX8R@1
M"0-FGK5QX;#;C#O+[:;XAO.6^PNOD4W_]EL\\]-3Z!*N/',:,Y-(NL+0-\J
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MF%KU]_0V@-(92*"TC*<1F7B7$E$JI\B"LT;7+M?=0,;0;9[KZ/AA6ZF#Q-V
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M5O2#:^:#9-Z +2H<'.=?9K.T'H)\GDW2T7EI_?[/3E,C9A55*2(;&&42R:A
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M&N[9;O<Z^U(P<*>OMI#Y(FIL()3>,BY#N>A#F9S,I2HO45!X(8,C+DCNO#.
M/ZQ=_KC_4)/^NGTU \J*^FJB^N)6?L757;51^!669[.TGDD5-IK(O"?>EY';
M4DEB-;.$.^FLYLE:5KL;V$Z$#=PEK#E4UM?F\)'+-6\K;FX[I+_[^G'\,'\U
M"E$)S5%RR4F//@JEQ*'U)U;$Z!7C6M+:PV-WHVS@CF3-8;4'?;8#UH<MNMY<
MT;,2]Q?_K:17HXL6?4;B453%G\[$\A+%V6 ,2%Z*K.N;U:<)&[B_67-0K:_-
M)DJ)NF;Z&V1VW>+DYE7 2"J(@>+^0WX,D: R"58Y8GS4S$C@EHK*0-V9N-W
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M)<O$[\2) PTD*,!=:K@17CZ%VET6^A%N,IX#H#O%/365T*:M?.4GI63I\QG
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M+%6-%,GTM:O_]B!S6'^M NY>2D4-H'!5J@\[L99,AI0L)2H6!S,*W&"EPWR
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M^O7/S:R0NO7H_WI",=&%J5 \ R5XG0$=566HJBGZF)W3J30_B=^#S,X9HL>
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MP(,O+)?6Y^Z/4]2Y;WI#V3\!JP,$T=N8?5Q,OY(DIN'\;SC#:_G?'LFT:XQ
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MES@] (4[CQ[7G58#"!S&O#&)?CH[([[\(YQ?X*?IV9?5\NUR>8%YHFUQ7*
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M+V_RXR8$K6*[]GN;0H-EIW&0PXCJ/"-R#\Z-:W!DL)PT-@>]'N)0BJFW)8'
MCX5VI0^VM.Y#V83P@XU"^H+YXAP_E%]O3YI]_>/&K-GEZQ]7<ZBW"6&72:]D
M^+R(24!,M5M$2 Q\#!*<RR9J)05K7E70@.P7,;MR!]3>L1DGEOP(/"!B=(U"
M+PW>I^GR/U__N&H.YT-2/ H)2=>.NJJVD:SI_,IQ3E80N2I'.!!^B)S.;9!/
M#8V[Q\1-Y#1&R%UK%%<L=T85A.PU>7R6/+[ !'T(QEJN-8^V=:^K1\CI"[EF
M(G\*2GOR?PQ0VNRY.TO:E \EE05I_ "8*W-XL$!1J &?4LS&QXC-$Y:?(&ED
MD-I7]+<AU5 .8X#5W9WW&F?I"SG]_WG9-K5PZRGZ \Y,N,Q.\]8B".V3LD4$
M(XZNIF[1U+E3^_C,X_X2&R4"MZO9[E8GN+19@'1.D@$(]498%(@EQU1S)+DX
MOF]VDZ:1J;:#$/ DO X0QPC@M9ZEO-F?[W&UU=)(+'*)7(FD*X<BT@;D"GBQ
M42?KF#2MKVSN)61L0#I$UK<CS(,9WWW"Z75=?KFQ>)3,D<HV6I'CP+@ 1Z$V
M>.D9SUEK/RQ,?'+,Z>TW=YX0T<GD-9!"9PS5?C<?RHTU;+96U+1DM!DPU; F
MDR/J/.T&+6,H)=B29(N)N0\2T*]%T*$2G;=F;^^,U\TY^:OM8,6:LI]-!NWK
M59 0M;VO\I"DREP:A\$-ZTMX\[G]!-Y(2O,V+!N)M%]O2&?%&>^T :LD@DKH
M2"]&#S8JEH07%F\? STN[=>]AV,?3]K[L&PDTGYSU5H[AJQL@.@=N3_1)@BH
M2-L%RP.+7B8WK/O;S>?V<0^.*^U]6-9;VC5[>5%O<K93.EP16HOJXSI!/$BT
MBD*K<,4P9"(5M'J0N&\]N$]9]I'D?0C31A!@WG&);S#GW56&ARF&($O!4Z)U
MT;*L)O?&D>KB4L581(Q,#7'X=LD2'$9:'S3U#BZ.*;\1P/).;/\S"9=/6(XR
M&QF )\E 65^[8_  +&2*QG4(*K5.O'Z,GLZ=WHX!@*=.U?:5Q@O,NIK_".=7
M]3^]LJSN):)W5M73G!E5%E7FE@M&49AT%+LKXP,$DR(()6V)&*2\W5#_9611
M_3)=AK.S!9YM7K41V*5IREEG6G@$R3EY,VC(D4F1F&*-MRI(GFQKL_\8/2\A
M[VD7G-U6Q,UDU?E@\>-BGB_2ZL/B#UQ\GZ;+5(DHO4Y8')BP+BHS"9PJ&;26
M)1?I,B]E"-:>.%.\[]U]<=5.JO.&+!X'1.KTY,T*EML9E9@TBMIP73D-JI 3
M4],2P-I2-+<V<XSM<'*7@'Y'D8?+]"Y #F3P"&*%C:.Q;43,I&$J:& IF]K:
MF-CAHH?(F43C/";5.AGZ!@'=T7&H0.>MN-O]..N2\O_]XQL]=;IM5!T3!=O6
M90I7+)G?4%LK6L%(GPJMHF%.QV$GUO<^OJ\A.4!6\Z:,&XGH/_TX#_^]G?D5
MK5?9.P0NZRV+4AD"IV!5F\!8M,E*-JP;TST/[YO3U5;L>S.MM]!_H_B2&+8]
MB&4Q)<.LARQY;<#A.?@< ABF/9?6H$K#FK?=?&[?7(9&HCZ 5;VEO.' K]_G
M7_$\;/-RJ@<DC*R7I_6#$> R$V 4<RPYZ5 -:]I_W]/['C"WW=S[LVTD<O^,
MBRDQCMB?\>WL/S!5.6SOT8U.@0E#H;12!&/#P&EE((<<4G 46D>W"PH>>5>?
MOK''P40KEO9&R#_"GS.\^%Y[;F\O7TTJQCGR>[E&PG>(Y/>2FN.\)*\L+W@[
M]_:A&9FW']VGVVMC^1_&L-[BWC#AP^H++C;D2V]S%)J#RA0 *T(G>*,C!)N+
MH-44J7;R[:\]NT]+UN-L^'U9UEOB;XGCL[-I/,?-0EXME[C:QB?<$G2)+1!E
M78[VFE05HP\4_(I /$MAV&9_]#5].JXVQD$[1NX-B>^XB/,V7O_FJ/V^I20A
M?'9& Y::C(')U,/34&_6G="%9>Z'>02/O:5/!];F$4$C-O9'Q.^!]$V]>ZDI
M_&_"M]5T.3_?#MA$@U9D ;H.NE*UIW3,V4**9-],#,H,[,/[R$OZ)2^V/0%L
MRLR1PN+-?+'U?43QFG//P+IJ"347Q"*=R/<A_Y>Q7/C Q.4G7M1Q=E<S83Z)
MD#WYVMO#N'\M'_[Q]I?-8H)P:.N Z&)KV%R(2]Z1E2S*N^1%P1*&9< ^]::.
MP[E.B)(].=L;)MM6P-N,JVWM=$@\80%A1*IGI10K.QTH5F9>"&8M#W(0-NY]
M?+\DZ2-8E<,9V-6>7"5_7K)C>XH:K#>%-H/.R=8Q3 Z"8AF*R1%C""6)UC>/
M-PCH:%@:R/-V_>7>K.VM'-X1V;,E_H:X=9^-+5Z8$,CD>:(^\ (^N0*VQ%RT
M=HG=+M=]0#'<>71'*]%.Y VX-H(LA >2>-Y=)> 6Y[W+P@%%U;2>S )X2?Q1
MANL8BRU,#TIO.CR5[MU.J?-'N[9LGO9T%%&, %H;^G\C#MXWA.#7/]/Y19[.
MSFK,3O_GS^'/"?(@:(T9$F:DW5.[JSDRS4(RE[CGMC2?5KP'F:/,N]L3)[?S
M9HXLM)>72O\FG*>+\_7?S,NO83&CGRV_734N[I)9/XBFSHGVN_-M5'GW-I2"
M.FC0IM;#"EL+GP*#$F51(F!TNK6F&D7>_;7*L8W,KIIT3\\O5IA?_[CLY/WF
M/"PWE6(V*6V2X"#65K$HA"!E@A1$8"&(J%GSD1.[D_D2LO1W0>4CW4F/(MD1
MN"2O2 /ENICI=_PYSN#2J&&^-'I?OUUL.7V;#Z]_W/^ =4)SSDZNAQBCK/V?
M.$\08YTH2L& C(G\?LX:@_R(RQE--]3C0/'VU/.1X&*T6Z16H&_;4XE8B@P6
M0N18[UEK(XA$RPO6^\25\\W;=C]%4U^PC@8\@T"]IR1'@,Q/2$9NFFCWKX>$
M;,Y;L@^"XAT.T: '%96DY9@$3$1TQ>8L8FH>,=Y#R!@QN*^L[\2$AS)^!.CY
ME6*N^0_$]1(^?+N6+)@*BB0<0BXU>TQ1N!PR<D"TJ3 L46%K!#U(3-^CK:.B
MJ(T 1H D\LZ_XV)5\Y!^P;CZR:CMQLC$%\\#))$**!9E[5;@(#(IK0K(LCU"
MZ]3'2.J;_']45+44Q@BP]8"[^_-L3Q5F3 GD!G ?:Y\>6@]#"['4)MI6%ZU:
M1QE/T32:SM G"16:2F@$B/LGUFF1F%_1-@IGN!U3O5[;\L/%:KD*LWK@6X_Z
MTL1I[6W6-=,ZT.)J_Q27E0++HG$BN2QO9QL=#+^=".S<U*8I-N:G$M0(4/AV
MEBYG28;SS1S ];)>K<CQC!0ZT:[]/+\[Z/?GM+7EA*-&\D(1>,X4*NEHJY(7
M$(POCCNO?6Q]('LXU7UUYU'Q>F*1C@#$#^S0#5?O;-2)9-RGP@NXR,@,)6L@
MD&D"K;F@($HBSZT1NR.)?1W''NJTB;#VQ^*<=LL83KI??:VW=1/-R5H878^?
M6*K=USAX;:M[KEQT7&>'K4.9)H3WK7T]*FY/+]AQ7MF_.L/9Q?(S68ME6)=^
M'G#5_N"S&ER1#Z.ST=7VZXLE@6RY) C$Z6Q[?;@NBGF5_NMBNIRN_VE[6VA4
MDM'D"#:F>EOH,R&2?$:&O*@4C4A^4$NB';;W;A0>K 5O/7?;N+0$DTF5!U,<
MJ7)3P!>.D(/VR*/@]*FU5KN/D+[!RA&Q<D=G'2R&SEV]WE2EB0MB[.I'/;A:
MW\T(@\E9+:L"MZ!DHA!+*@W,Z\"\<J1+6S1^N^_=G2\;#A?GO"%O.V/C$WZ[
M6*0O%,.\.EO@.G*YO:3-.:<7DJPM=T N8VVAJ!($)Q$,YERBI@6606=W3P!F
M,$']>GX=+O/YL070.Q__TF^@(/I_;"N-#'JIHH3"5:TTTAE<X!P*TQA2Q.2%
M>LK1N??)_6!P),G-6[%Q'!C8C&; _'$Q/UN$K]OBDEK"[)T%'A*Y\**000ZV
MCF@(&(V6QJ9AS8,>>TN_HN"38:,!>\?1<_1F?TWI2Q2ISH- 9*"8D_25]%"(
M&]R*F$T<E*9SK+:TQ[O$;NJ=',S;<6#CGBI(EY322A+ 911D;NF#,]E#3#8Y
M&6+,J-L!9/3]:'>2Z:!^M+LPN+>E>?W[']X9I<0V)2-J0^RP=:>$FI+AJ^(S
M$%U1/@>;BAS6<.+6@[L+_5 YS1LQK;? 7_WMU_="6KDMD-<INCH2M*1 ]!,3
MP+& P$1QQAKK^, N1#>?.\:>(GN+^P"6]9;VV_=O7OV-B'=ZVR"5,XNV-DXT
M=6Z4#>0S*>G('$:&2@B?U+#:WMM/'F.]_]X2/XAM8Y&Y9]O()WO'K&? HR<7
M",G"1<<4N"AEH?^2O7W:^X3,MT_N-QCMB#+?BVV]9?[[_U9.;@G/S 5=V^-)
M83.H&!P$;0.4H#DFGJ7B YM&77MJGPZB1Y+UWNSJ+>>__^V]9'S;^"Y:E@P7
MD!Q&4-PC>%53);B/65N9$,,@.5]_:I].H4>2\][LZBWGUQ\^OW[U;D.XXIP%
M@0FD10[*Y51S$2BB1<FTPL2X'N:C77]JGP:AQW+(]V77")*'?L>PO+A,F'H[
M^W:Q^DQ_=SFFV^>$21OPZ-8U_!%"U!F*]]RBS-DTGV7U$"V=\\B;'>PTY?E(
ML;/92Y;L&(4IAIQ5I+WD/+$GNP2HC TB."G0G@ ]8ZC3:R/M 1#:@_4C!-&O
M?W[#6O/U&1?;,W$1I="E,$B,A=KHPY)*%1%0H\EH@C.B=>+$TU2-#U3[R/\)
M6!THC!'"Z[("[!_SV@'D?'K5"5A)5+&V_@W1*?+.8H0H% (RH[+(HI3FN3G#
M*.M[J7$BF#40R@BA5D?__K9 ?%MO#W&Y^A16V\9O66@5,GF%=5IU#08RA'KI
MAQD=M[%V!G5'AMO#U/5UMTX$N4;"&2'LUOFV'Q<_VT%&)97R10%ZH4&Q%"CR
MY!Q8SIXQ4Q/)\Y'!=INFOHG2)X+808(8 ;!N!S[OKA+)-3K'4!"#O*_#[9*%
M$ )QR=N 644?=.O&2@\2TQ=*[8/#-ESO?8)T_X"$][B:%&Z4S[4E;:Z\J:.T
M8A8>3&%%L^A,L<..AQ]\Q;BR5/>4W]/3)G9EYC@@<35#99M=M9VC2/9WXD(Q
M7)*Z54%*TKZ)07#60C(I8HZ.9ZUWP,9C[QI7LE SD#1C[TC1\OOTG)RU^8SL
MZCPAYN5Z8;QDRTU.P W:.I:)7PY-*(PI'<GFDE$_!#?WOG5<IY+'0]#A+.^-
MI<V*-FIT=G:UM(^X2%5H9_BA_.U\'L,Y*=7US(5)8I(E:3)(6VC#L'I,%Y4
M(Y6DD!2#')B9LL?+Q^72-$#6L070&V"_X&+Z/=32R+>SY6IQL:XHSWG-OG#^
M>_AS^O7BZ]O9=]I']4<3EVAM*68HCH)+I2C>"$EZL$(5C5ZA#<-RZG=\<=\Y
MG$< UC$9WQM4M[V^S6K>A&_353C_8WZQJ%MIHC+3@=D"SDI:4K"\)I!FL+Z@
M9B9XQ/W\Z?O?UW>4YPF<ZP9L[HV<S1*NU.WUL&&B3!%)U*MIZSR%##F"QRR
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M26W7.OEY#!P=IW489D!%K#D;0D-P+A:O;4KIV)WO[E(U/E#M(_\G8'6@,$8
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M-TRK];'E+Y@OTFKM#WRM*2"3B)B%T1PX-[3MA&(0-7WK71(VIH*9MS[F:[J
M8?A]$9<U)Y+R")V\9N[O];3?21;*AL@LY)@YJ)H0$(+C!%B=HDQ,.V/W]1./
M0O$PK#^?*YKQBGL$:O[*3WJX1NR?6&>'$"^^XX+\\;\OL5R<OYL6G!1;C'.&
M-CBW]9X@67#9&@C&<:&$=?)V#]6#M?HA] X#]O.[U#F9#%^2SEX?45R_7M5.
MJA)*!(U1U,ZFQ AN/2#3PEJ?O+##&@(?D\IA$'YF%U"C$6O7AK5K5OS,XOHY
M;WKCCUU-"YY8Z>LE2@+&4]VR,H-+*@,/@6O%BS%AF$<QY&W#$/=\+JJ.P^81
M6/(]<@+O#->123JY+OJNYVVJQ *!QPP*G:?MDXH+K1N,-"![&$1?RJ75\20Z
M_G%)5W/'EO-RTQB$^Q.IF@Q5VO.MC4<OM5A[GP%-GFE-%EA"\JA!,2XA*LV@
M>!U5C)IY<X(\QC$-:*J9?/56 R)3"(K[!-$41ZK!%!6M<SFV#IQ>]("F71!V
M\("F780W(K_@]F 8QD/)CNR!,\'3,ERJ#605F&Q\MEXH;T\Q0N?Y#6C:2?X#
M!S3M(HR18NKFO!&9N<4L&0A%WHZ*OG918 &2$%QD3TZ)B"= US,8T+23Z'<>
MT+2+''H?[]R<,20I^ J&*-?%L\J7 )XY"9A021:"*"P]Y<4]OP%-.\GKX0%-
MNS!OG/KD9P@5N<L>.0<=<YW0@!Q"98F4+@J-.<MP E5R1<\S&[K3V%KM)Y81
M0:S%(>,ZP626:^+\]W!>TYTGF%/TT5BP,M&&2]G2O@T9F#:53>2,FA,D^C9<
MT>@4Y9[(.V+6XX$PZ&UNF[)B/EM'8I>_.G'H9?0Y@9'*U:$Z"9RP2-8HD7$V
M'F/A@VSW\6@<<67X/O@>DT3[7Z,TOU':<"&CX3;1SM9"!]K>S-6YE^M9&N2F
M*RV5$B?']34"1UQ2/@I0[RO+E^:_U*J6V>KZ#](Z@V7Y,?Q8>XU!^!1DX!0P
M:%>G!D?PWI+K6&2)D3@0V+&F=Y]D@2.N0A^-=],4)+OO('^Y@V9X5G-H/X_/
MYWD[2_.O^#G\N>4'R\D4+A!\4G46,M8:%X,@4X[*"!]D.7T&R6TJ1US8/@H3
M<9!4^Z/\A/TH$!UG65E(/%4#FCEXY@LP[Z5U7'$E3M !JD=[DC[Y56,Q# W@
M\#+WR7M<341DV@660?(Z:%@G"Y%[!*Z98B$:GX]V6-EH"2-N3#"6';"KH/</
M'^:K<'Z*Q)K3)=/T2Z!Y7DDSD27T%(1"%K7JU3H*3Y,EMT.P>HX8I$ZG*.<;
M4=*,UMD9B;$.HZ'=KZ0!IXT"*TK*1KG";&N.O.BDF5T0=G#2S"["&]%IR^W+
M>BR:Z<(CH*M--!V+M;HG@72:LT",D^P$=8S/,&EF)_D/3)K911@CQ=3-RW^F
M"N/>><@N95#D08#GAKP+9"5H;9TPY@3H>@9),SN)?N>DF5WDT/L6[_W\>YB]
MG:7M9#41G73DARKF><V$)!?9U %N11FMK"GQ=G/P!\Z@;CYW?"@X0&+S-NSK
M>LTU*%[2RB2A:E/]A(:4;D[@I4!((BIC8RRZ^6S.%Y0YT]AD[2>6$=FM(Z5,
M&"Q"V3JW+18&*B@#L60&W*),PI"#ZHXU0>,OESFS$_).FSFS"PQ&I7E;\./C
M8OX-%ZL?'\_#;+5AS+=U$6)DA7,>#"1;FSY;0X8-N0.4+*-/Z%0YP;"/]@L;
M<?K-6#9)&U#T]D^;IF]\6]<[SL[>85CBI]K2X$/Y^W+SIQ-19# E1=!<$UN*
M=^!K@D<TF1DNC;',#_)]3T?SB!-V]MD&8Y;XB]H(U_*8*"[A)D<#Z&O#&><M
MN+B^KHY&Q2C)<)Z^O]"N.6E]4FW& ?$]9?GBG*!K]\K;[9UR%+YD0.,2*,TR
M1)$T6*^R\T$:@6-V?NXL:,2Y-V-Q>@X#P0N+EI]NJVP\S[DVE<R!9*>8X!!*
M<< ]BT[IA$7AB'=(F][;?=)QQK)CVH)D%%;EBG(GN:KM4X 5ID$9K\D42E>O
M*)V513&E6I\-[82\/FDPAR!O+]:^,+5Z-[-Y:W4^X7><7>#$5*."60%+M5>.
M\PR<L@G(-<M6%8FE^?#HDRYPQ%,^QJ)6VX+DT(3'D86?-Z+RZTF@)J6@4=7)
M=)("F#KGQPLEH 1OT(9L[K3Z.?D1S*[)OGTF>XPC-&TBY_[)OL?O,FF#=\G:
M C[4>^.@'+A,'A=/Y',94QO_YM/C?J_FH7UFB(P#[X>(M:N*W_+XD?%K[W'U
MH5P?C3%)%%>'% 3XH@6H8BUXET-U 8TRF;'$6^>J[T+?F,>3'.*E'$U&S=+,
MVVG8=_,P^PUI@\UJG(HDP]7$EF"]CPD2$[0D3YLJ,%<@V<R-J8-'X][7-/>\
M;\RC1UIJO4-9/<X@[Z$I?7PB+'(C:%/(7"B 313 KNNWL^#!(F*T\@25-@_2
M-^:)(8UCK#8R:GCRU+1,YH]PCO/R$<^G*<RVJP]UDWVG+58U^73V<3']NB :
M7D_G[\.B,N(['E O<^@K&Q3.-%UUHPJ:]9R-^N*+J]"DEO7,,OW@VWP9SO^V
MF%]\6UX5.)B,@O,8(7E!,!=R':08<)+)J!A:<[N#W,$:8D<2#U68E\7*?Y!X
MURV?7X?S.L+YCR^(-6'D5<[KC1_.*UGG\]H9>OGZQTU2Z!'G%YEBO/M)OTR%
M1&F(75$ HJZID K!Q6(ARL)XW>/*M)Y;=Z*E]4W6.R:B;RON,6)E!#['Y?3S
M/S!=+-8QW^L?;V?Y@OC]X[+0()6BDE'@1 C$<:TA('(HG@>E@B7#)ALC_W&*
M^@)VE"":'TVB(\3G=BW;1I]<%ZV%A<)4 A50@\?JU$7I4M*, L;6%\"/4]07
MGRUE_P2L#A!$[U2TZKB1)*:T)7&&JVE:;A?AB?B8"C!CB?20,X3H&*CL>2DQ
M*&WT4\[KHV\8%SH.$>&\-3\[@F*Y6$VN=/H?"6=A,9VO-XR/+#,>-,CBU@<(
MM "M"T6*R@MOG7%A4)-X>L,UU4+?_50K#[Z\;XKXF"U=&WGU!MR&[K_/EM\P
M3<L4\Z:8KS"& 64"GERD10B$H(0#Z3FRE"+:,NADYRG0/41 'R752*CSUAP>
M"4Q^FR\PA>5JHUF)'0&5+5"2DJ L4Q"<39 TK8&VE"NZ)49NOKTC0-J(]!Z0
M',#?S@AY4YL2XH*8M_KQ/GS%]9Z1A@@/BH,,M3) :MHSSD?0 H.,3 8_[.SG
M"7S<]^Z^-1UCMUL'2ZLSVC[AM]N3 F\O:;,CM5<IRWIO+ NI;2=UO;IS8+V+
MD14M;6SA.PTFJ)_6.ESF\V,+8 PAV>8L?:.!4[0ABIA FT(*W>CUS(8 *:DB
MO<F!Z!\<B]UX=#\@'$EVMV.Q_1G9&P:OSG!VL?Q(S)CA8ET">K8(7S<+T2Q&
M)RF:]$;6^#1%B-4ZVR11)RL-9VP0(AY[2Y^HZT3@:,;>SD:(",\7:?5A\0<N
MOD_31J%R%W.4'K+W&FIR-QECQH%CDAYS##8-JI9ZPM[<]^Z^-7YC=WD.EM8X
MT%;OI38K6&XV(JTY.D,;,:7:!#/7_!*-&K3WCOX=3>"#[@6'0>XN ?TLV>$R
MO0N0 QG<VW;59($WGW[GWFX4:M#18?0)C-7$CNQT';U>ZTQL1%J IWTTS(.Y
M]>3N8C]44O-6;.LM\ZOQZ6O\9R:E#8KP'WTF_'-+E$L$C+9VK/#2Y6'-QVX\
MMF_5[)B-RX$B& UXMFZ=C=YZ3)"M]J"T#^ 8#Y5VJYV72J5AQ2.W'MQ'71PJ
MG'MEO >G>DOY-9[/_W6U@(V.*]%Z[S$ XQ28*9^KI:PEJ3)(SHM.: :.RKCG
MZ6.0]SZ"FK?D6F^QOXKS[WA[ 5KS.L94 9,,:]$IH\ M:&")XBY5F*9@?%@$
M>\_3^T2N;<5^,-=&D+%RP_B].0_+Y;1,4[CJW<ID[5BE,SBI BW'&/!<UF1D
M7G*)JB"VGBWU!$E]NPR,V<,XADS'#='M#A8\TW^T;\NZQ9J5X&,D[][&E&VV
MF'CK"O GB>J>J]H. L/AM8<\Q@:PRV]H0Y;7/VI>_?OYZOY]NM'W"EE.N@[7
MK/Q30G@(TGJP.B4?5>2E><[I(?2.%I;[0.<Q8!Y3CB/ [/'MT.4AF6,FHHP@
MHZJMV[DA,\05>*5UY-IPRUHWI3[-ROIVC'D.7L0($3:"?;?3 J_=@JE0:_B<
M IVEK;WJ-00>.&2E$_,B)[Q]0=S63 PG]:77+.R.NL?,S)$@T/M 8%-+^!G3
ME]G\?'[VXW_-S^LBES^G+V11E#-649QL=$T)(;7B44(LBA8H!?+;W>P>N3!X
M_%TC<EJ.)>_;EPP-F3\"K7FUG]<^WX?RQVJ>_O.RR$.HP*5WH!.9*0I$+'E^
MB)!#2+$(5IAK71C^(#%]&VT]!Y^@C1Q' ,CK]&^VJTR1E5R/:NFKVB6I0'#.
M0Z+%H U)162-D7B7BLZ#PMJ(=]Z4UV- R_SKU_ELO8!MFIJ)BL7@@!5/"T@B
M@^?(H39B#-Y:X5)KM76'B+Y8.52JMT%R$(M'@)&/V_=>7X-%+Z(J"H**#%2T
M'!Q+#+R0FNE<7!:MO?[[Z.A;G-48*0<S>@1@>?6OL,B?Z9<O#V,U0Q^-AZC7
M;:/J,.X2(W#TP6-@R+!UX]P;!/3MK/@<_)[]Y34"L/WQA>3P.BPQDY+]AK/E
M1K2+,#M;LYSX^?-W-@W/UBO^N>Q9KH-MK@4W+"LO$VU9D3/M8,X41!,M2*FY
M##8C9ZV;C!QC'7UMZ &PNNV8]Y;Q"'#^"9>KQ32M;EH&M,78[ 2$4L_UN2+/
MU5$\S@R24\O)E2BA,5#O):2S9]\='_/6PNI>ZKJ=4'G9J.!W7'V97^NX=?=?
M$:_*J33C.J<00%>/5GE/_D^($L@0*5-BD#JT*8C=G\;._6?'[!6<5/R=8?[0
M.JX<>=3,D\U"<MS)[PZ>;);@0!Q%I6666J@&0'Z<BIX5WJ="P?PH(NE^S7"G
M_J\$C0FE)G*3!F6K!5#>@$9B5A9D!?(M0(V_D+*EP!ZOGMR%>R/PV(ZOY-]=
MM5%E7I6@I <C:W<?IS-$E C6F^29"98UGQ)RPN5U;K\]9FL]=K#UUL$WEOCX
M"M<1PHT&PA,AM=<NUB8FZ,ACYPRB=0:2<"8%D[41PVH##B+CI><L[(FL>1<Q
M]P;T#<H_AFG^;;YX-=NV67\[^SA?U8[() _\CN?S]93FJRS^20J)BVR)K;E>
M.VAC*H,94(BKF:Q,$,/JF@XBXZ6W4VL Z-.)N3>@KZB^?G;SB80S4<4X;TL
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M^HI5\,ZFD$&+RO=41[W%6"#I;&)6S*([:M;O;N3^=9J[G/*49U\\]-\!NVJ
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M3#@)=9AF'8CB(!O'":]2*]$1]K?)[=/X[]GB_"!I/Z_9ZE=+O0RUWLV7RUI
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M]7R_KDGSY$5.!$YA:U?@).BHJ[F)R)A/9!4K-TS1VQ>&'<2+.("F=Q?8J"5
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M#*OL?6FE?1W&GS%>?,1TN5B_EWRCSZX6))VZ=6^LH\HV2Y$47>O,2T:G*I=
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M*][OZV 2F4U>:09H#%EFI8I="0U"2K*9Z'@1*,8ZI(<P,.Y#1/^X;X^"#K;
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M@,DZ<I@52:*,"63RC"M&8K&Y,33_!W2CV 90A^Q&L8UV.T#VDZ69S'(5HY2
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M1]#<:>*3?G>B;5*H2@$K7,V*+1$\*@ZB!N:2DK05.\ G_>XP?)Y2*..(FNL
MGV_.OX;IHHJMBO ^FVL)G%4)3%2QQGMG(-#V Q6*@H@YU>!?CDH8Y+9U1O)
MTH8A\!0#((?030>0NVW?=1OAN?W>'W@QT9%IKVT$HVKG<A8Y!,$5.*V5JXG=
MW+5V;UXD:AC,3C$>TE8?'0#L?AGDZSD)C([KN!I03%\N26<?JN8F1K%0LZ<@
ML-K41ED)(64'V;ODM8I)VM;O/D-I&Y8'?(I1E(-HISO4K7,@[J9<A<1SR,*2
M8Z5R'=_%P*E4ZEAX:;-6AHG6)MT+) W#V"E&55KJH@-HW=DD3W'V9KF\Q/SG
MU_GL=@N14<!U$22Y&&HYN3 !7.VRKM%9Q5$Z:UN7/^Q YC (GF:@Y; Z&SNY
M[E7.JQJ-<+9N[S;%Y0=,2%9#K.4<I+B:U+R,88GY[92^NIC/<#G13I&#%!48
M7G.9N>/@F=1@L9C"4#T> KEIAL).ZP_#VRD%3HZEC+'QMF+@NM_OFSJA@KAX
M,UM]^P-^P]DE3E8MG2)3@'2,@_**+(;L&2"S0::,Z-BP0IH!BPU#TBF%-@XB
MY@YNSP^D&B+@RZM9_IDX.)NODKVNWFTFT<J(JB3P.=9^T<E S+8V"&/D/R=I
MV,/BJ_T;@CY'T#!<G6)$HIT>NHC<ODJI3LJY<]"2J_S'?)8N%U70$]39<Q,=
M%,<0E,0,D0NDR[RHI!/7Z%L#ZP62AD'K%&,)+74Q]D7WF)=/N#B?F!R4D0&!
M65,;TJ,!E\EO(6^816V<(PD-,YR>_/QAV#BE=_Q6PNP/#Z\*??33Y8)77D<-
M65P/S7EU7O_WB; J:F2E3H,T=9A)+>%)#&2AW5 T8_'AF^I@_.Q"SS"\G=*K
M_5C*&O4R;,+T78]X$@W+HG9-3-EP\DF8!.?H*U9$3(S+'$TX"D[O4C4,K:?T
M^#^NXD[]3+U]LWF_F":<8&'"J)P@<2Y :1[ JXP@HW>!ON))#!MBWIBP86T>
M3BF*,+KZQH;NK],9L3B]?NGYO@X'D[G[^LK6500HY@M)E3E11ZPJ"$%[X))8
MX2*ZXLT@++ZTTC!PG5+XH+V FZ'E__SK(RD3K_]<_6CUD_I_?<#RO^I___SP
MYM[GGTT_AUG^ES0_7W_X3^&L;I./7Q OKO;2SW@1IF?+Z]JX<*<L[NI']UE:
M3L^_GN%+.-IMH7^]Y>HAOU?K/0+2 3C$OR]PENGNWW=$XUU:KE9Z%9>K![9)
M)M-.HE:@4XZ@E$[@0BY@73!%UB;U=MAF?6FE=@T+-Y9/KAOR:6EYBD:#B3*!
M2HQ!(&, @B8'JSCIC&Y=?3B4MG%ZQ+4'PN8^A@UUT\4;VT9^?OI>1_ZM&LAJ
MYR4+=%NGXNLDAEC *:= V6!5'0(H'SZ,'*YZ^I:L7OH1MD3$T#KJ'9730:A@
ML[3N#)BL?9A*98ED1BSI#&0">+ HHHHI:BU;)Z<-(&M<O#6'PE"H[:B7#J#V
MKA1R/6X8N6IC'$RV3$9RHI.1=3]:")XV)4\IR^*+"*%U4Y$G">D43KNJ>]Y:
M]EW<CK]C6.*7^5E^<_YU,?]V;[:>M\RXJ!3$(%05CP4G52$GQ2%W3&@G6O=8
M>X:<<;N:'AI.K?0P_DMNG9YU26?<C81JC?B\7/Q%<KYB*&:2A7.>&)*9_&H;
M:9=(!,9,SJP@%WQ8'.KEM<9M4GHHU!Q"T%T<1Z_GJP>V5!7T9K::H([+ZWT@
M,K)2LXPDXQJ4J6,>,C-  HI9"HZ:MQZ/^1P]X_88/?2!U$P3'=A)&V5U^]2G
ME+/6>@W)AECG;@GPS">(Q%STN1 RCN8!WE#52R/O,1S W533,]A^6]3^XU$&
MA2)S,+6QA)(JD MCZ6Y/S"BNT/';GC"'!MJ*HD[-]!WU/Q1>VRNCB_OQ3C?[
MNYW$Z.LS7*EL=J\'ST;V)U(D10Y)KJ/AR*84$2'6$H:2D!GB.IGFPSM;T=ZI
M(] &L*,H>'MH^S6T9_AY-5CAH.=FK1X,W$INI"3'IR9;9;)A'2H)V4LKI8QD
M>."Q3LVAA9S']RH.?&9NJXC=+^/Y13@[?N"R=C3[:WI&/\ZK6,O#>NF#!#&'
M+GK0@.9.G!\EN*DUUT4S!-2&CK&(#B(A&0AS*%@4)CX<BSAZ</.9I@]7]K*+
M&E?#OV,.](?)X+5@8#1Y4U8;6WQK/W8X=3T'.+<!P^8 9U/]=.!P/,//3]_?
MAO^<+U:3@E<!%(=6HJI3[$W0=?A\ 6^]@2B*"4FJ*'/K-M%;D-=+P+,M0H;W
MA-E+77TC\9:Q.W,[G2\!G;; E1:@;(X0T 00H0CA&>UTV=H)V9+$<1%Y,*@,
MA^3>>NL EN_)1YF1F_()TY?9_&S^^?O5,Z94RB2M)4G*)%",<0@%"Y3,K! I
MRM2^:?X&6KH%VOX >.A>M-!&%X\QGQ8AK\807S^+FYB5RC$ %]:2UR4%N!C)
M&D4F(R]%8FP=>7](P[B/(\?$T5[2[P(_KR^7%_-S7'S LY6&EE^F7Z^985HF
MS94"KO-5Z,878<#F)$LMD0ZJ^7RSS>2,^]YQ3%2UTDD? +NJP;\,9Q^FG[_<
M)!20?9J2MPER0C(8M+3@.0M0K"TZD"&;FD_WV$#*N#'4HP*K@2XZL*6>$=GM
MZZ/P5KO:9LN*1!O%.4TW.0\@D_(268KVX:/-(>WZ[L*I8[F7NRFH ]!=/T].
M=-)6&B&AF)K_F;V#J*2&*&7@7$H>F_=#N%Z[6P-]1ZT^')2VBX@[@,8S@EF'
M>#-CZ+6F6YH<X!JP6!5%.'"LH/8HM1!'/(N&1]S'L-';0*FI2OJ&V)UH[;W1
M-\)Y9J*N;2$,<2@M0E!TG@OR1$)P5C'NC@>Z#51V:]0?'(8MU-9%S/PA8W_@
MQ9M9.KNL#2IO3_2(.0@1(%?GF*Q6.M$CL>:+U"JAE Y;NY)#Z.K6]&\#O^:J
M.;5H^K6].R^WC: /&$=_>;F#1M"WY';/V/E-$<J"Z+LZO6K"[OQLFL-5FM#[
M.SRN?(YU1?I'^LZZNN FK%H<T]R1DT&7KR,75&2(A9$%J&W@,?D0?.MJM":$
MMVLBOW:[R.76)JD$*3&2 U]U^,H(3#G-7*AC[5N;B@](&-?).#Z:-K>1WUXC
M'5B*M^3?]@GY,%W^<Q6@RRH&PZ.JS],(*B@ZYB5/H 7/@B5R^7/KK(_GZ!D7
M:GLI>B-H]I1Z5PBZ?B^\4\Z1$Y?,<$8<A 0JN@(1)8/B@T6/(:38.@GR.7IZ
M0="^6M\(ISU5,':7G_=A<3'#Q:IT)YQ?OS<[<G*$41$P!4:B<1&\\77N2TK%
M)*2CNKQDA6W^^%XPL:_JYDWEV,'!LFH;_^YKU<05 V@L)H$"8@X*5)(<G%>V
M3OP)S!3N<VC]1O&(B'%?PIK#I8VP1T3+<G$Q>5V]&ER0""^^U]C7ZD M*,@E
M#1J*XC7T63(X62Q(&207J8;=![D(M, =H-#?;D&R:>U>,+*[H=)$JB.CX@-^
MO5RD+V&)KSXO$-<=\.ZS=%UTFE/ER0#:6JU>DH0@)7VE8[%%<A1FT(R:%Z R
MF*!QKJ0V.I\?6@&CVRB+Z?EBOL2?IO/KD]*7[ 49;-'5.6&8:C6>H6LVI)K^
M[7@9V&/XT4>/!X0#Z6[>3)!CP^#59YQ=+M_,TK]<$<^Q6"<P@3!KXF4E7H)Q
M 85 '?#A?;.I&>J#3Q[G-CD2"/828P=&ZNUE>_L&+X74T:,!HEO4>49D.?%8
M:N)-2B[H;'+K.>!/D#%NK.PPKR6[R;@KF%R%5FZ'-&3CO7?:@??)$."1T]:A
M/Y)-NO!D,C:?&K^9FEZ<X1T5O1$X>TF]B\3(.QL*%^?ORK7_-Y'<%<EJ]@LK
M[JK"3#(%NO*7$U,BMJY(V41++WY/:_3L(?%3ZX1\54M[W5GZ(''/#6L<--@Y
MA*^N(IRR2&&8K>%[%6IV1X#@D@==HDHN,Q5$ZVW=183SX^7Y>5A\O]O>_-_F
M9S4%87EM26AOF'1@ I(WJD@F@>< LGAF$Y*9T?R^?(FF'R$&N@W>'CT>MM19
M!];:+1LW;5Q).M(SLE]E4*KFF'KPNL[ZR!ZU"<(6TSJ-]S$5(Q<;-]7RH]RC
MO43>'6A>TP;[/%]<;<LKWU;'(*31"3S6T=[>T&ZKT;[D@S4>79*A=3S]9:K&
M!=6^>G\61GLKH0-8U58V%]\_(CDNTSK@]HJ+(K6A'18 BUO-^:"]9D,M\^'6
M,F>Y,ZWK@)^FI"?X[*_O>7/A=^$\_B,L%N&FX[,(W 3N$E@9:8,%D\!)+2!;
M-#D6(21K;4'=(V!<-_' D-E=U%T@Y?[0]BLNLK*>9>4@:$*YTL'05U*#Y\9;
MU,Y)T1HP3]$Q[HOF@7&SM^!'A4^-%MQ6"ZZ/S;=X\66>;\7V^+N(-S%&+%ED
MS01$+VJ=:BC@C2/1Y2"]BEP6.RCC_X40[#XTCER+>0CK^ZAJ&SD=8!,?5Q&L
M8I6E_2EHL]96#$86B,9&8-I$B<F4X ;E%KT P.>I&"_>>SP4S ^BDK'#P8^#
MV4YRSS1=!M;4K FC+/A(OHPR)CK-&/=<W0=4_UD!+17V?"K -M(;6_<DB3?O
MKGV#F.N53337J3]D\85$,F 1'.>9NVH$\&%I '<_=;P4@$-I?&>9=>"2/W,5
MWT:>4L[9"QU!AUHQK%2ID2<-=194<8))60;EE+5YIOZ]CZR @SXA-E=+!U![
M$+9:3HP)S-3$*!&SJR/2#7@=,_!*>_$E*M^Z%_]#&KI]A=Y1RP^G9.TC\H9.
MV)$"OI73&8'P^W2VXOR ]:[/+W70\.\67'85!?;)\>3([DE9UW)N[LD,$G5,
MF^4YL5CD0VOBQX@"W^CK:OKT^G8(.C@EB@$>,(#*0D'4T8#E+M/M4) W3ZQ[
MDI ?(=Z[#;*>BK+LIYT.KM;WE_%LFOZ\F)ZMGO9O>%I/[60Q>U0:4A1TYEMD
MX&ICSV2L5%G'U#Z\\AP]XP=9]E3WP\?.5K+O&$=W"K.8R5I')+N!U<$FJF9'
MU_YY7"++$DMVMODHD!>I&GF(4C,$#(36CNH8^VWA_^+9\O+;^?3Z6:3.P2'?
M"'BIL7'T EPR"8+E7/DBD60UZ'7A_N?VB85=539O([\.SI8;4=RZ-BQGIK-*
M4"2=O:MQO2[05L'(A;(\1!++H6R@[5X1#AK!;7L?[2GGGI#RC_GBGZOAEPF7
MM8/3N_*!M+,@=W:2&(LQ" &!. ,Z$!)$Y"0F$1UWEJ056@^,'$!6)[;-CIK?
M!*1&:N@)61_"7V_)C5B0/_& (Q.LC](@9-0%%'.F-A;P8*UE,5C:F \+(-L!
M:R-5G9Q1C7'51@D]P:J.:"MDGJB:;4Q"(8-/:#+XI-7@5>T=C(DKW?JQ_.[Z
MXR>6' (JVPKVU+KUT=\6ET3B-,0KR_$@KY:;ESGHB^5 [HXST2YY'XL-)#*-
M9'V3:>4M<D*1448KNKV*>$G 1YEH=R6T#_/OX:R*[,I ?#7+=TK_-.>8M>6@
MDY*@/(L0LM-@3?$FU$YPO'4J_Q"ZNIYBMP4 GA@/VU8G'5Q>O]"1,O^.N!JY
M<6^37G$W49J9A$G3N2WKP5L\D'57N_(D9:*D?9%;WV@O$C6.171XA+75QM@O
M/O\>SB[Q5:8S_5/X^P,FG'ZK_BW=YM?<>!'I4B<>O*H\I%C(=] !,F,6I<U!
ME&&/0"\N-8YA=#C$'$# ^S;5_M3L4+HZ:,GG+.1SDH["V:]XNP>TERB5)5:R
MX*!0&0A<:##6!E?H!T&W[JG]/$7C=-,^VH770@]CGT57K'R\C.FJ^'V^^.7O
MKSA;WO+C?4!C@X>LF ;:-A("':E0E$.+*FKWL"G?IKXW+R\V"#+Z="!S$"%W
M IKKL60_X]?Y<GIQPXJT47&N$+(D?I3. 3RB!IZ9TV@-4V98-\_GUQD$%7.:
M4&DAVDY0\O'RZ]>S*3X"O)918J3;5PH;:SO<VKC#1# .?5$IE!R'94\_O\X@
ME-C31$D+T8Z-DM^GJ=*.*Y;"V34+R%PN))P:#BR@N,W@LT303&C,67*AY"!T
M//WY@U#A3@P5#439@>>]SMY[]#9VS8W!'$R(#%QD= )ZYVIE;@ F9&"*<>%\
MZTR+YRD:!"5_.E Z@!XZ0-5F1J+E=*7Z G2/6E#")Q)/M& 4$UED7ZL=#N,U
M[8@ESDX/3&W$?VKQB]I/;#K[3$L<.H3Q[$H'C6(,Y_$H@0PE2A"%<R@E&G*C
MR%0.LC8VQX0:M?9#)PD<.I!Q6X[YT^5R.L/E\E7ZK\LI&?MUP/-/W^_\;9W]
MXIV4/A0RZE1-D,HY@Z,3%Y)D,BIAG'Q8;;A_N=&6-/8<X-@&&(_JC@ZIJPXN
MQR>X6F5I.IN==LD :CJ@5W-_8W$!#)<I('IR/5MGXV\@9>2*I(/J?]Y>&9UB
MJGZYP.N,SY ,>IXTV% '&0:,X 79DEF*FL-9N[2V#J"]2-2X.&NB^@%PVET/
M8[\6O/Z>\>_W7\+B/"2\O)BF4"N_TG4S%6.0F^J3*#K9E4L(,28&W"N.*11N
MW; LAF>7Z0\C>^AS?A#ACMJI9L7+6[K^8UA.EY_(+@A?5^Q<%Z.C59XE(4%$
MGT&E7" RXR%D'4L*V;J!T=5G%ADW-_& (&DEV"YZ83TAI]]O4O2\#IA,CH#<
M>A)1U."-<)#I..8^"TY2._S]]'L?&?ECFT"[J67TZ^J1<_S]P_SL[-?YXJ^P
MR!.;A(BJCO:V@?[07(+WAN[UY!1W/F<N!]Y7SZ[3W86UHS+GAY'LV"!Y0D"W
MW-7RWRDI:*6N]_,+^M8TG+T.RR_OP_=:[_OJXI=9?E?>XV(Z)[Y#--QD!D('
M7BM]#3A7Z)3GV6AC>0H\#4)40Z)&?!5HB9)Y!RK;&:I?5VM]O B+BP:=L-9L
M+#_-;YE>I5Q]F'[^LNK501MCPJP04F9>&P?5 ($@>[&0,9"U<-))1ISQ05 <
MM-R(F8^' EE[,8^?R;9B[-<P7:P8>8MA>;E8M2WX:WKQY<_9/-92EVH_O)E]
MO;Q8?L TGR42Z4J3'VJ7W@4)XJ=J?]X(^^;C7N7_O%RW='GR47KB1:JCIY"V
M%FJZ;#BYT8%'B$DGQ]!B4L,:=XW$P(BYFH?"^"E 87QGMN5U@SHGQ&R &UO?
MDM"0>X8").-%8^ 947=I(1PF3_04+(1M5+:GA4#+CC21Z/?Y[#,9U.>'CI2^
MM-CA9Q0-Y?0H\5)F@T2E<BT?E 1PYB!(S^BO9$E@*JZ8,.@X.'2\]'HVUS_H
M=KC.CKS9LG?JC)CV,8>L(?MUDP !42<)5H3"?3*RV-9]?0:2UG-T=!L8/'RM
M.81FQO;)_YPMR-[X/)O^]ZJ&Y"><89G>&R_(#'(E:^MW6>WN;&I^G7?@8@G(
M!*L]4P=MG!>7ZKFH:Q?<'$# '<0[5Z+Z>#G+M<K[YF"_PX\Q)EAI%8C :CLV
M*\C/#V1*U"&5L?#<ON'82S3U7/RUSXG45!>]8.MI3I2G/:(R@E2"'!DM%3C&
M$S".7K+BT*=!3>VW1=7N>!JIWFMO/.TO_S[3%Y]RP=?-4^G7[C!]]>,<+F[^
MCX=^^!X&^P&H:&#)'UHVC3K1WBSZ\W29SN:5E%O@.X^2:V8@$\)!%1<A*E'
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MU(R+NO$0\K -2AMUC9]/_V1-P/5SIBJH!+>0!-F[BD6D"T=GT )+XCHF[QX
M;W!-YLTBX[H4H^.IJ0XZ.,8VM>W ;)41Y(J+5!NFQ2 A\N2 [!EE8G8HV#$:
MG RU!ILG9O5E#;;04J=@N]_:05E,W)(U4DQAY$VA@$!>.C@;N=4Y6\36*8$G
MVE=G*]5OW5=G&SV,G>_^^OO/^/?5Z<NC8#;Q3%Y^(:G4%'U7H@"%IHAD1&!N
M6 N].Q_:G_[WT-6\@>#&5OA-&Y?K!^3DB@TE@$Z:!! E@R"U@R)19N[K;6X&
M*?W!!_?>!V=GQ>\CP!&5OUQ<3#X$LKM6!Z#/F2E!]RD7BJPW&2,AUA;P3EJ)
M*IKL!EDH]*EWK@GZV^T5<6_!<:8[]&&'["[Y'N!RA7*5R<\3SH$LO-078 FA
MV 3$,Z?3K3#[L&/-[H 9\^;80UD/U;V#Y$96^-OP]_3\\OSZ8-,.-1E(((VA
MN\Q[.M@L 1YMU(XERQW*!BJ_M^C(2M]%9?,6\AM;\=/9'<)S8$HQRX!95<?-
MD@/N6+8@%4KGG5+Q82^AW11_=]%QS(5FBM]9?ATXEI^FYZMWH.OGH7?EM_D\
MOUNLGXC6!V$*1;*0.!0K#1V$DH/WR$!8E"4$G8P9=!9L$SUXF:QQ!@'U854<
M2GO] _+*@'>,"Q.8 6>D(J94@A =&?".$U_!!E2#3JEVD.SAQ:,Y'+:#VPZZ
MZ0%P5\S4_?H-%\3C]87 HBSDTY.H5*UI\B( 7>H2M,OD]&MFHFA^[FTBIFM@
M[:+X#0'1_;0PLB7U?C'/E^GB_H:S@L?@"T)8-9V2NHY S@)2,J4DQ776NH%!
M]=3:XTQ!Z^.*;**//O!T&[+#ZP!<1L[(GR#CU'F^?G?R6B80',FQ8%SI884Q
MPT#UF(#Q7+7]=?H8('L*>.Q7W9]K5MW\:PW0?L#/EV?U=[^_GI^?XZ*&;]].
MSW!Y,9]A9?/3%!=WAK9?G;%1V,19L<"X)_GE0MR:.C4E9V2*%X5N6&_TO4D9
M'5C[8F$^FF+&AN'[+V&)\C7]K,X0^+2H'*ZY$"7IX,F?-II84<8S(),@@"27
MVB-73NLX"%X;EQCO!>$ L&DCR Y,ZU_^ZW)Z\?UCO=%7E_Y/W]_,\N7R8K&N
MB,U"%Q=EKN33M6XC@@N8@<=HN!;)<=]Z!M_S%(TS'[0/>^D .NL0@=>\7.TG
M7W+R(A;0R282E#:T18T%3\>N\!R+S.' "+Q/T;AN7DO=OP"K/10Q^CVWF)Z3
M)NA4_@UG>&<0BN;!Q.(S:)_H=%::Y*-3KM59V0<7K75^V#6W886^T+&/"N>M
MY3FRI_:ZMGO%!0GRXOL?X7SME7"6LZ_U]ZDH45M?1I*()2M !L8-V0;"#3I=
M7G#2GEI[G/'$?=QD3?0Q=O0=OUXN4K4#7WU>(*Y;FM]GZ<K*M"9:Q(R078S$
M%+D)P58>([I8LI))#ZH'?RDV/Y2@\1RX_74^/[0"QKZZ7GW&V>7R/7$PJ]XF
M^2Z?%^$Z<JD,ES$I#<9C >7ICG><Q^JYZ!Q"W8'#>ML^M\J(,?[#:'1^"/%V
M8#G?*0U=U6[6HH#5CBHF*!YD@*#JDT0A ]!)1(@D)UE0"&=:)QIOHF6DP>E]
M7'--%=4IX*XV)'IK!-)>+*).0BW20'1UOIR.TJF 3C0?@KV9FG&-\#;:'@"A
M'43?(8AJJ\IZR'\(%]?Q1&%+6:7]ZEA/7T7;+&9BT!>NK(ZJ*-6Z%O9EJOH#
MU2[Z?P%6>RJC WBU./%_OQF#:$,QQG,'Q1O:LBDI<,X)\)8\YA)%$J['5K2_
M;S6;E/]/Z0)Z=$ATL!_NE 0_T1UX(GS(P19=\U]YC5X1-Y+L7L$=DS;ZX)JW
M]'F>HDZ:1AT?*O.#Z:T#%#Y\F/SUVQ_3U^M._6L17K?M)\<K!\$BV"HHI92I
M"0,>;""/SSB!S+<NS1U*6R?]ID9'YD%T.?:SR\^XF'XC97Y;R_<C*79E%=VI
ML7\_7Q>J_5)G RRG="O],KL\OQH6]\?\XFIW8O[U+'R>>)N%KW+50DAB/B<(
M4NGZ0E'_<3X_''>U,5^C+66GWX!H/QB/K^X.SN,'_"\G(F5?K J@30WD,*^
MS'T2K(MTI=B<3&IM!SRDX?1[(;0Y7_?230?86E/]E-&261'$"%T(!@VH8#4$
M)):"0YXX.95<MP;91F).O^*U#=K::*O9!*4]!_&^GI]'.L"?F>KZ>"3Q'9:#
MUB+S["'8F*M5G2!F9R!)[G)$EA&'=5AH0\_IUT\UN*I'4&T7K2SO"/LI?ECT
M)3+!"7RLIB[F&C"U##2O#2TB70K-*U^>I^CT*QG:'*@-]3;VJ7J3_4Q[[RL9
MP>L)[V0J3Y3.R2D?(8=()DET')SV''Q2R2B?R!P>ED>U<8G33_1L</:U4<#8
MOO4?ES60\*Y<SR->3J+D-G%-[I&LD3 F"Y 4(J"3S$8=&4ED$'P>??3I9U4U
M@,U^ N_ A7C@ CV,4DU"R!E%*I#"JB\U]^!=(H (SC K'6-J/73H!9)^@#R'
M@WBO>ZEN[(/K"=/S[M9:FZ KL7^8?OYRL7RS7%YB?H^+ZUY6'[^0]B9D>1I5
MVPY'\IE *4NF9PF66/;D0SD?,Z9=O8H=Z/D!8H*'<2L.K=O3A/.OI,%?0OKR
MU*]\I,V.RPD7T2CD"%K( ,J0)EQ4"K175I A8K0[),!?IG 8Y'_@V$T_^A][
M$SS+\14_E@ED@N1:-&?$#]U6OH@(J7!>D"NCPK!BR &+#8/FCQZ/::V5L5'V
MQ%:[F?](7(;EE_?A^[J3]_Q)GO]M?D::7TXTIF!T<N"1&6*:1?+SZ"L2;;#:
M%HY^F*?4BJ)A>/V!PS3CZ;<#Q^Q.5LHD!:ZS]PZ$(KDILGW *<M!9,\YV3\>
M=>LLS3O+#\/A_X  SJXJZ0!-U^\3_YA>?'E]N;R8GY-Y7>7YVV*^7$Z49-I[
M;@%Y/?"MX^"U8B!U5)S5?8.F,<">IV@8YG[@@,P!%-<,AO_G7Q]IA9C]Y^I'
MJY_4_^L#EO]5__OGAS?W/O]L^CG,\K^D^?GZPY\:OT9RG<\2B7OUV?.RGI3V
MY @.O C3L^5]%I?3\Z]G^-)=W6;A?[WE^J$\KM9_!,PC2 !K)DW&_+\;97C?
M1E66K^)R!<A)3BGR&D])ADQ#Q0J'(*4$&XVTUK L;>LSXSEZ&F>S/[')5[OZ
MS]D\+G'QK:9*KY[9[FOJ=3A+M;5-#1[,S\Y^G2_^"HL\81Q9-LZ #O4$*$:2
M%9(52!<8FJR*DOE0LCH /YUD#N^+RA>RU\>#0 <&PU.'4KV#'C&_O,_]?5&M
M!+GZF F67 2OK1"9H9N*EP0^E +1<Y&**=Z5UE'TUCQT OO1T3E@!OC1H++S
M5OF*B^D\?[P(BXO>-LS[J]+LY80EKZU)' Q+F<R[$* .@H7L6= JL.BQ=5.H
M0_#153[_#[EQ=H-,3_?,J_R?EVOG^EWY1U@L0O6RR4VBVUS2_D]U-(W3!J(.
M"5A)3OJ8)).MR^N?):BKC/X.@;RW$GM"Y/Z[\K<PG?U.;OJ;63J[)'?LS>R7
ML)C1KRSY) ;KH\D,<B)_766N(7CG(&11C!>>&3Q8O>M!.>NJN*##/=(/K'ZL
MS?81+R[.</TZ6[R0S(4"IM1+4&8'WJL$Q0D1$]-&Y]:UC8?AI*O:B1]R,^T*
MF^TWCU]OGAE^#A>8/_6XA];^5TC>J1(0+&GH:HBCTQ*$<TQGX=&QCJ^FX:[Z
ML<('/^2^V1XJ>[KJO\QRV^VRE3+N7;QWBECI#IZ?XVWEZN_3Y<5$QIBC]+4[
M3*WGJFVOH^(>./)0N!99Q(.Y[0?CJA,G_F"/OGW H2>;[/F8YQY'&.>&<27H
MX!)(1BJS'B(/ 33/UF$T)KB#[8]#,=7)T\#!MD<78.AI=VQYA2X_/,@.N*J@
M7-^CUFN%PDDP*7!0+D6(U@7 +%56*GH;>C&YGF6DDQ!)'V!M9'RU0\[HP9)U
MB_-G\_6NT_5J\HI"Y4G(PI&9ZP1$J8E#PT.2)C#NAQ6(#UJN$^.F*]P>2%G[
M.LX=^<PW6W'SB]S$H7=6Z@0FUW8UDDFZ?#6Y:UHG;=&Z_'#<3R?.] #F.K%Y
MNMHU?2/LAS6@7&!)IB@A)5Y?1;B"(*P&K6566?*BHNUDF^UO0!T^>O)#;:EV
MR#GI)ZQ'9\E+[Q:.!RZSB9 %HUM]U?1 (X)W00=7HD$Q:%CKP9^QMN6LDTW6
MQU/606%Q.CGG?]1TA5I,WSBE_-'G'BAC_'GZCY$0+GUP5C$-&;DE7!2$Z+$V
M2G&9?H".N=:#"8Z8$+Y'1VTRT))R,D'05H"*BH.KPPETU$PRGW6*!\[^WIWX
M3AYT]L7;(1J5;Z_<GJSOG[[?.3S68;TZ.<-(9VTQ!I(V"92H8PV%INL(2XA&
M,VW"P:HZGB:I$P0>%RB;X-I :SV!\'9;UTJY5^=U(,;UQ.#(<@C.&6(GU!$;
MJC845'5.%$/+8]:"'ZQ@X!FZ.H%C"R!L EDKK72 M/?SQ4HU%S?,/<'E]81-
M&0WW*@ SI1!KP8 W7D*)#(OWCEG;>O[M%N1U@KMFV)@?1U$=8/"7Y<7TG%RJ
M=V4 ;XHX")&1<\6#J_Y?)AE:\O_HUF V1M2F=:G_-O2-B\*#@>3AW(5#::P#
M-+XF/_$[628?\"M)$_-Z"V]F+V8;8K(%F);$7BUC]_5&T3PP'K36,;:^AK<D
M<=S8W;$P>4B]=0#+C:/\N% ,R9,#)R-=*J9.TA:2 \\JB&0#E[)U*O=>$S:[
M;FVVOR?21$^=XNW*C.'9,6(ETLZ)HJ;K.8@RTU]+YDYA\L:U#B6=W(#-K;0]
M?,#F-J+O$$1/S'14.5LTF,'$.IE)%MIU+$E0P47AD^3ZX1SI_\D#-K?2__8#
M-K=1QM@S[\/L\WJKY6)TJO-&/=F6U6B(X#P=V5Z:K)Q/6>(@C^"EF?;7"W:2
MU#'*+;>[Y'N RQ7*.3=6%C(KK>*I3I,1]5W<0[8V16NX=6E0T?00P(P^QWXW
M93U4]PZ2&UGA;Z>SZ?GE^17AEDGA'+D3/-:7EQ@$8=UE\ &-D2F++ >%WEY0
M^;U%1U;Z+BJ;MY#?V(H/?]\AG*LB,D\*/-H:BZ?SS9-O1V>>T\S2-:=B:J'X
MNXN.XP8U4_S.\NO X&S;EY"'D!R&#%'H5 .H DB,&I*(1G(AA#M<F=K11FYW
MW1^W863PZ(CH8#M\HO.@IB6M>']S_I5D4<W_UU_"XC,N)R8:M+9(.L8%R94S
M39O;<2C1%.V\5D&UGEWR/$6=Q'".#Y7YP?36 0I_F\_S7].S,Y+7&U+GDZQ-
M@C/.!X6092:',R;BR2')3/*4'2_"-&_A/(2NTW_2;(/(YCKL )?O+K[@XH49
M>5ZJQ+6(D#$Q4-Z2_>-E!,Z"-MD7+7WKM\X!9)W^$T0;5+;6X-BS&F[Z%W^8
M?P]G%]\W3\05GI=2H@ F70!5@H.8K(446)W/'!FF!U&?#=5_@Y<\?6-R/\P=
M4$%=PN[1N+1BI/$E)C!,TT;2Y ]Z\@!!6%>B\UB"U;M#;J<I=B<R4Z$MW/92
M3)_U!K]C;<W9HL)@PR<UJ"D80F.C*H+U4C=YW!YMXM68RDZ0?M$7"#%K<!EE
M+HQT75HW^;Q/P=[SHY%PBZO/_!F7:3']6H6_]NT#AI*E1O)EE 85,D+PQD)Q
MWF?!%=/#'NBV8FXC.>,ZH'OH_='HYT8B'_DQ]_UBGB_3Q;O%1UQ\FZ9U)*-P
MG[D5$I(GYT(ES2%RSB$Q:ZPPBGLV*&3\PION4VN/C8]&2ITWE' ?"*E7]!4'
MU]FV J-/WBO 4,M?6$H0#0\@3!39::OCL)D]PV#RF(#QXC_[Z_0Q0/84\-@F
M[MM 'T2&U,=PALO7@3;.<GYV%>.0&7U.>C44J-I/D8Y8BV2O9[>J)\U"RD&&
M[3.+C Z&??4W/X P>\@)6%>%""N8]W1D5C]-1>\@U*D*HC8'"G5&=!S47:II
M"LG!7A4/<8WL)LL> '"-6\^%BIF1Q@R"XK4E=(BUM6T.TKHH,+7($.@L*60K
M96U("ME&<EWE!GA;LM*8Z?PCP"OD=$I%IL DGJPV5C,[*'.Z>6[ P9-"ME+9
MQMR ;>0W]D['</;+LO9MH&OP54J7Y[7U"N:?D:A)ZSX/=\["=X5NS:^XN/B^
MWB7.\AIJAN)+)'%Q#T$7!TY$7Y0)2N"@^O27SH9]B!PW)'"0*^5H.CL!</X1
MSO&6P^MZPL)Y+E&!EH4D*Y*$Z%@ 9"EZ:5FQ1\/E4_2->-8=#SI; G9O/8[M
M2+TKA5R(-[.?YLN+^>QM6"Y#^G*YQ(O:QGUU+92@C5<V@PR,Q!>M@>!, I)H
MBLSIP >.K']QJ;X!MK^JYP>3>R\H^G\NOT[I(W\]FR^F.=Q8)UFADQYXJ>E>
MQD4(.7N(5HA"UT=@<CL /;7*B$F:HV%G;VEWD+3QM*5Q&VL3(7OR7,@4Q5(?
M-;P '[D$;QU/.:9D6.M>0B^0-&[@O+5E=@@]C'T:70\'?#T_/Y^NIK.]GL^6
M4U+,2DWOPS1_FO],>Y3\Y5*;*F4(@GPFY40!\I9J34661J!)20Q+NQB\9(\1
MAQVU/#^XR$\ 2*_.5I^!Q-Z;V3?ZC?GB^R1DETRH%W;1DL3(:4MB8>1)6YY0
MT+DN5"M8/45 C^^1QP'9WNKHX$I<=1I_5_Y<KK-5WL4+LA96'9#_)O9GG_'7
M^6*=2;(6\DU#RPDZ[J1)!FST2"9C),D69H I(Y2T3JCF,Q9W)K;'!X[],'I<
M_74 U+M,W*8-UY:JDT 4!Y84L.P-<8(<'/,6)!:192XFZ=:]I393TZ/%U@9J
MC330&98>;* JH22Y3,!-]81+1(C2('#M952UQYMOWD]T,SGC9C(>"TW[Z* #
M.*W%=(\AK$[W=/9Y];=/N#B?I"BSEJ'VGI8D*R\-.*EHBR0MA4TAJ>P/XEL^
M3]>XLQP/";#F6ND :9MJNA"#]Y@@.Q7(S8F.CM]@@8=DR0]GW(K6V-JC!L^>
M(IH:2+X#_*PE].[KRHFYV@=/[(I2VYM%JXD-;>K4!@<^A_HXK+S6:#,?UN1B
MZ[/J)<H&X<N=(KX.H)EN\3;#O\+9^OB56HNXZF]5WX]KW"P$U" X[2+I@Y+F
M.$"[(6D0POR/@[#==#'V6]F:ES>SM%B+:OW?-[/[W*WK;WZ^Q$_SM_,\+=.T
M4N0$?;0^!&(2E0.5;7T0I)L_I>AL*#F4\B"Y=\.+V5YD#'N<9:<$M2/KIH,#
M[B4V;Y];<E%)"%D@1Z>(,5<@EF1 NYQ\9&1_-G^D&$S<,"B>5*#@L KJ 'GW
MV?@'5A<:\ZMO]-W/3U@.?"(+%\:Y!*'V?%"Q,* SG3P?Y9PNZ'G(S:O1MZ1Q
M& Y/*I9P%'7U#L>[W2+?XR+5?@_:!23_.D! EHF_3):LB1FX0$;;T+/0OCG"
MEC0.@^-)A@T.JJ[NX'@]9W>",?#H?:%=E$AD3B&XP@(4,CF2EDHIT;I@]&E*
MAD'K),,$#43?'8!^^?LKSI8X$6AEKEE.UJ.J\\ #..$8"&6MKWGK(;?V5Y\D
M9!A\3C(NL+_@.T#/Q\MXMK8VZXC'B1%"6%TD*$/7N#*LY@3D#(R<F12XR>EA
MPY6]87.?@F%X.<EG_CU$W0%0[H8G!AB%KB9<*J9 9$&"LLY K(VV&6T!GHJM
M?QXP.-G*@C_)", !5=4W$)\R!UEV62JAP47-UP'_$%T@C]E&FU"Y7%I'G+:C
M<!@03S)4<$!5=0;$-S/Z7%Q>7!F1[V['*4\,USX:D>KT@MH6R6?B2@1(/.MZ
MU--W6EMBPR@;!KR3C" <0#6= N[:[,3@:LMK,B2XK'WO>2UMB 509!6L=]FE
M0]ZW#\@9EFE[4A&#UDKHN479C6=#/[O+[SH4$NZUB=N[B]DNBS5K=+8WIX?I
MA5:PE-4;:I0^U<IUN>Y9@E;0D66QI.9I,FU[H5TU%+SFAPEC;2'#TCNM06']
MJD8LK"Q!*Z]+%*W'']VG8.SZDIVU^V1VSVZ"[> &>Q#3?Y!,:4JRK,@(VM39
M+1C)(Q9)0"C"YVBD=\-:6>W\9K5+2NO!0+./II]]J=I'[#MCB*S^.#]"4K0*
M7*(2$5*L12TI>KK:I87(G!6FR*!RZV;_^R9%'RQ*V!!!K40^*GZNDCZ>8$&&
MK#T) 3+2L:QR[>;.(H.DI30FJLCBL,JTG4%PL-A< Q"TD=ONU\_\(IRU2?*[
M->9N!$+7KUI)0/C$22#) IUZY!H8I;1"+ Q;#S9^@HRQ2Q.;V2?[BKB+"^8.
M$Z\O%U6"-[S$9 UJ[H#Y.OPA<0W.D8N7$UV4GIF4;?,\T(W4C&S5[JOJS=#9
M1^K=F;DW[TU77$V"Y407)O#*L3JSC(.W9'_%@)%I1MM+MZY'?9ZB;G"TE]Z?
M-7KW4D(7A]*3M;'7W*!W1H="![4/%E2I,VGH+H?@-!ED3C"O6SO8S]$S\G5V
M&$ U4T G1O C'F)P.21/(O&ECETV9,BC\K0EK!&Y,*6*'6X%[X2)PZ6HM<5$
M(RGV91/_,9^E![)Q5GE+P ;/JFQJ3^UH6>US; K]*Y$]A$1+<^<Q0=T<+*TM
MGCUEWZ_1<\O8Q#N!VFD/QJ<"2H3:B"GYVL<A\&@5"M[:U7J1J&Y,GWT!,,SZ
MV5$;_1I =QG2RBDA-#!4"A3+&2+S ;*VWA;4FKG6LQ5?(*F;TZHQN%IJ8OP"
MO7NU-<62]2^TA!+KVT>V"5PT 6(,O&:GI!###C90-\;/7O?6O@+KP-QY ;H?
M:\/*59I(N9E*]GZ^G%9-_5)#O<LZ$?3WZ9+L/,=T*F3B:5,GCR/:.K(H0&(E
M!A(L???(Q\UPXL?N,M7LN7$<=?:<N_$V7%PN5EM]7C9E-[1,W]AQO689'"WX
M/4P2A];)(]+A&D.@6U"+>L(Z <EZ)+]2F("MZVC;)G$\;4.2$*]+97Z^Q%LO
M6M+=+I0A![J:DUYR\#%(\GUU1B^%L7+09)&]C?NGZ>LJ 60;9 PS[!LHI0,7
M\JG&#S>G^AW^_J -^^DO//N&;^>SBR_+B0N2*UO;.5>'1D4O(.2"(%0F6Y0Y
M+4-K\.U*Z[A /!QZ!O3P:*[*$X+L?V!8?/IK/LE&EN)%[8@3 WG=F"!RZP"C
M1"&MSEFVMAJW)'%<I[4[@.ZBN%/#)0$-)\D71>Y:!+=JDU[3>!Q##2;XP*6V
MSMK6F5-;$SFNW](G-K=6WHFA\]?YY6(B0W3*Y0S9U<QZ88D_D1B48&OGUJ""
M.LS\Y.$TCMM.MTML;JVZ4X/F]!M.?&"Z)#3@-:.+@0<2)O?$7U'U]<(GC:U#
M[]O2.&YOWCZAN:WJ3@B:KPJM><.DLSK:5'P=DU0GWU@+3O,"J=3&UU)E&_1(
M^+Q'Z+C]?;L#Z>Y*/"&D3KRT*%G-'<\D1.4T ^\<\87_7WMOUMQ6CNP/OL]W
MP0SVY64B5%[J^A]NVV&KZTX_,;#*O$WQN$E*9=]//PF2VKD3AP!5]=#5MFSC
MY/++1":0R/1<)0\1MJR5N-?M$-P<'O=25<6+GL4HL-7L7,:Q'>?>R)/N=GXM
MD.>B_)F/B0?14"NY-0A'X(EK&I#%!N)I&ED@-&HJ=AMYM/>GZW8*[AUG)]#'
M_F@S"[2-X]5\*,YI_-X_QV'9]""&=S\]_-6+Z_R[@4\T0B "<0>16;;2(1-B
M0I(1A:D/EM"39M[K"*W;<;@-CUA$B<<"ML]ZK8%0DOA$(O(^GW99DPM#X+="
M6&DQLSX$5QB-1S5[[:V+P,D 5T(3S59HK9$7\,&Q%!')Y#7(BV-D*0M(!_#L
MS!/A=)^3D I<%I[J-=8QEX4]*:2!#&-EX<>F>R4E,%8I4B18;M=-$@B4$(](
M,DX;;:0TI8M/]Z6Q[M5@7UC9I6*GE.+. )AW]TF,21\% :$Y VQ%(I!1RB*:
M4K!1<<E8Z4=@.Y)6U_LU L-#U'0NZ)O?&''"($BA'@4&80H73B'G<Y]209T/
MU/,83U*^V-XU7TL(W%M59X+!^<V0MX%HP1/2#.>9Q\H@ZQ0&.0HN-"?!%1_>
MM"MM=2_S&D+@WHHZ%P#.[W^\\MXF"*BIS?W_F :^HLE=FST7"0)L5OIJ9%?:
MZE[9M03 ?15U!@!\>K>#L; V28Z\#KFR2 %SR@N$74C*$\,9/C4*&[J8:P2*
MAZOL#/ X\#I2BD-""KO\&,P0I*.,* JA7!0>.WV2]@'-7+\U@KJ]%%/[TFTE
M,QNN>*CVA$=ND0H27+EG#N(+3<&I$R&LB0:'9S5=:Z[<]OQPW0NWGI'5NR;:
MN6Q;R>7:^QF>C"0@,H3]_+VKF\]/Q@@;*[S./7^+MR#=B\"ZEVLU_5T1E34.
MRP$CC@FC(862(B!NL4?6&HD@=^+.&"Z%/ G\*M^IU<397CIH\XGGV^AFG^PD
MWQ;>QB.>;JY<I\"3S.WT%7IJF3^41TB,NNG-Y $S08MHJ=1(&:+R9$R#7*(D
MWQI8[CF#_:WTW?5J2HYU(GG5#V-8ZR;;Q:5UHSA0GD;FHD6!SKO+<X(<-Q +
M1DTU9]ZP6#I/7$%&W4NJ GI_[BN.%74#^=U3%BY^#J<#22*-.2_5\VH]3CAD
MJ$X@101/WCEK?1^6\)2*^E@Y2K$;@;*WE)O#R2=['=]V>1[4 $?OHZ06)1;F
MIVH"6<P3R,82GY\/.=*O:WF@I27,[*_CC9 Y4."U.^2\Z<:W<3++G3*^Q?&P
MFWSJ9C&':J!3]H]X[>)D(*B0(4B"I"42<64=<LX%Y 4E 3PS(1QO"TIV_5A+
M"#E4I5V/\FW T7SLQE>PVG46UB7\F[DAB2B(U%(AA:/+%9(6F6@QHBXH&Q4A
M(13OA[&"CKKE#:4WI:,EW2!:E@8EC70L7SB&J'))I8-TC<: , Y")B5TXL7?
MAJRDI'+OD*,UO 4R!XB[ = \\IIS?_G%_LK&M/278#^2\BP5'4CN;L? &4-J
M8+5P6 8JHRY=4K^1H+8@=(C&N[[$WP"6/@['\7-Z Q\>SI8<1(65I=0CRN*\
MGALX,+F+;\(F126Q=:5G$;VDHG(=<GG4'"GH!J#R[F<NU+\93K\OVLIEX<P]
M,B.!*N<A33"Y?UP>YZQS4[OH$T1K$IRS*MTI>1TM=<OG2D<X123>*'(>F96"
M]#)@[Q$FCB.>^7(^<)1?5O*@"26IM,/93%'=+:N,UG> TH$JJ)V4SS?=K_''
MS<1_M],8WMY,@+5E#_HO<3+LPN6?W5WV&$A0DFI$J%' &+A7K0E#$A)):KU1
M(+J=LO-]OMH>?@Y5=7<*N3?@H1;[\GOKY]=E<VNC4@;CB4&)QCP;GB9D1 @(
M**>6<<?D\W;(Q\?1+ZBH6XQ;>C\[4LK-X61I4<:J* S%2 (3B#.7C[\ ZSPY
MS)-UFEC2*U):V+6.U>U&J!P@Z ; \C7>=J/;[".?,+/TD#H9H#NGAR+H/(0@
M(<L(11Y'$;4+.N+24<]&@EJ"SR'Z[OH2?D4D32>SP5<[OEJ<?!D< A'>(:I"
MGE9K [(*6V1"2I(J95S8Z5005GV$%OC= U*>?+!N(7ZIS>=P&;:@^"5>.;&*
M1\"K<4P@GFL5C10:42IB]$H%%T,IU==T!T<HZ[FZ#Y!<987_8S@>7M]<+PG'
M&),\C ]%!WSSG.A99PT*PA(LN8PREK#V)Q^MK/1#5-:5D%]MQ=N?CPB/+"2B
M(".+.K_S(1((%Q@V0>E<"H+(%Q?*ARG^\4?K'+<64_S!\FL@2OS#3H9Y<_MJ
M9TNOQYW427'D+63-7"F*G'8*89\LELDD9DSAP/ Y#77?/95..X^2<&,(64;&
M41/8_(Q#6)L<&6.#G%0)!2>2U]%YJ4O7N+VDHF[&<)Q6-T#D !$W ))OT=_
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MH?IH"$MW,S:))I3SB(A6$%(0PY&&: )2/$X2DT$G6;H,_BD%=?%TN";70.(
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M,F]; R.4"9A+Q+BFB'M#D+,^(A$I5E(P8<J_ZRY%?%,]GO;!U M?6D6=S;Z
MF/]T^M#L=#Y/]EG/.)##TR*&+*"+G\/I ,= C P&19//D85-R#IJ$?/,18D#
MT?@TX[J/8J/RRX8Z@-PIQ#@=.L[;0%X*X&V7CZD&W&.-I15(2PV>*AF!K%>0
MGWBCB6!6Z-3+D**R;+3X].>$T"QG*D5P4KL3^4LF/H_C/^+B::T%TD.PB+ \
M_Y$ZX ,3@D(P2EI%K2%R6Q2][2-GB\8RVN]Z4$5[D+K\LUORP8R7FBB%I(6M
MC4LBD$OYHBTIGR)-A.#=FMIO^$B+[ZB:@=1AJF@04H"..^.0!#,=E$#<Z=PT
M3Q-D./<(C(8[G+1+G!X*JH?/M/@(J!U8':B.]H#UOKN9+!E)4AIMHD(,LY3E
MHY C,@_HU%X:L!K(6P_$U<-76GRZT@RL#E1&@Z@:WMYOY51#G.H%\E)&2.RL
M05IYC%2BS@::?-3^4%3=?Z7%]Q?MH.HP9;2'JF_#GTL^C!7).4]1,)0BKE,>
M2R@YLLHR9TQRS![JJNX_4K?NN7%,'::*!B$5;^-XR4D@CAM!/#(ZS^3-5=H6
M"XVDDCB/:TN:J4-!]?"9NK6_K</J0'6T!ZQWN?!KR0D6*L00<OJ:(T07,7)>
M!F ,ZQB\-E3N-NMSXV?J%L,V#JQ#U=$>L#X-[T])<+*.X01[>,H-=%5N4AIP
M0(0JAB$/(<GP W'U\)6ZU9Z-P^I 9;2'JLM[MYN88)Y2AH0Q^2+&&>0TH2C/
MQH*MG@C\?-K)[J<+>^V!_95%-@ZJPW31["747K.>\S0(+SU'SH)'YE93L"?8
M_D&T,F$:H[/-U'C=4UWY!+;A.]C>=-\LV@_T(A^[/^-D\:OA]7 V4$DI+6)"
MRA"V&(SB+.@C^12L%98+<YH'^F7X:?':JS]L]GGG>@Q07IO1_//'CZ>RD"RD
M_*0Z6*T0A]T1@78\XB0RC!,FT9RF[V\9?EJ\V#M/HSD&**_-:.Z&-#^JJ%W6
MV Z2(#%)IY#E>:1\B H28X*1<(X&GH0PONE-9SUK+5YFGJ<I%8)/*U;UXE'/
M@6)Y*8Z=^QEXI7T@1*&$([@@DQ)R>32U@Q2/$$ZXE[W4H=9GO<6[X--:97T=
M[ 6_OYS5/ODGO\6KX3C+\#<+R_E(!H(Z >&"0#KF*5$Q1&1(=GLR0 0A:5*R
MEPK91OAO\=;]E=IO02"V8L2E(Y)'CVSO(A(6<)*:*:0PTX@GK9'64B!I/*>1
MYOZLIVD%7)RU%HL3SCN@/1(^K5A5*8_T4AR;/!(9!&6-IH(@3?.(0A < I=D
M$'6:B!"=,[SI*'9/?ENLXCC/K:]/H!4SRI[?=%],IS?7"^:+ON!>L6XO[[6W
MT=_/ZVQ,@XD$6T2"48@309'C6*,D!: ;B^2P+.QR6GV=#?:KB5=YBC+7^5&Q
M1]9Y^*USGCFIJ77%$Y%7^3I['TSU]SI['W56##RFD]G@X5EB"OE4G5%D9<PM
MX8%R;;Q'@4:EB3+!QIU:M\*JC_ 'OWO WI,/OI:7SWLINSM6\BW Y:[ $V.L
MH_2(>@WL\L"0U0PCXGW, ;;!HAA@:KZ^/$)9S]5]@.0J*_P?P_'P^N;Z[JV4
M]T(1!S2S?$5@M$*.6HL8Q5%#(&/Y;@=F6U3^Y*.5E7Z(RKH2\JNM>/OS$>&)
M$9FHA8B5YW0C"(6,=QY)20DSF#J00@G%/_YHG?OS8HH_6'ZM'$4<EZ &QC47
M(B)J(1SCEL_O)0@*3D@J(U-6ZM(A[=^5@$?$))5T?\YH?V^'DWFOND<)]-?A
M]-_O)S$WLXN G]E7.\OZ$%[DDTB:<BL[&C R(D%NHEG43F$KV&EZ%15DZNQK
M O=":2DCZ04RY]U8=)5([II%_M&-8)D1I/@+H6#/J X2!4CEP;EA4%DP!D7,
MB&(F*4Z:*2_?G:VS+Q1LQI(*P*:5_>B0=L6;1++H4Z\UIY8IC:BB'G&I'0+-
M,:0H)*\V2AE4Z8Z8_7%S]E6!1]M-?9"<RQ7-5]A7)\/,X_S/+OQL> L_+GI=
ML^4;O5S=[,-7/]<XU*1@<H<O$EB^T+,$:4,TTBPYC6,PB9:N.F[U&H=2(15W
M$I&H\Q00PU">OX@D]EQ;+15)I6^T7N<USCZ8ZN\:9Q]U-A V+"B'OSP_I]9&
M*9\49 T2-AC.C$2.L("TSKX=*R9BZ9W^"0&OY7IG+Q!TI332 )P.%]P#V^.0
MJT8^V>N[9]8R4BYQ"(AAB"^X8P0B<9*0<I8DHX52_<R'+,Q'77 ? :M]DZ^^
M==P SI]%4,L#>T*LI80F9$,^?A%Y!_+,($,MYX8FPGEIH*XDI/%3MM[QT956
M5@.(*Y$Y>DMHH!+AW$^"4^7R\$>-5 K1JA!9?-[K\>_;E29"@A/K_IS1OL@)
M/HS!XF_F6OD\^QXGE]_M>%EH^JD;W\ZG"WWM1J/WW23_HP%/RH:H,<(VOX=R
M/"(3(T6"PG88*(U&GN81>5\<-KXC%,9O*?/I'TSG?0FSNWP6#RX&0DI)6&[
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MM'IL''N*(ZN[4F#X"Q?3:9Q-<\*YD.YHU/UI(9@?!.U9-"HAZF3([W4P<BK
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M)O&S;%U/;,(Z<9"%4KE4CQ&DI3#(*N53=%&1XDUIUM'2B",Z0L];H7. T)L
M#ZPUMJ.O\3:.;^*W.+D=^OCAZ[?EM )I(2U0C"*F2 1VN$-&68QR_2=15A-+
MRA^Y;22I-2@=HO<78"JGA 8P]>1B\/_<3(;3,/1907=C5[E2R5*'F.#S,:\!
MN605HC9QJQRVY:/"+20U\NZL)*9**J$!3*T<I4)=[AAA"5)<A7SS@9&S42)F
MN<*4",Y<Z9/3@Z?7]']]51(]1XN[ <C<G\\^CAH7P\2T3HIHBP03&G&=!T9P
M')%G+FA*05*A]*:VEIBZKJ?/Z+J,_%L%TJ,144S&J*UUX#MAC^;@6)'U#K):
M19.F+ND42Y?7;R&I;HQ42/&[P.E +30 JKOBDZ5O3>!2D]0$T7Q_Q&.F7FF&
M&&>1RQ QI:6WLJ<4- B90Y7;%9-T[>JT-W8T!&&,AQ8BN4_QS_^3E_UUQ]!*
MH=US:52^BT28Y1;3.!GDG "F'3/>)9^?C>Q4F78P"74WMCX =4*5-."@WM@?
MPWRI\BPP6#)CDW,*0R20<(3@,M?-.4P4(DF'H((DE,O"_FHC075C\#[=5SD]
M- "J]?'FQ_OA<N"<J7*4H"!!8CREA!Q1'%GI/"0P26!<>BO<@:RZ .LS3B^M
MDZ9A-HA))J8$1H+FWDW22J0-8\CGKB1:1J.3.QFZ6KU:.5#Q.P-K+RTT@*?5
M&<VR$!<'2GD,2)C<Q\;S@"SW"6&/93+*!5)\ZN@&<EH]3BB#J%)Z: !2_QQ/
MHN^NQL/_G5>]+JMEII??[>R_NYM1^'#]P_K9?5'XW;MO$AT1W'DDL;.Y$3=%
M)H'UD&0<UMQ&+TJC[3!*6]TORP#Q!-IK?C[MHYKM_)L2]5 KERQ;$[6=ZA/4
M16'*M#?,HA1=OGRQ!AD#B,#&>2=ID+*_3KGEZZ)>%.__/@&K>RCUD40)X\'.
M]+RS=PK(^9RL4&<CB40E7;HL:C-%C=P@'XF+=;WT"VBA@>WQ!3>;@LF@L5;4
MH*1R-RK%(?G!/$$&Q+ #KQHL[VNDR [DM3&!J00JM@&ND(I:1-_*P',ZP(SF
M-E$R#YC/I?0BG[XHAK3'A$H1L76EH[$=26MCOM(I4%= -;6/^5_PM#SSR]'E
MW<GRQ3B\C;=QU/W(KSA A-XZ&@4*#H,( XC0\/PBSDBII8%H5OIM@=>!WVYC
M4%)!:)U"!XTZM;N?+=]L/&G8.PYW:<V&3I TT> 3)@ASGL^SF4(F<H?RF;9+
MCBF'^QI\6)*/-L8OG<A=GE3I+0)__B1N("3#7"J0*,]5E<$S2/TC1DE[H@+&
MAJJ^)LD^I:1N8]J31HA["[Y%^,P%--")>V5XGB:?$N)1"F0#)PBD137SGI!0
M^@9T-25U6\&>$C[["[Z!H7"[M#9(5@@?8T IY(:*+H_Z3 8C@2.E1%(M;5_S
M"(_M7-';L]93 NM(E;3SEO\%9Y]B'CR/(>B'+(@PK1&W7"-+!$9," +ID#!:
M](XNH*-ND]53PFE?H;?EI3X.K1N.AK-A?! /QX99#[NUUX0BCH$;0XQ!GAJ&
MC<4:K*4_"*V@J)$7&_V=X1ZKA8;.-!ZQ\GXX'L[BQ^%MGODZL^.K/&]@830#
MYY2B2@7(*J*%?1V;W)F5(V/S^[S@I3#/VD%N/]+8[=/-'-$>K?0U)QH]:*#)
M/>\1GXM48]YDP@!'.G@.7CA9Y#BV*++ J:' +"M=[;.!G&8.94OAK+0*FFA4
M]V(H]2.6!B 1056$E /3_(+!261BP$@RHH/)A\Z]'1JLHJ>9L]B^$'6T$H[V
M4SV'6 /OC/#6@9<ET8.4:(+$EA@4B$A.8X8%ZS$Z;P9+IPVI]I)Z:0B=:D+X
MFB*E?B:$;_E8OQ/"]^'T!.4]3LP?Y6M$\K-J;E0$3V4I)(!24D\4!_]U/N4]
MST<[KA'VNY]^=!.&XZM%/>;TRV+X OS@LGOWTUX/QXOI-?,Y3-.OW6CT?G%7
M.Z#,2TUD'@*I$Y@W <<.00&28.W>6&&#*-T'OF^>VBTQV@>;+U_2-82$!FX&
MUO _B QSYS%#2N03:LLITE(;1*CS*7@2HBP-Z#6DU,5A6WC9K81W+^4=C,$?
M<3+LPK>9G<SZ1"(X@DG, T6^QNG-*)=FO0<EO;F99.U]F=-P^7@X#K4:)X,Q
M$II)X-T(I'E@R*4H+6?&!URZ+K4,Y74SZW/$>9_0:-<UK^;Z"W [6<&SH'G\
M(TN(D)QG)D^0%5(B)JWU+( :6.F.QR7HKIO(O1YC* &+=DWA;=R'9ZZ=%9@2
M1+5@B"N2.P.[@ RV3D)&#G27KG8H07?=NJYS-(7^8-'.C<&ZT$](+SW''FE*
M\E#59)"A*2#&J+ 60W94?%+.,7%[;R5AYXC;O91W9-S^;ASZ.L[[=N.F\3\W
ML-"[6_C/$6=U:U8J<!"W"XV%3MF>?>K1W8(R6(<8D0M>H'S3 'H7!CGA'?:1
M2QY+O[Q81\O1[3*?KKMHZ( ]M52G/#O$6\2]%<@X!^"VW&@IB16B],7E*CKJ
MGA\4T?Z+QIC'BKN!D.XY#_#/YOW5C!':)<N0]+F\5IC<H9%HV)TU=U);$7#/
M5G%'2E/ .4#'6T!SB,#;Q,VR0Y&%M,6:X)!A^64Z5Q+DX@1B&!.E&;:I>-.=
MM<2TA9V#5+T=/@?(O3T +9M011>ET)P@$<&H.$\<.4T"PMY92P2AGO3L=EKH
M85A(R9NA<X#$*\(FQ.'@(V1OHW?CV5W7?1>!>.(U\M':?) (N[BF%"FF#2/8
M>ADV@64:_?]]U=W^/[#T B?PBP=XK/A@W:/A8CO1L:*LC((%U4M[P(28I+A!
M6D:"N,066&<8*4Z\)2R!.6RZ']\.@<=?J^,4CE975T!VM6N ORSGV4^F2[?%
M-;,0G%-DYF,WHB6+1]DA4I][B$MO=ROQ?;YR/24?KIRNE*1JJWE>Y_F"@Q2B
M"-9A1*+B$"_E4_((LH@X>DX [)Z&G72]<ODZ7KV<PH^7646M3R>SP3?_/8:;
M4?R<WOWG!@3RCSC[WH4/X]NXF#/Y\J<QYHZH<T^8**.*A( 8A=2=VXB139*A
M:"DS5IM(R4X%$D#(HV 1?O>P#1Q+8]U+M&)APTE551F2Z_A8VJHT 2P*@S69
M&!'7N5V#E0Y9XHECA*>D= '0;::BSD9U6A1TO:BD]B[W_LW_A[&ZF\@D$PF:
M&12X ;\?I$<N6HTP\?/$# NV6WOUQZO6PT9)-74E9-;>4<?'^[Z1Q"K!' _(
MZPBY=^(,.2H$(M(G:XR/3)2^)5Q'2]WK[;Y/60\3>0/0^6)_S4=M7W87'BQK
M$K],NG S[P2Z?&EG>1"*"X("9F +26+DE- HAF@%P91&47IX]5:BFCH].U#W
M79^*: !97Z./P]ML:/\]G'W_</WC9C9_QQE!6[/WUL=E,V3'I1>!.A1LSDLT
M@?21&8U\HM(XZP0WI?&U(VE-'<>505D?2FD :R^,YU,WFS^]63([\!QLQH"D
M_+R*@\*&;F C1U1X:Y-V4HO2-6';:&HJ:^O)AQVCAH-A=1LGKBO35OK)&6[T
M8?&!BUP8=#F\'HZO'EZM;*][67DPG!==@,F'!PRM_L*>]3 '$W]D00Q\:K#X
MRO7\$P\AX*'B6+_B@7[C\8+_&/\8YD4O@>W?X __783,EZM6"5FVZN+.A'>2
M2$5/_X2^>?)76%_/UJRR]1^FK=72:$177^"SL\GU.+P?V:LBFGJZ8I5-]" ]
MK91$(UK*%O]F/ V3<FIZMF25[/]@[_=2%HTHZK^Z/Q_H*^L!URQ=I;K[(,5M
MEDUE!=[OJ</K&-YWD]RH]@\[.MK<-JU;I=GF7JK;02HM&-[T#83)\;*[)S<G
M,P6M;\OZ57I;[F^"NTFI67WVI,8ZK20+::\1I7T8A^'M,-S8T?RZ^QA%/5NJ
M;E*V6>;=-@'4-J71Z(&NNUJ7HXQHU8+5-+1&YMUN FC@4'1A_W>/',H>;CY=
MNVZRO),5;11* \I:/<+@8C*QXZLX/U3][=?#WUD>M,Z9>>!H'+Z,[/A1 4?A
MF]T^2*QZD;<:#,]O>GO43 / >W?]8]3]BO';#(*TSS\R;UM=^2'H6?^=NG>Y
M?6JWVU/4#<!A3MO%#_B\7SRI_CJ\^CZ;?KOX^JT76&S_7MU+V!/"8V?1UX[[
M5FVZ$ AE#LLG47<+[P(#TUN,<7 :]4PN+:CNG^,P&?VZ^A;]S631!?=Z=KS>
M5JZZDVO'];6V220MJ.S=SXG_,AGZ O;UL-1.RFG@1O(%\RUHY'?8 69O[2R^
MM\-)GLE20#4KUMQ)1PW<0ZX71V5E/;7L7__X]VP.I3??QU=?_'%N;\O2.ZFN
M[M7D;L(IIL'"93CO)O/[@IY*<%ZN7J3\9@O1!4IO<D>DVSCY]3F]^-8+,!R$
M^YT^<(3)+E>]^\SQA_,K%ZQVKKB/?AX;ZR:Q5':R7^,49#?/A_(></0A_:KU
MJNEKH]R[G83PE[X^Z24ZV54I?U^<_'UQLI=N/G7C3[$KH92G*]6[:-PDZVX+
MXPWM*Q&6O!Z.YS++_K78!O-BX6I.[=#(8!<QU79Y5U>S)5-'GS8]7:I: >BA
MVEHMBLKZN2-H;$>_IL-IF=JFM8M6*P8],O9>*Y[*VOLV^_>7B?\\N9Q.WDUG
MPVN[N%HJ5R6_TP>J58H>JM5]Q%99PY]O9N#CQ_,.QN5<Z?I5JY6.'JK+K0)J
M9P/\U,W^%>]WZEBJC'N7#U2K)"VP66X56V4-OX=%NW&\X[3$A>B:):M5E!ZJ
MQ<VB:4MO;V]B;@F?[_IS_YEQZB9^'EH?ZVSW^4ZUR^Y"&MY%B VJ_8]A-UK.
M$?BO[CJ^R4_A)[\^VC_[T/W&C]6[."^)@%WDV2 ,@./_W-C1, W]DOI'PQOZ
M@,+6#]:[JB\)AUWEVA8DP(V-['A)\(?K'[FK/S P'\_[JTSL=M@7Z]4&% +%
M?I)M)P,K&>)M6+9> 4&!)*S-6&\%@87SZ.?+[J3$ILZZMLNHH5N!+DXA+_P:
MY]UF[F\#BSCE/3ZSDY*;.OK:7X:M5@%]N>VK NCIRD6J?S806Z#RYXO]]4>>
M; ;9UK4=^UBZ\&>7]8^P:Q#.\;4^]XM4NW#=0PN/+?(Y][4OA'Y&?Y.;#[X!
M-W'537X=73JR>L5Z:GHN[VY'YFL?)(]&S\D;QD)%).L7KE=]M5$5W7YRJ:RZ
M+[$KH*>'56K6E&R7=;>!\?I%/D#2IR+J>+Y6O;?0>RIEC1#^KE4\Y4[S=WWB
MW_6)^^DF_,]E-\_'CS6/IRM5*Z/:9!TKF:VM@-'HGJPRIO%\N7K;^DIQ=[OP
M7ELI5U>S^:NE\73\AP7C_79S?;TXMYK.QI<N3_.^^#%RHW]-2NAL[Z_5C-36
M::PK(+X&U)YI!A:GWV[]F^FLD'97+EHSLMM1B9N$43OY*:VG@W74CZ%MDWZW
MFR@:T=*7R:2XHIZO6<^>#M#5&H'4/J7[S^S7Q9^3,,TD%E#5JO7J=5C>R>UM
M$$$KRNDY'-GG._7.\3:H:94VSR8&><+8NY]^= 41U-<?DUEXR4)I"]WM<_4>
M:>ZI\[TE6%GU_YJ\&X?WN=U%'E2X9.+WR3@3_N9V$OXUR7?I87QU,0[_'-].
M9Z$   [^:!NFOY]^NW+"KHR5G%Y]&"_I?T[I<WX@V/C7I,1^?OA7VW :!Z/E
M:'%7ALL?P.#5V]E*O ,?\,?WL"\ D_V_5BTH+ ./@\7;CA>YF'Y.2S8^ISF"
M[]DHC(Z#/UKMF6=Q'W*0L&N7,=\1OJ!W'%[NFPO']WX4YKR]Z<9A^G8"ORB%
MG$(D5'M86@9'9151&55O;T.8?IY\GGV?O ,*IU_"Y_$]-Y]F^>=_3K^FD<]L
M7<Y&64!YL$<I2)7X?K7'K67P5% %M8?B1)OKXHZ^RGR\3K5-9]-%Y@I&:Q_T
M+JDM4RO]<K5ZU1;'E5^V]NSD3?<MCJ*?Q;#$T-$O3E:O6._^_S!];91+[?(R
M("7<UV)]3FGH8=WWXS*VMGWU>B[P,%WN+*_:/C/&R>^3[N;'A^GTIJ!&-ZU;
M+?8]U(]NEU%MC_H]]^X/]X26TN*F=:M%G(=ZU^TRJFZ+W64WLZ,2S_>>KU6M
M2\K!-K=2%O4U=.%G-W8T^O7%#D,A1:U:LEH_E,/UM4$RM6NJ\I4[4#C/&@NY
MQG5K5FMS<J#BMLBF=MAY5]!_<7M5S#>N7;1>AY)#H\PMXFE(>W/*'GF(DDI<
MM7:]]B(%=+E!6"VXTGM2BSO4M2O7:PQRC%_=)JCJ=3XWP]FO/-ID(4I(;Z[G
M(]S>#A,0$X';4MK=\U/U^H0<J.[#1%D[;7SF9OZ8SC>1^?"W[]T(I/QU5BJ3
MW.]3]5J,''QV=X@HF]/_ISC[,/;==:$S])T^4*_32#%=KQ=;<QI^<<C<EZ8W
M?&@GC3=U=G2 &"MK?H7[R9PO#[_**'W7;^RD[Y9.G_847G-&_GGV/4YZMN_5
MW]A)U2T=7.TIO-I6;=W-R$X^#J>S@E?=ZU?=29TM'6=M%5!M!;[T+,>>A*Q9
M<J=JA98.LS:+IOK)_YWS+Z_ ;6OOI,F6CK)V%%9%E=[-)[\/W#]VTTWU6H>,
M@7^Z]DY*;.4 :Z-XJD<[SR+O8\UOY8([J:NE ZA-8JG=H38'5)FC0@I;M=Y.
M^FKIP&B#4%HXXB\RU>SQ0CLIJ*53GE5BJ!Z$=$>72MZML9,^6CJ#><9\&V7>
M1ZMCWWI5VM(Q28-EJMWX=PA<EH2]C5,_&<ZO80K5J6Y??B<EMG0 LKO(JN]+
M89CILB..Z>T#=Z6NG[>MOI-F6SH+V5E@M;>U\73\VSC-\A.B8O7':];<Z4U
M2Z<B6X13O8+@X?57N5*!U6ONI+J6CD&V"*?5Z0,?QM,A"/-R8N>3)R>37#>=
MIRH\.P$X<A3!AL\4F4NP*QL%AA2\^-0+6!S8['?MLL><0-\O]UN>9'/\>(*5
M"U;LA+M-%T_.G#<(H_9-P3UI1[\E?;94-=ULE/9*K33TNO1B-%KA2\JTRUV_
M< .ZVM Y=ZM _NZ\7LN&_N["_G<7]OU.M&:3T66<7$\_I\M) 'R5B>8W+%O-
MAO:+$;8+IGJDD*DJ,;GQZ4K5WL_O&\.M8+\5E5P.9T>'UT^6JO80_D"E/!%
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M+\-6T?FIFRU)+7/>O_M7&CG^/U+/&^37OT=?_D'^C[/3^/_^7_\_4$L#!!0
M   ( $. 7%K':1&72@,  #8A   :    ;&=N9%\Q,C,Q,C1X97AH:6)I=#(Q
M,2YH=&WM6FV/VC@0_GZ_PI?JKE\VD$!VEPTL$@6N2X^R*V"['RLG'HA5QXYL
MPR[WZ^LX<.V*TN.JJM*&(!$EC&?FF7G&;SB=1*>LVTD D^YOG=]=%PU$O$J!
M:Q1+P!H(6BG*E^B!@/J$7'?;JB^RC:3+1*.&USA'#T)^HFM<R#75#+H[.YUZ
M\=RI6R>=2)!-MT/H&E%R[=#+B[C9;+;\!5FT@KAQ%44!/H^!M$CL!]Y%\-%W
MC*II7N@HO6%P[:24NPGD_L/+1J;;CY3H)/0][P_'MNMV%H)KXTP:Y>*VL+%G
M2<.3=C&C2Q[:>)Q"=2>.!1,R?.793SN7N N<4K8)7\]I"@I-X!%-18KYZS.%
MN7(52+HH&BKZ#QA,!IY]?-SB-788Y;##[S=RT,.GA$;49-.O^<\1?QMK;#(+
MTCD8YQ%:OSK$\>AM;S) =S>]Z?M>?W@_'_5[XQD:3?JWT[O;:6\^'+R &&9S
M=/L7FMV_F8T&H]YT-)SM@?Y14C2.&.P:1$(2D*X)C.%,0;B[:1.J,H8W(>46
MGE5JIU@N39>(A-8B#<]-+&N0FL:8;9U8?X5XVUE:?JUQ;ON+-C@UV3G>=J6:
M%=4UV9<%5[6K5G!0[-7\@[+OF6W6&LVKGVXU:-:"R\NCS-9M(HIDF'2K#/-K
MI^GL%#),B!D)PT;VA'R3X:\H9+#8RWB1[%]?IW8,G. 4_JV];=S?"<G+ W*.
M:OH2HG^WDE01&FLJ.!(+-.*QD)F0./_A65I>).7!-X/N94"EB?<--0Z7-%;H
M;1K=G$(1',C'2FE)<5GI[F\&\(3N$BQ3',/*XE)G>:G7T)^O_ NO??SU=(MD
M  P_8@EEK9+QS:1?%$7%<6DYIDO,";H1+(>LT/W?:*S)"1,^Y$N69R3_/F &
MJN3,&\('L 8F,KMO'].4FGU[Q?\)\5]Q?BJ<OP>SX\>**C1/0.+,+OU4-<>7
M>XZ?P$J*)7#4/["1K=@N$=MWP'0BGO?PJH.7F_(%<+.?KT@N-<G%OS4B XK/
MT'C<KZ@N*]4S,W*;^;I:EY6;Y@\@N8%1+<:/([UN3RO_YU'IU^?\F5 T7_N&
MTOC0= U[)_]?SD_M4:CW105'2K"5WE?YCY<%MM?BO86Z?5_B,U!+ P04
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M?$_C:T@+>?!U\):$Y(_>=@B? 0[+<#CDB0^*JY_QV^9S^J;Z?U!+ P04
M" !#@%Q:;3!C!K\&  !Y,@  &@   &QG;F1?,3(S,3(T>&5X:&EB:70S,C$N
M:'1M[1MK3^,X\/O]"E_1L:S4ACSZ;A<)09&J6P$"]O:^G9S$:2R2.&<[E.ZO
MO[&3T!=E"RH4;HM0E=CC\<QX/,^V'\HX.NJ'!/M'O_5_K]70*?.RF"02>9Q@
M27R4"9J,T'>?B%M4JQ50)RR=<#H*);)-NX&^,WY+[W ^+ZF,R%&)IW^8O_</
M]29]E_F3H[Y/[Q#UOU1H8#GM3L?T.W;;KA,?8^P2J]FV.[C><7#3_\>JP%(
MS]<(.8G(ETI,DUI(U/[=EIW*WICZ,NQ:IOE'1<,=]0.62-B,P^+\,<>QA$F2
M>UG#$1TE7<U/)5]:3GLL8KR[9^J_GIJI!3BFT:3[Z8;&1*!S,D97+,;)IZK
MB:@)PFF0 PKZ@P!-0)Y^'1?T IZ()J2DWVHY0/3@/J0NE<BQ#6N>XI_3^@B;
MLZ+"? 32<IF4+.XV@9H9-!X<$.%;XOED<'4S/!N>'-\,+\[1Q1FZO!J>GPPO
MC[^BP=^#DV\WP[\&, P0@ZNG94(3'QCI.L#=J_-2?Y2788(\EB3$DY0E:$QE
MB&1(T'&29#A"5R1E7"(6H*]TA!,?78:8Q]@CF:0>C@0:)A[C *,OW(%:N;_7
MMFVS=\+B%"<3_6;U/B- ?L9XC"RS]B<*&->[3 CFB( ,?'1*/!*[A._O64VS
MYUA5=3_K580%"F@$  ^D71,OXU12D(&B:'#OA3@9$;C9<4R%4&S OX+T@2H4
M$DZ _EG:<JY*TJIH6$4WS/?1B8%.\1T557024A( :MA*TCN"+H* >H0K02@\
M!7-5!&.2!O"09EQD&(Y/,F2UT3?CV@!LUX58+:=A:E:PSU(EJ5GP$JAC-DO\
MUYB[."&B=G$?D0DZ]O01V*9I5V$>ZV7Q!-TF; RB&9']O4:[M^9%:I47:5[W
M)'8C4JYP&?<)KX$.1C@5I%L^]'PJT@A/NC31FJ07]>;Q-P#_G1(+Z$=Q6?5V
M^71A\#H=PVFTE<V38 &D7VY<F$-#F\-#Z2_/M8U&J[5RUC2LE7-/8NT8MNVL
MA?904YQ3#7(1H A?*DZE7)!BWP>WT[73>V3-VZR(!,NB86GEB<-2+J+ 6-.6
M4XV\O:70[NG ^KS@D@I1O:D4U/*N\X[$<@/WM3"3019%$Q!'G$;*.CU8+$[^
MS2@G*J@0ZB)/S<(!!LO(IP.- _]S;BA2P.&IZU5], I3N_=@\PK+8'6<W%3B
M6%M3L >=GK*.CQS8:^CO5M31GJKCAA5Q6VI$$W",,=:J $Y98H#R850??ZEC
MF')0LI03H=2IJJ9Q%"%8!AN#RX:)%-1)5/6J@"8X\=0X(/2I1JV\)D!E4:Z-
M+"5<[RD6W)LQ)U^M-X?:XL_XF"TXCK;3>8GCL$RCWFANW'/8MN$X]<VC;1CM
MYN:I=9I&I[X>M86=* %*9<T-[=.7S517K;+6O7P#T,T:O)CZ?D2>Y:W>DQ,_
M!3/Q2+3X,@NJF5D44"Z%+;%W1ER>83Y!=ELG$(UGN(AGZ-<KA36/*LI<L+X]
MQ=G?J[=Z0G_.)TLO#S&V9B8*+P7'TP58)%A$?52*\%7L03&B=GS.J;]IK6-%
M7++ZK#\NQQICETK8S5M#!BNJ ;^H- XN.860,H68<DDDCV6(CP>."[)2DID6
MP9XN#+Z3RIF*V"%>)R.FRLQY)0@,@PZQJ4 N4<-!QA,J0@CCP<H0"-PE0]CS
M\@![-JY?JX $@3M@3I@LL>O*F*JFP?*4"3*;7N:5-,#U_/QQ;BL@R%6YR4RA
MSYU  A$03A)/S2B>@!N@1A&U6",;AP3>.60H/@%,2F0JY\4!*/5BF:X*>$>8
M@T45FA6%=D022%"B&0J41"*@/\,CM3T2F1<6NQOH& FX-$ D@\L$V4^4$P3,
MC(%[20!<PH:Z4U DYIJAV3)<B-7Y 6C*V1U5Y4E@<88I+9XQA;3+5=E]D:BY
MDR68Z?$7"-8I7G)$(3,#*H, 92F,*#*)D,;2C?C?EM'/AN?'\ A/NS+Z1RJC
M7W@2X@2&!B*E"?N!RTKZV4,98E=)WWA!Q.J\J))NF89MMC=?2F\9C8Z]*Z7O
M2NF[4OH'J3WO2NGOH92^4&G57P^!F%YOU.4DPBK16OK"R-31Z/MM3I=@%U*.
M3"XO^<EW3/+/D$_/?41J+B?XMJ9C]BZ.QG@B*AO^7LL6'*?IO-AQVJ_028#)
MYN;],:"UG=73+W;S1JNU>:R. S')>J)=T9]PEOH35F/7']CU!]ZT/[!K):S;
M2EA,&%^AF]#<=1/>33?AZ>/^N$R_J*&P5!3Y1:4QTU!8$LFNH;!K*.P:"N^J
MH;#*D+S&JO>1"Q_F/_TXU#\Y^0]02P$"% ,4    " !#@%Q:S5S%M](_  !S
MC0$ '@              @ $     97AH:6)I=#$Y,5]I;G-I9&5R=')A9&EN
M9V,N:'1M4$L! A0#%     @ 0X!<6NF\]="XI0, !5PI !$
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M9"TR,#(T,3(S,5]G,2YJ<&=02P$"% ,4    " !#@%Q:DS!=F*=( @!@B0(
M%               @ $O7 4 ;&=N9"TR,#(T,3(S,5]G,BYJ<&=02P$"% ,4
M    " !#@%Q:7^( 9,A= 0!?C $ %               @ $(I0< ;&=N9"TR
M,#(T,3(S,5]G,RYJ<&=02P$"% ,4    " !#@%Q:RW5ES_HH P#,W04 %
M            @ $" PD ;&=N9"TR,#(T,3(S,5]G-"YJ<&=02P$"% ,4
M" !#@%Q:3)ZK!EX! @"!!Q0 %0              @ $N+ P ;&=N9"TR,#(T
M,3(S,5]L86(N>&UL4$L! A0#%     @ 0X!<6H\]TWP/- $ &5D. !4
M         ( !ORT. &QG;F0M,C R-#$R,S%?<')E+GAM;%!+ 0(4 Q0    (
M $. 7%K':1&72@,  #8A   :              "  0%B#P!L9VYD7S$R,S$R
M-'AE>&AI8FET,C$Q+FAT;5!+ 0(4 Q0    ( $. 7%HW?:^/QP,  $$8   :
M              "  8-E#P!L9VYD7S$R,S$R-'AE>&AI8FET,C,Q+FAT;5!+
M 0(4 Q0    ( $. 7%I.*\TA" @  &0]   :              "  8)I#P!L
M9VYD7S$R,S$R-'AE>&AI8FET,S$Q+FAT;5!+ 0(4 Q0    ( $. 7%J9N/[O
M[0<  %H]   :              "  <)Q#P!L9VYD7S$R,S$R-'AE>&AI8FET
M,S$R+FAT;5!+ 0(4 Q0    ( $. 7%IM,&,&OP8  'DR   :
M  "  >=Y#P!L9VYD7S$R,S$R-'AE>&AI8FET,S(Q+FAT;5!+!08     $  0
+ $8$  #>@ \    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>lgnd-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:lgnd="http://www.ligand.com/20241231"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lgnd-20241231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2025-02-25</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusPartneredProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-29</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:IntangibleRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:FinancialRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:FinancialRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:FinancialRoyaltyAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueAndOtherIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueAndOtherIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueAndOtherIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:NucorionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:NucorionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:NucorionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:APEIRONMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:APEIRONMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lgnd:DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lgnd:DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">lgnd:DevelopmentAndLicensingOfBiopharmaceuticalAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:PartnerCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">lgnd:RecordatiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusPartneredProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-18</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusPartneredProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">lgnd:PrimordialGeneticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-18</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2010-01-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyKyprolisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyRylazeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyRylazeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyRylazeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:FilspariMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:FilspariMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:FilspariMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyEvomelaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyTeriparatideInjectionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyTeriparatideInjectionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyTeriparatideInjectionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:VaxneuvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:VaxneuvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:VaxneuvanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:RoyaltyOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCoreMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCOVIDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCOVIDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolCOVIDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:LicenseFeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2007-01-01</startDate>
            <endDate>2007-12-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">lgnd:VestingPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">lgnd:RestrictedStockUnitsAndPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-29</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-29</startDate>
            <endDate>2024-05-29</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MK4830Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-29</startDate>
            <endDate>2024-05-29</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:INCAGN2390Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-29</startDate>
            <endDate>2024-05-29</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:INCAGN2385Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-29</startDate>
            <endDate>2024-05-29</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:BMS986442Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-29</startDate>
            <endDate>2024-05-29</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:UGN301Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-29</startDate>
            <endDate>2024-05-29</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:AGEN2373Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-29</startDate>
            <endDate>2024-05-29</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:BOTBALMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-29</startDate>
            <endDate>2024-05-29</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-29</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-29</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-29</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-29</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:APEIRONMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-15</startDate>
            <endDate>2024-07-15</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:APEIRONMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-15</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:InvIOsHoldingAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-15</startDate>
            <endDate>2024-07-15</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:InvIOsHoldingAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-15</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:InvIOsHoldingAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-15</startDate>
            <endDate>2024-07-15</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-27</startDate>
            <endDate>2023-09-27</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:BridgeLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-27</startDate>
            <endDate>2023-09-27</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-27</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-27</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:NovanIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-27</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-18</startDate>
            <endDate>2023-09-18</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-18</startDate>
            <endDate>2023-09-18</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-18</startDate>
            <endDate>2023-09-18</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-18</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PeliCRM197Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lgnd:MilestoneAxis">lgnd:BelowMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PeliCRM197Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:PeliCRM197Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lgnd:MilestoneAxis">lgnd:AboveMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-18</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lgnd:ConsiderationClassficationAxis">lgnd:EquityMethodInvestmentsAllocationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-18</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lgnd:ConsiderationClassficationAxis">lgnd:EquitySecuritiesAllocationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-18</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="lgnd:ConsiderationClassficationAxis">lgnd:DerivativeAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-18</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">lgnd:PelicanTechnologyHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-18</startDate>
            <endDate>2023-09-18</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2023-09-18</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusPartneredProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">lgnd:PrimordialGeneticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusPartneredProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">lgnd:PrimordialGeneticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-26</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:ContractRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:QARZIBAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:QARZIBAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ToleranceTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ToleranceTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:EnsifentrineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:EnsifentrineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:InvIOsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:InvIOsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:OvidTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:OvidTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:OvidTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:SelexisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:QARZIBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:APEIRONMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-15</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:InvIOsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:APEIRONMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-15</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:ToleranceTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:ToleranceTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:EnsifentrineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:EnsifentrineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-31</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:ElutiaAndCorMatrixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:OvidTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:SoticlestatMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MutualFundMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DemandDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:VikingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:VikingTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:VikingTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">lgnd:VikingTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">lgnd:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lgnd:PartnerProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lgnd:PartnerProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lgnd:PartnerProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:VikingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lgnd:CollarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">lgnd:OtherDerivativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:PrimroseBioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:InvIOsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:InvIOsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-16</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-16</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:RoyaltyAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:PalvellaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">lgnd:ZelsuvmiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PublicUtilitiesInventoryAxis">lgnd:ZelsuvmiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CydexPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:CyDexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">lgnd:ContingentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusPartneredProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusPartneredProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">lgnd:AgenusPartneredProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">lgnd:MetabasisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2010-01-01</startDate>
            <endDate>2010-01-31</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2010-01-01</startDate>
            <endDate>2010-01-31</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:DevelopmentRegulatoryCommercialMilestonesAndTieredRoyaltiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:Phase3ClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TimingOfTransferOfGoodOrServiceAxis">us-gaap:TransferredOverTimeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">lgnd:MaterialSalesCaptisolMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">lgnd:OfficeInBostonMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">lgnd:OfficeInJupiterFloridaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-15</startDate>
            <endDate>2023-05-15</endDate>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">lgnd:NotesRepurchasedDuringCurrentPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">lgnd:ConvertibleSeniorNotesDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-12</instant>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-12</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-12</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-12</endDate>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-12</endDate>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-12</endDate>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-12</startDate>
            <endDate>2023-10-12</endDate>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-08</instant>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-29</instant>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2022-11-02</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">lgnd:ExercisePriceRangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:OmniabSeparationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:OmniabSeparationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:TwoThousandTwoStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">lgnd:AmendedESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <instant>2023-04-30</instant>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgnd:AtTheMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">lgnd:AtTheMarketEquityOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">lgnd:USDistrictCourtForTheNorthernDistrictOfOhioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-31</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lgnd:CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">lgnd:CaliforniaAndNewJerseyResearchTaxCreditCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:CapitalLossCarryforwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:FCX007Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lgnd:PurchasersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-24</startDate>
            <endDate>2025-02-24</endDate>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:FCX007Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-24</startDate>
            <endDate>2025-02-24</endDate>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">lgnd:FCX007Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">lgnd:OtherPurchasersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-24</startDate>
            <endDate>2025-02-24</endDate>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-24</instant>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-24</startDate>
            <endDate>2025-02-24</endDate>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>lgnd:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="contract">
        <measure>lgnd:contract</measure>
    </unit>
    <unit id="right">
        <measure>lgnd:right</measure>
    </unit>
    <unit id="pure">
        <measure>lgnd:pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="position">
        <measure>lgnd:position</measure>
    </unit>
    <unit id="cvr">
        <measure>lgnd:cvr</measure>
    </unit>
    <unit id="complaint">
        <measure>lgnd:complaint</measure>
    </unit>
    <dei:AmendmentFlag contextRef="c-1" id="f-32">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-33">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-35">0000886163</dei:EntityCentralIndexKey>
    <us-gaap:AccountingStandardsUpdateExtensibleList contextRef="c-29" id="f-270">http://fasb.org/us-gaap/2024#AccountingStandardsUpdate202006Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-82" id="f-611">P1Y0M0D</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-128" decimals="4" id="f-709" unitRef="number">0.1250</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-129" decimals="4" id="f-710" unitRef="number">0.0208</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-82" id="f-1090">P1Y0M0D</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList contextRef="c-1" id="f-1303">http://fasb.org/us-gaap/2024#GainLossOnInvestments</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="c-1" id="f-1309">http://www.ligand.com/20241231#NonCashChangeInEstimatedFairValueOfContingentValueRights</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList contextRef="c-22" id="f-1313">http://fasb.org/us-gaap/2024#GainLossOnInvestments</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationAssetGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList contextRef="c-22" id="f-1320">http://www.ligand.com/20241231#NonCashChangeInEstimatedFairValueOfContingentValueRights</us-gaap:FairValueRecurringBasisUnobservableInputReconciliationLiabilityGainLossStatementOfIncomeExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-6" id="f-1373">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList contextRef="c-5" id="f-1374">http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent</us-gaap:FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <lgnd:ShareBasedCompensationInitialOfferingPeriod contextRef="c-424" id="f-1686">P6M</lgnd:ShareBasedCompensationInitialOfferingPeriod>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-33093</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">LIGAND PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">77-0160744</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">555 Heritage Drive, Suite 200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Jupiter</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">33458</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">550-7500</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">LGND</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-8" id="f-29" unitRef="usd">1100000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">19255353</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-31">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Portions of the Proxy Statement for the Registrant&#x2019;s 2025 Annual Meeting of Stockholders to be filed with the Commission within 120 days of December&#160;31, 2024 are incorporated by reference in Part&#160;III of this Annual Report on Form&#160;10-K.&#160;With the exception of those portions that are specifically incorporated by reference in this Annual Report on Form&#160;10-K, such Proxy Statement shall not be deemed filed as part of this Report or incorporated by reference herein.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-36">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information. Our cybersecurity risk management program includes a cybersecurity incident response plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We design and assess our program based on the National Institute of Standards and Technology (&#x201c;NIST&#x201d;), the International Organization for Standardization (&#x201c;ISO&#x201d;) and other applicable industry standards. This does not imply that we &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;meet any particular technical standards, specifications, or requirements, only that we use the NIST, ISO and other standards as a guide to help us identify, assess, and manage cybersecurity risks relevant to our business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity risk management program is integrated into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity risk management program includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our broader enterprise information technology environment;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;a security team principally responsible for managing (i) our cybersecurity risk assessment processes, (ii) our security controls, and (iii) our response to cybersecurity incidents;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;cybersecurity awareness training of our employees, incident response personnel, and senior management; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;a third-party risk management process for service providers, suppliers, and vendors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-37">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cybersecurity risk management program is integrated into our overall enterprise risk management program, and shares common methodologies, reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, and financial risk areas.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-38">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-39">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-40">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-41">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-43">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#x201c;Committee&#x201d;) oversight of cybersecurity and other information technology risks. The Committee oversees management&#x2019;s implementation of our cybersecurity risk management program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Committee receives regular reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also receives briefings from senior management on our cyber risk management program. Board members receive presentations on cybersecurity topics from senior management, or external experts as part of the Board&#x2019;s continuing education on topics that impact public companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our senior management team, including the Senior Director, IT and Facilities, is responsible for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. The Senior Director, IT and Facilities has over 20 years of industry experiences leading and overseeing cybersecurity programs at public and private companies.&lt;/span&gt;&lt;/div&gt;Our senior management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information technology environment.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-42">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#x201c;Committee&#x201d;) oversight of cybersecurity and other information technology risks. The Committee oversees management&#x2019;s implementation of our cybersecurity risk management program. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Committee receives regular reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also receives briefings from senior management on our cyber risk management program. Board members receive presentations on cybersecurity topics from senior management, or external experts as part of the Board&#x2019;s continuing education on topics that impact public companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our senior management team, including the Senior Director, IT and Facilities, is responsible for assessing and managing our material risks from cybersecurity threats. The team has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained external cybersecurity consultants. The Senior Director, IT and Facilities has over 20 years of industry experiences leading and overseeing cybersecurity programs at public and private companies.&lt;/span&gt;&lt;/div&gt;Our senior management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the information technology environment.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-45">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#x201c;Committee&#x201d;) oversight of cybersecurity and other information technology risks. The Committee oversees management&#x2019;s implementation of our cybersecurity risk management program.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-44">Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the &#x201c;Committee&#x201d;) oversight of cybersecurity and other information technology risks. The Committee oversees management&#x2019;s implementation of our cybersecurity risk management program.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-46">The Committee receives regular reports from management on our cybersecurity risks. In addition, management updates the Committee, as necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-47">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also receives briefings from senior management on our cyber risk management program. Board members receive presentations on cybersecurity topics from senior management, or external experts as part of the Board&#x2019;s continuing education on topics that impact public companies.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-48">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-49">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-50">The Senior Director, IT and Facilities has over 20 years of industry experiences leading and overseeing cybersecurity programs at public and private companies.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <dei:AuditorFirmId contextRef="c-1" id="f-51">42</dei:AuditorFirmId>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="c-4" decimals="-5" id="f-52" unitRef="usd">21300000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <dei:AuditorName contextRef="c-1" id="f-53">Ernst &amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-54">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-55" unitRef="usd">72307000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-56" unitRef="usd">22954000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments contextRef="c-5" decimals="-3" id="f-57" unitRef="usd">183858000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-6" decimals="-3" id="f-58" unitRef="usd">147355000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">38376000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-6" decimals="-3" id="f-60" unitRef="usd">32917000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">14114000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-6" decimals="-3" id="f-62" unitRef="usd">23969000</us-gaap:InventoryNet>
    <us-gaap:IncomeTaxesReceivable contextRef="c-5" decimals="-3" id="f-63" unitRef="usd">4073000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable contextRef="c-6" decimals="-3" id="f-64" unitRef="usd">6395000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">1934000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-6" decimals="-3" id="f-66" unitRef="usd">1182000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">16897000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-68" unitRef="usd">2657000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-69" unitRef="usd">331559000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="-3" id="f-70" unitRef="usd">237429000</us-gaap:AssetsCurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-71" unitRef="usd">266648000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-6" decimals="-3" id="f-72" unitRef="usd">299606000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-73" unitRef="usd">105250000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-6" decimals="-3" id="f-74" unitRef="usd">103370000</us-gaap:Goodwill>
    <lgnd:FinancialRoyaltyAssetsNonCurrent contextRef="c-5" decimals="-3" id="f-75" unitRef="usd">185024000</lgnd:FinancialRoyaltyAssetsNonCurrent>
    <lgnd:FinancialRoyaltyAssetsNonCurrent contextRef="c-6" decimals="-3" id="f-76" unitRef="usd">62291000</lgnd:FinancialRoyaltyAssetsNonCurrent>
    <us-gaap:DerivativeAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-77" unitRef="usd">10583000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent contextRef="c-6" decimals="-3" id="f-78" unitRef="usd">3531000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-79" unitRef="usd">15133000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-80" unitRef="usd">15607000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-81" unitRef="usd">6907000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-82" unitRef="usd">6062000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-83" unitRef="usd">2766000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-84" unitRef="usd">3393000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:EquityMethodInvestments contextRef="c-5" decimals="-3" id="f-85" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-6" decimals="-3" id="f-86" unitRef="usd">12595000</us-gaap:EquityMethodInvestments>
    <us-gaap:OtherInvestments contextRef="c-5" decimals="-3" id="f-87" unitRef="usd">10908000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c-6" decimals="-3" id="f-88" unitRef="usd">36726000</us-gaap:OtherInvestments>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-5" decimals="-3" id="f-89" unitRef="usd">72000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-6" decimals="-3" id="f-90" unitRef="usd">214000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-91" unitRef="usd">6924000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-6" decimals="-3" id="f-92" unitRef="usd">6392000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-93" unitRef="usd">941774000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-6" decimals="-3" id="f-94" unitRef="usd">787216000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-95" unitRef="usd">5233000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-3" id="f-96" unitRef="usd">2427000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-97" unitRef="usd">27906000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-98" unitRef="usd">12467000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-5" decimals="-3" id="f-99" unitRef="usd">1199000</us-gaap:TaxesPayableCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-100" unitRef="usd">1278000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-6" decimals="-3" id="f-101" unitRef="usd">1222000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <lgnd:CurrentPortionOfLiabilityForContingentValueRights contextRef="c-5" decimals="-3" id="f-102" unitRef="usd">206000</lgnd:CurrentPortionOfLiabilityForContingentValueRights>
    <lgnd:CurrentPortionOfLiabilityForContingentValueRights contextRef="c-6" decimals="-3" id="f-103" unitRef="usd">256000</lgnd:CurrentPortionOfLiabilityForContingentValueRights>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-104" unitRef="usd">1266000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-105" unitRef="usd">403000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-106" unitRef="usd">24000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-107" unitRef="usd">7000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-108" unitRef="usd">37112000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-109" unitRef="usd">16782000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeNoncurrent contextRef="c-5" decimals="-3" id="f-110" unitRef="usd">2246000</us-gaap:DeferredIncomeNoncurrent>
    <us-gaap:DeferredIncomeNoncurrent contextRef="c-6" decimals="-3" id="f-111" unitRef="usd">1444000</us-gaap:DeferredIncomeNoncurrent>
    <lgnd:LiabilityForContingentValueRights contextRef="c-5" decimals="-3" id="f-112" unitRef="usd">3475000</lgnd:LiabilityForContingentValueRights>
    <lgnd:LiabilityForContingentValueRights contextRef="c-6" decimals="-3" id="f-113" unitRef="usd">2942000</lgnd:LiabilityForContingentValueRights>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-114" unitRef="usd">5815000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-115" unitRef="usd">5755000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-5" decimals="-3" id="f-116" unitRef="usd">32524000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-6" decimals="-3" id="f-117" unitRef="usd">31622000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-118" unitRef="usd">30163000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-6" decimals="-3" id="f-119" unitRef="usd">27758000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-120" unitRef="usd">111335000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-6" decimals="-3" id="f-121" unitRef="usd">86303000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-122" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-6" id="f-123" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-124"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-125"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="-3" id="f-126" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="-3" id="f-127" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-6" decimals="-3" id="f-128" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-6" decimals="-3" id="f-129" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="-3" id="f-130" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="-3" id="f-131" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-3" id="f-132" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-6" decimals="-3" id="f-133" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-134"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-135"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="-3" id="f-136" unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="-3" id="f-137" unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="-3" id="f-138" unitRef="shares">19106000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="-3" id="f-139" unitRef="shares">19106000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="-3" id="f-140" unitRef="shares">17556000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="-3" id="f-141" unitRef="shares">17556000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-142" unitRef="usd">20000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="-3" id="f-143" unitRef="usd">18000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="-3" id="f-144" unitRef="usd">337377000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-6" decimals="-3" id="f-145" unitRef="usd">198696000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-146" unitRef="usd">-5942000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-6" decimals="-3" id="f-147" unitRef="usd">-817000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-148" unitRef="usd">498984000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-3" id="f-149" unitRef="usd">503016000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-150" unitRef="usd">830439000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-151" unitRef="usd">700913000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-152" unitRef="usd">941774000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="-3" id="f-153" unitRef="usd">787216000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-154" unitRef="usd">95329000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-155" unitRef="usd">83910000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-156" unitRef="usd">72527000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-157" unitRef="usd">13444000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-158" unitRef="usd">1049000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-159" unitRef="usd">385000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-160" unitRef="usd">108773000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-161" unitRef="usd">84959000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-3" id="f-162" unitRef="usd">72912000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-16" decimals="-3" id="f-163" unitRef="usd">30883000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-17" decimals="-3" id="f-164" unitRef="usd">28372000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-18" decimals="-3" id="f-165" unitRef="usd">104495000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-19" decimals="-3" id="f-166" unitRef="usd">27477000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-20" decimals="-3" id="f-167" unitRef="usd">17983000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-21" decimals="-3" id="f-168" unitRef="usd">18838000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-169" unitRef="usd">167133000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-22" decimals="-3" id="f-170" unitRef="usd">131314000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-23" decimals="-3" id="f-171" unitRef="usd">196245000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostDirectMaterial contextRef="c-1" decimals="-3" id="f-172" unitRef="usd">11074000</us-gaap:CostDirectMaterial>
    <us-gaap:CostDirectMaterial contextRef="c-22" decimals="-3" id="f-173" unitRef="usd">10512000</us-gaap:CostDirectMaterial>
    <us-gaap:CostDirectMaterial contextRef="c-23" decimals="-3" id="f-174" unitRef="usd">52827000</us-gaap:CostDirectMaterial>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">32959000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-22" decimals="-3" id="f-176" unitRef="usd">33654000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-23" decimals="-3" id="f-177" unitRef="usd">34237000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-178" unitRef="usd">21425000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-22" decimals="-3" id="f-179" unitRef="usd">24537000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-23" decimals="-3" id="f-180" unitRef="usd">36082000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-181" unitRef="usd">78654000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-22" decimals="-3" id="f-182" unitRef="usd">52790000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-23" decimals="-3" id="f-183" unitRef="usd">70062000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-1" decimals="-3" id="f-184" unitRef="usd">30572000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-22" decimals="-3" id="f-185" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-23" decimals="-3" id="f-186" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c-1" decimals="-3" id="f-187" unitRef="usd">-15055000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c-22" decimals="-3" id="f-188" unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c-23" decimals="-3" id="f-189" unitRef="usd">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-1" decimals="-3" id="f-190" unitRef="usd">189739000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-22" decimals="-3" id="f-191" unitRef="usd">121493000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses contextRef="c-23" decimals="-3" id="f-192" unitRef="usd">193208000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-1" decimals="-3" id="f-193" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-22" decimals="-3" id="f-194" unitRef="usd">2121000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-23" decimals="-3" id="f-195" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-196" unitRef="usd">-22606000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-22" decimals="-3" id="f-197" unitRef="usd">11942000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-23" decimals="-3" id="f-198" unitRef="usd">3037000</us-gaap:OperatingIncomeLoss>
    <us-gaap:GainLossOnInvestments contextRef="c-1" decimals="-3" id="f-199" unitRef="usd">75024000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-22" decimals="-3" id="f-200" unitRef="usd">46365000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-23" decimals="-3" id="f-201" unitRef="usd">28540000</us-gaap:GainLossOnInvestments>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-202" unitRef="usd">8055000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-22" decimals="-3" id="f-203" unitRef="usd">7711000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-23" decimals="-3" id="f-204" unitRef="usd">2046000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c-1" decimals="-3" id="f-205" unitRef="usd">3037000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-22" decimals="-3" id="f-206" unitRef="usd">656000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-23" decimals="-3" id="f-207" unitRef="usd">1799000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-208" unitRef="usd">-54918000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-22" decimals="-3" id="f-209" unitRef="usd">-1702000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-23" decimals="-3" id="f-210" unitRef="usd">4187000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-211" unitRef="usd">25124000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-22" decimals="-3" id="f-212" unitRef="usd">51718000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-23" decimals="-3" id="f-213" unitRef="usd">32974000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-214" unitRef="usd">2518000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-22" decimals="-3" id="f-215" unitRef="usd">63660000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-23" decimals="-3" id="f-216" unitRef="usd">36011000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-217" unitRef="usd">6550000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-22" decimals="-3" id="f-218" unitRef="usd">9841000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-23" decimals="-3" id="f-219" unitRef="usd">41230000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-1" decimals="-3" id="f-220" unitRef="usd">-4032000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-22" decimals="-3" id="f-221" unitRef="usd">53819000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-23" decimals="-3" id="f-222" unitRef="usd">-5219000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-22" decimals="-3" id="f-223" unitRef="usd">-1665000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-23" decimals="-3" id="f-224" unitRef="usd">-28142000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-225" unitRef="usd">-4032000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-22" decimals="-3" id="f-226" unitRef="usd">52154000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-23" decimals="-3" id="f-227" unitRef="usd">-33361000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-228"
      unitRef="usdPerShare">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-22"
      decimals="2"
      id="f-229"
      unitRef="usdPerShare">3.11</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-23"
      decimals="2"
      id="f-230"
      unitRef="usdPerShare">-0.31</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-231"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-22"
      decimals="2"
      id="f-232"
      unitRef="usdPerShare">-0.10</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-23"
      decimals="2"
      id="f-233"
      unitRef="usdPerShare">-1.67</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-234"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-22"
      decimals="2"
      id="f-235"
      unitRef="usdPerShare">3.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-23"
      decimals="2"
      id="f-236"
      unitRef="usdPerShare">-1.98</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-237" unitRef="shares">18290000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-22" decimals="-3" id="f-238" unitRef="shares">17298000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-23" decimals="-3" id="f-239" unitRef="shares">16868000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-240"
      unitRef="usdPerShare">-0.22</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-22"
      decimals="2"
      id="f-241"
      unitRef="usdPerShare">3.03</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-23"
      decimals="2"
      id="f-242"
      unitRef="usdPerShare">-0.31</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-243"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c-22"
      decimals="2"
      id="f-244"
      unitRef="usdPerShare">-0.09</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c-23"
      decimals="2"
      id="f-245"
      unitRef="usdPerShare">-1.67</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-246"
      unitRef="usdPerShare">-0.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-22"
      decimals="2"
      id="f-247"
      unitRef="usdPerShare">2.94</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-23"
      decimals="2"
      id="f-248"
      unitRef="usdPerShare">-1.98</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-249" unitRef="shares">18290000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-22" decimals="-3" id="f-250" unitRef="shares">17757000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-23" decimals="-3" id="f-251" unitRef="shares">16868000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-252" unitRef="usd">-4032000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-22" decimals="-3" id="f-253" unitRef="usd">52154000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-23" decimals="-3" id="f-254" unitRef="usd">-33361000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-255" unitRef="usd">45000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-22" decimals="-3" id="f-256" unitRef="usd">167000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-23" decimals="-3" id="f-257" unitRef="usd">-67000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-258" unitRef="usd">-5170000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-22" decimals="-3" id="f-259" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-23" decimals="-3" id="f-260" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-261" unitRef="usd">-9157000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-22" decimals="-3" id="f-262" unitRef="usd">52321000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-23" decimals="-3" id="f-263" unitRef="usd">-33428000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-24" decimals="-3" id="f-264" unitRef="shares">16767000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-265" unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-25" decimals="-3" id="f-266" unitRef="usd">372969000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-267" unitRef="usd">-917000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-268" unitRef="usd">449090000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-269" unitRef="usd">821159000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-271" unitRef="usd">-51130000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-272" unitRef="usd">35133000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-273" unitRef="usd">-15997000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-33" decimals="-3" id="f-274" unitRef="shares">184000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-34" decimals="-3" id="f-275" unitRef="usd">-5004000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-23" decimals="-3" id="f-276" unitRef="usd">-5004000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-34" decimals="-3" id="f-277" unitRef="usd">60285000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-23" decimals="-3" id="f-278" unitRef="usd">60285000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-35" decimals="-3" id="f-279" unitRef="usd">-67000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-23" decimals="-3" id="f-280" unitRef="usd">-67000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction contextRef="c-34" decimals="-3" id="f-281" unitRef="usd">202000</lgnd:AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction contextRef="c-23" decimals="-3" id="f-282" unitRef="usd">202000</lgnd:AdjustmentsToAdditionalPaidInCapitalBondHedgeTransaction>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation contextRef="c-34" decimals="-3" id="f-283" unitRef="usd">229732000</lgnd:AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation contextRef="c-23" decimals="-3" id="f-284" unitRef="usd">229732000</lgnd:AdjustmentsToAdditionalPaidInCapitalDecreaseDueToSeparation>
    <us-gaap:NetIncomeLoss contextRef="c-36" decimals="-3" id="f-285" unitRef="usd">-33361000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-23" decimals="-3" id="f-286" unitRef="usd">-33361000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-37" decimals="-3" id="f-287" unitRef="shares">16951000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-3" id="f-288" unitRef="usd">17000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-3" id="f-289" unitRef="usd">147590000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-3" id="f-290" unitRef="usd">-984000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-291" unitRef="usd">450862000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-292" unitRef="usd">597485000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-42" decimals="-3" id="f-293" unitRef="shares">605000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-42" decimals="-3" id="f-294" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-43" decimals="-3" id="f-295" unitRef="usd">17901000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-22" decimals="-3" id="f-296" unitRef="usd">17902000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-43" decimals="-3" id="f-297" unitRef="usd">25743000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-22" decimals="-3" id="f-298" unitRef="usd">25743000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-44" decimals="-3" id="f-299" unitRef="usd">167000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-22" decimals="-3" id="f-300" unitRef="usd">167000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation contextRef="c-43" decimals="-3" id="f-301" unitRef="usd">-1665000</lgnd:AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation contextRef="c-22" decimals="-3" id="f-302" unitRef="usd">-1665000</lgnd:AdjustmentsToAdditionalPaidInCapitalIncreaseDueToSeparation>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision contextRef="c-43" decimals="-3" id="f-303" unitRef="usd">5797000</lgnd:AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision>
    <lgnd:AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision contextRef="c-22" decimals="-3" id="f-304" unitRef="usd">5797000</lgnd:AdjustmentsToAdditionalPaidInCapitalTaxReturnToProvision>
    <us-gaap:NetIncomeLoss contextRef="c-22" decimals="-3" id="f-305" unitRef="usd">52154000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-45" decimals="-3" id="f-306" unitRef="shares">17556000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-307" unitRef="usd">18000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-308" unitRef="usd">198696000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-47" decimals="-3" id="f-309" unitRef="usd">-817000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-3" id="f-310" unitRef="usd">503016000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-311" unitRef="usd">700913000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-49" decimals="-3" id="f-312" unitRef="shares">1190000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-49" decimals="-3" id="f-313" unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-50" decimals="-3" id="f-314" unitRef="usd">60452000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-3" id="f-315" unitRef="usd">60454000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-49" decimals="-3" id="f-316" unitRef="shares">360000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-50" decimals="-3" id="f-317" unitRef="usd">37140000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-318" unitRef="usd">37140000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-50" decimals="-3" id="f-319" unitRef="usd">41089000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-320" unitRef="usd">41089000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-51" decimals="-3" id="f-321" unitRef="usd">45000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-322" unitRef="usd">45000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-51" decimals="-3" id="f-323" unitRef="usd">-5170000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-324" unitRef="usd">-5170000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss contextRef="c-52" decimals="-3" id="f-325" unitRef="usd">-4032000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-326" unitRef="usd">-4032000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-53" decimals="-3" id="f-327" unitRef="shares">19106000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-3" id="f-328" unitRef="usd">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-3" id="f-329" unitRef="usd">337377000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-3" id="f-330" unitRef="usd">-5942000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-56" decimals="-3" id="f-331" unitRef="usd">498984000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-332" unitRef="usd">830439000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-333" unitRef="usd">-4032000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-22" decimals="-3" id="f-334" unitRef="usd">52154000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-23" decimals="-3" id="f-335" unitRef="usd">-33361000</us-gaap:NetIncomeLoss>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-1" decimals="-3" id="f-336" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-22" decimals="-3" id="f-337" unitRef="usd">2121000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-23" decimals="-3" id="f-338" unitRef="usd">0</us-gaap:GainLossOnSaleOfBusiness>
    <lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights contextRef="c-1" decimals="-3" id="f-339" unitRef="usd">-683000</lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights>
    <lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights contextRef="c-22" decimals="-3" id="f-340" unitRef="usd">265000</lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights>
    <lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights contextRef="c-23" decimals="-3" id="f-341" unitRef="usd">748000</lgnd:NonCashChangeInEstimatedFairValueOfContingentValueRights>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-342" unitRef="usd">35239000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-22" decimals="-3" id="f-343" unitRef="usd">36521000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-23" decimals="-3" id="f-344" unitRef="usd">51534000</us-gaap:DepreciationDepletionAndAmortization>
    <lgnd:GainLossOnShortTermInvestments contextRef="c-1" decimals="-3" id="f-345" unitRef="usd">67901000</lgnd:GainLossOnShortTermInvestments>
    <lgnd:GainLossOnShortTermInvestments contextRef="c-22" decimals="-3" id="f-346" unitRef="usd">46365000</lgnd:GainLossOnShortTermInvestments>
    <lgnd:GainLossOnShortTermInvestments contextRef="c-23" decimals="-3" id="f-347" unitRef="usd">28540000</lgnd:GainLossOnShortTermInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-3" id="f-348" unitRef="usd">1331000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-22" decimals="-3" id="f-349" unitRef="usd">1318000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-23" decimals="-3" id="f-350" unitRef="usd">-16000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-351" unitRef="usd">486000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-22" decimals="-3" id="f-352" unitRef="usd">240000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-23" decimals="-3" id="f-353" unitRef="usd">734000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-1" decimals="-3" id="f-354" unitRef="usd">-20010000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-22" decimals="-3" id="f-355" unitRef="usd">250000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-23" decimals="-3" id="f-356" unitRef="usd">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-357" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-22" decimals="-3" id="f-358" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-23" decimals="-3" id="f-359" unitRef="usd">4192000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <lgnd:NonCashIncomeFromFinancialRoyaltyAssets contextRef="c-1" decimals="-3" id="f-360" unitRef="usd">5467000</lgnd:NonCashIncomeFromFinancialRoyaltyAssets>
    <lgnd:NonCashIncomeFromFinancialRoyaltyAssets contextRef="c-22" decimals="-3" id="f-361" unitRef="usd">878000</lgnd:NonCashIncomeFromFinancialRoyaltyAssets>
    <lgnd:NonCashIncomeFromFinancialRoyaltyAssets contextRef="c-23" decimals="-3" id="f-362" unitRef="usd">164000</lgnd:NonCashIncomeFromFinancialRoyaltyAssets>
    <lgnd:CurrentAndExpectedCreditLossAdjustment contextRef="c-1" decimals="-3" id="f-363" unitRef="usd">-4315000</lgnd:CurrentAndExpectedCreditLossAdjustment>
    <lgnd:CurrentAndExpectedCreditLossAdjustment contextRef="c-22" decimals="-3" id="f-364" unitRef="usd">3595000</lgnd:CurrentAndExpectedCreditLossAdjustment>
    <lgnd:CurrentAndExpectedCreditLossAdjustment contextRef="c-23" decimals="-3" id="f-365" unitRef="usd">0</lgnd:CurrentAndExpectedCreditLossAdjustment>
    <lgnd:ImpairmentLossOnFinancialRoyaltyAssets contextRef="c-1" decimals="-3" id="f-366" unitRef="usd">30572000</lgnd:ImpairmentLossOnFinancialRoyaltyAssets>
    <lgnd:ImpairmentLossOnFinancialRoyaltyAssets contextRef="c-22" decimals="-3" id="f-367" unitRef="usd">924000</lgnd:ImpairmentLossOnFinancialRoyaltyAssets>
    <lgnd:ImpairmentLossOnFinancialRoyaltyAssets contextRef="c-23" decimals="-3" id="f-368" unitRef="usd">0</lgnd:ImpairmentLossOnFinancialRoyaltyAssets>
    <lgnd:FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization contextRef="c-1" decimals="-3" id="f-369" unitRef="usd">2126000</lgnd:FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization>
    <lgnd:FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization contextRef="c-22" decimals="-3" id="f-370" unitRef="usd">1735000</lgnd:FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization>
    <lgnd:FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization contextRef="c-23" decimals="-3" id="f-371" unitRef="usd">5521000</lgnd:FinanceLeaseAndOperatingLeaseRightOfUseAssetAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-372" unitRef="usd">41089000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-22" decimals="-3" id="f-373" unitRef="usd">25743000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-23" decimals="-3" id="f-374" unitRef="usd">60285000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-3" id="f-375" unitRef="usd">-12821000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-22" decimals="-3" id="f-376" unitRef="usd">-1829000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-23" decimals="-3" id="f-377" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-3" id="f-378" unitRef="usd">-25788000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-22" decimals="-3" id="f-379" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-23" decimals="-3" id="f-380" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-1" decimals="-3" id="f-381" unitRef="usd">15800000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-22" decimals="-3" id="f-382" unitRef="usd">-11696000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-23" decimals="-3" id="f-383" unitRef="usd">-20723000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-1" decimals="-3" id="f-384" unitRef="usd">7723000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-22" decimals="-3" id="f-385" unitRef="usd">739000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-23" decimals="-3" id="f-386" unitRef="usd">365000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-387" unitRef="usd">6459000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-22" decimals="-3" id="f-388" unitRef="usd">2601000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-23" decimals="-3" id="f-389" unitRef="usd">-55319000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-390" unitRef="usd">-9619000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-22" decimals="-3" id="f-391" unitRef="usd">10870000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-23" decimals="-3" id="f-392" unitRef="usd">-12058000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent contextRef="c-1" decimals="-3" id="f-393" unitRef="usd">0</us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent>
    <us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent contextRef="c-22" decimals="-3" id="f-394" unitRef="usd">5000000</us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent>
    <us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent contextRef="c-23" decimals="-3" id="f-395" unitRef="usd">0</us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-3" id="f-396" unitRef="usd">13903000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-22" decimals="-3" id="f-397" unitRef="usd">-4704000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-23" decimals="-3" id="f-398" unitRef="usd">-3340000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c-1" decimals="-3" id="f-399" unitRef="usd">-2310000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c-22" decimals="-3" id="f-400" unitRef="usd">1781000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable contextRef="c-23" decimals="-3" id="f-401" unitRef="usd">-1579000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-402" unitRef="usd">-1308000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-22" decimals="-3" id="f-403" unitRef="usd">419000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-23" decimals="-3" id="f-404" unitRef="usd">-6281000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-1" decimals="-3" id="f-405" unitRef="usd">-1291000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-22" decimals="-3" id="f-406" unitRef="usd">9865000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-23" decimals="-3" id="f-407" unitRef="usd">-6342000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-408" unitRef="usd">97047000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-22" decimals="-3" id="f-409" unitRef="usd">49577000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-23" decimals="-3" id="f-410" unitRef="usd">137850000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <lgnd:PaymentsToAcquireFinancialRoyaltyAssets contextRef="c-1" decimals="-3" id="f-411" unitRef="usd">17819000</lgnd:PaymentsToAcquireFinancialRoyaltyAssets>
    <lgnd:PaymentsToAcquireFinancialRoyaltyAssets contextRef="c-22" decimals="-3" id="f-412" unitRef="usd">50328000</lgnd:PaymentsToAcquireFinancialRoyaltyAssets>
    <lgnd:PaymentsToAcquireFinancialRoyaltyAssets contextRef="c-23" decimals="-3" id="f-413" unitRef="usd">0</lgnd:PaymentsToAcquireFinancialRoyaltyAssets>
    <lgnd:ProceedsFromFinancialRoyaltyAssets contextRef="c-1" decimals="-3" id="f-414" unitRef="usd">7429000</lgnd:ProceedsFromFinancialRoyaltyAssets>
    <lgnd:ProceedsFromFinancialRoyaltyAssets contextRef="c-22" decimals="-3" id="f-415" unitRef="usd">418000</lgnd:ProceedsFromFinancialRoyaltyAssets>
    <lgnd:ProceedsFromFinancialRoyaltyAssets contextRef="c-23" decimals="-3" id="f-416" unitRef="usd">92000</lgnd:ProceedsFromFinancialRoyaltyAssets>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-417" unitRef="usd">1821000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-22" decimals="-3" id="f-418" unitRef="usd">3521000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-23" decimals="-3" id="f-419" unitRef="usd">17923000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-1" decimals="-3" id="f-420" unitRef="usd">226384000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-22" decimals="-3" id="f-421" unitRef="usd">126764000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="c-23" decimals="-3" id="f-422" unitRef="usd">51226000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="c-1" decimals="-3" id="f-423" unitRef="usd">229367000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="c-22" decimals="-3" id="f-424" unitRef="usd">148765000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments contextRef="c-23" decimals="-3" id="f-425" unitRef="usd">209561000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="c-1" decimals="-3" id="f-426" unitRef="usd">33131000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="c-22" decimals="-3" id="f-427" unitRef="usd">45402000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="c-23" decimals="-3" id="f-428" unitRef="usd">24830000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-57" decimals="-3" id="f-429" unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-58" decimals="-3" id="f-430" unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-59" decimals="-3" id="f-431" unitRef="usd">750000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-60" decimals="-3" id="f-432" unitRef="usd">998000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-61" decimals="-3" id="f-433" unitRef="usd">15249000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="c-62" decimals="-3" id="f-434" unitRef="usd">0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c-1" decimals="-3" id="f-435" unitRef="usd">2500000</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c-22" decimals="-3" id="f-436" unitRef="usd">0</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c-23" decimals="-3" id="f-437" unitRef="usd">0</us-gaap:PaymentsToAcquireNotesReceivable>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-3" id="f-438" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-22" decimals="-3" id="f-439" unitRef="usd">10405000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-23" decimals="-3" id="f-440" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsForDerivativeInstrumentInvestingActivities contextRef="c-1" decimals="-3" id="f-441" unitRef="usd">75000000</us-gaap:PaymentsForDerivativeInstrumentInvestingActivities>
    <us-gaap:PaymentsForDerivativeInstrumentInvestingActivities contextRef="c-22" decimals="-3" id="f-442" unitRef="usd">0</us-gaap:PaymentsForDerivativeInstrumentInvestingActivities>
    <us-gaap:PaymentsForDerivativeInstrumentInvestingActivities contextRef="c-23" decimals="-3" id="f-443" unitRef="usd">0</us-gaap:PaymentsForDerivativeInstrumentInvestingActivities>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired contextRef="c-1" decimals="-3" id="f-444" unitRef="usd">91996000</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired contextRef="c-22" decimals="-3" id="f-445" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired contextRef="c-23" decimals="-3" id="f-446" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessTwoNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi contextRef="c-1" decimals="-3" id="f-447" unitRef="usd">4196000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi contextRef="c-22" decimals="-3" id="f-448" unitRef="usd">0</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi contextRef="c-23" decimals="-3" id="f-449" unitRef="usd">0</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:ProceedsFromDerivativeInstrumentInvestingActivities contextRef="c-1" decimals="-3" id="f-450" unitRef="usd">7123000</us-gaap:ProceedsFromDerivativeInstrumentInvestingActivities>
    <us-gaap:ProceedsFromDerivativeInstrumentInvestingActivities contextRef="c-22" decimals="-3" id="f-451" unitRef="usd">0</us-gaap:ProceedsFromDerivativeInstrumentInvestingActivities>
    <us-gaap:ProceedsFromDerivativeInstrumentInvestingActivities contextRef="c-23" decimals="-3" id="f-452" unitRef="usd">0</us-gaap:ProceedsFromDerivativeInstrumentInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-1" decimals="-3" id="f-453" unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-22" decimals="-3" id="f-454" unitRef="usd">0</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-23" decimals="-3" id="f-455" unitRef="usd">960000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-456" unitRef="usd">-143664000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-22" decimals="-3" id="f-457" unitRef="usd">-11682000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-23" decimals="-3" id="f-458" unitRef="usd">163624000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-459" unitRef="usd">37140000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-22" decimals="-3" id="f-460" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-23" decimals="-3" id="f-461" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <lgnd:PaymentsForSeparation contextRef="c-1" decimals="-3" id="f-462" unitRef="usd">0</lgnd:PaymentsForSeparation>
    <lgnd:PaymentsForSeparation contextRef="c-22" decimals="-3" id="f-463" unitRef="usd">0</lgnd:PaymentsForSeparation>
    <lgnd:PaymentsForSeparation contextRef="c-23" decimals="-3" id="f-464" unitRef="usd">1840000</lgnd:PaymentsForSeparation>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-3" id="f-465" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-22" decimals="-3" id="f-466" unitRef="usd">76854000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-23" decimals="-3" id="f-467" unitRef="usd">260949000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-1" decimals="-3" id="f-468" unitRef="usd">25000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-22" decimals="-3" id="f-469" unitRef="usd">45000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c-23" decimals="-3" id="f-470" unitRef="usd">54000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities contextRef="c-1" decimals="-3" id="f-471" unitRef="usd">0</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities contextRef="c-22" decimals="-3" id="f-472" unitRef="usd">0</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities contextRef="c-23" decimals="-3" id="f-473" unitRef="usd">6800000</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-474" unitRef="usd">426000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-22" decimals="-3" id="f-475" unitRef="usd">949000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-23" decimals="-3" id="f-476" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromHedgeFinancingActivities contextRef="c-1" decimals="-3" id="f-477" unitRef="usd">0</us-gaap:ProceedsFromHedgeFinancingActivities>
    <us-gaap:ProceedsFromHedgeFinancingActivities contextRef="c-22" decimals="-3" id="f-478" unitRef="usd">0</us-gaap:ProceedsFromHedgeFinancingActivities>
    <us-gaap:ProceedsFromHedgeFinancingActivities contextRef="c-23" decimals="-3" id="f-479" unitRef="usd">202000</us-gaap:ProceedsFromHedgeFinancingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-480" unitRef="usd">65588000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-22" decimals="-3" id="f-481" unitRef="usd">22448000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-23" decimals="-3" id="f-482" unitRef="usd">3232000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-483" unitRef="usd">5136000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-22" decimals="-3" id="f-484" unitRef="usd">4547000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-23" decimals="-3" id="f-485" unitRef="usd">8236000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <lgnd:PaymentsToContingentValueRightHoldersFinancingActivity contextRef="c-1" decimals="-3" id="f-486" unitRef="usd">0</lgnd:PaymentsToContingentValueRightHoldersFinancingActivity>
    <lgnd:PaymentsToContingentValueRightHoldersFinancingActivity contextRef="c-22" decimals="-3" id="f-487" unitRef="usd">0</lgnd:PaymentsToContingentValueRightHoldersFinancingActivity>
    <lgnd:PaymentsToContingentValueRightHoldersFinancingActivity contextRef="c-23" decimals="-3" id="f-488" unitRef="usd">1545000</lgnd:PaymentsToContingentValueRightHoldersFinancingActivity>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-489" unitRef="usd">97141000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-22" decimals="-3" id="f-490" unitRef="usd">-59947000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-23" decimals="-3" id="f-491" unitRef="usd">-275990000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-492" unitRef="usd">-1171000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-22" decimals="-3" id="f-493" unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-23" decimals="-3" id="f-494" unitRef="usd">0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-495" unitRef="usd">49353000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-22" decimals="-3" id="f-496" unitRef="usd">-22052000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-23" decimals="-3" id="f-497" unitRef="usd">25484000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-498" unitRef="usd">22954000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-41" decimals="-3" id="f-499" unitRef="usd">45006000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-28" decimals="-3" id="f-500" unitRef="usd">19522000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-501" unitRef="usd">72307000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-502" unitRef="usd">22954000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-41" decimals="-3" id="f-503" unitRef="usd">45006000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-504" unitRef="usd">263000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-22" decimals="-3" id="f-505" unitRef="usd">288000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-23" decimals="-3" id="f-506" unitRef="usd">1428000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-3" id="f-507" unitRef="usd">19206000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-22" decimals="-3" id="f-508" unitRef="usd">8770000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-23" decimals="-3" id="f-509" unitRef="usd">11642000</us-gaap:IncomeTaxesPaid>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived contextRef="c-63" decimals="-3" id="f-510" unitRef="usd">8965000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived contextRef="c-64" decimals="-3" id="f-511" unitRef="usd">17887000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived contextRef="c-41" decimals="-3" id="f-512" unitRef="usd">0</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssetsAcquiredNetOfCashAndRestrictedCashReceived>
    <us-gaap:Goodwill contextRef="c-63" decimals="-3" id="f-513" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-64" decimals="-3" id="f-514" unitRef="usd">3709000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-41" decimals="-3" id="f-515" unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-63" decimals="-3" id="f-516" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-64" decimals="-3" id="f-517" unitRef="usd">10700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-41" decimals="-3" id="f-518" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets contextRef="c-63" decimals="-3" id="f-519" unitRef="usd">106156000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets contextRef="c-64" decimals="-3" id="f-520" unitRef="usd">0</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets contextRef="c-41" decimals="-3" id="f-521" unitRef="usd">0</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-63" decimals="-3" id="f-522" unitRef="usd">23125000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-64" decimals="-3" id="f-523" unitRef="usd">21891000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities contextRef="c-41" decimals="-3" id="f-524" unitRef="usd">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-65" decimals="-3" id="f-525" unitRef="usd">91996000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-66" decimals="-3" id="f-526" unitRef="usd">10405000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-23" decimals="-3" id="f-527" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <lgnd:BusinessCombinationAcquisitionCostIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-528" unitRef="usd">0</lgnd:BusinessCombinationAcquisitionCostIncurredButNotYetPaid>
    <lgnd:BusinessCombinationAcquisitionCostIncurredButNotYetPaid contextRef="c-22" decimals="-3" id="f-529" unitRef="usd">998000</lgnd:BusinessCombinationAcquisitionCostIncurredButNotYetPaid>
    <lgnd:BusinessCombinationAcquisitionCostIncurredButNotYetPaid contextRef="c-23" decimals="-3" id="f-530" unitRef="usd">0</lgnd:BusinessCombinationAcquisitionCostIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-531" unitRef="usd">1769000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-22" decimals="-3" id="f-532" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-23" decimals="-3" id="f-533" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <lgnd:AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-534" unitRef="usd">0</lgnd:AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid>
    <lgnd:AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid contextRef="c-22" decimals="-3" id="f-535" unitRef="usd">52000</lgnd:AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid>
    <lgnd:AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid contextRef="c-23" decimals="-3" id="f-536" unitRef="usd">0</lgnd:AccruedRoyaltyFromCommercialLicenseRightsIncurredButNotYetPaid>
    <lgnd:AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-537" unitRef="usd">0</lgnd:AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid>
    <lgnd:AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid contextRef="c-22" decimals="-3" id="f-538" unitRef="usd">347000</lgnd:AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid>
    <lgnd:AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid contextRef="c-23" decimals="-3" id="f-539" unitRef="usd">0</lgnd:AccruedCommercialLicenseRightsPurchasesIncurredButNotYetPaid>
    <lgnd:AccruedDebtIssuanceCostsIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-540" unitRef="usd">42000</lgnd:AccruedDebtIssuanceCostsIncurredButNotYetPaid>
    <lgnd:AccruedDebtIssuanceCostsIncurredButNotYetPaid contextRef="c-22" decimals="-3" id="f-541" unitRef="usd">41000</lgnd:AccruedDebtIssuanceCostsIncurredButNotYetPaid>
    <lgnd:AccruedDebtIssuanceCostsIncurredButNotYetPaid contextRef="c-23" decimals="-3" id="f-542" unitRef="usd">0</lgnd:AccruedDebtIssuanceCostsIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-543" unitRef="usd">71000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-22" decimals="-3" id="f-544" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-23" decimals="-3" id="f-545" unitRef="usd">2333000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-1" decimals="-3" id="f-546" unitRef="usd">45000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-22" decimals="-3" id="f-547" unitRef="usd">167000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments contextRef="c-23" decimals="-3" id="f-548" unitRef="usd">-67000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-549">Basis of Presentation and Summary of Significant Accounting Policies&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. We do this by providing financing, licensing our technologies or both.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating and one reportable segment: development and licensing of biopharmaceutical assets. The Company's Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is Todd Davis, our Chief Executive Officer. The CODM uses net income (loss) from continuing operations as a single segment profit or loss measure to evaluate our single segment performance, and in deciding whether to reinvest into the existing assets, or to new potential opportunities. Our CODM relies on internal management reporting processes that provide information on segment operating income (loss) for making financial decisions and allocating resources. CODM does not evaluate, manage or measure performance of segments using asset information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information on significant segment expenses that are regularly provided to the CODM, and other segment items included within the reported segment profit or loss measure, is presented in a table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total revenues and other income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(60,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other segment items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(34,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,841)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(99,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(103,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;* Other items for the years ended December 31, 2024, 2023, and 2022, include the amount of other general, administrative, research and development expenses of $56.7 million, $48.7 million, and $42.0 million (net of share-based compensation and depreciation expenses), respectively, and additional income and expense items that are presented in consolidated statements of operations such as financial royalty assets impairment, Fair value adjustments to partner program derivatives, cost of Captisol and other non-operating income and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to the previously issued audited consolidated financial statements to conform with the current period presentation. Specifically, within the consolidated balance sheet as of December 31, 2023, our commercial license and other economic rights line has been reclassified to long-term portion of financial royalty assets, net, and to other assets, and a portion of other investments has been reclassified from other assets. Moreover, noncurrent derivative assets as of December 31, 2023, have been reclassified from other assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, within the consolidated statements of operations for the years ended December 31, 2023 and 2022, royalties have been reclassified to revenue from intangible royalty assets, and a portion of the contract revenue has been reclassified to income from financial royalty assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the spin-off of the OmniAb Business in November 2022 in connection with the OmniAb Transactions met the criteria for classification as a discontinued operation in accordance with ASC Subtopic 205-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued Operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 205-20&#x201d;). For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (5), Spin-off of OmniAb&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. All disclosures have been adjusted to reflect continuing operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Business Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue and other income from significant partners, which is defined as 10% or more of our total revenue, was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;lt;10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;lt;10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are exposed to credit risk through our counterparties, including risks associated with royalty assets, receivables, and financial instruments such as derivatives and available-for-sale debt securities. Most of our royalty assets and receivables come from contractual agreements that generate royalties based on sales of pharmaceutical products across the United States, Europe, and other regions. This risk is primarily mitigated by the broad range of marketers responsible for paying royalties and the geographic diversity of product sales. Our royalty portfolio includes products marketed by leading biopharmaceutical &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;companies such as Amgen, Merck, Jazz, Recordati, and Sanofi. As of December&#160;31, 2024, Recordati was the largest individual marketer and payor of our financial royalty assets, representing 54% of the financial royalty asset balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We actively monitor the financial performance and creditworthiness of counterparties to our royalty agreements, derivative financial instruments, and available-for-sale debt securities to assess and respond to changes in their credit profiles. So far, we have not incurred any significant losses related to the collection of income or revenue from royalty assets, available-for-sale debt securities, or the settlement of derivative financial instruments. However, if a counterparty faces bankruptcy or financial difficulties and fails to meet its obligations under a derivative financial instrument, we could face substantial delays in recovering amounts owed during bankruptcy or reorganization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We obtain Captisol primarily from two sites related to a single supplier, Hovione.&#160;If this supplier were not able to supply the requested amounts of Captisol from each site, and if our safety stocks of material were depleted, we would be unable to continue to derive revenues from the sale of Captisol until we obtained material from an alternative source, which could take a considerable length of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments with maturities of three months or less from the date of acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments primarily consist of investments in debt and equity securities. We classify our short-term investments as &#x201c;available-for-sale&#x201d;. Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statements of comprehensive income (loss), net of tax, and unrealized gains and losses on equity securities included the consolidated statements of operations. We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and include net realized gains and losses as a component of non-operating income and expenses within the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities consist of certificates of deposit, corporate debt securities, and securities of government-sponsored entities. Debt securities have effective maturities greater than&#160;three months and less than thirty-six months from the date of acquisition. Debt securities available-for-sale in an unrealized loss position are assessed for current expected credit losses. We start by assessing whether we intend to sell the security, or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Equity securities consist of bond funds, investments in privately held companies (non-marketable equity securities), and companies that have completed initial public offerings (marketable equity securities). Bond funds are valued at their publicly quoted net asset value (&#x201c;NAV&#x201d;) price on the last day of the period. Our non-marketable equity securities without readily determinable market values are initially measured at cost and adjusted to fair value for observable transactions for identical or similar investments of the same issuer or impairment. Our marketable equity securities are measured at fair value. Equity investments are classified as short-term investments, equity method investment in Primrose Bio, or other investments, based on the nature of the securities and their availability for use in current operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information, see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Balance Sheet Account Details&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#x201d; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Credit Losses &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers. During the years ended December&#160;31, 2024, 2023 and 2022, we considered the current and expected future economic and market conditions and concluded a decrease of $0.1&#160;million, an increase of $0.2&#160;million, and a decrease of $0.3&#160;million of allowance for credit losses, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, which consists of finished goods (Captisol), is stated at the lower of cost or net realizable value. We determine cost using the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements. During the years ended December&#160;31, 2024, 2023 and 2022, we recorded an obsolete inventory charge of $0.2&#160;million, $0.2&#160;million and $1.1&#160;million, respectively. In addition to finished goods, as of December&#160;31, 2024 and 2023, inventory included prepayments of $3.1&#160;million and $4.6&#160;million, respectively, to our supplier for Captisol.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from &lt;span style="-sec-ix-hidden:f-611"&gt;one&lt;/span&gt; to nine years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information, see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Balance Sheet Account Details&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#x201d; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets and Other Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at the reporting unit level at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment at the reporting unit level during the fourth quarter of 2024, noting no impairment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset. We did not identify indicators of impairment for the finite-lived intangibles at December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information, see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Balance Sheet Account Details&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#x201d; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Royalty Assets, net (formerly known as Commercial License Rights)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial royalty assets represent a portfolio of future milestone and royalty payment rights acquired that are passive in nature (i.e., we do not own the intellectual property or have the right to commercialize the underlying products).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we account for financial royalty assets under ASC 310, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Our financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Imputation of Interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is recalculated in each reporting period as the difference between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by accrued interest income (except for assets under the non-accrual method) and decreased by cash receipts in the period to arrive at the ending balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate financial royalty assets for recoverability on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the total amount of expected undiscounted cash flows is below the amortized cost basis, we measure and record an allowance for the change in expected cash flows. This allowance is measured as the difference between the financial royalty asset&#x2019;s amortized cost basis and the net present value of the expected future cash flows, calculated using the original effective interest rate. In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance in part or in full.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the above allowance, we recognize an allowance for current expected credit losses under ASC 326, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on our financial royalty assets. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the credit loss provision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of financial royalty assets is presented net of the cumulative allowances for changes in expected future cash flows and expected credit losses. The initial amount and subsequent revisions in allowances for changes in expected future cash flows and expected credit losses are recorded as part of general and administrative expenses on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When we are reasonably certain that a part of a financial royalty asset&#x2019;s net carrying value (or all of it) is not recoverable, we recognize an impairment which is recorded in financial royalty assets impairment on the consolidated statements of operations. To the extent there was an allowance previously recorded for this asset, the amount of such impairment is written off against the allowance at the time that such a determination is made. Any future recoveries from such impairment are recognized when cash is collected in a respective period earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The current portion of financial royalty assets represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter. This portion is presented in other current assets on our consolidated balance sheets, net of the allowance for expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (6), Financial Royalty Assets, net (formerly known as Commercial License Rights)&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative assets include instruments used for risk-management purposes, and other instruments. Derivative assets which are not used for risk management purposes, include: (a) acquired rights in future milestone and royalty payments from Agenus Partnered Programs (as defined in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (2), Agenus Transaction&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), (b) Agenus Warrant (as defined &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (2), Agenus Transaction&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), (c) option to invest up to $25 million to milestone and royalty rights which expires on June 30, 2025 (&#x201c;Upsize Option&#x201d;), and (d) rights to receive from Primrose Bio 50% of milestones on two contracts previously entered into by Primordial Genetics.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June 30, 2024, we entered into a collar arrangement to hedge against the fluctuation risk in Viking's share price (the &#x201c;Viking Share Collar&#x201d;). However, because the Viking stock investment is remeasured at fair value through earnings under ASC 321, the Viking Share Collar is not eligible for hedge accounting, but is considered as an economic hedge. The Viking Share Collar was fully exercised during three month period ending December 31, 2024. During the three months ended December 31, 2024, we entered into a put arrangement to hedge against the fluctuation risk in Viking's share price (the &#x201c;Viking Share Put&#x201d;) which expired within the same quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All derivatives are measured at fair value on the consolidated balance sheets. For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (8), Fair Value Measurement&#x201d; and &#x201c;Note (7), Balance Sheet Account Details&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Method Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments that we do not consolidate but in which we have significant influence over the operating and financial policies of the investee are classified as equity method investments and are accounted for using the equity method of accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In applying the equity method of accounting, investments are initially recorded at cost and are subsequently adjusted based on our proportionate share of net income or loss of the investee, net of any distributions received from the investee and any impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information, see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (4), Sale of Pelican Business and Investment in Primrose Bio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other investments represent our investments in equity securities of third parties in which we do not have control or significant influence. Our equity securities investments do not have a readily determinable or estimable fair value and are measured using the measurement alternative, which is cost less impairment, if any, and adjustments resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. The amount of such impairment or adjustment recognized during the period is presented in other non-operating (expense) income, net in our consolidated statements of operations. For additional information, see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Balance Sheet Account Details&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&#x201d; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of CyDex in January 2011, we recorded a contingent liability for amounts potentially due to holders of the CyDex CVRs and former license holders. The liability is periodically assessed based on events and circumstances related to the underlying milestones, royalties and material sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs for each Metabasis share. The fair values of the CVRs are remeasured at each reporting date through the term of the related agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Any change in fair value is recorded in other non-operating (expense) income, net in our consolidated statements of operations. For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (8), Fair Value Measurement&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Balance Sheet Account Details&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue and Other Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, income from financial royalty assets, and contract revenue for license fees, technical, regulatory and sales-based milestone payments. Other operating income is primarily related to milestone income received for financial royalty assets that have been fully amortized or where there is no underlying asset recognized on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply the following five-step model in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Intangible Royalty Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive royalty revenue from intangible royalty assets on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than when the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted in the period in which they become known, typically the following quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Financial Royalty Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2024, we introduced a new line item &#x201c;income from financial royalty assets&#x201d;, which was included in &#x201c;contract revenue&#x201d; in prior periods. Accordingly, the prior year period amounts have been reclassified to align with the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. Income is calculated by multiplying the carrying value of the financial royalty asset by the periodic effective interest rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for financial royalty assets related to developmental pipeline or recently commercialized products on a non-accrual basis. Developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. Newly commercialized products typically do not have an established reliable sales pattern, and thus have uncertain cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Captisol Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from Captisol sales is recognized when control of Captisol material is transferred or intellectual property license rights are granted to our customers in an amount that reflects the consideration we expect to receive from our customers &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in exchange for those products or rights. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. For Captisol material or intellectual property license rights, we consider our performance obligation satisfied once we have transferred control of the product or granted the intellectual property rights, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost of freight and shipping when control over Captisol material has transferred to the customer as an expense in cost of Captisol in our consolidated statements of operations. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Revenue and Other Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with customers often include variable consideration in the form of contingent milestone payments. We include contingent milestone payments in the estimated transaction price when it is probable a significant reversal in the amount of cumulative revenue recognized will not occur. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone payment is based on sales, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some customer contracts are sublicenses which require that we make payments to an upstream licensor related to license fees, milestones and royalties which we receive from customers. In such cases, we evaluate the determination of gross revenue as a principal versus net revenue as an agent reporting based on each individual agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income is primarily related to milestone income received for financial royalty assets that have been fully amortized or where there is no underlying asset recognized on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue and certain service revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue. During the year ended December&#160;31, 2024, the amount recognized as revenue that was previously deferred at December&#160;31, 2023 was $1.3 million. During the year ended December&#160;31, 2023, the amount recognized as revenue that was previously deferred at December&#160;31, 2022 was $0.1 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties for 2024, 2023 and 2022 for continuing operations are reported as below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Kyprolis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rylaze &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Filspari&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Evomela&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Teriparatide injection &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vaxneuvance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue from intangible royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents disaggregation of Captisol and contract revenue and other income for continuing operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Captisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Captisol - Core&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Captisol - COVID&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Captisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract revenue and other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Milestone and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total contract revenue and other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Captisol - COVID represents revenue on Captisol supplied for use in formulation with remdesivir, an antiviral treatment for COVID-19.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, contract research organization (&#x201c;CRO&#x201d;) costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incur share-based compensation expense related to restricted stock, ESPP, and stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit (&#x201c;RSU&#x201d;) and performance stock unit (&#x201c;PSU&#x201d;) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment. A limited amount of PSUs contain a market condition dependent upon the Company&#x2019;s relative and absolute total stockholder return over a three-year period, with a range of 0% to 200% of the target amount granted to be issued under the award. Share-based compensation expense for these PSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the market conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock purchases under our ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatility of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income (Loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive common shares consist of shares issuable under the 2023 Notes, stock options and restricted stock. Although we paid off the 2023 Notes in May 2023, it would have a dilutive impact when the average market price of our common stock exceeded the maximum conversion price during the year ended December 31, 2023. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded. For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (11), Stockholders&#x2019; Equity&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 260, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, if a company had a discontinuing operation, the company uses income from continuing operations, adjusted for preferred dividends and similar adjustments, as its control number to determine whether potential common shares a dilutive. The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.189%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;2023 Convertible Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares used to compute diluted income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Potentially dilutive shares excluded from calculation due to anti-dilutive effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Euro is the functional currency of Apeiron and the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Translation of Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented for unrealized gains and losses on available-for-sale debt securities and foreign currency translation adjustments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Standards Updates, Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We have adopted the updated accounting guidance in our Annual Report on the Form 10-K for the year ended December&#160;31, 2024. We have updated our segment disclosure (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (1), Basis of Presentation and Summary of Significant Accounting Policies&#x201d;) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;including, among other required items, the information on significant segment expenses that are regularly provided to the CODM and included within the reported segment profit or loss measure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December 15, 2024, with early adoption permitted. We have not yet completed the assessment of the impact of ASU 2023-09 on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income (Subtopic 220-40): Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This update requires entities to disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. We are currently evaluating the new guidance to determine the impact it may have on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <lgnd:BusinessSpinOffAndMigrationPolicyTextBlock contextRef="c-1" id="f-550">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. We do this by providing financing, licensing our technologies or both.&lt;/span&gt;&lt;/div&gt;</lgnd:BusinessSpinOffAndMigrationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-551">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our consolidated financial statements have been prepared in accordance with U.S. GAAP and include the accounts of our parent company and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c-1" id="f-552">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has one operating and one reportable segment: development and licensing of biopharmaceutical assets. The Company's Chief Operating Decision Maker (&#x201c;CODM&#x201d;) is Todd Davis, our Chief Executive Officer. The CODM uses net income (loss) from continuing operations as a single segment profit or loss measure to evaluate our single segment performance, and in deciding whether to reinvest into the existing assets, or to new potential opportunities. Our CODM relies on internal management reporting processes that provide information on segment operating income (loss) for making financial decisions and allocating resources. CODM does not evaluate, manage or measure performance of segments using asset information.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-553"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-554"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-555">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The information on significant segment expenses that are regularly provided to the CODM, and other segment items included within the reported segment profit or loss measure, is presented in a table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total revenues and other income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;167,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25,743)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(60,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other segment items:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32,959)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(33,654)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(34,237)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation of property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,841)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other *&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(99,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(22,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(103,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net income (loss) from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,219)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;* Other items for the years ended December 31, 2024, 2023, and 2022, include the amount of other general, administrative, research and development expenses of $56.7 million, $48.7 million, and $42.0 million (net of share-based compensation and depreciation expenses), respectively, and additional income and expense items that are presented in consolidated statements of operations such as financial royalty assets impairment, Fair value adjustments to partner program derivatives, cost of Captisol and other non-operating income and expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-67" decimals="-3" id="f-556" unitRef="usd">167133000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-68" decimals="-3" id="f-557" unitRef="usd">131314000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-69" decimals="-3" id="f-558" unitRef="usd">196245000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ShareBasedCompensation contextRef="c-67" decimals="-3" id="f-559" unitRef="usd">41089000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-68" decimals="-3" id="f-560" unitRef="usd">25743000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-69" decimals="-3" id="f-561" unitRef="usd">60285000</us-gaap:ShareBasedCompensation>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-67" decimals="-3" id="f-562" unitRef="usd">32959000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-68" decimals="-3" id="f-563" unitRef="usd">33654000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-69" decimals="-3" id="f-564" unitRef="usd">34237000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:Depreciation contextRef="c-67" decimals="-3" id="f-565" unitRef="usd">2300000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-68" decimals="-3" id="f-566" unitRef="usd">2905000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-69" decimals="-3" id="f-567" unitRef="usd">3841000</us-gaap:Depreciation>
    <us-gaap:InterestIncomeOperating contextRef="c-67" decimals="-3" id="f-568" unitRef="usd">8055000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating contextRef="c-68" decimals="-3" id="f-569" unitRef="usd">7711000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating contextRef="c-69" decimals="-3" id="f-570" unitRef="usd">2046000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-67" decimals="-3" id="f-571" unitRef="usd">3037000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-68" decimals="-3" id="f-572" unitRef="usd">656000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c-69" decimals="-3" id="f-573" unitRef="usd">1799000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-67" decimals="-3" id="f-574" unitRef="usd">99835000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-68" decimals="-3" id="f-575" unitRef="usd">22248000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-69" decimals="-3" id="f-576" unitRef="usd">103348000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:OperatingIncomeLoss contextRef="c-67" decimals="-3" id="f-577" unitRef="usd">-4032000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-68" decimals="-3" id="f-578" unitRef="usd">53819000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-69" decimals="-3" id="f-579" unitRef="usd">-5219000</us-gaap:OperatingIncomeLoss>
    <lgnd:OtherExpenseItemsNet contextRef="c-1" decimals="-3" id="f-580" unitRef="usd">56700000</lgnd:OtherExpenseItemsNet>
    <lgnd:OtherExpenseItemsNet contextRef="c-22" decimals="-3" id="f-581" unitRef="usd">48700000</lgnd:OtherExpenseItemsNet>
    <lgnd:OtherExpenseItemsNet contextRef="c-23" decimals="-3" id="f-582" unitRef="usd">42000000.0</lgnd:OtherExpenseItemsNet>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c-1" id="f-583">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain reclassifications have been made to the previously issued audited consolidated financial statements to conform with the current period presentation. Specifically, within the consolidated balance sheet as of December 31, 2023, our commercial license and other economic rights line has been reclassified to long-term portion of financial royalty assets, net, and to other assets, and a portion of other investments has been reclassified from other assets. Moreover, noncurrent derivative assets as of December 31, 2023, have been reclassified from other assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, within the consolidated statements of operations for the years ended December 31, 2023 and 2022, royalties have been reclassified to revenue from intangible royalty assets, and a portion of the contract revenue has been reclassified to income from financial royalty assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:DiscontinuedOperationsPolicyTextBlock contextRef="c-1" id="f-584">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the spin-off of the OmniAb Business in November 2022 in connection with the OmniAb Transactions met the criteria for classification as a discontinued operation in accordance with ASC Subtopic 205-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Discontinued Operations&lt;/span&gt; (&#x201c;ASC 205-20&#x201d;).</us-gaap:DiscontinuedOperationsPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-585">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires the use of estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results may differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:BusinessCombinationsPolicy contextRef="c-1" id="f-586">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We first determine whether a set of assets acquired constitute a business and should be accounted for as a business combination. If the assets acquired are not a business, we account for the transaction as an asset acquisition. Business combinations are accounted for by using the acquisition method of accounting which requires us to use significant estimates and assumptions, especially with respect to intangible assets. We record the excess consideration over the aggregate fair value of tangible and intangible assets, net of liabilities assumed, as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the acquisition method of accounting, we recognize separately from goodwill the identifiable assets acquired, the liabilities assumed, including contingent consideration and all contractual contingencies, generally at the acquisition date fair value. Contingent purchase consideration to be settled in cash are remeasured to estimated fair value at each reporting period with the change in fair value recorded in statement of operations. Costs that we incur to complete the business combination such as investment banking, legal and other professional fees are not considered part of consideration and we charge them to general and administrative expense as they incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Should the initial accounting for a business combination be incomplete by the end of a reporting period that falls within the measurement period, we report provisional amounts in our financial statements. During the measurement period, we adjust the provisional amounts recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date that, if known, would have affected the measurement of the amounts recognized as of that date and we record those adjustments to our financial statements in the period of change, if any.&lt;/span&gt;&lt;/div&gt;Under the acquisition method of accounting for business combinations, if we identify changes to acquired deferred tax asset valuation allowances or liabilities related to uncertain tax positions during the measurement period and they relate to new information obtained about facts and circumstances that existed as of the acquisition date, those changes are considered a measurement period adjustment and we record the offset to goodwill. We record all other changes to deferred tax asset valuation allowances and liabilities related to uncertain tax positions in current period income tax expense.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-587">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Business Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents and investments. We invest excess cash principally in United States government debt securities, investment grade corporate debt securities, mutual funds and certificates of deposit. We maintain some cash and cash equivalents balances with financial institutions that are in excess of the Federal Deposit Insurance Corporation insurance limits. We have established guidelines relative to diversification and maturities that maintain safety and liquidity. These guidelines are periodically reviewed and modified to take advantage of trends in yields and interest rates.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="c-1" id="f-588">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue and other income from significant partners, which is defined as 10% or more of our total revenue, was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Partner C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;lt;10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&amp;lt;10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-70" decimals="2" id="f-589" unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-71" decimals="2" id="f-590" unitRef="number">0.33</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-72" decimals="2" id="f-591" unitRef="number">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-73" decimals="2" id="f-592" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-74" decimals="2" id="f-593" unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-75" decimals="2" id="f-594" unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-76" decimals="2" id="f-595" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-77" decimals="2" id="f-596" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-78" decimals="2" id="f-597" unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-79" decimals="2" id="f-598" unitRef="number">0.54</us-gaap:ConcentrationRiskPercentage1>
    <lgnd:CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock contextRef="c-1" id="f-599">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of highly liquid investments with maturities of three months or less from the date of acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments primarily consist of investments in debt and equity securities. We classify our short-term investments as &#x201c;available-for-sale&#x201d;. Such investments are carried at fair value, with unrealized gains and losses on debt securities included in the statements of comprehensive income (loss), net of tax, and unrealized gains and losses on equity securities included the consolidated statements of operations. We determine the cost of investments based on the specific identification method. We determine the realized gains or losses on the sale of available-for-sale securities using the specific identification method and include net realized gains and losses as a component of non-operating income and expenses within the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities consist of certificates of deposit, corporate debt securities, and securities of government-sponsored entities. Debt securities have effective maturities greater than&#160;three months and less than thirty-six months from the date of acquisition. Debt securities available-for-sale in an unrealized loss position are assessed for current expected credit losses. We start by assessing whether we intend to sell the security, or whether it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value through earnings. For debt securities available-for-sale that do not meet the aforementioned criteria, we evaluate whether the decline in fair value has resulted from credit losses or other factors. In making this assessment, we consider the extent to which fair value is less than amortized cost, any changes in interest rates, and any changes to the rating of the security by a rating agency, among other factors. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security is compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded, limited by the amount that the fair value is less than the amortized cost basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income or loss, as applicable.&lt;/span&gt;&lt;/div&gt;Equity securities consist of bond funds, investments in privately held companies (non-marketable equity securities), and companies that have completed initial public offerings (marketable equity securities). Bond funds are valued at their publicly quoted net asset value (&#x201c;NAV&#x201d;) price on the last day of the period. Our non-marketable equity securities without readily determinable market values are initially measured at cost and adjusted to fair value for observable transactions for identical or similar investments of the same issuer or impairment. Our marketable equity securities are measured at fair value. Equity investments are classified as short-term investments, equity method investment in Primrose Bio, or other investments, based on the nature of the securities and their availability for use in current operations.</lgnd:CashCashEquivalentsandShorttermInvestmentsPolicyTextBlock>
    <us-gaap:CreditLossFinancialInstrumentPolicyTextBlock contextRef="c-1" id="f-600">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable and Allowance for Credit Losses &lt;/span&gt;&lt;/div&gt;Our accounts receivable arise primarily from sales on credit to customers. We establish an allowance for credit losses to present the net amount of accounts receivable expected to be collected. The allowance is determined by using the loss-rate method, which requires an estimation of loss rates based upon historical loss experience adjusted for factors that are relevant to determining the expected collectability of accounts receivable. Some of these factors include macroeconomic conditions that correlate with historical loss experience, delinquency trends, aging behavior of receivables and credit and liquidity quality indicators for industry groups, customer classes or individual customers.</us-gaap:CreditLossFinancialInstrumentPolicyTextBlock>
    <us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease contextRef="c-1" decimals="-5" id="f-601" unitRef="usd">-100000</us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease>
    <us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease contextRef="c-22" decimals="-5" id="f-602" unitRef="usd">200000</us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease>
    <us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease contextRef="c-23" decimals="-5" id="f-603" unitRef="usd">-300000</us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-604">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;Inventory, which consists of finished goods (Captisol), is stated at the lower of cost or net realizable value. We determine cost using the specific identification method. We analyze our inventory levels periodically and write down inventory to net realizable value if it has become obsolete, has a cost basis in excess of its expected net realizable value or is in excess of expected requirements.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryWriteDown contextRef="c-1" decimals="-5" id="f-605" unitRef="usd">200000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-22" decimals="-5" id="f-606" unitRef="usd">200000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-23" decimals="-5" id="f-607" unitRef="usd">1100000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryNet contextRef="c-80" decimals="-5" id="f-608" unitRef="usd">3100000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-81" decimals="-5" id="f-609" unitRef="usd">4600000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-610">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, subject to review for impairment, and depreciated over the estimated useful lives of the assets, which generally range from &lt;span style="-sec-ix-hidden:f-611"&gt;one&lt;/span&gt; to nine years, using the straight-line method. Amortization of leasehold improvements is recorded over the shorter of the lease term or estimated useful life of the related asset. Maintenance and repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is included in operating income or expense.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information, see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Balance Sheet Account Details&lt;/span&gt;.&#x201d;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-83" id="f-612">P9Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-613">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill, Intangible Assets and Other Long-Lived Assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill, which has an indefinite useful life, represents the excess of cost over fair value of net assets acquired. Goodwill is reviewed for impairment at the reporting unit level at least annually during the fourth quarter, or more frequently if an event occurs indicating the potential for impairment. During the goodwill impairment review, we assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than the carrying amount, including goodwill. The qualitative factors include, but are not limited to, macroeconomic conditions, industry and market considerations, and the overall financial performance. If, after assessing the totality of these qualitative factors, we determine that it is not more likely than not that the fair value of our reporting unit is less than the carrying amount, then no additional assessment is deemed necessary. Otherwise, we proceed to perform the quantitative assessment. We will then evaluate goodwill for impairment by comparing the estimated fair value of the reporting unit to its carrying value, including the associated goodwill. To determine the fair value, we generally use a combination of market approach based on Ligand and comparable publicly traded companies in similar lines of businesses and the income approach based on estimated discounted future cash flows. Our cash flow assumptions consider historical and forecasted revenue, operating costs and other relevant factors. We may also elect to bypass the qualitative assessment in a period and elect to proceed to perform the quantitative assessment for the goodwill impairment test. We performed the annual assessment for goodwill impairment at the reporting unit level during the fourth quarter of 2024, noting no impairment. &lt;/span&gt;&lt;/div&gt;Our identifiable intangible assets are typically composed of acquired core technologies, licensed technologies, contractual relationships, customer relationships and trade names. The cost of identifiable intangible assets with finite lives is generally amortized on a straight-line basis over the assets&#x2019; respective estimated useful lives. We regularly perform reviews to determine if any event has occurred that may indicate that intangible assets with finite useful lives and other long-lived assets are potentially impaired. If indicators of impairment exist, an impairment test is performed to assess the recoverability of the affected assets by determining whether the carrying amount of such assets exceeds the undiscounted expected future cash flows. If the affected assets are not recoverable, we estimate the fair value of the assets and record an impairment loss if the carrying value of the assets exceeds the fair value. Factors that may indicate potential impairment include market conditions, industry and economic trends, changes in regulations, clinical success, historical and forecasted financial results, market capitalization, significant changes in the ability of a particular asset to generate positive cash flows, and the pattern of utilization of a particular asset.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <lgnd:FinancialRoyaltyAssetsPolicyTextBlock contextRef="c-1" id="f-614">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Royalty Assets, net (formerly known as Commercial License Rights)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial royalty assets represent a portfolio of future milestone and royalty payment rights acquired that are passive in nature (i.e., we do not own the intellectual property or have the right to commercialize the underlying products).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although a financial royalty asset does not have the contractual terms typical of a loan (such as contractual principal and interest), we account for financial royalty assets under ASC 310, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Our financial royalty assets are classified similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Imputation of Interest&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is recalculated in each reporting period as the difference between expected cash flows and actual cash flows are realized and as there are changes to expected future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gross carrying value of a financial royalty asset is made up of the opening balance, or net purchase price for a new financial royalty asset, which is increased by accrued interest income (except for assets under the non-accrual method) and decreased by cash receipts in the period to arrive at the ending balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate financial royalty assets for recoverability on an individual basis by comparing the effective interest rate at each reporting date to that of the prior period. If the total amount of expected undiscounted cash flows is below the amortized cost basis, we measure and record an allowance for the change in expected cash flows. This allowance is measured as the difference between the financial royalty asset&#x2019;s amortized cost basis and the net present value of the expected future cash flows, calculated using the original effective interest rate. In a subsequent period, if there is an increase in expected future cash flows, or if actual cash flows are greater than cash flows previously expected, we reduce the previously established cumulative allowance in part or in full.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the above allowance, we recognize an allowance for current expected credit losses under ASC 326, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on our financial royalty assets. The credit rating, which is primarily based on publicly available data and updated quarterly, is the primary credit quality indicator used to determine the credit loss provision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of financial royalty assets is presented net of the cumulative allowances for changes in expected future cash flows and expected credit losses. The initial amount and subsequent revisions in allowances for changes in expected future cash flows and expected credit losses are recorded as part of general and administrative expenses on the consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When we are reasonably certain that a part of a financial royalty asset&#x2019;s net carrying value (or all of it) is not recoverable, we recognize an impairment which is recorded in financial royalty assets impairment on the consolidated statements of operations. To the extent there was an allowance previously recorded for this asset, the amount of such impairment is written off against the allowance at the time that such a determination is made. Any future recoveries from such impairment are recognized when cash is collected in a respective period earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The current portion of financial royalty assets represents an estimation for current quarter royalty receipts which are collected during the subsequent quarter. This portion is presented in other current assets on our consolidated balance sheets, net of the allowance for expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (6), Financial Royalty Assets, net (formerly known as Commercial License Rights)&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</lgnd:FinancialRoyaltyAssetsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c-1" id="f-615">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative assets include instruments used for risk-management purposes, and other instruments. Derivative assets which are not used for risk management purposes, include: (a) acquired rights in future milestone and royalty payments from Agenus Partnered Programs (as defined in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (2), Agenus Transaction&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), (b) Agenus Warrant (as defined &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (2), Agenus Transaction&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), (c) option to invest up to $25 million to milestone and royalty rights which expires on June 30, 2025 (&#x201c;Upsize Option&#x201d;), and (d) rights to receive from Primrose Bio 50% of milestones on two contracts previously entered into by Primordial Genetics.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <lgnd:DerivativeInstrumentAdditionalMaximumInvestment contextRef="c-4" decimals="-6" id="f-616" unitRef="usd">25000000</lgnd:DerivativeInstrumentAdditionalMaximumInvestment>
    <lgnd:MilestoneCompensationRate contextRef="c-84" decimals="2" id="f-617" unitRef="number">0.50</lgnd:MilestoneCompensationRate>
    <lgnd:NumberOfContracts
      contextRef="c-85"
      decimals="INF"
      id="f-618"
      unitRef="contract">2</lgnd:NumberOfContracts>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="c-1" id="f-619">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Method Investment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments that we do not consolidate but in which we have significant influence over the operating and financial policies of the investee are classified as equity method investments and are accounted for using the equity method of accounting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In applying the equity method of accounting, investments are initially recorded at cost and are subsequently adjusted based on our proportionate share of net income or loss of the investee, net of any distributions received from the investee and any impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information, see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (4), Sale of Pelican Business and Investment in Primrose Bio&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;.&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsPolicy>
    <lgnd:OtherInvestmentsPolicyPolicyTextBlock contextRef="c-1" id="f-620">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Investments&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other investments represent our investments in equity securities of third parties in which we do not have control or significant influence. Our equity securities investments do not have a readily determinable or estimable fair value and are measured using the measurement alternative, which is cost less impairment, if any, and adjustments resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. The amount of such impairment or adjustment recognized during the period is presented in other non-operating (expense) income, net in our consolidated statements of operations. For additional information, see &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Balance Sheet Account Details&lt;/span&gt;.&#x201d;</lgnd:OtherInvestmentsPolicyPolicyTextBlock>
    <lgnd:NumberOfContingentValueRightsIssued contextRef="c-86" decimals="INF" id="f-621" unitRef="right">4</lgnd:NumberOfContingentValueRightsIssued>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-622">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue and Other Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our revenue is generated primarily from royalties on sales of products commercialized by our partners, Captisol material sales, income from financial royalty assets, and contract revenue for license fees, technical, regulatory and sales-based milestone payments. Other operating income is primarily related to milestone income received for financial royalty assets that have been fully amortized or where there is no underlying asset recognized on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply the following five-step model in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Intangible Royalty Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive royalty revenue from intangible royalty assets on sales by our partners of products covered by patents that we or our partners own under contractual agreements. We do not have future performance obligations under these license arrangements. We generally satisfy our obligation to grant intellectual property rights on the effective date of the contract. However, we apply the royalty recognition constraint required under the guidance for sales-based royalties which requires a royalty to be recorded no sooner than when the underlying sale occurs. Therefore, royalties on sales of products commercialized by our partners are recognized in the quarter the product is sold. Our partners generally report sales information to us on a one quarter lag. Thus, we estimate the expected royalty proceeds based on an analysis of historical experience and interim data provided by our partners including their publicly announced sales. Differences between actual and estimated royalty revenues, which have not been material, are adjusted in the period in which they become known, typically the following quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income from Financial Royalty Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2024, we introduced a new line item &#x201c;income from financial royalty assets&#x201d;, which was included in &#x201c;contract revenue&#x201d; in prior periods. Accordingly, the prior year period amounts have been reclassified to align with the current period presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize income from financial royalty assets when there is a reasonable expectation about the timing and amount of cash flows expected to be collected. Income is calculated by multiplying the carrying value of the financial royalty asset by the periodic effective interest rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for financial royalty assets related to developmental pipeline or recently commercialized products on a non-accrual basis. Developmental pipeline products are non-commercialized, non-approved products that require FDA or other regulatory approval, and thus have uncertain cash flows. Newly commercialized products typically do not have an established reliable sales pattern, and thus have uncertain cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Captisol Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from Captisol sales is recognized when control of Captisol material is transferred or intellectual property license rights are granted to our customers in an amount that reflects the consideration we expect to receive from our customers &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in exchange for those products or rights. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. For Captisol material or intellectual property license rights, we consider our performance obligation satisfied once we have transferred control of the product or granted the intellectual property rights, meaning the customer has the ability to use and obtain the benefit of the Captisol material or intellectual property license right. We recognize revenue for satisfied performance obligations only when we determine there are no uncertainties regarding payment terms or transfer of control. Sales tax and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. We have elected to recognize the cost of freight and shipping when control over Captisol material has transferred to the customer as an expense in cost of Captisol in our consolidated statements of operations. We expense incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that we would have recognized is one year or less or the amount is immaterial. We did not incur any incremental costs of obtaining a contract during the periods reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Revenue and Other Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with customers often include variable consideration in the form of contingent milestone payments. We include contingent milestone payments in the estimated transaction price when it is probable a significant reversal in the amount of cumulative revenue recognized will not occur. These estimates are based on historical experience, anticipated results and our best judgment at the time. If the contingent milestone payment is based on sales, we apply the royalty recognition constraint and record revenue when the underlying sale has taken place. Significant judgments must be made in determining the transaction price for our sales of intellectual property. Because of the risk that products in development with our partners will not reach development milestones or receive regulatory approval, we generally recognize any contingent payments that would be due to us upon the development milestone or regulatory approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some customer contracts are sublicenses which require that we make payments to an upstream licensor related to license fees, milestones and royalties which we receive from customers. In such cases, we evaluate the determination of gross revenue as a principal versus net revenue as an agent reporting based on each individual agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income is primarily related to milestone income received for financial royalty assets that have been fully amortized or where there is no underlying asset recognized on the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;Depending on the terms of the arrangement, we may also defer a portion of the consideration received if we have to satisfy a future obligation. The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (contract assets), and customer advances and deposits (contract liabilities) on the consolidated balance sheet. Except for royalty revenue and certain service revenue, we generally receive payment at the point we satisfy our obligation or soon after. Therefore, we do not generally carry a contract asset balance. Any fees billed in advance of being earned are recorded as deferred revenue.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-5" id="f-623" unitRef="usd">1300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-22" decimals="-5" id="f-624" unitRef="usd">100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-625">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalties for 2024, 2023 and 2022 for continuing operations are reported as below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Kyprolis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rylaze &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Filspari&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Evomela&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Teriparatide injection &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vaxneuvance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Revenue from intangible royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income from financial royalty assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total royalties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents disaggregation of Captisol and contract revenue and other income for continuing operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.601%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Captisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Captisol - Core&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Captisol - COVID&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(a)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Captisol&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract revenue and other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Milestone and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total contract revenue and other income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(a) Captisol - COVID represents revenue on Captisol supplied for use in formulation with remdesivir, an antiviral treatment for COVID-19.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-87" decimals="-3" id="f-626" unitRef="usd">38377000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-88" decimals="-3" id="f-627" unitRef="usd">35640000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-89" decimals="-3" id="f-628" unitRef="usd">30116000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-90" decimals="-3" id="f-629" unitRef="usd">13743000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-91" decimals="-3" id="f-630" unitRef="usd">13520000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-92" decimals="-3" id="f-631" unitRef="usd">8796000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-93" decimals="-3" id="f-632" unitRef="usd">12179000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-94" decimals="-3" id="f-633" unitRef="usd">2655000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-95" decimals="-3" id="f-634" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-96" decimals="-3" id="f-635" unitRef="usd">8680000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-3" id="f-636" unitRef="usd">10212000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-98" decimals="-3" id="f-637" unitRef="usd">10197000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-99" decimals="-3" id="f-638" unitRef="usd">8221000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-100" decimals="-3" id="f-639" unitRef="usd">11061000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-101" decimals="-3" id="f-640" unitRef="usd">15785000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-102" decimals="-3" id="f-641" unitRef="usd">5184000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-103" decimals="-3" id="f-642" unitRef="usd">4062000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-104" decimals="-3" id="f-643" unitRef="usd">1083000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-105" decimals="-3" id="f-644" unitRef="usd">8945000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-106" decimals="-3" id="f-645" unitRef="usd">6760000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-107" decimals="-3" id="f-646" unitRef="usd">6550000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-647" unitRef="usd">95329000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-648" unitRef="usd">83910000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-649" unitRef="usd">72527000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-650" unitRef="usd">13444000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-651" unitRef="usd">1049000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-652" unitRef="usd">385000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-653" unitRef="usd">108773000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-14" decimals="-3" id="f-654" unitRef="usd">84959000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-15" decimals="-3" id="f-655" unitRef="usd">72912000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-108" decimals="-3" id="f-656" unitRef="usd">30883000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-109" decimals="-3" id="f-657" unitRef="usd">28372000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-110" decimals="-3" id="f-658" unitRef="usd">16429000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-111" decimals="-3" id="f-659" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-112" decimals="-3" id="f-660" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-113" decimals="-3" id="f-661" unitRef="usd">88066000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-16" decimals="-3" id="f-662" unitRef="usd">30883000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-17" decimals="-3" id="f-663" unitRef="usd">28372000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-18" decimals="-3" id="f-664" unitRef="usd">104495000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-114" decimals="-3" id="f-665" unitRef="usd">25533000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-115" decimals="-3" id="f-666" unitRef="usd">17983000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-116" decimals="-3" id="f-667" unitRef="usd">18838000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-117" decimals="-3" id="f-668" unitRef="usd">1944000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-118" decimals="-3" id="f-669" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-119" decimals="-3" id="f-670" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-120" decimals="-3" id="f-671" unitRef="usd">27477000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-121" decimals="-3" id="f-672" unitRef="usd">17983000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-122" decimals="-3" id="f-673" unitRef="usd">18838000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-674">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;Research and development expense consists of labor, material, equipment, and allocated facilities costs of our scientific staff who are working pursuant to our collaborative agreements and other research and development projects. Also included in research and development expenses are third-party costs incurred for our research programs including in-licensing costs, contract research organization (&#x201c;CRO&#x201d;) costs and costs incurred by other research and development service vendors. We expense these costs as they are incurred. When we make payments for research and development services prior to the services being rendered, we record those amounts as prepaid assets on our consolidated balance sheet and we expense them as the services are provided.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-675">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incur share-based compensation expense related to restricted stock, ESPP, and stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock unit (&#x201c;RSU&#x201d;) and performance stock unit (&#x201c;PSU&#x201d;) are all considered restricted stock. The fair value of restricted stock is determined by the closing market price of our common stock on the date of grant. We recognize share-based compensation expense based on the fair value on a straight-line basis over the requisite service periods of the awards, taking into consideration of forfeitures as they occur. PSU generally represents a right to receive a certain number of shares of common stock based on the achievement of corporate performance goals and continued employment during the vesting period. At each reporting period, we reassess the probability of the achievement of such corporate performance goals and any expense change resulting from an adjustment in the estimated shares to be released are treated as a cumulative catch-up in the period of adjustment. A limited amount of PSUs contain a market condition dependent upon the Company&#x2019;s relative and absolute total stockholder return over a three-year period, with a range of 0% to 200% of the target amount granted to be issued under the award. Share-based compensation expense for these PSUs is measured using the Monte-Carlo simulation valuation model and is not adjusted for the achievement, or lack thereof, of the market conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Black-Scholes-Merton option-pricing model is used to estimate the fair value of stock purchases under our ESPP and stock options granted. The model assumptions include expected volatility, term, dividends, and the risk-free interest rate. We look to historical and implied volatility of our stock to determine the expected volatility. The expected term of an award is based on historical forfeiture experience, exercise activity, and on the terms and conditions of the stock awards. The expected dividend yield is determined to be 0% given that except for 2007, during which we declared a cash dividend on our common stock of $2.50 per share, we have not paid any dividends on our common stock in the past and currently do not expect to pay cash dividends or make any other distributions on common stock in the future. The risk-free interest rate is based upon U.S. Treasury securities with remaining terms similar to the expected term of the share-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We grant options, RSUs and PSUs to employees and non-employee directors. Non-employee directors are accounted for as employees. Options and RSUs granted to certain non-employee directors typically vest one year from the date of grant. Options granted to employees typically vest 1/8 on the six month anniversary of the date of grant, and 1/48 each month thereafter for forty-two months. RSUs and PSUs granted to employees vest over three years. All option awards generally expire ten years from the date of grant.&lt;/span&gt;&lt;/div&gt;Share-based compensation expense for awards to employees and non-employee directors is recognized on a straight-line basis over the vesting period until the last tranche vests.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-123" id="f-676">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-124"
      decimals="INF"
      id="f-677"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-125"
      decimals="INF"
      id="f-678"
      unitRef="number">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:EquitySecuritiesFvNiMeasurementInput contextRef="c-126" decimals="2" id="f-679" unitRef="number">0</us-gaap:EquitySecuritiesFvNiMeasurementInput>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-127"
      decimals="INF"
      id="f-680"
      unitRef="usdPerShare">2.50</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-128" id="f-681">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-129" id="f-682">P42M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-130" id="f-683">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-131" id="f-684">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-685">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes is computed using the asset and liability method, under which deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for the expected future tax benefit to be derived from tax loss and credit carryforwards. Deferred tax assets and liabilities are determined using the enacted tax rates in effect for the years in which those tax assets are expected to be realized. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the provision for income taxes in the period that includes the enactment date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets are regularly assessed to determine the likelihood they will be recovered from future taxable income. A valuation allowance is established when we believe it is more likely than not the future realization of all or some of a deferred tax asset will not be achieved. In evaluating the ability to recover deferred tax assets within the jurisdiction which they arise we consider all available positive and negative evidence. Factors reviewed include the cumulative pre-tax book income for the past three years, scheduled reversals of deferred tax liabilities, history of earnings and reliable forecasting, projections of pre-tax book income over the foreseeable future, and the impact of any feasible and prudent tax planning strategies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize the impact of a tax position in our financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Tax authorities regularly examine our returns in the jurisdictions in which we do business and we regularly assess the tax risk of our return filing positions. Due to the complexity of some of the uncertainties, the ultimate resolution may result in payments that are materially different from our current estimate of the tax liability. These differences, as well as any interest and penalties, will be reflected in the provision for income taxes in the period in which they are determined.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-686">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income (Loss) Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic income (loss) per share is calculated by dividing net income (loss) by the weighted-average number of common shares outstanding during the period. Diluted income per share is computed based on the sum of the weighted average number of common shares and potentially dilutive common shares outstanding during the period. Diluted loss per share is computed based on the sum of the weighted average number of common shares outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive common shares consist of shares issuable under the 2023 Notes, stock options and restricted stock. Although we paid off the 2023 Notes in May 2023, it would have a dilutive impact when the average market price of our common stock exceeded the maximum conversion price during the year ended December 31, 2023. It is our intent and policy to settle conversions through combination settlement, which essentially involves payment in cash equal to the principal portion and delivery of shares of common stock for the excess of the conversion value over the principal portion. Potentially dilutive common shares from stock options and restricted stock are determined using the average share price for each period under the treasury stock method. In addition, the following amounts are assumed to be used to repurchase shares: proceeds from exercise of stock options and the average amount of unrecognized compensation expense for stock options and restricted stock. In loss periods, basic net loss per share and diluted net loss per share are identical since the effect of otherwise dilutive potential common shares is anti-dilutive and therefore excluded. For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (11), Stockholders&#x2019; Equity&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with ASC 260, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Earnings per Share&lt;/span&gt;, if a company had a discontinuing operation, the company uses income from continuing operations, adjusted for preferred dividends and similar adjustments, as its control number to determine whether potential common shares a dilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-687">The following table presents the calculation of weighted average shares used to calculate basic and diluted income (loss) per share (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.189%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;2023 Convertible Senior Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares used to compute diluted income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Potentially dilutive shares excluded from calculation due to anti-dilutive effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-688" unitRef="shares">18290000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-22" decimals="-3" id="f-689" unitRef="shares">17298000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-23" decimals="-3" id="f-690" unitRef="shares">16868000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-132"
      decimals="-3"
      id="f-691"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-133"
      decimals="-3"
      id="f-692"
      unitRef="shares">85000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-134"
      decimals="-3"
      id="f-693"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-135"
      decimals="-3"
      id="f-694"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-136"
      decimals="-3"
      id="f-695"
      unitRef="shares">255000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-137"
      decimals="-3"
      id="f-696"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-138"
      decimals="-3"
      id="f-697"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-139"
      decimals="-3"
      id="f-698"
      unitRef="shares">119000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-140"
      decimals="-3"
      id="f-699"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-700" unitRef="shares">18290000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-22" decimals="-3" id="f-701" unitRef="shares">17757000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-23" decimals="-3" id="f-702" unitRef="shares">16868000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-703" unitRef="shares">1530000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-22" decimals="-3" id="f-704" unitRef="shares">4357000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-23" decimals="-3" id="f-705" unitRef="shares">6241000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-706">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Euro is the functional currency of Apeiron and the corresponding financial statements have been translated into U.S. Dollars in accordance with ASC 830-30, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Translation of Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Assets and liabilities are translated at end-of-period rates while revenues and expenses are translated at average rates in effect during the period in which the activity took &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;place. Equity is translated at historical rates and the resulting cumulative translation adjustments are included as a component of accumulated other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-707">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;Comprehensive income (loss) represents net income (loss) adjusted for the change during the periods presented for unrealized gains and losses on available-for-sale debt securities and foreign currency translation adjustments.</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-708">&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Standards Updates, Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We have adopted the updated accounting guidance in our Annual Report on the Form 10-K for the year ended December&#160;31, 2024. We have updated our segment disclosure (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (1), Basis of Presentation and Summary of Significant Accounting Policies&#x201d;) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;including, among other required items, the information on significant segment expenses that are regularly provided to the CODM and included within the reported segment profit or loss measure.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting Standards Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The update requires a public business entity to disclose, on an annual basis, a tabular rate reconciliation using both percentages and currency amounts, broken out into specified categories with certain reconciling items further broken out by nature and jurisdiction to the extent those items exceed a specified threshold. In addition, all entities are required to disclose income taxes paid, net of refunds received disaggregated by federal, state/local, and foreign and by jurisdiction if the amount is at least 5% of total income tax payments, net of refunds received. Adoption of the ASU allows for either the prospective or retrospective application of the amendment and is effective for annual periods beginning after December 15, 2024, with early adoption permitted. We have not yet completed the assessment of the impact of ASU 2023-09 on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement&#x2014;Reporting Comprehensive Income (Subtopic 220-40): Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. This update requires entities to disaggregate operating expenses into specific categories, such as salaries and wages, depreciation, and amortization, to provide enhanced transparency into the nature and function of expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. ASU 2024-03 may be applied retrospectively or prospectively. We are currently evaluating the new guidance to determine the impact it may have on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We do not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AssetAcquisitionTextBlock contextRef="c-1" id="f-711">Agenus Transaction&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 29, 2024, we closed the transactions pursuant to the $75&#160;million purchase and sale agreement (the &#x201c;Agenus Agreement&#x201d;), dated May 6, 2024, among us and Agenus Inc., &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Agenus Royalty Fund, LLC, and Agenus Holdings 2024, LLC &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(collectively, &#x201c;Agenus&#x201d;). Under the terms of the Agenus Agreement, we received (i) 18.75% of the licensed royalties and 31.875% of the future licensed milestones paid to Agenus on six-partnered oncology programs, including BMS-986442 (Bristol Myers Squibb), AGEN2373 (Gilead Sciences), INCAGN2385 and INCAGN2390 (Incyte), MK-4830 (Merck), and UGN-301 (UroGen Pharma) (collectively referred as &#x201c;Agenus Partnered Programs&#x201d;), and (ii) a synthetic 2.625% royalty on future global net sales of Agenus&#x2019; novel immuno-oncology botensilimab in combination with balstilimab (&#x201c;BOT/BAL&#x201d;) program, collectively subject to certain events which may adjust the royalty and milestone percentages paid to us. In addition, we received the option to commit an additional $25&#160;million in the same assets on a pro rata basis which expires on June 30, 2025 (&#x201c;Upsize Option&#x201d;). We have also agreed to allow Agenus to raise up to an additional $100&#160;million bringing the total syndicated purchase price up to an aggregate of $200&#160;million. As part of the Agenus Agreement, Agenus granted us security over certain assets related to the programs included in the Agenus Agreement, subject to certain customary exceptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with entry into the Agenus Agreement, Agenus issued us a 5-year warrant (&#x201c;Agenus Warrant&#x201d;) to purchase 867,052 shares of its common stock, at an exercise price equal to $17.30.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for all Agenus Partnered Programs, Agenus Warrant and Upsize Option as derivative assets. All derivatives, except for Upsize Option, were presented in noncurrent derivative assets line in our consolidated balance sheets. Agenus Partnered Programs were recognized as derivative assets under ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as they have different underlyings (milestone payments and royalties). The commercial milestones and royalties are dependent on the development milestones and the commercial milestone and royalties underlyings are not determined to be predominate. The derivative assets were recorded at fair value as of May 29, 2024, and are marked to fair value at each subsequent reporting period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Agenus Partnered Programs derivative assets is determined as a present value of expected future cash flows adjusted for the level of risk appropriate for a respective program stage. As of Agenus Transaction date, it was $21.3&#160;million. During the three months ended September 30, 2024, certain Agenus partners discontinued development of their partnered programs. These programs may be relicensed at a later date, and Ligand would retain its economic interest upon any relicense activity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Agenus Warrant is determined using a Black-Scholes model. The following assumptions were used as of May 29, 2024, and December&#160;31, 2024, respectively: expected term of 4.0 years and 3.4 years, volatility of 84% and 102%, risk-free rate of 4.7% and 4.3%, Agenus stock price of $15.03 and $2.74. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Upsize Option was determined using the binomial option pricing model under which we assessed and considered the possible upwards and downwards scenarios through the expiration date of the Upsize Option. The fair value of the Upsize Option was written down to zero as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on the Agenus Partnered Program derivative assets, Agenus Warrant, and Upsize Option, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (8), Fair Value Measurements&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We accounted for the acquired BOT/BAL rights as a financial royalty asset which is currently put under the non-accrual method as management cannot reliably estimate future cash flows from this program. The amount of BOT/BAL financial royalty asset was determined as a residual value from the $75&#160;million aggregate investment amount, less fair value of all acquired derivative assets as of May 29, 2024. For additional information on the Agenus BOT/BAL rights, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (6), Financial Royalty Assets, net (formerly known as Commercial License Rights)&#x201d;.&lt;/span&gt;&lt;/div&gt;</us-gaap:AssetAcquisitionTextBlock>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-141" decimals="-6" id="f-712" unitRef="usd">75000000</lgnd:FinancialRoyaltyAssetsNet>
    <lgnd:FinanceRoyaltyAgreementRoyaltyRate
      contextRef="c-142"
      decimals="INF"
      id="f-713"
      unitRef="number">0.1875</lgnd:FinanceRoyaltyAgreementRoyaltyRate>
    <lgnd:FinanceRoyaltyAgreementMilestoneProceedsRate
      contextRef="c-143"
      decimals="INF"
      id="f-714"
      unitRef="number">0.31875</lgnd:FinanceRoyaltyAgreementMilestoneProceedsRate>
    <lgnd:FinanceRoyaltyAgreementMilestoneProceedsRate
      contextRef="c-144"
      decimals="INF"
      id="f-715"
      unitRef="number">0.31875</lgnd:FinanceRoyaltyAgreementMilestoneProceedsRate>
    <lgnd:FinanceRoyaltyAgreementMilestoneProceedsRate
      contextRef="c-145"
      decimals="INF"
      id="f-716"
      unitRef="number">0.31875</lgnd:FinanceRoyaltyAgreementMilestoneProceedsRate>
    <lgnd:FinanceRoyaltyAgreementMilestoneProceedsRate
      contextRef="c-146"
      decimals="INF"
      id="f-717"
      unitRef="number">0.31875</lgnd:FinanceRoyaltyAgreementMilestoneProceedsRate>
    <lgnd:FinanceRoyaltyAgreementMilestoneProceedsRate
      contextRef="c-147"
      decimals="INF"
      id="f-718"
      unitRef="number">0.31875</lgnd:FinanceRoyaltyAgreementMilestoneProceedsRate>
    <lgnd:FinanceRoyaltyAgreementMilestoneProceedsRate
      contextRef="c-148"
      decimals="INF"
      id="f-719"
      unitRef="number">0.31875</lgnd:FinanceRoyaltyAgreementMilestoneProceedsRate>
    <lgnd:RoyaltyFinancingAgreementPercentageOfGlobalNetSales
      contextRef="c-149"
      decimals="INF"
      id="f-720"
      unitRef="number">0.02625</lgnd:RoyaltyFinancingAgreementPercentageOfGlobalNetSales>
    <lgnd:DerivativeInstrumentAdditionalMaximumInvestment contextRef="c-4" decimals="-6" id="f-721" unitRef="usd">25000000</lgnd:DerivativeInstrumentAdditionalMaximumInvestment>
    <lgnd:FinancialRoyaltyMaximumCapitalSourcing contextRef="c-141" decimals="-6" id="f-722" unitRef="usd">100000000</lgnd:FinancialRoyaltyMaximumCapitalSourcing>
    <lgnd:MaximumFinancingRoyaltyAsset contextRef="c-141" decimals="-6" id="f-723" unitRef="usd">200000000</lgnd:MaximumFinancingRoyaltyAsset>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c-141" id="f-724">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-141"
      decimals="INF"
      id="f-725"
      unitRef="shares">867052</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-141"
      decimals="INF"
      id="f-726"
      unitRef="usdPerShare">17.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="c-4" decimals="-5" id="f-727" unitRef="usd">21300000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c-150" decimals="1" id="f-728" unitRef="pure">4.0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c-151" decimals="1" id="f-729" unitRef="pure">3.4</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c-152" decimals="2" id="f-730" unitRef="number">0.84</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c-153" decimals="2" id="f-731" unitRef="number">1.02</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c-154" decimals="3" id="f-732" unitRef="number">0.047</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput contextRef="c-155" decimals="4" id="f-733" unitRef="number">0.043</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c-156"
      decimals="INF"
      id="f-734"
      unitRef="usdPerShare">15.03</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c-157"
      decimals="INF"
      id="f-735"
      unitRef="usdPerShare">2.74</us-gaap:DerivativeLiabilityMeasurementInput>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-141" decimals="-6" id="f-736" unitRef="usd">75000000</lgnd:FinancialRoyaltyAssetsNet>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-737">Acquisitions&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Apeiron &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2024, we acquired all the outstanding shares of Biologics AG (&#x201c;Apeiron&#x201d;), including the royalty rights to Qarziba (dinutuximab beta) for the treatment of high-risk neuroblastoma (the &#x201c;Apeiron Acquisition&#x201d;) for $100.5&#160;million base consideration. We funded the Apeiron Acquisition from our available cash on hand. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to base consideration, we would also pay Apeiron shareholders an additional consideration based on future commercial and regulatory events, including up to $28&#160;million if Qarziba royalties exceed certain predetermined thresholds by either 2030 or 2034, and pay additional earn-outs on specific future events, primarily related to Qarziba regulatory approval and commercialization in the USA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluated this acquisition in accordance with ASC 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to discern whether the assets and operations of Apeiron met the definition of a business. We accounted for this transaction as assets acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred $4.9&#160;million of transaction costs related to the Apeiron Acquisition, which were included in the amount of total purchase consideration. All assets acquired (except for contract assets) and liabilities assumed in the Apeiron Acquisition were recognized at their fair values. Contract assets acquired were recognized on a relative fair value basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract assets (financial royalty assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total fair value of net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets acquired are accounted for as financial royalty assets, similar to loans receivable and are measured at amortized cost using the prospective effective interest method described in ASC 835-30. The acquired contracts assets include Qarziba and other development phase contract assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As Qarziba is a commercial phase program, we are able to reasonably estimate future cash flows and, as such, we recognize income from Qarziba financial royalty assets starting from the Apeiron Acquisition effective date, which is calculated by multiplying the carrying value of the financial royalty asset by the periodic effective interest rate. As described in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (1), Basis of Presentation and Significant Accounting Policies&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the effective interest rate is calculated by forecasting the expected cash flows to be received over the life of the asset relative to the initial invested amount. The effective interest rate is recalculated in each reporting period as the differences between expected cash flows and actual cash flows are realized and as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;there are changes to expected future cash flows. We account for other Apeiron development phase financial royalty assets on a non-accrual basis as there is a higher level of uncertainty over the related expected cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For tax purposes this transaction is treated as a stock purchase. As a result, we will not obtain a tax stepped-up basis in Apeiron&#x2019;s underlying assets and will assume the carryover tax basis. As part of the tax purchase price accounting, deferred tax liabilities of $18.1&#160;million have been recorded to reflect the difference between the book and tax basis of the acquired assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for the earnout liabilities in the Apeiron Acquisition in accordance with ASC450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and will recognize respective liability when the contingency is resolved, and the liability becomes payable. No earnout liability is recognized as of the acquisition date or as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the Apeiron Acquisition, we have also invested $4.2&#160;million (including $0.2&#160;million transaction costs) in InvIOs Holding AG (&#x201c;InvIOs&#x201d;) common shares, a privately held spin-off of Apeiron. This investment was part of an &#x20ac;8 million (approximately $8.8&#160;million) round with other investors which would help finance the research and development of three innovative early-stage immuno-oncology assets. Apeiron has previously outlicensed these assets to InvIOs and is entitled to future royalties and milestone payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the result of this investment, we did not obtain control or significant influence in InvIOs. We determined that common stock of InvIOs did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investment at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. When fair value becomes determinable, from observable price changes in orderly transactions, our investment will be marked to fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Novan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 27, 2023, we closed the transaction to acquire certain assets of Novan, Inc. (&#x201c;Novan&#x201d;) pursuant to the agreement we entered into with Novan on July 17, 2023 for $15 million in cash (which agreement contemplated Novan filing for bankruptcy relief) and provided up to $15 million in debtor-in-possession (&#x201c;DIP&#x201d;) financing inclusive of a $3 million bridge loan funded on the same day. Novan filed for Chapter 11 reorganization on July 17, 2023. On September 27, 2023, the bankruptcy court approved our $12.2 million bid to purchase from Novan its lead product candidate berdazimer topical gel, 10.3%, all other assets related to the NITRICIL technology platform and the rights to one commercial stage asset. The remaining commercial assets of Novan will be sold to other parties. The approved $12.2 million bid was credited to the $15 million DIP financing, with the balance of $2.8 million and accrued interest repaid to us. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition was accounted for as business combination. We recorded $3.1 million of acquisition-related costs for legal, due diligence and other costs in connection with the acquisition within operating expenses in our consolidated statement of operations for the year ended December 31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have finalized purchase accounting for the Novan acquisition. The following table sets forth an allocation of the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.327%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets acquired &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for Novan, including restricted cash received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;DIP loan fees and interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None of the goodwill is deductible for tax purposes. Acquired intangible assets of $10.7&#160;million related to core technology. The fair value of the core technology was based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the licensing of the related technologies. These projected cash flows were discounted to present value using a discount rate of 29%. The fair value of the core technology is being amortized on a straight-line basis over the estimated useful life of 15 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Acquired other liabilities of $13.7&#160;million related to a royalty and milestone payments purchase agreement, entered by Novan in 2019 and assumed as part of the acquisition, which previously provided Novan $25&#160;million of funding used primarily in the clinical development of berdazimer topical gel, 10.3%. Pursuant to the purchase agreement, Novan will pay ongoing quarterly payments, calculated based on an applicable percentage per product of any upfront fees, milestone payments, royalty payments or equivalent payments received by Novan pursuant to any out-license agreement, net of any upfront fees, milestone payments, royalty payments or equivalent payments paid by Novan to third parties pursuant to any agreements under which Novan has in-licensed intellectual property with respect to such products. If Novan decides to commercialize any product on its own following regulatory approval, as opposed to commercializing through an out-license agreement or other third-party arrangement, Novan will be obligated to pay a low single digits royalty on net sales of such products. This contract liability was fair valued based on the discounted cash flow method that estimated the present value of the potential royalties, milestones, and collaboration revenue streams derived from the related programs mentioned above, by applying a discount rate of 14% (revenue risk-adjusted discount rate).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 3, 2024, we announced the creation of Pelthos Therapeutics to focus on the commercialization of innovative, safe, and efficacious therapeutic products for patients suffering from conditions with limited treatment options. ZELSUVMI (berdazimer topical gel, 10.3%), its first product, is the FDA-approved prescription medicine for the treatment of the highly transmissible molluscum contagiosum (molluscum) viral skin infection in adults and pediatric patients one year of age and older. ZELSUVMI received a Novel Drug designation from the FDA in January 2024 to treat molluscum viral skin infection. ZELSUVMI was developed using Pelthos' proprietary nitric oxide-based NITRICIL technology platform. The rights to ZELSUVMI and all assets related to the NITRICIL technology platform were acquired from Novan in September 2023 in the Novan acquisition described above.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-158" decimals="-5" id="f-738" unitRef="usd">100500000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-159" decimals="-5" id="f-739" unitRef="usd">28000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c-159" decimals="-5" id="f-740" unitRef="usd">4900000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c-1" id="f-741">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of purchase consideration was allocated to the acquisition date fair values of acquired assets and assumed liabilities as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract assets (financial royalty assets)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,740)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18,109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total fair value of net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have finalized purchase accounting for the Novan acquisition. The following table sets forth an allocation of the purchase price to the identifiable tangible and intangible assets acquired and liabilities assumed, with the excess recorded to goodwill (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.327%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets acquired &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,700)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for Novan, including restricted cash received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;DIP loan fees and interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-159" decimals="-3" id="f-742" unitRef="usd">13437000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets contextRef="c-159" decimals="-3" id="f-743" unitRef="usd">106156000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets contextRef="c-159" decimals="-3" id="f-744" unitRef="usd">8965000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="c-159" decimals="-3" id="f-745" unitRef="usd">3740000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable contextRef="c-159" decimals="-3" id="f-746" unitRef="usd">1276000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIncomeTaxPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-159" decimals="-3" id="f-747" unitRef="usd">18109000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-159" decimals="-3" id="f-748" unitRef="usd">105433000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-159" decimals="-5" id="f-749" unitRef="usd">18100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi contextRef="c-160" decimals="-5" id="f-750" unitRef="usd">4200000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <lgnd:EquityIssuanceCost contextRef="c-161" decimals="-5" id="f-751" unitRef="usd">200000</lgnd:EquityIssuanceCost>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi contextRef="c-162" decimals="-6" id="f-752" unitRef="eur">8000000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireEquitySecuritiesFvNi contextRef="c-162" decimals="-5" id="f-753" unitRef="usd">8800000</us-gaap:PaymentsToAcquireEquitySecuritiesFvNi>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-163" decimals="-5" id="f-754" unitRef="usd">15000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-163" decimals="-5" id="f-755" unitRef="usd">15000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-164" decimals="-5" id="f-756" unitRef="usd">3000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-165" decimals="-5" id="f-757" unitRef="usd">12200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <lgnd:BusinessCombinationAcquiredPercentage contextRef="c-166" decimals="3" id="f-758" unitRef="number">0.103</lgnd:BusinessCombinationAcquiredPercentage>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-165" decimals="-5" id="f-759" unitRef="usd">12200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-163" decimals="-5" id="f-760" unitRef="usd">15000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:CashAcquiredFromAcquisition contextRef="c-163" decimals="-5" id="f-761" unitRef="usd">2800000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-66" decimals="-5" id="f-762" unitRef="usd">3100000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-166" decimals="-3" id="f-763" unitRef="usd">583000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-166" decimals="-3" id="f-764" unitRef="usd">13054000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets contextRef="c-166" decimals="-3" id="f-765" unitRef="usd">3683000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets contextRef="c-166" decimals="-3" id="f-766" unitRef="usd">137000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets contextRef="c-166" decimals="-3" id="f-767" unitRef="usd">1013000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-166" decimals="-3" id="f-768" unitRef="usd">10700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill contextRef="c-166" decimals="-3" id="f-769" unitRef="usd">3709000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue contextRef="c-166" decimals="-3" id="f-770" unitRef="usd">4508000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities contextRef="c-166" decimals="-3" id="f-771" unitRef="usd">3683000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseLiabilities>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities contextRef="c-166" decimals="-3" id="f-772" unitRef="usd">13700000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-163" decimals="-3" id="f-773" unitRef="usd">10988000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <lgnd:BusinessCombinationLoanFeesAndInterest contextRef="c-163" decimals="-3" id="f-774" unitRef="usd">1162000</lgnd:BusinessCombinationLoanFeesAndInterest>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-163" decimals="-3" id="f-775" unitRef="usd">12150000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount contextRef="c-166" decimals="INF" id="f-776" unitRef="usd">0</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="c-166" decimals="-5" id="f-777" unitRef="usd">10700000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate contextRef="c-163" decimals="2" id="f-778" unitRef="number">0.29</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsDiscountRate>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-163" id="f-779">P15Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities contextRef="c-166" decimals="-5" id="f-780" unitRef="usd">13700000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherLiabilities>
    <lgnd:ContingentMilestonePurchaseAgreement contextRef="c-166" decimals="-5" id="f-781" unitRef="usd">25000000</lgnd:ContingentMilestonePurchaseAgreement>
    <lgnd:BusinessCombinationAcquiredPercentage contextRef="c-166" decimals="3" id="f-782" unitRef="number">0.103</lgnd:BusinessCombinationAcquiredPercentage>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-167" decimals="INF" id="f-783" unitRef="pure">0.14</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <lgnd:BusinessCombinationAcquiredPercentage contextRef="c-166" decimals="3" id="f-784" unitRef="number">0.103</lgnd:BusinessCombinationAcquiredPercentage>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-785">Sale of Pelican Business and Investment in Primrose Bio&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 18, 2023, we entered into a merger agreement, pursuant to which our subsidiary, Pelican Technology Holdings, Inc. (&#x201c;Pelican&#x201d;) became a wholly owned subsidiary of Primrose Bio. Primrose Bio is a private company focused on synthetic biology. Pelican has developed technology related to PET (protein expression technology) and PelicCRM197 (vaccine material), and has property and equipment, as well as leased property in San Diego, CA. As part of the transaction, we received 2,146,957 common shares, 4,278,293 preferred shares and 474,746 restricted shares of Primrose Bio. Simultaneous with the merger, we entered into a Purchase and Sale Agreement with Primrose Bio and contributed $15 million in exchange for 50% of potential development milestones and certain commercial milestones from two contracts previously entered into by Primordial Genetics. In addition, starting January 1, 2025, we will receive 25% of sales revenue of PeliCRM197 above $3 million and 35% of all PeliCRM197 licensing revenue in perpetuity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We retained contractual relationships utilizing the Pelican Expression Technology, including the commercial royalty rights to Jazz&#x2019;s Rylaze, Merck&#x2019;s Vaxneuvance and V116 vaccines, Alvogen&#x2019;s Teriparatide, Serum Institute of India&#x2019;s vaccine programs, including Pneumosil and MenFive vaccines, among others.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that the sale of Pelican meets the definition of a deconsolidation of a business. Net assets sold together with allocated goodwill and cash consideration paid were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net assets sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Allocated goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash consideration paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;47,063&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of the consideration received includes the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;49,184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill allocated to the selling business based on the relative fair value of the Pelican business and Ligand that was written off was $4.1&#160;million, resulting in a $2.1&#160;million gain on sale of Pelican recorded to income (loss) from operations for the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction costs of $1.2&#160;million were allocated to the equity method investment and equity securities based on the relative fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As described above, we will receive 25% of sales revenue of PeliCRM197 above $3.0&#160;million and 35% of all PeliCRM197 licensing revenue in perpetuity. The considerations were recognized as contingent consideration under the loss recovery model and they will be measured based on the gain contingency model under ASC 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and thus, will be recognized as the underlying contingencies are resolved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we will receive 50% of potential development milestones and certain commercial milestones from two contracts previously entered into by Primordial Genetics. The considerations were recognized as derivative assets with a fair value of $3.2&#160;million, at the disposition date, which was included in noncurrent derivative assets in our consolidated balance sheets. They are recognized as derivative assets under ASC 815, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as they have two underlyings (development and commercial milestones) and (i) the commercial milestones are dependent on the development milestones and (ii) the commercial milestone underlying is not determined to be predominate. The derivative assets are recorded at fair value as of September 18, 2023, and will be marketed to fair value at each reporting period going forward. During the year ended December&#160;31, 2024, an adjustment of $(0.1)&#160;million was recorded to market the derivative assets to fair value and was included in fair value adjustments to partner program derivatives in our consolidated statement of operations. During the year ended December&#160;31, 2023, an adjustment of $0.3&#160;million was recorded to market the derivative assets to fair value and was included in other non-operating (expense) income, net in our consolidated statement of operations. For additional information, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (8), Fair Value Measurement&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note (7), Balance Sheet Account Details&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Primrose Bio&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply the equity method to investments in common stock and to other investments in entities that have risk and reward characteristics that are substantially similar to an investment in the investee&#x2019;s common stock. Since the preferred stock and restricted share investment in Primrose Bio has a substantive liquidation preference, it is not substantially similar to the common stock investment and is therefore recorded as an equity security under ASC 321, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for our common stock investment in Primrose Bio under the equity method as we have the ability to exercise significant influence over Primrose Bio's operating and financial results. In applying the equity method, we record the investment at fair value. Our proportionate share of net loss of Primrose Bio is recorded in our consolidated statements of operations. Our equity method investment is reviewed for indicators of impairment at each reporting period and is written down to fair value if there is evidence of a loss in value that is other-than-temporary. In June 2024, Primrose Bio received an equity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;investment from an equity firm. In July 2024, Primrose Bio raised additional funds from another equity firm. As a result, we recognized an impairment loss on our equity method investment in the amount of $5.8&#160;million during the year ended December&#160;31, 2024. There was no impairment to our equity method investment during the year ended December&#160;31, 2023. Our share of the net loss of Primrose Bio for the years ended December&#160;31, 2024 and 2023 was $7.0&#160;million and $1.8&#160;million, respectively, which reduced Ligand's equity method investment accordingly. Any income or loss from our equity method investment (including the impairment) is presented in other non-operating (expense) income, net in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that the Series A preferred stock and reserve stock investments in Primrose Bio did not have a readily determinable fair value and therefore elected the measurement alternative in ASC 321 to subsequently record the investments at cost, less any impairments, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. When fair value becomes determinable, from observable price changes in orderly transactions, our investments will be marked to fair value. Our investments in Series A preferred stock and reserve stock have been reduced by $25.8&#160;million during the year ended December&#160;31, 2024 in connection with the above mentioned equity funding received by Primrose Bio in June and July 2024. There were no no observable price changes or impairment to our investments in Series A preferred stock and reserve stock during the year ended December&#160;31, 2023. Any income or loss from our investments in Series A preferred stock and reserve stock (including the impairment) is presented in other non-operating (expense) income, net in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Former President and Chief Operating Officer Matt Korenberg served as a board member of Primrose Bio beginning in the fourth quarter of 2023. His employment with Ligand concluded in October 2024, after which Lauren Hay, Vice President of Strategic Planning &amp;amp; Investment Analytics, succeeded him as a board member of Primrose Bio. &lt;/span&gt;&lt;/div&gt;Spin-off of OmniAb&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 23, 2022, we entered into the OmniAb Separation and Distribution Agreement to separate our OmniAb Business and the OmniAb Merger Agreement, pursuant to which Merger Sub would merge with and into OmniAb, with OmniAb continuing as the surviving corporation and wholly owned subsidiary of New OmniAb following the effectiveness of such merger, resulting in New OmniAb&#x2019;s acquisition of our OmniAb Business, in a Reverse Morris Trust transaction (collectively, the &#x201c;OmniAb Transactions&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After the final closing date of the OmniAb Transactions on November 1, 2022, the historical financial results of OmniAb have been reflected in our consolidated financial statements as discontinued operations under GAAP for all periods presented through the date of the OmniAb Distribution. Pursuant to the OmniAb Separation and Distribution Agreement, Ligand contributed to OmniAb cash and certain specific assets and liabilities constituting the OmniAb Business. Pursuant to the OmniAb Distribution, Ligand distributed on a pro rata basis to its stockholders as of October 26, 2022 shares of the common stock of OmniAb representing 100% of Ligand&#x2019;s interest in OmniAb. Immediately following the OmniAb Distribution, Merger Sub merged with and into OmniAb, with OmniAb continuing as the surviving company in the OmniAb Merger and as a wholly owned subsidiary of New OmniAb. The entire transaction was completed on November 1, 2022, and following the OmniAb Merger, New OmniAb is an independent, publicly traded company whose common stock trades on NASDAQ under the symbol &#x201c;OABI.&#x201d; After the OmniAb Distribution, we do not beneficially own any shares of common stock in OmniAb and no longer consolidate OmniAb into our financial results for periods ending after November 1, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Discontinued operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the OmniAb Merger, the Company determined its OmniAb Business qualified for discontinued operations accounting treatment in accordance with ASC 205-20. We recognized a $1.7 million tax provision adjustment related to deferred taxes during the year ended December 31, 2023 that was attributable to the discontinued operations. The following table summarizes revenue and expenses of the discontinued operations for the year ended December 31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating costs and expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other income (expense):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain from short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss before income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28,142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the significant non-cash items, capital expenditures of the discontinued operations, and financing activities that are included in the consolidated statements of cash flows for the year ended December 31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for acquisition, net of cash acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchase of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments to CVR Holders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments to CVR Holders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Supplemental cash flow disclosures:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases of property, plant and equipment included in accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationShareConsideration
      contextRef="c-168"
      decimals="INF"
      id="f-786"
      unitRef="shares">2146957</lgnd:DisposalGroupIncludingDiscontinuedOperationShareConsideration>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationShareConsideration
      contextRef="c-169"
      decimals="INF"
      id="f-787"
      unitRef="shares">4278293</lgnd:DisposalGroupIncludingDiscontinuedOperationShareConsideration>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationShareConsideration
      contextRef="c-170"
      decimals="INF"
      id="f-788"
      unitRef="shares">474746</lgnd:DisposalGroupIncludingDiscontinuedOperationShareConsideration>
    <lgnd:ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone contextRef="c-171" decimals="-5" id="f-789" unitRef="usd">15000000</lgnd:ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone>
    <lgnd:MilestoneCompensationRate contextRef="c-84" decimals="2" id="f-790" unitRef="number">0.50</lgnd:MilestoneCompensationRate>
    <lgnd:NumberOfContracts
      contextRef="c-85"
      decimals="INF"
      id="f-791"
      unitRef="contract">2</lgnd:NumberOfContracts>
    <lgnd:SalesContractInterestInSalesRevenue contextRef="c-172" decimals="3" id="f-792" unitRef="number">0.25</lgnd:SalesContractInterestInSalesRevenue>
    <lgnd:SalesRevenueMilestone contextRef="c-173" decimals="-5" id="f-793" unitRef="usd">3000000</lgnd:SalesRevenueMilestone>
    <lgnd:SalesContractInterestInSalesRevenue contextRef="c-174" decimals="3" id="f-794" unitRef="number">0.35</lgnd:SalesContractInterestInSalesRevenue>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock contextRef="c-1" id="f-795">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that the sale of Pelican meets the definition of a deconsolidation of a business. Net assets sold together with allocated goodwill and cash consideration paid were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(630)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(495)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net assets sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Allocated goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash consideration paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;47,063&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The following table summarizes revenue and expenses of the discontinued operations for the year ended December 31, 2022 (in thousands):&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating costs and expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating costs and expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(36,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other income (expense):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gain from short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss before income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(35,578)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28,142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the significant non-cash items, capital expenditures of the discontinued operations, and financing activities that are included in the consolidated statements of cash flows for the year ended December 31, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for acquisition, net of cash acquired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchase of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,572)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments to CVR Holders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(960)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments to CVR Holders&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Supplemental cash flow disclosures:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases of property, plant and equipment included in accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment contextRef="c-175" decimals="-3" id="f-796" unitRef="usd">8250000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets contextRef="c-175" decimals="-3" id="f-797" unitRef="usd">19895000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets contextRef="c-175" decimals="-3" id="f-798" unitRef="usd">717000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset contextRef="c-175" decimals="-3" id="f-799" unitRef="usd">8693000</lgnd:DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAsset>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset contextRef="c-175" decimals="-3" id="f-800" unitRef="usd">20000</lgnd:DisposalGroupIncludingDiscontinuedOperationFinancingLeaseRightOfUseAsset>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities contextRef="c-175" decimals="-3" id="f-801" unitRef="usd">630000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenue contextRef="c-175" decimals="-3" id="f-802" unitRef="usd">495000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredRevenue>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities contextRef="c-175" decimals="-3" id="f-803" unitRef="usd">8445000</lgnd:DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities contextRef="c-175" decimals="-3" id="f-804" unitRef="usd">74000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherLiabilities>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationNetAsset contextRef="c-175" decimals="-3" id="f-805" unitRef="usd">27931000</lgnd:DisposalGroupIncludingDiscontinuedOperationNetAsset>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1 contextRef="c-175" decimals="-3" id="f-806" unitRef="usd">4132000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <lgnd:ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone contextRef="c-175" decimals="-3" id="f-807" unitRef="usd">15000000</lgnd:ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationNetContributions contextRef="c-175" decimals="-3" id="f-808" unitRef="usd">47063000</lgnd:DisposalGroupIncludingDiscontinuedOperationNetContributions>
    <lgnd:ScheduleOfFairValueOfTheConsiderationTableTextBlock contextRef="c-1" id="f-809">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of the consideration received includes the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;49,184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lgnd:ScheduleOfFairValueOfTheConsiderationTableTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-176" decimals="-3" id="f-810" unitRef="usd">13706000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-177" decimals="-3" id="f-811" unitRef="usd">32278000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-178" decimals="-3" id="f-812" unitRef="usd">3200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration contextRef="c-175" decimals="-3" id="f-813" unitRef="usd">49184000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit contextRef="c-179" decimals="-5" id="f-814" unitRef="usd">4100000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GainLossOnSaleOfBusiness contextRef="c-179" decimals="-5" id="f-815" unitRef="usd">2100000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:BusinessExitCosts1 contextRef="c-180" decimals="-5" id="f-816" unitRef="usd">1200000</us-gaap:BusinessExitCosts1>
    <lgnd:SalesContractInterestInSalesRevenue contextRef="c-172" decimals="3" id="f-817" unitRef="number">0.25</lgnd:SalesContractInterestInSalesRevenue>
    <lgnd:SalesRevenueMilestone contextRef="c-173" decimals="-5" id="f-818" unitRef="usd">3000000</lgnd:SalesRevenueMilestone>
    <lgnd:SalesContractInterestInSalesRevenue contextRef="c-174" decimals="3" id="f-819" unitRef="number">0.35</lgnd:SalesContractInterestInSalesRevenue>
    <lgnd:MilestoneCompensationRate contextRef="c-84" decimals="2" id="f-820" unitRef="number">0.50</lgnd:MilestoneCompensationRate>
    <lgnd:NumberOfContracts
      contextRef="c-85"
      decimals="INF"
      id="f-821"
      unitRef="contract">2</lgnd:NumberOfContracts>
    <us-gaap:DerivativeAssetsNoncurrent contextRef="c-181" decimals="-5" id="f-822" unitRef="usd">3200000</us-gaap:DerivativeAssetsNoncurrent>
    <lgnd:DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag contextRef="c-1" id="f-823">consolidated balance sheets</lgnd:DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-182" decimals="-5" id="f-824" unitRef="usd">-100000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-183" decimals="-5" id="f-825" unitRef="usd">300000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-184" decimals="-5" id="f-826" unitRef="usd">5800000</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment contextRef="c-185" decimals="INF" id="f-827" unitRef="usd">0</us-gaap:EquityMethodInvestmentOtherThanTemporaryImpairment>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-184" decimals="-5" id="f-828" unitRef="usd">-7000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-185" decimals="-5" id="f-829" unitRef="usd">-1800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount contextRef="c-184" decimals="-4" id="f-830" unitRef="usd">25800000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed
      contextRef="c-186"
      decimals="INF"
      id="f-831"
      unitRef="number">1</lgnd:DisposalGroupIncludingDiscontinuedOperationPercentageOfVotingInterestsDisposed>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-187" decimals="-5" id="f-832" unitRef="usd">-1700000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-188" decimals="-3" id="f-833" unitRef="usd">1289000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-189" decimals="-3" id="f-834" unitRef="usd">25275000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="c-190" decimals="-3" id="f-835" unitRef="usd">26564000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization contextRef="c-190" decimals="-3" id="f-836" unitRef="usd">10847000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDepreciationAndAmortization>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment contextRef="c-190" decimals="-3" id="f-837" unitRef="usd">38466000</lgnd:DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopment>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense contextRef="c-190" decimals="-3" id="f-838" unitRef="usd">13383000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense contextRef="c-190" decimals="-3" id="f-839" unitRef="usd">62696000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss contextRef="c-190" decimals="-3" id="f-840" unitRef="usd">-36132000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments contextRef="c-190" decimals="-3" id="f-841" unitRef="usd">0</lgnd:DisposalGroupIncludingDiscontinuedOperationGainLossOnShortTermInvestments>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense contextRef="c-190" decimals="-3" id="f-842" unitRef="usd">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense contextRef="c-190" decimals="-3" id="f-843" unitRef="usd">554000</lgnd:DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpense>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense contextRef="c-190" decimals="-3" id="f-844" unitRef="usd">554000</lgnd:DisposalGroupIncludingDiscontinuedOperationNonoperatingIncomeExpense>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax contextRef="c-190" decimals="-3" id="f-845" unitRef="usd">-35578000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax>
    <us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation contextRef="c-190" decimals="-3" id="f-846" unitRef="usd">-7436000</us-gaap:DiscontinuedOperationTaxEffectOfDiscontinuedOperation>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity contextRef="c-190" decimals="-3" id="f-847" unitRef="usd">-28142000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration contextRef="c-190" decimals="-3" id="f-848" unitRef="usd">-554000</lgnd:DisposalGroupIncludingDiscontinuedOperationChangeInAmountOfContingentConsideration>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations contextRef="c-190" decimals="-3" id="f-849" unitRef="usd">13218000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense contextRef="c-190" decimals="-3" id="f-850" unitRef="usd">9404000</lgnd:DisposalGroupIncludingDiscontinuedOperationShareBasedPaymentArrangementExpense>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-190" decimals="-3" id="f-851" unitRef="usd">0</lgnd:DisposalGroupIncludingDiscontinuedOperationPaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:CapitalExpenditureDiscontinuedOperations contextRef="c-190" decimals="-3" id="f-852" unitRef="usd">5572000</us-gaap:CapitalExpenditureDiscontinuedOperations>
    <lgnd:PaymentsToContingentValueRightHoldersInvestingActivity contextRef="c-190" decimals="-3" id="f-853" unitRef="usd">960000</lgnd:PaymentsToContingentValueRightHoldersInvestingActivity>
    <lgnd:PaymentsToContingentValueRightHoldersFinancingActivity contextRef="c-190" decimals="-3" id="f-854" unitRef="usd">1545000</lgnd:PaymentsToContingentValueRightHoldersFinancingActivity>
    <lgnd:DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid contextRef="c-190" decimals="-3" id="f-855" unitRef="usd">2310000</lgnd:DisposalGroupIncludingDiscontinuedOperationsCapitalExpendituresIncurredButNotYetPaid>
    <lgnd:FinancialRoyaltyAssetsTextBlock contextRef="c-1" id="f-856">Financial Royalty Assets, net (formerly known as Commercial License Rights)&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, financial royalty assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross carrying value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Allowance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net carrying value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross carrying value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Allowance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net carrying value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Qarziba&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(484)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Agenus (Bot/Bal)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tolerance Therapeutics (Tzield)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ensifentrine inventors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Elutia (CorMatrix)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;InvIOs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selexis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ovid (Soticlestat)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) The amounts of allowance include accumulated allowance for changes in expected cash flows and current expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(2) The amounts include $10.0 million current portion of financial royalty assets which represents an estimation for current quarter royalty receipts that are collected during the subsequent quarter. This portion is presented in other current assets on our consolidated balance sheet as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial royalty assets represent a portfolio of future milestone and royalty payment rights acquired in the Apeiron Acquisition in July 2024, from Agenus in May 2024, Selexis, S.A. (&#x201c;Selexis&#x201d;) in April 2013 and May 2015, CorMatrix Cardiovascular, Inc. (&#x201c;CorMatrix&#x201d;) in May 2016, which was later acquired by Aziyo (Aziyo changed its corporate name to Elutia Inc. (&#x201c;Elutia&#x201d;) in September 2023) in 2017, Ovid Therapeutics Inc. (&#x201c;Ovid&#x201d;) in October 2023, Tolerance Therapeutics, Inc. (&#x201c;Tolerance Therapeutics&#x201d;) in November 2023, and from certain ensifentrine inventors in March and August 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2024, we recorded a $30.3 million impairment loss for Ovid (Soticlestat) financial royalty asset and a $0.3 million impairment loss for Selexis financial royalty asset. During the year ended December&#160;31, 2023, we recorded a $0.9 million impairment loss for Selexis financial royalty asset as a result of reduced programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Apeiron Financial Royalty Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (3), Acquisitions&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we acquired certain financial royalty assets within the Apeiron Acquisition, including Qarziba and certain InvIOs programs, recorded at $104.9 million and $1.3 million, respectively as of Apeiron Acquisition date. As Qarziba is a commercial phase program, we are able to reasonably estimate future cash flows and, as such, we recognized income from Qarziba financial royalty assets starting from the Apeiron Acquisition effective date. We accounted for InvIOs financial royalty assets using the non-accrual method until we are able to reliably estimate future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Tzield Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, we acquired Tolerance Therapeutics for $20 million in cash. Tolerance Therapeutics is a holding company, owned by the inventors of Tzield (teplizumab), and is owed a royalty of less than 1% on worldwide net sales of Tzield. Tzield is marketed by Sanofi, starting in 2023. For tax purposes this transaction was treated as a stock deal, so there is no step-up in basis and tax attributes. Therefore, during the year ended December&#160;31, 2024, a deferred tax liability (DTL) of $5.5 million was recognized on the book basis and tax basis difference and recorded to the book value of the Tolerance Therapeutics&#x2019; financial royalty asset. Due to the early stages of Tzield's commercialization, management has placed the investment on the non-accrual method until we are able to reliably estimate future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ensifentrine Inventors Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March and August 2024, we acquired future milestone and royalty rights related to ensifentrine from certain ensifentrine inventors for a total of $3.8 million and $13.6 million, respectively. On June 26, 2024, Verona Pharma plc received FDA approval for ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease (&#x201c;COPD&#x201d;). During the third quarter of 2024, Verona started commercial sales of ensifentrine (marketed as Ohtuvayre) in the U.S. Due to the early stages of Ohtuvayre's commercialization, management has placed the investment on the non-accrual method until we are able to reliably estimate future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Elutia Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2016, Ligand entered into a purchase agreement to acquire certain financial royalty assets from CorMatrix. In 2017, CorMatrix sold its marketed products to Elutia where Elutia assumed the Ligand royalty obligation. In 2017, we amended the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;terms of the royalty agreement with Elutia where we received $10 million to buydown the royalty rates on the products CorMatrix sold to Elutia (the &#x201c;CorMatrix Asset Sale&#x201d;). Per the amended agreement with Elutia, we will receive a 5% royalty, with certain annual minimum payments, on the products Elutia acquired in the CorMatrix Asset Sale and up to $10 million of milestones tied to cumulative net sales of these products. The royalty agreement will terminate on May 31, 2027. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2023, due to Elutia's nonpayment of the minimum payments under the amended royalty agreement over several quarters, we placed the Elutia asset on the non-accrual method. In January 2024, we executed an amendment to our agreement with Elutia which will allow us to reliably estimate future cash flows. As such, the Elutia asset was switched from the non-accrual method to the effective interest method during the first quarter of 2024. We further considered the current and expected future economic and market conditions, current company performance and recent payments received from Elutia. During the years ended December&#160;31, 2024 and 2023, we recorded a reduction of $5.2 million and an increase of $3.2 million, respectively, to Elutia allowance of expected credit loss. The credit loss adjustments were included in general and administrative expense in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Soticlestat Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2023, we made an investment of $30 million to acquire a 13% portion of the royalties and milestones owed to Ovid Therapeutics related to the potential approval and commercialization of soticlestat. &lt;/span&gt;&lt;/div&gt;In June 2024, Takeda announced topline results of the phase 3 clinical trial of soticlestat, narrowly missing its primary endpoint to reduce convulsive seizure frequency compared to placebo in patients with Dravet syndrome, and missing its primary endpoint to reduce major motor drop seizure frequency compared to a placebo in patients with Lennox-Gastaut syndrome. In January 2025, Takeda announced its decision to discontinue its soticlestat program. As a result, in the year ended December&#160;31, 2024, we recognized a full impairment of the soticlestat financial royalty asset.</lgnd:FinancialRoyaltyAssetsTextBlock>
    <lgnd:ScheduleOfFinancialRoyaltyAssetsTableTextBlock contextRef="c-1" id="f-857">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, financial royalty assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.605%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross carrying value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Allowance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net carrying value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross carrying value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Allowance &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net carrying value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Qarziba&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(484)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Agenus (Bot/Bal)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tolerance Therapeutics (Tzield)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ensifentrine inventors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Elutia (CorMatrix)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;InvIOs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selexis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(58)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(179)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ovid (Soticlestat)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total financial royalty assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;198,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,073)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) The amounts of allowance include accumulated allowance for changes in expected cash flows and current expected credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(2) The amounts include $10.0 million current portion of financial royalty assets which represents an estimation for current quarter royalty receipts that are collected during the subsequent quarter. This portion is presented in other current assets on our consolidated balance sheet as of December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</lgnd:ScheduleOfFinancialRoyaltyAssetsTableTextBlock>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-191" decimals="-3" id="f-858" unitRef="usd">105329000</lgnd:FinancialRoyaltyAssetsGross>
    <lgnd:FinancialRoyaltyAssetsAllowance contextRef="c-191" decimals="-3" id="f-859" unitRef="usd">484000</lgnd:FinancialRoyaltyAssetsAllowance>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-191" decimals="-3" id="f-860" unitRef="usd">104845000</lgnd:FinancialRoyaltyAssetsNet>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-192" decimals="-3" id="f-861" unitRef="usd">0</lgnd:FinancialRoyaltyAssetsGross>
    <lgnd:FinancialRoyaltyAssetsAllowance contextRef="c-192" decimals="-3" id="f-862" unitRef="usd">0</lgnd:FinancialRoyaltyAssetsAllowance>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-192" decimals="-3" id="f-863" unitRef="usd">0</lgnd:FinancialRoyaltyAssetsNet>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-193" decimals="-3" id="f-864" unitRef="usd">40815000</lgnd:FinancialRoyaltyAssetsGross>
    <lgnd:FinancialRoyaltyAssetsAllowance contextRef="c-193" decimals="-3" id="f-865" unitRef="usd">408000</lgnd:FinancialRoyaltyAssetsAllowance>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-193" decimals="-3" id="f-866" unitRef="usd">40407000</lgnd:FinancialRoyaltyAssetsNet>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-194" decimals="-3" id="f-867" unitRef="usd">0</lgnd:FinancialRoyaltyAssetsGross>
    <lgnd:FinancialRoyaltyAssetsAllowance contextRef="c-194" decimals="-3" id="f-868" unitRef="usd">0</lgnd:FinancialRoyaltyAssetsAllowance>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-194" decimals="-3" id="f-869" unitRef="usd">0</lgnd:FinancialRoyaltyAssetsNet>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-195" decimals="-3" id="f-870" unitRef="usd">25613000</lgnd:FinancialRoyaltyAssetsGross>
    <lgnd:FinancialRoyaltyAssetsAllowance contextRef="c-195" decimals="-3" id="f-871" unitRef="usd">101000</lgnd:FinancialRoyaltyAssetsAllowance>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-195" decimals="-3" id="f-872" unitRef="usd">25512000</lgnd:FinancialRoyaltyAssetsNet>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-196" decimals="-3" id="f-873" unitRef="usd">25810000</lgnd:FinancialRoyaltyAssetsGross>
    <lgnd:FinancialRoyaltyAssetsAllowance contextRef="c-196" decimals="-3" id="f-874" unitRef="usd">101000</lgnd:FinancialRoyaltyAssetsAllowance>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-196" decimals="-3" id="f-875" unitRef="usd">25709000</lgnd:FinancialRoyaltyAssetsNet>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-197" decimals="-3" id="f-876" unitRef="usd">15969000</lgnd:FinancialRoyaltyAssetsGross>
    <lgnd:FinancialRoyaltyAssetsAllowance contextRef="c-197" decimals="-3" id="f-877" unitRef="usd">157000</lgnd:FinancialRoyaltyAssetsAllowance>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-197" decimals="-3" id="f-878" unitRef="usd">15812000</lgnd:FinancialRoyaltyAssetsNet>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-198" decimals="-3" id="f-879" unitRef="usd">0</lgnd:FinancialRoyaltyAssetsGross>
    <lgnd:FinancialRoyaltyAssetsAllowance contextRef="c-198" decimals="-3" id="f-880" unitRef="usd">0</lgnd:FinancialRoyaltyAssetsAllowance>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-198" decimals="-3" id="f-881" unitRef="usd">0</lgnd:FinancialRoyaltyAssetsNet>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-199" decimals="-3" id="f-882" unitRef="usd">9418000</lgnd:FinancialRoyaltyAssetsGross>
    <lgnd:FinancialRoyaltyAssetsAllowance contextRef="c-199" decimals="-3" id="f-883" unitRef="usd">2268000</lgnd:FinancialRoyaltyAssetsAllowance>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-199" decimals="-3" id="f-884" unitRef="usd">7150000</lgnd:FinancialRoyaltyAssetsNet>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-200" decimals="-3" id="f-885" unitRef="usd">13304000</lgnd:FinancialRoyaltyAssetsGross>
    <lgnd:FinancialRoyaltyAssetsAllowance contextRef="c-200" decimals="-3" id="f-886" unitRef="usd">7490000</lgnd:FinancialRoyaltyAssetsAllowance>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-200" decimals="-3" id="f-887" unitRef="usd">5814000</lgnd:FinancialRoyaltyAssetsNet>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-201" decimals="-3" id="f-888" unitRef="usd">1238000</lgnd:FinancialRoyaltyAssetsGross>
    <lgnd:FinancialRoyaltyAssetsAllowance contextRef="c-201" decimals="-3" id="f-889" unitRef="usd">62000</lgnd:FinancialRoyaltyAssetsAllowance>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-201" decimals="-3" id="f-890" unitRef="usd">1176000</lgnd:FinancialRoyaltyAssetsNet>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-202" decimals="-3" id="f-891" unitRef="usd">0</lgnd:FinancialRoyaltyAssetsGross>
    <lgnd:FinancialRoyaltyAssetsAllowance contextRef="c-202" decimals="-3" id="f-892" unitRef="usd">0</lgnd:FinancialRoyaltyAssetsAllowance>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-202" decimals="-3" id="f-893" unitRef="usd">0</lgnd:FinancialRoyaltyAssetsNet>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-203" decimals="-3" id="f-894" unitRef="usd">205000</lgnd:FinancialRoyaltyAssetsGross>
    <lgnd:FinancialRoyaltyAssetsAllowance contextRef="c-203" decimals="-3" id="f-895" unitRef="usd">58000</lgnd:FinancialRoyaltyAssetsAllowance>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-203" decimals="-3" id="f-896" unitRef="usd">147000</lgnd:FinancialRoyaltyAssetsNet>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-204" decimals="-3" id="f-897" unitRef="usd">940000</lgnd:FinancialRoyaltyAssetsGross>
    <lgnd:FinancialRoyaltyAssetsAllowance contextRef="c-204" decimals="-3" id="f-898" unitRef="usd">179000</lgnd:FinancialRoyaltyAssetsAllowance>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-204" decimals="-3" id="f-899" unitRef="usd">761000</lgnd:FinancialRoyaltyAssetsNet>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-205" decimals="-3" id="f-900" unitRef="usd">0</lgnd:FinancialRoyaltyAssetsGross>
    <lgnd:FinancialRoyaltyAssetsAllowance contextRef="c-205" decimals="-3" id="f-901" unitRef="usd">0</lgnd:FinancialRoyaltyAssetsAllowance>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-205" decimals="-3" id="f-902" unitRef="usd">0</lgnd:FinancialRoyaltyAssetsNet>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-206" decimals="-3" id="f-903" unitRef="usd">30310000</lgnd:FinancialRoyaltyAssetsGross>
    <lgnd:FinancialRoyaltyAssetsAllowance contextRef="c-206" decimals="-3" id="f-904" unitRef="usd">303000</lgnd:FinancialRoyaltyAssetsAllowance>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-206" decimals="-3" id="f-905" unitRef="usd">30007000</lgnd:FinancialRoyaltyAssetsNet>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-5" decimals="-3" id="f-906" unitRef="usd">198587000</lgnd:FinancialRoyaltyAssetsGross>
    <lgnd:FinancialRoyaltyAssetsAllowance contextRef="c-5" decimals="-3" id="f-907" unitRef="usd">3538000</lgnd:FinancialRoyaltyAssetsAllowance>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-5" decimals="-3" id="f-908" unitRef="usd">195049000</lgnd:FinancialRoyaltyAssetsNet>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-6" decimals="-3" id="f-909" unitRef="usd">70364000</lgnd:FinancialRoyaltyAssetsGross>
    <lgnd:FinancialRoyaltyAssetsAllowance contextRef="c-6" decimals="-3" id="f-910" unitRef="usd">8073000</lgnd:FinancialRoyaltyAssetsAllowance>
    <lgnd:FinancialRoyaltyAssetsNet contextRef="c-6" decimals="-3" id="f-911" unitRef="usd">62291000</lgnd:FinancialRoyaltyAssetsNet>
    <lgnd:FinancialRoyaltyAssetsNetCurrent contextRef="c-5" decimals="-5" id="f-912" unitRef="usd">10000000.0</lgnd:FinancialRoyaltyAssetsNetCurrent>
    <lgnd:ImpairmentLossOnFinancialRoyaltyAssets contextRef="c-207" decimals="-5" id="f-913" unitRef="usd">30300000</lgnd:ImpairmentLossOnFinancialRoyaltyAssets>
    <lgnd:ImpairmentLossOnFinancialRoyaltyAssets contextRef="c-208" decimals="-5" id="f-914" unitRef="usd">300000</lgnd:ImpairmentLossOnFinancialRoyaltyAssets>
    <lgnd:ImpairmentLossOnFinancialRoyaltyAssets contextRef="c-209" decimals="-5" id="f-915" unitRef="usd">900000</lgnd:ImpairmentLossOnFinancialRoyaltyAssets>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets contextRef="c-210" decimals="-5" id="f-916" unitRef="usd">104900000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets>
    <lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets contextRef="c-211" decimals="-5" id="f-917" unitRef="usd">1300000</lgnd:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractAssets>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-212" decimals="-6" id="f-918" unitRef="usd">20000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <lgnd:ProductRoyaltyPercentage contextRef="c-213" decimals="2" id="f-919" unitRef="number">0.01</lgnd:ProductRoyaltyPercentage>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-213" decimals="-5" id="f-920" unitRef="usd">5500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-214" decimals="-5" id="f-921" unitRef="usd">3800000</lgnd:FinancialRoyaltyAssetsGross>
    <lgnd:FinancialRoyaltyAssetsGross contextRef="c-215" decimals="-5" id="f-922" unitRef="usd">13600000</lgnd:FinancialRoyaltyAssetsGross>
    <us-gaap:ProceedsFromRoyaltiesReceived contextRef="c-216" decimals="-6" id="f-923" unitRef="usd">10000000</us-gaap:ProceedsFromRoyaltiesReceived>
    <lgnd:ProductRoyaltyPercentage
      contextRef="c-217"
      decimals="INF"
      id="f-924"
      unitRef="number">0.05</lgnd:ProductRoyaltyPercentage>
    <lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones contextRef="c-218" decimals="INF" id="f-925" unitRef="usd">10000000</lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones>
    <lgnd:CommercialLicenseRightsCreditLossAdjustment contextRef="c-219" decimals="-5" id="f-926" unitRef="usd">-5200000</lgnd:CommercialLicenseRightsCreditLossAdjustment>
    <lgnd:CommercialLicenseRightsCreditLossAdjustment contextRef="c-220" decimals="-5" id="f-927" unitRef="usd">3200000</lgnd:CommercialLicenseRightsCreditLossAdjustment>
    <lgnd:ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone contextRef="c-221" decimals="-6" id="f-928" unitRef="usd">30000000</lgnd:ConsiderationPaidForAnInterestInPotentialDevelopmentMilestone>
    <lgnd:SalesContractInterestInSalesRevenue contextRef="c-221" decimals="2" id="f-929" unitRef="number">0.13</lgnd:SalesContractInterestInSalesRevenue>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-930">Balance Sheet Account Details&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-term Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.321%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of Deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Bond fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(537)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of Deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain (loss) from short-term investments on our consolidated statements of operations includes both realized and unrealized gain (loss) from our short-term investments in public equity and warrant securities, and realized gain (loss) from available-for-sale debt securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.189%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12 months or greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of Deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of Deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment policy is capital preservation and we only invested in U.S.-dollar denominated investments. We held a total of 45 securities which were in an unrealized loss position with a total of $0.03 million unrealized losses as of December&#160;31, 2024. We believe that we will collect the principal and interest due on our debt securities that have an amortized cost in excess of fair value. The unrealized losses are largely due to changes in interest rates and not to unfavorable changes in the credit quality associated with these securities that impacted our assessment on collectability of principal and interest. In July 2024, we sold certain securities before the recovery of the amortized cost basis to fund the Apeiron Acquisition. Accordingly, we wrote down the amortized cost of $0.05&#160;million during the second quarter of 2024. We do not intend to sell these securities and it is unlikely that we will be required to sell these securities before the recovery of the amortized cost basis as of December&#160;31, 2024. Accordingly, there was no credit loss recognized for the year ended December&#160;31, 2024. There was no credit losses recognized for the year ended December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Short-term Investments: Investment in Viking&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We held 1.0 million shares of Viking common stock as of December&#160;31, 2024, and we account for it as an investment in available-for-sale equity securities, which is measured at fair value, with changes in fair value recognized in net income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and December&#160;31, 2023, our investment in Viking was $40.2 million and $32.2 million, respectively, and was included in short-term investments on the consolidated balance sheets. During the year ended December&#160;31, 2024, we sold 0.7 million shares of Viking common stock and recognized a total realized gain of $60.0 million. During the year ended December&#160;31, 2023, we sold 5.0 million shares of Viking common stock and recognized a total realized gain of $44.4 million. There were no sales of Viking common stock during the year ended December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost and consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lab and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation of equipment is computed using the straight-line method over the estimated useful lives of the assets which ranges from &lt;span style="-sec-ix-hidden:f-1090"&gt;one&lt;/span&gt; to nine years. Leasehold improvements are amortized using the straight-line method over their estimated useful lives or their related lease term, whichever is shorter. Depreciation expense of $2.3 million, $2.9 million, and $3.8 million was recognized for the years ended December&#160;31, 2024, 2023, and 2022, respectively, and was included in general and administrative and research and development expenses in our consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and intangible assets, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and identifiable intangible assets consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,894)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,843)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Contractual relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;360,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;360,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(122,638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(93,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total goodwill and other identifiable intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;402,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A change in a goodwill carrying value for the year ended December 31, 2024, relates to finalization of Novan Acquisition purchase accounting in the first quarter of 2024. Amortization of finite-lived intangible assets is computed using the straight-line method over the estimated useful life of the asset of up to 20 years. Amortization expense of $33.0 million, $33.7 million, and $34.2 million were recognized for the years ended December&#160;31, 2024, 2023, and 2022, respectively. Estimated amortization expense for the years ending December&#160;31, 2025 through 2029 is $32.7 million per year. For each of the years ended December&#160;31, 2024, 2023, and 2022, there was no impairment of intangible assets with finite lives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Primrose mRNA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Agenus Partner Programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Agenus Warrant (5 years contractual term)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total noncurrent derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A change in the fair value of Agenus Partner Programs and Primrose mRNA derivative that amounted to $(15.0) million and $(0.1) million, respectively, for the year ended December&#160;31, 2024, was included in fair value adjustments to partner program derivatives in the consolidated statement of operations. A net increase in fair value of Viking Share Collar and Viking Share Put that amounted to $7.1 million for the year ended December 31, 2024, was recognized in gain from short-term investments in the consolidated statements of operations. A change in the fair value of other derivatives that amounted to $(12.1) million for the year ended December&#160;31, 2024, was recognized in other non-operating (expense) income, net in the consolidated statements of operations. We acquired the Primrose mRNA derivative on September 18, 2023 with the sale of Pelican business and investment in Primrose Bio transaction. A change in the fair value of the Primrose mRNA derivative that amounted to $0.3 million during the year ended December&#160;31, 2023 was included in the consolidated statements of operations. We did not have any other derivative instruments during the years ended December&#160;31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other investments consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities in Primrose Bio&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;InvIOs investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Neuritek warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Palvella Series C preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total other investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2024, we recognized a full impairment for our investment in Neuritek warrants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 13, 2024, Palvella Therapeutics, Inc. (&#x201c;Palvella&#x201d;) announced the completion of its previously announced merger with Pieris Pharmaceuticals, Inc. (&#x201c;Pieris&#x201d;). The combined company will operate under the name Palvella Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market on December 16, 2024, under the ticker symbol &#x201c;PVLA&#x201d;. In conjunction with the transaction, the Series C Preferred Shares we held were converted to common shares using an exchange ratio of approximately 0.3095, converting the 189,112 Series C preferred shares into 58,524 common shares. We account for the Palvella common shares as a short-term investment included in our consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Assets and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets include economic rights related to the 2023 expansion of our strategic partnership with Palvella to accelerate Phase 3 development of Qtorin rapamycin for the treatment of Microcystic Lymphatic Malformations (&#x201c;Microcystic LM&#x201d;). According to the terms of the second amendment to our development funding and royalties agreement with Palvella (the &#x201c;Palvella Second Amendment&#x201d;), Palvella received an upfront payment of $5 million from Ligand. In return for the upfront payment, among other contractual changes, the tiered royalty payable by Palvella to Ligand was increased to between 8.0% and 9.8% based on annual aggregate worldwide net sales of Qtorin rapamycin. We are not obligated to provide additional funding to Palvella for development or commercialization of Qtorin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined the economic rights related to Palvella should be characterized as a funded research and development arrangement, because the contract designated the funds usage for research and development activities, and thus we account for them in accordance with ASC 730-20, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Arrangement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. We reduce our asset as the funds are expended by Palvella. As of December&#160;31, 2024, of the $5 million upfront funding related to the Palvella Second Amendment, $1.2 million of the funding to Palvella was expended. Our CEO and director, Todd Davis, is a director of Palvella. Mr. Davis recused himself from both board's consideration of the agreement between us and Palvella, including any financial analysis, the terms of the Palvella Second Amendment and the vote to approve the Palvella Second Amendment and the related transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2024, we funded Palvella $2.5 million in exchange for a convertible note with a maturity of three years, which is included in other assets in the consolidated balance sheets. In conjunction with Pavella's merger with Pieris as discussed above, the convertible note automatically converted into Pavella common shares. The $2.6 million principal and interest converted into 184,595 shares, using a conversion price of $13.9965 per share. We account for the Palvella common shares as a short-term investment in our consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets primarily include $10.0 million current portion of financial royalty assets (disclosed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (6), Financial Royalty Assets, net (formerly known as Commercial License Rights)&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), and $4.5 million inventory (raw materials and work in process related to the manufacturing of finished goods) for the preparation of commercial supplies of ZELSUVMI by Pelthos Therapeutics, a wholly owned subsidiary of Ligand. For additional information on ZELSUVMI, see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (3), Acquisitions&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Below is a summary of the ZELSUVMI related inventory included in other current assets (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Pelthos inventory in other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalties owed to third parties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;UK value-added tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subcontractor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer deposit &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Supplier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amounts owed to former licensees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes roll-forward of contingent liabilities as of December&#160;31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.201%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.698%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.698%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.698%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.698%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cydex&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Metabasis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,513&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,198&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;683&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,681&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Novan (Pelthos) contract liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock contextRef="c-1" id="f-931">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding our investments in Viking, the following table summarizes the various investment categories at December&#160;31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.321%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of Deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,595)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Bond fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(537)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of Deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,578&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,007&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,235)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120,874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-222" decimals="-3" id="f-932" unitRef="usd">78442000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-222" decimals="-3" id="f-933" unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-222" decimals="-3" id="f-934" unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-222" decimals="-3" id="f-935" unitRef="usd">78448000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-223" decimals="-3" id="f-936" unitRef="usd">23483000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-223" decimals="-3" id="f-937" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-223" decimals="-3" id="f-938" unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-223" decimals="-3" id="f-939" unitRef="usd">23482000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-224" decimals="-3" id="f-940" unitRef="usd">22812000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-224" decimals="-3" id="f-941" unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-224" decimals="-3" id="f-942" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-224" decimals="-3" id="f-943" unitRef="usd">22820000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-225" decimals="-3" id="f-944" unitRef="usd">15496000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-225" decimals="-3" id="f-945" unitRef="usd">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-225" decimals="-3" id="f-946" unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-225" decimals="-3" id="f-947" unitRef="usd">15509000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-226" decimals="-3" id="f-948" unitRef="usd">9954000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-226" decimals="-3" id="f-949" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-226" decimals="-3" id="f-950" unitRef="usd">6595000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-226" decimals="-3" id="f-951" unitRef="usd">3359000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-5" decimals="-3" id="f-952" unitRef="usd">150187000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-5" decimals="-3" id="f-953" unitRef="usd">57000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-5" decimals="-3" id="f-954" unitRef="usd">6626000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-5" decimals="-3" id="f-955" unitRef="usd">143618000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-227" decimals="-3" id="f-956" unitRef="usd">63763000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-227" decimals="-3" id="f-957" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-227" decimals="-3" id="f-958" unitRef="usd">537000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-227" decimals="-3" id="f-959" unitRef="usd">63226000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-228" decimals="-3" id="f-960" unitRef="usd">17165000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-228" decimals="-3" id="f-961" unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-228" decimals="-3" id="f-962" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-228" decimals="-3" id="f-963" unitRef="usd">17176000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-229" decimals="-3" id="f-964" unitRef="usd">14850000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-229" decimals="-3" id="f-965" unitRef="usd">40000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-229" decimals="-3" id="f-966" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-229" decimals="-3" id="f-967" unitRef="usd">14888000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-230" decimals="-3" id="f-968" unitRef="usd">11578000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-230" decimals="-3" id="f-969" unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-230" decimals="-3" id="f-970" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-230" decimals="-3" id="f-971" unitRef="usd">11586000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-231" decimals="-3" id="f-972" unitRef="usd">6736000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-231" decimals="-3" id="f-973" unitRef="usd">18000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-231" decimals="-3" id="f-974" unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-231" decimals="-3" id="f-975" unitRef="usd">6751000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-232" decimals="-3" id="f-976" unitRef="usd">1007000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-232" decimals="-3" id="f-977" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-232" decimals="-3" id="f-978" unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-232" decimals="-3" id="f-979" unitRef="usd">1003000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-233" decimals="-3" id="f-980" unitRef="usd">5775000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-233" decimals="-3" id="f-981" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-233" decimals="-3" id="f-982" unitRef="usd">5235000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-233" decimals="-3" id="f-983" unitRef="usd">540000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-6" decimals="-3" id="f-984" unitRef="usd">120874000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-6" decimals="-3" id="f-985" unitRef="usd">79000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-6" decimals="-3" id="f-986" unitRef="usd">5783000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-6" decimals="-3" id="f-987" unitRef="usd">115170000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-988">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities by contractual maturity (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Within one year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;127,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;After one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;140,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c-5" decimals="-3" id="f-989" unitRef="usd">127296000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-5" decimals="-3" id="f-990" unitRef="usd">127331000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="c-5" decimals="-3" id="f-991" unitRef="usd">12937000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-5" decimals="-3" id="f-992" unitRef="usd">12928000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis contextRef="c-5" decimals="-3" id="f-993" unitRef="usd">140233000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate contextRef="c-5" decimals="-3" id="f-994" unitRef="usd">140259000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock contextRef="c-1" id="f-995">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our available-for-sale debt securities in an unrealized loss position (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.291%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.189%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less than 12 months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;12 months or greater&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of Deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,965&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificates of Deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate notes/bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-224" decimals="-3" id="f-996" unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-224" decimals="-3" id="f-997" unitRef="usd">6195000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-224" decimals="-3" id="f-998" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-224" decimals="-3" id="f-999" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-224" decimals="-3" id="f-1000" unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-224" decimals="-3" id="f-1001" unitRef="usd">6195000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-225" decimals="-3" id="f-1002" unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-225" decimals="-3" id="f-1003" unitRef="usd">866000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-225" decimals="-3" id="f-1004" unitRef="usd">7000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-225" decimals="-3" id="f-1005" unitRef="usd">3026000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-225" decimals="-3" id="f-1006" unitRef="usd">8000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-225" decimals="-3" id="f-1007" unitRef="usd">3892000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-223" decimals="-3" id="f-1008" unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-223" decimals="-3" id="f-1009" unitRef="usd">9344000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-223" decimals="-3" id="f-1010" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-223" decimals="-3" id="f-1011" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-223" decimals="-3" id="f-1012" unitRef="usd">6000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-223" decimals="-3" id="f-1013" unitRef="usd">9344000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-222" decimals="-3" id="f-1014" unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-222" decimals="-3" id="f-1015" unitRef="usd">29965000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-222" decimals="-3" id="f-1016" unitRef="usd">9000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-222" decimals="-3" id="f-1017" unitRef="usd">4764000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-222" decimals="-3" id="f-1018" unitRef="usd">13000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-222" decimals="-3" id="f-1019" unitRef="usd">34729000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-5" decimals="-3" id="f-1020" unitRef="usd">15000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-5" decimals="-3" id="f-1021" unitRef="usd">46370000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-5" decimals="-3" id="f-1022" unitRef="usd">16000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-5" decimals="-3" id="f-1023" unitRef="usd">7790000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-5" decimals="-3" id="f-1024" unitRef="usd">31000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-5" decimals="-3" id="f-1025" unitRef="usd">54160000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-228" decimals="-3" id="f-1026" unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-228" decimals="-3" id="f-1027" unitRef="usd">4175000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-228" decimals="-3" id="f-1028" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-228" decimals="-3" id="f-1029" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-228" decimals="-3" id="f-1030" unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-228" decimals="-3" id="f-1031" unitRef="usd">4175000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-229" decimals="-3" id="f-1032" unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-229" decimals="-3" id="f-1033" unitRef="usd">1410000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-229" decimals="-3" id="f-1034" unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-229" decimals="-3" id="f-1035" unitRef="usd">1447000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-229" decimals="-3" id="f-1036" unitRef="usd">2000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-229" decimals="-3" id="f-1037" unitRef="usd">2857000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-230" decimals="-3" id="f-1038" unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-230" decimals="-3" id="f-1039" unitRef="usd">10222000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-230" decimals="-3" id="f-1040" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-230" decimals="-3" id="f-1041" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-230" decimals="-3" id="f-1042" unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-230" decimals="-3" id="f-1043" unitRef="usd">10222000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-232" decimals="-3" id="f-1044" unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-232" decimals="-3" id="f-1045" unitRef="usd">1004000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-232" decimals="-3" id="f-1046" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-232" decimals="-3" id="f-1047" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-232" decimals="-3" id="f-1048" unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-232" decimals="-3" id="f-1049" unitRef="usd">1004000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-231" decimals="-3" id="f-1050" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-231" decimals="-3" id="f-1051" unitRef="usd">998000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-231" decimals="-3" id="f-1052" unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-231" decimals="-3" id="f-1053" unitRef="usd">1502000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-231" decimals="-3" id="f-1054" unitRef="usd">3000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-231" decimals="-3" id="f-1055" unitRef="usd">2500000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss contextRef="c-6" decimals="-3" id="f-1056" unitRef="usd">10000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months contextRef="c-6" decimals="-3" id="f-1057" unitRef="usd">17809000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss contextRef="c-6" decimals="-3" id="f-1058" unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="c-6" decimals="-3" id="f-1059" unitRef="usd">2949000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-6" decimals="-3" id="f-1060" unitRef="usd">14000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition contextRef="c-6" decimals="-3" id="f-1061" unitRef="usd">20758000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="c-5"
      decimals="INF"
      id="f-1062"
      unitRef="position">45</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss contextRef="c-5" decimals="-4" id="f-1063" unitRef="usd">30000.00</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <lgnd:DebtSecuritiesAvailableForSaleAmortization contextRef="c-234" decimals="-4" id="f-1064" unitRef="usd">50000.00</lgnd:DebtSecuritiesAvailableForSaleAmortization>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff contextRef="c-1" decimals="INF" id="f-1065" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff contextRef="c-22" decimals="INF" id="f-1066" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff>
    <us-gaap:CommonStockValueOutstanding contextRef="c-235" decimals="-5" id="f-1067" unitRef="usd">1000000.0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-5" decimals="-5" id="f-1068" unitRef="usd">40200000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-6" decimals="-5" id="f-1069" unitRef="usd">32200000</us-gaap:EquitySecuritiesFvNi>
    <lgnd:NumberOfSharesSoldOfEquityMethodInvestee
      contextRef="c-236"
      decimals="-5"
      id="f-1070"
      unitRef="shares">700000</lgnd:NumberOfSharesSoldOfEquityMethodInvestee>
    <us-gaap:GainLossOnInvestments contextRef="c-236" decimals="-5" id="f-1071" unitRef="usd">60000000.0</us-gaap:GainLossOnInvestments>
    <lgnd:NumberOfSharesSoldOfEquityMethodInvestee
      contextRef="c-237"
      decimals="-5"
      id="f-1072"
      unitRef="shares">5000000.0</lgnd:NumberOfSharesSoldOfEquityMethodInvestee>
    <us-gaap:GainLossOnInvestments contextRef="c-237" decimals="-5" id="f-1073" unitRef="usd">44400000</us-gaap:GainLossOnInvestments>
    <lgnd:NumberOfSharesSoldOfEquityMethodInvestee
      contextRef="c-238"
      decimals="-5"
      id="f-1074"
      unitRef="shares">0</lgnd:NumberOfSharesSoldOfEquityMethodInvestee>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-1075">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost and consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lab and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-239" decimals="-3" id="f-1076" unitRef="usd">6868000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-240" decimals="-3" id="f-1077" unitRef="usd">7068000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-241" decimals="-3" id="f-1078" unitRef="usd">10464000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-242" decimals="-3" id="f-1079" unitRef="usd">10363000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-243" decimals="-3" id="f-1080" unitRef="usd">1850000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-244" decimals="-3" id="f-1081" unitRef="usd">716000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-245" decimals="-3" id="f-1082" unitRef="usd">4219000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-246" decimals="-3" id="f-1083" unitRef="usd">4115000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-3" id="f-1084" unitRef="usd">23401000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-6" decimals="-3" id="f-1085" unitRef="usd">22262000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-1086" unitRef="usd">8268000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-1087" unitRef="usd">6655000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-1088" unitRef="usd">15133000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-1089" unitRef="usd">15607000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-83" id="f-1091">P9Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-1092" unitRef="usd">2300000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-22" decimals="-5" id="f-1093" unitRef="usd">2900000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-23" decimals="-5" id="f-1094" unitRef="usd">3800000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="c-1" id="f-1095">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill and identifiable intangible assets consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Definite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,894)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,843)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,710)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,652)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Contractual relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;360,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;360,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(122,638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(93,782)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total goodwill and other identifiable intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;402,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-1096" unitRef="usd">105250000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-6" decimals="-3" id="f-1097" unitRef="usd">103370000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-247" decimals="-3" id="f-1098" unitRef="usd">39249000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-248" decimals="-3" id="f-1099" unitRef="usd">42911000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-247" decimals="-3" id="f-1100" unitRef="usd">19710000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-248" decimals="-3" id="f-1101" unitRef="usd">20894000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-249" decimals="-3" id="f-1102" unitRef="usd">2642000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-250" decimals="-3" id="f-1103" unitRef="usd">2642000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-249" decimals="-3" id="f-1104" unitRef="usd">1843000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-250" decimals="-3" id="f-1105" unitRef="usd">1710000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-251" decimals="-3" id="f-1106" unitRef="usd">29600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-252" decimals="-3" id="f-1107" unitRef="usd">29600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-251" decimals="-3" id="f-1108" unitRef="usd">20652000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-252" decimals="-3" id="f-1109" unitRef="usd">19161000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-253" decimals="-3" id="f-1110" unitRef="usd">360000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-254" decimals="-3" id="f-1111" unitRef="usd">360000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-253" decimals="-3" id="f-1112" unitRef="usd">122638000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-254" decimals="-3" id="f-1113" unitRef="usd">93782000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="c-5" decimals="-3" id="f-1114" unitRef="usd">371898000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="c-6" decimals="-3" id="f-1115" unitRef="usd">402976000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-83" id="f-1116">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-1" decimals="-5" id="f-1117" unitRef="usd">33000000.0</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-22" decimals="-5" id="f-1118" unitRef="usd">33700000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization contextRef="c-23" decimals="-5" id="f-1119" unitRef="usd">34200000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-5" decimals="-5" id="f-1120" unitRef="usd">32700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-5" decimals="-5" id="f-1121" unitRef="usd">32700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-5" decimals="-5" id="f-1122" unitRef="usd">32700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-5" decimals="-5" id="f-1123" unitRef="usd">32700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-5" decimals="-5" id="f-1124" unitRef="usd">32700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-22" decimals="INF" id="f-1125" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-1" decimals="INF" id="f-1126" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-23" decimals="INF" id="f-1127" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock contextRef="c-1" id="f-1128">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative assets consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Primrose mRNA&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Agenus Partner Programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Agenus Warrant (5 years contractual term)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total noncurrent derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock>
    <us-gaap:DerivativeAssetsNoncurrent contextRef="c-255" decimals="-3" id="f-1129" unitRef="usd">3451000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent contextRef="c-256" decimals="-3" id="f-1130" unitRef="usd">3531000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent contextRef="c-257" decimals="-3" id="f-1131" unitRef="usd">6326000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent contextRef="c-258" decimals="-3" id="f-1132" unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeTermOfContract contextRef="c-259" id="f-1133">P5Y</us-gaap:DerivativeTermOfContract>
    <us-gaap:DerivativeAssetsNoncurrent contextRef="c-260" decimals="-3" id="f-1134" unitRef="usd">806000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent contextRef="c-261" decimals="-3" id="f-1135" unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-1136" unitRef="usd">10583000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent contextRef="c-6" decimals="-3" id="f-1137" unitRef="usd">3531000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c-262" decimals="-5" id="f-1138" unitRef="usd">-15000000.0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c-263" decimals="-5" id="f-1139" unitRef="usd">-100000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c-264" decimals="-5" id="f-1140" unitRef="usd">7100000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c-265" decimals="-5" id="f-1141" unitRef="usd">-12100000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet contextRef="c-266" decimals="-5" id="f-1142" unitRef="usd">300000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:SummaryInvestmentHoldingsTextBlock contextRef="c-1" id="f-1143">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other investments consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity securities in Primrose Bio&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;InvIOs investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Neuritek warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Palvella Series C preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total other investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryInvestmentHoldingsTextBlock>
    <us-gaap:OtherInvestments contextRef="c-267" decimals="-3" id="f-1144" unitRef="usd">6712000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c-268" decimals="-3" id="f-1145" unitRef="usd">32726000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c-269" decimals="-3" id="f-1146" unitRef="usd">4196000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c-270" decimals="-3" id="f-1147" unitRef="usd">0</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c-271" decimals="-3" id="f-1148" unitRef="usd">0</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c-272" decimals="-3" id="f-1149" unitRef="usd">3000000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c-273" decimals="-3" id="f-1150" unitRef="usd">0</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c-274" decimals="-3" id="f-1151" unitRef="usd">1000000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c-275" decimals="-3" id="f-1152" unitRef="usd">10908000</us-gaap:OtherInvestments>
    <us-gaap:OtherInvestments contextRef="c-6" decimals="-3" id="f-1153" unitRef="usd">36726000</us-gaap:OtherInvestments>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="c-276"
      decimals="4"
      id="f-1154"
      unitRef="number">0.3095</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c-276"
      decimals="INF"
      id="f-1155"
      unitRef="shares">189112</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="c-277"
      decimals="INF"
      id="f-1156"
      unitRef="shares">58524</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones contextRef="c-278" decimals="-6" id="f-1157" unitRef="usd">5000000</lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones>
    <lgnd:SalesContractInterestInSalesRevenue
      contextRef="c-279"
      decimals="3"
      id="f-1158"
      unitRef="number">0.080</lgnd:SalesContractInterestInSalesRevenue>
    <lgnd:SalesContractInterestInSalesRevenue
      contextRef="c-280"
      decimals="3"
      id="f-1159"
      unitRef="number">0.098</lgnd:SalesContractInterestInSalesRevenue>
    <lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones contextRef="c-278" decimals="-6" id="f-1160" unitRef="usd">5000000</lgnd:AdditionalRoyaltiesReceivableUnderSalesbasedMilestones>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-281" decimals="-5" id="f-1161" unitRef="usd">1200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:AccountsReceivableNetNoncurrent contextRef="c-282" decimals="-5" id="f-1162" unitRef="usd">2500000</us-gaap:AccountsReceivableNetNoncurrent>
    <lgnd:AccountsReceivableTerm contextRef="c-282" id="f-1163">P3Y</lgnd:AccountsReceivableTerm>
    <lgnd:AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount contextRef="c-283" decimals="-5" id="f-1164" unitRef="usd">2600000</lgnd:AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentAmount>
    <lgnd:AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued
      contextRef="c-283"
      decimals="INF"
      id="f-1165"
      unitRef="shares">184595</lgnd:AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentSharesIssued>
    <lgnd:AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice
      contextRef="c-284"
      decimals="4"
      id="f-1166"
      unitRef="usdPerShare">13.9965</lgnd:AccountsReceivableAfterAllowanceForCreditLossConvertedInstrumentConversionPrice>
    <lgnd:FinancialRoyaltyAssetsNetCurrent contextRef="c-5" decimals="-5" id="f-1167" unitRef="usd">10000000.0</lgnd:FinancialRoyaltyAssetsNetCurrent>
    <us-gaap:InventoryNet contextRef="c-285" decimals="-5" id="f-1168" unitRef="usd">4500000</us-gaap:InventoryNet>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-1169">Below is a summary of the ZELSUVMI related inventory included in other current assets (in thousands):&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total Pelthos inventory in other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-285" decimals="-3" id="f-1170" unitRef="usd">3923000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-286" decimals="-3" id="f-1171" unitRef="usd">195000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-285" decimals="-3" id="f-1172" unitRef="usd">603000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-286" decimals="-3" id="f-1173" unitRef="usd">420000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-285" decimals="-3" id="f-1174" unitRef="usd">4526000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-286" decimals="-3" id="f-1175" unitRef="usd">615000</us-gaap:InventoryNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-1176">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalties owed to third parties&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;UK value-added tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subcontractor&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Customer deposit &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Supplier&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amounts owed to former licensees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-5" decimals="-3" id="f-1177" unitRef="usd">6500000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c-6" decimals="-3" id="f-1178" unitRef="usd">900000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-1179" unitRef="usd">5522000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-1180" unitRef="usd">4682000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <lgnd:ValueAddedTaxReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-1181" unitRef="usd">-5159000</lgnd:ValueAddedTaxReceivableNetCurrent>
    <lgnd:ValueAddedTaxReceivableNetCurrent contextRef="c-6" decimals="-3" id="f-1182" unitRef="usd">0</lgnd:ValueAddedTaxReceivableNetCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-5" decimals="-3" id="f-1183" unitRef="usd">4858000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-6" decimals="-3" id="f-1184" unitRef="usd">2394000</us-gaap:AccruedProfessionalFeesCurrent>
    <lgnd:AccruedSubcontractorExpensesCurrent contextRef="c-5" decimals="-3" id="f-1185" unitRef="usd">1756000</lgnd:AccruedSubcontractorExpensesCurrent>
    <lgnd:AccruedSubcontractorExpensesCurrent contextRef="c-6" decimals="-3" id="f-1186" unitRef="usd">1756000</lgnd:AccruedSubcontractorExpensesCurrent>
    <lgnd:AccruedCustomerDepositsCurrent contextRef="c-5" decimals="-3" id="f-1187" unitRef="usd">621000</lgnd:AccruedCustomerDepositsCurrent>
    <lgnd:AccruedCustomerDepositsCurrent contextRef="c-6" decimals="-3" id="f-1188" unitRef="usd">621000</lgnd:AccruedCustomerDepositsCurrent>
    <lgnd:AccruedSupplierExpensesCurrent contextRef="c-5" decimals="-3" id="f-1189" unitRef="usd">0</lgnd:AccruedSupplierExpensesCurrent>
    <lgnd:AccruedSupplierExpensesCurrent contextRef="c-6" decimals="-3" id="f-1190" unitRef="usd">303000</lgnd:AccruedSupplierExpensesCurrent>
    <lgnd:LicenseeAccrualCurrent contextRef="c-5" decimals="-3" id="f-1191" unitRef="usd">0</lgnd:LicenseeAccrualCurrent>
    <lgnd:LicenseeAccrualCurrent contextRef="c-6" decimals="-3" id="f-1192" unitRef="usd">45000</lgnd:LicenseeAccrualCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-1193" unitRef="usd">3490000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-1194" unitRef="usd">1766000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-1195" unitRef="usd">27906000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-1196" unitRef="usd">12467000</us-gaap:AccruedLiabilitiesCurrent>
    <lgnd:ScheduleofContingentLiabilitiesTableTextBlock contextRef="c-1" id="f-1197">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes roll-forward of contingent liabilities as of December&#160;31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.201%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.698%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.698%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.734%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.698%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.698%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.739%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cydex&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Metabasis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,513&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,198&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;683&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;3,681&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lgnd:ScheduleofContingentLiabilitiesTableTextBlock>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod contextRef="c-287" decimals="-3" id="f-1198" unitRef="usd">84000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders contextRef="c-288" decimals="-3" id="f-1199" unitRef="usd">50000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities contextRef="c-288" decimals="-3" id="f-1200" unitRef="usd">286000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod contextRef="c-289" decimals="-3" id="f-1201" unitRef="usd">320000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders contextRef="c-290" decimals="-3" id="f-1202" unitRef="usd">200000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities contextRef="c-290" decimals="-3" id="f-1203" unitRef="usd">263000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod contextRef="c-291" decimals="-3" id="f-1204" unitRef="usd">383000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod contextRef="c-292" decimals="-3" id="f-1205" unitRef="usd">3429000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders contextRef="c-293" decimals="-3" id="f-1206" unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities contextRef="c-293" decimals="-3" id="f-1207" unitRef="usd">-551000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod contextRef="c-294" decimals="-3" id="f-1208" unitRef="usd">2878000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders contextRef="c-295" decimals="-3" id="f-1209" unitRef="usd">0</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities contextRef="c-295" decimals="-3" id="f-1210" unitRef="usd">420000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod contextRef="c-296" decimals="-3" id="f-1211" unitRef="usd">3298000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod contextRef="c-41" decimals="-3" id="f-1212" unitRef="usd">3513000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders contextRef="c-22" decimals="-3" id="f-1213" unitRef="usd">50000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities contextRef="c-22" decimals="-3" id="f-1214" unitRef="usd">-265000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod contextRef="c-6" decimals="-3" id="f-1215" unitRef="usd">3198000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <lgnd:PaymentsToContingentValueRightHolders contextRef="c-1" decimals="-3" id="f-1216" unitRef="usd">200000</lgnd:PaymentsToContingentValueRightHolders>
    <lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities contextRef="c-1" decimals="-3" id="f-1217" unitRef="usd">683000</lgnd:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustmentContingentLiabilities>
    <lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod contextRef="c-5" decimals="-3" id="f-1218" unitRef="usd">3681000</lgnd:BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-1219">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Novan (Pelthos) contract liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,758&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-1220" unitRef="usd">15938000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-1221" unitRef="usd">13700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <lgnd:UnrecognizedTaxBenefitsNoncurrent contextRef="c-5" decimals="-3" id="f-1222" unitRef="usd">14160000</lgnd:UnrecognizedTaxBenefitsNoncurrent>
    <lgnd:UnrecognizedTaxBenefitsNoncurrent contextRef="c-6" decimals="-3" id="f-1223" unitRef="usd">14039000</lgnd:UnrecognizedTaxBenefitsNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-1224" unitRef="usd">65000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherSundryLiabilitiesNoncurrent contextRef="c-6" decimals="-3" id="f-1225" unitRef="usd">19000</us-gaap:OtherSundryLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-1226" unitRef="usd">30163000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-41" decimals="-3" id="f-1227" unitRef="usd">27758000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock contextRef="c-1" id="f-1228">Fair Value Measurement&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We measure certain financial assets and liabilities at fair value on a recurring basis. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. We establish a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels are described in the below with level 1 having the highest priority and level 3 having the lowest:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - Observable inputs such as quoted prices in active markets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - Inputs other than the quoted prices in active markets that are observable either directly or indirectly &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments, excluding Viking&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;194,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - CyDex&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Metabasis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments, excluding Viking&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - CyDex&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Metabasis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Excluding our investment in Viking, corporate equity securities, and US government securities, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in bond funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we had investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and were at level 3 of the fair value hierarchy, based on Black-Scholes value estimated by management on the last day of the period. This investment in warrants expired in January 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(2) Derivative assets include instruments used for risk-management purposes, and other instruments. Derivative assets which are not used for risk management purposes include: (a) acquired rights in future milestone and royalty payments from Agenus Partnered Programs, (b) Agenus Warrant, (c) Upsize Option, (d) Viking Share Collar (e) and rights to receive from Primrose Bio 50% of milestones on two contracts previously entered into by Primordial Genetics. The considerations were recognized as derivative assets included under current derivative assets and noncurrent derivative assets in our consolidated balance sheet. They are recognized as derivative assets under ASC 815, Derivatives and Hedging. The fair value of the Agenus Partnered Programs and the Primrose Bio derivative assets was determined using a discounted cash flow approach, utilizing the mostly-likely cash flows which considered the probability of success for the underlying clinical programs. The discount rate used contemplates the underlying credit and business risk of the partnered programs. At December&#160;31, 2024, the discount rates used range between 15% and 28%. At December&#160;31, 2023, the discount rate used was 25%. The fair value of the Agenus Warrant was determined using a Black-Scholes-Merton model. The fair value of the Upsize Option was determined using a binomial option pricing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(3) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;significantly based upon quoted market prices and actual amounts paid under the agreements may be materially different than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#x3b2; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10 million payment upon initiation of a Phase 3 clinical trial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2024 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:45pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions to derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1303"&gt;Fair value adjustments to derivative assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercise of derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,826)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments to CVR holders and other contingent payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1309"&gt;Fair value adjustments to contingent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2023 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:45pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1313"&gt;Fair value adjustments to equity security warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions to derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value adjustments to derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments to CVR holders and other contingency payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1320"&gt;Fair value adjustments to contingent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Assets Measured on a Non-Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We apply fair value techniques on a non-recurring basis associated with valuing potential impairment losses related to our goodwill, intangible assets with estimated useful lives and long-lived assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate goodwill annually for impairment and whenever circumstances occur indicating that goodwill might be impaired. We determine the fair value of our reporting unit based on a combination of inputs, including the market capitalization of Ligand, as well as Level 3 inputs such as discounted cash flows, which are not observable from the market, directly or indirectly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate intangible assets with estimated useful lives whenever circumstances occur indicating that intangible assets may not be recoverable. An impairment evaluation is based on an undiscounted cash flow analysis at the lowest level at which cash flows of the long-lived assets are largely independent of other groups of assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no impairment of our goodwill, intangible assets, or long-lived assets recorded during the years ended December&#160;31, 2024 and 2023. Other than the finance lease equipment discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x201c;Note (9), Leases&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there was no impairment of our goodwill, intangible assets, or long-lived assets recorded during the year ended and December&#160;31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our cash and cash equivalents, accounts receivable, other current assets, financial royalty assets, accounts payable, accrued liabilities, deferred revenue, current operating lease liabilities, current finance lease liabilities and Novan (Pelthos) other long-term liabilities are financial instruments and are recorded at cost in the consolidated balance sheets. The estimated &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fair value of the Novan (Pelthos) other long-term liabilities is $19.1&#160;million compared to a carrying value of $15.9&#160;million. The estimated fair value of the remaining financial instruments approximates their carrying value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Assets Not Measured at Fair Value&lt;/span&gt;&lt;/div&gt;Financial royalty assets are measured and carried on the balance sheet at amortized cost using the effective interest method or on a non-accrual basis. Management calculates the fair value of financial royalty assets using a forecasted royalty receipts. The projected future cash flows derive from royalty payments and milestones, then discounted using appropriate individual discount rates. The fair value of financial royalty assets and other economic rights assets is classified as Level 3 within the fair value hierarchy since it is determined based upon inputs that are both significant and unobservable. The estimated fair value and related carrying values of financial royalty assets as of December&#160;31, 2024 were $196.6&#160;million and $195.0&#160;million, respectively. The estimated fair value and related carrying value of the financial royalty assets as of December&#160;31, 2023 were $75.9&#160;million and $62.3&#160;million, respectively. To determine the fair value of long-term financial royalty assets, we estimated future underlying product sales, applied a probability of technical and regulatory success for development stage programs, estimated a timeline for any development and regulatory milestones, and applied a discount rate based on the level of partner execution and commercialization risk, in the range of 15-30% and 10-45% as of December 31, 2024, and 2023, respectively.</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="c-1" id="f-1229">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2024 and 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.829%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments, excluding Viking&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;194,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - CyDex&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Metabasis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.473%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements at Reporting Date Using&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted Prices in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Active Markets&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;for Identical&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Observable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Short-term investments, excluding Viking&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investment in Viking common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Derivative assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - CyDex&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent liabilities - Metabasis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Excluding our investment in Viking, corporate equity securities, and US government securities, our short-term investments in marketable debt and equity securities are classified as available-for-sale securities based on management's intentions and are at level 2 of the fair value hierarchy, as these investment securities are valued based upon quoted prices for identical or similar instruments in markets that are not active, and model-based valuation techniques for which all significant assumptions are observable in the market. Short-term investments in bond funds are valued at their net asset value (NAV) on the last day of the period. We have classified marketable securities with original maturities of greater than one year as short-term investments based upon our ability and intent to use any and all of those marketable securities to satisfy the liquidity needs of our current operations. In addition, we had investment in warrants resulting from Seelos Therapeutics Inc. milestone payments that were settled in shares during the first quarter of 2019 and were at level 3 of the fair value hierarchy, based on Black-Scholes value estimated by management on the last day of the period. This investment in warrants expired in January 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(2) Derivative assets include instruments used for risk-management purposes, and other instruments. Derivative assets which are not used for risk management purposes include: (a) acquired rights in future milestone and royalty payments from Agenus Partnered Programs, (b) Agenus Warrant, (c) Upsize Option, (d) Viking Share Collar (e) and rights to receive from Primrose Bio 50% of milestones on two contracts previously entered into by Primordial Genetics. The considerations were recognized as derivative assets included under current derivative assets and noncurrent derivative assets in our consolidated balance sheet. They are recognized as derivative assets under ASC 815, Derivatives and Hedging. The fair value of the Agenus Partnered Programs and the Primrose Bio derivative assets was determined using a discounted cash flow approach, utilizing the mostly-likely cash flows which considered the probability of success for the underlying clinical programs. The discount rate used contemplates the underlying credit and business risk of the partnered programs. At December&#160;31, 2024, the discount rates used range between 15% and 28%. At December&#160;31, 2023, the discount rate used was 25%. The fair value of the Agenus Warrant was determined using a Black-Scholes-Merton model. The fair value of the Upsize Option was determined using a binomial option pricing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(3) In connection with our acquisition of Metabasis in January 2010, we issued Metabasis stockholders four tradable CVRs, one CVR from each of four respective series of CVR, for each Metabasis share. The CVRs entitle Metabasis stockholders to cash payments as frequently as every six months as cash is received by us from proceeds from the sale or partnering of any of the Metabasis drug development programs, among other triggering events. The liability for the CVRs is determined using quoted prices in a market that is not active for the underlying CVR. The carrying amount of the liability may fluctuate &lt;/span&gt;&lt;/div&gt;significantly based upon quoted market prices and actual amounts paid under the agreements may be materially different than the carrying amount of the liability. Several of the Metabasis drug development programs have been outlicensed to Viking, including VK2809. VK2809 is a novel selective TR-&#x3b2; agonist with potential in multiple indications, including hypercholesterolemia, dyslipidemia, NASH, and X-ALD. Under the terms of the agreement with Viking, we may be entitled to up to $375 million of development, regulatory and commercial milestones and tiered royalties on potential future sales including a $10 million payment upon initiation of a Phase 3 clinical trial.</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-297" decimals="-3" id="f-1230" unitRef="usd">143618000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-298" decimals="-3" id="f-1231" unitRef="usd">81807000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-299" decimals="-3" id="f-1232" unitRef="usd">61811000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-300" decimals="-3" id="f-1233" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-301" decimals="-3" id="f-1234" unitRef="usd">40240000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-302" decimals="-3" id="f-1235" unitRef="usd">40240000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-303" decimals="-3" id="f-1236" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-304" decimals="-3" id="f-1237" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <lgnd:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag contextRef="c-1" id="f-1238">Derivative assets(2)</lgnd:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:DerivativeAssets contextRef="c-301" decimals="-3" id="f-1239" unitRef="usd">10583000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-302" decimals="-3" id="f-1240" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-303" decimals="-3" id="f-1241" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-304" decimals="-3" id="f-1242" unitRef="usd">10583000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-301" decimals="-3" id="f-1243" unitRef="usd">194441000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-302" decimals="-3" id="f-1244" unitRef="usd">122047000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-303" decimals="-3" id="f-1245" unitRef="usd">61811000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-304" decimals="-3" id="f-1246" unitRef="usd">10583000</us-gaap:AssetsFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-305" decimals="-3" id="f-1247" unitRef="usd">383000</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-306" decimals="-3" id="f-1248" unitRef="usd">0</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-307" decimals="-3" id="f-1249" unitRef="usd">0</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-308" decimals="-3" id="f-1250" unitRef="usd">383000</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-309" decimals="-3" id="f-1251" unitRef="usd">3298000</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-310" decimals="-3" id="f-1252" unitRef="usd">0</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-311" decimals="-3" id="f-1253" unitRef="usd">3298000</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-312" decimals="-3" id="f-1254" unitRef="usd">0</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-301" decimals="-3" id="f-1255" unitRef="usd">3681000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-302" decimals="-3" id="f-1256" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-303" decimals="-3" id="f-1257" unitRef="usd">3298000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-304" decimals="-3" id="f-1258" unitRef="usd">383000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-313" decimals="-3" id="f-1259" unitRef="usd">115170000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-314" decimals="-3" id="f-1260" unitRef="usd">7291000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-315" decimals="-3" id="f-1261" unitRef="usd">107879000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-316" decimals="-3" id="f-1262" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-317" decimals="-3" id="f-1263" unitRef="usd">32185000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-318" decimals="-3" id="f-1264" unitRef="usd">32185000</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-319" decimals="-3" id="f-1265" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent contextRef="c-320" decimals="-3" id="f-1266" unitRef="usd">0</us-gaap:EquitySecuritiesFvNiCurrentAndNoncurrent>
    <lgnd:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag contextRef="c-22" id="f-1267">Derivative assets(2)</lgnd:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:DerivativeAssets contextRef="c-317" decimals="-3" id="f-1268" unitRef="usd">3531000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-318" decimals="-3" id="f-1269" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-319" decimals="-3" id="f-1270" unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets contextRef="c-320" decimals="-3" id="f-1271" unitRef="usd">3531000</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-317" decimals="-3" id="f-1272" unitRef="usd">150886000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-318" decimals="-3" id="f-1273" unitRef="usd">39476000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-319" decimals="-3" id="f-1274" unitRef="usd">107879000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-320" decimals="-3" id="f-1275" unitRef="usd">3531000</us-gaap:AssetsFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-321" decimals="-3" id="f-1276" unitRef="usd">320000</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-322" decimals="-3" id="f-1277" unitRef="usd">0</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-323" decimals="-3" id="f-1278" unitRef="usd">0</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-324" decimals="-3" id="f-1279" unitRef="usd">320000</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-325" decimals="-3" id="f-1280" unitRef="usd">2878000</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-326" decimals="-3" id="f-1281" unitRef="usd">0</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-327" decimals="-3" id="f-1282" unitRef="usd">2878000</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure contextRef="c-328" decimals="-3" id="f-1283" unitRef="usd">0</lgnd:BusinessCombinationContingentConsiderationLiabilityFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-317" decimals="-3" id="f-1284" unitRef="usd">3198000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-318" decimals="-3" id="f-1285" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-319" decimals="-3" id="f-1286" unitRef="usd">2878000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-329" decimals="-3" id="f-1287" unitRef="usd">320000</us-gaap:LiabilitiesFairValueDisclosure>
    <lgnd:MilestoneCompensationRate contextRef="c-84" decimals="2" id="f-1288" unitRef="number">0.50</lgnd:MilestoneCompensationRate>
    <lgnd:NumberOfContracts
      contextRef="c-85"
      decimals="INF"
      id="f-1289"
      unitRef="contract">2</lgnd:NumberOfContracts>
    <us-gaap:DerivativeAssetMeasurementInput
      contextRef="c-330"
      decimals="2"
      id="f-1290"
      unitRef="number">0.15</us-gaap:DerivativeAssetMeasurementInput>
    <us-gaap:DerivativeAssetMeasurementInput
      contextRef="c-331"
      decimals="2"
      id="f-1291"
      unitRef="number">0.28</us-gaap:DerivativeAssetMeasurementInput>
    <us-gaap:DerivativeAssetMeasurementInput
      contextRef="c-332"
      decimals="2"
      id="f-1292"
      unitRef="number">0.25</us-gaap:DerivativeAssetMeasurementInput>
    <lgnd:BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare contextRef="c-333" decimals="INF" id="f-1293" unitRef="cvr">4</lgnd:BusinessCombinationNumberOfContingentValueRightsIssuedPerAcquireeShare>
    <lgnd:BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries contextRef="c-333" decimals="INF" id="f-1294" unitRef="cvr">1</lgnd:BusinessCombinationNumberOfContingentValueRightsIssuedFromEachContingentValueRightSeries>
    <lgnd:NumberOfContingentValueRightsSeries contextRef="c-334" decimals="INF" id="f-1295" unitRef="cvr">4</lgnd:NumberOfContingentValueRightsSeries>
    <lgnd:BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders contextRef="c-333" id="f-1296">P6M</lgnd:BusinessCombinationFrequencyOfCashPaymentsToContingentValueRightsHolders>
    <us-gaap:Investments contextRef="c-335" decimals="INF" id="f-1297" unitRef="usd">375000000</us-gaap:Investments>
    <us-gaap:ContractWithCustomerAssetGross contextRef="c-336" decimals="-5" id="f-1298" unitRef="usd">10000000</us-gaap:ContractWithCustomerAssetGross>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-1300">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2024 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:45pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions to derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1303"&gt;Fair value adjustments to derivative assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercise of derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,826)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments to CVR holders and other contingent payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1309"&gt;Fair value adjustments to contingent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2023 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:45pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1313"&gt;Fair value adjustments to equity security warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions to derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value adjustments to derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments to CVR holders and other contingency payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1320"&gt;Fair value adjustments to contingent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-1299">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2024 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:45pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions to derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1303"&gt;Fair value adjustments to derivative assets&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercise of derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8,826)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments to CVR holders and other contingent payments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1309"&gt;Fair value adjustments to contingent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the level 3 financial instruments as of December&#160;31, 2023 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:45pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.497%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1313"&gt;Fair value adjustments to equity security warrants&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(135)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additions to derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value adjustments to derivative assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments to CVR holders and other contingency payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1320"&gt;Fair value adjustments to contingent liabilities&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fair value of level 3 financial instruments as of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-6" decimals="-3" id="f-1301" unitRef="usd">3531000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases contextRef="c-1" decimals="-3" id="f-1302" unitRef="usd">35888000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-1" decimals="-3" id="f-1304" unitRef="usd">-20010000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements contextRef="c-1" decimals="-3" id="f-1305" unitRef="usd">8826000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-5" decimals="-3" id="f-1306" unitRef="usd">10583000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-6" decimals="-3" id="f-1307" unitRef="usd">320000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <lgnd:PaymentsToContingentValueRightHolders contextRef="c-1" decimals="-3" id="f-1308" unitRef="usd">200000</lgnd:PaymentsToContingentValueRightHolders>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="-3" id="f-1310" unitRef="usd">263000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-5" decimals="-3" id="f-1311" unitRef="usd">383000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-41" decimals="-3" id="f-1312" unitRef="usd">135000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="c-22" decimals="-3" id="f-1314" unitRef="usd">-135000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases contextRef="c-22" decimals="-3" id="f-1315" unitRef="usd">3281000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1 contextRef="c-22" decimals="-3" id="f-1316" unitRef="usd">250000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="c-6" decimals="-3" id="f-1317" unitRef="usd">3531000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-41" decimals="-3" id="f-1318" unitRef="usd">84000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <lgnd:PaymentsToContingentValueRightHolders contextRef="c-22" decimals="-3" id="f-1319" unitRef="usd">50000</lgnd:PaymentsToContingentValueRightHolders>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-22" decimals="-3" id="f-1321" unitRef="usd">286000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-6" decimals="-3" id="f-1322" unitRef="usd">320000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-22" decimals="INF" id="f-1323" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-1" decimals="INF" id="f-1324" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-1" decimals="INF" id="f-1325" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-22" decimals="INF" id="f-1326" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:GoodwillAndIntangibleAssetImpairment contextRef="c-23" decimals="INF" id="f-1327" unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-23" decimals="INF" id="f-1328" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="c-337" decimals="-5" id="f-1329" unitRef="usd">19100000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <us-gaap:OtherLiabilitiesFairValueDisclosure contextRef="c-338" decimals="-5" id="f-1330" unitRef="usd">15900000</us-gaap:OtherLiabilitiesFairValueDisclosure>
    <lgnd:FinancialRoyaltyAssetsFairValueDisclosure contextRef="c-337" decimals="-5" id="f-1331" unitRef="usd">196600000</lgnd:FinancialRoyaltyAssetsFairValueDisclosure>
    <lgnd:FinancialRoyaltyAssetsFairValueDisclosure contextRef="c-338" decimals="-5" id="f-1332" unitRef="usd">195000000</lgnd:FinancialRoyaltyAssetsFairValueDisclosure>
    <lgnd:FinancialRoyaltyAssetsFairValueDisclosure contextRef="c-339" decimals="-5" id="f-1333" unitRef="usd">75900000</lgnd:FinancialRoyaltyAssetsFairValueDisclosure>
    <lgnd:FinancialRoyaltyAssetsFairValueDisclosure contextRef="c-340" decimals="-5" id="f-1334" unitRef="usd">62300000</lgnd:FinancialRoyaltyAssetsFairValueDisclosure>
    <lgnd:FinancialRoyaltyAssetMeasurementInput
      contextRef="c-341"
      decimals="2"
      id="f-1335"
      unitRef="number">0.15</lgnd:FinancialRoyaltyAssetMeasurementInput>
    <lgnd:FinancialRoyaltyAssetMeasurementInput
      contextRef="c-342"
      decimals="2"
      id="f-1336"
      unitRef="number">0.10</lgnd:FinancialRoyaltyAssetMeasurementInput>
    <lgnd:FinancialRoyaltyAssetMeasurementInput
      contextRef="c-343"
      decimals="2"
      id="f-1337"
      unitRef="number">0.45</lgnd:FinancialRoyaltyAssetMeasurementInput>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-1339">Leases&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finance lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020 and January 2021, we entered into an agreement and the first amendment with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol, respectively. The agreements are considered to include an embedded finance lease under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as it provides the Company the right to use the underlying equipment to exclusively manufacture Captisol. As of December 31, 2021, we had fully paid consideration of $69.1 million for prepaid inventory and capacity ramp-up fee. We allocated consideration in the agreements between lease and non-lease components using relative standalone prices. Since the inception of the agreements, we have allocated $50.2 million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and being amortized to cost of Captisol based on the usage. The remaining balance of $18.9 million was recognized as a right of use asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, given the COVID status, our forecast for COVID-related Captisol had been significantly reduced, which triggered an indicator of impairment of the right of use asset. We performed a recoverability test at the asset group level by comparing the sum of the estimated undiscounted future cash flows attributable to the asset group to its carrying value and identified the asset was impaired. We recorded a $9.8&#160;million of impairment charge based on the fair value of the right of use asset which has been recognized in cost of Captisol in our consolidated statement of operations for the year ended December 31, 2022. As of December 31, 2022, the remaining right of use asset balance was $4.0&#160;million which will be amortized straight-line over the remaining 6 years lease term. During the years ended December&#160;31, 2024 and 2023, no impairment to this asset group was recorded as there were no indicators of impairment. As of December&#160;31, 2024 and 2023, the remaining right of use asset balance is $2.7&#160;million and $3.4&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating lease &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease certain office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to eight years, some of which include options to extend the leases for up to five years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2024, we entered into lease agreements for our offices located in Boston, Massachusetts, and Jupiter, Florida, which resulted in a $1.6&#160;million and $0.1&#160;million, respectively, increase in both operating lease assets and operating lease liabilities at lease commencement. During the year ended December 31, 2023, we entered into an amendment to the lease agreement for our office located in San Diego, California, which resulted in a $1.1&#160;million increase in both operating lease assets and operating lease liabilities at lease commencement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating and finance lease assets and liabilities (in thousands) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.683%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1373"&gt;&lt;span style="-sec-ix-hidden:f-1374"&gt;Long-term finance lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities   &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of operating and finance lease liabilities as of December&#160;31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finance &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, our operating leases had a weighted-average remaining lease term of 5.8 years and a weighted-average discount rate of 7.5%. As of December&#160;31, 2023, our operating leases had a weighted-average remaining lease term of 7.4 years and a weighted-average discount rate of 7.7%. Cash paid for amounts included in the measurement of operating lease liabilities was $1.3 million and $1.4 million, respectively, for the years ended December&#160;31, 2024 and 2023. Operating lease expense was $1.3 million (net of sublease income of $0.1 million) and $1.4 million (net of sublease income of $0.3 million) for the years ended December&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, our finance leases had a weighted-average remaining lease term of 3.3 years and a weighted-average discount rate of 6.6%. As of December&#160;31, 2023, our finance leases had a weighted-average remaining lease term of 3.4 years and a weighted-average discount rate of 6.8%. We excluded the Hovione equipment lease in the calculation of weighted average remaining lease term and weighted average discount rate because the Hovione lease was fully paid off as of December 31, 2021. Cash paid for amounts included in the measurement of these finance lease liabilities was $0.02&#160;million and $0.05&#160;million, respectively, for the years ended December&#160;31, 2024 and 2023. Finance lease expense was $0.5 million and $0.7 million, respectively, for the years ended December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock contextRef="c-1" id="f-1338">Leases&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Finance lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020 and January 2021, we entered into an agreement and the first amendment with Hovione, our third-party manufacturer, to increase our manufacturing of Captisol, respectively. The agreements are considered to include an embedded finance lease under ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as it provides the Company the right to use the underlying equipment to exclusively manufacture Captisol. As of December 31, 2021, we had fully paid consideration of $69.1 million for prepaid inventory and capacity ramp-up fee. We allocated consideration in the agreements between lease and non-lease components using relative standalone prices. Since the inception of the agreements, we have allocated $50.2 million of the consideration paid to the non-lease component which is accounted for as prepaid inventory and being amortized to cost of Captisol based on the usage. The remaining balance of $18.9 million was recognized as a right of use asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, given the COVID status, our forecast for COVID-related Captisol had been significantly reduced, which triggered an indicator of impairment of the right of use asset. We performed a recoverability test at the asset group level by comparing the sum of the estimated undiscounted future cash flows attributable to the asset group to its carrying value and identified the asset was impaired. We recorded a $9.8&#160;million of impairment charge based on the fair value of the right of use asset which has been recognized in cost of Captisol in our consolidated statement of operations for the year ended December 31, 2022. As of December 31, 2022, the remaining right of use asset balance was $4.0&#160;million which will be amortized straight-line over the remaining 6 years lease term. During the years ended December&#160;31, 2024 and 2023, no impairment to this asset group was recorded as there were no indicators of impairment. As of December&#160;31, 2024 and 2023, the remaining right of use asset balance is $2.7&#160;million and $3.4&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating lease &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We lease certain office facilities and equipment primarily under various operating leases. Our operating leases have remaining contractual terms up to eight years, some of which include options to extend the leases for up to five years. Our lease agreements do not contain any material residual value guarantees, material restrictive covenants, or material termination options. Our operating lease costs are primarily related to facility leases for administration offices and research and development facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lease assets and lease liabilities are recognized at the commencement of an arrangement where it is determined at inception that a lease exists. Lease assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. These assets and liabilities are initially recognized based on the present value of lease payments over the lease term calculated using our incremental borrowing rate generally applicable to the location of the lease asset, unless the implicit rate is readily determinable. Lease assets also include any upfront lease payments made and lease incentives. Lease terms include options to extend or terminate the lease when it is reasonably certain that those options will be exercised.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to base rent, certain of our operating leases require variable payments, such as insurance and common area maintenance. These variable lease costs, other than those dependent upon an index or rate, are expensed when the obligation for those payments is incurred. Leases with an initial term of twelve months or less are not recorded on the consolidated balance sheet, and the expense for these short-term leases and for operating leases is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The depreciable life of lease assets and leasehold improvements is limited by the expected lease term, unless there is a transfer of title or purchase option reasonably certain of exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2024, we entered into lease agreements for our offices located in Boston, Massachusetts, and Jupiter, Florida, which resulted in a $1.6&#160;million and $0.1&#160;million, respectively, increase in both operating lease assets and operating lease liabilities at lease commencement. During the year ended December 31, 2023, we entered into an amendment to the lease agreement for our office located in San Diego, California, which resulted in a $1.1&#160;million increase in both operating lease assets and operating lease liabilities at lease commencement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating and finance lease assets and liabilities (in thousands) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.683%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1373"&gt;&lt;span style="-sec-ix-hidden:f-1374"&gt;Long-term finance lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities   &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of operating and finance lease liabilities as of December&#160;31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finance &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, our operating leases had a weighted-average remaining lease term of 5.8 years and a weighted-average discount rate of 7.5%. As of December&#160;31, 2023, our operating leases had a weighted-average remaining lease term of 7.4 years and a weighted-average discount rate of 7.7%. Cash paid for amounts included in the measurement of operating lease liabilities was $1.3 million and $1.4 million, respectively, for the years ended December&#160;31, 2024 and 2023. Operating lease expense was $1.3 million (net of sublease income of $0.1 million) and $1.4 million (net of sublease income of $0.3 million) for the years ended December&#160;31, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, our finance leases had a weighted-average remaining lease term of 3.3 years and a weighted-average discount rate of 6.6%. As of December&#160;31, 2023, our finance leases had a weighted-average remaining lease term of 3.4 years and a weighted-average discount rate of 6.8%. We excluded the Hovione equipment lease in the calculation of weighted average remaining lease term and weighted average discount rate because the Hovione lease was fully paid off as of December 31, 2021. Cash paid for amounts included in the measurement of these finance lease liabilities was $0.02&#160;million and $0.05&#160;million, respectively, for the years ended December&#160;31, 2024 and 2023. Finance lease expense was $0.5 million and $0.7 million, respectively, for the years ended December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <lgnd:PurchaseCommitmentConsiderationPaidToDate contextRef="c-344" decimals="-5" id="f-1340" unitRef="usd">69100000</lgnd:PurchaseCommitmentConsiderationPaidToDate>
    <lgnd:PurchaseCommitmentConsiderationPaidAllocatedToInventory contextRef="c-344" decimals="-5" id="f-1341" unitRef="usd">50200000</lgnd:PurchaseCommitmentConsiderationPaidAllocatedToInventory>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability contextRef="c-345" decimals="-5" id="f-1342" unitRef="usd">18900000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:FinanceLeaseImpairmentLoss contextRef="c-18" decimals="-5" id="f-1343" unitRef="usd">9800000</us-gaap:FinanceLeaseImpairmentLoss>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-346" decimals="-5" id="f-1344" unitRef="usd">4000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm contextRef="c-346" id="f-1345">P6Y</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:AssetImpairmentCharges contextRef="c-17" decimals="-5" id="f-1346" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-16" decimals="-5" id="f-1347" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-80" decimals="-5" id="f-1348" unitRef="usd">2700000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-81" decimals="-5" id="f-1349" unitRef="usd">3400000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c-83" id="f-1350">P8Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-83" id="f-1351">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-347" decimals="-5" id="f-1352" unitRef="usd">1600000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <lgnd:LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification contextRef="c-347" decimals="-5" id="f-1353" unitRef="usd">1600000</lgnd:LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification>
    <lgnd:LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification contextRef="c-348" decimals="-5" id="f-1354" unitRef="usd">100000</lgnd:LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-348" decimals="-5" id="f-1355" unitRef="usd">100000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <lgnd:LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification contextRef="c-22" decimals="-5" id="f-1356" unitRef="usd">1100000</lgnd:LesseeIncreaseDecreaseInOperatingLeaseAssetsDueToModification>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-22" decimals="-5" id="f-1357" unitRef="usd">1100000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <lgnd:AssetsAndLiabilitiesLesseeTableTextBlock contextRef="c-1" id="f-1358">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating and finance lease assets and liabilities (in thousands) are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.683%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1373"&gt;&lt;span style="-sec-ix-hidden:f-1374"&gt;Long-term finance lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease liabilities   &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</lgnd:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-1359" unitRef="usd">6907000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-1360" unitRef="usd">6062000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-1361" unitRef="usd">2766000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-1362" unitRef="usd">3393000</us-gaap:FinanceLeaseRightOfUseAsset>
    <lgnd:LeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-1363" unitRef="usd">9673000</lgnd:LeaseRightOfUseAsset>
    <lgnd:LeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-1364" unitRef="usd">9455000</lgnd:LeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-1365" unitRef="usd">1266000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-1366" unitRef="usd">403000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-1367" unitRef="usd">24000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-1368" unitRef="usd">7000</us-gaap:FinanceLeaseLiabilityCurrent>
    <lgnd:LeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-1369" unitRef="usd">1290000</lgnd:LeaseLiabilityCurrent>
    <lgnd:LeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-1370" unitRef="usd">410000</lgnd:LeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-1371" unitRef="usd">5815000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-1372" unitRef="usd">5755000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-1375" unitRef="usd">49000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-1376" unitRef="usd">19000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <lgnd:LeaseLiability contextRef="c-5" decimals="-3" id="f-1377" unitRef="usd">7154000</lgnd:LeaseLiability>
    <lgnd:LeaseLiability contextRef="c-6" decimals="-3" id="f-1378" unitRef="usd">6184000</lgnd:LeaseLiability>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-1380">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of operating and finance lease liabilities as of December&#160;31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finance &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-1379">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturity of operating and finance lease liabilities as of December&#160;31, 2024 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.499%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturity Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finance &lt;br/&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less tenant improvement allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,983)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-5" decimals="-3" id="f-1381" unitRef="usd">1537000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-5" decimals="-3" id="f-1382" unitRef="usd">27000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-5" decimals="-3" id="f-1383" unitRef="usd">1637000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo contextRef="c-5" decimals="-3" id="f-1384" unitRef="usd">27000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-5" decimals="-3" id="f-1385" unitRef="usd">1634000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree contextRef="c-5" decimals="-3" id="f-1386" unitRef="usd">18000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-5" decimals="-3" id="f-1387" unitRef="usd">1560000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour contextRef="c-5" decimals="-3" id="f-1388" unitRef="usd">9000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-5" decimals="-3" id="f-1389" unitRef="usd">1109000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive contextRef="c-5" decimals="-3" id="f-1390" unitRef="usd">3000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-5" decimals="-3" id="f-1391" unitRef="usd">2005000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-5" decimals="-3" id="f-1392" unitRef="usd">0</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-5" decimals="-3" id="f-1393" unitRef="usd">9482000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue contextRef="c-5" decimals="-3" id="f-1394" unitRef="usd">84000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <lgnd:OperatingLeaseLiabilityTenantImprovementAllowance contextRef="c-5" decimals="-3" id="f-1395" unitRef="usd">418000</lgnd:OperatingLeaseLiabilityTenantImprovementAllowance>
    <lgnd:FinanceLeaseLiabilityTenantImprovementAllowance contextRef="c-5" decimals="-3" id="f-1396" unitRef="usd">0</lgnd:FinanceLeaseLiabilityTenantImprovementAllowance>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-5" decimals="-3" id="f-1397" unitRef="usd">1983000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount contextRef="c-5" decimals="-3" id="f-1398" unitRef="usd">11000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-1399" unitRef="usd">7081000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c-5" decimals="-3" id="f-1400" unitRef="usd">73000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-1401">P5Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-1402" unitRef="number">0.075</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-6" id="f-1403">P7Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-6" decimals="3" id="f-1404" unitRef="number">0.077</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-5" id="f-1405" unitRef="usd">1300000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-22" decimals="-5" id="f-1406" unitRef="usd">1400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseExpense contextRef="c-1" decimals="-5" id="f-1407" unitRef="usd">1300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubleaseIncome contextRef="c-1" decimals="-5" id="f-1408" unitRef="usd">100000</us-gaap:SubleaseIncome>
    <us-gaap:OperatingLeaseExpense contextRef="c-22" decimals="-5" id="f-1409" unitRef="usd">1400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:SubleaseIncome contextRef="c-22" decimals="-5" id="f-1410" unitRef="usd">300000</us-gaap:SubleaseIncome>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-1411">P3Y3M18D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-1412" unitRef="number">0.066</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-6" id="f-1413">P3Y4M24D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c-6" decimals="3" id="f-1414" unitRef="number">0.068</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-1" decimals="-4" id="f-1415" unitRef="usd">20000.00</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability contextRef="c-22" decimals="-4" id="f-1416" unitRef="usd">50000.00</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-1" decimals="-5" id="f-1417" unitRef="usd">500000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c-22" decimals="-5" id="f-1418" unitRef="usd">700000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-1419">Debt&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;0.75% Convertible Senior Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, we issued $750 million aggregate principal amount of 2023 Notes, bearing cash interest at a rate of 0.75% per year, payable semi-annually. The net proceeds from the offering, after deducting the initial purchasers' discount and offering expenses, were approximately $733.1 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the issuance of the 2023 Notes, we incurred $16.9 million of issuance costs, which primarily consisted of underwriting, legal and other professional fees and was being amortized to interest expense using the effective interest method over the five years expected life of the 2023 Notes. On May 15, 2023, the 2023 Notes maturity date, we paid the remaining $76.9 million principal amount and $0.3 million accrued interest in cash. The effective interest rate for the year ended December 31, 2023 was 0.5%. During the year ended December 31, 2023, we recognized a total of $0.6 million in interest expense, including $0.4 million in contractual interest expense and $0.2 million in amortized issuance costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2022, we repurchased $266.4 million in principal amount of the 2023 Notes for $261.4 million in cash, including accrued interest of $0.5 million We accounted for the repurchase as a debt extinguishment, which resulted in a gain of $4.2 million reflected in other non-operating (expense) income, net, in our consolidated statement of operations for the year ended December 31, 2022, and a $1.3 million reduction in debt discount. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Convertible Bond Hedge and Warrant Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In conjunction with the 2023 Notes, in May 2018, we entered into convertible bond hedges and sold warrants covering 3,018,327 shares of our common stock to minimize the impact of potential dilution to our common stock and/or offset the cash payments we are required to make in excess of the principal amount upon conversion of the 2023 Notes. The convertible bond hedges have an exercise price of $206.65 per share and are exercisable when and if the 2023 Notes are converted. We paid $140.3 million for these convertible bond hedges. If upon conversion of the 2023 Notes, the price of our common stock is above the exercise price of the convertible bond hedges, the counterparties will deliver shares of common stock and/or cash with an aggregate value approximately equal to the difference between the price of common stock at the conversion date and the exercise price, multiplied by the number of shares of common stock related to the convertible bond hedge transaction being exercised. The convertible bond hedges and warrants described below are separate transactions entered into by us and are not part of the terms of the 2023 Notes. Holders of the 2023 Notes and warrants did not have any rights with respect to the convertible bond hedges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concurrently with the convertible bond hedge transactions, we entered into warrant transactions whereby we sold warrants covering 3,018,327 shares of common stock with an exercise price of $315.38 per share, subject to certain adjustments. We received $90.0 million for these warrants. The warrants have various expiration dates ranging from August 15, 2023 to February 6, 2024. The warrants will have a dilutive effect to the extent the market price per share of common stock exceeds the applicable exercise price of the warrants, as measured under the terms of the warrant transactions. The common stock issuable upon exercise of the warrants will be in unregistered shares, and we do not have the obligation and do not intend to file any registration statement with the SEC registering the issuance of the shares under the warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, in connection with the repurchases of $227.8&#160;million in principal of the 2023 Notes for $223.7&#160;million in cash, including accrued interest of $0.4&#160;million made during the six months ended June 30, 2022, we entered into Bond Hedge Unwind Agreements with Barclays Bank PLC, Deutsche Bank AG, and Goldman Sachs &amp;amp; Co. LLC to unwind a portion of the convertible note hedges transactions we initially entered into in connection with the issuance of the 2023 Notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, there are no warrants that remain outstanding. The warrants expired on February 6, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revolving Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 12, 2023, we entered into a $75 million revolving credit facility (the &#x201c;Revolving Credit Facility&#x201d;) with Citibank, N.A. as the Administrative Agent (as defined in the Credit Agreement). We, our material domestic subsidiaries, as Guarantors (as defined in the Credit Agreement), and the Lenders (as defined in the Credit Agreement) entered into a credit agreement (the &#x201c;Credit Agreement&#x201d;) with the Administrative Agent, under which the Lenders, the Swingline Lender and the L/C Issuer (each as defined in the Credit Agreement) agreed to make revolving loans, swingline loans and other financial accommodations to us (including the issuance of letters of credit) in an aggregate amount of up to $75 million. Borrowings under the Revolving Credit Facility accrue interest at a rate equal to either Term Secured Overnight Financing Rate (&#x201c;Term SOFR&#x201d;) or a specified base rate plus an applicable margin linked to our leverage ratio, ranging from 1.75% to 2.50% per annum for Term SOFR loans and 0.75% to 1.50% per annum for base rate loans. The Revolving Credit Facility is subject to a commitment fee payable on the unused Revolving Credit Facility commitments ranging from 0.30% to 0.45%, depending on our leverage ratio. During the term of the Revolving Credit Facility, we may borrow, repay and re-borrow amounts available under the Revolving Credit Facility, subject to voluntary reductions of the swing line, letter of credit and revolving credit commitments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the Revolving Credit Facility are secured by certain of our collateral and that of the Guarantors. In specified circumstances, additional guarantors are required to be added to the Credit Agreement. The Credit Agreement contains customary affirmative and negative covenants, including certain financial maintenance covenants, and events of default applicable to us. In the event of violation of the representations, warranties and covenants made in the Credit Agreement, we may not be able to utilize the Revolving Credit Facility or repayment of amounts owed thereunder could be accelerated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amendment to Revolving Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 8, 2024, we entered into the first amendment (the &#x201c;Amendment&#x201d;) to the Credit Agreement, which amends the Credit Agreement to, among other things, increase the aggregate revolving credit facility amount from $75 million to $125 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, we had $124.4&#160;million in available borrowing under the Revolving Credit Facility, after utilizing $0.6&#160;million for letter of credit. As of December&#160;31, 2023, we had $74.5&#160;million in available borrowing under the Revolving Credit Facility, after utilizing $0.5&#160;million for letter of credit. The maturity date of the Revolving Credit Facility, as amended, is October 12, 2026. As of December&#160;31, 2024 and 2023, there were no events of default or violation of any covenants under our financing obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-349"
      decimals="INF"
      id="f-1420"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-349" decimals="INF" id="f-1421" unitRef="usd">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-349"
      decimals="INF"
      id="f-1422"
      unitRef="number">0.0075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c-350" decimals="-5" id="f-1423" unitRef="usd">733100000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DeferredFinanceCostsGross contextRef="c-349" decimals="-5" id="f-1424" unitRef="usd">16900000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:DebtInstrumentTerm contextRef="c-350" id="f-1425">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-351" decimals="-5" id="f-1426" unitRef="usd">76900000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:InterestPaid contextRef="c-351" decimals="-5" id="f-1427" unitRef="usd">300000</us-gaap:InterestPaid>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-352"
      decimals="3"
      id="f-1428"
      unitRef="number">0.005</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:InterestExpenseDebt contextRef="c-353" decimals="-5" id="f-1429" unitRef="usd">600000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="c-353" decimals="-5" id="f-1430" unitRef="usd">400000</us-gaap:InterestExpenseDebtExcludingAmortization>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c-353" decimals="-5" id="f-1431" unitRef="usd">200000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DebtInstrumentRepurchaseAmount contextRef="c-354" decimals="-5" id="f-1432" unitRef="usd">266400000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-355" decimals="-5" id="f-1433" unitRef="usd">261400000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:InterestPaid contextRef="c-355" decimals="-5" id="f-1434" unitRef="usd">500000</us-gaap:InterestPaid>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-355" decimals="-5" id="f-1435" unitRef="usd">4200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <lgnd:IncreaseDecreaseInDebtDiscount contextRef="c-355" decimals="-5" id="f-1436" unitRef="usd">-1300000</lgnd:IncreaseDecreaseInDebtDiscount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-349"
      decimals="INF"
      id="f-1437"
      unitRef="shares">3018327</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c-349"
      decimals="2"
      id="f-1438"
      unitRef="usdPerShare">206.65</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <lgnd:PaymentsforConvertibleBondHedges contextRef="c-350" decimals="-5" id="f-1439" unitRef="usd">140300000</lgnd:PaymentsforConvertibleBondHedges>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-349"
      decimals="INF"
      id="f-1440"
      unitRef="shares">3018327</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-349"
      decimals="2"
      id="f-1441"
      unitRef="usdPerShare">315.38</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c-350" decimals="-5" id="f-1442" unitRef="usd">90000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <lgnd:DebtInstrumentRepurchasedAmountDuringPeriod contextRef="c-356" decimals="-5" id="f-1443" unitRef="usd">227800000</lgnd:DebtInstrumentRepurchasedAmountDuringPeriod>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c-356" decimals="-5" id="f-1444" unitRef="usd">223700000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:InterestPaid contextRef="c-357" decimals="-5" id="f-1445" unitRef="usd">400000</us-gaap:InterestPaid>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-358" decimals="INF" id="f-1446" unitRef="usd">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-358" decimals="INF" id="f-1447" unitRef="usd">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-359"
      decimals="INF"
      id="f-1448"
      unitRef="number">0.0175</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-360"
      decimals="INF"
      id="f-1449"
      unitRef="number">0.0250</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-361"
      decimals="INF"
      id="f-1450"
      unitRef="number">0.0075</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-362"
      decimals="INF"
      id="f-1451"
      unitRef="number">0.0150</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="c-363"
      decimals="INF"
      id="f-1452"
      unitRef="number">0.0030</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="c-364"
      decimals="INF"
      id="f-1453"
      unitRef="number">0.0045</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-358" decimals="INF" id="f-1454" unitRef="usd">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-365" decimals="INF" id="f-1455" unitRef="usd">125000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="c-366" decimals="-5" id="f-1456" unitRef="usd">124400000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-366" decimals="-5" id="f-1457" unitRef="usd">600000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity contextRef="c-367" decimals="-5" id="f-1458" unitRef="usd">74500000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-367" decimals="-5" id="f-1459" unitRef="usd">500000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-1460">Stockholders&#x2019; Equity&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense from continuing operations (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense as a component of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Conversion and Modification of Equity Awards Outstanding at Separation Date&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the OmniAb Separation on November 1, 2022, under the provisions of the existing plans, we adjusted our outstanding equity awards in accordance with the OmniAb Merger Agreement to preserve the intrinsic value of the awards immediately before and after the OmniAb Distribution. Upon the OmniAb Distribution, employees holding stock options, restricted stock units and performance restricted stock units denominated in pre-OmniAb Distribution Ligand stock received a number of otherwise-similar awards either in post-OmniAb Distribution Ligand stock or in a combination of post-OmniAb Distribution Ligand stock and OmniAb stock based on conversion ratios outlined for each group of employees in the OmniAb Merger Agreement. The equity awards that were granted prior to March 2, 2022 were converted under the shareholder method, wherein employees holding outstanding equity awards received equity awards in both Ligand and OmniAb. For equity awards granted after March 2, 2022, for Ligand employees, the number of awards that were outstanding at the OmniAb Separation were proportionately adjusted into post-OmniAb Distribution Ligand stock to maintain the aggregate intrinsic value of the awards at the date of the OmniAb Separation; for OmniAb employees, the number of awards that were outstanding at the OmniAb Separation were proportionately adjusted into post-OmniAb Distribution OmniAb stock to maintain the aggregate intrinsic value of the awards at the date of the OmniAb Separation. The conversion ratio was determined based on the relative values of Ligand common stock in the &#x201c;regular way&#x201d; and &#x201c;ex-distribution&#x201d; markets during the five-trading day period prior to the closing of the business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These modified awards otherwise retained substantially the same terms and conditions, including term and vesting provisions. Additionally, we will not incur any future compensation cost related to equity awards held by OmniAb employees and directors. We will incur future compensation cost related to OmniAb equity awards held by our employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, our stockholders approved the amendment and restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan (the &#x201c;2002 Plan&#x201d;). The amended and restated 2002 Plan, which is referred to herein as the &#x201c;Restated Plan&#x201d; was amended to increase the shares available for issuance by 1.0 million. In June 2024, our stockholders approved the amendment and restatement of the Ligand Pharmaceuticals Incorporated 2002 Stock Incentive Plan, which increased the shares available for issuance by 1.3 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 29, 2022, our board of directors (the &#x201c;Board&#x201d;) approved the Ligand Pharmaceuticals Incorporated 2022 Employment Inducement Plan (the &#x201c;2022 Inducement Plan&#x201d;). The terms of the 2022 Inducement Plan are substantially similar &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to the terms of the Restated Plan with the exception that incentive stock options may not be issued under the 2022 Inducement Plan and awards under the 2022 Inducement Plan may only be issued to eligible recipients under the applicable Nasdaq Listing Rules. The 2022 Inducement Plan was adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Board has initially reserved 300,000 shares of the Company&#x2019;s common stock for issuance pursuant to awards granted under the 2022 Inducement Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, there were 1.6 million shares available for future option grants or direct issuance under the Restated Plan and the 2022 Inducement Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a summary of our stock option plan activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.120%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.244%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,199,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;863,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(34,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(40,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at October 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,987,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at October 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,769,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of October 31, 2022, before the OmniAb Separation and Regrant&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,987,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cancellation due to OmniAb Separation, Before Regrant&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,987,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at November 1, 2022, Before Regrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,584,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(542,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,991,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,559,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,991,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;537,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(489,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(399,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,640,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,784,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,640,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;783,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,080,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(117,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,226,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,229,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,226,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Options granted primarily relate to the modifications in connection with the OmniAb Separation which resulted in new stock option grants at the modification date fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant-date fair value of all stock options granted during 2024, 2023 and 2022 was $37.81, $36.65, and $28.90 per share, respectively. The total intrinsic value of all options exercised during 2024, 2023 and 2022 was approximately $38.6 million, $12.0 million, and $4.6 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash received from options exercised, net of fees paid, in 2024, 2023 and 2022 was $65.2 million, $22.2 million and $2.6 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a further breakdown of the options outstanding as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.212%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of exercise prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;remaining life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;in&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;exercise price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;exercise&#160;price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$32.78-$52.84&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$54.81-$63.62&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$64.65-$68.74&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;312,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$69.39-$73.76&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;233,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$73.92-$75.09&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$78.56-$88.27&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;155,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$89.20-$89.20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;444,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$89.86-$103.42&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;244,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$104.30-$114.15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$122.70-$122.70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,226,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,229,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5%-4.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7%-4.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4%-4.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44%-46%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45%-54%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49%-55%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.1 to 4.8 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7 to 5.3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0 to 6.5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, there was $34.0 million of total unrecognized compensation cost related to non-vested stock options under the 2002 Plan. That cost is expected to be recognized over a weighted average period of 2.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, there was $0.1 million of total unrecognized compensation cost related to non-vested OmniAb stock options received in connection with the OmniAb Transactions described above. That cost is expected to be recognized over a weighted average period of 0.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of our restricted stock activity and related information:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;348,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;203,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(181,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;318,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(167,308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(64,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;437,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, unrecognized compensation cost related to non-vested stock awards under the 2002 Plan amounted to $19.6 million. That cost is expected to be recognized over a weighted average period of 1.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, 24,493 shares of our common stock are available for future issuance under the Amended Employee Stock Purchase Plan, or ESPP. The ESPP permits eligible employees to purchase up to 1,250 shares of Ligand common stock per calendar year at a discount through payroll deductions. The price at which stock is purchased under the ESPP is equal to 85% of the fair market value of the common stock on the first of a &lt;span style="-sec-ix-hidden:f-1686"&gt;six&lt;/span&gt; month offering period or purchase date, whichever is lower. There were 6,308, 5,080 and 8,479 shares issued under the ESPP in 2024, 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2023, our Board of Directors has approved a stock repurchase program authorizing, but not requiring, the repurchase of up to $50 million of our common stock from time to time through April 2026. We expect to acquire shares, if at all, primarily through open-market transactions in accordance with all applicable requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The timing and amount of repurchase transactions will be determined by management based on our evaluation of market conditions, share price, legal requirements and other factors. During the years ended December&#160;31, 2024, 2023 and 2022, we did not repurchase any common stock, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At-the Market Equity Offering Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2022, we filed a registration statement on Form S-3 (the &#x201c;Shelf Registration Statement&#x201d;), which became automatically effective upon filing, covering the offering of common stock, preferred stock, debt securities, warrants and units. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2022, we also entered into an At-The-Market Equity Offering Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with Stifel, Nicolaus &amp;amp; Company, Incorporated (the &#x201c;Agent&#x201d;), under which we may, from time to time, sell shares of our common stock having an aggregate offering price of up to $100&#160;million in &#x201c;at the market&#x201d; offerings through the Agent (the &#x201c;ATM Offering&#x201d;). The Shelf Registration Statement included a prospectus covering the offering, issuance and sale of up to $100&#160;million of our common stock from time to time through the ATM Offering. The shares to be sold under the Sales Agreement may be issued and sold pursuant to the Shelf Registration Statement. During the year ended December&#160;31, 2024, we issued 360,325 shares of common stock in the ATM Offering, generating proceeds of $37.4&#160;million, net of commissions and other transaction costs. During the year ended December&#160;31, 2023 and 2022, we did not issue any shares of common stock in the ATM Offering.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-1461">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense from continuing operations (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:64.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.869%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense as a component of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-368" decimals="-3" id="f-1462" unitRef="usd">3544000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-369" decimals="-3" id="f-1463" unitRef="usd">6248000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-370" decimals="-3" id="f-1464" unitRef="usd">10970000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-371" decimals="-3" id="f-1465" unitRef="usd">37545000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-372" decimals="-3" id="f-1466" unitRef="usd">19495000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-373" decimals="-3" id="f-1467" unitRef="usd">39911000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-1" decimals="-3" id="f-1468" unitRef="usd">41089000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-22" decimals="-3" id="f-1469" unitRef="usd">25743000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-23" decimals="-3" id="f-1470" unitRef="usd">50881000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-374"
      decimals="-5"
      id="f-1471"
      unitRef="shares">1000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-375"
      decimals="-5"
      id="f-1472"
      unitRef="shares">1300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-376"
      decimals="INF"
      id="f-1473"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-377"
      decimals="-5"
      id="f-1474"
      unitRef="shares">1600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-1475">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a summary of our stock option plan activity and related information:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.120%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.244%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Term in&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,199,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.34&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;113,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;863,245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(34,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(40,069)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at October 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,987,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at October 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,769,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of October 31, 2022, before the OmniAb Separation and Regrant&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,987,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,835&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cancellation due to OmniAb Separation, Before Regrant&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,987,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at November 1, 2022, Before Regrant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,584,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50,449)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(542,838)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,991,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,559,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,991,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;537,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(489,076)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(399,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,640,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,784,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,640,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.63&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;783,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,080,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(117,114)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,226,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,229,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,226,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) Options granted primarily relate to the modifications in connection with the OmniAb Separation which resulted in new stock option grants at the modification date fair value.</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-28"
      decimals="INF"
      id="f-1476"
      unitRef="shares">2199598</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-28"
      decimals="2"
      id="f-1477"
      unitRef="usdPerShare">106.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-29" id="f-1478">P6Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-28" decimals="-3" id="f-1479" unitRef="usd">113302000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-378"
      decimals="INF"
      id="f-1480"
      unitRef="shares">863245</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-378"
      decimals="2"
      id="f-1481"
      unitRef="usdPerShare">91.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-378"
      decimals="INF"
      id="f-1482"
      unitRef="shares">34941</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-378"
      decimals="2"
      id="f-1483"
      unitRef="usdPerShare">38.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-378"
      decimals="INF"
      id="f-1484"
      unitRef="shares">40069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-378"
      decimals="2"
      id="f-1485"
      unitRef="usdPerShare">78.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-379"
      decimals="INF"
      id="f-1486"
      unitRef="shares">2987833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-379"
      decimals="2"
      id="f-1487"
      unitRef="usdPerShare">102.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-378" id="f-1488">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-379" decimals="-3" id="f-1489" unitRef="usd">14835000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-379"
      decimals="INF"
      id="f-1490"
      unitRef="shares">1769629</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-379"
      decimals="2"
      id="f-1491"
      unitRef="usdPerShare">102.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-378" id="f-1492">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-379" decimals="-3" id="f-1493" unitRef="usd">13722000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-379"
      decimals="INF"
      id="f-1494"
      unitRef="shares">2987833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-379"
      decimals="2"
      id="f-1495"
      unitRef="usdPerShare">102.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-378" id="f-1496">P0Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-379" decimals="-3" id="f-1497" unitRef="usd">14835000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-380"
      decimals="INF"
      id="f-1498"
      unitRef="shares">2987833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-381"
      decimals="INF"
      id="f-1499"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-382"
      decimals="INF"
      id="f-1500"
      unitRef="shares">3584760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-382"
      decimals="2"
      id="f-1501"
      unitRef="usdPerShare">60.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-382"
      decimals="INF"
      id="f-1502"
      unitRef="shares">50449</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-382"
      decimals="2"
      id="f-1503"
      unitRef="usdPerShare">30.24</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-382"
      decimals="INF"
      id="f-1504"
      unitRef="shares">542838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-382"
      decimals="2"
      id="f-1505"
      unitRef="usdPerShare">56.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-41"
      decimals="INF"
      id="f-1506"
      unitRef="shares">2991473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-41"
      decimals="2"
      id="f-1507"
      unitRef="usdPerShare">61.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-382" id="f-1508">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-41" decimals="-3" id="f-1509" unitRef="usd">30477000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-41"
      decimals="INF"
      id="f-1510"
      unitRef="shares">1559662</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-41"
      decimals="2"
      id="f-1511"
      unitRef="usdPerShare">60.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-382" id="f-1512">P4Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-41" decimals="-3" id="f-1513" unitRef="usd">17951000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-41"
      decimals="INF"
      id="f-1514"
      unitRef="shares">2991473</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-41"
      decimals="2"
      id="f-1515"
      unitRef="usdPerShare">61.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-382" id="f-1516">P6Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-41" decimals="-3" id="f-1517" unitRef="usd">30477000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-22"
      decimals="INF"
      id="f-1518"
      unitRef="shares">537432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-22"
      decimals="2"
      id="f-1519"
      unitRef="usdPerShare">72.69</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-22"
      decimals="INF"
      id="f-1520"
      unitRef="shares">489076</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-22"
      decimals="2"
      id="f-1521"
      unitRef="usdPerShare">45.83</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-22"
      decimals="INF"
      id="f-1522"
      unitRef="shares">399371</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-22"
      decimals="2"
      id="f-1523"
      unitRef="usdPerShare">66.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-6"
      decimals="INF"
      id="f-1524"
      unitRef="shares">2640458</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-1525"
      unitRef="usdPerShare">65.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-22" id="f-1526">P5Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-6" decimals="-3" id="f-1527" unitRef="usd">8784000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-6"
      decimals="INF"
      id="f-1528"
      unitRef="shares">1784209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-1529"
      unitRef="usdPerShare">64.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-22" id="f-1530">P4Y3M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-6" decimals="-3" id="f-1531" unitRef="usd">7300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-6"
      decimals="INF"
      id="f-1532"
      unitRef="shares">2640458</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-1533"
      unitRef="usdPerShare">65.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-22" id="f-1534">P5Y7M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-6" decimals="-3" id="f-1535" unitRef="usd">8784000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-1"
      decimals="INF"
      id="f-1536"
      unitRef="shares">783064</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1537"
      unitRef="usdPerShare">86.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-1"
      decimals="INF"
      id="f-1538"
      unitRef="shares">1080135</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1539"
      unitRef="usdPerShare">60.64</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-1"
      decimals="INF"
      id="f-1540"
      unitRef="shares">117114</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1541"
      unitRef="usdPerShare">74.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-5"
      decimals="INF"
      id="f-1542"
      unitRef="shares">2226273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-1543"
      unitRef="usdPerShare">75.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-1544">P6Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-5" decimals="-3" id="f-1545" unitRef="usd">71538000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-5"
      decimals="INF"
      id="f-1546"
      unitRef="shares">1229294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-1547"
      unitRef="usdPerShare">72.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-1548">P5Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-5" decimals="-3" id="f-1549" unitRef="usd">43120000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-5"
      decimals="INF"
      id="f-1550"
      unitRef="shares">2226273</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-1551"
      unitRef="usdPerShare">75.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-1552">P6Y6M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-5" decimals="-3" id="f-1553" unitRef="usd">71538000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-1554"
      unitRef="usdPerShare">37.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-22"
      decimals="2"
      id="f-1555"
      unitRef="usdPerShare">36.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-23"
      decimals="2"
      id="f-1556"
      unitRef="usdPerShare">28.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-1557" unitRef="usd">38600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-22" decimals="-5" id="f-1558" unitRef="usd">12000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-23" decimals="-5" id="f-1559" unitRef="usd">4600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-383" decimals="-5" id="f-1560" unitRef="usd">65200000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-384" decimals="-5" id="f-1561" unitRef="usd">22200000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-385" decimals="-5" id="f-1562" unitRef="usd">2600000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c-1" id="f-1563">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a further breakdown of the options outstanding as of December&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.040%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.212%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Range of exercise prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;remaining life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;in&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;exercise price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;exercise&#160;price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$32.78-$52.84&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;195,152&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$54.81-$63.62&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;191,316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$64.65-$68.74&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;312,067&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;245,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$69.39-$73.76&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;233,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.66&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;125,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$73.92-$75.09&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$78.56-$88.27&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;155,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.57&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$89.20-$89.20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;444,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.35&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$89.86-$103.42&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;244,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$104.30-$114.15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.73&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;114.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$122.70-$122.70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9.92&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,226,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.58&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,229,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-386"
      decimals="2"
      id="f-1564"
      unitRef="usdPerShare">32.78</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-386"
      decimals="2"
      id="f-1565"
      unitRef="usdPerShare">52.84</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-387"
      decimals="INF"
      id="f-1566"
      unitRef="shares">281644</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-386" id="f-1567">P5Y9M10D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-387"
      decimals="2"
      id="f-1568"
      unitRef="usdPerShare">49.42</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-387"
      decimals="INF"
      id="f-1569"
      unitRef="shares">195152</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-387"
      decimals="2"
      id="f-1570"
      unitRef="usdPerShare">48.02</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-388"
      decimals="2"
      id="f-1571"
      unitRef="usdPerShare">54.81</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-388"
      decimals="2"
      id="f-1572"
      unitRef="usdPerShare">63.62</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-389"
      decimals="INF"
      id="f-1573"
      unitRef="shares">228498</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-388" id="f-1574">P4Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-389"
      decimals="2"
      id="f-1575"
      unitRef="usdPerShare">58.54</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-389"
      decimals="INF"
      id="f-1576"
      unitRef="shares">191316</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-389"
      decimals="2"
      id="f-1577"
      unitRef="usdPerShare">58.32</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-390"
      decimals="2"
      id="f-1578"
      unitRef="usdPerShare">64.65</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-390"
      decimals="2"
      id="f-1579"
      unitRef="usdPerShare">68.74</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-391"
      decimals="INF"
      id="f-1580"
      unitRef="shares">312067</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-390" id="f-1581">P5Y1M13D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-391"
      decimals="2"
      id="f-1582"
      unitRef="usdPerShare">67.47</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-391"
      decimals="INF"
      id="f-1583"
      unitRef="shares">245199</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-391"
      decimals="2"
      id="f-1584"
      unitRef="usdPerShare">67.67</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-392"
      decimals="2"
      id="f-1585"
      unitRef="usdPerShare">69.39</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-392"
      decimals="2"
      id="f-1586"
      unitRef="usdPerShare">73.76</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-393"
      decimals="INF"
      id="f-1587"
      unitRef="shares">233288</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-392" id="f-1588">P7Y7M28D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-393"
      decimals="2"
      id="f-1589"
      unitRef="usdPerShare">70.78</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-393"
      decimals="INF"
      id="f-1590"
      unitRef="shares">125319</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-393"
      decimals="2"
      id="f-1591"
      unitRef="usdPerShare">71.02</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-394"
      decimals="2"
      id="f-1592"
      unitRef="usdPerShare">73.92</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-394"
      decimals="2"
      id="f-1593"
      unitRef="usdPerShare">75.09</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-395"
      decimals="INF"
      id="f-1594"
      unitRef="shares">288134</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-394" id="f-1595">P7Y8M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-395"
      decimals="2"
      id="f-1596"
      unitRef="usdPerShare">74.76</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-395"
      decimals="INF"
      id="f-1597"
      unitRef="shares">105797</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-395"
      decimals="2"
      id="f-1598"
      unitRef="usdPerShare">74.88</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-396"
      decimals="2"
      id="f-1599"
      unitRef="usdPerShare">78.56</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-396"
      decimals="2"
      id="f-1600"
      unitRef="usdPerShare">88.27</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-397"
      decimals="INF"
      id="f-1601"
      unitRef="shares">155478</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-396" id="f-1602">P8Y6M25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-397"
      decimals="2"
      id="f-1603"
      unitRef="usdPerShare">82.22</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-397"
      decimals="INF"
      id="f-1604"
      unitRef="shares">32249</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-397"
      decimals="2"
      id="f-1605"
      unitRef="usdPerShare">81.71</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-398"
      decimals="2"
      id="f-1606"
      unitRef="usdPerShare">89.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-398"
      decimals="2"
      id="f-1607"
      unitRef="usdPerShare">89.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-399"
      decimals="INF"
      id="f-1608"
      unitRef="shares">444229</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-398" id="f-1609">P8Y4M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-399"
      decimals="2"
      id="f-1610"
      unitRef="usdPerShare">89.20</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-399"
      decimals="INF"
      id="f-1611"
      unitRef="shares">103190</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-399"
      decimals="2"
      id="f-1612"
      unitRef="usdPerShare">89.20</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-400"
      decimals="2"
      id="f-1613"
      unitRef="usdPerShare">89.86</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-400"
      decimals="2"
      id="f-1614"
      unitRef="usdPerShare">103.42</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-401"
      decimals="INF"
      id="f-1615"
      unitRef="shares">244385</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-400" id="f-1616">P4Y7M20D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-401"
      decimals="2"
      id="f-1617"
      unitRef="usdPerShare">98.53</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-401"
      decimals="INF"
      id="f-1618"
      unitRef="shares">218106</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-401"
      decimals="2"
      id="f-1619"
      unitRef="usdPerShare">98.24</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-402"
      decimals="2"
      id="f-1620"
      unitRef="usdPerShare">104.30</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-402"
      decimals="2"
      id="f-1621"
      unitRef="usdPerShare">114.15</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-403"
      decimals="INF"
      id="f-1622"
      unitRef="shares">28290</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-402" id="f-1623">P6Y8M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-403"
      decimals="2"
      id="f-1624"
      unitRef="usdPerShare">110.98</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-403"
      decimals="INF"
      id="f-1625"
      unitRef="shares">12966</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-403"
      decimals="2"
      id="f-1626"
      unitRef="usdPerShare">114.15</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-404"
      decimals="2"
      id="f-1627"
      unitRef="usdPerShare">122.70</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-404"
      decimals="2"
      id="f-1628"
      unitRef="usdPerShare">122.70</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-405"
      decimals="INF"
      id="f-1629"
      unitRef="shares">10260</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-404" id="f-1630">P9Y11M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-405"
      decimals="2"
      id="f-1631"
      unitRef="usdPerShare">122.70</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-405"
      decimals="INF"
      id="f-1632"
      unitRef="shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-405"
      decimals="2"
      id="f-1633"
      unitRef="usdPerShare">0</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-5"
      decimals="INF"
      id="f-1634"
      unitRef="shares">2226273</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-1635">P6Y6M29D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c-5"
      decimals="2"
      id="f-1636"
      unitRef="usdPerShare">75.14</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-5"
      decimals="INF"
      id="f-1637"
      unitRef="shares">1229294</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c-5"
      decimals="2"
      id="f-1638"
      unitRef="usdPerShare">72.15</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1639">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used for the specified reporting periods and the resulting estimates of weighted-average grant date fair value per share of options granted:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.701%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.227%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.5%-4.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7%-4.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.4%-4.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44%-46%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45%-54%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49%-55%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.1 to 4.8 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.7 to 5.3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.0 to 6.5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-406"
      decimals="3"
      id="f-1640"
      unitRef="number">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-407"
      decimals="3"
      id="f-1641"
      unitRef="number">0.045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-408"
      decimals="3"
      id="f-1642"
      unitRef="number">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-409"
      decimals="3"
      id="f-1643"
      unitRef="number">0.046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-410"
      decimals="3"
      id="f-1644"
      unitRef="number">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c-411"
      decimals="3"
      id="f-1645"
      unitRef="number">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-406"
      decimals="2"
      id="f-1646"
      unitRef="number">0.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-407"
      decimals="2"
      id="f-1647"
      unitRef="number">0.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-408"
      decimals="2"
      id="f-1648"
      unitRef="number">0.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-409"
      decimals="2"
      id="f-1649"
      unitRef="number">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-410"
      decimals="2"
      id="f-1650"
      unitRef="number">0.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c-411"
      decimals="2"
      id="f-1651"
      unitRef="number">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-406" id="f-1652">P4Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-407" id="f-1653">P4Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-408" id="f-1654">P4Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-409" id="f-1655">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-410" id="f-1656">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-411" id="f-1657">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-412" decimals="-5" id="f-1658" unitRef="usd">34000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-413" id="f-1659">P2Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-414" decimals="-5" id="f-1660" unitRef="usd">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-415" id="f-1661">P0Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-1662">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of our restricted stock activity and related information:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.721%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Grant&#160;Date Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;348,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;203,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(181,246)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,054)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65.35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;350,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;318,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(167,308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(64,313)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77.28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;437,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-416"
      decimals="INF"
      id="f-1663"
      unitRef="shares">348453</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-416"
      decimals="2"
      id="f-1664"
      unitRef="usdPerShare">75.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-417"
      decimals="INF"
      id="f-1665"
      unitRef="shares">203752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-417"
      decimals="2"
      id="f-1666"
      unitRef="usdPerShare">83.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-417"
      decimals="INF"
      id="f-1667"
      unitRef="shares">181246</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-417"
      decimals="2"
      id="f-1668"
      unitRef="usdPerShare">74.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-417"
      decimals="INF"
      id="f-1669"
      unitRef="shares">20054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-417"
      decimals="2"
      id="f-1670"
      unitRef="usdPerShare">65.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-418"
      decimals="INF"
      id="f-1671"
      unitRef="shares">350905</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-418"
      decimals="2"
      id="f-1672"
      unitRef="usdPerShare">81.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-419"
      decimals="INF"
      id="f-1673"
      unitRef="shares">318588</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-419"
      decimals="2"
      id="f-1674"
      unitRef="usdPerShare">85.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-419"
      decimals="INF"
      id="f-1675"
      unitRef="shares">167308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-419"
      decimals="2"
      id="f-1676"
      unitRef="usdPerShare">84.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-419"
      decimals="INF"
      id="f-1677"
      unitRef="shares">64313</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-419"
      decimals="2"
      id="f-1678"
      unitRef="usdPerShare">77.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-420"
      decimals="INF"
      id="f-1679"
      unitRef="shares">437872</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-420"
      decimals="2"
      id="f-1680"
      unitRef="usdPerShare">83.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-421" decimals="-5" id="f-1681" unitRef="usd">19600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-422" id="f-1682">P1Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-423"
      decimals="INF"
      id="f-1683"
      unitRef="shares">24493</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
      contextRef="c-424"
      decimals="INF"
      id="f-1684"
      unitRef="shares">1250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-424"
      decimals="INF"
      id="f-1685"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-424"
      decimals="INF"
      id="f-1687"
      unitRef="shares">6308</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-425"
      decimals="INF"
      id="f-1688"
      unitRef="shares">5080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="c-426"
      decimals="INF"
      id="f-1689"
      unitRef="shares">8479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-427" decimals="INF" id="f-1690" unitRef="usd">50000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-1" decimals="INF" id="f-1691" unitRef="usd">0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-23" decimals="INF" id="f-1692" unitRef="usd">0</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-22" decimals="INF" id="f-1693" unitRef="usd">0</us-gaap:StockRepurchasedDuringPeriodValue>
    <lgnd:SaleOfStockAuthorizedOfferingAmount contextRef="c-428" decimals="-5" id="f-1694" unitRef="usd">100000000</lgnd:SaleOfStockAuthorizedOfferingAmount>
    <lgnd:SaleOfStockAuthorizedOfferingAmount contextRef="c-428" decimals="-5" id="f-1695" unitRef="usd">100000000</lgnd:SaleOfStockAuthorizedOfferingAmount>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-429"
      decimals="INF"
      id="f-1696"
      unitRef="shares">360325</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-429" decimals="-5" id="f-1697" unitRef="usd">37400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-1698">Commitment and Contingencies: Legal Proceedings&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We record an estimate of a loss when the loss is considered probable and estimable. Where a liability is probable and there is a range of estimated loss and no amount in the range is more likely than any other number in the range, we record the minimum estimated liability related to the claim in accordance with ASC 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As additional information becomes available, we assess the potential liability related to our pending litigation and revises our estimates. Revisions in our estimates of potential liability could materially impact our results of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 31, 2019, we received three civil complaints filed in the U.S. District Court for the Northern District of Ohio on behalf of several Indian tribes. The Northern District of Ohio is the Court that the Judicial Panel on Multi-District Litigation (&#x201c;JPML&#x201d;) has assigned more than one thousand civil cases which have been designated as a Multi-District Litigation (&#x201c;MDL&#x201d;) and captioned In Re: National Prescription Opiate Litigation. The allegations in these complaints focus on the activities of defendants other than the Company and no individualized factual allegations have been advanced against us in any of the three complaints. We reject all claims raised in the complaints and intend to vigorously defend these matters. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 22, 2024, CyDex Pharmaceuticals, Inc. filed a Verified Complaint in the Delaware Court of Chancery against Bexson Biomedical, Inc. (&#x201c;Bexson&#x201d;), asserting claims for declaratory relief and breach of contract arising out of a Captisol In Vivo Agreement (the &#x201c;In Vivo Agreement&#x201d;) between the parties, pursuant to which CyDex provided Bexson with research-grade Captisol and related confidential and proprietary information for a potential new formulation of ketamine being developed by Bexson. CyDex alleges that Bexson breached its obligations under the In Vivo Agreement, including by misusing confidential information and materials provided by CyDex and by using CyDex&#x2019;s confidential information and materials to file patent applications that purport to cover formulations that are &#x201c;not ketamine.&#x201d; CyDex also asserts that Bexson failed to return and destroy Cydex&#x2019;s confidential information and materials as required by the Agreement. CyDex seeks relief including specific performance of certain co-ownership provisions of the Agreement and disgorgement from Bexson for any benefits obtained in violation of the In Vivo Agreement. On September 27, 2024, Bexson filed a Motion to Dismiss the Verified Complaint. A Verified Amended Complaint was filed by CyDex on November 6, 2024, and a Motion to Dismiss the Verified Amended Complaint was filed by Bexson on January 17, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may also become subject to other legal proceedings or claims arising in the ordinary course of our business. We currently believe that none of the claims or actions pending against us is likely to have, individually or in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;aggregate, a material adverse effect on our business, financial condition or results of operations. Given the unpredictability inherent in litigation, however, we cannot predict the outcome of these matters.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-430"
      decimals="INF"
      id="f-1699"
      unitRef="complaint">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="c-430"
      decimals="INF"
      id="f-1700"
      unitRef="complaint">3</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1701">Income Taxes&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2024, 2023, and 2022, the Company has the following income before income tax from continuing operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.590%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.282%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income before income tax from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.048%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.941%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.062%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.062%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.063%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subpart F income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Officer compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign tax differential on income/loss of foreign subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision to return adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate change for changes in federal, foreign or state law&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(405)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;FDII&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of our deferred tax assets and liabilities as of December&#160;31, 2024 and 2023 are shown below. We assess the positive and negative evidence to determine if sufficient future taxable income will be generated to realize the existing deferred tax assets. Our evaluation of evidence resulted in management concluding that the majority of our deferred tax assets will be realized. However, we maintain a valuation allowance to offset certain net deferred tax assets as management believes realization of such assets are uncertain as of December&#160;31, 2024, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We offset all deferred tax assets and liabilities by jurisdiction, as well as any related valuation allowance, and present them on our consolidated balance sheet as a non-current deferred income tax asset or liability (as applicable). Deferred tax assets (liabilities) are comprised of the following (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(55,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Identified intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(69,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32,452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, we had federal net operating loss carryforwards set to expire through 2037 of $21.4 million and $162.8 million of state net operating loss carryforwards that begin to expire in 2028. We also have $6.2 million of federal research and development credit carryforwards, which expire through 2040. We have $29.5 million of California research and development credit carryforwards that have no expiration date. In addition, we have approximately $98.4 million of non-U.S. net operating loss carryovers and approximately $14.4 million of non-U.S. capital loss carryovers that have no expiration date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, we had federal net operating loss carryforwards set to expire through 2037 of $48.0 million and $165.1 million of state net operating loss carryforwards that begin to expire in 2028. We also had $8.5 million of federal research and development credit carryforwards, which expire through 2040. We had $29.4 million of California research and development credit carryforwards that have no expiration date. In addition, we had approximately $95.5 million of non-U.S. net operating loss carryovers and approximately $16.5 million of non-U.S. capital loss carryovers that have no expiration date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to Section 382 and 383 of the Internal Revenue Code of 1986, as amended, utilization of our net operating losses and credits may be subject to annual limitations in the event of any significant future changes in its ownership structure. These annual limitations may result in the expiration of net operating losses and credits prior to utilization. The deferred tax assets as of December&#160;31, 2024 are net of any previous limitations due to Section 382 and 383.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income taxes by evaluating a probability threshold that a tax position must meet before a financial statement benefit is recognized. The minimum threshold is a tax position that is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. Our remaining liabilities for uncertain tax positions are presented net of the deferred tax asset balances on the accompanying consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2024, 2023 and 2022 is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.048%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in the balance of unrecognized tax benefits at December&#160;31, 2024 is $20.7 million of tax benefits that, if recognized would impact the effective rate. There are no positions for which it is reasonably possible that the uncertain tax benefit will significantly increase or decrease within twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize interest and penalties related to uncertain tax positions in income tax expense. As of December&#160;31, 2024 and December&#160;31, 2023, we recognized an immaterial amount of interest and penalties. We file income tax returns in the United States, various state jurisdictions, Austria, and United Kingdom with varying statutes of limitations. The federal statute of limitation remains open for the 2021 tax year to the present.&#160;he United Kingdom statute of limitation remains open for the 2020 tax year to the present. The Austrian statute of limitation remains open for the 2020 tax year to the present.&#160;Net operating loss and research credit carryforwards arising prior to these years are also open to examination if and when utilized. The Company's 2019 and 2020 California tax returns are under examination by the California Franchise Tax Board. The Company does not anticipate that the examination will result in a material adjustment to its financial statements. No other income tax returns are currently under examination. We believe our reserve for unrecognized tax benefits and contingent tax issues is adequate with respect to all open years.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-1702">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2024, 2023, and 2022, the Company has the following income before income tax from continuing operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.590%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.282%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income before income tax from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;63,660&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the income tax expense (benefit) for continuing operations are as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.048%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,186)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;718&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred expense (benefit):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17,767)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15,800)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total income tax expense (benefit)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-431" decimals="-3" id="f-1703" unitRef="usd">-25855000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-432" decimals="-3" id="f-1704" unitRef="usd">62140000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-433" decimals="-3" id="f-1705" unitRef="usd">33339000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-434" decimals="-3" id="f-1706" unitRef="usd">28373000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-435" decimals="-3" id="f-1707" unitRef="usd">1520000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-436" decimals="-3" id="f-1708" unitRef="usd">2672000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-1709" unitRef="usd">2518000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-22" decimals="-3" id="f-1710" unitRef="usd">63660000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-23" decimals="-3" id="f-1711" unitRef="usd">36011000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1712" unitRef="usd">18277000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-22" decimals="-3" id="f-1713" unitRef="usd">-1186000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-23" decimals="-3" id="f-1714" unitRef="usd">10097000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1715" unitRef="usd">718000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-22" decimals="-3" id="f-1716" unitRef="usd">218000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-23" decimals="-3" id="f-1717" unitRef="usd">193000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1718" unitRef="usd">3355000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-22" decimals="-3" id="f-1719" unitRef="usd">780000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-23" decimals="-3" id="f-1720" unitRef="usd">452000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1721" unitRef="usd">22350000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-22" decimals="-3" id="f-1722" unitRef="usd">-188000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-23" decimals="-3" id="f-1723" unitRef="usd">10742000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1724" unitRef="usd">-17767000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-22" decimals="-3" id="f-1725" unitRef="usd">9374000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-23" decimals="-3" id="f-1726" unitRef="usd">-3656000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1727" unitRef="usd">77000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-22" decimals="-3" id="f-1728" unitRef="usd">655000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-23" decimals="-3" id="f-1729" unitRef="usd">34144000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1730" unitRef="usd">1890000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-22" decimals="-3" id="f-1731" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-23" decimals="-3" id="f-1732" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1733" unitRef="usd">-15800000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-22" decimals="-3" id="f-1734" unitRef="usd">10029000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-23" decimals="-3" id="f-1735" unitRef="usd">30488000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1736" unitRef="usd">6550000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-22" decimals="-3" id="f-1737" unitRef="usd">9841000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-23" decimals="-3" id="f-1738" unitRef="usd">41230000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1739">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of income tax expense (benefit) from continuing operations to the amount computed by applying the statutory federal income tax rate to the net income (loss) from continuing operations is summarized as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.941%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.062%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.062%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.063%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subpart F income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Officer compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign tax differential on income/loss of foreign subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provision to return adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;293&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Rate change for changes in federal, foreign or state law&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(535)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Debt repurchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State, net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(324)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(405)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;FDII&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,037)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,395)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,638)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-1740" unitRef="usd">529000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-22" decimals="-3" id="f-1741" unitRef="usd">13448000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-23" decimals="-3" id="f-1742" unitRef="usd">7562000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <lgnd:EffectiveIncomeTaxRateReconciliationOtherIncome contextRef="c-1" decimals="-3" id="f-1743" unitRef="usd">5649000</lgnd:EffectiveIncomeTaxRateReconciliationOtherIncome>
    <lgnd:EffectiveIncomeTaxRateReconciliationOtherIncome contextRef="c-22" decimals="-3" id="f-1744" unitRef="usd">479000</lgnd:EffectiveIncomeTaxRateReconciliationOtherIncome>
    <lgnd:EffectiveIncomeTaxRateReconciliationOtherIncome contextRef="c-23" decimals="-3" id="f-1745" unitRef="usd">853000</lgnd:EffectiveIncomeTaxRateReconciliationOtherIncome>
    <lgnd:EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount contextRef="c-1" decimals="-3" id="f-1746" unitRef="usd">3921000</lgnd:EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount contextRef="c-22" decimals="-3" id="f-1747" unitRef="usd">844000</lgnd:EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount contextRef="c-23" decimals="-3" id="f-1748" unitRef="usd">5869000</lgnd:EffectiveIncomeTaxRateReconciliationOfficerCompensationAmount>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="-3" id="f-1749" unitRef="usd">1115000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-22" decimals="-3" id="f-1750" unitRef="usd">-38000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-23" decimals="-3" id="f-1751" unitRef="usd">103000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-3" id="f-1752" unitRef="usd">602000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-22" decimals="-3" id="f-1753" unitRef="usd">1241000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-23" decimals="-3" id="f-1754" unitRef="usd">1279000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount contextRef="c-1" decimals="-3" id="f-1755" unitRef="usd">-293000</lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount contextRef="c-22" decimals="-3" id="f-1756" unitRef="usd">-2200000</lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount contextRef="c-23" decimals="-3" id="f-1757" unitRef="usd">-2232000</lgnd:EffectiveIncomeTaxRateReconciliationProvisionToReturnAdjustmentsAmount>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-1" decimals="-3" id="f-1758" unitRef="usd">111000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-22" decimals="-3" id="f-1759" unitRef="usd">342000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="c-23" decimals="-3" id="f-1760" unitRef="usd">-535000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
    <lgnd:IncomeTaxReconciliationContingentValueRights contextRef="c-1" decimals="-3" id="f-1761" unitRef="usd">88000</lgnd:IncomeTaxReconciliationContingentValueRights>
    <lgnd:IncomeTaxReconciliationContingentValueRights contextRef="c-22" decimals="-3" id="f-1762" unitRef="usd">-116000</lgnd:IncomeTaxReconciliationContingentValueRights>
    <lgnd:IncomeTaxReconciliationContingentValueRights contextRef="c-23" decimals="-3" id="f-1763" unitRef="usd">15000</lgnd:IncomeTaxReconciliationContingentValueRights>
    <lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions contextRef="c-1" decimals="-3" id="f-1764" unitRef="usd">-94000</lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions contextRef="c-22" decimals="-3" id="f-1765" unitRef="usd">7206000</lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions contextRef="c-23" decimals="-3" id="f-1766" unitRef="usd">158000</lgnd:EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions>
    <lgnd:EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount contextRef="c-1" decimals="-3" id="f-1767" unitRef="usd">0</lgnd:EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount contextRef="c-22" decimals="-3" id="f-1768" unitRef="usd">0</lgnd:EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount>
    <lgnd:EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount contextRef="c-23" decimals="-3" id="f-1769" unitRef="usd">626000</lgnd:EffectiveIncomeTaxRateReconciliationDebtRepurchasesAmount>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-1770" unitRef="usd">-85000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-22" decimals="-3" id="f-1771" unitRef="usd">397000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-23" decimals="-3" id="f-1772" unitRef="usd">264000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch contextRef="c-1" decimals="-3" id="f-1773" unitRef="usd">-324000</lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch>
    <lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch contextRef="c-22" decimals="-3" id="f-1774" unitRef="usd">-405000</lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch>
    <lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch contextRef="c-23" decimals="-3" id="f-1775" unitRef="usd">256000</lgnd:EffectiveIncomeTaxRateReconciliationExpiredTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount contextRef="c-1" decimals="-3" id="f-1776" unitRef="usd">832000</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount contextRef="c-22" decimals="-3" id="f-1777" unitRef="usd">1037000</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount contextRef="c-23" decimals="-3" id="f-1778" unitRef="usd">2395000</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiAmount>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-1779" unitRef="usd">-1638000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-22" decimals="-3" id="f-1780" unitRef="usd">-1184000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-23" decimals="-3" id="f-1781" unitRef="usd">24799000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign contextRef="c-1" decimals="-3" id="f-1782" unitRef="usd">3232000</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign contextRef="c-22" decimals="-3" id="f-1783" unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationTaxCreditsForeign contextRef="c-23" decimals="-3" id="f-1784" unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxCreditsForeign>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-1" decimals="-3" id="f-1785" unitRef="usd">259000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-22" decimals="-3" id="f-1786" unitRef="usd">876000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="c-23" decimals="-3" id="f-1787" unitRef="usd">460000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1788" unitRef="usd">6550000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-22" decimals="-3" id="f-1789" unitRef="usd">9841000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-23" decimals="-3" id="f-1790" unitRef="usd">41230000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1791">Deferred tax assets (liabilities) are comprised of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized R&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance for deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(55,649)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57,699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Identified intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(69,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(73,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(77,470)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32,452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31,408)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-3" id="f-1792" unitRef="usd">40385000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-6" decimals="-3" id="f-1793" unitRef="usd">45702000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-5" decimals="-3" id="f-1794" unitRef="usd">24404000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-6" decimals="-3" id="f-1795" unitRef="usd">26611000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <lgnd:DeferredTaxAssetsCapitalizedResearchAndDevelopment contextRef="c-5" decimals="-3" id="f-1796" unitRef="usd">7090000</lgnd:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <lgnd:DeferredTaxAssetsCapitalizedResearchAndDevelopment contextRef="c-6" decimals="-3" id="f-1797" unitRef="usd">4550000</lgnd:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-1798" unitRef="usd">10726000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-6" decimals="-3" id="f-1799" unitRef="usd">11886000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-3" id="f-1800" unitRef="usd">13733000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-6" decimals="-3" id="f-1801" unitRef="usd">15012000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-1802" unitRef="usd">96338000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-6" decimals="-3" id="f-1803" unitRef="usd">103761000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-1804" unitRef="usd">55649000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-1805" unitRef="usd">57699000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-5" decimals="-3" id="f-1806" unitRef="usd">40689000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-6" decimals="-3" id="f-1807" unitRef="usd">46062000</us-gaap:DeferredTaxAssetsNet>
    <lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets contextRef="c-5" decimals="-3" id="f-1808" unitRef="usd">69150000</lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets>
    <lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets contextRef="c-6" decimals="-3" id="f-1809" unitRef="usd">66966000</lgnd:DeferredTaxLiabilitiesFiniteLivedIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-5" decimals="-3" id="f-1810" unitRef="usd">3991000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther contextRef="c-6" decimals="-3" id="f-1811" unitRef="usd">10504000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-3" id="f-1812" unitRef="usd">73141000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-6" decimals="-3" id="f-1813" unitRef="usd">77470000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-5" decimals="-3" id="f-1814" unitRef="usd">32452000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-6" decimals="-3" id="f-1815" unitRef="usd">31408000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwards contextRef="c-437" decimals="-5" id="f-1816" unitRef="usd">21400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-438" decimals="-5" id="f-1817" unitRef="usd">162800000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-439" decimals="-5" id="f-1818" unitRef="usd">6200000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-440" decimals="-5" id="f-1819" unitRef="usd">29500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-441" decimals="-5" id="f-1820" unitRef="usd">98400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-442" decimals="-5" id="f-1821" unitRef="usd">14400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-443" decimals="-5" id="f-1822" unitRef="usd">48000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-444" decimals="-5" id="f-1823" unitRef="usd">165100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-445" decimals="-5" id="f-1824" unitRef="usd">8500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-446" decimals="-5" id="f-1825" unitRef="usd">29400000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-447" decimals="-5" id="f-1826" unitRef="usd">95500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-448" decimals="-5" id="f-1827" unitRef="usd">16500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-1828">&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the amount of unrecognized tax benefits at December&#160;31, 2024, 2023 and 2022 is as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.048%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,783)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(512)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-3" id="f-1829" unitRef="usd">22363000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-41" decimals="-3" id="f-1830" unitRef="usd">29096000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-28" decimals="-3" id="f-1831" unitRef="usd">29550000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1832" unitRef="usd">27000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-22" decimals="-3" id="f-1833" unitRef="usd">47000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-23" decimals="-3" id="f-1834" unitRef="usd">58000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1835" unitRef="usd">477000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-22" decimals="-3" id="f-1836" unitRef="usd">3000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-23" decimals="-3" id="f-1837" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-1838" unitRef="usd">396000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-22" decimals="-3" id="f-1839" unitRef="usd">6783000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-23" decimals="-3" id="f-1840" unitRef="usd">512000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-3" id="f-1841" unitRef="usd">22471000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-3" id="f-1842" unitRef="usd">22363000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-41" decimals="-3" id="f-1843" unitRef="usd">29096000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-5" decimals="-5" id="f-1844" unitRef="usd">20700000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-1845">Subsequent Event&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 24, 2025, we entered into a Purchase and Sale Agreement (the &#x201c;Agreement&#x201d;) with Castle Creek Biosciences, Inc., Castle Creek Biosciences, LLC (collectively, &#x201c;Castle Creek&#x201d;) and a syndicate of co-investors for which Ligand acted as representative (collectively, including Ligand, the &#x201c;Purchasers&#x201d;), to support Castle Creek&#x2019;s autologous human fibroblast cell-based gene therapy genetically modified to express COL7, also known as FCX-007 (dabocemagene autoficel) (&#x201c;D-Fi&#x201d;) Phase 3 clinical study, its lead candidate for patients with dystrophic epidermolysis bullosa (&#x201c;DEB&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Agreement, we and the other Purchasers obtained, for an aggregate purchase price of $75&#160;million, $50 million of which was paid by Ligand and $25&#160;million of which was paid by the other Purchasers collectively, (i) a high single digit royalty on worldwide sales of D-Fi and (ii) warrants to purchase shares of Castle Creek Biosciences, Inc. Series D-1 Preferred Stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the transaction we also acquired an unsecured subordinated promissory note issued by Castle Creek Biosciences, LLC with an aggregate principal amount of $8.3&#160;million, which is due and payable upon Castle Creek&#x2019;s receipt of U.S. Food and Drug Administration approval of D-Fi for treatment of DEB and certain other conditions to payment. We paid $1.8&#160;million for the unsecured subordinated promissory note.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="c-449" decimals="-6" id="f-1846" unitRef="usd">75000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="c-450" decimals="-6" id="f-1847" unitRef="usd">50000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="c-451" decimals="-6" id="f-1848" unitRef="usd">25000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:ReceivableWithImputedInterestFaceAmount contextRef="c-452" decimals="-5" id="f-1849" unitRef="usd">8300000</us-gaap:ReceivableWithImputedInterestFaceAmount>
    <us-gaap:PaymentsToAcquireNotesReceivable contextRef="c-453" decimals="-5" id="f-1850" unitRef="usd">1800000</us-gaap:PaymentsToAcquireNotesReceivable>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-454" id="f-1851">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-454" id="f-1852">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-454" id="f-1853">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-454" id="f-1854">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-1855">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
